Physical O O
mapping O O
220 O O
kb O O
centromeric O O
of O O
the O O
human B-GENE B-GENE
MHC E-GENE E-GENE
and O O
DNA O O
sequence O O
analysis O O
of O O
the O O
43 O O
- O O
kb O O
segment O O
including O O
the O O
RING1 S-GENE S-GENE
, O O
HKE6 S-GENE S-GENE
, O O
and O O
HKE4 B-GENE B-GENE
genes E-GENE E-GENE
. O O
The O O
synthesis O O
of O O
endo O O
- O O
adduct O O
[ O O
4aS O O
, O O
5S O O
, O O
8R O O
, O O
8aR O O
, O O
SS O O
] O O
- O O
9d O O
resulting O O
from O O
cycloaddition O O
on O O
the O O
substituted O O
C O O
( O O
2 O O
) O O
- O O
C O O
( O O
3 O O
) O O
double O O
bond O O
was O O
achieved O O
in O O
a O O
chemo O O
- O O
and O O
diastereoselective O O
way O O
from O O
quinone O O
1d O O
in O O
the O O
presence O O
of O O
ZnBr O O
( O O
2 O O
) O O
. O O
DNA O O
elements O O
recognizing O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
and O O
Sp1 S-GENE S-GENE
regulate O O
the O O
human B-GENE B-GENE
multidrug I-GENE I-GENE
- I-GENE I-GENE
resistance I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
. O O
Radioimmunoassay O O
of O O
plasma B-GENE O
gonadotropins E-GENE O
; O O
problems O O
of O O
specificity O O
Patients O O
randomized O O
into O O
the O O
active O O
treatment O O
groups O O
A30 O O
( O O
n O O
= O O
49 O O
) O O
and O O
A60 O O
( O O
n O O
= O O
48 O O
) O O
received O O
topical O O
treatment O O
with O O
3 O O
. O O
0 O O
% O O
diclofenac O O
in O O
2 O O
. O O
5 O O
% O O
hyaluronan O O
gel O O
0 O O
. O O
5 O O
g O O
twice O O
daily O O
for O O
30 O O
or O O
60 O O
days O O
, O O
respectively O O
. O O
As O O
tat S-GENE O
itself O O
dramatically O O
increases O O
HIV O B-GENE
- O I-GENE
1 O I-GENE
gene O E-GENE
expression O O
, O O
it O O
too O O
is O O
presumably O O
regulated O O
in O O
the O O
latent O O
state O O
, O O
and O O
may O O
also O O
be O O
activated O O
by O O
mitogenic O O
stimulation O O
. O O
To O O
clarify O O
the O O
difference O O
, O O
both O O
the O O
Crk B-GENE B-GENE
II E-GENE E-GENE
and O O
Crk B-GENE B-GENE
II I-GENE I-GENE
- I-GENE I-GENE
23 E-GENE E-GENE
, O O
proteins O O
were O O
expressed O O
in O O
E O O
. O O
coli O O
and O O
examined O O
their O O
binding O O
capacity O O
in O O
vitro O O
. O O
CONCLUSIONS O O
: O O
Systemic O O
factors O O
that O O
increase O O
bone O O
mineral O O
density O O
appear O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
ossification O O
of O O
the O O
posterior O O
longitudinal O O
ligament O O
, O O
and O O
these O O
factors O O
may O O
be O O
activated O O
after O O
middle O O
age O O
. O O
Thus O O
, O O
in O O
V O O
. O O
furnissii O O
, O O
the O O
E B-GENE O
. I-GENE O
coli I-GENE O
manX I-GENE O
equivalent E-GENE O
comprises O O
two O O
genes O O
, O O
which O O
are O O
separated O O
in O O
the O O
genome O O
by O O
two O O
other O O
genes O O
of O O
the O O
ptsM B-GENE O
complex E-GENE O
. O O
Id B-GENE O
- I-GENE O
1H E-GENE O
and O O
Id B-GENE O
- I-GENE O
2H E-GENE O
seem O O
to O O
be O O
human O O
homologues O O
of O O
mouse B-GENE O
Id I-GENE O
- I-GENE O
1 E-GENE O
and O O
Id B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
respectively O O
, O O
and O O
have O O
potential O O
to O O
encode O O
154 O O
and O O
135 O O
amino O O
acid O O
proteins O O
. O O
Characterization O O
of O O
insertion O O
mutations O O
in O O
the O O
Saccharomyces B-GENE O
cerevisiae I-GENE O
MSH1 E-GENE S-GENE
and O O
MSH2 B-GENE B-GENE
genes E-GENE E-GENE
: O O
evidence O O
for O O
separate O O
mitochondrial O O
and O O
nuclear O O
functions O O
. O O
Transcription O O
of O O
FN B-GENE B-GENE
promoter E-GENE E-GENE
- O O
chloramphenicol B-GENE O
acetyltransferase E-GENE O
fusion O O
genes O O
carrying O O
the O O
base O O
substitution O O
in O O
one O O
or O O
more O O
of O O
these O O
G O O
- O O
rich O O
sequences O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
revealed O O
that O O
the O O
base O O
substitution O O
in O O
any O O
G O O
- O O
rich O O
sequence O O
results O O
in O O
reduction O O
of O O
promoter O O
activity O O
, O O
although O O
the O O
downstream O O
GC O O
box O O
( O O
GCd O O
) O O
plays O O
a O O
primary O O
role O O
. O O
Morphologically O O
, O O
corrugation O O
of O O
the O O
internal O O
elastic O O
lamina O O
of O O
vessels O O
was O O
often O O
observed O O
in O O
the O O
vehicle O O
- O O
treated O O
group O O
, O O
but O O
was O O
not O O
prominent O O
in O O
the O O
GLNVA O O
- O O
treated O O
groups O O
or O O
healthy O O
controls O O
. O O
A O O
GT O O
- O O
rich O O
sequence O O
binding O O
the O O
transcription B-GENE O
factor I-GENE O
Sp1 E-GENE S-GENE
is O O
crucial O O
for O O
high O O
expression O O
of O O
the O O
human B-GENE B-GENE
type I-GENE I-GENE
VII I-GENE I-GENE
collagen I-GENE I-GENE
gene E-GENE E-GENE
( O O
COL7A1 S-GENE S-GENE
) O O
in O O
fibroblasts O O
and O O
keratinocytes O O
. O O
Each O O
received O O
20 O O
mL O O
of O O
one O O
of O O
three O O
test O O
solutions O O
: O O
levobupivacaine O O
control O O
, O O
levobupivacaine O O
and O O
fentanyl O O
2 O O
microg O O
/ O O
mL O O
, O O
or O O
levobupivacaine O O
and O O
fentanyl O O
3 O O
microg O O
/ O O
mL O O
. O O
The O O
XPR2 B-GENE B-GENE
gene E-GENE E-GENE
from O O
Yarrowia O O
lipolytica O O
encodes O O
an O O
inducible O O
alkaline B-GENE O
extracellular I-GENE O
protease E-GENE O
. O O
CONCLUSIONS O O
: O O
This O O
study O O
shows O O
that O O
the O O
annual O O
rate O O
of O O
de O O
novo O O
aneurysm O O
formation O O
is O O
relatively O O
high O O
( O O
0 O O
. O O
89 O O
% O O
) O O
and O O
that O O
the O O
cumulative O O
risk O O
becomes O O
significant O O
after O O
9 O O
years O O
. O O
It O O
was O O
found O O
that O O
Nopp140 S-GENE S-GENE
binds O O
primarily O O
to O O
the O O
CK2 B-GENE B-GENE
regulatory I-GENE I-GENE
subunit I-GENE E-GENE
, I-GENE O
beta E-GENE O
. O O
Juvenile O O
idiopathic O O
inflammatory O O
myopathies O O
: O O
the O O
value O O
of O O
magnetic O O
resonance O O
imaging O O
in O O
the O O
detection O O
of O O
muscle O O
involvement O O
. O O
Previous O O
analysis O O
of O O
this O O
motif O O
in O O
the O O
lactose B-GENE O
permease E-GENE O
( O O
A O O
. O O
Combined O O
chemotherapy O O
with O O
VM O O
26 O O
and O O
BCNU O O
for O O
recurrent O O
malignant O O
gliomas O O
after O O
operation O O
and O O
irradiation O O
. O O
Like O O
other O O
IAPs S-GENE S-GENE
, O O
ch B-GENE O
- I-GENE O
IAP1 E-GENE O
contains O O
the O O
N B-GENE O
- I-GENE O
terminal I-GENE O
baculovirus I-GENE O
IAP I-GENE O
repeats E-GENE O
and O O
C O O
- O O
terminal O O
RING O O
finger O O
motifs O O
. O O
Effects O O
of O O
long O O
- O O
term O O
use O O
of O O
raloxifene O O
, O O
a O O
selective O O
estrogen B-GENE O
receptor E-GENE O
modulator O O
, O O
on O O
thyroid O O
function O O
test O O
profiles O O
. O O
The O O
donors O O
of O O
10 O O
patients O O
were O O
ABO O O
- O O
incompatible O O
, O O
and O O
for O O
five O O
pairs O O
the O O
ABO O O
incompatibility O O
was O O
major O O
. O O
Alternative O O
splicing O O
of O O
the O O
human B-GENE B-GENE
serotonin I-GENE I-GENE
transporter I-GENE I-GENE
gene E-GENE E-GENE
. O O
Interestingly O O
, O O
basal O O
MAPK S-GENE S-GENE
, O O
but O O
not O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
activity O O
was O O
constitutively O O
enhanced O O
in O O
Jak1 S-GENE O
- O O
deficient O O
HeLa O O
cells O O
. O O
This O O
case O O
report O O
describes O O
the O O
treatment O O
of O O
a O O
patient O O
with O O
periodontosis O O
. O O
The O O
aim O O
of O O
this O O
work O O
was O O
to O O
organize O O
chemical O O
data O O
in O O
a O O
client O O
- O O
server O O
environment O O
using O O
Database O O
Management O O
System O O
and O O
Web O O
fashion O O
for O O
the O O
client O O
interface O O
. O O
Cerumen O O
management O O
in O O
hearing O O
conservation O O
: O O
the O O
Dallas O O
( O O
Texas O O
) O O
Independent O O
School O O
District O O
program O O
. O O
Lactate O O
, O O
pyruvate O O
and O O
actual O O
pH O O
values O O
in O O
the O O
venous O O
blood O O
of O O
newborn O O
calves O O
This O O
article O O
focuses O O
on O O
a O O
general O O
approach O O
to O O
the O O
use O O
of O O
ARV O O
agents O O
. O O
Platelets O O
and O O
RBCs O O
from O O
each O O
animal O O
were O O
labeled O O
with O O
51Cr O O
and O O
99mTc O O
, O O
respectively O O
, O O
and O O
were O O
rapidly O O
injected O O
into O O
the O O
right O O
atrium O O
while O O
blood O O
was O O
sampled O O
from O O
the O O
ascending O O
aorta O O
. O O
The O O
comparisons O O
of O O
swimming O O
performance O O
before O O
and O O
after O O
treatments O O
with O O
deltamethrin O O
have O O
shown O O
a O O
significant O O
effect O O
on O O
locomotory O O
ability O O
of O O
rainbow O O
trout O O
which O O
at O O
the O O
end O O
of O O
strong O O
exposure O O
( O O
e O O
. O O
g O O
. O O
Protection O O
levels O O
of O O
33 O O
. O O
3 O O
% O O
, O O
36 O O
. O O
6 O O
% O O
and O O
37 O O
. O O
0 O O
% O O
were O O
achieved O O
in O O
groups O O
which O O
had O O
received O O
, O O
respectively O O
, O O
1000 O O
20 O O
- O O
krad O O
cercariae O O
, O O
1000 O O
10 O O
- O O
krad O O
cercariae O O
, O O
2000 O O
40 O O
- O O
krad O O
cercariae O O
and O O
2000 O O
60 O O
- O O
krad O O
cercariae O O
. O O
In O O
Types O O
I O O
and O O
II O O
, O O
capillary O O
walls O O
became O O
thinner O O
and O O
more O O
capillary O O
lumens O O
were O O
visiable O O
. O O
Thus O O
, O O
primate O O
vs O O
. O O
rodent O O
promoter O O
selectivity O O
mediated O O
by O O
the O O
TBP S-GENE B-GENE
- O I-GENE
TAFI S-GENE I-GENE
complex O E-GENE
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
cumulative O O
subtle O O
differences O O
between O O
individual O O
subunits O O
that O O
lead O O
to O O
species O O
- O O
specific O O
properties O O
of O O
RNA B-GENE O
polymerase I-GENE O
I E-GENE O
transcription O O
. O O
The O O
effects O O
of O O
pretreatment O O
with O O
the O O
non O O
- O O
competitive O O
NMDA O S-GENE
antagonist O O
( O O
+ O O
) O O
MK O O
- O O
801 O O
on O O
the O O
behavioral O O
alterations O O
induced O O
by O O
repeated O O
restraint O O
stress O O
were O O
investigated O O
. O O
When O O
gene O O
conversion O O
is O O
initiated O O
by O O
a O O
double O O
- O O
strand O O
break O O
( O O
DSB O O
) O O
, O O
any O O
nonhomologous O O
DNA O O
that O O
may O O
be O O
present O O
at O O
the O O
ends O O
must O O
be O O
removed O O
before O O
new O O
DNA O O
synthesis O O
can O O
be O O
initiated O O
. O O
In O O
this O O
reconstituted O O
system O O
, O O
RNAP B-GENE B-GENE
IIA E-GENE E-GENE
, O O
but O O
not O O
RNAP B-GENE B-GENE
IIB E-GENE E-GENE
, O O
can O O
transcribe O O
from O O
the O O
DHFR B-GENE B-GENE
promoter E-GENE E-GENE
. O O
The O O
cDNA O O
clones O O
encode O O
a O O
polypeptide O O
of O O
657 O O
amino O O
acids O O
with O O
a O O
bHLH O S-GENE
( O O
basic O O
- O O
helix O O
- O O
loop O O
- O O
helix O O
) O O
domain O O
, O O
characteristic O O
of O O
a O O
large O O
family O O
of O O
transcription O O
factors O O
, O O
and O O
a O O
PAS S-GENE O
( O O
Per S-GENE O
- O O
Arnt S-GENE O
- O O
Sim S-GENE O
) O O
domain O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
region O O
. O O
FTF O S-GENE
( O O
Joint O O
Council O O
of O O
Civil O O
Servants O O
and O O
Functionaries O O
) O O
: O O
clarification O O
about O O
membership O O
in O O
the O O
main O O
organizations O O
Lumbar O O
spine O O
bone O O
mineral O O
density O O
( O O
BMD O O
) O O
by O O
dual O O
- O O
energy O O
X O O
- O O
ray O O
absorptiometry O O
( O O
DXA O O
) O O
increased O O
by O O
0 O O
. O O
6 O O
% O O
, O O
3 O O
. O O
6 O O
% O O
and O O
8 O O
. O O
1 O O
% O O
after O O
48 O O
weeks O O
in O O
groups O O
L O O
, O O
M O O
and O O
H O O
respectively O O
, O O
responses O O
in O O
groups O O
M O O
and O O
H O O
being O O
significantly O O
higher O O
than O O
in O O
L O O
( O O
p O O
< O O
0 O O
. O O
05 O O
, O O
Mann O O
- O O
Whitney O O
U O O
- O O
test O O
) O O
. O O
Synergy O O
between O O
interferon B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
and O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
in O O
transcriptional O O
activation O O
is O O
mediated O O
by O O
cooperation O O
between O O
signal B-GENE O
transducer I-GENE O
and I-GENE O
activator I-GENE O
of I-GENE O
transcription I-GENE O
1 E-GENE O
and O O
nuclear B-GENE O
factor I-GENE O
kappaB E-GENE S-GENE
. O O
1H O O
and O O
15N O O
magnetic O O
resonance O O
assignments O O
, O O
secondary O O
structure O O
, O O
and O O
tertiary O O
fold O O
of O O
Escherichia B-GENE O
coli I-GENE O
DnaJ I-GENE O
( I-GENE O
1 I-GENE O
- I-GENE O
78 I-GENE O
) E-GENE O
. O O
A O O
cDNA O O
for O O
human B-GENE O
microfibril I-GENE O
- I-GENE O
associated I-GENE O
glycoprotein I-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
( O O
MAGP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
) O O
was O O
used O O
to O O
screen O O
a O O
human O O
leukocyte O O
genomic O O
DNA O O
library O O
in O O
EMBL O O
- O O
3 O O
vector O O
. O O
Furthermore O O
, O O
ERK S-GENE S-GENE
phosphorylation O O
was O O
substantially O O
prolonged O O
in O O
LC O O
/ O O
BRY O O
- O O
treated O O
cells O O
compared O O
to O O
those O O
exposed O O
to O O
BRY O O
alone O O
, O O
and O O
pretreatment O O
with O O
the O O
highly O O
specific O O
MEK S-GENE S-GENE
inhibitors O O
, O O
PD98059 O S-GENE
, O O
U0126 O S-GENE
, O O
and O O
SL327 O S-GENE
, O O
opposed O O
ERK S-GENE S-GENE
activation O O
while O O
protecting O O
cells O O
from O O
LC O O
/ O O
BRY O O
- O O
induced O O
lethality O O
. O O
The O O
cholesterol B-GENE B-GENE
7alpha I-GENE I-GENE
- I-GENE I-GENE
hydroxylase I-GENE I-GENE
gene E-GENE E-GENE
( O O
CYP7A S-GENE S-GENE
) O O
is O O
transcriptionally O O
regulated O O
by O O
a O O
number O O
of O O
factors O O
, O O
including O O
hormones O O
, O O
bile O O
acids O O
, O O
and O O
diurnal O O
rhythm O O
. O O
CNS O O
preventive O O
treatment O O
without O O
cranial O O
irradiation O O
was O O
effective O O
in O O
all O O
the O O
groups O O
of O O
ALL O O
patients O O
. O O
Additionally O O
, O O
the O O
members O O
of O O
this O O
family O O
display O O
strong O O
sequence O O
homologies O O
between O O
their O O
larger O O
C O O
- O O
terminal O O
effector O O
binding O O
/ O O
oligomerization O O
domains O O
. O O
Aspartame O O
is O O
a O O
synthetic O O
sweetener O O
commonly O O
used O O
in O O
soft O O
drinks O O
and O O
many O O
foods O O
. O O
The O O
rat O O
anococcygeus O O
muscle O O
was O O
used O O
in O O
postsynaptic O O
studies O O
. O O
The O O
purpose O O
of O O
this O O
presentation O O
is O O
to O O
review O O
the O O
current O O
state O O
of O O
knowledge O O
regarding O O
5 O O
, O O
8 O O
, O O
11 O O
, O O
14 O O
- O O
eicosatetraynoic O O
acid O O
( O O
ETYA O O
, O O
Ro O O
3 O O
- O O
1428 O O
) O O
and O O
its O O
effects O O
on O O
lipid O O
metabolism O O
. O O
A O O
Meis1 B-GENE O
cDNA E-GENE O
clone O O
that O O
encoded O O
a O O
novel O O
member O O
of O O
the O O
homeobox B-GENE B-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
was O O
identified O O
. O O
The O O
S B-GENE O
. I-GENE O
typhimurium I-GENE O
aspartyl I-GENE O
/ I-GENE O
asparaginyl I-GENE O
beta I-GENE O
- I-GENE O
hydroxylase I-GENE O
homologue E-GENE O
( O O
designated O O
lpxO S-GENE O
) O O
was O O
cloned O O
into O O
pBluescriptSK O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
K O O
- O O
12 O O
, O O
which O O
does O O
not O O
contain O O
lpxO S-GENE O
. O O
The O O
levels O O
of O O
soluble O O
L B-GENE O
- I-GENE O
selectin E-GENE O
and O O
ICAM B-GENE O
- I-GENE O
1 E-GENE O
in O O
the O O
serum O O
were O O
determined O O
by O O
the O O
ELISA O O
method O O
. O O
The O O
highest O O
TTX S-GENE O
content O O
is O O
10 O O
. O O
0 O O
microg O O
/ O O
g O O
in O O
N O O
. O O
livescens O O
. O O
On O O
the O O
other O O
hand O O
hypokalemia O O
, O O
induced O O
by O O
diuretics O O
, O O
may O O
also O O
be O O
accompanied O O
by O O
a O O
significant O O
depletion O O
of O O
total O O
body O O
K O O
, O O
bringing O O
about O O
more O O
general O O
consequences O O
. O O
Glutathione B-GENE B-GENE
reductase E-GENE E-GENE
activities O O
in O O
liver O O
, O O
kidney O O
, O O
lung O O
, O O
and O O
brain O O
were O O
not O O
affected O O
by O O
diet O O
. O O
Here O O
, O O
we O O
describe O O
the O O
nucleotide O O
( O O
nt O O
) O O
sequence O O
and O O
genomic O O
organization O O
of O O
ipiB S-GENE S-GENE
and O O
ipiO S-GENE O
. O O
Vancomycin O O
and O O
tetracycline O O
eliminated O O
toxin O O
in O O
stools O O
and O O
delayed O O
death O O
. O O
Soluble O O
fibrin S-GENE O
monomer O O
complexes O O
in O O
thromboembolism O O
Comparison O O
to O O
the O O
murine O O
homologues O O
of O O
these O O
molecules O O
reveals O O
a O O
high O O
degree O O
of O O
conservation O O
between O O
the O O
products O O
of O O
one O O
of O O
these O O
genes O O
, O O
Fc B-GENE B-GENE
gamma I-GENE I-GENE
RIIb E-GENE E-GENE
, O O
and O O
the O O
murine B-GENE B-GENE
beta I-GENE I-GENE
gene E-GENE E-GENE
in O O
primary O O
sequence O O
, O O
splicing O O
pattern O O
, O O
and O O
tissue O O
distribution O O
. O O
Acidosis O O
provoked O O
by O O
30 O O
% O O
CO2 O O
irreversibly O O
increased O O
the O O
BDRT O O
, O O
however O O
the O O
TRT O O
were O O
not O O
changed O O
. O O
Others O O
as O O
for O O
example O O
C O O
- O O
11 O O
labeled O O
short O O
chain O O
fatty O O
acids O O
are O O
on O O
the O O
horizon O O
. O O
The O O
average O O
progression O O
was O O
11 O O
. O O
6 O O
( O O
SD O O
9 O O
. O O
0 O O
) O O
. O O
80 O O
bp O O
) O O
surrounding O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O
Ultrastructure O O
and O O
toxin O O
formation O O
of O O
Cor O O
. O O
diphtheriae O O
PW O O
- O O
8 O O
cultured O O
in O O
the O O
presence O O
of O O
penicillin O O
EMT S-GENE S-GENE
was O O
localized O O
to O O
chromosome O O
5q31 O B-GENE
- O I-GENE
32 O E-GENE
, O O
a O O
region O O
that O O
contains O O
the O O
genes O O
for O O
several O O
growth O O
factors O O
and O O
receptors O O
as O O
well O O
as O O
early O O
activation O O
genes O O
, O O
particularly O O
those O O
involved O O
in O O
the O O
hematopoietic O O
system O O
. O O
Tbx6 S-GENE O
maps O O
to O O
chromosome O O
7 O O
and O O
does O O
not O O
appear O O
to O O
be O O
linked O O
to O O
any O O
known O O
mutation O O
. O O
Kaposi O O
' O O
s O O
eruptive O O
disease O O
. O O
It O O
is O O
not O O
tested O O
yet O O
, O O
whether O O
the O O
extent O O
of O O
glaucoma O O
damage O O
should O O
be O O
better O O
quantified O O
using O O
reference O O
plane O O
1 O O
or O O
2 O O
. O O
Importin B-GENE O
beta E-GENE O
mediates O O
nuclear O O
translocation O O
of O O
Smad B-GENE B-GENE
3 E-GENE E-GENE
. O O
The O O
encoded O O
protein O O
contains O O
an O O
amino O O
terminal O O
PDZ S-GENE B-GENE
domain O E-GENE
, O O
followed O O
by O O
a O O
predicted O O
coiled O O
- O O
coil O O
region O O
, O O
a O O
PEST O O
domain O O
, O O
and O O
a O O
carboxy O O
- O O
terminal O O
SAM O O
domain O O
. O O
Using O O
lasers O O
, O O
PRK O O
involves O O
reshaping O O
the O O
cornea O O
so O O
that O O
its O O
refractive O O
power O O
is O O
increased O O
. O O
However O O
, O O
sphincter O O
length O O
decreased O O
with O O
age O O
from O O
24 O O
. O O
3 O O
to O O
14 O O
. O O
8 O O
mm O O
. O O
, O O
maximal O O
urethral O O
pressure O O
from O O
88 O O
. O O
7 O O
to O O
55 O O
cm O O
. O O
water O O
and O O
maximal O O
urethral O O
pressure O O
during O O
voluntary O O
contraction O O
from O O
221 O O
. O O
4 O O
to O O
166 O O
. O O
3 O O
cm O O
. O O
water O O
. O O
Several O O
studies O O
have O O
demonstrated O O
that O O
the O O
corticotropin B-GENE O
- I-GENE O
releasing I-GENE O
factor E-GENE O
test O O
( O O
CRF S-GENE O
) O O
is O O
useful O O
for O O
the O O
aetiological O O
diagnosis O O
of O O
Cushing O O
' O O
s O O
syndrome O O
: O O
in O O
Cushing O O
' O O
s O O
disease O O
, O O
as O O
opposed O O
to O O
ectopic O O
ACTH S-GENE O
secretion O O
syndrome O O
, O O
the O O
hypothalamus O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
axis O O
can O O
still O O
be O O
stimulated O O
by O O
CRF S-GENE O
. O O
Transcription O O
initiation O O
from O O
this O O
region O O
was O O
also O O
detected O O
in O O
vivo O O
, O O
when O O
the O O
cloned O O
rRNA O O
gene O O
cluster O O
was O O
present O O
on O O
a O O
multi O O
- O O
copy O O
plasmid O O
. O O
The O O
results O O
of O O
the O O
transient O O
- O O
transfection O O
assay O O
showed O O
that O O
the O O
Sp1 B-GENE S-GENE
binding I-GENE O
element E-GENE O
located O O
in O O
the O O
core O O
region O O
( O O
positions O O
- O O
- O O
64 O O
to O O
+ O O
1 O O
) O O
of O O
the O O
alpha2 B-GENE B-GENE
- I-GENE I-GENE
integrin I-GENE I-GENE
promoter E-GENE E-GENE
plays O O
an O O
essential O O
role O O
in O O
the O O
alpha2 B-GENE B-GENE
- I-GENE I-GENE
integrin I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
and O O
its O O
downregulation O O
by O O
Erb S-GENE B-GENE
- O I-GENE
B2 S-GENE E-GENE
. O O
Principal O O
component O O
analysis O O
using O O
psychosocial O O
factors O O
in O O
women O O
showed O O
two O O
psychosocial O O
structures O O
, O O
i O O
. O O
e O O
. O O
the O O
second O O
principal O O
( O O
high O O
SOC O O
, O O
high O O
lifestyle O O
, O O
and O O
low O O
stress O O
) O O
and O O
the O O
4th O O
principal O O
components O O
( O O
high O O
supernatural O O
HLC O O
, O O
and O O
high O O
PHLC O O
) O O
. O O
Expression O O
of O O
FNCAT S-GENE S-GENE
increased O O
on O O
serum O O
treatment O O
indicating O O
that O O
the O O
region O O
of O O
the O O
FN B-GENE B-GENE
gene E-GENE E-GENE
between O O
positions O O
+ O O
69 O O
and O O
- O O
510 O O
bp O O
mediated O O
serum O O
responsiveness O O
. O O
Interaction O O
of O O
the O O
v B-GENE B-GENE
- I-GENE I-GENE
rel I-GENE I-GENE
protein E-GENE E-GENE
with O O
an O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
DNA I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
. O O
This O O
increase O O
is O O
not O O
the O O
result O O
of O O
alterations O O
in O O
the O O
deposition O O
of O O
inhaled O O
particles O O
of O O
capsaicin O O
brought O O
about O O
by O O
volume O O
restriction O O
. O O
Providing O O
appropriate O O
care O O
to O O
both O O
sexes O O
. O O
To O O
test O O
this O O
hypothesis O O
, O O
we O O
developed O O
a O O
system O O
of O O
transient O O
transfection O O
of O O
rat O O
adipocytes O O
with O O
constructs O O
containing O O
glyceraldehyde B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
dehydrogenase E-GENE E-GENE
( O O
GAPDH S-GENE S-GENE
) O O
and O O
fatty B-GENE B-GENE
acid I-GENE I-GENE
synthetase E-GENE E-GENE
( O O
FAS S-GENE S-GENE
) O O
promoters O O
fused O O
to O O
gene B-GENE O
reporter I-GENE O
CAT E-GENE O
. O O
In O O
the O O
green O O
unicellular O O
alga O O
Chlamydomonas O O
eugametos O O
, O O
cellular O O
division O O
is O O
readily O O
synchronized O O
by O O
light O O
/ O O
dark O O
cycles O O
. O O
SHBG S-GENE S-GENE
concentrations O O
in O O
women O O
were O O
also O O
significantly O O
higher O O
at O O
T O O
- O O
2 O O
and O O
T O O
- O O
3 O O
when O O
compared O O
to O O
T O O
- O O
1 O O
values O O
. O O
Simvastatin O O
decreased O O
levels O O
of O O
total O O
cholesterol O O
by O O
20 O O
. O O
8 O O
% O O
, O O
LDL B-GENE O
cholesterol E-GENE O
by O O
29 O O
. O O
7 O O
% O O
, O O
triglycerides O O
by O O
13 O O
. O O
6 O O
% O O
, O O
apolipoprotein B-GENE O
B E-GENE O
by O O
22 O O
. O O
4 O O
% O O
, O O
alpha O O
- O O
tocopherol O O
by O O
16 O O
. O O
2 O O
% O O
, O O
beta O O
- O O
carotene O O
by O O
19 O O
. O O
5 O O
% O O
, O O
and O O
ubiquinol O O
- O O
10 O O
by O O
22 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
for O O
all O O
) O O
and O O
increased O O
levels O O
of O O
HDL B-GENE O
cholesterol E-GENE O
by O O
7 O O
. O O
0 O O
% O O
( O O
P O O
< O O
. O O
001 O O
) O O
and O O
serum B-GENE O
insulin E-GENE O
by O O
13 O O
. O O
2 O O
% O O
( O O
P O O
= O O
. O O
005 O O
) O O
. O O
The O O
more O O
severe O O
the O O
CRF O O
, O O
the O O
more O O
likely O O
that O O
total O O
HDL S-GENE O
and O O
HDL2 B-GENE O
cholesterol E-GENE O
will O O
be O O
low O O
. O O
They O O
are O O
growth O O
- O O
inhibited O O
by O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
. O O
To O O
investigate O O
the O O
in O O
vivo O O
role O O
of O O
this O O
chimeric B-GENE O
bZIP I-GENE B-GENE
protein E-GENE E-GENE
in O O
oncogenic O O
transformation O O
, O O
its O O
expression O O
was O O
directed O O
to O O
the O O
lymphoid O O
compartments O O
of O O
transgenic O O
mice O O
. O O
This O O
is O O
consistent O O
with O O
the O O
need O O
for O O
a O O
nuclear O O
retinoid B-GENE O
receptor E-GENE O
function O O
in O O
RA O O
- O O
induced O O
ERK2 S-GENE S-GENE
activation O O
. O O
In O O
the O O
virus O O
- O O
infected O O
cells O O
, O O
translation O O
of O O
the O O
M1 B-GENE B-GENE
protein E-GENE E-GENE
was O O
reduced O O
to O O
10 O O
to O O
20 O O
% O O
of O O
that O O
of O O
the O O
wild O O
- O O
type O O
virus O O
; O O
however O O
, O O
the O O
translation O O
of O O
neither O O
the O O
nucleoprotein O O
nor O O
NS1 S-GENE S-GENE
was O O
significantly O O
interfered O O
with O O
, O O
indicating O O
the O O
important O O
role O O
of O O
NS1 S-GENE S-GENE
in O O
translational O O
stimulation O O
of O O
the O O
M1 B-GENE B-GENE
protein E-GENE E-GENE
. O O
Some O O
cells O O
were O O
excited O O
, O O
others O O
inhibited O O
by O O
, O O
and O O
only O O
some O O
were O O
directionally O O
sensitive O O
to O O
the O O
optomotor O O
stimulus O O
. O O
LT B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
transcription O O
is O O
maximal O O
in O O
the O O
thymic O O
medulla O O
and O O
in O O
splenic O O
white O O
pulp O O
. O O
A O O
novel O O
Cdc42Hs B-GENE B-GENE
mutant E-GENE E-GENE
induces O O
cellular O O
transformation O O
. O O
Interactions O O
were O O
also O O
detected O O
between O O
full O O
- O O
length O O
HSF1 S-GENE O
and O O
the O O
small O O
subunit O O
( O O
gamma O O
) O O
of O O
TFIIA S-GENE S-GENE
. O O
We O O
report O O
that O O
Nim1 S-GENE S-GENE
possesses O O
intrinsic O O
serine B-GENE B-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
, O O
threonine B-GENE B-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
and O O
tyrosine B-GENE B-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
activities O O
. O O
A O O
short O O
conserved O O
motif O O
is O O
required O O
for O O
repressor O O
domain O O
function O O
in O O
the O O
myeloid O O
- O O
specific O O
transcription O O
factor O O
CCAAT B-GENE S-GENE
/ I-GENE O
enhancer I-GENE O
- I-GENE O
binding I-GENE O
protein I-GENE O
epsilon E-GENE O
. O O
Androgen O O
ablation O O
- O O
- O O
50 O O
years O O
later O O
. O O
In O O
conclusion O O
, O O
ORCA3 S-GENE S-GENE
regulates O O
jasmonate O O
- O O
responsive O O
expression O O
of O O
the O O
Str B-GENE B-GENE
gene E-GENE E-GENE
via O O
direct O O
interaction O O
with O O
the O O
JERE O S-GENE
. O O
Also O O
, O O
the O O
absence O O
of O O
PdNi O O
between O O
the O O
segments O O
reduces O O
the O O
heat O O
production O O
of O O
the O O
seed O O
. O O
Theoretical O O
mechanisms O O
of O O
hyperuricemia O O
. O O
ORF3 O S-GENE
encodes O O
a O O
putative O O
periplasmic B-GENE O
c I-GENE O
- I-GENE O
type I-GENE O
cytochrome E-GENE O
with O O
a O O
molecular O O
mass O O
of O O
94 O O
, O O
000 O O
Da O O
and O O
contains O O
seven O O
c O O
- O O
heme O O
- O O
binding O O
motifs O O
but O O
shows O O
no O O
sequence O O
homology O O
to O O
occ S-GENE O
or O O
ORF1 O S-GENE
. O O
Doxazosin O O
produced O O
increases O O
in O O
both O O
mean O O
and O O
maximum O O
urinary O O
flow O O
rates O O
of O O
1 O O
. O O
01 O O
ml O O
/ O O
s O O
and O O
3 O O
. O O
2 O O
ml O O
/ O O
s O O
respectively O O
, O O
compared O O
with O O
0 O O
. O O
21 O O
ml O O
/ O O
s O O
and O O
2 O O
. O O
2 O O
ml O O
/ O O
s O O
on O O
placebo O O
. O O
Hypoxia O O
decreased O O
the O O
rate O O
of O O
spontaneous O O
impulse O O
initiation O O
in O O
SA O O
nodal O O
fibers O O
by O O
decreasing O O
the O O
slope O O
of O O
diastolic O O
depolarization O O
. O O
BACKGROUND O O
- O O
- O O
Platelet B-GENE B-GENE
activating I-GENE I-GENE
factor E-GENE E-GENE
( O O
PAF S-GENE S-GENE
) O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
airway O O
hyperresponsiveness O O
in O O
asthma O O
. O O
TFEC B-GENE B-GENE
RNA E-GENE E-GENE
is O O
found O O
in O O
many O O
tissues O O
of O O
adult O O
rats O O
, O O
but O O
the O O
relative O O
concentrations O O
of O O
TFEC S-GENE S-GENE
and O O
TFE3 B-GENE B-GENE
RNAs E-GENE E-GENE
vary O O
considerably O O
in O O
these O O
different O O
tissues O O
. O O
Our O O
results O O
show O O
that O O
unlike O O
the O O
case O O
for O O
sos1 S-GENE S-GENE
, O O
sos2 B-GENE B-GENE
gene E-GENE E-GENE
function O O
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
, O O
growth O O
, O O
and O O
fertility O O
. O O
Studies O O
of O O
HS2 B-GENE B-GENE
- I-GENE I-GENE
gamma I-GENE I-GENE
gene I-GENE E-GENE
reporter I-GENE O
constructs E-GENE O
carrying O O
CACCC O S-GENE
box O O
deletions O O
revealed O O
that O O
the O O
CACCC O S-GENE
box O O
sequence O O
of O O
the O O
gamma O B-GENE
gene O I-GENE
promoter O E-GENE
mediates O O
the O O
activation O O
of O O
the O O
gamma O B-GENE
gene O E-GENE
by O O
FKLF S-GENE S-GENE
. O O
Advisory O O
Committee O O
report O O
recommends O O
that O O
US O O
make O O
amends O O
for O O
human O O
radiation O O
experiments O O
. O O
Animals O O
were O O
divided O O
into O O
six O O
equal O O
groups O O
as O O
follows O O
: O O
( O O
1 O O
) O O
no O O
oral O O
drug O O
( O O
water O O
) O O
, O O
no O O
hemodilution O O
, O O
no O O
IV O O
drug O O
( O O
saline O O
) O O
; O O
( O O
2 O O
) O O
oral O O
water O O
, O O
hemodilution O O
, O O
IV O O
saline O O
; O O
( O O
3 O O
) O O
oral O O
water O O
, O O
no O O
hemodilution O O
, O O
IV O O
propranolol O O
; O O
( O O
4 O O
) O O
oral O O
water O O
, O O
hemodilution O O
, O O
IV O O
propranolol O O
; O O
( O O
5 O O
) O O
oral O O
propranolol O O
, O O
no O O
hemodilution O O
, O O
IV O O
saline O O
; O O
and O O
( O O
6 O O
) O O
oral O O
propranolol O O
, O O
hemodilution O O
, O O
IV O O
saline O O
. O O
First O O
, O O
a O O
GATA B-GENE O
- I-GENE O
1 I-GENE O
motif E-GENE O
was O O
found O O
to O O
bind O O
nuclear O O
factor O O
( O O
s O O
) O O
, O O
presumably O O
the O O
GATA B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
factor E-GENE E-GENE
, O O
present O O
in O O
K O O
- O O
562 O O
cell O O
extracts O O
and O O
in O O
living O O
K O O
- O O
562 O O
cells O O
. O O
BPN O O
can O O
be O O
experimentally O O
produced O O
by O O
intratracheal O O
inoculation O O
of O O
microorganisms O O
in O O
high O O
concentrations O O
and O O
ventilator O O
- O O
associated O O
BPN O O
by O O
ventilating O O
baboons O O
with O O
oleic O O
- O O
acid O O
lung O O
injury O O
. O O
A O O
mouth O O
asymmetry O O
study O O
. O O
Additionally O O
, O O
these O O
findings O O
have O O
important O O
implications O O
for O O
the O O
understanding O O
of O O
the O O
mechanisms O O
of O O
HIV O O
- O O
1 O O
latency O O
and O O
reactivation O O
. O O
This O O
inhibition O O
was O O
due O O
to O O
competition O O
from O O
the O O
EMC O B-GENE
virus O I-GENE
IRES O E-GENE
present O O
in O O
pEP B-GENE O
- I-GENE O
2A I-GENE O
transcripts E-GENE O
, O O
as O O
well O O
as O O
the O O
expression O O
of O O
proteolytically O O
active O O
2Apro S-GENE S-GENE
. O O
Some O O
may O O
affect O O
the O O
folding O O
pathway O O
or O O
the O O
affinity O O
for O O
chaperonins S-GENE O
. O O
Diet O O
imbalances O O
and O O
aflatoxicosis O O
48 O O
. O O
35 O O
+ O O
/ O O
- O O
5 O O
. O O
07 O O
mg O O
/ O O
l O O
in O O
R3 O O
; O O
p O O
< O O
0 O O
. O O
05 O O
) O O
and O O
in O O
the O O
AUC O O
( O O
0 O O
. O O
50 O O
h O O
) O O
( O O
1429 O O
. O O
92 O O
+ O O
/ O O
- O O
284 O O
. O O
23 O O
in O O
PR O O
vs O O
. O O
The O O
effect O O
on O O
FIV B-GENE B-GENE
LTR I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
of O O
progressively O O
deleting O O
these O O
nuclear O O
factor O O
binding O O
sites O O
was O O
examined O O
by O O
linking O O
LTR O O
deletion O O
mutants O O
to O O
the O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
gene O O
. O O
A O O
series O O
of O O
sequence O O
fragments O O
were O O
placed O O
5 O O
' O O
to O O
the O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
reporter O O
gene O O
and O O
ability O O
to O O
mediate O O
transcription O O
of O O
CAT S-GENE S-GENE
in O O
response O O
to O O
IFN B-GENE B-GENE
gamma E-GENE E-GENE
or O O
LPS O O
treatment O O
was O O
studied O O
following O O
transient O O
transfection O O
in O O
the O O
macrophage O O
- O O
like O O
cell O O
line O O
RAW O O
264 O O
. O O
7 O O
. O O
As O O
part O O
of O O
a O O
large O O
Dutch O O
prospective O O
multicenter O O
study O O
( O O
Netherlands O O
Cooperative O O
Study O O
on O O
the O O
Adequacy O O
of O O
Dialysis O O
- O O
2 O O
) O O
, O O
we O O
consecutively O O
included O O
all O O
new O O
patients O O
with O O
end O O
- O O
stage O O
renal O O
disease O O
for O O
whom O O
residual O O
renal O O
function O O
could O O
be O O
obtained O O
0 O O
to O O
4 O O
weeks O O
before O O
the O O
start O O
of O O
dialysis O O
therapy O O
. O O
Module O O
2 O O
of O O
RifA S-GENE S-GENE
lacks O O
a O O
beta B-GENE O
- I-GENE O
ketoacyl I-GENE O
: I-GENE O
acyl I-GENE B-GENE
carrier I-GENE I-GENE
protein I-GENE I-GENE
reductase E-GENE E-GENE
( O O
KR S-GENE S-GENE
) O O
domain O O
and O O
the O O
one O O
in O O
module O O
3 O O
has O O
an O O
apparently O O
inactive O O
NADPH B-GENE O
binding I-GENE O
motif E-GENE O
, O O
similar O O
to O O
one O O
found O O
in O O
the O O
Er B-GENE B-GENE
PKS E-GENE E-GENE
, O O
while O O
the O O
other O O
eight O O
KR B-GENE O
domains E-GENE O
of O O
the O O
Rf B-GENE B-GENE
PKS E-GENE E-GENE
should O O
be O O
functional O O
. O O
In O O
murine O O
cells O O
, O O
FPGS S-GENE S-GENE
expression O O
is O O
controlled O O
by O O
two O O
promoters O O
that O O
, O O
as O O
we O O
show O O
here O O
, O O
vary O O
substantially O O
in O O
their O O
efficiency O O
, O O
at O O
least O O
in O O
the O O
context O O
of O O
a O O
reporter O O
gene O O
assay O O
. O O
Should O O
we O O
use O O
thiazide O O
diuretics O O
in O O
hypertensive O O
patients O O
with O O
non O O
- O O
insulin S-GENE O
- O O
dependent O O
diabetes O O
mellitus O O
? O O
Reduced O O
glutathione O O
in O O
whole O O
blood O O
decreases O O
within O O
a O O
blood O O
Se O O
range O O
of O O
1 O O
. O O
01 O O
to O O
2 O O
. O O
28 O O
micrograms O O
in O O
the O O
high O O
Se O O
area O O
. O O
Sucrose O O
produced O O
in O O
source O O
leaves O O
is O O
the O O
predominant O O
carbon O O
source O O
for O O
developing O O
sink O O
tissues O O
in O O
most O O
higher O O
plants O O
. O O
A O O
personal O O
view O O
of O O
future O O
trends O O
in O O
the O O
field O O
of O O
immunoassay O O
concludes O O
this O O
review O O
. O O
In O O
accordance O O
with O O
Ann O O
Arbor O O
classification O O
, O O
we O O
observed O O
12 O O
CS O O
IA O O
( O O
21 O O
. O O
3 O O
% O O
) O O
, O O
2 O O
CS O O
IB O O
( O O
3 O O
. O O
5 O O
% O O
) O O
, O O
14 O O
CS O O
IIA O O
( O O
25 O O
. O O
4 O O
% O O
) O O
and O O
27 O O
CS O O
IIB O O
( O O
49 O O
. O O
7 O O
% O O
) O O
. O O
Numerous O O
genes O O
of O O
this O O
family O O
have O O
been O O
identified O O
in O O
animals O O
, O O
with O O
the O O
largest O O
number O O
found O O
in O O
vertebrates O O
. O O
The O O
GST S-GENE B-GENE
- O I-GENE
CBL S-GENE I-GENE
- O I-GENE
LZIP S-GENE I-GENE
fusion O I-GENE
protein O E-GENE
contains O O
a O O
binding O O
site O O
for O O
the O O
SH2 B-GENE B-GENE
domain E-GENE E-GENE
of O O
the O O
p85 B-GENE B-GENE
subunit E-GENE E-GENE
of O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
, O O
which O O
mapped O O
to O O
Tyr731 O S-GENE
, O O
which O O
is O O
present O O
in O O
the O O
sequence O O
YEAM O S-GENE
. O O
We O O
have O O
previously O O
shown O O
that O O
UNC B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
expression O O
in O O
the O O
VA O O
motor O O
neurons O O
specifies O O
the O O
wild O O
- O O
type O O
pattern O O
of O O
presynaptic O O
input O O
. O O
Significant O O
differences O O
were O O
observed O O
in O O
the O O
composition O O
of O O
nuclear O O
transcription O O
factors O O
bound O O
to O O
cis O O
- O O
elements O O
within O O
the O O
LDH B-GENE S-GENE
/ I-GENE O
C I-GENE O
proximal I-GENE O
promoter I-GENE O
region E-GENE O
in O O
somatic O O
versus O O
germ O O
cells O O
. O O
Above O O
this O O
transition O O
temperature O O
the O O
calcium O O
antagonist O O
lowers O O
fm O O
more O O
pronouncedly O O
than O O
below O O
. O O
( O O
1986 O O
) O O
described O O
optic O O
nerve O O
degenerations O O
in O O
patients O O
with O O
Alzheimer O O
' O O
s O O
disease O O
and O O
Sadun O O
published O O
a O O
dropout O O
of O O
retinal O O
ganglion O O
cells O O
that O O
range O O
from O O
30 O O
% O O
to O O
60 O O
% O O
. O O
It O O
has O O
become O O
clear O O
that O O
there O O
is O O
not O O
one O O
mediator O O
responsible O O
for O O
ALI O O
, O O
but O O
rather O O
a O O
complex O O
interplay O O
exists O O
between O O
diverse O O
proinflammatory O O
( O O
e O O
. O O
g O O
. O O
, O O
lipopolysaccharide O O
, O O
complement O O
products O O
, O O
cytocains O O
, O O
chemocains O O
, O O
reactive O O
oxygen O O
species O O
and O O
arachidonic O O
acid O O
products O O
) O O
and O O
anti O O
- O O
inflammatory O O
( O O
IL B-GENE O
- I-GENE O
10 E-GENE O
, O O
IL B-GENE O
- I-GENE O
1 I-GENE O
- I-GENE O
RA E-GENE O
, O O
PGI2 O O
) O O
mediators O O
. O O
We O O
then O O
supplemented O O
these O O
spliceosomes O O
with O O
purified O O
proteins O O
or O O
yeast O O
extract O O
fractions O O
as O O
a O O
functional O O
assay O O
for O O
second O O
- O O
step O O
splicing O O
factors O O
. O O
Contrast O O
radiography O O
appears O O
to O O
be O O
an O O
especially O O
inaccurate O O
method O O
to O O
document O O
PUD O O
in O O
CF O O
because O O
the O O
duodenal O O
mucosa O O
typically O O
appears O O
nodular O O
and O O
distorted O O
with O O
poor O O
definition O O
of O O
the O O
mucosal O O
folds O O
. O O
We O O
now O O
show O O
that O O
the O O
FRAP S-GENE B-GENE
Ser2035 O I-GENE
- O I-GENE
- O I-GENE
> O I-GENE
Ala O I-GENE
mutant O E-GENE
displays O O
similar O O
binding O O
affinity O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
protein O O
, O O
whereas O O
all O O
other O O
mutations O O
at O O
this O O
site O O
, O O
including O O
mimics O O
of O O
phosphoserine O O
, O O
abolish O O
binding O O
, O O
presumably O O
due O O
to O O
either O O
unfavorable O O
steric O O
interactions O O
or O O
induced O O
conformational O O
changes O O
. O O
A O O
Brassica O O
cDNA O O
clone O O
encoding O O
a O O
bifunctional O B-GENE
hydroxymethylpyrimidine B-GENE I-GENE
kinase E-GENE E-GENE
/ O O
thiamin B-GENE O
- I-GENE O
phosphate I-GENE O
pyrophosphorylase E-GENE O
involved O O
in O O
thiamin O O
biosynthesis O O
. O O
Titres O O
of O O
antistreptolysin B-GENE O
O E-GENE O
in O O
mothers O O
of O O
children O O
affected O O
with O O
Down O O
' O O
s O O
syndrome O O
. O O
Differential O O
decay O O
of O O
a O O
polycistronic O O
Escherichia O O
coli O O
transcript O O
is O O
initiated O O
by O O
RNaseE S-GENE O
- O O
dependent O O
endonucleolytic O O
processing O O
. O O
Defects O O
in O O
RT6 S-GENE S-GENE
expression O O
coincide O O
with O O
increased O O
susceptibility O O
in O O
animal O O
models O O
for O O
insulin S-GENE O
- O O
dependent O O
diabetes O O
mellitus O O
and O O
other O O
autoimmune O O
diseases O O
. O O
By O O
means O O
of O O
early O O
detection O O
and O O
correction O O
of O O
the O O
possible O O
causes O O
, O O
the O O
goal O O
of O O
increasing O O
therapeutic O O
efficacy O O
can O O
be O O
achieved O O
. O O
We O O
have O O
previously O O
described O O
the O O
partial O O
purification O O
of O O
Ap4A B-GENE B-GENE
hydrolase E-GENE E-GENE
from O O
S O O
. O O
pombe O O
[ O O
Robinson O O
, O O
de O O
la O O
Pena O O
and O O
Barnes O O
( O O
1993 O O
) O O
Biochim O O
. O O
Effect O O
of O O
a O O
new O O
positive O O
inotropic O O
agent O O
( O O
OPC O B-GENE
- O I-GENE
8212 O E-GENE
) O O
on O O
intracellular O O
potential O O
of O O
isolated O O
canine O O
ventricular O O
papillary O O
muscle O O
The O O
unc B-GENE O
- I-GENE O
101 E-GENE O
, O O
sli B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
rok B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
genes E-GENE E-GENE
encode O O
a O O
distinct O O
set O O
of O O
negative O O
regulators O O
of O O
vulval O O
differentiation O O
. O O
Thirty O O
- O O
seven O O
patients O O
with O O
severe O O
temporal O O
lobe O O
epilepsy O O
were O O
studied O O
interictally O O
with O O
[ O O
18F O O
] O O
fluorodeoxyglucose O O
- O O
PET O O
in O O
each O O
of O O
three O O
conditions O O
: O O
resting O O
, O O
during O O
emotional O O
speech O O
, O O
and O O
while O O
performing O O
a O O
visual O O
recognition O O
task O O
. O O
SYC1 S-GENE S-GENE
( O O
suppressor B-GENE O
of I-GENE O
yeast I-GENE B-GENE
cbf5 I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
was O O
identified O O
as O O
a O O
multicopy O O
suppressor O O
of O O
cbf5 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
subsequently O O
was O O
found O O
to O O
be O O
identical O O
to O O
RRN3 S-GENE S-GENE
, O O
an O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
I I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
. O O
Newly O O
hatched O O
F1 O O
nymphs O O
of O O
Aiolopus O O
thalassinus O O
( O O
Fabr O O
. O O
) O O
were O O
fed O O
on O O
food O O
treated O O
with O O
various O O
concentrations O O
of O O
HgCl2 O O
, O O
CdCl2 O O
, O O
and O O
PbCl2 O O
until O O
the O O
end O O
of O O
adult O O
life O O
. O O
Neuronal O O
activity O O
of O O
58 O O
dopaminergic O O
( O O
DA O O
) O O
and O O
200 O O
non O O
- O O
dopaminergic O O
( O O
non O O
- O O
DA O O
) O O
neurons O O
in O O
the O O
ventral O O
tegmental O O
area O O
( O O
VTA O O
) O O
of O O
female O O
monkeys O O
was O O
recorded O O
, O O
and O O
correlation O O
to O O
bar O O
press O O
feeding O O
, O O
sensory O O
stimulation O O
and O O
change O O
in O O
motivation O O
was O O
investigated O O
. O O
Both O O
sequence O O
analysis O O
and O O
restriction O O
fragment O O
length O O
polymorphism O O
analysis O O
revealed O O
a O O
high O O
degree O O
of O O
sequence O O
( O O
97 O O
% O O
homology O O
) O O
and O O
structural O O
similarity O O
among O O
members O O
of O O
the O O
ART S-GENE O
- O O
CH S-GENE O
family O O
, O O
indicating O O
their O O
common O O
origin O O
and O O
recent O O
penetration O O
into O O
chicken O O
DNA O O
. O O
Three O O
of O O
these O O
positions O O
are O O
novel O O
in O O
that O O
they O O
had O O
not O O
been O O
identified O O
to O O
be O O
important O O
for O O
binding O O
PC O O
by O O
previous O O
crystallographic O O
analysis O O
. O O
We O O
demonstrate O O
inhibition O O
of O O
2 O O
- O O
deoxyglucose O O
uptake O O
in O O
isolated O O
primary O O
rat O O
adipocytes O O
and O O
3T3 O O
- O O
L1 O O
adipocytes O O
pretreated O O
with O O
U73122 O O
. O O
The O O
elevated O O
levels O O
of O O
inositol O O
phosphates O O
resulting O O
from O O
N B-GENE O
( I-GENE O
epi I-GENE O
) I-GENE O
alpha I-GENE O
qQ209L E-GENE O
expression O O
were O O
similar O O
to O O
those O O
obtained O O
with O O
carbachol O O
activation O O
of O O
the O O
M1 B-GENE B-GENE
muscarinic I-GENE I-GENE
acetylcholine I-GENE I-GENE
receptor E-GENE E-GENE
. O O
In O O
addition O O
, O O
wild O O
- O O
type O O
and O O
mutated O O
DNA O O
templates O O
were O O
used O O
as O O
probes O O
in O O
DNase B-GENE O
I E-GENE O
protection O O
experiments O O
to O O
determine O O
sites O O
of O O
protein O O
- O O
DNA O O
interaction O O
. O O
We O O
tested O O
the O O
hypothesis O O
that O O
PEH O O
is O O
associated O O
with O O
reductions O O
in O O
TPR O O
and O O
sympathetic O O
nerve O O
activity O O
( O O
SNA O O
) O O
. O O
Salt O O
wars O O
. O O
RESULTS O O
: O O
BMK B-GENE O
- I-GENE O
1 E-GENE O
and O O
other O O
19 O O
contents O O
significantly O O
decreased O O
depolarization O O
parameters O O
Vmax O O
, O O
APA O O
, O O
OS O O
, O O
and O O
MDP O O
, O O
which O O
was O O
similar O O
to O O
that O O
of O O
TTX S-GENE O
and O O
different O O
from O O
that O O
of O O
Nim O O
and O O
BaCl2 O O
. O O
In O O
the O O
latter O O
, O O
the O O
cells O O
and O O
adjacent O O
matrix O O
had O O
several O O
characteristics O O
of O O
fibrocartilage O O
, O O
including O O
chondrocytes O O
. O O
Mannich O O
bases O O
of O O
vanillin O O
oxime O O
. O O
All O O
exon O O
/ O O
intron O O
splice O O
junctions O O
follow O O
the O O
GT O O
/ O O
AG O O
rule O O
. O O
Previous O O
work O O
has O O
shown O O
that O O
glucose O O
repression O O
of O O
PRB1 S-GENE S-GENE
transcription O O
is O O
not O O
mediated O O
by O O
HXK2 S-GENE S-GENE
or O O
by O O
the O O
SNF1 S-GENE S-GENE
, O O
SNF4 S-GENE S-GENE
, O O
and O O
SNF6 B-GENE B-GENE
genes E-GENE E-GENE
( O O
C O O
. O O
Comparison O O
of O O
the O O
encoded O O
ERCC3Dm B-GENE B-GENE
protein E-GENE E-GENE
with O O
the O O
homologous O O
proteins O O
of O O
mouse O O
and O O
man O O
shows O O
a O O
strong O O
amino O O
acid O O
conservation O O
( O O
71 O O
% O O
identity O O
) O O
, O O
especially O O
in O O
the O O
postulated O O
DNA O O
binding O O
region O O
and O O
seven O O
' B-GENE O
helicase I-GENE O
' I-GENE O
domains E-GENE O
. O O
The O O
pyridostigmine O O
inhibited O O
AChE S-GENE O
recovered O O
only O O
in O O
the O O
100 O O
mumol O O
kg O O
- O O
1 O O
kg O O
oxime O O
groups O O
at O O
the O O
end O O
of O O
the O O
experiment O O
. O O
In O O
the O O
case O O
of O O
a O O
moderate O O
buccal O O
Class O O
II O O
tendency O O
, O O
55 O O
% O O
of O O
the O O
molars O O
were O O
in O O
a O O
Class O O
I O O
relationship O O
when O O
evaluated O O
from O O
the O O
lingual O O
side O O
, O O
whereas O O
45 O O
% O O
belonged O O
to O O
mild O O
( O O
1st O O
degrees O O
) O O
Class O O
II O O
with O O
molar O O
rotations O O
present O O
in O O
81 O O
% O O
of O O
the O O
cases O O
. O O
Mutation O O
of O O
this O O
threonine O O
to O O
isoleucine O O
had O O
no O O
observable O O
effect O O
on O O
either O O
nuclear O O
localization O O
of O O
E1 S-GENE S-GENE
or O O
DNA O O
replication O O
of O O
the O O
intact O O
viral O O
genome O O
. O O
Serum B-GENE B-GENE
prolactin E-GENE E-GENE
and O O
oestradiol O O
levels O O
at O O
different O O
stages O O
of O O
puberty O O
. O O
This O O
suggests O O
that O O
the O O
duration O O
of O O
varicocele O O
per O O
se O O
could O O
affect O O
DHT O O
seminal O O
plasma O O
levels O O
. O O
Left O O
ventricular O O
responses O O
to O O
dopamine O O
in O O
dilated O O
cardiomyopathy O O
as O O
assessed O O
by O O
two O O
- O O
dimensional O O
echocardiography O O
and O O
compared O O
with O O
findings O O
of O O
thallium O O
- O O
201 O O
scintigraphy O O
. O O
Detailed O O
comparison O O
of O O
the O O
urinary O O
excretion O O
of O O
purines O O
in O O
a O O
patient O O
with O O
the O O
Lesch O O
- O O
Nyhan O O
syndrome O O
and O O
a O O
control O O
subject O O
. O O
This O O
enzyme O O
is O O
distinct O O
from O O
other O O
known O O
E3s S-GENE S-GENE
, O O
including O O
E3 B-GENE B-GENE
alpha E-GENE E-GENE
/ O O
UBR1 S-GENE S-GENE
, O O
E3 B-GENE B-GENE
beta E-GENE E-GENE
, O O
and O O
E6 B-GENE B-GENE
- I-GENE I-GENE
AP E-GENE E-GENE
. O O
This O O
evidence O O
, O O
together O O
with O O
the O O
ability O O
of O O
a O O
carboxyl O O
- O O
terminal O O
coding O O
sequence O O
starting O O
from O O
the O O
BamHI B-GENE B-GENE
site E-GENE E-GENE
to O O
complement O O
a O O
shy1 B-GENE B-GENE
mutant E-GENE E-GENE
, O O
suggests O O
that O O
the O O
Shy1p S-GENE S-GENE
contains O O
two O O
domains O O
that O O
can O O
be O O
separately O O
expressed O O
to O O
form O O
a O O
functional O O
protein O O
. O O
The O O
zinc B-GENE O
finger I-GENE O
protein I-GENE O
A20 E-GENE S-GENE
is O O
a O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor E-GENE E-GENE
( O O
TNF S-GENE S-GENE
) O O
- O O
and O O
interleukin B-GENE B-GENE
1 E-GENE E-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
- O O
inducible O O
protein O O
that O O
negatively O O
regulates O O
nuclear B-GENE O
factor I-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
( O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
) O O
- O O
dependent O O
gene O O
expression O O
. O O
A O O
visibly O O
distinct O O
muscular O O
hypertrophy O O
( O O
mh O O
) O O
, O O
commonly O O
known O O
as O O
double O O
muscling O O
, O O
occurs O O
with O O
high O O
frequency O O
in O O
the O O
Belgian O O
Blue O O
and O O
Piedmontese O O
cattle O O
breeds O O
. O O
For O O
the O O
population O O
of O O
patients O O
with O O
melanoma O O
levels O O
III O O
and O O
IV O O
significant O O
differences O O
in O O
survival O O
rate O O
were O O
associated O O
with O O
thickness O O
( O O
less O O
than O O
2 O O
mm O O
or O O
greater O O
than O O
or O O
equal O O
to O O
2 O O
mm O O
; O O
p O O
less O O
than O O
0 O O
, O O
001 O O
) O O
, O O
though O O
not O O
with O O
level O O
. O O
At O O
least O O
one O O
such O O
complex O O
is O O
eliminated O O
by O O
preincubating O O
the O O
nuclear O O
extract O O
with O O
an O O
antibody O O
with O O
broad O O
cross O O
- O O
reactivity O O
with O O
Ets B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
Ets B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
proteins E-GENE E-GENE
, O O
thus O O
confirming O O
that O O
an O O
ETS B-GENE B-GENE
transcription I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
s I-GENE O
) E-GENE O
recognizes O O
the O O
- O O
12 O O
motif O O
. O O
Mutant O B-GENE
beta2 B-GENE I-GENE
- I-GENE I-GENE
adrenergic I-GENE I-GENE
receptors E-GENE E-GENE
with O O
a O O
Tyr O O
- O O
to O O
- O O
Phe O O
substitution O O
at O O
Tyr O O
- O O
350 O O
do O O
not O O
display O O
agonist O O
- O O
induced O O
desensitization O O
, O O
Src S-GENE S-GENE
recruitment O O
, O O
or O O
Src S-GENE S-GENE
activation O O
. O O
Role O O
of O O
distinct O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
pathways O O
and O O
cooperation O O
between O O
Ets B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
ATF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
and O O
Jun B-GENE B-GENE
family I-GENE E-GENE
members E-GENE O
in O O
human B-GENE B-GENE
urokinase I-GENE I-GENE
- I-GENE I-GENE
type I-GENE I-GENE
plasminogen I-GENE I-GENE
activator I-GENE I-GENE
gene E-GENE E-GENE
induction O O
by O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O
Immunoblot O O
analysis O O
of O O
purified O O
and O O
protease O O
- O O
digested O O
intracellular O O
mature O O
virus O O
( O O
IMV O S-GENE
) O O
and O O
extracellular O O
enveloped O O
virus O O
( O O
EEV O O
) O O
showed O O
that O O
the O O
A36R B-GENE B-GENE
proteins E-GENE E-GENE
were O O
present O O
on O O
the O O
surface O O
of O O
EEV O O
with O O
type O O
II O O
membrane O O
topology O O
, O O
but O O
were O O
absent O O
from O O
IMV O O
. O O
Here O O
we O O
demonstrate O O
that O O
several O O
genes O O
associated O O
with O O
NHEJ O S-GENE
perform O O
essential O O
functions O O
in O O
the O O
repair O O
of O O
endonuclease O O
- O O
induced O O
DSBs O O
in O O
vivo O O
. O O
The O O
failure O O
suggests O O
that O O
these O O
assembly O O
competent O O
but O O
complementation O O
- O O
negative O O
alpha O O
mutants O O
lack O O
an O O
as O O
yet O O
unidentified O O
function O O
( O O
s O O
) O O
. O O
Psychopathological O O
, O O
vegetative O O
, O O
and O O
vital O O
parameters O O
were O O
assessed O O
every O O
hour O O
. O O
RESULTS O O
: O O
Considering O O
an O O
inulin O O
clearance O O
of O O
less O O
than O O
80 O O
ml O O
/ O O
min O O
/ O O
1 O O
. O O
73 O O
m2 O O
, O O
the O O
cut O O
- O O
off O O
value O O
for O O
serum O O
creatinine O O
was O O
11 O O
. O O
5 O O
mumol O O
/ O O
liter O O
for O O
men O O
and O O
90 O O
mumol O O
/ O O
liter O O
for O O
women O O
. O O
These O O
data O O
may O O
indicate O O
redundancy O O
between O O
members O O
of O O
the O O
NGFI B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
/ O O
Nurr1 S-GENE S-GENE
/ O O
Nor1 S-GENE B-GENE
subfamily O E-GENE
and O O
could O O
explain O O
why O O
no O O
phenotypic O O
disturbances O O
have O O
yet O O
been O O
found O O
in O O
mice O O
in O O
which O O
the O O
NGFI B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
gene E-GENE E-GENE
has O O
been O O
inactivated O O
. O O
Manual O O
sample O O
clean O O
- O O
up O O
procedures O O
as O O
well O O
as O O
the O O
addition O O
of O O
an O O
internal O O
standard O O
are O O
not O O
needed O O
. O O
To O O
directly O O
address O O
this O O
issue O O
, O O
we O O
used O O
a O O
tetracycline O O
- O O
regulated O O
system O O
in O O
human O O
U2OS O O
osteosarcoma O O
cells O O
and O O
thus O O
found O O
that O O
BCL6 S-GENE S-GENE
mediates O O
growth O O
suppression O O
associated O O
with O O
impaired O O
S O O
phase O O
progression O O
and O O
apoptosis O O
. O O
TAAG O B-GENE
sites O E-GENE
that O O
serve O O
as O O
functional O O
late O O
promoters O O
in O O
OpMNPV O S-GENE
were O O
found O O
to O O
mediate O O
transcription O O
initiation O O
at O O
only O O
basal O O
levels O O
in O O
the O O
context O O
of O O
the O O
AcMNPV O B-GENE
genome O E-GENE
, O O
suggesting O O
that O O
late O O
promoter O O
activation O O
may O O
be O O
virus O O
specific O O
within O O
the O O
family O O
Baculoviridae O O
. O O
Stability O O
of O O
125 O O
I O O
- O O
labeled O O
insulin S-GENE O
used O O
in O O
radioimmunoassay O O
of O O
insulin S-GENE S-GENE
. O O
In O O
absence O O
of O O
i O O
. O O
m O O
. O O
medication O O
, O O
levels O O
over O O
1 O O
, O O
000 O O
U O O
must O O
be O O
carefully O O
screened O O
in O O
order O O
to O O
rule O O
out O O
SNM O O
or O O
organic O O
pathology O O
associated O O
. O O
Paclitaxel O O
caused O O
a O O
rapid O O
and O O
transient O O
increase O O
in O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
NH2 I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
( O O
JNK S-GENE S-GENE
) O O
activity O O
, O O
a O O
proposed O O
mediator O O
of O O
stress O O
activation O O
pathways O O
. O O
These O O
results O O
indicate O O
that O O
H B-GENE B-GENE
- I-GENE I-GENE
2RIIBP E-GENE E-GENE
( O O
i O O
) O O
is O O
a O O
member O O
of O O
the O O
superfamily O O
of O O
nuclear B-GENE O
hormone I-GENE O
receptors E-GENE O
and O O
( O O
ii O O
) O O
may O O
regulate O O
not O O
only O O
MHC B-GENE B-GENE
class I-GENE I-GENE
I I-GENE I-GENE
genes E-GENE E-GENE
but O O
also O O
genes O O
containing O O
the O O
ERE O S-GENE
and O O
related O O
sequences O O
. O O
Two O O
courses O O
of O O
chemotherapy O O
( O O
CBCDA O O
+ O O
VDS O O
) O O
failed O O
to O O
gain O O
any O O
improvement O O
, O O
and O O
the O O
pain O O
resulting O O
from O O
recurrent O O
bone O O
metastases O O
was O O
managed O O
mainly O O
by O O
the O O
administration O O
of O O
the O O
best O O
supportive O O
care O O
. O O
We O O
show O O
here O O
that O O
Spb1p S-GENE S-GENE
is O O
able O O
to O O
bind O O
[ O O
( O O
3 O O
) O O
H O O
] O O
AdoMet O O
in O O
vitro O O
, O O
suggesting O O
that O O
it O O
is O O
a O O
novel O O
methylase O O
, O O
whose O O
possible O O
substrates O O
will O O
be O O
discussed O O
. O O
RESULTS O O
: O O
Lateral O O
PF O O
OA O O
was O O
more O O
common O O
than O O
medial O O
PF O O
OA O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
. O O
CONCLUSION O O
: O O
Urbanisation O O
is O O
associated O O
with O O
an O O
increase O O
in O O
the O O
prevalence O O
rates O O
of O O
some O O
risk O O
behaviours O O
. O O
However O O
, O O
additional O O
studies O O
on O O
cell O O
lines O O
and O O
whole O O
animals O O
are O O
required O O
to O O
understand O O
GnRH S-GENE S-GENE
signaling O O
in O O
the O O
context O O
of O O
other O O
hormones O O
during O O
the O O
reproductive O O
cycle O O
of O O
mouse O O
and O O
human O O
. O O
Serum B-GENE O
angiogenin E-GENE O
concentrations O O
in O O
young O O
patients O O
with O O
diabetes O O
mellitus O O
. O O
This O O
duplicated O O
genomic O O
region O O
is O O
also O O
linked O O
tightly O O
to O O
D1Z2 S-GENE S-GENE
, O O
a O O
genetic O O
marker O O
containing O O
a O O
highly O O
polymorphic O O
VNTR O O
( O O
variable O O
number O O
tandem O O
repeat O O
) O O
consisting O O
of O O
an O O
unusual O O
40 O O
- O O
bp O O
reiterated O O
sequence O O
. O O
ATF6 S-GENE S-GENE
, O O
a O O
basic B-GENE O
- I-GENE O
leucine I-GENE O
zipper I-GENE O
protein E-GENE O
, O O
was O O
isolated O O
by O O
binding O O
to O O
SRF S-GENE S-GENE
and O O
in O O
particular O O
to O O
its O O
transcriptional O O
activation O O
domain O O
. O O
Cetn1 S-GENE S-GENE
possesses O O
the O O
sequence O O
features O O
of O O
an O O
expressed O O
retroposon O O
: O O
the O O
gene O O
lacks O O
introns O O
, O O
the O O
open O O
reading O O
frame O O
is O O
not O O
interrupted O O
by O O
stop O O
codons O O
, O O
and O O
the O O
coding O O
region O O
is O O
flanked O O
by O O
a O O
pair O O
of O O
direct O O
repeats O O
. O O
The O O
largest O O
one O O
probably O O
corresponds O O
to O O
the O O
precursor O O
form O O
of O O
PS2 S-GENE O
in O O
E O O
. O O
coli O O
. O O
The O O
Aspergillus B-GENE B-GENE
uvsH I-GENE I-GENE
gene E-GENE E-GENE
encodes O O
a O O
product O O
homologous O O
to O O
yeast B-GENE O
RAD18 E-GENE S-GENE
and O O
Neurospora B-GENE O
UVS I-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
. O O
On O O
average O O
these O O
maximum O O
potency O O
estimates O O
were O O
within O O
one O O
order O O
of O O
magnitude O O
of O O
the O O
inverse O O
maximum O O
dose O O
tested O O
. O O
VAV S-GENE S-GENE
and O O
SOCS1 S-GENE S-GENE
form O O
a O O
protein O O
complex O O
through O O
interactions O O
between O O
the O O
VAV B-GENE B-GENE
NH I-GENE E-GENE
( I-GENE O
2 I-GENE O
) I-GENE O
- I-GENE O
terminal I-GENE O
regulatory I-GENE O
region E-GENE O
and O O
the O O
SH2 B-GENE B-GENE
domain E-GENE E-GENE
of O O
SOCS1 S-GENE S-GENE
in O O
a O O
phosphotyrosine O O
- O O
independent O O
manner O O
. O O
The O O
originally O O
embryonic B-GENE O
gamma I-GENE O
- I-GENE O
globin I-GENE O
locus E-GENE O
duplicated O O
and O O
acquired O O
a O O
novel O O
( O O
fetal O O
) O O
pattern O O
of O O
expression O O
in O O
a O O
defined O O
time O O
period O O
( O O
55 O O
- O O
40 O O
million O O
years O O
ago O O
) O O
during O O
primate O O
phylogeny O O
. O O
Clostridium O O
botulinum O O
in O O
marine O O
sediment O O
Northern O O
blot O O
analysis O O
with O O
GPR37 S-GENE O
probes O O
revealed O O
a O O
main O O
3 O O
. O O
8 O O
- O O
kb O O
mRNA O O
and O O
a O O
less O O
abundant O O
8 O O
- O O
kb O O
mRNA O O
, O O
both O O
expressed O O
in O O
human O O
brain O O
tissues O O
, O O
particularly O O
in O O
corpus O O
callosum O O
, O O
medulla O O
, O O
putamen O O
, O O
and O O
caudate O O
nucleus O O
. O O
Our O O
studies O O
indicate O O
no O O
single O O
trans O O
- O O
acting O O
factor O O
is O O
absolutely O O
essential O O
for O O
enhancer O O
activity O O
, O O
and O O
that O O
the O O
enhancer O O
activity O O
of O O
MerI S-GENE S-GENE
is O O
mediated O O
via O O
a O O
combinatorial O O
and O O
additive O O
mechanism O O
. O O
In O O
human O O
WI38 O O
cells O O
, O O
the O O
E1B B-GENE B-GENE
19K I-GENE I-GENE
gene I-GENE E-GENE
mutant E-GENE O
viruses O O
had O O
a O O
substantial O O
growth O O
advantage O O
over O O
the O O
wild O O
- O O
type O O
virus O O
, O O
yielding O O
500 O O
- O O
fold O O
- O O
higher O O
titers O O
. O O
To O O
elucidate O O
the O O
mechanism O O
of O O
these O O
hormonal O O
effects O O
, O O
we O O
have O O
studied O O
the O O
regulatory O O
regions O O
of O O
the O O
PFK B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
in O O
transfection O O
experiments O O
. O O
Consequently O O
, O O
during O O
the O O
evolution O O
of O O
mammals O O
, O O
it O O
is O O
the O O
CKbeta4GT B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
gene E-GENE E-GENE
lineage O O
that O O
has O O
been O O
recruited O O
for O O
the O O
biosynthesis O O
of O O
lactose O O
. O O
Furthermore O O
, O O
disruption O O
of O O
pcr1 S-GENE S-GENE
reduced O O
expression O O
of O O
fbp1 S-GENE S-GENE
, O O
a O O
glucose O B-GENE
- O I-GENE
repressible O I-GENE
gene O E-GENE
negatively O O
regulated O O
by O O
PKA S-GENE S-GENE
. O O
In O O
solution O O
, O O
[ O O
( O O
125 O O
) O O
I O O
] O O
- O O
labeled O O
ankyrin S-GENE O
was O O
found O O
by O O
ND O B-GENE
- O I-GENE
PAGE3 O E-GENE
to O O
enhance O O
the O O
affinity O O
of O O
spectrin S-GENE O
self O O
- O O
association O O
by O O
10 O O
- O O
fold O O
. O O
Transcription O O
analysis O O
of O O
the O O
EcoRI B-GENE O
D I-GENE O
region E-GENE O
of O O
the O O
baculovirus O O
Autographa O O
californica O O
nuclear O O
polyhedrosis O O
virus O O
identifies O O
an O O
early O O
4 O O
- O O
kilobase O O
RNA O O
encoding O O
the O O
essential O O
p143 B-GENE B-GENE
gene E-GENE E-GENE
. O O
Anesthesia O O
in O O
the O O
radical O O
surgery O O
of O O
arteriosclerotic O O
coronary O O
disease O O
5 O O
Intravenous O O
prizidilol O O
hydrochloride O O
decreases O O
resting O O
blood O O
pressure O O
and O O
left O O
ventricular O O
area O O
, O O
increases O O
pulse O O
rate O O
and O O
has O O
virtually O O
no O O
effect O O
on O O
left O O
ventricular O O
ejection O O
fraction O O
. O O
In O O
this O O
study O O
, O O
the O O
subcellular O O
location O O
, O O
domain O O
structure O O
, O O
and O O
biochemical O O
function O O
of O O
metaxin S-GENE O
were O O
investigated O O
. O O
The O O
human O O
cDNA O O
was O O
cloned O O
and O O
sequenced O O
; O O
it O O
was O O
shown O O
to O O
have O O
an O O
open O O
reading O O
frame O O
encoding O O
a O O
296 O O
- O O
amino O O
- O O
acid O O
protein O O
in O O
which O O
could O O
be O O
identified O O
four O O
peptides O O
previously O O
identified O O
by O O
micro O O
- O O
sequencing O O
purified O O
protein O O
. O O
Our O O
aim O O
was O O
to O O
evaluate O O
this O O
technique O O
by O O
cross O O
- O O
calibrating O O
the O O
DXA O O
method O O
with O O
the O O
carcass O O
chemical O O
analysis O O
in O O
a O O
heterogeneous O O
population O O
of O O
nondiabetic O O
Wistar O O
and O O
diabetic O O
GK O O
rats O O
( O O
21 O O
animals O O
were O O
used O O
for O O
precision O O
error O O
and O O
reproducibility O O
determinations O O
and O O
26 O O
were O O
used O O
for O O
accuracy O O
studies O O
) O O
. O O
Flux O O
of O O
the O O
paramyxovirus O O
hemagglutinin S-GENE O
- O O
neuraminidase S-GENE O
glycoprotein O O
through O O
the O O
endoplasmic O O
reticulum O O
activates O O
transcription O O
of O O
the O O
GRP78 S-GENE B-GENE
- O I-GENE
BiP S-GENE I-GENE
gene O E-GENE
. O O
The O O
preference O O
for O O
third O O
base O O
codon O O
in O O
Y O O
position O O
prolines O O
is O O
U O O
for O O
the O O
alpha B-GENE B-GENE
2 I-GENE E-GENE
( I-GENE O
VI I-GENE O
) I-GENE O
collagen E-GENE O
as O O
it O O
is O O
for O O
the O O
human B-GENE B-GENE
fibrillar I-GENE I-GENE
collagen I-GENE I-GENE
genes E-GENE E-GENE
. O O
Small O O
cell O O
tumors O O
in O O
children O O
: O O
contribution O O
to O O
the O O
solution O O
of O O
the O O
problem O O
of O O
differential O O
diagnosis O O
with O O
immunohistochemistry O O
and O O
electron O O
microscopy O O
Detonation O O
- O O
traumatic O O
load O O
during O O
military O O
service O O
In O O
static O O
conditions O O
, O O
body O O
sway O O
was O O
assessed O O
using O O
a O O
conventional O O
force O O
platform O O
with O O
eyes O O
open O O
and O O
with O O
eyes O O
closed O O
. O O
Soggy S-GENE O
, O O
a O O
spermatocyte O O
- O O
specific O O
gene O O
, O O
lies O O
3 O O
. O O
8 O O
kb O O
upstream O O
of O O
and O O
antipodal O O
to O O
TEAD B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
a O O
transcription O O
factor O O
expressed O O
at O O
the O O
beginning O O
of O O
mouse O O
development O O
. O O
Teratospermia O O
is O O
therefore O O
an O O
important O O
factor O O
in O O
evaluating O O
fertilization O O
capacity O O
. O O
Results O O
of O O
the O O
study O O
suggest O O
that O O
Chinese O O
medicine O O
use O O
among O O
this O O
population O O
depends O O
on O O
health O O
conditions O O
, O O
and O O
that O O
having O O
a O O
regular O O
source O O
of O O
care O O
for O O
Chinese O O
medicine O O
as O O
well O O
as O O
a O O
preference O O
for O O
Chinese O O
medicine O O
are O O
two O O
predictors O O
for O O
its O O
use O O
. O O
The O O
greatest O O
risk O O
of O O
preterm O O
prelabour O O
rupture O O
of O O
membranes O O
( O O
PPROM O O
) O O
is O O
preterm O O
delivery O O
. O O
DISCUSSION O O
: O O
The O O
higher O O
absolute O O
knee O O
extension O O
strength O O
measures O O
of O O
leg O O
and O O
the O O
similar O O
extension O O
strength O O
of O O
the O O
trunk O O
in O O
the O O
obese O O
sample O O
compared O O
to O O
the O O
lean O O
might O O
be O O
explained O O
by O O
the O O
training O O
effect O O
of O O
weight O O
bearing O O
and O O
support O O
of O O
a O O
larger O O
body O O
mass O O
. O O
Residues O O
of O O
Stauffer O O
R O O
- O O
3828 O O
and O O
its O O
oxygen O O
analogue O O
in O O
the O O
body O O
tissues O O
of O O
cattle O O
fed O O
R O O
- O O
3828 O O
in O O
the O O
diet O O
. O O
The O O
goals O O
of O O
these O O
experiments O O
were O O
to O O
determine O O
whether O O
lactational O O
anestrus O O
would O O
be O O
prolonged O O
by O O
a O O
48 O O
- O O
h O O
fast O O
at O O
days O O
13 O O
and O O
14 O O
postpartum O O
( O O
pp O O
) O O
and O O
, O O
if O O
so O O
, O O
to O O
determine O O
whether O O
this O O
effect O O
could O O
be O O
reversed O O
by O O
treatment O O
with O O
the O O
Ob B-GENE B-GENE
protein E-GENE I-GENE
leptin S-GENE E-GENE
. O O
In O O
pituitary O O
GH3 O O
cells O O
, O O
vitamin O O
D O O
increases O O
the O O
levels O O
of O O
PRL B-GENE B-GENE
transcripts E-GENE E-GENE
and O O
stimulates O O
the O O
PRL B-GENE B-GENE
promoter E-GENE E-GENE
. O O
However O O
, O O
electron O O
microscopy O O
revealed O O
that O O
while O O
sec4 B-GENE O
mutant E-GENE O
cells O O
accumulate O O
secretory O O
vesicles O O
, O O
ypt31 B-GENE S-GENE
/ I-GENE O
32 I-GENE O
mutant E-GENE O
cells O O
accumulate O O
aberrant O O
Golgi O O
structures O O
. O O
METHODS O O
: O O
We O O
retrospectively O O
analyzed O O
the O O
data O O
of O O
20 O O
patients O O
who O O
underwent O O
both O O
gated O O
fluorine O O
18 O O
deoxyglucose O O
( O O
FDG O O
) O O
- O O
PET O O
and O O
equilibrium O O
radionuclide O O
angiography O O
( O O
ERNA O O
) O O
. O O
However O O
, O O
it O O
is O O
now O O
suggested O O
that O O
the O O
use O O
of O O
more O O
slowly O O
digested O O
starchy O O
foods O O
may O O
have O O
positive O O
health O O
benefits O O
. O O
Northern O O
blot O O
analysis O O
demonstrated O O
that O O
the O O
genes O O
are O O
transcribed O O
separately O O
. O O
Complete O O
activation O O
of O O
signal B-GENE O
transducer I-GENE O
and I-GENE O
activator I-GENE O
of I-GENE O
transcription I-GENE O
1 E-GENE O
( O O
STAT1 S-GENE S-GENE
) O O
requires O O
phosphorylation O O
at O O
both O O
Y701 O S-GENE
and O O
a O O
conserved O O
PMS O O
( O O
727 O O
) O O
P O O
sequence O O
. O O
Over O O
half O O
of O O
the O O
children O O
initially O O
unresponsive O O
to O O
H O O
. O O
influenzae O O
type O O
b O O
meningitis O O
subsequently O O
developed O O
specific O O
antibodies O O
. O O
It O O
is O O
important O O
to O O
understand O O
the O O
etiology O O
of O O
HITT O O
because O O
of O O
its O O
devastating O O
clinical O O
consequences O O
. O O
Five O O
sequence O O
variants O O
were O O
identified O O
. O O
The O O
Ras B-GENE B-GENE
GTPase I-GENE E-GENE
- I-GENE O
activating I-GENE O
- I-GENE O
protein I-GENE O
- I-GENE O
related I-GENE O
human I-GENE O
protein E-GENE O
IQGAP2 S-GENE S-GENE
harbors O O
a O O
potential O O
actin B-GENE O
binding I-GENE O
domain E-GENE O
and O O
interacts O O
with O O
calmodulin S-GENE O
and O O
Rho B-GENE B-GENE
family I-GENE I-GENE
GTPases E-GENE E-GENE
. O O
We O O
anticipated O O
SNS O S-GENE
function O O
after O O
CVA O O
to O O
be O O
asymmetric O O
and O O
selected O O
null O O
hypotheses O O
of O O
bilaterally O O
symmetric O O
SSR O O
latencies O O
and O O
amplitudes O O
irrespective O O
of O O
side O O
of O O
stimulation O O
and O O
/ O O
or O O
recording O O
. O O
Partial O O
hepatectomy O O
in O O
metastatic O O
Wilms O O
' O O
tumor O O
. O O
The O O
adoption O O
of O O
a O O
twisted O O
structure O O
of O O
importin B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
is O O
essential O O
for O O
the O O
protein O O
- O O
protein O O
interaction O O
required O O
for O O
nuclear O O
transport O O
. O O
The O O
presence O O
of O O
a O O
short O O
( O O
70 O O
bp O O
) O O
intron O O
near O O
the O O
N O O
- O O
terminus O O
of O O
the O O
atX B-GENE O
gene E-GENE O
was O O
predicted O O
that O O
contains O O
the O O
canonical O O
GT O O
and O O
AG O O
dinucleotides O O
at O O
its O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
splicing O O
junctions O O
. O O
Moreover O O
, O O
a O O
hybrid O O
protein O O
composed O O
of O O
a O O
PvALF B-GENE S-GENE
activation I-GENE O
domain E-GENE O
and O O
the O O
DNA O O
binding O O
and O O
dimerization O O
domain O O
of O O
ROM2 S-GENE B-GENE
activated O I-GENE
gene O E-GENE
expression O O
, O O
indicating O O
that O O
ROM2 S-GENE S-GENE
recognizes O O
the O O
DLEC2 B-GENE B-GENE
enhancer E-GENE E-GENE
in O O
vivo O O
; O O
consequently O O
, O O
ROM2 S-GENE S-GENE
functions O O
as O O
a O O
DNA O O
binding O O
site O O
- O O
dependent O O
repressor O O
. O O
Tc O O
- O O
99m O O
HMPAO O O
brain O O
SPECT O O
compared O O
to O O
CT O O
and O O
EEG O O
after O O
seizures O O
in O O
childhood O O
. O O
We O O
found O O
that O O
the O O
central O O
nonconserved O O
region O O
of O O
the O O
large O O
subunit O O
is O O
not O O
essential O O
for O O
function O O
and O O
likely O O
acts O O
as O O
a O O
spacer O O
between O O
the O O
conserved O O
N O O
- O O
and O O
C O O
- O O
terminal O O
regions O O
. O O
On O O
the O O
other O O
hand O O
, O O
NE O O
transport O O
and O O
antagonist O O
( O O
[ O O
125I O O
] O O
RTI O O
- O O
55 O O
) O O
binding O O
assays O O
on O O
whole O O
LLC O O
- O O
NET O O
cells O O
treated O O
with O O
tunicamycin O O
reveal O O
a O O
pronounced O O
reduction O O
in O O
NE O O
transport O O
activity O O
and O O
hNET S-GENE O
membrane O O
density O O
paralleled O O
by O O
an O O
inability O O
of O O
NET B-GENE O
proteins E-GENE O
to O O
replenish O O
the O O
higher O O
M O O
( O O
r O O
) O O
hNET S-GENE O
pool O O
. O O
We O O
show O O
that O O
the O O
upstream O O
region O O
of O O
the O O
beta B-GENE B-GENE
- I-GENE I-GENE
MyHC I-GENE I-GENE
gene E-GENE E-GENE
( O O
- O O
5518 O S-GENE
to O O
- O O
2490 O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
) O O
directed O O
high O O
levels O O
of O O
transcriptional O O
activity O O
only O O
when O O
stably O O
integrated O O
, O O
but O O
not O O
when O O
expressed O O
extrachromosomally O O
in O O
transient O O
assays O O
. O O
DNase B-GENE B-GENE
I E-GENE E-GENE
protection O O
analysis O O
as O O
well O O
as O O
oligonucleotide O O
competition O O
experiments O O
indicate O O
that O O
this O O
binding O O
is O O
sequence O O
specific O O
. O O
Plasmid O O
pSP64E6E7 O O
which O O
contains O O
the O O
reading O O
frames O O
of O O
both O O
E6 S-GENE O
and O O
E7 S-GENE O
was O O
constructed O O
in O O
order O O
to O O
study O O
the O O
expression O O
of O O
both O O
proteins O O
in O O
a O O
coupled O O
transcription O O
/ O O
rabbit O O
reticulocyte O O
translation O O
system O O
. O O
In O O
transient O O
transfections O O
using O O
luciferase B-GENE O
reporter I-GENE O
genes E-GENE O
driven O O
by O O
1 O O
kb O O
of O O
the O O
5 O O
' O O
flanking O O
DNA O O
of O O
the O O
three O O
CALM B-GENE O
genes E-GENE O
, O O
the O O
promoter O O
activity O O
correlated O O
with O O
the O O
endogenous B-GENE O
CALM E-GENE O
transcriptional O O
activity O O
, O O
but O O
only O O
when O O
the O O
5 O O
' O O
untranslated O O
regions O O
were O O
included O O
in O O
the O O
constructs O O
. O O
These O O
findings O O
suggest O O
that O O
PGE1 O S-GENE
is O O
effective O O
in O O
increasing O O
PVF O O
in O O
the O O
liver O O
transplanted O O
condition O O
; O O
however O O
, O O
the O O
hepatic O O
circulatory O O
improvement O O
attributed O O
to O O
this O O
agent O O
would O O
be O O
limited O O
to O O
the O O
first O O
few O O
days O O
following O O
transplantation O O
. O O
The O O
derepressed O O
expression O O
of O O
fixN S-GENE S-GENE
was O O
not O O
observed O O
in O O
a O O
purH B-GENE B-GENE
mutant E-GENE E-GENE
. O O
Nearly O O
1 O O
. O O
5 O O
million O O
American O O
men O O
age O O
65 O O
and O O
older O O
have O O
osteoporosis O O
, O O
and O O
another O O
3 O O
. O O
5 O O
million O O
are O O
at O O
risk O O
. O O
Both O O
viruses O O
express O O
the O O
mil S-GENE O
/ O O
raf S-GENE O
oncogene O O
product O O
as O O
a O O
gag B-GENE O
- I-GENE O
fusion E-GENE O
polyprotein O O
, O O
while O O
the O O
myc S-GENE B-GENE
oncogene O E-GENE
of O O
MH2 O S-GENE
is O O
expressed O O
via O O
a O O
subgenomic O B-GENE
mRNA O E-GENE
. O O
CONCLUSION O O
: O O
DaunoXome O O
has O O
an O O
improved O O
pharmacokinetic O O
profile O O
compared O O
with O O
free O O
daunorubicin O O
, O O
and O O
is O O
well O O
tolerated O O
. O O
This O O
regimen O O
may O O
be O O
considered O O
front O O
- O O
line O O
therapy O O
when O O
autologous O O
stem O O
cell O O
transplantation O O
is O O
not O O
feasible O O
and O O
when O O
a O O
rapid O O
response O O
is O O
particularly O O
important O O
. O O
Recombinant O O
protein O O
encoded O O
by O O
ESX S-GENE S-GENE
( O O
for O O
epithelial B-GENE O
- I-GENE O
restricted I-GENE O
with I-GENE O
serine I-GENE O
box E-GENE O
) O O
exhibits O O
Ets B-GENE O
- I-GENE O
like E-GENE O
DNA O O
binding O O
specificity O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
transactivates O O
Ets B-GENE O
- I-GENE O
responsive I-GENE O
promoter I-GENE O
elements E-GENE O
including O O
that O O
found O O
in O O
the O O
HER2 S-GENE S-GENE
/ O O
neu S-GENE O
oncogene O O
. O O
In O O
area O O
CA1 O O
of O O
the O O
hippocampus O O
, O O
numbers O O
of O O
normal O O
neurons O O
were O O
increased O O
11 O O
- O O
to O O
14 O O
- O O
fold O O
by O O
MK O O
- O O
801 O O
treatment O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O
The O O
temporal O O
changes O O
in O O
the O O
plasma O O
concentration O O
of O O
immunoreactive B-GENE B-GENE
atrial I-GENE I-GENE
natriuretic I-GENE I-GENE
factor E-GENE E-GENE
( O O
iANF S-GENE O
) O O
were O O
studied O O
in O O
six O O
conscious O O
dogs O O
with O O
an O O
arteriovenous O O
( O O
AV O O
) O O
fistula O O
, O O
a O O
model O O
of O O
chronic O O
high O O
- O O
output O O
heart O O
failure O O
. O O
The O O
revaluation O O
at O O
the O O
end O O
of O O
the O O
study O O
showed O O
a O O
good O O
compliance O O
for O O
the O O
proposed O O
diet O O
scheme O O
by O O
children O O
, O O
but O O
a O O
poor O O
compliance O O
by O O
their O O
families O O
. O O
The O O
delta O O
G O O
values O O
of O O
these O O
regions O O
were O O
higher O O
, O O
i O O
. O O
e O O
. O O
potential O O
secondary O O
structural O O
elements O O
were O O
fewer O O
, O O
than O O
in O O
TIR O O
of O O
genes O O
from O O
E O O
. O O
coli O O
. O O
Two O O
closely O O
related O O
groups O O
of O O
transcripts O O
, O O
Sagrp1 S-GENE S-GENE
and O O
Sagrp2 S-GENE S-GENE
, O O
controlled O O
by O O
a O O
circadian O O
rhythm O O
have O O
been O O
isolated O O
. O O
Of O O
921 O O
specimens O O
, O O
95 O O
yielded O O
non O O
- O O
albicans O O
species O O
, O O
mainly O O
from O O
patients O O
with O O
low O O
CD4 S-GENE O
lymphocyte O O
counts O O
and O O
extensive O O
previous O O
azole O O
exposure O O
. O O
These O O
findings O O
suggest O O
that O O
eIF5 S-GENE B-GENE
- O I-GENE
eIF2beta S-GENE E-GENE
interaction O O
plays O O
an O O
essential O O
role O O
in O O
eIF5 S-GENE S-GENE
function O O
in O O
eukaryotic O O
cells O O
. O O
Three O O
simple O O
methods O O
of O O
detecting O O
malnutrition O O
on O O
medical O O
wards O O
. O O
Compared O O
with O O
controls O O
, O O
patients O O
in O O
the O O
unmedicated O O
state O O
had O O
low O O
smooth O O
pursuit O O
gain O O
, O O
had O O
a O O
higher O O
rate O O
of O O
corrective O O
catch O O
- O O
up O O
saccades O O
, O O
and O O
tended O O
to O O
spend O O
less O O
time O O
engaged O O
in O O
the O O
tracking O O
task O O
. O O
Cytokine O B-GENE
- O I-GENE
mediated O I-GENE
I B-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
alpha E-GENE E-GENE
reappearance O O
was O O
completely O O
blocked O O
by O O
the O O
protein O O
synthesis O O
inhibitor O O
cycloheximide O O
. O O
Development O O
of O O
P O O
carinii O O
pneumonia O O
was O O
associated O O
with O O
the O O
stage O O
of O O
Kaposi O O
' O O
s O O
sarcoma O O
, O O
B O O
subtype O O
disease O O
, O O
and O O
the O O
presence O O
of O O
0 O O
. O O
20 O O
X O O
10 O O
( O O
9 O O
) O O
/ O O
L O O
( O O
200 O O
/ O O
mm3 O O
) O O
or O O
fewer O O
CD4 S-GENE O
cells O O
at O O
study O O
entry O O
. O O
The O O
effects O O
of O O
tilmicosin O O
administration O O
in O O
the O O
feed O O
at O O
400 O O
mg O O
/ O O
kg O O
and O O
an O O
injection O O
therapy O O
of O O
clinically O O
diseased O O
pigs O O
with O O
long O O
- O O
acting O O
oxytetracycline O O
( O O
Terramycine O O
LA O O
) O O
at O O
20 O O
mg O O
/ O O
kg O O
bodyweight O O
were O O
compared O O
. O O
Those O O
participating O O
in O O
this O O
investigation O O
( O O
65 O O
centers O O
= O O
79 O O
% O O
) O O
received O O
a O O
series O O
of O O
computer O O
disks O O
containing O O
50 O O
99mTc O O
- O O
DMSA O O
studies O O
. O O
Pathogenesis O O
of O O
fever O O
. O O
Two O O
full O O
- O O
length O O
clones O O
( O O
pBCH1 O O
and O O
pBCH2 O O
) O O
were O O
isolated O O
. O O
Childbirth O O
and O O
authoritative O O
knowledge O O
. O O
The O O
ends O O
of O O
the O O
barrel O O
are O O
capped O O
by O O
short O O
helices O O
. O O
Non O O
- O O
finger O O
- O O
coding O O
modules O O
conserved O O
among O O
members O O
of O O
subfamilies O O
of O O
zinc B-GENE O
finger I-GENE O
genes E-GENE O
have O O
been O O
described O O
in O O
the O O
murine O O
genome O O
( O O
finger O O
- O O
associated O O
boxes O O
, O O
or O O
FAX O O
domain O O
) O O
and O O
the O O
human O O
genome O O
( O O
Kruppel B-GENE O
- I-GENE O
associated I-GENE O
boxes E-GENE O
, O O
or O O
KRAB B-GENE B-GENE
domain E-GENE E-GENE
) O O
. O O
This O O
combination O O
is O O
considered O O
pathognomonic O O
for O O
factitious O O
hyperinsulinism O O
. O O
Comparison O O
of O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
the O O
mouse B-GENE O
J I-GENE O
kappa I-GENE O
elements E-GENE O
, O O
including O O
the O O
conserved O O
putative O O
recombination O O
target O O
sequences O O
, O O
shows O O
no O O
obvious O O
differences O O
consistent O O
with O O
the O O
variation O O
in O O
recombinational O O
efficiency O O
, O O
so O O
we O O
conclude O O
that O O
, O O
although O O
the O O
consensus O O
heptamer O O
and O O
nonamer O O
signals O O
may O O
be O O
sufficient O O
to O O
identify O O
a O O
recombination O O
site O O
, O O
the O O
probability O O
that O O
that O O
site O O
will O O
be O O
used O O
depends O O
also O O
on O O
other O O
determinants O O
. O O
The O O
melanoma B-GENE O
growth I-GENE O
stimulatory I-GENE O
activity I-GENE O
/ I-GENE O
growth I-GENE O
- I-GENE O
regulated I-GENE O
protein E-GENE O
, O O
CXCL1 S-GENE S-GENE
, O O
is O O
constitutively O O
expressed O O
at O O
high O O
levels O O
during O O
inflammation O O
and O O
progression O O
of O O
melanocytes O O
into O O
malignant O O
melanoma O O
. O O
Genetic O O
analysis O O
places O O
CWH43 S-GENE O
upstream O O
of O O
the O O
BCK2 S-GENE S-GENE
branch O O
of O O
the O O
PKC1 S-GENE S-GENE
signalling O O
pathway O O
, O O
since O O
cwh43 S-GENE O
mutations O O
were O O
synthetic O O
lethal O O
with O O
pkc1 S-GENE O
deletion O O
, O O
whereas O O
the O O
cwh43 S-GENE O
defects O O
could O O
be O O
rescued O O
by O O
overexpression O O
of O O
BCK2 S-GENE S-GENE
and O O
not O O
by O O
high O O
- O O
copy O O
- O O
number O O
expression O O
of O O
genes O O
encoding O O
downstream O O
proteins O O
of O O
the O O
PKC1 S-GENE S-GENE
pathway O O
However O O
, O O
unlike O O
BCK2 S-GENE S-GENE
, O O
whose O O
disruption O O
in O O
a O O
cln3 B-GENE B-GENE
mutant E-GENE E-GENE
resulted O O
in O O
growth O O
arrest O O
in O O
G O O
( O O
1 O O
) O O
, O O
no O O
growth O O
defect O O
was O O
observed O O
in O O
a O O
double O O
cwh43 S-GENE B-GENE
cln3 B-GENE I-GENE
mutants E-GENE E-GENE
. O O
Twelve O O
( O O
92 O O
% O O
) O O
showed O O
cognitive O O
dysfunction O O
including O O
impairments O O
in O O
memory O O
, O O
attention O O
, O O
and O O
affective O O
disturbances O O
( O O
anxiety O O
, O O
depression O O
, O O
irritability O O
, O O
and O O
poor O O
frustration O O
tolerance O O
) O O
. O O
To O O
clarify O O
the O O
mechanisms O O
that O O
regulate O O
transcription O O
of O O
the O O
GTP B-GENE B-GENE
cyclohydrolase I-GENE I-GENE
I I-GENE I-GENE
gene E-GENE E-GENE
and O O
to O O
generate O O
multiple O O
species O O
of O O
mRNA O O
, O O
we O O
isolated O O
genomic O O
DNA O O
clones O O
for O O
the O O
human O O
and O O
mouse O B-GENE
GTP B-GENE I-GENE
cyclohydrolase I-GENE I-GENE
I I-GENE I-GENE
genes E-GENE E-GENE
. O O
Therefore O O
, O O
a O O
structural O O
interaction O O
between O O
PsaL S-GENE O
and O O
PsaI S-GENE S-GENE
may O O
stabilize O O
the O O
association O O
of O O
PsaL S-GENE O
with O O
the O O
photosystem B-GENE O
I I-GENE O
core E-GENE O
. O O
Reversal O O
of O O
' O O
refractory O O
septic O O
shock O O
' O O
by O O
infusion O O
of O O
amrinone O O
and O O
angiotensin B-GENE B-GENE
II E-GENE E-GENE
in O O
an O O
anthracycline O O
- O O
treated O O
patient O O
. O O
The O O
present O O
study O O
deals O O
with O O
the O O
screening O O
of O O
11 O O
of O O
these O O
plants O O
against O O
the O O
opportunistic O O
pathogen O O
fungus O O
Candida O O
albicans O O
. O O
Negative O O
modulation O O
of O O
alpha1 B-GENE S-GENE
( I-GENE O
I I-GENE S-GENE
) I-GENE O
procollagen I-GENE B-GENE
gene E-GENE E-GENE
expression O O
in O O
human O O
skin O O
fibroblasts O O
: O O
transcriptional O O
inhibition O O
by O O
interferon B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
. O O
On O O
the O O
basis O O
of O O
this O O
homology O O
, O O
we O O
examined O O
the O O
potential O O
role O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Rel E-GENE E-GENE
in O O
controlling O O
IL B-GENE B-GENE
- I-GENE I-GENE
2R I-GENE I-GENE
alpha E-GENE E-GENE
transcription O O
. O O
Expression O O
of O O
CBP S-GENE S-GENE
/ O O
p300 S-GENE S-GENE
potentiated O O
HS2 O O
- O O
mediated O O
transactivation O O
. O O
We O O
next O O
developed O O
a O O
rapid O O
purification O O
method O O
for O O
bacterial B-GENE O
recombinant I-GENE O
MyoD I-GENE B-GENE
- I-GENE I-GENE
bHLH I-GENE I-GENE
domain E-GENE E-GENE
by O O
affinity O O
chromatography O O
using O O
a O O
calmodulin S-GENE O
- O O
Sepharose O O
column O O
and O O
investigated O O
the O O
phosphorylation O O
of O O
that O O
peptide O O
by O O
PKC S-GENE S-GENE
and O O
its O O
interactions O O
with O O
calmodulin S-GENE O
and O O
S100a S-GENE S-GENE
. O O
According O O
to O O
the O O
penetration O O
of O O
Ca O O
- O O
45 O O
, O O
the O O
microleakage O O
level O O
was O O
scored O O
for O O
each O O
section O O
. O O
HL S-GENE S-GENE
is O O
hypothesized O O
to O O
directly O O
couple O O
HDL S-GENE O
lipid O O
metabolism O O
to O O
tissue O O
/ O O
cellular O O
lipid O O
metabolism O O
. O O
Epstein B-GENE O
- I-GENE O
Barr I-GENE O
virus I-GENE O
nuclear I-GENE O
antigen I-GENE O
2 E-GENE O
exerts O O
its O O
transactivating O O
function O O
through O O
interaction O O
with O O
recombination B-GENE O
signal I-GENE O
binding I-GENE O
protein I-GENE O
RBP I-GENE B-GENE
- I-GENE I-GENE
J I-GENE I-GENE
kappa E-GENE E-GENE
, O O
the O O
homologue O O
of O O
Drosophila B-GENE O
Suppressor I-GENE O
of I-GENE O
Hairless E-GENE O
. O O
Maduromycosis O O
in O O
Italy O O
Two O O
patient O O
groups O O
were O O
studied O O
: O O
Type O O
I O O
- O O
- O O
with O O
a O O
new O O
ePTFE O O
graft O O
; O O
and O O
Type O O
II O O
- O O
- O O
with O O
thrombectomy O O
and O O
/ O O
or O O
revision O O
of O O
a O O
previously O O
placed O O
ePTFE O O
graft O O
. O O
The O O
author O O
describes O O
the O O
technique O O
in O O
detail O O
and O O
presents O O
the O O
findings O O
for O O
25 O O
patients O O
( O O
10 O O
men O O
and O O
15 O O
women O O
) O O
examined O O
for O O
suspected O O
ileostomy O O
dysfunction O O
, O O
recurrent O O
Crohn O O
' O O
s O O
disease O O
or O O
ileal O O
obstruction O O
remote O O
from O O
the O O
stoma O O
. O O
Increased O O
susceptibility O O
of O O
aphasics O O
to O O
a O O
distractor O O
task O O
in O O
the O O
recall O O
of O O
verbal O O
commands O O
. O O
Lasting O O
paraplegia O O
caused O O
by O O
loss O O
of O O
lumbar O O
spinal O O
cord O O
interneurons O O
in O O
rats O O
: O O
no O O
direct O O
correlation O O
with O O
motor O O
neuron O O
loss O O
. O O
The O O
existence O O
of O O
universal O O
non O O
- O O
specific O O
mechanism O O
of O O
action O O
of O O
external O O
factors O O
upon O O
the O O
living O O
tissue O O
based O O
on O O
the O O
DEL O O
- O O
reaction O O
is O O
suggested O O
. O O
Rv O O
was O O
7 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
mmHg O O
. O O
ml O O
- O O
1 O O
. O O
min O O
. O O
100 O O
g O O
- O O
1 O O
and O O
Cv O O
was O O
0 O O
. O O
59 O O
+ O O
/ O O
- O O
0 O O
. O O
25 O O
ml O O
/ O O
mmHg O O
, O O
tau O O
v O O
calculated O O
from O O
the O O
product O O
of O O
Rv O O
and O O
Cv O O
was O O
4 O O
. O O
20 O O
+ O O
/ O O
- O O
1 O O
. O O
58 O O
s O O
and O O
from O O
the O O
ratio O O
of O O
delta O O
V O O
to O O
delta O O
Q O O
was O O
4 O O
. O O
95 O O
+ O O
/ O O
- O O
1 O O
. O O
53 O O
s O O
( O O
P O O
= O O
NS O O
) O O
at O O
a O O
mean O O
Pel O O
of O O
17 O O
. O O
6 O O
+ O O
/ O O
- O O
3 O O
. O O
7 O O
mmHg O O
. O O
delta O O
V O O
was O O
also O O
produced O O
by O O
changing O O
Pv O O
; O O
the O O
average O O
tau O O
v O O
( O O
1 O O
. O O
95 O O
+ O O
/ O O
- O O
0 O O
. O O
37 O O
s O O
) O O
, O O
was O O
shorter O O
than O O
that O O
with O O
changes O O
in O O
flow O O
. O O
We O O
constructed O O
a O O
stable O O
, O O
doubly O O
transfected O O
cell O O
line O O
( O O
TIS O O
- O O
10 O O
) O O
carrying O O
a O O
chromosomally O O
integrated O O
ptetO7 B-GENE O
- I-GENE O
CMV I-GENE O
- I-GENE O
L E-GENE O
reporter O O
construct O O
and O O
expressing O O
the O O
TetR S-GENE B-GENE
- O I-GENE
KRAB S-GENE I-GENE
protein O E-GENE
. O O
We O O
suggest O O
that O O
electrical O O
stimulation O O
of O O
the O O
NTS O O
in O O
rats O O
undergoing O O
such O O
surgical O O
preparation O O
to O O
observe O O
the O O
pressor O O
response O O
and O O
/ O O
or O O
increase O O
in O O
pVP O O
, O O
represents O O
a O O
rapid O O
approach O O
for O O
screening O O
the O O
neurosecretory O O
function O O
of O O
the O O
central O O
neural O O
integration O O
to O O
release O O
vasopressin S-GENE O
. O O
To O O
study O O
adaptive O O
processes O O
following O O
spinal O O
cord O O
injury O O
, O O
unstructured O O
audiotaped O O
interviews O O
were O O
conducted O O
on O O
an O O
almost O O
daily O O
basis O O
with O O
a O O
30 O O
- O O
year O O
- O O
old O O
divorced O O
male O O
during O O
the O O
first O O
3 O O
months O O
of O O
his O O
initial O O
comprehensive O O
inpatient O O
rehabilitation O O
. O O
Melioidosis O O
in O O
Sika O O
deer O O
( O O
Cervus O O
nippon O O
nippon O O
) O O
. O O
Enterobius O O
vermicularis O O
eggs O O
were O O
demonstrated O O
during O O
microscopic O O
examination O O
of O O
a O O
smear O O
taken O O
from O O
the O O
posterior O O
fornix O O
of O O
the O O
vagina O O
. O O
Together O O
with O O
previous O O
work O O
our O O
results O O
suggest O O
that O O
C B-GENE O
/ I-GENE O
EBP E-GENE O
may O O
be O O
a O O
general O O
cooperation O O
partner O O
for O O
v B-GENE O
- I-GENE O
Myb E-GENE O
in O O
myelomonocytic O O
cells O O
. O O
When O O
medical O O
aid O O
was O O
sought O O
a O O
false O O
history O O
was O O
given O O
and O O
the O O
true O O
nature O O
of O O
the O O
child O O
' O O
s O O
illness O O
, O O
heat O O
stroke O O
, O O
was O O
not O O
determined O O
until O O
after O O
death O O
. O O
Both O O
DMP2 S-GENE S-GENE
and O O
DMP3 S-GENE S-GENE
are O O
closely O O
localized O O
on O O
mouse O O
chromosome O O
5q21 O S-GENE
, O O
corresponding O O
to O O
human O O
chromosome O O
4q21 O O
. O O
This O O
article O O
expands O O
the O O
analysis O O
of O O
a O O
numeric O O
example O O
included O O
in O O
the O O
SAS O O
GLM O O
procedure O O
to O O
cover O O
several O O
crucial O O
statistical O O
aspects O O
relevant O O
to O O
ANCOVA O O
, O O
and O O
to O O
highlight O O
the O O
meaning O O
of O O
the O O
statistical O O
results O O
obtained O O
. O O
A O O
novel O O
alternative O O
spliced O O
variant O O
of O O
the O O
transcription O O
factor O O
AP2alpha S-GENE S-GENE
is O O
expressed O O
in O O
the O O
murine O O
ocular O O
lens O O
. O O
Fig1p S-GENE S-GENE
and O O
Fig2p S-GENE S-GENE
are O O
likely O O
to O O
act O O
at O O
the O O
cell O O
surface O O
as O O
Fig1 S-GENE S-GENE
: O O
: O O
beta B-GENE O
- I-GENE O
gal E-GENE O
and O O
Fig2 S-GENE S-GENE
: O O
: O O
beta B-GENE O
- I-GENE O
gal I-GENE O
fusion I-GENE O
proteins E-GENE O
localize O O
to O O
the O O
periphery O O
of O O
mating O O
cells O O
. O O
Crystals O O
of O O
the O O
triple O O
mutant O O
A42D S-GENE O
/ O O
D47P S-GENE O
/ O O
A63L S-GENE O
, O O
which O O
are O O
stable O O
for O O
days O O
in O O
its O O
oxidized O O
form O O
, O O
were O O
grown O O
from O O
ammonium O O
sulfate O O
, O O
with O O
the O O
cell O O
constants O O
a O O
= O O
b O O
= O O
34 O O
. O O
3 O O
A O O
and O O
c O O
= O O
111 O O
. O O
8 O O
A O O
belonging O O
to O O
space O O
group O O
P3 O O
( O O
2 O O
) O O
21 O O
. O O
Nevertheless O O
, O O
PEG O O
influenced O O
in O O
vitro O O
drug O O
availability O O
considerably O O
, O O
by O O
increasing O O
both O O
drug O O
solubility O O
and O O
dissolution O O
rate O O
. O O
Normal O O
replication O O
of O O
DNA B-GENE O
A E-GENE O
still O O
carrying O O
the O O
AC3 B-GENE B-GENE
ORF E-GENE I-GENE
mutation O E-GENE
was O O
found O O
in O O
extracts O O
from O O
these O O
plants O O
. O O
Such O O
saturation O O
often O O
occurs O O
for O O
several O O
recording O O
sweeps O O
after O O
large O O
amplitude O O
signals O O
such O O
as O O
eye O O
blinks O O
are O O
rejected O O
. O O
Muscle O O
and O O
liver O O
biopsies O O
demonstrated O O
the O O
same O O
anomalies O O
, O O
again O O
without O O
branching B-GENE O
enzyme E-GENE O
deficiency O O
in O O
the O O
liver O O
. O O
Possibility O O
of O O
using O O
gynecologic O O
nurses O O
in O O
the O O
independently O O
administered O O
health O O
centers O O
Airborne O O
rabies O O
encephalitis O O
: O O
demonstration O O
of O O
rabies O O
virus O O
in O O
the O O
human O O
central O O
nervous O O
system O O
. O O
T1 O O
and O O
T2 O O
values O O
were O O
calculated O O
from O O
guinea O O
pig O O
brain O O
in O O
vivo O O
at O O
0 O O
. O O
5 O O
T O O
. O O
Autophosphorylation O O
on O O
the O O
major O O
phosphorylation O O
site O O
Y1235 O S-GENE
upregulates O O
the O O
kinase O O
activity O O
of O O
the O O
receptor O O
, O O
increasing O O
the O O
Vmax O O
of O O
the O O
phosphotransfer O O
reaction O O
. O O
Clinical O O
development O O
of O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
10 E-GENE E-GENE
. O O
By O O
cloning O O
genes O O
encoding O O
benzene O O
- O O
degradative O O
enzymes O O
, O O
we O O
found O O
that O O
strain O O
JS150 O S-GENE
also O O
carries O O
genes O O
for O O
a O O
toluene B-GENE O
/ I-GENE O
benzene I-GENE O
- I-GENE O
2 I-GENE O
- I-GENE O
monooxygenase E-GENE O
. O O
Our O O
data O O
suggest O O
that O O
association O O
of O O
TBP S-GENE S-GENE
with O O
the O O
TATA O O
box O O
may O O
be O O
regulated O O
, O O
directly O O
or O O
indirectly O O
, O O
by O O
a O O
substrate O O
of O O
Snf1 S-GENE S-GENE
. O O
Fusion O O
proteins O O
were O O
isolated O O
by O O
affinity O O
chromatography O O
on O O
APTG O O
- O O
Sepharose O O
. O O
It O O
differed O O
from O O
cued O O
recall O O
only O O
in O O
the O O
instructions O O
, O O
which O O
directed O O
subjects O O
away O O
from O O
the O O
memory O O
aspects O O
of O O
the O O
test O O
and O O
asked O O
them O O
to O O
complete O O
each O O
three O O
- O O
letter O O
cue O O
with O O
the O O
first O O
word O O
that O O
came O O
to O O
mind O O
. O O
Real O O
- O O
time O O
two O O
- O O
dimensional O O
echocardiographic O O
studies O O
of O O
the O O
mitral O O
valve O O
in O O
short O O
- O O
axis O O
view O O
were O O
obtained O O
from O O
10 O O
normal O O
subjects O O
. O O
RESULTS O O
: O O
Sixty O O
- O O
one O O
percent O O
of O O
the O O
patients O O
had O O
damage O O
within O O
7 O O
years O O
of O O
onset O O
( O O
mean O O
3 O O
. O O
8 O O
yrs O O
) O O
. O O
It O O
was O O
previously O O
shown O O
that O O
Vi B-GENE B-GENE
antigen E-GENE E-GENE
expression O O
was O O
regulated O O
by O O
a O O
system O O
similar O O
to O O
the O O
rcs S-GENE O
regulatory O O
system O O
involved O O
in O O
colanic O O
acid O O
synthesis O O
in O O
Escherichia O O
coli O O
. O O
The O O
map O O
is O O
based O O
on O O
the O O
CEPH O O
reference O O
pedigrees O O
and O O
includes O O
over O O
4000 O O
new O O
genotypes O O
, O O
our O O
previously O O
reported O O
data O O
plus O O
29 O O
allele O O
systems O O
from O O
the O O
published O O
CEPH O O
version O O
5 O O
database O O
, O O
and O O
was O O
constructed O O
using O O
the O O
program O O
package O O
CRI O O
- O O
MAP O O
. O O
To O O
identify O O
the O O
GRK6 B-GENE B-GENE
homologue E-GENE E-GENE
on O O
chromsome O O
13 O O
, O O
several O O
sets O O
of O O
closely O O
- O O
spaced O O
primers O O
were O O
designed O O
based O O
on O O
the O O
GRK6 B-GENE B-GENE
cDNA I-GENE I-GENE
sequence E-GENE E-GENE
and O O
then O O
used O O
to O O
amplify O O
human O O
genomic O O
DNA O O
by O O
PCR O O
. O O
In O O
the O O
absence O O
of O O
Mg2 O O
+ O O
, O O
the O O
extent O O
of O O
destabilization O O
of O O
tRNAPhe S-GENE S-GENE
is O O
greater O O
but O O
appears O O
to O O
be O O
confined O O
to O O
internal O O
regions O O
of O O
the O O
acceptor O O
and O O
T O B-GENE
psi O I-GENE
C O I-GENE
helices O E-GENE
, O O
as O O
evidenced O O
by O O
the O O
selectively O O
enhanced O O
exchange O O
rates O O
for O O
imino O O
protons O O
associated O O
with O O
these O O
base O O
pairs O O
. O O
Studies O O
in O O
26 O O
patients O O
. O O
Serum B-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
amylase E-GENE E-GENE
, O O
trypsin S-GENE S-GENE
, O O
trypsin B-GENE O
inhibitor E-GENE O
, O O
lipase S-GENE S-GENE
and O O
total O O
protease O O
activity O O
in O O
the O O
pancreatic O O
tissue O O
was O O
studied O O
as O O
indicator O O
of O O
the O O
treatment O O
efficacy O O
with O O
5 O O
- O O
fluorouracil O O
electro O O
- O O
cumulation O O
. O O
1 O O
The O O
effects O O
of O O
high O O
doses O O
of O O
piretanide O O
, O O
a O O
new O O
diuretic O O
agent O O
chemically O O
related O O
to O O
frusemide O O
and O O
bumetanide O O
were O O
evaluated O O
in O O
twelve O O
patients O O
with O O
severe O O
chronic O O
renal O O
insufficiency O O
( O O
creatinine O O
clearance O O
below O O
25 O O
ml O O
/ O O
min O O
) O O
. O O
Synthesis O O
of O O
22 O O
- O O
oxavitamin O O
D3 O O
analogues O O
. O O
This O O
effect O O
is O O
independent O O
of O O
the O O
Gal4 B-GENE B-GENE
protein E-GENE E-GENE
, O O
as O O
it O O
operates O O
in O O
a O O
gal4 B-GENE B-GENE
mutant E-GENE E-GENE
background O O
as O O
well O O
. O O
Consistent O O
with O O
the O O
large O O
pocket O O
of O O
Rb S-GENE O
binding O O
to O O
TAF B-GENE O
( I-GENE O
II I-GENE O
) I-GENE O
250 E-GENE O
, O O
the O O
large O O
pocket O O
domains O O
of O O
both O O
p107 S-GENE S-GENE
and O O
p130 S-GENE S-GENE
are O O
able O O
to O O
bind O O
to O O
TAF B-GENE S-GENE
( I-GENE O
II I-GENE O
) I-GENE O
250 E-GENE O
in O O
vivo O O
. O O
50 O O
- O O
nucleotide O O
) O O
intron O O
to O O
AA O O
. O O
The O O
educational O O
program O O
was O O
the O O
significant O O
factor O O
that O O
influenced O O
the O O
change O O
of O O
concern O O
trajectories O O
, O O
and O O
the O O
recurrent O O
/ O O
non O O
- O O
recurrent O O
factor O O
influenced O O
the O O
change O O
of O O
concern O O
only O O
in O O
pamphlet O O
group O O
. O O
Amplification O O
of O O
4q21 O B-GENE
- O I-GENE
q22 O E-GENE
and O O
the O O
MXR B-GENE B-GENE
gene E-GENE E-GENE
in O O
independently O O
derived O O
mitoxantrone O O
- O O
resistant O O
cell O O
lines O O
. O O
Activation O O
of O O
the O O
receptor O O
induces O O
Ret S-GENE O
phosphorylation O O
that O O
leads O O
the O O
survival O O
- O O
promoting O O
effects O O
. O O
In O O
patients O O
in O O
which O O
these O O
criteria O O
were O O
not O O
met O O
only O O
the O O
reproducibility O O
of O O
the O O
VO2 O O
obtained O O
in O O
both O O
the O O
P O O
- O O
MET O O
and O O
the O O
C O O
- O O
MET O O
indicated O O
that O O
the O O
maximal O O
VO2 O O
for O O
these O O
4 O O
patients O O
had O O
been O O
reached O O
. O O
This O O
paper O O
describes O O
a O O
course O O
of O O
therapy O O
with O O
an O O
agoraphobic O O
female O O
patient O O
. O O
A O O
previously O O
developed O O
kinetic O O
model O O
was O O
used O O
to O O
identify O O
major O O
chemical O O
reaction O O
pathways O O
involving O O
PAH O O
in O O
the O O
afterburner O O
. O O
Henry O O
Quastler O O
brought O O
experience O O
from O O
an O O
actual O O
x O O
- O O
ray O O
treatment O O
, O O
and O O
Dr O O
. O O
Critical O O
review O O
of O O
tests O O
for O O
the O O
HBs B-GENE B-GENE
antigen E-GENE E-GENE
in O O
the O O
detection O O
of O O
infectious O O
blood O O
A O O
direct O O
statistically O O
reliable O O
correction O O
of O O
decrease O O
of O O
the O O
enzymes O O
with O O
the O O
initial O O
state O O
of O O
the O O
patients O O
has O O
been O O
established O O
in O O
an O O
analysis O O
of O O
25 O O
patients O O
aged O O
from O O
18 O O
to O O
60 O O
years O O
in O O
prosthesis O O
of O O
+ O O
the O O
mitral O O
valve O O
( O O
n O O
- O O
9 O O
) O O
and O O
closed O O
mitral O O
commissurotomy O O
( O O
n O O
- O O
16 O O
) O O
. O O
DSS4 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
a O O
dominant O O
suppressor O O
of O O
sec4 B-GENE B-GENE
- I-GENE I-GENE
8 E-GENE E-GENE
that O O
encodes O O
a O O
nucleotide O O
exchange O O
protein O O
that O O
aids O O
Sec4p S-GENE S-GENE
function O O
. O O
These O O
findings O O
indicate O O
that O O
KCTG O O
can O O
contribute O O
to O O
improved O O
monitoring O O
in O O
high O O
- O O
risk O O
pregnancies O O
. O O
The O O
MI O O
site O O
is O O
predictive O O
of O O
hemodynamic O O
left O O
ventricular O O
dysfunction O O
both O O
at O O
rest O O
and O O
during O O
exercise O O
: O O
anterior O O
MIs O O
are O O
more O O
impaired O O
than O O
inferior O O
MIs O O
. O O
The O O
vaccine O O
was O O
highly O O
immunogenic O O
, O O
since O O
111 O O
of O O
113 O O
patients O O
( O O
98 O O
% O O
) O O
produced O O
anti B-GENE O
- I-GENE O
HBs E-GENE O
( O O
10 O O
mIU O O
/ O O
ml O O
or O O
more O O
) O O
. O O
The O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
receptor I-GENE I-GENE
alpha E-GENE E-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
2R I-GENE I-GENE
alpha E-GENE E-GENE
) O O
chain O O
gene O O
contains O O
a O O
sequence O O
similar O O
to O O
the O O
immunoglobulin B-GENE O
( I-GENE O
Ig I-GENE S-GENE
) I-GENE O
kappa E-GENE S-GENE
( O O
kappa O S-GENE
) O O
enhancer O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
. O O
Comparison O O
of O O
the O O
derived O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
HCMV B-GENE B-GENE
UL99 I-GENE I-GENE
gene I-GENE E-GENE
product E-GENE O
reveals O O
34 O O
. O O
8 O O
% O O
identity O O
in O O
an O O
overlap O O
of O O
66 O O
amino O O
acids O O
. O O
Although O O
mutant B-GENE O
pex5delta E-GENE O
cells O O
expressing O O
a O O
yeast B-GENE O
/ I-GENE O
tobacco I-GENE O
Pex5p I-GENE O
chimaera E-GENE O
failed O O
to O O
import O O
a O O
GFP S-GENE B-GENE
- O I-GENE
Eci1p S-GENE I-GENE
reporter O I-GENE
protein O E-GENE
, O O
they O O
were O O
able O O
to O O
grow O O
on O O
oleic O O
acid O O
. O O
Consistent O O
with O O
this O O
observation O O
, O O
introduction O O
of O O
Smad B-GENE B-GENE
sites E-GENE E-GENE
into O O
a O O
TGFbeta S-GENE O
- O O
insensitive O O
LEF1 S-GENE S-GENE
/ O O
TCF S-GENE S-GENE
target O O
gene O O
confers O O
cooperative O O
TGFbeta S-GENE S-GENE
and O O
Wnt S-GENE S-GENE
responsiveness O O
to O O
the O O
promoter O O
. O O
In O O
analogy O O
to O O
human B-GENE O
CD70 E-GENE S-GENE
, O O
mCD70 B-GENE S-GENE
transcript E-GENE O
levels O O
are O O
strongly O O
but O O
transiently O O
up O O
- O O
regulated O O
during O O
lymphocyte O O
activation O O
, O O
which O O
is O O
in O O
line O O
with O O
a O O
role O O
for O O
the O O
CD27 B-GENE B-GENE
- I-GENE I-GENE
CD70 I-GENE I-GENE
receptor E-GENE E-GENE
pair O O
early O O
in O O
the O O
immune O O
response O O
. O O
Serum B-GENE B-GENE
IgM E-GENE E-GENE
levels O O
showed O O
a O O
highly O O
significant O O
increase O O
in O O
all O O
types O O
of O O
brain O O
tumour O O
when O O
compared O O
to O O
controls O O
. O O
Beyond O O
the O O
first O O
year O O
post O O
- O O
renal O O
transplantation O O
there O O
was O O
no O O
difference O O
in O O
C O O
( O O
IO O O
) O O
between O O
LRD O O
and O O
CAD O O
allografts O O
. O O
Vk8 S-GENE S-GENE
/ O O
Jk2 S-GENE S-GENE
and O O
Vk1 S-GENE S-GENE
/ O O
Jk5 S-GENE S-GENE
rearrangements O O
encoded O O
the O O
respective O O
L B-GENE O
chain I-GENE O
V I-GENE O
- I-GENE O
regions E-GENE O
. O O
The O O
phenomena O O
of O O
nursing O O
are O O
deeply O O
rooted O O
in O O
the O O
human O O
condition O O
. O O
Clinical O O
findings O O
plaque O O
index O O
, O O
PI O O
; O O
gingival O O
index O O
, O O
GI O O
; O O
bleeding O O
on O O
probing O O
, O O
BOP O O
; O O
pus O O
discharge O O
, O O
pus O O
; O O
and O O
probing O O
depth O O
, O O
PD O O
at O O
both O O
PT O O
- O O
01 O O
and O O
control O O
sites O O
were O O
measured O O
at O O
every O O
visit O O
for O O
4 O O
weeks O O
. O O
One O O
of O O
these O O
elements O O
resembles O O
the O O
binding O O
site O O
of O O
a O O
previously O O
identified O O
cellular O O
" O O
transcription O O
" O O
factor O O
. O O
NER O S-GENE
was O O
also O O
measured O O
by O O
a O O
plasmid O O
host O O
cell O O
re O O
- O O
activation O O
assay O O
using O O
a O O
vector O O
containing O O
a O O
luciferase B-GENE O
reporter I-GENE O
gene E-GENE O
. O O
Plasma O O
Pi O O
, O O
tibia O O
breaking O O
strength O O
, O O
and O O
percentage O O
of O O
tibia O O
ash O O
were O O
increased O O
by O O
raising O O
dietary O O
Pav O O
in O O
the O O
presence O O
of O O
. O O
392 O O
% O O
A1 O O
with O O
either O O
level O O
of O O
Ca O O
. O O
A O O
total O O
of O O
114 O O
animals O O
were O O
infected O O
by O O
E O O
. O O
coli O O
O2 O O
: O O
K1 O O
: O O
H4 O O
by O O
the O O
hematogenic O O
route O O
. O O
In O O
the O O
fungus O O
Neurospora O O
crassa O O
, O O
nit B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
the O O
major O O
nitrogen O O
regulatory O O
gene O O
, O O
activates O O
the O O
expression O O
of O O
unlinked O O
structural O O
genes O O
that O O
specify O O
nitrogen O O
- O O
catabolic O O
enzymes O O
during O O
conditions O O
of O O
nitrogen O O
limitation O O
. O O
The O O
matrix O O
of O O
the O O
CBs O O
contains O O
the O O
diagnostic O O
protein O O
p80 S-GENE O
- O O
coilin S-GENE O
, O O
which O O
is O O
colocalized O O
with O O
the O O
U7 B-GENE O
small I-GENE O
nuclear I-GENE O
ribonucleoprotein E-GENE O
( O O
snRNP O O
) O O
, O O
whereas O O
the O O
attached O O
and O O
embedded O O
B O O
- O O
snurposomes O O
contain O O
splicing O O
snRNPs O O
. O O
During O O
an O O
observation O O
period O O
of O O
12 O O
weeks O O
after O O
halving O O
atenolol O O
from O O
a O O
mean O O
dose O O
of O O
82 O O
mg O O
to O O
41 O O
mg O O
, O O
no O O
significant O O
changes O O
in O O
systolic O O
and O O
diastolic O O
blood O O
pressure O O
or O O
in O O
response O O
rate O O
( O O
defined O O
as O O
a O O
diastolic O O
blood O O
pressure O O
of O O
95 O O
mm O O
Hg O O
or O O
less O O
) O O
were O O
observed O O
. O O
Comparative O O
volumetric O O
analysis O O
is O O
defined O O
as O O
the O O
difference O O
between O O
mean O O
corpuscular O O
erythrocyte O O
volume O O
in O O
peripheral O O
blood O O
( O O
MCVB O O
) O O
diluted O O
in O O
urine O O
supernatant O O
after O O
centrifugation O O
and O O
mean O O
corpuscular O O
volume O O
of O O
urinary O O
erythrocytes O O
( O O
MCVU O O
) O O
. O O
PATIENTS O O
: O O
33 O O
HIV O O
- O O
infected O O
, O O
zidovudine O O
- O O
experienced O O
patients O O
with O O
serum O O
HIV O O
RNA O O
levels O O
of O O
at O O
least O O
20 O O
, O O
000 O O
copies O O
/ O O
mL O O
and O O
CD4 S-GENE O
counts O O
ranging O O
from O O
50 O O
to O O
400 O O
cells O O
/ O O
mm3 O O
. O O
Within O O
the O O
last O O
few O O
years O O
, O O
the O O
WWW O O
has O O
grown O O
enormously O O
. O O
These O O
data O O
, O O
taken O O
together O O
, O O
suggest O O
that O O
CRF S-GENE O
produces O O
its O O
behavioral O O
activating O O
and O O
anxiogenic O O
effects O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
increasing O O
the O O
activity O O
of O O
LC O O
noradrenergic O O
neurons O O
. O O
On O O
the O O
basis O O
of O O
8 O O
cases O O
, O O
the O O
authors O O
report O O
different O O
clinical O O
pictures O O
all O O
caused O O
by O O
cardiac O O
toxicity O O
of O O
5FU O O
. O O
The O O
sequence O O
of O O
Vac1p S-GENE S-GENE
contains O O
two O O
putative O O
zinc O O
- O O
binding O O
RING O O
motifs O O
, O O
a O O
zinc O O
finger O O
motif O O
, O O
and O O
a O O
coiled O O
- O O
coil O O
motif O O
. O O
Although O O
cardiac O O
output O O
decreased O O
slightly O O
with O O
PCF O O
, O O
hemodynamic O O
changes O O
due O O
to O O
PCF O O
were O O
unlikely O O
to O O
account O O
for O O
the O O
observed O O
fall O O
in O O
PaO2 O O
. O O
Anti B-GENE O
- I-GENE O
Jo I-GENE O
- I-GENE O
1 I-GENE O
antibody E-GENE O
was O O
not O O
present O O
. O O
The O O
first O O
operon O O
, O O
orf1 O B-GENE
- O I-GENE
tolQRA S-GENE E-GENE
, O O
is O O
iron O O
regulated O O
throughout O O
growth O O
, O O
but O O
iron O O
- O O
regulated O O
expression O O
of O O
tolB S-GENE S-GENE
and O O
oprL B-GENE O
fusions E-GENE O
occurs O O
only O O
in O O
late O O
log O O
phase O O
. O O
S O O
. O O
aureus O O
leakage O O
into O O
the O O
totally O O
submerged O O
test O O
specimens O O
was O O
detected O O
in O O
1 O O
of O O
5 O O
samples O O
incubated O O
for O O
4 O O
weeks O O
, O O
while O O
no O O
leakage O O
was O O
detected O O
in O O
specimens O O
incubated O O
for O O
3 O O
, O O
5 O O
, O O
6 O O
, O O
7 O O
, O O
and O O
8 O O
weeks O O
. O O
We O O
examined O O
the O O
contribution O O
of O O
a O O
cryptic O O
plasmid O O
, O O
pRmeGR4b O O
, O O
to O O
the O O
nodulation O O
of O O
Medicago O O
sativa O O
by O O
strain O O
GR4 O O
of O O
Rhizobium O O
meliloti O O
. O O
It O O
also O O
appears O O
that O O
in O O
patients O O
with O O
laboratory O O
diagnosis O O
of O O
prerenal O O
acute O O
renal O O
failure O O
( O O
i O O
. O O
e O O
. O O
, O O
a O O
RFT O O
less O O
than O O
1 O O
. O O
0 O O
) O O
, O O
the O O
response O O
to O O
treatment O O
is O O
unpredictable O O
and O O
in O O
fact O O
may O O
have O O
a O O
worse O O
prognosis O O
than O O
in O O
those O O
with O O
a O O
RFI O O
greater O O
than O O
1 O O
. O O
0 O O
( O O
5 O O
/ O O
7 O O
deaths O O
vs O O
10 O O
/ O O
48 O O
deaths O O
) O O
. O O
Paraplegia O O
associated O O
with O O
intraaortic O O
balloon O O
pump O O
counterpulsation O O
. O O
CTP O O
, O O
GDP O O
, O O
GTP O O
, O O
ITP O O
) O O
did O O
not O O
affect O O
the O O
response O O
. O O
Using O O
green B-GENE O
fluorescent I-GENE O
protein E-GENE O
fusions O O
we O O
demonstrate O O
that O O
the O O
SYT S-GENE S-GENE
, O O
SSX S-GENE S-GENE
and O O
the O O
SYT S-GENE B-GENE
- O I-GENE
SSX S-GENE I-GENE
proteins O E-GENE
are O O
nuclear O O
proteins O O
. O O
The O O
anaesthetic O O
management O O
of O O
41 O O
patients O O
who O O
underwent O O
cardiac O O
transplantation O O
during O O
a O O
40 O O
month O O
period O O
at O O
Clinica O O
Puerta O O
de O O
Hierro O O
is O O
reviewed O O
. O O
Acute O O
respiratory O O
distress O O
syndrome O O
. O O
These O O
data O O
suggested O O
that O O
mutant B-GENE O
PS1 E-GENE O
may O O
cause O O
disease O O
as O O
a O O
result O O
of O O
reduction O O
in O O
PS1 S-GENE O
function O O
. O O
The O O
analysis O O
of O O
the O O
organization O O
of O O
the O O
sequence O O
of O O
the O O
human O B-GENE
ABP S-GENE E-GENE
/ O O
DAO S-GENE B-GENE
gene O E-GENE
reveals O O
that O O
the O O
2 O O
. O O
4 O O
- O O
kilobase O O
messenger O O
RNA O O
is O O
transcribed O O
from O O
two O O
close O O
origins O O
identifying O O
the O O
proximal O O
promoter O O
. O O
Most O O
important O O
, O O
after O O
all O O
, O O
is O O
not O O
the O O
ionization O O
technique O O
but O O
the O O
stage O O
with O O
a O O
47 O O
. O O
1 O O
% O O
five O O
- O O
year O O
survival O O
rate O O
in O O
T1N0 O O
as O O
compared O O
to O O
T2N0 O O
with O O
28 O O
. O O
6 O O
% O O
and O O
T1N1 O O
with O O
19 O O
. O O
4 O O
% O O
. O O
To O O
investigate O O
the O O
step O O
of O O
spliceosome O O
assembly O O
at O O
which O O
Snu17p S-GENE S-GENE
acts O O
, O O
we O O
have O O
used O O
nondenaturing O O
gel O O
electrophoresis O O
. O O
We O O
also O O
show O O
that O O
an O O
internal O O
fragment O O
of O O
U24 B-GENE S-GENE
methylation I-GENE O
guide I-GENE O
snoRNA E-GENE O
, O O
encompassing O O
the O O
upstream O O
antisense O O
element O O
and O O
the O O
D O O
' O O
and O O
C O O
' O O
box O O
motifs O O
, O O
can O O
support O O
the O O
site O O
- O O
specific O O
methylation O O
of O O
rRNA O O
. O O
Mammalian O B-GENE
ribonucleotide B-GENE I-GENE
reductase E-GENE E-GENE
shows O O
S O O
- O O
phase O O
specific O O
expression O O
and O O
consists O O
of O O
two O O
non O O
- O O
identical O O
subunits O O
, O O
proteins B-GENE O
R1 E-GENE S-GENE
( O O
large O O
subunit O O
) O O
and O O
R2 S-GENE S-GENE
( O O
small O O
subunit O O
) O O
. O O
Effects O O
of O O
dexamethasone O O
on O O
the O O
development O O
of O O
radiation O O
nephropathy O O
in O O
the O O
rat O O
. O O
Recombinant B-GENE O
MsERK1 E-GENE S-GENE
( O O
rMsERK1 S-GENE S-GENE
) O O
, O O
when O O
overexpressed O O
in O O
Escherichia O O
coli O O
, O O
is O O
recognized O O
by O O
antibodies O O
raised O O
against O O
MAP B-GENE O
kinases I-GENE O
from I-GENE O
rat I-GENE O
, I-GENE O
Xenopus I-GENE O
, I-GENE O
and I-GENE O
sea I-GENE O
star E-GENE O
and O O
by O O
anti B-GENE O
- I-GENE O
phosphotyrosine I-GENE O
antibodies E-GENE O
. O O
The O O
identification O O
of O O
SRP54sc S-GENE S-GENE
and O O
SRP54sp S-GENE S-GENE
provides O O
the O O
first O O
evidence O O
for O O
SRP S-GENE B-GENE
related O I-GENE
proteins O E-GENE
in O O
yeast O O
. O O
We O O
previously O O
demonstrated O O
that O O
AKT2 S-GENE S-GENE
, O O
a O O
member O O
of O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
B I-GENE I-GENE
family E-GENE E-GENE
, O O
is O O
activated O O
by O O
a O O
number O O
of O O
growth O O
factors O O
via O O
Ras S-GENE S-GENE
and O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
signaling O O
pathways O O
. O O
So O O
it O O
is O O
sometimes O O
more O O
convenient O O
to O O
use O O
the O O
back O O
Radon O O
transform O O
R O O
- O O
1 O O
and O O
then O O
to O O
correct O O
the O O
result O O
, O O
taking O O
into O O
account O O
attenuation O O
. O O
Before O O
flecainide O O
, O O
all O O
patients O O
had O O
easily O O
inducible O O
VT O O
that O O
was O O
morphologically O O
identical O O
to O O
their O O
spontaneously O O
occurring O O
arrhythmia O O
. O O
An O O
additional O O
dose O O
of O O
20 O O
- O O
25 O O
Gy O O
was O O
delivered O O
to O O
the O O
site O O
of O O
original O O
involvement O O
using O O
an O O
implant O O
when O O
feasible O O
. O O
The O O
prominent O O
fracture O O
of O O
women O O
older O O
than O O
75 O O
years O O
is O O
the O O
hip O O
fracture O O
( O O
type O O
II O O
osteoporosis O O
) O O
. O O
The O O
expected O O
products O O
of O O
the O O
cloned O O
bph B-GENE B-GENE
genes E-GENE E-GENE
, O O
except O O
bphA3 S-GENE S-GENE
, O O
were O O
observed O O
in O O
E O O
. O O
coli O O
in O O
an O O
in O O
vitro O O
transcription O O
- O O
translation O O
system O O
. O O
It O O
is O O
our O O
conclusion O O
that O O
Sonoclot O O
coagulation O O
analysis O O
is O O
unlikely O O
to O O
identify O O
patients O O
with O O
prolonged O O
bleeding O O
time O O
in O O
whom O O
platelet O O
count O O
and O O
other O O
coagulation O O
factors O O
are O O
normal O O
. O O
RESULTS O O
: O O
Analysis O O
by O O
Pearson O O
' O O
s O O
correlation O O
showed O O
that O O
the O O
subjects O O
who O O
had O O
higher O O
scores O O
of O O
SSMS O O
during O O
the O O
drum O O
rotation O O
generated O O
the O O
following O O
: O O
a O O
) O O
a O O
higher O O
rating O O
of O O
over O O
- O O
all O O
sickness O O
( O O
r O O
= O O
0 O O
. O O
76 O O
) O O
; O O
b O O
) O O
a O O
higher O O
ratio O O
of O O
spectral O O
power O O
of O O
EGG O O
at O O
4 O O
- O O
9 O O
cycles O O
per O O
minute O O
( O O
cpm O O
) O O
between O O
drum O O
rotation O O
and O O
baseline O O
periods O O
( O O
r O O
= O O
0 O O
. O O
63 O O
) O O
; O O
c O O
) O O
a O O
higher O O
net O O
percent O O
increase O O
of O O
spectral O O
power O O
in O O
the O O
EEG O O
frequency O O
band O O
0 O O
. O O
5 O O
- O O
4 O O
Hz O O
between O O
drum O O
rotation O O
and O O
baseline O O
periods O O
on O O
C3 O O
( O O
r O O
= O O
0 O O
. O O
29 O O
) O O
and O O
C4 O O
( O O
r O O
= O O
0 O O
. O O
31 O O
) O O
; O O
d O O
) O O
a O O
higher O O
ratio O O
of O O
spectral O O
power O O
of O O
EEG O O
frequency O O
band O O
0 O O
. O O
5 O O
- O O
4 O O
Hz O O
between O O
drum O O
rotation O O
and O O
baseline O O
periods O O
on O O
C3 O O
( O O
r O O
= O O
0 O O
. O O
31 O O
) O O
; O O
and O O
e O O
) O O
a O O
higher O O
level O O
of O O
net O O
increase O O
in O O
skin O O
conductance O O
from O O
baseline O O
to O O
drum O O
rotation O O
( O O
r O O
= O O
0 O O
. O O
30 O O
) O O
. O O
Salts O O
of O O
these O O
four O O
metal O O
ions O O
may O O
be O O
added O O
to O O
the O O
growth O O
medium O O
to O O
facilitate O O
selective O O
isolation O O
of O O
Acinetobacter O O
. O O
The O O
consensus O O
mammalian O O
ER O O
stress O O
response O O
element O O
( O O
ERSE O S-GENE
) O O
conserved O O
among O O
grp B-GENE S-GENE
promoters E-GENE O
consists O O
of O O
a O O
tripartite O O
structure O O
CCAAT O S-GENE
( O O
N9 O O
) O O
CCACG O O
, O O
with O O
N O O
being O O
a O O
strikingly O O
GC O O
- O O
rich O O
region O O
of O O
9 O O
bp O O
. O O
Acute O O
toxicity O O
tests O O
were O O
conducted O O
to O O
measure O O
the O O
response O O
of O O
first O O
instar O O
Toxorhynchites O O
splendens O O
to O O
commonly O O
used O O
mosquito O O
adulticides O O
: O O
malathion O O
, O O
naled O O
and O O
resmethrin O O
. O O
A O O
positive O O
correlation O O
was O O
also O O
established O O
between O O
the O O
level O O
of O O
FP9C S-GENE S-GENE
binding O O
and O O
the O O
degree O O
of O O
cell O O
differentiation O O
in O O
vitro O O
. O O
Effects O O
of O O
acute O O
exposure O O
to O O
cold O O
on O O
pulmonary O O
arterial O O
blood O O
pressure O O
in O O
awake O O
rats O O
. O O
When O O
labeled O O
by O O
the O O
described O O
method O O
, O O
99mTc O O
on O O
DTPA O S-GENE
coupled O O
antibodies O O
shows O O
instability O O
in O O
serum O O
but O O
superior O O
stability O O
than O O
99mTc O O
on O O
antibodies O O
without O O
the O O
attached O O
DTPA O S-GENE
. O O
Unlike O O
CSK S-GENE S-GENE
, O O
the O O
SH3 B-GENE S-GENE
domain E-GENE O
of O O
HYL S-GENE S-GENE
was O O
unique O O
since O O
the O O
ALYDY O B-GENE
motif O E-GENE
was O O
absent O O
. O O
As O O
the O O
mechanism O O
of O O
the O O
intractability O O
, O O
cell O O
function O O
involved O O
in O O
the O O
defense O O
against O O
infection O O
was O O
evaluated O O
. O O
88 O O
, O O
3739 O O
- O O
3743 O O
) O O
) O O
. O O
OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
fulminant O O
neuropathy O O
with O O
severe O O
quadriparesis O O
associated O O
with O O
vincristine O O
chemotherapy O O
. O O
The O O
median O O
survival O O
time O O
was O O
18 O O
months O O
. O O
Hemorrheological O O
evaluation O O
and O O
proposed O O
pharmacological O O
uses O O
. O O
Its O O
phosphorylation O O
strongly O O
potentiates O O
its O O
ability O O
to O O
activate O O
transcription O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
promoter E-GENE E-GENE
through O O
a O O
ternary O O
complex O O
assembled O O
on O O
the O O
c B-GENE O
- I-GENE O
fos I-GENE O
serum I-GENE O
response I-GENE O
element E-GENE O
. O O
Fus3p S-GENE S-GENE
and O O
Kss1p S-GENE S-GENE
together O O
increase O O
the O O
expression O O
of O O
CLN3 S-GENE S-GENE
and O O
PCL2 B-GENE B-GENE
genes E-GENE E-GENE
that O O
promote O O
budding O O
, O O
and O O
Kss1p S-GENE S-GENE
inhibits O O
the O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
cascade O O
. O O
Consistent O O
with O O
our O O
observation O O
that O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
binding O O
does O O
not O O
contribute O O
to O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE I-GENE
coactivation O E-GENE
is O O
the O O
observation O O
that O O
the O O
activation O O
of O O
PU B-GENE B-GENE
. I-GENE I-GENE
1 E-GENE E-GENE
by O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
is O O
blocked O O
by O O
overexpression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos E-GENE E-GENE
. O O
A O O
possible O O
correlation O O
between O O
mandibular O O
growth O O
retardation O O
and O O
palatal O O
clefting O O
is O O
discussed O O
. O O
Time O O
dependence O O
of O O
frequency O O
potentiation O O
in O O
the O O
isolated O O
guinea O O
- O O
pig O O
' O O
s O O
atrium O O
. O O
We O O
found O O
4 O O
highly O O
conserved O O
regions O O
to O O
vertebrate B-GENE O
Hsp90 E-GENE S-GENE
exclusively O O
and O O
27 O O
amino O O
acids O O
conserved O O
among O O
but O O
differing O O
between O O
Hsp90 B-GENE B-GENE
alpha E-GENE E-GENE
and O O
Hsp90 B-GENE B-GENE
beta I-GENE I-GENE
sequences E-GENE E-GENE
. O O
Characterization O O
of O O
trinucleotide O O
- O O
and O O
tandem O O
repeat O O
- O O
containing O O
transcripts O O
obtained O O
from O O
human O O
spinal O O
cord O O
cDNA O O
library O O
by O O
high O O
- O O
density O O
filter O O
hybridization O O
. O O
We O O
present O O
here O O
the O O
complete O O
primary O O
structure O O
of O O
human B-GENE B-GENE
gp330 E-GENE E-GENE
, O O
the O O
human O O
variant O O
of O O
the O O
principal O O
kidney O O
autoantigen O O
causing O O
Heymann O O
membranous O O
glomerulonephritis O O
in O O
rats O O
. O O
The O O
platelet B-GENE O
membrane I-GENE O
glycoprotein I-GENE O
IIb I-GENE S-GENE
/ I-GENE O
IIIa I-GENE B-GENE
receptor E-GENE E-GENE
inhibitor O O
abciximab O O
is O O
used O O
for O O
the O O
treatment O O
of O O
patients O O
undergoing O O
high O O
- O O
risk O O
percutaneous O O
coronary O O
interventions O O
and O O
is O O
used O O
in O O
approximately O O
one O O
third O O
of O O
coronary O O
interventions O O
in O O
the O O
United O O
States O O
and O O
a O O
growing O O
number O O
of O O
procedures O O
in O O
Europe O O
. O O
In O O
the O O
conscious O O
animals O O
the O O
increase O O
reached O O
statistical O O
significance O O
when O O
the O O
animals O O
were O O
exposed O O
to O O
12 O O
% O O
oxygen O O
in O O
nitrogen O O
, O O
which O O
produced O O
a O O
fall O O
in O O
arterial O O
PaO2 O O
of O O
44 O O
. O O
7 O O
+ O O
/ O O
- O O
5 O O
. O O
0 O O
% O O
. O O
Prenatal O O
diagnosis O O
of O O
genetic O O
diseases O O
. O O
Human B-GENE B-GENE
epidermal I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
EGF S-GENE S-GENE
) O O
, O O
a O O
naturally O O
occurring O O
protein O O
, O O
has O O
been O O
implicated O O
in O O
the O O
protection O O
of O O
gastrointestinal O O
mucosal O O
integrity O O
. O O
A O O
ready O O
- O O
made O O
prosthesis O O
is O O
placed O O
on O O
the O O
external O O
side O O
of O O
the O O
ribs O O
vertically O O
bridging O O
the O O
flailed O O
chest O O
segment O O
, O O
and O O
fixed O O
to O O
the O O
first O O
upper O O
and O O
first O O
lower O O
intact O O
rib O O
as O O
well O O
as O O
to O O
the O O
mobile O O
segments O O
of O O
the O O
affected O O
ribs O O
. O O
DESIGN O O
: O O
Prospective O O
case O O
study O O
( O O
Canadian O O
Task O O
Force O O
classification O O
II O O
- O O
2 O O
) O O
. O O
Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
T4 B-GENE B-GENE
endonuclease I-GENE I-GENE
V I-GENE I-GENE
gene E-GENE E-GENE
: O O
role O O
of O O
lysine O O
- O O
130 O O
. O O
A O O
minimal O O
pheromone O O
induction O O
domain O O
, O O
delineated O O
as O O
residues O O
301 O O
to O O
335 O O
of O O
Ste12p S-GENE S-GENE
, O O
is O O
dependent O O
on O O
the O O
pheromone O B-GENE
mitogen B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
MAP I-GENE S-GENE
) I-GENE O
kinase E-GENE O
pathway O O
for O O
induction O O
activity O O
. O O
The O O
library O O
will O O
thus O O
be O O
useful O O
for O O
the O O
selection O O
of O O
cosmid O O
clones O O
which O O
carry O O
CDC B-GENE O
genes I-GENE O
from I-GENE O
yeast E-GENE O
by O O
complementing O O
first O O
, O O
with O O
the O O
vectorial O O
yeast B-GENE O
gene I-GENE O
URA1 E-GENE S-GENE
, O O
the O O
pyrimidine O O
auxotrophy O O
of O O
most O O
cdc S-GENE O
- O O
strains O O
and O O
then O O
, O O
with O O
the O O
respective O O
CDC B-GENE O
wild I-GENE O
- I-GENE O
type I-GENE O
genes E-GENE O
, O O
of O O
the O O
temperature O O
- O O
sensitive O O
mutant O O
alleles O O
. O O
These O O
mutant B-GENE O
rps7 E-GENE O
leaders O O
were O O
ligated O O
into O O
an O O
aadA O O
expression O O
cassette O O
and O O
transformed O O
into O O
the O O
chloroplast O O
of O O
C O O
. O O
reinhardtii O O
and O O
into O O
E O O
. O O
coli O O
. O O
In O O
addition O O
, O O
both O O
activated O O
Ral B-GENE B-GENE
- I-GENE I-GENE
GDS I-GENE I-GENE
- I-GENE I-GENE
like E-GENE I-GENE
factor O E-GENE
and O O
Raf S-GENE B-GENE
stimulate O I-GENE
cyclin B-GENE I-GENE
D I-GENE I-GENE
( I-GENE I-GENE
1 I-GENE E-GENE
) E-GENE O
transcription O O
and O O
E2F S-GENE S-GENE
activity O O
and O O
act O O
in O O
synergy O O
with O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
. O O
From O O
the O O
present O O
results O O
a O O
concept O O
of O O
hormone O O
- O O
dependent O O
AR S-GENE O
activation O O
is O O
proposed O O
, O O
which O O
requires O O
a O O
functional O O
, O O
direct O O
or O O
indirect O O
intramolecular O O
interaction O O
between O O
the O O
TAD O O
and O O
the O O
LBD O S-GENE
. O O
Like O O
the O O
DMA S-GENE S-GENE
, O O
but O O
unlike O O
all O O
other O O
mammalian B-GENE O
class I-GENE O
II I-GENE O
A I-GENE O
genes E-GENE O
, O O
the O O
zebrafish O O
gene O O
codes O O
for O O
two O O
cysteine O O
residues O O
which O O
might O O
potentially O O
be O O
involved O O
in O O
the O O
formation O O
of O O
a O O
disulfide O O
bond O O
in O O
the O O
alpha O B-GENE
1 O I-GENE
domain O E-GENE
. O O
Down O O
- O O
regulation O O
of O O
Id1 B-GENE B-GENE
mRNA E-GENE E-GENE
correlated O O
with O O
mitogenesis O O
and O O
occurred O O
when O O
quiescent O O
cells O O
were O O
treated O O
with O O
growth O O
factors O O
that O O
activate O O
G B-GENE O
protein I-GENE O
- I-GENE O
coupled I-GENE O
receptors E-GENE O
and O O
receptor B-GENE B-GENE
protein I-GENE I-GENE
tyrosine I-GENE I-GENE
kinases E-GENE E-GENE
but O O
not O O
with O O
a O O
non O O
- O O
mitogenic O O
cAMP O O
analog O O
. O O
Secretogranin B-GENE B-GENE
II E-GENE E-GENE
( O O
SgII S-GENE S-GENE
) O O
is O O
a O O
secretory O O
polypeptide O O
stored O O
in O O
large O O
dense O O
core O O
vesicles O O
of O O
neuroendocrine O O
and O O
neuronal O O
cells O O
. O O
CONCLUSIONS O O
: O O
In O O
the O O
results O O
of O O
this O O
study O O
, O O
SDB O O
, O O
even O O
snoring O O
, O O
was O O
independently O O
associated O O
with O O
hypertension O O
in O O
both O O
men O O
and O O
women O O
. O O
The O O
electron O O
spin O O
resonance O O
study O O
also O O
demonstrated O O
that O O
the O O
formation O O
of O O
superoxide O B-GENE
- O I-GENE
DMPO O E-GENE
spin O O
adduct O O
was O O
strongly O O
inhibited O O
by O O
a O O
selective O O
cyclooxygenase B-GENE O
- I-GENE O
2 E-GENE O
inhibitor O O
, O O
etodolac O O
, O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O
BK S-GENE O
- O O
induced O O
translocation O O
and O O
overexpression O O
of O O
PKC B-GENE B-GENE
isoforms E-GENE E-GENE
as O O
well O O
as O O
coexpression O O
of O O
inactive O O
or O O
constitutively O O
active O O
mutants O O
of O O
different O O
PKC B-GENE B-GENE
isozymes E-GENE E-GENE
provided O O
evidence O O
for O O
a O O
role O O
of O O
the O O
diacylglycerol O O
- O O
sensitive O O
PKCs B-GENE B-GENE
alpha I-GENE E-GENE
and I-GENE O
epsilon E-GENE O
in O O
BK S-GENE S-GENE
signaling O O
toward O O
MAPK S-GENE S-GENE
. O O
Embryonal O O
mortality O O
A O O
lead O O
phthalocyanin O O
method O O
for O O
the O O
demonstration O O
of O O
acid B-GENE O
hydrolases E-GENE O
in O O
plant O O
and O O
animal O O
tissues O O
. O O
Here O O
we O O
describe O O
the O O
characterization O O
of O O
cDNAs O S-GENE
encoding O O
two O O
unusual O O
E2Fs S-GENE S-GENE
, O O
E2F B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
and O O
E2F B-GENE B-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
, O O
each O O
identified O O
by O O
the O O
ability O O
of O O
their O O
gene O O
product O O
to O O
interact O O
with O O
p130 S-GENE S-GENE
in O O
a O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O
Interestingly O O
, O O
unlike O O
PAK65 S-GENE S-GENE
, O O
HPK1 S-GENE S-GENE
does O O
not O O
contain O O
the O O
small B-GENE O
GTPase E-GENE O
Rac1 S-GENE S-GENE
/ O O
Cdc42 S-GENE S-GENE
- O O
binding O O
domain O O
and O O
does O O
not O O
bind O O
to O O
either O O
Rac1 S-GENE S-GENE
or O O
Cdc42 S-GENE S-GENE
, O O
suggesting O O
that O O
HPK1 S-GENE S-GENE
. O O
activation O O
is O O
Rac1 S-GENE S-GENE
/ O O
Cdc42 S-GENE S-GENE
- O O
independent O O
. O O
The O O
results O O
were O O
compared O O
with O O
the O O
findings O O
in O O
pair O O
- O O
fed O O
non O O
- O O
treated O O
animals O O
( O O
Control O O
Group O O
) O O
. O O
Tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor E-GENE E-GENE
levels O O
were O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunoabsorbent O O
assay O O
in O O
plasma O O
samples O O
obtained O O
from O O
the O O
hyperthermic O O
isolated O O
limb O O
perfusion O O
circuit O O
and O O
systemic O O
circulation O O
. O O
However O O
, O O
only O O
plasma B-GENE O
fibrinogen E-GENE O
concentrations O O
showed O O
statistically O O
significant O O
positive O O
associations O O
with O O
IMT O O
in O O
both O O
groups O O
. O O
Without O O
a O O
team O O
, O O
there O O
is O O
little O O
hope O O
for O O
fetal O O
survival O O
; O O
mortality O O
will O O
be O O
80 O O
- O O
100 O O
% O O
. O O
Analysis O O
of O O
deletion O O
and O O
substitution O O
mutations O O
in O O
the O O
MER2 B-GENE O
5 I-GENE O
' I-GENE O
exon E-GENE O
demonstrates O O
that O O
the O O
unusually O O
large O O
size O O
of O O
this O O
exon O O
plays O O
an O O
important O O
role O O
in O O
splicing O O
regulation O O
. O O
To O O
study O O
the O O
signaling O O
pathways O O
that O O
regulate O O
cytoskeletal O O
rearrangements O O
in O O
T O O
lymphocytes O O
, O O
we O O
set O O
up O O
a O O
conjugate O O
formation O O
assay O O
using O O
Jurkat O O
T O O
cells O O
as O O
effectors O O
and O O
cell O O
- O O
sized O O
latex O O
beads O O
coated O O
with O O
various O O
antibodies O O
as O O
artificial O O
APCs O O
. O O
Reexamination O O
of O O
the O O
cdc4 B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
mutant E-GENE E-GENE
revealed O O
that O O
, O O
in O O
addition O O
to O O
being O O
defective O O
in O O
the O O
onset O O
of O O
S O O
phase O O
, O O
it O O
is O O
also O O
defective O O
in O O
G O O
( O O
2 O O
) O O
/ O O
M O O
transition O O
when O O
released O O
from O O
hydroxyurea O O
- O O
induced O O
S O O
- O O
phase O O
arrest O O
. O O
All O O
such O O
polypeptides O O
containing O O
263 O O
or O O
more O O
residues O O
derived O O
from O O
the O O
C O O
- O O
terminus O O
of O O
P130gag S-GENE O
- O O
fps S-GENE O
( O O
i O O
. O O
e O O
. O O
residues O O
920 O O
- O O
1182 O O
) O O
were O O
enzymatically O O
active O O
as O O
tyrosine B-GENE B-GENE
kinases E-GENE E-GENE
. O O
A O O
structural O O
model O O
for O O
Vpu S-GENE S-GENE
is O O
proposed O O
in O O
which O O
the O O
membrane O O
anchor O O
precedes O O
a O O
region O O
comprising O O
two O O
amphipathic O O
alpha O O
- O O
helices O O
of O O
opposed O O
polarity O O
, O O
joined O O
by O O
a O O
strongly O O
acidic O O
turn O O
that O O
protrudes O O
into O O
the O O
cytoplasm O O
and O O
contains O O
the O O
CK B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
phosphorylation I-GENE O
sites E-GENE O
. O O
The O O
recombinant O O
containing O O
the O O
full O O
- O O
length O O
polyhedrin S-GENE O
leader O O
sequence O O
gave O O
levels O O
of O O
N B-GENE O
mRNA E-GENE O
comparable O O
to O O
those O O
of O O
AcNPV B-GENE B-GENE
polyhedrin I-GENE I-GENE
mRNA E-GENE E-GENE
. O O
Immune O O
and O O
clinical O O
impact O O
of O O
Lactobacillus O O
acidophilus O O
on O O
asthma O O
. O O
Thus O O
, O O
CARP S-GENE S-GENE
is O O
a O O
YB B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
associated I-GENE O
factor E-GENE O
and O O
represents O O
the O O
first O O
identified O O
cardiac O O
- O O
restricted O O
downstream O O
regulatory O O
gene O O
in O O
the O O
homeobox O B-GENE
gene O I-GENE
Nkx2 B-GENE I-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
pathway O O
and O O
may O O
serve O O
as O O
a O O
negative O O
regulator O O
of O O
HF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
- O O
dependent O O
pathways O O
for O O
ventricular O O
muscle O O
gene O O
expression O O
. O O
Each O O
receptor O O
must O O
therefore O O
engage O O
a O O
unique O O
subset O O
of O O
the O O
available O O
signaling O O
elements O O
- O O
- O O
at O O
least O O
partly O O
through O O
the O O
selection O O
of O O
proteins O O
with O O
src B-GENE B-GENE
- I-GENE I-GENE
homology I-GENE I-GENE
2 I-GENE I-GENE
domains E-GENE E-GENE
( O O
SH2 B-GENE B-GENE
proteins E-GENE E-GENE
) O O
. O O
A O O
proposed O O
method O O
. O O
A O O
model O O
for O O
the O O
SMase S-GENE O
- O O
sphingomyelin O O
complex O O
structure O O
was O O
built O O
to O O
investigate O O
how O O
the O O
SMase S-GENE O
specifically O O
recognizes O O
its O O
substrate O O
. O O
Two O O
estimates O O
of O O
the O O
fractal O O
exponent O O
are O O
considered O O
which O O
do O O
not O O
suffer O O
from O O
this O O
limit O O
: O O
one O O
derived O O
from O O
the O O
Allan O O
variance O O
, O O
which O O
was O O
developed O O
by O O
the O O
authors O O
, O O
and O O
one O O
based O O
on O O
the O O
periodogram O O
. O O
Births O O
, O O
marriages O O
, O O
divorces O O
, O O
and O O
deaths O O
for O O
July O O
1997 O O
. O O
In O O
conclusion O O
, O O
in O O
coronary O O
artery O O
disease O O
patients O O
, O O
exercise O O
- O O
redistribution O O
201Thallium O O
cardiac O O
imaging O O
with O O
reinjection O O
at O O
rest O O
can O O
identify O O
severely O O
ischemic O O
but O O
still O O
viable O O
myocardium O O
and O O
may O O
be O O
particularly O O
useful O O
in O O
the O O
prognosis O O
of O O
such O O
patients O O
. O O
However O O
, O O
the O O
recovery O O
curve O O
of O O
the O O
R2 O O
component O O
of O O
the O O
blink O O
reflex O O
diminished O O
in O O
patients O O
with O O
tension O O
- O O
type O O
headache O O
compared O O
with O O
the O O
other O O
groups O O
. O O
When O O
recombinant B-GENE O
gE E-GENE O
produced O O
in O O
HeLa O O
cells O O
was O O
probed O O
with O O
the O O
same O O
antiphosphotyrosine O O
antibody O O
, O O
a O O
dimeric B-GENE O
gE E-GENE O
form O O
at O O
130 O O
kDa O O
was O O
detected O O
on O O
the O O
cell O O
surface O O
. O O
Transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
( O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
) O O
inhibits O O
cell O O
cycle O O
progression O O
, O O
in O O
part O O
through O O
up O O
- O O
regulation O O
of O O
gene O O
expression O O
of O O
the O O
p21 S-GENE S-GENE
( O O
WAF1 S-GENE S-GENE
/ O O
Cip1 S-GENE S-GENE
) O O
( O O
p21 S-GENE S-GENE
) O O
cell O O
cycle O O
inhibitor O O
. O O
The O O
results O O
suggest O O
that O O
both O O
superficial O O
and O O
deep O O
cortical O O
venous O O
drainage O O
of O O
the O O
cat O O
kidney O O
should O O
be O O
considered O O
when O O
measuring O O
renal B-GENE O
renin E-GENE O
release O O
. O O
CONCLUSION O O
: O O
Detection O O
of O O
recurrent O O
head O O
and O O
neck O O
cancer O O
is O O
feasible O O
with O O
FDG O O
PET O O
. O O
There O O
were O O
no O O
differences O O
in O O
the O O
incidence O O
of O O
fractured O O
zonas O O
. O O
DSIP O S-GENE
was O O
found O O
to O O
significantly O O
increase O O
slow O O
- O O
waves O O
( O O
delta O O
sleep O O
) O O
in O O
the O O
sleep O O
EEG O O
. O O
Accuracy O O
and O O
predictive O O
value O O
of O O
ultrasound O O
in O O
acute O O
rejection O O
. O O
7 O O
- O O
Nitroindazole O O
( O O
7NI O O
) O O
, O O
a O O
relatively O O
selective O O
neuronal O O
nitric B-GENE O
oxide I-GENE O
synthase E-GENE O
( O O
nNOS S-GENE S-GENE
) O O
inhibitor O O
. O O
was O O
intraperitoneally O O
administered O O
to O O
the O O
guinea O O
pigs O O
30 O O
minutes O O
before O O
the O O
onset O O
of O O
local O O
anoxia O O
. O O
Mutations O O
that O O
extend O O
the O O
specificity O O
of O O
the O O
endonuclease O O
activity O O
of O O
lambda B-GENE O
terminase E-GENE O
. O O
The O O
gene O O
set O O
in O O
this O O
mitochondrial O O
genome O O
is O O
a O O
subset O O
of O O
that O O
of O O
Reclinomonas O O
americana O O
, O O
an O O
amoeboid O O
protozoan O O
. O O
An O O
evaluation O O
of O O
a O O
positive O O
control O O
for O O
platelet O O
neutralization O O
procedure O O
testing O O
with O O
seven O O
commercial O O
activated O O
partial O O
thromboplastin S-GENE O
time O O
reagents O O
. O O
The O O
prosomal B-GENE O
RNA I-GENE O
- I-GENE O
binding I-GENE O
protein I-GENE O
p27K E-GENE S-GENE
is O O
a O O
member O O
of O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
human I-GENE I-GENE
prosomal I-GENE I-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
. O O
A O O
single O O
clone O O
, O O
which O O
was O O
conserved O O
and O O
had O O
near O O
- O O
perfect O O
homology O O
to O O
eight O O
human O O
/ O O
rodent O O
expressed O O
sequence O O
tags O O
, O O
was O O
used O O
as O O
template O O
for O O
5 O O
' O O
and O O
3 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
and O O
SPICE O O
( O O
system O O
for O O
polymerase O O
chain O O
reaction O O
amplification O O
of O O
cDNA O O
ends O O
) O O
reactions O O
to O O
obtain O O
the O O
3 O O
. O O
6 O O
- O O
kb O O
cDNA O O
, O O
LGL2 S-GENE S-GENE
( O O
Genbank B-GENE O
, I-GENE O
AF I-GENE B-GENE
110195 E-GENE E-GENE
) O O
encoding O O
a O O
deduced O O
polypeptide O O
( O O
lgl2 S-GENE S-GENE
) O O
of O O
963 O O
amino O O
acids O O
. O O
These O O
tiny O O
premature O O
infants O O
also O O
received O O
PN O O
for O O
significantly O O
longer O O
periods O O
of O O
time O O
, O O
and O O
the O O
longer O O
the O O
infusions O O
were O O
administered O O
the O O
greater O O
was O O
the O O
risk O O
of O O
cholestasis O O
developing O O
. O O
The O O
SM O O
- O O
specific O O
selection O O
of O O
exon O O
2 O O
results O O
from O O
the O O
inhibition O O
of O O
exon O O
3 O O
. O O
It O O
is O O
always O O
present O O
and O O
has O O
a O O
discrete O O
origin O O
and O O
insertion O O
. O O
Medical O O
management O O
of O O
early O O
- O O
stage O O
breast O O
cancer O O
. O O
Five O O
girls O O
with O O
Turner O O
' O O
s O O
syndrome O O
aged O O
12 O O
to O O
17 O O
years O O
showed O O
LH S-GENE O
values O O
( O O
5 O O
. O O
0 O O
- O O
14 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
at O O
the O O
upper O O
end O O
of O O
or O O
slightly O O
above O O
the O O
normal O O
range O O
and O O
pathologically O O
high O O
values O O
( O O
22 O O
. O O
2 O O
- O O
43 O O
. O O
5 O O
IU O O
/ O O
12 O O
h O O
) O O
for O O
FSH S-GENE O
. O O
In O O
vitro O O
death O O
assays O O
with O O
transient O O
overexpression O O
of O O
deletion O O
constructs O O
of O O
both O O
isoforms O O
using O O
beta B-GENE O
- I-GENE O
galactosidase E-GENE O
as O O
a O O
reporter O O
gene O O
in O O
MCF7 O O
cells O O
suggest O O
the O O
following O O
: O O
1 O O
) O O
the O O
nucleotide O O
binding O O
domain O O
may O O
act O O
as O O
a O O
negative O O
regulator O O
of O O
the O O
killing O O
activity O O
of O O
DEFCAP S-GENE B-GENE
; O I-GENE
2 O E-GENE
) O O
the O O
LRR S-GENE S-GENE
/ O O
CARD S-GENE O
represents O O
a O O
putative O O
constitutively O O
active O O
inducer O O
of O O
apoptosis O O
; O O
3 O O
) O O
the O O
killing O O
activity O O
of O O
LRR S-GENE O
/ O O
CARD S-GENE O
is O O
inhibitable O O
by O O
benzyloxycarbonyl O O
- O O
Val O O
- O O
Ala O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
and O O
to O O
a O O
lesser O O
extent O O
by O O
Asp O O
- O O
Glu O O
- O O
Val O O
- O O
Asp O O
( O O
OMe O O
) O O
- O O
fluoromethyl O O
ketone O O
; O O
and O O
4 O O
) O O
the O O
CARD S-GENE O
is O O
critical O O
for O O
killing O O
activity O O
of O O
DEFCAP S-GENE O
. O O
In O O
6 O O
patients O O
( O O
9 O O
kidneys O O
) O O
irrigation O O
with O O
Solution O O
G O O
in O O
the O O
renal O O
pelvis O O
was O O
performed O O
for O O
the O O
dissolution O O
of O O
their O O
infectious O O
stones O O
. O O
The O O
use O O
of O O
sigma B-GENE O
54 I-GENE O
promoters E-GENE O
, O O
known O O
to O O
require O O
cognate O O
binding O O
proteins O O
, O O
could O O
allow O O
the O O
fine O O
- O O
tuning O O
that O O
provides O O
the O O
temporal O O
ordering O O
of O O
flagellar O O
gene O O
transcription O O
. O O
The O O
association O O
of O O
I B-GENE O
- I-GENE O
92 E-GENE O
with O O
p92 S-GENE O
, O O
p84 S-GENE O
, O O
p75 S-GENE S-GENE
, O O
p73 S-GENE S-GENE
, O O
p69 S-GENE O
, O O
and O O
p57 S-GENE O
was O O
completely O O
reversible O O
after O O
treatment O O
with O O
the O O
detergent O O
deoxycholate O O
( O O
DOC O O
) O O
. O O
To O O
our O O
knowledge O O
no O O
transcription O O
factors O O
have O O
previously O O
been O O
identified O O
that O O
exhibit O O
androgen O O
- O O
dependent O O
expression O O
in O O
the O O
epididymis O O
. O O
Focal O O
or O O
regional O O
8 O O
- O O
to O O
20 O O
- O O
Hz O O
low O O
- O O
voltage O O
epileptiform O O
paroxysms O O
in O O
either O O
hippocampus O O
( O O
10 O O
patients O O
) O O
, O O
amygdala O O
( O O
1 O O
patient O O
) O O
, O O
or O O
both O O
( O O
1 O O
patient O O
) O O
preceded O O
initial O O
motionless O O
staring O O
. O O
The O O
lack O O
of O O
heterozygous O O
positions O O
essentially O O
facilitates O O
on O O
the O O
one O O
hand O O
the O O
data O O
analysis O O
and O O
on O O
the O O
other O O
hand O O
the O O
detection O O
of O O
new O O
alleles O O
. O O
Epithelial O O
cell O O
- O O
specific O O
activation O O
is O O
achieved O O
by O O
the O O
cooperative O O
interaction O O
of O O
apparently O O
ubiquitous O O
transcriptional O O
factors O O
. O O
Human B-GENE B-GENE
parvovirus I-GENE I-GENE
B19 I-GENE I-GENE
gene E-GENE E-GENE
expression O O
from O O
the O O
viral B-GENE B-GENE
p6 I-GENE I-GENE
promoter E-GENE E-GENE
( O O
B19p6 S-GENE S-GENE
) O O
is O O
restricted O O
to O O
primary O O
human O O
hematopoietic O O
cells O O
undergoing O O
erythroid O O
differentiation O O
. O O
The O O
effectiveness O O
and O O
pathogenetic O O
expediency O O
of O O
correcting O O
disorders O O
of O O
lipid O O
metabolism O O
in O O
atherosclerosis O O
with O O
enterosorbents O O
is O O
substantiated O O
. O O
To O O
prevent O O
section O O
wrinkles O O
usually O O
encountered O O
with O O
the O O
use O O
of O O
coated O O
single O O
- O O
hole O O
grids O O
, O O
a O O
simple O O
method O O
was O O
developed O O
. O O
The O O
Cryotherapy O O
for O O
Retinopathy O O
of O O
Prematurity O O
Study O O
has O O
shown O O
that O O
this O O
number O O
can O O
be O O
halved O O
with O O
treatment O O
. O O
Ultrasound O O
- O O
guided O O
fine O O
- O O
needle O O
aspiration O O
biopsy O O
( O O
US O O
- O O
FNAB O O
) O O
revealed O O
normal O O
- O O
looking O O
squamous O O
cells O O
. O O
Bleeding O O
was O O
successfully O O
prevented O O
in O O
28 O O
patients O O
with O O
the O O
use O O
of O O
a O O
combined O O
treatment O O
incorporating O O
IV O O
desmopressin O O
, O O
an O O
antifibrinolytic O O
agent O O
( O O
tranexamic O O
acid O O
) O O
, O O
and O O
local O O
methods O O
( O O
surgical O O
glue O O
and O O
compression O O
techniques O O
) O O
. O O
Hetero O O
- O O
oligomerization O O
of O O
Smad4 S-GENE S-GENE
with O O
the O O
pathway O O
- O O
restricted O O
SMAD B-GENE B-GENE
proteins E-GENE E-GENE
is O O
essential O O
for O O
Smad4 S-GENE S-GENE
- O O
mediated O O
transcription O O
. O O
This O O
fragment O O
contains O O
two O O
complete O O
endo B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
, I-GENE O
4 I-GENE O
- I-GENE O
glucanase I-GENE O
- I-GENE O
encoding I-GENE O
genes E-GENE O
, O O
designated O O
celCCC S-GENE S-GENE
and O O
celCCG S-GENE S-GENE
. O O
One O O
of O O
them O O
is O O
its O O
limited O O
sensitivity O O
to O O
weak O O
interactions O O
, O O
which O O
are O O
common O O
in O O
the O O
mammalian O O
cerebral O O
cortex O O
. O O
Analysis O O
of O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
the O O
transcripts O O
produced O O
in O O
vivo O O
from O O
the O O
puf B-GENE O
operon I-GENE O
of I-GENE O
R I-GENE O
. I-GENE O
sphaeroides E-GENE O
PUF B-GENE O
delta I-GENE O
348 I-GENE O
- I-GENE O
420 E-GENE O
( O O
three O O
transcripts O O
; O O
0 O O
. O O
59 O O
, O O
0 O O
. O O
64 O O
, O O
and O O
2 O O
. O O
63 O O
kilobases O O
) O O
lacking O O
the O O
puf O O
- O O
intercistronic O O
terminator O O
structure O O
were O O
identical O O
to O O
those O O
of O O
the O O
corresponding O O
puf B-GENE O
transcripts E-GENE O
derived O O
from O O
wild O O
- O O
type O O
R O O
. O O
sphaeroides O O
2 O O
. O O
4 O O
. O O
1 O O
( O O
four O O
transcripts O O
; O O
0 O O
. O O
50 O O
, O O
0 O O
. O O
66 O O
, O O
0 O O
. O O
71 O O
, O O
and O O
2 O O
. O O
7 O O
kilobases O O
) O O
showing O O
that O O
the O O
transcripts O O
begin O O
and O O
end O O
at O O
the O O
same O O
sites O O
. O O
The O O
optimum O O
cooling O O
rate O O
from O O
RT O O
to O O
5 O O
degrees O O
C O O
resulting O O
in O O
maximum O O
survival O O
of O O
human O O
spermatozoa O O
was O O
found O O
to O O
be O O
0 O O
. O O
5 O O
to O O
1 O O
degree O O
per O O
minute O O
when O O
cooled O O
from O O
RT O O
to O O
5 O O
degrees O O
C O O
and O O
subsequently O O
frozen O O
- O O
thawed O O
in O O
liquid O O
nitrogen O O
( O O
LN2 O O
) O O
. O O
The O O
cerebellar O O
cortical O O
vessels O O
: O O
they O O
are O O
compared O O
to O O
the O O
cerebral O O
vessels O O
. O O
Transesophageal O O
echocardiography O O
risk O O
factors O O
for O O
stroke O O
in O O
nonvalvular O O
atrial O O
fibrillation O O
. O O
22 O O
- O O
Veneto O O
Region O O
) O O
Preventive O O
health O O
counseling O O
tailored O O
to O O
the O O
needs O O
of O O
this O O
group O O
may O O
be O O
most O O
beneficial O O
. O O
Strains O O
lacking O O
a O O
functional B-GENE O
RPL16A I-GENE B-GENE
gene E-GENE E-GENE
grow O O
as O O
rapidly O O
as O O
wild O O
type O O
, O O
whereas O O
those O O
containing O O
a O O
null O O
allele O O
of O O
RPL16B S-GENE S-GENE
grow O O
more O O
slowly O O
than O O
wild O O
type O O
. O O
Neonatal O O
hyperthyroidism O O
After O O
Northern O O
blot O O
hybridization O O
, O O
two O O
Cx31 B-GENE O
transcripts I-GENE O
of I-GENE O
2 I-GENE O
. I-GENE O
2 I-GENE O
and I-GENE O
1 I-GENE O
. I-GENE O
8 I-GENE O
kb E-GENE O
were O O
detected O O
in O O
total O O
RNA O O
of O O
the O O
human O O
keratinocyte O O
cell O O
line O O
HaCaT O O
and O O
two O O
transcripts O O
of O O
2 O O
. O O
2 O O
and O O
1 O O
. O O
9 O O
kb O O
in O O
total O O
RNA O O
of O O
E6 S-GENE O
/ O O
E7 S-GENE O
transfected O O
human O O
keratinocytes O O
( O O
HEK O O
cells O O
) O O
. O O
In O O
summary O O
, O O
FGFR3 S-GENE S-GENE
signaling O O
pathway O O
utilizes O O
two O O
GRB2 B-GENE S-GENE
- I-GENE O
containing I-GENE O
complexes E-GENE O
; O O
Shc S-GENE O
. O O
GRB2 S-GENE S-GENE
. O O
Sos S-GENE S-GENE
and O O
80K B-GENE B-GENE
- I-GENE I-GENE
H E-GENE E-GENE
. O O
pp66 S-GENE S-GENE
. O O
GRB2 S-GENE S-GENE
. O O
Sos S-GENE O
; O O
these O O
two O O
complexes O O
may O O
alternatively O O
link O O
FGFG3 S-GENE S-GENE
to O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
. O O
In O O
an O O
effort O O
to O O
identify O O
factors O O
involved O O
in O O
the O O
expression O O
of O O
this O O
important O O
erythroid O O
- O O
specific O O
regulatory O O
protein O O
, O O
we O O
have O O
isolated O O
the O O
mouse B-GENE B-GENE
EKLF I-GENE I-GENE
gene E-GENE E-GENE
and O O
systematically O O
analyzed O O
the O O
promoter O O
region O O
. O O
Their O O
main O O
representatives O O
are O O
the O O
American O O
diagnostic O O
and O O
statistical O O
manual O O
of O O
mental O O
disorders O O
, O O
DSM O O
- O O
III O O
, O O
its O O
revised O O
version O O
DSM O O
- O O
III O O
- O O
R O O
and O O
the O O
new O O
international O O
classification O O
of O O
mental O O
disorders O O
iCD O O
- O O
10 O O
. O O
Any O O
opacity O O
on O O
a O O
chest O O
radiograph O O
has O O
a O O
wide O O
differential O O
diagnosis O O
. O O
At O O
the O O
same O O
acoustic O O
power O O
, O O
the O O
rate O O
of O O
chloride O O
formation O O
with O O
20 O O
kHz O O
ultrasound O O
was O O
greater O O
when O O
a O O
probe O O
with O O
a O O
larger O O
tip O O
area O O
was O O
used O O
, O O
but O O
significantly O O
less O O
than O O
the O O
rate O O
with O O
900 O O
kHz O O
. O O
In O O
contrast O O
to O O
Torpedo O O
, O O
where O O
only O O
a O O
single O O
transcript O O
is O O
seen O O
, O O
the O O
mouse O O
expresses O O
several O O
mRNAs O O
encoding O O
different O O
isoforms O O
. O O
Four O O
families O O
of O O
homing B-GENE O
endonucleases E-GENE O
have O O
been O O
identified O O
, O O
including O O
the O O
LAGLIDADG S-GENE O
, O O
the O O
His B-GENE O
- I-GENE O
Cys I-GENE O
box E-GENE O
, O O
the O O
GIY B-GENE O
- I-GENE O
YIG E-GENE O
and O O
the O O
H B-GENE O
- I-GENE O
N I-GENE O
- I-GENE O
H I-GENE O
endonucleases E-GENE O
. O O
Convergence O O
of O O
trigeminal O O
input O O
with O O
visceral O O
and O O
phrenic O O
inputs O O
on O O
primate O O
C1 O O
- O O
C2 O O
spinothalamic O O
tract O O
neurons O O
. O O
The O O
GvpE B-GENE B-GENE
protein E-GENE E-GENE
involved O O
in O O
the O O
regulation O O
of O O
gas O O
vesicles O O
synthesis O O
in O O
halophilic O O
archaea O O
has O O
been O O
identified O O
as O O
the O O
transcriptional O O
activator O O
for O O
the O O
promoter O O
located O O
upstream O O
of O O
the O O
gvpA B-GENE B-GENE
gene E-GENE E-GENE
encoding O O
the O O
major O O
gas O O
vesicle O O
structural O O
protein O O
GvpA S-GENE S-GENE
. O O
Nosographic O O
problems O O
In O O
early O O
midgestation O O
embryos O O
it O O
is O O
expressed O O
in O O
telencephalic O O
, O O
diencephalic O O
and O O
mesencephalic O O
regions O O
but O O
from O O
day O O
11 O O
. O O
75 O O
of O O
gestation O O
its O O
expression O O
disappears O O
from O O
dorsal O O
telencephalon O O
and O O
is O O
confined O O
to O O
diencephalic O O
and O O
mesencephalic O O
regions O O
. O O
The O O
training O O
programs O O
had O O
a O O
duration O O
of O O
30 O O
days O O
, O O
5 O O
days O O
/ O O
week O O
, O O
and O O
was O O
performed O O
on O O
a O O
motor O O
- O O
driven O O
treadmill O O
. O O
Phylogenetic O O
analysis O O
using O O
a O O
neighbor O O
- O O
joining O O
algorithm O O
showed O O
closest O O
similarity O O
of O O
the O O
horse B-GENE O
mu I-GENE O
chain I-GENE O
- I-GENE O
encoding I-GENE O
constant I-GENE O
region I-GENE O
gene E-GENE O
to O O
human O O
and O O
dog O O
sequences O O
. O O
Using O O
probes O O
from O O
these O O
regions O O
, O O
rearrangements O O
have O O
been O O
identified O O
in O O
each O O
of O O
nine O O
cases O O
of O O
t O O
( O O
8 O O
; O O
21 O O
) O O
AML O O
examined O O
. O O
Cloning O O
and O O
nucleotide O O
sequence O O
analysis O O
reveals O O
that O O
BUR6 S-GENE S-GENE
encodes O O
a O O
homolog O O
of O O
DRAP1 S-GENE S-GENE
( O O
also O O
called O O
NC2alpha S-GENE S-GENE
) O O
, O O
a O O
mammalian O O
repressor O O
of O O
basal O O
transcription O O
. O O
BRAP2 S-GENE S-GENE
also O O
shares O O
significant O O
homology O O
with O O
a O O
hypothetical O O
protein O O
from O O
yeast O O
Saccharomyces O O
cerevisiae O O
, O O
especially O O
in O O
the O O
zinc O O
finger O O
region O O
. O O
Earlier O O
published O O
data O O
, O O
indicating O O
Sp1 S-GENE S-GENE
binding O O
to O O
the O O
R1 B-GENE B-GENE
alpha I-GENE E-GENE
/ I-GENE O
beta I-GENE O
regions E-GENE O
, O O
could O O
not O O
be O O
confirmed O O
, O O
suggesting O O
that O O
the O O
R1 O O
initiator O O
element O O
may O O
function O O
independent O O
of O O
Sp1 S-GENE S-GENE
. O O
In O O
addition O O
, O O
reduced O O
metabolism O O
to O O
cotinine O O
from O O
the O O
proliposomes O O
and O O
MP O O
was O O
apparently O O
responsible O O
for O O
the O O
sustained O O
plasma O O
nicotine O O
levels O O
. O O
Activation O O
of O O
HIV O B-GENE
- O I-GENE
1 O E-GENE
requires O O
the O O
binding O O
of O O
host O O
cell O O
transcription O O
factors O O
to O O
cis O O
elements O O
in O O
the O O
proviral O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O
The O O
yeast B-GENE O
mitochondrial I-GENE O
Hsp70 E-GENE S-GENE
, O O
Ssc1p S-GENE S-GENE
, O O
functions O O
as O O
a O O
molecular O O
chaperone O O
with O O
its O O
partner O O
proteins O O
, O O
Mdj1p S-GENE S-GENE
( O O
DnaJ B-GENE S-GENE
homologue E-GENE O
) O O
and O O
Yge1p S-GENE S-GENE
( O O
GrpE B-GENE S-GENE
homologue E-GENE O
) O O
. O O
Increased O O
TRE O O
DNA O O
binding O O
failed O O
to O O
lead O O
to O O
increased O O
transactivation O O
correlating O O
with O O
the O O
inability O O
of O O
SB O B-GENE
203580 O E-GENE
to O O
increase O O
phosphorylation O O
of O O
these O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
proteins E-GENE E-GENE
. O O
The O O
rice O O
gene O O
consists O O
of O O
four O O
exons O O
. O O
However O O
, O O
and O O
in O O
contrast O O
to O O
other O O
MMP B-GENE B-GENE
genes E-GENE E-GENE
, O O
no O O
significative O O
synergistic O O
effect O O
on O O
CAT S-GENE O
activity O O
between O O
the O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
PEA B-GENE O
- I-GENE O
3 I-GENE O
elements E-GENE O
found O O
in O O
the O O
collagenase B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
was O O
found O O
. O O
The O O
equation O O
for O O
mean O O
trabecular O O
number O O
passed O O
the O O
test O O
, O O
whereas O O
the O O
validity O O
of O O
the O O
equations O O
for O O
mean O O
trabecular O O
separation O O
and O O
Tb O O
. O O
Wi O O
appeared O O
limited O O
. O O
Methodological O O
considerations O O
limiting O O
causal O O
assertions O O
permissible O O
with O O
nonexperimental O O
data O O
are O O
discussed O O
. O O
In O O
contrast O O
, O O
postmitotic O O
neurons O O
possessed O O
extremely O O
low O O
levels O O
of O O
E2F1 B-GENE B-GENE
protein E-GENE E-GENE
as O O
assessed O O
by O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
Western O O
blotting O O
. O O
Recurrence O O
of O O
the O O
hepatic O O
cyst O O
after O O
partial O O
excision O O
and O O
drainage O O
was O O
complicated O O
by O O
fistula O O
formation O O
between O O
the O O
cyst O O
and O O
the O O
duodenum O O
. O O
Reversal O O
of O O
mefloquine O O
resistance O O
in O O
rodent O O
Plasmodium O O
. O O
Possible O O
consequences O O
of O O
such O O
binder O O
distribution O O
through O O
powder O O
aggregates O O
are O O
discussed O O
. O O
The O O
human B-GENE B-GENE
parvalbumin I-GENE I-GENE
mRNA E-GENE E-GENE
contains O O
the O O
putative O O
polyadenylation O O
signal O O
AATAAA O S-GENE
13 O O
nucleotides O O
upstream O O
from O O
the O O
polyadenylation O O
site O O
. O O
The O O
delta O O
Mo O O
+ O O
SV O O
tumor O O
DNAs O O
from O O
B O O
- O O
lineage O O
tumors O O
were O O
typically O O
rearranged O O
at O O
the O O
immunoglobulin B-GENE B-GENE
gene I-GENE I-GENE
loci E-GENE E-GENE
and O O
contained O O
germ O O
line O O
configurations O O
of O O
the O O
T B-GENE B-GENE
- I-GENE I-GENE
cell I-GENE I-GENE
receptor I-GENE I-GENE
beta I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
experimental O O
results O O
suggest O O
equilibrium O O
complex O O
formation O O
between O O
OTC O O
and O O
PVP O O
, O O
it O O
being O O
mainly O O
the O O
complex O O
which O O
is O O
i O O
. O O
v O O
. O O
injected O O
when O O
both O O
products O O
are O O
combined O O
in O O
an O O
injection O O
formulation O O
. O O
We O O
conclude O O
that O O
the O O
MMF O O
lesion O O
is O O
secondary O O
to O O
intramuscular O O
injection O O
of O O
aluminium O O
hydroxide O O
- O O
containing O O
vaccines O O
, O O
shows O O
both O O
long O O
- O O
term O O
persistence O O
of O O
aluminium O O
hydroxide O O
and O O
an O O
ongoing O O
local O O
immune O O
reaction O O
, O O
and O O
is O O
detected O O
in O O
patients O O
with O O
systemic O O
symptoms O O
which O O
appeared O O
subsequently O O
to O O
vaccination O O
. O O
To O O
examine O O
the O O
effect O O
of O O
the O O
cAMP O O
signal O O
transduction O O
pathway O O
on O O
transcription O O
of O O
the O O
gene O O
encoding O O
the O O
catalytic O O
subunit O O
of O O
glucose B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
- I-GENE I-GENE
phosphatase E-GENE E-GENE
( O O
G6Pase S-GENE S-GENE
) O O
, O O
G6Pase S-GENE B-GENE
- O I-GENE
chloramphenicol B-GENE I-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
fusion O O
genes O O
were O O
transiently O O
transfected O O
into O O
either O O
the O O
liver O O
- O O
derived O O
HepG2 O O
or O O
kidney O O
- O O
derived O O
LLC O O
- O O
PK O O
cell O O
line O O
. O O
Whereas O O
the O O
sequence O O
of O O
alpha B-GENE B-GENE
- I-GENE I-GENE
actinin E-GENE E-GENE
( O O
Noegel O O
, O O
A O O
. O O
, O O
W O O
. O O
By O O
contrast O O
, O O
clonidine O O
( O O
1 O O
micrograms O O
/ O O
kg O O
) O O
elicited O O
an O O
immediate O O
and O O
prolonged O O
fall O O
in O O
blood O O
pressure O O
and O O
heart O O
rate O O
when O O
given O O
into O O
the O O
vertebral O O
artery O O
, O O
but O O
not O O
intravenously O O
. O O
The O O
shift O O
from O O
complex O O
I O O
to O O
complex O O
II O O
seen O O
only O O
in O O
SCM B-GENE O
- I-GENE O
1 E-GENE O
- O O
producer O O
T O O
cell O O
lines O O
upon O O
activation O O
was O O
completely O O
suppressed O O
by O O
cyclosporin O O
A O O
. O O
( O O
We O O
observed O O
a O O
ferritin S-GENE O
value O O
as O O
high O O
as O O
47 O O
mg O O
/ O O
L O O
in O O
one O O
patient O O
. O O
) O O
Results O O
with O O
all O O
these O O
kits O O
did O O
not O O
inter O O
- O O
compare O O
well O O
for O O
ferritin S-GENE O
concentrations O O
greater O O
than O O
300 O O
micrograms O O
/ O O
L O O
, O O
a O O
finding O O
that O O
casts O O
further O O
doubt O O
on O O
the O O
controversial O O
use O O
of O O
serum B-GENE O
ferritin E-GENE O
measurement O O
in O O
cases O O
of O O
iron O O
overload O O
. O O
Post O O
- O O
CPB O O
cardiac O O
index O O
was O O
superior O O
in O O
group O O
B O O
( O O
3 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
vs O O
. O O
ER B-GENE B-GENE
beta E-GENE E-GENE
was O O
less O O
potent O O
than O O
ER B-GENE B-GENE
alpha E-GENE E-GENE
in O O
activating O O
E2 O O
- O O
stimulated O O
ERELuc S-GENE S-GENE
activity O O
( O O
4 O O
- O O
vs O O
. O O
The O O
expression O O
pattern O O
of O O
LjEmx S-GENE S-GENE
changed O O
dramatically O O
during O O
embryogenesis O O
; O O
expression O O
was O O
seen O O
initially O O
in O O
the O O
entire O O
neural O O
tube O O
and O O
mesoderm O O
, O O
which O O
were O O
secondarily O O
downregulated O O
, O O
and O O
secondarily O O
in O O
cranial O O
nerve O O
ganglia O O
and O O
in O O
the O O
craniofacial O O
mesenchyme O O
. O O
Disruption O O
of O O
PML B-GENE B-GENE
subnuclear I-GENE I-GENE
domains E-GENE E-GENE
by O O
the O O
acidic B-GENE O
IE1 I-GENE B-GENE
protein E-GENE E-GENE
of O O
human O O
cytomegalovirus O O
is O O
mediated O O
through O O
interaction O O
with O O
PML S-GENE S-GENE
and O O
may O O
modulate O O
a O O
RING O O
finger O O
- O O
dependent O O
cryptic O O
transactivator O O
function O O
of O O
PML S-GENE S-GENE
. O O
Furthermore O O
, O O
the O O
GC O O
- O O
rich O O
sequences O O
could O O
confer O O
Sp1 S-GENE S-GENE
- O O
dependent O O
transactivation O O
to O O
a O O
heterologous O O
prolactin B-GENE O
minimal I-GENE O
promoter E-GENE O
. O O
Twelve O O
patients O O
of O O
leprosy O O
with O O
arthritis O O
and O O
161 O O
patients O O
without O O
arthritis O O
were O O
studied O O
for O O
immunological O O
parameters O O
like O O
immunoglobulins S-GENE O
( O O
IgG S-GENE S-GENE
, O O
IgM S-GENE S-GENE
, O O
IgA S-GENE S-GENE
) O O
, O O
C B-GENE O
- I-GENE O
reactive I-GENE O
proteins E-GENE O
and O O
rheumatoid B-GENE O
factor E-GENE O
. O O
Several O O
reports O O
assert O O
that O O
prolactin S-GENE O
affects O O
the O O
delta O O
5 O O
and O O
delta O O
4 O O
pathways O O
through O O
its O O
effect O O
on O O
the O O
activity O O
of O O
3beta B-GENE B-GENE
- I-GENE I-GENE
hydroxysteroid I-GENE I-GENE
dehydrogenase E-GENE E-GENE
( O O
3beta B-GENE O
- I-GENE O
OHSD E-GENE S-GENE
) O O
. O O
The O O
NrfC B-GENE B-GENE
polypeptide E-GENE E-GENE
, O O
M B-GENE O
( I-GENE O
r I-GENE O
) I-GENE O
24 I-GENE O
, I-GENE O
567 E-GENE O
, O O
contains O O
16 O O
cysteine O O
residues O O
arranged O O
in O O
four O O
clusters O O
typical O O
of O O
the O O
CooF B-GENE B-GENE
super I-GENE I-GENE
- I-GENE I-GENE
family E-GENE E-GENE
of O O
non O O
- O O
haem O O
iron O O
- O O
sulphur O O
proteins O O
. O O
Zonography O O
in O O
urology O O
( O O
author O O
' O O
s O O
transl O O
) O O
( O O
i O O
) O O
p60 S-GENE O
bound O O
fast O O
- O O
migrating O O
, O O
underprocessed O O
wild B-GENE O
- I-GENE O
type I-GENE O
ICP22 E-GENE O
and O O
ICP22 S-GENE S-GENE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
24 O O
amino O O
acids O O
but O O
not O O
ICP22 S-GENE S-GENE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
40 O O
amino O O
acids O O
, O O
whereas O O
the O O
previously O O
identified O O
cellular B-GENE O
protein I-GENE O
p78 E-GENE S-GENE
( O O
R O O
. O O
Stress O O
thallium O O
- O O
201 O O
myocardial O O
imaging O O
was O O
used O O
in O O
two O O
angina O O
- O O
free O O
patients O O
with O O
severe O O
congestive O O
heart O O
failure O O
to O O
identify O O
clinically O O
silent O O
areas O O
of O O
ischemic O O
myocardium O O
and O O
to O O
distinguish O O
between O O
scar O O
and O O
reversibly O O
ischemic O O
myocardium O O
as O O
a O O
cause O O
for O O
akinesia O O
of O O
left O O
ventricular O O
wall O O
segments O O
. O O
The O O
community O O
- O O
acquired O O
bacteremia O O
was O O
mainly O O
due O O
to O O
E O O
. O O
coli O O
. O O
Y1 S-GENE O
, O O
Y2 S-GENE O
, O O
and O O
Y4 S-GENE O
/ O O
PP1 S-GENE O
. O O
Low O O
plasma O O
glucose O O
concentrations O O
that O O
may O O
or O O
may O O
not O O
be O O
sufficiently O O
low O O
to O O
result O O
in O O
symptoms O O
can O O
be O O
observed O O
as O O
a O O
concomitant O O
of O O
several O O
diverse O O
diseases O O
. O O
Developmentally O O
- O O
regulated O O
interaction O O
of O O
a O O
transcription O O
factor O O
complex O O
containing O O
CDP S-GENE O
/ O O
cut S-GENE O
with O O
the O O
early B-GENE O
histone I-GENE B-GENE
H3 I-GENE I-GENE
gene I-GENE I-GENE
promoter I-GENE E-GENE
of I-GENE O
the I-GENE O
sea I-GENE O
urchin I-GENE O
Tetrapygus I-GENE O
niger E-GENE O
is O O
associated O O
with O O
changes O O
in O O
chromatin O O
structure O O
and O O
gene O O
expression O O
. O O
Procedures O O
with O O
perfected O O
method O O
After O O
a O O
shift O O
to O O
37 O O
degrees O O
C O O
, O O
the O O
mutant O O
Rat7 B-GENE O
- I-GENE O
1p E-GENE O
/ O O
Nup159 B-GENE O
- I-GENE O
1p E-GENE O
is O O
lost O O
from O O
the O O
nuclear O O
rim O O
of O O
rat7 O O
- O O
1 O O
cells O O
and O O
NPCs O O
, O O
which O O
are O O
clustered O O
together O O
in O O
these O O
cells O O
grown O O
under O O
permissive O O
conditions O O
become O O
substantially O O
less O O
clustered O O
. O O
The O O
mRNA O O
for O O
this O O
protein O O
is O O
expressed O O
in O O
the O O
T O O
- O O
ALL O O
cell O O
line O O
Jurkat O O
and O O
has O O
been O O
designated O O
HUG1 S-GENE S-GENE
, O O
for O O
HOX11 B-GENE B-GENE
Upstream I-GENE I-GENE
Gene E-GENE E-GENE
. O O
The O O
STS B-GENE B-GENE
sequence I-GENE I-GENE
WI I-GENE I-GENE
- I-GENE I-GENE
14920 E-GENE E-GENE
is O O
in O O
fact O O
derived O O
from O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
the O O
human B-GENE B-GENE
PUNC I-GENE I-GENE
gene E-GENE E-GENE
. O O
Its O O
activity O O
was O O
twice O O
that O O
of O O
a O O
construct O O
where O O
the O O
CAT B-GENE B-GENE
gene E-GENE E-GENE
was O O
driven O O
by O O
the O O
H B-GENE O
- I-GENE O
2Kb I-GENE O
5 I-GENE O
' I-GENE O
enhancer I-GENE O
region E-GENE O
( O O
H2TF1 S-GENE O
/ O O
KBF1 S-GENE O
site O O
) O O
and O O
comparable O O
to O O
that O O
of O O
pRSVCAT O O
construct B-GENE O
carrying I-GENE O
the I-GENE O
strong I-GENE O
Rous I-GENE O
sarcoma I-GENE O
virus I-GENE O
LTR I-GENE O
enhancer E-GENE O
. O O
ORF3 O S-GENE
appears O O
to O O
encode O O
the O O
homologue O O
of O O
the O O
well O O
- O O
conserved O O
proteasomal B-GENE O
26S I-GENE O
regulatory I-GENE O
subunit E-GENE O
. O O
The O O
tam B-GENE O
A I-GENE O
gene I-GENE O
of I-GENE O
Aspergillus I-GENE O
nidulans E-GENE O
encodes O O
a O O
739 O O
- O O
amino O O
acid O O
protein O O
with O O
similarity O O
to O O
Uga35p S-GENE S-GENE
/ O O
Dal81p S-GENE S-GENE
/ O O
DurLp S-GENE S-GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O
Little O O
honoured O O
in O O
his O O
own O O
country O O
: O O
statues O O
in O O
recognition O O
of O O
Edward O O
Jenner O O
MD O O
FRS O O
. O O
A O O
pharmacokinetic O O
interaction O O
between O O
LY354740 O O
and O O
diazepam O O
, O O
leading O O
to O O
the O O
lowering O O
of O O
the O O
plasma O O
level O O
of O O
free O O
diazepam O O
, O O
was O O
also O O
demonstrated O O
. O O
The O O
promoter O O
of O O
this O O
methyltransferase O O
gene O O
lacks O O
an O O
identifiable O O
TATA O O
box O O
but O O
is O O
characterized O O
by O O
a O O
CpG O O
island O O
which O O
begins O O
approximately O O
723 O O
nucleotides O O
upstream O O
of O O
the O O
major O O
transcriptional O O
start O O
site O O
and O O
extends O O
through O O
exon O O
1 O O
and O O
into O O
the O O
first O O
intron O O
. O O
No O O
promoter O O
activity O O
could O O
be O O
detected O O
with O O
various O O
mouse B-GENE O
Fli I-GENE O
- I-GENE O
1 I-GENE O
promoter E-GENE O
- O O
CAT S-GENE O
constructs O O
containing O O
600 O O
bp O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
, O O
the O O
complete O O
exon O O
1 O O
, O O
the O O
5 O O
' O O
end O O
of O O
intron O O
1 O O
and O O
/ O O
or O O
retroviral O O
LTR O O
sequence O O
. O O
The O O
D O O
. O O
discoideum O O
proteins O O
were O O
entirely O O
conserved O O
over O O
the O O
four O O
regions O O
known O O
to O O
be O O
important O O
for O O
GTP O S-GENE
binding O O
and O O
all O O
contained O O
the O O
C O O
- O O
terminal O O
CAAX O O
aa O O
motifs O O
shared O O
by O O
other O O
Rho B-GENE B-GENE
proteins E-GENE E-GENE
. O O
An O O
81 O O
- O O
nt O O
tandem O O
duplication O O
of O O
the O O
C O O
- O O
terminal O O
coding O O
region O O
is O O
located O O
adjacent O O
to O O
the O O
termination O O
codon O O
of O O
the O O
CyIIIb B-GENE B-GENE
gene E-GENE E-GENE
, O O
a O O
potential O O
relic O O
of O O
a O O
slipped O O
mispairing O O
and O O
replication O O
event O O
. O O
Only O O
53 O O
% O O
of O O
all O O
injuries O O
and O O
12 O O
. O O
5 O O
% O O
of O O
serious O O
injuries O O
involved O O
children O O
, O O
and O O
in O O
contrast O O
to O O
the O O
1950s O O
and O O
early O O
1960s O O
, O O
young O O
adults O O
appear O O
at O O
greatest O O
risk O O
in O O
the O O
1980s O O
. O O
The O O
method O O
was O O
tested O O
on O O
7 O O
rats O O
with O O
48 O O
- O O
hr O O
- O O
old O O
myocardial O O
infarction O O
and O O
4 O O
sham O O
- O O
operated O O
controls O O
. O O
Here O O
we O O
examine O O
the O O
population O O
of O O
gammaS B-GENE O
transcripts E-GENE O
in O O
adult O O
human O O
lens O O
and O O
the O O
structure O O
of O O
the O O
human B-GENE B-GENE
CRYGS I-GENE I-GENE
genes E-GENE E-GENE
. O O
The O O
slope O O
of O O
QD O O
versus O O
QEMF O O
for O O
the O O
four O O
tubes O O
was O O
near O O
unity O O
. O O
The O O
extent O O
of O O
the O O
odontoblast O O
process O O
in O O
human O O
dentin O O
. O O
Mouse B-GENE B-GENE
macrophage I-GENE I-GENE
beta I-GENE I-GENE
subunit I-GENE E-GENE
( I-GENE O
CD11b I-GENE S-GENE
) I-GENE O
cDNA E-GENE O
for O O
the O O
CR3 B-GENE B-GENE
complement I-GENE I-GENE
receptor E-GENE E-GENE
/ O O
Mac B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
antigen E-GENE E-GENE
. O O
Enoxacin O O
has O O
been O O
shown O O
to O O
be O O
an O O
effective O O
well O O
tolerated O O
and O O
convenient O O
treatment O O
for O O
gonorrhoea O O
. O O
We O O
assessed O O
cardiovascular O O
variables O O
and O O
blood O O
O2 O O
contents O O
in O O
order O O
to O O
characterize O O
O2 O O
transport O O
in O O
ponies O O
during O O
treadmill O O
exercise O O
. O O
The O O
findings O O
are O O
discussed O O
with O O
reference O O
to O O
possible O O
mechanisms O O
by O O
which O O
parasite O O
development O O
might O O
be O O
controlled O O
. O O
The O O
80 O O
kb O O
preceding O O
the O O
expression O O
site O O
has O O
few O O
, O O
if O O
any O O
, O O
functional O O
ORFs O O
, O O
but O O
contains O O
50 O O
bp O O
repeats O O
, O O
INGI B-GENE O
retrotransposon I-GENE O
- I-GENE O
like I-GENE O
elements E-GENE O
, O O
and O O
novel O O
4 O O
- O O
12 O O
kb O O
repeats O O
found O O
near O O
other O O
telomeres O O
. O O
The O O
predicted O O
proteins O O
show O O
strong O O
homology O O
to O O
an O O
ABA B-GENE O
- I-GENE O
inducible I-GENE O
glycine I-GENE O
- I-GENE O
rich I-GENE O
protein E-GENE O
from O O
maize O O
embryos O O
and O O
to O O
the O O
mammalian B-GENE B-GENE
RNA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
A1 E-GENE E-GENE
of O O
the O O
heterogeneous O O
nuclear O O
ribonucleoprotein O O
complex O O
involved O O
in O O
pre O O
- O O
mRNA O O
splicing O O
. O O
Increase O O
in O O
[ O O
Ca O O
+ O O
+ O O
] O O
counteracted O O
the O O
effects O O
of O O
verapamil O O
on O O
RAD O O
. O O
We O O
compared O O
the O O
quantities O O
collected O O
with O O
both O O
pollen O O
traps O O
during O O
February O O
, O O
March O O
and O O
April O O
1988 O O
and O O
1989 O O
. O O
Cbl S-GENE S-GENE
is O O
a O O
signaling O O
molecule O O
with O O
multiple O O
functional O O
domains O O
: O O
an O O
SH2 B-GENE S-GENE
domain E-GENE O
which O O
binds O O
phosphotyrosine O O
residues O O
, O O
a O O
RING O O
finger O O
domain O O
which O O
acts O O
as O O
a O O
ubiquitin B-GENE B-GENE
ligase E-GENE E-GENE
, O O
a O O
proline O O
- O O
rich O O
region O O
which O O
serves O O
as O O
a O O
docking O O
site O O
for O O
SH3 B-GENE B-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
proteins E-GENE E-GENE
, O O
phosphotyrosine O O
residues O O
which O O
serve O O
as O O
docking O O
sites O O
for O O
SH2 B-GENE B-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
proteins E-GENE E-GENE
such O O
a O O
CrkL S-GENE S-GENE
and O O
the O O
p85 B-GENE B-GENE
subunit E-GENE E-GENE
of O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
, O O
and O O
a O O
nuclear O O
localization O O
signal O O
. O O
Surprisingly O O
, O O
apo B-GENE B-GENE
- I-GENE I-GENE
iso I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
- I-GENE I-GENE
cytochrome I-GENE I-GENE
c E-GENE E-GENE
is O O
absent O O
in O O
cyc3 B-GENE O
- E-GENE O
strains O O
, O O
although O O
apo B-GENE B-GENE
- I-GENE I-GENE
iso I-GENE I-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
- I-GENE I-GENE
cytochrome I-GENE I-GENE
c E-GENE E-GENE
is O O
present O O
at O O
approximately O O
the O O
same O O
level O O
at O O
which O O
holo B-GENE O
- I-GENE O
iso I-GENE O
- I-GENE O
2 I-GENE O
- I-GENE O
cytochrome I-GENE O
c E-GENE O
is O O
found O O
in O O
CYC3 B-GENE O
+ E-GENE O
strains O O
. O O
Here O O
, O O
we O O
identify O O
the O O
analytical O O
form O O
of O O
the O O
PDF O O
of O O
one O O
such O O
measure O O
, O O
the O O
order O O
parameter O O
in O O
the O O
low O O
temperature O O
phase O O
of O O
the O O
2D O O
XY O O
model O O
. O O
The O O
ventricular O O
demand O O
pacemaker O O
( O O
VVI O O
) O O
was O O
implanted O O
three O O
years O O
ago O O
and O O
because O O
of O O
further O O
impairment O O
of O O
cardiac O O
performance O O
an O O
av O O
- O O
sequential O O
pacemaker O O
( O O
DDD O O
) O O
was O O
used O O
to O O
restore O O
atrio O O
- O O
ventricular O O
synchronisation O O
. O O
It O O
was O O
predicted O O
that O O
the O O
Stroop O O
task O O
would O O
trigger O O
greater O O
consumption O O
of O O
ice O O
cream O O
than O O
a O O
fearful O O
film O O
, O O
and O O
that O O
this O O
effect O O
would O O
be O O
more O O
pronounced O O
for O O
binge O O
- O O
eaters O O
than O O
non O O
- O O
binge O O
- O O
eaters O O
. O O
Our O O
data O O
are O O
in O O
line O O
with O O
the O O
hypothesis O O
that O O
E2F S-GENE S-GENE
functions O O
as O O
a O O
growth O O
- O O
and O O
cell O O
cycle O O
regulated O O
tethering O O
factor O O
between O O
Sp1 S-GENE S-GENE
and O O
the O O
basic O O
transcription O O
machinery O O
. O O
There O O
was O O
a O O
positive O O
correlation O O
between O O
change O O
from O O
baseline O O
in O O
parietal O O
lobe O O
gray O O
- O O
matter O O
cytosolic O O
choline O O
, O O
expressed O O
in O O
terms O O
of O O
choline O O
/ O O
creatine O O
resonance O O
ratios O O
, O O
and O O
cognitive O O
performance O O
as O O
measured O O
with O O
the O O
Alzheimer O O
' O O
s O O
Disease O O
Assessment O O
Scale O O
Cognitive O O
Subscale O O
. O O
Colonization O O
increased O O
with O O
level O O
of O O
care O O
: O O
from O O
9 O O
per O O
cent O O
in O O
independent O O
residents O O
of O O
apartments O O
to O O
60 O O
per O O
cent O O
in O O
patients O O
on O O
an O O
acute O O
hospital O O
ward O O
( O O
P O O
less O O
than O O
0 O O
. O O
0001 O O
) O O
. O O
IRA2 S-GENE S-GENE
, O O
a O O
second O O
gene O O
of O O
Saccharomyces O O
cerevisiae O O
that O O
encodes O O
a O O
protein O O
with O O
a O O
domain O O
homologous O O
to O O
mammalian O B-GENE
ras B-GENE I-GENE
GTPase I-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
. O O
Exon O O
A1a O O
encodes O O
most O O
of O O
the O O
5 O O
' O O
- O O
untranslated O O
region O O
. O O
Co O O
- O O
operativity O O
of O O
functional O O
domains O O
in O O
the O O
muscle B-GENE O
- I-GENE O
specific I-GENE O
transcription I-GENE O
factor I-GENE O
Myf I-GENE B-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
. O O
Creatinine O O
and O O
creatine B-GENE O
phosphokinase E-GENE O
( O O
CPK S-GENE O
) O O
. O O
In O O
our O O
initial O O
studies O O
, O O
we O O
treated O O
MCF O O
- O O
7 O O
cells O O
with O O
paclitaxel O O
, O O
which O O
results O O
in O O
the O O
arrest O O
of O O
cells O O
in O O
G1 O O
with O O
4n O O
DNA O O
content O O
( O O
pseudo O O
G1 O O
) O O
. O O
These O O
alterations O O
occurred O O
at O O
both O O
the O O
mRNA O O
and O O
protein O O
levels O O
but O O
did O O
not O O
significantly O O
affect O O
the O O
subcellular O O
distribution O O
of O O
any O O
of O O
the O O
four O O
isoforms O O
. O O
The O O
glyoxysomal O O
and O O
plastid O O
molecular O O
chaperones O O
( O O
70 B-GENE O
- I-GENE O
kDa I-GENE O
heat I-GENE O
shock I-GENE O
protein E-GENE O
) O O
of O O
watermelon O O
cotyledons O O
are O O
encoded O O
by O O
a O O
single O O
gene O O
. O O
Suspected O O
pelvic O O
endometriosis O O
was O O
prospectively O O
evaluated O O
in O O
31 O O
women O O
with O O
T1 O O
- O O
and O O
T2 O O
- O O
weighted O O
conventional O O
spin O O
- O O
echo O O
( O O
CSE O O
) O O
magnetic O O
resonance O O
imaging O O
alone O O
and O O
in O O
combination O O
with O O
T1 O O
- O O
weighted O O
fat O O
- O O
suppressed O O
( O O
T1FS O O
) O O
and O O
gadolinium O O
- O O
enhanced O O
T1FS O O
( O O
Gd O O
- O O
T1FS O O
) O O
spin O O
- O O
echo O O
techniques O O
. O O
Seroconversion O O
after O O
hepatitis O O
B O O
vaccination O O
. O O
A O O
case O O
of O O
bilateral O O
testicular O O
germ O O
cell O O
tumors O O
in O O
a O O
23 O O
- O O
year O O
- O O
old O O
male O O
is O O
reported O O
. O O
Total O O
body O O
BMD O O
( O O
r O O
= O O
0 O O
. O O
30 O O
; O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
femoral O O
neck O O
BMD O O
( O O
r O O
= O O
0 O O
. O O
39 O O
; O O
P O O
= O O
0 O O
. O O
002 O O
) O O
were O O
positively O O
correlated O O
with O O
weight O O
- O O
bearing O O
activity O O
but O O
not O O
with O O
non O O
- O O
weight O O
- O O
bearing O O
activity O O
. O O
The O O
effects O O
of O O
castor O O
oil O O
, O O
alone O O
, O O
as O O
well O O
as O O
in O O
combination O O
with O O
PGI2 O O
and O O
indomethacin O O
on O O
gastrointestinal O O
functions O O
have O O
been O O
examined O O
in O O
rats O O
. O O
Checking O O
for O O
patient O O
compliance O O
, O O
samples O O
( O O
n O O
= O O
10 O O
) O O
with O O
a O O
FK O O
I O O
concentration O O
of O O
0 O O
ng O O
/ O O
mL O O
were O O
re O O
- O O
analyzed O O
. O O
K O O
. O O
The O O
hematopoietic O O
form O O
of O O
PTPN6 B-GENE B-GENE
transcript E-GENE E-GENE
is O O
initiated O O
at O O
a O O
downstream O O
promoter O O
separated O O
by O O
7 O O
kb O O
from O O
the O O
first O O
. O O
The O O
residual O O
small O O
rRNAs O O
in O O
[ O O
poky O O
] O O
appear O O
to O O
be O O
synthesized O O
via O O
the O O
upstream O O
promoter O O
( O O
s O O
) O O
, O O
but O O
are O O
missing O O
37 O O
- O O
44 O O
nucleotides O O
from O O
their O O
5 O O
' O O
ends O O
, O O
indicating O O
either O O
that O O
pre O O
- O O
rRNAs O O
are O O
processed O O
abnormally O O
or O O
that O O
abnormal O O
5 O O
' O O
RNA O O
ends O O
are O O
unstable O O
. O O
Extra O O
dose O O
due O O
to O O
extravehicular O O
activity O O
during O O
the O O
NASA4 O S-GENE
mission O O
measured O O
by O O
an O O
on O O
- O O
board O O
TLD O O
system O O
. O O
Unconventional O O
mRNA O O
processing O O
in O O
the O O
expression O O
of O O
two O O
calcineurin B-GENE B-GENE
B I-GENE I-GENE
isoforms E-GENE E-GENE
in O O
Dictyostelium O O
. O O
The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
this O O
open O O
reading O O
frame O O
is O O
significantly O O
homologous O O
to O O
the O O
HSV B-GENE B-GENE
1 I-GENE I-GENE
UL49 I-GENE I-GENE
. I-GENE I-GENE
5 I-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
, O O
and O O
as O O
with O O
UL49 B-GENE B-GENE
. I-GENE I-GENE
5 E-GENE E-GENE
, O O
it O O
contains O O
a O O
potential O O
signal O O
sequence O O
and O O
transmembrane O O
domain O O
characteristic O O
of O O
membrane O O
- O O
associated O O
proteins O O
. O O
It O O
has O O
been O O
demonstrated O O
that O O
stimulation O O
of O O
the O O
pontomesencephalic O O
parabrachial O O
region O O
( O O
PBR O O
) O O
by O O
microinjection O O
of O O
cholinergic O O
drugs O O
or O O
electricity O O
in O O
the O O
cat O O
produces O O
potent O O
pain O O
suppression O O
which O O
is O O
not O O
antagonized O O
by O O
the O O
opiate O O
antagonist O O
, O O
naloxone O O
. O O
GAGA B-GENE B-GENE
factor E-GENE E-GENE
is O O
known O O
to O O
remodel O O
the O O
chromatin O O
structure O O
in O O
concert O O
with O O
nucleosome B-GENE O
- I-GENE O
remodeling I-GENE O
factor E-GENE O
NURF S-GENE S-GENE
in O O
a O O
Drosophila O O
embryonic O O
S150 O O
extract O O
. O O
Also O O
, O O
like O O
TUB S-GENE O
, O O
it O O
has O O
a O O
wider O O
pattern O O
of O O
tissue O O
expression O O
than O O
either O O
TULP1 S-GENE O
or O O
TULP2 S-GENE S-GENE
. O O
After O O
nine O O
months O O
GFR O O
improved O O
spontaneously O O
to O O
32 O O
ml O O
/ O O
min O O
/ O O
1 O O
. O O
73 O O
m2 O O
despite O O
no O O
improvement O O
in O O
his O O
hypertension O O
. O O
First O O
, O O
ste12Delta S-GENE O
cells O O
differ O O
from O O
cells O O
with O O
disruptions O O
of O O
the O O
upstream O O
signaling O O
elements O O
( O O
e O O
. O O
g O O
. O O
, O O
ste4Delta S-GENE O
, O O
ste20Delta S-GENE O
, O O
ste5Delta S-GENE O
, O O
ste11Delta S-GENE O
, O O
ste7Delta S-GENE O
, O O
or O O
fus3Delta S-GENE O
kss1Delta S-GENE O
cells O O
) O O
in O O
that O O
they O O
clearly O O
retain O O
some O O
capacity O O
for O O
inducing O O
Ste3p S-GENE O
phosphorylation O O
. O O
Herein O O
, O O
we O O
report O O
that O O
CRE O O
- O O
decoy O O
oligonucleotide O O
treatment O O
results O O
in O O
an O O
increase O O
in O O
the O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
level O O
in O O
MCF O O
- O O
7 O O
human O O
breast O O
cancer O O
cells O O
that O O
express O O
wild O O
- O O
type O O
p53 S-GENE S-GENE
. O O
The O O
selective O O
5 B-GENE B-GENE
- I-GENE I-GENE
HT2 I-GENE I-GENE
receptor E-GENE E-GENE
blocker O O
ketanserin O O
was O O
found O O
to O O
reduce O O
maximal O O
urethral O O
pressures O O
in O O
healthy O O
females O O
by O O
about O O
40 O O
% O O
without O O
reducing O O
blood O O
pressure O O
. O O
It O O
thus O O
seems O O
likely O O
that O O
genistein O O
affects O O
a O O
common O O
pathway O O
downstream O O
of O O
these O O
signals O O
. O O
Studies O O
in O O
B O O
. O O
glabrata O O
, O O
B O O
. O O
straminea O O
and O O
B O O
. O O
tenagophila O O
under O O
outdoor O O
conditions O O
. O O
The O O
electrocardiogram O O
in O O
tachycardia O O
. O O
Identification O O
of O O
a O O
putative O O
chromosomal O O
replication O O
origin O O
from O O
Helicobacter O O
pylori O O
and O O
its O O
interaction O O
with O O
the O O
initiator B-GENE O
protein I-GENE O
DnaA E-GENE S-GENE
. O O
The O O
primary O O
structure O O
of O O
cholesterol B-GENE O
esterase E-GENE O
displayed O O
no O O
significant O O
homology O O
with O O
other O O
lipases S-GENE O
, O O
although O O
the O O
putative O O
lipid O O
interfacial O O
recognition O O
site O O
of O O
G O O
- O O
X O O
- O O
S O O
- O O
X O O
- O O
G O O
is O O
present O O
in O O
the O O
cholesterol B-GENE O
esterase I-GENE O
sequence E-GENE O
. O O
The O O
essential O O
questions O O
about O O
hepatitis O O
C O O
The O O
transcriptional O O
initiation O O
site O O
of O O
RAG1 S-GENE S-GENE
was O O
localized O O
at O O
A O O
, O O
26 O O
bp O O
upstream O O
of O O
the O O
putative O O
translational O O
initiation O O
codon O O
, O O
ATG O S-GENE
, O O
by O O
the O O
primer O O
extension O O
assay O O
. O O
Coronary O O
arteriographies O O
and O O
ventriculographies O O
corresponding O O
to O O
274 O O
consecutive O O
patients O O
( O O
January O O
, O O
1975 O O
- O O
October O O
, O O
1978 O O
) O O
with O O
significant O O
coronary O O
lesions O O
are O O
reviewed O O
. O O
Visualization O O
of O O
the O O
cells O O
by O O
phase O O
contrast O O
microscopy O O
indicated O O
that O O
murine B-GENE O
PKCepsilon E-GENE O
expression O O
in O O
the O O
presence O O
of O O
glycerol O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
the O O
number O O
of O O
yeast O O
cells O O
exhibiting O O
very O O
small O O
buds O O
. O O
Sonography O O
depicted O O
the O O
true O O
morphology O O
of O O
these O O
cystic O O
lesions O O
more O O
clearly O O
than O O
CT O O
, O O
and O O
the O O
sonographic O O
findings O O
virtually O O
excluded O O
uncomplicated O O
hepatic O O
cyst O O
as O O
a O O
diagnosis O O
. O O
Protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
transiently O O
activated O O
heteromeric B-GENE O
N I-GENE O
- I-GENE O
methyl I-GENE O
- I-GENE O
D I-GENE O
- I-GENE O
aspartate I-GENE O
receptor I-GENE O
channels E-GENE O
independent O O
of O O
the O O
phosphorylatable O O
C O O
- O O
terminal O O
splice O O
domain O O
and O O
of O O
consensus O O
phosphorylation O O
sites O O
. O O
A O O
24 O O
- O O
year O O
- O O
old O O
pregnant O O
woman O O
started O O
to O O
have O O
hyperemesis O O
gravidarum O O
6 O O
weeks O O
before O O
admission O O
. O O
Highly O O
significant O O
similarities O O
were O O
detected O O
between O O
the O O
N O O
- O O
terminal O O
region O O
of O O
P30 S-GENE O
and O O
those O O
of O O
GENA S-GENE O
[ O O
the O O
product O O
of O O
another O O
unidentified O O
gene O O
( O O
geneA S-GENE S-GENE
) O O
located O O
upstream O O
of O O
the O O
aceEF S-GENE B-GENE
- O I-GENE
lpd S-GENE I-GENE
operon O E-GENE
] O O
, O O
and O O
GNTR S-GENE S-GENE
( O O
a O O
putative O O
transcriptional O O
repressor O O
of O O
the O O
gluconate B-GENE O
operon E-GENE O
of O O
Bacillus O O
subtilis O O
) O O
. O O
In O O
vitro O O
DNA O O
binding O O
assays O O
indicate O O
that O O
the O O
elements O O
identified O O
can O O
specifically O O
interact O O
with O O
c B-GENE B-GENE
- I-GENE I-GENE
Ets I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
protein E-GENE E-GENE
. O O
They O O
are O O
found O O
to O O
have O O
several O O
advantages O O
over O O
the O O
conventional O O
indices O O
of O O
skewness O O
and O O
kurtosis O O
( O O
square O O
root O O
of O O
b1 O O
and O O
b2 O O
) O O
and O O
no O O
serious O O
drawbacks O O
. O O
They O O
elicit O O
similar O O
regional O O
cerebral O O
blood O O
flow O O
( O O
rCBF O O
) O O
patterns O O
, O O
even O O
though O O
sign O O
language O O
is O O
dependent O O
on O O
spatial O O
information O O
. O O
Siglec B-GENE B-GENE
- I-GENE I-GENE
9 E-GENE E-GENE
is O O
predicted O O
to O O
contain O O
three O O
extracellular O O
immunoglobulin B-GENE O
- I-GENE O
like I-GENE O
domains E-GENE O
that O O
comprise O O
an O O
N B-GENE O
- I-GENE O
terminal I-GENE O
V I-GENE O
- I-GENE O
set I-GENE O
domain E-GENE O
and O O
two O O
C2 B-GENE O
- I-GENE O
set I-GENE O
domains E-GENE O
, O O
a O O
transmembrane O O
region O O
and O O
a O O
cytoplasmic O O
tail O O
containing O O
two O O
putative O O
tyrosine O O
- O O
based O O
signaling O O
motifs O O
. O O
Determination O O
of O O
the O O
LD O O
50 O O
( O O
30 O O
) O O
during O O
infant O O
period O O
and O O
growth O O
period O O
The O O
availability O O
of O O
a O O
commercial O O
program O O
( O O
PCNONLIN O O
) O O
is O O
needed O O
to O O
carry O O
out O O
matrix O O
handling O O
calculations O O
. O O
The O O
introduction O O
gives O O
also O O
the O O
history O O
of O O
Research O O
Programme O O
MZ O O
- O O
XVII O O
and O O
its O O
implementation O O
in O O
several O O
regions O O
of O O
Poland O O
. O O
The O O
fecal O O
excretion O O
is O O
found O O
to O O
be O O
only O O
one O O
third O O
of O O
that O O
measured O O
in O O
urine O O
. O O
The O O
COR S-GENE B-GENE
biosynthetic O I-GENE
gene O E-GENE
cluster O O
in O O
P O O
. O O
syringae O O
pv O O
. O O
glycinea O O
PG4180 O S-GENE
is O O
encoded O O
by O O
a O O
32 O O
- O O
kb O O
region O O
which O O
contains O O
both O O
the O O
structural O O
and O O
regulatory O O
genes O O
needed O O
for O O
COR S-GENE S-GENE
synthesis O O
. O O
Model O O
experiments O O
on O O
pheasants O O
using O O
single O O
doses O O
of O O
the O O
insecticide O O
( O O
Lindane O O
) O O
the O O
herbicide O O
( O O
Terbutryn O O
) O O
a O O
mineral O O
fertilizer O O
( O O
calcium O O
ammonium O O
nitrate O O
) O O
and O O
the O O
fungicide O O
( O O
HCB O O
) O O
. O O
In O O
this O O
technique O O
, O O
the O O
posterior O O
wall O O
of O O
the O O
neopharynx O O
consists O O
only O O
of O O
the O O
prevertebral O O
tissue O O
, O O
while O O
the O O
flap O O
forms O O
the O O
anterior O O
and O O
lateral O O
walls O O
. O O
The O O
most O O
common O O
hosts O O
were O O
equines O O
( O O
31 O O
% O O
) O O
, O O
bovines O O
( O O
25 O O
% O O
) O O
and O O
raccoons O O
( O O
19 O O
% O O
) O O
. O O
A O O
single O O
HD O O
session O O
using O O
cellulose O O
triacetate O O
or O O
polysulfone O O
membrane O O
significantly O O
increased O O
water O O
content O O
both O O
at O O
forearm O O
and O O
lower O O
leg O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O
Both O O
claR S-GENE O
and O O
car S-GENE O
are O O
expressed O O
as O O
monocistronic O O
transcripts O O
; O O
the O O
level O O
of O O
transcript O O
declined O O
rapidly O O
after O O
48h O O
in O O
complex O O
media O O
, O O
but O O
low O O
sustained O O
levels O O
of O O
both O O
transcripts O O
were O O
observed O O
in O O
defined O O
GSPG O O
medium O O
until O O
96h O O
. O O
claR S-GENE S-GENE
and O O
car S-GENE O
were O O
not O O
significantly O O
expressed O O
in O O
mutants O O
disrupted O O
in O O
the O O
ccaR B-GENE B-GENE
gene E-GENE E-GENE
, O O
a O O
regulatory O O
gene O O
that O O
controls O O
positively O O
clavulanic O O
acid O O
and O O
cephamycin O O
biosynthesis O O
. O O
Whereas O O
mutant B-GENE O
6C4 E-GENE S-GENE
specified O O
a O O
wild B-GENE O
- I-GENE O
type I-GENE O
- I-GENE O
size I-GENE O
Pol I-GENE O
protein E-GENE O
, O O
we O O
detected O O
no O O
full B-GENE O
- I-GENE O
length I-GENE O
Pol I-GENE O
protein E-GENE O
in O O
7E4 O O
- O O
infected O O
cell O O
extracts O O
. O O
The O O
hepatic O O
isoform O O
of O O
6 B-GENE B-GENE
- I-GENE I-GENE
phosphofructo I-GENE I-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
/ O O
fructose B-GENE O
- I-GENE O
2 I-GENE O
, I-GENE O
6 I-GENE O
- I-GENE O
bisphosphatase E-GENE O
( O O
PF2K S-GENE O
/ O O
Fru B-GENE O
- I-GENE O
2 I-GENE O
, I-GENE O
6 I-GENE O
- I-GENE O
BPase E-GENE O
) O O
is O O
transcriptionally O O
stimulated O O
by O O
glucocorticoids O O
, O O
whereas O O
insulin S-GENE O
blocks O O
this O O
stimulatory O O
effect O O
. O O
Being O O
implicated O O
in O O
insulin S-GENE S-GENE
and O O
GK B-GENE B-GENE
gene E-GENE E-GENE
regulations O O
as O O
a O O
common O O
transcription O O
factor O O
, O O
IPF1 S-GENE S-GENE
/ O O
STF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
/ O O
PDX B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
likely O O
to O O
play O O
an O O
essential O O
role O O
in O O
maintaining O O
normal O O
beta O O
- O O
cell O O
functions O O
. O O
The O O
Caenorhabditis B-GENE O
elegans I-GENE O
NK I-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
class I-GENE O
homeoprotein I-GENE O
CEH I-GENE O
- I-GENE O
22 E-GENE O
is O O
involved O O
in O O
combinatorial O O
activation O O
of O O
gene O O
expression O O
in O O
pharyngeal O O
muscle O O
. O O
Mouse O O
embryo O O
cells O O
( O O
C57BL O O
/ O O
6 O O
, O O
H O O
- O O
2b O O
) O O
transformed O O
by O O
the O O
E1A S-GENE S-GENE
and O O
E1B S-GENE B-GENE
genes O E-GENE
of O O
adenovirus O O
type O O
5 O O
( O O
Ad5E1 O O
MEC O O
) O O
are O O
highly O O
immunogenic O O
. O O
The O O
largest O O
age O O
adjusted O O
differences O O
between O O
men O O
with O O
low O O
and O O
normal O O
mood O O
were O O
for O O
the O O
AH4 O O
( O O
3 O O
points O O
, O O
t O O
= O O
5 O O
. O O
6 O O
, O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
the O O
CAMCOG O O
( O O
2 O O
points O O
, O O
t O O
= O O
5 O O
. O O
8 O O
, O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
. O O
Our O O
findings O O
suggest O O
that O O
resting O O
Tl O O
- O O
201 O O
scintigraphy O O
has O O
limited O O
value O O
in O O
the O O
detection O O
of O O
coronary O O
artery O O
disease O O
in O O
patients O O
with O O
Hurler O O
syndrome O O
. O O
We O O
demonstrate O O
that O O
the O O
WRM B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
protein E-GENE E-GENE
binds O O
to O O
LIT B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
vivo O O
and O O
that O O
WRM B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
can O O
activate O O
the O O
LIT B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
when O O
coexpressed O O
in O O
vertebrate O O
tissue O O
culture O O
cells O O
. O O
RESULTS O O
: O O
All O O
primary O O
tumors O O
were O O
positive O O
for O O
CAM5 B-GENE O
. I-GENE O
2 E-GENE O
. O O
Nuclear O O
extracts O O
from O O
Sertoli O O
cells O O
were O O
found O O
to O O
cause O O
an O O
E O O
- O O
box O O
gel O O
shift O O
when O O
the O O
cells O O
were O O
stimulated O O
to O O
differentiate O O
in O O
culture O O
, O O
but O O
not O O
under O O
basal O O
conditions O O
. O O
On O O
the O O
sixth O O
postirradiation O O
day O O
the O O
absorption O O
of O O
phenobarbitone O O
, O O
sulphafurazole O O
and O O
mecamylamine O O
had O O
returned O O
to O O
the O O
control O O
level O O
, O O
but O O
the O O
absorption O O
of O O
quinidine O O
and O O
isoniazid O O
was O O
still O O
retarded O O
. O O
To O O
determine O O
the O O
transactivation O O
potential O O
of O O
each O O
of O O
the O O
four O O
Ahr S-GENE B-GENE
Sp1 B-GENE I-GENE
sites E-GENE E-GENE
, O O
we O O
fused O O
the O O
Ahr B-GENE B-GENE
promoter E-GENE E-GENE
to O O
a O O
luciferase S-GENE O
( O O
LUC S-GENE O
) O O
reporter O O
gene O O
and O O
transfected O O
the O O
construct O O
into O O
the O O
Drosophila O O
cell O O
line O O
Schneider O O
- O O
2 O O
, O O
which O O
contains O O
no O O
Sp1 S-GENE S-GENE
or O O
Sp1 B-GENE S-GENE
- I-GENE O
like I-GENE O
factors E-GENE O
. O O
We O O
determined O O
that O O
Hop B-GENE O
( I-GENE O
T42 I-GENE O
) E-GENE O
contains O O
a O O
glutamic O O
acid O O
- O O
to O O
- O O
lysine O O
substitution O O
at O O
amino O O
acid O O
residue O O
695 O O
( O O
E695K O O
) O O
. O O
The O O
organotins O O
. O O
Results O O
of O O
these O O
studies O O
indicate O O
that O O
binding O O
of O O
biotin O O
to O O
the O O
protein O O
results O O
in O O
protection O O
of O O
regions O O
of O O
the O O
central O O
domain O O
in O O
the O O
vicinity O O
of O O
the O O
active O O
site O O
and O O
the O O
C O O
- O O
terminal O O
domain O O
from O O
chemical O O
cleavage O O
. O O
The O O
psh3 B-GENE S-GENE
( I-GENE O
+ I-GENE O
) I-GENE O
gene E-GENE O
encodes O O
a O O
protein O O
of O O
215 O O
amino O O
acids O O
, O O
which O O
shares O O
a O O
high O O
degree O O
of O O
structural O O
and O O
functional O O
similarity O O
with O O
Shr3p S-GENE S-GENE
. O O
The O O
impairment O O
of O O
the O O
nocturnal O O
secretion O O
was O O
related O O
to O O
the O O
subjects O O
' O O
age O O
and O O
, O O
for O O
the O O
GH S-GENE O
secretory O O
pattern O O
only O O
, O O
also O O
to O O
the O O
MMSE O O
score O O
. O O
Thus O O
, O O
the O O
antibody O O
class O O
switch O O
appears O O
to O O
be O O
directed O O
by O O
induction O O
of O O
accessibility O O
, O O
as O O
assayed O O
by O O
transcription O O
of O O
germ O O
line O O
CH S-GENE B-GENE
genes O E-GENE
. O O
This O O
growth O O
- O O
inhibitory O O
effect O O
was O O
suppressed O O
by O O
the O O
mpk1 B-GENE B-GENE
delta E-GENE I-GENE
mutation O E-GENE
, O O
suggesting O O
that O O
hyperactivation O O
of O O
the O O
Mpk1 S-GENE S-GENE
pathway O O
is O O
toxic O O
to O O
cells O O
. O O
The O O
chicken O O
genome O O
contains O O
two O O
functional O O
nonallelic O O
beta1 B-GENE O
, I-GENE O
4 I-GENE O
- I-GENE O
galactosyltransferase I-GENE O
genes E-GENE O
. O O
Recombinant B-GENE B-GENE
Human I-GENE I-GENE
Erythropoietin E-GENE E-GENE
and O O
Platinum O O
- O O
Based O O
Chemotherapy O O
In O O
Advanced O O
Ovarian O O
Cancer O O
Homodimers O O
of O O
RIP60 S-GENE S-GENE
( O O
replication B-GENE O
initiation I-GENE O
- I-GENE O
region I-GENE O
protein I-GENE O
60 I-GENE O
kDA E-GENE O
) O O
purified O O
from O O
nuclear O O
extract O O
bind O O
two O O
ATT O O
- O O
rich O O
sites O O
in O O
oribeta O O
and O O
foster O O
the O O
formation O O
of O O
a O O
twisted O O
720 O O
bp O O
DNA O O
loop O O
in O O
vitro O O
. O O
Endodontic O O
treatment O O
of O O
deciduous O O
teeth O O
using O O
the O O
formocresol O O
amputation O O
method O O
Some O O
of O O
these O O
physiological O O
responses O O
are O O
regulated O O
via O O
activation O O
of O O
transcription O O
factors O O
such O O
as O O
activator B-GENE B-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
( O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
. O O
To O O
test O O
the O O
role O O
of O O
myb B-GENE B-GENE
family I-GENE E-GENE
members E-GENE O
in O O
progression O O
through O O
the O O
cell O O
cycle O O
, O O
we O O
comicroinjected O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
myc E-GENE E-GENE
and O O
myb S-GENE S-GENE
expression O O
vectors O O
into O O
serum O O
- O O
deprived O O
quiescent O O
SMCs O O
. O O
Overall O O
graft O O
and O O
patient O O
survival O O
after O O
HAT O O
were O O
33 O O
. O O
3 O O
% O O
and O O
75 O O
% O O
, O O
respectively O O
. O O
LAC9 S-GENE S-GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
that O O
regulates O O
transcription O O
of O O
the O O
lactose B-GENE O
- I-GENE O
galactose I-GENE O
regulon E-GENE O
in O O
Kluyveromyces O O
lactis O O
. O O
We O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
gypsy B-GENE O
element E-GENE O
present O O
at O O
the O O
forked B-GENE O
locus E-GENE O
of O O
Drosophila O O
melanogaster O O
in O O
the O O
f1 O B-GENE
allele O E-GENE
. O O
The O O
same O O
high O O
degree O O
of O O
sequence O O
homology O O
between O O
the O O
two O O
F O O
. O O
diplosiphon O B-GENE
PC B-GENE I-GENE
alpha E-GENE E-GENE
and O O
PC B-GENE B-GENE
beta I-GENE I-GENE
sequences E-GENE E-GENE
( O O
85 O O
and O O
77 O O
% O O
, O O
respectively O O
) O O
was O O
found O O
at O O
both O O
the O O
nucleotide O O
and O O
amino O O
acid O O
levels O O
, O O
and O O
similar O O
results O O
were O O
obtained O O
for O O
interspecies O O
comparisons O O
. O O
A O O
wound O O
model O O
for O O
decubitus O O
and O O
leg O O
ulcers O O
consisting O O
of O O
human O O
dermal O O
fibroblasts O O
in O O
type B-GENE O
I I-GENE O
collagen E-GENE O
dermal O O
" O O
equivalent O O
" O O
matrix O O
( O O
DEM O O
) O O
was O O
exposed O O
in O O
vitro O O
to O O
electric O O
fields O O
similar O O
to O O
postulated O O
endogenous O O
fields O O
in O O
wounds O O
. O O
A O O
group O O
of O O
factors O O
known O O
as O O
activating B-GENE O
transcription I-GENE O
factors E-GENE O
( O O
ATF S-GENE S-GENE
) O O
have O O
been O O
found O O
to O O
bind O O
to O O
the O O
latter O O
and O O
related O O
sequences O O
found O O
upstream O O
of O O
early O O
adenovirus O O
promoters O O
induced O O
by O O
E1A S-GENE S-GENE
, O O
and O O
these O O
factors O O
are O O
highly O O
homologous O O
to O O
the O O
CREB B-GENE B-GENE
protein E-GENE E-GENE
. O O
In O O
addition O O
to O O
these O O
cases O O
, O O
patients O O
w O O
with O O
high O O
Loa O O
microfilaremia O O
also O O
developed O O
milder O O
neurologic O O
manifestations O O
causing O O
functional O O
impairment O O
lasting O O
for O O
at O O
least O O
one O O
week O O
after O O
treatment O O
. O O
The O O
vertebrate B-GENE O
transcription I-GENE O
factors I-GENE O
TCF E-GENE S-GENE
( O O
T B-GENE B-GENE
cell I-GENE I-GENE
factor E-GENE E-GENE
) O O
and O O
LEF S-GENE S-GENE
( O O
lymphocyte B-GENE B-GENE
enhancer I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
) O O
interact O O
with O O
beta B-GENE B-GENE
- I-GENE I-GENE
catenin E-GENE E-GENE
and O O
are O O
hypothesized O O
to O O
mediate O O
Wingless S-GENE O
/ O O
Wnt S-GENE S-GENE
signaling O O
. O O
Some O O
of O O
these O O
DNA O O
: O O
protein O O
complexes O O
were O O
also O O
present O O
, O O
but O O
at O O
lower O O
levels O O
, O O
in O O
nuclear O O
extracts O O
from O O
untransformed O O
rat O O
cells O O
suggesting O O
the O O
possible O O
involvement O O
of O O
cellular O O
factors O O
in O O
the O O
mechanism O O
of O O
down O O
- O O
regulation O O
mediated O O
by O O
Ad12 B-GENE B-GENE
E1A E-GENE E-GENE
. O O
Hypocalcemia O O
is O O
usually O O
due O O
to O O
either O O
a O O
disturbance O O
in O O
the O O
parathyroid B-GENE B-GENE
hormone E-GENE I-GENE
- O I-GENE
adenylate B-GENE I-GENE
cyclase E-GENE E-GENE
system O O
or O O
a O O
disturbance O O
in O O
vitamin O O
D O O
metabolism O O
. O O
Activity O O
was O O
reconstituted O O
, O O
however O O
, O O
by O O
combining O O
fractions O O
that O O
were O O
enriched O O
in O O
the O O
two O O
components O O
. O O
If O O
failure O O
to O O
solve O O
invisible O O
displacements O O
was O O
due O O
to O O
increased O O
memory O O
requirements O O
, O O
then O O
the O O
primates O O
should O O
perform O O
at O O
chance O O
level O O
on O O
all O O
3 O O
problems O O
. O O
In O O
seven O O
patients O O
( O O
7 O O
. O O
8 O O
% O O
) O O
with O O
new O O
Q O O
- O O
waves O O
and O O
a O O
pathologic O O
CK B-GENE O
- I-GENE O
MB E-GENE O
profile O O
( O O
group O O
II O O
) O O
troponin B-GENE O
T E-GENE O
reached O O
median O O
levels O O
of O O
10 O O
. O O
47 O O
micrograms O O
/ O O
l O O
( O O
quartile O O
6 O O
. O O
34 O O
- O O
12 O O
. O O
50 O O
micrograms O O
/ O O
l O O
) O O
( O O
P O O
< O O
0 O O
. O O
001 O O
I O O
vs O O
II O O
) O O
. O O
Mineralized O O
bone O O
nodule O O
formation O O
in O O
vitro O O
by O O
cell O O
populations O O
from O O
young O O
adult O O
rabbit O O
alveolar O O
bone O O
. O O
Mouse B-GENE O
GRK6 I-GENE O
- I-GENE O
C E-GENE O
displays O O
none O O
of O O
these O O
motifs O O
. O O
Comparisons O O
of O O
the O O
efficacy O O
of O O
benazepril O O
and O O
hydrochlorothiazide O O
alone O O
and O O
in O O
combination O O
have O O
shown O O
that O O
benazepril O O
20 O O
mg O O
once O O
daily O O
is O O
as O O
effective O O
as O O
or O O
more O O
effective O O
in O O
lowering O O
diastolic O O
blood O O
pressure O O
than O O
hydrochlorothiazide O O
25 O O
mg O O
once O O
daily O O
and O O
that O O
the O O
combination O O
of O O
benazepril O O
20 O O
mg O O
and O O
hydrochlorothiazide O O
25 O O
mg O O
has O O
a O O
possibly O O
synergistic O O
effect O O
on O O
diastolic O O
blood O O
pressure O O
. O O
The O O
132 B-GENE O
- I-GENE O
bp I-GENE O
PHO8p I-GENE O
fragment E-GENE O
, O O
connected O O
at O O
position O O
- O O
281 O O
of O O
the O O
5 O O
' O O
upstream O O
region O O
of O O
a O O
HIS5 B-GENE B-GENE
' E-GENE I-GENE
- O I-GENE
' B-GENE I-GENE
lacZ E-GENE I-GENE
fused O I-GENE
gene O E-GENE
, O O
could O O
sense O O
Pi O O
signals O O
in O O
vivo O O
, O O
but O O
a O O
20 O O
- O O
bp O O
synthetic O O
oligonucleotide O O
having O O
the O O
same O O
sequence O O
from O O
- O O
544 O O
to O O
- O O
525 O O
of O O
the O O
PHO8p B-GENE O
DNA E-GENE O
could O O
not O O
. O O
1988 O O
) O O
. O O
Sequences O O
within O O
the O O
UAS2 O S-GENE
element O O
of O O
the O O
ENO2 B-GENE B-GENE
gene E-GENE E-GENE
bound O O
a O O
second O O
protein O O
which O O
corresponded O O
to O O
the O O
ABFI S-GENE S-GENE
( O O
autonomously B-GENE O
replicating I-GENE O
sequence I-GENE O
- I-GENE O
binding I-GENE O
factor E-GENE O
) O O
protein O O
. O O
Plasmid O O
subclones O O
of O O
recombinant O O
phage O O
lambda O O
Asm152 O S-GENE
were O O
able O O
to O O
complement O O
both O O
Escherichia B-GENE O
coli I-GENE O
gltB E-GENE O
and O O
A O O
. O O
sesbaniae O O
Asm O B-GENE
- O I-GENE
Vi O I-GENE
mutants O E-GENE
; O O
NADPH B-GENE B-GENE
- I-GENE I-GENE
glutamate I-GENE I-GENE
synthase E-GENE E-GENE
activity O O
was O O
detected O O
in O O
all O O
such O O
strains O O
complemented O O
to O O
Asm O O
+ O O
. O O
The O O
sequence O O
of O O
LZ321 S-GENE S-GENE
matched O O
that O O
of O O
RREB1 S-GENE S-GENE
, O O
a O O
transcription O O
factor O O
that O O
bound O O
to O O
a O O
Ras B-GENE B-GENE
responsive I-GENE I-GENE
element E-GENE E-GENE
( O O
RRE S-GENE S-GENE
) O O
very O O
different O O
from O O
the O O
sequence O O
with O O
which O O
we O O
isolated O O
LZ321 S-GENE O
. O O
Steady O O
- O O
state O O
levels O O
of O O
murine B-GENE B-GENE
MMR I-GENE I-GENE
mRNA E-GENE E-GENE
were O O
measured O O
in O O
the O O
macrophage O O
cell O O
line O O
J774E O S-GENE
, O O
which O O
is O O
known O O
to O O
express O O
the O O
protein O O
at O O
the O O
cell O O
surface O O
. O O
Basal O O
level O O
expression O O
was O O
reduced O O
to O O
20 O O
and O O
50 O O
% O O
when O O
the O O
UGA O O
stop O O
codon O O
was O O
replaced O O
by O O
UAG O O
or O O
UAA O O
, O O
respectively O O
, O O
consistent O O
with O O
the O O
finding O O
that O O
in O O
E O O
. O O
coli O O
translation O O
terminates O O
more O O
efficiently O O
at O O
UAG O O
and O O
UAA O O
than O O
at O O
UGA O O
. O O
Discriminant O O
function O O
analysis O O
suggests O O
that O O
AUDIT O O
scores O O
can O O
successfully O O
identify O O
SAT O O
- O O
positive O O
and O O
SAT O O
- O O
negative O O
patients O O
; O O
the O O
analysis O O
accounted O O
for O O
42 O O
. O O
5 O O
% O O
of O O
the O O
variance O O
and O O
correctly O O
classified O O
84 O O
. O O
6 O O
% O O
of O O
the O O
sample O O
. O O
Coronatine S-GENE O
( O O
COR S-GENE O
) O O
is O O
a O O
plasmid O O
- O O
encoded O O
phytotoxin O O
synthesized O O
by O O
several O O
pathovars O O
of O O
phytopathogenic O O
Pseudomonas O O
syringae O O
. O O
Both O O
the O O
5 O O
' O O
and O O
3 O O
' O O
untranslated O O
regions O O
also O O
show O O
significant O O
similarity O O
to O O
the O O
murine O B-GENE
gene O E-GENE
, O O
with O O
79 O O
and O O
70 O O
% O O
sequence O O
identity O O
, O O
respectively O O
. O O
One O O
patient O O
exhibited O O
a O O
non O O
- O O
sense O O
mutation O O
( O O
codon O O
388 O O
) O O
, O O
which O O
changed O O
a O O
glutamine O O
codon O O
( O O
CAG O O
) O O
to O O
a O O
stop O O
codon O O
( O O
TAG O O
) O O
. O O
The O O
transcriptional O O
activity O O
of O O
P B-GENE B-GENE
- I-GENE I-GENE
450 I-GENE I-GENE
( I-GENE I-GENE
11 I-GENE I-GENE
beta I-GENE I-GENE
) I-GENE I-GENE
gene E-GENE E-GENE
was O O
studied O O
with O O
an O O
in O O
vitro O O
transcription O O
system O O
using O O
nuclear O O
extracts O O
prepared O O
from O O
bovine O O
adrenal O O
cortex O O
. O O
Renal O O
dysplasia O O
with O O
multisystem O O
malformation O O
- O O
- O O
a O O
study O O
of O O
9 O O
cases O O
. O O
This O O
bud O O
morphology O O
results O O
at O O
least O O
in O O
part O O
from O O
a O O
cell O O
cycle O O
delay O O
imposed O O
by O O
the O O
Cdc28p S-GENE B-GENE
- O I-GENE
inhibitory O I-GENE
kinase O I-GENE
Swe1p S-GENE E-GENE
. O O
Eleven O O
of O O
the O O
12 O O
exons O O
have O O
complete O O
sequence O O
homology O O
with O O
the O O
RBM B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
sequence E-GENE E-GENE
. O O
Copyright O O
1998 O O
Academic O O
Press O O
. O O
Laparoscopic O O
examination O O
1 O O
year O O
after O O
surgery O O
revealed O O
an O O
enlarged O O
, O O
thin O O
- O O
walled O O
, O O
and O O
fluid O O
- O O
filled O O
uterine O O
segment O O
cranial O O
to O O
the O O
midcornus O O
occlusion O O
sites O O
in O O
all O O
animals O O
. O O
The O O
three O O
proteins O O
copurified O O
through O O
several O O
biochemical O O
fractionation O O
steps O O
and O O
could O O
be O O
coimmunoprecipitated O O
by O O
using O O
antibodies O O
against O O
GCD1 S-GENE S-GENE
or O O
GCD2 S-GENE S-GENE
. O O
Cellular O O
fractionation O O
and O O
Percoll O O
gradient O O
centrifugation O O
combined O O
with O O
immunoblotting O O
show O O
that O O
p67 S-GENE O
cofractionates O O
with O O
nuclei O O
and O O
is O O
enriched O O
in O O
resistant O O
structure O O
that O O
is O O
insoluble O O
in O O
2 O O
M O O
NaCl O O
, O O
25 O O
mM O O
lithium O O
3 O O
, O O
5 O O
' O O
- O O
diiodosalicylate O O
, O O
and O O
1 O O
% O O
Triton O O
but O O
is O O
soluble O O
in O O
8 O O
M O O
urea O O
. O O
For O O
the O O
first O O
time O O
also O O
a O O
genomic O O
sequence O O
for O O
a O O
red B-GENE O
algal I-GENE B-GENE
lhc I-GENE I-GENE
gene E-GENE E-GENE
is O O
presented O O
. O O
Elimination O O
of O O
brush O O
border O O
as O O
well O O
as O O
of O O
glomerular O O
marker O O
proteins O O
was O O
significantly O O
lower O O
after O O
intravenous O O
injection O O
of O O
low O O
- O O
osmolar O O
CM O O
iopamidol O O
370 O O
( O O
832 O O
mOsm O O
/ O O
kg O O
) O O
than O O
after O O
meglumine O O
diatrizoate O O
76 O O
( O O
2100 O O
mOsm O O
/ O O
kg O O
) O O
. O O
Raman O O
scattering O O
from O O
VO2 O O
single O O
crystals O O
: O O
A O O
study O O
of O O
the O O
effects O O
of O O
surface O O
oxidation O O
. O O
Combination O O
chemotherapy O O
in O O
advanced O O
ovarian O O
cancer O O
. O O
Making O O
sense O O
out O O
of O O
oxygen O O
sensor O O
. O O
In O O
comparison O O
to O O
a O O
silent O O
baseline O O
, O O
CBF O O
increases O O
were O O
observed O O
in O O
auditory O O
cortex O O
bilaterally O O
and O O
in O O
the O O
right O O
superior O O
parietal O O
, O O
right O O
dorsolateral O O
frontal O O
, O O
and O O
right O O
premotor O O
regions O O
, O O
with O O
no O O
modulation O O
as O O
a O O
function O O
of O O
attentional O O
condition O O
. O O
In O O
vitro O O
, O O
c B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE E-GENE
phosphorylated O O
FAK B-GENE S-GENE
Tyr I-GENE O
- I-GENE O
925 E-GENE O
in O O
a O O
glutathione B-GENE O
S I-GENE O
- I-GENE O
transferase E-GENE O
- O O
FAK S-GENE S-GENE
C O O
- O O
terminal O O
domain O O
fusion O O
protein O O
, O O
whereas O O
FAK O S-GENE
did O O
not O O
. O O
METHODS O O
AND O O
RESULTS O O
: O O
The O O
effect O O
of O O
prolonged O O
nitrate O O
therapy O O
between O O
2 O O
days O O
and O O
6 O O
weeks O O
during O O
healing O O
after O O
infarction O O
on O O
serial O O
parameters O O
of O O
ventricular O O
remodeling O O
( O O
scar O O
expansion O O
, O O
scar O O
thinning O O
, O O
ventricular O O
dilation O O
, O O
and O O
hypertrophy O O
) O O
and O O
function O O
( O O
asynergy O O
or O O
akinesis O O
plus O O
dyskinesis O O
and O O
ejection O O
fraction O O
) O O
by O O
serial O O
two O O
- O O
dimensional O O
echocardiography O O
, O O
hemodynamics O O
, O O
postmortem O O
topography O O
( O O
computerized O O
planimetry O O
, O O
geometric O O
maps O O
, O O
and O O
radiographs O O
) O O
, O O
and O O
collagen S-GENE O
content O O
( O O
hydroxyproline O O
) O O
was O O
studied O O
in O O
64 O O
instrumented O O
dogs O O
randomized O O
2 O O
days O O
after O O
left O O
anterior O O
descending O O
coronary O O
artery O O
ligation O O
to O O
various O O
nitrate O O
regimens O O
( O O
n O O
= O O
32 O O
) O O
over O O
the O O
first O O
2 O O
weeks O O
( O O
subgroup O O
1 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
6 O O
; O O
subgroup O O
2 O O
: O O
2 O O
% O O
transdermal O O
nitroglycerin O O
plus O O
2 O O
. O O
6 O O
mg O O
of O O
sustained O O
- O O
release O O
oral O O
nitroglycerin O O
at O O
8 O O
AM O O
, O O
3 O O
PM O O
, O O
and O O
10 O O
PM O O
, O O
n O O
= O O
5 O O
; O O
subgroup O O
3 O O
: O O
oral O O
isosorbide O O
dinitrate O O
, O O
30 O O
mg O O
at O O
8 O O
AM O O
and O O
4 O O
PM O O
, O O
n O O
= O O
11 O O
) O O
or O O
6 O O
weeks O O
( O O
subgroup O O
4 O O
: O O
isosorbide O O
dinitrate O O
, O O
n O O
= O O
10 O O
) O O
and O O
in O O
matching O O
controls O O
( O O
n O O
= O O
32 O O
) O O
. O O
The O O
essential O O
oil O O
composition O O
of O O
three O O
Zingiberaceae O O
widely O O
used O O
as O O
medicinal O O
aromatic O O
plants O O
from O O
S O O
. O O
Gel O O
shift O O
analysis O O
of O O
protein O O
binding O O
from O O
nuclear O O
extracts O O
to O O
these O O
caveolin B-GENE O
promoter I-GENE O
DNA I-GENE O
sequences E-GENE O
, O O
together O O
with O O
DNase B-GENE O
I E-GENE O
footprinting O O
, O O
confirmed O O
nucleoprotein O O
binding O O
to O O
the O O
SRE O O
- O O
like O O
elements O O
as O O
part O O
of O O
the O O
transcriptional O O
response O O
to O O
LDL B-GENE B-GENE
- I-GENE I-GENE
FC E-GENE E-GENE
. O O
A O O
new O O
model O O
for O O
objective O O
assessment O O
of O O
cervical O O
ripening O O
: O O
the O O
effect O O
of O O
prostaglandin O O
E2 O O
and O O
prelabor O O
contractility O O
. O O
CONCLUSIONS O O
: O O
The O O
MC O O
/ O O
UA O O
ratio O O
improves O O
the O O
sensitivity O O
for O O
the O O
prediction O O
of O O
poor O O
perinatal O O
outcome O O
when O O
it O O
is O O
combined O O
with O O
the O O
NST O O
. O O
Evaluation O O
of O O
materials O O
and O O
technics O O
in O O
vascular O O
surgery O O
using O O
111 O O
- O O
Indium O O
The O O
claustrocortical O O
connection O O
was O O
investigated O O
in O O
13 O O
cats O O
with O O
selective O O
injections O O
of O O
30 O O
% O O
HRP O O
in O O
the O O
three O O
subdivisions O O
of O O
the O O
auditory O O
cortex O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O
Applying O O
the O O
experience O O
mentioned O O
above O O
, O O
4 O O
- O O
META O O
was O O
used O O
to O O
bond O O
a O O
proprietary O O
photocuring O O
microfilled O O
composite O O
material O O
to O O
Class O O
V O O
cavities O O
in O O
freshly O O
extracted O O
human O O
teeth O O
. O O
The O O
phP1 S-GENE O
mutation O O
was O O
induced O O
by O O
insertion O O
of O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
P B-GENE O
element E-GENE O
into O O
the O O
5 O O
' O O
transcribed O O
nontranslated O O
region O O
of O O
the O O
proximal O B-GENE
polyhomeotic B-GENE I-GENE
gene E-GENE E-GENE
. O O
METHOD O O
: O O
Six O O
instruments O O
were O O
reviewed O O
: O O
the O O
Berg O O
Balance O O
Scale O O
( O O
Berg O O
) O O
, O O
the O O
Clinical O O
Test O O
of O O
Sensory O O
Interaction O O
and O O
Balance O O
( O O
CTSIB O O
) O O
, O O
the O O
Functional O O
Reach O O
Test O O
, O O
the O O
Tinetti O O
Balance O O
Test O O
of O O
the O O
Performance O O
- O O
Oriented O O
Assessment O O
of O O
Mobility O O
Problems O O
( O O
Tinetti O O
) O O
, O O
the O O
Timed O O
" O O
Up O O
and O O
Go O O
" O O
Test O O
( O O
TU O O
& O O
GT O O
) O O
, O O
and O O
the O O
Physical O O
Performance O O
Test O O
( O O
PPT O O
) O O
. O O
Genome O O
timeline O O
. O O
Initial O O
computer O O
based O O
similarity O O
searches O O
identified O O
human B-GENE B-GENE
retinoblastoma I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
( O O
RBP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
, O O
Drosophila B-GENE O
melanogaster I-GENE O
male I-GENE O
specific I-GENE O
lethal I-GENE O
- I-GENE O
3 E-GENE O
( O O
Msl B-GENE O
- I-GENE O
3 E-GENE O
) O O
, O O
S B-GENE O
. I-GENE O
pombe I-GENE O
altered I-GENE O
polarity I-GENE O
- I-GENE O
13 E-GENE O
( O O
Alp13 S-GENE O
) O O
and O O
S B-GENE O
. I-GENE O
cerevisiae I-GENE O
Eaf3p E-GENE O
, O O
a O O
component O O
of O O
the O O
yeast B-GENE B-GENE
NuA4 E-GENE I-GENE
HAT S-GENE I-GENE
complex O E-GENE
( O O
Galarneau O O
et O O
al O O
. O O
, O O
2000 O O
. O O
The O O
pressure O O
measurements O O
under O O
steady O O
flow O O
conditions O O
showed O O
that O O
the O O
hemodynamic O O
performance O O
( O O
including O O
pressure O O
gradient O O
and O O
effective O O
orifice O O
area O O
) O O
of O O
SPAB O O
is O O
superior O O
to O O
that O O
of O O
its O O
stented O O
counterpart O O
, O O
especially O O
in O O
the O O
smaller O O
sizes O O
. O O
Serum O O
prolactin S-GENE O
rapidly O O
decreased O O
after O O
institution O O
of O O
treatment O O
, O O
with O O
actual O O
normalization O O
( O O
less O O
than O O
20 O O
ng O O
/ O O
ml O O
) O O
by O O
the O O
3rd O O
month O O
. O O
We O O
report O O
five O O
of O O
13 O O
evaluable O O
patients O O
undergoing O O
allogeneic O O
sibling O O
BM O O
or O O
PBSC O O
transplantation O O
for O O
MM O O
between O O
1990 O O
and O O
1997 O O
who O O
met O O
the O O
criteria O O
for O O
adjuvant O O
alpha B-GENE O
- I-GENE O
IFN E-GENE O
therapy O O
. O O
Moist O O
healing O O
versus O O
wet O O
- O O
to O O
- O O
dry O O
. O O
In O O
this O O
report O O
, O O
we O O
identify O O
Tyr319 O S-GENE
as O O
a O O
functionally O O
important O O
phosphorylation O O
site O O
in O O
the O O
ZAP B-GENE O
- I-GENE O
70 I-GENE O
interdomain I-GENE O
B I-GENE O
region E-GENE O
. O O
These O O
findings O O
suggest O O
that O O
low O O
- O O
power O O
laser O O
irradiation O O
can O O
be O O
used O O
for O O
promotion O O
of O O
vascularization O O
and O O
take O O
of O O
tissue O O
transplants O O
. O O
RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
26 O O
IDDM O O
patients O O
with O O
normoalbuminuria O O
were O O
randomized O O
into O O
two O O
groups O O
, O O
with O O
one O O
group O O
receiving O O
placebo O O
( O O
n O O
= O O
13 O O
, O O
age O O
36 O O
+ O O
/ O O
- O O
3 O O
years O O
, O O
BMI O O
24 O O
. O O
5 O O
+ O O
/ O O
- O O
1 O O
. O O
1 O O
kg O O
/ O O
m2 O O
) O O
and O O
the O O
other O O
group O O
receiving O O
an O O
average O O
of O O
15 O O
mg O O
lisinopril O O
daily O O
( O O
n O O
= O O
13 O O
, O O
age O O
34 O O
+ O O
/ O O
- O O
2 O O
years O O
, O O
BMI O O
24 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
kg O O
/ O O
m2 O O
) O O
. O O
Previously O O
, O O
a O O
cDNA O O
( O O
GT2 S-GENE S-GENE
) O O
encoding O O
this O O
protein O O
was O O
isolated O O
from O O
a O O
mouse O O
3T3 O O
- O O
L1 O O
adipocyte O O
library O O
and O O
was O O
sequenced O O
. O O
Expression O O
of O O
human B-GENE B-GENE
complement I-GENE I-GENE
receptor I-GENE I-GENE
type I-GENE I-GENE
2 E-GENE E-GENE
( O O
CR2 S-GENE S-GENE
/ O O
CD21 S-GENE S-GENE
) O O
is O O
primarily O O
restricted O O
to O O
mature O O
B O O
cells O O
and O O
follicular O O
dendritic O O
cells O O
. O O
The O O
6 O O
. O O
5 O O
- O O
kb O O
genomic O O
fragment O O
contains O O
the O O
complete O O
coding O O
region O O
of O O
MyoD S-GENE O
, O O
distributed O O
over O O
three O O
exons O O
, O O
plus O O
2 O O
. O O
3 O O
kb O O
of O O
5 O O
' O O
- O O
noncoding O O
sequence O O
and O O
1 O O
. O O
4 O O
kb O O
of O O
3 O O
' O O
- O O
noncoding O O
sequence O O
. O O
Synthetic O O
studies O O
on O O
furan O O
derivatives O O
by O O
the O O
wittig O O
reaction O O
The O O
apparent O O
binding O O
constant O O
of O O
6 O O
to O O
calf O O
thymus O O
DNA O O
is O O
1 O O
. O O
68 O O
X O O
10 O O
( O O
5 O O
) O O
M O O
- O O
1 O O
whereas O O
netropsin S-GENE O
under O O
similar O O
conditions O O
gives O O
a O O
value O O
of O O
1 O O
. O O
85 O O
X O O
10 O O
( O O
7 O O
) O O
M O O
- O O
1 O O
. O O
Phenotypic O O
screening O O
of O O
mutations O O
in O O
Pmr1 S-GENE S-GENE
, O O
the O O
yeast B-GENE O
secretory I-GENE O
pathway I-GENE O
Ca2 I-GENE B-GENE
+ I-GENE E-GENE
/ I-GENE O
Mn2 I-GENE B-GENE
+ I-GENE I-GENE
- I-GENE I-GENE
ATPase E-GENE E-GENE
, O O
reveals O O
residues O O
critical O O
for O O
ion O O
selectivity O O
and O O
transport O O
. O O
Molecular O O
cloning O O
of O O
cDNAs O B-GENE
encoding O I-GENE
alpha O I-GENE
- O I-GENE
subunits O E-GENE
of O O
guanine B-GENE O
nucleotide I-GENE O
- I-GENE O
binding I-GENE O
regulatory I-GENE O
proteins E-GENE O
( O O
G B-GENE B-GENE
- I-GENE I-GENE
proteins E-GENE E-GENE
) O O
has O O
revealed O O
the O O
existence O O
of O O
nine O O
species O O
of O O
alpha O B-GENE
- O I-GENE
subunits O E-GENE
. O O
No O O
transactivation O O
of O O
the O O
ovalbumin B-GENE B-GENE
promoter E-GENE E-GENE
( O O
pLovTATA S-GENE S-GENE
) O O
template O O
control O O
was O O
observed O O
. O O
Pros O O
and O O
cons O O
of O O
selective O O
inhibition O O
of O O
cyclooxygenase B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
versus O O
dual O O
lipoxygenase S-GENE O
/ O O
cyclooxygenase S-GENE O
inhibition O O
: O O
is O O
two O O
better O O
than O O
one O O
? O O
At O O
11 O O
. O O
5 O O
years O O
of O O
follow O O
- O O
up O O
, O O
521 O O
major O O
coronary O O
disease O O
events O O
had O O
occurred O O
, O O
261 O O
fatal O O
and O O
260 O O
non O O
- O O
fatal O O
. O O
The O O
etiology O O
was O O
established O O
in O O
73 O O
( O O
76 O O
. O O
8 O O
% O O
) O O
out O O
of O O
95 O O
cases O O
. O O
Morphometry O O
of O O
the O O
intestine O O
of O O
the O O
pig O O
. O O
Serum O O
zinc O O
and O O
copper O O
levels O O
and O O
urine O O
copper O O
concentrations O O
in O O
men O O
were O O
significantly O O
lower O O
than O O
in O O
women O O
, O O
while O O
there O O
were O O
no O O
differences O O
in O O
serum O O
or O O
urinary O O
zinc O O
and O O
copper O O
levels O O
with O O
age O O
. O O
HDE S-GENE S-GENE
was O O
found O O
to O O
be O O
exclusively O O
targeted O O
to O O
and O O
imported O O
into O O
peroxisomes O O
in O O
both O O
heterologous O O
expression O O
systems O O
. O O
GeneCalling O O
analysis O O
was O O
successful O O
in O O
detecting O O
members O O
of O O
complex O O
metabolic O O
pathways O O
and O O
uncovering O O
novel O O
genes O O
that O O
were O O
either O O
coincidentally O O
regulated O O
or O O
directly O O
involved O O
in O O
such O O
pathways O O
. O O
Transformations O O
with O O
circular O O
plasmids O O
yielded O O
slowly O O
and O O
irregularly O O
growing O O
geneticin O O
- O O
resistant O O
mycelia O O
in O O
which O O
1 O O
% O O
of O O
nuclei O O
contained O O
plasmid O O
sequences O O
. O O
CONCLUSION O O
: O O
In O O
these O O
patients O O
control O O
of O O
ventricular O O
response O O
rate O O
with O O
either O O
HBA O O
+ O O
VVIR O O
pacemaker O O
or O O
atrioventricular O O
modifying O O
drugs O O
+ O O
VVI O O
pacemaker O O
will O O
lead O O
to O O
a O O
significant O O
improvement O O
in O O
exercise O O
duration O O
and O O
quality O O
of O O
life O O
. O O
The O O
other O O
regions O O
include O O
potential O O
binding O O
sites O O
for O O
transcription O O
factors O O
ATF S-GENE S-GENE
, O O
NF1 S-GENE S-GENE
, O O
and O O
a O O
CCAAT B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
. O O
Both O O
purH S-GENE S-GENE
and O O
purD B-GENE B-GENE
genes E-GENE E-GENE
constitute O O
a O O
single O O
operon O O
and O O
are O O
coregulated O O
in O O
expression O O
by O O
purines O O
as O O
other O O
purine B-GENE O
genes E-GENE O
are O O
. O O
The O O
patient O O
demographics O O
( O O
means O O
+ O O
/ O O
- O O
standard O O
deviations O O
) O O
were O O
as O O
follows O O
: O O
age O O
, O O
57 O O
+ O O
/ O O
- O O
12 O O
years O O
; O O
sex O O
, O O
nine O O
males O O
and O O
three O O
females O O
; O O
APACHE O O
II O O
score O O
, O O
15 O O
+ O O
/ O O
- O O
3 O O
; O O
diagnosis O O
, O O
9 O O
of O O
12 O O
patients O O
with O O
pneumonia O O
. O O
In O O
situ O O
hybridization O O
reveals O O
strong O O
signals O O
for O O
Zep B-GENE B-GENE
mRNA E-GENE E-GENE
in O O
the O O
cerebellum O O
and O O
olfactory O O
bulb O O
with O O
moderate O O
signals O O
detected O O
in O O
the O O
hippocampus O O
and O O
cortex O O
. O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
effect O O
was O O
eliminated O O
by O O
a O O
2 O O
- O O
bp O O
substitution O O
mutation O O
in O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B1 I-GENE E-GENE
binding I-GENE O
half I-GENE O
site E-GENE O
of O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
cis I-GENE I-GENE
element E-GENE E-GENE
. O O
UV O O
- O O
cross O O
- O O
linking O O
studies O O
suggested O O
that O O
these O O
two O O
complexes O O
represent O O
one O O
and O O
two O O
molecules O O
of O O
ADR1 S-GENE S-GENE
bound O O
to O O
DNA O O
. O O
As O O
already O O
available O O
for O O
the O O
other O O
known O O
mammalian O O
members O O
of O O
this O O
enzyme O O
family O O
, O O
we O O
here O O
define O O
structural O O
and O O
functional O O
features O O
of O O
human B-GENE O
lymphoma I-GENE O
proprotein I-GENE O
convertase E-GENE O
( O O
LPC S-GENE O
) O O
. O O
The O O
M O O
- O O
phase O O
induction O O
activity O O
of O O
Cdc2 S-GENE B-GENE
- O I-GENE
Cdc13 S-GENE E-GENE
is O O
inhibited O O
by O O
Wee1 B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
, O O
which O O
phosphorylates O O
Cdc2 S-GENE S-GENE
on O O
tyrosine O O
- O O
15 O O
. O O
Nucleotide O O
sequencing O O
revealed O O
a O O
2076 O O
- O O
base O O
pair O O
open O O
reading O O
frame O O
encoding O O
a O O
692 O O
- O O
amino O O
acid O O
protein O O
. O O
But O O
it O O
is O O
possible O O
that O O
the O O
two O O
hemispheres O O
differ O O
in O O
the O O
manner O O
in O O
which O O
they O O
make O O
use O O
of O O
semantic O O
structures O O
: O O
the O O
left O O
hemisphere O O
in O O
a O O
selective O O
manner O O
, O O
appropriate O O
for O O
the O O
solution O O
of O O
a O O
specific O O
task O O
, O O
and O O
the O O
right O O
hemisphere O O
in O O
a O O
more O O
diffuse O O
and O O
global O O
manner O O
. O O
Supportive O O
therapy O O
with O O
xenogenous O O
peptides O O
in O O
patients O O
with O O
metastatic O O
breast O O
cancer O O
undergoing O O
aggressive O O
chemotherapy O O
( O O
modified O O
AC O O
- O O
protocol O O
) O O
: O O
a O O
prospective O O
, O O
randomized O O
double O O
- O O
blind O O
study O O
The O O
pregnancies O O
were O O
terminated O O
at O O
19 O O
and O O
12 O O
weeks O O
of O O
gestation O O
, O O
respectively O O
. O O
Single O O
substitutions O O
of O O
three O O
highly O O
conserved O O
phenylalanine O O
residues O O
( O O
Phe O O
- O O
15 O O
, O O
Phe O O
- O O
17 O O
, O O
Phe O O
- O O
27 O O
) O O
by O O
alanine O O
and O O
substitution O O
of O O
one O O
histidine O O
( O O
His O O
- O O
29 O O
) O O
by O O
glutamine O O
, O O
all O O
located O O
within O O
the O O
putative O O
RNA O O
- O O
binding O O
sites O O
RNP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
RNP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
abolished O O
the O O
nucleic O O
acid O O
- O O
binding O O
activity O O
of O O
CspB S-GENE S-GENE
. O O
The O O
cases O O
with O O
terminal O O
forces O O
of O O
left O O
ventricular O O
activation O O
in O O
the O O
same O O
direction O O
as O O
the O O
delta O O
wave O O
, O O
superiorly O O
and O O
to O O
the O O
left O O
at O O
- O O
60 O O
degrees O O
or O O
inferiorly O O
and O O
to O O
the O O
right O O
at O O
+ O O
120 O O
degrees O O
, O O
forming O O
a O O
single O O
deflection O O
of O O
over O O
0 O O
, O O
12 O O
seconds O O
' O O
duration O O
, O O
are O O
the O O
result O O
of O O
delayed O O
activation O O
of O O
the O O
anterior O O
or O O
posterior O O
fascicle O O
of O O
the O O
left O O
bundle O O
after O O
a O O
long O O
delay O O
. O O
The O O
genes O O
encoding O O
these O O
carotenoids O O
in O O
E O O
. O O
herbicola O O
Eho13 O O
are O O
clustered O O
in O O
a O O
7 O O
kb O O
DNA O O
fragment O O
. O O
The O O
results O O
show O O
that O O
while O O
a O O
larger O O
polypeptide O O
substrate O O
carrying O O
the O O
HD1 B-GENE B-GENE
/ I-GENE I-GENE
3C I-GENE I-GENE
site E-GENE E-GENE
was O O
processed O O
more O O
efficiently O O
than O O
a O O
polypeptide O O
substrate O O
carrying O O
the O O
POL B-GENE B-GENE
/ I-GENE I-GENE
Zn I-GENE I-GENE
site E-GENE E-GENE
, O O
cleavage O O
of O O
the O O
synthetic O O
peptide O O
substrates O O
containing O O
these O O
two O O
cleavage O O
sites O O
occurred O O
at O O
similar O O
efficiencies O O
. O O
Using O O
transgenic O O
lines O O
a O O
detailed O O
analysis O O
of O O
the O O
Hoxa B-GENE O
- I-GENE O
7 E-GENE O
enhancer O O
- O O
directed O O
expression O O
during O O
embryogenesis O O
was O O
performed O O
. O O
lacZ S-GENE S-GENE
expression O O
was O O
first O O
detected O O
in O O
the O O
allantois O O
at O O
day O O
7 O O
. O O
5 O O
p O O
. O O
c O O
. O O
and O O
in O O
mesoderm O O
and O O
ectoderm O O
at O O
day O O
8 O O
. O O
5 O O
of O O
gestation O O
. O O
An O O
ERp60 B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
protein E-GENE E-GENE
from O O
the O O
filarial O O
parasite O O
Dirofilaria O O
immitis O O
has O O
both O O
transglutaminase O O
and O O
protein O O
disulfide O O
isomerase O O
activity O O
. O O
At O O
promoters O O
that O O
initiate O O
with O O
+ O O
1 O O
GGG O O
, O O
T7 B-GENE O
RNAP E-GENE O
synthesizes O O
a O O
ladder O O
of O O
poly O O
( O O
G O O
) O O
products O O
as O O
a O O
result O O
of O O
slippage O O
of O O
the O O
transcript O O
on O O
the O O
three O O
C O O
residues O O
in O O
the O O
template O O
strand O O
from O O
+ O O
1 O O
to O O
+ O O
3 O O
. O O
Serum O O
levels O O
of O O
angiotensin B-GENE O
converting I-GENE O
enzyme E-GENE O
were O O
well O O
maintained O O
. O O
The O O
UL3 B-GENE O
ORF E-GENE O
of O O
204 O O
amino O O
acids O O
shows O O
significant O O
homology O O
to O O
UL3 S-GENE S-GENE
( O O
nuclear O O
phosphoprotein O O
) O O
of O O
HSV O O
- O O
1 O O
( O O
62 O O
% O O
) O O
and O O
PRV O O
( O O
53 O O
% O O
) O O
. O O
On O O
Western O O
blots O O
, O O
the O O
same O O
antibodies O O
recognized O O
the O O
recombinant O O
protein O O
migrating O O
slightly O O
slower O O
on O O
SDS O O
/ O O
PAGE O O
than O O
chicken B-GENE O
axonin I-GENE O
- I-GENE O
1 E-GENE O
. O O
For O O
routine O O
medical O O
applications O O
, O O
no O O
sophisticated O O
adjustment O O
of O O
the O O
CHESS O O
pulse O O
is O O
needed O O
, O O
as O O
reported O O
in O O
previous O O
methods O O
. O O
The O O
10 O O
eyes O O
injected O O
with O O
human O O
RPE O O
cells O O
showed O O
STAGE O O
2 O O
or O O
less O O
in O O
4 O O
weeks O O
. O O
This O O
report O O
establishes O O
that O O
the O O
effect O O
of O O
homozygous O O
sickle O O
cell O O
disease O O
on O O
growth O O
patterns O O
in O O
childhood O O
is O O
apparent O O
before O O
the O O
age O O
of O O
6 O O
years O O
. O O
The O O
remaining O O
77 O O
nucleotides O O
at O O
the O O
3 O O
' O O
end O O
of O O
domain O O
II O O
and O O
all O O
of O O
domains O O
III O O
( O O
655 O O
nucleotides O O
) O O
and O O
IV O O
( O O
770 O O
nucleotides O O
) O O
are O O
not O O
present O O
in O O
DIssE B-GENE B-GENE
RNA E-GENE E-GENE
. O O
The O O
biological O O
actions O O
of O O
VHR S-GENE S-GENE
in O O
oocytes O O
clearly O O
distinguish O O
it O O
from O O
other O O
dual O O
specificity O O
phosphatases O O
, O O
which O O
have O O
shown O O
inhibitory O O
effects O O
when O O
tested O O
in O O
oocytes O O
. O O
The O O
presence O O
of O O
chloroquine O O
in O O
saliva O O
from O O
seven O O
healthy O O
volunteers O O
for O O
21 O O
days O O
after O O
a O O
single O O
600 O O
mg O O
oral O O
dose O O
of O O
the O O
drug O O
was O O
established O O
by O O
chromatographic O O
and O O
spectroscopic O O
methods O O
. O O
The O O
gp41 B-GENE B-GENE
peptide I-GENE E-GENE
( I-GENE O
Glu I-GENE O
- I-GENE O
Leu I-GENE O
- I-GENE O
Asp I-GENE O
- I-GENE O
Lys I-GENE O
- I-GENE O
Trp I-GENE O
- I-GENE O
Ala I-GENE O
) E-GENE O
fused O O
to O O
the O O
C O O
- O O
terminus O O
of O O
Sj B-GENE O
GST E-GENE O
forms O O
a O O
loop O O
stabilized O O
by O O
symmetry O O
- O O
related O O
GSTs S-GENE O
. O O
Comparison O O
of O O
bioreactive O O
and O O
immunoreactive O O
gastrin S-GENE O
. O O
Also O O
, O O
PTx S-GENE O
had O O
no O O
effect O O
on O O
shear O O
- O O
dependent O O
activation O O
of O O
JNK S-GENE S-GENE
. O O
A O O
score O O
( O O
APACHE O O
II O O
) O O
was O O
calculated O O
to O O
assess O O
the O O
severity O O
of O O
disease O O
. O O
We O O
tested O O
several O O
growth O O
regulatory O O
genes O O
that O O
are O O
repressed O O
in O O
senescent O O
cells O O
for O O
ability O O
to O O
restore O O
activity O O
to O O
T B-GENE O
[ I-GENE O
K1 I-GENE O
] E-GENE O
. O O
We O O
analyzed O O
the O O
contribution O O
of O O
the O O
three O O
different O O
types O O
of O O
UV O B-GENE
- O I-GENE
inducible O I-GENE
mitogen B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
MAP I-GENE B-GENE
) I-GENE I-GENE
kinases E-GENE E-GENE
( O O
ERK S-GENE S-GENE
, O O
JNK S-GENE S-GENE
/ O O
SAPK S-GENE S-GENE
, O O
and O O
p38 S-GENE S-GENE
) O O
to O O
the O O
activation O O
of O O
the O O
murine O B-GENE
uPA S-GENE I-GENE
promoter O E-GENE
by O O
UV O O
. O O
The O O
high O O
degree O O
of O O
sequence O O
conservation O O
together O O
with O O
the O O
ability O O
to O O
direct O O
nucleolar O O
protein O O
transport O O
supports O O
the O O
hypothesis O O
that O O
MAK16 B-GENE B-GENE
proteins E-GENE E-GENE
play O O
a O O
key O O
role O O
in O O
the O O
biogenesis O O
of O O
60S B-GENE O
subunits E-GENE O
. O O
Characterization O O
of O O
a O O
nuclear B-GENE O
deformed I-GENE O
epidermal I-GENE B-GENE
autoregulatory I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
( O O
DEAF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
- O O
related O O
( O O
NUDR S-GENE S-GENE
) O O
transcriptional O O
regulator O O
protein O O
. O O
Here O O
we O O
show O O
that O O
the O O
sck1 B-GENE B-GENE
gene E-GENE E-GENE
, O O
cloned O O
as O O
a O O
high O O
copy O O
number O O
suppressor O O
of O O
a O O
mutation O O
in O O
git3 S-GENE O
, O O
is O O
able O O
to O O
suppress O O
the O O
defects O O
conferred O O
by O O
a O O
mutation O O
in O O
any O O
of O O
these O O
git B-GENE O
genes E-GENE O
. O O
Hamdija O O
Karamehmedovic O O
; O O
Ibn O O
al O O
- O O
Nefis O O
, O O
" O O
Mudzez O O
al O O
- O O
Kanum O O
" O O
, O O
Republicki O O
zavod O O
za O O
zdravstvenu O O
zastitu O O
Sarajevo O O
, O O
1961 O O
, O O
1 O O
- O O
219 O O
; O O
Mr O O
ph O O
Samuel O O
Elazar O O
, O O
Ajnija O O
Omanic O O
: O O
" O O
Bibliografija O O
medicinskih O O
djela O O
u O O
SR O O
BiH O O
do O O
1895 O O
. O O
" O O
Medicinska O O
knjiga O O
Beograd O O
- O O
Zagreb O O
1984 O O
; O O
Besides O O
, O O
the O O
great O O
contribution O O
in O O
bibliography O O
was O O
given O O
by O O
dr O O
Lujo O O
Taler O O
, O O
prof O O
. O O
dr O O
. O O
The O O
longest O O
cDNA O O
insert O O
identified O O
was O O
2 O O
. O O
2 O O
kb O O
and O O
encoded O O
the O O
entire O O
462 O O
- O O
amino O O
acid O O
open O O
reading O O
frame O O
of O O
rat B-GENE O
CgA E-GENE O
including O O
an O O
18 O O
- O O
amino O O
acid O O
hydrophobic O O
signal O O
peptide O O
. O O
We O O
have O O
used O O
systemic O O
application O O
of O O
the O O
ototoxic O O
drug O O
amikacin O O
, O O
to O O
induce O O
total O O
cochlear O O
haircell O O
loss O O
in O O
the O O
chinchilla O O
, O O
in O O
order O O
to O O
create O O
an O O
animal O O
model O O
of O O
profound O O
deafness O O
. O O
Cotransfection O O
with O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE O
and O O
GATA B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
expression O O
vectors O O
produced O O
a O O
5 O O
- O O
fold O O
increase O O
compared O O
with O O
cotransfection O O
with O O
the O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE O
or O O
GATA B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
expression O O
vectors O O
individually O O
. O O
Among O O
the O O
different O O
epithelial O O
cell O O
lines O O
tested O O
, O O
only O O
RTS3b O O
cells O O
allowed O O
an O O
expression O O
pattern O O
similar O O
to O O
that O O
observed O O
in O O
naturally O O
infected O O
benign O O
condylomas O O
. O O
In O O
contrast O O
to O O
the O O
p16 S-GENE S-GENE
- O O
mediated O O
G1 O O
block O O
, O O
G1 O S-GENE
arrest O O
mediated O O
by O O
the O O
cdk S-GENE S-GENE
inhibitors O O
p21Cip1 S-GENE S-GENE
or O O
p27Kip1 S-GENE S-GENE
cannot O O
be O O
bypassed O O
either O O
by O O
inactivation O O
of O O
pRb S-GENE S-GENE
or O O
overexpression O O
of O O
E2F B-GENE B-GENE
family I-GENE E-GENE
members E-GENE O
. O O
In O O
addition O O
, O O
the O O
authors O O
found O O
one O O
an3 B-GENE B-GENE
allele E-GENE E-GENE
( O O
an3 B-GENE B-GENE
- I-GENE I-GENE
W138A E-GENE E-GENE
) O O
in O O
which O O
a O O
dTph1 B-GENE O
element E-GENE O
had O O
inserted O O
30 O O
bp O O
upstream O O
the O O
translation O O
start O O
, O O
without O O
inactivating O O
the O O
gene O O
. O O
Case O O
of O O
nephrotic O O
syndrome O O
caused O O
by O O
gold O O
preparations O O
To O O
investigate O O
the O O
role O O
of O O
bHLH B-GENE B-GENE
proteins E-GENE E-GENE
in O O
MC3T3 O S-GENE
- O O
E1 O O
osteoblasts O O
, O O
which O O
undergo O O
a O O
developmental O O
sequence O O
in O O
vitro O O
, O O
we O O
analyzed O O
the O O
transcriptional O O
control O O
of O O
osteocalcin B-GENE B-GENE
gene E-GENE E-GENE
expression O O
by O O
stable O O
transfection O O
of O O
an O O
osteocalcin B-GENE B-GENE
promoter E-GENE I-GENE
- O I-GENE
luciferase S-GENE I-GENE
chimeric O I-GENE
gene O E-GENE
( O O
p637OC B-GENE O
- I-GENE O
luc E-GENE O
) O O
and O O
assessed O O
the O O
role O O
of O O
E O O
- O O
box O O
cis O O
- O O
acting O O
elements O O
in O O
osteocalcin B-GENE O
promoter E-GENE O
by O O
DNA O O
binding O O
assays O O
. O O
In O O
summary O O
, O O
the O O
only O O
treatment O O
- O O
related O O
effect O O
noted O O
in O O
this O O
study O O
was O O
hydrocarbon O O
nephropathy O O
in O O
male O O
rats O O
, O O
which O O
is O O
not O O
considered O O
relevant O O
for O O
human O O
health O O
. O O
In O O
this O O
study O O
, O O
we O O
show O O
that O O
HNF B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
, O O
a O O
member O O
of O O
the O O
steroid B-GENE B-GENE
hormone I-GENE I-GENE
receptor I-GENE I-GENE
superfamily E-GENE E-GENE
, O O
binds O O
the O O
AF B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
site E-GENE E-GENE
on O O
the O O
apoB B-GENE B-GENE
promoter E-GENE E-GENE
and O O
through O O
it O O
activates O O
transcription O O
in O O
transient O O
transfection O O
assays O O
in O O
both O O
liver O O
and O O
non O O
- O O
liver O O
cell O O
lines O O
, O O
HepG2 O O
and O O
HeLa O O
, O O
respectively O O
. O O
Gastrointestinal O O
accumulation O O
of O O
indium O O
- O O
111 O O
labelled O O
granulocytes O O
in O O
reactive O O
arthritis O O
. O O
Acute O O
intoxication O O
with O O
cypermethrin O O
( O O
NRDC O O
149 O O
) O O
. O O
We O O
have O O
previously O O
shown O O
that O O
the O O
transcriptional O O
activator O O
CREM S-GENE S-GENE
is O O
highly O O
expressed O O
in O O
postmeiotic O O
cells O O
. O O
No O O
interaction O O
with O O
epidural O O
anesthesia O O
was O O
observed O O
. O O
In O O
late O O
October O O
, O O
1974 O O
, O O
Staphylococcus O O
aureus O O
postoperative O O
wound O O
infection O O
was O O
recorded O O
in O O
a O O
nonhuman O O
primate O O
( O O
Macaca O O
mulatta O O
) O O
which O O
had O O
recently O O
undergone O O
surgical O O
operation O O
. O O
Twenty O O
- O O
six O O
calves O O
were O O
subjected O O
to O O
a O O
technique O O
of O O
cryoablation O O
in O O
order O O
to O O
establish O O
an O O
animal O O
model O O
of O O
complete O O
cardiac O O
denervation O O
. O O
Our O O
current O O
study O O
aims O O
at O O
clarifying O O
the O O
role O O
of O O
myristoylation O O
in O O
caveolar O O
targeting O O
using O O
well O O
- O O
characterized O O
acylation O O
mutants O O
of O O
two O O
model O O
proteins O O
, O O
namely O O
Gi1 B-GENE B-GENE
alpha E-GENE E-GENE
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE E-GENE
. O O
The O O
effect O O
of O O
deferoxamine O O
B O O
on O O
the O O
blood O O
sugar O O
behavior O O
in O O
intravenous O O
glucose O O
loading O O
in O O
healthy O O
persons O O
We O O
infer O O
that O O
RecA S-GENE S-GENE
- O O
mediated O O
cleavage O O
of O O
UmuD S-GENE S-GENE
is O O
another O O
role O O
for O O
RecA S-GENE S-GENE
in O O
SOS O O
mutagenesis O O
, O O
probably O O
activating O O
UmuD S-GENE O
for O O
its O O
mutagenic O O
function O O
. O O
SETTING O O
: O O
Participants O O
in O O
the O O
Physicians O O
' O O
Health O O
Study O O
, O O
a O O
randomized O O
trial O O
of O O
aspirin O O
and O O
beta O O
- O O
carotene O O
among O O
U O O
. O O
S O O
. O O
male O O
physicians O O
. O O
The O O
prevalence O O
of O O
microalbuminuria O O
, O O
defined O O
as O O
an O O
UAER O O
in O O
the O O
range O O
of O O
15 O O
- O O
150 O O
micrograms O O
min O O
- O O
1 O O
in O O
an O O
overnight O O
urine O O
sample O O
, O O
was O O
3 O O
% O O
( O O
95 O O
% O O
C O O
. O O
I O O
. O O
interval O O
: O O
1 O O
. O O
9 O O
- O O
4 O O
. O O
0 O O
) O O
. O O
The O O
Rep B-GENE B-GENE
proteins E-GENE E-GENE
of O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O O
) O O
are O O
known O O
to O O
bind O O
to O O
Rep B-GENE O
recognition I-GENE O
sequences E-GENE O
( O O
RRSs S-GENE S-GENE
) O O
in O O
the O O
AAV O O
inverted O O
terminal O O
repeats O O
( O O
ITRs O S-GENE
) O O
, O O
the O O
AAV B-GENE B-GENE
p5 I-GENE I-GENE
promoter E-GENE E-GENE
, O O
and O O
the O O
preferred O O
AAV O O
integration O O
site O O
in O O
human O O
chromosome O O
19 O O
, O O
called O O
AAVS1 O O
. O O
LIP O O
and O O
DIP O O
are O O
less O O
common O O
IIPs O O
, O O
both O O
characterized O O
by O O
ground O O
- O O
glass O O
attenuation O O
. O O
The O O
levels O O
of O O
TPAR1 B-GENE B-GENE
mRNAs E-GENE E-GENE
were O O
dramatically O O
down O O
- O O
regulated O O
in O O
regenerating O O
rat O O
liver O O
when O O
compared O O
to O O
normal O O
adult O O
liver O O
. O O
Copyright O O
1999 O O
Academic O O
Press O O
. O O
The O O
authors O O
suggest O O
that O O
alprazolam O O
may O O
have O O
enhanced O O
specificity O O
for O O
a O O
subpopulation O O
of O O
benzodiazepine B-GENE O
receptors E-GENE O
. O O
Southern O O
hybridization O O
analysis O O
of O O
BenR S-GENE S-GENE
and O O
BenS B-GENE O
transformants E-GENE O
suggested O O
that O O
plasmid O O
integration O O
occurred O O
most O O
frequently O O
at O O
the O O
chromosomal O O
bens B-GENE O
locus E-GENE O
, O O
however O O
evidence O O
for O O
gene O O
conversion O O
and O O
heterologous O O
recombination O O
was O O
also O O
observed O O
. O O
The O O
analysis O O
of O O
the O O
effects O O
of O O
eight O O
signaling O O
molecules O O
in O O
the O O
TGFbeta S-GENE S-GENE
, O O
FGF S-GENE S-GENE
, O O
Hh S-GENE S-GENE
, O O
Wnt S-GENE S-GENE
, O O
and O O
EGF B-GENE S-GENE
families E-GENE O
in O O
tooth O O
explant O O
cultures O O
revealed O O
that O O
the O O
expression O O
of O O
edar S-GENE O
was O O
induced O O
by O O
activinbetaA S-GENE O
, O O
whereas O O
Wnt6 S-GENE O
induced O O
ectodysplasin S-GENE O
expression O O
. O O
In O O
mouse O O
, O O
two O O
high O O
- O O
affinity O O
binding O O
sites O O
with O O
an O O
apparent O O
dissociation O O
constant O O
( O O
Kd O O
) O O
of O O
50 O O
to O O
100 O O
nM O O
have O O
been O O
mapped O O
in O O
the O O
5 O O
' O O
ETS S-GENE O
upstream O O
from O O
the O O
early O O
pre O O
- O O
rRNA O O
processing O O
site O O
. O O
Single O O
oblique O O
- O O
view O O
mammography O O
for O O
periodic O O
screening O O
for O O
breast O O
cancer O O
in O O
women O O
. O O
Radiative O O
corrections O O
to O O
pi O O
l2 O O
decays O O
. O O
This O O
deletion O O
disrupts O O
the O O
PU B-GENE B-GENE
. I-GENE I-GENE
1 E-GENE I-GENE
Ets B-GENE I-GENE
domain E-GENE E-GENE
. O O
In O O
turn O O
, O O
production O O
of O O
sufficient O O
amounts O O
of O O
TraR S-GENE S-GENE
apparently O O
is O O
sensitive O O
to O O
a O O
cellular O O
function O O
requiring O O
RNase B-GENE O
D E-GENE O
. O O
The O O
predicted O O
product O O
exhibits O O
91 O O
% O O
amino O O
acid O O
identity O O
to O O
the O O
murine B-GENE O
voltage I-GENE O
- I-GENE O
gated I-GENE O
potassium I-GENE O
channel I-GENE O
protein I-GENE O
Kv1 I-GENE O
. I-GENE O
7 E-GENE O
( O O
Kcna7 S-GENE O
) O O
, O O
which O O
plays O O
an O O
important O O
role O O
in O O
the O O
repolarization O O
of O O
cell O O
membranes O O
. O O
Phytohemagglutinin S-GENE O
( O O
PHA S-GENE O
) O O
, O O
the O O
seed B-GENE O
lectin E-GENE O
of O O
the O O
common O O
bean O O
, O O
accumulates O O
in O O
protein O O
storage O O
vacuoles O O
of O O
storage O O
parenchyma O O
cells O O
in O O
cotyledons O O
. O O
This O O
dynamic O O
nature O O
may O O
be O O
relevant O O
to O O
the O O
ability O O
of O O
E47 S-GENE S-GENE
both O O
to O O
homodimerize O O
and O O
to O O
heterodimerize O O
with O O
MyoD S-GENE S-GENE
, O O
Id S-GENE O
, O O
and O O
Tal1 S-GENE S-GENE
. O O
Blood O O
samples O O
( O O
30 O O
ml O O
) O O
were O O
collected O O
via O O
an O O
indwelling O O
arm O O
catheter O O
at O O
rest O O
, O O
and O O
at O O
minutes O O
13 O O
and O O
28 O O
of O O
exercise O O
for O O
determinations O O
of O O
plasma O O
EPI O O
, O O
serum O O
free O O
fatty O O
acid O O
( O O
FFA O O
) O O
, O O
serum O O
glycerol O O
( O O
GLY O O
) O O
, O O
blood O O
glucose O O
( O O
GLU O O
) O O
, O O
and O O
blood O O
lactate O O
( O O
LA O O
) O O
concentrations O O
. O O
Among O O
these O O
, O O
four O O
patients O O
had O O
the O O
AIDS O O
syndrome O O
, O O
while O O
42 O O
individuals O O
were O O
HIV O O
carriers O O
. O O
Subjects O O
were O O
73 O O
male O O
and O O
female O O
employees O O
of O O
the O O
Xerox O O
Corporation O O
joining O O
a O O
newly O O
developed O O
health O O
fitness O O
program O O
. O O
Overexpression O O
of O O
p50 S-GENE S-GENE
in O O
transient O O
cotransfection O O
studies O O
using O O
the O O
proximal O O
CRP B-GENE B-GENE
promoter E-GENE E-GENE
( O O
- O O
125 O O
/ O O
+ O O
9 O O
) O O
linked O O
to O O
a O O
luciferase B-GENE O
reporter E-GENE O
caused O O
a O O
3 O O
- O O
fold O O
increase O O
of O O
luciferase S-GENE O
activity O O
, O O
while O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE O
overexpression O O
caused O O
an O O
18 O O
- O O
fold O O
increase O O
; O O
simultaneous O O
overexpression O O
of O O
both O O
transcription O O
factors O O
increased O O
luciferase S-GENE O
activity O O
approximately O O
600 O O
- O O
fold O O
. O O
Our O O
results O O
suggest O O
that O O
it O O
might O O
be O O
possible O O
to O O
augment O O
IN S-GENE O
function O O
in O O
vivo O O
through O O
a O O
heterologous O O
domain O O
. O O
While O O
differential O O
expression O O
of O O
the O O
two O O
transcripts O O
was O O
not O O
found O O
, O O
the O O
promoter O O
controlling O O
LT1 S-GENE S-GENE
/ O O
LT2 S-GENE S-GENE
transcription O O
is O O
regulated O O
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
. O O
Schottky O O
- O O
barrier O O
heights O O
of O O
Ti O O
and O O
TiSi2 O O
on O O
n O O
- O O
type O O
and O O
p O O
- O O
type O O
Si O O
( O O
100 O O
) O O
. O O
A O O
survey O O
of O O
children O O
with O O
HBsAg B-GENE O
markers E-GENE O
related O O
to O O
their O O
parents O O
HBV O O
markers O O
. O O
Immunological O O
studies O O
also O O
failed O O
to O O
demonstrate O O
any O O
significant O O
change O O
except O O
for O O
a O O
significant O O
increase O O
of O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
activity O O
after O O
IFN B-GENE O
- I-GENE O
gamma E-GENE O
infusion O O
. O O
Fetal O O
PaO2 O O
fell O O
somewhat O O
during O O
the O O
recovery O O
stages O O
in O O
both O O
NIT O O
and O O
control O O
groups O O
. O O
Genetic O O
analyses O O
indicate O O
that O O
most O O
of O O
the O O
dominant O O
mutants O O
are O O
cis O O
- O O
acting O O
and O O
that O O
the O O
recessive O O
mutants O O
define O O
a O O
minimum O O
of O O
three O O
complementation O O
groups O O
, O O
indicating O O
that O O
defects O O
in O O
several O O
different O O
genes O O
can O O
restore O O
higher O O
levels O O
of O O
HIS4C S-GENE S-GENE
expression O O
. O O
Rat B-GENE O
cholesterol I-GENE O
side I-GENE O
- I-GENE O
chain I-GENE O
cleavage I-GENE O
cytochrome I-GENE O
P I-GENE O
- I-GENE O
450 E-GENE O
( O O
P B-GENE O
- I-GENE O
450scc E-GENE O
) O O
gene O O
. O O
Histopathologic O O
studies O O
displaying O O
spongiform O O
changes O O
in O O
the O O
gray O O
matter O O
, O O
neuronal O O
loss O O
, O O
and O O
atrogliosis O O
confirmed O O
the O O
clinical O O
diagnosis O O
of O O
Creutzfeldt O O
- O O
Jakob O O
disease O O
. O O
Pig O B-GENE
uPA S-GENE I-GENE
promoter O E-GENE
- O O
CAT S-GENE O
constructs O O
were O O
more O O
active O O
than O O
mouse O O
constructs O O
in O O
this O O
assay O O
. O O
Cloning O O
the O O
cDNA O O
for O O
a O O
new O O
human B-GENE O
zinc I-GENE O
finger I-GENE O
protein E-GENE O
defines O O
a O O
group O O
of O O
closely O O
related O O
Kruppel B-GENE O
- I-GENE O
like I-GENE O
transcription I-GENE O
factors E-GENE O
. O O
By O O
computed O O
homology O O
search O O
, O O
we O O
noticed O O
significant O O
similarities O O
between O O
US3 B-GENE B-GENE
PK E-GENE E-GENE
and O O
p21 B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PAK S-GENE S-GENE
) O O
, O O
which O O
is O O
activated O O
by O O
the O O
Cdc42 S-GENE S-GENE
or O O
Rac S-GENE S-GENE
. O O
The O O
mean O O
amount O O
of O O
blood O O
loss O O
prior O O
to O O
time O O
of O O
injection O O
was O O
4 O O
. O O
5 O O
units O O
( O O
a O O
range O O
of O O
3 O O
to O O
10 O O
units O O
) O O
. O O
In O O
response O O
to O O
acoustical O O
stimulation O O
the O O
properties O O
of O O
response O O
latency O O
, O O
discharge O O
pattern O O
, O O
frequency O O
tuning O O
, O O
binaural O O
interaction O O
, O O
and O O
habituation O O
were O O
examined O O
to O O
allow O O
an O O
appraisal O O
of O O
the O O
differentiation O O
of O O
the O O
MGB O O
by O O
electrophysiological O O
means O O
. O O
These O O
8 B-GENE O
- I-GENE O
oxoguanine I-GENE O
DNA I-GENE O
glycosylases E-GENE O
, O O
hOgg1 S-GENE S-GENE
( O O
human O O
) O O
and O O
mOgg1 S-GENE S-GENE
( O O
murine O O
) O O
, O O
are O O
homologous O O
to O O
each O O
other O O
and O O
to O O
yeast B-GENE O
Ogg1 E-GENE O
. O O
The O O
CHED B-GENE B-GENE
protein E-GENE E-GENE
includes O O
the O O
consensus O O
ATP O O
binding O O
and O O
phosphorylation O O
domains O O
characteristic O O
of O O
kinases O O
, O O
displays O O
34 O O
- O O
42 O O
% O O
identically O O
aligned O O
amino O O
acid O O
residues O O
with O O
other O O
cdc2 B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
kinases E-GENE E-GENE
, O O
and O O
is O O
considerably O O
longer O O
at O O
its O O
amino O O
and O O
carboxyl O O
termini O O
. O O
CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
, O O
by O O
interacting O O
with O O
cellular O O
transcription O O
factors O O
and O O
cofactors O O
, O O
vIRF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
may O O
modulate O O
the O O
expression O O
of O O
the O O
early O O
inflammatory O O
genes O O
and O O
potentially O O
deregulate O O
the O O
immune O O
system O O
. O O
However O O
, O O
in O O
7 O O
patients O O
with O O
normal O O
CT O O
results O O
the O O
latter O O
method O O
showed O O
areas O O
of O O
cerebral O O
activity O O
anatomically O O
correlated O O
with O O
neurological O O
signs O O
or O O
vascular O O
lesions O O
. O O
We O O
report O O
that O O
Gcn5 S-GENE S-GENE
, O O
a O O
histone B-GENE O
H3 I-GENE O
acetylase E-GENE O
, O O
plays O O
a O O
central O O
role O O
in O O
initiation O O
of O O
meiosis O O
via O O
effects O O
on O O
IME2 S-GENE S-GENE
expression O O
. O O
The O O
carboxy O O
- O O
proximal O O
regions O O
of O O
the O O
VP1 S-GENE S-GENE
, O O
which O O
contain O O
very O O
low O O
amino O O
acid O O
homology O O
, O O
displayed O O
evidence O O
of O O
conservation O O
in O O
structural O O
features O O
such O O
as O O
a O O
hydrophilic O O
, O O
highly O O
basic O O
domain O O
. O O
Interferon B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
inducibility O O
of O O
IFI16 S-GENE S-GENE
may O O
be O O
regulated O O
by O O
an O O
interferon B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE E-GENE
/ I-GENE O
beta E-GENE O
- O O
stimulated O O
response O O
consensus O O
element O O
in O O
the O O
5 O O
' O O
UT O O
exon O O
, O O
as O O
a O O
similar O O
motif O O
is O O
conserved O O
in O O
the O O
corresponding O O
position O O
in O O
the O O
related O O
myeloid B-GENE O
cell I-GENE O
nuclear I-GENE O
differentiation I-GENE O
antigen E-GENE O
gene O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O
DESIGN O O
- O O
- O O
A O O
randomised O O
double O O
blind O O
placebo O O
controlled O O
parallel O O
arm O O
trial O O
. O O
Genealogical O O
analysis O O
suggested O O
mainly O O
a O O
mother O O
- O O
to O O
- O O
offspring O O
transmission O O
of O O
this O O
STLV O B-GENE
- O I-GENE
1 O E-GENE
. O O
These O O
back O O
mutations O O
led O O
to O O
a O O
modest O O
decrease O O
in O O
kinase O O
activity O O
, O O
decreased O O
tumorigenic O O
potential O O
in O O
chickens O O
, O O
and O O
an O O
unexpected O O
increase O O
in O O
transforming O O
activity O O
in O O
rat O O
cells O O
. O O
The O O
quantification O O
limit O O
was O O
50 O O
ng O O
/ O O
ml O O
for O O
each O O
of O O
PHT O O
, O O
m O O
- O O
HPPH O O
and O O
p O O
- O O
HPPH O O
. O O
Individual O O
intolerance O O
to O O
betaxolol O O
will O O
continue O O
to O O
occur O O
and O O
care O O
is O O
always O O
required O O
when O O
patients O O
with O O
cardiac O O
or O O
respiratory O O
dysfunction O O
are O O
exposed O O
to O O
any O O
beta O O
- O O
antagonist O O
. O O
Pretoria O O
Pasteurisation O O
is O O
feasible O O
and O O
reliable O O
under O O
a O O
range O O
of O O
conditions O O
. O O
In O O
the O O
present O O
study O O
we O O
use O O
a O O
tnaC S-GENE O
- O O
UGA O O
- O O
' B-GENE O
lacZ E-GENE O
construct O O
lacking O O
the O O
tnaC S-GENE O
- O O
tnaA S-GENE O
spacer O O
region O O
to O O
analyze O O
the O O
effect O O
of O O
TnaC S-GENE S-GENE
synthesis O O
on O O
the O O
behavior O O
of O O
the O O
ribosome O O
that O O
translates O O
tnaC S-GENE O
. O O
The O O
in O O
vitro O O
activity O O
of O O
KP O O
- O O
103 O O
, O O
a O O
novel O O
triazole O O
derivative O O
, O O
against O O
pathogenic O O
fungi O O
that O O
cause O O
dermatomycoses O O
and O O
its O O
therapeutic O O
efficacy O O
against O O
plantar O O
tinea O O
pedis O O
and O O
cutaneous O O
candidiasis O O
in O O
guinea O O
pigs O O
were O O
investigated O O
. O O
Restriction O O
analysis O O
of O O
the O O
isolated O O
genomic O O
clones O O
indicated O O
that O O
the O O
endogenous O O
sequences O O
abutting O O
the O O
3 O O
' O O
ends O O
of O O
the O O
94 O O
- O O
A O O
and O O
94 O O
- O O
K O O
transgenes O O
are O O
separated O O
by O O
less O O
than O O
20 O O
kb O O
, O O
providing O O
strong O O
support O O
for O O
the O O
single O O
integration O O
model O O
. O O
Serum O O
triglycerides O O
also O O
showed O O
an O O
increase O O
from O O
birth O O
to O O
6 O O
months O O
of O O
age O O
, O O
but O O
a O O
decrease O O
from O O
6 O O
months O O
to O O
1 O O
years O O
of O O
age O O
. O O
Female O O
Wistar O O
rats O O
receiving O O
alcohol O O
( O O
5 O O
% O O
) O O
in O O
drinking O O
water O O
during O O
lactation O O
( O O
N O O
= O O
7 O O
) O O
were O O
compared O O
to O O
normal O O
controls O O
fed O O
ad O O
libitum O O
( O O
N O O
= O O
6 O O
) O O
. O O
Antisense O O
oligonucleotides O O
complementary O O
to O O
the O O
5 O O
' O O
end O O
of O O
PKC B-GENE B-GENE
- I-GENE I-GENE
zeta I-GENE I-GENE
mRNA I-GENE I-GENE
sequences E-GENE E-GENE
significantly O O
reduced O O
the O O
collagen S-GENE O
lattice O O
- O O
stimulated O O
alpha2 O S-GENE
and O O
MMP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
mRNA E-GENE E-GENE
levels O O
. O O
Overexpression O O
of O O
a O O
HIF B-GENE B-GENE
- I-GENE I-GENE
1alpha E-GENE E-GENE
construct O O
with O O
deletions O O
of O O
the O O
basic O O
domain O O
and O O
carboxy O O
terminus O O
blocked O O
reporter O O
gene O O
activation O O
by O O
endogenous O O
HIF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
hypoxic O O
cells O O
. O O
We O O
hypothesized O O
that O O
conjugated O O
estrogens O O
, O O
which O O
contain O O
several O O
vasoactive O O
estrogenic O O
compounds O O
, O O
may O O
favorably O O
influence O O
the O O
vasomotor O O
response O O
to O O
acetylcholine O O
in O O
men O O
. O O
In O O
Experiment O O
2 O O
, O O
levels O O
were O O
: O O
amprolium O O
and O O
ethopabate O O
, O O
. O O
02 O O
% O O
; O O
salinomycin O O
, O O
55 O O
mg O O
/ O O
kg O O
; O O
monensin O O
, O O
99 O O
mg O O
/ O O
kg O O
; O O
and O O
lasalocid O O
, O O
110 O O
mg O O
/ O O
kg O O
. O O
Residues O O
crucial O O
for O O
Ras S-GENE S-GENE
interaction O O
with O O
GDP B-GENE O
- I-GENE O
GTP I-GENE O
exchangers E-GENE O
. O O
4 O O
. O O
In O O
serum O O
- O O
starved O O
NIH O O
3T3 O O
cells O O
, O O
v B-GENE O
- I-GENE O
raf E-GENE O
increased O O
mdr1 B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
approximately O O
10 O O
- O O
fold O O
compared O O
to O O
a O O
v B-GENE O
- I-GENE O
raf E-GENE O
frame O O
- O O
shift O O
control O O
. O O
Searching O O
the O O
human O O
DNA O O
data O O
base O O
of O O
expressed O O
sequence O O
tags O O
( O O
EST O O
) O O
revealed O O
novel O O
partial O O
sequences O O
similar O O
to O O
, O O
but O O
distinct O O
from O O
, O O
the O O
sequences O O
of O O
the O O
previously O O
known O O
PEF B-GENE B-GENE
proteins E-GENE E-GENE
. O O
Under O O
control O O
conditions O O
and O O
in O O
the O O
presence O O
of O O
3 O O
micromol O O
/ O O
kg O O
MIB O O
and O O
VER O O
the O O
maximal O O
effect O O
of O O
noradrenaline O O
was O O
reached O O
at O O
0 O O
. O O
1 O O
micromol O O
/ O O
kg O O
whereas O O
in O O
the O O
presence O O
of O O
10 O O
micromol O O
/ O O
kg O O
MIB O O
and O O
VER O O
it O O
was O O
reached O O
at O O
a O O
dose O O
of O O
1 O O
micromol O O
/ O O
kg O O
. O O
It O O
is O O
also O O
affected O O
by O O
the O O
HAP2 B-GENE B-GENE
/ I-GENE I-GENE
3 I-GENE I-GENE
/ I-GENE I-GENE
4 I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE E-GENE
complex E-GENE O
and O O
by O O
SNF1 S-GENE S-GENE
and O O
SSN6 S-GENE S-GENE
. O O
The O O
effective O O
use O O
of O O
superoxide B-GENE O
dismutase E-GENE O
from O O
human O O
erythrocytes O O
in O O
the O O
late O O
stages O O
of O O
experimental O O
influenza O O
infection O O
Two O O
different O O
genes O O
( O O
polA S-GENE S-GENE
and O O
polB S-GENE S-GENE
) O O
encoding O O
family B-GENE O
B I-GENE O
DNA I-GENE O
polymerases E-GENE O
were O O
cloned O O
from O O
the O O
organism O O
by O O
PCR O O
using O O
degenerated O O
primers O O
based O O
on O O
the O O
two O O
conserved O O
motifs O O
( O O
motif O O
A O O
and O O
B O O
) O O
. O O
The O O
effects O O
on O O
survival O O
of O O
adjuvant O O
treatments O O
, O O
including O O
pre O O
- O O
or O O
postoperative O O
systemic O O
or O O
postoperative O O
intra O O
- O O
arterial O O
chemotherapy O O
, O O
are O O
currently O O
under O O
evaluation O O
. O O
Structure O O
and O O
regulation O O
of O O
the O O
luteinizing B-GENE B-GENE
hormone I-GENE I-GENE
receptor I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
disease O O
processes O O
that O O
affect O O
transplant O O
patients O O
both O O
before O O
and O O
after O O
transplantation O O
are O O
not O O
seen O O
frequently O O
in O O
the O O
general O O
practice O O
of O O
gastroenterology O O
. O O
METHODS O O
: O O
Single O O
white O O
flash O O
ERG O O
, O O
photopic O O
ERG O O
, O O
scotopic O O
ERG O O
and O O
flicker O O
ERG O O
were O O
recorded O O
in O O
30 O O
cases O O
of O O
unilateral O O
CRVO O O
. O O
However O O
, O O
to O O
encourage O O
good O O
contact O O
between O O
the O O
farmers O O
and O O
the O O
inseminating O O
personnel O O
, O O
it O O
is O O
beneficial O O
that O O
herdsmen O O
are O O
present O O
when O O
cows O O
are O O
inseminated O O
. O O
Soft O O
independent O O
modelling O O
of O O
class O O
analogy O O
( O O
SIMCA O O
) O O
is O O
applied O O
to O O
identify O O
near O O
- O O
infrared O O
( O O
NIR O O
) O O
spectra O O
of O O
ten O O
excipients O O
used O O
in O O
the O O
pharmaceutical O O
industry O O
. O O
Multiple O O
organ O O
failure O O
( O O
MOF O O
) O O
following O O
major O O
trauma O O
occurs O O
in O O
response O O
to O O
perfusion O O
deficits O O
, O O
a O O
persistent O O
inflammatory O O
focus O O
, O O
or O O
a O O
persistent O O
focus O O
of O O
dead O O
and O O
/ O O
or O O
injured O O
tissue O O
. O O
Western O O
immunoblot O O
analysis O O
detected O O
p55gag S-GENE O
and O O
its O O
cleavage O O
products O O
p39 S-GENE S-GENE
and O O
p27 S-GENE S-GENE
in O O
purified O O
particles O O
derived O O
by O O
expression O O
of O O
gag S-GENE O
and O O
gag S-GENE O
- O O
pol S-GENE O
, O O
respectively O O
. O O
Cefminox O O
shows O O
greater O O
in O O
vivo O O
activity O O
than O O
that O O
expected O O
for O O
the O O
MICs O O
, O O
excellent O O
efficacy O O
and O O
safety O O
. O O
CONCLUSION O O
: O O
high O O
resolution O O
MF O O
- O O
ERG O O
seems O O
more O O
sensitive O O
than O O
low O O
resolution O O
MF O O
- O O
ERG O O
. O O
3 O O
- O O
5 O O
- O O
fold O O
increases O O
in O O
EGF B-GENE B-GENE
receptor E-GENE E-GENE
but O O
not O O
p185 S-GENE S-GENE
( O O
neu S-GENE S-GENE
) O O
tyrosine O O
phosphorylation O O
occur O O
following O O
Gi B-GENE O
- I-GENE O
coupled I-GENE O
receptor E-GENE O
stimulation O O
. O O
Next O O
, O O
to O O
examine O O
the O O
regulation O O
mechanism O O
of O O
CD44 S-GENE S-GENE
/ O O
ERM S-GENE S-GENE
interaction O O
in O O
vivo O O
, O O
we O O
reexamined O O
the O O
immunoprecipitated O O
CD44 S-GENE S-GENE
/ O O
ERM S-GENE S-GENE
complex O O
from O O
BHK O O
cells O O
and O O
found O O
that O O
it O O
contains O O
Rho B-GENE B-GENE
- I-GENE I-GENE
GDP I-GENE I-GENE
dissociation I-GENE I-GENE
inhibitor E-GENE E-GENE
( O O
GDI S-GENE S-GENE
) O O
, O O
a O O
regulator O O
of O O
Rho B-GENE B-GENE
GTPase E-GENE E-GENE
. O O
The O O
results O O
showed O O
a O O
significant O O
group O O
effect O O
only O O
on O O
the O O
active O O
task O O
. O O
On O O
days O O
7 O O
, O O
21 O O
, O O
and O O
35 O O
postinoculation O O
( O O
PI O O
) O O
, O O
all O O
birds O O
received O O
sheep O O
erythrocytes O O
intravenously O O
. O O
To O O
determine O O
cis O O
- O O
acting O O
elements O O
controlling O O
the O O
rat O B-GENE
B B-GENE I-GENE
- I-GENE I-GENE
50 E-GENE I-GENE
/ O I-GENE
GAP B-GENE I-GENE
- I-GENE I-GENE
43 E-GENE I-GENE
gene O E-GENE
expression O O
, O O
the O O
genomic O O
DNA O O
encoding O O
exon O O
1 O O
and O O
the O O
5 O O
' O O
flanking O O
sequence O O
was O O
isolated O O
. O O
In O O
this O O
paper O O
, O O
the O O
authors O O
used O O
measured O O
weight O O
for O O
1 O O
, O O
259 O O
white O O
women O O
aged O O
65 O O
- O O
74 O O
years O O
from O O
the O O
Epidemiologic O O
Follow O O
- O O
up O O
Study O O
of O O
the O O
First O O
National O O
Health O O
and O O
Nutrition O O
Examination O O
Survey O O
to O O
examine O O
the O O
effect O O
of O O
overweight O O
on O O
coronary O O
heart O O
disease O O
incidence O O
( O O
mean O O
length O O
of O O
follow O O
- O O
up O O
, O O
14 O O
years O O
) O O
. O O
Through O O
genomic O O
library O O
screening O O
and O O
PCR O O
- O O
based O O
genomic O O
walking O O
we O O
have O O
now O O
cloned O O
the O O
mouse B-GENE B-GENE
E I-GENE I-GENE
- I-GENE I-GENE
Tmod I-GENE I-GENE
gene E-GENE E-GENE
, O O
whose O O
coding O O
region O O
spans O O
approximately O O
60kb O O
containing O O
nine O O
exons O O
and O O
eight O O
introns O O
. O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
stimulated O O
these O O
changes O O
in O O
part O O
by O O
increasing O O
transcription O O
and O O
stabilization O O
of O O
RNA O O
for O O
amphiregulin S-GENE O
, O O
an O O
EGF B-GENE B-GENE
receptor E-GENE E-GENE
ligand O O
, O O
and O O
amphiregulin S-GENE O
directly O O
increased O O
HPV O B-GENE
- O I-GENE
16 O I-GENE
E6 S-GENE E-GENE
/ O O
E7 S-GENE S-GENE
and O O
cyclin B-GENE O
A I-GENE O
RNAs E-GENE O
. O O
The O O
data O O
obtained O O
included O O
1 O O
) O O
the O O
mean O O
frequency O O
of O O
abnormal O O
teased O O
myelinated O O
fibers O O
and O O
its O O
upper O O
limit O O
value O O
of O O
95 O O
% O O
confidence O O
interval O O
, O O
and O O
2 O O
) O O
the O O
mean O O
densities O O
of O O
total O O
, O O
large O O
and O O
small O O
myelinated O O
fibers O O
and O O
of O O
unmyelinated O O
fibers O O
and O O
their O O
lower O O
limit O O
value O O
of O O
95 O O
% O O
confidence O O
interval O O
for O O
each O O
decade O O
. O O
Fusions O O
between O O
the O O
GAL B-GENE O
DNA I-GENE O
binding I-GENE O
domain E-GENE O
and O O
full B-GENE O
- I-GENE O
length I-GENE O
mSin3 E-GENE O
were O O
also O O
capable O O
of O O
repression O O
. O O
None O O
of O O
the O O
19 O O
women O O
with O O
probable O O
RA O O
and O O
100 O O
of O O
the O O
116 O O
women O O
with O O
definite O O
RA O O
met O O
the O O
1987 O O
criteria O O
. O O
The O O
initial O O
oral O O
administration O O
of O O
the O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
doses O O
of O O
enoximone O O
improved O O
central O O
hemodynamic O O
parameters O O
with O O
apparent O O
preferential O O
reduction O O
of O O
limb O O
vascular O O
resistance O O
and O O
augmentation O O
of O O
blood O O
flow O O
to O O
the O O
limb O O
region O O
( O O
peripheral O O
musculoskeletal O O
system O O
) O O
. O O
Antibodies O O
against O O
REAP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
inhibit O O
in O O
vitro O O
RNA O O
editing O O
reactions O O
confirming O O
its O O
role O O
in O O
RNA O O
editing O O
. O O
The O O
full O O
- O O
length O O
cDNA O O
was O O
cloned O O
and O O
sequenced O O
, O O
and O O
the O O
inferred O O
amino O O
acid O O
sequence O O
was O O
found O O
to O O
encode O O
a O O
novel O O
protein O O
, O O
which O O
we O O
named O O
cystatin B-GENE O
M E-GENE O
, O O
with O O
40 O O
% O O
homology O O
to O O
human B-GENE O
family I-GENE O
2 I-GENE O
cystatins E-GENE O
and O O
similar O O
overall O O
structure O O
. O O
42nd O O
annual O O
meeting O O
of O O
the O O
American O O
Academy O O
of O O
Oral O O
Pathology O O
. O O
BAG B-GENE O
- I-GENE O
1 E-GENE O
also O O
prevented O O
growth O O
arrest O O
following O O
UV O O
- O O
irradiation O O
- O O
induced O O
genotoxic O O
injury O O
without O O
interfering O O
with O O
accumulation O O
of O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
or O O
p21 S-GENE S-GENE
( O O
waf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
expression O O
. O O
The O O
side O O
effect O O
of O O
pulmonary O O
fibrosis O O
occurs O O
in O O
20 O O
to O O
30 O O
percent O O
of O O
patients O O
receiving O O
this O O
drug O O
. O O
These O O
larger O O
sizes O O
, O O
however O O
, O O
are O O
consistent O O
with O O
predictions O O
from O O
the O O
DNA O O
sequence O O
of O O
the O O
pol B-GENE B-GENE
gene E-GENE E-GENE
. O O
Primary O O
care O O
programs O O
for O O
the O O
indigent O O
. O O
N0 O O
disease O O
is O O
more O O
favorable O O
than O O
N1 O O
or O O
N2 O O
disease O O
. O O
In O O
serial O O
recall O O
from O O
short O O
- O O
term O O
memory O O
, O O
repeated O O
items O O
are O O
recalled O O
well O O
when O O
close O O
together O O
( O O
repetition O O
facilitation O O
) O O
, O O
but O O
not O O
when O O
far O O
apart O O
( O O
repetition O O
inhibition O O
; O O
the O O
Ranschburg O O
effect O O
) O O
. O O
In O O
addition O O
, O O
two O O
cis O O
- O O
acting O O
elements O O
direct O O
the O O
first O O
zygotic O O
expression O O
of O O
Kr S-GENE O
in O O
a O O
striped O O
subpattern O O
within O O
the O O
central O O
region O O
of O O
the O O
blastoderm O O
embryo O O
. O O
Two O O
hundred O O
and O O
eighty O O
- O O
three O O
patients O O
, O O
217 O O
females O O
( O O
median O O
age O O
24 O O
years O O
, O O
range O O
0 O O
. O O
5 O O
- O O
73 O O
) O O
and O O
66 O O
males O O
( O O
median O O
age O O
20 O O
years O O
, O O
range O O
0 O O
. O O
75 O O
- O O
72 O O
) O O
, O O
were O O
examined O O
. O O
The O O
Robert O O
Wood O O
Johnson O O
Foundation O O
: O O
billion O O
dollar O O
force O O
for O O
health O O
- O O
care O O
change O O
. O O
We O O
have O O
isolated O O
a O O
unique O O
murine B-GENE O
FLT3 I-GENE B-GENE
cDNA E-GENE E-GENE
that O O
codes O O
for O O
a O O
variant O O
isoform O O
of O O
FLT3 S-GENE S-GENE
, O O
devoid O O
of O O
the O O
fifth O O
Ig B-GENE O
- I-GENE O
like I-GENE O
domain E-GENE O
, O O
by O O
comparison O O
with O O
the O O
prototypic O O
form O O
. O O
P53 B-GENE S-GENE
mutations E-GENE O
also O O
offer O O
new O O
approaches O O
to O O
the O O
study O O
of O O
the O O
origins O O
of O O
mutations O O
in O O
human O O
cancer O O
. O O
( O O
1993 O O
) O O
8 O O
, O O
94 O O
- O O
99 O O
) O O
. O O
Desarrollo O O
de O O
un O O
modelo O O
matematico O O
general O O
para O O
los O O
procesos O O
fermentativos O O
, O O
Cinetica O O
de O O
la O O
degradacion O O
anaerobia O O
, O O
Ph O O
. O O
D O O
. O O
Particle O O
bombardment O O
of O O
barley O O
aleurone O O
with O O
a O O
B22EL8 B-GENE B-GENE
promoter E-GENE I-GENE
- O I-GENE
GUS S-GENE E-GENE
( O O
beta B-GENE O
- I-GENE O
glucuronidase E-GENE O
) O O
construct O O
demonstrates O O
that O O
the O O
promoter O O
( O O
3 O O
kb O O
) O O
is O O
active O O
in O O
developing O O
barley O O
grains O O
. O O
Changes O O
in O O
BHR O O
were O O
found O O
to O O
correlate O O
significantly O O
with O O
changes O O
in O O
the O O
levels O O
of O O
24 O O
h O O
mean O O
SO2 O O
, O O
NO2 O O
and O O
smoke O O
; O O
48 O O
h O O
mean O O
NO2 O O
and O O
smoke O O
; O O
24 O O
h O O
lag O O
NO2 O O
; O O
although O O
the O O
effect O O
was O O
only O O
small O O
, O O
accounting O O
for O O
approximately O O
10 O O
% O O
of O O
the O O
variability O O
in O O
within O O
- O O
subject O O
BHR O O
between O O
visits O O
. O O
The O O
N O O
- O O
terminal O O
sequences O O
of O O
isoforms O O
beta O O
to O O
epsilon O O
contain O O
a O O
PEST O O
region O O
which O O
could O O
induce O O
rapid O O
intracellular O O
degradation O O
of O O
isoforms O O
beta O O
and O O
delta O O
. O O
Characterization O O
of O O
regions O O
of O O
fibronectin S-GENE O
besides O O
the O O
arginine O O
- O O
glycine O O
- O O
aspartic O O
acid O O
sequence O O
required O O
for O O
adhesive O O
function O O
of O O
the O O
cell O O
- O O
binding O O
domain O O
using O O
site O O
- O O
directed O O
mutagenesis O O
. O O
The O O
clinical O O
effects O O
of O O
valproate O O
and O O
ethosuximide O O
can O O
be O O
related O O
to O O
this O O
differential O O
modulation O O
of O O
thalamocortical O O
excitability O O
. O O
Elements O O
regulating O O
cell O O
- O O
and O O
stage O O
- O O
specific O O
expression O O
of O O
the O O
C O B-GENE
. O I-GENE
elegans O I-GENE
MyoD S-GENE I-GENE
family O I-GENE
homolog O I-GENE
hlh B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
An O O
analysis O O
of O O
the O O
c B-GENE O
- I-GENE O
kit I-GENE O
5 I-GENE O
' I-GENE O
flanking I-GENE O
region E-GENE O
using O O
the O O
bacterial B-GENE B-GENE
chloramphenicol I-GENE I-GENE
acetyltransferase I-GENE I-GENE
gene E-GENE E-GENE
( O O
CAT S-GENE O
assay O O
) O O
in O O
human O O
erythroleukemia O O
HEL O O
cells O O
, O O
which O O
express O O
the O O
endogenous O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
kit I-GENE I-GENE
mRNA E-GENE E-GENE
at O O
high O O
levels O O
, O O
showed O O
that O O
a O O
region O O
from O O
- O O
180 O O
to O O
- O O
22 O O
is O O
important O O
for O O
the O O
expression O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
kit I-GENE I-GENE
gene E-GENE E-GENE
. O O
After O O
5 O O
days O O
stimulation O O
with O O
G B-GENE O
- I-GENE O
CSF E-GENE O
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
1l O O
of O O
blood O O
was O O
drawn O O
, O O
kept O O
unprocessed O O
for O O
3 O O
days O O
and O O
reinfused O O
24 O O
h O O
after O O
completion O O
of O O
chemotherapy O O
. O O
OAT O O
has O O
become O O
safer O O
in O O
recent O O
years O O
, O O
particularly O O
if O O
monitored O O
in O O
special O O
anticoagulation O O
clinics O O
. O O
However O O
, O O
the O O
relative O O
substrate O O
specificity O O
of O O
RSK3 S-GENE S-GENE
differed O O
from O O
that O O
reported O O
for O O
other O O
isoforms O O
. O O
Our O O
data O O
indicate O O
that O O
the O O
various O O
subunits O O
of O O
the O O
human O B-GENE
P B-GENE I-GENE
- I-GENE I-GENE
TEFb E-GENE I-GENE
complex O E-GENE
may O O
play O O
distinct O O
roles O O
at O O
multiple O O
stages O O
to O O
mediate O O
Tat S-GENE O
activation O O
of O O
HIV O B-GENE
- O I-GENE
1 O E-GENE
transcription O O
elongation O O
. O O
Corresponding O O
oligonucleotides O O
were O O
used O O
to O O
screen O O
a O O
rat O O
liver O O
cDNA O O
library O O
constructed O O
in O O
the O O
plasmid O O
cloning O O
vector O O
, O O
pcDV O S-GENE
. O O
In O O
fifty O O
non O O
selected O O
ductal O O
carcinomas O O
of O O
the O O
breast O O
we O O
found O O
that O O
a O O
marked O O
tumoral O O
inflammatory O O
infiltrate O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
, O O
perinodal O O
tumoral O O
infiltrate O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
sinus O O
catarrh O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
follicular O O
hyperplasia O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
, O O
mixed O O
pattern O O
in O O
lymph O O
nodes O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
and O O
with O O
54 O O
years O O
of O O
age O O
or O O
younger O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
correlated O O
significantly O O
with O O
lymph O O
node O O
metastases O O
and O O
/ O O
or O O
high O O
histologic O O
grade O O
. O O
Capillary O O
tortuosity O O
was O O
a O O
function O O
of O O
sarcomere O O
length O O
in O O
all O O
animals O O
and O O
this O O
relationship O O
was O O
not O O
changed O O
by O O
hypoxia O O
. O O
Sox8 S-GENE O
maps O O
to O O
the O O
t B-GENE O
complex E-GENE O
on O O
mouse O O
chromosome O O
17 O O
and O O
to O O
human O O
chromosome O O
16p13 O O
. O O
3 O O
, O O
a O O
region O O
associated O O
with O O
the O O
microphthalmia O O
- O O
cataract O O
syndrome O O
CATM O O
and O O
the O O
alpha O B-GENE
- O I-GENE
thalassemia O E-GENE
/ O O
mental O O
retardation O O
syndrome O O
ATR O O
- O O
16 O O
. O O
Directional O O
growth O O
of O O
a O O
smectic O O
- O O
A O O
- O O
smectic O O
- O O
B O O
interface O O
lying O O
along O O
a O O
forbidden O O
orientation O O
. O O
The O O
TCR B-GENE B-GENE
beta I-GENE I-GENE
enhancer E-GENE E-GENE
was O O
active O O
on O O
both O O
the O O
minimal B-GENE O
simian I-GENE O
virus I-GENE O
40 I-GENE O
promoter E-GENE O
and O O
a O O
TCR B-GENE B-GENE
beta I-GENE I-GENE
variable I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
in O O
both O O
TCR B-GENE B-GENE
alpha I-GENE E-GENE
/ I-GENE O
beta E-GENE O
+ O O
and O O
TCR B-GENE B-GENE
gamma I-GENE E-GENE
/ I-GENE O
delta E-GENE O
+ O O
T O O
cells O O
. O O
U O O
. O O
Recently O O
, O O
we O O
demonstrated O O
that O O
platelet B-GENE B-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
PDGF I-GENE S-GENE
) I-GENE O
- I-GENE O
beta I-GENE O
receptor E-GENE O
stimulation O O
, O O
but O O
not O O
various O O
other O O
growth O O
factors O O
, O O
inhibits O O
transcription O O
of O O
alpha1D S-GENE O
- O O
, O O
but O O
not O O
alpha1A S-GENE O
- O O
or O O
alpha1B B-GENE B-GENE
- I-GENE I-GENE
ARs E-GENE E-GENE
, O O
resulting O O
in O O
reduced O O
norepinephrine O O
- O O
mediated O O
SMC O O
growth O O
. O O
Southern O O
blot O O
analysis O O
following O O
reverse O O
transcription O O
and O O
PCR O O
showed O O
that O O
B2R S-GENE S-GENE
is O O
expressed O O
in O O
most O O
mouse O O
tissues O O
, O O
except O O
the O O
liver O O
and O O
spleen O O
, O O
which O O
is O O
consistent O O
with O O
the O O
wide O O
distribution O O
of O O
B2R S-GENE S-GENE
activity O O
as O O
deduced O O
from O O
pharmacological O O
studies O O
. O O
Long O O
- O O
term O O
renal O O
function O O
in O O
on O O
- O O
heart O O
- O O
beating O O
donor O O
kidney O O
transplantation O O
: O O
a O O
single O O
- O O
center O O
experience O O
. O O
The O O
study O O
of O O
the O O
intensity O O
of O O
pain O O
evoked O O
by O O
heat O O
is O O
relatively O O
exhaustive O O
: O O
the O O
influence O O
of O O
various O O
local O O
, O O
stimulus O O
- O O
dependent O O
or O O
general O O
factors O O
upon O O
threshold O O
values O O
has O O
been O O
well O O
studied O O
, O O
as O O
has O O
the O O
relation O O
between O O
pain O O
and O O
stimulus O O
intensities O O
. O O
The O O
vaccine O O
was O O
at O O
least O O
80 O O
% O O
efficacious O O
against O O
Chlamydia O O
and O O
Campylobacter O O
spp O O
and O O
appeared O O
to O O
be O O
protective O O
. O O
The O O
centromeric O O
dodeca O O
- O O
satellite O O
of O O
Drosophila O O
forms O O
altered O O
DNA O O
structures O O
in O O
vitro O O
in O O
which O O
its O O
purine O O
- O O
rich O O
strand O O
( O O
G O O
- O O
strand O O
) O O
forms O O
stable O O
fold O O
- O O
back O O
structures O O
, O O
while O O
the O O
complementary O O
C O O
- O O
strand O O
remains O O
unstructured O O
. O O
Pneumatic O O
dilation O O
of O O
the O O
lower O O
esophageal O O
sphincter O O
was O O
accomplished O O
by O O
endoscopic O O
visualization O O
and O O
positioning O O
of O O
a O O
modified O O
polyurethane O O
dilator O O
( O O
90 O O
F O O
diameter O O
) O O
without O O
fluoroscopy O O
in O O
17 O O
consecutive O O
patients O O
with O O
advanced O O
symptomatic O O
achalasia O O
. O O
Mean O O
CD4 S-GENE O
percentages O O
were O O
lower O O
postpartum O O
( O O
21 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
4 O O
) O O
than O O
prepartum O O
( O O
45 O O
. O O
1 O O
+ O O
/ O O
- O O
6 O O
. O O
7 O O
) O O
in O O
all O O
five O O
patients O O
studied O O
, O O
although O O
proliferative O O
responses O O
to O O
the O O
mitogens B-GENE O
phytohemagglutinin I-GENE O
and I-GENE O
pokeweed E-GENE O
were O O
unchanged O O
during O O
the O O
study O O
period O O
. O O
The O O
second O O
system O O
( O O
VacFix O O
) O O
uses O O
a O O
0 O O
. O O
15 O O
mm O O
thick O O
plastic O O
bag O O
loosely O O
filled O O
with O O
1 O O
mm O O
polysterol O O
spheres O O
. O O
Mean O O
24 O O
h O O
urinary O O
excretion O O
values O O
confirmed O O
this O O
observation O O
. O O
However O O
, O O
the O O
safety O O
of O O
design O O
4 O O
was O O
assured O O
as O O
long O O
as O O
all O O
patients O O
received O O
three O O
courses O O
of O O
chemotherapy O O
, O O
which O O
is O O
unusual O O
in O O
phase O O
I O O
studies O O
in O O
Japan O O
. O O
The O O
results O O
indicate O O
that O O
the O O
RNA O O
in O O
T7 B-GENE B-GENE
RNA I-GENE I-GENE
polymerase E-GENE E-GENE
is O O
not O O
free O O
of O O
steric O O
interactions O O
in O O
the O O
ternary O O
complex O O
and O O
not O O
available O O
for O O
structure O O
formation O O
until O O
it O O
is O O
at O O
least O O
10 O O
bases O O
away O O
from O O
the O O
site O O
of O O
polymerization O O
. O O
The O O
STP1 B-GENE B-GENE
locus E-GENE E-GENE
is O O
located O O
on O O
chromosome O O
IV O O
close O O
to O O
at O O
least O O
two O O
other O O
genes O O
involved O O
in O O
RNA O O
splicing O O
: O O
PRP3 S-GENE S-GENE
and O O
SPP41 S-GENE S-GENE
. O O
An O O
ICU O O
length O O
of O O
stay O O
shorter O O
than O O
24 O O
h O O
was O O
not O O
related O O
to O O
the O O
frequency O O
of O O
group O O
C O O
errors O O
. O O
In O O
vitro O O
, O O
SHIP S-GENE O
catalyzes O O
the O O
conversion O O
of O O
the O O
phosphoinositide B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PI3K S-GENE S-GENE
) O O
product O O
phosphatidylinositol O O
3 O O
, O O
4 O O
, O O
5 O O
- O O
trisphosphate O O
( O O
PIP3 O O
) O O
into O O
phosphatidylinositol O O
3 O O
, O O
4 O O
- O O
bisphosphate O O
. O O
Like O O
pimethixene O O
and O O
cyproheptadine O O
, O O
WA O O
335 O O
has O O
no O O
distinct O O
antagonistic O O
qualities O O
against O O
bradykinin S-GENE O
. O O
To O O
confirm O O
the O O
data O O
obtained O O
using O O
the O O
HPLC O O
- O O
ESI O O
- O O
MS O O
procedure O O
, O O
fractions O O
of O O
the O O
glycosides O O
from O O
four O O
berries O O
were O O
separated O O
, O O
hydrolyzed O O
, O O
silylated O O
and O O
the O O
sugars O O
were O O
analyzed O O
using O O
gas O O
chromatography O O
- O O
mass O O
spectrometry O O
. O O
This O O
clone O O
will O O
be O O
useful O O
for O O
identifying O O
the O O
genetic O O
determinants O O
of O O
FIV O O
- O O
Oma O O
' O O
s O O
biological O O
activities O O
. O O
The O O
WEB2 B-GENE B-GENE
gene E-GENE E-GENE
encodes O O
a O O
1 O O
, O O
522 O O
- O O
amino O O
- O O
acid O O
protein O O
with O O
homology O O
to O O
nucleic B-GENE O
acid I-GENE O
- I-GENE O
dependent I-GENE O
ATPases E-GENE O
. O O
Evidence O O
that O O
the O O
AT1A B-GENE B-GENE
receptor E-GENE E-GENE
activates O O
transcription B-GENE O
factor I-GENE O
- I-GENE O
Stat91 E-GENE S-GENE
and O O
/ O O
or O O
a O O
related O O
protein O O
. O O
There O O
was O O
91 O O
% O O
concordance O O
between O O
ST O O
- O O
RD O O
/ O O
RI O O
/ O O
LRD O O
201Tl O O
and O O
R O O
- O O
ST O O
/ O O
N O O
+ O O
Inf O O
99Tcm O O
- O O
tetrofosmin O O
imaging O O
regarding O O
reversibility O O
. O O
The O O
two O O
complexes O O
were O O
detected O O
with O O
a O O
similar O O
activation O O
kinetics O O
upon O O
IL B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
stimulation O O
. O O
These O O
results O O
suggest O O
that O O
dauricine O O
and O O
verapamil O O
have O O
a O O
salutary O O
effect O O
in O O
extracorporeal O O
circulation O O
. O O
These O O
results O O
demonstrate O O
the O O
preferential O O
endometrial O O
cell O O
- O O
type O O
expression O O
of O O
BTEB S-GENE S-GENE
and O O
suggest O O
its O O
regulatory O O
role O O
in O O
pregnancy O O
- O O
associated O O
endometrial O O
epithelial O O
gene O O
expression O O
. O O
Spen S-GENE S-GENE
is O O
the O O
only O O
known O O
homeotic B-GENE O
protein E-GENE O
with O O
RNP O S-GENE
binding O O
motifs O O
, O O
which O O
indicates O O
that O O
splicing O O
, O O
transport O O
, O O
or O O
other O O
RNA O O
regulatory O O
steps O O
are O O
involved O O
in O O
the O O
diversification O O
of O O
segmental O O
morphology O O
. O O
Long O O
- O O
term O O
follow O O
- O O
up O O
of O O
kidney O O
donors O O
: O O
a O O
longitudinal O O
study O O
. O O
Recent O O
research O O
on O O
lipolysis O O
. O O
CONCLUSIONS O O
: O O
The O O
present O O
study O O
showed O O
it O O
is O O
possible O O
to O O
use O O
a O O
modified O O
Stroop O O
task O O
as O O
a O O
measure O O
of O O
implicit O O
processing O O
of O O
alcohol O O
stimuli O O
. O O
Six O O
patients O O
( O O
24 O O
% O O
) O O
developed O O
sepsis O O
and O O
only O O
one O O
survived O O
. O O
None O O
of O O
the O O
10 O O
sequences O O
has O O
hitherto O O
been O O
recognized O O
as O O
part O O
of O O
the O O
p53 S-GENE S-GENE
signaling O O
pathway O O
. O O
The O O
Prompt O O
and O O
Praise O O
condition O O
was O O
superior O O
to O O
the O O
other O O
two O O
conditions O O
in O O
encouraging O O
participation O O
in O O
low O O
- O O
interest O O
recreational O O
activities O O
. O O
The O O
majority O O
of O O
the O O
human B-GENE O
Ig I-GENE O
heavy I-GENE O
chain I-GENE O
( I-GENE O
IgH I-GENE O
) I-GENE O
constant I-GENE O
( I-GENE O
C I-GENE O
) I-GENE O
region I-GENE O
locus E-GENE O
has O O
been O O
cloned O O
and O O
mapped O O
. O O
A O O
. O O
We O O
analyzed O O
right O O
ventricular O O
size O O
and O O
function O O
and O O
201Tl O O
uptake O O
to O O
determine O O
if O O
there O O
was O O
a O O
relationship O O
between O O
201Tl O O
uptake O O
and O O
systolic O O
function O O
in O O
19 O O
patients O O
with O O
pulmonary O O
artery O O
hypertension O O
who O O
were O O
being O O
evaluated O O
for O O
heart O O
- O O
lung O O
transplantation O O
. O O
The O O
transcriptional O O
start O O
site O O
( O O
s O O
) O O
of O O
the O O
IA B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
was O O
mapped O O
by O O
5 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
to O O
97 O O
bp O O
upstream O O
of O O
the O O
translational O O
start O O
site O O
. O O
The O O
RAG B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
encodes O O
a O O
component O O
of O O
the O O
V B-GENE O
( I-GENE O
D I-GENE O
) I-GENE O
J I-GENE O
recombinase E-GENE O
which O O
is O O
essential O O
for O O
the O O
assembly O O
of O O
antigen O B-GENE
receptor O I-GENE
genes O E-GENE
in O O
B O O
and O O
T O O
lymphocytes O O
. O O
The O O
lamina O O
densa O O
was O O
always O O
interrupted O O
by O O
numerous O O
small O O
gaps O O
and O O
in O O
some O O
areas O O
the O O
basement O O
membrane O O
could O O
not O O
be O O
identified O O
over O O
a O O
long O O
distance O O
. O O
We O O
have O O
characterized O O
21 O O
mutations O O
in O O
the O O
type B-GENE B-GENE
VII I-GENE I-GENE
collagen I-GENE I-GENE
gene E-GENE E-GENE
( O O
COL7A1 S-GENE S-GENE
) O O
encoding O O
the O O
anchoring O O
fibrils O O
, O O
18 O O
of O O
which O O
were O O
not O O
previously O O
reported O O
, O O
in O O
patients O O
from O O
15 O O
unrelated O O
families O O
with O O
recessive O O
dystrophic O O
epidermolysis O O
bullosa O O
( O O
RDEB O O
) O O
. O O
The O O
data O O
when O O
used O O
to O O
stimulate O O
the O O
collection O O
of O O
the O O
information O O
at O O
antenatal O O
or O O
postnatal O O
visits O O
, O O
nonetheless O O
provide O O
an O O
accurate O O
description O O
of O O
under O O
- O O
3 O O
mortality O O
trends O O
and O O
differences O O
for O O
the O O
two O O
periods O O
examined O O
- O O
- O O
before O O
1984 O O
and O O
before O O
1989 O O
. O O
Both O O
residues O O
are O O
conserved O O
in O O
the O O
three O O
phosphorylated O O
paralogs O O
but O O
are O O
absent O O
in O O
the O O
ones O O
that O O
were O O
not O O
substrates O O
of O O
RsbT S-GENE O
: O O
YetI S-GENE O
and O O
YezB S-GENE O
, O O
each O O
of O O
which O O
bears O O
only O O
one O O
of O O
the O O
conserved O O
residues O O
; O O
and O O
YtvA S-GENE O
, O O
which O O
lacks O O
both O O
residues O O
and O O
instead O O
possesses O O
an O O
N O O
- O O
terminal O O
PAS S-GENE O
domain O O
. O O
There O O
is O O
a O O
good O O
correlation O O
between O O
the O O
occurrence O O
in O O
any O O
particular O O
vascular O O
segment O O
of O O
the O O
transient O O
contractile O O
response O O
and O O
intrinsic O O
tone O O
as O O
assessed O O
by O O
relaxation O O
to O O
papaverine O O
( O O
10 O O
( O O
- O O
6 O O
) O O
M O O
) O O
. O O
Both O O
atracurium O O
1 O O
- O O
100 O O
mumol O O
litre O O
- O O
1 O O
and O O
laudanosine O O
1 O O
- O O
50 O O
mumol O O
litre O O
- O O
1 O O
enhanced O O
the O O
release O O
of O O
3H O O
- O O
NA O O
evoked O O
by O O
field O O
stimulation O O
( O O
2 O O
Hz O O
, O O
24 O O
stimuli O O
) O O
, O O
but O O
did O O
not O O
affect O O
resting O O
release O O
. O O
S16 O O
, O O
16 O O
. O O
8 O O
% O O
, O O
P O O
= O O
0 O O
. O O
001 O O
) O O
. O O
The O O
Zn B-GENE O
- I-GENE O
15 I-GENE O
DNA I-GENE O
- I-GENE O
binding I-GENE O
domain E-GENE O
comprises O O
three O O
zinc O O
fingers O O
separated O O
by O O
unusually O O
long O O
linker O O
sequences O O
that O O
would O O
be O O
expected O O
to O O
interrupt O O
specific O O
DNA O O
site O O
recognition O O
. O O
Replication O O
regions O O
from O O
plant O O
- O O
pathogenic O O
Pseudomonas O O
syringae O O
plasmids O O
are O O
similar O O
to O O
ColE2 O O
- O O
related O O
replicons O O
. O O
There O O
has O O
been O O
no O O
significant O O
toxicity O O
associated O O
with O O
repeated O O
5 O O
- O O
FU O O
instillation O O
into O O
the O O
airway O O
. O O
Twenty O O
male O O
volunteers O O
were O O
studied O O
during O O
almokalant O O
infusion O O
aiming O O
at O O
plasma O O
concentrations O O
( O O
Cpl O O
) O O
of O O
20 O O
, O O
50 O O
, O O
100 O O
, O O
and O O
150 O O
nmol O O
/ O O
l O O
. O O
Consistently O O
, O O
we O O
show O O
that O O
phosphorylation O O
by O O
protein B-GENE B-GENE
kinase I-GENE E-GENE
A E-GENE O
inhibits O O
Sfl1 S-GENE O
DNA O O
binding O O
in O O
vitro O O
, O O
and O O
that O O
a O O
tpk2Delta S-GENE O
mutation O O
increases O O
the O O
levels O O
of O O
Sfl1 B-GENE B-GENE
protein E-GENE E-GENE
associated O O
with O O
specific O O
promoter O O
elements O O
in O O
vivo O O
. O O
The O O
response O O
sequences O O
were O O
localized O O
between O O
- O O
67 O O
and O O
+ O O
30 O O
in O O
the O O
simian O B-GENE
cytomegalovirus O I-GENE
IE94 B-GENE I-GENE
promoter E-GENE E-GENE
and O O
upstream O O
of O O
position O O
+ O O
9 O O
in O O
the O O
HCMV B-GENE B-GENE
IE68 I-GENE I-GENE
promoter E-GENE E-GENE
. O O
Some O O
CHOP S-GENE B-GENE
- O I-GENE
C B-GENE E-GENE
/ I-GENE O
EBP E-GENE O
heterodimers O O
apparently O O
bind O O
to O O
alternative O O
DNA O O
sequence O O
and O O
thereby O O
regulate O O
the O O
transcription O O
of O O
other O O
genes O O
. O O
To O O
identify O O
and O O
determine O O
the O O
function O O
of O O
Ino2p S-GENE S-GENE
in O O
yeast O O
cells O O
, O O
we O O
raised O O
antibodies O O
to O O
a O O
beta B-GENE O
- I-GENE O
galactosidase E-GENE O
/ O O
Ino2 S-GENE B-GENE
fusion O I-GENE
protein O E-GENE
. O O
Northern O O
blot O O
analyses O O
were O O
used O O
to O O
examine O O
the O O
regulated O O
expression O O
of O O
the O O
cys B-GENE B-GENE
- I-GENE I-GENE
14 I-GENE I-GENE
+ I-GENE I-GENE
gene E-GENE E-GENE
. O O
Typicality O O
is O O
probably O O
a O O
better O O
representation O O
of O O
Alexander O O
, O O
Dunbar O O
and O O
others O O
' O O
conclusions O O
than O O
specificity O O
, O O
which O O
was O O
always O O
too O O
absolute O O
a O O
term O O
. O O
Additions O O
of O O
NH4 O O
+ O O
up O O
to O O
200 O O
micrograms O O
1 O O
( O O
- O O
1 O O
) O O
were O O
not O O
stimulatory O O
, O O
whereas O O
at O O
1 O O
. O O
0 O O
mg O O
1 O O
( O O
- O O
1 O O
) O O
levels O O
, O O
Ke O O
was O O
50 O O
% O O
greater O O
than O O
for O O
NO3 O O
- O O
enriched O O
medium O O
. O O
Cardiovascular O O
drug O O
use O O
and O O
hospitalizations O O
attributable O O
to O O
type O O
2 O O
diabetes O O
. O O
The O O
arrangement O O
of O O
amino O O
acids O O
in O O
the O O
helix O O
1 O O
and O O
helix O O
2 O O
regions O O
is O O
quite O O
similar O O
to O O
those O O
of O O
Mxi S-GENE O
and O O
Mad S-GENE O
, O O
but O O
different O O
from O O
those O O
of O O
E2F B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
DP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
They O O
contain O O
a O O
large O O
( O O
0 O O
. O O
9 O O
X O O
10 O O
( O O
3 O O
) O O
to O O
1 O O
. O O
88 O O
X O O
10 O O
( O O
3 O O
) O O
base O O
- O O
pairs O O
) O O
intron O O
in O O
the O O
middle O O
of O O
the O O
gene O O
and O O
are O O
further O O
interrupted O O
close O O
to O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
. O O
The O O
present O O
study O O
also O O
emphasizes O O
the O O
need O O
of O O
establishing O O
dose O O
- O O
response O O
curves O O
to O O
correctly O O
assess O O
the O O
relative O O
contribution O O
of O O
the O O
different O O
regions O O
of O O
steroid B-GENE O
hormone I-GENE O
receptors E-GENE O
in O O
activation O O
of O O
transcription O O
. O O
Routine O O
and O O
default O O
retrieval O O
home O O
visits O O
were O O
given O O
to O O
ensure O O
maximal O O
drug O O
compliance O O
. O O
D O O
. O O
, O O
and O O
Long O O
, O O
C O O
. O O
By O O
contrast O O
with O O
ama B-GENE O
- I-GENE O
1 E-GENE O
, O O
rpc B-GENE O
- I-GENE O
1 E-GENE O
was O O
not O O
deleted O O
by O O
mDf4 O O
or O O
larger O O
deficiencies O O
examined O O
, O O
indicating O O
that O O
these O O
genes O O
are O O
no O O
closer O O
than O O
150 O O
kb O O
. O O
Accordingly O O
, O O
constitutive O O
downregulation O O
of O O
expression O O
of O O
accessory O O
molecules O O
of O O
the O O
MHC B-GENE B-GENE
class I-GENE I-GENE
I I-GENE E-GENE
pathway E-GENE O
can O O
reveal O O
differences O O
between O O
H2 B-GENE B-GENE
class I-GENE I-GENE
I I-GENE I-GENE
alleles E-GENE E-GENE
in O O
antigen O O
presentation O O
not O O
encountered O O
when O O
the O O
expression O O
levels O O
are O O
augmented O O
. O O
Anovulatory O O
cycles O O
with O O
an O O
apparently O O
normal O O
level O O
of O O
blood O O
prolactin S-GENE O
. O O
Legionella B-GENE O
antibodies E-GENE O
in O O
domestic O O
animals O O
By O O
differential O O
screening O O
of O O
a O O
Xenopus O O
laevis O O
egg O O
cDNA O O
library O O
, O O
we O O
have O O
isolated O O
a O O
2 O O
, O O
111 O O
bp O O
cDNA O O
which O O
corresponds O O
to O O
a O O
maternal O O
mRNA O O
specifically O O
deadenylated O O
after O O
fertilisation O O
. O O
Similar O O
immunological O O
disturbances O O
were O O
observed O O
in O O
SCI O O
but O O
not O O
in O O
the O O
PC2 O O
subgroup O O
, O O
i O O
. O O
e O O
. O O
patients O O
examined O O
later O O
than O O
6 O O
months O O
after O O
injury O O
. O O
This O O
study O O
demonstrates O O
that O O
Fluosol O O
significantly O O
attenuates O O
neutrophil O O
adherence O O
, O O
cytotoxicity O O
, O O
and O O
enzyme O O
release O O
in O O
an O O
in O O
vitro O O
model O O
of O O
microvascular O O
injury O O
. O O
Using O O
the O O
same O O
electrical O O
analog O O
, O O
we O O
present O O
an O O
analysis O O
that O O
allows O O
calculation O O
of O O
these O O
parameters O O
, O O
as O O
well O O
as O O
the O O
corner O O
frequency O O
of O O
the O O
network O O
( O O
f1 O O
) O O
, O O
without O O
need O O
for O O
similar O O
assumptions O O
. O O
We O O
further O O
examined O O
the O O
interaction O O
of O O
JAK2 S-GENE S-GENE
with O O
the O O
GHR S-GENE B-GENE
cytoplasmic O I-GENE
domain O E-GENE
by O O
two O O
lines O O
of O O
investigation O O
. O O
These O O
p21 S-GENE S-GENE
- O O
E2F S-GENE S-GENE
complexes O O
, O O
while O O
present O O
in O O
young O O
G1 O O
cells O O
at O O
very O O
low O O
levels O O
, O O
were O O
elevated O O
in O O
senescent O O
cells O O
. O O
There O O
is O O
little O O
similarity O O
among O O
the O O
sequences O O
upstream O O
from O O
the O O
CAP O O
site O O
of O O
the O O
Spec2 B-GENE B-GENE
genes E-GENE E-GENE
except O O
the O O
TATA O O
consensus O O
sequence O O
and O O
a O O
repeating O O
trinucleotide O O
, O O
AAC O O
. O O
Thus O O
, O O
d O O
- O O
delta3 O O
- O O
carene O O
was O O
about O O
four O O
times O O
more O O
potent O O
as O O
a O O
sensory O O
irritant O O
than O O
I O O
- O O
beta O O
- O O
pinene O O
, O O
whereas O O
the O O
difference O O
with O O
I O O
- O O
alpha O O
- O O
pinene O O
was O O
more O O
marked O O
; O O
as O O
a O O
sensory O O
irritant O O
, O O
I O O
- O O
alpha O O
- O O
pinene O O
is O O
almost O O
inactive O O
. O O
The O O
reconstituted O O
RNA B-GENE O
polymerases E-GENE O
containing O O
the O O
mutant O B-GENE
alpha O I-GENE
subunits O E-GENE
were O O
examined O O
for O O
their O O
response O O
to O O
transcription O O
activation O O
by O O
cAMP B-GENE O
- I-GENE O
CRP E-GENE S-GENE
and O O
the O O
rrnBP1 B-GENE S-GENE
UP I-GENE O
element E-GENE O
. O O
The O O
study O O
drugs O O
( O O
combination O O
vinblastine O O
- O O
CCNU O O
and O O
single O O
- O O
agent O O
triazinate O O
or O O
dactinomycin O O
) O O
failed O O
to O O
provide O O
any O O
meaningful O O
antitumor O O
activity O O
for O O
these O O
patients O O
with O O
advanced O O
renal O O
cell O O
cancer O O
. O O
Our O O
results O O
indicate O O
that O O
GCN4 S-GENE S-GENE
contains O O
two O O
activation O O
domains O O
of O O
similar O O
potency O O
that O O
can O O
function O O
independently O O
to O O
promote O O
high O O
- O O
level O O
transcription O O
of O O
the O O
target O O
genes O O
HIS3 S-GENE S-GENE
and O O
HIS4 S-GENE S-GENE
. O O
Those O O
diagnosed O O
as O O
having O O
affective O O
disorder O O
( O O
n O O
= O O
96 O O
) O O
, O O
according O O
to O O
DSM O O
- O O
IIIR O O
criteria O O
, O O
were O O
compared O O
with O O
the O O
other O O
non O O
- O O
affective O O
suicide O O
attempters O O
( O O
n O O
= O O
161 O O
) O O
. O O
Tax S-GENE O
was O O
demonstrated O O
to O O
interact O O
directly O O
with O O
CREB1 S-GENE S-GENE
but O O
not O O
with O O
other O O
bZIP B-GENE B-GENE
proteins E-GENE E-GENE
, O O
including O O
CREB2 S-GENE S-GENE
and O O
Jun S-GENE S-GENE
. O O
Anxiogenic O O
effects O O
of O O
pentagastrin O O
in O O
patients O O
with O O
social O O
phobia O O
and O O
healthy O O
controls O O
. O O
Ischaemia O O
and O O
reperfusion O O
injury O O
in O O
the O O
kidney O O
: O O
current O O
status O O
and O O
future O O
direction O O
. O O
Non O O
- O O
dialyzable O O
transfer B-GENE O
factor E-GENE O
We O O
also O O
demonstrate O O
that O O
a O O
p110RB1 B-GENE B-GENE
mutant E-GENE E-GENE
, O O
which O O
is O O
refractory O O
to O O
cell O O
cycle O O
phosphorylation O O
but O O
intact O O
in O O
E1a S-GENE S-GENE
/ O O
large B-GENE O
T I-GENE O
antigen E-GENE O
- O O
binding O O
properties O O
, O O
represses O O
EIIaE S-GENE O
with O O
50 O O
- O O
to O O
80 O O
- O O
fold O O
greater O O
efficiency O O
than O O
wild B-GENE O
- I-GENE O
type I-GENE O
p110RB1 E-GENE O
. O O
Subgroup O O
analysis O O
failed O O
to O O
show O O
any O O
benefit O O
for O O
etoposide O O
in O O
patients O O
with O O
monocytic O O
or O O
myelomonocytic O O
disease O O
, O O
or O O
in O O
any O O
other O O
diagnostic O O
subgroup O O
. O O
The O O
IGFBP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
IRS S-GENE O
and O O
PEPCK S-GENE S-GENE
IRS S-GENE O
both O O
bind O O
the O O
alpha O O
and O O
beta O O
forms O O
of O O
hepatic B-GENE B-GENE
nuclear I-GENE I-GENE
factor I-GENE I-GENE
3 E-GENE E-GENE
( O O
HNF B-GENE O
- I-GENE O
3 E-GENE O
) O O
, O O
although O O
the O O
latter O O
does O O
so O O
with O O
a O O
sixfold O O
- O O
lower O O
relative O O
affinity O O
. O O
Polyglutamine O O
- O O
containing O O
protein O O
fragments O O
have O O
been O O
shown O O
to O O
accumulate O O
as O O
aggregates O O
in O O
the O O
nucleus O O
and O O
in O O
the O O
cytoplasm O O
, O O
and O O
to O O
induce O O
cell O O
death O O
when O O
expressed O O
in O O
cultured O O
cells O O
, O O
leading O O
to O O
the O O
proposal O O
that O O
polyglutamine O O
aggregation O O
is O O
an O O
important O O
step O O
in O O
the O O
pathogenesis O O
. O O
It O O
is O O
suggested O O
that O O
on O O
presentation O O
of O O
tail O O
tip O O
necrosis O O
in O O
kittens O O
a O O
diagnosis O O
of O O
neonatal O O
isoerythrolysis O O
or O O
isoagglutination O O
should O O
be O O
considered O O
. O O
Microscopically O O
, O O
cartilage O O
showed O O
markedly O O
stunted O O
and O O
disorganized O O
endochondral O O
ossification O O
. O O
Our O O
data O O
provide O O
the O O
first O O
evidence O O
that O O
differential O O
splicing O O
in O O
the O O
extracellular O O
region O O
of O O
a O O
receptor O O
gene O O
generates O O
receptor O O
variants O O
with O O
different O O
ligand O O
- O O
binding O O
specificities O O
. O O
Sucrose O O
- O O
specific O O
signalling O O
represses O O
translation O O
of O O
the O O
Arabidopsis B-GENE O
ATB2 I-GENE B-GENE
bZIP I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
gene E-GENE E-GENE
. O O
Wolf O O
- O O
Hirschhorn O O
syndrome O O
( O O
WHS O O
) O O
is O O
a O O
malformation O O
syndrome O O
associated O O
with O O
a O O
hemizygous O O
deletion O O
of O O
the O O
distal O O
short O O
arm O O
of O O
chromosome O O
4 O O
( O O
4p16 O O
. O O
3 O O
) O O
. O O
Our O O
aim O O
was O O
to O O
check O O
whether O O
, O O
during O O
PG O O
- O O
DS O O
administration O O
, O O
serum O B-GENE
lipase S-GENE E-GENE
activity O O
changes O O
simultaneously O O
with O O
serum O B-GENE
amylase S-GENE E-GENE
activity O O
, O O
and O O
, O O
if O O
so O O
, O O
what O O
the O O
reason O O
is O O
for O O
the O O
detected O O
change O O
. O O
A O O
long O O
- O O
term O O
follow O O
- O O
up O O
study O O
of O O
a O O
children O O
' O O
s O O
psychiatric O O
day O O
treatment O O
center O O
. O O
Sequencing O O
and O O
restriction O O
enzyme O O
analysis O O
demonstrated O O
that O O
this O O
single O O
- O O
copy O O
gene O O
contains O O
11 O O
exons O O
and O O
spans O O
9596 O O
base O O
pairs O O
. O O
In O O
phase O O
II O O
studies O O
, O O
MDL O O
72 O O
, O O
974A O O
is O O
proving O O
to O O
be O O
a O O
useful O O
adjunct O O
to O O
conventional O O
therapy O O
. O O
However O O
, O O
no O O
consensus O O
on O O
indications O O
exists O O
and O O
, O O
according O O
to O O
the O O
literature O O
, O O
results O O
are O O
contradictory O O
. O O
The O O
effect O O
of O O
the O O
NMDA B-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
antagonist O O
( O O
+ O O
/ O O
- O O
) O O
- O O
CPP O O
on O O
the O O
conditioned O O
- O O
reflex O O
activation O O
of O O
an O O
operant O O
reaction O O
in O O
the O O
brain O O
electrical O O
self O O
- O O
stimulation O O
test O O
in O O
rats O O
Within O O
any O O
cell O O
line O O
, O O
several O O
Tcfs S-GENE O
and O O
TLEs S-GENE S-GENE
are O O
co O O
- O O
expressed O O
. O O
Constructs O O
containing O O
fragments O O
of O O
the O O
upstream O O
region O O
of O O
the O O
cytotactin B-GENE B-GENE
gene E-GENE E-GENE
fused O O
to O O
a O O
promoterless O O
gene O O
for O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
were O O
transiently O O
transfected O O
into O O
chicken O O
embryo O O
fibroblasts O O
to O O
define O O
functional O O
promoter O O
sequences O O
. O O
We O O
investigated O O
the O O
pattern O O
of O O
evolution O O
of O O
bronchial O O
albumin S-GENE O
, O O
IgA S-GENE S-GENE
, O O
and O O
IgG S-GENE S-GENE
levels O O
in O O
ventilated O O
ICU O O
patients O O
in O O
relation O O
to O O
nosocomial O O
pneumonia O O
. O O
Mortality O O
among O O
patients O O
with O O
CAVB O O
is O O
still O O
high O O
and O O
has O O
not O O
declined O O
within O O
the O O
last O O
decade O O
. O O
Mutations O O
away O O
from O O
splice O O
site O O
recognition O O
sequences O O
might O O
cis O O
- O O
modulate O O
alternative O O
splicing O O
of O O
goat O B-GENE
alpha B-GENE I-GENE
s1 I-GENE I-GENE
- I-GENE I-GENE
casein I-GENE I-GENE
transcripts E-GENE E-GENE
. O O
SETTING O O
: O O
A O O
private O O
office O O
- O O
based O O
fertility O O
program O O
. O O
Promoter O O
, O O
spliced O O
leader O O
, O O
and O O
coding O O
sequence O O
for O O
BICP4 S-GENE S-GENE
, O O
the O O
largest O O
of O O
the O O
immediate B-GENE O
- I-GENE O
early I-GENE O
proteins I-GENE O
of I-GENE O
bovine I-GENE B-GENE
herpesvirus I-GENE I-GENE
1 E-GENE E-GENE
. O O
The O O
limb O O
defects O O
, O O
oligodactyly O O
and O O
syndactyly O O
, O O
have O O
been O O
traced O O
to O O
improper O O
differentiation O O
of O O
the O O
apical O O
ectodermal O O
ridge O O
( O O
AER O O
) O O
and O O
shortening O O
of O O
the O O
anteroposterior O O
limb O O
axis O O
. O O
Our O O
data O O
suggest O O
that O O
the O O
ZF B-GENE B-GENE
- I-GENE I-GENE
HD E-GENE E-GENE
class O O
of O O
homeodomain B-GENE O
proteins E-GENE O
may O O
be O O
involved O O
in O O
the O O
establishment O O
of O O
the O O
characteristic O O
expression O O
pattern O O
of O O
the O O
C4 B-GENE B-GENE
PEPCase I-GENE I-GENE
gene E-GENE E-GENE
. O O
There O O
was O O
no O O
correlation O O
between O O
starting O O
platelet O O
- O O
associated O O
IgG S-GENE S-GENE
levels O O
or O O
changes O O
in O O
platelet O O
- O O
associated O O
IgG S-GENE S-GENE
levels O O
with O O
therapy O O
and O O
the O O
increment O O
in O O
the O O
patient O O
' O O
s O O
platelet O O
count O O
. O O
We O O
investigated O O
whether O O
two O O
WT1 B-GENE O
splice I-GENE O
variants E-GENE O
lacking O O
or O O
including O O
a O O
three O O
- O O
amino O O
- O O
acid O O
( O O
KTS O O
) O O
insertion O O
between O O
the O O
third O O
and O O
fourth O O
zinc O O
finger O O
in O O
the O O
DNA O O
- O O
binding O O
domain O O
could O O
repress O O
the O O
IR B-GENE B-GENE
promoter E-GENE E-GENE
in O O
vitro O O
. O O
An O O
oligomer O O
synthesized O O
to O O
this O O
region O O
of O O
homology O O
produced O O
two O O
DNA O O
- O O
protein O O
complexes O O
with O O
oviduct O O
nuclear O O
proteins O O
. O O
The O O
deduced O O
amino O O
acid O O
sequence O O
exhibits O O
95 O O
. O O
3 O O
and O O
76 O O
. O O
1 O O
% O O
identity O O
with O O
the O O
CAD B-GENE O
sequences I-GENE O
of I-GENE O
hamster I-GENE O
and I-GENE O
Squalus I-GENE O
acanthias E-GENE O
. O O
In O O
contrast O O
translocation O O
of O O
G1 S-GENE O
to O O
the O O
Golgi O O
was O O
not O O
observed O O
when O O
G1 S-GENE O
was O O
coexpressed O O
with O O
NSm S-GENE O
, O O
although O O
NSm S-GENE O
itself O O
was O O
still O O
detected O O
in O O
the O O
Golgi O O
. O O
Since O O
simian B-GENE O
virus I-GENE O
40 I-GENE O
( I-GENE O
SV40 I-GENE O
) I-GENE O
large I-GENE O
T I-GENE O
antigen E-GENE O
and O O
human B-GENE O
papillomavirus I-GENE O
type I-GENE O
16 I-GENE O
( I-GENE O
HPV16 I-GENE S-GENE
) I-GENE O
E7 I-GENE B-GENE
protein E-GENE E-GENE
also O O
bind O O
host O O
regulatory O O
factors O O
, O O
we O O
investigated O O
whether O O
these O O
viral O O
proteins O O
can O O
complement O O
E1A B-GENE B-GENE
mutants E-GENE E-GENE
which O O
are O O
defective O O
in O O
early O O
gene O O
activation O O
. O O
We O O
further O O
showed O O
a O O
significant O O
repression O O
of O O
promoter O O
activity O O
( O O
> O O
40 O O
fold O O
) O O
by O O
E2 B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
( O O
lacking O O
the O O
amino O O
acid O O
sequence O O
RSRS O O
) O O
when O O
the O O
E47 B-GENE O
reporter I-GENE O
construct E-GENE O
, O O
containing O O
a O O
hexameric O O
E O O
- O O
box O O
site O O
, O O
was O O
used O O
. O O
Similar O O
observations O O
were O O
obtained O O
when O O
these O O
mutated O O
versions O O
of O O
site O O
A O O
were O O
evaluated O O
by O O
transient O O
cotransfection O O
assays O O
in O O
CV1 O O
cells O O
. O O
The O O
shear O O
bond O O
strength O O
recorded O O
for O O
the O O
Novabond O O
system O O
was O O
significantly O O
lower O O
( O O
17 O O
MPa O O
) O O
. O O
A O O
400 O O
- O O
bp O O
fragment O O
( O O
bp O O
- O O
339 O O
through O O
+ O O
71 O O
) O O
of O O
the O O
CD22 B-GENE B-GENE
promoter I-GENE E-GENE
region E-GENE O
was O O
subcloned O O
into O O
a O O
pGEM O O
- O O
chloramphenicol B-GENE O
acetyltransferase E-GENE O
vector O O
and O O
after O O
transfection O O
into O O
B O O
and O O
T O O
cells O O
was O O
found O O
to O O
be O O
active O O
in O O
both O O
B O O
and O O
T O O
cells O O
. O O
RESULTS O O
: O O
There O O
were O O
no O O
significant O O
differences O O
in O O
the O O
mean O O
serum O O
vitamin O O
A O O
, O O
E O O
concentrations O O
and O O
vitamin O O
E O O
/ O O
cholesterol O O
ratio O O
between O O
pregnant O O
women O O
with O O
normal O O
hemoglobin S-GENE O
and O O
hemoglobinopathies O O
, O O
while O O
confounding O O
variables O O
that O O
might O O
affect O O
serum O O
vitamin O O
levels O O
i O O
. O O
e O O
. O O
maternal O O
age O O
, O O
gravida O O
, O O
BMI O O
, O O
gestational O O
age O O
, O O
hematocrit O O
, O O
hemoglobin S-GENE O
, O O
mean O O
corpuscular O O
hemoglobin S-GENE O
concentration O O
and O O
blood O O
group O O
were O O
not O O
different O O
. O O
Fourteen O O
samples O O
, O O
seven O O
each O O
of O O
IR64 O O
and O O
IR66 O O
were O O
studied O O
with O O
regard O O
to O O
moisture O O
content O O
, O O
germination O O
test O O
, O O
abnormal O O
seedlings O O
, O O
speed O O
of O O
germination O O
, O O
conductance O O
of O O
leachates O O
, O O
total O O
dehydrogenase O O
activity O O
, O O
total O O
free O O
amino O O
acids O O
, O O
total O O
soluble O O
sugar O O
, O O
fat O O
acidity O O
, O O
gelatinization O O
temperature O O
, O O
gel O O
consistency O O
, O O
amylose O O
content O O
, O O
translucency O O
, O O
and O O
per O O
cent O O
whiteness O O
. O O
Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
between O O
viral O O
RNA O O
and O O
BMV B-GENE B-GENE
CP I-GENE I-GENE
peptides E-GENE E-GENE
with O O
either O O
proline O O
or O O
alanine O O
substitutions O O
revealed O O
that O O
the O O
interaction O O
is O O
nonspecific O O
. O O
Thus O O
, O O
over O O
a O O
wide O O
range O O
of O O
arterial O O
dimensions O O
, O O
results O O
obtained O O
with O O
caliper O O
estimates O O
of O O
luminal O O
area O O
and O O
diameter O O
are O O
comparable O O
to O O
those O O
obtained O O
with O O
videodensitometry O O
using O O
the O O
XR O O
- O O
70 O O
system O O
. O O
CONCLUSIONS O O
: O O
Neurodevelopmental O O
assessment O O
at O O
1 O O
year O O
is O O
predictive O O
of O O
school O O
performance O O
and O O
outcome O O
in O O
the O O
adolescent O O
period O O
. O O
We O O
reviewed O O
the O O
different O O
published O O
cases O O
of O O
acute O O
high O O
dose O O
methotrexate O O
neurotoxicity O O
and O O
the O O
different O O
underlying O O
mechanisms O O
. O O
Drug O O
therapy O O
of O O
AAPMC O O
is O O
directed O O
at O O
reducing O O
the O O
amount O O
of O O
Cl O O
. O O
difficile O O
in O O
the O O
colon O O
and O O
promoting O O
normalization O O
of O O
intestinal O O
flora O O
. O O
The O O
yield O O
of O O
endocervical O O
cells O O
and O O
the O O
incidence O O
of O O
dysplasia O O
was O O
determined O O
for O O
both O O
the O O
prenatal O O
and O O
the O O
postpartum O O
Pap O O
smears O O
performed O O
for O O
this O O
group O O
of O O
patients O O
. O O
No O O
significant O O
difference O O
in O O
plasma O O
ET S-GENE O
levels O O
was O O
found O O
between O O
cardiac O O
and O O
peripheral O O
sampling O O
sites O O
( O O
pulmonary O O
artery O O
; O O
1 O O
. O O
07 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
right O O
atrium O O
; O O
1 O O
. O O
02 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
peripheral O O
artery O O
; O O
1 O O
. O O
12 O O
+ O O
/ O O
- O O
0 O O
. O O
23 O O
, O O
peripheral O O
vein O O
; O O
1 O O
. O O
14 O O
+ O O
/ O O
- O O
0 O O
. O O
38 O O
fmol O O
/ O O
ml O O
: O O
N O O
. O O
S O O
. O O
) O O
, O O
or O O
among O O
patients O O
with O O
uncomplicated O O
MI O O
, O O
unstable O O
angina O O
( O O
1 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
32 O O
fmol O O
/ O O
ml O O
) O O
, O O
and O O
healthy O O
subjects O O
( O O
1 O O
. O O
01 O O
+ O O
/ O O
- O O
0 O O
. O O
29 O O
fmol O O
/ O O
ml O O
) O O
. O O
Dose O O
- O O
dependent O O
pharmacokinetics O O
: O O
emphasis O O
on O O
phase O O
I O O
metabolism O O
. O O
Inhibition O O
of O O
DNA B-GENE B-GENE
topoisomerase I-GENE I-GENE
II I-GENE I-GENE
alpha I-GENE I-GENE
gene E-GENE E-GENE
expression O O
by O O
the O O
p53 B-GENE S-GENE
tumor I-GENE O
suppressor E-GENE O
. O O
Activation O O
of O O
HIV O O
gene O O
expression O O
by O O
UV O O
must O O
therefore O O
involve O O
additional O O
cellular O O
processes O O
, O O
such O O
as O O
those O O
triggered O O
by O O
DNA O O
damage O O
, O O
for O O
generation O O
of O O
a O O
full O O
gene O O
expression O O
response O O
. O O
4 O O
. O O
Microsporum O O
persicolor O O
, O O
an O O
easily O O
misinterpreted O O
dermatophyt O O
We O O
propose O O
that O O
, O O
while O O
Y O O
. O O
lipolytica O O
CEN O O
DNA O O
is O O
essential O O
for O O
plasmid O O
maintenance O O
, O O
this O O
function O O
can O O
be O O
supplied O O
by O O
several O O
sub O O
- O O
fragments O O
which O O
, O O
together O O
, O O
form O O
the O O
active O O
chromosomal O O
centromere O O
. O O
In O O
this O O
second O O
clinical O O
paper O O
, O O
the O O
genetic O O
features O O
of O O
the O O
case O O
of O O
microphthalmia O O
in O O
sheep O O
reported O O
by O O
Wagenaar O O
is O O
discussed O O
in O O
greater O O
detail O O
. O O
Our O O
study O O
reveals O O
a O O
consequence O O
of O O
adhesion O O
receptor O O
- O O
mediated O O
signaling O O
in O O
T O O
cells O O
, O O
which O O
is O O
potentially O O
important O O
in O O
the O O
regulation O O
of O O
T O O
cell O O
activation O O
, O O
including O O
production O O
of O O
cytokines O O
and O O
expression O O
of O O
proto O O
- O O
oncogenes O O
, O O
many O O
of O O
which O O
are O O
controlled O O
through O O
3 O O
' O O
AU O O
- O O
rich O O
elements O O
. O O
The O O
gap S-GENE O
protein O O
knirps S-GENE O
mediates O O
both O O
quenching O O
and O O
direct O O
repression O O
in O O
the O O
Drosophila O O
embryo O O
. O O
The O O
family O O
histories O O
were O O
obtained O O
from O O
the O O
parents O O
. O O
The O O
DW O O
directions O O
uniformly O O
sampled O O
the O O
diffusion O O
ellipsoid O O
surface O O
. O O
Here O O
we O O
demonstrate O O
that O O
CD40 S-GENE S-GENE
or O O
IgM B-GENE B-GENE
receptor E-GENE E-GENE
stimulation O O
of O O
primary O O
B O O
cells O O
results O O
in O O
transactivation O O
of O O
this O O
enhancer O O
. O O
This O O
cell O O
line O O
expresses O O
productively O O
rearranged O O
immunoglobulin B-GENE O
genes E-GENE O
as O O
well O O
as O O
the O O
Oct B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
at O O
high O O
levels O O
which O O
are O O
comparable O O
to O O
those O O
observed O O
in O O
activated O O
murine O O
splenic O O
B O O
cells O O
. O O
The O O
relationship O O
between O O
CSF B-GENE O
somatostatin E-GENE O
and O O
peripheral O O
thyroid O O
hormones O O
was O O
assessed O O
in O O
11 O O
affectively O O
ill O O
patients O O
before O O
and O O
during O O
carbamazepine O O
treatment O O
. O O
Both O O
RNA14 S-GENE S-GENE
and O O
RNA15 B-GENE B-GENE
wild I-GENE I-GENE
- I-GENE I-GENE
type I-GENE I-GENE
genes E-GENE E-GENE
, O O
when O O
cloned O O
on O O
a O O
multicopy O O
plasmid O O
, O O
are O O
able O O
to O O
suppress O O
the O O
temperature O O
- O O
sensitive O O
phenotype O O
of O O
strains O O
bearing O O
either O O
the O O
rna14 S-GENE S-GENE
or O O
the O O
rna15 B-GENE S-GENE
mutation E-GENE O
, O O
suggesting O O
that O O
the O O
encoded O O
proteins O O
could O O
interact O O
with O O
each O O
other O O
. O O
Treatments O O
were O O
two O O
adrenocorticotrophin S-GENE O
( O O
ACTH S-GENE O
) O O
preparations O O
given O O
intramuscularly O O
at O O
2 O O
. O O
2 O O
U O O
/ O O
kg O O
, O O
one O O
of O O
the O O
ACTH S-GENE O
preparations O O
given O O
intramuscularly O O
at O O
1 O O
U O O
/ O O
kg O O
and O O
a O O
synthetic O O
polypeptide O O
with O O
ACTH B-GENE O
- I-GENE O
like E-GENE O
activity O O
( O O
tetracosactrin O O
, O O
cosyntropin O O
) O O
given O O
intravenously O O
at O O
5 O O
micrograms O O
/ O O
kg O O
. O O
It O O
is O O
very O O
probable O O
that O O
this O O
change O O
was O O
due O O
to O O
mechanical O O
effects O O
induced O O
by O O
injecting O O
a O O
hypertonic O O
solution O O
of O O
MT O O
- O O
141 O O
at O O
a O O
rate O O
of O O
70 O O
- O O
- O O
130 O O
ml O O
/ O O
dog O O
. O O
It O O
is O O
not O O
well O O
known O O
that O O
giant O O
cell O O
arteritis O O
can O O
cause O O
fatal O O
complications O O
due O O
to O O
rupture O O
of O O
aortic O O
aneurysms O O
or O O
cerebral O O
and O O
myocardial O O
infarctions O O
. O O
PRIP S-GENE S-GENE
contains O O
two O O
LXXLL O O
signature O O
motifs O O
. O O
Basal O O
urinary O O
17 O O
- O O
hydroxycorticoid O O
( O O
17 O O
- O O
OHCS O O
) O O
values O O
were O O
elevated O O
in O O
9 O O
/ O O
12 O O
patients O O
and O O
low O O
dose O O
dexamethasone O O
suppression O O
test O O
favoured O O
Cushing O O
' O O
s O O
syndrome O O
in O O
8 O O
/ O O
9 O O
patients O O
. O O
Like O O
the O O
human O B-GENE
gene O E-GENE
, O O
the O O
Drosophila O O
gene O O
encodes O O
at O O
least O O
three O O
isoforms O O
of O O
full B-GENE O
length I-GENE O
dystrophin I-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
proteins E-GENE E-GENE
( O O
dmDLP1 S-GENE S-GENE
, O O
dmDLP2 S-GENE S-GENE
and O O
dmDLP3 S-GENE S-GENE
, O O
) O O
, O O
regulated O O
by O O
different O O
promoters O O
located O O
at O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
, O O
and O O
a O O
smaller O O
product O O
regulated O O
by O O
an O O
internal O O
promoter O O
( O O
dmDp186 S-GENE S-GENE
) O O
. O O
Accordingly O O
, O O
infection O O
of O O
IFN S-GENE O
- O O
pretreated O O
HeLa O O
S3 O O
cells O O
with O O
an O O
E3L O O
- O O
deficient O O
VV O O
( O O
VVDeltaE3L O O
) O O
resulted O O
in O O
increased O O
phosphorylation O O
levels O O
of O O
both O O
PKR S-GENE S-GENE
and O O
eIF2alpha S-GENE O
. O O
The O O
goal O O
of O O
our O O
work O O
was O O
to O O
determine O O
hearing O O
thresholds O O
in O O
patients O O
with O O
hearing O O
impairment O O
due O O
to O O
hereditary O O
motor O O
and O O
sensory O O
neuropathy O O
( O O
HMSN O O
I O O
) O O
. O O
Influence O O
of O O
dietary O O
supplementation O O
with O O
Streptococcus O O
faecium O O
M O O
- O O
74 O O
on O O
broiler O O
body O O
weight O O
, O O
feed O O
conversion O O
, O O
carcass O O
characteristics O O
, O O
and O O
intestinal O O
microbial O O
colonization O O
. O O
The O O
results O O
reveal O O
preferences O O
for O O
particular O O
initiating O O
nucleotides O O
( O O
ATP O O
> O O
or O O
= O O
GTP O O
> O O
UTP O O
> O O
> O O
CTP O O
) O O
and O O
for O O
starting O O
positions O O
downstream O O
of O O
the O O
Pribnow O O
box O O
( O O
7 O O
> O O
> O O
6 O O
and O O
8 O O
> O O
9 O O
> O O
10 O O
) O O
. O O
Trimethylcolchicinic O O
acid O O
methyl O O
ether O O
d O O
- O O
tartrate O O
( O O
TMCA O O
; O O
NSC O O
- O O
36351 O O
) O O
was O O
administered O O
daily O O
by O O
mouth O O
to O O
71 O O
patients O O
with O O
malignant O O
lymphomas O O
. O O
Gene O O
transcripts O O
are O O
detected O O
on O O
tissues O O
such O O
as O O
bovine O O
liver O O
, O O
kidney O O
, O O
lung O O
, O O
and O O
brain O O
. O O
Assessment O O
of O O
ammonia O O
and O O
urea O O
blood O O
content O O
in O O
metabolic O O
acid O O
- O O
base O O
disorders O O
in O O
white O O
rats O O
. O O
The O O
immediate O O
and O O
remote O O
results O O
of O O
surgical O O
treatment O O
of O O
renal O O
adenocarcinomas O O
. O O
Vibrio O O
cholerae O O
iron O O
transport O O
: O O
haem O O
transport O O
genes O O
are O O
linked O O
to O O
one O O
of O O
two O O
sets O O
of O O
tonB S-GENE S-GENE
, O O
exbB S-GENE S-GENE
, O O
exbD B-GENE B-GENE
genes E-GENE E-GENE
. O O
The O O
predicted O O
amino O O
- O O
acid O O
sequence O O
includes O O
an O O
N O O
- O O
terminal O O
signal O O
sequence O O
of O O
27 O O
amino O O
acids O O
, O O
a O O
27 O O
amino O O
- O O
acid O O
pro O O
- O O
region O O
, O O
a O O
251 O O
amino O O
- O O
acid O O
catalytic O O
domain O O
typical O O
of O O
a O O
serine B-GENE O
protease E-GENE O
with O O
trypsin S-GENE O
- O O
like O O
specificity O O
, O O
and O O
a O O
C O O
- O O
terminal O O
hydrophobic O O
extension O O
which O O
is O O
predicted O O
to O O
function O O
as O O
a O O
membrane O O
anchor O O
. O O
To O O
examine O O
the O O
biochemical O O
mechanism O O
of O O
Tax1 S-GENE S-GENE
transactivation O O
, O O
we O O
have O O
developed O O
an O O
in O O
vitro O O
transactivation O O
assay O O
in O O
which O O
wild O O
- O O
type O O
Tax1 S-GENE S-GENE
is O O
able O O
to O O
specifically O O
transactivate O O
a O O
polymerase B-GENE B-GENE
II E-GENE I-GENE
promoter O E-GENE
through O O
upstream O O
Tax1 B-GENE O
- I-GENE O
responsive I-GENE O
elements E-GENE O
. O O
Interestingly O O
, O O
PMA O O
- O O
, O O
PDGF S-GENE O
- O O
, O O
and O O
serum O O
- O O
induced O O
GHR S-GENE O
proteolysis O O
was O O
associated O O
with O O
substantial O O
decreases O O
in O O
GH S-GENE O
- O O
induced O O
activation O O
of O O
Janus B-GENE B-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
which O O
were O O
also O O
prevented O O
by O O
IC3 O S-GENE
. O O
Thus O O
, O O
IF O O
- O O
laser O O
therapy O O
has O O
a O O
certain O O
antioxidative O O
effect O O
by O O
increasing O O
SOD S-GENE O
activity O O
in O O
RA O O
patients O O
' O O
blood O O
cells O O
and O O
reducing O O
the O O
production O O
of O O
highly O O
reactive O O
oxygen O O
and O O
nitrogen O O
forms O O
. O O
Reactive O O
mesothelial O O
cells O O
, O O
usually O O
seen O O
as O O
exfoliated O O
cells O O
, O O
were O O
consistently O O
strongly O O
positive O O
for O O
alpha B-GENE B-GENE
1 I-GENE I-GENE
- I-GENE I-GENE
antichymotrypsin E-GENE E-GENE
and O O
more O O
variably O O
for O O
alpha B-GENE B-GENE
1 I-GENE I-GENE
- I-GENE I-GENE
antitrypsin E-GENE E-GENE
and O O
lysozyme S-GENE O
. O O
Recombinant O O
propeptides O O
containing O O
mutations O O
of O O
one O O
of O O
the O O
three O O
tryptophan O O
residues O O
were O O
three O O
orders O O
of O O
magnitude O O
less O O
effective O O
as O O
inhibitors O O
of O O
mature B-GENE O
cathepsin I-GENE O
S E-GENE O
than O O
the O O
wild O O
- O O
type O O
propeptide O O
. O O
The O O
highest O O
incidence O O
was O O
observed O O
for O O
V O O
. O O
alginolyticus O O
( O O
92 O O
- O O
100 O O
% O O
) O O
, O O
followed O O
by O O
V O O
. O O
parahaemolyticus O O
( O O
67 O O
- O O
92 O O
% O O
) O O
, O O
V O O
. O O
fluvialis O O
( O O
34 O O
- O O
67 O O
% O O
) O O
, O O
V O O
. O O
vulnificus O O
( O O
8 O O
- O O
17 O O
% O O
) O O
, O O
V O O
. O O
furnissii O O
( O O
0 O O
- O O
17 O O
% O O
) O O
, O O
V O O
. O O
mimicus O O
( O O
0 O O
- O O
17 O O
% O O
) O O
and O O
V O O
. O O
cholerae O O
non O O
- O O
O1 O O
( O O
0 O O
- O O
8 O O
% O O
) O O
. O O
Acute O O
morphine O O
treatment O O
did O O
not O O
increase O O
the O O
locomotor O O
activity O O
of O O
mice O O
withdrawn O O
for O O
1 O O
day O O
, O O
after O O
withdrawal O O
for O O
3 O O
days O O
the O O
increase O O
was O O
similar O O
to O O
that O O
in O O
controls O O
, O O
and O O
after O O
5 O O
days O O
the O O
increase O O
was O O
clearly O O
larger O O
than O O
in O O
controls O O
. O O
In O O
patients O O
with O O
active O O
TB O O
, O O
cytokines O O
that O O
were O O
elevated O O
in O O
serum O O
were O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
, O O
IL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
and O O
IL B-GENE O
- I-GENE O
10 E-GENE O
. O O
Isolation O O
and O O
properties O O
of O O
Drosophila B-GENE O
melanogaster I-GENE O
ferritin E-GENE O
- O O
- O O
molecular O O
cloning O O
of O O
a O O
cDNA O O
that O O
encodes O O
one O O
subunit O O
, O O
and O O
localization O O
of O O
the O O
gene O O
on O O
the O O
third O O
chromosome O O
. O O
We O O
show O O
that O O
Fos S-GENE O
down O O
regulates O O
several O O
immediate B-GENE O
- I-GENE O
early I-GENE O
genes E-GENE O
( O O
c B-GENE B-GENE
- I-GENE I-GENE
fos E-GENE E-GENE
, O O
Egr B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
Egr B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
) O O
after O O
mitogenic O O
stimulation O O
. O O
This O O
study O O
demonstrates O O
a O O
novel O O
link O O
between O O
alterations O O
in O O
platelet B-GENE B-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
PDGF S-GENE S-GENE
) O O
regulation O O
of O O
ornithine B-GENE O
decarboxylase E-GENE O
( O O
ODC S-GENE O
) O O
expression O O
during O O
malignant O O
conversion O O
. O O
Circulating O O
immune O O
complexes O O
were O O
determined O O
by O O
the O O
method O O
of O O
phagocytosis O O
and O O
immunofluorescence O O
. O O
The O O
human B-GENE B-GENE
IFI16 I-GENE I-GENE
gene E-GENE E-GENE
is O O
a O O
member O O
of O O
an O O
interferon S-GENE O
- O O
inducible O O
family O O
of O O
mouse O O
and O O
human O O
genes O O
closely O O
linked O O
on O O
syntenic O O
regions O O
of O O
chromosome O O
1 O O
. O O
In O O
agreement O O
with O O
this O O
model O O
, O O
elimination O O
of O O
the O O
ADAM13 B-GENE B-GENE
cytoplasmic I-GENE I-GENE
domain E-GENE E-GENE
increased O O
developmental O O
alterations O O
attributable O O
to O O
ADAM13 S-GENE S-GENE
proteolytic O O
activity O O
. O O
Diabetic O O
osteopathy O O
. O O
A O O
third O O
GEF S-GENE S-GENE
, O O
GRP3 S-GENE S-GENE
( O O
KIAA0846 S-GENE S-GENE
) O O
, O O
activated O O
both O O
Ras S-GENE S-GENE
and O O
Rap1 S-GENE S-GENE
and O O
shared O O
significant O O
sequence O O
homology O O
with O O
the O O
calcium O O
- O O
and O O
diacylglycerol O O
- O O
activated O O
GEFs S-GENE S-GENE
, O O
GRP1 S-GENE S-GENE
and O O
GRP2 S-GENE S-GENE
. O O
A O O
new O O
simple O O
identification O O
of O O
rheumatoid B-GENE O
factor E-GENE O
on O O
nitrocellulose O O
was O O
developed O O
that O O
allows O O
quantitative O O
detection O O
. O O
Comparisons O O
of O O
defective O O
HTLV O O
- O O
I O O
proviruses O O
predict O O
the O O
mode O O
of O O
origin O O
and O O
coding O O
potential O O
of O O
internally O O
deleted O O
genomes O O
. O O
Reversal O O
of O O
biliary O O
sphincter O O
spasm O O
with O O
low O O
dose O O
glucagon S-GENE O
during O O
operative O O
cholangiography O O
. O O
Previous O O
studies O O
have O O
shown O O
that O O
the O O
IME1 B-GENE B-GENE
gene E-GENE E-GENE
is O O
required O O
for O O
sporulation O O
and O O
the O O
expression O O
of O O
meiosis O O
specific O O
genes O O
in O O
Saccharomyces O O
cerevisiae O O
. O O
A O O
case O O
comparison O O
of O O
acquired O O
immune O O
deficiency O O
syndrome O O
( O O
AIDS O O
) O O
in O O
homosexual O O
males O O
with O O
spindle O O
- O O
endothelial O O
cell O O
abnormalities O O
and O O
with O O
recrudescent O O
melioidosis O O
. O O
Intrathecal O O
injections O O
of O O
small O O
volumes O O
of O O
the O O
alpha B-GENE O
2 I-GENE O
- I-GENE O
adrenoceptor E-GENE O
agonists O O
, O O
xylazine O O
and O O
clonidine O O
, O O
into O O
the O O
cervical O O
region O O
of O O
the O O
spinal O O
cord O O
of O O
conscious O O
unrestrained O O
sheep O O
produced O O
a O O
dose O O
- O O
dependent O O
analgesia O O
of O O
the O O
forelimbs O O
as O O
measured O O
using O O
a O O
mechanical O O
pressure O O
device O O
. O O
Second O O
, O O
CGGA O O
- O O
containing O O
sequences O O
placed O O
at O O
- O O
88 O O
in O O
the O O
delta B-GENE O
MTV I-GENE O
- I-GENE O
CAT I-GENE O
reporter E-GENE O
plasmid O O
conferred O O
insulin S-GENE O
responsiveness O O
to O O
the O O
mammary B-GENE O
tumor I-GENE O
virus I-GENE O
promoter E-GENE O
. O O
In O O
the O O
absence O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
gene E-GENE E-GENE
expression O O
, O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos I-GENE I-GENE
protein E-GENE E-GENE
appears O O
to O O
be O O
replaced O O
by O O
proteins O O
of O O
Fos B-GENE B-GENE
family E-GENE E-GENE
( O O
Fra B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
and O O
ATF B-GENE B-GENE
family E-GENE E-GENE
( O O
ATF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
ATFa S-GENE S-GENE
) O O
. O O
The O O
dopamine B-GENE B-GENE
D1 I-GENE I-GENE
dopamine I-GENE I-GENE
receptor E-GENE E-GENE
antagonist O O
SCH O O
23390 O O
dose O O
dependently O O
( O O
7 O O
. O O
5 O O
- O O
30 O O
micrograms O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
antagonized O O
the O O
stimulant O O
locomotor O O
effect O O
on O O
both O O
drugs O O
but O O
did O O
not O O
prevent O O
their O O
antiimmobility O O
effect O O
on O O
the O O
behavioral O O
despair O O
test O O
. O O
The O O
results O O
obtained O O
show O O
that O O
expression O O
of O O
the O O
gene O O
is O O
low O O
at O O
23 O O
degrees O O
C O O
and O O
is O O
induced O O
rapidly O O
at O O
37 O O
degrees O O
C O O
. O O
Characterization O O
of O O
Chlamydomonas O O
reinhardtii O O
zygote O O
- O O
specific O O
cDNAs O S-GENE
that O O
encode O O
novel O O
proteins O O
containing O O
ankyrin S-GENE O
repeats O O
and O O
WW O B-GENE
domains O E-GENE
. O O
Adenomas O O
in O O
the O O
upper O O
gastrointestinal O O
tract O O
were O O
found O O
in O O
all O O
of O O
the O O
patients O O
: O O
Vater O O
' O O
s O O
papilla O O
- O O
- O O
12 O O
, O O
duodenum O O
- O O
- O O
nine O O
, O O
and O O
gastric O O
antrum O O
- O O
- O O
seven O O
. O O
Microenvironments O O
dominated O O
by O O
cyanobacteria O O
( O O
BPC O O
) O O
had O O
a O O
higher O O
pH O O
( O O
pH O O
7 O O
- O O
8 O O
) O O
than O O
those O O
dominated O O
by O O
lichen O O
( O O
LTL O O
) O O
( O O
pH O O
4 O O
. O O
5 O O
- O O
5 O O
. O O
5 O O
) O O
. O O
A O O
total O O
of O O
64 O O
uncomplicated O O
Type O O
- O O
2 O O
diabetic O O
individuals O O
of O O
higher O O
middle O O
class O O
to O O
rich O O
socio O O
- O O
economic O O
status O O
were O O
studied O O
. O O
A O O
drop O O
of O O
methylprednisolone O O
acetate O O
or O O
vehicle O O
constituent O O
was O O
placed O O
on O O
the O O
dissected O O
plantar O O
nerve O O
proximal O O
to O O
the O O
stimulating O O
electrodes O O
after O O
recording O O
control O O
responses O O
( O O
A O O
- O O
fibre O O
volley O O
in O O
the O O
sciatic O O
nerve O O
and O O
C O O
- O O
fibre O O
evoked O O
reflex O O
discharge O O
in O O
flexor O O
motoneurons O O
) O O
. O O
Basic B-GENE O
helix I-GENE O
- I-GENE O
loop I-GENE O
- I-GENE O
helix I-GENE O
proteins E-GENE O
can O O
act O O
at O O
the O O
E O O
- O O
box O O
within O O
the O O
serum O O
response O O
element O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
promoter E-GENE E-GENE
to O O
influence O O
hormone O O
- O O
induced O O
promoter O O
activation O O
in O O
Sertoli O O
cells O O
. O O
Using O O
yeast O O
two O O
- O O
hybrid O O
screening O O
, O O
we O O
isolated O O
histone B-GENE O
H3 E-GENE O
as O O
an O O
interacting O O
factor O O
of O O
CIA S-GENE O
. O O
Concentrations O O
of O O
Co O O
, O O
Cu O O
, O O
Fe O O
, O O
Hg O O
, O O
Mn O O
, O O
Sb O O
, O O
Se O O
and O O
Zn O O
in O O
IAEA O O
milk O O
( O O
dry O O
) O O
standard O O
A O O
- O O
11 O O
were O O
re O O
- O O
evaluated O O
with O O
the O O
help O O
of O O
instrumental O O
and O O
radiochemical O O
neutron O O
activation O O
analysis O O
( O O
NAA O O
) O O
. O O
Gallstone O O
- O O
formation O O
has O O
traditionally O O
been O O
attributed O O
to O O
supersaturation O O
of O O
bile O O
with O O
cholesterol O O
. O O
Sixteen O O
patients O O
on O O
maintenance O O
hemodialysis O O
underwent O O
dialysis O O
with O O
either O O
cuprophane O O
( O O
n O O
= O O
8 O O
) O O
or O O
polymethylmethacrylate O O
( O O
PMMA O O
; O O
n O O
= O O
8 O O
) O O
membranes O O
for O O
1 O O
week O O
and O O
then O O
switched O O
to O O
the O O
opposite O O
membrane O O
during O O
the O O
second O O
week O O
. O O
Gene O O
expression O O
is O O
in O O
part O O
controlled O O
by O O
chromatin O O
remodeling O O
factors O O
and O O
the O O
acetylation O O
state O O
of O O
nucleosomal B-GENE O
histones E-GENE O
. O O
Each O O
patient O O
was O O
seen O O
for O O
5 O O
to O O
13 O O
postsurgical O O
maintenance O O
visits O O
. O O
Furthermore O O
, O O
Grap S-GENE S-GENE
is O O
associated O O
with O O
a O O
Ras B-GENE B-GENE
guanine I-GENE I-GENE
nucleotide I-GENE I-GENE
exchange I-GENE I-GENE
factor E-GENE I-GENE
mSos1 S-GENE E-GENE
, O O
primarily O O
through O O
its O O
N B-GENE O
- I-GENE O
terminal I-GENE O
SH3 I-GENE B-GENE
domain E-GENE E-GENE
. O O
Recurrent O O
infections O O
, O O
episodic O O
lymphopenia O O
and O O
impaired O O
cellular O O
immunity O O
. O O
After O O
3 O O
months O O
of O O
intervention O O
, O O
sustained O O
physical O O
training O O
was O O
associated O O
with O O
the O O
decrease O O
of O O
FVII S-GENE O
and O O
PAI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
levels O O
. O O
Thirty O O
- O O
three O O
percent O O
had O O
elevated O O
titers O O
( O O
above O O
1 O O
: O O
20 O O
dilution O O
) O O
. O O
Xa4 S-GENE S-GENE
is O O
a O O
dominantly O O
inherited O O
rice O O
gene O O
that O O
confers O O
resistance O O
to O O
Philippine O O
race O O
1 O O
of O O
the O O
bacterial O O
blight O O
pathogen O O
Xanthomonas O O
oryzae O O
pv O O
. O O
oryzae O O
in O O
rice O O
. O O
In O O
uraemic O O
patients O O
, O O
similar O O
maximum O O
serum O O
concentrations O O
were O O
found O O
after O O
a O O
single O O
7 O O
. O O
5 O O
mg O O
/ O O
kg O O
iv O O
dose O O
. O O
The O O
effect O O
of O O
buthionine O O
sulfoximine O O
( O O
BSO O O
) O O
and O O
disulfiram O O
( O O
DSF O O
) O O
on O O
the O O
urotoxicity O O
induced O O
by O O
cyclophosphamide O O
( O O
CPA O O
) O O
was O O
examined O O
in O O
mice O O
. O O
All O O
the O O
previously O O
mapped O O
structural O O
protein O O
- O O
encoding O O
genes O O
of O O
phage O B-GENE
LL O I-GENE
- O I-GENE
H O E-GENE
were O O
included O O
in O O
the O O
sequence O O
. O O
When O O
a O O
longer O O
- O O
714 O O
to O O
+ O O
78 O O
fragment O O
of O O
the O O
PBGD B-GENE B-GENE
promoter E-GENE E-GENE
is O O
used O O
, O O
the O O
- O O
70 O O
GATA O O
mutant O O
still O O
displays O O
erythroid O O
- O O
specific O O
activity O O
and O O
is O O
cis O O
- O O
activated O O
by O O
the O O
5 B-GENE O
' I-GENE O
HS I-GENE O
- I-GENE O
2 I-GENE O
enhancer E-GENE O
, O O
while O O
the O O
- O O
100 O O
CCACC O B-GENE
mutant O E-GENE
is O O
completely O O
inactive O O
in O O
the O O
absence O O
or O O
in O O
the O O
presence O O
of O O
the O O
5 B-GENE O
' I-GENE O
HS I-GENE O
- I-GENE O
2 I-GENE O
enhancer E-GENE O
. O O
Surprisingly O O
, O O
in O O
adult O O
animals O O
, O O
the O O
suprabasal O O
expression O O
of O O
dnRXR B-GENE B-GENE
alpha E-GENE E-GENE
significantly O O
reduced O O
the O O
ability O O
of O O
topically O O
applied O O
tRA O O
to O O
stimulate O O
proliferation O O
of O O
undifferentiated O O
keratinocytes O O
in O O
the O O
basal O O
layer O O
of O O
epidermis O O
. O O
In O O
many O O
other O O
contractile O B-GENE
protein O I-GENE
gene O E-GENE
families O O
, O O
genes O O
encoding O O
cardiac O O
isoforms O O
are O O
expressed O O
early O O
in O O
skeletal O O
muscle O O
development O O
and O O
are O O
later O O
repressed O O
. O O
1995 O O
. O O
For O O
il8ra S-GENE O
, O O
it O O
is O O
formed O O
from O O
two O O
exons O O
, O O
whereas O O
for O O
il8rb S-GENE O
, O O
seven O O
distinct O O
neutrophil O B-GENE
mRNAs O E-GENE
are O O
formed O O
by O O
alternative O O
splicing O O
of O O
11 O O
exons O O
. O O
Endocarditis O O
remains O O
a O O
life O O
- O O
threatening O O
disease O O
with O O
substantial O O
morbidity O O
and O O
mortality O O
. O O
The O O
gene O O
encoding O O
the O O
cellulase S-GENE O
( O O
Avicelase S-GENE O
) O O
Cel1 S-GENE S-GENE
from O O
Streptomyces O O
reticuli O O
and O O
analysis O O
of O O
protein O O
domains O O
. O O
From O O
this O O
comparison O O
of O O
aa O O
sequences O O
, O O
the O O
ATPK7 B-GENE B-GENE
protein E-GENE E-GENE
is O O
considered O O
to O O
be O O
a O O
member O O
of O O
a O O
novel O O
subfamily O O
of O O
Ser B-GENE O
/ I-GENE O
Thr I-GENE O
PKs E-GENE O
in O O
plants O O
. O O
Of O O
these O O
, O O
23 O O
( O O
13 O O
. O O
6 O O
% O O
) O O
were O O
due O O
to O O
GIB O O
( O O
Upper O O
GIB O O
= O O
19 O O
, O O
Lower O O
GIB O O
= O O
4 O O
) O O
. O O
The O O
E O O
. O O
multilocularis O O
/ O O
Mongolian O O
gerbil O O
system O O
can O O
replace O O
the O O
natural O O
canid O O
hosts O O
as O O
a O O
new O O
way O O
to O O
obtain O O
infective O O
eggs O O
and O O
to O O
analyze O O
host O O
- O O
parasite O O
interactions O O
. O O
E1 S-GENE S-GENE
recognition O O
sequences O O
in O O
the O O
bovine O O
papillomavirus O O
type O O
1 O O
origin O O
of O O
DNA O O
replication O O
: O O
interaction O O
between O O
half O O
sites O O
of O O
the O O
inverted O O
repeats O O
. O O
We O O
found O O
that O O
secretion O O
of O O
chitinolytic O O
enzymes O O
by O O
cultured O O
L O O
. O O
major O O
parasites O O
is O O
inhibited O O
by O O
blood O O
or O O
hemoglobin S-GENE O
, O O
and O O
hence O O
these O O
enzymes O O
are O O
apparently O O
absent O O
from O O
the O O
blood O O
- O O
fed O O
infected O O
flies O O
, O O
where O O
the O O
cardiac O O
valve O O
appears O O
undamaged O O
. O O
Patients O O
in O O
the O O
mucinous O O
cyst O O
group O O
had O O
significantly O O
lower O O
CA B-GENE O
125 E-GENE O
cystic O O
fluid O O
levels O O
compared O O
with O O
women O O
with O O
endometriomas O O
and O O
dermoids O O
( O O
P O O
& O O
lt O O
; O O
0 O O
. O O
05 O O
) O O
. O O
SATB1 S-GENE S-GENE
interacted O O
with O O
CDP S-GENE O
through O O
its O O
DNA O O
- O O
binding O O
domain O O
, O O
as O O
demonstrated O O
by O O
glutathione B-GENE B-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
( O O
GST S-GENE S-GENE
) O O
pull O O
- O O
down O O
assays O O
. O O
Plasma B-GENE O
prolactin E-GENE O
concentrations O O
in O O
pinealectomized O O
ewes O O
receiving O O
melatonin O O
treatment O O
and O O
in O O
pineal O O
intact O O
ewes O O
maintained O O
under O O
a O O
non O O
- O O
24 O O
- O O
hour O O
photoperiod O O
. O O
It O O
is O O
targeted O O
to O O
peroxisomes O O
when O O
expressed O O
in O O
mammalian O O
cells O O
and O O
yeast O O
. O O
The O O
transcriptional O O
start O O
site O O
, O O
identified O O
by O O
primer O O
extension O O
and O O
S1 B-GENE O
nuclease E-GENE O
assay O O
, O O
is O O
34 O O
nt O O
upstream O O
of O O
the O O
translation O O
initiation O O
codon O O
. O O
Nonlinearities O O
in O O
cochlear O O
hydrodynamics O O
. O O
Electronic O O
structure O O
and O O
optical O O
properties O O
of O O
the O O
B12O2 O S-GENE
crystal O O
. O O
Spongiosa O O
regeneration O O
in O O
the O O
millipore O O
chamber O O
The O O
predicted O O
5 O O
' O O
and O O
3 O O
' O O
ends O O
of O O
the O O
transcript O O
are O O
in O O
very O O
good O O
agreement O O
with O O
the O O
previously O O
determined O O
size O O
of O O
the O O
LEU3 S-GENE O
message O O
. O O
This O O
cDNA O O
corresponded O O
to O O
FGF B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
FGF B-GENE B-GENE
- I-GENE I-GENE
BP E-GENE E-GENE
) O O
, O O
a O O
secreted O O
protein O O
previously O O
shown O O
to O O
bind O O
acidic O O
and O O
basic B-GENE O
FGF E-GENE S-GENE
and O O
to O O
modulate O O
their O O
activities O O
. O O
Analysis O O
of O O
replicative O O
intermediates O O
shows O O
that O O
plasmid O O
YRp7 O S-GENE
, O O
which O O
contains O O
the O O
chromosomal O O
replicator O O
ARS1 O S-GENE
, O O
initiates O O
bidirectional O O
replication O O
in O O
a O O
100 O O
bp O O
region O O
within O O
the O O
sequence O O
required O O
for O O
autonomous O O
replication O O
in O O
vivo O O
. O O
Such O O
results O O
suggest O O
that O O
there O O
are O O
no O O
differences O O
in O O
the O O
BMR O O
of O O
age O O
- O O
and O O
weight O O
- O O
matched O O
Asian O O
Indian O O
males O O
, O O
other O O
tropical O O
populations O O
and O O
Americans O O
. O O
Rewarding O O
properties O O
of O O
methylphenidate O O
: O O
sensitization O O
by O O
prior O O
exposure O O
to O O
the O O
drug O O
and O O
effects O O
of O O
dopamine B-GENE O
D1 I-GENE O
- I-GENE O
and I-GENE O
D2 I-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
antagonists O O
. O O
Similar O O
to O O
what O O
was O O
observed O O
for O O
P O O
. O O
putida O O
, O O
a O O
psrA S-GENE O
null O O
mutant O O
of O O
P O O
. O O
aeruginosa O O
also O O
showed O O
a O O
90 O O
% O O
reduction O O
in O O
rpoS B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
; O O
both O O
mutants O O
could O O
be O O
complemented O O
for O O
rpoS B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
when O O
the O O
psrA B-GENE B-GENE
gene E-GENE E-GENE
was O O
provided O O
in O O
trans O O
. O O
psrA B-GENE S-GENE
mutants E-GENE O
of O O
both O O
Pseudomonas O O
species O O
lost O O
the O O
ability O O
to O O
induce O O
rpoS S-GENE O
expression O O
at O O
stationary O O
phase O O
, O O
but O O
they O O
retained O O
the O O
ability O O
to O O
produce O O
quorum O O
- O O
sensing O O
autoinducer O O
molecules O O
. O O
The O O
role O O
of O O
the O O
putative O O
C2 S-GENE O
domain O O
of O O
Nedd4 S-GENE O
has O O
not O O
been O O
elucidated O O
. O O
ZF87 S-GENE S-GENE
specifically O O
binds O O
the O O
ME1a1 O S-GENE
element O O
with O O
higher O O
affinity O O
than O O
the O O
ME1a2 O B-GENE
element O E-GENE
. O O
We O O
found O O
a O O
significant O O
increase O O
of O O
thromboxane O O
as O O
evidenced O O
by O O
the O O
major O O
urinary O O
metabolite O O
2 O O
, O O
3 O O
- O O
dinorthromboxane O O
B2 O O
in O O
the O O
oestrogen O O
group O O
as O O
compared O O
to O O
the O O
orchidectomy O O
group O O
. O O
Multivariable O O
logistic O O
regression O O
showed O O
that O O
mean O O
blood O O
glucose O O
level O O
for O O
the O O
first O O
2 O O
days O O
( O O
p O O
= O O
0 O O
. O O
002 O O
) O O
, O O
obesity O O
( O O
p O O
< O O
0 O O
. O O
002 O O
) O O
, O O
and O O
use O O
of O O
the O O
internal O O
mammary O O
artery O O
( O O
p O O
< O O
0 O O
. O O
02 O O
) O O
were O O
all O O
independent O O
predictors O O
of O O
deep O O
wound O O
infection O O
. O O
However O O
the O O
precise O O
function O O
of O O
DNA B-GENE O
- I-GENE O
PK E-GENE O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
is O O
not O O
known O O
. O O
This O O
new O O
receptor O O
, O O
TOR S-GENE S-GENE
( O O
thymus B-GENE B-GENE
orphan I-GENE I-GENE
receptor E-GENE E-GENE
) O O
, O O
is O O
most O O
closely O O
related O O
in O O
both O O
its O O
DNA O O
- O O
binding O O
domain O O
and O O
ligand O O
- O O
binding O O
domain O O
, O O
90 O O
% O O
and O O
53 O O
% O O
, O O
respectively O O
, O O
to O O
ROR B-GENE B-GENE
alpha E-GENE E-GENE
/ O O
RZR B-GENE B-GENE
alpha E-GENE E-GENE
and O O
clusters O O
with O O
these O O
two O O
receptors O O
and O O
RZR B-GENE B-GENE
beta E-GENE E-GENE
in O O
a O O
phylogenetic O O
tree O O
, O O
when O O
both O O
the O O
DNA O O
- O O
binding O O
domain O O
and O O
the O O
ligand O O
- O O
binding O O
domain O O
sequences O O
of O O
nuclear O O
receptors O O
are O O
compared O O
. O O
In O O
this O O
report O O
, O O
we O O
have O O
examined O O
whether O O
PTP1B S-GENE S-GENE
effects O O
transformation O O
induced O O
by O O
p210 S-GENE B-GENE
bcr S-GENE I-GENE
- O I-GENE
abl S-GENE E-GENE
. O O
S1 B-GENE S-GENE
nuclease E-GENE O
analysis O O
of O O
the O O
RNA O O
from O O
a O O
number O O
of O O
QT6 O O
- O O
LD O O
clones O O
gave O O
similar O O
results O O
, O O
indicating O O
that O O
the O O
LD O O
population O O
was O O
composed O O
of O O
viruses O O
with O O
similar O O
but O O
not O O
identical O O
deletion O O
endpoints O O
. O O
Association O O
of O O
Smads S-GENE S-GENE
with O O
lymphoid B-GENE B-GENE
enhancer I-GENE I-GENE
binding I-GENE I-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
/ O O
T B-GENE O
cell I-GENE O
- I-GENE O
specific I-GENE O
factor E-GENE O
mediates O O
cooperative O O
signaling O O
by O O
the O O
transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
and O O
wnt S-GENE S-GENE
pathways O O
. O O
The O O
three O O
OAS B-GENE B-GENE
genes E-GENE E-GENE
are O O
flanked O O
by O O
markers B-GENE O
WI I-GENE O
- I-GENE O
10614 E-GENE O
( O O
cen S-GENE O
) O O
and O O
D12S2293 S-GENE O
( O O
tel S-GENE O
) O O
and O O
are O O
contained O O
within O O
three O O
sets O O
of O O
overlapping O O
cosmid O O
clones O O
. O O
22 O O
. O O
6 O O
% O O
of O O
patients O O
were O O
found O O
to O O
be O O
positive O O
at O O
histology O O
in O O
the O O
corpus O O
mucosa O O
; O O
all O O
but O O
one O O
of O O
these O O
patients O O
had O O
elevated O O
circulating O O
IgG S-GENE O
to O O
H O O
. O O
pylori O O
( O O
Group O O
C O O
) O O
. O O
Rottlerin O O
also O O
inhibited O O
the O O
activation O O
of O O
MAP B-GENE B-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MEK S-GENE S-GENE
) O O
in O O
response O O
to O O
activated O O
Raf S-GENE O
, O O
but O O
had O O
no O O
effect O O
upon O O
c B-GENE B-GENE
- I-GENE I-GENE
Raf E-GENE E-GENE
activity O O
or O O
ERK S-GENE S-GENE
activation O O
by O O
activated O O
MEK S-GENE S-GENE
. O O
Quasidiatomic O O
study O O
of O O
Ly O O
- O O
alpha O O
- O O
producing O O
H2 O O
+ O O
- O O
Ne O O
collisions O O
at O O
keV O O
energies O O
. O O
The O O
NH O O
( O O
2 O O
) O O
- O O
terminus O O
of O O
all O O
three O O
proteins O O
contains O O
a O O
POZ O B-GENE
domain O E-GENE
, O O
a O O
conserved O O
120 O O
amino O O
acid O O
motif O O
involved O O
in O O
transcriptional O O
repression O O
and O O
protein O O
dimerization O O
. O O
The O O
isolation O O
of O O
crt5 B-GENE O
- I-GENE O
262 E-GENE O
, O O
an O O
additional O O
cdc B-GENE O
allele E-GENE O
of O O
POL1 S-GENE S-GENE
/ O O
CDC17 S-GENE S-GENE
, O O
suggests O O
for O O
the O O
first O O
time O O
that O O
directly O O
blocking O O
DNA O O
replication O O
can O O
provide O O
a O O
signal O O
to O O
induce O O
the O O
DNA O O
damage O O
response O O
. O O
crt2 B-GENE B-GENE
mutants E-GENE E-GENE
show O O
a O O
defect O O
in O O
basal O O
level O O
expression O O
of O O
RNR1 S-GENE B-GENE
- O I-GENE
lacZ S-GENE E-GENE
reporter O O
constructs O O
. O O
Greer O O
, O O
and O O
L O O
. O O
A O O
. O O
We O O
prospectively O O
studied O O
serum B-GENE O
prolactin E-GENE O
( O O
PRL S-GENE O
) O O
elevation O O
after O O
different O O
types O O
of O O
documented O O
seizures O O
in O O
17 O O
patients O O
. O O
However O O
, O O
both O O
peptides O O
1 O O
- O O
49 O O
and O O
63 O O
- O O
87 O O
bound O O
to O O
PDE B-GENE B-GENE
alpha I-GENE E-GENE
/ I-GENE O
beta E-GENE O
in O O
a O O
solid O O
- O O
phase O O
binding O O
assay O O
. O O
Values O O
of O O
K1 O O
and O O
Vd O O
were O O
significantly O O
increased O O
in O O
the O O
tumour O O
tissue O O
. O O
The O O
mutation O O
also O O
preferentially O O
limits O O
( O O
compared O O
with O O
total O O
protein O O
synthesis O O
) O O
translation O O
of O O
an O O
induced O O
gene O O
that O O
depends O O
on O O
five O O
AGA O O
codons O O
, O O
i O O
. O O
e O O
. O O
, O O
the O O
lambda B-GENE B-GENE
cI I-GENE I-GENE
repressor I-GENE I-GENE
gene E-GENE E-GENE
. O O
Five O O
RNA O O
transcripts O O
of O O
about O O
1 O O
. O O
2 O O
to O O
1 O O
. O O
7 O O
kilobases O O
were O O
mapped O O
to O O
a O O
part O O
of O O
the O O
genome O O
of O O
insect O O
iridescent O O
virus O O
type O O
6 O O
( O O
Chilo O O
iridescent O O
virus O O
; O O
CIV O O
) O O
between O O
genome O O
coordinates O O
0 O O
. O O
832 O O
and O O
0 O O
. O O
856 O O
within O O
the O O
EcoRI B-GENE O
DNA I-GENE O
fragment I-GENE O
F E-GENE O
. O O
Other O O
similar O O
patients O O
must O O
be O O
found O O
before O O
it O O
is O O
established O O
that O O
the O O
colloid O O
cyst O O
is O O
part O O
of O O
the O O
nevoid O O
basal O O
cell O O
carcinoma O O
syndrome O O
. O O
Portions O O
of O O
the O O
3 O O
' O O
- O O
coding O O
and O O
3 O O
' O O
- O O
untranslated O O
regions O O
were O O
found O O
to O O
be O O
missing O O
from O O
the O O
7 B-GENE O
. I-GENE O
2 I-GENE O
- I-GENE O
and I-GENE O
4 I-GENE O
. I-GENE O
8 I-GENE O
- I-GENE O
kb I-GENE O
topo I-GENE O
II I-GENE O
alpha I-GENE O
mRNAs E-GENE O
by O O
Northern O O
blot O O
analysis O O
. O O
In O O
addition O O
, O O
a O O
double O O
mutant O O
( O O
E482A O O
, O O
D489A O O
) O O
which O O
removed O O
negative O O
charges O O
along O O
one O O
side O O
of O O
the O O
helix O O
had O O
negligible O O
effects O O
on O O
fusion O O
activity O O
. O O
A O O
GTP O O
/ O O
GDP O O
exchange O O
assay O O
was O O
used O O
to O O
assess O O
the O O
potential O O
role O O
of O O
Ras S-GENE S-GENE
in O O
the O O
pathway O O
leading O O
to O O
ERK S-GENE S-GENE
phosphorylation O O
; O O
DADLE O S-GENE
failed O O
to O O
stimulate O O
GTP O O
/ O O
GDP O O
exchange O O
in O O
comparison O O
to O O
PMA O O
. O O
Phenotypic O O
analysis O O
demonstrates O O
that O O
trio S-GENE O
and O O
Abl S-GENE S-GENE
cooperate O O
in O O
regulating O O
axon O O
outgrowth O O
in O O
the O O
embryonic O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
. O O
Recombinant B-GENE O
caspases E-GENE O
are O O
typically O O
produced O O
in O O
Escherichia O O
coli O O
expression O O
systems O O
with O O
the O O
attendant O O
problems O O
of O O
solubilization O O
, O O
re O O
- O O
folding O O
and O O
activation O O
of O O
the O O
protease O O
. O O
The O O
gene O O
encoding O O
rat O B-GENE
peptidylglycine B-GENE I-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
amidating I-GENE I-GENE
monooxygenase E-GENE E-GENE
( O O
PAM S-GENE O
) O O
contains O O
26 O O
protein O O
- O O
coding O O
exons O O
. O O
This O O
bound O O
[ O O
3H O O
] O O
iloprost O O
with O O
high O O
affinity O O
and O O
stimulated O O
cAMP O O
production O O
when O O
exposed O O
to O O
agonist O O
. O O
Structure O O
of O O
the O O
connective O O
stroma O O
of O O
the O O
epididymis O O
in O O
the O O
zebu O O
Free O O
protein B-GENE O
S E-GENE O
deficiency O O
in O O
acute O O
ischemic O O
stroke O O
. O O
In O O
a O O
series O O
of O O
papers O O
, O O
the O O
staging O O
system O O
for O O
melanoma O O
was O O
critically O O
analyzed O O
, O O
and O O
many O O
shortcomings O O
were O O
identified O O
. O O
Reproduction O O
and O O
maternal O O
response O O
of O O
the O O
rat O O
when O O
thiamine O O
intake O O
is O O
limited O O
. O O
Total O O
meso O O
- O O
pore O O
volume O O
and O O
surface O O
area O O
ranged O O
from O O
0 O O
. O O
004 O O
- O O
0 O O
. O O
08 O O
cm3 O O
g O O
( O O
- O O
1 O O
) O O
and O O
from O O
0 O O
. O O
33 O O
- O O
6 O O
. O O
9 O O
m2 O O
g O O
( O O
- O O
1 O O
) O O
respectively O O
, O O
accounting O O
for O O
up O O
33 O O
% O O
of O O
the O O
BET O O
surface O O
area O O
. O O
The O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
precursor O O
p100 S-GENE O
( O O
lyt B-GENE O
- I-GENE O
10 E-GENE O
, O O
p97 S-GENE S-GENE
, O O
p98 S-GENE S-GENE
) O O
generates O O
after O O
proteolytic O O
processing O O
a O O
52 O O
kDa O O
subunit O O
, O O
which O O
can O O
bind O O
to O O
kappa B-GENE B-GENE
B I-GENE I-GENE
- I-GENE I-GENE
motifs E-GENE E-GENE
. O O
CONCLUSION O O
: O O
The O O
biodistribution O O
of O O
111In O B-GENE
IgG S-GENE E-GENE
is O O
similar O O
to O O
that O O
of O O
99mTc O O
- O O
HMPAO O O
- O O
labeled O O
leukocytes O O
. O O
Based O O
on O O
29 O O
determinations O O
of O O
the O O
glucose O O
from O O
sinigrin O O
, O O
analyzed O O
under O O
different O O
conditions O O
, O O
accuracy O O
of O O
the O O
total O O
glucosinolate O O
determination O O
was O O
94 O O
. O O
8 O O
+ O O
/ O O
- O O
7 O O
. O O
3 O O
% O O
. O O
Receptor B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
serine I-GENE I-GENE
/ I-GENE I-GENE
threonine I-GENE I-GENE
kinases E-GENE E-GENE
( O O
RSKs S-GENE S-GENE
) O O
have O O
been O O
organized O O
into O O
two O O
distinct O O
classes O O
known O O
as O O
types O O
I O O
and O O
II O O
on O O
the O O
basis O O
of O O
sequence O O
similarity O O
. O O
In O O
a O O
previous O O
study O O
of O O
transforming B-GENE O
growth I-GENE O
factor I-GENE O
- I-GENE O
beta1 E-GENE O
- O O
mediated O O
inhibition O O
of O O
the O O
cyclin B-GENE B-GENE
A I-GENE I-GENE
promoter E-GENE E-GENE
, O O
we O O
mapped O O
the O O
inhibitory O O
effect O O
to O O
the O O
ATF B-GENE B-GENE
site E-GENE E-GENE
; O O
in O O
the O O
present O O
study O O
of O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
treatment O O
, O O
functional O O
analysis O O
by O O
transient O O
transfection O O
showed O O
that O O
inhibition O O
of O O
the O O
cyclin B-GENE O
A I-GENE O
promoter E-GENE O
persisted O O
despite O O
mutation O O
of O O
the O O
ATF S-GENE O
, O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
, O O
or O O
CDE O O
elements O O
. O O
The O O
RsmA B-GENE B-GENE
- I-GENE I-GENE
mutant E-GENE E-GENE
, O O
like O O
its O O
parent O O
, O O
produces O O
N O O
- O O
( O O
3 O O
- O O
oxohexanoyl O O
) O O
- O O
L O O
- O O
homoserine O O
lactone O O
( O O
HSL O O
) O O
, O O
a O O
starvation O O
/ O O
cell O O
density O O
- O O
sensing O O
signal O O
required O O
for O O
extracellular O O
enzyme O O
production O O
. O O
The O O
inactive O O
X O O
allele O O
, O O
however O O
, O O
is O O
hypermethylated O O
in O O
leukocytes O O
, O O
presumably O O
reflecting O O
early O O
X O O
inactivation O O
events O O
that O O
become O O
important O O
for O O
gene O O
dosage O O
in O O
expressing O O
lineages O O
. O O
Intensive O O
therapy O O
of O O
viral O O
hepatitis O O
Also O O
, O O
the O O
RVW O O
hypertrophy O O
, O O
the O O
IVS O O
hypertrophy O O
, O O
and O O
the O O
RV O O
high O O
pressure O O
load O O
to O O
the O O
LV O O
through O O
the O O
IVS O O
may O O
be O O
related O O
to O O
the O O
small O O
LV O O
, O O
high O O
EF O O
, O O
and O O
abnormal O O
two O O
chamber O O
inflow O O
in O O
the O O
PS O O
group O O
before O O
BV O O
. O O
Analysis O O
of O O
the O O
DNA O O
- O O
binding O O
and O O
transcriptional O O
activation O O
functions O O
of O O
human B-GENE B-GENE
Fli I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
protein E-GENE E-GENE
. O O
This O O
pattern O O
of O O
expression O O
and O O
differential O O
processing O O
suggests O O
a O O
role O O
for O O
inrpk1 S-GENE O
in O O
some O O
aspect O O
of O O
SD O O
photoperiodic O O
- O O
induced O O
flowering O O
in O O
morning O O
glory O O
. O O
Progressive O O
immunodeficiency O O
in O O
a O O
patient O O
with O O
IgA S-GENE O
deficiency O O
RMR O O
was O O
positively O O
correlated O O
with O O
TEF O O
( O O
r O O
= O O
0 O O
. O O
613 O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
net O O
TEF O O
( O O
r O O
= O O
0 O O
. O O
648 O O
, O O
p O O
< O O
0 O O
. O O
005 O O
) O O
in O O
the O O
luteal O O
but O O
not O O
the O O
follicular O O
phase O O
. O O
ESR O O
spectra O O
of O O
Er3 O O
+ O O
in O O
SmB6 O O
single O O
crystals O O
: O O
Dynamic O O
Jahn O O
- O O
Teller O O
effect O O
in O O
a O O
mixed O O
- O O
valence O O
compound O O
. O O
The O O
N O O
- O O
terminal O O
exon1 O O
had O O
no O O
homology O O
at O O
the O O
amino O O
acid O O
level O O
with O O
NGFI B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
, O O
the O O
mammalian O O
homologue O O
. O O
This O O
paper O O
describes O O
a O O
longitudinal O O
study O O
in O O
which O O
clinical O O
parameters O O
and O O
aspartate B-GENE O
aminotransferase E-GENE O
( O O
AST S-GENE O
) O O
in O O
gingival O O
crevicular O O
fluid O O
( O O
GCF O O
) O O
were O O
monitored O O
bimonthly O O
over O O
a O O
6 O O
- O O
12 O O
months O O
period O O
in O O
970 O O
sites O O
from O O
7 O O
treated O O
periodontitis O O
patients O O
. O O
We O O
conclude O O
from O O
these O O
observations O O
that O O
the O O
cTnC B-GENE O
3 I-GENE O
' I-GENE O
Ile I-GENE O
element E-GENE O
is O O
a O O
composite O O
enhancer O O
that O O
functions O O
through O O
the O O
combined O O
interactions O O
of O O
at O O
least O O
five O O
regulatory O O
elements O O
and O O
their O O
cognate O O
binding O O
factors O O
: O O
three O O
or O O
four O O
E O O
- O O
boxes O O
, O O
a O O
MEF B-GENE O
- I-GENE O
2 I-GENE O
site E-GENE O
, O O
and O O
a O O
MEF B-GENE O
- I-GENE O
3 I-GENE O
site E-GENE O
. O O
The O O
analysis O O
consisted O O
of O O
1 O O
) O O
fitting O O
first O O
- O O
and O O
second O O
- O O
order O O
autoregressive O O
models O O
( O O
AR1 O O
and O O
AR2 O O
) O O
and O O
2 O O
) O O
obtaining O O
the O O
power O O
spectra O O
of O O
the O O
data O O
by O O
fast O O
- O O
Fourier O O
transform O O
. O O
We O O
identified O O
Tyr O O
( O O
112 O O
) O O
and O O
Leu O O
( O O
175 O O
) O O
within O O
the O O
RNA O O
- O O
binding O O
domain O O
of O O
the O O
U1 B-GENE B-GENE
70K I-GENE I-GENE
protein E-GENE E-GENE
to O O
be O O
cross O O
- O O
linked O O
to O O
G O O
( O O
28 O O
) O O
and O O
U O O
( O O
30 O O
) O O
in O O
stem O O
- O O
loop O O
I O O
, O O
respectively O O
. O O
Kudzu O O
extract O O
shows O O
potential O O
for O O
moderating O O
alcohol O O
abuse O O
. O O
Furthermore O O
, O O
the O O
data O O
suggest O O
an O O
immunological O O
non O O
- O O
responsiveness O O
to O O
enterotoxin B-GENE O
A E-GENE O
in O O
a O O
considerable O O
portion O O
of O O
the O O
patients O O
. O O
BCV B-GENE B-GENE
mRNAs I-GENE I-GENE
5 I-GENE E-GENE
and I-GENE O
5 I-GENE O
- I-GENE O
1 E-GENE O
appear O O
to O O
be O O
used O O
for O O
the O O
synthesis O O
of O O
the O O
12 O O
. O O
7 O O
- O O
and O O
9 O O
. O O
5 O O
- O O
kDa O O
proteins O O
, O O
respectively O O
, O O
which O O
demonstrates O O
a O O
pattern O O
of O O
expression O O
strikingly O O
different O O
from O O
that O O
utilized O O
by O O
MHV O O
. O O
Disaster O O
medicine O O
The O O
longest O O
S1 O O
- O O
S2 O O
interval O O
at O O
which O O
S2 O O
failed O O
to O O
capture O O
( O O
effective O O
refractory O O
period O O
) O O
was O O
longer O O
by O O
5 O O
. O O
5 O O
+ O O
/ O O
- O O
8 O O
. O O
2 O O
msec O O
at O O
twice O O
threshold O O
( O O
0 O O
. O O
05 O O
less O O
than O O
p O O
less O O
than O O
0 O O
. O O
10 O O
) O O
and O O
5 O O
. O O
5 O O
+ O O
/ O O
- O O
3 O O
. O O
5 O O
msec O O
at O O
5 O O
times O O
threshold O O
stimulation O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
when O O
the O O
basic O O
drive O O
and O O
extrastimuli O O
were O O
delivered O O
to O O
separate O O
sites O O
. O O
The O O
use O O
of O O
specific O O
somatic O O
cell O O
hybrids O O
have O O
allowed O O
us O O
to O O
locate O O
the O O
YAC O O
contig O O
telomeric O O
to O O
the O O
D3F15S2 B-GENE B-GENE
locus E-GENE E-GENE
, O O
in O O
a O O
region O O
which O O
is O O
frequently O O
deleted O O
in O O
lung O O
carcinomas O O
. O O
Experiments O O
were O O
performed O O
without O O
polarization O O
or O O
with O O
cathodic O O
and O O
anodic O O
polarization O O
of O O
the O O
adsorbent O O
. O O
Chronic O O
active O O
hepatitis O O
and O O
cirrhosis O O
of O O
the O O
liver O O
. O O
This O O
regulation O O
is O O
mediated O O
by O O
several O O
kinases O O
that O O
phosphorylate O O
specific O O
residues O O
in O O
the O O
different O O
functional O O
domains O O
of O O
the O O
p53 B-GENE S-GENE
molecule E-GENE O
. O O
These O O
data O O
show O O
that O O
the O O
processing O O
of O O
specific O O
target O O
transcripts O O
, O O
such O O
as O O
the O O
P B-GENE B-GENE
- I-GENE I-GENE
element I-GENE I-GENE
mRNA E-GENE E-GENE
, O O
is O O
regulated O O
by O O
a O O
functional O O
PSI S-GENE B-GENE
- O I-GENE
U1 S-GENE I-GENE
snRNP O E-GENE
interaction O O
in O O
Drosophila O O
. O O
Effect O O
of O O
dimethyl O O
sulfoxide O O
on O O
cooling O O
rates O O
of O O
unrestrained O O
rats O O
. O O
In O O
four O O
calves O O
given O O
Haemonchus O O
contortus O O
larvae O O
, O O
the O O
serum B-GENE O
pepsinogen E-GENE O
concentration O O
rose O O
quickly O O
to O O
reach O O
a O O
mean O O
of O O
3 O O
. O O
5 O O
iu O O
tyrosine O O
on O O
day O O
14 O O
after O O
infection O O
. O O
These O O
results O O
strongly O O
suggest O O
that O O
HSV O B-GENE
- O I-GENE
1 O E-GENE
infection O O
inhibits O O
host O O
cell O O
splicing O O
through O O
the O O
action O O
of O O
ICP27 S-GENE S-GENE
. O O
The O O
T O O
( O O
CCO2 O O
) O O
was O O
related O O
to O O
the O O
PCO2 O O
by O O
a O O
Pearson O O
product O O
coefficient O O
of O O
0 O O
. O O
79 O O
( O O
p O O
< O O
. O O
0005 O O
) O O
, O O
with O O
a O O
mean O O
difference O O
of O O
1 O O
. O O
94 O O
( O O
T O O
( O O
CCO2 O O
) O O
> O O
P O O
( O O
CO2 O O
) O O
and O O
95 O O
% O O
confidence O O
interval O O
of O O
- O O
0 O O
. O O
12 O O
to O O
4 O O
. O O
07 O O
. O O
Transformation O O
of O O
chicken O O
embryo O O
fibroblasts O O
( O O
CEF O S-GENE
) O O
with O O
the O O
Gag S-GENE B-GENE
- O I-GENE
Crk S-GENE I-GENE
fusion O I-GENE
protein O E-GENE
results O O
in O O
the O O
elevation O O
of O O
tyrosine O O
phosphorylation O O
on O O
specific O O
cellular O O
proteins O O
with O O
molecular O O
weights O O
of O O
130 O O
, O O
000 O O
, O O
110 O O
, O O
000 O O
, O O
and O O
70 O O
, O O
000 O O
( O O
p130 S-GENE O
, O O
p110 S-GENE O
, O O
and O O
p70 S-GENE O
, O O
respectively O O
) O O
, O O
an O O
event O O
which O O
has O O
been O O
correlated O O
with O O
cell O O
transformation O O
. O O
Urease S-GENE O
activity O O
, O O
judged O O
as O O
the O O
amount O O
of O O
ammonia O O
production O O
from O O
urea O O
, O O
could O O
be O O
measured O O
at O O
25 O O
ng O O
per O O
tube O O
( O O
S O O
/ O O
N O O
= O O
1 O O
. O O
5 O O
) O O
with O O
Jack B-GENE O
bean I-GENE O
meal I-GENE O
urease E-GENE O
. O O
Here O O
, O O
we O O
provide O O
direct O O
evidence O O
that O O
the O O
meiotic O O
defect O O
caused O O
by O O
either O O
unregulated O O
cAPK S-GENE S-GENE
activity O O
or O O
unregulated O O
ran1 B-GENE B-GENE
+ I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
is O O
due O O
to O O
inability O O
to O O
induce O O
transcription O O
of O O
the O O
mei2 B-GENE B-GENE
+ I-GENE I-GENE
gene E-GENE E-GENE
, O O
which O O
is O O
required O O
for O O
meiotic O O
initiation O O
. O O
Optical O O
rotation O O
of O O
the O O
second O O
harmonic O O
radiation O O
from O O
retinal O O
in O O
bacteriorhodopsin B-GENE O
monomers E-GENE O
in O O
Langmuir O O
- O O
Blodgett O O
film O O
: O O
evidence O O
for O O
nonplanar O O
retinal O O
structure O O
. O O
Ultrasonography O O
is O O
a O O
diagnostic O O
alternative O O
which O O
may O O
replace O O
arthrography O O
. O O
In O O
K562 O O
cells O O
, O O
using O O
the O O
bicistronic O O
vector O O
, O O
selection O O
with O O
colchicine O O
led O O
to O O
at O O
least O O
20 O O
- O O
fold O O
higher O O
expression O O
of O O
the O O
MDR1 B-GENE B-GENE
gene I-GENE E-GENE
product E-GENE O
than O O
did O O
selection O O
with O O
G418 O S-GENE
, O O
suggesting O O
that O O
the O O
stringent O O
MDR1 S-GENE S-GENE
selection O O
system O O
is O O
very O O
efficient O O
for O O
obtaining O O
overexpression O O
of O O
foreign O O
genes O O
. O O
In O O
this O O
report O O
, O O
several O O
health O O
behaviors O O
were O O
investigated O O
in O O
relation O O
to O O
maintaining O O
mobility O O
during O O
4 O O
years O O
of O O
follow O O
- O O
up O O
among O O
6 O O
, O O
981 O O
men O O
and O O
women O O
aged O O
65 O O
years O O
and O O
older O O
with O O
intact O O
mobility O O
at O O
baseline O O
between O O
1981 O O
and O O
1983 O O
who O O
lived O O
in O O
one O O
of O O
three O O
communities O O
: O O
East O O
Boston O O
, O O
Massachusetts O O
; O O
Iowa O O
and O O
Washington O O
counties O O
, O O
Iowa O O
; O O
and O O
New O O
Haven O O
, O O
Connecticut O O
. O O
Our O O
analysis O O
indicates O O
that O O
a O O
gene O O
correction O O
mechanism O O
has O O
been O O
operating O O
on O O
the O O
Hbbs S-GENE O
chromosome O O
to O O
keep O O
beta B-GENE O
s E-GENE O
and O O
beta B-GENE O
t E-GENE O
evolving O O
in O O
concert O O
, O O
whereas O O
on O O
the O O
Hbbd S-GENE O
chromosome O O
, O O
beta B-GENE O
dmin E-GENE O
has O O
diverged O O
considerably O O
from O O
beta B-GENE O
dmaj E-GENE O
. O O
Structure O O
and O O
regulation O O
of O O
KGD2 S-GENE S-GENE
, O O
the O O
structural O O
gene O O
for O O
yeast B-GENE O
dihydrolipoyl I-GENE O
transsuccinylase E-GENE O
. O O
In O O
dehydrated O O
animals O O
at O O
Ta O O
38 O O
degrees O O
C O O
, O O
Tb O O
and O O
EWL O O
were O O
both O O
significantly O O
altered O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
from O O
the O O
normally O O
hydrated O O
state O O
and O O
were O O
measured O O
at O O
39 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
degree O O
C O O
and O O
0 O O
. O O
84 O O
+ O O
/ O O
- O O
0 O O
. O O
09 O O
W O O
. O O
kg O O
- O O
1 O O
respectively O O
. O O
We O O
identify O O
YY1 S-GENE S-GENE
recognition O O
sequences O O
within O O
the O O
vitamin O O
D O O
response O O
element O O
( O O
VDRE O O
) O O
of O O
the O O
osteocalcin B-GENE O
gene E-GENE O
that O O
are O O
critical O O
for O O
YY1 S-GENE O
- O O
dependent O O
repression O O
of O O
vitamin O O
D O O
- O O
enhanced O O
promoter O O
activity O O
. O O
Back O O
- O O
ground O O
factors O O
which O O
affect O O
the O O
outcome O O
of O O
steroid O O
withdrawal O O
therapy O O
in O O
patients O O
with O O
chronic O O
type O O
B O O
hepatitis O O
- O O
- O O
statistical O O
evaluation O O
of O O
the O O
importance O O
of O O
the O O
mode O O
of O O
HBV O O
transmission O O
Point O O
mutations O O
of O O
Stat3 S-GENE S-GENE
within O O
the O O
interacting O O
domains O O
blocked O O
both O O
physical O O
interaction O O
of O O
Stat3 S-GENE S-GENE
with O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
and O O
their O O
cooperation O O
in O O
IL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
- O O
induced O O
transcription O O
directed O O
by O O
the O O
alpha B-GENE O
( I-GENE O
2 I-GENE O
) I-GENE O
- I-GENE O
macroglobulin I-GENE O
enhancer E-GENE O
. O O
Three O O
patients O O
with O O
Mirizzi O O
type O O
II O O
syndrome O O
and O O
two O O
patients O O
with O O
Mirizzi O O
type O O
I O O
syndrome O O
were O O
treated O O
laparoscopically O O
. O O
Synchronous O O
multicentric O O
giant O O
cell O O
tumour O O
: O O
a O O
case O O
report O O
with O O
review O O
of O O
literature O O
. O O
From O O
the O O
comparison O O
of O O
the O O
nod B-GENE O
box I-GENE O
sequences E-GENE O
of O O
( O O
brady O O
) O O
rhizobia O O
with O O
a O O
more O O
divergent O O
nod B-GENE O
box E-GENE O
from O O
Azorhizobium O O
caulinodans O O
, O O
we O O
now O O
propose O O
a O O
modular O O
build O O
- O O
up O O
of O O
the O O
nod B-GENE O
box E-GENE O
with O O
the O O
sequence O O
A O O
- O O
T O O
- O O
C O O
- O O
N9 O O
- O O
G O O
- O O
A O O
- O O
T O O
as O O
the O O
binding O O
target O O
of O O
the O O
NodD B-GENE B-GENE
protein E-GENE E-GENE
( O O
the O O
NodD B-GENE O
box E-GENE O
) O O
. O O
The O O
prgX B-GENE B-GENE
gene E-GENE E-GENE
is O O
adjacent O O
to O O
prgQ S-GENE S-GENE
which O O
provides O O
the O O
promoter O O
for O O
prgB S-GENE S-GENE
expression O O
. O O
METHODS O O
: O O
A O O
discriminant O O
function O O
predicting O O
surgery O O
outcome O O
( O O
seizure O O
- O O
free O O
vs O O
. O O
non O O
- O O
seizure O O
- O O
free O O
) O O
was O O
computed O O
separately O O
for O O
samples O O
of O O
patients O O
with O O
left O O
( O O
n O O
= O O
79 O O
) O O
and O O
right O O
( O O
n O O
= O O
62 O O
) O O
temporal O O
lobectomy O O
( O O
LATL O O
, O O
RATL O O
) O O
. O O
It O O
is O O
likely O O
that O O
these O O
recordings O O
are O O
incomplete O O
; O O
the O O
actual O O
number O O
of O O
activated O O
neurons O O
is O O
estimated O O
to O O
be O O
about O O
300 O O
in O O
the O O
acutely O O
sensitized O O
preparation O O
. O O
The O O
possibility O O
to O O
use O O
this O O
method O O
for O O
common O O
diagnostic O O
problems O O
is O O
indicated O O
. O O
Genetic O O
analysis O O
of O O
the O O
role O O
of O O
herpes B-GENE O
simplex I-GENE O
virus I-GENE O
type I-GENE O
1 I-GENE O
glycoprotein I-GENE O
K E-GENE O
in O O
infectious O O
virus O O
production O O
and O O
egress O O
. O O
A O O
conventional O O
N O O
- O O
terminal O O
signal O O
sequence O O
was O O
not O O
detected O O
in O O
the O O
NodO B-GENE B-GENE
protein E-GENE E-GENE
. O O
Dynamic O O
expression O O
of O O
broad B-GENE O
- I-GENE O
complex I-GENE O
isoforms E-GENE O
mediates O O
temporal O O
control O O
of O O
an O O
ecdysteroid O O
target O O
gene O O
at O O
the O O
onset O O
of O O
Drosophila O O
metamorphosis O O
. O O
The O O
study O O
was O O
carried O O
out O O
according O O
to O O
the O O
BSI O O
( O O
1980 O O
) O O
recommendations O O
for O O
testing O O
restorative O O
materials O O
in O O
vivo O O
. O O
Cellular O O
lysates O O
were O O
analyzed O O
for O O
luciferase S-GENE O
and O O
beta B-GENE O
- I-GENE O
galactosidase E-GENE O
activities O O
. O O
Cytokines O O
and O O
steroid O O
hormones O O
use O O
different O O
sets O O
of O O
signal O O
transduction O O
pathways O O
, O O
which O O
seem O O
to O O
be O O
unrelated O O
. O O
These O O
findings O O
suggest O O
that O O
the O O
proteolipids O O
of O O
the O O
vacuolar B-GENE B-GENE
H I-GENE I-GENE
+ I-GENE I-GENE
- I-GENE I-GENE
ATPases E-GENE E-GENE
were O O
evolved O O
in O O
parallel O O
with O O
the O O
eubacterial O O
proteolipid O O
, O O
from O O
a O O
common O O
ancestral O O
gene O O
that O O
underwent O O
gene O O
duplication O O
. O O
This O O
mutant O O
also O O
functions O O
in O O
vivo O O
as O O
a O O
trans O O
- O O
acting O O
dominant O O
negative O O
regulator O O
: O O
the O O
transcriptional O O
inducibility O O
of O O
the O O
HIV B-GENE O
long I-GENE O
terminal I-GENE O
repeat E-GENE O
( O O
which O O
contains O O
two O O
potential O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
binding I-GENE I-GENE
sites E-GENE E-GENE
) O O
by O O
phorbol O O
ester O O
( O O
PMA O O
) O O
is O O
inhibited O O
when O O
it O O
is O O
co O O
- O O
transfected O O
into O O
CD4 B-GENE O
+ E-GENE O
T O O
cells O O
with O O
the O O
delta O B-GENE
SP O I-GENE
mutant O E-GENE
. O O
In O O
addition O O
, O O
measurements O O
of O O
shielded O O
and O O
unshielded O O
syringes O O
containing O O
99mTc O O
- O O
labelled O O
radiopharmaceuticals O O
were O O
carried O O
out O O
. O O
This O O
study O O
tests O O
the O O
hypothesis O O
that O O
O2 O O
is O O
a O O
critical O O
component O O
in O O
myocardial O O
protection O O
afforded O O
by O O
BCP O O
. O O
Biomass O O
growth O O
monitoring O O
using O O
pressure O O
drop O O
in O O
a O O
cocurrent O O
biofilter O O
This O O
alternative O O
splice O O
acceptor O O
site O O
is O O
also O O
used O O
by O O
a O O
biologically O O
active O O
provirus O O
with O O
an O O
efficiency O O
of O O
approximately O O
5 O O
% O O
compared O O
with O O
the O O
upstream O O
site O O
. O O
Homology O O
is O O
much O O
higher O O
( O O
64 O O
% O O
) O O
between O O
the O O
28 O O
- O O
kDa O O
protein O O
and O O
regions O O
that O O
are O O
strongly O O
conserved O O
among O O
the O O
members O O
of O O
the O O
serine B-GENE B-GENE
protease I-GENE I-GENE
family E-GENE E-GENE
. O O
We O O
have O O
isolated O O
and O O
structurally O O
characterized O O
genomic O O
DNA O O
and O O
cDNA O O
sequences O O
encoding O O
ribulose B-GENE O
- I-GENE O
1 I-GENE O
, I-GENE O
5 I-GENE O
- I-GENE O
bisphosphate I-GENE O
carboxylase I-GENE O
/ I-GENE O
oxygenase I-GENE O
( I-GENE O
Rbu I-GENE O
- I-GENE O
P2 I-GENE O
carboxylase I-GENE O
) I-GENE O
activase E-GENE O
from O O
barley O O
( O O
Hordeum O O
vulgare O O
L O O
. O O
) O O
. O O
Expression O O
of O O
putative O O
constitutively O O
active O O
forms O O
of O O
DdMEK1 S-GENE S-GENE
in O O
a O O
ddmek1 S-GENE O
null O O
background O O
is O O
capable O O
, O O
at O O
least O O
partially O O
, O O
of O O
complementing O O
the O O
small O O
aggregate O O
size O O
defect O O
and O O
the O O
ability O O
to O O
activate O O
guanylyl B-GENE O
cyclase E-GENE O
. O O
Constant O O
slowing O O
of O O
median O O
MNCV O O
and O O
SNCV O O
and O O
ulnar O O
SNCV O O
without O O
changes O O
in O O
morphology O O
, O O
amplitude O O
and O O
duration O O
of O O
MAP O O
and O O
SAP O O
have O O
been O O
observed O O
in O O
92 O O
patients O O
, O O
with O O
persistent O O
abnormalities O O
in O O
64 O O
cases O O
after O O
six O O
months O O
. O O
Moreover O O
, O O
such O O
mutations O O
lead O O
to O O
a O O
dramatic O O
transition O O
in O O
chromatin O O
structure O O
: O O
the O O
DNase B-GENE O
I I-GENE O
hypersensitive I-GENE O
region E-GENE O
is O O
replaced O O
by O O
two O O
stable O O
, O O
sequence O O
- O O
positioned O O
nucleosomes O O
. O O
During O O
chronic O O
treatment O O
with O O
salmon B-GENE O
calcitonin E-GENE O
, O O
alkaline B-GENE O
phosphatase E-GENE O
activity O O
and O O
urinary O O
hydroxyproline O O
excretion O O
decrease O O
on O O
an O O
average O O
of O O
50 O O
% O O
in O O
patients O O
with O O
Paget O O
' O O
s O O
disease O O
. O O
187 O O
- O O
200 O O
. O O
Because O O
of O O
the O O
structural O O
similarities O O
the O O
new O O
gene O O
will O O
be O O
termed O O
scERV2 S-GENE S-GENE
from O O
now O O
on O O
. O O
Experience O O
in O O
a O O
Kenya O O
district O O
hospital O O
The O O
2 B-GENE O
. I-GENE O
3 I-GENE O
x I-GENE O
10 I-GENE O
( I-GENE O
3 I-GENE O
) I-GENE O
base I-GENE O
SUF12 I-GENE O
+ I-GENE O
transcript E-GENE O
contains O O
an O O
open O O
reading O O
frame O O
sufficient O O
to O O
encode O O
a O O
88 O O
x O O
10 O O
( O O
3 O O
) O O
Mr O O
protein O O
. O O
Cortical O O
somatosensory O O
evoked O O
potentials O O
to O O
median O O
nerve O O
stimulation O O
revealed O O
significantly O O
delayed O O
peak O O
latencies O O
of O O
N20 O O
, O O
P20 O O
, O O
P25 O O
, O O
and O O
N26 O O
, O O
although O O
N16 O O
latency O O
was O O
normal O O
. O O
A O O
new O O
family O O
of O O
rate O O
- O O
adaptive O O
pacemakers O O
accomplishes O O
this O O
circadian O O
rate O O
variation O O
by O O
modeling O O
the O O
patient O O
' O O
s O O
sleep O O
- O O
wake O O
cycle O O
using O O
a O O
time O O
- O O
of O O
- O O
day O O
clock O O
inside O O
the O O
device O O
. O O
Progestins O O
: O O
present O O
and O O
future O O
. O O
Bilirubin O O
and O O
red O O
cell O O
metabolism O O
in O O
relation O O
to O O
neonatal O O
jaundice O O
. O O
Each O O
of O O
these O O
materials O O
were O O
placed O O
by O O
means O O
of O O
three O O
different O O
placement O O
techniques O O
( O O
Bulk O O
pack O O
, O O
Horizontal O O
layering O O
and O O
Vertical O O
layering O O
) O O
into O O
class O O
II O O
cavities O O
in O O
extracted O O
human O O
molars O O
. O O
This O O
ligand O O
- O O
independent O O
pathway O O
can O O
function O O
through O O
another O O
androgen O O
- O O
regulated O O
promoter O O
as O O
shown O O
by O O
the O O
use O O
of O O
the O O
mouse B-GENE O
mammary I-GENE O
tumor I-GENE O
virus I-GENE O
MMTV I-GENE O
- I-GENE O
CAT I-GENE O
reporter E-GENE O
. O O
Stress O O
- O O
induced O O
suppression O O
of O O
the O O
prolactin S-GENE O
afternoon O O
surge O O
in O O
ovariectomized O O
, O O
estrogen O O
- O O
treated O O
rats O O
and O O
the O O
nocturnal O O
surge O O
in O O
pseudopregnant O O
rats O O
are O O
accompanied O O
by O O
an O O
increase O O
in O O
median O O
eminence O O
dihydroxyphenylacetic O O
acid O O
concentrations O O
. O O
The O O
sensitivity O O
for O O
ergometry O O
and O O
treadmill O O
testing O O
was O O
75 O O
and O O
62 O O
% O O
respectively O O
. O O
Morphologic O O
evidence O O
that O O
rhe O O
renal O O
calyx O O
and O O
pelvis O O
control O O
ureteric O O
activity O O
in O O
the O O
rabbit O O
. O O
Children O O
with O O
repeated O O
proteinuria O O
during O O
follow O O
- O O
up O O
tend O O
to O O
have O O
a O O
higher O O
incidence O O
of O O
pathologic O O
findings O O
on O O
the O O
i O O
. O O
v O O
. O O
- O O
pyelogram O O
. O O
Parelaphostrongylus O O
odocoilei O O
is O O
redescribed O O
from O O
worms O O
collected O O
from O O
the O O
type O O
host O O
( O O
Odocoileus O O
hemionus O O
columbianus O O
) O O
in O O
California O O
, O O
as O O
well O O
as O O
material O O
from O O
experimentally O O
infected O O
mule O O
deer O O
( O O
O O O
. O O
h O O
. O O
heminus O O
) O O
in O O
Alberta O O
. O O
The O O
carboxyl O O
globular O O
domain O O
was O O
found O O
to O O
be O O
encoded O O
by O O
six O O
exons O O
which O O
appear O O
to O O
delineate O O
its O O
structural O O
subdomains O O
. O O
Expression O O
of O O
the O O
Asp O O
but O O
not O O
the O O
Ala O O
gB S-GENE O
mutation O O
resulted O O
in O O
an O O
increase O O
in O O
the O O
steady O O
- O O
state O O
expression O O
of O O
gB S-GENE O
at O O
the O O
plasma O O
membrane O O
( O O
PM O O
) O O
in O O
U373 O O
cells O O
. O O
Thus O O
integration B-GENE O
host I-GENE O
factor E-GENE O
is O O
required O O
for O O
normal O O
type B-GENE O
1 I-GENE O
fimbriae E-GENE O
phase O O
variation O O
in O O
E O O
. O O
coli O O
. O O
Insulin S-GENE O
therapy O O
has O O
been O O
expanded O O
by O O
development O O
of O O
human B-GENE O
insulin E-GENE O
and O O
new O O
modes O O
of O O
injection O O
, O O
including O O
insulin S-GENE O
pumps O O
. O O
Because O O
levels O O
of O O
Vo2DIR O S-GENE
and O O
Vo2INDIR O O
were O O
similar O O
in O O
both O O
groups O O
, O O
we O O
pooled O O
data O O
from O O
septic O O
and O O
control O O
animals O O
. O O
Further O O
interventions O O
were O O
: O O
nephrectomy O O
( O O
2x O O
) O O
, O O
resection O O
and O O
ligation O O
of O O
the O O
inferior O O
vena O O
cava O O
( O O
1x O O
) O O
, O O
resection O O
and O O
replacement O O
of O O
the O O
left O O
renal O O
vein O O
( O O
1x O O
) O O
. O O
OBJECTIVES O O
: O O
The O O
present O O
study O O
tested O O
the O O
hypothesis O O
that O O
stimulating O O
the O O
central O O
noradrenergic O O
system O O
using O O
the O O
new O O
noradrenaline O O
re O O
- O O
uptake O O
inhibitor O O
reboxetine O O
would O O
result O O
in O O
a O O
dose O O
- O O
dependent O O
enhancement O O
of O O
memory O O
for O O
emotional O O
material O O
in O O
man O O
. O O
We O O
examined O O
the O O
mechanisms O O
by O O
which O O
two O O
different O O
types O O
of O O
photonic O O
radiation O O
, O O
short O O
wavelength O O
UV O O
( O O
UV O O
- O O
C O O
) O O
and O O
gamma O O
radiation O O
, O O
activate O O
transcription O O
factor O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
. O O
However O O
, O O
coligation O O
of O O
Fc B-GENE B-GENE
gamma I-GENE I-GENE
RIIB1 E-GENE E-GENE
with O O
B B-GENE B-GENE
cell I-GENE I-GENE
Ag I-GENE I-GENE
receptors E-GENE E-GENE
( O O
BCR S-GENE S-GENE
) O O
inhibits O O
BCR S-GENE S-GENE
- O O
mediated O O
signaling O O
by O O
a O O
mechanism O O
that O O
may O O
involve O O
recruitment O O
of O O
phosphatases B-GENE O
SHP I-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
SHP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
and O O
the O O
SH2 B-GENE B-GENE
containing I-GENE I-GENE
inositol I-GENE I-GENE
5 I-GENE I-GENE
' I-GENE I-GENE
phosphatase E-GENE E-GENE
( O O
SHIP S-GENE O
) O O
to O O
the O O
phosphorylated O O
Fc B-GENE O
gamma I-GENE O
RIIB1 I-GENE S-GENE
immunoreceptor I-GENE O
tyrosine I-GENE O
- I-GENE O
based I-GENE O
inhibitory I-GENE O
motif E-GENE O
. O O
Using O O
the O O
standard O O
scoring O O
, O O
children O O
with O O
full O O
scale O O
IQ O O
< O O
or O O
= O O
84 O O
on O O
the O O
Wechsler O O
Preschool O O
and O O
Primary O O
Scale O O
of O O
Intelligence O O
at O O
age O O
4 O O
- O O
5 O O
years O O
were O O
poorly O O
identified O O
( O O
sensitivity O O
54 O O
% O O
) O O
from O O
the O O
composite O O
S O O
- O O
B O O
IV O O
score O O
at O O
age O O
3 O O
. O O
11 O O
: O O
5801 O O
- O O
5812 O O
, O O
1991 O O
) O O
present O O
evidence O O
that O O
the O O
Vps18 S-GENE S-GENE
/ O O
Pep3 S-GENE B-GENE
protein O E-GENE
colocalizes O O
with O O
the O O
Vps11 S-GENE S-GENE
/ O O
Pep5 S-GENE B-GENE
protein O E-GENE
to O O
the O O
cytosolic O O
face O O
of O O
the O O
vacuolar O O
membrane O O
. O O
This O O
study O O
includes O O
200 O O
patients O O
treated O O
from O O
1964 O O
to O O
1978 O O
, O O
with O O
an O O
age O O
range O O
from O O
15 O O
to O O
102 O O
years O O
, O O
who O O
required O O
329 O O
generators O O
. O O
We O O
conclude O O
that O O
the O O
BR B-GENE B-GENE
- I-GENE I-GENE
C I-GENE E-GENE
early I-GENE O
gene E-GENE O
directly O O
activates O O
late B-GENE O
gene E-GENE O
transcription O O
by O O
interacting O O
with O O
late B-GENE O
gene E-GENE O
cis O O
- O O
acting O O
regulatory O O
elements O O
and O O
that O O
this O O
interaction O O
is O O
responsible O O
for O O
the O O
temporal O O
linkage O O
of O O
early O O
and O O
late O O
ecdysone O O
- O O
induced O O
gene O O
expression O O
. O O
The O O
specificity O O
and O O
sensitivity O O
of O O
this O O
method O O
( O O
limit O O
of O O
detection O O
in O O
plasma O O
0 O O
. O O
025 O O
micrograms O O
/ O O
mL O O
and O O
< O O
or O O
= O O
0 O O
. O O
0125 O O
micrograms O O
/ O O
mL O O
for O O
febantel O O
and O O
its O O
metabolites O O
, O O
respectively O O
) O O
were O O
sufficiently O O
high O O
to O O
enable O O
us O O
to O O
characterize O O
the O O
time O O
course O O
of O O
the O O
drug O O
in O O
the O O
plasma O O
after O O
oral O O
administration O O
of O O
therapeutic O O
doses O O
to O O
sheep O O
. O O
We O O
have O O
identified O O
the O O
gene O O
encoding O O
sigma B-GENE O
E E-GENE O
using O O
a O O
genetic O O
screen O O
designed O O
to O O
isolate O O
trans O O
- O O
acting O O
mutations O O
that O O
abolish O O
expression O O
from O O
either O O
htrA S-GENE S-GENE
or O O
rpoHP3 S-GENE S-GENE
, O O
two O O
promoters O O
recognized O O
uniquely O O
by O O
sigma B-GENE B-GENE
E E-GENE I-GENE
- O I-GENE
containing O I-GENE
RNA B-GENE I-GENE
polymerase E-GENE E-GENE
. O O
Cytokinetics O O
of O O
the O O
Krebs O O
2 O O
carcinoma O O
. O O
Through O O
effective O O
use O O
of O O
laboratory O O
testing O O
database O O
, O O
it O O
will O O
be O O
possible O O
to O O
shift O O
away O O
our O O
vague O O
management O O
of O O
pre O O
- O O
analytic O O
phase O O
of O O
quality O O
control O O
so O O
far O O
to O O
its O O
established O O
system O O
based O O
on O O
objective O O
evaluation O O
. O O
These O O
patients O O
developed O O
severe O O
diabetic O O
symptoms O O
including O O
glucose O O
intolerance O O
, O O
weight O O
loss O O
, O O
impaired O O
energy O O
utilization O O
, O O
and O O
nerve O O
and O O
brain O O
disorders O O
that O O
were O O
refractory O O
to O O
insulin S-GENE O
. O O
One O O
promoter O O
, O O
p53P1 S-GENE S-GENE
, O O
is O O
located O O
100 O O
- O O
250 O O
bp O O
upstream O O
of O O
the O O
218 O O
- O O
bp O O
noncoding O O
first O O
exon O O
; O O
a O O
second O O
, O O
stronger O O
promoter O O
, O O
p53P2 S-GENE S-GENE
, O O
maps O O
within O O
the O O
first O O
intron O O
. O O
Both O O
PMP20 B-GENE B-GENE
gene I-GENE E-GENE
products E-GENE O
contain O O
the O O
carboxyl O O
- O O
terminal O O
sequence O O
AKL O S-GENE
, O O
similar O O
to O O
the O O
putative O O
SKL O O
peroxisomal O O
sorting O O
sequence O O
( O O
Gould O O
, O O
S O O
. O O
The O O
likelihood O O
of O O
death O O
was O O
more O O
than O O
3 O O
times O O
higher O O
among O O
patients O O
in O O
the O O
ERA O O
- O O
II O O
group O O
( O O
mortality O O
risk O O
ratio O O
3 O O
. O O
82 O O
[ O O
95 O O
% O O
CI O O
1 O O
. O O
48 O O
% O O
to O O
9 O O
. O O
84 O O
] O O
, O O
p O O
= O O
0 O O
. O O
006 O O
) O O
. O O
Barium O O
mucosal O O
coating O O
was O O
judged O O
to O O
be O O
better O O
in O O
the O O
members O O
to O O
whom O O
magnesium O O
sulphate O O
was O O
administered O O
( O O
p O O
= O O
0 O O
. O O
0007 O O
) O O
. O O
In O O
both O O
immortalized O O
and O O
normal O O
diploid O O
human O O
cells O O
, O O
wt O O
AAV O O
targeted O O
integration O O
to O O
ch O O
- O O
19 O O
. O O
The O O
corresponding O O
tetrapeptide O O
sequences O O
SSPD O S-GENE
and O O
SATD O S-GENE
for O O
human B-GENE O
and I-GENE O
mouse I-GENE B-GENE
PKC I-GENE I-GENE
- I-GENE I-GENE
epsilon E-GENE E-GENE
, O O
respectively O O
, O O
are O O
unusual O O
for O O
caspase B-GENE B-GENE
- I-GENE I-GENE
3 E-GENE E-GENE
. O O
The O O
lipopolysaccharide O O
- O O
binding O O
protein O O
is O O
a O O
secretory B-GENE O
class I-GENE O
1 I-GENE O
acute I-GENE O
- I-GENE O
phase I-GENE O
protein E-GENE O
whose O O
gene O O
is O O
transcriptionally O O
activated O O
by O O
APRF S-GENE S-GENE
/ O O
STAT B-GENE B-GENE
/ I-GENE I-GENE
3 E-GENE E-GENE
and O O
other O O
cytokine O O
- O O
inducible O O
nuclear O O
proteins O O
. O O
Tritium O O
concentrations O O
in O O
environmental O O
water O O
samples O O
were O O
found O O
to O O
be O O
determined O O
within O O
an O O
accuracy O O
of O O
10 O O
% O O
by O O
this O O
method O O
when O O
Vi O O
/ O O
Vf O O
was O O
14 O O
- O O
25 O O
. O O
This O O
region O O
does O O
not O O
contain O O
a O O
consensus O O
estrogen O O
response O O
element O O
, O O
and O O
ER S-GENE O
binding O O
to O O
this O O
DNA O O
sequence O O
was O O
not O O
observed O O
. O O
These O O
proteins O O
, O O
called O O
variant B-GENE O
surface I-GENE O
glycoproteins E-GENE O
( O O
VSGs S-GENE S-GENE
) O O
, O O
are O O
expressed O O
from O O
a O O
specific O O
locus O O
, O O
the O O
VSG B-GENE B-GENE
gene I-GENE E-GENE
expression I-GENE O
site I-GENE O
( I-GENE O
ES I-GENE O
) E-GENE O
. O O
The O O
strangulated O O
intestinal O O
pathologies O O
of O O
horses O O
are O O
accompanied O O
by O O
a O O
local O O
activation O O
of O O
the O O
neutrophils O O
, O O
that O O
can O O
be O O
revealed O O
by O O
measuring O O
the O O
tissular O O
enzymatic O O
activity O O
of O O
the O O
granulocytic O O
enzyme O O
myeloperoxidase S-GENE O
( O O
MPO S-GENE S-GENE
) O O
. O O
A O O
deletion O O
analysis O O
of O O
the O O
FAS1 B-GENE B-GENE
promoter E-GENE E-GENE
lacking O O
the O O
previously O O
characterized O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
defined O O
a O O
region O O
( O O
nucleotides O O
- O O
760 O O
to O O
- O O
850 O O
) O O
responsible O O
for O O
most O O
of O O
the O O
remaining O O
activation O O
potency O O
. O O
Here O O
we O O
report O O
the O O
fabrication O O
of O O
single O O
- O O
molecule O O
transistors O O
based O O
on O O
individual O O
C60 O O
molecules O O
connected O O
to O O
gold O O
electrodes O O
. O O
The O O
homeodomain B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
CDP S-GENE O
/ O O
cut S-GENE O
interacts O O
with O O
the O O
cell O O
cycle O O
regulatory O O
element O O
of O O
histone B-GENE B-GENE
H4 I-GENE I-GENE
genes E-GENE E-GENE
packaged O O
into O O
nucleosomes O O
. O O
They O O
encode O O
proteins O O
whose O O
core O O
regions O O
display O O
great O O
similarity O O
to O O
Aspergillus B-GENE O
HAPB E-GENE S-GENE
, O O
HAPC S-GENE S-GENE
and O O
HAPE S-GENE S-GENE
and O O
to O O
known O O
HAP B-GENE O
homologs E-GENE O
from O O
other O O
organisms O O
. O O
Furthermore O O
, O O
the O O
cognate O O
binding O O
protein O O
is O O
present O O
in O O
both O O
rat O O
and O O
human O O
( O O
HeLa O O
) O O
cell O O
nuclear O O
extracts O O
. O O
Transient O O
cotransfection O O
analyses O O
indicate O O
that O O
the O O
cooperative O O
association O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
IL I-GENE I-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
and O O
RelA S-GENE S-GENE
with O O
the O O
IL B-GENE B-GENE
- I-GENE I-GENE
8 I-GENE I-GENE
promoter E-GENE E-GENE
results O O
in O O
synergistic O O
transcriptional O O
activation O O
. O O
Heart O O
rate O O
during O O
the O O
behavioral O O
avoidance O O
test O O
was O O
shown O O
to O O
be O O
as O O
susceptible O O
to O O
experimental O O
demand O O
as O O
other O O
studies O O
have O O
shown O O
approach O O
behaviors O O
to O O
be O O
influenced O O
. O O
Function O O
was O O
retained O O
when O O
one O O
copy O O
of O O
the O O
sequence O O
was O O
present O O
, O O
suggesting O O
that O O
this O O
sequence O O
represents O O
an O O
essential O O
element O O
. O O
Decreased O O
plasma O O
level O O
of O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
was O O
assumed O O
to O O
be O O
one O O
of O O
the O O
major O O
factors O O
underlying O O
hypercoagulable O O
state O O
in O O
nephrotic O O
syndrome O O
. O O
NO2 O O
pollution O O
on O O
major O O
trunk O O
roads O O
frequently O O
exceeded O O
British O O
and O O
European O O
Union O O
air O O
quality O O
standards O O
, O O
while O O
particle O O
pollution O O
was O O
lower O O
. O O
Cotransfection O O
of O O
pINV O B-GENE
- O I-GENE
2473 O E-GENE
, O O
a O O
construct O O
containing O O
2473 O O
base O O
pairs O O
of O O
hINV B-GENE O
upstream I-GENE O
sequence E-GENE O
linked O O
to O O
luciferase S-GENE O
, O O
with O O
POU B-GENE S-GENE
homeodomain I-GENE O
transcription I-GENE O
factors E-GENE O
Oct1 S-GENE S-GENE
, O O
Oct2 S-GENE S-GENE
, O O
Brn4 S-GENE S-GENE
, O O
SCIP S-GENE S-GENE
, O O
Skn1a S-GENE S-GENE
or O O
Skn1i S-GENE S-GENE
, O O
results O O
in O O
a O O
strong O O
suppression O O
of O O
basal O O
promoter O O
activity O O
. O O
87 O O
, O O
7270 O O
- O O
7274 O O
) O O
. O O
I O O
. O O
Transcripts O O
initiating O O
at O O
the O O
CAGT O B-GENE
motif O E-GENE
( O O
proximal O O
transcripts O O
) O O
were O O
abolished O O
by O O
deletion O O
of O O
the O O
proximal O O
TATA O O
box O O
located O O
at O O
- O O
29 O O
relative O O
to O O
CAGT O O
. O O
Genomic O O
DNA O O
blot O O
analysis O O
indicates O O
that O O
the O O
trout B-GENE O
L2 I-GENE O
locus E-GENE O
has O O
a O O
cluster O O
- O O
like O O
organization O O
similar O O
to O O
the O O
trout B-GENE O
L1 I-GENE O
locus E-GENE O
and O O
the O O
IgL B-GENE B-GENE
locus E-GENE E-GENE
of O O
several O O
teleost O O
fish O O
. O O
Although O O
the O O
energy O O
- O O
based O O
DFT O O
was O O
not O O
affected O O
by O O
isoproterenol O O
( O O
from O O
6 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
to O O
6 O O
. O O
0 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
J O O
) O O
, O O
it O O
was O O
decreased O O
to O O
3 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
6 O O
J O O
in O O
the O O
third O O
stage O O
by O O
infusion O O
of O O
E4031 O O
and O O
isoproterenol O O
( O O
p O O
< O O
0 O O
. O O
01 O O
vs O O
. O O
baseline O O
and O O
vs O O
. O O
isoproterenol O O
) O O
. O O
Gore O O
& O O
Associates O O
, O O
Inc O O
. O O
) O O
standard O O
wall O O
graft O O
segments O O
varying O O
in O O
length O O
from O O
4 O O
to O O
12 O O
cm O O
. O O
The O O
dynamics O O
of O O
N O O
- O O
interaction O O
and O O
N O O
- O O
retention O O
during O O
3 O O
hr O O
CPB O O
was O O
quantified O O
with O O
autologous O O
In O O
- O O
111 O O
labeled O O
neutrophils O O
( O O
INN O O
) O O
in O O
4 O O
groups O O
of O O
20 O O
Yorkshire O O
pigs O O
( O O
28 O O
- O O
35 O O
kg O O
, O O
5 O O
sham O O
; O O
5 O O
CPB O O
, O O
1 O O
hr O O
; O O
5 O O
CPB O O
, O O
3 O O
hr O O
and O O
5 O O
CPB O O
with O O
heparinized O O
circuit O O
, O O
3 O O
hr O O
) O O
; O O
anesthetized O O
pigs O O
were O O
injected O O
with O O
INN O O
( O O
500 O O
- O O
650 O O
microCi O O
) O O
, O O
30 O O
min O O
before O O
CPB O O
and O O
heparinized O O
, O O
and O O
underwent O O
CPB O O
with O O
a O O
roller O O
pump O O
, O O
a O O
hollow O O
fiber O O
OX O O
( O O
Bentley O O
CM O O
50 O O
, O O
5 O O
. O O
0 O O
m2 O O
) O O
and O O
AF O O
( O O
Bentley O O
AF O O
025 O O
, O O
0 O O
. O O
25 O O
m2 O O
) O O
at O O
2 O O
. O O
5 O O
- O O
3 O O
. O O
6 O O
l O O
/ O O
min O O
for O O
3 O O
hr O O
. O O
The O O
region O O
immediately O O
following O O
the O O
promoter O O
and O O
5 O O
' O O
to O O
ORF1 O S-GENE
has O O
a O O
potential O O
transcription O O
terminator O O
sequence O O
. O O
Studies O O
on O O
recurrences O O
in O O
gingival O O
hyperplasia O O
Preface O O
and O O
acknowledgements O O
. O O
We O O
conclude O O
that O O
clonidine O O
3 O O
micrograms O O
/ O O
kg O O
produces O O
sedation O O
comparable O O
to O O
diazepam O O
0 O O
. O O
2 O O
mg O O
/ O O
kg O O
and O O
also O O
attenuates O O
the O O
intubation O O
response O O
without O O
increasing O O
the O O
incidence O O
of O O
complications O O
. O O
Pancreatic O O
expression O O
of O O
the O O
glucagon B-GENE B-GENE
gene E-GENE E-GENE
depends O O
on O O
multiple O O
transcription O O
factors O O
interacting O O
with O O
at O O
least O O
three O O
DNA O O
control O O
elements O O
: O O
G1 O O
, O O
the O O
upstream O O
promoter O O
element O O
, O O
and O O
G2 O S-GENE
and O O
G3 O S-GENE
, O O
two O O
enhancer O O
- O O
like O O
sequences O O
. O O
We O O
have O O
compared O O
the O O
ability O O
of O O
GST S-GENE B-GENE
- O I-GENE
Bem3 S-GENE E-GENE
to O O
serve O O
as O O
a O O
GAP S-GENE O
for O O
Cdc42Hs S-GENE O
relative O O
to O O
other O O
members O O
of O O
the O O
rho S-GENE B-GENE
- O I-GENE
GAP S-GENE I-GENE
subfamily O E-GENE
and O O
found O O
the O O
following O O
order O O
of O O
potency O O
: O O
human B-GENE O
platelet I-GENE O
Cdc42Hs I-GENE O
GAP E-GENE O
> O O
p190 S-GENE O
> O O
Bem3 S-GENE O
> O O
break B-GENE O
point I-GENE O
cluster I-GENE O
region I-GENE O
protein E-GENE O
, O O
whereas O O
p85 S-GENE S-GENE
, O O
like O O
Bem2 S-GENE O
, O O
shows O O
no O O
GAP S-GENE O
activity O O
or O O
any O O
ability O O
to O O
bind O O
to O O
the O O
GTP O O
- O O
bound O O
form O O
of O O
Cdc42Hs S-GENE S-GENE
. O O
CONCLUSION O O
: O O
Men O O
presenting O O
with O O
urethritis O O
and O O
women O O
presenting O O
with O O
PID O O
both O O
have O O
significantly O O
greater O O
peripheral O O
blood O O
mononuclear O O
cell O O
proliferative O O
responses O O
to O O
the O O
DK20 O O
strain O O
of O O
C O O
trachomatis O O
than O O
controls O O
. O O
The O O
PDSS O O
identified O O
17 O O
( O O
94 O O
% O O
) O O
of O O
the O O
women O O
diagnosed O O
with O O
major O O
postpartum O O
depression O O
, O O
the O O
EPDS O O
identified O O
14 O O
of O O
these O O
women O O
( O O
78 O O
% O O
) O O
, O O
and O O
the O O
BDI O O
- O O
II O O
identified O O
10 O O
of O O
the O O
18 O O
women O O
( O O
56 O O
% O O
) O O
. O O
Men O O
and O O
women O O
entering O O
psychotherapy O O
more O O
often O O
had O O
negative O O
Wish O O
elements O O
than O O
others O O
. O O
Single O O
amino O O
acid O O
substitutions O O
were O O
shown O O
to O O
result O O
from O O
the O O
mutations O O
pdr1 B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
( O O
M308I O O
) O O
, O O
pdr1 B-GENE B-GENE
- I-GENE I-GENE
3 E-GENE E-GENE
( O O
F815S O O
) O O
, O O
pdr1 B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
( O O
K302Q O O
) O O
, O O
pdr1 B-GENE O
- I-GENE O
7 E-GENE O
( O O
P298A O O
) O O
and O O
pdr1 B-GENE B-GENE
- I-GENE I-GENE
8 E-GENE E-GENE
( O O
L1036 O O
W O O
) O O
, O O
whereas O O
the O O
intragenic O O
suppressor O O
mutant O O
pdr1 B-GENE O
- I-GENE O
100 E-GENE O
is O O
deleted O O
for O O
the O O
two O O
amino O O
acids O O
L537 O S-GENE
and O O
A538 O S-GENE
. O O
Both O O
merR B-GENE B-GENE
genes E-GENE E-GENE
consist O O
of O O
a O O
408 O O
bp O O
ORF O O
coding O O
for O O
135 O O
amino O O
acids O O
. O O
Amniotic O O
fluid O O
ionic O O
concentration O O
in O O
response O O
to O O
chronic O O
fetal B-GENE O
vasopressin E-GENE O
infusion O O
. O O
The O O
same O O
slice O O
was O O
imaged O O
three O O
times O O
each O O
with O O
sequences O O
using O O
spatial O O
presaturation O O
or O O
not O O
. O O
Molecular O O
cloning O O
of O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE I-GENE
CP2 S-GENE E-GENE
. O O
The O O
most O O
distal O O
active O O
site O O
in O O
TIGA S-GENE O
is O O
created O O
by O O
excision O O
of O O
a O O
66 O O
- O O
bp O O
intron O O
. O O
Denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
with O O
sequence O O
analysis O O
showed O O
that O O
PGCL4 S-GENE S-GENE
is O O
a O O
major O O
member O O
in O O
the O O
female O O
mammary O O
gland O O
, O O
and O O
in O O
the O O
submaxillary O O
and O O
lachrymal O O
glands O O
of O O
both O O
sexes O O
, O O
while O O
the O O
counterpart O O
in O O
male O O
liver O O
and O O
the O O
coagulate O O
glands O O
was O O
found O O
to O O
be O O
PGCL1 S-GENE O
. O O
All O O
possessed O O
cutaneous O O
receptive O O
fields O O
on O O
the O O
distal O O
segments O O
of O O
digits O O
2 O O
, O O
3 O O
, O O
or O O
4 O O
. O O
Sesame O O
seed O O
should O O
also O O
be O O
considered O O
a O O
cause O O
of O O
allergic O O
reactions O O
to O O
drug O O
products O O
and O O
cosmetics O O
. O O
Ligand O O
binding O O
of O O
multi O B-GENE
- O I-GENE
chain O I-GENE
antigen O I-GENE
receptors O E-GENE
and O O
hematopoietin S-GENE S-GENE
/ O O
cytokine O O
receptors O O
results O O
in O O
rapid O O
activation O O
of O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PTK S-GENE S-GENE
) O O
- O O
dependent O O
signalling O O
molecules O O
such O O
as O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
) O O
. O O
The O O
UASB O O
reactors O O
treated O O
a O O
VFA O O
mixture O O
( O O
with O O
an O O
acetate O O
: O O
propionate O O
: O O
butyrate O O
ratio O O
of O O
5 O O
: O O
3 O O
: O O
2 O O
on O O
COD O O
basis O O
) O O
or O O
acetate O O
as O O
the O O
sole O O
substrate O O
at O O
different O O
COD O O
: O O
sulfate O O
ratios O O
. O O
The O O
authors O O
emphasize O O
absence O O
of O O
specific O O
signs O O
of O O
vagal O O
involvement O O
, O O
importance O O
for O O
diagnosis O O
of O O
surgical O O
extirpation O O
, O O
and O O
mildness O O
of O O
post O O
operative O O
course O O
. O O
Now O O
: O O
pleasure O O
in O O
work O O
This O O
article O O
reviews O O
current O O
concepts O O
of O O
pathophysiology O O
and O O
summarises O O
clinical O O
features O O
, O O
natural O O
history O O
and O O
available O O
treatments O O
. O O
Previous O O
data O O
suggested O O
a O O
subtle O O
increase O O
in O O
serum O O
P O O
at O O
the O O
time O O
of O O
hCG S-GENE O
injection O O
without O O
LH S-GENE O
surge O O
reduces O O
the O O
PR O O
of O O
women O O
having O O
oocyte O O
retrievals O O
for O O
IVF O O
; O O
this O O
study O O
compared O O
PRs O O
of O O
recipients O O
in O O
a O O
shared O O
oocyte O O
program O O
according O O
to O O
the O O
donors O O
' O O
pre B-GENE O
- I-GENE O
hCG E-GENE O
P O O
level O O
. O O
Adequacy O O
of O O
the O O
Haldane O O
transformation O O
in O O
the O O
computation O O
of O O
exercise O O
V O O
O2 O O
in O O
man O O
. O O
M O O
. O O
, O O
Adrich O O
, O O
Z O O
. O O
, O O
Fournet O O
, O O
B O O
. O O
, O O
Capon O O
, O O
C O O
. O O
, O O
Bonicel O O
, O O
J O O
. O O
Association O O
between O O
hyperhomocysteinemia O O
and O O
ischemic O O
heart O O
disease O O
in O O
Sri O O
Lankans O O
. O O
Radiological O O
imaging O O
such O O
as O O
UGI O O
series O O
and O O
CT O O
scan O O
was O O
useful O O
to O O
arrive O O
at O O
an O O
accurate O O
diagnosis O O
. O O
The O O
architecture O O
of O O
the O O
hRap1 S-GENE B-GENE
Myb B-GENE I-GENE
domain E-GENE E-GENE
is O O
very O O
close O O
to O O
that O O
of O O
each O O
of O O
the O O
Myb B-GENE B-GENE
domains E-GENE E-GENE
from O O
TRF1 S-GENE S-GENE
, O O
scRap1p S-GENE S-GENE
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb E-GENE E-GENE
. O O
80 O O
v B-GENE O
- I-GENE O
ets E-GENE O
- O O
encoded O O
amino O O
- O O
acids O O
located O O
immediately O O
after O O
the O O
v B-GENE O
- I-GENE O
myb E-GENE O
/ O O
v B-GENE O
- I-GENE O
ets E-GENE O
junction O O
are O O
not O O
found O O
in O O
P54 S-GENE S-GENE
/ O O
56c B-GENE O
- I-GENE O
ets E-GENE O
, O O
the O O
translation O O
product O O
of O O
the O O
c B-GENE O
- I-GENE O
ets I-GENE O
proto I-GENE O
- I-GENE O
oncogene E-GENE O
, O O
nor O O
in O O
a O O
set O O
of O O
cellular O O
proteins O O
of O O
64 O O
, O O
62 O O
, O O
and O O
60 O O
kDa O O
related O O
to O O
but O O
distinct O O
from O O
P54 S-GENE S-GENE
/ O O
56c B-GENE O
- I-GENE O
ets E-GENE O
. O O
We O O
have O O
raised O O
antibodies O O
against O O
a O O
peptide O O
specific O O
to O O
the O O
predicted O O
protein O O
product O O
of O O
this O O
second O O
mRNA O O
. O O
Because O O
controlled O O
- O O
release O O
niacin O O
seems O O
to O O
be O O
more O O
potent O O
than O O
crystalline O O
niacin O O
, O O
product O O
substitution O O
without O O
dose O O
adjustment O O
should O O
be O O
avoided O O
. O O
Interobserver O O
agreement O O
of O O
the O O
Nottingham O O
histologic O O
grading O O
scheme O O
for O O
infiltrating O O
duct O O
carcinoma O O
breast O O
. O O
This O O
dose O O
of O O
Na3 O O
citrate O O
produced O O
no O O
clinical O O
symptoms O O
suggestive O O
of O O
hypocalcaemia O O
in O O
these O O
subjects O O
, O O
even O O
though O O
the O O
use O O
of O O
acid O O
- O O
citrate O O
- O O
dextrose O O
, O O
NIH O O
formula O O
A O O
( O O
ACD O O
- O O
A O O
) O O
under O O
identical O O
conditions O O
has O O
been O O
reported O O
to O O
reduce O O
significantly O O
the O O
level O O
of O O
total O O
calcium O O
in O O
serum O O
, O O
and O O
concomitantly O O
increase O O
the O O
number O O
or O O
reactions O O
occurring O O
in O O
donors O O
. O O
Latex O O
products O O
( O O
gloves O O
, O O
balloons O O
, O O
and O O
condoms O O
) O O
directly O O
bound O O
IgE S-GENE S-GENE
from O O
all O O
four O O
patients O O
. O O
The O O
phosphoprotein B-GENE O
pUL69 E-GENE O
of O O
human O O
cytomegalovirus O O
( O O
HCMV O O
) O O
, O O
which O O
is O O
a O O
herpesvirus O O
of O O
considerable O O
medical O O
importance O O
in O O
immunosuppressed O O
patients O O
and O O
newborns O O
, O O
has O O
previously O O
been O O
identified O O
as O O
an O O
early B-GENE O
- I-GENE O
late I-GENE O
viral I-GENE O
protein E-GENE O
that O O
can O O
stimulate O O
several O O
viral O O
and O O
cellular O O
promoters O O
and O O
thus O O
exerts O O
a O O
rather O O
broad O O
activation O O
pattern O O
. O O
Southern O O
blot O O
analysis O O
performed O O
on O O
genomic O O
DNA O O
demonstrated O O
altered O O
CpG O O
methylation O O
within O O
intron O O
1 O O
in O O
DNA O O
from O O
all O O
BCC O O
compared O O
to O O
normal O O
, O O
mortal O O
human O O
mammary O O
epithelial O O
cells O O
( O O
HMEC O O
) O O
. O O
Previous O O
studies O O
have O O
shown O O
that O O
TGFbeta1 S-GENE S-GENE
expression O O
is O O
upregulated O O
in O O
mouse O O
keratinocytes O O
infected O O
with O O
a O O
v B-GENE O
- I-GENE O
rasHa E-GENE O
retrovirus O O
, O O
although O O
the O O
functional O O
significance O O
of O O
this O O
has O O
not O O
been O O
clear O O
. O O
An O O
increased O O
incidence O O
of O O
ATN O O
has O O
been O O
reported O O
since O O
the O O
introduction O O
of O O
cyclosporin O O
A O O
. O O
Using O O
a O O
GTP O O
- O O
dependent O O
, O O
brefeldin O O
A O O
- O O
sensitive O O
in O O
vitro O O
AP B-GENE O
- I-GENE O
1 E-GENE O
binding O O
assay O O
, O O
we O O
have O O
determined O O
here O O
the O O
parameters O O
of O O
the O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
binding O O
reaction O O
. O O
The O O
overall O O
rate O O
of O O
biohydrogenation O O
of O O
C18 O O
: O O
2 O O
was O O
14 O O
. O O
3 O O
% O O
/ O O
h O O
, O O
but O O
declined O O
1 O O
. O O
2 O O
% O O
/ O O
h O O
for O O
each O O
percentage O O
unit O O
increase O O
in O O
C18 O O
: O O
2 O O
added O O
to O O
the O O
substrate O O
. O O
Plasma B-GENE O
enteroglucagon E-GENE O
was O O
measured O O
before O O
and O O
during O O
three O O
hours O O
after O O
a O O
standard O O
meal O O
in O O
21 O O
untreated O O
adult O O
patients O O
with O O
suspected O O
coeliac O O
disease O O
who O O
all O O
had O O
villous O O
atrophy O O
of O O
the O O
small O O
intestinal O O
mucosa O O
and O O
malabsorption O O
, O O
and O O
in O O
nine O O
control O O
subjects O O
. O O
After O O
control O O
for O O
body O O
mass O O
index O O
, O O
trait O O
anxiety O O
and O O
anger O O
- O O
in O O
remained O O
independent O O
predictors O O
of O O
diastolic O O
blood O O
pressure O O
among O O
the O O
women O O
. O O
Regulation O O
of O O
the O O
human B-GENE O
stress I-GENE O
response I-GENE O
gene I-GENE O
GADD153 E-GENE S-GENE
expression O O
: O O
role O O
of O O
ETS1 S-GENE S-GENE
and O O
FLI B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene I-GENE E-GENE
products E-GENE O
. O O
The O O
PRP4 B-GENE B-GENE
protein I-GENE E-GENE
of I-GENE O
Saccharomyces I-GENE O
cerevisiae E-GENE O
is O O
an O O
essential O O
part O O
of O O
the O O
U4 S-GENE S-GENE
/ O O
U6 S-GENE B-GENE
snRNP O E-GENE
, O O
a O O
component O O
of O O
the O O
mRNA O O
splicing O O
apparatus O O
. O O
132 O O
varix O O
ligations O O
were O O
performed O O
during O O
44 O O
separate O O
EVL O O
sessions O O
. O O
Here O O
RFX S-GENE S-GENE
/ O O
X2BP S-GENE O
/ O O
DNA O O
complexes O O
were O O
formed O O
on O O
all O O
class O O
II O O
isotypes O O
regardless O O
of O O
the O O
ability O O
of O O
the O O
X O O
box O O
region O O
to O O
bind O O
either O O
factor O O
individually O O
. O O
The O O
psi B-GENE B-GENE
zeta I-GENE I-GENE
gene E-GENE E-GENE
has O O
a O O
nonsense O O
mutation O O
in O O
exon O O
1 O O
but O O
has O O
identical O O
promoter O O
sequence O O
and O O
RNA O O
processing O O
sites O O
to O O
the O O
zeta B-GENE B-GENE
gene E-GENE E-GENE
, O O
raising O O
the O O
possibility O O
that O O
both O O
psi B-GENE B-GENE
zeta E-GENE E-GENE
and O O
zeta S-GENE O
are O O
transcriptionally O O
active O O
. O O
Prospects O O
of O O
chemosterilant O O
and O O
genetic O O
control O O
of O O
rodents O O
. O O
Serum O O
PRL S-GENE O
concentrations O O
significantly O O
increased O O
after O O
MCP O O
administration O O
in O O
normal O O
women O O
, O O
hyperprolactinemic O O
patients O O
with O O
normal O O
sella O O
and O O
patients O O
with O O
microadenoma O O
, O O
but O O
not O O
in O O
macroadenoma O O
patients O O
with O O
and O O
without O O
suprasellar O O
expansion O O
( O O
SSE O O
) O O
. O O
The O O
Id4 B-GENE B-GENE
protein E-GENE E-GENE
contains O O
a O O
HLH O S-GENE
domain O O
highly O O
conserved O O
among O O
the O O
dnHLH B-GENE B-GENE
proteins E-GENE E-GENE
from O O
mouse O O
and O O
drosophila O O
. O O
The O O
coding O O
region O O
of O O
nifA S-GENE S-GENE
was O O
determined O O
using O O
a O O
translational O O
lacZ B-GENE O
fusion E-GENE O
and O O
by O O
site O O
- O O
directed O O
mutagenesis O O
to O O
identify O O
which O O
of O O
four O O
in O O
frame O O
AUG O O
codons O O
was O O
used O O
. O O
Peptide O O
competition O O
studies O O
have O O
localized O O
a O O
cyclin B-GENE O
A I-GENE O
interaction I-GENE O
site E-GENE O
to O O
a O O
Lys381Lys382Leu383Met384Phe385 O O
sequence O O
within O O
C O O
- O O
terminal O O
negative O O
regulatory O O
domain O O
of O O
human B-GENE B-GENE
p53 E-GENE E-GENE
. O O
Heterodimerization B-GENE O
mutant I-GENE O
RXR E-GENE S-GENE
failed O O
to O O
alter O O
GFP S-GENE B-GENE
- O I-GENE
VDR S-GENE E-GENE
and O O
nlsGFP S-GENE B-GENE
- O I-GENE
VDR S-GENE E-GENE
distribution O O
or O O
activity O O
. O O
Like O O
troponin B-GENE O
Cs E-GENE O
and O O
calmodulins S-GENE O
, O O
PfCPK S-GENE S-GENE
also O O
contains O O
four O O
EF O O
hand O O
calcium O O
- O O
binding O O
motifs O O
. O O
A O O
third O O
group O O
( O O
n O O
= O O
10 O O
) O O
was O O
assigned O O
to O O
receive O O
the O O
canalith O O
repositioning O O
maneuver O O
without O O
mastoid O O
vibration O O
. O O
Upstream O O
of O O
the O O
afa B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
gene I-GENE E-GENE
cluster E-GENE O
, O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
region O O
was O O
found O O
to O O
be O O
96 O O
% O O
identical O O
to O O
the O O
RepFIB B-GENE O
sequence E-GENE O
of O O
one O O
of O O
the O O
enterotoxigenic O O
E O O
. O O
coli O O
plasmids O O
( O O
P307 O O
) O O
, O O
suggesting O O
a O O
common O O
ancestor O O
plasmid O O
. O O
The O O
cats O O
with O O
stage O O
- O O
2 O O
lymphomas O O
that O O
were O O
FeLV O O
- O O
test O O
negative O O
had O O
the O O
best O O
response O O
to O O
treatment O O
. O O
We O O
hypothesize O O
that O O
the O O
ability O O
of O O
these O O
acidic O O
activators O O
to O O
specifically O O
interact O O
with O O
multiple O O
components O O
of O O
the O O
transcription O O
initiation O O
complex O O
likely O O
underlies O O
the O O
dramatic O O
functional O O
synergy O O
exhibited O O
by O O
this O O
class O O
of O O
activation O O
domains O O
in O O
vivo O O
. O O
Where O O
the O O
resonator O O
has O O
two O O
holes O O
, O O
these O O
terms O O
should O O
be O O
somewhat O O
modified O O
: O O
A O O
is O O
the O O
combined O O
area O O
of O O
the O O
two O O
holes O O
, O O
L O O
is O O
16 O O
/ O O
3pi O O
r O O
( O O
~ O O
1 O O
. O O
7r O O
) O O
for O O
a O O
simple O O
hole O O
in O O
a O O
thin O O
- O O
walled O O
vessel O O
and O O
r O O
is O O
the O O
radius O O
of O O
one O O
hole O O
( O O
Seto O O
, O O
1971 O O
) O O
. O O
Histological O O
and O O
immunophenotypic O O
studies O O
revealed O O
12 O O
large O O
cell O O
lymphomas O O
( O O
11 O O
B O O
cell O O
and O O
one O O
T O O
cell O O
) O O
, O O
two O O
small O O
noncleaved O O
cell O O
lymphomas O O
( O O
B O O
- O O
cell O O
phenotype O O
) O O
, O O
and O O
five O O
low O O
grade O O
B O O
- O O
cell O O
lymphomas O O
( O O
two O O
small O O
lymphocytic O O
and O O
three O O
follicular O O
mixed O O
lymphomas O O
) O O
. O O
The O O
deviation O O
site O O
is O O
equivalent O O
to O O
the O O
exon O O
1 O O
/ O O
exon O O
2 O O
splice O O
site O O
of O O
the O O
mouse O B-GENE
C O I-GENE
- O I-GENE
subunit O E-GENE
. O O
The O O
determination O O
of O O
diacetyl O O
, O O
2 O O
, O O
3 O O
- O O
pentanedione O O
and O O
acetoin O O
was O O
performed O O
in O O
two O O
steps O O
. O O
There O O
also O O
may O O
be O O
osmotic O O
challenges O O
to O O
mucosal O O
cell O O
function O O
as O O
evidenced O O
by O O
the O O
different O O
reaction O O
rates O O
with O O
hyper O O
- O O
and O O
hypotonic O O
saline O O
. O O
In O O
F9 O O
, O O
which O O
is O O
a O O
prototype O O
of O O
embryonal O O
carcinoma O O
cells O O
expressing O O
hst S-GENE O
, O O
the O O
expression O O
of O O
hst B-GENE B-GENE
gene E-GENE E-GENE
is O O
positively O O
regulated O O
by O O
a O O
downstream O O
octamer O O
motif O O
that O O
functions O O
as O O
an O O
enhancer O O
. O O
The O O
reading O O
achievement O O
of O O
students O O
with O O
learning O O
disabilities O O
who O O
received O O
reading O O
instruction O O
through O O
the O O
DISTAR O O
program O O
was O O
compared O O
to O O
that O O
of O O
similar O O
students O O
using O O
basal O O
reader O O
materials O O
. O O
Two O O
putative O O
ATP O O
- O O
binding O O
domains O O
were O O
identified O O
, O O
one O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
argA B-GENE B-GENE
- I-GENE I-GENE
encoded I-GENE I-GENE
protein E-GENE E-GENE
and O O
the O O
other O O
in O O
the O O
carboxy O O
- O O
terminal O O
half O O
. O O
Chronic O O
granulocytic O O
leukemia O O
in O O
children O O
. O O
Purified O O
phosphorylated O O
PhoP S-GENE O
( O O
PhoPP S-GENE O
) O O
had O O
a O O
half O O
- O O
life O O
of O O
approximately O O
2 O O
. O O
5 O O
h O O
, O O
which O O
was O O
reduced O O
to O O
about O O
15 O O
min O O
by O O
addition O O
of O O
the O O
same O O
molar O O
amount O O
of O O
* B-GENE O
PhoR E-GENE O
( O O
the O O
cytoplasmic O O
region O O
of O O
PhoR S-GENE O
) O O
. O O
This O O
transformation O O
suppression O O
by O O
Rb S-GENE S-GENE
was O O
further O O
shown O O
to O O
be O O
due O O
to O O
transcriptional O O
repression O O
of O O
neu S-GENE O
using O O
Rb S-GENE S-GENE
expressing O O
effector O O
plasmid O O
and O O
neu S-GENE B-GENE
promoter O I-GENE
- O I-GENE
chloramphenicol B-GENE I-GENE
acetyltransferase E-GENE I-GENE
reporter O I-GENE
gene O E-GENE
. O O
Before O O
therapy O O
was O O
started O O
, O O
trabecular O O
bone O O
alterations O O
could O O
be O O
observed O O
which O O
were O O
typical O O
for O O
Paget O O
' O O
s O O
disease O O
of O O
bone O O
as O O
there O O
were O O
bulky O O
trabeculare O O
, O O
increased O O
remodelling O O
surfaces O O
and O O
giant O O
osteoclasts O O
. O O
T O O
. O O
infestans O O
, O O
T O O
. O O
delpontei O O
, O O
T O O
. O O
rubrovaria O O
, O O
T O O
. O O
sordida O O
, O O
T O O
. O O
guasayana O O
and O O
T O O
. O O
vitticeps O O
from O O
infestans O O
subgroup O O
and O O
T O O
. O O
pallidipennis O O
from O O
rubrofasciata O O
, O O
were O O
studied O O
. O O
Overexpression O O
of O O
N O O
- O O
terminal O O
mutations O O
disturbs O O
mitosis O O
and O O
produces O O
elongated O O
cells O O
, O O
Using O O
a O O
PCR O O
approach O O
, O O
we O O
isolated O O
a O O
putative O O
homologue O O
of O O
Prp4 S-GENE S-GENE
from O O
human O O
and O O
mouse O O
cells O O
. O O
1 O O
. O O
Biochemical O O
studies O O
and O O
studies O O
of O O
cells O O
expressing O O
mutant O B-GENE
IL B-GENE I-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
receptors E-GENE E-GENE
indicate O O
that O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE I-GENE
- O I-GENE
induced O I-GENE
tyrosine B-GENE I-GENE
kinase E-GENE E-GENE
activation O O
initiates O O
a O O
complex O O
signaling O O
cascade O O
. O O
BACKGROUND O O
: O O
Peripheral O O
kappa B-GENE B-GENE
receptor E-GENE E-GENE
agonists O O
may O O
provide O O
a O O
new O O
therapeutic O O
approach O O
for O O
the O O
treatment O O
of O O
functional O O
dyspepsia O O
. O O
Fourteen O O
eyes O O
( O O
38 O O
. O O
9 O O
% O O
) O O
developed O O
DLK O O
after O O
an O O
epithelial O O
defect O O
, O O
representing O O
an O O
odds O O
ratio O O
of O O
13 O O
times O O
. O O
The O O
yeast O O
genome O O
contains O O
a O O
single O O
ORD1 B-GENE B-GENE
gene E-GENE E-GENE
that O O
resides O O
on O O
chromosome O O
XI O O
. O O
The O O
system O O
consists O O
of O O
a O O
TV O O
unit O O
compatible O O
to O O
IBM O O
PC O O
/ O O
AT O O
and O O
software O O
. O O
The O O
N O O
- O O
terminal O O
sequence O O
of O O
the O O
extracellular B-GENE O
MEP20 E-GENE O
, O O
TKVAS S-GENE S-GENE
, O O
was O O
found O O
at O O
aa O O
194 O O
- O O
198 O O
within O O
the O O
ORF O O
. O O
Isolates O O
of O O
B O O
. O O
burgdorferi O O
from O O
humans O O
, O O
rodents O O
, O O
and O O
I O O
. O O
dammini O O
are O O
usually O O
indistinguishable O O
, O O
but O O
strains O O
of O O
B O O
. O O
burgdorferi O O
with O O
different O O
major O O
proteins O O
have O O
been O O
identified O O
. O O
Cloning O O
of O O
the O O
GATA B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
that O O
regulates O O
endothelin B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
endothelial O O
cells O O
. O O
The O O
Synechococcus B-GENE B-GENE
gene I-GENE I-GENE
rps1 E-GENE I-GENE
encoding O I-GENE
S1 S-GENE E-GENE
is O O
located O O
1 O O
. O O
1 O O
kb O O
downstream O O
from O O
psbB S-GENE S-GENE
, O O
which O O
encodes O O
the O O
photosystem B-GENE B-GENE
II I-GENE I-GENE
P680 I-GENE E-GENE
chlorophyll I-GENE O
a I-GENE O
apoprotein E-GENE O
. O O
Two O O
- O O
dimensional O O
echocardiographic O O
parasternal O O
long O O
- O O
and O O
short O O
- O O
axis O O
views O O
were O O
obtained O O
during O O
graded O O
bleeding O O
by O O
rapid O O
withdrawal O O
of O O
blood O O
from O O
an O O
arterial O O
cannula O O
, O O
with O O
increments O O
of O O
5 O O
% O O
each O O
up O O
to O O
30 O O
% O O
of O O
calculated O O
blood O O
volume O O
. O O
A O O
comparison O O
of O O
the O O
rate O O
of O O
recovery O O
and O O
time O O
for O O
detection O O
of O O
mycobacteria O O
from O O
clinical O O
specimens O O
of O O
the O O
newly O O
developed O O
Mycobacteria O O
Growth O O
Indicator O O
Tube O O
( O O
MGIT O O
) O O
, O O
the O O
biphasic O O
Septi O O
- O O
Chek O O
, O O
and O O
the O O
egg O O
- O O
based O O
Ogawa O O
medium O O
was O O
made O O
. O O
As O O
in O O
IncP O B-GENE
alpha O E-GENE
plasmids O O
, O O
these O O
operons O O
are O O
transcribed O O
from O O
a O O
bidirectional O O
promoter O O
region O O
consisting O O
of O O
trfAp S-GENE S-GENE
for O O
the O O
trfA B-GENE B-GENE
operon E-GENE E-GENE
and O O
trbAp S-GENE S-GENE
and O O
trbBp S-GENE S-GENE
for O O
the O O
trb B-GENE B-GENE
operon E-GENE E-GENE
. O O
CONCLUSIONS O O
: O O
These O O
principally O O
structural O O
studies O O
support O O
the O O
hypothesis O O
that O O
the O O
thrombus O O
is O O
a O O
self O O
- O O
sustaining O O
entity O O
that O O
may O O
have O O
significance O O
in O O
the O O
pathophysiologic O O
mechanism O O
of O O
abdominal O O
aortic O O
aneurysms O O
. O O
The O O
BHV B-GENE O
- I-GENE O
1 I-GENE O
UL24 E-GENE O
, O O
UL25 S-GENE O
, O O
UL26 S-GENE O
and O O
UL26 B-GENE O
. I-GENE O
5 I-GENE O
transcripts E-GENE O
all O O
terminated O O
at O O
a O O
common O O
3 O O
' O O
- O O
polyadenylation O O
site O O
and O O
varied O O
significantly O O
in O O
their O O
relative O O
abundance O O
. O O
Electrophoretic O O
mobility O O
shift O O
analysis O O
of O O
protein O O
- O O
DNA O O
complexes O O
formed O O
with O O
nuclear O O
proteins O O
isolated O O
from O O
I3C O O
- O O
treated O O
and O O
- O O
untreated O O
cells O O
, O O
in O O
combination O O
with O O
supershift O O
assays O O
using O O
Sp1 B-GENE S-GENE
antibodies E-GENE O
, O O
demonstrated O O
that O O
the O O
Sp1 B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
in O O
the O O
CDK6 B-GENE B-GENE
promoter E-GENE E-GENE
forms O O
a O O
specific O O
I3C O S-GENE
- O O
responsive O O
DNA O O
- O O
protein O O
complex O O
that O O
contains O O
the O O
Sp1 B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
. O O
These O O
results O O
suggest O O
that O O
both O O
the O O
distinct O O
DNA O O
binding O O
properties O O
of O O
PMLRAR B-GENE S-GENE
homodimers E-GENE O
and O O
the O O
sequestration O O
of O O
RXR S-GENE S-GENE
by O O
PMLRARs S-GENE S-GENE
may O O
contribute O O
to O O
the O O
molecular O O
mechanisms O O
which O O
underlie O O
the O O
pathogenesis O O
of O O
APL O O
. O O
The O O
analysis O O
showed O O
that O O
the O O
morning O O
active O O
( O O
MA O O
) O O
individuals O O
rose O O
earlier O O
and O O
went O O
to O O
bed O O
earlier O O
than O O
the O O
evening O O
active O O
( O O
EA O O
) O O
individuals O O
, O O
and O O
the O O
former O O
had O O
a O O
longer O O
sleep O O
length O O
than O O
the O O
latter O O
during O O
days O O
with O O
a O O
morning O O
shift O O
, O O
while O O
the O O
opposite O O
was O O
true O O
for O O
afternoon O O
and O O
night O O
shifts O O
. O O
This O O
ERD O O
is O O
recorded O O
over O O
the O O
contralateral O O
central O O
region O O
. O O
Deletion O O
mutations O O
were O O
constructed O O
, O O
removing O O
residues O O
2 O O
- O O
30 O O
, O O
31 O O
- O O
60 O O
, O O
61 O O
- O O
90 O O
, O O
and O O
49 O O
- O O
78 O O
of O O
the O O
N O O
- O O
terminal O O
cytoplasmic O O
domain O O
, O O
as O O
well O O
as O O
a O O
missense O O
mutation O O
of O O
a O O
dileucine O O
motif O O
. O O
Kluyveromyces O O
lactis O O
, O O
a O O
budding O O
yeast O O
related O O
to O O
Saccharomyces O O
cerevisiae O O
, O O
can O O
grow O O
on O O
a O O
wider O O
variety O O
of O O
substrates O O
and O O
shows O O
less O O
sensitivity O O
to O O
glucose O O
repression O O
than O O
does O O
Saccharomyces O O
cerevisiae O O
. O O
Low O O
- O O
affinity O O
E2 B-GENE O
- I-GENE O
binding I-GENE O
site E-GENE O
mediates O O
downmodulation O O
of O O
E2 S-GENE S-GENE
transactivation O O
of O O
the O O
human B-GENE O
papillomavirus I-GENE O
type I-GENE O
8 I-GENE O
late I-GENE O
promoter E-GENE O
. O O
Untransformed O O
3T3 O O
cells O O
carry O O
abundant O O
1 O O
. O O
9 O O
kb O O
Hox B-GENE O
1 I-GENE O
. I-GENE O
3 E-GENE O
RNA O O
, O O
whereas O O
the O O
methylcholanthrene O O
- O O
transformed O O
MB66 O O
and O O
LTK O O
- O O
cells O O
or O O
3T3 O O
cells O O
transformed O O
by O O
the O O
oncogenes O B-GENE
src S-GENE E-GENE
, O O
fos S-GENE S-GENE
or O O
SV40 B-GENE B-GENE
T I-GENE I-GENE
antigen E-GENE E-GENE
express O O
only O O
low O O
levels O O
. O O
Although O O
analysis O O
of O O
the O O
similarity O O
between O O
the O O
44 O O
- O O
kDa O O
protein O O
and O O
the O O
E B-GENE B-GENE
. I-GENE I-GENE
coli I-GENE I-GENE
RecA I-GENE I-GENE
protein E-GENE E-GENE
did O O
not O O
show O O
any O O
significant O O
homology O O
between O O
them O O
, O O
it O O
revealed O O
their O O
identity O O
by O O
five O O
amino O O
- O O
acid O O
residues O O
involved O O
in O O
the O O
formation O O
of O O
the O O
epitope O O
that O O
recognized O O
the O O
paratope O O
of O O
the O O
RecA B-GENE B-GENE
protein I-GENE E-GENE
antibody E-GENE O
for O O
subsequent O O
epitope O O
- O O
paratope O O
binding O O
of O O
these O O
proteins O O
. O O
Ureases S-GENE O
were O O
purified O O
from O O
the O O
recombinant O O
cells O O
and O O
shown O O
to O O
be O O
identical O O
to O O
control O O
enzyme O O
when O O
analyzed O O
by O O
gel O O
filtration O O
chromatography O O
and O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gel O O
electrophoresis O O
; O O
however O O
, O O
in O O
every O O
case O O
the O O
activity O O
levels O O
correlated O O
to O O
nickel O O
contents O O
as O O
analyzed O O
by O O
atomic O O
absorption O O
analysis O O
. O O
Deoxyuridine O O
- O O
suppression O O
test O O
and O O
bone O O
marrow O O
culture O O
for O O
the O O
diagnosis O O
of O O
macrocytic O O
refractory O O
anaemias O O
. O O
Finally O O
, O O
synthetic O O
peptides O O
corresponding O O
to O O
the O O
mutant O O
proteins O O
were O O
assessed O O
for O O
the O O
ability O O
to O O
act O O
as O O
substrates O O
for O O
PR S-GENE O
. O O
These O O
psoralens O O
are O O
being O O
used O O
in O O
research O O
projects O O
sponsored O O
by O O
the O O
National O O
Toxicology O O
Program O O
. O O
Root O O
surface O O
caries O O
incidence O O
in O O
the O O
groups O O
inoculated O O
with O O
A O O
. O O
viscosus O O
and O O
A O O
. O O
viscosus O O
plus O O
S O O
. O O
sobrinus O O
did O O
not O O
differ O O
. O O
These O O
results O O
demonstrate O O
that O O
the O O
entire O O
E3L B-GENE B-GENE
gene E-GENE E-GENE
is O O
required O O
for O O
pathogenesis O O
in O O
the O O
mouse O O
model O O
. O O
The O O
development O O
of O O
various O O
pathological O O
lesions O O
in O O
thymus O O
, O O
spleen O O
, O O
lymph O O
nodes O O
and O O
bone O O
- O O
marrow O O
is O O
frequently O O
observed O O
. O O
Recently O O
, O O
we O O
have O O
demonstrated O O
that O O
mouse O O
microglial O O
cells O O
, O O
the O O
brain O O
macrophages O O
, O O
express O O
both O O
IL B-GENE B-GENE
- I-GENE I-GENE
15 E-GENE E-GENE
and O O
IL B-GENE B-GENE
- I-GENE I-GENE
15 I-GENE E-GENE
/ I-GENE O
IL I-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
receptors E-GENE E-GENE
. O O
We O O
have O O
analyzed O O
the O O
role O O
of O O
the O O
HU B-GENE B-GENE
protein E-GENE E-GENE
in O O
invertasome O O
assembly O O
when O O
the O O
enhancer O O
is O O
located O O
at O O
variable O O
positions O O
close O O
to O O
one O O
of O O
the O O
recombination O O
sites O O
. O O
The O O
mode O O
of O O
action O O
is O O
often O O
suggested O O
as O O
an O O
explanation O O
for O O
the O O
different O O
slopes O O
of O O
concentration O O
- O O
effect O O
curves O O
. O O
This O O
may O O
be O O
another O O
example O O
of O O
the O O
principle O O
- O O
- O O
less O O
is O O
more O O
. O O
A O O
wide O O
conservation O O
of O O
iscSUA B-GENE B-GENE
genes E-GENE E-GENE
in O O
nature O O
and O O
evidence O O
that O O
NifU S-GENE S-GENE
and O O
NifS S-GENE S-GENE
participate O O
in O O
the O O
mobilization O O
of O O
iron O O
and O O
sulfur O O
for O O
nitrogenase S-GENE O
- O O
specific O O
iron O O
- O O
sulfur O O
cluster O O
formation O O
suggest O O
that O O
the O O
products O O
of O O
the O O
iscSUA B-GENE B-GENE
genes E-GENE E-GENE
could O O
play O O
a O O
general O O
role O O
in O O
the O O
formation O O
or O O
repair O O
of O O
iron O O
- O O
sulfur O O
clusters O O
. O O
On O O
transfer O O
from O O
glucose O O
, O O
succinate O O
, O O
malate O O
, O O
or O O
glycerol O O
medium O O
to O O
citrate O O
medium O O
, O O
the O O
Cit O O
+ O O
Escherichia O O
coli O O
strains O O
showed O O
a O O
delay O O
of O O
36 O O
to O O
48 O O
h O O
before O O
growth O O
. O O
These O O
results O O
suggest O O
that O O
camptothecin O O
resistance O O
in O O
CEM O O
/ O O
DOX O O
cells O O
is O O
due O O
to O O
different O O
mechanism O O
( O O
s O O
) O O
than O O
topoisomerase S-GENE O
- O O
or O O
P B-GENE O
- I-GENE O
glycoprotein E-GENE O
- O O
associated O O
multidrug O O
resistance O O
. O O
Jornvall O O
, O O
B O O
. O O
The O O
pattern O O
of O O
expression O O
of O O
this O O
and O O
other O O
Chi26 S-GENE S-GENE
/ O O
Chi33 S-GENE S-GENE
chimeric O O
promoters O O
suggest O O
that O O
the O O
E B-GENE O
- I-GENE O
region E-GENE O
contains O O
cis O O
- O O
acting O O
sequences O O
which O O
activate O O
transcription O O
in O O
aleurone O O
and O O
silence O O
transcription O O
in O O
leaves O O
. O O
Spontaneous O O
coronary O O
artery O O
spasm O O
during O O
coronary O O
angiography O O
in O O
a O O
patient O O
with O O
exercise O O
- O O
induced O O
ST O O
segment O O
elevation O O
. O O
Four O O
newborns O O
in O O
this O O
group O O
became O O
HBsAg S-GENE O
carriers O O
. O O
Effectively O O
, O O
the O O
upstream O O
, O O
housekeeping O O
- O O
type O O
promoter O O
responds O O
to O O
FIXK S-GENE S-GENE
and O O
positively O O
regulates O O
the O O
downstream O O
, O O
sigma B-GENE B-GENE
54 I-GENE I-GENE
- I-GENE I-GENE
type I-GENE I-GENE
promoter E-GENE E-GENE
. O O
K O O
. O O
, O O
Weiss O O
, O O
M O O
. O O
New O O
TB O O
respirator O O
standards O O
mean O O
more O O
choices O O
at O O
less O O
cost O O
. O O
Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
using O O
oligonucleotides O O
derived O O
from O O
these O O
sites O O
demonstrated O O
formation O O
of O O
specific O O
DNA O O
- O O
protein O O
complexes O O
. O O
A O O
5789 B-GENE O
- I-GENE O
nucleotide I-GENE O
- I-GENE O
long I-GENE O
EcoRI I-GENE O
fragment E-GENE O
from O O
the O O
genome O O
of O O
Thermotoga O O
maritima O O
, O O
identified O O
by O O
cross O O
- O O
hybridization O O
to O O
L11 S-GENE S-GENE
, O O
L1 S-GENE S-GENE
, O O
L10 S-GENE S-GENE
, O O
and O O
L12 B-GENE B-GENE
ribosomal I-GENE I-GENE
protein I-GENE I-GENE
gene I-GENE E-GENE
sequences I-GENE O
from I-GENE O
Escherichia I-GENE O
coli E-GENE O
, O O
was O O
cloned O O
and O O
sequenced O O
. O O
Background O O
reduction O O
with O O
various O O
agents O O
had O O
a O O
prominent O O
effect O O
on O O
DTIn1 O O
as O O
well O O
as O O
99mTc O O
- O O
DTPA O O
biodistribution O O
. O O
These O O
data O O
suggest O O
that O O
reduction O O
in O O
PRA O O
may O O
have O O
contributed O O
to O O
the O O
hemodynamic O O
effects O O
of O O
this O O
peak B-GENE O
III I-GENE O
PDE E-GENE O
inhibitor O O
. O O
The O O
following O O
parameters O O
were O O
measured O O
: O O
onset O O
time O O
( O O
time O O
interval O O
from O O
injection O O
to O O
maximal O O
or O O
total O O
block O O
) O O
, O O
T125 O O
/ O O
75 O O
( O O
time O O
for O O
T1 O O
to O O
reach O O
25 O O
% O O
or O O
75 O O
% O O
of O O
control O O
) O O
, O O
TOF70 O O
( O O
time O O
for O O
TOF O O
ratio O O
to O O
reach O O
70 O O
% O O
of O O
control O O
) O O
, O O
heart O O
rate O O
and O O
blood O O
pressure O O
. O O
A O O
. O O
Prematurely O O
inactivating O O
p42 B-GENE O
MAPK E-GENE S-GENE
in O O
egg O O
extracts O O
resulted O O
in O O
a O O
corresponding O O
hastening O O
of O O
the O O
first O O
mitosis O O
. O O
The O O
use O O
of O O
ALAD S-GENE S-GENE
activity O O
and O O
EP O O
as O O
cumulative O O
lead O O
exposure O O
indicators O O
is O O
suggested O O
. O O
Binding O O
of O O
C B-GENE O
/ I-GENE O
EBPs E-GENE S-GENE
to O O
all O O
three O O
spi B-GENE O
2 I-GENE O
. I-GENE O
3 I-GENE O
3 I-GENE O
' I-GENE O
UTR I-GENE O
repressor I-GENE O
sites E-GENE O
, O O
although O O
rather O O
weak O O
, O O
was O O
confirmed O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
that O O
otherwise O O
failed O O
to O O
reveal O O
specific O O
interactions O O
with O O
other O O
liver O O
nuclear O O
proteins O O
in O O
vitro O O
. O O
Cell O O
cycle O O
regulatory O O
components O O
have O O
been O O
largely O O
conserved O O
in O O
eukaryotes O O
; O O
however O O
, O O
orthologs O O
of O O
neither O O
CAK1 S-GENE S-GENE
nor O O
csk1 S-GENE S-GENE
have O O
been O O
identified O O
in O O
other O O
species O O
to O O
date O O
. O O
In O O
this O O
study O O
, O O
we O O
cloned O O
the O O
full O O
- O O
length O O
cDNA O O
of O O
mouse O O
PAX4 S-GENE O
by O O
RACE O O
( O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
) O O
using O O
RNA O O
from O O
MIN6 O O
cells O O
, O O
a O O
mouse O O
insulinoma O O
cell O O
line O O
. O O
Kohtz O O
, O O
J O O
. O O
Hence O O
the O O
GAP1 B-GENE B-GENE
gene E-GENE E-GENE
encodes O O
a O O
protein O O
with O O
characteristics O O
typical O O
of O O
integral O O
membrane O O
proteins O O
translocating O O
ligants O O
across O O
cellular O O
membranes O O
. O O
The O O
results O O
suggest O O
that O O
proenzyme O O
processing O O
is O O
not O O
essential O O
for O O
secretion O O
of O O
PC2 S-GENE S-GENE
, O O
but O O
peptides O O
containing O O
mutations O O
that O O
affect O O
the O O
ability O O
of O O
the O O
propeptide O O
( O O
and O O
cleavage O O
sites O O
) O O
to O O
fold O O
within O O
the O O
catalytic O O
pocket O O
are O O
not O O
transferred O O
beyond O O
the O O
early O O
stages O O
of O O
the O O
secretory O O
pathway O O
. O O
These O O
results O O
suggest O O
that O O
transcription O O
influences O O
aspects O O
of O O
gene O O
conversion O O
after O O
initiation O O
, O O
such O O
as O O
strand O O
invasion O O
and O O
/ O O
or O O
mismatch O O
repair O O
( O O
MMR O O
) O O
. O O
Important O O
prognostic O O
factors O O
for O O
the O O
results O O
of O O
physiotherapeutic O O
exercises O O
in O O
intermittent O O
claudication O O
Finally O O
, O O
in O O
samples O O
obtained O O
from O O
two O O
patients O O
with O O
drug O O
refractory O O
ALL O O
, O O
BAC O O
- O O
derived O O
probes O O
applied O O
to O O
archived O O
marrow O O
cells O O
demonstrated O O
that O O
a O O
breakpoint O O
occurred O O
between O O
MDR1 S-GENE O
and O O
sequences O O
500 O O
- O O
1000 O O
KB O O
telomeric O O
to O O
MDR1 S-GENE O
, O O
consistent O O
with O O
a O O
random O O
chromosomal O O
rearrangement O O
. O O
Application O O
of O O
the O O
method O O
using O O
an O O
11 O O
- O O
year O O
microseismicity O O
record O O
revealed O O
systematic O O
spatial O O
and O O
temporal O O
changes O O
in O O
the O O
slip O O
rate O O
that O O
were O O
synchronous O O
with O O
earthquake O O
activity O O
and O O
other O O
independent O O
measures O O
of O O
fault O O
- O O
zone O O
slip O O
. O O
PC12 O S-GENE
cultures O O
that O O
had O O
been O O
" O O
primed O O
" O O
in O O
this O O
way O O
showed O O
an O O
accelerated O O
and O O
augmented O O
differentiation O O
response O O
to O O
nerve B-GENE O
growth I-GENE O
factor E-GENE O
. O O
One O O
of O O
these O O
clones O O
encodes O O
Xenopus B-GENE B-GENE
N I-GENE I-GENE
- I-GENE I-GENE
ras E-GENE E-GENE
. O O
The O O
Molteno O O
implant O O
is O O
an O O
effective O O
procedure O O
in O O
the O O
treatment O O
of O O
complicated O O
and O O
refractory O O
cases O O
of O O
glaucoma O O
in O O
high O O
- O O
risk O O
eyes O O
. O O
The O O
median O O
levels O O
of O O
t B-GENE O
- I-GENE O
PA I-GENE O
Ag E-GENE O
and O O
PAI S-GENE O
in O O
plasma O O
were O O
respectively O O
10 O O
. O O
7 O O
ng O O
/ O O
ml O O
( O O
interquartile O O
range O O
8 O O
. O O
6 O O
ng O O
/ O O
ml O O
) O O
and O O
15 O O
. O O
7 O O
IU O O
/ O O
ml O O
( O O
interquartile O O
range O O
12 O O
. O O
2 O O
IU O O
/ O O
ml O O
) O O
. O O
In O O
the O O
remaining O O
91 O O
patients O O
( O O
group O O
2 O O
) O O
, O O
Pseudomonas O O
( O O
18 O O
) O O
, O O
coagulase S-GENE O
- O O
negative O O
Staphylococci O O
( O O
15 O O
) O O
, O O
Staphylococcus O O
epidermidis O O
( O O
23 O O
) O O
, O O
Staphylococcus O O
aureus O O
( O O
16 O O
) O O
, O O
Corynebacterium O O
species O O
( O O
12 O O
) O O
, O O
and O O
others O O
( O O
seven O O
) O O
were O O
isolated O O
. O O
Stamps O O
in O O
cardiology O O
: O O
de O O
Musset O O
sign O O
. O O
A O O
factor O O
present O O
in O O
nuclear O O
extracts O O
of O O
wounded O O
potato O O
tubers O O
was O O
found O O
to O O
bind O O
specifically O O
to O O
nucleotides O O
located O O
between O O
- O O
135 O O
to O O
- O O
105 O O
, O O
suggesting O O
that O O
this O O
region O O
contains O O
important O O
cis O O
- O O
regulatory O O
elements O O
. O O
The O O
leucine O O
zipper O O
region O O
of O O
ATF B-GENE B-GENE
proteins E-GENE E-GENE
is O O
also O O
similar O O
to O O
that O O
of O O
the O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
/ O O
c B-GENE B-GENE
- I-GENE I-GENE
jun E-GENE I-GENE
family O E-GENE
of O O
transcription O O
factors O O
, O O
whose O O
DNA O O
- O O
binding O O
site O O
differs O O
from O O
the O O
ATF S-GENE O
- O O
binding O O
site O O
at O O
a O O
single O O
position O O
. O O
The O O
R260A O B-GENE
mutant O E-GENE
, O O
as O O
expected O O
, O O
was O O
unable O O
to O O
support O O
mRNA O O
synthesis O O
in O O
vitro O O
in O O
a O O
transcription O O
reconstitution O O
reaction O O
as O O
well O O
as O O
transcription O O
in O O
vivo O O
of O O
a O O
minigenome O O
using O O
a O O
reverse O O
genetic O O
approach O O
. O O
PEAP O O
was O O
significantly O O
higher O O
in O O
IDC O O
patients O O
compared O O
to O O
controls O O
( O O
48 O O
. O O
7 O O
+ O O
/ O O
- O O
32 O O
. O O
6 O O
vs O O
. O O
Uterine O O
contractions O O
began O O
with O O
a O O
mean O O
latency O O
of O O
62 O O
min O O
in O O
the O O
PGF2 O B-GENE
alpha O E-GENE
infused O O
women O O
, O O
in O O
controls O O
uterine O O
activity O O
remained O O
unchanged O O
. O O
Were O O
this O O
hypothesis O O
correct O O
, O O
the O O
requirement O O
for O O
elF4A S-GENE S-GENE
should O O
correlate O O
with O O
the O O
degree O O
of O O
mRNA O O
secondary O O
structure O O
. O O
In O O
spite O O
of O O
the O O
presence O O
of O O
a O O
physician O O
, O O
the O O
real O O
pathology O O
of O O
an O O
indian O O
population O O
of O O
Colombie O O
is O O
not O O
very O O
well O O
known O O
. O O
Taken O O
together O O
, O O
these O O
results O O
demonstrate O O
that O O
the O O
BSMV B-GENE B-GENE
coat I-GENE I-GENE
protein E-GENE E-GENE
is O O
the O O
sole O O
translation O O
product O O
of O O
the O O
genomic B-GENE O
RNA I-GENE O
beta E-GENE O
, O O
whereas O O
sgRNA B-GENE B-GENE
beta I-GENE I-GENE
1 E-GENE E-GENE
serves O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
the O O
beta B-GENE B-GENE
b I-GENE I-GENE
protein E-GENE E-GENE
, O O
and O O
sgRNA B-GENE B-GENE
beta I-GENE I-GENE
2 E-GENE E-GENE
functions O O
as O O
a O O
messenger O O
for O O
translation O O
of O O
beta B-GENE B-GENE
c E-GENE E-GENE
and O O
beta B-GENE O
d E-GENE O
and O O
the O O
newly O O
discovered O O
beta B-GENE B-GENE
d I-GENE I-GENE
' I-GENE I-GENE
protein E-GENE E-GENE
. O O
A O O
retrospective O O
study O O
of O O
clozapine O O
and O O
electroencephalographic O O
abnormalities O O
in O O
schizophrenic O O
patients O O
. O O
The O O
concepts O O
were O O
developed O O
by O O
Mines O O
and O O
Garrey O O
during O O
the O O
next O O
10 O O
years O O
. O O
When O O
the O O
measured O O
beta B-GENE O
- I-GENE O
galactosidase E-GENE O
activity O O
in O O
the O O
pWP O O
- O O
transfected O O
cells O O
was O O
normalized O O
to O O
the O O
pCH110 O O
- O O
transfected O O
cells O O
( O O
an O O
appropriate O O
control O O
if O O
the O O
SV40 B-GENE O
early I-GENE O
region I-GENE O
promoter E-GENE O
functions O O
constitutively O O
in O O
various O O
cell O O
lines O O
) O O
, O O
the O O
results O O
suggested O O
that O O
the O O
promoter O O
region O O
of O O
the O O
PLP B-GENE B-GENE
gene E-GENE E-GENE
contains O O
the O O
information O O
necessary O O
for O O
initiation O O
of O O
transcription O O
in O O
a O O
C6 O O
cell O O
- O O
specific O O
manner O O
. O O
PKK S-GENE O
exists O O
in O O
three O O
discernible O O
forms O O
at O O
steady O O
state O O
: O O
an O O
underphosphorylated O O
form O O
of O O
100 O O
kDa O O
; O O
a O O
soluble O O
, O O
cytosolic O O
, O O
phosphorylated O O
form O O
of O O
110 O O
kDa O O
; O O
and O O
a O O
phosphorylated O O
, O O
detergent O O
- O O
insoluble O O
form O O
of O O
112 O O
kDa O O
. O O
The O O
P B-GENE O
- I-GENE O
ITIM I-GENE O
- I-GENE O
compelled I-GENE O
multi I-GENE O
- I-GENE O
phosphoprotein I-GENE O
complex E-GENE O
binds O O
to O O
and O O
activates O O
SHP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
which O O
in O O
turn O O
dephosphorylates O O
SHIP S-GENE O
and O O
Shc S-GENE O
and O O
probably O O
other O O
substrates O O
. O O
When O O
PCR O O
was O O
used O O
to O O
amplify O O
agar O O
cultures O O
which O O
do O O
not O O
express O O
the O O
fimbriae O O
, O O
the O O
switch O O
region O O
was O O
OFF O O
only O O
. O O
Mechanisms O O
of O O
action O O
of O O
local O O
anaesthetics O O
. O O
Student O O
health O O
We O O
now O O
report O O
that O O
both O O
HSCR S-GENE S-GENE
mutations O O
impair O O
the O O
fixation O O
of O O
Shc S-GENE S-GENE
to O O
RET S-GENE S-GENE
and O O
consequently O O
prevent O O
its O O
phosphorylation O O
. O O
The O O
only O O
quantities O O
which O O
were O O
significantly O O
different O O
between O O
appendicitis O O
and O O
a O O
normal O O
appendix O O
were O O
sex O O
, O O
duration O O
of O O
symptoms O O
, O O
anorexia O O
and O O
vomiting O O
. O O
We O O
propose O O
that O O
U73 S-GENE S-GENE
is O O
involved O O
in O O
methylation O O
of O O
the O O
G1739 O S-GENE
residue O O
of O O
the O O
human B-GENE B-GENE
28S I-GENE I-GENE
rRNA E-GENE E-GENE
. O O
At O O
the O O
start O O
of O O
the O O
performance O O
ride O O
, O O
plasma O O
glucose O O
averaged O O
4 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
, O O
5 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
, O O
and O O
5 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
mmol O O
. O O
l O O
- O O
1 O O
in O O
CON O O
, O O
CHO O O
- O O
7 O O
, O O
and O O
CHO O O
- O O
0 O O
/ O O
21 O O
, O O
respectively O O
( O O
all O O
different O O
, O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O
Therefore O O
prostaglandin O O
E2 O O
is O O
characterized O O
in O O
relation O O
to O O
prostaglandin O B-GENE
F2 O I-GENE
- O I-GENE
alpha O E-GENE
not O O
only O O
by O O
a O O
stronger O O
uterine O O
effectiveness O O
, O O
but O O
also O O
at O O
the O O
same O O
time O O
a O O
pronounced O O
influence O O
on O O
the O O
cardiovascular O O
system O O
. O O
Copyright O O
1999 O O
Academic O O
Press O O
. O O
Ganglia O O
are O O
cysts O O
which O O
frequently O O
occur O O
in O O
the O O
proximity O O
of O O
joints O O
. O O
Lysates O O
of O O
COS O O
cells O O
transfected O O
with O O
modified B-GENE O
hGrzB I-GENE B-GENE
cDNA E-GENE E-GENE
were O O
able O O
to O O
hydrolyze O O
tert O O
- O O
butyloxycarbonyl O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
thiobenzyl O O
ester O O
( O O
Boc O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
SBzl O O
) O O
, O O
whereas O O
lysates O O
transfected O O
with O O
unmodified B-GENE O
hGrzB I-GENE O
cDNA E-GENE O
were O O
inactive O O
. O O
Proteins O B-GENE
PBP B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
PBP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
bind O O
to O O
two O O
of O O
the O O
three O O
promoter O O
elements O O
in O O
the O O
trypanosomatid O O
Leptomonas O O
seymouri O O
. O O
Expression O O
of O O
medical O O
efficiency O O
by O O
integration O O
indicators O O
with O O
the O O
rational O O
utilization O O
of O O
budgeted O O
funds O O
The O O
present O O
study O O
tries O O
to O O
associate O O
some O O
of O O
the O O
causes O O
of O O
hot O O
ischaemia O O
during O O
the O O
agony O O
of O O
the O O
corpse O O
donor O O
and O O
to O O
evaluate O O
those O O
that O O
may O O
be O O
caused O O
by O O
sympathetic O O
efference O O
during O O
removal O O
. O O
The O O
enzyme O O
encoded O O
by O O
the O O
cloned O O
fragment O O
is O O
equally O O
active O O
on O O
pyruvate O O
and O O
hydroxypyruvate O O
, O O
indicating O O
that O O
the O O
enzyme O O
has O O
both O O
D B-GENE O
- I-GENE O
lactate I-GENE O
and I-GENE O
D I-GENE B-GENE
- I-GENE I-GENE
glycerate I-GENE I-GENE
dehydrogenase E-GENE E-GENE
activities O O
. O O
Noise O O
in O O
STM O O
due O O
to O O
atoms O O
moving O O
in O O
the O O
tunneling O O
space O O
. O O
The O O
human O O
sequence O O
contains O O
the O O
element O O
TGACTCT O S-GENE
that O O
also O O
is O O
found O O
in O O
a O O
murine B-GENE O
ras I-GENE O
- I-GENE O
responsive I-GENE O
enhancer E-GENE O
. O O
There O O
is O O
an O O
overall O O
functional O O
similarity O O
between O O
IL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
and O O
c B-GENE O
- I-GENE O
fos I-GENE O
promoters E-GENE O
, O O
since O O
transfection O O
of O O
excess O O
amounts O O
of O O
either O O
promoter O O
DNA O O
into O O
intact O O
HeLa O O
cells O O
modulates O O
the O O
function O O
of O O
the O O
heterologous O O
promoter O O
construct O O
. O O
Enhanced O O
phospholipid O O
hydrolysis O O
with O O
free O O
fatty O O
acid O O
and O O
thromboxane O O
accumulation O O
, O O
increased O O
release O O
of O O
excitatory O O
amino O O
acids O O
, O O
and O O
decreased O O
tissue O O
magnesium O O
levels O O
may O O
each O O
serve O O
to O O
worsen O O
secondary O O
tissue O O
damage O O
and O O
diminish O O
neurologic O O
recovery O O
after O O
spinal O O
cord O O
injury O O
associated O O
with O O
acute O O
alcohol O O
intoxication O O
. O O
To O O
determine O O
whether O O
the O O
transcript O O
encodes O O
an O O
active O O
enzyme O O
, O O
we O O
developed O O
a O O
novel O O
transient O O
embryonic O O
excision O O
assay O O
in O O
which O O
zebrafish O O
fertilized O O
eggs O O
were O O
co O O
- O O
injected O O
with O O
RNA O O
transcribed O O
in O O
vitro O O
using O O
the O O
Tol2 B-GENE B-GENE
cDNA E-GENE E-GENE
as O O
a O O
template O O
and O O
a O O
plasmid O O
DNA O O
harboring O O
a O O
nonautonomous O O
Tol2 B-GENE O
element E-GENE O
, O O
which O O
has O O
a O O
deletion O O
in O O
the O O
transposase B-GENE O
coding I-GENE O
region E-GENE O
. O O
The O O
overall O O
objective O O
response O O
rate O O
( O O
RR O O
) O O
was O O
50 O O
% O O
[ O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
= O O
29 O O
- O O
71 O O
% O O
] O O
including O O
four O O
complete O O
responses O O
and O O
eight O O
partial O O
responses O O
. O O
We O O
suggest O O
that O O
this O O
relatively O O
small O O
deletion O O
affects O O
a O O
segment O O
containing O O
3 B-GENE O
' I-GENE O
VH I-GENE O
genes E-GENE O
with O O
important O O
regulatory O O
functions O O
, O O
the O O
loss O O
of O O
which O O
leads O O
to O O
the O O
ali O O
phenotype O O
. O O
Two O O
SH2 B-GENE S-GENE
domains E-GENE O
of O O
p120 S-GENE B-GENE
Ras S-GENE I-GENE
GTPase B-GENE E-GENE
- I-GENE O
activating I-GENE O
protein E-GENE O
bind O O
synergistically O O
to O O
tyrosine O O
phosphorylated O O
p190 S-GENE B-GENE
Rho O I-GENE
GTPase B-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
. O O
p120 S-GENE B-GENE
GTPase B-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
( O O
GAP S-GENE S-GENE
) O O
is O O
a O O
negative O O
regulator O O
of O O
Ras S-GENE S-GENE
that O O
functions O O
at O O
a O O
key O O
relay O O
point O O
in O O
signal O O
transduction O O
pathways O O
that O O
control O O
cell O O
proliferation O O
. O O
A O O
homologue O O
of O O
the O O
MAP S-GENE S-GENE
/ O O
ERK S-GENE S-GENE
family O O
of O O
protein O B-GENE
kinase O I-GENE
genes O E-GENE
is O O
expressed O O
in O O
vegetative O O
and O O
in O O
female O O
reproductive O O
organs O O
of O O
Petunia O O
hybrida O O
. O O
Its O O
prognostic O O
impact O O
is O O
superior O O
to O O
the O O
T1 O O
/ O O
2 O O
one O O
( O O
RR O O
= O O
2 O O
. O O
9 O O
; O O
p O O
= O O
0 O O
. O O
0010 O O
) O O
. O O
It O O
encodes O O
a O O
sequence O O
- O O
specific O O
transcription O O
factor O O
that O O
controls O O
, O O
in O O
concert O O
with O O
other O O
gene O O
products O O
, O O
differentiative O O
pathways O O
of O O
tissues O O
in O O
which O O
Scr S-GENE O
is O O
expressed O O
. O O
CONCLUSION O O
: O O
DMIPP O O
detects O O
regionally O O
hypoperfused O O
myocardium O O
, O O
in O O
which O O
agreement O O
between O O
MBF O S-GENE
and O O
fatty O O
acid O O
uptake O O
deteriorates O O
. O O
The O O
effect O O
of O O
guaiphenesin O O
on O O
absorption O O
and O O
bioavailability O O
of O O
paracetamol O O
from O O
composite O O
analgesic O O
preparations O O
. O O
Transcription O O
of O O
the O O
inserted O O
gene O O
into O O
the O O
predicted O O
subgenomic O B-GENE
polyadenylated O I-GENE
mRNA O E-GENE
was O O
demonstrated O O
by O O
Northern O O
( O O
RNA O O
) O O
blot O O
hybridization O O
analysis O O
, O O
and O O
the O O
encoded O O
protein O O
was O O
detected O O
by O O
enzyme O O
assay O O
and O O
by O O
radioimmunoprecipitation O O
. O O
These O O
results O O
suggest O O
that O O
panretinal O O
photocoagulation O O
offers O O
a O O
highly O O
effective O O
means O O
of O O
dealing O O
with O O
early O O
and O O
moderately O O
advanced O O
cases O O
of O O
angle O O
neovascularization O O
. O O
NBSII O S-GENE
is O O
essential O O
for O O
ribosome O O
- O O
stimulated O O
activity O O
. O O
Sixteen O O
patients O O
( O O
25 O O
. O O
4 O O
% O O
) O O
encountered O O
rejection O O
while O O
weaning O O
at O O
median O O
period O O
of O O
9 O O
. O O
5 O O
months O O
( O O
range O O
, O O
1 O O
- O O
63 O O
months O O
) O O
from O O
the O O
start O O
of O O
weaning O O
. O O
ALT S-GENE S-GENE
( O O
alanine B-GENE O
aminotransferase E-GENE O
) O O
and O O
Hb S-GENE O
( O O
hemoglobin S-GENE O
) O O
appeared O O
to O O
be O O
predictive O O
for O O
efficacy O O
. O O
Theophylline O O
QID O O
, O O
TID O O
, O O
BID O O
and O O
now O O
QD O O
? O O
A O O
report O O
on O O
24 O O
- O O
hour O O
dosing O O
with O O
slow O O
- O O
release O O
theophylline O O
formulations O O
with O O
emphasis O O
on O O
analyses O O
of O O
data O O
used O O
to O O
obtain O O
Food O O
and O O
Drug O O
Administration O O
approval O O
for O O
Theo O O
- O O
24 O O
. O O
Signal O O
transduction O O
in O O
fibroblasts O O
stably O O
transformed O O
by O O
[ O O
Val12 O S-GENE
] O O
Ras O O
- O O
- O O
the O O
activities O O
of O O
extracellular B-GENE O
- I-GENE O
signal I-GENE O
- I-GENE O
regulated I-GENE O
kinase E-GENE O
and O O
Jun B-GENE B-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
are O O
only O O
moderately O O
increased O O
, O O
and O O
the O O
activity O O
of O O
the O O
delta O O
- O O
inhibitor O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
is O O
not O O
alleviated O O
. O O
Time O O
for O O
action O O
on O O
hepatitis O O
B O O
immunisation O O
. O O
Escherichia O O
coli O O
cells O O
expressing O O
a O O
mutant B-GENE O
glyV E-GENE S-GENE
( O O
glycine B-GENE B-GENE
tRNA E-GENE E-GENE
) O O
gene O O
have O O
a O O
UVM O O
- O O
constitutive O O
phenotype O O
: O O
implications O O
for O O
mechanisms O O
underlying O O
the O O
mutA S-GENE O
or O O
mutC B-GENE O
mutator E-GENE O
effect O O
. O O
By O O
24 O O
h O O
, O O
there O O
was O O
no O O
significant O O
difference O O
in O O
FFA O O
levels O O
from O O
shams O O
. O O
This O O
result O O
suggests O O
that O O
the O O
target O O
protein O O
specificity O O
of O O
E2s S-GENE S-GENE
can O O
be O O
altered O O
by O O
the O O
addition O O
of O O
appropriate O O
C O O
- O O
terminal O O
extensions O O
, O O
thus O O
providing O O
a O O
way O O
to O O
modify O O
the O O
selectivity O O
of O O
the O O
ubiquitin S-GENE O
system O O
. O O
Here O O
we O O
report O O
the O O
cloning O O
of O O
the O O
hemF B-GENE B-GENE
gene E-GENE E-GENE
, O O
encoding O O
the O O
aerobic O B-GENE
coproporphyrinogen B-GENE I-GENE
III I-GENE I-GENE
oxidase I-GENE E-GENE
from I-GENE O
Escherichia I-GENE O
coli E-GENE O
, O O
by O O
functional O O
complementation O O
of O O
a O O
Saccharomyces B-GENE O
cerevisiae I-GENE O
HEM13 I-GENE B-GENE
mutant E-GENE E-GENE
. O O
This O O
study O O
was O O
undertaken O O
to O O
evaluate O O
the O O
physical O O
and O O
biological O O
characteristics O O
of O O
nebulized O B-GENE
interleukin B-GENE I-GENE
2 E-GENE E-GENE
liposomes O O
. O O
The O O
atopic O O
disposition O O
, O O
indicated O O
by O O
positive O O
skin O O
reactions O O
and O O
IgE S-GENE S-GENE
antibody O O
titers O O
etc O O
. O O
, O O
and O O
the O O
bronchial O O
reactivity O O
to O O
inhaled O O
acetylcholine O O
were O O
examined O O
on O O
the O O
following O O
three O O
groups O O
: O O
( O O
1 O O
) O O
20 O O
young O O
adults O O
with O O
a O O
history O O
of O O
childhood O O
asthma O O
who O O
have O O
been O O
symptom O O
- O O
free O O
for O O
more O O
than O O
4 O O
yr O O
; O O
( O O
2 O O
) O O
20 O O
current O O
asthmatics O O
, O O
and O O
( O O
3 O O
) O O
20 O O
healthy O O
young O O
adults O O
. O O
Previous O O
studies O O
showed O O
that O O
a O O
palindromic O O
sequence O O
located O O
at O O
- O O
159 O O
base O O
pairs O O
is O O
essential O O
for O O
induction O O
of O O
cutinase B-GENE B-GENE
gene E-GENE E-GENE
in O O
Fusarium O O
solani O O
f O O
. O O
sp O O
. O O
pisi O O
( O O
Nectria O O
haematococca O O
mating O O
type O O
VI O O
) O O
by O O
the O O
hydroxy O O
fatty O O
acids O O
from O O
plant O O
cutin O O
and O O
that O O
a O O
50 O O
- O O
kDa O O
nuclear O O
protein O O
binds O O
to O O
a O O
promoter O O
that O O
contains O O
this O O
element O O
. O O
This O O
preliminary O O
study O O
reports O O
an O O
initial O O
evaluation O O
of O O
HMPAO O O
- O O
SPECT O O
imaging O O
for O O
assessing O O
regional O O
alterations O O
in O O
brain O O
function O O
during O O
opiate O O
dependence O O
and O O
withdrawal O O
. O O
We O O
conclude O O
that O O
these O O
cDNAs O S-GENE
belong O O
to O O
a O O
novel O O
GST S-GENE S-GENE
class O O
hereby O O
designated O O
Kappa O S-GENE
, O O
with O O
the O O
rat B-GENE B-GENE
GST I-GENE I-GENE
subunit I-GENE I-GENE
13 I-GENE I-GENE
gene E-GENE E-GENE
designated O O
rGSTK1 S-GENE S-GENE
and O O
the O O
human O B-GENE
gene O E-GENE
being O O
called O O
hGSTK1 S-GENE S-GENE
. O O
Based O O
on O O
PCR O O
strategies O O
and O O
expression O O
studies O O
, O O
we O O
define O O
the O O
genomic O O
organization O O
of O O
the O O
FUT8b B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
present O O
study O O
demonstrates O O
that O O
the O O
proto B-GENE B-GENE
- I-GENE I-GENE
oncogene I-GENE I-GENE
c I-GENE I-GENE
- I-GENE I-GENE
jun E-GENE E-GENE
represses O O
transcription O O
of O O
the O O
human B-GENE B-GENE
CG I-GENE I-GENE
alpha E-GENE E-GENE
and O O
CG B-GENE B-GENE
beta I-GENE E-GENE
promoters E-GENE O
. O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
repressed O O
the O O
CG B-GENE B-GENE
alpha I-GENE I-GENE
promoter E-GENE E-GENE
through O O
a O O
canonical O O
cAMP O O
response O O
element O O
( O O
CRE O S-GENE
) O O
that O O
is O O
known O O
to O O
bind O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
and O O
other O O
members O O
of O O
the O O
B B-GENE B-GENE
- I-GENE I-GENE
Zip I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
family E-GENE E-GENE
. O O
Pulse O O
monitors O O
in O O
outpatient O O
dental O O
anaesthesia O O
. O O
Previous O O
studies O O
using O O
partial O O
sequences O O
have O O
suggested O O
the O O
potential O O
of O O
26S S-GENE S-GENE
or O O
large B-GENE O
- I-GENE O
subunit E-GENE O
( O O
LSU S-GENE O
) O O
rDNA O O
for O O
phylogeny O O
retrieval O O
at O O
taxonomic O O
levels O O
comparable O O
to O O
those O O
investigated O O
with O O
18S B-GENE B-GENE
rDNA E-GENE E-GENE
. O O
The O O
sensitivity O O
of O O
99mTc O O
- O O
IgG S-GENE O
scintigraphy O O
ranged O O
between O O
71 O O
% O O
and O O
100 O O
% O O
. O O
The O O
index O O
patient O O
, O O
a O O
10 O O
- O O
year O O
- O O
old O O
boy O O
, O O
presents O O
typical O O
symptoms O O
of O O
OPD O O
type O O
I O O
together O O
with O O
bowing O O
of O O
the O O
long O O
bones O O
and O O
abnormalities O O
of O O
the O O
thorax O O
and O O
spinal O O
column O O
. O O
The O O
cause O O
for O O
the O O
increase O O
in O O
plasma B-GENE O
ANP E-GENE O
levels O O
in O O
the O O
active O O
phase O O
remains O O
to O O
be O O
determined O O
. O O
A O O
genomic O O
clone O O
representing O O
the O O
5 O O
' O O
part O O
of O O
the O O
message O O
was O O
also O O
isolated O O
. O O
Antibiotics O O
and O O
CDCA O O
- O O
mediation O O
are O O
essential O O
for O O
symptomatic O O
therapy O O
. O O
The O O
main O O
side O O
- O O
effects O O
were O O
myelosuppression O O
, O O
mucositis O O
and O O
peripheral O O
neuropathy O O
, O O
which O O
were O O
all O O
common O O
and O O
often O O
severe O O
. O O
The O O
column O O
densities O O
of O O
frozen O O
molecular O O
hydrogen O O
and O O
methanol O O
are O O
inferred O O
to O O
be O O
about O O
2 O O
. O O
5 O O
x O O
10 O O
( O O
18 O O
) O O
and O O
3 O O
. O O
0 O O
x O O
10 O O
( O O
19 O O
) O O
, O O
respectively O O
. O O
Similarly O O
, O O
an O O
increase O O
in O O
CAT S-GENE O
expression O O
from O O
the O O
same O O
construct O O
( O O
pBLCAT O O
- O O
ENDOA S-GENE O
) O O
was O O
also O O
observed O O
in O O
7AQS2 O O
. O O
1 O O
cells O O
. O O
The O O
prevalence O O
of O O
antibodies O O
to O O
HRES B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
peptides I-GENE O
pep14 I-GENE O
- I-GENE O
24 I-GENE O
and I-GENE O
pep117 I-GENE O
- I-GENE O
127 E-GENE O
was O O
determined O O
in O O
65 O O
normal O O
blood O O
donors O O
and O O
146 O O
patients O O
with O O
immunological O O
disorders O O
. O O
We O O
recently O O
reported O O
the O O
cloning O O
and O O
sequencing O O
of O O
the O O
alpha B-GENE O
7 I-GENE O
integrin I-GENE O
chain E-GENE O
and O O
its O O
regulated O O
expression O O
during O O
the O O
development O O
of O O
skeletal O O
muscle O O
( O O
Song O O
et O O
al O O
. O O
The O O
contractile O O
effects O O
of O O
oxytocin S-GENE O
, O O
prostaglandin O B-GENE
F2 O I-GENE
alpha O E-GENE
and O O
their O O
combined O O
use O O
on O O
human O O
pregnant O O
myometrium O O
were O O
studied O O
in O O
vitro O O
. O O
These O O
involve O O
( O O
1 O O
) O O
subcloning O O
a O O
promoterless O O
sucCD B-GENE O
fragment E-GENE O
downstream O O
of O O
the O O
lac B-GENE B-GENE
promoter E-GENE E-GENE
in O O
M13mp10 O S-GENE
, O O
and O O
( O O
2 O O
) O O
precise O O
splicing O O
of O O
the O O
suc B-GENE O
coding I-GENE O
regions E-GENE O
with O O
the O O
efficient O O
atpE B-GENE O
ribosome I-GENE O
- I-GENE O
binding I-GENE O
site E-GENE O
and O O
expression O O
from O O
the O O
thermoinducible O O
lambda O O
promoters O O
in O O
the O O
pJLA503 O B-GENE
vector O E-GENE
. O O
These O O
mutations O O
prevent O O
FKBP12 S-GENE S-GENE
- O O
rapamycin O O
binding O O
to O O
TOR2 S-GENE S-GENE
, O O
as O O
assayed O O
with O O
the O O
two O O
- O O
hybrid O O
system O O
. O O
Transcription O O
of O O
eukaryotic O B-GENE
tRNA O I-GENE
genes O E-GENE
is O O
dependent O O
on O O
the O O
A O O
- O O
and O O
B O O
- O O
Box O O
internal O O
control O O
regions O O
( O O
ICRs O S-GENE
) O O
and O O
the O O
upstream O O
transcription O O
modulatory O O
region O O
. O O
Failure O O
to O O
demonstrate O O
a O O
major O O
anti O O
- O O
inflammatory O O
effect O O
with O O
alpha O O
tocopherol O O
supplementation O O
( O O
400 O O
IU O O
/ O O
day O O
) O O
in O O
normal O O
subjects O O
. O O
Results O O
on O O
the O O
use O O
of O O
amiodarone O O
in O O
the O O
prevention O O
of O O
paroxysmal O O
AF O O
have O O
been O O
equivocal O O
; O O
this O O
may O O
be O O
attributed O O
to O O
differences O O
in O O
defining O O
paroxysmal O O
AF O O
. O O
High O O
- O O
level O O
expression O O
of O O
sccypB S-GENE O
as O O
well O O
as O O
of O O
sccypA S-GENE O
cloned O O
into O O
the O O
expression O O
vector O O
pIJ702 O S-GENE
did O O
not O O
produce O O
detectable O O
changes O O
in O O
growth O O
and O O
morphology O O
of O O
S O O
. O O
chrysomallus O O
and O O
S O O
. O O
lividans O O
. O O
Fas S-GENE S-GENE
( O O
APO B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
/ O O
CD95 S-GENE S-GENE
) O O
, O O
which O O
is O O
a O O
member O O
of O O
the O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
superfamily E-GENE E-GENE
, O O
is O O
a O O
cell O O
surface O O
receptor O O
that O O
induces O O
apoptosis O O
. O O
In O O
the O O
future O O
, O O
transoesophageal O O
echocardiography O O
may O O
be O O
used O O
to O O
measure O O
variations O O
in O O
wall O O
thickness O O
which O O
change O O
the O O
global O O
loading O O
conditions O O
in O O
the O O
basal O O
midwall O O
compartments O O
of O O
the O O
left O O
ventricle O O
. O O
We O O
studied O O
18 O O
dogs O O
, O O
anaesthetised O O
and O O
spontaneously O O
breathing O O
both O O
room O O
air O O
and O O
after O O
the O O
inhalation O O
of O O
a O O
gas O O
mixture O O
containing O O
10 O O
% O O
CO2 O O
, O O
20 O O
. O O
9 O O
% O O
O2 O O
, O O
and O O
69 O O
. O O
1 O O
% O O
N2 O O
, O O
to O O
determine O O
the O O
role O O
of O O
histamine O O
, O O
serotonin O O
, O O
and O O
acidaemia O O
in O O
pulmonary O O
hypertension O O
produced O O
by O O
hypercapnia O O
. O O
Sequencing O O
of O O
this O O
fragment O O
showed O O
that O O
the O O
MRP13 S-GENE S-GENE
coding O O
region O O
specifies O O
a O O
324 O O
- O O
amino O O
- O O
acid O O
basic O O
protein O O
with O O
a O O
calculated O O
Mr O O
of O O
37 O O
, O O
366 O O
. O O
Viral O O
complementary O O
15 B-GENE O
S I-GENE O
mRNA E-GENE O
that O O
directs O O
the O O
synthesis O O
of O O
N B-GENE O
protein E-GENE O
and O O
hybridizes O O
to O O
the O O
predicted O O
N B-GENE O
gene E-GENE O
DNA O O
has O O
been O O
identified O O
in O O
infected O O
cell O O
extracts O O
. O O
Electrophoretic O O
mobility O O
shift O O
assays O O
and O O
DNase B-GENE B-GENE
I E-GENE E-GENE
protection O O
analyses O O
revealed O O
that O O
FP B-GENE B-GENE
I E-GENE E-GENE
was O O
bound O O
by O O
the O O
transcription O B-GENE
factor O I-GENE
PU B-GENE I-GENE
. I-GENE I-GENE
1 E-GENE I-GENE
/ O I-GENE
Spi B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
Retroviral O O
vector O O
producer O O
cell O O
populations O O
and O O
cell O O
clones O O
were O O
established O O
for O O
each O O
chLTR S-GENE O
vector O O
, O O
and O O
all O O
were O O
capable O O
of O O
yielding O O
high O O
vector O O
titers O O
( O O
> O O
10 O O
( O O
5 O O
) O O
G418R S-GENE O
cfu O O
/ O O
ml O O
on O O
NIH O O
- O O
3T3 O O
) O O
. O O
However O O
, O O
a O O
few O O
sites O O
in O O
the O O
genomes O O
of O O
EC O O
cells O O
permit O O
M B-GENE O
- I-GENE O
MuLVneo I-GENE O
delta I-GENE O
Enh E-GENE O
proviral O O
expression O O
. O O
Increasing O O
insulin S-GENE O
sensitivity O O
in O O
type O O
I O O
diabetic O O
patients O O
should O O
alert O O
clinicians O O
to O O
the O O
possibility O O
of O O
glucocorticoid O O
deficiency O O
. O O
However O O
, O O
differential O O
utilization O O
of O O
these O O
determinants O O
mediate O O
RAR S-GENE B-GENE
- O I-GENE
RXR S-GENE I-GENE
heterodimer O E-GENE
binding O O
to O O
DR O B-GENE
- O I-GENE
2 O E-GENE
and O O
DR O O
- O O
5 O O
RAREs O O
. O O
Galactorrhoea O O
is O O
a O O
rare O O
presentation O O
of O O
an O O
empty O O
sella O O
syndrome O O
. O O
The O O
addition O O
of O O
novel O O
techniques O O
, O O
such O O
as O O
histopathologic O O
ultrastaging O O
, O O
immunohistochemistry O O
staining O O
, O O
and O O
reverse B-GENE O
transcriptase E-GENE O
polymerase O O
chain O O
reaction O O
assays O O
, O O
will O O
help O O
increase O O
the O O
accuracy O O
and O O
rate O O
of O O
detection O O
of O O
disease O O
. O O
Several O O
of O O
the O O
drugs O O
used O O
in O O
the O O
management O O
of O O
MAC O O
have O O
been O O
associated O O
with O O
significant O O
drug O O
interactions O O
involving O O
the O O
cytochrome B-GENE B-GENE
P450 E-GENE E-GENE
( O O
CYP S-GENE S-GENE
) O O
enzyme O O
system O O
. O O
Arterial O O
compliance O O
measurements O O
using O O
intraarterial O O
pulse O O
contour O O
analysis O O
and O O
a O O
modified O O
Windkessel O O
model O O
were O O
carried O O
out O O
in O O
19 O O
patients O O
with O O
isolated O O
systolic O O
hypertension O O
( O O
> O O
or O O
= O O
160 O O
/ O O
< O O
or O O
= O O
90 O O
mm O O
Hg O O
) O O
and O O
compared O O
to O O
measurements O O
in O O
29 O O
patients O O
with O O
essential O O
hypertension O O
( O O
diastolic O O
blood O O
pressure O O
[ O O
BP O O
] O O
> O O
or O O
= O O
95 O O
mm O O
Hg O O
) O O
and O O
47 O O
normotensive O O
control O O
subjects O O
. O O
Rather O O
than O O
seeking O O
a O O
blanket O O
characterization O O
of O O
an O O
essentially O O
heterogeneous O O
group O O
, O O
it O O
may O O
be O O
more O O
useful O O
to O O
consider O O
idiom O O
comprehension O O
a O O
secondary O O
manifestation O O
of O O
semantic O O
and O O
/ O O
or O O
pragmatic O O
difficulties O O
. O O
Methylprednisolone O O
and O O
U O O
- O O
74006F O O
were O O
equally O O
effective O O
at O O
preventing O O
neurological O O
dysfunction O O
compared O O
to O O
the O O
control O O
group O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
; O O
U O O
- O O
78517F O O
was O O
slightly O O
less O O
effective O O
than O O
U O O
- O O
74006F O O
and O O
methylprednisolone O O
but O O
was O O
significantly O O
better O O
than O O
vehicle O O
in O O
preventing O O
neurological O O
dysfunction O O
. O O
The O O
women O O
in O O
the O O
intermediate O O
calcium O O
group O O
had O O
approximately O O
the O O
same O O
mean O O
BMD O O
values O O
as O O
those O O
in O O
the O O
low O O
calcium O O
group O O
. O O
International O O
efforts O O
are O O
now O O
being O O
made O O
to O O
standardize O O
haemolytic O O
test O O
conditions O O
and O O
the O O
present O O
study O O
is O O
meant O O
as O O
a O O
contribution O O
to O O
this O O
. O O
The O O
transition O O
from O O
expression O O
of O O
early O O
meiotic O O
genes O O
to O O
expression O O
of O O
middle O O
sporulation O O
- O O
specific O O
genes O O
occurs O O
at O O
about O O
the O O
time O O
that O O
cells O O
exit O O
from O O
pachytene O O
and O O
form O O
the O O
meiosis O O
I O O
spindle O O
. O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE I-GENE
DNA O I-GENE
- O I-GENE
protein O E-GENE
binding O O
and O O
ICAM B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
were O O
enhanced O O
by O O
IL B-GENE B-GENE
- I-GENE I-GENE
1beta E-GENE E-GENE
and O O
these O O
effects O O
were O O
inhibited O O
by O O
tyrphostin O O
23 O O
, O O
but O O
not O O
by O O
PD O O
98059 O O
or O O
SB O O
203580 O O
. O O
Peripheral O O
neuropathy O O
in O O
the O O
cherry O O
- O O
red O O
spot O O
- O O
myoclonus O O
syndrome O O
( O O
sialidosis O O
type O O
I O O
) O O
. O O
Using O O
the O O
two O O
- O O
hybrid O O
screening O O
method O O
, O O
we O O
have O O
identified O O
an O O
additional O O
component O O
of O O
the O O
CCAAT B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
. O O
The O O
myb B-GENE B-GENE
proto I-GENE I-GENE
oncogene I-GENE I-GENE
product E-GENE E-GENE
( O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb E-GENE E-GENE
) O O
is O O
a O O
transcriptional O O
regulator O O
and O O
its O O
expression O O
and O O
function O O
are O O
tightly O O
linked O O
to O O
the O O
cellular O O
entry O O
into O O
S O O
phase O O
and O O
DNA O O
synthesis O O
. O O
Both O O
the O O
p38 B-GENE B-GENE
kinase E-GENE E-GENE
inhibitor O O
SB205380 O S-GENE
( O O
SB O S-GENE
) O O
and O O
cotransfection O O
of O O
a O O
dominant O O
- O O
negative O O
mutant O O
of O O
p38 B-GENE B-GENE
kinase E-GENE E-GENE
reduced O O
IL B-GENE B-GENE
- I-GENE I-GENE
1beta E-GENE E-GENE
stimulation O O
of O O
the O O
hBNP B-GENE B-GENE
promoter E-GENE E-GENE
. O O
CLINICAL O O
FEATURES O O
: O O
This O O
30 O O
- O O
yr O O
- O O
old O O
gravida O O
V O O
para O O
0 O O
woman O O
presented O O
to O O
the O O
anaesthesia O O
consultation O O
clinic O O
at O O
37 O O
- O O
wk O O
gestation O O
to O O
discuss O O
pain O O
relief O O
options O O
for O O
labour O O
and O O
delivery O O
. O O
The O O
TaqI S-GENE O
and O O
HaeIII S-GENE O
RFLPs O S-GENE
will O O
provide O O
tools O O
for O O
the O O
genetic O O
analysis O O
of O O
CR2 S-GENE O
. O O
In O O
addition O O
, O O
because O O
SB203580 O S-GENE
had O O
no O O
effect O O
of O O
TNF S-GENE S-GENE
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
, O O
our O O
results O O
strongly O O
argue O O
against O O
a O O
role O O
for O O
p38 B-GENE B-GENE
MAPK E-GENE E-GENE
in O O
the O O
induction O O
of O O
TNF S-GENE S-GENE
- O O
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
. O O
Cognitive O O
measures O O
of O O
attention O O
included O O
the O O
Stroop O O
and O O
Controlled O O
Oral O O
Word O O
Association O O
Test O O
using O O
the O O
letters O O
" O O
C O O
, O O
" O O
" O O
F O O
, O O
" O O
and O O
" O O
L O O
" O O
( O O
COWAT O O
, O O
CFL O O
version O O
) O O
. O O
Ptx1 S-GENE S-GENE
belongs O O
to O O
an O O
expanding O O
family O O
of O O
bicoid B-GENE O
- I-GENE O
related E-GENE O
vertebrate O O
homeobox O O
genes O O
. O O
Effects O O
of O O
dietary O O
lipids O O
on O O
whole O O
- O O
body O O
retention O O
and O O
organ O O
distribution O O
of O O
organic O O
and O O
inorganic O O
mercury O O
in O O
mice O O
. O O
Differential O O
transcription O O
of O O
plastome O B-GENE
- O I-GENE
encoded O I-GENE
genes O E-GENE
in O O
the O O
mesophyll O O
and O O
bundle O O
- O O
sheath O O
chloroplasts O O
of O O
the O O
monocotyledonous O O
NADP O O
- O O
malic B-GENE O
enzyme E-GENE O
- O O
type O O
C4 O O
plants O O
maize O O
and O O
Sorghum O O
. O O
Sequential O O
immunoprecipitation O O
showed O O
all O O
detectable O O
p53 S-GENE S-GENE
to O O
be O O
of O O
the O O
PAb246 B-GENE O
+ E-GENE O
class O O
in O O
each O O
LPV O O
- O O
transformed O O
cell O O
line O O
, O O
suggesting O O
that O O
the O O
stable O O
p53 S-GENE S-GENE
was O O
indeed O O
wild O O
type O O
. O O
Tissue O O
- O O
specific O O
gene O O
regulation O O
of O O
eukaryotic O O
organisms O O
is O O
to O O
a O O
large O O
extent O O
mediated O O
by O O
transcription O O
factors O O
that O O
interact O O
with O O
genomic O O
DNA O O
sequences O O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
. O O
Enhanced O O
quantum O O
correlations O O
in O O
bound O O
higher O O
- O O
order O O
solitons O O
Quantum O O
effects O O
in O O
N O O
- O O
bound O O
solitons O O
can O O
be O O
drastically O O
enhanced O O
compared O O
to O O
the O O
fundamental O O
soliton O O
. O O
The O O
data O O
suggest O O
that O O
compromised O O
fibrinolytic O O
capacity O O
may O O
be O O
a O O
contributing O O
factor O O
in O O
the O O
development O O
of O O
thrombosis O O
in O O
patients O O
with O O
the O O
lupus O O
anticoagulant O O
. O O
The O O
MEE O O
was O O
significantly O O
greater O O
than O O
the O O
BEE O O
and O O
significantly O O
less O O
than O O
the O O
calculated O O
energy O O
expenditure O O
. O O
These O O
results O O
suggest O O
that O O
E6010 S-GENE O
may O O
be O O
of O O
clinical O O
value O O
in O O
the O O
treatment O O
of O O
coronary O O
occlusion O O
. O O
To O O
better O O
understand O O
the O O
relationship O O
between O O
expression O O
of O O
an O O
oncogene O O
and O O
genetic O O
instability O O
, O O
we O O
have O O
studied O O
a O O
cell O O
line O O
expressing O O
an O O
activated B-GENE O
human I-GENE B-GENE
Ha I-GENE I-GENE
- I-GENE I-GENE
ras E-GENE E-GENE
under O O
the O O
control O O
of O O
bacterial B-GENE O
lactose I-GENE O
operon I-GENE O
regulatory I-GENE O
elements E-GENE O
for O O
changes O O
in O O
methotrexate O O
resistance O O
and O O
dihydrofolate B-GENE B-GENE
reductase E-GENE E-GENE
( O O
dhfr S-GENE S-GENE
) O O
gene O O
amplification O O
following O O
mutant B-GENE B-GENE
Ha I-GENE I-GENE
- I-GENE I-GENE
ras E-GENE E-GENE
induction O O
. O O
On O O
a O O
variety O O
of O O
fronts O O
, O O
chronic O O
bacterial O O
infection O O
is O O
being O O
found O O
to O O
be O O
significantly O O
associated O O
with O O
the O O
development O O
of O O
atherosclerosis O O
and O O
the O O
clinical O O
complications O O
of O O
unstable O O
angina O O
, O O
myocardial O O
infarction O O
, O O
and O O
stroke O O
. O O
Long O O
- O O
term O O
results O O
and O O
curative O O
mechanisms O O
of O O
vesicoureteral O O
reflux O O
by O O
endoscopic O O
injection O O
of O O
blood O O
. O O
Inspection O O
of O O
X B-GENE O
. I-GENE O
tropicalis I-GENE O
, I-GENE O
mouse I-GENE O
and I-GENE O
human I-GENE O
U6 I-GENE O
DNA I-GENE O
upstream I-GENE O
sequences E-GENE O
revealed O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
as O O
well O O
as O O
of O O
the O O
proximal O O
and O O
enhancer O O
( O O
octamer O O
motif O O
) O O
elements O O
contained O O
in O O
snRNA O B-GENE
genes O E-GENE
transcribed O O
by O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II E-GENE E-GENE
. O O
Characterization O O
of O O
an O O
unusual O O
tRNA O O
- O O
like O O
sequence O O
found O O
inserted O O
in O O
a O O
Neurospora O O
retroplasmid O O
. O O
Repeated O O
time O O
course O O
studies O O
in O O
the O O
same O O
patient O O
were O O
reproducible O O
although O O
the O O
absolute O O
concentrations O O
showed O O
some O O
variation O O
. O O
The O O
present O O
work O O
represents O O
an O O
attempt O O
to O O
develop O O
a O O
method O O
for O O
measuring O O
relative O O
blood O O
flow O O
in O O
intestinal O O
capillaries O O
, O O
by O O
the O O
use O O
of O O
sodium O O
fluorescein O O
( O O
Na O O
- O O
F O O
) O O
as O O
an O O
indicator O O
substance O O
. O O
The O O
human B-GENE B-GENE
PAX8 I-GENE I-GENE
gene E-GENE E-GENE
generates O O
at O O
least O O
five O O
different O O
alternatively O O
spliced O O
transcripts O O
encoding O O
different O O
PAX8 B-GENE B-GENE
isoforms E-GENE E-GENE
. O O
These O O
data O O
show O O
that O O
both O O
Sp1 S-GENE S-GENE
and O O
Sp3 B-GENE S-GENE
transcription I-GENE O
factors E-GENE O
upregulate O O
HGF B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
by O O
binding O O
to O O
the O O
Sp1 B-GENE S-GENE
binding I-GENE O
site E-GENE O
at O O
position O O
- O O
318 O O
to O O
- O O
303 O O
bp O O
in O O
the O O
HGF B-GENE B-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
. O O
After O O
a O O
1 O O
- O O
h O O
rest O O
( O O
for O O
T2 O O
return O O
to O O
baseline O O
) O O
, O O
subjects O O
repeated O O
the O O
5 O O
- O O
min O O
protocol O O
, O O
followed O O
by O O
a O O
final O O
MRI O O
/ O O
MRS O O
. O O
The O O
cells O O
arrest O O
in O O
the O O
G1 O O
phase O O
of O O
the O O
cell O O
cycle O O
and O O
grow O O
a O O
projection O O
towards O O
one O O
another O O
forming O O
a O O
shmoo O O
projection O O
. O O
Mammalian O O
homologues O O
of O O
the O O
Polycomb B-GENE B-GENE
- I-GENE I-GENE
group I-GENE I-GENE
gene E-GENE I-GENE
Enhancer B-GENE E-GENE
of I-GENE O
zeste E-GENE O
mediate O O
gene O O
silencing O O
in O O
Drosophila O O
heterochromatin O O
and O O
at O O
S O O
. O O
cerevisiae O O
telomeres O O
. O O
With O O
six O O
reports O O
in O O
the O O
literature O O
that O O
show O O
there O O
is O O
an O O
order O O
to O O
melanoma O O
nodal O O
metastases O O
and O O
that O O
the O O
SLN O O
histology O O
is O O
reflective O O
of O O
the O O
histology O O
of O O
the O O
remainder O O
of O O
the O O
nodal O O
basin O O
, O O
the O O
more O O
conservative O O
SLN O O
biopsy O O
can O O
be O O
performed O O
to O O
adequately O O
stage O O
nodally O O
the O O
patient O O
with O O
melanoma O O
. O O
The O O
results O O
obtained O O
with O O
[ B-GENE O
F304 I-GENE O
] I-GENE O
R2 E-GENE O
indicate O O
that O O
structural O O
changes O O
in O O
E B-GENE O
. I-GENE O
coli I-GENE O
R2 E-GENE O
in O O
the O O
vicinity O O
of O O
this O O
helix O O
distortion O O
can O O
influence O O
the O O
catalytic O O
activity O O
of O O
the O O
holoenzyme O O
. O O
Cloning O O
and O O
characterization O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
of O O
human B-GENE B-GENE
ATP I-GENE I-GENE
- I-GENE I-GENE
citrate I-GENE I-GENE
lyase I-GENE I-GENE
gene E-GENE E-GENE
. O O
Cryoglobulinaemia O O
among O O
maintenance O O
haemodialysis O O
patients O O
and O O
its O O
relation O O
to O O
hepatitis O O
C O O
infection O O
. O O
The O O
S3 B-GENE B-GENE
protein E-GENE E-GENE
also O O
contains O O
a O O
DNA O O
repair O O
activity O O
, O O
efficiently O O
processing O O
8 O O
- O O
oxoguanine O O
residues O O
in O O
DNA O O
via O O
an O O
N B-GENE O
- I-GENE O
glycosylase E-GENE O
/ O O
apurinic B-GENE O
- I-GENE O
apyrimidinic I-GENE O
( I-GENE O
AP I-GENE O
) I-GENE O
lyase E-GENE O
activity O O
. O O
25 O O
patients O O
received O O
20 O O
mgs O O
of O O
hyoscine O O
N O O
- O O
butyl O O
bromide O O
and O O
the O O
rest O O
5 O O
mgs O O
propinoxate O O
, O O
i O O
. O O
v O O
. O O
plus O O
diazepam O O
. O O
We O O
present O O
here O O
a O O
statistical O O
technique O O
we O O
developed O O
to O O
identify O O
the O O
sequence O O
elements O O
that O O
may O O
be O O
responsible O O
for O O
this O O
cell O O
cycle O O
regulation O O
. O O
Computed O O
tomographic O O
( O O
CT O O
) O O
findings O O
of O O
pancreatic O O
ductal O O
adenocarcinoma O O
were O O
studied O O
with O O
the O O
combined O O
method O O
of O O
early O O
enhancement O O
CT O O
and O O
high O O
dose O O
enhancement O O
CT O O
in O O
72 O O
carcinomas O O
. O O
No O O
other O O
transcripts O O
of O O
different O O
length O O
could O O
be O O
detected O O
after O O
prolonged O O
exposure O O
. O O
We O O
conclude O O
, O O
therefore O O
, O O
that O O
in O O
the O O
absence O O
of O O
E1A S-GENE S-GENE
, O O
E4orf4 S-GENE S-GENE
is O O
sufficient O O
by O O
itself O O
to O O
trigger O O
a O O
p53 S-GENE S-GENE
- O O
independent O O
apoptosis O O
pathway O O
that O O
may O O
operate O O
independently O O
of O O
the O O
known O O
zVAD O S-GENE
- O O
inhibitable O O
caspases S-GENE O
, O O
and O O
that O O
may O O
involve O O
an O O
as O O
yet O O
uncharacterized O O
mechanism O O
. O O
The O O
antiserum O O
used O O
for O O
immunoblotting O O
specifically O O
supershifts O O
uteroglobin B-GENE O
promoter I-GENE O
- I-GENE O
protein I-GENE O
complexes E-GENE O
in O O
gel O O
shift O O
experiments O O
. O O
The O O
nucleotide O O
sequence O O
of O O
the O O
estrogen B-GENE B-GENE
receptor I-GENE I-GENE
gene I-GENE E-GENE
of I-GENE O
Oreochromis I-GENE O
aureus E-GENE O
( O O
OaER S-GENE S-GENE
) O O
indicates O O
that O O
the O O
hormone O O
- O O
binding O O
E O O
domain O O
is O O
composed O O
of O O
4 O O
exons O O
interspersed O O
by O O
short O O
introns O O
of O O
only O O
0 O O
. O O
18 O O
- O O
1 O O
. O O
3 O O
kb O O
each O O
. O O
The O O
expression O O
of O O
Scmh1 S-GENE S-GENE
and O O
rae28 S-GENE O
/ O O
mph1 S-GENE S-GENE
is O O
well O O
correlated O O
in O O
most O O
tissues O O
of O O
embryos O O
. O O
The O O
nucleoporin B-GENE B-GENE
98 I-GENE I-GENE
gene E-GENE E-GENE
( O O
NUP98 S-GENE O
) O O
, O O
which O O
is O O
rearranged O O
in O O
several O O
acute O O
myeloid O O
leukemia O O
translocations O O
, O O
is O O
located O O
within O O
this O O
region O O
. O O
We O O
have O O
isolated O O
and O O
sequenced O O
cDNA O O
sequences O O
corresponding O O
to O O
two O O
novel O O
genes O O
that O O
map O O
to O O
Xq28 O S-GENE
. O O
A O O
new O O
direct O O
hemagglutination O O
test O O
( O O
HI O O
- O O
GONAVIS O O
) O O
for O O
urinary O O
LH S-GENE O
was O O
compared O O
with O O
the O O
serum O O
radioimmuno O O
- O O
assay O O
of O O
LH S-GENE S-GENE
. O O
Diffusion O O
epidemic O O
models O O
with O O
incubation O O
and O O
crisscross O O
dynamics O O
. O O
CERIP S-GENE S-GENE
interaction O O
. O O
The O O
encoded O O
Arabidopsis B-GENE O
U3 I-GENE O
snRNAs E-GENE O
can O O
be O O
folded O O
into O O
a O O
secondary O O
structure O O
which O O
is O O
more O O
similar O O
to O O
that O O
of O O
U3 B-GENE B-GENE
RNAs E-GENE E-GENE
from O O
lower O O
eukaryotes O O
rather O O
than O O
from O O
metazoa O O
. O O
Therapy O O
and O O
prevention O O
of O O
irreversible O O
shock O O
with O O
pharmacological O O
doses O O
of O O
some O O
corticosteroids O O
Fentanyl O O
citrate O O
( O O
0 O O
. O O
1 O O
mL O O
) O O
and O O
2H5 O O
- O O
fentanyl O O
( O O
internal O O
standard O O
, O O
0 O O
. O O
05 O O
mL O O
, O O
100 O O
mg O O
/ O O
L O O
) O O
were O O
extracted O O
with O O
Toxi O O
- O O
A O O
tubes O O
( O O
Toxi O O
- O O
Lab O O
, O O
Irvine O O
, O O
CA O O
) O O
and O O
analyzed O O
by O O
gas O O
chromatography O O
- O O
mass O O
spectrometry O O
. O O
Positive O O
effects O O
of O O
radioactive O O
therapy O O
in O O
Guarapari O O
The O O
LT B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
gene E-GENE E-GENE
is O O
expressed O O
in O O
lymphoid O O
cells O O
and O O
organs O O
, O O
but O O
little O O
is O O
known O O
about O O
its O O
inducible O O
regulation O O
. O O
Ciprofloxacin O O
attained O O
a O O
peak O O
serum O O
concentration O O
of O O
1 O O
. O O
2 O O
mg O O
/ O O
l O O
and O O
a O O
serum O O
half O O
- O O
life O O
of O O
34 O O
min O O
. O O
Dmyd S-GENE O
clone O O
encodes O O
a O O
polypeptide O O
of O O
332 O O
amino O O
acids O O
with O O
82 O O
% O O
identity O O
to O O
MyoD S-GENE O
in O O
the O O
41 O O
amino O O
acids O O
of O O
the O O
putative O O
helix O O
- O O
loop O O
- O O
helix O O
region O O
and O O
100 O O
% O O
identity O O
in O O
the O O
13 O O
amino O O
acids O O
of O O
the O O
basic O O
domain O O
proposed O O
to O O
contain O O
the O O
essential O O
recognition O O
code O O
for O O
muscle O O
- O O
specific O O
gene O O
activation O O
. O O
Identification O O
of O O
an O O
osteocalcin B-GENE O
gene I-GENE O
promoter I-GENE O
sequence E-GENE O
that O O
binds O O
AP1 S-GENE S-GENE
. O O
Treatment O O
is O O
based O O
on O O
antifungal O O
drugs O O
, O O
most O O
frequently O O
nystatin O O
, O O
amphotericin O O
B O O
and O O
ketoconazole O O
. O O
Mutations O O
abolishing O O
MalK S-GENE S-GENE
function O O
not O O
only O O
result O O
in O O
inability O O
to O O
transport O O
maltose O O
but O O
also O O
cause O O
constitutive O O
expression O O
of O O
the O O
maltose B-GENE O
regulon E-GENE O
. O O
Drosophila B-GENE B-GENE
melanogaster I-GENE I-GENE
casein I-GENE I-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
( O O
DmCKII S-GENE S-GENE
) O O
is O O
composed O O
of O O
catalytic O O
( O O
alpha O O
) O O
and O O
regulatory O O
( O O
beta O O
) O O
subunits O O
associated O O
as O O
an O O
alpha2beta2 O O
heterotetramer O O
. O O
The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
whether O O
the O O
EORTC O O
( O O
European O O
Organisation O O
for O O
Research O O
and O O
Treatment O O
of O O
Cancer O O
) O O
QLQ O O
- O O
C30 O O
core O O
questionnaire O O
alone O O
could O O
distinguish O O
between O O
two O O
clinically O O
different O O
groups O O
of O O
patients O O
and O O
to O O
design O O
a O O
module O O
, O O
which O O
included O O
relevant O O
patient O O
- O O
defined O O
gastric O O
cancer O O
- O O
specific O O
variables O O
. O O
On O O
both O O
indocyanine O O
green O O
video O O
and O O
fluorescein O O
angiography O O
, O O
hypofluorescent O O
lesions O O
were O O
almost O O
the O O
same O O
size O O
as O O
the O O
light O O
yellow O O
area O O
and O O
the O O
dark O O
yellow O O
center O O
of O O
a O O
placoid O O
lesion O O
. O O
We O O
have O O
measured O O
percentage O O
O3 O O
uptake O O
in O O
30 O O
adult O O
Sprague O O
- O O
Dawley O O
rats O O
exposed O O
, O O
nose O O
only O O
, O O
for O O
1 O O
hr O O
to O O
0 O O
. O O
3 O O
, O O
0 O O
. O O
6 O O
, O O
or O O
1 O O
. O O
0 O O
ppm O O
O3 O O
. O O
The O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
( O O
SNR O O
) O O
was O O
calculated O O
in O O
the O O
T2 O O
- O O
weighted O O
sequence O O
. O O
Cell O O
rounding O O
was O O
abrogated O O
by O O
expression O O
of O O
either O O
kinase O O
- O O
dead O O
forms O O
of O O
US3 B-GENE B-GENE
PK E-GENE E-GENE
or O O
a O O
mutant O O
protein O O
lacking O O
the O O
acidic O O
cluster O O
in O O
the O O
kinase O O
regulatory O O
domain O O
. O O
Three O O
distinct O O
human B-GENE O
HDACs E-GENE S-GENE
are O O
homologous O O
to O O
RPD3 S-GENE S-GENE
, O O
a O O
yeast O O
transcriptional O O
regulator O O
. O O
The O O
4 O O
- O O
nt O O
sequence O O
of O O
the O O
rotavirus O O
3 O O
' O O
TE O O
represents O O
by O O
far O O
the O O
shortest O O
of O O
any O O
of O O
the O O
sequence O O
enhancers O O
known O O
to O O
stimulate O O
translation O O
. O O
OBJECTIVE O O
: O O
The O O
audiologic O O
presentation O O
of O O
vestibular O O
schwannoma O O
( O O
VS O O
) O O
associated O O
with O O
neurofibromatosis O O
type O O
2 O O
( O O
NF2 O O
) O O
has O O
not O O
been O O
well O O
characterized O O
. O O
Expression O O
of O O
these O O
chemokines O O
is O O
similar O O
in O O
that O O
both O O
require O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
element E-GENE E-GENE
and O O
additional O O
regions O O
such O O
as O O
the O O
CAAT B-GENE B-GENE
/ I-GENE I-GENE
enhancer I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
C B-GENE O
/ I-GENE O
EBP E-GENE S-GENE
) O O
element O O
of O O
the O O
IL B-GENE B-GENE
- I-GENE I-GENE
8 I-GENE I-GENE
promoter E-GENE E-GENE
. O O
The O O
meaning O O
of O O
hope O O
in O O
health O O
and O O
illness O O
. O O
Assessment O O
of O O
two O O
anion O O
- O O
exchange O O
resins O O
for O O
direct O O
use O O
in O O
the O O
screening O O
method O O
for O O
urinary O O
porphobilinogen O O
. O O
Aggravation O O
of O O
peripheral O O
- O O
blood O O
cytopenia O O
during O O
the O O
first O O
weeks O O
and O O
hypocellularity O O
of O O
bone O O
- O O
marrow O O
aspirates O O
at O O
the O O
end O O
of O O
therapy O O
suggest O O
that O O
low O O
- O O
dose O O
Ara O O
C O O
exerts O O
its O O
main O O
activity O O
by O O
suppression O O
of O O
leukaemic O O
growth O O
, O O
rather O O
than O O
by O O
induction O O
of O O
differentiation O O
in O O
malignant O O
cells O O
. O O
All O O
depressive O O
groups O O
showed O O
improved O O
error O O
measures O O
post O O
- O O
treatment O O
. O O
Triaxiality O O
in O O
the O O
proton O O
- O O
neutron O O
interacting O O
boson O O
model O O
: O O
Perturbed O O
O O O
( O O
6 O O
) O O
symmetry O O
with O O
application O O
to O O
the O O
mass O O
A O O
The O O
best O O
sequences O O
for O O
pelvic O O
study O O
are O O
, O O
in O O
our O O
experience O O
, O O
IR O O
or O O
short O O
TR O O
spin O O
- O O
echo O O
for O O
T1 O O
- O O
weighted O O
images O O
, O O
and O O
spin O O
- O O
echo O O
with O O
1200 O O
TR O O
for O O
T2 O O
images O O
. O O
Cells O O
were O O
co O O
- O O
infected O O
simultaneously O O
with O O
IBV O S-GENE
, O O
the O O
recombinant O B-GENE
FPV O E-GENE
( O O
rFPV O S-GENE
) O O
containing O O
the O O
D O O
- O O
RNA O O
sequence O O
and O O
a O O
second O O
rFPV O S-GENE
expressing O O
T7 B-GENE B-GENE
RNA I-GENE I-GENE
polymerase E-GENE E-GENE
for O O
the O O
initial O O
expression O O
of O O
the O O
D O O
- O O
RNA O O
transcript O O
, O O
subsequently O O
rescued O O
by O O
helper O O
IBV O O
. O O
Seasonal O O
variation O O
of O O
the O O
cadmium O O
content O O
of O O
Murex O O
trunculus O O
in O O
a O O
non O O
- O O
cadmium O O
polluted O O
environment O O
. O O
These O O
results O O
are O O
discussed O O
in O O
relation O O
to O O
predicted O O
isoform O O
L O O
diversity O O
across O O
human O O
tissues O O
and O O
cells O O
. O O
Doctors O O
given O O
intrathecal O O
methotrexate O O
had O O
headache O O
when O O
20 O O
gauge O O
standard O O
needle O O
was O O
used O O
. O O
The O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
recruited O O
by O O
ARF1 B-GENE O
. I-GENE O
GTP E-GENE S-GENE
is O O
released O O
from O O
the O O
Golgi O O
membrane O O
by O O
treatment O O
with O O
1 O O
M O O
Tris O O
- O O
HCl O O
( O O
pH O O
7 O O
) O O
or O O
upon O O
reincubation O O
at O O
37 O O
degreesC O O
, O O
whereas O O
AP B-GENE O
- I-GENE O
1 E-GENE O
recruited O O
with O O
GTPgammaS O O
or O O
by O O
a O O
constitutively O O
active O O
point O O
mutant O O
, O O
ARF1 B-GENE S-GENE
( I-GENE O
Q71L I-GENE S-GENE
) E-GENE O
, O O
remains O O
membrane O O
bound O O
after O O
either O O
treatment O O
. O O
The O O
formation O O
of O O
tumorlike O O
lesions O O
in O O
the O O
cockroach O O
leucophaea O O
maderae O O
after O O
anal O O
blockage O O
. O O
Fine O O
tangled O O
pili O O
expressed O O
by O O
Haemophilus O O
ducreyi O O
are O O
a O O
novel O O
class O O
of O O
pili O O
. O O
We O O
found O O
remarkable O O
differences O O
in O O
the O O
expression O O
patterns O O
of O O
MTB B-GENE B-GENE
- I-GENE I-GENE
Zf I-GENE I-GENE
mRNA E-GENE E-GENE
and O O
two O O
other O O
hybridizable O O
mRNAs O O
of O O
5kb O O
and O O
8 O O
. O O
5 O O
kb O O
when O O
human O O
brain O O
and O O
primary O O
brain O O
tumors O O
were O O
compared O O
. O O
The O O
two O O
redox O O
centers O O
in O O
the O O
protein O O
, O O
FAD O O
and O O
a O O
[ O O
4Fe4S O O
] O O
+ O O
2 O O
, O O
+ O O
1 O O
cluster O O
, O O
are O O
present O O
in O O
a O O
64 O O
- O O
kDa O O
monomer O O
. O O
The O O
pra2 B-GENE B-GENE
gene E-GENE E-GENE
encodes O O
a O O
pea B-GENE O
( I-GENE O
Pisum I-GENE O
sativum I-GENE O
) I-GENE O
small I-GENE O
GTPase E-GENE O
belonging O O
to O O
the O O
YPT S-GENE S-GENE
/ O O
rab S-GENE B-GENE
family O E-GENE
, O O
and O O
its O O
expression O O
is O O
down O O
- O O
regulated O O
by O O
light O O
, O O
mediated O O
by O O
phytochrome S-GENE O
. O O
Carotid O O
body O O
chemoreceptor O O
activity O O
as O O
recorded O O
from O O
the O O
petrosal O O
ganglion O O
in O O
cats O O
. O O
Human B-GENE O
and I-GENE O
murine I-GENE B-GENE
cytotoxic I-GENE I-GENE
T I-GENE I-GENE
lymphocyte I-GENE I-GENE
serine I-GENE I-GENE
proteases E-GENE E-GENE
: O O
subsite O O
mapping O O
with O O
peptide O O
thioester O O
substrates O O
and O O
inhibition O O
of O O
enzyme O O
activity O O
and O O
cytolysis O O
by O O
isocoumarins O O
. O O
To O O
explore O O
further O O
the O O
role O O
of O O
the O O
carboxyl O O
- O O
terminal O O
domain O O
in O O
determining O O
the O O
cell O O
cycle O O
function O O
of O O
CDC34 S-GENE S-GENE
, O O
we O O
constructed O O
and O O
characterized O O
genes O O
encoding O O
chimeric B-GENE O
E2s E-GENE O
incorporating O O
sequences O O
from O O
CDC34 S-GENE S-GENE
and O O
the O O
related O O
but O O
functionally O O
distinct O O
E2 S-GENE B-GENE
RAD6 S-GENE E-GENE
( O O
UBC2 S-GENE S-GENE
) O O
. O O
MAPKK B-GENE B-GENE
kinase E-GENE E-GENE
/ O O
MEKK S-GENE S-GENE
phosphorylates O O
and O O
activates O O
its O O
downstream O O
protein O B-GENE
kinase O E-GENE
, O O
MAPK B-GENE B-GENE
kinase E-GENE E-GENE
/ O O
MEK S-GENE S-GENE
, O O
which O O
in O O
turn O O
activates O O
MAPK S-GENE S-GENE
. O O
Kondo O O
effect O O
in O O
Cu O O
( O O
Fe O O
) O O
films O O
. O O
However O O
, O O
ADAR1 S-GENE S-GENE
and O O
the O O
related O O
deaminase B-GENE O
ADAR2 E-GENE S-GENE
showed O O
significant O O
expression O O
in O O
all O O
regions O O
of O O
the O O
brain O O
examined O O
, O O
including O O
cortex O O
, O O
hippocampus O O
, O O
olfactory O O
bulb O O
, O O
and O O
striatum O O
, O O
where O O
the O O
5 B-GENE O
- I-GENE O
HT2CR I-GENE O
pre I-GENE O
- I-GENE O
mRNA E-GENE O
was O O
extensively O O
edited O O
. O O
To O O
investigate O O
its O O
transcription O O
, O O
1 O O
. O O
1 O O
kilobases O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
sequence O O
were O O
fused O O
to O O
a O O
luciferase B-GENE O
reporter I-GENE O
gene E-GENE O
. O O
Influence O O
of O O
copper O O
addition O O
. O O
The O O
0 O O
. O O
018 O O
- O O
inch O O
FloWire O O
provides O O
a O O
high O O
- O O
fidelity O O
continuous O O
Doppler O O
signal O O
. O O
Monosulfates O O
of O O
16 O O
- O O
oxygenated O O
ketonic O O
C19 O O
steroids O O
in O O
adult O O
human O O
urine O O
. O O
Under O O
anaerobic O O
conditions O O
( O O
a O O
50 O O
- O O
day O O
experiment O O
) O O
these O O
organisms O O
degraded O O
15 O O
- O O
18 O O
% O O
of O O
the O O
TEM O O
, O O
20 O O
- O O
25 O O
% O O
of O O
some O O
alkanes O O
, O O
and O O
15 O O
- O O
18 O O
% O O
of O O
selected O O
polycyclic O O
aromatic O O
hydrocarbons O O
. O O
In O O
addition O O
, O O
WR O O
- O O
3689 O O
, O O
WR O O
- O O
109342 O O
, O O
and O O
WR O O
- O O
168643 O O
were O O
used O O
with O O
per O O
os O O
administration O O
to O O
determine O O
hematopoietic O O
lethality O O
. O O
Further O O
, O O
we O O
will O O
review O O
our O O
evaluation O O
of O O
the O O
survival O O
rate O O
and O O
prognostic O O
factors O O
for O O
9 O O
, O O
262 O O
patients O O
from O O
1981 O O
to O O
1996 O O
. O O
MEASURES O O
: O O
SF O O
- O O
36 O O
questionnaires O O
were O O
completed O O
by O O
patients O O
at O O
both O O
initial O O
and O O
discharge O O
examinations O O
. O O
In O O
contrast O O
, O O
corticotropin B-GENE B-GENE
releasing I-GENE I-GENE
factor E-GENE E-GENE
( O O
CRF S-GENE S-GENE
) O O
, O O
injected O O
centrally O O
produces O O
a O O
suppression O O
of O O
punished O O
and O O
non O O
- O O
punished O O
responding O O
in O O
the O O
conflict O O
test O O
consistent O O
with O O
its O O
hypothesized O O
role O O
in O O
mediating O O
behavioral O O
responses O O
to O O
stress O O
. O O
Temporal O O
recruitment O O
of O O
the O O
mSin3A S-GENE B-GENE
- O I-GENE
histone B-GENE I-GENE
deacetylase E-GENE E-GENE
corepressor O O
complex O O
to O O
the O O
ETS B-GENE B-GENE
domain I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE I-GENE
Elk B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
The O O
cluster O O
was O O
mapped O O
to O O
nucleotides O O
- O O
464 O O
to O O
- O O
434 O O
( O O
relative O O
to O O
nucleotide O O
A O O
in O O
the O O
initiation O O
codon O O
) O O
in O O
genomic O O
DNA O O
. O O
In O O
addition O O
, O O
FOP S-GENE O
- O O
FGFR1 S-GENE O
- O O
expressing O O
cells O O
show O O
constitutive O O
phosphorylation O O
of O O
the O O
positive O O
regulator O O
of O O
translation O O
p70S6 B-GENE B-GENE
kinase E-GENE E-GENE
; O O
this O O
phosphorylation O O
is O O
inhibited O O
by O O
PI3 B-GENE B-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
and O O
mTOR S-GENE S-GENE
( O O
mammalian B-GENE O
target I-GENE O
of I-GENE O
rapamycin E-GENE O
) O O
inhibitors O O
. O O
The O O
authors O O
report O O
two O O
cases O O
of O O
orbital O O
cavernous O O
hemangioma O O
diagnosed O O
by O O
Tc O O
- O O
99m O O
RBC O O
SPECT O O
. O O
Ciprofloxacin O O
levels O O
in O O
serum O O
and O O
blister O O
fluid O O
at O O
the O O
end O O
of O O
the O O
dosing O O
interval O O
( O O
8 O O
h O O
) O O
were O O
superior O O
or O O
almost O O
superior O O
to O O
MICs O O
for O O
sensitive O O
organisms O O
including O O
Pseudomonas O O
aeruginosa O O
. O O
Antibiotic O O
prophylaxis O O
in O O
a O O
surgical O O
setting O O
We O O
identified O O
clones O O
of O O
Chlamydomonas O O
genomic O O
DNA O O
that O O
rescued O O
the O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
axonemal O O
microtubule O O
severing O O
defect O O
of O O
fa1 B-GENE B-GENE
mutants E-GENE E-GENE
. O O
These O O
changes O O
persisted O O
during O O
the O O
first O O
week O O
. O O
Hyperlipemia O O
has O O
been O O
recently O O
described O O
in O O
children O O
with O O
migraine O O
, O O
being O O
suggested O O
that O O
this O O
alteration O O
is O O
in O O
the O O
base O O
of O O
the O O
disease O O
. O O
Plasma B-GENE O
hemopexin E-GENE O
homeostasis O O
during O O
the O O
acute O O
phase O O
response O O
. O O
The O O
newly O O
identified O O
repressor O O
element O O
is O O
a O O
rare O O
example O O
of O O
a O O
naturally O O
occurring O O
perfect O O
palindromic O O
binding O O
motif O O
for O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
/ O O
Rel S-GENE S-GENE
family O O
of O O
transcription O O
factors O O
. O O
Tryptophan O O
induction O O
prevents O O
Rho S-GENE O
- O O
dependent O O
transcription O O
termination O O
in O O
the O O
leader O O
region O O
of O O
the O O
operon O O
. O O
There O O
remains O O
the O O
physiological O O
problem O O
- O O
- O O
one O O
which O O
has O O
always O O
been O O
foremost O O
in O O
Moruzzi O O
' O O
s O O
thinking O O
about O O
the O O
intrinsic O O
regulation O O
of O O
brain O O
activity O O
- O O
- O O
of O O
how O O
the O O
separate O O
actions O O
of O O
the O O
different O O
arousal O O
systems O O
are O O
brought O O
together O O
into O O
a O O
functional O O
whole O O
. O O
The O O
nramp2 B-GENE B-GENE
gene E-GENE E-GENE
is O O
comprised O O
of O O
17 O O
exons O O
and O O
spans O O
more O O
than O O
36 O O
kb O O
. O O
The O O
immune O O
response O O
seems O O
to O O
be O O
partially O O
responsible O O
for O O
both O O
protection O O
and O O
the O O
destructive O O
consequences O O
of O O
chlamydial O O
infection O O
. O O
Results O O
: O O
hepatic O O
hydatidosis O O
: O O
177 O O
patients O O
. O O
This O O
is O O
similar O O
to O O
previous O O
reports O O
of O O
muscle B-GENE O
creatine I-GENE O
phosphokinase E-GENE O
release O O
in O O
psychiatric O O
patients O O
. O O
The O O
majority O O
of O O
putative O O
TSC2 B-GENE S-GENE
mutations E-GENE O
were O O
found O O
in O O
sporadic O O
rather O O
than O O
TSC2 S-GENE O
- O O
linked O O
families O O
. O O
Murine B-GENE B-GENE
ELAM I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
encoded O O
by O O
a O O
single O O
- O O
copy O O
gene O O
, O O
spanning O O
about O O
13 O O
kb O O
, O O
which O O
is O O
structurally O O
organized O O
into O O
14 O O
exons O O
and O O
13 O O
introns O O
; O O
very O O
similar O O
to O O
that O O
of O O
its O O
human O O
counterpart O O
. O O
A O O
biopsy O O
specimen O O
taken O O
from O O
the O O
frontal O O
branch O O
of O O
the O O
right O O
superficial O O
artery O O
revealed O O
segmental O O
intimal O O
thickening O O
consistent O O
with O O
intimal O O
fibroplasia O O
type O O
FMD O O
upon O O
histological O O
examination O O
. O O
Thus O O
in O O
this O O
study O O
we O O
used O O
in O O
vitro O O
methods O O
to O O
directly O O
evaluate O O
whether O O
isolated O O
human O O
saphenous O O
vein O O
segments O O
respond O O
to O O
vasoconstrictor O O
agents O O
at O O
arterial O O
pressure O O
levels O O
. O O
We O O
found O O
that O O
the O O
PRP20 B-GENE B-GENE
gene E-GENE E-GENE
is O O
identical O O
to O O
the O O
yeast B-GENE B-GENE
SRM1 I-GENE I-GENE
gene E-GENE E-GENE
( O O
Clark O O
and O O
Sprague O O
1989 O O
) O O
. O O
Basal O O
JNK B-GENE B-GENE
MAPK I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
was O O
also O O
specifically O O
induced O O
by O O
deltaEGFR S-GENE S-GENE
, O O
which O O
correlated O O
with O O
increased O O
phosphorylation O O
of O O
a O O
54 B-GENE B-GENE
- I-GENE I-GENE
kDa I-GENE I-GENE
JNK2 I-GENE I-GENE
protein E-GENE E-GENE
observed O O
in O O
deltaEGFR S-GENE O
- O O
containing O O
cells O O
. O O
Deletion O O
analysis O O
defines O O
distinct O O
functional O O
domains O O
for O O
protein O O
- O O
protein O O
and O O
nucleic O O
acid O O
interactions O O
in O O
the O O
ORF1 B-GENE B-GENE
protein E-GENE E-GENE
of O O
mouse O B-GENE
LINE B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
PMA O O
produced O O
similar O O
results O O
, O O
but O O
the O O
induction O O
of O O
the O O
WT B-GENE B-GENE
AP1 E-GENE I-GENE
c B-GENE I-GENE
- I-GENE I-GENE
jun E-GENE I-GENE
promoter O I-GENE
- O I-GENE
CAT O I-GENE
plasmid O E-GENE
was O O
smaller O O
. O O
The O O
determination O O
of O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
( O O
AT B-GENE O
III E-GENE O
) O O
and O O
its O O
clinical O O
significance O O
One O O
ORF O O
extends O O
from O O
nucleotides O O
415 O O
to O O
1620 O O
, O O
encodes O O
402 O O
amino O O
acids O O
, O O
and O O
is O O
preceded O O
by O O
a O O
ribosome O O
- O O
binding O O
site O O
. O O
Glucose O O
consumption O O
of O O
the O O
human O O
brain O O
under O O
the O O
influence O O
of O O
intravenous O O
infusions O O
of O O
glucose O O
, O O
glucagon S-GENE O
and O O
glucose O O
- O O
insulin S-GENE O
D O O
. O O
, O O
Hughes O O
, O O
F O O
. O O
Deletion O O
of O O
CDC5 S-GENE O
was O O
lethal O O
and O O
resulted O O
in O O
a O O
dumbbell O O
- O O
shaped O O
terminal O O
morphology O O
, O O
with O O
the O O
nuclei O O
almost O O
divided O O
but O O
still O O
connected O O
. O O
These O O
cDNAs O O
were O O
found O O
to O O
be O O
derived O O
from O O
the O O
3 O O
" O O
- O O
untranslated O O
region O O
( O O
3 O O
" O O
- O O
UTR O O
) O O
of O O
the O O
methyl B-GENE B-GENE
- I-GENE I-GENE
CpG I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
( O O
MeCP2 S-GENE S-GENE
) O O
. O O
A O O
) O O
During O O
O2 O O
- O O
ischemia O O
both O O
extracellular O O
[ O O
K O O
+ O O
] O O
and O O
change O O
of O O
pH O O
in O O
the O O
subepicardium O O
are O O
significantly O O
less O O
than O O
in O O
the O O
midmyocardium O O
. O O
The O O
generation O O
of O O
dorso O O
- O O
ventral O O
polarity O O
during O O
Drosophila O O
embryogenesis O O
is O O
regulated O O
by O O
the O O
action O O
of O O
12 O O
maternally O O
expressed O O
gene O O
products O O
, O O
the O O
dorsal B-GENE O
group E-GENE O
. O O
Ultimobranchial O O
body O O
and O O
parathyroid O O
glands O O
of O O
the O O
freshwater O O
snake O O
Natrix O O
piscator O O
in O O
response O O
to O O
vitamin O O
D3 O O
administration O O
. O O
These O O
observations O O
suggest O O
that O O
the O O
AF O B-GENE
- O I-GENE
1 O E-GENE
region O O
of O O
PPARalpha S-GENE S-GENE
is O O
partially O O
silenced O O
by O O
corepressor O O
proteins O O
, O O
which O O
might O O
interact O O
in O O
a O O
phosphorylation O O
- O O
dependent O O
manner O O
. O O
Two O O
authors O O
, O O
two O O
journal O O
titles O O
, O O
two O O
drug O O
names O O
, O O
and O O
two O O
topics O O
of O O
a O O
general O O
medical O O
nature O O
were O O
retrieved O O
under O O
identical O O
circumstances O O
and O O
conditions O O
on O O
the O O
hosts O O
DATA O O
- O O
STAR O O
, O O
DIALOG O O
, O O
DIMDI O O
, O O
and O O
STN O O
. O O
However O O
, O O
in O O
a O O
variation O O
of O O
this O O
assay O O
in O O
which O O
the O O
protease O O
is O O
omitted O O
, O O
the O O
mutant O O
enzymes O O
exhibited O O
substantial O O
levels O O
of O O
prolyl B-GENE B-GENE
isomerase E-GENE E-GENE
activity O O
( O O
5 O O
- O O
20 O O
% O O
of O O
wild O O
- O O
type O O
) O O
, O O
revealing O O
that O O
these O O
mutations O O
confer O O
sensitivity O O
to O O
protease O O
digestion O O
and O O
that O O
the O O
classic O O
in O O
vitro O O
assay O O
for O O
prolyl B-GENE B-GENE
isomerase E-GENE E-GENE
activity O O
may O O
be O O
misleading O O
. O O
As O O
a O O
test O O
of O O
this O O
hypothesis O O
, O O
we O O
predicted O O
that O O
mice O O
which O O
have O O
altered O O
expression O O
of O O
class O O
I O O
gene O O
products O O
, O O
the O O
beta2 B-GENE O
- I-GENE O
microglobulin E-GENE O
knockout O O
mice O O
, O O
[ B-GENE O
beta2m I-GENE O
( I-GENE O
- I-GENE O
/ I-GENE O
- I-GENE O
) I-GENE O
] E-GENE O
, O O
would O O
develop O O
Fe O O
overload O O
. O O
Nucleotide O O
sequence O O
of O O
the O O
gag B-GENE B-GENE
gene E-GENE E-GENE
and O O
gag S-GENE O
- O O
pol S-GENE O
junction O O
of O O
feline O O
leukemia O O
virus O O
. O O
Clinical O O
trial O O
endpoints O O
based O O
on O O
magnitude O O
of O O
reduction O O
in O O
HIV O O
- O O
1 O O
RNA O O
levels O O
provide O O
an O O
important O O
complement O O
to O O
endpoints O O
based O O
on O O
percentage O O
of O O
patients O O
achieving O O
complete O O
virologic O O
suppression O O
. O O
It O O
also O O
describes O O
the O O
preliminary O O
results O O
of O O
a O O
Phase O O
II O O
trial O O
going O O
on O O
at O O
the O O
Central O O
Institute O O
for O O
Tumors O O
in O O
Zagreb O O
, O O
using O O
a O O
combination O O
of O O
cis O O
- O O
DDP O O
, O O
5 O O
- O O
fluorouracil O O
and O O
vincristine O O
. O O
On O O
the O O
basis O O
of O O
the O O
physical O O
interactions O O
between O O
Sxl S-GENE S-GENE
and O O
Snf S-GENE S-GENE
, O O
we O O
present O O
a O O
model O O
for O O
Sxl S-GENE O
splicing O O
regulation O O
. O O
Though O O
it O O
has O O
been O O
established O O
that O O
skinfold O O
anthropometry O O
has O O
severe O O
limitations O O
as O O
a O O
method O O
of O O
deriving O O
total O O
body O O
fat O O
( O O
TBF O O
) O O
, O O
the O O
possibility O O
that O O
the O O
problem O O
might O O
be O O
related O O
more O O
to O O
the O O
assumptions O O
implicit O O
in O O
densitometry O O
has O O
to O O
be O O
addressed O O
. O O
The O O
average O O
mean O O
difference O O
compared O O
with O O
the O O
low O O
and O O
the O O
intermediate O O
calcium O O
group O O
was O O
11 O O
% O O
for O O
the O O
femoral O O
neck O O
, O O
8 O O
- O O
11 O O
% O O
for O O
the O O
lumbar O O
spine O O
and O O
5 O O
- O O
6 O O
% O O
for O O
total O O
body O O
BMDs O O
. O O
We O O
cloned O O
the O O
BamHI B-GENE O
- I-GENE O
F I-GENE O
fragment E-GENE O
from O O
the O O
left O O
end O O
of O O
Ad4 O O
in O O
pUC13 O O
- O O
1 O O
between O O
the O O
SalI S-GENE O
and O O
BamHI B-GENE B-GENE
sites E-GENE E-GENE
in O O
order O O
to O O
carry O O
out O O
the O O
structural O O
analysis O O
of O O
the O O
E1A B-GENE O
region I-GENE O
of I-GENE O
Ad4 E-GENE O
. O O
We O O
reviewed O O
81 O O
patients O O
with O O
dementia O O
and O O
autopsy O O
findings O O
of O O
Alzheimer O O
' O O
s O O
disease O O
( O O
AD O O
) O O
to O O
identify O O
patients O O
with O O
seizures O O
or O O
myoclonus O O
after O O
onset O O
of O O
dementia O O
. O O
BACKGROUND O O
: O O
In O O
lung O O
protective O O
strategy O O
, O O
positive O O
end O O
- O O
expiratory O O
pressure O O
( O O
PEEP O O
) O O
slightly O O
higher O O
than O O
the O O
Pflex O O
( O O
the O O
airway O O
pressure O O
corresponding O O
to O O
the O O
lower O O
inflection O O
point O O
( O O
LIP O O
) O O
on O O
the O O
inspiratory O O
pressure O O
- O O
volume O O
( O O
P O O
- O O
V O O
) O O
curve O O
measured O O
with O O
ZEEP O O
) O O
is O O
generally O O
recommended O O
. O O
3 O O
. O O
In O O
both O O
RAW O O
cells O O
and O O
the O O
microglia O O
cell O O
line O O
EOC20 O S-GENE
, O O
two O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
- O O
activated O O
transcription O O
factors O O
, O O
STAT B-GENE B-GENE
- I-GENE I-GENE
1alpha E-GENE E-GENE
and O O
IRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
bind O O
the O O
GAS S-GENE O
and O O
IRF B-GENE S-GENE
elements E-GENE O
, O O
respectively O O
. O O
Thermal O O
changes O O
of O O
the O O
bovine O O
uterus O O
following O O
administration O O
of O O
estradiol O O
- O O
17beta O O
. O O
The O O
starting O O
dose O O
was O O
8 O O
mg O O
/ O O
m2 O O
administered O O
intravenously O O
( O O
IV O O
) O O
as O O
a O O
short O O
infusion O O
daily O O
for O O
5 O O
days O O
, O O
repeated O O
every O O
3 O O
weeks O O
with O O
dose O O
adjustments O O
depending O O
on O O
patient O O
tolerance O O
. O O
In O O
agreement O O
with O O
other O O
authors O O
, O O
we O O
recommend O O
the O O
procedure O O
as O O
a O O
safe O O
one O O
, O O
providing O O
satisfactory O O
results O O
. O O
After O O
inhibition O O
of O O
monoamine B-GENE O
oxidase E-GENE O
with O O
pargyline O O
( O O
10 O O
mg O O
/ O O
kg O O
. O O
i O O
. O O
v O O
. O O
) O O
, O O
the O O
effects O O
of O O
tyramine O O
( O O
1000 O O
micrograms O O
) O O
injected O O
into O O
the O O
hepatic O O
artery O O
were O O
potentiated O O
. O O
Helenalin O O
triggers O O
a O O
CD95 B-GENE S-GENE
death I-GENE O
receptor E-GENE O
- O O
independent O O
apoptosis O O
that O O
is O O
not O O
affected O O
by O O
overexpression O O
of O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
x I-GENE E-GENE
( I-GENE O
L I-GENE O
) E-GENE O
or O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
. O O
Of O O
the O O
47 O O
women O O
with O O
AGCUS O O
, O O
16 O O
had O O
intraepithelial O O
or O O
invasive O O
neoplasms O O
( O O
34 O O
% O O
; O O
95 O O
% O O
confidence O O
interval O O
, O O
21 O O
- O O
49 O O
% O O
) O O
, O O
including O O
9 O O
low O O
or O O
high O O
grade O O
squamous O O
intraepithelial O O
lesions O O
, O O
1 O O
adenocarcinoma O O
in O O
situ O O
of O O
the O O
cervix O O
, O O
3 O O
adenocarcinomas O O
of O O
the O O
cervix O O
, O O
2 O O
adenocarcinomas O O
of O O
the O O
endometrium O O
and O O
1 O O
adenoid O O
basal O O
cell O O
carcinoma O O
of O O
the O O
cervix O O
. O O
The O O
DF3 S-GENE S-GENE
/ O O
MUC1 S-GENE B-GENE
gene O E-GENE
encodes O O
a O O
high B-GENE O
molecular I-GENE O
weight I-GENE O
mucin I-GENE O
- I-GENE O
like I-GENE O
glycoprotein E-GENE O
which O O
is O O
overexpressed O O
at O O
the O O
transcriptional O O
level O O
in O O
the O O
majority O O
of O O
human O O
breast O O
cancers O O
. O O
The O O
organization O O
of O O
the O O
MBP B-GENE B-GENE
- I-GENE I-GENE
A I-GENE I-GENE
gene E-GENE E-GENE
is O O
very O O
similar O O
to O O
the O O
arrangement O O
of O O
the O O
gene O O
encoding O O
the O O
highly O O
homologous B-GENE O
pulmonary I-GENE O
surfactant I-GENE O
apoprotein E-GENE O
, O O
although O O
one O O
of O O
the O O
intron O O
positions O O
is O O
shifted O O
by O O
a O O
single O O
amino O O
acid O O
. O O
Hip O O
fracture O O
mortality O O
and O O
prospective O O
payment O O
system O O
. O O
These O O
results O O
indicate O O
that O O
patients O O
with O O
SS O O
and O O
evidence O O
of O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
may O O
have O O
decreased O O
myocardial O O
oxygen O O
supply O O
due O O
to O O
low O O
hemoglobin S-GENE O
levels O O
and O O
increased O O
myocardial O O
oxygen O O
demand O O
( O O
elevated O O
double O O
products O O
) O O
when O O
compared O O
to O O
subjects O O
with O O
SS O O
who O O
do O O
not O O
have O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
depression O O
. O O
Although O O
hSSTR5 S-GENE O
displays O O
approximately O O
75 O O
% O O
sequence O O
identity O O
with O O
rat B-GENE B-GENE
SSTR5 E-GENE E-GENE
, O O
the O O
two O O
receptors O O
display O O
significantly O O
different O O
pharmacological O O
profiles O O
, O O
especially O O
with O O
respect O O
to O O
their O O
binding O O
affinities O O
for O O
the O O
SST S-GENE O
analogue O O
SMS O O
201 O O
- O O
995 O O
. O O
A O O
significant O O
and O O
specific O O
reduction O O
in O O
binaural O O
peak O O
amplitude O O
and O O
area O O
of O O
the O O
echo O O
- O O
evoked O O
middle O O
- O O
latency O O
component O O
Pa O O
was O O
observed O O
. O O
EMBO O O
( O O
Eur O O
. O O
Using O O
this O O
oligonucleotide O O
as O O
a O O
probe O O
, O O
an O O
8 O O
- O O
kilobase O O
HindIII S-GENE O
fragment O O
of O O
genomic O O
DNA O O
was O O
isolated O O
and O O
subjected O O
to O O
Sanger O O
dideoxy O O
DNA O O
sequencing O O
. O O
Arg O O
- O O
130 O O
, O O
Gly O O
- O O
132 O O
and O O
Lys O O
- O O
167 O O
are O O
conserved O O
in O O
all O O
members O O
of O O
the O O
type B-GENE B-GENE
IB I-GENE I-GENE
topoisomerase I-GENE I-GENE
family E-GENE E-GENE
. O O
Four O O
cDNAs O O
( O O
Kox4 S-GENE O
, O O
Kox7 S-GENE O
, O O
Kox12 S-GENE O
, O O
and O O
Kox15 S-GENE O
) O O
were O O
identified O O
that O O
match O O
one O O
or O O
more O O
genomic O O
clones O O
; O O
these O O
matches O O
were O O
confirmed O O
by O O
nucleotide O O
sequence O O
analysis O O
. O O
2 O O
. O O
Prevalence O O
of O O
use O O
, O O
claims O O
volume O O
, O O
and O O
expenditures O O
were O O
compared O O
for O O
cisapride O O
, O O
proton O O
pump O O
inhibitors O O
, O O
histamine B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
receptor E-GENE E-GENE
antagonists O O
, O O
and O O
the O O
prokinetic O O
agent O O
metoclopramide O O
during O O
these O O
periods O O
. O O
Relaxant O O
effect O O
of O O
prostaglandin O O
E1 O O
( O O
PGE1 O O
) O O
and O O
papaverine O O
( O O
PAP O O
) O O
were O O
measured O O
in O O
strips O O
of O O
corpus O O
cavernosum O O
smooth O O
muscle O O
taken O O
from O O
a O O
healthy O O
control O O
group O O
of O O
men O O
( O O
A O O
; O O
n O O
= O O
5 O O
) O O
, O O
from O O
arteriogenically O O
impotent O O
men O O
( O O
B O O
; O O
n O O
= O O
6 O O
) O O
and O O
from O O
additionally O O
diabetic O O
impotent O O
men O O
( O O
C O O
; O O
n O O
= O O
5 O O
) O O
with O O
venous O O
leakage O O
. O O
Primer O O
extension O O
experiments O O
using O O
dbcAMP O O
- O O
differentiated O O
U937 O B-GENE
RNA O E-GENE
indicated O O
a O O
single O O
transcriptional O O
initiation O O
site O O
. O O
In O O
contrast O O
, O O
group O O
II O O
showed O O
a O O
significant O O
improvement O O
in O O
peak O O
VO2 O O
with O O
rate O O
adaptive O O
AV O O
delay O O
compared O O
to O O
fixed O O
AV O O
delay O O
programming O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O
Effect O O
of O O
family O O
visits O O
on O O
the O O
blood O O
pressure O O
and O O
heart O O
rate O O
of O O
patients O O
in O O
the O O
coronary O O
- O O
care O O
unit O O
. O O
Sequence O O
analysis O O
and O O
electrophoretic O O
mobility O O
shift O O
experiments O O
suggest O O
that O O
GnSE B-GENE S-GENE
response I-GENE O
elements E-GENE O
interact O O
, O O
in O O
these O O
two O O
regions O O
, O O
with O O
GATA B-GENE O
- I-GENE O
and I-GENE O
LIM I-GENE O
- I-GENE O
related I-GENE O
factors E-GENE O
, O O
respectively O O
. O O
The O O
transfer O O
by O O
conjugation O O
to O O
E O O
. O O
coli O O
K12 O O
of O O
ampicillin O O
and O O
carbenicillin O O
resistance O O
was O O
obtained O O
with O O
14 O O
strains O O
: O O
( O O
E O O
. O O
coli O O
: O O
9 O O
, O O
C O O
. O O
freundii O O
: O O
1 O O
, O O
K O O
. O O
pneumoniae O O
: O O
1 O O
, O O
E O O
. O O
cloacae O O
: O O
2 O O
, O O
P O O
. O O
stuartii O O
: O O
1 O O
) O O
. O O
Wild O O
type O O
MEKK1 S-GENE S-GENE
enhances O O
promoter O O
activity O O
and O O
the O O
activity O O
can O O
be O O
inhibited O O
by O O
dominant O O
negative O O
MEKK1 S-GENE S-GENE
, O O
MEK1 S-GENE S-GENE
, O O
MEK7 S-GENE S-GENE
, O O
MEK3 S-GENE S-GENE
, O O
p38 S-GENE S-GENE
/ O O
RK S-GENE O
, O O
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
. O O
250 O O
, O O
302 O O
- O O
311 O O
] O O
. O O
The O O
studies O O
permit O O
considering O O
the O O
detected O O
shifts O O
in O O
the O O
immunity O O
system O O
an O O
important O O
component O O
of O O
the O O
pathogenesis O O
of O O
chronic O O
nontumorous O O
diseases O O
of O O
the O O
parotid O O
glands O O
. O O
Coexistence O O
of O O
Turner O O
' O O
s O O
syndrome O O
and O O
schizophrenia O O
An O O
scrR B-GENE B-GENE
promoter I-GENE E-GENE
fragment E-GENE O
, O O
which O O
dose O O
not O O
contain O O
a O O
sequence O O
resembling O O
OB S-GENE O
, O O
was O O
not O O
shifted O O
by O O
the O O
fusion O O
protein O O
. O O
Using O O
the O O
conflict O O
drinking O O
test O O
as O O
a O O
model O O
, O O
we O O
studied O O
in O O
rats O O
the O O
effect O O
of O O
the O O
nonselective O O
beta B-GENE O
- I-GENE O
adrenoceptor E-GENE O
blockers O O
pindolol O O
and O O
cyanopindolol O O
which O O
bind O O
to O O
5 B-GENE O
- I-GENE O
HT1A I-GENE O
and I-GENE O
5 I-GENE O
- I-GENE O
HT1B I-GENE O
receptors E-GENE O
, O O
and O O
of O O
the O O
selective O O
beta B-GENE O
1 I-GENE O
- I-GENE O
and I-GENE O
beta I-GENE O
2 I-GENE O
- I-GENE O
adrenoceptor E-GENE O
antagonists O O
betaxolol O O
and O O
ICI O O
118 O O
, O O
551 O O
, O O
respectively O O
, O O
which O O
have O O
a O O
negligible O O
affinity O O
for O O
5 B-GENE O
- I-GENE O
HT I-GENE O
receptors E-GENE O
. O O
Although O O
several O O
other O O
signal O O
transduction O O
molecules O O
also O O
contain O O
tandemly O O
occurring O O
SH3 S-GENE S-GENE
and O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
, O O
the O O
function O O
of O O
these O O
closely O O
spaced O O
domains O O
is O O
not O O
well O O
understood O O
. O O
Glycoprotein O O
biosynthesis O O
in O O
Saccharomyces O O
cerevisiae O O
: O O
ngd29 S-GENE S-GENE
, O O
an O O
N O O
- O O
glycosylation O O
mutant O O
allelic O O
to O O
och1 S-GENE O
having O O
a O O
defect O O
in O O
the O O
initiation O O
of O O
outer O O
chain O O
formation O O
. O O
CONCLUSIONS O O
: O O
In O O
the O O
majority O O
of O O
patients O O
with O O
severe O O
ulcerative O O
colitis O O
, O O
circulating O O
concentrations O O
of O O
NOX O O
are O O
increased O O
at O O
presentation O O
and O O
fall O O
promptly O O
during O O
parenteral O O
steroid O O
therapy O O
, O O
irrespective O O
of O O
clinical O O
outcome O O
. O O
The O O
duration O O
of O O
naloxone O O
appears O O
to O O
be O O
dose O O
- O O
related O O
, O O
statistically O O
significant O O
up O O
to O O
approximately O O
1 O O
. O O
5 O O
hr O O
. O O
But O O
if O O
one O O
equalizes O O
the O O
upper O O
limits O O
of O O
normal O O
for O O
both O O
markers O O
to O O
a O O
common O O
95 O O
% O O
specificity O O
, O O
the O O
tumour O O
- O O
indicating O O
sensitivity O O
of O O
CA B-GENE O
19 I-GENE O
- I-GENE O
9 E-GENE O
clearly O O
surpasses O O
that O O
of O O
CA B-GENE O
50 E-GENE O
. O O
These O O
motions O O
were O O
found O O
in O O
the O O
N O O
- O O
and O O
C O O
- O O
terminal O O
tails O O
, O O
in O O
segment O O
33 O O
- O O
35 O O
which O O
forms O O
the O O
turn O O
between O O
beta O O
- O O
strands O O
S1 O O
and O O
S2 O O
, O O
and O O
residues O O
47 O O
- O O
52 O O
located O O
in O O
a O O
long O O
loop O O
preceding O O
strand O O
S3 O O
. O O
Genomic O O
Southern O O
analysis O O
reveals O O
10 O O
to O O
15 O O
hybridising O O
fragments O O
, O O
suggesting O O
that O O
maize O O
contains O O
a O O
small O O
gene O O
family O O
. O O
Custom O O
- O O
made O O
orthoses O O
play O O
an O O
invaluable O O
role O O
in O O
achieving O O
a O O
wide O O
range O O
of O O
therapeutic O O
goals O O
: O O
improving O O
function O O
and O O
pinch O O
, O O
stabilizing O O
individual O O
joints O O
, O O
preventing O O
positional O O
contractures O O
, O O
protecting O O
joints O O
from O O
trauma O O
, O O
stretching O O
the O O
intrinsic O O
muscles O O
, O O
correcting O O
joint O O
- O O
and O O
soft O O
- O O
tissue O O
contractures O O
, O O
and O O
controlling O O
inflammation O O
. O O
Is O O
exposure O O
to O O
a O O
patient O O
with O O
Crohn O O
' O O
s O O
disease O O
an O O
environmental O O
factor O O
for O O
developing O O
the O O
disease O O
. O O
The O O
ZAG1 B-GENE B-GENE
protein E-GENE E-GENE
from O O
in O O
vitro O O
translations O O
binds O O
to O O
a O O
consensus O O
target O O
site O O
that O O
is O O
recognized O O
by O O
the O O
AG B-GENE B-GENE
protein E-GENE E-GENE
. O O
The O O
uap100 S-GENE O
cis O O
- O O
acting O O
, O O
up O O
- O O
promoter O O
, O O
constitutive O O
mutation O O
is O O
a O O
duplication O O
that O O
comprises O O
two O O
GATA O B-GENE
sites O E-GENE
and O O
suppresses O O
weakly O O
the O O
AREA B-GENE O
zinc I-GENE O
finger I-GENE O
mutation E-GENE O
but O O
does O O
not O O
alleviate O O
the O O
need O O
for O O
functional O O
UAY S-GENE S-GENE
and O O
AREA B-GENE O
proteins E-GENE O
. O O
Pituitary O O
thyrotropic O O
adenoma O O
associated O O
with O O
congenital O O
hypothyroidism O O
. O O
This O O
region O O
was O O
unfavourable O O
, O O
due O O
to O O
malaria O O
in O O
the O O
past O O
. O O
Indeed O O
, O O
after O O
a O O
single O O
oral O O
dose O O
, O O
the O O
role O O
of O O
the O O
mu B-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
agonist O O
component O O
of O O
the O O
antinociceptive O O
effect O O
of O O
tramadol O O
appears O O
to O O
be O O
minor O O
, O O
with O O
most O O
of O O
the O O
analgesic O O
effect O O
being O O
attributable O O
to O O
nonopioid O O
properties O O
of O O
the O O
parent O O
compound O O
. O O
CHIEF O O
OUTCOME O O
MEASURES O O
: O O
Endoluminal O O
release O O
of O O
prostacyclin O O
( O O
6 O O
- O O
Keto O O
- O O
PGF1 O O
alpha O O
) O O
and O O
thromboxane O O
B2 O O
( O O
TxB2 O O
) O O
, O O
patency O O
, O O
EC O O
coverage O O
and O O
cell O O
identity O O
. O O
Somatic O O
and O O
visceral O O
inputs O O
to O O
the O O
thoracic O O
spinal O O
cord O O
of O O
the O O
cat O O
: O O
effects O O
of O O
noxious O O
stimulation O O
of O O
the O O
biliary O O
system O O
. O O
We O O
have O O
produced O O
the O O
Ure2 B-GENE B-GENE
protein E-GENE E-GENE
to O O
high O O
yield O O
in O O
Escherichia O O
coli O O
from O O
a O O
synthetic O O
gene O O
. O O
Transfection O O
of O O
both O O
Calu O O
- O O
6 O O
and O O
JEG O O
- O O
3 O O
cells O O
with O O
a O O
PKA S-GENE S-GENE
expression O O
vector O O
resulted O O
in O O
a O O
10 O O
- O O
fold O O
induction O O
of O O
human B-GENE O
renin E-GENE O
transcriptional O O
activity O O
in O O
constructs O O
containing O O
the O O
native O O
or O O
consensus O O
CRE O O
and O O
5 O O
- O O
fold O O
activation O O
in O O
a O O
construct O O
containing O O
a O O
nonfunctional O O
CRE O O
. O O
We O O
undertook O O
this O O
study O O
to O O
examine O O
the O O
relationship O O
between O O
systemic O O
oxygen O O
delivery O O
( O O
DO2 O O
) O O
and O O
tissue O O
oxygen O O
tension O O
( O O
TPO2 O O
) O O
in O O
hypovolemic O O
shock O O
. O O
White O O
female O O
cases O O
were O O
more O O
likely O O
to O O
have O O
worked O O
as O O
registered O O
nurses O O
than O O
were O O
the O O
controls O O
( O O
OR O O
= O O
1 O O
. O O
9 O O
, O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
0 O O
- O O
3 O O
. O O
5 O O
) O O
. O O
METHODS O O
: O O
Children O O
with O O
attention O O
- O O
deficit O O
/ O O
hyperactivity O O
disorder O O
( O O
ADHD O O
; O O
n O O
= O O
282 O O
) O O
, O O
all O O
subtypes O O
, O O
ages O O
6 O O
to O O
12 O O
years O O
, O O
were O O
randomized O O
to O O
placebo O O
( O O
n O O
= O O
90 O O
) O O
, O O
immediate O O
- O O
release O O
methylphenidate O O
( O O
IR O O
MPH O O
) O O
3 O O
times O O
a O O
day O O
( O O
tid O O
; O O
dosed O O
every O O
4 O O
hours O O
; O O
n O O
= O O
97 O O
) O O
, O O
or O O
OROS O O
MPH O O
once O O
a O O
day O O
( O O
qd O O
; O O
n O O
= O O
95 O O
) O O
in O O
a O O
double O O
- O O
blind O O
, O O
28 O O
- O O
day O O
trial O O
. O O
Immunologic O O
tolerance O O
in O O
rats O O
during O O
13 O O
weeks O O
of O O
inhalation O O
exposure O O
to O O
trimellitic O O
anhydride O O
. O O
They O O
cause O O
temporary O O
disability O O
, O O
invalidity O O
and O O
mortality O O
of O O
a O O
great O O
part O O
of O O
the O O
productive O O
population O O
, O O
significantly O O
damaging O O
the O O
economic O O
status O O
of O O
the O O
country O O
. O O
Cloning O O
and O O
sequence O O
analysis O O
of O O
a O O
chymotrypsinlike B-GENE O
protease I-GENE O
from I-GENE O
Treponema E-GENE O
denticola O O
. O O
METHODS O O
AND O O
RESULTS O O
: O O
The O O
QTd O O
and O O
JTd O O
intervals O O
in O O
39 O O
children O O
with O O
long O O
QT O O
syndrome O O
were O O
compared O O
to O O
those O O
of O O
50 O O
normal O O
age O O
- O O
matched O O
children O O
. O O
V B-GENE O
- I-GENE O
ErbB I-GENE O
- I-GENE O
mediated I-GENE O
complex E-GENE O
formation O O
and O O
transformation O O
have O O
been O O
shown O O
to O O
occur O O
independently O O
of O O
Ras S-GENE S-GENE
activation O O
. O O
Both O O
parameters O O
were O O
determined O O
in O O
an O O
individual O O
eye O O
by O O
applying O O
the O O
dye O O
first O O
by O O
iontophoresis O O
and O O
then O O
by O O
intravitreal O O
injection O O
, O O
which O O
allows O O
the O O
influence O O
of O O
fluorescein O O
glucuronide O O
on O O
the O O
fluorophotometric O O
measurements O O
to O O
be O O
excluded O O
. O O
Organization O O
of O O
exons O O
suggests O O
that O O
, O O
similar O O
to O O
the O O
human B-GENE B-GENE
VEGF I-GENE I-GENE
gene E-GENE E-GENE
, O O
alternative O O
splicing O O
generates O O
the O O
120 O O
- O O
, O O
164 O O
- O O
, O O
and O O
188 O O
- O O
amino O O
acid O O
isoforms O O
, O O
but O O
does O O
not O O
predict O O
a O O
fourth O O
VEGF B-GENE B-GENE
isoform E-GENE E-GENE
corresponding O O
to O O
human B-GENE B-GENE
VEGF206 E-GENE E-GENE
. O O
Electron O O
microscopy O O
of O O
pH O O
7 O O
. O O
5 O O
- O O
treated O O
TMV O O
particles O O
incubated O O
in O O
SPN S-GENE O
- O O
treated O O
wheatgerm O O
extract O O
or O O
rabbit O O
reticulocyte O O
lysate O O
, O O
showed O O
that O O
approximately O O
10 O O
% O O
of O O
virions O O
complexed O O
with O O
one O O
ribosome O O
and O O
approximately O O
10 O O
% O O
with O O
two O O
bound O O
ribosomes O O
, O O
confirming O O
that O O
omega O O
at O O
least O O
had O O
been O O
uncoated O O
. O O
The O O
sequence O O
contained O O
five O O
repeats O O
of O O
the O O
hypothetical O O
leucine O O
zipper O O
motif O O
: O O
one O O
is O O
in O O
the O O
N O O
- O O
terminal O O
globular O O
domain O O
, O O
and O O
four O O
are O O
in O O
the O O
central O O
alpha O O
- O O
helical O O
stalk O O
. O O
Postheparin O B-GENE
lipoprotein B-GENE I-GENE
lipase E-GENE E-GENE
, O O
measured O O
using O O
fat O O
emulsion O O
as O O
substrate O O
, O O
also O O
was O O
significantly O O
greater O O
in O O
female O O
rats O O
compared O O
with O O
males O O
. O O
The O O
authors O O
report O O
a O O
case O O
of O O
a O O
painful O O
wrist O O
related O O
to O O
a O O
" O O
Manieux O O
muscle O O
" O O
of O O
the O O
dorsal O O
aspect O O
of O O
the O O
hand O O
. O O
Genomic O O
organization O O
of O O
the O O
human B-GENE O
multidrug I-GENE O
resistance I-GENE O
( I-GENE O
MDR1 I-GENE S-GENE
) I-GENE O
gene E-GENE O
and O O
origin O O
of O O
P B-GENE O
- I-GENE O
glycoproteins E-GENE O
. O O
The O O
response O O
to O O
nitroglycerin O O
, O O
however O O
, O O
remained O O
intact O O
regardless O O
of O O
initial O O
reperfusion O O
pressure O O
. O O
Deletion O O
analysis O O
revealed O O
that O O
only O O
the O O
TM O O
domain O O
of O O
E2 S-GENE S-GENE
was O O
required O O
for O O
Golgi O O
targeting O O
. O O
In O O
addition O O
, O O
putative O O
binding O O
sites O O
for O O
SH3 S-GENE S-GENE
and O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
are O O
present O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
molecule O O
. O O
Since O O
nearly O O
all O O
transformants O O
involving O O
homeologous O O
DNAs O O
carried O O
a O O
single O O
recombinant O O
plasmid O O
in O O
both O O
Pms B-GENE O
+ E-GENE O
and O O
Pms B-GENE O
- E-GENE O
strains O O
, O O
stable O O
heteroduplex O O
DNA O O
appears O O
less O O
likely O O
than O O
for O O
homologous O O
DNAs O O
. O O
All O O
rights O O
reserved O O
. O O
One O O
new O O
ORF O O
, O O
YBR0224 S-GENE S-GENE
, O O
was O O
detected O O
, O O
coding O O
for O O
a O O
protein O O
with O O
918 O O
amino O O
acids O O
. O O
A O O
sequence O O
- O O
ready O O
3 O O
- O O
Mb O O
PAC O O
contig O O
covering O O
16 O O
breakpoints O O
of O O
the O O
Wilms B-GENE O
tumor I-GENE O
/ I-GENE O
anirida I-GENE O
region E-GENE O
of O O
human O O
chromosome O O
11p13 O O
. O O
The O O
MAP B-GENE B-GENE
kinase I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE I-GENE
MLK2 S-GENE E-GENE
co O O
- O O
localizes O O
with O O
activated O O
JNK S-GENE S-GENE
along O O
microtubules O O
and O O
associates O O
with O O
kinesin B-GENE O
superfamily E-GENE O
motor O O
KIF3 S-GENE S-GENE
. O O
Bone O O
scintigraphy O O
is O O
an O O
excellent O O
screening O O
test O O
for O O
bone O O
lesions O O
and O O
Ga O O
- O O
67 O O
scintigraphy O O
is O O
a O O
useful O O
tool O O
for O O
detecting O O
inflammatory O O
lesions O O
. O O
Spontaneous O O
fracture O O
of O O
the O O
tarsal O O
bone O O
in O O
2 O O
cases O O
of O O
leprosy O O
They O O
are O O
transduced O O
through O O
TM O O
to O O
the O O
cytoplasmic O O
portion O O
( O O
cytoloops O O
and O O
the O O
C O O
- O O
terminal O O
tail O O
) O O
of O O
the O O
receptor O O
and O O
then O O
, O O
transferred O O
to O O
cytoplasmic O O
signaling O O
molecules O O
, O O
such O O
as O O
G B-GENE O
protein E-GENE O
. O O
Serum B-GENE B-GENE
alkaline I-GENE I-GENE
phosphatase E-GENE E-GENE
and O O
creatine B-GENE B-GENE
kinase E-GENE E-GENE
activities O O
were O O
significantly O O
increased O O
in O O
the O O
A O O
praelongus O O
- O O
fed O O
pigs O O
and O O
significantly O O
decreased O O
in O O
Na2SeO4 O O
- O O
fed O O
pigs O O
. O O
This O O
group O O
showed O O
the O O
presence O O
of O O
bacteria O O
infiltrated O O
at O O
the O O
dentinal O O
tubules O O
coronally O O
and O O
into O O
the O O
root O O
canals O O
. O O
Seven O O
Zebu O O
cattle O O
were O O
also O O
exposed O O
to O O
challenge O O
at O O
the O O
same O O
time O O
. O O
However O O
, O O
the O O
quasiparticle O O
scattering O O
rate O O
tau O O
( O O
- O O
1 O O
) O O
is O O
such O O
that O O
Planck O O
' O O
s O O
over O O
2pi O O
/ O O
tau O O
approximately O O
6t O O
( O O
perpendicular O O
) O O
, O O
implying O O
that O O
kappa O O
- O O
( O O
BEDT O O
- O O
TTF O O
) O O
2Cu O O
( O O
NCS O O
) O O
( O O
2 O O
) O O
meets O O
the O O
criterion O O
used O O
to O O
identify O O
interlayer O O
incoherence O O
. O O
The O O
effect O O
on O O
kidney O O
length O O
was O O
considerably O O
prolonged O O
compared O O
with O O
the O O
vascular O O
effect O O
. O O
Although O O
polyubiquitin B-GENE O
chains E-GENE O
linked O O
through O O
Lys O O
( O O
29 O O
) O O
of O O
ubiquitin S-GENE O
have O O
been O O
implicated O O
in O O
the O O
targeting O O
of O O
certain O O
substrates O O
to O O
proteasomes O O
, O O
the O O
signaling O O
properties O O
of O O
these O O
chains O O
are O O
poorly O O
understood O O
. O O
Diabetic O O
osteopenia O O
, O O
a O O
known O O
chronic O O
complication O O
of O O
diabetes O O
, O O
has O O
been O O
demonstrated O O
with O O
alterations O O
in O O
the O O
calcium O O
- O O
vitamin O O
D O O
endocrine O O
system O O
. O O
An O O
in O O
vitro O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
kinase E-GENE E-GENE
assay O O
, O O
however O O
, O O
failed O O
to O O
detect O O
LPS O O
- O O
induced O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
suggesting O O
that O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
kinase E-GENE E-GENE
is O O
not O O
an O O
activating O O
component O O
of O O
the O O
LPS O S-GENE
signaling O O
pathway O O
regulating O O
MAPK S-GENE S-GENE
activity O O
or O O
sIL B-GENE B-GENE
- I-GENE I-GENE
1Ra I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
. O O
Phosphorylation O O
of O O
the O O
ras S-GENE B-GENE
GTPase B-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
( O O
GAP S-GENE S-GENE
) O O
by O O
the O O
p93c B-GENE B-GENE
- I-GENE I-GENE
fes E-GENE I-GENE
protein B-GENE I-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
in O O
vitro O O
and O O
formation O O
of O O
GAP S-GENE O
- O O
fes S-GENE O
complexes O O
via O O
an O O
SH2 S-GENE S-GENE
domain O O
- O O
dependent O O
mechanism O O
. O O
Gingival O O
retraction O O
for O O
class O O
V O O
restorations O O
. O O
Two O O
methods O O
for O O
the O O
routine O O
determination O O
of O O
blood O O
hemoglobin S-GENE O
oxygen O O
affinity O O
are O O
described O O
. O O
Thirty O O
minutes O O
after O O
reperfusion O O
, O O
lung O O
lymph O O
flow O O
( O O
QL O O
) O O
increased O O
from O O
4 O O
. O O
3 O O
to O O
8 O O
. O O
3 O O
ml O O
/ O O
30 O O
minutes O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
lymph O O
/ O O
plasma O O
protein O O
ratio O O
was O O
unchanged O O
from O O
0 O O
. O O
6 O O
, O O
and O O
the O O
lymph O O
protein O O
clearance O O
increased O O
from O O
2 O O
. O O
6 O O
to O O
4 O O
. O O
6 O O
ml O O
/ O O
30 O O
minutes O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
data O O
consistent O O
with O O
increased O O
microvascular O O
permeability O O
. O O
U O O
. O O
S O O
. O O
A O O
. O O
RET S-GENE S-GENE
/ O O
PTC S-GENE S-GENE
oncogenes O O
, O O
generated O O
by O O
chromosomal O O
rearrangements O O
in O O
papillary O O
thyroid O O
carcinomas O O
, O O
are O O
constitutively O O
activated O O
versions O O
of O O
proto B-GENE B-GENE
- I-GENE I-GENE
RET E-GENE E-GENE
, O O
a O O
gene O O
coding O O
for O O
a O O
receptor B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
( O O
TK S-GENE S-GENE
) O O
whose O O
ligand O O
is O O
still O O
unknown O O
. O O
PCC O B-GENE
6803 O I-GENE
mutant O E-GENE
impaired O O
in O O
cytochrome B-GENE O
c E-GENE O
maturation O O
. O O
STUDY O O
OBJECTIVE O O
: O O
to O O
characterize O O
gas O O
exchange O O
and O O
cardiopulmonary O O
performance O O
during O O
maximal O O
progressive O O
arm O O
crank O O
exercise O O
. O O
In O O
this O O
study O O
, O O
we O O
show O O
that O O
the O O
activating O O
effect O O
of O O
this O O
mutation O O
is O O
not O O
the O O
result O O
of O O
creating O O
an O O
exonic O O
splicing O O
enhancer O O
( O O
ESE O O
) O O
or O O
disrupting O O
a O O
putative O O
secondary O O
structure O O
. O O
The O O
kinase O O
domains O O
encoded O O
in O O
the O O
COOH O O
- O O
terminal O O
moiety O O
are O O
94 O O
% O O
conserved O O
; O O
the O O
NH2 O O
- O O
terminal O O
moieties O O
are O O
approximately O O
65 O O
% O O
homologous O O
, O O
suggesting O O
this O O
region O O
may O O
encode O O
sequences O O
conferring O O
differential O O
regulation O O
of O O
the O O
two O O
kinases O O
. O O
In O O
rats O O
exposed O O
to O O
Cd O O
for O O
30 O O
d O O
, O O
the O O
levels O O
of O O
urinary O O
excretion O O
of O O
cAMP O O
after O O
treatment O O
with O O
parathyroid B-GENE O
hormone E-GENE O
( O O
PTH S-GENE O
) O O
, O O
parathyroidectomy O O
( O O
PTX O O
) O O
, O O
or O O
1 O O
alpha O O
- O O
hydroxycholecalciferol O O
( O O
1 O O
alpha O O
- O O
OH O O
- O O
D3 O O
) O O
showed O O
almost O O
the O O
same O O
patterns O O
as O O
those O O
of O O
control O O
rats O O
: O O
the O O
response O O
of O O
urinary O O
cAMP O O
to O O
treatment O O
with O O
PTH S-GENE O
was O O
not O O
influenced O O
by O O
continuous O O
oral O O
administration O O
of O O
Cd O O
. O O
The O O
goal O O
of O O
this O O
investigation O O
was O O
to O O
determine O O
whether O O
BMIPP O O
uptake O O
can O O
be O O
used O O
to O O
differentiate O O
viable O O
myocardium O O
from O O
scar O O
tissue O O
soon O O
after O O
coronary O O
thrombolysis O O
for O O
acute O O
myocardial O O
infarction O O
. O O
There O O
are O O
three O O
types O O
of O O
problems O O
: O O
problems O O
arising O O
before O O
the O O
drug O O
enters O O
the O O
body O O
( O O
solubilization O O
, O O
stabilization O O
and O O
improved O O
acceptability O O
) O O
; O O
problems O O
associated O O
with O O
the O O
penetration O O
and O O
fate O O
of O O
the O O
drug O O
in O O
the O O
body O O
( O O
absorption O O
, O O
barrier O O
crossing O O
, O O
duration O O
of O O
action O O
) O O
; O O
problems O O
relating O O
to O O
the O O
therapeutic O O
target O O
( O O
selective O O
local O O
delivery O O
) O O
. O O
In O O
the O O
absence O O
of O O
shock O O
, O O
sepsis O O
, O O
or O O
other O O
identifiable O O
causes O O
of O O
lactic O O
acidosis O O
, O O
the O O
severe O O
anemia O O
( O O
hemoglobin S-GENE O
1 O O
. O O
2 O O
g O O
/ O O
dl O O
) O O
appeared O O
to O O
be O O
the O O
primary O O
etiologic O O
factor O O
. O O
The O O
cumulative O O
experience O O
in O O
liver O O
transplantation O O
since O O
the O O
introduction O O
of O O
cyclosporine O O
A O O
has O O
confirmed O O
its O O
efficacy O O
in O O
the O O
treatment O O
of O O
diverse O O
liver O O
diseases O O
in O O
children O O
and O O
adults O O
. O O
Northern O O
blot O O
analysis O O
of O O
liver O O
, O O
muscle O O
, O O
fat O O
, O O
and O O
pituitary O O
RNA O O
from O O
normal O O
( O O
DwDw O O
) O O
chickens O O
shows O O
a O O
major O O
transcript O O
of O O
4 O O
. O O
3 O O
kilobases O O
( O O
kb O O
) O O
and O O
three O O
minor O O
transcripts O O
( O O
0 O O
. O O
8 O O
, O O
1 O O
. O O
7 O O
, O O
and O O
3 O O
. O O
2 O O
kb O O
) O O
, O O
which O O
correspond O O
to O O
the O O
cGHR S-GENE O
. O O
Copyright O O
1999 O O
Academic O O
Press O O
. O O
Despite O O
a O O
lowering O O
of O O
her O O
plasma O O
ACTH S-GENE O
concentration O O
during O O
therapy O O
with O O
valproic O O
acid O O
, O O
the O O
patient O O
' O O
s O O
tumour O O
showed O O
no O O
evidence O O
of O O
regression O O
while O O
she O O
was O O
taking O O
the O O
drug O O
. O O
The O O
Htf9 B-GENE B-GENE
- I-GENE I-GENE
a I-GENE I-GENE
gene E-GENE I-GENE
encodes O E-GENE
the O O
RanBP1 B-GENE B-GENE
protein E-GENE E-GENE
, O O
a O O
major O O
partner O O
of O O
the O O
Ran B-GENE B-GENE
GTPase E-GENE E-GENE
. O O
STUDY O O
DESIGN O O
: O O
Retrospective O O
review O O
. O O
Sequence O O
divergence O O
of O O
approximately O O
16 O O
% O O
reduced O O
transformation O O
frequencies O O
by O O
at O O
least O O
10 O O
- O O
fold O O
. O O
Our O O
studies O O
suggest O O
that O O
the O O
helicase S-GENE O
assembly O O
protein O O
is O O
responsible O O
for O O
loading O O
T4 B-GENE B-GENE
gene I-GENE E-GENE
41 I-GENE O
helicase E-GENE O
specifically O O
at O O
replication O O
forks O O
, O O
and O O
that O O
its O O
binding O O
sites O O
for O O
each O O
arm O O
must O O
hold O O
more O O
than O O
six O O
, O O
but O O
not O O
more O O
than O O
12 O O
nucleotides O O
. O O
During O O
the O O
1st O O
week O O
of O O
treatment O O
all O O
subjects O O
received O O
either O O
mianserin O O
30 O O
mg O O
or O O
clomipramine O O
75 O O
mg O O
once O O
daily O O
. O O
CBD O O
exploration O O
was O O
avoided O O
in O O
7 O O
patients O O
with O O
normal O O
POC O O
. O O
The O O
human B-GENE B-GENE
SHBG I-GENE I-GENE
proximal I-GENE I-GENE
promoter E-GENE E-GENE
was O O
analyzed O O
by O O
DNase B-GENE O
I E-GENE O
footprinting O O
, O O
and O O
the O O
functional O O
significance O O
of O O
6 O O
footprinted O O
regions O O
( O O
FP1 O O
- O O
FP6 O O
) O O
within O O
the O O
proximal O O
promoter O O
was O O
studied O O
in O O
human O O
HepG2 O O
hepatoblastoma O O
cells O O
. O O
We O O
exposed O O
Dorper O O
- O O
cross O O
ewes O O
at O O
approximately O O
120 O O
- O O
135 O O
days O O
of O O
gestation O O
to O O
a O O
hot O O
( O O
40 O O
degrees O O
C O O
, O O
60 O O
% O O
relative O O
humidity O O
) O O
and O O
a O O
cold O O
( O O
4 O O
degrees O O
C O O
, O O
90 O O
% O O
relative O O
humidity O O
) O O
environment O O
and O O
to O O
treadmill O O
exercise O O
( O O
2 O O
. O O
1 O O
km O O
/ O O
h O O
, O O
5 O O
degrees O O
gradient O O
) O O
and O O
measured O O
fetal O O
lamb O O
and O O
ewe O O
body O O
temperatures O O
using O O
previously O O
implanted O O
abdominal O O
radiotelemeters O O
. O O
Previously O O
identified O O
mutations O O
in O O
this O O
variant O O
have O O
been O O
within O O
or O O
close O O
to O O
the O O
coding O O
region O O
of O O
exon O O
1 O O
of O O
the O O
HMBS B-GENE B-GENE
gene E-GENE E-GENE
, O O
the O O
only O O
exon O O
that O O
is O O
expressed O O
solely O O
in O O
the O O
ubiquitous O O
isoform O O
. O O
As O O
an O O
approach O O
to O O
the O O
determination O O
of O O
structure O O
- O O
function O O
relationships O O
in O O
the O O
PRP4 B-GENE B-GENE
protein E-GENE E-GENE
, O O
we O O
have O O
isolated O O
more O O
than O O
fifty O O
new O O
alleles O O
of O O
the O O
PRP4 B-GENE B-GENE
gene E-GENE E-GENE
through O O
random O O
and O O
site O O
- O O
directed O O
mutagenesis O O
, O O
and O O
have O O
analyzed O O
the O O
phenotypes O O
of O O
many O O
of O O
them O O
. O O
Over O O
a O O
period O O
of O O
five O O
training O O
sessions O O
( O O
2 O O
. O O
5 O O
days O O
) O O
, O O
the O O
animals O O
learned O O
not O O
to O O
breathe O O
, O O
and O O
the O O
number O O
of O O
stimuli O O
received O O
in O O
the O O
fifth O O
session O O
was O O
significantly O O
lower O O
than O O
in O O
the O O
first O O
session O O
. O O
The O O
5 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
gene O O
, O O
approximately O O
1 O O
. O O
1 O O
kbp O O
long O O
, O O
had O O
no O O
known O O
regulatory O O
elements O O
for O O
transcription O O
such O O
as O O
TATA O O
, O O
GC O O
, O O
and O O
CCAAT O O
boxes O O
. O O
We O O
find O O
that O O
Fus3p S-GENE S-GENE
and O O
Kss1p S-GENE S-GENE
both O O
control O O
G1 O O
arrest O O
through O O
multiple O O
functions O O
that O O
operate O O
in O O
parallel O O
with O O
Far1p S-GENE S-GENE
. O O
Tag S-GENE O
expression O O
induced O O
apoptosis O O
in O O
mammary O O
epithelial O O
cells O O
during O O
late O O
pregnancy O O
. O O
The O O
composition O O
of O O
renal O O
stones O O
analysed O O
by O O
infrared O O
spectroscopy O O
. O O
14 O O
. O O
9 O O
x O O
109 O O
L O O
- O O
1 O O
) O O
was O O
equal O O
for O O
both O O
groups O O
, O O
but O O
CCI O O
values O O
were O O
significantly O O
higher O O
for O O
the O O
bedside O O
filtered O O
PC O O
( O O
14 O O
. O O
1 O O
+ O O
/ O O
- O O
9 O O
. O O
5 O O
vs O O
. O O
In O O
this O O
study O O
, O O
the O O
case O O
of O O
a O O
patient O O
presenting O O
a O O
second O O
hepatocellular O O
carcinoma O O
13 O O
years O O
after O O
resection O O
of O O
a O O
first O O
tumor O O
of O O
the O O
same O O
type O O
is O O
reported O O
. O O
The O O
time O O
- O O
dependent O O
changes O O
in O O
measured O O
facility O O
of O O
outflow O O
or O O
" O O
washout O O
phenomenon O O
" O O
appeared O O
to O O
result O O
from O O
the O O
gradual O O
dissolution O O
of O O
the O O
hyaluronidase S-GENE O
- O O
sensitive O O
component O O
of O O
the O O
barriers O O
to O O
aqueous O O
outflow O O
in O O
the O O
canine O O
eye O O
. O O
The O O
factors O O
defective O O
in O O
groups O O
A O O
( O O
CIITA S-GENE O
) O O
, O O
C O O
( O O
RFX5 S-GENE O
) O O
and O O
D O O
( O O
RFXAP S-GENE O
) O O
have O O
been O O
identified O O
. O O
It O O
differed O O
significantly O O
by O O
country O O
( O O
from O O
2 O O
. O O
4 O O
% O O
in O O
the O O
United O O
Kingdom O O
to O O
24 O O
. O O
7 O O
% O O
in O O
Portugal O O
) O O
and O O
by O O
transmission O O
category O O
( O O
2 O O
. O O
7 O O
% O O
among O O
homo O O
/ O O
bisexuals O O
, O O
5 O O
. O O
8 O O
% O O
among O O
injecting O O
drug O O
users O O
, O O
13 O O
. O O
6 O O
% O O
among O O
heterosexual O O
subgroup O O
1 O O
) O O
. O O
On O O
a O O
national O O
level O O
, O O
undiscounted O O
costs O O
are O O
expected O O
to O O
increase O O
up O O
to O O
approximately O O
DF1 O O
42 O O
million O O
annually O O
during O O
the O O
first O O
40 O O
years O O
after O O
introduction O O
of O O
the O O
preventative O O
strategy O O
. O O
By O O
deletion O O
analysis O O
, O O
we O O
identified O O
the O O
regions O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
encoding O O
transformation O O
and O O
transactivation O O
functions O O
. O O
A O O
survey O O
of O O
274 O O
late O O
detected O O
cases O O
of O O
CDH O O
born O O
in O O
the O O
years O O
1970 O O
- O O
- O O
74 O O
is O O
presented O O
. O O
To O O
test O O
for O O
progesterone B-GENE O
receptor E-GENE O
- O O
mediated O O
activation O O
of O O
transcription O O
in O O
yeast O O
, O O
reporter O O
plasmids O O
were O O
constructed O O
to O O
transform O O
yeast O O
cells O O
expressing O O
PRB S-GENE S-GENE
or O O
C1C2 B-GENE B-GENE
receptors E-GENE E-GENE
. O O
Fli B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
a O O
proto O O
- O O
oncogene O O
which O O
is O O
rearranged O O
in O O
tumors O O
induced O O
by O O
three O O
different O O
retroviruses O O
, O O
Cas O O
- O O
Br O O
- O O
E O O
, O O
F O O
- O O
MuLV O O
, O O
and O O
10A1 O S-GENE
. O O
Ionic O O
composition O O
( O O
Na O O
+ O O
, O O
K O O
+ O O
, O O
Ca O O
+ O O
2 O O
, O O
and O O
Mg2 O O
+ O O
) O O
of O O
cerebrospinal O O
fluid O O
and O O
feeding O O
behavior O O
in O O
sheep O O
. O O
Materials O O
are O O
presented O O
of O O
a O O
comparative O O
study O O
of O O
morphological O O
and O O
cultural O O
properties O O
and O O
virulence O O
of O O
liophylized O O
cultures O O
of O O
Leishmania O O
tropica O O
major O O
after O O
their O O
rehydration O O
or O O
after O O
a O O
long O O
passage O O
on O O
the O O
NNN O O
medium O O
. O O
CONCLUSIONS O O
: O O
These O O
findings O O
imply O O
that O O
the O O
spinal O O
cord O O
is O O
not O O
a O O
simple O O
command O O
- O O
carrying O O
medium O O
from O O
the O O
brain O O
to O O
the O O
limbs O O
, O O
and O O
implies O O
that O O
some O O
computational O O
activities O O
take O O
place O O
at O O
the O O
spinal O O
cord O O
level O O
. O O
The O O
101st O O
annual O O
meeting O O
of O O
the O O
Japanese O O
Ophthalmological O O
Society O O
. O O
The O O
results O O
corroborate O O
the O O
proposed O O
physiological O O
function O O
of O O
CCoAOMT S-GENE S-GENE
in O O
elicited O O
plant O O
cells O O
and O O
may O O
shed O O
new O O
light O O
on O O
the O O
sequential O O
action O O
of O O
trans O O
- O O
active O O
factors O O
in O O
the O O
regulation O O
of O O
phenylpropanoid O B-GENE
genes O E-GENE
. O O
In O O
src S-GENE O
- O O
transformed O O
cells O O
GAP S-GENE O
forms O O
heteromeric O O
complexes O O
, O O
notably O O
with O O
a O O
highly O O
tyrosine O B-GENE
phosphorylated O I-GENE
62 B-GENE I-GENE
- I-GENE I-GENE
kDa I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
p62 I-GENE S-GENE
) E-GENE O
. O O
A O O
study O O
of O O
characteristics O O
in O O
adult O O
asthmatics O O
who O O
are O O
sensitized O O
by O O
cats O O
and O O
dogs O O
allergens O O
PrRP S-GENE S-GENE
rapidly O O
and O O
transiently O O
activated O O
extracellular B-GENE O
signal I-GENE O
- I-GENE O
regulated I-GENE O
protein I-GENE B-GENE
kinase E-GENE E-GENE
( O O
ERK S-GENE S-GENE
) O O
in O O
both O O
types O O
of O O
cells O O
. O O
Cell O O
- O O
free O O
extracts O O
of O O
E O O
. O O
coli O O
( O O
fpg S-GENE O
mutY S-GENE O
) O O
harboring O O
pYSB10 O S-GENE
possess O O
an O O
enzymatic O O
activity O O
that O O
cleaves O O
a O O
34 O O
- O O
mer O O
oligonucleotide O O
containing O O
a O O
single O O
8 O O
- O O
oxoG O O
opposite O O
a O O
cytosine O O
( O O
8 O O
- O O
OxoG O O
/ O O
C O O
) O O
. O O
Estrogen O O
pretreated O O
castrated O O
males O O
also O O
showed O O
no O O
change O O
in O O
myocardial O O
blood O O
flow O O
after O O
17 O O
beta O O
- O O
estradiol O O
, O O
but O O
coronary O O
flow O O
velocity O O
decreased O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
compared O O
with O O
baseline O O
1 O O
h O O
after O O
the O O
200 O O
ng O O
/ O O
kg O O
dose O O
( O O
from O O
1 O O
. O O
69 O O
+ O O
/ O O
- O O
0 O O
. O O
61 O O
to O O
1 O O
. O O
41 O O
+ O O
/ O O
- O O
0 O O
. O O
42 O O
kHz O O
) O O
and O O
diastolic O O
coronary O O
resistance O O
increased O O
significantly O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
compared O O
with O O
control O O
at O O
this O O
time O O
( O O
51 O O
+ O O
/ O O
- O O
15 O O
compared O O
with O O
39 O O
+ O O
/ O O
- O O
14 O O
mmHg O O
/ O O
mkHz O O
) O O
. O O
Acute O O
renal O O
vein O O
thrombosis O O
in O O
renal O O
allografts O O
: O O
detection O O
with O O
duplex O O
Doppler O O
US O O
. O O
Several O O
DNA O O
clones O O
were O O
obtained O O
by O O
this O O
procedure O O
, O O
one O O
of O O
which O O
, O O
clone O O
18 O O
, O O
is O O
reported O O
and O O
characterized O O
here O O
. O O
Long O O
- O O
range O O
mapping O O
by O O
pulse O O
- O O
field O O
gel O O
electrophoresis O O
indicated O O
that O O
the O O
three O O
mdr B-GENE O
genes E-GENE O
are O O
closely O O
linked O O
on O O
a O O
genomic O O
DNA O O
segment O O
of O O
approximately O O
625 O O
kilobases O O
. O O
These O O
sequences O O
were O O
further O O
tested O O
for O O
the O O
presence O O
of O O
an O O
enhancer O O
element O O
, O O
by O O
their O O
ability O O
to O O
activate O O
a O O
fusion O O
reporter O O
gene O O
consisting O O
of O O
the O O
CAT B-GENE B-GENE
gene E-GENE E-GENE
linked O O
to O O
the O O
gamma B-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
, O O
in O O
erythroid O O
( O O
K562 O S-GENE
) O O
and O O
non O O
- O O
erythroid O O
( O O
HeLa O O
) O O
cells O O
. O O
Two O O
sibs O O
with O O
identical O O
features O O
of O O
short O O
- O O
limbed O O
dwarfism O O
, O O
a O O
normal O O
skull O O
and O O
face O O
and O O
normal O O
intelligence O O
are O O
described O O
. O O
This O O
article O O
describes O O
a O O
program O O
that O O
resulted O O
in O O
a O O
75 O O
- O O
percent O O
reduction O O
of O O
inventory O O
over O O
a O O
five O O
- O O
year O O
interval O O
. O O
Further O O
comparative O O
analysis O O
identified O O
an O O
ADNP S-GENE O
paralog O O
( O O
33 O O
% O O
identity O O
and O O
46 O O
% O O
similarity O O
) O O
, O O
indicating O O
that O O
these O O
genes O O
belong O O
to O O
a O O
novel O O
protein O O
family O O
with O O
a O O
nine O O
- O O
zinc O O
finger O O
motif O O
followed O O
by O O
a O O
homeobox O O
domain O O
. O O
All O O
patients O O
received O O
marrow O O
from O O
HLA S-GENE O
- O O
identical O O
sibling O O
donors O O
, O O
underwent O O
similar O O
myeloablative O O
regimens O O
, O O
and O O
had O O
similar O O
pretreatment O O
characteristics O O
. O O
In O O
female O O
toads O O
, O O
Bufo O O
bufo O O
, O O
feeding O O
at O O
different O O
rates O O
, O O
the O O
uncorrected O O
value O O
of O O
n O O
was O O
0 O O
. O O
44 O O
, O O
when O O
metabolism O O
and O O
growth O O
were O O
expressed O O
as O O
kJ O B-GENE
kJ O I-GENE
- O I-GENE
1 O E-GENE
. O O
METHODS O O
: O O
Two O O
patients O O
developed O O
cervical O O
myelopathy O O
or O O
radiculopathy O O
after O O
spinal O O
manipulation O O
therapy O O
, O O
and O O
magnetic O O
resonance O O
imaging O O
showed O O
herniated O O
cervical O O
discs O O
at O O
C4 O O
- O O
C5 O O
and O O
C6 O O
- O O
C7 O O
, O O
respectively O O
. O O
Subclones O O
stably O O
expressing O O
alpha1A S-GENE O
- O O
, O O
alpha1B S-GENE O
- O O
, O O
and O O
alpha1D S-GENE B-GENE
- O I-GENE
ARs O E-GENE
under O O
control O O
of O O
an O O
inducible O O
promoter O O
, O O
or O O
at O O
high O O
and O O
low O O
receptor O O
density O O
, O O
were O O
isolated O O
and O O
characterized O O
. O O
Analysis O O
of O O
WT1 B-GENE B-GENE
target I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
stably O O
transfected O O
cell O O
lines O O
. O O
Soluble O O
recombinant O O
RI S-GENE S-GENE
and O O
soluble O O
recombinant O B-GENE
C B-GENE I-GENE
alpha E-GENE E-GENE
can O O
associate O O
in O O
vitro O O
and O O
be O O
activated O O
by O O
cyclic O O
AMP O O
. O O
IRIS S-GENE O
/ O O
GAS S-GENE O
DNA O O
also O O
formed O O
a O O
number O O
of O O
specific O O
complexes O O
with O O
constitutively O O
expressed O O
factors O O
, O O
none O O
of O O
which O O
were O O
affected O O
by O O
the O O
above O O
Abs O O
. O O
Simulation O O
results O O
based O O
on O O
the O O
presented O O
model O O
are O O
compared O O
with O O
the O O
experimental O O
data O O
for O O
two O O
types O O
of O O
cMUTs O O
reported O O
in O O
the O O
recent O O
literature O O
. O O
Tre O O
during O O
exercise O O
at O O
35 O O
W O O
at O O
23 O O
degrees O O
C O O
correlated O O
r O O
= O O
- O O
70 O O
with O O
Vo2max O O
and O O
r O O
= O O
0 O O
. O O
80 O O
with O O
Tre O O
during O O
exercise O O
in O O
heat O O
. O O
Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
with O O
nuclear O O
extracts O O
from O O
COS O O
- O O
1 O O
cells O O
transfected O O
with O O
expression O O
vectors O O
for O O
SMADs B-GENE B-GENE
1 I-GENE I-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
indicate O O
that O O
SMAD3 S-GENE S-GENE
forms O O
a O O
complex O O
with O O
a O O
migration O O
similar O O
to O O
that O O
of O O
the O O
endogenous B-GENE O
TGF I-GENE B-GENE
- I-GENE I-GENE
beta I-GENE E-GENE
- I-GENE O
specific I-GENE O
complex E-GENE O
observed O O
in O O
fibroblast O O
extracts O O
. O O
The O O
newly O O
identified O O
NF B-GENE B-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
enhancer E-GENE E-GENE
( O O
TGGAAATTCC O S-GENE
) O O
is O O
bound O O
by O O
a O O
TNF B-GENE B-GENE
alpha E-GENE E-GENE
- O O
induced O O
nuclear O O
protein O O
and O O
appears O O
to O O
be O O
the O O
key O O
element O O
in O O
rapid O O
transcription O O
induction O O
by O O
TNF B-GENE B-GENE
alpha E-GENE E-GENE
( O O
and O O
TPA O S-GENE
) O O
, O O
while O O
transactivation O O
of O O
this O O
element O O
is O O
repressed O O
by O O
the O O
ligand O O
- O O
bound O O
glucocorticoid B-GENE O
receptor E-GENE O
. O O
Our O O
results O O
showed O O
that O O
the O O
5 O O
- O O
hydroxytryptamine O O
( O O
5 O O
- O O
HT O O
) O O
content O O
in O O
platelets O O
was O O
: O O
( O O
1 O O
) O O
increased O O
in O O
the O O
subgroup O O
of O O
anti O O
- O O
social O O
alcoholics O O
; O O
( O O
2 O O
) O O
transiently O O
and O O
differently O O
altered O O
in O O
alcoholics O O
compared O O
to O O
opiate O O
addicts O O
; O O
and O O
( O O
3 O O
) O O
lowered O O
in O O
drinking O O
alcoholics O O
and O O
normal O O
in O O
alcoholics O O
who O O
were O O
drinking O O
as O O
well O O
as O O
smoking O O
( O O
that O O
may O O
occur O O
via O O
MAO B-GENE O
- I-GENE O
B E-GENE O
inhibition O O
by O O
smoke O O
) O O
. O O
In O O
the O O
second O O
group O O
, O O
which O O
consisted O O
of O O
babies O O
of O O
33 O O
to O O
36 O O
weeks O O
of O O
gestational O O
age O O
, O O
haptoglobin S-GENE O
was O O
detected O O
in O O
6 O O
infants O O
, O O
with O O
levels O O
less O O
than O O
25 O O
mg O O
/ O O
dl O O
in O O
3 O O
. O O
The O O
polypeptide O O
encoded O O
by O O
the O O
cDNA O O
contained O O
450 O O
amino O O
acids O O
with O O
a O O
calculated O O
M O O
( O O
r O O
) O O
of O O
52 O O
, O O
057 O O
, O O
and O O
showed O O
significant O O
homology O O
with O O
human O O
and O O
mouse B-GENE O
CAD E-GENE O
( O O
22 O O
% O O
identity O O
) O O
. O O
Correlation O O
of O O
alpha O O
activity O O
between O O
the O O
frontal O O
and O O
occipital O O
cortex O O
. O O
In O O
situ O O
localization O O
of O O
PCP B-GENE B-GENE
- I-GENE I-GENE
A1 I-GENE I-GENE
transcripts E-GENE E-GENE
revealed O O
that O O
they O O
accumulate O O
specifically O O
in O O
pollen O O
at O O
the O O
late O O
binucleate O O
/ O O
trinucleate O O
stage O O
of O O
development O O
rather O O
than O O
in O O
the O O
tapetum O O
, O O
which O O
previously O O
was O O
taken O O
to O O
be O O
the O O
principal O O
source O O
of O O
the O O
pollen O O
coat O O
. O O
Successful O O
resolution O O
of O O
progressive O O
multifocal O O
leukoencephalopathy O O
after O O
combination O O
therapy O O
with O O
cidofovir O O
and O O
cytosine O O
arabinoside O O
. O O
The O O
species O O
composition O O
and O O
abundance O O
upon O O
treatment O O
of O O
manure O O
with O O
polyethylene O O
, O O
polystyrene O O
and O O
glass O O
particles O O
was O O
similar O O
to O O
that O O
of O O
the O O
treatment O O
control O O
, O O
i O O
. O O
e O O
. O O
natural O O
and O O
inert O O
sand O O
. O O
However O O
, O O
H19 S-GENE S-GENE
and O O
IGF2 S-GENE S-GENE
lie O O
within O O
a O O
larger O O
imprinted O O
domain O O
, O O
and O O
the O O
gene O O
specificity O O
of O O
H19 S-GENE S-GENE
epimutation O O
has O O
been O O
a O O
persistent O O
question O O
. O O
Here O O
we O O
report O O
the O O
cloning O O
, O O
by O O
either O O
peptide O O
sequencing O O
or O O
by O O
sequence O O
similarity O O
to O O
the O O
human O B-GENE
cDNAs O E-GENE
, O O
of O O
the O O
S O O
. O O
cerevisiae O O
genes O O
RFC1 S-GENE S-GENE
, O O
RFC2 S-GENE S-GENE
, O O
RFC3 S-GENE S-GENE
, O O
RFC4 S-GENE S-GENE
, O O
and O O
RFC5 S-GENE S-GENE
. O O
It O O
is O O
of O O
interest O O
that O O
, O O
aside O O
from O O
starvation O O
, O O
the O O
nutrition O O
catastrophes O O
of O O
the O O
past O O
, O O
including O O
scurvy O O
( O O
vitamin O O
C O O
deficiency O O
) O O
resulting O O
from O O
lack O O
of O O
fresh O O
vegetables O O
and O O
fruit O O
and O O
beriberi O O
( O O
vitamin O O
B1 O O
deficiency O O
) O O
from O O
consumption O O
of O O
polished O O
rice O O
, O O
are O O
forgotten O O
and O O
only O O
of O O
interest O O
as O O
history O O
. O O
This O O
sequence O O
can O O
interact O O
with O O
at O O
least O O
two O O
proteins O O
in O O
a O O
fibroblast O O
nuclear O O
extract O O
that O O
have O O
binding O O
characteristics O O
of O O
an O O
Ets B-GENE B-GENE
family I-GENE I-GENE
protein E-GENE E-GENE
and O O
a O O
serum B-GENE B-GENE
response I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
like I-GENE I-GENE
protein E-GENE E-GENE
. O O
As O O
much O O
thrombin S-GENE O
was O O
formed O O
during O O
cardiopulmonary O O
bypass O O
( O O
measured O O
by O O
the O O
prothrombin B-GENE B-GENE
activation I-GENE I-GENE
fragment I-GENE I-GENE
F1 I-GENE I-GENE
+ I-GENE I-GENE
2 E-GENE E-GENE
and O O
thrombin S-GENE O
- O O
antithrombin S-GENE O
complexes O O
) O O
as O O
in O O
normal O O
patients O O
, O O
showing O O
that O O
factor B-GENE B-GENE
XII E-GENE E-GENE
was O O
not O O
necessary O O
for O O
thrombin S-GENE O
generation O O
. O O
The O O
molecular O O
event O O
( O O
s O O
) O O
underlying O O
the O O
functional O O
specificities O O
of O O
these O O
receptors O O
( O O
in O O
regulating O O
the O O
expression O O
of O O
their O O
native O O
target O O
genes O O
) O O
is O O
a O O
very O O
important O O
issue O O
that O O
remains O O
poorly O O
understood O O
. O O
MUS81 S-GENE S-GENE
encodes O O
a O O
novel O O
helix B-GENE O
- I-GENE O
hairpin I-GENE O
- I-GENE O
helix I-GENE O
protein E-GENE O
involved O O
in O O
the O O
response O O
to O O
UV O O
- O O
and O O
methylation O O
- O O
induced O O
DNA O O
damage O O
in O O
Saccharomyces O O
cerevisiae O O
. O O
Treatment O O
of O O
chronic O O
hepatitis O O
B O O
with O O
interferon S-GENE O
: O O
experience O O
in O O
western O O
countries O O
. O O
Several O O
positive O O
clones O O
were O O
isolated O O
, O O
one O O
of O O
which O O
encoded O O
the O O
C O O
- O O
terminal O O
253 O O
amino O O
acids O O
of O O
a O O
putative O O
RNA B-GENE O
helicase E-GENE O
, O O
a O O
DEAD B-GENE O
box I-GENE O
protein E-GENE O
designated O O
DDX3 S-GENE S-GENE
. O O
Kerstin O O
takes O O
the O O
abbreviated O O
medical O O
education O O
. O O
In O O
vitro O O
binding O O
studies O O
previously O O
showed O O
that O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE I-GENE
p50 S-GENE E-GENE
homodimer O O
binds O O
the O O
switch B-GENE O
nuclear I-GENE O
B I-GENE B-GENE
- I-GENE I-GENE
site I-GENE I-GENE
protein E-GENE E-GENE
( O O
SNIP S-GENE S-GENE
) O O
of O O
the O O
S B-GENE O
gamma I-GENE O
3 I-GENE O
tandem I-GENE O
repeat E-GENE O
. O O
In O O
this O O
case O O
myogenic O O
factors O O
are O O
not O O
initially O O
expressed O O
and O O
these O O
migratory O O
cells O O
are O O
characterized O O
by O O
the O O
expression O O
of O O
the O O
paired S-GENE O
- O O
box O O
gene O O
Pax3 S-GENE S-GENE
. O O
It O O
is O O
concluded O O
that O O
the O O
atherogenic O O
process O O
includes O O
stimulation O O
of O O
collagen S-GENE O
and O O
elastin S-GENE O
synthesis O O
. O O
These O O
results O O
indicate O O
that O O
( O O
1 O O
) O O
RXR S-GENE O
- O O
TR S-GENE O
heterodimers O O
play O O
a O O
role O O
in O O
basal O O
transactivation O O
and O O
T3 O O
suppression O O
of O O
negatively O O
regulated O O
genes O O
, O O
and O O
( O O
2 O O
) O O
RXRs S-GENE S-GENE
increase O O
the O O
dominant O O
negative O O
effect O O
of O O
some O O
mutant O O
TRs S-GENE O
on O O
specific O O
negative O O
TREs O O
. O O
Phenotypic O O
responses O O
of O O
additional O O
mutants O O
, O O
including O O
exo1 S-GENE O
, O O
srs2 S-GENE S-GENE
, O O
rad5 S-GENE O
, O O
and O O
rdh54 S-GENE O
strains O O
, O O
suggest O O
roles O O
in O O
recombinational O O
repair O O
, O O
but O O
not O O
in O O
NHEJ O O
. O O
Furthermore O O
, O O
the O O
induction O O
of O O
cytochrome B-GENE B-GENE
P I-GENE I-GENE
- I-GENE I-GENE
450 I-GENE I-GENE
1A1 E-GENE E-GENE
observed O O
in O O
the O O
cormorant O O
indicates O O
that O O
the O O
Ah B-GENE B-GENE
receptor E-GENE E-GENE
- O O
mediated O O
process O O
, O O
by O O
which O O
TCDD O O
and O O
related O O
chemicals O O
exert O O
many O O
of O O
their O O
toxicities O O
, O O
has O O
been O O
activated O O
. O O
RESULT O O
( O O
S O O
) O O
: O O
A O O
prospective O O
study O O
was O O
conducted O O
with O O
44 O O
cycles O O
for O O
34 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
1 O O
) O O
and O O
47 O O
cycles O O
for O O
40 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
2 O O
) O O
with O O
a O O
long O O
IVF O O
protocol O O
; O O
68 O O
cycles O O
for O O
46 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
3 O O
) O O
and O O
56 O O
cycles O O
for O O
39 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
4 O O
) O O
with O O
a O O
short O O
IVF O O
protocol O O
; O O
39 O O
cycles O O
for O O
32 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
5 O O
) O O
and O O
50 O O
cycles O O
for O O
30 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
6 O O
) O O
with O O
a O O
long O O
ICSI O O
protocol O O
; O O
and O O
87 O O
cycles O O
for O O
60 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
7 O O
) O O
and O O
81 O O
cycles O O
for O O
61 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
8 O O
) O O
with O O
a O O
short O O
ICSI O O
protocol O O
. O O
This O O
study O O
demonstrates O O
the O O
feasibility O O
and O O
potential O O
usefulness O O
of O O
syngeneic O O
BM O O
Txp O O
in O O
myeloma O O
. O O
5 O O
. O O
3 O O
+ O O
/ O O
- O O
6 O O
. O O
6 O O
for O O
risperidone O O
( O O
P O O
= O O
0 O O
. O O
09 O O
) O O
. O O
In O O
this O O
work O O
, O O
we O O
determined O O
the O O
sequences O O
of O O
eight O O
VirF B-GENE O
- I-GENE O
binding I-GENE O
sites E-GENE O
from O O
four O O
different O O
genes O O
, O O
by O O
DNase B-GENE B-GENE
I E-GENE E-GENE
or O O
hydroxyl O O
radical O O
footprinting O O
. O O
Although O O
they O O
are O O
similar O O
to O O
the O O
IL9R B-GENE B-GENE
gene E-GENE E-GENE
( O O
approximately O O
90 O O
% O O
identity O O
) O O
, O O
none O O
of O O
these O O
copies O O
encodes O O
a O O
functional O O
receptor O O
: O O
none O O
of O O
them O O
contains O O
sequences O O
homologous O O
to O O
the O O
5 O O
' O O
flanking O O
region O O
or O O
exon O O
1 O O
of O O
the O O
IL9R B-GENE B-GENE
gene E-GENE E-GENE
, O O
and O O
the O O
remaining O O
ORFs O O
have O O
been O O
inactivated O O
by O O
various O O
point O O
mutations O O
and O O
deletions O O
. O O
Type O O
II O O
neuroleptanalgesia O O
in O O
odonto O O
- O O
stomatology O O
273 O O
, O O
27420 O B-GENE
- O I-GENE
27429 O E-GENE
) O O
a O O
putative O O
peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
response O O
element O O
( O O
PPRE O S-GENE
) O O
is O O
present O O
from O O
- O O
458 O O
to O O
- O O
474 O O
. O O
While O O
reviewing O O
gastric O O
specimens O O
from O O
215 O O
baboons O O
, O O
we O O
found O O
diffuse O O
giant O O
mucosal O O
folds O O
in O O
2 O O
specimens O O
and O O
multiple O O
giant O O
mucosal O O
nodules O O
in O O
another O O
3 O O
. O O
To O O
investigate O O
whether O O
the O O
two O O
RPG B-GENE O
- I-GENE O
boxes E-GENE O
mediate O O
transcription O O
activation O O
of O O
both O O
the O O
L46 S-GENE S-GENE
and O O
S24 B-GENE B-GENE
gene E-GENE E-GENE
, O O
two O O
experimental O O
strategies O O
were O O
followed O O
: O O
cloning O O
of O O
the O O
respective O O
genes O O
on O O
multicopy O O
vectors O O
and O O
construction O O
of O O
fusion O O
genes O O
. O O
When O O
the O O
opioid O O
antagonist O O
was O O
administered O O
to O O
animals O O
24 O O
hr O O
after O O
termination O O
of O O
single O O
or O O
multiple O O
exposures O O
to O O
restraint O O
, O O
NALT O O
- O O
induced O O
increases O O
in O O
basal O O
plasma B-GENE O
LH E-GENE O
were O O
significantly O O
attenuated O O
in O O
the O O
chronically O O
stressed O O
rats O O
compared O O
to O O
animals O O
subjected O O
to O O
stress O O
only O O
once O O
or O O
not O O
at O O
all O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
The O O
psychosocial O O
features O O
of O O
people O O
using O O
self O O
- O O
ignition O O
as O O
a O O
method O O
of O O
suicide O O
are O O
consistent O O
with O O
those O O
of O O
suicide O O
in O O
general O O
. O O
This O O
was O O
further O O
suggested O O
by O O
transactivation O O
assays O O
in O O
which O O
mouse O O
fibroblasts O O
were O O
transiently O O
transfected O O
with O O
a O O
human B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
reporter I-GENE I-GENE
gene E-GENE E-GENE
in O O
the O O
absence O O
and O O
presence O O
of O O
an O O
LKLF B-GENE B-GENE
cDNA I-GENE E-GENE
construct E-GENE O
. O O
Plasma B-GENE O
colony I-GENE O
- I-GENE O
stimulating I-GENE O
factor E-GENE O
analysis O O
and O O
the O O
clinical O O
significance O O
Thus O O
, O O
in O O
addition O O
to O O
the O O
previously O O
characterized O O
FAS B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
interacting O O
with O O
the O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
, O O
a O O
second O O
motif O O
common O O
to O O
the O O
promoter O O
regions O O
of O O
both O O
FAS B-GENE B-GENE
genes E-GENE E-GENE
could O O
be O O
identified O O
. O O
Reconstruction O O
time O O
for O O
a O O
64 O O
x O O
64 O O
matrix O O
is O O
approximately O O
45 O O
s O O
/ O O
transaxial O O
slice O O
. O O
Sequence O O
analysis O O
identifies O O
a O O
ras B-GENE O
- I-GENE O
associating E-GENE O
( O O
RA S-GENE O
) O O
- O O
like O O
domain O O
in O O
the O O
N O O
- O O
termini O O
of O O
band B-GENE O
4 I-GENE O
. I-GENE O
1 I-GENE O
/ I-GENE O
JEF I-GENE O
domains E-GENE O
and O O
in O O
the O O
Grb7 B-GENE O
/ I-GENE O
10 I-GENE O
/ I-GENE O
14 I-GENE O
adapter I-GENE O
family E-GENE O
. O O
Patients O O
received O O
BPB O O
using O O
bupivacaine O O
2 O O
mg O O
kg O O
- O O
1 O O
with O O
adrenaline O O
1 O O
in O O
200 O O
, O O
000 O O
, O O
either O O
with O O
or O O
without O O
hyaluronidase S-GENE O
3000 O O
iu O O
, O O
in O O
a O O
volume O O
of O O
0 O O
. O O
5 O O
ml O O
per O O
2 O O
. O O
54 O O
cm O O
of O O
the O O
patient O O
' O O
s O O
height O O
. O O
Rhinovirus B-GENE B-GENE
2A I-GENE I-GENE
protease E-GENE E-GENE
and O O
foot B-GENE O
- I-GENE O
and I-GENE O
- I-GENE O
mouth I-GENE O
- I-GENE O
disease I-GENE O
virus I-GENE O
L I-GENE O
protease E-GENE O
were O O
used O O
to O O
analyze O O
the O O
association O O
of O O
eIF4G S-GENE S-GENE
with O O
eIF4A S-GENE S-GENE
, O O
eIF4E S-GENE S-GENE
, O O
and O O
eIF3 S-GENE S-GENE
. O O
One O O
hundred O O
cDNA O O
clones O O
were O O
sequenced O O
and O O
8 O O
RTKs S-GENE O
were O O
identified O O
, O O
as O O
well O O
as O O
12 O O
non O O
- O O
RTKs S-GENE O
and O O
2 O O
serine B-GENE O
/ I-GENE O
threonine I-GENE O
kinases E-GENE O
. O O
Roller O O
pumps O O
, O O
coronary O O
suction O O
and O O
an O O
open O O
cardiotomy O O
reservoir O O
were O O
used O O
. O O
Furthermore O O
, O O
it O O
was O O
found O O
that O O
the O O
Shb S-GENE O
- O O
overexpressing O O
cells O O
extended O O
neurites O O
in O O
response O O
to O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
. O O
Levels O O
of O O
p53 S-GENE S-GENE
were O O
substantially O O
increased O O
by O O
E1A S-GENE S-GENE
expression O O
during O O
adenovirus O O
infection O O
. O O
In O O
cases O O
of O O
intracapsular O O
prostatic O O
cancer O O
the O O
level O O
of O O
prostatic B-GENE O
acid I-GENE O
phosphatase E-GENE O
( O O
PAP S-GENE O
) O O
measured O O
by O O
radioimmunoassay O O
was O O
1 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
micrograms O O
/ O O
l O O
. O O
Healthy O O
subjects O O
received O O
the O O
following O O
regimens O O
, O O
dosed O O
to O O
steady O O
state O O
: O O
trovafloxacin O O
300 O O
mg O O
/ O O
24 O O
h O O
; O O
ciprofloxacin O O
400 O O
mg O O
/ O O
12 O O
h O O
; O O
trovafloxacin O O
300 O O
mg O O
/ O O
24 O O
h O O
plus O O
cefepime O O
2 O O
g O O
/ O O
12 O O
h O O
, O O
and O O
ciprofloxacin O O
400 O O
mg O O
/ O O
12 O O
h O O
plus O O
cefepime O O
2 O O
g O O
/ O O
12 O O
h O O
. O O
In O O
EGF B-GENE B-GENE
receptor E-GENE E-GENE
- O O
mediated O O
signaling O O
, O O
the O O
protein B-GENE O
kinase I-GENE O
PKB E-GENE S-GENE
/ O O
Akt S-GENE S-GENE
and O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
c I-GENE I-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
, O O
but O O
not O O
extracellular B-GENE B-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase I-GENE I-GENE
2 E-GENE E-GENE
, O O
function O O
downstream O O
of O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
) O O
. O O
Immunoprecipitation O O
of O O
cell O O
lysates O O
with O O
anti B-GENE O
- I-GENE O
phosphotyrosine E-GENE O
and O O
immunoblotting O O
showed O O
phosphorylated O O
forms O O
of O O
the O O
mitogenic O O
pathway O O
proteins O O
Shc S-GENE S-GENE
and O O
MAPK S-GENE S-GENE
in O O
addition O O
to O O
p185 S-GENE S-GENE
( O O
neu S-GENE S-GENE
) O O
, O O
suggesting O O
that O O
the O O
Ras S-GENE S-GENE
to O O
MAPK S-GENE S-GENE
mitogenic O O
pathway O O
is O O
activated O O
. O O
Acad O O
. O O
We O O
suggest O O
that O O
this O O
effect O O
of O O
Myc S-GENE S-GENE
is O O
mediated O O
by O O
its O O
action O O
upstream O O
of O O
cyclin B-GENE B-GENE
E E-GENE I-GENE
- O I-GENE
CDK2 S-GENE E-GENE
, O O
and O O
occurs O O
via O O
the O O
neutralization O O
of O O
p27 S-GENE S-GENE
( O O
Kip1 S-GENE S-GENE
) O O
family O O
proteins O O
, O O
rather O O
than O O
induction O O
of O O
Cdc25A S-GENE S-GENE
. O O
Bile O O
reflux O O
demonstrated O O
by O O
99m O O
Tc O O
disofenin O O
. O O
These O O
data O O
suggest O O
that O O
certain O O
of O O
the O O
nuclear O O
protein O O
import O O
functions O O
of O O
NTF2 S-GENE S-GENE
and O O
Ran S-GENE O
/ O O
TC4 S-GENE S-GENE
are O O
closely O O
linked O O
and O O
that O O
NTF2 S-GENE S-GENE
may O O
serve O O
to O O
modulate O O
a O O
transport O O
step O O
involving O O
Ran S-GENE O
/ O O
TC4 S-GENE S-GENE
. O O
Almost O O
every O O
image O O
that O O
appears O O
during O O
a O O
therapy O O
session O O
reveals O O
a O O
symbolic O O
nature O O
, O O
but O O
the O O
very O O
concept O O
of O O
symbol O O
is O O
not O O
free O O
from O O
ambiguity O O
some O O
positions O O
originated O O
in O O
different O O
areas O O
of O O
investigation O O
are O O
mentioned O O
, O O
ending O O
with O O
a O O
description O O
of O O
the O O
traits O O
that O O
, O O
according O O
to O O
the O O
writer O O
, O O
bestow O O
a O O
symbolic O O
character O O
to O O
images O O
. O O
The O O
severity O O
of O O
the O O
psychomotor O O
retardation O O
varied O O
from O O
mild O O
to O O
severe O O
. O O
Both O O
oligonucleotide O O
cross O O
- O O
competition O O
and O O
antibody O O
supershift O O
experiments O O
established O O
that O O
the O O
double O O
- O O
strand O O
binding O O
protein O O
is O O
equivalent O O
to O O
Sp1 S-GENE S-GENE
. O O
The O O
wet O O
and O O
dry O O
methods O O
of O O
the O O
HA O O
synthesis O O
are O O
considered O O
. O O
All O O
these O O
abnormalities O O
returned O O
to O O
normal O O
after O O
removal O O
of O O
the O O
tumor O O
. O O
Although O O
FKH2 S-GENE S-GENE
is O O
redundant O O
with O O
FKH1 S-GENE S-GENE
in O O
controlling O O
pseudohyphal O O
growth O O
, O O
the O O
two O O
genes O O
have O O
different O O
functions O O
in O O
silencing O O
HMRa S-GENE S-GENE
. O O
Molecular O O
analysis O O
indicated O O
that O O
inactivation O O
of O O
H B-GENE O
- I-GENE O
2L E-GENE O
expression O O
in O O
nearly O O
every O O
null O O
clone O O
resulted O O
from O O
an O O
apparent O O
deletion O O
or O O
rearrangement O O
of O O
5 B-GENE O
' I-GENE O
- I-GENE O
flanking I-GENE O
and I-GENE O
5 I-GENE O
' I-GENE O
- I-GENE O
coding I-GENE O
H I-GENE O
- I-GENE O
2L I-GENE O
sequences E-GENE O
, O O
with O O
breakpoints O O
consistently O O
mapping O O
to O O
within O O
a O O
550 O O
bp O O
GC O O
- O O
rich O O
region O O
between O O
exon O O
1 O O
and O O
the O O
middle O O
of O O
intron O O
2 O O
. O O
However O O
, O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
beta E-GENE E-GENE
stimulated O O
transcription O O
primarily O O
through O O
the O O
cAMP O O
- O O
responsive O O
element O O
( O O
CRE O O
) O O
, O O
which O O
maps O O
between O O
positions O O
- O O
77 O O
to O O
- O O
94 O O
, O O
but O O
not O O
at O O
the O O
more O O
5 O O
' O O
- O O
binding O O
sites O O
. O O
Heliox O O
improves O O
pulsus O O
paradoxus O O
and O O
peak O O
expiratory O O
flow O O
in O O
nonintubated O O
patients O O
with O O
severe O O
asthma O O
. O O
50 O O
- O O
fold O O
increase O O
in O O
foreign O O
protein O O
production O O
. O O
Ion O O
- O O
Bernstein O O
- O O
wave O O
heating O O
and O O
improved O O
confinement O O
in O O
the O O
Alcator O O
C O O
tokamak O O
. O O
However O O
, O O
the O O
molecular O O
mechanisms O O
by O O
which O O
specific O O
cis O O
- O O
and O O
trans O O
- O O
acting O O
factors O O
control O O
activity O O
of O O
the O O
prodynorphin B-GENE B-GENE
promoter E-GENE E-GENE
are O O
not O O
as O O
clearly O O
defined O O
. O O
Finally O O
, O O
antisense O O
mediated O O
reduction O O
of O O
Elk B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
GH4 O O
cells O O
decreased O O
insulin S-GENE O
- O O
increased O O
prolactin B-GENE B-GENE
gene E-GENE E-GENE
expression O O
and O O
confirmed O O
the O O
requirement O O
for O O
Elk B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
for O O
insulin S-GENE O
- O O
increased O O
prolactin B-GENE B-GENE
gene E-GENE E-GENE
expression O O
. O O
Substitutions O O
of O O
Asp11 O O
led O O
to O O
dominant O O
lethality O O
. O O
Three O O
modern O O
hematology O O
analyzers O O
( O O
Abbott O O
Cell O O
- O O
Dyn O O
3000 O O
, O O
Coulter O O
STKS O O
, O O
and O O
Sysmex O O
NE O O
- O O
8000 O O
) O O
with O O
high O O
throughput O O
and O O
5 O O
- O O
part O O
differential O O
capability O O
were O O
evaluated O O
using O O
a O O
protocol O O
designed O O
by O O
a O O
quality O O
team O O
. O O
Each O O
subject O O
was O O
injected O O
in O O
the O O
antecubital O O
vein O O
with O O
7 O O
mg O O
/ O O
kg O O
of O O
sodium O O
fluorescein O O
( O O
25 O O
% O O
solution O O
) O O
and O O
measurements O O
were O O
taken O O
1 O O
hr O O
postinjection O O
at O O
4 O O
. O O
5 O O
mm O O
and O O
7 O O
. O O
5 O O
mm O O
from O O
the O O
retina O O
. O O
The O O
cleft O O
walls O O
are O O
lined O O
with O O
highly O O
conserved O O
residues O O
and O O
NADP O O
is O O
bound O O
along O O
one O O
wall O O
. O O
cDNA O O
cloning O O
, O O
sequencing O O
and O O
chromosome O O
mapping O O
of O O
a O O
non B-GENE O
- I-GENE O
erythroid I-GENE O
spectrin E-GENE O
, O O
human B-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
fodrin E-GENE E-GENE
. O O
The O O
aromatic B-GENE B-GENE
hydrocarbon I-GENE I-GENE
receptor E-GENE E-GENE
( O O
AHR S-GENE S-GENE
) O O
is O O
a O O
ligand O O
- O O
activated O O
transcription O O
factor O O
that O O
regulates O O
the O O
expression O O
of O O
several O O
drug O O
- O O
metabolizing O O
enzymes O O
and O O
has O O
been O O
implicated O O
in O O
immunosuppression O O
, O O
teratogenesis O O
, O O
cell O O
- O O
specific O O
hyperplasia O O
, O O
and O O
certain O O
types O O
of O O
malignancies O O
and O O
toxicities O O
. O O
( O O
1996 O O
) O O
J O O
. O O
To O O
define O O
the O O
molecular O O
mechanism O O
regulating O O
FGFR B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
proliferating O O
myoblasts O O
and O O
post O O
- O O
mitotic O O
muscle O O
fibers O O
, O O
we O O
have O O
isolated O O
and O O
partially O O
characterized O O
the O O
avian O B-GENE
FGFR B-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE I-GENE
promoter O E-GENE
. O O
Moreover O O
, O O
FACT S-GENE O
specifically O O
interacts O O
with O O
nucleosomes O O
and O O
histone O O
H2A S-GENE S-GENE
/ O O
H2B S-GENE S-GENE
dimers O O
, O O
indicating O O
that O O
it O O
may O O
work O O
by O O
promoting O O
nucleosome O O
disassembly O O
upon O O
transcription O O
. O O
Measures O O
of O O
sedation O O
, O O
BIS O O
, O O
deltaBIS O O
( O O
absolute O O
change O O
of O O
BIS O O
after O O
a O O
painful O O
stimulus O O
) O O
, O O
memory O O
, O O
and O O
drug O O
concentration O O
were O O
obtained O O
at O O
each O O
target O O
drug O O
concentration O O
. O O
ER O O
and O O
DR O O
were O O
significantly O O
correlated O O
with O O
MIB B-GENE O
- I-GENE O
1 E-GENE O
LI O O
( O O
P O O
< O O
0 O O
. O O
01 O O
and O O
P O O
< O O
0 O O
. O O
05 O O
, O O
respectively O O
) O O
, O O
but O O
RI O O
and O O
Td O O
/ O O
Te O O
were O O
not O O
. O O
Positive O O
linear O O
correlations O O
were O O
found O O
when O O
the O O
AUC O O
( O O
0 O O
- O O
12 O O
) O O
( O O
r O O
= O O
0 O O
. O O
68 O O
; O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
the O O
maximum O O
plasma O O
concentration O O
( O O
r O O
= O O
0 O O
. O O
34 O O
; O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
the O O
minimum O O
plasma O O
concentration O O
( O O
r O O
= O O
0 O O
. O O
55 O O
; O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
and O O
the O O
elimination O O
t1 O O
/ O O
2 O O
( O O
r O O
= O O
0 O O
. O O
46 O O
; O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
were O O
regressed O O
with O O
age O O
. O O
Psychophysical O O
evidence O O
is O O
given O O
for O O
the O O
existence O O
of O O
two O O
distinct O O
systems O O
in O O
human O O
vision O O
: O O
a O O
fast O O
, O O
sign O O
- O O
invariant O O
system O O
concerned O O
with O O
extracting O O
contours O O
and O O
a O O
slower O O
, O O
sign O O
- O O
sensitive O O
system O O
concerned O O
with O O
assigning O O
surface O O
color O O
. O O
Peripheral O O
visual O O
acuity O O
with O O
monovision O O
and O O
other O O
contact O O
lens O O
corrections O O
for O O
presbyopia O O
. O O
Fourteen O O
Centers O O
participated O O
in O O
this O O
trial O O
. O O
The O O
program O O
for O O
myogenic O O
differentiation O O
is O O
subject O O
to O O
negative O O
control O O
by O O
several O O
peptide O O
growth O O
factors O O
and O O
by O O
the O O
products O O
of O O
mutationally O O
activated O O
ras B-GENE O
oncogenes E-GENE O
, O O
which O O
persistently O O
activate O O
intracellular O O
cascades O O
normally O O
triggered O O
by O O
specific O O
growth O O
factors O O
. O O
Tetrazepam O O
: O O
a O O
benzodiazepine O O
which O O
dissociates O O
sedation O O
from O O
other O O
benzodiazepine O O
activities O O
. O O
The O O
difference O O
between O O
the O O
effects O O
of O O
the O O
two O O
dose O O
levels O O
of O O
Z O O
. O O
Mutation O O
of O O
the O O
distal O O
E2F B-GENE S-GENE
binding I-GENE O
site E-GENE O
in O O
the O O
cdc25A B-GENE B-GENE
promoter E-GENE E-GENE
abolished O O
E2 S-GENE O
- O O
induced O O
repression O O
, O O
whereas O O
mutation O O
of O O
the O O
proximal O B-GENE
E2F B-GENE I-GENE
site E-GENE E-GENE
or O O
the O O
E2 B-GENE B-GENE
site E-GENE E-GENE
had O O
no O O
effect O O
. O O
Plasmid O O
pNK21 O O
, O O
in O O
which O O
2 O O
. O O
05 O O
- O O
kb O O
sequence O O
covering O O
the O O
region O O
encoding O O
the O O
nitrilase S-GENE O
was O O
was O O
placed O O
under O O
the O O
control O O
of O O
the O O
lac B-GENE B-GENE
promoter E-GENE E-GENE
, O O
directed O O
overproduction O O
of O O
enzymatically B-GENE O
active I-GENE O
nitrilase E-GENE O
in O O
response O O
to O O
addition O O
of O O
isopropyl O O
beta O O
- O O
D O O
- O O
thiogalactopyranoside O O
in O O
Escherichia O O
coli O O
. O O
A O O
method O O
for O O
determining O O
the O O
toxicity O O
of O O
neutralizers O O
for O O
antimicrobial O O
agents O O
to O O
A O O
. O O
castellanii O O
was O O
also O O
evaluated O O
. O O
Expression O O
in O O
all O O
lines O O
was O O
decreased O O
by O O
the O O
inclusion O O
of O O
regions O O
further O O
upstream O O
, O O
and O O
extinguished O O
by O O
the O O
inclusion O O
of O O
the O O
first O O
intron O O
. O O
Static O O
and O O
dynamic O O
MRI O O
of O O
the O O
normal O O
and O O
pathological O O
female O O
pelvic O O
floor O O
IENF O O
density O O
at O O
the O O
calf O O
was O O
lower O O
than O O
that O O
obtained O O
from O O
skin O O
at O O
more O O
proximal O O
sites O O
, O O
indicating O O
the O O
length O O
dependency O O
of O O
small O O
- O O
fiber O O
loss O O
in O O
these O O
neuropathies O O
. O O
These O O
results O O
demonstrate O O
a O O
specific O O
association O O
of O O
SIV O O
and O O
HIV B-GENE O
- I-GENE O
2 I-GENE O
nef E-GENE O
, O O
but O O
not O O
HIV B-GENE O
- I-GENE O
1 I-GENE O
nef E-GENE O
, O O
with O O
TCRzeta S-GENE O
. O O
Insertion O O
of O O
alternatively O O
spliced O O
exon O O
W O O
into O O
CREB B-GENE B-GENE
mRNA E-GENE E-GENE
during O O
spermatogenesis O O
results O O
in O O
a O O
polycistronic O O
RNA O O
that O O
encodes O O
two O O
novel O O
internally O O
translated O O
CREB B-GENE S-GENE
repressor I-GENE O
isoforms E-GENE O
called O O
I B-GENE B-GENE
- I-GENE I-GENE
CREBs E-GENE E-GENE
, O O
consisting O O
of O O
the O O
carboxy O O
- O O
terminal O O
DNA O O
- O O
binding O O
domain O O
devoid O O
of O O
the O O
transactivation O O
domains O O
. O O
A O O
continuous O O
- O O
flow O O
BIPAP O O
system O O
consists O O
of O O
a O O
high O O
- O O
flow O O
CPAP O O
system O O
, O O
a O O
reservoir O O
bag O O
, O O
and O O
a O O
pneumatically O O
controlled O O
membrane O O
valve O O
in O O
the O O
expiratory O O
limb O O
. O O
Older O O
females O O
had O O
lumbar O O
( O O
0 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
) O O
and O O
TB O O
( O O
1 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
1 O O
) O O
BMD O O
Z O O
scores O O
greater O O
than O O
0 O O
( O O
both O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O
Smooth O O
pursuit O O
gain O O
and O O
the O O
percentage O O
of O O
total O O
eye O O
movement O O
due O O
to O O
various O O
saccadic O O
subtypes O O
were O O
computed O O
using O O
infrared O O
oculography O O
and O O
computerized O O
pattern O O
recognition O O
software O O
. O O
Upon O O
incubation O O
of O O
the O O
most O O
highly O O
purified O O
fractions O O
with O O
Mn O O
- O O
ATP O O
or O O
Mg O O
- O O
ATP O O
, O O
p40 S-GENE O
was O O
the O O
only O O
protein O O
phosphorylated O O
on O O
tyrosine O O
. O O
Consistent O O
with O O
this O O
hypothesis O O
, O O
alpha1 B-GENE O
- I-GENE O
PDX E-GENE O
prevents O O
cleavage O O
of O O
BMP B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
in O O
an O O
oocyte O O
translation O O
assay O O
. O O
A O O
p53 B-GENE S-GENE
cDNA E-GENE O
deletion O O
mutant O O
( O O
delta O O
pro O O
AE O O
) O O
, O O
which O O
lacks O O
this O O
entire O O
proline O O
- O O
rich O O
domain O O
( O O
deleted O O
for O O
amino O O
acids O O
62 O O
- O O
91 O O
) O O
, O O
was O O
created O O
and O O
characterized O O
for O O
a O O
variety O O
of O O
p53 S-GENE S-GENE
functions O O
. O O
Multiple O O
aortic O O
thrombi O O
associated O O
with O O
protein B-GENE O
C E-GENE O
and O O
S S-GENE O
deficiency O O
. O O
Our O O
results O O
suggest O O
that O O
Bry1 S-GENE S-GENE
/ O O
Skn7 S-GENE S-GENE
can O O
influence O O
the O O
expression O O
of O O
MCB O S-GENE
- O O
and O O
SCB O S-GENE
- O O
driven O O
gene O O
expression O O
in O O
budding O O
yeast O O
, O O
perhaps O O
including O O
genes O O
involved O O
in O O
cell O O
wall O O
metabolism O O
, O O
via O O
a O O
two O O
- O O
component O O
signal O O
transduction O O
pathway O O
which O O
activates O O
Bry1 S-GENE S-GENE
/ O O
Skn7 S-GENE S-GENE
in O O
response O O
to O O
an O O
unidentified O O
signal O O
. O O
( O O
1992 O O
) O O
J O O
. O O
A O O
constructed O O
phylogenetic O O
tree O O
suggests O O
that O O
the O O
UbcP1 B-GENE B-GENE
protein E-GENE E-GENE
may O O
represent O O
a O O
member O O
of O O
a O O
distinct O O
subfamily O O
of O O
E2s S-GENE S-GENE
. O O
Platelet B-GENE B-GENE
factor I-GENE I-GENE
4 E-GENE E-GENE
levels O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O
We O O
functionally O O
characterised O O
AtXPO1 S-GENE S-GENE
by O O
its O O
interaction O O
with O O
NESs O O
of O O
animal O O
and O O
plant O O
proteins O O
, O O
which O O
is O O
inhibited O O
by O O
the O O
cytotoxin O B-GENE
leptomycin O I-GENE
B O E-GENE
( O O
LMB O O
) O O
, O O
and O O
also O O
by O O
its O O
interaction O O
with O O
the O O
small B-GENE O
GTPase E-GENE B-GENE
Ran1 S-GENE E-GENE
in O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O
A O O
backward O O
look O O
at O O
urinary O O
tract O O
infections O O
. O O
The O O
expression O O
of O O
cor14b S-GENE S-GENE
was O O
strongly O O
impaired O O
in O O
the O O
barley O O
albino O O
mutant O O
an O O
, O O
suggesting O O
the O O
involvement O O
of O O
a O O
plastidial O O
factor O O
in O O
the O O
control O O
of O O
gene O O
expression O O
. O O
MRS O O
allowed O O
the O O
differentiation O O
of O O
the O O
following O O
metabolites O O
in O O
5 O O
patients O O
: O O
N O O
- O O
acetyl O O
- O O
aspartate O O
( O O
NAA O O
) O O
, O O
creatine O O
and O O
phosphocreatine O O
, O O
phosphorylcholine O O
and O O
glycerophosphorylcholine O O
, O O
beta O O
- O O
and O O
gamma O B-GENE
- O I-GENE
glutamate O E-GENE
( O O
GLU O O
) O O
. O O
Overall O O
, O O
free O O
- O O
chlorine O O
treatments O O
( O O
0 O O
. O O
3 O O
or O O
1 O O
. O O
0 O O
mg O O
/ O O
L O O
) O O
showed O O
significantly O O
lower O O
heterotrophic O O
plate O O
numbers O O
than O O
those O O
without O O
free O O
chlorine O O
. O O
S1 B-GENE S-GENE
nuclease E-GENE O
protection O O
mapping O O
and O O
primer O O
extension O O
analysis O O
allowed O O
us O O
to O O
propose O O
that O O
the O O
A O O
residue O O
located O O
19 O O
bp O O
upstream O O
from O O
the O O
translation O O
initiation O O
codon O O
is O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O
Various O O
stimuli O O
inactivate O O
IkappaB B-GENE B-GENE
alpha E-GENE E-GENE
by O O
triggering O O
phosphorylation O O
of O O
the O O
N O O
- O O
terminal O O
residues O O
Ser32 O O
and O O
Ser36 O S-GENE
. O O
There O O
was O O
no O O
difference O O
in O O
the O O
day O O
- O O
42 O O
cure O O
rates O O
between O O
the O O
QC7 O O
( O O
n O O
= O O
65 O O
) O O
and O O
A7 O O
( O O
n O O
= O O
64 O O
) O O
regimens O O
with O O
an O O
efficacy O O
of O O
100 O O
% O O
in O O
both O O
, O O
confirmed O O
by O O
parasite O O
genotyping O O
. O O
In O O
addition O O
, O O
the O O
results O O
suggest O O
that O O
N O O
region O O
diversity O O
at O O
V S-GENE O
( O O
D S-GENE O
) O O
J S-GENE O
junctions O O
within O O
rearranged O O
immunoglobulin S-GENE O
and O O
T B-GENE B-GENE
cell I-GENE I-GENE
receptor I-GENE I-GENE
gene I-GENE E-GENE
loci E-GENE O
can O O
only O O
be O O
introduced O O
after O O
the O O
generation O O
of O O
RAG S-GENE O
- O O
catalyzed O O
DNA O O
double O O
- O O
strand O O
breaks O O
, O O
i O O
. O O
e O O
. O O
during O O
the O O
DNA O O
end O O
joining O O
phase O O
of O O
the O O
V S-GENE O
( O O
D S-GENE O
) O O
J S-GENE O
recombination O O
reaction O O
. O O
We O O
conclude O O
that O O
99mTc O O
- O O
HL91 O O
is O O
a O O
potent O O
marker O O
of O O
myocardial O O
viability O O
when O O
used O O
during O O
the O O
early O O
acute O O
phase O O
after O O
reperfusion O O
. O O
Three O O
patients O O
treated O O
with O O
amphotericin O O
B O O
, O O
single O O
course O O
as O O
well O O
as O O
multiple O O
courses O O
, O O
and O O
other O O
antifungal O O
agents O O
( O O
hydroxystilbamidine O O
and O O
miconazole O O
) O O
have O O
all O O
relapsed O O
. O O
An O O
infant O O
of O O
8 O O
months O O
with O O
congenital O O
glaucoma O O
and O O
hemophilia O O
A O O
lost O O
one O O
eye O O
due O O
to O O
haemorrhages O O
after O O
trabeculotomy O O
in O O
an O O
eye O O
hospital O O
. O O
Anderson O O
Hospital O O
and O O
Tumor O O
Institute O O
at O O
Houston O O
during O O
a O O
30 O O
- O O
year O O
interval O O
( O O
1944 O O
to O O
1974 O O
) O O
, O O
with O O
a O O
minimum O O
of O O
ten O O
years O O
of O O
follow O O
- O O
up O O
, O O
we O O
determined O O
that O O
the O O
major O O
prognostic O O
factor O O
of O O
survival O O
was O O
the O O
number O O
of O O
positive O O
nodes O O
. O O
We O O
have O O
now O O
isolated O O
cDNA O O
for O O
an O O
invertebrate B-GENE O
Pax I-GENE B-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
protein I-GENE E-GENE
from I-GENE O
sea I-GENE O
urchin I-GENE O
embryos E-GENE O
. O O
To O O
study O O
structural O O
diversity O O
of O O
the O O
three O O
homologous O O
loci O O
encoding O O
a O O
KN1 B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
homeobox I-GENE I-GENE
protein E-GENE E-GENE
in O O
the O O
hexaploid O O
wheat O O
genome O O
, O O
we O O
isolated O O
clones O O
from O O
a O O
cDNA O O
library O O
of O O
young O O
spikes O O
of O O
Japanese O O
common O O
wheat O O
cultivar O O
' O O
Norin O O
26 O O
' O O
. O O
Whether O O
or O O
not O O
these O O
novel O O
repeated O O
sequences O O
throughout O O
the O O
SMA B-GENE O
region E-GENE O
are O O
involved O O
in O O
the O O
disease O O
remains O O
to O O
be O O
determined O O
. O O
Thus O O
, O O
Shp2 S-GENE S-GENE
regulates O O
phosphotyrosine O O
- O O
signalling O O
events O O
during O O
the O O
complex O O
ectodermal O O
- O O
mesenchymal O O
interactions O O
that O O
regulate O O
mammalian O O
budding O O
morphogenesis O O
. O O
Moyamoya O O
is O O
an O O
intriguing O O
and O O
controversial O O
syndrome O O
. O O
However O O
, O O
elimination O O
of O O
the O O
kinase O O
activity O O
of O O
DCAMKL1 S-GENE S-GENE
has O O
no O O
detectable O O
effect O O
on O O
its O O
microtubule O O
polymerization O O
activity O O
. O O
We O O
have O O
thus O O
cloned O O
two O O
yeast O O
homologs O O
of O O
mammalian B-GENE O
p220 E-GENE S-GENE
. O O
The O O
glucose O O
effect O O
on O O
the O O
pyruvate B-GENE B-GENE
kinase I-GENE I-GENE
gene E-GENE E-GENE
is O O
reversibly O O
antagonized O O
by O O
agents O O
increasing O O
intracellular O O
cAMP O O
. O O
An O O
identical O O
polypeptide O O
was O O
detected O O
by O O
Western O O
blot O O
analysis O O
of O O
K1F O B-GENE
virions O E-GENE
. O O
Patients O O
with O O
PLM O O
show O O
excessive O O
daytime O O
sleepiness O O
or O O
insomnia O O
. O O
Coexpression O O
of O O
CREB B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
CBP S-GENE S-GENE
) O O
/ O O
p300 S-GENE S-GENE
with O O
TReP B-GENE B-GENE
- I-GENE I-GENE
132 E-GENE E-GENE
has O O
an O O
additive O O
effect O O
on O O
promoter O O
activity O O
, O O
and O O
the O O
proteins O O
were O O
demonstrated O O
to O O
interact O O
physically O O
. O O
It O O
is O O
believed O O
that O O
the O O
operation O O
is O O
effective O O
because O O
it O O
cuts O O
the O O
spinothalamic O O
tract O O
( O O
STT O O
) O O
, O O
a O O
primary O O
pathway O O
carrying O O
nociceptive O O
information O O
from O O
the O O
spinal O O
cord O O
to O O
the O O
brain O O
in O O
humans O O
. O O
Catalase S-GENE O
plays O O
a O O
key O O
role O O
as O O
an O O
antioxidant O O
, O O
protecting O O
aerobic O O
organisms O O
from O O
the O O
toxic O O
effects O O
of O O
hydrogen O O
peroxide O O
, O O
and O O
in O O
some O O
cases O O
has O O
been O O
postulated O O
to O O
be O O
a O O
virulence O O
factor O O
. O O
Recovery O O
rates O O
of O O
energy O O
level O O
and O O
intracellular O O
pH O O
during O O
stimulation O O
at O O
100Hz O O
were O O
greater O O
than O O
those O O
observed O O
during O O
stimulation O O
at O O
30Hz O O
. O O
Exhaled O O
NO O O
was O O
assessed O O
by O O
controlled O O
- O O
flow O O
chemoluminescence O O
after O O
adjusting O O
for O O
trapped O O
air O O
and O O
after O O
generating O O
pressure O O
in O O
the O O
oral O O
cavity O O
that O O
was O O
sufficient O O
to O O
close O O
the O O
soft O O
palate O O
( O O
Eco O O
Physics O O
CLD O O
77 O O
AM O O
analyzer O O
) O O
. O O
Recent O O
developments O O
in O O
the O O
study O O
of O O
growth O O
factors O O
: O O
GRF S-GENE S-GENE
and O O
somatomedins S-GENE O
. O O
New O O
concepts O O
of O O
condyloma O O
acuminata O O
in O O
children O O
. O O
This O O
is O O
the O O
first O O
clinical O O
case O O
report O O
of O O
NIHF O O
due O O
to O O
fetal O O
Kasabach O O
- O O
Merritt O O
syndrome O O
that O O
was O O
prenatally O O
diagnosed O O
by O O
sonography O O
, O O
computerized O O
tomography O O
, O O
and O O
percutaneous O O
umbilical O O
blood O O
sampling O O
. O O
Acetoacetate B-GENE O
decarboxylase E-GENE O
( O O
ADC S-GENE O
) O O
( O O
EC4 B-GENE O
. I-GENE O
1 I-GENE O
. I-GENE O
1 I-GENE O
. I-GENE O
4 E-GENE O
) O O
of O O
Clostridium O O
acetobutylicum O O
DSM O O
792 O O
was O O
purified O O
to O O
homogeneity O O
, O O
and O O
its O O
first O O
25 O O
N O O
- O O
terminal O O
amino O O
acids O O
were O O
determined O O
. O O
Transfer O O
of O O
health O O
care O O
to O O
natives O O
holds O O
much O O
promise O O
, O O
lecturers O O
say O O
. O O
The O O
sequence O O
of O O
the O O
127 B-GENE O
residue I-GENE O
NrfF I-GENE O
polypeptide I-GENE O
, I-GENE O
M I-GENE O
( I-GENE O
r I-GENE O
) I-GENE O
14 I-GENE O
, I-GENE O
522 E-GENE O
, O O
is O O
strikingly O O
similar O O
to O O
the O O
CcI2 B-GENE B-GENE
protein E-GENE E-GENE
of O O
R O O
. O O
capsulatus O O
, O O
especially O O
in O O
the O O
putative O O
haem O O
- O O
binding O O
motif O O
, O O
RCPQCQNQN O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O
CAT S-GENE O
assays O O
demonstrated O O
that O O
overexpression O O
of O O
RXRalpha S-GENE S-GENE
conferred O O
the O O
best O O
RA O O
response O O
, O O
consistent O O
with O O
our O O
previous O O
observation O O
that O O
9 O O
- O O
cis O O
- O O
RA O O
is O O
more O O
potent O O
than O O
all O O
- O O
trans O O
- O O
RA O O
for O O
inducing O O
the O O
expression O O
of O O
the O O
AFP B-GENE B-GENE
gene E-GENE E-GENE
. O O
For O O
rotating O O
stimuli O O
presented O O
to O O
the O O
dominant O O
eye O O
, O O
this O O
class O O
of O O
neurons O O
responded O O
best O O
to O O
rotation O O
of O O
the O O
visual O O
world O O
about O O
an O O
axis O O
oriented O O
near O O
the O O
horizontal O O
plane O O
and O O
approximately O O
45 O O
degrees O O
azimuth O O
. O O
None O O
of O O
these O O
patients O O
developed O O
clinical O O
events O O
before O O
disappearance O O
of O O
the O O
phospholipid O O
- O O
dependent O O
inhibitors O O
of O O
coagulation O O
. O O
In O O
spite O O
of O O
the O O
variability O O
of O O
DD95 O O
with O O
regard O O
to O O
body O O
weight O O
, O O
the O O
recovery O O
of O O
neuromuscular O O
transmission O O
in O O
the O O
patients O O
of O O
the O O
three O O
groups O O
is O O
comparable O O
. O O
We O O
have O O
studied O O
some O O
of O O
the O O
parameters O O
governing O O
the O O
expression O O
of O O
a O O
foreign O O
promoter O O
- O O
reporter O O
gene O O
construct O O
incorporated O O
into O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
type O O
1 O O
. O O
Relation O O
between O O
clinical O O
and O O
roentgenological O O
scores O O
and O O
measures O O
of O O
lung O O
function O O
in O O
cystic O O
fibrosis O O
, O O
with O O
special O O
reference O O
to O O
pulmonary O O
Xenon133 O O
elimination O O
. O O
Each O O
fusion O O
leads O O
, O O
in O O
principle O O
, O O
to O O
the O O
same O O
effect O O
: O O
The O O
ret B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
is O O
uncoupled O O
from O O
its O O
stringent O O
physiological O O
regulation O O
by O O
replacement O O
of O O
its O O
5 O O
' O O
end O O
and O O
is O O
aberrantly O O
activated O O
by O O
the O O
5 O O
' O O
parts O O
of O O
fused O O
genes O O
in O O
thyrocytes O O
that O O
do O O
not O O
normally O O
express O O
ret B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
. O O
He O O
had O O
complained O O
of O O
fever O O
and O O
right O O
hypochondralgia O O
2 O O
months O O
after O O
being O O
operated O O
for O O
appendicitis O O
. O O
In O O
the O O
predicted O O
amino O O
acid O O
sequence O O
of O O
NPS1 S-GENE S-GENE
, O O
sequences O O
homologous O O
to O O
the O O
catalytic O O
domain O O
of O O
protein O O
kinases O O
were O O
found O O
. O O
Carcinoma B-GENE O
- I-GENE O
related I-GENE O
protein E-GENE O
production O O
may O O
have O O
played O O
a O O
role O O
in O O
the O O
development O O
of O O
the O O
observed O O
renal O O
lesions O O
. O O
These O O
results O O
provide O O
strong O O
evidence O O
that O O
conserved O O
interhelical O O
packing O O
interactions O O
in O O
the O O
gp41 B-GENE O
core E-GENE O
are O O
important O O
determinants O O
of O O
HIV O O
- O O
1 O O
entry O O
and O O
its O O
inhibition O O
. O O
Lag O O
phases O O
were O O
14 O O
. O O
89 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
77 O O
, O O
13 O O
. O O
33 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
50 O O
, O O
20 O O
. O O
22 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
76 O O
, O O
and O O
20 O O
. O O
00 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
79 O O
, O O
respectively O O
, O O
for O O
endothelial O O
cell O O
- O O
induced O O
LDL S-GENE O
oxidation O O
. O O
Forty O O
- O O
eight O O
pregnant O O
adult O O
and O O
122 O O
fetal O O
guinea O O
pigs O O
were O O
sacrificed O O
at O O
intervals O O
throughout O O
gestation O O
and O O
the O O
carcasses O O
analyzed O O
for O O
a O O
variety O O
of O O
growth O O
parameters O O
. O O
Here O O
we O O
demonstrate O O
the O O
ability O O
of O O
oligonucleotides O O
containing O O
the O O
C4T O B-GENE
sequence O E-GENE
to O O
confer O O
heat O O
shock O O
inducibility O O
on O O
the O O
reporter O O
gene O O
and O O
show O O
that O O
the O O
presence O O
of O O
two O O
such O O
elements O O
produces O O
more O O
than O O
additive O O
effects O O
on O O
induction O O
. O O
The O O
HPV O B-GENE
E1 S-GENE E-GENE
and O O
E2 S-GENE B-GENE
proteins O E-GENE
along O O
with O O
cellular O O
factors O O
, O O
are O O
required O O
for O O
replication O O
of O O
the O O
viral O O
genome O O
. O O
The O O
observed O O
alterations O O
in O O
lung O O
functions O O
in O O
these O O
subjects O O
indicate O O
that O O
individuals O O
performing O O
heavy O O
continuous O O
exercise O O
are O O
more O O
likely O O
to O O
be O O
affected O O
by O O
lower O O
O3 O O
levels O O
. O O
In O O
ten O O
other O O
endotoxin O O
- O O
albumin S-GENE O
- O O
treated O O
pigs O O
PGE1 O O
infusion O O
( O O
0 O O
. O O
25 O O
micrograms O O
X O O
kg O O
- O O
1 O O
X O O
min O O
- O O
1 O O
) O O
was O O
begun O O
after O O
established O O
pulmonary O O
and O O
cardiovascular O O
dysfunction O O
, O O
for O O
closer O O
mimicking O O
of O O
clinical O O
use O O
. O O
The O O
main O O
new O O
features O O
of O O
this O O
version O O
are O O
that O O
end O O
- O O
tidal O O
PO2 O O
instead O O
of O O
inspiratory O O
PO2 O O
can O O
be O O
kept O O
constant O O
, O O
and O O
that O O
the O O
correcting O O
activity O O
of O O
both O O
controllers O O
( O O
capnostat O O
and O O
oxystat O O
) O O
is O O
proportional O O
to O O
the O O
magnitude O O
of O O
the O O
difference O O
between O O
the O O
actual O O
and O O
the O O
adjusted O O
end O O
- O O
tidal O O
PCO2 O O
or O O
PO2 O O
. O O
Like O O
the O O
human B-GENE B-GENE
erythrocyte I-GENE I-GENE
P4 I-GENE I-GENE
. I-GENE I-GENE
2 E-GENE E-GENE
, O O
mouse B-GENE O
erythrocyte I-GENE O
P4 I-GENE O
. I-GENE O
2 E-GENE O
contains O O
regions O O
strikingly O O
homologous O O
with O O
the O O
transglutaminase O O
( O O
TGase O S-GENE
) O O
proteins O O
although O O
it O O
too O O
most O O
likely O O
lacks O O
TGase O O
crosslinking O O
activity O O
. O O
It O O
spans O O
20 O O
kilobases O O
, O O
consists O O
of O O
7 O O
exons O O
and O O
6 O O
introns O O
, O O
and O O
contains O O
a O O
TATA O O
motif O O
24 O O
nucleotides O O
upstream O O
of O O
the O O
transcriptional O O
start O O
site O O
. O O
Nine O O
months O O
after O O
the O O
end O O
of O O
the O O
vaccination O O
anti B-GENE O
- I-GENE O
HBsAg E-GENE O
levels O O
had O O
dropped O O
to O O
9 O O
+ O O
/ O O
- O O
4 O O
IU O O
/ O O
1 O O
( O O
M O O
+ O O
/ O O
- O O
SE O O
) O O
, O O
with O O
a O O
geometric O O
mean O O
of O O
5 O O
IU O O
/ O O
1 O O
, O O
in O O
the O O
nine O O
remaining O O
evaluable O O
patients O O
. O O
CONCLUSION O O
: O O
Ultrasound O O
biomicroscopy O O
is O O
a O O
useful O O
tool O O
for O O
the O O
evaluation O O
of O O
APVR O O
, O O
which O O
is O O
difficult O O
by O O
ordinary O O
methods O O
. O O
It O O
is O O
postulated O O
that O O
the O O
synthesis O O
of O O
the O O
peptidoglycan O O
layer O O
was O O
affected O O
by O O
the O O
antimetabolites O O
since O O
the O O
morphological O O
effects O O
were O O
strikingly O O
similar O O
to O O
those O O
caused O O
by O O
treatment O O
of O O
E O O
. O O
cloacae O O
with O O
disodium O O
edetate O O
plus O O
lysozyme S-GENE O
. O O
DRAP27 S-GENE S-GENE
is O O
recognized O O
by O O
CD9 B-GENE B-GENE
antibodies E-GENE E-GENE
. O O
Furthermore O O
we O O
elucidate O O
the O O
subtle O O
highly O O
anisotropic O O
interchain O O
correlations O O
and O O
reveal O O
the O O
detailed O O
atomic O O
structure O O
of O O
the O O
low O O
- O O
temperature O O
( O O
8x2 O O
) O O
phase O O
. O O
Control O O
oligomers O O
of O O
scrambled O O
sequence O O
but O O
identical O O
base O O
composition O O
were O O
ineffective O O
, O O
and O O
no O O
TFO O O
- O O
induced O O
recombination O O
was O O
seen O O
in O O
a O O
control O O
LTK O O
( O O
- O O
) O O
cell O O
line O O
carrying O O
an O O
otherwise O O
identical O O
dual O O
TK B-GENE B-GENE
gene I-GENE E-GENE
construct E-GENE O
lacking O O
the O O
30 O O
- O O
bp O O
polypurine O O
target O O
site O O
. O O
To O O
quantify O O
the O O
normal O O
coupling O O
patterns O O
, O O
fresh O O
cadaveric O O
human O O
lumbar O O
spine O O
specimens O O
( O O
L1 O O
- O O
S1 O O
) O O
were O O
used O O
. O O
One O O
cytoplasmic O O
target O O
which O O
reflects O O
the O O
functional O O
state O O
of O O
the O O
plastids O O
is O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
. O O
These O O
three O O
chromosomes O O
share O O
the O O
transferrin B-GENE B-GENE
gene E-GENE E-GENE
( O O
TF S-GENE S-GENE
) O O
, O O
the O O
myosin B-GENE B-GENE
light I-GENE I-GENE
polypeptide I-GENE I-GENE
3 I-GENE I-GENE
gene E-GENE E-GENE
( O O
MYL3 S-GENE S-GENE
) O O
, O O
and O O
the O O
acylpeptide B-GENE B-GENE
hydrolase I-GENE I-GENE
gene E-GENE E-GENE
( O O
APEH S-GENE S-GENE
) O O
. O O
( O O
i O O
) O O
Several O O
ribosomal O O
proteins O O
were O O
synthesized O O
in O O
substantial O O
excess O O
. O O
This O O
experience O O
would O O
recommend O O
consideration O O
of O O
home O O
nutritional O O
support O O
in O O
patients O O
with O O
systemic O O
scleroderma O O
when O O
the O O
disease O O
is O O
relatively O O
stable O O
and O O
no O O
major O O
organ O O
failure O O
is O O
present O O
. O O
Based O O
on O O
our O O
sequence O O
data O O
, O O
ORF2 O S-GENE
from O O
most O O
isolates O O
excluding O O
G1 O O
encode O O
truncated O O
49 O O
aa O O
( O O
pORF2a O O
) O O
because O O
of O O
an O O
in O O
- O O
frame O O
stop O O
codon O O
, O O
although O O
ORF2s O O
from O O
most O O
G1 O O
isolates O O
encode O O
202 O O
aa O O
( O O
pORF2ab O O
) O O
. O O
In O O
the O O
present O O
study O O
we O O
prospectively O O
compared O O
side O O
effects O O
occurring O O
in O O
12 O O
patients O O
after O O
the O O
first O O
administration O O
of O O
low O O
- O O
dose O O
OKT3 O O
( O O
0 O O
. O O
5 O O
mg O O
twice O O
daily O O
) O O
induction O O
therapy O O
with O O
those O O
in O O
10 O O
patients O O
who O O
were O O
treated O O
with O O
a O O
conventional O O
dose O O
of O O
OKT3 O O
( O O
5 O O
mg O O
daily O O
) O O
for O O
acute O O
rejection O O
. O O
These O O
data O O
indicate O O
that O O
SB O B-GENE
203580 O E-GENE
sensitive O O
p38 B-GENE B-GENE
MAP I-GENE I-GENE
kinases E-GENE E-GENE
are O O
not O O
involved O O
in O O
okadaic O O
acid O O
mediated O O
increases O O
in O O
TRE O O
DNA O O
binding O O
and O O
transactivation O O
. O O
Together O O
, O O
these O O
results O O
indicate O O
that O O
YTS1 S-GENE S-GENE
is O O
a O O
bifunctional O O
protein O O
active O O
in O O
both O O
splicing O O
and O O
protein O O
synthesis O O
. O O
Oscillatory O O
flow O O
is O O
reestablished O O
in O O
the O O
model O O
at O O
the O O
capillary O O
- O O
cerebrospinal O O
fluid O O
and O O
capillary O O
- O O
venous O O
interfaces O O
. O O
Sgs B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
is O O
one O O
of O O
the O O
eight O O
known O O
genes O O
coding O O
for O O
larval O O
secretion O O
proteins O O
in O O
Drosophila O O
melanogaster O O
. O O
We O O
conclude O O
that O O
although O O
the O O
G3 O O
sequence O O
contains O O
two O O
protein O O
- O O
binding O O
motifs O O
, O O
the O O
organization O O
of O O
the O O
G3 O O
enhancer O O
- O O
like O O
element O O
is O O
not O O
bipartite O O
. O O
Human B-GENE B-GENE
myotonic I-GENE I-GENE
dystrophy I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
DMPK S-GENE S-GENE
) O O
is O O
a O O
member O O
of O O
a O O
novel O O
class O O
of O O
multidomain O B-GENE
protein O I-GENE
kinases O E-GENE
that O O
regulate O O
cell O O
size O O
and O O
shape O O
in O O
a O O
variety O O
of O O
organisms O O
. O O
The O O
human B-GENE B-GENE
BRCA1 I-GENE I-GENE
promoter E-GENE E-GENE
also O O
contains O O
a O O
conserved O O
E2F B-GENE B-GENE
site E-GENE E-GENE
and O O
is O O
similarly O O
regulated O O
by O O
E2F1 S-GENE S-GENE
and O O
Rb S-GENE S-GENE
. O O
The O O
translated O O
sequence O O
of O O
the O O
FLI B-GENE B-GENE
LRR I-GENE I-GENE
associated I-GENE I-GENE
protein E-GENE E-GENE
( O O
FLAP S-GENE S-GENE
) O O
encodes O O
a O O
novel O O
protein O O
not O O
represented O O
in O O
the O O
data O O
base O O
. O O
Corticosteroid O O
treatment O O
before O O
, O O
during O O
, O O
or O O
after O O
fludarabine O O
treatment O O
in O O
patients O O
with O O
alkylator O O
- O O
resistant O O
, O O
low O O
- O O
grade O O
lymphoid O O
malignancies O O
who O O
have O O
not O O
received O O
PCP O O
prophylaxis O O
is O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
opportunistic O O
pulmonary O O
infections O O
. O O
In O O
this O O
respect O O
, O O
the O O
promoter O O
structure O O
of O O
COX B-GENE O
genes E-GENE O
resemble O O
those O O
of O O
many O O
house O O
- O O
keeping O O
genes O O
. O O
In O O
vitro O O
, O O
cytokine O O
- O O
or O O
hypoxia O O
- O O
induced O O
up O O
- O O
regulation O O
of O O
Fas S-GENE S-GENE
expression O O
is O O
associated O O
with O O
RTC O S-GENE
apoptosis O O
. O O
The O O
site O O
of O O
acetylation O O
of O O
Tat S-GENE S-GENE
was O O
mapped O O
to O O
the O O
double O O
- O O
lysine O O
motif O O
in O O
a O O
highly O O
conserved O O
region O O
, O O
( O O
49 O O
) O O
RKKRRQ O O
( O O
54 O O
) O O
, O O
of O O
the O O
basic O O
RNA O O
- O O
binding O O
motif O O
of O O
Tat S-GENE S-GENE
. O O
These O O
results O O
suggest O O
that O O
the O O
PVB O O
therapy O O
is O O
not O O
sufficient O O
to O O
cure O O
the O O
cases O O
with O O
choriocarcinoma O O
element O O
or O O
bulky O O
metastasis O O
. O O
The O O
KEMAR O O
measurements O O
show O O
that O O
the O O
two O O
models O O
give O O
an O O
improvement O O
of O O
the O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
of O O
approximately O O
7 O O
. O O
5 O O
dB O O
in O O
a O O
diffuse O O
sound O O
field O O
. O O
Indirect O O
determination O O
of O O
maximal O O
O2 O O
consumption O O
in O O
man O O
. O O
Using O O
unidirectional O O
PCR O O
we O O
isolated O O
a O O
361 O O
- O O
bp O O
5 O O
' O O
promoter O O
region O O
and O O
delineated O O
the O O
intronic O O
/ O O
exonic O O
boundaries O O
which O O
include O O
a O O
non O O
- O O
coding O O
exon O O
1 O O
, O O
a O O
single O O
intron O O
, O O
and O O
a O O
coding O O
exon O O
2 O O
, O O
a O O
structure O O
that O O
is O O
typical O O
of O O
genes O O
of O O
the O O
RNase B-GENE B-GENE
A I-GENE I-GENE
superfamily E-GENE E-GENE
. O O
When O O
severe O O
hypoxia O O
was O O
acutely O O
produced O O
by O O
ventilation O O
with O O
low O O
- O O
oxygen O O
mixtures O O
in O O
experimental O O
( O O
PaO2 O O
, O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
torr O O
) O O
and O O
control O O
animals O O
( O O
PaO2 O O
, O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
torr O O
) O O
, O O
plasma B-GENE O
insulin E-GENE O
responses O O
were O O
markedly O O
inhibited O O
in O O
both O O
. O O
Uptake O O
of O O
colicins S-GENE O
required O O
different O O
domains O O
in O O
TonB S-GENE O
, O O
for O O
colicin B-GENE O
B I-GENE O
and I-GENE O
M E-GENE O
around O O
residue O O
160 O O
and O O
for O O
colicin B-GENE O
Ia E-GENE O
, O O
a O O
domain O O
closer O O
to O O
the O O
C O O
- O O
terminal O O
end O O
. O O
D O O
. O O
When O O
lipid O O
X O O
was O O
combined O O
with O O
ticarcillin O O
, O O
survival O O
differences O O
were O O
both O O
significant O O
and O O
prolonged O O
. O O
Central O O
treatment O O
unit O O
saves O O
nurses O O
, O O
adds O O
income O O
, O O
improves O O
care O O
. O O
Gold O O
flaxseed O O
( O O
whole O O
or O O
ground O O
) O O
fed O O
at O O
levels O O
of O O
5 O O
or O O
15 O O
% O O
were O O
compared O O
to O O
a O O
1 O O
. O O
5 O O
% O O
menhaden O O
oil O O
or O O
a O O
typical O O
control O O
layer O O
ration O O
. O O
It O O
is O O
dangerous O O
to O O
label O O
such O O
conditions O O
as O O
' O O
inappropriate O O
' O O
secretion O O
of O O
ADH S-GENE S-GENE
since O O
the O O
maintenance O O
of O O
circulating O O
volume O O
is O O
at O O
least O O
as O O
important O O
a O O
physiological O O
requirement O O
as O O
the O O
defence O O
of O O
tonicity O O
. O O
The O O
complete O O
nucleotide O O
sequence O O
of O O
odontoglossum O O
ringspot O O
virus O O
( O O
Cy O O
- O O
1 O O
strain O O
) O O
genomic O O
RNA O O
. O O
An O O
enhancement O O
of O O
benign O O
liver O O
tumors O O
( O O
tumorigenic O O
effect O O
) O O
was O O
observed O O
only O O
in O O
CF1 O O
male O O
mice O O
( O O
17 O O
/ O O
56 O O
at O O
the O O
only O O
tested O O
dose O O
: O O
400 O O
ppm O O
vs O O
. O O
Cells O O
were O O
cotransfected O O
with O O
this O O
plasmid O O
, O O
and O O
the O O
appropriate O O
responder O O
plasmids O O
and O O
clonies O O
were O O
selected O O
on O O
the O O
basis O O
of O O
their O O
resistance O O
to O O
Geneticin O O
( O O
via O O
the O O
neomycin B-GENE B-GENE
aminoglycoside I-GENE I-GENE
phosphotransferase I-GENE I-GENE
gene E-GENE E-GENE
) O O
. O O
This O O
C O O
- O O
terminal O O
domain O O
contains O O
several O O
YxxI O S-GENE
/ O O
L O O
motifs O O
reminiscent O O
of O O
LMP2A S-GENE S-GENE
and O O
a O O
putative O O
TRAF B-GENE S-GENE
binding I-GENE O
site E-GENE O
as O O
in O O
LMP1 S-GENE O
. O O
Omitting O O
part O O
of O O
the O O
experimental O O
NOE O O
- O O
derived O O
distances O O
results O O
in O O
reduced O O
restraint O O
violations O O
and O O
lower O O
R O O
factors O O
but O O
impairs O O
structural O O
convergence O O
in O O
the O O
rMD O O
refinement O O
. O O
Cardiac O O
lesion O O
in O O
exotoxic O O
shock O O
Risk O O
factors O O
for O O
atherosclerosis O O
related O O
to O O
nutrition O O
are O O
hypercholesterolemia O O
, O O
hyperglycemia O O
- O O
diabetes O O
, O O
and O O
for O O
hypertension O O
, O O
obesity O O
, O O
high O O
salt O O
intake O O
, O O
and O O
excessive O O
use O O
of O O
alcohol O O
. O O
This O O
mutation O O
was O O
associated O O
with O O
reduced O O
or O O
absent O O
expression O O
of O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
RI I-GENE I-GENE
protein E-GENE E-GENE
and O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
in O O
tumor O O
tissues O O
. O O
SCAN S-GENE O
boxes O O
are O O
found O O
in O O
eight O O
other O O
genes O O
in O O
the O O
GenBank O O
database O O
, O O
five O O
of O O
which O O
are O O
also O O
in O O
the O O
Kruppel B-GENE B-GENE
family E-GENE E-GENE
of O O
zinc B-GENE O
finger I-GENE O
proteins E-GENE O
lacking O O
KRAB B-GENE S-GENE
A I-GENE O
and I-GENE O
B E-GENE O
domains O O
and O O
thereby O O
define O O
a O O
new O O
subclass O O
of O O
zinc B-GENE O
finger I-GENE O
proteins E-GENE O
. O O
However O O
, O O
they O O
had O O
no O O
cross O O
- O O
resistance O O
to O O
quinolone O O
, O O
josamycin O O
and O O
tylosin O O
. O O
Seventy O O
- O O
nine O O
percent O O
of O O
the O O
children O O
screened O O
and O O
91 O O
. O O
0 O O
% O O
of O O
the O O
children O O
with O O
PbB O O
at O O
least O O
10 O O
micrograms O O
/ O O
dL O O
were O O
Hispanic O O
. O O
Normal O O
dogs O O
were O O
exposed O O
to O O
either O O
10 O O
, O O
15 O O
, O O
or O O
30 O O
Gy O O
of O O
X O O
rays O O
to O O
a O O
single O O
hemisphere O O
and O O
the O O
gross O O
and O O
histopathologic O O
changes O O
were O O
evaluated O O
qualitatively O O
. O O
YACs O S-GENE
selected O O
from O O
our O O
contig O O
will O O
be O O
the O O
starting O O
point O O
for O O
the O O
cloning O O
of O O
the O O
LGMD2B B-GENE B-GENE
gene E-GENE E-GENE
and O O
thereby O O
establish O O
the O O
biological O O
basis O O
for O O
this O O
form O O
of O O
muscular O O
dystrophy O O
and O O
its O O
relationship O O
with O O
the O O
other O O
limb O O
- O O
girdle O O
muscular O O
dystrophies O O
. O O
The O O
amount O O
of O O
ERCC1 S-GENE O
detectable O O
by O O
immunoblotting O O
is O O
reduced O O
in O O
group O O
1 O O
, O O
group O O
4 O O
and O O
XP O O
- O O
F O O
extracts O O
. O O
In O O
the O O
plant B-GENE O
malate I-GENE O
synthases E-GENE O
, O O
the O O
extension O O
is O O
probably O O
involved O O
in O O
routing O O
to O O
the O O
microbodies O O
, O O
since O O
it O O
contains O O
the O O
potential O O
peroxisomal O O
targeting O O
signal O O
, O O
Ser O O
- O O
Arg O O
/ O O
Lys O O
- O O
Leu O O
, O O
at O O
the O O
carboxy O O
terminus O O
. O O
Optimized O O
USF S-GENE S-GENE
and O O
MYC S-GENE O
DNA O O
- O O
binding O O
sites O O
, O O
which O O
differ O O
in O O
the O O
nucleotides O O
bordering O O
the O O
hexanucleotide O O
box O O
displace O O
the O O
E B-GENE B-GENE
- I-GENE I-GENE
C4 I-GENE I-GENE
factor E-GENE E-GENE
in O O
competition O O
assays O O
but O O
with O O
lesser O O
efficiency O O
than O O
the O O
E B-GENE O
- I-GENE O
C4 I-GENE O
site E-GENE O
itself O O
. O O
Screening O O
of O O
human O O
cDNA O O
libraries O O
has O O
identified O O
two O O
different O O
5 O O
' O O
- O O
termini O O
and O O
alternatively O O
spliced O O
forms O O
of O O
the O O
human B-GENE B-GENE
Fli I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
( O O
Fli B-GENE B-GENE
- I-GENE I-GENE
1b E-GENE E-GENE
) O O
, O O
suggesting O O
the O O
possible O O
existence O O
of O O
two O O
independent O O
promoters O O
. O O
A O O
surge O O
in O O
the O O
rate O O
of O O
ascorbyl O O
radical O O
production O O
, O O
directly O O
correlated O O
with O O
oxyradical O O
stress O O
and O O
an O O
abrupt O O
fall O O
in O O
superoxide B-GENE O
dismutase E-GENE O
activity O O
in O O
the O O
granuloma O O
, O O
indicates O O
' O O
switching O O
on O O
' O O
of O O
a O O
free O O
radical O O
- O O
dependent O O
machinery O O
for O O
the O O
formation O O
of O O
granuloma O O
after O O
vasectomy O O
. O O
After O O
5 O O
- O O
h O O
thermal O O
induction O O
of O O
cells O O
carrying O O
the O O
runaway O O
recombinant O O
pBS1 O S-GENE
, O O
protein B-GENE O
B2 E-GENE O
constituted O O
40 O O
% O O
of O O
the O O
soluble O O
protein O O
fraction O O
of O O
the O O
cells O O
. O O
A O O
regulatory O O
element O O
of O O
the O O
empty B-GENE O
spiracles E-GENE O
homeobox O O
gene O O
is O O
composed O O
of O O
three O O
distinct O O
conserved O O
regions O O
that O O
bind O O
regulatory O O
proteins O O
. O O
Peak O O
reactive O O
hyperemia O O
( O O
mL O O
. O O
min O O
- O O
1 O O
. O O
100 O O
mL O O
- O O
1 O O
) O O
was O O
determined O O
in O O
the O O
calf O O
and O O
forearm O O
immediately O O
before O O
and O O
after O O
12 O O
weeks O O
of O O
training O O
. O O
These O O
characteristics O O
add O O
to O O
the O O
suitability O O
of O O
NM441 O S-GENE
as O O
an O O
effective O O
prodrug O O
of O O
NM394 O S-GENE
. O O
Vorozole O O
( O O
Rivizor O O
) O O
is O O
a O O
potent O O
and O O
stereospecific O O
inhibitor O O
of O O
aromatase S-GENE O
having O O
shown O O
promising O O
endocrine O O
effects O O
in O O
phase O O
I O O
studies O O
. O O
In O O
5 O O
cases O O
, O O
combined O O
sensitization O O
to O O
mercury O O
and O O
other O O
metal O O
salts O O
, O O
particularly O O
gold O O
sodium O O
thiosulfate O O
( O O
GST O O
) O O
and O O
palladium O O
chloride O O
( O O
PDC O O
) O O
, O O
was O O
observed O O
. O O
Gene O O
structure O O
and O O
precursor O O
processing O O
. O O
The O O
content O O
of O O
monoamine O O
metabolites O O
, O O
5 O O
- O O
hydroxyindoleacetic O O
acid O O
, O O
5 O O
- O O
HIAA O O
, O O
and O O
homovanillic O O
acid O O
( O O
HVA O O
) O O
, O O
and O O
- O O
- O O
for O O
17 O O
patients O O
- O O
- O O
tryptophan O O
, O O
in O O
the O O
cerebrospinal O O
fluid O O
was O O
determined O O
. O O
One O O
month O O
after O O
administration O O
of O O
131I O O
, O O
the O O
29 O O
cats O O
evaluated O O
were O O
clinically O O
improved O O
, O O
and O O
24 O O
( O O
83 O O
% O O
) O O
of O O
the O O
29 O O
cats O O
evaluated O O
had O O
normal O O
serum O O
T4 O O
concentrations O O
, O O
3 O O
cats O O
( O O
10 O O
% O O
) O O
remained O O
hyperthyroxinemic O O
, O O
and O O
2 O O
cats O O
( O O
7 O O
% O O
) O O
were O O
hypothyroxinemic O O
. O O
These O O
findings O O
suggest O O
that O O
T3R S-GENE S-GENE
can O O
repress O O
or O O
activate O O
transcription O O
while O O
tethered O O
to O O
the O O
LBD O O
of O O
GAL4 S-GENE B-GENE
- O I-GENE
RXR S-GENE E-GENE
and O O
that O O
heterodimerization O O
can O O
occur O O
in O O
vivo O O
without O O
stabilization O O
by O O
hormone O O
response O O
elements O O
. O O
Most O O
interestingly O O
, O O
although O O
the O O
effector O O
plasmid O O
containing O O
the O O
ICP27 B-GENE B-GENE
gene E-GENE E-GENE
had O O
little O O
effect O O
on O O
its O O
own O O
, O O
two O O
different O O
and O O
marked O O
effects O O
depending O O
on O O
the O O
target O O
were O O
observed O O
when O O
ICP27 S-GENE O
was O O
combined O O
with O O
ICP4 S-GENE O
or O O
ICP0 S-GENE O
or O O
both O O
. O O
In O O
renal O O
vein O O
thrombosis O O
, O O
similar O O
pattern O O
to O O
acute O O
tubular O O
necrosis O O
was O O
found O O
but O O
RI O O
venography O O
was O O
helpful O O
. O O
TOM1 S-GENE S-GENE
encodes O O
a O O
member O O
of O O
the O O
hect S-GENE O
- O O
domain O O
- O O
containing O O
E3 S-GENE B-GENE
ubiquitin B-GENE I-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
ligase E-GENE I-GENE
family O E-GENE
that O O
is O O
required O O
for O O
growth O O
at O O
elevated O O
temperatures O O
. O O
Genomic O O
clones O O
containing O O
the O O
C O B-GENE
. O I-GENE
briggsae O I-GENE
gene O E-GENE
are O O
able O O
to O O
completely O O
rescue O O
the O O
unc B-GENE O
- I-GENE O
119 I-GENE O
phenotype E-GENE O
in O O
transgenic O O
C O O
. O O
elegans O O
mutants O O
. O O
The O O
rapid O O
decrease O O
of O O
plasma O O
potassium O O
during O O
the O O
first O O
two O O
hours O O
of O O
standard O O
HD O O
causes O O
a O O
membrane O O
hyperpolarization O O
. O O
Region O O
- O O
specific O O
enhancers O O
near O O
two O O
mammalian B-GENE O
homeo I-GENE O
box I-GENE O
genes E-GENE O
define O O
adjacent O O
rostrocaudal O O
domains O O
in O O
the O O
central O O
nervous O O
system O O
. O O
In O O
this O O
study O O
, O O
we O O
report O O
the O O
cloning O O
and O O
sequencing O O
of O O
several O O
overlapping O O
cDNAs O O
encoding O O
approximately O O
4 O O
. O O
1 O O
kb O O
of O O
the O O
human B-GENE O
homologue I-GENE O
of I-GENE O
Wnt I-GENE B-GENE
- I-GENE I-GENE
5A E-GENE E-GENE
. O O
Subtype O O
- O O
and O O
response O O
element O O
- O O
dependent O O
differences O O
in O O
transactivation O O
by O O
peroxisome B-GENE B-GENE
proliferator I-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
receptors I-GENE I-GENE
alpha I-GENE E-GENE
and I-GENE O
gamma E-GENE O
. O O
MRI O O
visualization O O
of O O
proteoglycan O O
depletion O O
in O O
articular O O
cartilage O O
via O O
intravenous O O
administration O O
of O O
Gd O O
- O O
DTPA O O
. O O
We O O
then O O
developed O O
a O O
yeast O O
artificial O O
chromosome O O
( O O
YAC O O
) O O
contig O O
for O O
this O O
region O O
. O O
We O O
suggest O O
that O O
the O O
induction O O
of O O
IFNA B-GENE B-GENE
promoter I-GENE E-GENE
region E-GENE O
requires O O
cooperation O O
between O O
alpha B-GENE B-GENE
F1 I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
and O O
IRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
Heterologous O O
hybridization O O
with O O
a O O
rps12 B-GENE B-GENE
gene E-GENE E-GENE
specific O O
probe O O
from O O
Euglena O O
has O O
revealed O O
the O O
presence O O
of O O
rps12 B-GENE S-GENE
homologous I-GENE O
sequences E-GENE O
within O O
the O O
inverted O O
repeat O O
of O O
Spirodela O O
chloroplast O O
DNA O O
on O O
the O O
fragment B-GENE O
BamHI I-GENE O
- I-GENE O
V E-GENE O
. O O
To O O
investigate O O
the O O
effect O O
of O O
hyperthyroidism O O
on O O
the O O
pattern O O
and O O
time O O
course O O
of O O
O2 O O
uptake O O
( O O
VO2 O O
) O O
following O O
the O O
transition O O
from O O
rest O O
to O O
exercise O O
, O O
six O O
patients O O
and O O
six O O
healthy O O
subjects O O
performed O O
cycle O O
exercise O O
at O O
an O O
average O O
work O O
rate O O
( O O
WR O O
) O O
of O O
18 O O
and O O
20 O O
W O O
respectively O O
. O O
However O O
, O O
to O O
date O O
, O O
no O O
viable O O
in O O
vitro O O
- O O
generated O O
deletion O O
mutant O O
of O O
PSTVd O S-GENE
has O O
been O O
reported O O
. O O
This O O
raises O O
the O O
possibility O O
that O O
recombination O O
occurred O O
between O O
corresponding O O
LTR O O
and O O
vif B-GENE O
loci E-GENE O
of O O
the O O
quasi O O
- O O
species O O
present O O
in O O
the O O
isolates O O
described O O
here O O
. O O
In O O
HMEC O O
stably O O
transfected O O
with O O
an O O
ER B-GENE O
mutant E-GENE O
containing O O
a O O
deletion O O
in O O
the O O
second O O
zinc O O
finger O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
, O O
E O O
and O O
HT O O
had O O
different O O
effects O O
on O O
EBBP B-GENE B-GENE
gene E-GENE E-GENE
expression O O
; O O
EBBP S-GENE S-GENE
regulation O O
by O O
E O O
was O O
dramatically O O
reduced O O
while O O
the O O
effects O O
of O O
HT O O
were O O
augmented O O
. O O
The O O
gene B-GENE B-GENE
atp6 E-GENE E-GENE
, O O
encoding O O
subunit O O
6 O O
of O O
the O O
mitochondrial O O
F0 S-GENE B-GENE
- O I-GENE
ATPase S-GENE E-GENE
complex O O
, O O
has O O
been O O
characterized O O
from O O
both O O
the O O
normal O O
( O O
fertile O O
) O O
and O O
Ogura O O
( O O
male O O
- O O
sterile O O
) O O
radish O O
cytoplasms O O
in O O
order O O
to O O
determine O O
if O O
previously O O
identified O O
atp6 S-GENE O
transcriptional O O
differences O O
could O O
play O O
a O O
role O O
in O O
cytoplasmic O O
male O O
sterility O O
. O O
When O O
the O O
same O O
single O O
- O O
amino O O
- O O
acid O O
mutations O O
were O O
directly O O
introduced O O
into O O
the O O
parental O O
PV O O
/ O O
CBV4 O O
- O O
2A O O
genome O O
, O O
chimeric O O
viruses O O
with O O
a O O
large O O
- O O
plaque O O
phenotype O O
and O O
a O O
wild O O
- O O
type O O
PV O O
- O O
like O O
growth O O
pattern O O
were O O
obtained O O
upon O O
transfection O O
, O O
an O O
observation O O
demonstrating O O
that O O
these O O
point O O
mutations O O
alone O O
had O O
a O O
drastic O O
effect O O
on O O
the O O
growth O O
of O O
the O O
PV O O
/ O O
CBV4 O O
chimeric O O
virus O O
. O O
The O O
gag S-GENE B-GENE
- O I-GENE
myc S-GENE I-GENE
proteins O I-GENE
encoded O E-GENE
by O O
these O O
variants O O
efficiently O O
localized O O
to O O
the O O
cell O O
nucleus O O
. O O
Hpr1 S-GENE S-GENE
forms O O
, O O
together O O
with O O
Tho2 S-GENE S-GENE
, O O
Mft1 S-GENE S-GENE
, O O
and O O
Thp2 S-GENE S-GENE
, O O
the O O
THO B-GENE O
complex E-GENE O
, O O
which O O
controls O O
transcription O O
elongation O O
and O O
genome O O
stability O O
in O O
Saccharomyces O O
cerevisiae O O
. O O
UPR O S-GENE
elements O O
present O O
in O O
other O O
ER O B-GENE
chaperone O I-GENE
genes O E-GENE
, O O
such O O
as O O
yeast B-GENE O
KAR2 E-GENE S-GENE
( O O
BiP S-GENE S-GENE
) O O
, O O
mammalian B-GENE O
GRP78 E-GENE S-GENE
( O O
BiP S-GENE S-GENE
) O O
, O O
and O O
GRP94 S-GENE S-GENE
, O O
function O O
in O O
an O O
analogous O O
manner O O
to O O
that O O
in O O
FKB2 S-GENE S-GENE
. O O
The O O
objective O O
of O O
this O O
research O O
was O O
to O O
determine O O
if O O
ergotamine O O
, O O
an O O
ergopeptine O O
alkaloid O O
isolated O O
from O O
Neotyphodium O O
- O O
infected O O
grasses O O
and O O
associated O O
with O O
toxicoses O O
in O O
livestock O O
, O O
altered O O
plasma O O
concentrations O O
of O O
reproductive O O
hormones O O
in O O
follicular O O
phase O O
heifers O O
and O O
in O O
cows O O
given O O
a O O
progestin O O
implant O O
. O O
Acute O O
spontaneous O O
subdural O O
haematoma O O
. O O
Strains O O
carrying O O
a O O
snf1 B-GENE O
mutation E-GENE O
are O O
unable O O
to O O
grow O O
on O O
sucrose O O
, O O
galactose O O
, O O
maltose O O
, O O
melibiose O O
, O O
or O O
nonfermentable O O
carbon O O
sources O O
; O O
utilization O O
of O O
these O O
carbon O O
sources O O
is O O
regulated O O
by O O
glucose O O
repression O O
. O O
2 O O
) O O
Depending O O
on O O
the O O
structure O O
, O O
certain O O
compounds O O
are O O
sequestered O O
in O O
the O O
cornea O O
( O O
presumably O O
the O O
stroma O O
) O O
and O O
form O O
a O O
release O O
system O O
into O O
the O O
anterior O O
aqueous O O
. O O
The O O
results O O
of O O
the O O
neural O O
network O O
were O O
compared O O
with O O
those O O
of O O
a O O
density O O
mask O O
( O O
thresholds O O
, O O
- O O
750 O O
/ O O
- O O
300 O O
H O O
) O O
, O O
with O O
a O O
radiologist O O
serving O O
as O O
the O O
gold O O
standard O O
. O O
These O O
data O O
also O O
suggest O O
the O O
existence O O
of O O
a O O
mechanism O O
by O O
which O O
regulatory O O
subunits O O
modulate O O
the O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
- O O
mediated O O
signals O O
, O O
independent O O
of O O
the O O
kinase O O
activity O O
, O O
possibly O O
through O O
subcellular O O
localization O O
of O O
the O O
catalytic O O
subunit O O
or O O
interaction O O
with O O
additional O O
signaling O O
molecules O O
. O O
These O O
results O O
suggest O O
that O O
the O O
PVB O O
therapy O O
is O O
not O O
sufficient O O
to O O
cure O O
the O O
cases O O
with O O
choriocarcinoma O O
element O O
or O O
bulky O O
metastasis O O
. O O
Right O O
- O O
sided O O
hemiplegia O O
of O O
5 O O
years O O
duration O O
occurred O O
in O O
the O O
remaining O O
case O O
. O O
Plasmid O O
subclones O O
of O O
the O O
hr1a S-GENE O
- O O
containing O O
AcMNPV O O
HindIII S-GENE O
- O O
N O O
fragment O O
were O O
examined O O
for O O
their O O
ability O O
to O O
replicate O O
in O O
virus O O
- O O
infected O O
( O O
Spodoptera O O
frugiperda O O
) O O
Sf9 O O
cells O O
, O O
and O O
to O O
stimulate O O
transcription O O
when O O
linked O O
in O O
cis O O
with O O
a O O
39K B-GENE B-GENE
gene I-GENE E-GENE
promoter I-GENE O
- I-GENE O
beta I-GENE O
- I-GENE O
glucuronidase I-GENE O
fusion E-GENE O
and O O
cotransfected O O
into O O
cells O O
along O O
with O O
a O O
plasmid O O
( O O
ple O B-GENE
- O I-GENE
1 O E-GENE
) O O
containing O O
the O O
gene O O
encoding O O
the O O
trans O O
- O O
acting O O
factor O O
IE B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
Transfection O O
of O O
H B-GENE O
chain I-GENE O
loss I-GENE O
variant E-GENE O
myeloma O O
with O O
the O O
complete O O
12 O O
kb O O
construct O O
, O O
termed O O
238H B-GENE O
- I-GENE O
Cmicro E-GENE O
, O O
resulted O O
in O O
secretion O O
of O O
intact O O
Ig O O
pairing O O
238H B-GENE O
- I-GENE O
Cmicro E-GENE O
, O O
with O O
a O O
lambda B-GENE O
L I-GENE O
chain E-GENE O
; O O
however O O
, O O
transfectant B-GENE O
Ig E-GENE O
lacked O O
autoreactivity O O
and O O
pathogenicity O O
. O O
Divergent O O
regions O O
of O O
the O O
posterior O O
left O O
hemisphere O O
used O O
for O O
decoding O O
and O O
storage O O
of O O
information O O
emerged O O
in O O
each O O
working O O
memory O O
versus O O
control O O
task O O
comparison O O
. O O
In O O
normal O O
B O O
cells O O
stimulated O O
by O O
LPS O O
or O O
IL B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
, O O
new O O
complexes O O
appear O O
that O O
bind O O
to O O
C B-GENE O
/ I-GENE O
EBP E-GENE O
and O O
NF B-GENE O
- I-GENE O
IL I-GENE O
- I-GENE O
4 I-GENE O
elements E-GENE O
, O O
respectively O O
, O O
located O O
within O O
the O O
- O O
125 O O
/ O O
- O O
101 O O
region O O
. O O
Here O O
, O O
we O O
describe O O
the O O
crystal O O
structure O O
at O O
2 O O
. O O
5 O O
A O O
resolution O O
of O O
a O O
fragment O O
of O O
the O O
integrase B-GENE O
of I-GENE O
Rous I-GENE O
sarcoma I-GENE O
virus I-GENE O
( I-GENE O
residues I-GENE O
49 I-GENE O
- I-GENE O
286 I-GENE O
) E-GENE O
containing O O
both O O
the O O
conserved O O
catalytic O O
domain O O
and O O
a O O
modulatory O O
DNA O O
- O O
binding O O
domain O O
( O O
C O B-GENE
domain O E-GENE
) O O
. O O
Vectorcardiography O O
in O O
coronary O O
patients O O
with O O
the O O
electrocardiographic O O
RS O O
segment O O
in O O
the O O
V1 O O
lead O O
The O O
B B-GENE O
. I-GENE O
aphidicola I-GENE O
argS I-GENE O
- I-GENE O
rrn I-GENE O
DNA I-GENE O
fragments E-GENE O
from O O
endosymbionts O O
from O O
seven O O
species O O
of O O
aphids O O
had O O
promoter O O
activities O O
in O O
E O O
. O O
coli O O
which O O
ranged O O
from O O
6 O O
to O O
135 O O
% O O
of O O
that O O
observed O O
with O O
a O O
comparable O O
DNA O O
fragment O O
of O O
E B-GENE O
. I-GENE O
coli I-GENE O
rrnB E-GENE O
. O O
The O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O B-GENE
- O I-GENE
2 O E-GENE
) O O
Rep78 S-GENE S-GENE
/ O O
Rep68 S-GENE O
regulatory O O
proteins O O
are O O
pleiotropic O O
effectors O O
of O O
viral O O
and O O
cellular O O
DNA O O
replication O O
, O O
of O O
cellular O O
transformation O O
by O O
viral O O
and O O
cellular O O
oncogenes O O
, O O
and O O
of O O
homologous O O
and O O
heterologous O O
gene O O
expression O O
. O O
Role O O
of O O
the O O
CCAAT B-GENE S-GENE
/ I-GENE O
enhancer I-GENE B-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
in O O
the O O
glucocorticoid O O
stimulation O O
of O O
p21waf1 S-GENE S-GENE
/ O O
cip1 S-GENE B-GENE
gene O I-GENE
promoter O E-GENE
activity O O
in O O
growth O O
- O O
arrested O O
rat O O
hepatoma O O
cells O O
. O O
Long O O
- O O
term O O
ambulatory O O
measurement O O
of O O
transcutaneous O O
arterial O O
CO2 O O
pressure O O
( O O
PCO2 O O
) O O
offers O O
an O O
opportunity O O
to O O
test O O
directly O O
the O O
co O O
- O O
occurrence O O
of O O
panic O O
and O O
hyperventilation O O
under O O
natural O O
conditions O O
. O O
The O O
highly O O
conserved O O
region O O
of O O
U6 B-GENE B-GENE
snRNA E-GENE E-GENE
has O O
a O O
structural O O
similarity O O
with O O
the O O
catalytic O O
domain O O
of O O
the O O
negative O O
strand O O
of O O
the O O
satellite O O
RNA O O
of O O
tobacco O O
ring O O
spot O O
virus O O
[ O O
( O O
- O O
) O O
sTRSV O O
] O O
, O O
suggesting O O
that O O
the O O
highly O O
conserved O O
region O O
of O O
U6 B-GENE B-GENE
snRNA E-GENE E-GENE
forms O O
the O O
catalytic O O
center O O
. O O
Here O O
we O O
show O O
that O O
one O O
nudF B-GENE O
suppressor E-GENE O
also O O
suppresses O O
hs O O
- O O
mutations O O
in O O
nudA S-GENE O
, O O
nudC S-GENE S-GENE
, O O
and O O
nudG S-GENE O
and O O
deletions O O
in O O
nudA S-GENE O
and O O
nudF S-GENE O
. O O
Treatment O O
of O O
cells O O
for O O
10 O O
min O O
with O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
resulted O O
in O O
activation O O
of O O
p44 B-GENE S-GENE
/ I-GENE O
42 E-GENE O
MAPK O S-GENE
, O O
p38 S-GENE S-GENE
, O O
and O O
JNK S-GENE S-GENE
. O O
This O O
report O O
describes O O
the O O
isolation O O
and O O
recombinant O O
expression O O
of O O
a O O
cDNA O O
clone O O
encoding O O
HER4 S-GENE S-GENE
, O O
the O O
fourth O O
member O O
of O O
the O O
human B-GENE B-GENE
epidermal I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor E-GENE E-GENE
( O O
EGFR S-GENE S-GENE
) O O
family O O
. O O
In O O
conclusion O O
, O O
when O O
pulmonary O O
abnormalities O O
are O O
found O O
in O O
HTLV O O
- O O
1 O O
carriers O O
, O O
we O O
should O O
be O O
careful O O
in O O
determining O O
whether O O
such O O
pulmonary O O
involvements O O
are O O
etiologically O O
related O O
to O O
HTLV O O
- O O
1 O O
infection O O
. O O
A O O
clinical O O
trial O O
of O O
a O O
new O O
mitomycin O O
C O O
derivative O O
, O O
KW O O
- O O
2083 O O
( O O
7 O O
- O O
N O O
- O O
( O O
p O O
- O O
hydroxyphenyl O O
) O O
- O O
mitomycin O O
C O O
) O O
Excess O O
recombinant B-GENE O
PTB E-GENE S-GENE
squelches O O
the O O
splicing O O
switch O O
and O O
reestablishes O O
exon O O
skipping O O
as O O
the O O
predominant O O
splicing O O
pathway O O
. O O
A O O
child O O
presumed O O
to O O
have O O
the O O
21 B-GENE O
- I-GENE O
hydroxylase E-GENE O
deficiency O O
form O O
of O O
congenital O O
adrenal O O
hyperplasia O O
was O O
studied O O
extensively O O
as O O
an O O
infant O O
. O O
Sixtieth O O
anniversary O O
of O O
Angiotensin S-GENE O
. O O
Inability O O
of O O
niacin O O
to O O
protect O O
from O O
in O O
vivo O O
hyperoxia O O
or O O
in O O
vitro O O
microsomal O O
lipid O O
peroxidation O O
. O O
MDA O O
- O O
MB O O
- O O
468 O O
cells O O
were O O
stably O O
transfected O O
with O O
either O O
a O O
plasmid O O
having O O
a O O
CMV B-GENE B-GENE
promoter E-GENE E-GENE
- O O
driven O O
rabbit B-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene E-GENE E-GENE
or O O
plasmids O O
having O O
a O O
CMV B-GENE B-GENE
promoter E-GENE E-GENE
- O O
driven O O
chimeric O O
gadd45 S-GENE O
5 O O
" O O
- O O
UTR O O
- O O
rabbit B-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
globin E-GENE I-GENE
gene O E-GENE
, O O
where O O
the O O
entire B-GENE O
gadd45 I-GENE O
5 I-GENE O
" I-GENE O
- I-GENE O
UTR I-GENE O
( I-GENE O
from I-GENE O
+ I-GENE O
1 I-GENE O
to I-GENE O
+ I-GENE O
298 I-GENE O
) E-GENE O
or O O
a O O
45 O O
bp O O
subfragment O O
of O O
the O O
gadd45 B-GENE O
5 I-GENE O
" I-GENE O
- I-GENE O
UTR I-GENE O
( I-GENE O
from I-GENE O
+ I-GENE O
10 I-GENE O
to I-GENE O
+ I-GENE O
55 I-GENE O
) E-GENE O
was O O
positioned O O
at O O
the O O
5 O O
" O O
- O O
end O O
of O O
the O O
rabbit B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
University O O
of O O
North O O
Carolina O O
caries O O
risk O O
assessment O O
was O O
conducted O O
between O O
1986 O O
and O O
1989 O O
with O O
5000 O O
children O O
initially O O
in O O
grades O O
1 O O
and O O
5 O O
from O O
low O O
fluoride O O
sites O O
in O O
South O O
Carolina O O
and O O
Maine O O
. O O
Following O O
EGF S-GENE S-GENE
or O O
NGF S-GENE S-GENE
stimulation O O
of O O
the O O
v O O
- O O
CrkPC12 O O
cells O O
, O O
the O O
v B-GENE B-GENE
- I-GENE I-GENE
Crk E-GENE I-GENE
protein O E-GENE
itself O O
became O O
tyrosine O O
phosphorylated O O
within O O
1 O O
min O O
. O O
BCR S-GENE B-GENE
- O I-GENE
ABL S-GENE E-GENE
expression O O
confers O O
cross O O
- O O
resistance O O
to O O
multiple O O
genotoxic O O
anticancer O O
drugs O O
by O O
inhibition O O
of O O
the O O
apoptotic O O
response O O
to O O
DNA O O
damage O O
in O O
association O O
with O O
cell O O
cycle O O
arrest O O
at O O
the O O
G2 O O
- O O
M O O
restriction O O
point O O
. O O
RESULTS O O
: O O
After O O
lavage O O
, O O
a O O
rapid O O
decrease O O
in O O
arterial O O
pH O O
and O O
PaO2 O O
, O O
and O O
an O O
increase O O
in O O
PaCO2 O O
and O O
PIP O O
were O O
observed O O
in O O
all O O
animals O O
. O O
CONCLUSIONS O O
: O O
Elevation O O
of O O
TBARS O O
and O O
decrease O O
of O O
GSH O S-GENE
show O O
the O O
presence O O
of O O
oxidative O O
stress O O
during O O
the O O
PFD O O
treatment O O
with O O
hemodiafilter O O
SG3 O O
. O O
Ozone O O
uptake O O
was O O
assessed O O
in O O
awake O O
, O O
spontaneously O O
breathing O O
Fischer O O
- O O
344 O O
Sprague O O
- O O
Dawley O O
, O O
and O O
Long O O
- O O
Evans O O
rats O O
and O O
Hartley O O
guinea O O
pigs O O
to O O
provide O O
data O O
on O O
the O O
dosimetry O O
of O O
O3 O O
in O O
small O O
laboratory O O
animals O O
. O O
E O O
. O O
R O O
. O O
C O O
. O O
P O O
. O O
is O O
an O O
important O O
advance O O
in O O
diagnosis O O
. O O
Deletion O O
analysis O O
of O O
the O O
3 O O
. O O
5kb O O
DNA O O
fragment O O
revealed O O
that O O
the O O
region O O
between O O
- O O
125 O O
to O O
+ O O
1 O O
, O O
containing O O
a O O
single O O
Sp1 B-GENE S-GENE
binding I-GENE O
site E-GENE O
, O O
is O O
essential O O
for O O
transcription O O
of O O
the O O
embigin B-GENE B-GENE
gene E-GENE E-GENE
. O O
Resistance O O
to O O
Mup O O
was O O
classified O O
as O O
low O O
( O O
minimal O O
inhibitory O O
concentration O O
[ O O
MIC O O
] O O
> O O
or O O
= O O
8 O O
microg O O
/ O O
mL O O
) O O
or O O
high O O
( O O
MIC O O
> O O
or O O
= O O
512 O O
microg O O
/ O O
mL O O
) O O
degree O O
. O O
Extragonadal O O
endodermal O O
sinus O O
tumors O O
in O O
the O O
head O O
and O O
neck O O
are O O
very O O
rare O O
. O O
Lesions O O
of O O
this O O
kind O O
resemble O O
those O O
in O O
vitamin O O
A O O
- O O
deficient O O
chickens O O
and O O
are O O
the O O
first O O
to O O
be O O
induced O O
by O O
excess O O
vitamin O O
E O O
. O O
Essential O O
fatty O O
acid O O
deficiency O O
in O O
childhood O O
The O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
inhibitor O O
GF O B-GENE
- O I-GENE
109203X O E-GENE
abolished O O
the O O
activation O O
by O O
phorbol O O
ester O O
and O O
inhibited O O
the O O
effect O O
of O O
CCK S-GENE S-GENE
by O O
78 O O
% O O
but O O
had O O
no O O
effect O O
on O O
EGF S-GENE S-GENE
- O O
activated O O
MAPK S-GENE S-GENE
activity O O
. O O
Activated O O
FGFR3 S-GENE S-GENE
predominantly O O
interacts O O
with O O
GRB2 B-GENE S-GENE
. I-GENE O
Sos E-GENE S-GENE
in O O
complex O O
with O O
a O O
previously O O
identified O O
90 O O
- O O
kDa O O
protein O O
and O O
designated O O
protein B-GENE O
80K I-GENE B-GENE
- I-GENE I-GENE
H E-GENE E-GENE
. O O
The O O
rate O O
of O O
collagen S-GENE O
synthesis O O
in O O
normal O O
scar O O
was O O
approximately O O
constant O O
between O O
6 O O
months O O
and O O
20 O O
years O O
after O O
the O O
initial O O
wounding O O
, O O
but O O
in O O
both O O
hypertrophic O O
scar O O
and O O
keloid O O
the O O
rate O O
was O O
initially O O
approximately O O
twice O O
that O O
in O O
normal O O
scar O O
, O O
and O O
2 O O
- O O
3 O O
years O O
after O O
wounding O O
it O O
fell O O
to O O
approximately O O
the O O
same O O
level O O
as O O
in O O
normal O O
scar O O
. O O
Evidence O O
for O O
a O O
role O O
of O O
Smad6 S-GENE O
in O O
chick O O
cardiac O O
development O O
. O O
Excellent O O
results O O
were O O
recorded O O
in O O
390 O O
( O O
83 O O
. O O
69 O O
% O O
) O O
of O O
the O O
patients O O
, O O
improvement O O
in O O
46 O O
( O O
9 O O
. O O
87 O O
% O O
) O O
where O O
in O O
the O O
majority O O
a O O
varicose O O
complex O O
was O O
involved O O
. O O
Mutational O O
analysis O O
of O O
yeast B-GENE O
CEG1 E-GENE S-GENE
demonstrated O O
that O O
four O O
of O O
the O O
five O O
conserved O O
motifs O O
are O O
essential O O
for O O
capping B-GENE O
enzyme E-GENE O
function O O
in O O
vivo O O
. O O
We O O
report O O
on O O
a O O
case O O
discovered O O
in O O
a O O
13 O O
year O O
- O O
old O O
girl O O
presenting O O
with O O
anaemia O O
. O O
The O O
LIF S-GENE O
appeared O O
to O O
be O O
released O O
by O O
the O O
patient O O
' O O
s O O
peripheral O O
blood O O
lymphocytes O O
when O O
cultured O O
with O O
optimal O O
doses O O
of O O
propranolol O O
. O O
STUDY O O
SELECTION O O
: O O
Not O O
applicable O O
. O O
Co O O
- O O
expression O O
of O O
PLD1 S-GENE S-GENE
in O O
COS O O
- O O
7 O O
cells O O
with O O
the O O
two O O
recombinant B-GENE B-GENE
CK2 I-GENE I-GENE
subunits E-GENE E-GENE
, O O
alpha O O
or O O
beta O O
, O O
suggests O O
that O O
the O O
association O O
of O O
PLD1 S-GENE S-GENE
with O O
the O O
kinase O O
is O O
through O O
the O O
beta O B-GENE
subunit O E-GENE
. O O
For O O
capsules O O
containing O O
only O O
the O O
drug O O
, O O
the O O
value O O
of O O
T50 O O
increased O O
as O O
the O O
particle O O
size O O
of O O
the O O
drug O O
decreased O O
. O O
The O O
LAB O O
in O O
the O O
cecum O O
( O O
mean O O
9 O O
. O O
4 O O
log O O
CFU O O
/ O O
g O O
) O O
increased O O
slightly O O
with O O
increasing O O
abattoir O O
holding O O
time O O
. O O
Our O O
objective O O
was O O
to O O
find O O
possible O O
predictors O O
for O O
the O O
expression O O
and O O
progression O O
of O O
LJM O O
and O O
to O O
evaluate O O
the O O
relationship O O
between O O
LJM O O
and O O
other O O
long O O
- O O
term O O
complications O O
of O O
insulin S-GENE O
- O O
dependent O O
diabetes O O
mellitus O O
. O O
Human B-GENE B-GENE
recombinant I-GENE I-GENE
erythropoietin E-GENE E-GENE
( O O
r B-GENE O
- I-GENE O
HuEPO E-GENE O
, O O
EprexR S-GENE O
) O O
was O O
administered O O
to O O
8 O O
children O O
with O O
chronic O O
renal O O
failure O O
and O O
high O O
transfusion O O
requirement O O
. O O
CONCLUSIONS O O
: O O
LHB O O
is O O
simple O O
, O O
easy O O
and O O
safe O O
to O O
implement O O
, O O
and O O
is O O
the O O
only O O
technique O O
capable O O
of O O
maintaining O O
independent O O
upper O O
and O O
lower O O
body O O
perfusion O O
pressure O O
. O O
Northern O O
analyses O O
further O O
confirm O O
that O O
the O O
expression O O
of O O
endogenous O B-GENE
alpha B-GENE I-GENE
- I-GENE I-GENE
ENaC I-GENE I-GENE
gene E-GENE E-GENE
in O O
salivary O O
Pa O O
- O O
4 O O
cells O O
is O O
suppressed O O
by O O
an O O
ectopic O O
HMGI B-GENE B-GENE
- I-GENE I-GENE
C E-GENE E-GENE
overexpression O O
. O O
Removal O O
of O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependant I-GENE I-GENE
kinases E-GENE E-GENE
( O O
cdks S-GENE S-GENE
) O O
or O O
cdk2 S-GENE S-GENE
from O O
these O O
extracts O O
using O O
affinity O O
matrices O O
severely O O
inhibits O O
initiation O O
of O O
S O O
phase O O
. O O
Gel O O
mobility O O
shift O O
analyses O O
reveal O O
that O O
FRTL O O
- O O
5 O O
thyroid O O
cell O O
nuclear O O
extracts O O
form O O
a O O
specific O O
protein O O
/ O O
DNA O O
complex O O
with O O
this O O
region O O
, O O
which O O
is O O
prevented O O
by O O
the O O
TTF B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
binding I-GENE O
element E-GENE O
from O O
the O O
TG B-GENE B-GENE
promoter E-GENE E-GENE
; O O
FRT O S-GENE
and O O
BRL O O
cell O O
nuclear O O
extracts O O
do O O
not O O
have O O
TTF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
do O O
not O O
form O O
this O O
complex O O
. O O
The O O
Sty1 B-GENE B-GENE
kinase E-GENE E-GENE
is O O
stimulated O O
by O O
a O O
variety O O
of O O
different O O
stress O O
conditions O O
including O O
osmotic O O
and O O
oxidative O O
stress O O
and O O
heat O O
shock O O
. O O
No O O
viral O O
RNA O O
replication O O
could O O
be O O
detected O O
in O O
cells O O
transfected O O
with O O
mutant O B-GENE
RNAs O E-GENE
. O O
Acad O O
. O O
Comparison O O
of O O
the O O
genes O O
coding O O
for O O
mouse O O
and O O
human O B-GENE
p36 S-GENE E-GENE
( O O
annexin B-GENE B-GENE
II E-GENE E-GENE
) O O
and O O
mouse O O
, O O
rat O O
and O O
human O B-GENE
p35 S-GENE E-GENE
( O O
annexin B-GENE B-GENE
I E-GENE E-GENE
) O O
and O O
pigeon O O
cp35 S-GENE S-GENE
( O O
an O O
annexin B-GENE B-GENE
I I-GENE I-GENE
- I-GENE I-GENE
related I-GENE I-GENE
protein E-GENE E-GENE
) O O
shows O O
strong O O
genomic O O
structural O O
conservation O O
supporting O O
the O O
hypothesis O O
that O O
these O O
genes O O
had O O
a O O
common O O
ancestor O O
. O O
When O O
incubated O O
with O O
infective O O
larvae O O
which O O
had O O
penetrated O O
mouse O O
skin O O
, O O
both O O
normal O O
and O O
immune O O
cells O O
attached O O
to O O
larvae O O
in O O
the O O
absence O O
of O O
serum O O
. O O
A O O
31 O O
- O O
year O O
- O O
old O O
man O O
with O O
primary O O
myelofibrosis O O
initially O O
received O O
low O O
dose O O
Ara O O
C O O
. O O
Collectively O O
, O O
these O O
studies O O
suggest O O
that O O
the O O
major O O
EGF S-GENE S-GENE
- O O
stimulated O O
mitotic O O
growth O O
pathways O O
may O O
not O O
be O O
absolutely O O
linked O O
to O O
the O O
stat91 S-GENE S-GENE
signaling O O
pathways O O
and O O
that O O
such O O
transcription O O
complexes O O
are O O
more O O
complex O O
than O O
previously O O
reported O O
. O O
FEurea O O
was O O
also O O
measured O O
during O O
stable O O
graft O O
function O O
, O O
7 O O
- O O
14 O O
days O O
prior O O
to O O
allograft O O
dysfunction O O
. O O
Nonsuicidal O O
mortality O O
in O O
late O O
- O O
life O O
depression O O
. O O
Few O O
triers O O
or O O
users O O
had O O
received O O
SLT O O
counseling O O
from O O
their O O
dentist O O
despite O O
high O O
dental O O
utilization O O
rates O O
. O O
However O O
, O O
UV O O
resistance O O
is O O
only O O
minimally O O
restored O O
, O O
and O O
mutant O O
cells O O
remain O O
sensitive O O
to O O
gamma O O
radiation O O
. O O
The O O
oxalate B-GENE O
oxidase E-GENE O
method O O
results O O
in O O
a O O
mean O O
and O O
reference O O
interval O O
for O O
oxalate O O
excretion O O
that O O
are O O
comparable O O
with O O
those O O
by O O
isotope O O
dilution O O
, O O
gas O O
- O O
chromatographic O O
, O O
colorimetric O O
, O O
and O O
other O O
enzymic O O
procedures O O
. O O
In O O
addition O O
, O O
we O O
show O O
that O O
expression O O
of O O
antisense O O
mRNA O O
for O O
p130CAS S-GENE S-GENE
resulted O O
in O O
reversion O O
of O O
the O O
transformed O O
phenotype O O
of O O
all O O
these O O
cell O O
lines O O
. O O
Starches O O
had O O
no O O
effect O O
. O O
Maximal O O
Expiratory O O
Flow O O
Rates O O
such O O
as O O
Peak O O
Expiratory O O
Flow O O
Rate O O
( O O
PEFR O O
) O O
, O O
rates O O
at O O
25 O O
% O O
, O O
50 O O
% O O
and O O
75 O O
% O O
of O O
forced O O
vital O O
capacity O O
( O O
V O O
max O O
25 O O
% O O
, O O
V O O
max O O
50 O O
% O O
and O O
V O O
max O O
75 O O
% O O
) O O
and O O
forced O O
expiratory O O
flow O O
during O O
the O O
middle O O
half O O
of O O
forced O O
vital O O
capacity O O
( O O
FEF O O
25 O O
- O O
75 O O
% O O
) O O
were O O
measured O O
in O O
273 O O
healthy O O
non O O
- O O
smoking O O
adults O O
( O O
144 O O
males O O
, O O
129 O O
females O O
) O O
aged O O
15 O O
- O O
63 O O
years O O
living O O
in O O
Madras O O
. O O
The O O
amino O O
acid O O
sequence O O
of O O
the O O
protein O O
encoded O O
by O O
MSK1 S-GENE S-GENE
is O O
homologous O O
to O O
yeast B-GENE O
cytoplasmic I-GENE O
lysyl I-GENE B-GENE
- I-GENE I-GENE
tRNA I-GENE I-GENE
synthetase E-GENE E-GENE
and O O
to O O
the O O
product O O
of O O
the O O
herC B-GENE B-GENE
gene E-GENE E-GENE
, O O
which O O
has O O
recently O O
been O O
suggested O O
to O O
code O O
for O O
the O O
Escherichia O O
coli O O
enzyme O O
. O O
Similar O O
to O O
the O O
D S-GENE O
, O O
B S-GENE O
/ O O
B B-GENE O
' E-GENE O
and O O
E B-GENE O
proteins E-GENE O
, O O
the O O
F S-GENE O
and O O
G B-GENE O
proteins E-GENE O
do O O
not O O
possess O O
any O O
of O O
the O O
known O O
RNA O O
binding O O
motifs O O
, O O
suggesting O O
that O O
other O O
types O O
of O O
RNA O O
- O O
protein O O
interactions O O
occur O O
in O O
the O O
snRNP O O
core O O
. O O
These O O
observations O O
suggest O O
that O O
clr4 B-GENE O
+ E-GENE O
and O O
rik1 B-GENE O
+ E-GENE O
must O O
play O O
a O O
role O O
in O O
the O O
assembly O O
of O O
Swi6p S-GENE S-GENE
into O O
a O O
transcriptionally O O
silent O O
, O O
inaccessible O O
chromatin O O
structure O O
at O O
fission O O
yeast O O
centromeres O O
which O O
is O O
required O O
to O O
facilitate O O
interactions O O
with O O
spindle O O
microtubules O O
and O O
to O O
ensure O O
normal O O
chromosome O O
segregation O O
. O O
Characterization O O
of O O
a O O
DEAD B-GENE O
box I-GENE O
ATPase E-GENE S-GENE
/ O O
RNA B-GENE O
helicase E-GENE O
protein O O
of O O
Arabidopsis O O
thaliana O O
. O O
Amplitude O O
of O O
late O O
surface O O
( O O
P2 O O
and O O
N2 O O
) O O
and O O
depth O O
( O O
B O O
and O O
C O O
) O O
components O O
significantly O O
decreased O O
when O O
patients O O
shifted O O
from O O
SWS O O
IV O O
to O O
PS O O
and O O
increased O O
from O O
PS O O
to O O
W2 O O
. O O
Oligo O O
- O O
[ O O
alpha O O
] O O
- O O
deoxynucleotides O O
can O O
be O O
derived O O
by O O
stabilizing O O
( O O
intercalating O O
) O O
agents O O
or O O
reactive O O
groups O O
( O O
cleaving O O
reagents O O
, O O
cross O O
- O O
linkers O O
. O O
. O O
. O O
) O O
. O O
This O O
vector O O
should O O
be O O
applicable O O
for O O
high O O
- O O
throughput O O
characterization O O
of O O
new O O
open O O
reading O O
frames O O
found O O
in O O
genome O O
sequencing O O
. O O
The O O
subjects O O
were O O
17 O O
patients O O
with O O
android O O
obesity O O
( O O
four O O
men O O
and O O
13 O O
women O O
) O O
aged O O
21 O O
to O O
58 O O
years O O
with O O
a O O
body O O
mass O O
index O O
( O O
BMI O O
) O O
ranging O O
from O O
32 O O
. O O
0 O O
to O O
52 O O
. O O
2 O O
kg O O
/ O O
m2 O O
and O O
an O O
abdominal O O
- O O
gluteal O O
ratio O O
greater O O
than O O
1 O O
. O O
0 O O
. O O
No O O
universally O O
accepted O O
standardized O O
classification O O
system O O
for O O
acne O O
vulgaris O O
exists O O
, O O
although O O
there O O
is O O
a O O
strong O O
need O O
for O O
it O O
. O O
Blood O O
samples O O
for O O
determination O O
of O O
fibrinolytic O O
activity O O
and O O
factor B-GENE O
VIII E-GENE O
in O O
plasma O O
were O O
obtained O O
before O O
and O O
immediately O O
after O O
the O O
end O O
of O O
compression O O
and O O
application O O
of O O
a O O
stocking O O
, O O
respectively O O
. O O
Neither O O
symptoms O O
, O O
virions O O
, O O
nor O O
viral O O
RNA O O
was O O
detectable O O
in O O
plants O O
inoculated O O
with O O
this O O
mutant O O
or O O
a O O
mutant O O
with O O
a O O
frameshift O O
mutation O O
in O O
the O O
coat B-GENE O
gene E-GENE O
. O O
The O O
cumulative O O
length O O
of O O
the O O
RGSV O O
genome O O
, O O
including O O
RNAs O O
5 O O
and O O
6 O O
, O O
was O O
25142 O O
nt O O
. O O
Risk O O
ratios O O
decreased O O
with O O
increasing O O
age O O
and O O
increased O O
with O O
number O O
of O O
breast O O
biopsies O O
, O O
family O O
history O O
of O O
breast O O
cancer O O
, O O
estrogen O O
use O O
, O O
time O O
between O O
screenings O O
, O O
no O O
comparison O O
with O O
previous O O
mammograms O O
, O O
and O O
the O O
radiologist O O
' O O
s O O
tendency O O
to O O
call O O
mammograms O O
abnormal O O
. O O
The O O
AtNMT1 S-GENE S-GENE
expression O O
profile O O
indicated O O
ubiquity O O
in O O
roots O O
, O O
stem O O
, O O
leaves O O
, O O
flowers O O
, O O
and O O
siliques O O
( O O
approximately O O
1 O O
. O O
7 O O
kb O O
transcript O O
and O O
approximately O O
50 O O
kDa O O
immunoreactive O O
polypeptide O O
) O O
but O O
a O O
greater O O
level O O
in O O
the O O
younger O O
tissue O O
, O O
which O O
are O O
developmentally O O
very O O
active O O
. O O
The O O
ossification O O
was O O
located O O
on O O
the O O
left O O
side O O
of O O
C3 O O
- O O
4 O O
. O O
At O O
a O O
cutoff O O
point O O
for O O
KISA O O
% O O
of O O
100 O O
, O O
280 O O
of O O
281 O O
participants O O
( O O
99 O O
. O O
6 O O
% O O
) O O
were O O
correctly O O
classified O O
. O O
Following O O
replicate O O
control O O
measurements O O
, O O
test O O
ramps O O
were O O
repeated O O
in O O
the O O
presence O O
of O O
sodium O O
nitroprusside O O
( O O
1 O O
microM O O
) O O
and O O
phentolamine O O
( O O
1 O O
microM O O
) O O
to O O
eliminate O O
potential O O
smooth O O
muscle O O
and O O
alpha B-GENE O
1 I-GENE O
- I-GENE O
adrenoceptor E-GENE O
effects O O
, O O
respectively O O
. O O
Behavioral O O
effects O O
of O O
benzodiazepine O O
ligands O O
in O O
non O O
- O O
dependent O O
, O O
diazepam O O
- O O
dependent O O
and O O
diazepam O O
- O O
withdrawn O O
baboons O O
. O O
This O O
paper O O
reports O O
estimates O O
of O O
the O O
prevalence O O
of O O
mental O O
retardation O O
and O O
associated O O
factors O O
based O O
on O O
a O O
population O O
survey O O
of O O
2 O O
- O O
to O O
9 O O
- O O
year O O
- O O
old O O
children O O
in O O
Greater O O
Karachi O O
, O O
Pakistan O O
. O O
Thus O O
, O O
an O O
increase O O
in O O
lactate O O
concentration O O
of O O
the O O
magnitude O O
observed O O
during O O
alkali O O
therapy O O
need O O
not O O
indicate O O
a O O
worsening O O
of O O
the O O
metabolic O O
picture O O
in O O
lactic O O
acidosis O O
. O O
Adjusting O O
a O O
steady O O
- O O
state O O
warfarin O O
dose O O
depends O O
on O O
the O O
measured O O
INR O O
values O O
and O O
clinical O O
factors O O
: O O
the O O
dose O O
does O O
not O O
need O O
to O O
be O O
adjusted O O
for O O
a O O
single O O
INR O O
that O O
is O O
slightly O O
out O O
of O O
range O O
, O O
and O O
most O O
changes O O
should O O
alter O O
the O O
total O O
weekly O O
dose O O
by O O
5 O O
% O O
to O O
20 O O
% O O
. O O
All O O
of O O
this O O
region O O
is O O
part O O
of O O
a O O
prominent O O
CpG O O
island O O
that O O
may O O
be O O
acting O O
as O O
an O O
extended O O
, O O
enhancer O O
- O O
independent O O
promoter O O
. O O
Comparison O O
of O O
Healon O O
and O O
Amvisc O O
. O O
Large O O
volumes O O
of O O
bone O O
marrow O O
may O O
be O O
required O O
for O O
certain O O
types O O
of O O
autologous O O
bone O O
marrow O O
transplants O O
. O O
Further O O
analysis O O
of O O
the O O
CAP59 B-GENE B-GENE
locus I-GENE E-GENE
of I-GENE O
Cryptococcus I-GENE O
neoformans E-GENE O
: O O
structure O O
defined O O
by O O
forced O O
expression O O
and O O
description O O
of O O
a O O
new O O
ribosomal B-GENE O
protein I-GENE O
- I-GENE O
encoding I-GENE O
gene E-GENE O
. O O
We O O
speculate O O
that O O
the O O
enhancing O O
effect O O
of O O
glucose O O
and O O
galactose O O
on O O
fructose O O
absorption O O
may O O
be O O
due O O
to O O
activation O O
of O O
the O O
fructose B-GENE O
carrier E-GENE O
. O O
Virol O O
. O O
The O O
DFGF B-GENE B-GENE
- I-GENE I-GENE
R I-GENE I-GENE
protein E-GENE E-GENE
may O O
thus O O
participate O O
in O O
receiving O O
spatial O O
cues O O
that O O
guide O O
tracheal O O
cell O O
outgrowth O O
. O O
The O O
data O O
from O O
animal O O
experiments O O
indicate O O
that O O
the O O
incidence O O
of O O
solid O O
tumors O O
in O O
marrow O O
transplant O O
patients O O
may O O
still O O
rise O O
in O O
the O O
coming O O
decades O O
. O O
Patients O O
adopt O O
new O O
sets O O
based O O
partly O O
on O O
the O O
original O O
topic O O
and O O
partly O O
on O O
their O O
own O O
personal O O
idiosyncratic O O
concerns O O
. O O
The O O
NS B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
isoforms E-GENE E-GENE
were O O
resolved O O
at O O
a O O
pI O O
value O O
close O O
to O O
5 O O
. O O
5 O O
as O O
three O O
groups O O
of O O
unevenly O O
phosphorylated O O
polypeptides O O
, O O
each O O
composed O O
of O O
at O O
least O O
two O O
protein O O
species O O
. O O
Prevalence O O
of O O
rheumatic O O
diseases O O
in O O
a O O
rural O O
population O O
in O O
western O O
India O O
: O O
a O O
WHO O O
- O O
ILAR O O
COPCORD O O
Study O O
. O O
A O O
. O O
nidulans O O
transformants O O
secreted O O
high O O
amounts O O
of O O
PGI S-GENE O
and O O
PGII S-GENE O
in O O
comparison O O
to O O
the O O
previously O O
characterized O O
A O O
. O O
niger O O
transformants O O
and O O
a O O
novel O O
polygalacturonase S-GENE O
( O O
PGC S-GENE O
) O O
was O O
produced O O
at O O
high O O
levels O O
by O O
A O O
. O O
nidulans O O
transformed O O
with O O
the O O
subcloned O B-GENE
pgaC B-GENE I-GENE
gene E-GENE E-GENE
. O O
This O O
interaction O O
is O O
functional O O
as O O
it O O
leads O O
to O O
retargeting O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE I-GENE
p50 S-GENE E-GENE
from O O
the O O
nucleus O O
to O O
the O O
cytoplasm O O
. O O
The O O
orf2 O B-GENE
gene O E-GENE
product O O
is O O
a O O
protein O O
of O O
79 O O
amino O O
acids O O
with O O
characteristics O O
similar O O
to O O
those O O
of O O
the O O
Tat S-GENE S-GENE
( O O
transactivator S-GENE O
) O O
proteins O O
of O O
the O O
ungulate O O
lentiviruses O O
. O O
The O O
use O O
of O O
medication O O
is O O
of O O
minor O O
importance O O
in O O
the O O
treatment O O
of O O
flight O O
phobia O O
. O O
Elevated O O
total O O
serum O O
calcium O O
to O O
a O O
level O O
of O O
11 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
mg O O
/ O O
dl O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
compared O O
to O O
control O O
group O O
) O O
developed O O
in O O
the O O
gentamicin O O
/ O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2 O O
vitamin O O
D3 O O
group O O
on O O
day O O
4 O O
, O O
2 O O
days O O
prior O O
to O O
pronounced O O
structural O O
damage O O
, O O
and O O
continued O O
to O O
be O O
elevated O O
through O O
day O O
7 O O
. O O
Rac2 S-GENE S-GENE
, O O
a O O
member O O
of O O
the O O
Rho B-GENE B-GENE
family E-GENE E-GENE
of O O
GTPases S-GENE S-GENE
, O O
is O O
highly O O
expressed O O
in O O
myeloid O O
cells O O
and O O
is O O
a O O
regulator O O
of O O
the O O
NADPH B-GENE B-GENE
- I-GENE I-GENE
oxidase I-GENE E-GENE
complex E-GENE O
. O O
In O O
vitro O O
kinase O O
assays O O
on O O
isolated O O
microvilli O O
and O O
microvillar O O
fractions O O
enriched O O
in O O
the O O
putative O O
signal O O
transduction O O
particle O O
showed O O
a O O
high O O
specific O O
activity O O
of O O
tyrosine B-GENE B-GENE
kinase E-GENE E-GENE
activity O O
compared O O
to O O
that O O
of O O
membranes O O
from O O
EGF B-GENE B-GENE
receptor E-GENE E-GENE
- O O
overexpressing O O
A431 O O
cells O O
maximally O O
activated O O
by O O
EGF S-GENE S-GENE
. O O
Effect O O
of O O
infantile O O
undernutrition O O
on O O
adult O O
sucrose O O
solution O O
consumption O O
in O O
the O O
rat O O
. O O
In O O
the O O
studies O O
described O O
in O O
this O O
report O O
, O O
we O O
have O O
identified O O
two O O
potential O O
Ets S-GENE O
binding O O
sites O O
, O O
EBS1 S-GENE S-GENE
and O O
EBS2 S-GENE S-GENE
, O O
which O O
are O O
conserved O O
in O O
both O O
the O O
human O O
and O O
murine O B-GENE
interleukin B-GENE I-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
enhancers O O
. O O
KatA S-GENE S-GENE
, O O
AhpCF S-GENE S-GENE
, O O
heme O O
biosynthesis O O
enzymes O O
, O O
and O O
MrgA S-GENE S-GENE
are O O
also O O
induced O O
upon O O
entry O O
into O O
stationary O O
phase O O
under O O
conditions O O
of O O
iron O O
and O O
manganese O O
limitation O O
. O O
Although O O
the O O
Gly252Arg O O
substitution O O
observed O O
in O O
UM O O
: O O
JG5 O O
is O O
non O O
- O O
conservative O O
, O O
it O O
was O O
not O O
possible O O
to O O
distinguish O O
whether O O
it O O
is O O
a O O
mutation O O
or O O
a O O
polymorphism O O
. O O
This O O
region O O
shows O O
46 O O
% O O
identity O O
with O O
the O O
calmodulin B-GENE O
- I-GENE O
binding I-GENE O
region E-GENE O
of O O
rat B-GENE B-GENE
brain I-GENE I-GENE
Ca2 I-GENE I-GENE
+ I-GENE E-GENE
/ I-GENE O
calmodulin I-GENE O
- I-GENE O
dependent I-GENE O
protein I-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
and O O
32 O O
% O O
identity O O
with O O
the O O
equivalent O O
region O O
of O O
chicken B-GENE O
smooth I-GENE O
muscle I-GENE O
myosin I-GENE B-GENE
light I-GENE I-GENE
chain I-GENE I-GENE
kinase E-GENE E-GENE
. O O
The O O
perforated O O
splint O O
gives O O
superior O O
results O O
by O O
virtue O O
of O O
the O O
fact O O
that O O
it O O
does O O
not O O
require O O
to O O
be O O
removed O O
for O O
purposes O O
of O O
hygiene O O
and O O
can O O
thus O O
produce O O
a O O
satisfactory O O
result O O
even O O
in O O
those O O
patients O O
who O O
fail O O
to O O
grasp O O
the O O
technique O O
of O O
removal O O
and O O
replacement O O
of O O
the O O
splint O O
. O O
It O O
contains O O
31 O O
exons O O
and O O
a O O
high O O
proportion O O
of O O
class O O
0 O O
introns O O
, O O
alternative O O
splicing O O
of O O
which O O
results O O
in O O
significant O O
levels O O
of O O
variant O O
transcripts O O
that O O
maintain O O
the O O
original O O
open O O
reading O O
frame O O
of O O
MRP B-GENE B-GENE
mRNA E-GENE E-GENE
. O O
Issues O O
discussed O O
include O O
the O O
validity O O
of O O
the O O
MMPI O O
Mf O O
scale O O
, O O
questions O O
of O O
sample O O
representativeness O O
, O O
whether O O
" O O
straights O O
" O O
can O O
do O O
adequate O O
research O O
on O O
homosexuality O O
, O O
differences O O
in O O
heterosexual O O
and O O
homosexual O O
sexuality O O
, O O
the O O
role O O
of O O
subculture O O
acculturation O O
in O O
homosexual O O
psychological O O
adjustment O O
, O O
and O O
the O O
use O O
of O O
cluster O O
- O O
analysis O O
to O O
generate O O
typologies O O
of O O
homosexualities O O
. O O
A O O
brief O O
discussion O O
for O O
the O O
relationship O O
among O O
these O O
formulas O O
is O O
given O O
. O O
Lamivudine O O
therapy O O
for O O
acute O O
hepatitis O O
B O O
infection O O
following O O
peripheral O O
blood O O
stem O O
cell O O
transplantation O O
. O O
These O O
findings O O
suggest O O
that O O
NMDA B-GENE B-GENE
receptor E-GENE E-GENE
blockade O O
may O O
ameliorate O O
the O O
dyskinetic O O
complications O O
of O O
long O O
- O O
term O O
levodopa O O
therapy O O
, O O
without O O
diminishing O O
the O O
beneficial O O
effects O O
on O O
parkinsonian O O
signs O O
. O O
Furthermore O O
, O O
the O O
secondary O O
stress O O
responses O O
were O O
more O O
pronounced O O
and O O
the O O
ability O O
to O O
recover O O
from O O
them O O
seemed O O
to O O
be O O
impaired O O
in O O
exposed O O
fish O O
as O O
compared O O
to O O
unexposed O O
fish O O
. O O
The O O
distinct O O
spatial O O
pattern O O
of O O
expression O O
, O O
and O O
unusual O O
amino O O
acid O O
sequence O O
in O O
its O O
DNA O O
binding O O
domain O O
, O O
may O O
indicate O O
a O O
particular O O
role O O
for O O
DTEF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
cell O O
- O O
specific O O
gene O O
regulation O O
. O O
As O O
usual O O
tests O O
, O O
such O O
as O O
" O O
time O O
" O O
of O O
cephalin O O
are O O
slightly O O
sensible O O
to O O
LMW O O
- O O
Hep O O
, O O
only O O
anti O O
- O O
Xa O O
activity O O
can O O
be O O
used O O
. O O
Usher O O
syndrome O O
1C O O
( O O
USH1C O O
) O O
is O O
a O O
congenital O O
condition O O
manifesting O O
profound O O
hearing O O
loss O O
, O O
the O O
absence O O
of O O
vestibular O O
function O O
, O O
and O O
eventual O O
retinal O O
degeneration O O
. O O
Implantation O O
is O O
contraindicated O O
for O O
severe O O
dysplasia O O
of O O
the O O
cochlea O O
and O O
for O O
the O O
recently O O
described O O
variety O O
of O O
x O O
- O O
linked O O
deafness O O
with O O
deficient O O
bone O O
at O O
the O O
fundus O O
of O O
the O O
internal O O
auditory O O
meatus O O
. O O
Over O O
9 O O
kb O O
of O O
DNA O O
sequence O O
was O O
obtained O O
for O O
one O O
clone O O
( O O
A1 O O
) O O
with O O
a O O
total O O
IGS O O
length O O
of O O
approximately O O
12 O O
. O O
4 O O
kb O O
. O O
Scleraxis S-GENE O
overexpression O O
enhanced O O
expression O O
of O O
the O O
aggrecan B-GENE B-GENE
gene E-GENE E-GENE
, O O
which O O
is O O
not O O
normally O O
expressed O O
at O O
high O O
levels O O
in O O
these O O
osteoblastic O O
cells O O
. O O
This O O
study O O
demonstrates O O
that O O
the O O
exposure O O
to O O
sulphur O O
mustard O O
results O O
in O O
very O O
low O O
androgen O O
levels O O
and O O
hypo O O
- O O
responsiveness O O
to O O
GnRH S-GENE S-GENE
in O O
the O O
first O O
five O O
weeks O O
and O O
normalization O O
by O O
the O O
twelfth O O
week O O
after O O
injury O O
. O O
New O O
results O O
of O O
importance O O
for O O
optimization O O
of O O
the O O
postoperative O O
course O O
] O O
Complications O O
after O O
major O O
surgery O O
may O O
be O O
related O O
to O O
factors O O
in O O
the O O
surgical O O
stress O O
response O O
with O O
endocrine O O
- O O
metabolic O O
and O O
inflammatory O O
changes O O
. O O
Four O O
multicannulated O O
Holstein O O
steers O O
( O O
initial O O
BW O O
424 O O
+ O O
/ O O
- O O
16 O O
kg O O
) O O
were O O
used O O
in O O
a O O
4 O O
x O O
4 O O
Latin O O
square O O
to O O
determine O O
the O O
influence O O
of O O
protein O O
supplementation O O
on O O
forage O O
intake O O
, O O
site O O
and O O
extent O O
of O O
digestion O O
, O O
and O O
nutrient O O
flow O O
in O O
steers O O
consuming O O
dormant O O
bluestem O O
- O O
range O O
forage O O
( O O
2 O O
. O O
3 O O
% O O
CP O O
) O O
. O O
Patients O O
with O O
risk O O
factors O O
were O O
compared O O
with O O
those O O
without O O
risk O O
factors O O
. O O
The O O
dermatoglyphic O O
pattern O O
demostrates O O
a O O
distal O O
triradius O O
and O O
small O O
whorl O O
abnormalities O O
. O O
The O O
term O O
Kartagener O O
syndrome O O
applies O O
to O O
this O O
syndrome O O
when O O
accompanied O O
by O O
infertility O O
and O O
dextrocardia O O
or O O
situs O O
inversus O O
. O O
Finally O O
, O O
we O O
tested O O
whether O O
activation O O
by O O
either O O
of O O
these O O
factors O O
is O O
dependent O O
on O O
components O O
of O O
the O O
SAGA B-GENE O
complex E-GENE O
. O O
Eight O O
of O O
the O O
17 O O
seropositive O O
patients O O
failed O O
to O O
develop O O
detectable O O
hepatitis B-GENE O
B I-GENE O
surface I-GENE O
antibody E-GENE O
within O O
three O O
months O O
of O O
the O O
third O O
injection O O
compared O O
with O O
only O O
one O O
of O O
the O O
18 O O
seronegative O O
patients O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O
The O O
antimicrobial O O
of O O
choice O O
for O O
initial O O
prophylactic O O
therapy O O
among O O
asymptomatic O O
pregnant O O
women O O
exposed O O
to O O
Bacillus O O
anthracis O O
is O O
ciprofloxacin O O
, O O
500 O O
mg O O
twice O O
a O O
day O O
for O O
60 O O
days O O
. O O
Overexpression O O
of O O
eIF4E S-GENE S-GENE
transforms O O
cells O O
, O O
and O O
mutations O O
in O O
eIF4E S-GENE S-GENE
arrest O O
cells O O
in O O
G O O
, O O
in O O
cdc33 B-GENE O
mutants E-GENE O
. O O
Benzyl O O
alcohol O O
administration O O
in O O
neonates O O
. O O
Repression O O
of O O
the O O
herpes B-GENE B-GENE
simplex I-GENE I-GENE
virus I-GENE I-GENE
1 I-GENE I-GENE
alpha I-GENE I-GENE
4 I-GENE I-GENE
gene E-GENE E-GENE
by O O
its O O
gene O O
product O O
( O O
ICP4 S-GENE S-GENE
) O O
within O O
the O O
context O O
of O O
the O O
viral O O
genome O O
is O O
conditioned O O
by O O
the O O
distance O O
and O O
stereoaxial O O
alignment O O
of O O
the O O
ICP4 B-GENE O
DNA I-GENE O
binding I-GENE O
site E-GENE O
relative O O
to O O
the O O
TATA O O
box O O
. O O
As O O
anticipated O O
, O O
both O O
intracellular O O
p54 S-GENE S-GENE
- O O
SAPKbeta S-GENE S-GENE
activation O O
and O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
phosphorylation O O
are O O
blocked O O
by O O
co O O
- O O
transfection O O
with O O
the O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
specific O O
phosphatase O O
MKP3 S-GENE S-GENE
/ O O
PYST1 S-GENE S-GENE
. O O
Relation O O
between O O
circulating O O
immune O O
complexes O O
and O O
serum B-GENE O
ferritin E-GENE O
in O O
hemosiderosis O O
of O O
different O O
etiologies O O
PATIENT O O
( O O
S O O
) O O
: O O
Two O O
hundred O O
thirty O O
- O O
eight O O
patients O O
with O O
RPLs O O
, O O
48 O O
patients O O
with O O
recurrent O O
IVF O O
- O O
ET O O
failure O O
and O O
179 O O
nonpregnant O O
and O O
120 O O
pregnant O O
control O O
group O O
women O O
. O O
Many O O
of O O
the O O
metabolic O O
effects O O
induced O O
by O O
thiazide O O
diuretics O O
, O O
however O O
, O O
can O O
be O O
limited O O
by O O
the O O
use O O
of O O
low O O
doses O O
. O O
Teboroxime O O
is O O
a O O
new O O
boronic O O
acid O O
adduct O O
of O O
technetium O O
dioxime O O
( O O
BATO O O
) O O
compound O O
that O O
demonstrates O O
favorable O O
characteristics O O
in O O
preliminary O O
studies O O
. O O
The O O
total O O
area O O
under O O
the O O
blood O O
glucose O O
curve O O
over O O
the O O
initial O O
value O O
was O O
not O O
altered O O
2 O O
h O O
after O O
treatment O O
with O O
SH O O
B O O
209 O O
AB O O
or O O
Neogynon O O
. O O
Treatment O O
of O O
excessive O O
bleeding O O
after O O
cardiopulmonary O O
bypass O O
was O O
based O O
on O O
an O O
algorithm O O
using O O
point O O
- O O
of O O
- O O
care O O
testing O O
with O O
whole O O
blood B-GENE O
prothrombin E-GENE O
time O O
, O O
activated O O
partial O O
thromboplastin S-GENE O
time O O
, O O
heparinase S-GENE O
activated O O
clotting O O
time O O
, O O
and O O
platelet O O
count O O
. O O
In O O
all O O
cases O O
, O O
a O O
large O O
fraction O O
of O O
soluble O O
Al O O
became O O
insoluble O O
in O O
the O O
stomach O O
after O O
ingestion O O
. O O
To O O
assess O O
the O O
safety O O
of O O
the O O
angiotensin B-GENE O
converting I-GENE O
enzyme E-GENE O
inhibitor O O
enalapril O O
a O O
multicenter O O
, O O
open O O
, O O
randomized O O
, O O
prazosin O O
- O O
controlled O O
trial O O
was O O
designed O O
comparing O O
the O O
incidence O O
and O O
severity O O
of O O
symptomatic O O
hypotension O O
on O O
the O O
first O O
day O O
of O O
treatment O O
. O O
Glucose O O
may O O
reduce O O
slightly O O
the O O
pool O O
of O O
amino O O
nitrogen O O
available O O
for O O
albumin S-GENE O
and O O
urea O O
synthesis O O
by O O
diverting O O
some O O
of O O
the O O
infused O O
amino O O
acids O O
from O O
protein O O
synthesis O O
by O O
the O O
liver O O
to O O
muscle O O
. O O
BACKGROUND O O
. O O
We O O
have O O
previously O O
reported O O
the O O
first O O
isolation O O
of O O
a O O
c B-GENE O
- I-GENE O
myc I-GENE O
- I-GENE O
null E-GENE O
cell O O
line O O
. O O
Results O O
demonstrated O O
that O O
for O O
both O O
S O O
. O O
europaea O O
and O O
A O O
. O O
prostrata O O
, O O
the O O
total O O
number O O
of O O
seeds O O
that O O
germinated O O
decreased O O
throughout O O
the O O
growing O O
season O O
. O O
A O O
nationwide O O
record O O
linkage O O
of O O
the O O
Finnish O O
Twin O O
Cohort O O
Study O O
( O O
FTCS O O
) O O
with O O
the O O
Hospital O O
Discharge O O
Registry O O
and O O
the O O
Registry O O
of O O
Rights O O
for O O
Free O O
medication O O
is O O
presented O O
. O O
Considering O O
these O O
two O O
facts O O
together O O
, O O
we O O
propose O O
that O O
vasectomy O O
may O O
lead O O
to O O
decrease O O
in O O
the O O
incidence O O
of O O
prostatic O O
tumors O O
- O O
a O O
disease O O
that O O
claims O O
nearly O O
22 O O
, O O
000 O O
lives O O
each O O
year O O
in O O
the O O
United O O
States O O
alone O O
. O O
Antibodies O O
specific O O
to O O
the O O
different O O
members O O
of O O
the O O
Jun S-GENE S-GENE
and O O
Fos B-GENE B-GENE
family I-GENE E-GENE
of I-GENE O
transcription I-GENE O
factors E-GENE O
show O O
that O O
, O O
in O O
gel O O
retardation O O
assays O O
, O O
a O O
Jun B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
factor E-GENE E-GENE
is O O
a O O
component O O
of O O
the O O
H3 B-GENE O
. I-GENE O
2 I-GENE O
specific I-GENE O
complex E-GENE O
. O O
She O O
had O O
been O O
diagnosed O O
with O O
severe O O
aplastic O O
anemia O O
1 O O
year O O
previously O O
and O O
, O O
while O O
hospitalized O O
, O O
had O O
received O O
methyl O O
prednisolone O O
pulse O O
therapy O O
, O O
which O O
was O O
not O O
successful O O
. O O
The O O
recombinant B-GENE B-GENE
L I-GENE I-GENE
/ I-GENE I-GENE
F I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
is O O
as O O
active O O
as O O
the O O
previously O O
purified O O
wild O O
type O O
enzyme O O
and O O
contains O O
no O O
detectable O O
RNA O O
component O O
. O O
Cord O O
formation O O
in O O
BACTEC O O
7H12 O O
medium O O
for O O
rapid O O
, O O
presumptive O O
identification O O
of O O
Mycobacterium O O
tuberculosis O O
complex O O
. O O
Moreover O O
, O O
site O O
- O O
specific O O
integration O O
of O O
the O O
ITR O O
- O O
flanked O O
DNA O O
was O O
also O O
detected O O
by O O
PCR O O
amplification O O
of O O
the O O
ITR B-GENE O
- I-GENE O
aavs1 I-GENE O
junction E-GENE O
in O O
transduced O O
human O O
fibroblasts O O
. O O
Oct B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
a O O
ubiquitously O O
expressed O O
regulatory O O
gene O O
of O O
the O O
POU B-GENE B-GENE
domain I-GENE I-GENE
family E-GENE E-GENE
. O O
In O O
both O O
study O O
stages O O
. O O
post O O
- O O
exposure O O
treatment O O
consisted O O
of O O
five O O
injections O O
of O O
vaccine O O
[ O O
( O O
D O O
) O O
ays O O
0 O O
, O O
3 O O
, O O
7 O O
, O O
14 O O
, O O
28 O O
] O O
, O O
together O O
with O O
a O O
dose O O
of O O
rabies B-GENE O
immunoglobulin E-GENE O
( O O
RIG S-GENE O
) O O
of O O
equine O O
or O O
human O O
origin O O
on O O
D0 O O
. O O
( O O
3 O O
) O O
With O O
the O O
exception O O
of O O
the O O
anteroposterior O O
direction O O
of O O
layers O O
II O O
- O O
- O O
III O O
and O O
the O O
mediolateral O O
direction O O
of O O
layer O O
IV O O
, O O
the O O
vertical O O
conductivity O O
of O O
the O O
cortex O O
was O O
always O O
greater O O
than O O
either O O
of O O
the O O
horizontal O O
conductivities O O
. O O
Our O O
study O O
investigated O O
the O O
hypothesis O O
that O O
the O O
combination O O
of O O
a O O
high O O
NaCl O O
diet O O
and O O
social O O
isolation O O
stress O O
would O O
increase O O
systolic O O
blood O O
pressure O O
( O O
SBP O O
) O O
and O O
endogenous O O
sodium O O
pump O O
ligands O O
( O O
SPL O O
) O O
, O O
ouabainlike O O
compound O O
( O O
OLC O O
) O O
, O O
and O O
marinobufagenin O O
( O O
MBG O O
) O O
. O O
The O O
relationship O O
between O O
polymorphonuclear O O
granulocytes O O
and O O
cartilage O O
destruction O O
in O O
rheumatoid O O
arthritis O O
. O O
It O O
is O O
suggested O O
that O O
the O O
loss O O
of O O
weight O O
, O O
the O O
decrease O O
in O O
food O O
intake O O
and O O
the O O
increase O O
in O O
brain O O
MOPEG O O
- O O
SO4 O O
induced O O
by O O
cyanamide O O
reflect O O
possible O O
anorectic O O
properties O O
of O O
the O O
drug O O
. O O
RESULTS O O
: O O
Twenty O O
- O O
two O O
patients O O
( O O
30 O O
% O O
) O O
showed O O
ST O O
- O O
segment O O
depression O O
during O O
AEM O O
and O O
34 O O
( O O
49 O O
% O O
) O O
on O O
ExT O O
. O O
The O O
virus O O
must O O
progress O O
past O O
the O O
immediate O O
- O O
early O O
phase O O
and O O
express O O
an O O
early B-GENE O
gene I-GENE O
product I-GENE O
( I-GENE O
s I-GENE O
) E-GENE O
for O O
activation O O
of O O
cyclin B-GENE B-GENE
E E-GENE E-GENE
expression O O
. O O
In O O
CYP7A1 S-GENE O
transgenic O O
mice O O
, O O
livers O O
contained O O
approximately O O
3 O O
- O O
fold O O
more O O
sterol B-GENE O
response I-GENE O
element I-GENE O
- I-GENE O
binding I-GENE O
protein I-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
mRNA E-GENE E-GENE
. O O
Adenocarcinoma O O
and O O
large O O
cell O O
carcinoma O O
have O O
a O O
worse O O
prognosis O O
than O O
squamous O O
cell O O
carcinoma O O
in O O
the O O
T1N1 O O
and O O
T2N1 O O
subsets O O
. O O
In O O
group O O
I O O
during O O
the O O
pain O O
free O O
period O O
26 O O
of O O
81 O O
patients O O
had O O
positive O O
thallium O O
- O O
201 O O
scans O O
, O O
whereas O O
20 O O
patients O O
had O O
an O O
abnormal O O
ECG O O
at O O
that O O
time O O
; O O
during O O
angina O O
18 O O
patients O O
had O O
transient O O
ECG O O
changes O O
. O O
The O O
prototype O O
now O O
structures O O
oncology O O
- O O
related O O
information O O
available O O
on O O
the O O
Internet O O
and O O
also O O
places O O
resources O O
maintained O O
locally O O
at O O
users O O
' O O
disposal O O
. O O
Binding O O
of O O
the O O
TorR B-GENE O
regulator E-GENE O
to O O
cis O O
- O O
acting O O
direct O O
repeats O O
activates O O
tor B-GENE O
operon E-GENE O
expression O O
. O O
For O O
the O O
most O O
part O O
, O O
only O O
aerobic O O
microbial O O
degradation O O
systems O O
have O O
been O O
reported O O
so O O
far O O
. O O
Asymptomatic O O
ischaemia O O
during O O
daily O O
life O O
in O O
stable O O
coronary O O
artery O O
disease O O
: O O
relevant O O
or O O
redundant O O
? O O
This O O
is O O
a O O
consensus O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
( O O
CKII S-GENE S-GENE
) O O
site O O
and O O
, O O
using O O
purified O O
wild O O
- O O
type O O
and O O
mutant O O
proteins O O
, O O
we O O
show O O
that O O
it O O
is O O
the O O
main O O
CKII B-GENE B-GENE
site E-GENE E-GENE
in O O
the O O
body O O
of O O
the O O
N O O
- O O
terminal O O
complex O O
- O O
forming O O
region O O
. O O
In O O
contrast O O
to O O
Phase O O
III O O
, O O
which O O
has O O
a O O
single O O
study O O
design O O
- O O
- O O
the O O
controlled O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
study O O
- O O
- O O
Phase O O
IV O O
requires O O
different O O
designs O O
for O O
each O O
of O O
the O O
many O O
different O O
questions O O
. O O
Treatment O O
with O O
polyinosinic O O
- O O
polycytidylic O O
acid O O
to O O
induce O O
expression O O
of O O
Cre S-GENE O
resulted O O
in O O
complete O O
disruption O O
of O O
the O O
Arnt B-GENE B-GENE
gene E-GENE E-GENE
and O O
loss O O
of O O
ARNT B-GENE B-GENE
messenger I-GENE I-GENE
RNA E-GENE E-GENE
( O O
mRNA O O
) O O
expression O O
in O O
liver O O
. O O
Physical O O
map O O
of O O
the O O
genome O O
of O O
sonchus O O
yellow O O
net O O
virus O O
, O O
a O O
plant O O
rhabdovirus O O
with O O
six O O
genes O O
and O O
conserved O O
gene O O
junction O O
sequences O O
. O O
Tubular O O
dysfunction O O
in O O
renal O O
lithiasis O O
: O O
cause O O
or O O
consequence O O
? O O
] O O
To O O
investigate O O
whether O O
overall O O
tubular O O
dysfunction O O
is O O
encountered O O
in O O
a O O
particular O O
subgroup O O
of O O
patients O O
with O O
urolithiasis O O
, O O
the O O
following O O
parameters O O
of O O
renal O O
tubular O O
function O O
have O O
been O O
measured O O
in O O
fasting O O
morning O O
urine O O
in O O
124 O O
male O O
stone O O
formers O O
: O O
excretion O O
of O O
lysozyme S-GENE O
and O O
gamma B-GENE O
- I-GENE O
glutamyl I-GENE O
transpeptidase E-GENE O
( O O
gamma B-GENE O
- I-GENE O
GT E-GENE O
) O O
, O O
fractional O O
excretion O O
( O O
FE O O
) O O
or O O
glucose O O
, O O
insulin S-GENE O
, O O
bicarbonate O O
after O O
an O O
alkali O O
load O O
, O O
and O O
theoretical O O
phosphate O O
threshold O O
( O O
TmP O O
/ O O
GFR O O
) O O
. O O
Interaction O O
between O O
the O O
tobacco O O
DNA O O
- O O
binding O O
activity O O
CBF S-GENE S-GENE
and O O
the O O
cyt B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
promoter I-GENE E-GENE
element E-GENE O
of O O
the O O
Agrobacterium O B-GENE
tumefaciens O I-GENE
T O I-GENE
- O I-GENE
DNA O I-GENE
gene O I-GENE
T B-GENE I-GENE
- I-GENE I-GENE
CYT E-GENE E-GENE
correlates O O
with O O
cyt B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
directed O O
gene O O
expression O O
in O O
multiple O O
tobacco O O
tissue O O
types O O
. O O
As O O
expected O O
, O O
the O O
QOLS O O
- O O
N O O
had O O
a O O
lower O O
correlation O O
with O O
physical O O
health O O
( O O
r O O
= O O
0 O O
. O O
24 O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
and O O
self O O
- O O
reported O O
symptoms O O
( O O
r O O
= O O
- O O
0 O O
. O O
20 O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
and O O
a O O
higher O O
correlation O O
with O O
mental O O
health O O
( O O
r O O
= O O
0 O O
. O O
52 O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
. O O
The O O
N1 O O
- O O
P2 O O
amplitudes O O
of O O
the O O
AEP O O
decreased O O
with O O
increasing O O
strength O O
of O O
muscular O O
innervation O O
. O O
SN O O
- O O
38 O O
rebound O O
concentrations O O
were O O
observed O O
in O O
many O O
courses O O
at O O
about O O
0 O O
. O O
5 O O
to O O
1 O O
hour O O
following O O
the O O
end O O
of O O
the O O
i O O
. O O
v O O
. O O
infusion O O
, O O
which O O
is O O
suggestive O O
of O O
enterohepatic O O
recycling O O
. O O
Sequence O O
analysis O O
of O O
AEBP2 B-GENE B-GENE
cDNA E-GENE E-GENE
revealed O O
that O O
it O O
encodes O O
a O O
protein O O
containing O O
three O O
Gli S-GENE B-GENE
- O I-GENE
Kruppel S-GENE E-GENE
( O O
Cys2 O O
- O O
His2 O O
) O O
- O O
type O O
zinc O O
fingers O O
. O O
In O O
the O O
case O O
of O O
the O O
pT181 O B-GENE
plasmid O E-GENE
, O O
inactivation O O
of O O
the O O
initiator B-GENE O
RepC I-GENE B-GENE
protein E-GENE E-GENE
occurs O O
by O O
the O O
attachment O O
of O O
an O O
oligonucleotide O O
to O O
its O O
active O O
tyrosine O O
residue O O
. O O
Xanthoepocin O O
, O O
a O O
new O O
antibiotic O O
from O O
Penicillium O O
simplicissimum O O
IFO5762 O O
. O O
Extracellular B-GENE B-GENE
regulated I-GENE I-GENE
kinases I-GENE E-GENE
( I-GENE O
ERK I-GENE S-GENE
) I-GENE O
1 E-GENE O
and O O
ERK2 S-GENE S-GENE
are O O
authentic O O
substrates O O
for O O
the O O
dual B-GENE O
- I-GENE O
specificity I-GENE O
protein I-GENE O
- I-GENE O
tyrosine I-GENE O
phosphatase I-GENE O
VHR E-GENE S-GENE
. O O
Leukocytoclasic O O
vasculitis O O
during O O
treatment O O
with O O
low O O
- O O
dose O O
captopril O O
H O O
. O O
Truncations O O
from O O
Hip S-GENE O
' O O
s O O
N O O
terminus O O
resulted O O
in O O
an O O
apparent O O
loss O O
of O O
Hip S-GENE O
homo O O
- O O
oligomerization O O
, O O
but O O
these O O
mutants O O
retained O O
association O O
with O O
hsp70 S-GENE S-GENE
and O O
were O O
recovered O O
in O O
receptor O O
complexes O O
. O O
The O O
biological O O
basis O O
for O O
the O O
changes O O
in O O
CNAPs O O
produced O O
by O O
CS2 O O
is O O
under O O
investigation O O
. O O
A O O
very O O
large O O
PC O O
LAN O O
as O O
the O O
basis O O
for O O
a O O
hospital O O
information O O
system O O
. O O
This O O
was O O
tragically O O
highlighted O O
by O O
the O O
death O O
of O O
a O O
17 O O
year O O
old O O
dental O O
nurse O O
after O O
taking O O
a O O
single O O
1 O O
g O O
tablet O O
of O O
sodium O O
nitrite O O
. O O
The O O
human O O
protein O O
is O O
encoded O O
by O O
a O O
900 O O
- O O
base O O
pair O O
- O O
long O O
mRNA O O
that O O
is O O
expressed O O
in O O
the O O
glandular O O
epithelial O O
cells O O
of O O
the O O
endometrium O O
in O O
a O O
cyclic O O
manner O O
; O O
in O O
addition O O
, O O
it O O
is O O
found O O
in O O
the O O
mucosal O O
epithelial O O
cells O O
of O O
the O O
fallopian O O
tubes O O
. O O
In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
renal O O
cell O O
carcinoma O O
who O O
experienced O O
ventricular O O
tachycardia O O
while O O
undergoing O O
treatment O O
with O O
high O O
- O O
dose O O
bolus O O
IL B-GENE O
- I-GENE O
2 E-GENE O
. O O
Four O O
antifungal O O
agents O O
were O O
compared O O
: O O
amphotericin O O
B O O
, O O
flucytosine O O
, O O
miconazole O O
, O O
and O O
ketoconazole O O
. O O
The O O
regulatory O O
genes O O
cnrYXH S-GENE S-GENE
have O O
been O O
cloned O O
, O O
overexpressed O O
, O O
and O O
purified O O
in O O
Escherichia O O
coli O O
. O O
Examination O O
of O O
the O O
Coomassie O O
- O O
stained O O
gels O O
revealed O O
that O O
the O O
capsid O O
- O O
like O O
particles O O
composed O O
of O O
the O O
N11 B-GENE B-GENE
- I-GENE I-GENE
VP1 E-GENE I-GENE
protein O E-GENE
did O O
not O O
contain O O
any O O
host O O
- O O
derived O O
histones S-GENE O
. O O
Conversion O O
of O O
an O O
NF B-GENE O
- I-GENE O
kappaB E-GENE O
into O O
a O O
GABP S-GENE O
binding O O
site O O
is O O
likely O O
to O O
have O O
occurred O O
also O O
during O O
the O O
worldwide O O
spread O O
of O O
HIV O O
- O O
1 O O
, O O
as O O
we O O
noticed O O
the O O
same O O
LTR O O
modification O O
in O O
subtype O O
E O O
isolates O O
from O O
Thailand O O
. O O
Protein O O
binding O O
to O O
UAS1MLS1 S-GENE S-GENE
was O O
observed O O
with O O
extracts O O
from O O
derepressed O O
but O O
not O O
from O O
repressed O O
cells O O
, O O
and O O
could O O
be O O
competed O O
for O O
by O O
an O O
excess O O
of O O
the O O
unlabelled O O
CSRE O O
( O O
ICL1 S-GENE O
) O O
sequence O O
. O O
We O O
then O O
isolated O O
the O O
full O O
- O O
length O O
coding O O
region O O
of O O
the O O
human B-GENE B-GENE
BACH1 I-GENE I-GENE
gene E-GENE E-GENE
using O O
expressed O O
sequence O O
tags O O
, O O
reverse O O
transcription O O
- O O
polymerase O O
chain O O
reaction O O
and O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
. O O
Authors O O
present O O
the O O
anatomical O O
variations O O
of O O
the O O
course O O
of O O
the O O
inferior O O
mesenteric O O
artery O O
and O O
its O O
branches O O
in O O
62 O O
human O O
fetus O O
. O O
The O O
7 B-GENE O
. I-GENE O
2 I-GENE O
kb I-GENE O
EcoRI I-GENE O
fragment I-GENE O
of I-GENE O
AfMNPV E-GENE S-GENE
was O O
cloned O O
and O O
the O O
nucleotide O O
sequences O O
of O O
the O O
polyhedrin S-GENE O
coding O O
region O O
and O O
its O O
flanking O O
regions O O
were O O
determined O O
. O O
1 O O
. O O
The O O
increments O O
in O O
median O O
plasma B-GENE O
secretin E-GENE O
concentration O O
were O O
1 O O
. O O
6 O O
, O O
3 O O
. O O
0 O O
, O O
and O O
6 O O
. O O
4 O O
pmol O O
x O O
1 O O
( O O
- O O
1 O O
) O O
after O O
secretin S-GENE O
, O O
125 O O
, O O
250 O O
and O O
500 O O
fmol O O
x O O
kg O O
- O O
1 O O
, O O
and O O
the O O
corresponding O O
15 O O
- O O
min O O
bicarbonate O O
output O O
283 O O
, O O
442 O O
, O O
and O O
1435 O O
micromol O O
, O O
respectively O O
. O O
The O O
resulting O O
threshold O O
elevation O O
curves O O
fell O O
into O O
a O O
small O O
number O O
of O O
distinct O O
groups O O
, O O
suggesting O O
the O O
existence O O
of O O
discrete O O
spatial O O
frequency O O
mechanisms O O
in O O
human O O
central O O
vision O O
. O O
Because O O
c B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE I-GENE
encodes O E-GENE
a O O
transcriptional O O
activator O O
that O O
functions O O
via O O
DNA O O
binding O O
, O O
it O O
is O O
likely O O
that O O
c B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE E-GENE
exerts O O
its O O
biological O O
activity O O
by O O
regulating O O
the O O
transcription O O
of O O
genes O O
required O O
for O O
DNA O O
synthesis O O
and O O
cell O O
cycle O O
progression O O
. O O
The O O
rest O O
of O O
the O O
3 O O
' O O
untranslated O O
sequences O O
were O O
common O O
to O O
both O O
cDNA O O
clones O O
. O O
Coexpression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Rel E-GENE E-GENE
in O O
combination O O
with O O
ATF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
CREB2 S-GENE O
, O O
or O O
ATF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
/ O O
CREB2 S-GENE O
leads O O
to O O
synergistic O O
transactivation O O
of O O
a O O
CD28RE B-GENE B-GENE
- I-GENE I-GENE
TRE I-GENE E-GENE
reporter E-GENE O
plasmid O O
in O O
quiescent O O
Jurkat O O
T O O
- O O
cells O O
. O O
Conventional O O
toxicological O O
considerations O O
suggest O O
that O O
the O O
adverse O O
health O O
effects O O
of O O
any O O
necessary O O
increase O O
in O O
coal O O
combustion O O
effluents O O
would O O
be O O
greatest O O
per O O
unit O O
of O O
coal O O
in O O
those O O
areas O O
which O O
are O O
most O O
heavily O O
populated O O
and O O
have O O
the O O
highest O O
preexisting O O
levels O O
of O O
the O O
gas O O
- O O
aerosol O O
complex O O
. O O
The O O
genes O O
on O O
each O O
chromosome O O
involved O O
in O O
this O O
translocation O O
have O O
been O O
identified O O
as O O
the O O
transcription O O
factor O O
- O O
encoding O O
genes O O
PAX3 S-GENE S-GENE
and O O
FKHR S-GENE S-GENE
. O O
A O O
search O O
was O O
conducted O O
for O O
suppressors O O
of O O
the O O
inositol O O
auxotrophic O O
phenotype O O
of O O
the O O
ino4 B-GENE B-GENE
- I-GENE I-GENE
8 I-GENE I-GENE
mutant E-GENE E-GENE
of O O
yeast O O
. O O
Anesthesia O O
was O O
induced O O
by O O
droperidol O O
0 O O
. O O
2 O O
mg O O
. O O
kg O O
- O O
1 O O
, O O
fentanyl O O
50 O O
micrograms O O
, O O
thiamylal O O
150 O O
- O O
250 O O
mg O O
, O O
and O O
succinylcholine O O
1 O O
mg O O
. O O
kg O O
- O O
1 O O
, O O
and O O
maintained O O
with O O
nitrous O O
oxide O O
and O O
O2 O O
( O O
67 O O
: O O
33 O O
) O O
supplemented O O
with O O
repeated O O
i O O
. O O
v O O
. O O
doses O O
of O O
fentanyl O O
( O O
within O O
15 O O
micrograms O O
. O O
kg O O
- O O
1 O O
) O O
. O O
Complexities O O
in O O
the O O
host O O
- O O
pathogen O O
interactions O O
during O O
actual O O
infection O O
with O O
Gram O O
- O O
negative O O
bacteria O O
may O O
account O O
for O O
the O O
difficulties O O
in O O
demonstrating O O
this O O
phenomena O O
in O O
vivo O O
. O O
This O O
novel O O
TRPC7 B-GENE B-GENE
gene E-GENE E-GENE
could O O
be O O
a O O
candidate O O
gene O O
for O O
genetic O O
disorders O O
such O O
as O O
bipolar O O
affective O O
disorder O O
, O O
nonsyndromic O O
hereditary O O
deafness O O
, O O
Knobloch O O
syndrome O O
, O O
and O O
holoprosencephaly O O
, O O
which O O
were O O
mapped O O
to O O
this O O
region O O
. O O
Paradoxically O O
, O O
loop O O
3i O O
from O O
the O O
M1Ach B-GENE B-GENE
- I-GENE I-GENE
muscarinic I-GENE I-GENE
receptor E-GENE E-GENE
also O O
maximally O O
inhibited O O
GnRH S-GENE S-GENE
agonist O O
- O O
stimulated O O
cAMP O O
accumulation O O
and O O
PRL S-GENE O
release O O
by O O
40 O O
% O O
( O O
both O O
effects O O
mediated O O
through O O
activation O O
of O O
the O O
Gs B-GENE B-GENE
protein E-GENE E-GENE
) O O
. O O
We O O
present O O
the O O
case O O
of O O
a O O
patient O O
who O O
presented O O
an O O
unusually O O
large O O
mucoid O O
cyst O O
measuring O O
38 O O
x O O
25 O O
mm O O
in O O
an O O
uncommon O O
localization O O
, O O
the O O
right O O
maxillary O O
. O O
Acoustic O O
- O O
property O O
measurements O O
of O O
the O O
oxide O O
superconductor O O
BaPb1 O O
- O O
xBixO3 O O
by O O
the O O
sphere O O
- O O
resonance O O
method O O
. O O
In O O
7 O O
men O O
and O O
1 O O
woman O O
who O O
died O O
suddenly O O
the O O
functionally O O
important O O
areas O O
of O O
myocardium O O
in O O
the O O
sino O O
- O O
auricular O O
area O O
and O O
the O O
subendocardial O O
layers O O
of O O
left O O
ventricle O O
were O O
obtained O O
by O O
necropsy O O
no O O
more O O
than O O
3 O O
h O O
after O O
death O O
, O O
and O O
then O O
prepared O O
for O O
study O O
by O O
electron O O
microscopy O O
. O O
IGF B-GENE B-GENE
- I-GENE I-GENE
I E-GENE E-GENE
levels O O
were O O
measured O O
in O O
the O O
CSF O O
of O O
11 O O
children O O
with O O
autism O O
( O O
4 O O
females O O
, O O
7 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
, O O
SD O O
1 O O
. O O
1 O O
) O O
using O O
a O O
sensitive O O
radioimmunoassay O O
method O O
and O O
compared O O
with O O
levels O O
in O O
11 O O
control O O
participants O O
( O O
6 O O
females O O
, O O
5 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
) O O
. O O
In O O
a O O
subsequent O O
phase O O
- O O
II O O
clinical O O
trial O O
safety O O
and O O
efficacy O O
of O O
transrectal O O
HIFU O O
as O O
a O O
novel O O
minimally O O
invasive O O
treatment O O
modality O O
for O O
patients O O
with O O
symptomatic O O
benign O O
prostatic O O
hyperplasia O O
( O O
BPH O O
; O O
n O O
= O O
102 O O
) O O
was O O
determined O O
. O O
Three O O
high O O
- O O
amylose O O
rice O O
varieties O O
, O O
IR42 O O
, O O
IR36 O O
, O O
and O O
IR62 O O
, O O
with O O
similar O O
chemical O O
composition O O
including O O
amylose O O
content O O
( O O
26 O O
. O O
7 O O
- O O
27 O O
. O O
0 O O
% O O
) O O
, O O
were O O
cooked O O
under O O
the O O
same O O
conditions O O
and O O
tested O O
for O O
in O O
vitro O O
digestibility O O
as O O
well O O
as O O
blood O O
glucose O O
and O O
insulin S-GENE O
responses O O
in O O
healthy O O
human O O
volunteers O O
. O O
Slowly O O
adapting O O
type O O
I O O
mechanoreceptor O O
discharge O O
as O O
a O O
function O O
of O O
dynamic O O
force O O
versus O O
dynamic O O
displacement O O
of O O
glabrous O O
skin O O
of O O
raccoon O O
and O O
squirrel O O
monkey O O
hand O O
. O O
Using O O
beta B-GENE O
1 I-GENE O
- I-GENE O
AR E-GENE O
- O O
luciferase S-GENE O
reporter O O
recombinants O O
, O O
we O O
have O O
previously O O
determined O O
that O O
important O O
beta B-GENE O
1 I-GENE O
- I-GENE O
AR E-GENE O
genetic O O
elements O O
controlling O O
expression O O
within O O
the O O
C6 O O
glioma O O
cell O O
line O O
are O O
contained O O
within O O
the O O
region O O
- O O
396 O O
to O O
- O O
299 O O
, O O
relative O O
to O O
the O O
translational O O
start O O
site O O
. O O
FACS O O
analysis O O
demonstrated O O
that O O
MCs O O
had O O
reached O O
middle O O
to O O
late O O
G1 O O
phase O O
of O O
cell O O
cycle O O
progression O O
at O O
this O O
timepoint O O
. O O
Our O O
case O O
, O O
however O O
, O O
had O O
no O O
histologic O O
evidence O O
of O O
malignancy O O
, O O
no O O
serum B-GENE O
alpha I-GENE O
fetoprotein E-GENE O
at O O
7 O O
months O O
of O O
age O O
, O O
and O O
no O O
recurrence O O
at O O
1 O O
years O O
. O O
Analysis O O
of O O
tobacco O O
mRNA O O
using O O
the O O
ACBF B-GENE B-GENE
cDNA E-GENE E-GENE
as O O
probe O O
showed O O
that O O
while O O
ACBF B-GENE B-GENE
mRNA E-GENE E-GENE
was O O
present O O
in O O
all O O
tissues O O
examined O O
, O O
the O O
highest O O
transcript O O
accumulation O O
occurred O O
in O O
stem O O
tissues O O
. O O
Cotransfection O O
experiments O O
revealed O O
that O O
both O O
hGATA B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
and O O
PMA O O
/ O O
A23187 O O
stimulation O O
are O O
necessary O O
for O O
the O O
IL B-GENE B-GENE
- I-GENE I-GENE
5 I-GENE I-GENE
promoter E-GENE E-GENE
activation O O
. O O
Here O O
we O O
show O O
that O O
expression O O
of O O
KRAB B-GENE S-GENE
domain E-GENE O
suppresses O O
in O O
vivo O O
the O O
activating O O
function O O
of O O
various O O
defined O O
activating B-GENE O
transcription I-GENE O
factors E-GENE O
, O O
and O O
we O O
demonstrate O O
that O O
the O O
KRAB B-GENE B-GENE
domain E-GENE E-GENE
specifically O O
silences O O
the O O
activity O O
of O O
promoters O O
whose O O
initiation O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
. O O
Adult O O
- O O
onset O O
parkinsonism O O
has O O
appeared O O
in O O
several O O
previously O O
unaffected O O
members O O
in O O
families O O
with O O
DRD O O
suggesting O O
that O O
this O O
may O O
be O O
an O O
additional O O
phenotypical O O
expression O O
of O O
the O O
disease O O
. O O
We O O
tested O O
the O O
effects O O
of O O
antifungal O O
drugs O O
on O O
adherence O O
of O O
Candida O O
albicans O O
in O O
vitro O O
. O O
The O O
signs O O
of O O
enterocolitis O O
, O O
pathological O O
microbial O O
flora O O
in O O
the O O
stool O O
and O O
changes O O
in O O
the O O
colon O O
mucosa O O
were O O
absent O O
. O O
These O O
results O O
support O O
an O O
in O O
vivo O O
interaction O O
between O O
Nck S-GENE S-GENE
and O O
CKI B-GENE B-GENE
- I-GENE I-GENE
gamma2 E-GENE E-GENE
and O O
suggest O O
that O O
CKI B-GENE B-GENE
- I-GENE I-GENE
gamma2 E-GENE E-GENE
could O O
be O O
involved O O
in O O
signaling O O
pathways O O
downstream O O
of O O
RTKs S-GENE S-GENE
. O O
Correlation O O
of O O
nitrogen O O
, O O
carbohydrate O O
and O O
lipid O O
metabolic O O
indices O O
in O O
rats O O
cooled O O
under O O
conditions O O
of O O
an O O
altered O O
gaseous O O
environment O O
Reactivation O O
of O O
hepatitis O O
B O O
virus O O
replication O O
is O O
a O O
rare O O
event O O
during O O
the O O
natural O O
history O O
of O O
chronic O O
hepatitis O O
B O O
. O O
A O O
minimal O O
region O O
which O O
stimulates O O
origin O O
function O O
mapped O O
to O O
50 O O
amino O O
acids O O
within O O
the O O
C O O
- O O
terminus O O
of O O
Abf1p S-GENE S-GENE
. O O
Cutaneous O O
melanoma O O
and O O
bilateral O O
retinoblastoma O O
. O O
Treatment O O
of O O
JEA2 O O
cells O O
with O O
interleukin B-GENE O
( I-GENE O
IL I-GENE S-GENE
) I-GENE O
- I-GENE O
7 E-GENE O
induces O O
CBLB S-GENE S-GENE
phosphorylation O O
as O O
well O O
. O O
Phosphorylation O O
by O O
Cdc28 S-GENE S-GENE
activates O O
the O O
Cdc20 S-GENE S-GENE
- O O
dependent O O
activity O O
of O O
the O O
anaphase O O
- O O
promoting O O
complex O O
. O O
METHOD O O
: O O
After O O
eligibility O O
, O O
patients O O
were O O
randomly O O
allocated O O
in O O
one O O
of O O
the O O
following O O
groups O O
: O O
M O O
= O O
methylprednisolone O O
30 O O
mg O O
. O O
kg O O
- O O
1 O O
over O O
1 O O
hour O O
, O O
followed O O
by O O
5 O O
. O O
4 O O
mg O O
. O O
kg O O
- O O
1 O O
. O O
h O O
- O O
1 O O
for O O
23 O O
hours O O
, O O
N O O
= O O
nimodipine O O
0 O O
. O O
015 O O
mg O O
. O O
kg O O
- O O
1 O O
. O O
h O O
- O O
1 O O
over O O
2 O O
hours O O
followed O O
by O O
0 O O
. O O
03 O O
mg O O
. O O
kg O O
- O O
1 O O
. O O
h O O
- O O
1 O O
for O O
7 O O
days O O
, O O
MN O O
or O O
P O O
. O O
The O O
amount O O
of O O
overlap O O
in O O
VFI O O
, O O
EF O O
, O O
and O O
RVF O O
values O O
among O O
the O O
clinical O O
groups O O
was O O
considerable O O
. O O
After O O
5 O O
, O O
850 O O
C14 O O
BP O O
, O O
the O O
decrease O O
in O O
Acer O O
stands O O
could O O
be O O
attributed O O
to O O
fire O O
as O O
suggested O O
by O O
the O O
strong O O
increase O O
in O O
Betula O O
and O O
by O O
the O O
delayed O O
expansion O O
of O O
Pinus O O
cembra O O
. O O
Assays O O
of O O
APRE O B-GENE
- O I-GENE
luciferase S-GENE E-GENE
reporter O O
plasmids O O
transfected O O
into O O
HepG2 O O
cells O O
show O O
that O O
a O O
mutated O O
APRE O S-GENE
that O O
binds O O
only O O
BPi S-GENE O
functions O O
as O O
an O O
IL B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
alpha E-GENE I-GENE
inducible O I-GENE
enhancer O E-GENE
, O O
whereas O O
a O O
mutated O O
APRE O S-GENE
that O O
binds O O
only O O
BPc S-GENE S-GENE
does O O
not O O
. O O
RNA O O
unwinding O O
in O O
U4 S-GENE S-GENE
/ O O
U6 S-GENE O
snRNPs O O
requires O O
ATP O O
hydrolysis O O
and O O
the O O
DEIH O B-GENE
- O I-GENE
box O I-GENE
splicing O I-GENE
factor O I-GENE
Brr2 S-GENE E-GENE
. O O
Several O O
sequences O O
resembling O O
binding O O
sites O O
for O O
liver O O
- O O
and O O
fat O O
body O O
- O O
specific O O
transcription O O
factors O O
were O O
identified O O
within O O
1 O O
kb O O
upstream O O
and O O
downstream O O
of O O
the O O
gene O O
. O O
Northern O O
blot O O
analysis O O
linked O O
Plk S-GENE O
expression O O
to O O
the O O
proliferative O O
activity O O
of O O
cells O O
and O O
tissues O O
. O O
It O O
also O O
showed O O
which O O
amino O O
acid O O
residues O O
would O O
contact O O
an O O
extended O O
TATA O O
box O O
with O O
a O O
B B-GENE O
recognition I-GENE O
element E-GENE O
, O O
and O O
evolutionary O O
conservation O O
of O O
the O O
TBP S-GENE O
- O O
TFB S-GENE O
- O O
DNA O O
complex O O
orientation O O
between O O
two O O
archaeal O O
organisms O O
with O O
widely O O
different O O
optimal O O
temperature O O
for O O
growth O O
( O O
37 O O
and O O
100 O O
degrees O O
C O O
) O O
. O O
Studies O O
with O O
and O O
without O O
attenuating O O
media O O
were O O
performed O O
, O O
and O O
myocardium O O
- O O
to O O
- O O
defect O O
count O O
ratios O O
and O O
defect O O
sizes O O
from O O
dual O O
- O O
isotope O O
SPECT O O
images O O
were O O
compared O O
to O O
myocardium O O
- O O
to O O
- O O
defect O O
count O O
ratios O O
and O O
defect O O
sizes O O
from O O
single O O
- O O
isotope O O
( O O
201Tl O O
and O O
99mTc O O
) O O
SPECT O O
images O O
. O O
Comparison O O
of O O
this O O
gene O O
with O O
the O O
available O O
databases O O
reveals O O
very O O
significant O O
homology O O
to O O
the O O
ETS B-GENE B-GENE
factor E-GENE I-GENE
PE B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
probable O O
near O O
- O O
identity O O
with O O
the O O
recently O O
cloned O O
factor O O
ERF S-GENE S-GENE
. O O
Patients O O
with O O
Eales O O
' O O
disease O O
, O O
chorioretinitis O O
, O O
central O O
serous O O
retinopathy O O
, O O
or O O
malignant O O
choroidal O O
melanoma O O
were O O
tested O O
for O O
HLA S-GENE B-GENE
antigen O E-GENE
deviation O O
. O O
Copyright O O
1999 O O
Academic O O
Press O O
. O O
The O O
1 O O
. O O
5 O O
- O O
Mb O O
region O O
was O O
covered O O
by O O
137 O O
cosmids O O
with O O
a O O
minimum O O
overlap O O
set O O
of O O
52 O O
cosmids O O
assigned O O
to O O
17 O O
bins O O
and O O
9 O O
contigs O O
. O O
Similarly O O
, O O
beta B-GENE O
adrenoceptors E-GENE O
blockade O O
has O O
been O O
shown O O
to O O
be O O
of O O
value O O
in O O
achieving O O
continence O O
in O O
a O O
small O O
group O O
of O O
patients O O
. O O
Estrogen O O
has O O
positive O O
effects O O
on O O
mood O O
, O O
sexual O O
function O O
, O O
target O O
end O O
organs O O
and O O
cognitive O O
function O O
, O O
and O O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
etiology O O
of O O
Alzheimer O O
' O O
s O O
Disease O O
by O O
acting O O
to O O
prevent O O
amyloid O O
plaque O O
formation O O
, O O
oxidative O O
stress O O
, O O
or O O
deterioration O O
of O O
the O O
cholinergic O O
neurotransmitter O O
system O O
. O O
These O O
data O O
also O O
demonstrate O O
that O O
insulin S-GENE S-GENE
and O O
TPA O S-GENE
activate O O
MBP S-GENE S-GENE
/ O O
MAP2 S-GENE B-GENE
kinase O E-GENE
activity O O
by O O
de O O
novo O O
phosphorylation O O
of O O
threonine O O
and O O
tyrosine O O
residues O O
via O O
a O O
very O O
similar O O
pathway O O
. O O
Effect O O
of O O
capsaicin O O
on O O
hexobarbital O O
- O O
anesthetized O O
rats O O
Triethylene O O
glycol O O
. O O
Such O O
tetranucleotides O O
are O O
common O O
in O O
promoter O O
regions O O
, O O
particularly O O
in O O
activating B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
/ O O
cyclic B-GENE O
AMP I-GENE B-GENE
response I-GENE I-GENE
element I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
ATF S-GENE S-GENE
/ O O
CREB S-GENE S-GENE
) O O
and O O
E O O
- O O
box O O
motifs O O
, O O
suggesting O O
that O O
PIF S-GENE S-GENE
may O O
modulate O O
the O O
transcription O O
of O O
many O O
genes O O
. O O
Red O O
blood O O
cell O O
binding O O
of O O
99mTc O O
- O O
EC O O
and O O
131I O O
- O O
OIH O O
was O O
6 O O
. O O
1 O O
% O O
and O O
20 O O
% O O
, O O
respectively O O
. O O
The O O
dominant O O
inhibitory O O
biological O O
activity O O
of O O
the O O
N O O
terminus O O
correlated O O
with O O
its O O
ability O O
to O O
impair O O
EGF S-GENE S-GENE
- O O
dependent O O
activation O O
of O O
GTP B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
and O O
of O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
, O O
as O O
well O O
with O O
the O O
ability O O
of O O
endogenous O O
Sos S-GENE O
to O O
form O O
a O O
stable O O
complex O O
with O O
activated O O
EGF B-GENE B-GENE
receptors E-GENE E-GENE
. O O
Brainstem O O
auditory O O
evoked O O
potential O O
responses O O
( O O
BAEPs O O
) O O
were O O
recorded O O
from O O
CZ O O
- O O
A1 O O
and O O
CZ O O
- O O
A2 O O
scalp O O
regions O O
in O O
23 O O
hypertensive O O
and O O
14 O O
normotensive O O
subjects O O
. O O
SM S-GENE S-GENE
binds O O
RNA O O
in O O
vitro O O
, O O
suggesting O O
that O O
sequence O O
- O O
or O O
structure O O
- O O
specific O O
mRNA O O
interactions O O
might O O
mediate O O
SM S-GENE O
specificity O O
. O O
The O O
characterization O O
of O O
fly O O
receptors O O
with O O
features O O
similar O O
to O O
mammalian B-GENE B-GENE
glycoprotein I-GENE I-GENE
hormone I-GENE I-GENE
receptors E-GENE E-GENE
allows O O
a O O
better O O
understanding O O
of O O
the O O
evolution O O
of O O
this O O
unique O O
group O O
of O O
GPCRs S-GENE S-GENE
and O O
future O O
elucidation O O
of O O
their O O
ligand O O
signaling O O
mechanisms O O
. O O
Here O O
we O O
show O O
that O O
these O O
sequences O O
are O O
essential O O
for O O
processing O O
of O O
U18 S-GENE S-GENE
and O O
snR38 B-GENE B-GENE
snoRNAs E-GENE E-GENE
and O O
that O O
they O O
compensate O O
for O O
the O O
lack O O
of O O
a O O
canonical O O
terminal O O
stem O O
. O O
The O O
use O O
of O O
aluminum O O
hydroxide O O
was O O
associated O O
with O O
an O O
increase O O
in O O
fecal O O
fluoride O O
excretion O O
and O O
a O O
decrease O O
in O O
net O O
absorption O O
of O O
fluoride O O
regardless O O
of O O
the O O
intake O O
fluoride O O
, O O
calcium O O
, O O
phosphorus O O
, O O
or O O
magnesium O O
. O O
In O O
humans O O
, O O
there O O
was O O
a O O
statistically O O
significant O O
decrease O O
of O O
TEWL O O
on O O
both O O
forearm O O
and O O
thigh O O
in O O
CS O O
- O O
treated O O
patients O O
compared O O
to O O
non O O
- O O
CS O O
- O O
treated O O
patients O O
and O O
controls O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O
Kramer O O
Hamburg O O
1988 O O
, O O
ISBN O O
: O O
3 O O
926952 O O
07 O O
5 O O
) O O
, O O
the O O
syndromatic O O
day O O
- O O
to O O
- O O
day O O
shifting O O
of O O
the O O
psychopathological O O
features O O
with O O
manic O O
, O O
depressive O O
and O O
several O O
mixed O O
states O O
has O O
a O O
well O O
- O O
defined O O
time O O
structure O O
, O O
as O O
in O O
25 O O
patients O O
studied O O
and O O
reported O O
on O O
in O O
this O O
paper O O
. O O
Ras S-GENE S-GENE
involvement O O
in O O
signal O O
transduction O O
by O O
the O O
serotonin B-GENE B-GENE
5 I-GENE I-GENE
- I-GENE I-GENE
HT2B I-GENE I-GENE
receptor E-GENE E-GENE
. O O
Analysis O O
of O O
exon O O
2 O O
of O O
the O O
factor B-GENE B-GENE
IX I-GENE I-GENE
gene E-GENE E-GENE
revealed O O
a O O
C O O
- O O
- O O
> O O
T O O
mutation O O
in O O
codon O O
10 O O
of O O
the O O
propeptide O O
region O O
, O O
resulting O O
in O O
the O O
substitution O O
of O O
alanine O O
by O O
valine O O
. O O
There O O
was O O
a O O
direct O O
proportional O O
relationship O O
between O O
the O O
spiral O O
artery O O
flow O O
and O O
the O O
pressure O O
difference O O
between O O
the O O
spiral O O
artery O O
and O O
the O O
amniotic O O
fluid O O
; O O
the O O
pressure O O
difference O O
per O O
flow O O
( O O
the O O
resistance O O
of O O
the O O
cotyledonary O O
unit O O
) O O
was O O
found O O
to O O
be O O
1 O O
- O O
- O O
3 O O
mm O O
Hg O O
. O O
ml O O
- O O
1 O O
. O O
min O O
( O O
8 O O
- O O
- O O
24kPa O O
. O O
ml O O
- O O
1 O O
. O O
s O O
) O O
. O O
Three O O
putative O O
ORFs O O
have O O
significant O O
homology O O
with O O
known O O
proteins O O
: O O
L0968 S-GENE S-GENE
is O O
a O O
new O O
member O O
of O O
the O O
very O O
large O O
' B-GENE O
seripauperins I-GENE O
' E-GENE O
family O O
, O O
comprising O O
at O O
least O O
20 O O
yeast O O
members O O
; O O
L1313 S-GENE S-GENE
is O O
a O O
new O O
ABC B-GENE O
transporter E-GENE O
highly O O
homologous O O
to O O
the O O
yeast O O
cadmium O O
resistance O O
protein O O
Ycf1p S-GENE S-GENE
and O O
to O O
the O O
human B-GENE O
multidrug I-GENE O
resistance I-GENE O
protein E-GENE O
hMRP1 S-GENE S-GENE
; O O
the O O
C O O
- O O
terminal O O
part O O
of O O
L1325 S-GENE S-GENE
present O O
in O O
our O O
sequence O O
is O O
very O O
homologous O O
to O O
the O O
fruit O O
fly O O
abdominal O O
segment O O
formation O O
protein O O
Pumilio S-GENE O
. O O
The O O
cells O O
were O O
densely O O
ciliated O O
, O O
each O O
cilium O O
showing O O
a O O
typical O O
9 O O
+ O O
2 O O
fibrilar O O
pattern O O
. O O
Immunofluorescence O O
obtained O O
using O O
antibodies O O
against O O
alphaI B-GENE B-GENE
SigmaI I-GENE I-GENE
/ I-GENE I-GENE
+ I-GENE I-GENE
+ I-GENE I-GENE
betaI I-GENE I-GENE
SigmaI I-GENE I-GENE
spectrin E-GENE E-GENE
and O O
Abl B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
but O O
not O O
against O O
alphaII B-GENE S-GENE
/ I-GENE O
betaII I-GENE S-GENE
spectrin E-GENE O
colocalized O O
with O O
the O O
overexpressed O O
green B-GENE O
fluorescent I-GENE O
protein E-GENE O
- O O
SH3 B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
. O O
Extracellular B-GENE B-GENE
protein I-GENE I-GENE
kinase I-GENE E-GENE
A E-GENE O
as O O
a O O
cancer O O
biomarker O O
: O O
its O O
expression O O
by O O
tumor O O
cells O O
and O O
reversal O O
by O O
a O O
myristate O O
- O O
lacking O O
Calpha O S-GENE
and O O
RIIbeta O B-GENE
subunit O E-GENE
overexpression O O
. O O
Detection O O
of O O
sinusoidal O O
gratings O O
by O O
pattern O O
- O O
specific O O
detectors O O
: O O
further O O
evidence O O
for O O
the O O
correlation O O
principle O O
in O O
human O O
vision O O
. O O
This O O
B O O
- O O
box O O
is O O
not O O
present O O
in O O
ETS1 S-GENE S-GENE
, O O
ETS2 S-GENE S-GENE
, O O
PEA3 S-GENE S-GENE
or O O
PU B-GENE B-GENE
. I-GENE I-GENE
1 E-GENE E-GENE
and O O
these O O
proteins O O
were O O
unable O O
to O O
form O O
ternary O O
complexes O O
with O O
SRF S-GENE S-GENE
and O O
Egrl S-GENE O
- O O
SREs O O
or O O
c B-GENE B-GENE
- I-GENE I-GENE
fos E-GENE I-GENE
SRE O E-GENE
. O O
MADS B-GENE B-GENE
- I-GENE I-GENE
box I-GENE I-GENE
genes E-GENE E-GENE
in O O
plants O O
are O O
a O O
diverse O O
class O O
of O O
transcription O O
factors O O
that O O
are O O
involved O O
in O O
regulating O O
developmental O O
processes O O
, O O
particularly O O
meristem O O
and O O
organ O O
identity O O
during O O
floral O O
development O O
. O O
Elevated O O
systolic O O
blood O O
pressure O O
and O O
high O O
postglucose O O
serum B-GENE O
insulin E-GENE O
levels O O
showed O O
an O O
independent O O
, O O
significant O O
association O O
with O O
left O O
ventricular O O
mass O O
in O O
female O O
diabetic O O
subjects O O
. O O
This O O
study O O
investigated O O
if O O
signal O O
- O O
averaged O O
low O O
amplitude O O
atrial O O
potentials O O
predict O O
atrial O O
fibrillation O O
or O O
flutter O O
( O O
AFF O O
) O O
. O O
Thirty O O
- O O
five O O
pts O O
were O O
transplanted O O
for O O
constitutional O O
disease O O
: O O
Fanconi O O
anemia O O
( O O
FA O O
) O O
( O O
26 O O
pts O O
) O O
, O O
Dyskeratosis O O
congenita O O
( O O
2 O O
pts O O
) O O
, O O
Blackfan O O
- O O
Diamond O O
erythroblastopenia O O
( O O
2 O O
pts O O
) O O
, O O
Glanzmann O O
thrombasthenia O O
( O O
1 O O
pt O O
) O O
, O O
osteopetrosis O O
( O O
1 O O
pt O O
) O O
and O O
Gaucher O O
' O O
s O O
disease O O
( O O
1 O O
pt O O
) O O
. O O
Viral B-GENE B-GENE
protein I-GENE I-GENE
U E-GENE E-GENE
( O O
Vpu S-GENE S-GENE
) O O
is O O
a O O
protein O O
encoded O O
by O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
that O O
promotes O O
the O O
degradation O O
of O O
the O O
virus O O
receptor O O
, O O
CD4 S-GENE S-GENE
, O O
and O O
enhances O O
the O O
release O O
of O O
virus O O
particles O O
from O O
cells O O
. O O
Because O O
the O O
variation O O
in O O
the O O
carbohydrate O O
content O O
of O O
human O O
milk O O
is O O
very O O
small O O
, O O
a O O
more O O
simple O O
alternative O O
approach O O
would O O
be O O
to O O
include O O
only O O
an O O
average O O
carbohydrate O O
value O O
for O O
an O O
estimate O O
of O O
energy O O
content O O
. O O
Level O O
II O O
mosaicism O O
occurred O O
in O O
0 O O
. O O
9 O O
per O O
cent O O
of O O
CVS O O
mesenchyme O O
and O O
1 O O
. O O
5 O O
per O O
cent O O
of O O
amniotic O O
fluid O O
cultures O O
and O O
in O O
general O O
was O O
not O O
perceived O O
to O O
be O O
of O O
sufficient O O
concern O O
to O O
warrant O O
cytogenetic O O
follow O O
- O O
up O O
studies O O
. O O
Biol O O
. O O
IV O O
. O O
Sleeping O O
position O O
and O O
sudden O O
infant O O
death O O
syndrome O O
( O O
SIDS O O
) O O
: O O
effect O O
of O O
an O O
intervention O O
programme O O
to O O
avoid O O
prone O O
sleeping O O
. O O
CSEn S-GENE S-GENE
stimulated O O
transcription O O
of O O
a O O
variety O O
of O O
promoters O O
, O O
including O O
the O O
hCS S-GENE S-GENE
, O O
human B-GENE O
growth I-GENE O
hormone E-GENE O
, O O
thymidine B-GENE B-GENE
kinase E-GENE E-GENE
, O O
and O O
Rous B-GENE O
sarcoma I-GENE O
virus I-GENE O
promoters E-GENE O
, O O
in O O
human O O
choriocarcinoma O O
cell O O
lines O O
( O O
BeWo O O
and O O
JEG O O
- O O
3 O O
) O O
but O O
not O O
HeLa O O
cells O O
or O O
rat O O
somatolactotrophes O O
( O O
GC O O
) O O
. O O
Pretreatment O O
of O O
human O O
skin O O
with O O
tRA O O
inhibited O O
UV O O
induction O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
protein E-GENE E-GENE
and O O
, O O
consequently O O
, O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
protein E-GENE E-GENE
inhibition O O
occurred O O
via O O
a O O
posttranscriptional O O
mechanism O O
, O O
since O O
tRA O S-GENE
did O O
not O O
inhibit O O
UV O O
induction O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
mRNA E-GENE E-GENE
. O O
Thus O O
, O O
apoptosis O O
in O O
hematopoietic O O
cells O O
is O O
the O O
end O O
result O O
of O O
a O O
conflict O O
between O O
death O O
and O O
survival O O
signals O O
, O O
rather O O
than O O
a O O
simple O O
death O O
by O O
default O O
. O O
Effect O O
of O O
age O O
on O O
glucose O O
, O O
reducing O O
sugars O O
and O O
plasma B-GENE O
insulin E-GENE O
in O O
blood O O
of O O
milk O O
- O O
fed O O
calves O O
. O O
CONCLUSIONS O O
: O O
Results O O
of O O
this O O
study O O
suggest O O
that O O
both O O
male O O
and O O
female O O
soldiers O O
who O O
are O O
diagnosed O O
with O O
chlamydia O O
infections O O
have O O
relatively O O
high O O
risks O O
of O O
reinfection O O
through O O
their O O
20s O O
. O O
During O O
seed O O
maturation O O
, O O
the O O
transcriptional O O
activity O O
of O O
napin B-GENE B-GENE
genes E-GENE E-GENE
is O O
regulated O O
by O O
developmental O O
signals O O
involving O O
the O O
transcriptional B-GENE O
activator I-GENE O
ABI3 E-GENE S-GENE
and O O
abscisic O O
acid O O
( O O
ABA O O
) O O
. O O
DESIGN O O
: O O
Intradermally O O
injected O O
human O O
squamous O O
cell O O
carcinoma O O
cells O O
were O O
grown O O
to O O
40 O O
to O O
80 O O
mm3 O O
in O O
athymic O O
nude O O
mice O O
and O O
irradiated O O
with O O
675 O O
- O O
nm O O
light O O
( O O
75 O O
J O O
/ O O
cm2 O O
, O O
75 O O
mW O O
/ O O
cm2 O O
) O O
24 O O
hours O O
after O O
the O O
intraperitoneal O O
injection O O
of O O
SiPc O O
IV O O
( O O
1 O O
. O O
0 O O
mg O O
/ O O
kg O O
) O O
. O O
This O O
results O O
in O O
a O O
decreased O O
secretion O O
of O O
immunoglobulin B-GENE O
A E-GENE O
, O O
and O O
, O O
consequently O O
, O O
a O O
decreased O O
resistance O O
against O O
infections O O
. O O
The O O
absolute O O
CD4 S-GENE O
count O O
of O O
patients O O
with O O
de O O
novo O O
IBD O O
was O O
210 O O
- O O
700 O O
cells O O
/ O O
ml O O
at O O
the O O
time O O
of O O
IBD O O
. O O
Categorisation O O
of O O
the O O
different O O
substructures O O
within O O
the O O
sections O O
allows O O
them O O
to O O
be O O
analysed O O
and O O
displayed O O
separately O O
. O O
To O O
study O O
the O O
mechanisms O O
and O O
the O O
signaling O O
pathways O O
involved O O
, O O
IGF B-GENE B-GENE
- I-GENE I-GENE
1R I-GENE I-GENE
promoter I-GENE E-GENE
reporter I-GENE O
constructs E-GENE O
were O O
transiently O O
transfected O O
in O O
CHO O O
- O O
AT1 O O
cells O O
that O O
overexpress O B-GENE
angiotensin B-GENE I-GENE
AT1 I-GENE I-GENE
receptors E-GENE E-GENE
. O O
With O O
this O O
study O O
, O O
a O O
total O O
of O O
13 O O
operators O O
for O O
the O O
glp B-GENE O
regulon E-GENE O
have O O
been O O
characterized O O
. O O
Natl O O
. O O
Coexpression O O
of O O
a O O
dominant B-GENE O
negative I-GENE O
c I-GENE B-GENE
- I-GENE I-GENE
jun E-GENE E-GENE
antagonized O O
the O O
ras S-GENE O
- O O
dependent O O
stimulation O O
of O O
the O O
92 B-GENE O
- I-GENE O
kDa I-GENE O
gelatinase I-GENE O
B E-GENE O
promoter O O
- O O
driven O O
CAT B-GENE O
reporter E-GENE O
. O O
In O O
two O O
patients O O
, O O
a O O
male O O
homosexual O O
and O O
an O O
hemophiliac O O
, O O
thrombocytopenia O O
was O O
associated O O
with O O
AIDS O O
- O O
related O O
complex O O
. O O
However O O
, O O
LXRalpha S-GENE S-GENE
inhibited O O
binding O O
of O O
PPARalpha S-GENE S-GENE
/ O O
RXRalpha S-GENE S-GENE
heterodimers O O
to O O
PPREs O S-GENE
, O O
and O O
coexpression O O
of O O
LXRalpha S-GENE S-GENE
in O O
mammalian O O
cells O O
antagonized O O
peroxisome O O
proliferator O O
signaling O O
mediated O O
by O O
PPARalpha S-GENE S-GENE
/ O O
RXRalpha S-GENE S-GENE
in O O
vivo O O
. O O
The O O
results O O
can O O
be O O
summarized O O
as O O
follows O O
. O O
A O O
case O O
of O O
heterotopic O O
gastric O O
mucosa O O
( O O
pyloric O O
gland O O
) O O
in O O
the O O
wall O O
of O O
the O O
gallbladder O O
was O O
reported O O
. O O
These O O
findings O O
suggest O O
that O O
the O O
mechanism O O
of O O
ribosomal O O
frameshifting O O
at O O
the O O
PVM O O
signal O O
is O O
different O O
from O O
the O O
one O O
described O O
by O O
the O O
' O O
simultaneous O O
slippage O O
' O O
model O O
in O O
that O O
only O O
the O O
string O O
of O O
four O O
adenosine O O
nucleotides O O
represents O O
the O O
slippery O O
sequence O O
involved O O
in O O
a O O
- O O
1 O O
P O O
- O O
site O O
slippage O O
. O O
CTDK1 S-GENE S-GENE
and O O
CTDK2 S-GENE S-GENE
also O O
differ O O
in O O
their O O
protein O O
substrate O O
specificity O O
. O O
This O O
communication O O
presents O O
two O O
patients O O
with O O
clinically O O
massive O O
PE O O
of O O
recent O O
onset O O
( O O
confirmed O O
by O O
lung O O
perfusion O O
scans O O
) O O
who O O
were O O
successfully O O
treated O O
with O O
a O O
single O O
i O O
. O O
v O O
. O O
dose O O
of O O
30 O O
mg O O
of O O
anisoylated B-GENE O
lys I-GENE O
- I-GENE O
plasminogen I-GENE O
streptokinase I-GENE O
activator I-GENE O
complex E-GENE O
( O O
APSAC S-GENE O
, O O
comparable O O
to O O
1 O O
, O O
500 O O
, O O
000 O O
U O O
of O O
streptokinase S-GENE O
) O O
followed O O
by O O
systemic O O
heparinization O O
for O O
7 O O
days O O
. O O
A O O
Laboratory O O
Manual O O
, O O
2nd O O
ed O O
. O O
Engineering O O
temperature O O
- O O
sensitive O O
SH3 B-GENE O
domains E-GENE O
. O O
A O O
mean O O
value O O
for O O
HbA1 S-GENE O
greater O O
than O O
10 O O
% O O
was O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
progression O O
of O O
retinopathy O O
and O O
a O O
mean O O
value O O
less O O
than O O
8 O O
. O O
7 O O
% O O
was O O
associated O O
with O O
a O O
diminished O O
risk O O
. O O
Allergic O O
field O O
: O O
how O O
to O O
detect O O
it O O
? O O
At O O
1 O O
min O O
postalfentanil O O
, O O
N2O O O
caused O O
significantly O O
more O O
rigidity O O
than O O
100 O O
% O O
O2 O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O
The O O
preparative O O
regimen O O
consisted O O
of O O
fractionated O O
total O O
body O O
irradiation O O
( O O
TBI O O
) O O
and O O
cyclophosphamide O O
( O O
CY O O
) O O
. O O
NGF S-GENE S-GENE
also O O
induced O O
a O O
synthetic O O
promoter O O
with O O
repeated O O
Sp1 B-GENE S-GENE
sites E-GENE O
linked O O
to O O
a O O
core O O
promoter O O
, O O
and O O
a O O
plasmid O O
regulated O O
by O O
a O O
chimeric O O
transactivator O O
in O O
which O O
the O O
Gal4 B-GENE O
DNA I-GENE O
binding I-GENE O
domain E-GENE O
is O O
fused O O
to O O
the O O
Sp1 B-GENE S-GENE
transactivation I-GENE O
domain E-GENE O
, O O
indicating O O
that O O
this O O
transactivation O O
domain O O
is O O
regulated O O
by O O
NGF S-GENE S-GENE
. O O
The O O
toxicity O O
of O O
copper O O
to O O
the O O
collembolan O O
Folsomia O O
fimetaria O O
L O O
. O O
was O O
studied O O
in O O
soil O O
incubated O O
with O O
copper O O
sulfate O O
for O O
different O O
periods O O
before O O
the O O
introduction O O
of O O
collembolans O O
, O O
to O O
assess O O
the O O
effect O O
of O O
aging O O
of O O
contamination O O
on O O
the O O
toxicity O O
of O O
copper O O
. O O
The O O
frequency O O
of O O
severe O O
congestive O O
heart O O
failure O O
( O O
Killip O O
class O O
III O O
or O O
IV O O
) O O
at O O
admission O O
was O O
significantly O O
higher O O
in O O
patients O O
with O O
early O O
presentation O O
, O O
than O O
with O O
late O O
presentation O O
( O O
30 O O
. O O
7 O O
% O O
vs O O
7 O O
. O O
6 O O
% O O
, O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O
Comparative O O
ultrafiltration O O
( O O
UF O O
) O O
studies O O
with O O
BiGG O O
and O O
standard O O
lactate O O
( O O
La O O
) O O
solutions O O
in O O
rabbits O O
showed O O
that O O
net O O
UF O O
with O O
La O O
solution O O
peaked O O
at O O
2 O O
h O O
and O O
decreased O O
significantly O O
at O O
4 O O
h O O
and O O
6 O O
h O O
. O O
The O O
Giessener O O
Tumordokumentationssystem O O
( O O
GTDS O O
) O O
is O O
such O O
a O O
disease O O
specific O O
system O O
. O O
Measurement O O
of O O
protein O O
in O O
natural O O
rubber O O
latex O O
. O O
In O O
cotransfection O O
assays O O
, O O
a O O
small O O
fragment O O
of O O
Sin S-GENE O
retaining O O
the O O
Src S-GENE B-GENE
- O I-GENE
SH3 S-GENE I-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
and O O
one O O
tyrosine O O
- O O
containing O O
motif O O
induced O O
c B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE E-GENE
activation O O
as O O
measured O O
by O O
a O O
transcriptional O O
reporter O O
. O O
The O O
related O O
tumor O O
suppressor O O
, O O
p130 S-GENE S-GENE
, O O
also O O
effects O O
this O O
function O O
. O O
p107 S-GENE S-GENE
levels O O
increase O O
substantially O O
as O O
cells O O
progress O O
through O O
S O O
phase O O
. O O
p107 S-GENE S-GENE
induction O O
of O O
E2F S-GENE S-GENE
DNA O O
binding O O
was O O
observed O O
primarily O O
in O O
S O O
phase O O
cells O O
coincident O O
with O O
the O O
increase O O
in O O
p107 B-GENE B-GENE
protein E-GENE E-GENE
levels O O
. O O
Both O O
flavoproteins O O
are O O
active O O
as O O
AhpC B-GENE O
reductases E-GENE O
and O O
mediate O O
electron O O
transfer O O
, O O
resulting O O
in O O
the O O
NADH O O
- O O
dependent O O
reduction O O
of O O
hydrogen O O
peroxide O O
and O O
cumene O O
hydroperoxide O O
. O O
Transcriptional O O
regulation O O
of O O
the O O
murine B-GENE B-GENE
k I-GENE I-GENE
- I-GENE I-GENE
fgf I-GENE I-GENE
gene E-GENE E-GENE
. O O
Further O O
, O O
cells O O
cotransfected O O
with O O
a O O
UF B-GENE B-GENE
promoter E-GENE I-GENE
- O I-GENE
luciferase S-GENE E-GENE
( O O
- O O
1935UF S-GENE O
- O O
Luc S-GENE O
) O O
reporter O O
gene O O
and O O
the O O
BTEB S-GENE S-GENE
expression O O
vector O O
had O O
2 O O
- O O
fold O O
higher O O
Luc S-GENE O
activity O O
than O O
those O O
cotransfected O O
with O O
reporter O O
gene O O
and O O
pcDNA O B-GENE
- O I-GENE
3 O E-GENE
. O O
Evasion O O
of O O
host O O
immunity O O
by O O
Toxocara O O
canis O O
infective O O
larvae O O
is O O
mediated O O
by O O
the O O
nematode O O
surface O O
coat O O
, O O
which O O
is O O
shed O O
in O O
response O O
to O O
binding O O
by O O
host O O
antibody O O
molecules O O
or O O
effector O O
cells O O
. O O
A O O
Frank O O
vectorcardiogram O O
was O O
recorded O O
before O O
and O O
every O O
15 O O
- O O
30 O O
minutes O O
for O O
10 O O
hours O O
after O O
the O O
occlusion O O
. O O
In O O
agreement O O
with O O
this O O
, O O
archaea O O
appear O O
to O O
lack O O
eIF5 S-GENE S-GENE
, O O
eIF2B S-GENE S-GENE
and O O
the O O
lysine O O
- O O
rich O O
binding O O
domain O O
for O O
these O O
factors O O
in O O
their O O
eIF2beta B-GENE B-GENE
homolog E-GENE E-GENE
. O O
Derepression O O
of O O
RAR S-GENE S-GENE
signaling O O
by O O
expressing O O
a O O
dominant O O
- O O
negative O O
corepressor O O
resulted O O
in O O
embryos O O
that O O
exhibited O O
phenotypes O O
similar O O
to O O
those O O
treated O O
by O O
RA O O
. O O
Chemiluminescence O O
induced O O
by O O
opsonized O O
zymosan O O
increased O O
significantly O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
after O O
treatment O O
with O O
bacterial O O
extracts O O
, O O
whereas O O
no O O
significant O O
changes O O
were O O
observed O O
in O O
the O O
fMLP O O
- O O
stimulated O O
PMNs O O
. O O
Lastly O O
, O O
several O O
restriction O O
length O O
polymorphisms O O
were O O
identified O O
and O O
mapped O O
within O O
a O O
1 O O
kb O O
region O O
located O O
immediately O O
upstream O O
from O O
the O O
JH B-GENE O
cluster E-GENE O
. O O
Radiographic O O
spatial O O
frequencies O O
essential O O
to O O
the O O
diagnosis O O
of O O
incipient O O
interproximal O O
lesions O O
. O O
Promoter O O
region O O
of O O
the O O
human B-GENE B-GENE
alpha I-GENE I-GENE
2A I-GENE I-GENE
adrenergic I-GENE I-GENE
receptor I-GENE I-GENE
gene E-GENE E-GENE
. O O
( O O
1982 O O
) O O
. O O
( O O
99m O O
) O O
Tc O O
Ethyl O O
Cysteinate O O
Dimer O O
stable O O
during O O
6h O O
has O O
contributed O O
to O O
develop O O
ictal O O
studies O O
to O O
evaluate O O
the O O
location O O
of O O
partial O O
seizure O O
. O O
LiF O O
thermoluminescence O O
dosimeters O O
( O O
TLD O O
) O O
in O O
chip O O
form O O
were O O
placed O O
onto O O
1 O O
eyelid O O
, O O
the O O
skin O O
over O O
the O O
thyroid O O
, O O
and O O
the O O
patient O O
' O O
s O O
clothes O O
covering O O
the O O
region O O
of O O
breasts O O
and O O
ovaries O O
of O O
female O O
patients O O
and O O
the O O
testicles O O
of O O
male O O
patients O O
. O O
Thus O O
, O O
the O O
in O O
vivo O O
function O O
of O O
Gle2p S-GENE S-GENE
is O O
strictly O O
coupled O O
to O O
the O O
short O O
GLEBS S-GENE S-GENE
within O O
Nup116p S-GENE S-GENE
which O O
links O O
this O O
putative O O
mRNA O O
transport O O
factor O O
to O O
the O O
nuclear O O
pores O O
. O O
DNMT2 S-GENE S-GENE
binds O O
AdoHcy O O
in O O
the O O
same O O
conformation O O
as O O
confirmed O O
m B-GENE O
( I-GENE O
5 I-GENE O
) I-GENE O
C I-GENE O
MTases E-GENE O
and O O
, O O
while O O
DNMT2 S-GENE O
shares O O
all O O
sequence O O
and O O
structural O O
features O O
with O O
m B-GENE O
( I-GENE O
5 I-GENE O
) I-GENE O
C I-GENE O
MTases E-GENE O
, O O
it O O
has O O
failed O O
to O O
demonstrate O O
detectable O O
transmethylase O O
activity O O
. O O
The O O
structure O O
of O O
the O O
murine B-GENE B-GENE
Dtk I-GENE I-GENE
gene E-GENE E-GENE
has O O
been O O
determined O O
. O O
In O O
previous O O
studies O O
, O O
we O O
showed O O
that O O
the O O
nuclear O O
import O O
of O O
SREBP B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
occurs O O
via O O
the O O
direct O O
interaction O O
of O O
importin B-GENE B-GENE
beta E-GENE E-GENE
with O O
the O O
HLH O B-GENE
- O I-GENE
Zip O I-GENE
domain O E-GENE
. O O
In O O
the O O
normal O O
controls O O
the O O
plasma B-GENE O
FPA E-GENE O
level O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
was O O
1 O O
. O O
43 O O
+ O O
/ O O
- O O
0 O O
. O O
46 O O
ng O O
/ O O
ml O O
. O O
In O O
this O O
study O O
we O O
cloned O O
the O O
cDNA O O
of O O
AD1 B-GENE O
Ag E-GENE O
from O O
a O O
rat O O
basophilic O O
leukemia O O
2H3 O O
cDNA O O
library O O
. O O
Ten O O
patients O O
( O O
aged O O
28 O O
- O O
76 O O
years O O
) O O
with O O
a O O
terminal O O
jejunostomy O O
located O O
within O O
the O O
first O O
meter O O
of O O
jejunum O O
were O O
treated O O
by O O
infusion O O
of O O
an O O
elemental O O
diet O O
into O O
the O O
distal O O
small O O
bowel O O
( O O
IEDDSB O O
) O O
. O O
The O O
procedure O O
was O O
technically O O
successful O O
in O O
12 O O
of O O
14 O O
( O O
86 O O
% O O
) O O
stenoses O O
in O O
the O O
fibromuscular O O
dysplasia O O
subgroup O O
but O O
in O O
only O O
one O O
of O O
five O O
( O O
20 O O
% O O
) O O
lesions O O
in O O
the O O
neurofibromatosis O O
subgroup O O
. O O
Conventional O O
and O O
digital O O
radiography O O
of O O
the O O
heart O O
, O O
aorta O O
, O O
and O O
pulmonary O O
vascularity O O
. O O
Regulation O O
of O O
the O O
p21 B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PAK S-GENE S-GENE
) O O
by O O
a O O
human B-GENE O
Gbeta I-GENE O
- I-GENE O
like E-GENE O
WD O B-GENE
- O I-GENE
repeat O I-GENE
protein O E-GENE
, O O
hPIP1 S-GENE S-GENE
. O O
Other O O
clinicopathological O O
features O O
have O O
no O O
definite O O
influence O O
in O O
survival O O
expectancy O O
. O O
These O O
studies O O
suggest O O
that O O
tandem O O
alpha O O
- O O
helices O O
located O O
near O O
the O O
C O O
- O O
terminus O O
of O O
PC B-GENE O
- I-GENE O
TP E-GENE O
facilitate O O
membrane O O
binding O O
and O O
extraction O O
of O O
phosphatidylcholines O O
. O O
The O O
striking O O
similarity O O
in O O
preference O O
for O O
mismatched O O
and O O
weakly O O
paired O O
nucleotides O O
for O O
binding O O
and O O
for O O
excision O O
suggests O O
a O O
functional O O
relationship O O
between O O
binding O O
and O O
cleavage O O
reactions O O
. O O
Interestingly O O
, O O
these O O
" O O
activation O O
- O O
defective O O
" O O
mutants O O
segregated O O
into O O
two O O
classes O O
: O O
1 O O
) O O
those O O
that O O
were O O
unable O O
to O O
form O O
dimers O O
but O O
that O O
could O O
still O O
form O O
higher O O
order O O
oligomers O O
and O O
transform O O
cells O O
, O O
and O O
2 O O
) O O
those O O
that O O
were O O
defective O O
for O O
PDGF B-GENE O
- I-GENE O
R E-GENE O
binding O O
and O O
were O O
transformation O O
- O O
incompetent O O
. O O
APL O O
patients O O
showed O O
a O O
low O O
, O O
yet O O
variable O O
, O O
level O O
of O O
JEM B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
mRNA E-GENE E-GENE
in O O
bone O O
marrow O O
. O O
CONCLUSIONS O O
: O O
The O O
results O O
show O O
that O O
intranasal O O
challenge O O
with O O
FLU O O
induces O O
changes O O
in O O
leukocyte O O
histamine O O
release O O
, O O
but O O
not O O
other O O
systemic O O
immune O O
and O O
inflammatory O O
responses O O
. O O
We O O
have O O
shown O O
previously O O
that O O
EGF B-GENE B-GENE
receptor E-GENE E-GENE
activation O O
stimulates O O
gastrin S-GENE B-GENE
gene O E-GENE
expression O O
through O O
a O O
GC O O
- O O
rich O O
element O O
called O O
gERE O S-GENE
. O O
We O O
have O O
earlier O O
proposed O O
that O O
CG O O
rich O O
sequences O O
resembling O O
CpG O O
islands O O
, O O
which O O
are O O
associated O O
with O O
many O O
imprinted O O
genes O O
and O O
often O O
subject O O
to O O
parental O O
- O O
specific O O
methylation O O
, O O
could O O
act O O
as O O
a O O
common O O
imprinting O O
element O O
. O O
The O O
secondary O O
end O O
points O O
included O O
creatine B-GENE O
kinase E-GENE O
peak O O
, O O
ventricular O O
fibrillation O O
/ O O
tachycardia O O
within O O
the O O
first O O
24 O O
hours O O
, O O
death O O
and O O
congestive O O
heart O O
failure O O
within O O
the O O
30 O O
- O O
day O O
follow O O
- O O
up O O
, O O
and O O
30 O O
- O O
day O O
left O O
ventricular O O
ejection O O
fraction O O
. O O
Prevention O O
of O O
gravid O O
Rhesus O O
isoimmunization O O
All O O
relapses O O
occurred O O
within O O
the O O
first O O
year O O
and O O
were O O
confined O O
to O O
patients O O
with O O
PS O O
II O O
disease O O
and O O
four O O
or O O
more O O
sites O O
of O O
involvement O O
. O O
This O O
demonstrates O O
the O O
presence O O
of O O
a O O
PKC S-GENE S-GENE
- O O
dependent O O
pathway O O
which O O
functions O O
independently O O
from O O
Lck S-GENE S-GENE
in O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
activation O O
. O O
This O O
interesting O O
exon O O
junction O O
resulted O O
in O O
novel O O
deduced O O
amino O O
terminal O O
open O O
reading O O
frames O O
, O O
which O O
are O O
completely O O
in O O
- O O
frame O O
with O O
sequences O O
located O O
further O O
downstream O O
. O O
Cell O O
lines O O
expressing O O
single O O
amino O O
acid O O
substitutions O O
of O O
the O O
carboxyl O O
- O O
terminal O O
asparagine O O
of O O
CD2 S-GENE O
are O O
incapable O O
of O O
avidity O O
regulation O O
by O O
TCR S-GENE S-GENE
signaling O O
, O O
PMA O O
treatment O O
, O O
or O O
elevation O O
of O O
intracellular O O
cAMP O O
levels O O
, O O
demonstrating O O
that O O
each O O
of O O
these O O
stimuli O O
utilizes O O
a O O
common O O
structural O O
element O O
for O O
regulating O O
CD2 S-GENE O
avidity O O
. O O
12 O O
per O O
cent O O
was O O
observed O O
with O O
the O O
use O O
of O O
tetracycline O O
and O O
4 O O
- O O
epianhydrotetracycline O O
in O O
doses O O
of O O
1000 O O
and O O
100gamma O O
per O O
embryo O O
respectively O O
. O O
Present O O
investigation O O
was O O
undertaken O O
to O O
elucidate O O
what O O
pharmacokinetic O O
parameters O O
in O O
animal O O
experiment O O
could O O
be O O
of O O
more O O
predictable O O
for O O
human O O
clinical O O
trial O O
of O O
beta O O
- O O
blocking O O
agents O O
. O O
The O O
atpA S-GENE O
reading O O
frame O O
ends O O
with O O
four O O
tandem O O
UGA O O
codons O O
which O O
overlap O O
four O O
tandem O O
AUG O O
codons O O
initiating O O
an O O
unidentified O O
reading O O
frame O O
, O O
orf214 O O
. O O
When O O
transfected O O
into O O
HepG2 O O
cells O O
, O O
which O O
lack O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
alpha E-GENE E-GENE
, O O
the O O
mouse B-GENE B-GENE
ob I-GENE I-GENE
promoter E-GENE E-GENE
was O O
only O O
weakly O O
active O O
. O O
Vasodilator O O
and O O
hypotensive O O
effects O O
of O O
the O O
optical O O
isomers O O
of O O
nicardipine O O
( O O
YC O O
- O O
93 O O
) O O
, O O
a O O
new O O
Ca2 O O
+ O O
- O O
antagonist O O
. O O
Between O O
1988 O O
and O O
1995 O O
, O O
341 O O
children O O
with O O
acute O O
myeloid O O
leukaemia O O
( O O
AML O O
) O O
were O O
treated O O
on O O
the O O
Medical O O
Research O O
Council O O
Acute O O
Myeloid O O
Leukaemia O O
Trial O O
( O O
MRC O O
AML10 O O
) O O
. O O
A O O
heterologous O O
promoter O O
construct O O
containing O O
three O O
repeats O O
of O O
a O O
consensus O O
Sp1 B-GENE B-GENE
site E-GENE E-GENE
, O O
cloned O O
upstream O O
of O O
a O O
single O O
copy O O
of O O
the O O
ZII S-GENE S-GENE
( O O
CREB S-GENE S-GENE
/ O O
AP1 S-GENE S-GENE
) O O
element O O
from O O
the O O
BZLF1 B-GENE B-GENE
promoter E-GENE E-GENE
linked O O
to O O
the O O
beta B-GENE B-GENE
- I-GENE I-GENE
globin E-GENE I-GENE
TATA O I-GENE
box O E-GENE
, O O
exhibited O O
phorbol O O
ester O O
inducibility O O
. O O
Nicotinic B-GENE O
receptor E-GENE O
antagonists O O
mecamylamine O O
( O O
0 O O
. O O
5 O O
and O O
1 O O
mg O O
/ O O
kg O O
) O O
and O O
hexamethonium O O
( O O
5 O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
reduced O O
the O O
response O O
induced O O
by O O
nicotine O O
( O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
. O O
Appl O O
. O O
Thus O O
, O O
the O O
predicted O O
M3 O B-GENE
ORF O E-GENE
is O O
a O O
functional O O
gene O O
that O O
encodes O O
an O O
abundant O O
secreted O O
protein O O
which O O
is O O
a O O
candidate O O
for O O
interacting O O
with O O
host O O
cellular O O
receptors O O
or O O
cytokines O O
. O O
Protein O O
metabolism O O
disorders O O
in O O
burns O O
The O O
cumulative O O
dose O O
to O O
nursing O O
staff O O
for O O
the O O
week O O
after O O
treatment O O
was O O
dependent O O
on O O
patient O O
mobility O O
and O O
was O O
estimated O O
at O O
0 O O
. O O
08 O O
mSv O O
for O O
a O O
self O O
- O O
caring O O
patient O O
to O O
6 O O
. O O
3 O O
mSv O O
for O O
a O O
totally O O
helpless O O
patient O O
( O O
1840 O O
MBq O O
/ O O
group O O
A O O
) O O
. O O
JCAHO O O
to O O
use O O
ORYX O O
data O O
to O O
detect O O
sentinel O O
events O O
. O O
We O O
also O O
show O O
that O O
psbH S-GENE S-GENE
and O O
psbT S-GENE S-GENE
are O O
transcribed O O
from O O
the O O
upstream O O
psbB B-GENE B-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
, O O
and O O
that O O
the O O
psbH B-GENE B-GENE
mRNA E-GENE E-GENE
has O O
its O O
own O O
target O O
sequence O O
for O O
Mbb1 S-GENE S-GENE
function O O
. O O
To O O
test O O
whether O O
Cd O O
exposure O O
would O O
increase O O
Ca O O
release O O
from O O
bone O O
during O O
pregnancy O O
and O O
lactation O O
in O O
relation O O
to O O
the O O
etiological O O
mechanism O O
of O O
Itai O O
- O O
Itai O O
disease O O
, O O
virgin O O
female O O
mice O O
with O O
45Ca O O
prelabeled O O
skeletons O O
( O O
15 O O
microCi O O
/ O O
mouse O O
) O O
were O O
subjected O O
to O O
one O O
round O O
of O O
pregnancy O O
/ O O
lactation O O
and O O
were O O
exposed O O
to O O
a O O
Ca O O
- O O
deficient O O
diet O O
containing O O
0 O O
, O O
5 O O
, O O
or O O
25 O O
ppm O O
Cd O O
or O O
25 O O
ppm O O
Pb O O
for O O
32 O O
days O O
, O O
from O O
conception O O
until O O
Lactation O O
Day O O
14 O O
. O O
O5257 S-GENE S-GENE
shows O O
homology O O
with O O
the O O
SAS2 B-GENE B-GENE
protein E-GENE E-GENE
and O O
another O O
hypothetical O O
protein O O
from O O
yeast O O
. O O
Principles O O
of O O
thyroid O O
hormone O O
treatment O O
Significance O O
of O O
esophagocardiac O O
reflexes O O
for O O
inducing O O
thoracic O O
pain O O
The O O
fate O O
of O O
ochratoxin O O
A O O
during O O
malting O O
and O O
brewing O O
. O O
METHODS O O
: O O
Precision O O
and O O
accuracy O O
were O O
measured O O
using O O
controls O O
and O O
method O O
comparison O O
studies O O
. O O
Messenger O O
RNA O O
for O O
the O O
Ad2 B-GENE B-GENE
DNA I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
: O O
DNA O O
sequences O O
encoding O O
the O O
first O O
leader O O
and O O
heterogenity O O
at O O
the O O
mRNA O O
5 O O
' O O
end O O
. O O
Consistent O O
with O O
this O O
hypothesis O O
, O O
stimulation O O
of O O
A B-GENE O
( I-GENE O
2A I-GENE O
) I-GENE O
- I-GENE O
R E-GENE O
or O O
PKA S-GENE O
enhanced O O
nuclear B-GENE O
aPKC E-GENE S-GENE
activity O O
. O O
Atrial O O
dissociation O O
. O O
The O O
gene O O
sequence O O
predicts O O
a O O
150 O O
, O O
825 O O
mol O O
wt O O
apoprotein O O
of O O
1363 O O
amino O O
acids O O
having O O
an O O
N O O
- O O
terminal O O
hydrophobic O O
signal O O
sequence O O
of O O
17 O O
amino O O
acids O O
, O O
19 O O
potential O O
N O O
- O O
linked O O
glycosylation O O
sites O O
, O O
a O O
hydrophobic O O
anchor O O
sequence O O
of O O
approximately O O
17 O O
amino O O
acids O O
near O O
the O O
C O O
terminus O O
, O O
and O O
a O O
hydrophilic O O
cysteine O O
- O O
rich O O
C O O
terminus O O
of O O
35 O O
amino O O
acids O O
. O O
However O O
, O O
depending O O
upon O O
the O O
promoter O O
context O O
, O O
we O O
observed O O
cooperative O O
interactions O O
between O O
the O O
two O O
domains O O
to O O
confer O O
high O O
DNA O O
- O O
binding O O
affinity O O
and O O
specificity O O
. O O
As O O
a O O
result O O
, O O
relative O O
biological O O
effects O O
( O O
RBE O O
) O O
of O O
2 O O
. O O
3 O O
- O O
2 O O
. O O
7 O O
was O O
obtained O O
from O O
the O O
straight O O
line O O
that O O
was O O
given O O
by O O
modifying O O
by O O
the O O
method O O
of O O
least O O
squares O O
the O O
curves O O
of O O
the O O
frequency O O
of O O
anomalous O O
fetuses O O
in O O
total O O
implants O O
and O O
survived O O
embryos O O
irradiated O O
from O O
20 O O
to O O
120 O O
rad O O
by O O
Cf O O
- O O
252 O O
and O O
from O O
80 O O
to O O
220 O O
rad O O
by O O
Co O O
- O O
60 O O
on O O
day O O
8 O O
of O O
pregnancy O O
. O O
Samples O O
( O O
1 O O
g O O
) O O
were O O
extracted O O
with O O
0 O O
. O O
5 O O
% O O
potassium O O
chloride O O
( O O
KCl O O
) O O
in O O
70 O O
% O O
methanol O O
( O O
5 O O
ml O O
) O O
and O O
diluted O O
subsequently O O
to O O
give O O
two O O
- O O
fold O O
to O O
ten O O
- O O
fold O O
step O O
- O O
wise O O
dilutions O O
in O O
phosphate O O
- O O
buffered O O
saline O O
containing O O
0 O O
. O O
05 O O
% O O
Tween O O
20 O O
and O O
0 O O
. O O
2 O O
% O O
bovine B-GENE O
serum I-GENE O
albumin E-GENE O
( O O
PBS O O
- O O
T O O
BSA S-GENE O
) O O
. O O
To O O
our O O
knowledge O O
108 O O
cases O O
of O O
EAT O O
treated O O
by O O
catheter O O
ablation O O
of O O
the O O
ectopic O O
focus O O
are O O
reported O O
in O O
the O O
literature O O
with O O
a O O
success O O
rate O O
superior O O
to O O
90 O O
% O O
. O O
Following O O
immunization O O
of O O
transgenic O O
mice O O
, O O
hybrid O O
molecules O O
were O O
isolated O O
from O O
B O O
cell O O
DNA O O
which O O
contained O O
the O O
transgene O O
recombined O O
with O O
the O O
endogenous B-GENE O
IgH I-GENE B-GENE
locus E-GENE E-GENE
. O O
It O O
produced O O
extrapyramidal O O
disturbances O O
in O O
nearly O O
every O O
subject O O
, O O
the O O
most O O
common O O
being O O
akathisia O O
and O O
the O O
most O O
severe O O
, O O
in O O
the O O
case O O
of O O
one O O
individual O O
, O O
being O O
acute O O
dystonia O O
. O O
Northern O O
blot O O
analysis O O
indicated O O
that O O
both O O
human O O
and O O
murine O O
genes O O
encode O O
approximately O O
6 O O
- O O
kb O O
transcripts O O
. O O
Transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
beta E-GENE E-GENE
activates O O
the O O
promoter O O
of O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase E-GENE E-GENE
inhibitor O O
p15INK4B S-GENE S-GENE
through O O
an O O
Sp1 B-GENE S-GENE
consensus I-GENE O
site E-GENE O
. O O
Cox O O
proportional O O
hazard O O
analysis O O
identified O O
dialysis O O
modality O O
and O O
pre O O
- O O
dialysis O O
UV O O
of O O
less O O
than O O
1 O O
, O O
000 O O
ml O O
/ O O
m2 O O
per O O
24 O O
h O O
as O O
the O O
only O O
significant O O
risk O O
factors O O
for O O
UV O O
survival O O
. O O
The O O
hyperpigmentation O O
is O O
linked O O
to O O
the O O
presence O O
of O O
numerous O O
single O O
melanosomes O O
and O O
polymelanosomes O O
in O O
keratinocytes O O
at O O
all O O
levels O O
of O O
the O O
epidermis O O
, O O
and O O
in O O
dermal O O
Factor B-GENE O
XIIIa E-GENE O
- O O
positive O O
dendrocytes O O
. O O
Possible O O
or O O
definite O O
neglect O O
or O O
abuse O O
before O O
36 O O
months O O
of O O
age O O
was O O
correlated O O
with O O
low O O
DBH S-GENE O
activity O O
. O O
Previously O O
, O O
we O O
identified O O
two O O
human B-GENE B-GENE
SMC I-GENE I-GENE
family I-GENE I-GENE
proteins E-GENE E-GENE
, O O
hCAP B-GENE B-GENE
- I-GENE I-GENE
C E-GENE E-GENE
and O O
hCAP B-GENE B-GENE
- I-GENE I-GENE
E E-GENE E-GENE
, O O
which O O
form O O
a O O
heterodimeric O O
complex O O
( O O
hCAP B-GENE O
- I-GENE O
C E-GENE O
- O O
hCAP B-GENE O
- I-GENE O
E E-GENE O
) O O
in O O
the O O
cell O O
. O O
The O O
mouse B-GENE B-GENE
alpha I-GENE I-GENE
A I-GENE I-GENE
- I-GENE I-GENE
CRYBP1 I-GENE I-GENE
gene E-GENE E-GENE
specifies O O
a O O
2 O O
, O O
688 O O
- O O
amino O O
acid O O
protein O O
with O O
72 O O
% O O
amino O O
acid O O
identity O O
to O O
its O O
human O O
homologue O O
, O O
PRDII B-GENE B-GENE
- I-GENE I-GENE
BF1 E-GENE E-GENE
. O O
Methylation O O
interference O O
analysis O O
established O O
at O O
single O O
nucleotide O O
resolution O O
that O O
purified O O
recombinant O O
Fos S-GENE S-GENE
and O O
Jun B-GENE B-GENE
proteins E-GENE E-GENE
bind O O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
to O O
the O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
sites E-GENE E-GENE
within O O
the O O
VDRE O S-GENE
and O O
OC B-GENE O
box E-GENE O
. O O
These O O
include O O
urinalysis O O
, O O
chest O O
X O O
- O O
P O O
, O O
ECG O O
, O O
hematological O O
examinations O O
( O O
RBC O O
, O O
WBC O O
, O O
Ht O O
, O O
Hb S-GENE O
, O O
PLT O O
and O O
ESR O O
) O O
and O O
biochemical O O
tests O O
( O O
AST S-GENE O
, O O
ALT S-GENE O
, O O
ALP S-GENE O
, O O
gamma B-GENE O
GTP E-GENE O
, O O
LDH S-GENE O
, O O
CPK S-GENE O
, O O
Chol O O
, O O
T O O
- O O
Bil O O
, O O
TP O O
, O O
Alb S-GENE O
, O O
TG O O
, O O
BUN O O
, O O
Cr O O
, O O
Glu O O
, O O
Na O O
, O O
K O O
, O O
Ca O O
, O O
P O O
and O O
CRP S-GENE O
) O O
. O O
Both O O
the O O
inactive O O
domain B-GENE O
II I-GENE B-GENE
P68 I-GENE I-GENE
mutant E-GENE E-GENE
and O O
the O O
deletion O O
mutant O O
lacking O O
aa O O
91 O O
- O O
243 O O
were O O
less O O
inhibitory O O
to O O
growth O O
in O O
yeast O O
due O O
to O O
the O O
reduced O O
ability O O
to O O
phosphorylate O B-GENE
initiation B-GENE I-GENE
factor I-GENE I-GENE
2 I-GENE I-GENE
alpha E-GENE E-GENE
in O O
vivo O O
. O O
All O O
patients O O
studied O O
were O O
pregnant O O
women O O
and O O
their O O
delivered O O
children O O
. O O
Current O O
body O O
size O O
( O O
wt O O
/ O O
ht2 O O
) O O
was O O
significantly O O
associated O O
with O O
life O O
- O O
time O O
weight O O
dissatisfaction O O
in O O
both O O
sexes O O
( O O
P O O
less O O
than O O
0 O O
. O O
0005 O O
) O O
. O O
Mad3 S-GENE S-GENE
and O O
Mad4 S-GENE S-GENE
: O O
novel O O
Max S-GENE O
- O O
interacting O O
transcriptional O O
repressors O O
that O O
suppress O O
c B-GENE B-GENE
- I-GENE I-GENE
myc E-GENE E-GENE
dependent O O
transformation O O
and O O
are O O
expressed O O
during O O
neural O O
and O O
epidermal O O
differentiation O O
. O O
CONCLUSIONS O O
: O O
Patients O O
' O O
attainment O O
of O O
TGB O O
monotherapy O O
was O O
associated O O
with O O
their O O
achievement O O
of O O
positive O O
changes O O
of O O
varying O O
degree O O
on O O
psychological O O
tests O O
. O O
The O O
pcaR B-GENE O
regulatory I-GENE O
locus E-GENE O
has O O
been O O
found O O
to O O
be O O
required O O
for O O
both O O
induction O O
of O O
all O O
of O O
the O O
genes O O
within O O
the O O
pca B-GENE B-GENE
regulon E-GENE E-GENE
( O O
pcaBDC S-GENE S-GENE
, O O
pcaIJ S-GENE S-GENE
, O O
and O O
pcaF S-GENE S-GENE
) O O
and O O
the O O
chemotactic O O
response O O
of O O
the O O
bacteria O O
to O O
aromatic O O
compounds O O
. O O
Furthermore O O
, O O
we O O
have O O
identified O O
the O O
major O O
open O O
reading O O
frame O O
( O O
RF4 O O
; O O
2 O O
. O O
3 O O
kb O O
) O O
as O O
being O O
essential O O
for O O
activation O O
, O O
and O O
we O O
have O O
shown O O
that O O
the O O
NF B-GENE B-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
, O O
SP1 S-GENE S-GENE
, O O
and O O
TATA O O
box O O
motifs O O
in O O
the O O
human B-GENE O
immunodeficiency I-GENE O
virus I-GENE O
LTR E-GENE O
are O O
all O O
required O O
for O O
full O O
induction O O
of O O
the O O
promoter O O
by O O
the O O
HHV B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
- I-GENE I-GENE
encoded I-GENE I-GENE
transactivator E-GENE E-GENE
. O O
However O O
, O O
mutations O O
of O O
the O O
C O O
- O O
rich O O
element O O
that O O
disrupted O O
a O O
GC O O
box O O
located O O
on O O
the O O
inverse O O
strand O O
eliminated O O
PMA O O
responsiveness O O
and O O
, O O
in O O
gel O O
mobility O O
shift O O
assays O O
, O O
eliminated O O
binding O O
of O O
Sp1 S-GENE S-GENE
. O O
TFIIB S-GENE S-GENE
and O O
VDR S-GENE S-GENE
can O O
also O O
interact O O
directly O O
, O O
and O O
these O O
factors O O
synergize O O
to O O
mediate O O
transactivation O O
. O O
Both O O
algorithms O O
have O O
been O O
implemented O O
and O O
applied O O
to O O
data O O
simulated O O
for O O
a O O
scanner O O
with O O
a O O
large O O
axial O O
aperture O O
( O O
30 O O
degrees O O
) O O
, O O
and O O
also O O
to O O
data O O
acquired O O
with O O
the O O
ECAT O O
HR O O
and O O
the O O
ECAT O O
HR O O
+ O O
scanners O O
. O O
The O O
well O O
- O O
trained O O
group O O
was O O
measured O O
once O O
in O O
the O O
respiration O O
chamber O O
for O O
36 O O
h O O
according O O
to O O
the O O
same O O
protocol O O
. O O
Samarium O O
- O O
153 O O
for O O
intravascular O O
irradiation O O
therapy O O
with O O
liquid O O
- O O
filled O O
balloons O O
to O O
prevent O O
restenosis O O
: O O
acute O O
and O O
long O O
- O O
term O O
results O O
in O O
a O O
hypercholesterolemic O O
rabbit O O
restenosis O O
model O O
. O O
Only O O
viable O O
bacteria O O
at O O
a O O
high O O
concentration O O
induced O O
purulent O O
otitis O O
media O O
, O O
which O O
was O O
culture O O
positive O O
in O O
58 O O
% O O
of O O
the O O
cases O O
on O O
day O O
4 O O
. O O
Polyoma O O
virus O O
in O O
urine O O
during O O
pregnancy O O
. O O
Transfer O O
of O O
F O O
- O O
like O O
plasmids O O
is O O
regulated O O
by O O
the O O
FinOP S-GENE O
system O O
, O O
which O O
controls O O
the O O
expression O O
of O O
traJ S-GENE S-GENE
, O O
a O O
positive O O
regulator O O
of O O
the O O
transfer O O
operon O O
. O O
PKCI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
a O O
member O O
of O O
the O O
HIT B-GENE O
family E-GENE O
of O O
proteins O O
, O O
shown O O
by O O
sequence O O
identity O O
to O O
be O O
conserved O O
in O O
a O O
broad O O
range O O
of O O
organisms O O
including O O
mycoplasma O O
, O O
plants O O
, O O
and O O
humans O O
. O O
Conversion O O
of O O
glucose O O
phosphate O O
- O O
14C O O
to O O
glucose O O
- O O
14C O O
in O O
passage O O
through O O
human O O
brain O O
in O O
vivo O O
. O O
A O O
simple O O
technique O O
for O O
obtaining O O
ultra O O
- O O
thin O O
sections O O
of O O
coccidian O O
oocysts O O
is O O
reported O O
. O O
It O O
was O O
found O O
that O O
on O O
the O O
14th O O
and O O
21st O O
day O O
after O O
cimetidine O O
administration O O
serum B-GENE B-GENE
gastrin E-GENE E-GENE
levels O O
were O O
significantly O O
elevated O O
. O O
Dual O O
signal O O
peptides O O
mediate O O
the O O
signal B-GENE O
recognition I-GENE O
particle E-GENE O
/ O O
Sec S-GENE O
- O O
independent O O
insertion O O
of O O
a O O
thylakoid O O
membrane O O
polyprotein O O
, O O
PsbY S-GENE S-GENE
. O O
The O O
resulting O O
score O O
, O O
which O O
allowed O O
the O O
disease O O
to O O
be O O
expressed O O
as O O
a O O
continuous O O
variable O O
, O O
was O O
effectively O O
utilized O O
to O O
see O O
the O O
correlations O O
between O O
the O O
severity O O
of O O
coronary O O
arterial O O
disease O O
( O O
CAD O O
) O O
and O O
individual O O
risk O O
factors O O
/ O O
risk O O
markers O O
. O O
On O O
guanidine O O
and O O
the O O
treatment O O
of O O
botulism O O
. O O
Electronic O O
structure O O
of O O
Si O O
( O O
111 O O
) O O
- O O
NiSi2 O O
( O O
111 O O
) O O
A O O
- O O
type O O
and O O
B O O
- O O
type O O
interfaces O O
. O O
In O O
our O O
case O O
the O O
development O O
of O O
the O O
tumor O O
at O O
the O O
posterior O O
side O O
of O O
the O O
prostate O O
, O O
the O O
lack O O
of O O
PSA S-GENE O
immunoreactivity O O
and O O
the O O
presence O O
of O O
mucinous O O
glands O O
, O O
sometimes O O
" O O
endocervical O O
- O O
like O O
" O O
, O O
could O O
suggest O O
an O O
origin O O
from O O
embryonic O O
mullerian O O
remnants O O
in O O
the O O
prostatic O O
utricle O O
rather O O
than O O
urogenital O O
sinus O O
. O O
Upon O O
increasing O O
the O O
Marangoni O O
number O O
beyond O O
this O O
threshold O O
, O O
the O O
initially O O
stationary O O
flow O O
becomes O O
quickly O O
time O O
dependent O O
. O O
The O O
results O O
showed O O
differential O O
activation O O
of O O
each O O
parahippocampal O O
region O O
during O O
verbal O O
memory O O
tasks O O
in O O
which O O
the O O
side O O
activated O O
shifted O O
depending O O
on O O
the O O
nature O O
of O O
the O O
task O O
employed O O
; O O
an O O
increase O O
in O O
rCBF O O
in O O
the O O
left O O
parahippocampal O O
gyrus O O
was O O
associated O O
with O O
retrieval O O
strategy O O
of O O
non O O
- O O
matching O O
, O O
and O O
an O O
increase O O
in O O
rCBF O O
in O O
the O O
right O O
parahippocampal O O
gyrus O O
was O O
associated O O
with O O
retrieval O O
strategy O O
of O O
matching O O
. O O
Evolution O O
of O O
cytomegalovirus O O
antibodies O O
of O O
maternal O O
origin O O
and O O
acquired O O
, O O
throughout O O
the O O
first O O
year O O
of O O
life O O
Demonstration O O
of O O
changes O O
in O O
fetal O O
liver O O
erythropoiesis O O
using O O
echo O O
- O O
planar O O
magnetic O O
resonance O O
imaging O O
. O O
The O O
actual O O
placement O O
of O O
the O O
lesions O O
was O O
determined O O
after O O
mapping O O
of O O
the O O
GPi O O
by O O
microrecording O O
, O O
using O O
stimulation O O
to O O
identify O O
the O O
sensorimotor O O
region O O
and O O
its O O
somatotopic O O
organization O O
. O O
Effect O O
of O O
prostaglandin O O
E2 O O
on O O
experimental O O
atherosclerosis O O
. O O
Both O O
the O O
arterial O O
and O O
venous O O
thrombi O O
were O O
clearly O O
discernible O O
at O O
2 O O
to O O
8 O O
h O O
after O O
injection O O
of O O
99Tcm O O
- O O
SZ O O
- O O
51 O O
. O O
The O O
effect O O
of O O
lung O O
edema O O
on O O
pulmonary O O
vasoactivity O O
of O O
furosemide O O
. O O
However O O
, O O
the O O
malaria O O
vectors O O
Anopheles O O
funestus O O
and O O
An O O
. O O
gambiae O O
have O O
both O O
become O O
more O O
abundant O O
during O O
the O O
1970s O O
and O O
1980s O O
and O O
sporozoite O O
- O O
positive O O
specimens O O
of O O
both O O
have O O
been O O
found O O
. O O
Soluble O O
extracts O O
from O O
FGF S-GENE O
- O O
treated O O
as O O
compared O O
with O O
quiescent O O
fibroblasts O O
exhibited O O
up O O
to O O
3 O O
- O O
fold O O
higher O O
kinase O O
activity O O
towards O O
S6 S-GENE S-GENE
in O O
exogenously O O
added O O
rat B-GENE O
liver I-GENE O
40S I-GENE O
ribosomes E-GENE O
and O O
a O O
synthetic O O
peptide O O
, O O
RRLSSLRA O S-GENE
. O O
In O O
bell O O
pepper O O
, O O
a O O
gene O O
encoding O O
a O O
major O O
plastid O O
- O O
lipid O O
associated O O
protein O O
is O O
expressed O O
as O O
both O O
partially O O
and O O
totally O O
spliced O O
transcripts O O
( O O
respectively O O
PAP2 S-GENE S-GENE
and O O
PAP1 S-GENE S-GENE
) O O
. O O
Inhibitory O O
receptors O O
are O O
characterized O O
by O O
the O O
presence O O
of O O
a O O
characteristic O O
sequence O O
known O O
as O O
an O O
immunoreceptor O O
tyrosine O O
- O O
based O O
inhibitory O O
motif O O
( O O
ITIM O S-GENE
) O O
in O O
their O O
cytoplasmic O O
tail O O
. O O
We O O
conclude O O
that O O
LGCS O S-GENE
is O O
successful O O
in O O
treating O O
esophageal O O
varices O O
in O O
the O O
setting O O
of O O
hyperdynamic O O
portal O O
circulation O O
with O O
acceptable O O
liver O O
function O O
. O O
Candidate O O
factors O O
have O O
been O O
identified O O
by O O
the O O
observation O O
that O O
changes O O
in O O
glucocorticoid O O
induction O O
parameters O O
in O O
CV O O
- O O
1 O O
cells O O
could O O
be O O
reproduced O O
by O O
varying O O
the O O
cellular O O
levels O O
of O O
coactivators O B-GENE
[ O I-GENE
transcriptional B-GENE I-GENE
intermediary I-GENE I-GENE
factor I-GENE I-GENE
2 E-GENE E-GENE
( O O
TIF2 S-GENE S-GENE
) O O
, O O
steroid B-GENE B-GENE
receptor I-GENE I-GENE
coactivator I-GENE I-GENE
1 E-GENE E-GENE
( O O
SRC B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
, O O
and O O
amplified B-GENE O
in I-GENE O
breast I-GENE O
cancer I-GENE O
1 E-GENE O
( O O
AIB1 S-GENE O
) O O
] O O
, O O
comodulator O O
[ O O
CREB B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
CBP S-GENE S-GENE
) O O
] O O
, O O
or O O
corepressor O O
[ O O
silencing B-GENE O
mediator I-GENE O
for I-GENE O
retinoid I-GENE O
and I-GENE O
thyroid I-GENE B-GENE
- I-GENE I-GENE
hormone I-GENE I-GENE
receptors E-GENE E-GENE
( O O
SMRT S-GENE S-GENE
) O O
] O O
without O O
concomitant O O
increases O O
in O O
GR S-GENE O
. O O
Immunoblot O O
analyses O O
revealed O O
that O O
the O O
loss O O
of O O
activator O O
function O O
coincides O O
with O O
selective O O
removal O O
of O O
the O O
C B-GENE O
- I-GENE O
terminal I-GENE O
domain I-GENE O
( I-GENE O
CTD I-GENE S-GENE
) I-GENE O
- I-GENE O
hyperphosphorylated I-GENE O
RNAP I-GENE O
IIO E-GENE O
along O O
with O O
NC2 S-GENE O
. O O
The O O
nucleotide O O
sequence O O
of O O
the O O
gene O O
encoding O O
this O O
product O O
was O O
determined O O
and O O
the O O
amino O O
acid O O
sequence O O
deduced O O
. O O
At O O
9 O O
months O O
postpartum O O
, O O
serum O O
fT4 O O
and O O
fT3 O O
levels O O
were O O
low O O
normal O O
( O O
8 O O
. O O
0 O O
and O O
1 O O
. O O
7 O O
pmol O O
/ O O
L O O
, O O
respectively O O
) O O
, O O
but O O
TSH S-GENE O
was O O
not O O
raised O O
( O O
0 O O
. O O
4 O O
mU O O
/ O O
L O O
) O O
. O O
RESULTS O O
: O O
Three O O
patients O O
did O O
not O O
tolerate O O
PPI O O
medication O O
and O O
were O O
managed O O
by O O
treatment O O
with O O
type O O
2 O O
histamine O O
( O O
H2 O O
) O O
blockers O O
. O O
It O O
is O O
considered O O
important O O
, O O
therefore O O
, O O
when O O
treating O O
diabetic O O
patients O O
with O O
peripheral O O
neuropathy O O
not O O
to O O
assume O O
that O O
the O O
diabetes O O
itself O O
is O O
the O O
cause O O
in O O
all O O
cases O O
. O O
TFIIIB S-GENE S-GENE
assembles O O
autonomously O O
on O O
the O O
upstream O O
promoter O O
of O O
the O O
yeast B-GENE B-GENE
U6 I-GENE I-GENE
snRNA E-GENE E-GENE
( O O
SNR6 S-GENE S-GENE
) O O
gene O O
in O O
vitro O O
, O O
through O O
the O O
interaction O O
of O O
its O O
TBP B-GENE B-GENE
subunit E-GENE E-GENE
with O O
a O O
consensus O O
TATA O O
box O O
located O O
at O O
base O O
pair O O
- O O
30 O O
. O O
Mutational O O
analysis O O
of O O
the O O
IME2 B-GENE B-GENE
UAS E-GENE E-GENE
reveals O O
two O O
critical O O
sequence O O
elements O O
: O O
a O O
G O O
+ O O
C O O
- O O
rich O O
sequence O O
( O O
called O O
URS1 O S-GENE
) O O
, O O
previously O O
identified O O
at O O
many O O
meiotic O O
genes O O
, O O
and O O
a O O
newly O O
described O O
element O O
, O O
the O O
T4C O B-GENE
site O E-GENE
, O O
that O O
we O O
found O O
at O O
a O O
subset O O
of O O
meiotic O O
genes O O
. O O
Molecular O O
analysis O O
of O O
the O O
mannitol O O
operon O O
of O O
Clostridium O O
acetobutylicum O O
encoding O O
a O O
phosphotransferase O O
system O O
and O O
a O O
putative O O
PTS O O
- O O
modulated O O
regulator O O
. O O
Our O O
results O O
show O O
that O O
a O O
combination O O
of O O
Pfu B-GENE O
exo I-GENE O
( I-GENE O
- I-GENE O
) E-GENE O
at O O
the O O
primer O O
extension O O
step O O
and O O
Taq S-GENE O
at O O
the O O
PCR O O
amplification O O
step O O
is O O
ideal O O
for O O
in O O
vivo O O
DNA O O
analysis O O
and O O
DNA O O
damage O O
mapping O O
using O O
LMPCR O O
. O O
Effect O O
of O O
TNF S-GENE S-GENE
, O O
IL B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
IL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
on O O
the O O
proliferation O O
of O O
human O O
Tenon O O
' O O
s O O
capsule O O
fibroblasts O O
in O O
tissue O O
culture O O
. O O
Estimating O O
the O O
health O O
care O O
costs O O
of O O
smokers O O
. O O
Using O O
lacZ S-GENE O
- O O
inducible O O
T O O
cells O O
as O O
a O O
probe O O
, O O
we O O
screened O O
a O O
splenic O O
cDNA O O
library O O
in O O
transiently O O
transfected O O
antigen O O
- O O
presenting O O
cells O O
( O O
APCs O O
) O O
and O O
isolated O O
a O O
cDNA O O
clone O O
that O O
allowed O O
expression O O
of O O
the O O
appropriate O O
peptide B-GENE O
/ I-GENE O
Kb I-GENE B-GENE
MHC I-GENE E-GENE
complex E-GENE O
in O O
APC O S-GENE
. O O
Endotoxemia O O
and O O
bacteremia O O
in O O
patients O O
with O O
sepsis O O
syndrome O O
in O O
the O O
intensive O O
care O O
unit O O
. O O
Early O O
attempts O O
for O O
modifying O O
growth O O
functions O O
to O O
annual O O
variations O O
dating O O
back O O
up O O
to O O
2 O O
decades O O
are O O
recalled O O
together O O
with O O
examples O O
for O O
their O O
application O O
showing O O
rather O O
different O O
degrees O O
of O O
approximation O O
. O O
A O O
significant O O
reduction O O
in O O
total O O
cellular O O
p27 B-GENE B-GENE
protein E-GENE E-GENE
levels O O
and O O
a O O
moderate O O
reduction O O
in O O
p27 B-GENE B-GENE
mRNA E-GENE E-GENE
are O O
observed O O
, O O
but O O
no O O
changes O O
in O O
Cdk S-GENE B-GENE
regulatory O I-GENE
kinases O E-GENE
and O O
phosphatases O O
occur O O
. O O
Genetic O O
linkage O O
mapping O O
of O O
the O O
CYP11A1 B-GENE B-GENE
gene E-GENE E-GENE
encoding O O
the O O
cholesterol O O
side O O
- O O
chain O O
cleavage O O
P450scc S-GENE O
close O O
to O O
the O O
CYP1A1 B-GENE B-GENE
gene E-GENE E-GENE
and O O
D15S204 S-GENE S-GENE
in O O
the O O
chromosome O O
15q22 O O
. O O
33 O O
- O O
q23 O O
region O O
. O O
Genetic O O
and O O
physiological O O
experiments O O
suggest O O
a O O
close O O
relationship O O
between O O
cdc27 B-GENE O
+ E-GENE O
and O O
the O O
cdc2 B-GENE B-GENE
+ I-GENE I-GENE
gene E-GENE E-GENE
, O O
a O O
key O O
regulator O O
of O O
mitosis O O
in O O
yeast O O
and O O
also O O
in O O
higher O O
eukaryotic O O
cells O O
. O O
The O O
study O O
was O O
performed O O
in O O
a O O
class O O
100 O O
laminar O O
flow O O
clean O O
bench O O
in O O
order O O
to O O
minimize O O
particulate O O
contamination O O
from O O
extraneous O O
sources O O
. O O
The O O
cloned O O
rRNA O O
operon O O
was O O
transcribed O O
in O O
vitro O O
by O O
using O O
purified B-GENE O
RNA I-GENE O
polymerase I-GENE O
of I-GENE O
Escherichia I-GENE O
coli E-GENE O
. O O
Of O O
the O O
CSF O O
tested O O
, O O
24 O O
stimulated O O
oxygen O O
consumption O O
above O O
our O O
cut O O
off O O
, O O
and O O
8 O O
did O O
not O O
( O O
0 O O
. O O
84 O O
+ O O
/ O O
- O O
0 O O
. O O
34 O O
, O O
n O O
= O O
24 O O
compared O O
with O O
the O O
rate O O
of O O
0 O O
. O O
27 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
mumol O O
/ O O
min O O
/ O O
g O O
dry O O
wt O O
, O O
respectively O O
; O O
SD O O
n O O
= O O
8 O O
) O O
at O O
180 O O
minutes O O
. O O
The O O
sequence O O
of O O
the O O
gene O O
upstream O O
to O O
the O O
cap O O
site O O
contains O O
characteristic O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II I-GENE I-GENE
promoter I-GENE E-GENE
- I-GENE O
binding I-GENE O
sites E-GENE O
: O O
a O O
putative O O
TATA O O
box O O
at O O
position O O
- O O
29 O O
and O O
a O O
Sp B-GENE O
1 I-GENE O
binding I-GENE O
site E-GENE O
( O O
GGGGCGGAGA O O
) O O
at O O
position O O
- O O
48 O O
. O O
The O O
kinetics O O
of O O
[ O O
14C O O
] O O
NG O O
in O O
the O O
blood O O
of O O
the O O
dosed O O
animals O O
was O O
followed O O
. O O
These O O
clones O O
contain O O
most O O
of O O
the O O
exon O O
of O O
cyclin B-GENE B-GENE
D2 E-GENE E-GENE
except O O
exon O O
5 O O
. O O
One O O
had O O
a O O
48 O O
- O O
hour O O
cycle O O
and O O
the O O
other O O
a O O
24 O O
- O O
hour O O
cycle O O
. O O
This O O
action O O
could O O
be O O
antagonized O O
by O O
aminophylline O O
, O O
a O O
competitive O O
antagonist O O
on O O
P1 B-GENE O
purinoceptors E-GENE O
. O O
Evidence O O
for O O
Gcr1p S-GENE S-GENE
/ O O
Gcr2p S-GENE S-GENE
interaction O O
has O O
been O O
presented O O
earlier O O
and O O
is O O
now O O
supported O O
by O O
the O O
isolation O O
of O O
mutations O O
in O O
Gcr1p S-GENE O
suppressing O O
gcr2 S-GENE O
, O O
as O O
assessed O O
by O O
growth O O
and O O
enzyme O O
assay O O
. O O
Keys O O
can O O
be O O
used O O
for O O
identifying O O
species O O
from O O
the O O
European O O
part O O
of O O
the O O
USSR O O
and O O
north O O
- O O
eastern O O
Kazakhstan O O
. O O
Promoter O O
constructs O O
containing O O
mutations O O
in O O
the O O
PTRE B-GENE B-GENE
sequence E-GENE E-GENE
that O O
selectively O O
abolished O O
the O O
binding O O
of O O
either O O
one O O
or O O
both O O
complexes O O
exerted O O
opposite O O
effects O O
on O O
the O O
transcriptional O O
activity O O
of O O
trypsin B-GENE O
promoters E-GENE O
in O O
A O O
. O O
gambiae O O
and O O
Aedes O O
aegypti O O
cell O O
lines O O
. O O
The O O
Rep78 B-GENE B-GENE
protein E-GENE E-GENE
of O O
adeno O O
- O O
associated O O
virus O O
( O O
AAV O O
) O O
contains O O
amino O O
acid O O
sequence O O
motifs O O
common O O
to O O
rolling B-GENE O
- I-GENE O
circle I-GENE O
replication I-GENE O
( I-GENE O
RCR I-GENE S-GENE
) I-GENE O
initiator I-GENE O
proteins E-GENE O
. O O
Plasma O O
prolactin S-GENE O
in O O
patients O O
with O O
colorectal O O
cancer O O
. O O
Reality O O
and O O
clinical O O
application O O
of O O
immunoglobulin S-GENE O
preparations O O
The O O
extent O O
of O O
myocardial O O
ischemia O O
in O O
the O O
coronary O O
sinus O O
study O O
was O O
significantly O O
correlated O O
to O O
the O O
coronary O O
diameters O O
of O O
the O O
proximal O O
and O O
middle O O
segments O O
of O O
the O O
Ramus O O
interventricularis O O
anterior O O
and O O
the O O
middle O O
segment O O
of O O
the O O
Ramus O O
circumflexus O O
( O O
r O O
= O O
0 O O
. O O
87 O O
, O O
p O O
< O O
0 O O
. O O
02 O O
) O O
. O O
The O O
in O O
- O O
plane O O
orientational O O
anisotropy O O
of O O
the O O
8CB O O
films O O
grown O O
on O O
unidirectionally O O
photopolymerized O O
PVCN O O
substrates O O
is O O
considerably O O
lower O O
than O O
the O O
intrinsic O O
surface O O
orientational O O
anisotropy O O
of O O
these O O
substrates O O
, O O
which O O
can O O
explain O O
the O O
generally O O
found O O
weak O O
surface O O
anchoring O O
of O O
liquid O O
crystals O O
on O O
PVCN O O
alignment O O
layers O O
. O O
Nuclear O O
transcription O O
assays O O
confirmed O O
that O O
cys B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
+ E-GENE E-GENE
was O O
under O O
sulfur O O
- O O
regulated O O
transcriptional O O
control O O
and O O
that O O
cys B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
+ E-GENE E-GENE
transcription O O
was O O
constitutive O O
in O O
sulfur B-GENE O
controller E-GENE O
( O O
scon S-GENE O
) O O
- O O
negative O O
regulator O O
mutants O O
. O O
The O O
rifampicin O O
resistance O O
of O O
uvsW S-GENE O
- O O
repressed O O
replication O O
suggests O O
that O O
it O O
involves O O
either O O
tertiary O O
initiation O O
or O O
some O O
novel O O
mode O O
of O O
initiation O O
. O O
Pharmacokinetics O O
of O O
skin O O
penetration O O
. O O
Furthermore O O
, O O
the O O
regulation O O
conferred O O
on O O
a O O
reporter O O
gene O O
in O O
Drosophila O O
by O O
three O O
closely O O
related O O
sequences O O
demonstrates O O
that O O
even O O
subtle O O
sequence O O
changes O O
within O O
an O O
E O O
box O O
or O O
flanking O O
bases O O
have O O
dramatic O O
consequences O O
on O O
the O O
overall O O
repertoire O O
of O O
proteins O O
that O O
can O O
bind O O
in O O
vivo O O
. O O
Buspirone O O
therapy O O
for O O
Type O O
A O O
behavior O O
, O O
hostility O O
, O O
and O O
perceived O O
stress O O
in O O
cardiac O O
patients O O
. O O
Recently O O
we O O
have O O
performed O O
a O O
detailed O O
analysis O O
of O O
specific O O
neuronal O O
populations O O
affected O O
by O O
the O O
mutation O O
which O O
shed O O
new O O
light O O
on O O
the O O
role O O
of O O
Krox B-GENE O
- I-GENE O
20 E-GENE O
in O O
the O O
segmentation O O
and O O
on O O
the O O
physiological O O
consequences O O
of O O
its O O
inactivation O O
. O O
A O O
species O O
comparison O O
of O O
cDNA O O
sequences O O
and O O
isolation O O
of O O
a O O
genomic O O
clone O O
. O O
The O O
inhibition O O
of O O
monoamine B-GENE B-GENE
oxidase E-GENE E-GENE
( O O
MAO S-GENE O
) O O
by O O
tranylcypromine O O
was O O
studied O O
in O O
6 O O
healthy O O
volunteers O O
given O O
increasing O O
doses O O
of O O
10 O O
, O O
15 O O
, O O
20 O O
and O O
25 O O
mg O O
/ O O
day O O
over O O
a O O
4 O O
- O O
week O O
period O O
. O O
Deletion O O
mutagenesis O O
of O O
the O O
promoter O O
indicated O O
that O O
a O O
positive O O
regulatory O O
element O O
( O O
PRE O O
) O O
was O O
likely O O
to O O
exist O O
downstream O O
of O O
the O O
UL94 B-GENE B-GENE
mRNA I-GENE E-GENE
start I-GENE O
site E-GENE O
, O O
while O O
a O O
negative O O
regulatory O O
element O O
( O O
NRE O O
) O O
was O O
present O O
upstream O O
of O O
the O O
TATA O O
box O O
. O O
Expression O O
of O O
Helios S-GENE O
was O O
detected O O
in O O
the O O
earliest O O
hematopoietic O O
sites O O
of O O
the O O
embryo O O
, O O
in O O
hematopoietic O O
stem O O
cells O O
in O O
the O O
adult O O
and O O
was O O
subsequently O O
restricted O O
to O O
a O O
subset O O
of O O
cells O O
in O O
the O O
T O O
cell O O
lineage O O
. O O
Metapsychiatry O O
is O O
a O O
term O O
born O O
of O O
necessity O O
to O O
designate O O
the O O
important O O
but O O
hitherto O O
unclassified O O
interface O O
between O O
psychiatry O O
and O O
mysticism O O
. O O
Effects O O
of O O
negative O O
pi O O
mesons O O
on O O
mouse O O
bone O O
marrow O O
cells O O
. O O
Using O O
probes O O
containing O O
C B-GENE O
/ I-GENE O
EBP I-GENE O
- I-GENE O
binding I-GENE O
sites E-GENE O
from O O
the O O
iNOS B-GENE B-GENE
gene E-GENE E-GENE
revealed O O
further O O
binding O O
of O O
different O O
complexes O O
, O O
all O O
of O O
which O O
were O O
strongly O O
inducible O O
by O O
cAMP O O
and O O
to O O
a O O
lower O O
extent O O
also O O
by O O
IL B-GENE B-GENE
- I-GENE I-GENE
1beta E-GENE E-GENE
. O O
The O O
Pi O O
signals O O
are O O
conveyed O O
to O O
PHO8 S-GENE S-GENE
by O O
binding O O
of O O
PHO4 B-GENE B-GENE
protein E-GENE E-GENE
, O O
a O O
positive O O
regulatory O O
factor O O
, O O
to O O
a O O
promoter O O
region O O
of O O
PHO8 S-GENE S-GENE
( O O
PHO8p S-GENE S-GENE
) O O
under O O
the O O
influence O O
of O O
the O O
PHO S-GENE S-GENE
regulatory O O
circuit O O
. O O
Thus O O
, O O
the O O
end O O
of O O
a O O
linearized O O
DNA O O
fragment O O
can O O
initiate O O
new O O
DNA O O
synthesis O O
by O O
BIR O O
in O O
which O O
the O O
newly O O
synthesized O O
DNA O O
is O O
displaced O O
and O O
subsequently O O
forms O O
circles O O
by O O
NHEJ O O
. O O
It O O
would O O
seem O O
that O O
caution O O
should O O
be O O
exercised O O
in O O
using O O
HPL S-GENE O
values O O
as O O
an O O
index O O
of O O
placental O O
function O O
in O O
anaemic O O
women O O
. O O
A O O
case O O
of O O
acquired O O
immune O O
deficiency O O
syndrome O O
before O O
1980 O O
. O O
These O O
data O O
suggest O O
that O O
multiple O O
genetic O O
recombination O O
among O O
bacteriophages O O
with O O
different O O
immunities O O
took O O
place O O
to O O
generate O O
the O O
prophage O O
VT1 O O
- O O
Sakai O O
. O O
The O O
adenovirus B-GENE O
E1B I-GENE O
19 I-GENE O
, I-GENE O
000 I-GENE O
- I-GENE O
molecular I-GENE O
- I-GENE O
weight I-GENE O
( I-GENE O
19K I-GENE S-GENE
) I-GENE O
protein E-GENE O
is O O
a O O
potent O O
inhibitor O O
of O O
apoptosis O O
and O O
cooperates O O
with O O
E1A S-GENE S-GENE
to O O
transform O O
primary O O
rodent O O
cells O O
. O O
Desensitization O O
of O O
the O O
growth B-GENE O
hormone E-GENE O
- O O
induced O O
Janus B-GENE B-GENE
kinase I-GENE I-GENE
2 E-GENE E-GENE
( O O
Jak B-GENE B-GENE
2 E-GENE E-GENE
) O O
/ O O
signal B-GENE O
transducer I-GENE O
and I-GENE O
activator I-GENE O
of I-GENE O
transcription I-GENE O
5 E-GENE O
( O O
Stat5 S-GENE S-GENE
) O O
- O O
signaling O O
pathway O O
requires O O
protein O O
synthesis O O
and O O
phospholipase B-GENE B-GENE
C E-GENE E-GENE
. O O
In O O
two O O
separate O O
studies O O
, O O
specimens O O
of O O
saliva O O
from O O
57 O O
individuals O O
over O O
the O O
age O O
of O O
65 O O
years O O
( O O
mean O O
age O O
, O O
76 O O
. O O
7 O O
years O O
) O O
and O O
37 O O
persons O O
under O O
the O O
age O O
of O O
40 O O
years O O
( O O
mean O O
age O O
, O O
28 O O
. O O
8 O O
years O O
) O O
were O O
examined O O
for O O
concentrations O O
of O O
IgA S-GENE O
as O O
functions O O
of O O
volume O O
, O O
total O O
protein O O
, O O
and O O
electrolyte O O
conductivity O O
; O O
some O O
were O O
also O O
tested O O
for O O
IgG S-GENE S-GENE
and O O
IgM S-GENE S-GENE
content O O
. O O
E2A S-GENE S-GENE
- O O
HLF S-GENE O
- O O
mediated O O
cell O O
transformation O O
requires O O
both O O
the O O
trans O O
- O O
activation O O
domains O O
of O O
E2A S-GENE S-GENE
and O O
the O O
leucine O O
zipper O O
dimerization O O
domain O O
of O O
HLF S-GENE S-GENE
. O O
Two O O
adjacent O O
, O O
highly O O
homologous B-GENE O
endoglucanase I-GENE O
genes E-GENE O
, O O
celD S-GENE S-GENE
and O O
celE S-GENE O
from O O
Fibrobacter O O
succinogenes O O
S85 O O
, O O
which O O
were O O
separated O O
by O O
an O O
AT O O
- O O
rich O O
223 O O
- O O
nucleotide O O
intergenic O O
region O O
were O O
characterized O O
. O O
The O O
Seldinger O O
technique O O
for O O
difficult O O
transurethral O O
catheterization O O
: O O
a O O
gentle O O
alternative O O
to O O
suprapubic O O
puncture O O
( O O
Br O O
J O O
Surg O O
2000 O O
; O O
87 O O
: O O
1729 O O
- O O
30 O O
) O O
. O O
We O O
screened O O
an O O
A O O
. O O
thaliana O O
cDNA O O
library O O
, O O
whose O O
inserts O O
are O O
under O O
the O O
control O O
of O O
the O O
galactose O B-GENE
- O I-GENE
inducible O I-GENE
GAL10 B-GENE I-GENE
promoter E-GENE E-GENE
, O O
for O O
cDNAs O O
which O O
enabled O O
YDH8 O O
cells O O
to O O
grow O O
at O O
the O O
restrictive O O
temperature O O
. O O
We O O
generated O O
" O O
signature O O
" O O
oligonucleotides O O
from O O
these O O
CDR3s S-GENE S-GENE
and O O
probed O O
PCR O O
amplified O O
V B-GENE O
kappa I-GENE O
products E-GENE O
from O O
the O O
synovium O O
and O O
PBLs O O
of O O
the O O
same O O
patient O O
, O O
and O O
from O O
PBLs O O
and O O
spleen O O
of O O
individuals O O
without O O
rheumatic O O
disease O O
. O O
One O O
of O O
the O O
major O O
transcripts O O
encodes O O
MEQ S-GENE S-GENE
, O O
a O O
339 O O
- O O
amino O O
- O O
acid O O
bZIP B-GENE B-GENE
protein E-GENE E-GENE
which O O
is O O
homologous O O
to O O
the O O
Jun S-GENE S-GENE
/ O O
Fos S-GENE S-GENE
family O O
of O O
transcription O O
factors O O
. O O
It O O
is O O
concluded O O
that O O
the O O
new O O
class O O
of O O
competitive O O
NMDA B-GENE B-GENE
receptor E-GENE E-GENE
antagonists O O
, O O
exemplified O O
by O O
CGP O B-GENE
37849 O E-GENE
, O O
is O O
the O O
most O O
promising O O
candidate O O
for O O
clinical O O
trials O O
in O O
anxiety O O
disorders O O
. O O
An O O
emended O O
diagnosis O O
of O O
Tylocephalum O O
is O O
proposed O O
excluding O O
this O O
feature O O
, O O
along O O
with O O
distribution O O
of O O
the O O
testes O O
in O O
the O O
preovarian O O
field O O
and O O
circummedullary O O
distribution O O
of O O
vitelline O O
follicles O O
. O O
Induction O O
of O O
interferon B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
( O O
IFNalpha S-GENE S-GENE
) O O
gene O O
expression O O
in O O
virus O O
- O O
infected O O
cells O O
requires O O
phosphorylation O O
- O O
induced O O
activation O O
of O O
the O O
transcription O O
factors O O
IRF3 S-GENE S-GENE
and O O
IRF7 S-GENE S-GENE
. O O
METHODS O O
: O O
The O O
prevalence O O
of O O
haemagglutination B-GENE O
inhibiting I-GENE O
( I-GENE O
HI I-GENE O
) I-GENE O
antibodies E-GENE O
to O O
JE O O
virus O O
( O O
JEV O O
) O O
, O O
West O O
Nile O O
virus O O
( O O
WNV O O
) O O
and O O
dengue O O
- O O
2 O O
virus O O
( O O
DEN O O
- O O
2 O O
) O O
was O O
detected O O
by O O
HI O O
test O O
and O O
IgM B-GENE O
antibody E-GENE O
capture O O
ELISA O O
( O O
MAC O O
ELISA O O
) O O
was O O
performed O O
to O O
determine O O
recent O O
infections O O
with O O
JE O O
virus O O
. O O
Moreover O O
, O O
since O O
the O O
integrated O O
transforming O O
DNA O O
was O O
not O O
altered O O
or O O
lost O O
expression O O
of O O
the O O
RbcS2 S-GENE S-GENE
: O O
: O O
aadA S-GENE S-GENE
: O O
: O O
RbcS2 B-GENE B-GENE
gene I-GENE E-GENE
( I-GENE O
s I-GENE O
) E-GENE O
appears O O
to O O
be O O
repressed O O
. O O
Donehower O O
and O O
H O O
. O O
A O O
characteristic O O
feature O O
is O O
their O O
tendency O O
to O O
form O O
homo O O
- O O
and O O
/ O O
or O O
heterodimeric O O
complexes O O
. O O
Further O O
, O O
more O O
recent O O
communications O O
suggest O O
that O O
liver O O
disease O O
led O O
to O O
a O O
differential O O
alteration O O
of O O
the O O
cytochrome B-GENE O
P I-GENE O
- I-GENE O
450s E-GENE O
with O O
regard O O
to O O
protein O O
content O O
and O O
activity O O
. O O
Apparent O O
Buschke O O
- O O
Loewenstein O O
tumour O O
of O O
the O O
penis O O
. O O
This O O
effect O O
was O O
stronger O O
after O O
multiple O O
predoses O O
of O O
sertraline O O
, O O
when O O
imipramine O O
Cmax O O
and O O
AUC O O
( O O
0 O O
- O O
infinity O O
) O O
were O O
increased O O
by O O
39 O O
% O O
and O O
68 O O
% O O
, O O
respectively O O
. O O
Mutations O O
in O O
nifR1 S-GENE S-GENE
( O O
ntrC S-GENE S-GENE
) O O
and O O
nifR4 S-GENE S-GENE
( O O
rpoN S-GENE S-GENE
, O O
encoding O O
sigma54 S-GENE O
) O O
had O O
no O O
influence O O
on O O
xdh B-GENE B-GENE
gene E-GENE E-GENE
expression O O
. O O
We O O
therefore O O
propose O O
that O O
PRR2 S-GENE S-GENE
, O O
and O O
not O O
PVR S-GENE S-GENE
, O O
is O O
the O O
true O O
human O O
homolog O O
of O O
MPH S-GENE O
. O O
Swarming O O
of O O
Moraxella O O
Biochem O O
. O O
In O O
contrast O O
, O O
vRel S-GENE O
lacks O O
a O O
strong O O
C O O
- O O
terminal O O
gene O O
activation O O
function O O
, O O
since O O
a O O
LexA B-GENE B-GENE
fusion I-GENE I-GENE
protein E-GENE E-GENE
containing O O
C B-GENE O
- I-GENE O
terminal I-GENE O
vRel I-GENE O
sequences E-GENE O
alone O O
only O O
weakly O O
activated O O
transcription O O
. O O
The O O
crystal O O
structure O O
of O O
the O O
yeast O O
Phe B-GENE O
- I-GENE O
tRNAPhe I-GENE O
ternary I-GENE O
complex E-GENE O
with O O
Thermus O O
aquaticus O O
EF B-GENE O
- I-GENE O
Tu E-GENE O
- O O
GDPNP O O
( O O
Phe B-GENE O
- I-GENE O
TC E-GENE O
) O O
has O O
previously O O
been O O
determined O O
as O O
one O O
representative O O
of O O
this O O
general O O
yet O O
highly O O
discriminating O O
complex O O
formation O O
. O O
Bovine O O
anaplasmosis O O
: O O
susceptibility O O
of O O
seronegative O O
cows O O
from O O
an O O
infected O O
herd O O
to O O
experimental O O
infection O O
with O O
Anaplasma O O
marginale O O
. O O
Because O O
of O O
gut O O
fermentation O O
, O O
a O O
substantial O O
portion O O
( O O
16 O O
- O O
80 O O
% O O
) O O
of O O
N O O
is O O
absorbed O O
as O O
ammonia O O
N O O
( O O
NH3N O O
) O O
. O O
Quantitative O O
measurement O O
of O O
antigamma B-GENE B-GENE
globulin I-GENE I-GENE
factors E-GENE E-GENE
( O O
rheumatoid B-GENE O
factors E-GENE O
) O O
using O O
laser O O
- O O
nephelometry O O
in O O
comparison O O
with O O
the O O
latex O O
agglutination O O
test O O
and O O
the O O
Waaler O O
- O O
Rose O O
test O O
The O O
densities O O
ranged O O
between O O
2 O O
and O O
3976 O O
neurites O O
/ O O
mm2 O O
skin O O
surface O O
, O O
but O O
the O O
overlap O O
between O O
subjects O O
and O O
without O O
PHN O O
was O O
small O O
. O O
Zoonotic O O
areas O O
in O O
which O O
HIV O O
co O O
- O O
infection O O
is O O
common O O
could O O
also O O
be O O
at O O
risk O O
as O O
sandflies O O
can O O
become O O
infected O O
from O O
co O O
- O O
infected O O
individuals O O
. O O
The O O
determination O O
of O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
( O O
AT B-GENE O
III E-GENE O
) O O
and O O
its O O
clinical O O
significance O O
The O O
kinetics O O
of O O
erythromycin O O
( O O
E O O
. O O
) O O
was O O
studied O O
in O O
16 O O
patients O O
with O O
different O O
degrees O O
of O O
impairment O O
of O O
renal O O
function O O
after O O
a O O
single O O
intravenous O O
dose O O
. O O
Base O O
substitutions O O
within O O
this O O
NFIL B-GENE O
- I-GENE O
6 I-GENE O
site E-GENE O
resulted O O
in O O
virtual O O
elimination O O
of O O
LPS O O
- O O
induced O O
IL B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
beta I-GENE I-GENE
gene E-GENE E-GENE
transcription O O
. O O
Mortality O O
rates O O
were O O
not O O
different O O
( O O
chi2 O O
: O O
0 O O
. O O
0298 O O
, O O
p O O
> O O
0 O O
. O O
5 O O
) O O
. O O
The O O
MALDI O O
- O O
TOF O O
experiment O O
, O O
however O O
, O O
proved O O
to O O
be O O
superior O O
to O O
the O O
GC O O
experiment O O
, O O
particularly O O
with O O
regard O O
to O O
baseline O O
resolution O O
of O O
unsaturated O O
acids O O
. O O
Modern O O
aspects O O
of O O
shock O O
- O O
treatment O O
in O O
extensive O O
burns O O
( O O
author O O
' O O
s O O
transl O O
) O O
Of O O
the O O
private O O
practices O O
accredited O O
in O O
August O O
1995 O O
, O O
40 O O
. O O
6 O O
per O O
cent O O
( O O
122 O O
) O O
participated O O
. O O
A O O
Drosophila O O
subobscura O O
genomic O O
fragment O O
containing O O
all O O
the O O
exons O O
and O O
the O O
late O O
and O O
early O O
promotors O O
in O O
the O O
Sxl B-GENE B-GENE
gene I-GENE E-GENE
of I-GENE O
D I-GENE O
. I-GENE O
melanogaster E-GENE O
was O O
isolated O O
. O O
Collectively O O
, O O
a O O
unique O O
mechanism O O
involving O O
NF B-GENE B-GENE
- I-GENE I-GENE
ATp E-GENE E-GENE
appears O O
to O O
regulate O O
the O O
cell O O
type O O
- O O
specific O O
and O O
activation O O
- O O
dependent O O
expression O O
of O O
the O O
SCM B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
genes E-GENE E-GENE
. O O
The O O
sensitivity O O
of O O
central B-GENE O
dopamine I-GENE O
receptors E-GENE O
was O O
assessed O O
with O O
the O O
growth B-GENE O
hormone E-GENE O
response O O
to O O
apomorphine O O
application O O
. O O
Oral O O
basal O O
body O O
temperature O O
( O O
BBT O O
) O O
recordings O O
of O O
46 O O
women O O
that O O
conceived O O
by O O
donor O O
insemination O O
and O O
who O O
had O O
midcycle O O
monitoring O O
of O O
luteinising B-GENE O
hormone E-GENE O
( O O
LH S-GENE S-GENE
) O O
were O O
analysed O O
to O O
establish O O
features O O
associated O O
with O O
an O O
optimal O O
cycle O O
. O O
Our O O
results O O
admit O O
that O O
a O O
ribosome O O
scanning O O
mechanism O O
of O O
the O O
MP B-GENE B-GENE
gene E-GENE E-GENE
expression O O
from O O
I O O
( O O
2 O O
) O O
sgRNA O O
operates O O
concurrently O O
. O O
The O O
three O O
- O O
dimensional O O
structure O O
of O O
the O O
E O O
. O O
coli O O
CR O O
domain O O
indicates O O
that O O
this O O
sequence O O
conservation O O
is O O
likely O O
to O O
result O O
in O O
a O O
conserved O O
structural O O
motif O O
. O O
Otosclerosis O O
in O O
monozygotic O O
twins O O
: O O
clinical O O
and O O
genetical O O
analysis O O
A O O
DNA O O
fragment O O
that O O
complements O O
the O O
uvs B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE I-GENE
mutation O E-GENE
was O O
subcloned O O
by O O
monitoring O O
its O O
ability O O
to O O
transform O O
the O O
uvs B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
mutant E-GENE E-GENE
to O O
MMS O O
resistance O O
. O O
The O O
human B-GENE B-GENE
lbc I-GENE I-GENE
oncogene I-GENE I-GENE
product E-GENE E-GENE
is O O
a O O
guanine B-GENE O
nucleotide I-GENE O
exchange I-GENE O
factor E-GENE O
that O O
specifically O O
activates O O
the O O
Rho B-GENE B-GENE
small I-GENE I-GENE
GTP I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
, O O
thus O O
resulting O O
in O O
biologically O O
active O O
, O O
GTP O B-GENE
- O I-GENE
bound O I-GENE
Rho S-GENE E-GENE
, O O
which O O
in O O
turn O O
mediates O O
actin S-GENE O
cytoskeletal O O
reorganization O O
, O O
gene O O
transcription O O
, O O
and O O
entry O O
into O O
the O O
mitotic O O
S O O
phase O O
. O O
Insulin S-GENE O
- O O
stimulated O O
autophosphorylation O O
at O O
specific O O
sites O O
in O O
the O O
tyrosine B-GENE B-GENE
kinase I-GENE E-GENE
domain E-GENE O
of O O
the O O
receptor O B-GENE
' O I-GENE
s O I-GENE
beta O I-GENE
- O I-GENE
subunit O E-GENE
is O O
correlated O O
kinetically O O
with O O
activation O O
of O O
kinase O O
- O O
catalyzed O O
phosphorylation O O
of O O
a O O
model O O
substrate O O
( O O
reduced O O
and O O
carboxyamidomethylated O O
lysozyme S-GENE O
; O O
RCAM B-GENE O
- I-GENE O
lysozyme E-GENE O
) O O
. O O
The O O
critical O O
obstacle O O
in O O
modeling O O
psychiatric O O
disorders O O
has O O
been O O
limited O O
information O O
about O O
their O O
origin O O
and O O
underlying O O
neural O O
mechanisms O O
. O O
BACKGROUND O O
: O O
Allergic O O
rhinoconjunctivitis O O
is O O
a O O
common O O
disorder O O
, O O
affecting O O
> O O
20 O O
% O O
of O O
people O O
of O O
all O O
socioeconomic O O
strata O O
. O O
The O O
results O O
of O O
these O O
studies O O
indicate O O
that O O
EHV B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gp13 E-GENE E-GENE
is O O
the O O
structural O O
homolog O O
of O O
herpes B-GENE O
simplex I-GENE O
virus I-GENE O
glycoprotein I-GENE O
C E-GENE O
and O O
further O O
suggest O O
that O O
the O O
epitope O O
- O O
containing O O
N O O
- O O
terminal O O
amino O O
acid O O
sequences O O
of O O
the O O
herpesvirus B-GENE O
gC I-GENE O
- I-GENE O
like I-GENE O
glycoproteins E-GENE O
have O O
undergone O O
more O O
extensive O O
evolutionary O O
divergence O O
than O O
the O O
C O O
- O O
terminal O O
sequences O O
. O O
Within O O
the O O
final O O
11 O O
amino O O
acids O O
there O O
are O O
5 O O
aromatic O O
, O O
2 O O
basic O O
, O O
and O O
no O O
acidic O O
residues O O
and O O
it O O
has O O
been O O
proposed O O
that O O
these O O
residues O O
stack O O
with O O
and O O
electrostatically O O
interact O O
with O O
the O O
kinked O O
DNA O O
at O O
the O O
site O O
of O O
a O O
pyrimidine O O
dimer O O
. O O
By O O
contrast O O
, O O
footprint O O
II O O
at O O
position O O
- O O
125 O O
is O O
common O O
to O O
both O O
HeLa O O
and O O
GH3 O O
cell O O
extracts O O
and O O
overlies O O
a O O
15 O O
- O O
base O O
- O O
pair O O
sequence O O
found O O
in O O
all O O
members O O
of O O
the O O
growth B-GENE B-GENE
hormone I-GENE I-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
. O O
Significance O O
of O O
the O O
determination O O
of O O
vascular O O
tonus O O
in O O
the O O
differential O O
diagnosis O O
of O O
rheumatic O O
and O O
arteriosclerotic O O
lesions O O
of O O
the O O
heart O O
and O O
vessels O O
in O O
middle O O
- O O
aged O O
and O O
elderly O O
persons O O
with O O
fibrillation O O
arrhythmia O O
The O O
gene O O
responsible O O
for O O
multiple O O
endocrine O B-GENE
neoplasia O I-GENE
type O I-GENE
1 O E-GENE
( O O
MEN1 S-GENE S-GENE
) O O
, O O
a O O
heritable O O
predisposition O O
to O O
endocrine O O
tumours O O
in O O
man O O
, O O
has O O
recently O O
been O O
identified O O
. O O
Toxicological O O
effects O O
of O O
dietary O O
Maillard O O
reaction O O
products O O
in O O
the O O
rat O O
. O O
AST S-GENE S-GENE
activity O O
in O O
PMNs O O
was O O
significantly O O
low O O
, O O
approximately O O
2 O O
% O O
of O O
that O O
observed O O
in O O
HPLFs O O
. O O
Specifically O O
, O O
we O O
engineered O O
two O O
chimeras O O
in O O
which O O
the O O
N O O
- O O
terminal O O
lobe O O
of O O
the O O
SH1 B-GENE O
domain E-GENE O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Abl E-GENE E-GENE
was O O
swapped O O
with O O
that O O
of O O
v B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE E-GENE
. O O
Biochemical O O
analyses O O
revealed O O
that O O
the O O
concentration O O
of O O
norepinephrine O O
was O O
reduced O O
significantly O O
in O O
cortex O O
- O O
hippocampus O O
and O O
olfactory O O
bulb O O
but O O
not O O
in O O
other O O
regions O O
, O O
while O O
dopamine O O
and O O
serotonin O O
levels O O
were O O
not O O
altered O O
in O O
any O O
brain O O
region O O
examined O O
. O O
The O O
cDNA O O
contains O O
a O O
reading O O
frame O O
for O O
a O O
145 O O
- O O
amino O O
- O O
acid O O
protein O O
and O O
it O O
lacks O O
the O O
UGA O B-GENE
codons O E-GENE
, O O
which O O
have O O
been O O
found O O
in O O
the O O
reading O O
frame O O
of O O
the O O
mouse B-GENE O
MCS I-GENE O
cDNA E-GENE O
and O O
have O O
been O O
presumed O O
to O O
encode O O
the O O
selenocysteine O O
in O O
the O O
amino O O
terminal O O
of O O
the O O
deduced O O
mouse O O
amino O O
acid O O
sequence O O
. O O
These O O
results O O
suggest O O
that O O
repetitive O O
GAA O O
sequences O O
enhance O O
splicing O O
by O O
binding O O
a O O
protein O O
complex O O
containing O O
a O O
sequence O O
- O O
specific O O
RNA O O
binding O O
protein O O
and O O
a O O
general O O
splicing O O
activator O O
that O O
, O O
in O O
turn O O
, O O
recruit O O
additional O O
SR B-GENE B-GENE
proteins E-GENE E-GENE
. O O
Letter O O
: O O
Dehydrated O O
test O O
strip O O
for O O
the O O
detection O O
of O O
yeasts O O
. O O
Cell O O
sloughing O O
with O O
proparacaine O O
. O O
Cytomegalovirus O O
infection O O
- O O
- O O
modern O O
diagnosis O O
Highly O O
conserved O O
regions O O
called O O
src B-GENE B-GENE
homology I-GENE I-GENE
2 E-GENE E-GENE
and O O
3 O O
( O O
SH2 S-GENE S-GENE
and O O
SH3 S-GENE S-GENE
) O O
, O O
comprising O O
amino O O
acid O O
residues O O
88 O O
to O O
250 O O
, O O
are O O
believed O O
to O O
modulate O O
the O O
protein B-GENE B-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
present O O
in O O
the O O
carboxy O O
- O O
terminal O O
halves O O
of O O
the O O
src B-GENE B-GENE
proteins E-GENE E-GENE
. O O
Interestingly O O
, O O
the O O
NES B-GENE B-GENE
mutant I-GENE I-GENE
proteins E-GENE E-GENE
appeared O O
to O O
have O O
altered O O
interactions O O
with O O
the O O
splicing O O
complex O O
, O O
binding O O
more O O
tightly O O
to O O
SC35 S-GENE S-GENE
in O O
co O O
- O O
immunoprecipitation O O
assays O O
. O O
We O O
propose O O
2 O O
separate O O
PAI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
inductory O O
pathways O O
for O O
PMA O S-GENE
and O O
IL B-GENE B-GENE
- I-GENE I-GENE
1alpha E-GENE E-GENE
in O O
HepG2 O S-GENE
, O O
both O O
involving O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
activation O O
; O O
the O O
serum O O
- O O
induced O O
signaling O O
pathway O O
may O O
( O O
partially O O
) O O
overlap O O
with O O
the O O
PMA O B-GENE
- O I-GENE
activated O I-GENE
protein B-GENE I-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
/ O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
pathway O O
, O O
leading O O
to O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE E-GENE
homodimer E-GENE O
binding O O
to O O
the O O
PAI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE I-GENE
TRE O E-GENE
. O O
We O O
show O O
that O O
sae1 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
sae3 B-GENE O
- I-GENE O
1 I-GENE O
mutations E-GENE O
each O O
confer O O
a O O
distinct O O
defect O O
in O O
meiotic O O
recombination O O
. O O
sae1 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
produces O O
recombinants O O
but O O
very O O
slowly O O
and O O
ultimately O O
to O O
less O O
than O O
half O O
the O O
wild O O
- O O
type O O
level O O
; O O
sae3 B-GENE O
- I-GENE O
1 E-GENE O
makes O O
persistent O O
hyper O O
- O O
resected O O
meiotic O O
double O O
- O O
strand O O
breaks O O
and O O
has O O
a O O
severe O O
defect O O
in O O
formation O O
of O O
recombinants O O
. O O
G6620 S-GENE S-GENE
is O O
the O O
3 O O
' O O
end O O
of O O
the O O
MOL1 B-GENE B-GENE
gene E-GENE E-GENE
coding O O
for O O
a O O
polypeptide O O
similar O O
to O O
stress O O
- O O
inducible O O
proteins O O
from O O
Fusarium O O
; O O
G6630 S-GENE S-GENE
is O O
the O O
NAT2 B-GENE B-GENE
gene E-GENE E-GENE
which O O
encodes O O
a O O
methionine B-GENE B-GENE
N I-GENE I-GENE
- I-GENE I-GENE
acetyltransferase E-GENE E-GENE
; O O
G6635 S-GENE S-GENE
is O O
the O O
RPL30B B-GENE B-GENE
gene E-GENE E-GENE
coding O O
for O O
the O O
ribosomal B-GENE O
protein I-GENE O
L30 E-GENE S-GENE
; O O
G6658 S-GENE S-GENE
is O O
RSR1 S-GENE S-GENE
encoding O O
a O O
ras B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
protein E-GENE E-GENE
; O O
G6667 S-GENE S-GENE
is O O
CYS4 S-GENE S-GENE
, O O
the O O
gene O O
for O O
cystathionine B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
synthase E-GENE E-GENE
; O O
G6670 S-GENE S-GENE
is O O
identical O O
to O O
ORF2 O S-GENE
located O O
close O O
to O O
CYS4 S-GENE S-GENE
; O O
G6673 S-GENE S-GENE
is O O
PEM1 S-GENE S-GENE
/ O O
CHO2 S-GENE S-GENE
encoding O O
a O O
phosphatidylethanolamine B-GENE B-GENE
methyltransferase E-GENE E-GENE
; O O
G7001 S-GENE S-GENE
is O O
the O O
NSR1 B-GENE B-GENE
gene E-GENE E-GENE
coding O O
for O O
a O O
nuclear O O
signal O O
recognition O O
protein O O
. O O
Transcriptional O O
analysis O O
of O O
this O O
gene O O
cluster O O
was O O
performed O O
by O O
detecting O O
the O O
presence O O
of O O
mRNAs O O
spanning O O
adjacent O O
genes O O
as O O
well O O
as O O
by O O
using O O
a O O
promoterless O O
lacZ B-GENE O
reporter I-GENE O
gene E-GENE O
fused O O
to O O
each O O
of O O
the O O
seven O O
genes O O
contained O O
in O O
the O O
tol S-GENE B-GENE
- O I-GENE
oprL S-GENE I-GENE
locus O E-GENE
. O O
Serum O B-GENE
IgG S-GENE E-GENE
and O O
IgA S-GENE S-GENE
level O O
were O O
decreased O O
. O O
Histopathologically O O
, O O
( O O
mice O O
killed O O
with O O
high O O
doses O O
of O O
GMC O O
- O O
II O O
, O O
given O O
orally O O
) O O
there O O
were O O
diffuse O O
hyperemia O O
of O O
the O O
liver O O
, O O
parenchymal O O
degeneration O O
of O O
the O O
kidney O O
tubuli O O
epithelium O O
, O O
and O O
edema O O
and O O
emphysema O O
of O O
the O O
lungs O O
. O O
The O O
contribution O O
of O O
reviewers O O
and O O
editors O O
to O O
the O O
scientific O O
work O O
of O O
the O O
authors O O
The O O
effects O O
of O O
space O O
radiation O O
are O O
partially O O
known O O
on O O
astronauts O O
, O O
but O O
much O O
remains O O
to O O
be O O
discovered O O
. O O
Therefore O O
the O O
effect O O
of O O
GAL11 S-GENE S-GENE
on O O
PGK S-GENE S-GENE
transcription O O
must O O
be O O
mediated O O
at O O
the O O
PGK B-GENE B-GENE
UAS E-GENE E-GENE
, O O
presumably O O
as O O
part O O
of O O
the O O
activation O O
complex O O
. O O
Wingless S-GENE O
/ O O
Wnt S-GENE S-GENE
signaling O O
directs O O
cell O O
- O O
fate O O
choices O O
during O O
embryonic O O
development O O
. O O
RNase S-GENE O
protection O O
analysis O O
reveals O O
a O O
10 O O
- O O
fold O O
increase O O
in O O
the O O
expression O O
of O O
SCD2 B-GENE B-GENE
mRNA E-GENE E-GENE
during O O
3T3 O S-GENE
- O O
L1 O O
preadipocyte O O
differentiation O O
. O O
To O O
determine O O
whether O O
transcription O O
of O O
orfX O S-GENE
and O O
vfr S-GENE O
are O O
controlled O O
by O O
the O O
same O O
mechanisms O O
that O O
control O O
transcription O O
of O O
the O O
region O O
of O O
the O O
divergent O O
ORF O O
( O O
dorf O O
) O O
and O O
of O O
crp S-GENE O
, O O
we O O
compared O O
the O O
vfr S-GENE O
- O O
orfX O O
and O O
crp S-GENE O
- O O
dorf O O
intergenic O O
regions O O
. O O
As O O
a O O
member O O
of O O
the O O
uncoupling B-GENE B-GENE
protein I-GENE I-GENE
family E-GENE E-GENE
, O O
UCP2 S-GENE S-GENE
is O O
ubiquitously O O
expressed O O
in O O
rodents O O
and O O
humans O O
, O O
implicating O O
a O O
major O O
role O O
in O O
thermogenesis O O
. O O
Copyright O O
1998 O O
Academic O O
Press O O
. O O
Parental O O
and O O
vector O O
- O O
transfected O O
MCF7 O O
cells O O
, O O
which O O
were O O
sensitive O O
to O O
the O O
growth O O
- O O
inhibitory O O
effects O O
of O O
atRA O S-GENE
, O O
exhibited O O
atRA O O
- O O
dependent O O
retinoic B-GENE B-GENE
acid I-GENE I-GENE
receptor E-GENE E-GENE
( O O
RAR S-GENE S-GENE
) O O
transactivation O O
and O O
transrepression O O
of O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
activity O O
. O O
The O O
majority O O
of O O
the O O
respondents O O
( O O
83 O O
. O O
4 O O
% O O
) O O
considered O O
that O O
coitus O O
should O O
not O O
be O O
stopped O O
during O O
pregnancy O O
. O O
Based O O
on O O
the O O
ratios O O
of O O
the O O
areas O O
under O O
the O O
concentration O O
- O O
time O O
curves O O
in O O
CSF O O
and O O
serum O O
, O O
the O O
overall O O
penetration O O
of O O
rifampicin O O
into O O
CSF O O
was O O
0 O O
. O O
13 O O
- O O
0 O O
. O O
42 O O
( O O
median O O
= O O
0 O O
. O O
22 O O
) O O
. O O
The O O
differential O O
diagnosis O O
of O O
mineral O O
oil O O
lipidosis O O
in O O
lymph O O
nodes O O
with O O
reaction O O
to O O
radiopaque O O
oils O O
and O O
Whipple O O
' O O
s O O
disease O O
is O O
discussed O O
. O O
With O O
rats O O
fed O O
on O O
the O O
Zn O O
- O O
sufficient O O
diet O O
, O O
NaFe3 O O
+ O O
EDTA O O
and O O
Na2EDTA O O
similarly O O
increased O O
the O O
absorption O O
, O O
urinary O O
excretion O O
and O O
retention O O
of O O
Zn O O
but O O
to O O
a O O
lesser O O
extent O O
. O O
99Tcm O O
- O O
labelled O O
albumin S-GENE O
colloid O O
, O O
albures O O
( O O
radius O O
250 O O
nm O O
) O O
or O O
nanocoll O O
( O O
radius O O
25 O O
nm O O
) O O
, O O
or O O
both O O
were O O
used O O
as O O
test O O
substances O O
to O O
study O O
the O O
kinetics O O
of O O
vascular O O
clearance O O
after O O
RES O O
stimulation O O
. O O
Meq S-GENE S-GENE
/ O O
c B-GENE O
- I-GENE O
Jun E-GENE O
heterodimers O O
bind O O
to O O
an O O
AP1 B-GENE O
- I-GENE O
like I-GENE O
sequence E-GENE O
in O O
the O O
meq B-GENE B-GENE
promoter I-GENE E-GENE
region E-GENE O
with O O
an O O
affinity O O
much O O
greater O O
than O O
that O O
of O O
Meq S-GENE O
/ O O
Meq S-GENE O
or O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
/ O O
c B-GENE O
- I-GENE O
Jun E-GENE O
homodimers O O
. O O
Moreover O O
, O O
the O O
noncoordinate O O
effects O O
of O O
FSK S-GENE O
on O O
PMA O O
- O O
stimulated O O
MKK S-GENE S-GENE
and O O
MAPK S-GENE S-GENE
activities O O
indicates O O
the O O
presence O O
of O O
a O O
additional O O
distal O O
cAMP O O
- O O
dependent O O
inhibitory O O
mechanisms O O
. O O
These O O
findings O O
indicated O O
that O O
p35 S-GENE S-GENE
is O O
a O O
trans O O
- O O
dominant O O
factor O O
that O O
facilitates O O
AcMNPV O S-GENE
growth O O
in O O
a O O
cell O O
line O O
- O O
specific O O
manner O O
. O O
Pseudotumor O O
form O O
of O O
pulmonary O O
nocardia O O
infection O O
( O O
Nocardia O O
nova O O
) O O
in O O
a O O
renal O O
transplant O O
patient O O
Hematological O O
parameters O O
( O O
leukocyte O O
, O O
neutrophil O O
and O O
platelet O O
counts O O
) O O
and O O
liver O O
function O O
tests O O
were O O
determined O O
by O O
standard O O
procedures O O
. O O
Karyo O O
- O O
and O O
cytometric O O
investigations O O
of O O
cortical O O
layer O O
V O O
pyramidal O O
neurons O O
of O O
albino O O
rat O O
after O O
three O O
various O O
fixations O O
Clinical O O
experience O O
gained O O
from O O
a O O
combined O O
study O O
of O O
252Cf O O
brachytherapy O O
by O O
the O O
staff O O
- O O
members O O
of O O
the O O
Research O O
Institute O O
of O O
Medical O O
Radiology O O
, O O
USSR O O
AMS O O
, O O
was O O
generalized O O
. O O
The O O
team O O
physician O O
and O O
conditioning O O
of O O
athletes O O
for O O
sports O O
: O O
a O O
consensus O O
statement O O
. O O
To O O
probe O O
the O O
inter O O
- O O
relationship O O
between O O
the O O
virion O O
- O O
anchoring O O
function O O
and O O
the O O
oligomerization O O
function O O
, O O
we O O
constructed O O
two O O
serotype O O
3 O O
( O O
T3 O S-GENE
) O O
sigma B-GENE O
1 E-GENE O
deletion O O
mutants O O
in O O
SV40 O O
expression O O
vectors O O
, O O
one O O
lacking O O
the O O
hydrophobic O O
tail O O
and O O
the O O
hinge O O
, O O
and O O
the O O
other O O
lacking O O
an O O
adjacent O O
region O O
which O O
constituted O O
part O O
of O O
the O O
coiled O O
- O O
coil O O
. O O
AIMS O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
static O O
and O O
dynamic O O
bone O O
changes O O
in O O
patients O O
suffering O O
from O O
rickets O O
. O O
The O O
law O O
and O O
the O O
chiropractor O O
. O O
In O O
contrast O O
, O O
overexpression O O
of O O
the O O
DREB2A B-GENE B-GENE
cDNA E-GENE E-GENE
induced O O
weak O O
expression O O
of O O
the O O
target O O
genes O O
under O O
unstressed O O
conditions O O
and O O
caused O O
growth O O
retardation O O
of O O
the O O
transgenic O O
plants O O
. O O
Our O O
findings O O
suggest O O
that O O
AIF O O
may O O
be O O
a O O
morphologic O O
correlate O O
of O O
tumor O O
regression O O
following O O
preoperative O O
cytotoxic O O
chemotherapy O O
. O O
Mean O O
total O O
homocysteine O O
( O O
tHcy O O
) O O
was O O
21 O O
. O O
1 O O
+ O O
/ O O
- O O
9 O O
. O O
5 O O
micromol O O
/ O O
L O O
and O O
median O O
concentration O O
was O O
19 O O
micromol O O
/ O O
L O O
. O O
Efficacy O O
of O O
probiotic O O
feed O O
additives O O
: O O
guidelines O O
for O O
the O O
evaluation O O
of O O
the O O
efficiency O O
of O O
microorganisms O O
in O O
dogs O O
, O O
cats O O
, O O
and O O
horses O O
] O O
Probiotic O O
microorganisms O O
are O O
frequently O O
in O O
use O O
as O O
feed O O
additives O O
for O O
farm O O
and O O
pet O O
animals O O
. O O
Lung O O
transplantation O O
is O O
warranted O O
for O O
stable O O
, O O
ventilator O O
- O O
dependent O O
recipients O O
. O O
Site O O
- O O
directed O O
mutagenesis O O
shows O O
that O O
sites O O
throughout O O
the O O
IRE S-GENE O
alter O O
negative O O
control O O
and O O
IRE B-GENE O
- I-GENE O
BP E-GENE O
binding O O
reflecting O O
the O O
fact O O
that O O
the O O
footprint O O
of O O
the O O
IRE B-GENE O
- I-GENE O
BP E-GENE O
is O O
over O O
the O O
entire O O
IRE S-GENE O
. O O
An O O
alternative O O
approach O O
to O O
random O O
integration O O
of O O
large O O
DNA O O
fragments O O
into O O
plants O O
is O O
to O O
utilize O O
one O O
of O O
several O O
site O O
- O O
specific O O
recombination O O
( O O
SSR O O
) O O
systems O O
, O O
such O O
as O O
Cre S-GENE O
/ O O
lox S-GENE O
. O O
Neonatal O O
masculinization O O
affects O O
maternal O O
behavior O O
sensitivity O O
in O O
female O O
rats O O
. O O
Recombinant B-GENE B-GENE
mouse I-GENE I-GENE
GSTT1 I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
was O O
catalytically O O
active O O
towards O O
1 O O
, O O
2 O O
- O O
epoxy O O
- O O
3 O O
- O O
( O O
p O O
- O O
nitrophenoxy O O
) O O
propane O O
, O O
4 O O
- O O
nitrobenzyl O O
chloride O O
and O O
dichloromethane O O
. O O
In O O
addition O O
, O O
six O O
other O O
landmarks O O
favored O O
the O O
xeroradiograph O O
but O O
not O O
to O O
the O O
degree O O
of O O
statistical O O
significance O O
. O O
Nonlethal O O
sec71 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
sec72 B-GENE O
- I-GENE O
1 I-GENE O
mutations E-GENE O
eliminate O O
proteins O O
associated O O
with O O
the O O
Sec63p S-GENE B-GENE
- O I-GENE
BiP S-GENE E-GENE
complex O O
from O O
S O O
. O O
cerevisiae O O
. O O
Sequence O O
and O O
deletion O O
analysis O O
of O O
the O O
recombination B-GENE O
enhancement I-GENE O
gene E-GENE O
( O O
ref S-GENE O
) O O
of O O
bacteriophage O O
P1 O O
: O O
evidence O O
for O O
promoter O O
- O O
operator O O
and O O
attenuator O O
- O O
antiterminator O O
control O O
. O O
A O O
high O O
titer O O
of O O
anti B-GENE O
- I-GENE O
HBc E-GENE O
, O O
thus O O
suggested O O
to O O
be O O
an O O
indicator O O
of O O
persistent O O
hepatitis O O
B O O
virus O O
infection O O
, O O
was O O
found O O
rarely O O
in O O
seronegative O O
patients O O
with O O
chronic O O
hepatitis O O
, O O
non O O
- O O
alcoholic O O
cirrhosis O O
, O O
or O O
alcoholic O O
liver O O
diseases O O
. O O
Adaptability O O
of O O
Nippostrongylus O O
brasiliensis O O
( O O
Travassos O O
, O O
1914 O O
) O O
to O O
lead O O
contamination O O
Eph B-GENE B-GENE
receptors E-GENE E-GENE
and O O
their O O
membrane O O
- O O
associated O O
ephrin B-GENE O
ligands E-GENE O
regulate O O
cell O O
- O O
cell O O
interactions O O
during O O
development O O
. O O
We O O
discuss O O
the O O
possibility O O
that O O
DNA O O
- O O
protein O O
interactions O O
at O O
homologous O O
nucleotide O O
sequences O O
like O O
those O O
identified O O
in O O
PII O S-GENE
are O O
part O O
of O O
a O O
regulatory O O
gene O O
cascade O O
that O O
participates O O
in O O
timing O O
fla B-GENE O
gene E-GENE O
expression O O
in O O
the O O
C O O
. O O
crescentus O O
cell O O
cycle O O
. O O
Postcontrast O O
images O O
were O O
also O O
acquired O O
in O O
the O O
sagittal O O
( O O
six O O
patients O O
) O O
and O O
coronal O O
( O O
three O O
patients O O
) O O
planes O O
. O O
Nature O O
of O O
the O O
thermopower O O
in O O
bipolar O O
semiconductors O O
. O O
To O O
increase O O
the O O
number O O
of O O
circulating O O
polymorphonuclear O O
neutrophils O O
, O O
the O O
patient O O
was O O
treated O O
with O O
recombinant O O
granulocyte B-GENE O
- I-GENE O
macrophage I-GENE O
colony I-GENE O
- I-GENE O
stimulating I-GENE O
factor E-GENE O
( O O
GM B-GENE O
- I-GENE O
CSF E-GENE O
) O O
at O O
a O O
dose O O
of O O
2 O O
micrograms O O
protein O O
/ O O
kg O O
bodyweight O O
s O O
. O O
c O O
. O O
/ O O
12 O O
h O O
. O O
By O O
using O O
methanol O O
- O O
0 O O
. O O
15 O O
M O O
borate O O
buffer O O
of O O
pH O O
8 O O
. O O
0 O O
, O O
cate B-GENE O
- I-GENE O
chol I-GENE O
- I-GENE O
O I-GENE O
- I-GENE O
methyltransferase E-GENE O
activity O O
might O O
be O O
assayed O O
. O O
All O O
patients O O
were O O
peritonitis O O
- O O
free O O
at O O
least O O
6 O O
weeks O O
before O O
each O O
PET O O
. O O
The O O
amino O O
acid O O
residues O O
and O O
subdomains O O
important O O
for O O
DNA O O
binding O O
, O O
hormone O O
binding O O
, O O
dimerization O O
, O O
and O O
transactivation O O
are O O
mostly O O
conserved O O
among O O
all O O
VDR S-GENE O
species O O
. O O
Transcripts O O
appear O O
to O O
be O O
initiated O O
from O O
an O O
upstream O O
promoter O O
, O O
P1 O O
, O O
located O O
in O O
front O O
of O O
the O O
tRNA B-GENE S-GENE
( I-GENE O
met1 I-GENE S-GENE
) I-GENE O
gene E-GENE O
and O O
from O O
three O O
internal O O
promoters O O
: O O
P2 O O
is O O
located O O
immediately O O
in O O
front O O
of O O
the O O
tRNA B-GENE S-GENE
( I-GENE O
met2 I-GENE S-GENE
) I-GENE O
gene E-GENE O
; O O
PL10 O S-GENE
is O O
near O O
the O O
beginning O O
of O O
the O O
L1 S-GENE O
- O O
L10 S-GENE O
intergenic O O
space O O
, O O
and O O
PL12 O S-GENE
is O O
at O O
the O O
end O O
of O O
the O O
L10 B-GENE B-GENE
gene I-GENE E-GENE
sequence E-GENE O
. O O
Based O O
on O O
the O O
deduced O O
amino O O
acid O O
sequence O O
identity O O
we O O
designated O O
GAPC1 S-GENE S-GENE
and O O
GAPC2 S-GENE S-GENE
as O O
group O O
I O O
( O O
97 O O
% O O
identical O O
) O O
and O O
GAPC3 S-GENE O
and O O
GAPC4 S-GENE O
as O O
group O O
II O O
( O O
99 O O
. O O
4 O O
% O O
identical O O
) O O
. O O
A O O
case O O
of O O
functioning O O
parathyroid O O
carcinoma O O
with O O
hypereninemic O O
hypertension O O
. O O
Finally O O
, O O
gel O O
shift O O
assays O O
showed O O
that O O
ORF2 O S-GENE
was O O
able O O
to O O
bind O O
to O O
promoter O O
fragment O O
566 O O
- O O
888 O O
. O O
Critical O O
review O O
of O O
general O O
results O O
Saturated O O
fatty O O
acids O O
induce O O
a O O
1 O O
. O O
6 O O
- O O
fold O O
increase O O
in O O
transcription O O
activity O O
, O O
whereas O O
a O O
large O O
family O O
of O O
unsaturated O O
fatty O O
acids O O
repress O O
OLE1 S-GENE S-GENE
transcription O O
as O O
much O O
as O O
60 O O
- O O
fold O O
. O O
This O O
polypeptide O O
includes O O
the O O
first O O
three O O
zinc O O
fingers O O
of O O
the O O
TFIIIA B-GENE O
DNA I-GENE O
binding I-GENE O
domain E-GENE O
. O O
An O O
exception O O
is O O
the O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
gene E-GENE E-GENE
, O O
encoding O O
a O O
transcription O O
factor O O
, O O
which O O
was O O
found O O
to O O
be O O
mutated O O
in O O
normal O O
human O O
memory O O
B O O
cells O O
. O O
3 O O
. O O
A O O
chest O O
- O O
X O O
ray O O
film O O
showed O O
infiltrative O O
shadows O O
in O O
the O O
right O O
middle O O
and O O
lower O O
lung O O
fields O O
, O O
but O O
a O O
chest O O
CT O O
scan O O
showed O O
an O O
abnormal O O
lung O O
density O O
in O O
the O O
right O O
lower O O
lobe O O
. O O
In O O
both O O
liver O O
and O O
pancreatic O O
islet O O
, O O
glucokinase S-GENE O
is O O
subject O O
to O O
inhibition O O
by O O
a O O
regulatory O O
protein O O
( O O
GCKR S-GENE S-GENE
) O O
. O O
MRI O O
measurements O O
of O O
the O O
brain O O
. O O
Similarly O O
, O O
TAM B-GENE O
- I-GENE O
67 E-GENE O
reverted O O
the O O
morphology O O
of O O
the O O
AdoMetDC B-GENE O
- I-GENE O
antisense I-GENE O
expressors E-GENE O
. O O
Of O O
concern O O
is O O
the O O
high O O
, O O
unexplained O O
prevalence O O
of O O
BV O O
among O O
African O O
- O O
American O O
women O O
, O O
who O O
are O O
also O O
at O O
extremely O O
high O O
risk O O
for O O
preterm O O
birth O O
. O O
The O O
use O O
of O O
bentonite O O
in O O
the O O
compounding O O
of O O
hydrogels O O
Cotransfection O O
of O O
expression O O
plasmids O O
encoding O O
the O O
protein B-GENE B-GENE
kinase I-GENE E-GENE
A E-GENE O
inhibitor O O
, O O
or O O
an O O
inactive O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
A E-GENE E-GENE
( O O
PKA S-GENE S-GENE
) O O
catalytic O B-GENE
beta O I-GENE
subunit O E-GENE
, O O
inhibited O O
both O O
forskolin O O
and O O
PACAP S-GENE S-GENE
activation O O
of O O
chromogranin B-GENE O
A E-GENE O
transcription O O
, O O
revealing O O
that O O
PACAP S-GENE S-GENE
- O O
induced O O
trans O O
- O O
activation O O
is O O
highly O O
dependent O O
on O O
PKA S-GENE S-GENE
. O O
GH S-GENE S-GENE
induced O O
rapid O O
tyrosine O O
phosphorylation O O
of O O
a O O
protein O O
at O O
approximately O O
93 O O
kDa O O
in O O
normal O O
fibroblasts O O
, O O
and O O
Western O O
blotting O O
with O O
STAT B-GENE O
- I-GENE O
specific I-GENE O
antibodies E-GENE O
revealed O O
STAT5 S-GENE S-GENE
activation O O
( O O
phosphorylation O O
) O O
by O O
GH O S-GENE
. O O
The O O
most O O
valid O O
method O O
was O O
the O O
AXB O O
bearing O O
with O O
the O O
cephalometric O O
clinical O O
diagnosis O O
a O O
90 O O
. O O
91 O O
% O O
concordance O O
. O O
The O O
cdc42W97R B-GENE O
temperature I-GENE O
- I-GENE O
sensitive I-GENE O
allele E-GENE O
in O O
S O O
. O O
cerevisiae O O
displayed O O
the O O
same O O
cell O O
- O O
division O O
- O O
cycle O O
arrest O O
phenotype O O
( O O
large O O
, O O
round O O
unbudded O O
cells O O
) O O
as O O
the O O
cdc42 B-GENE B-GENE
- I-GENE I-GENE
1ts I-GENE I-GENE
mutant E-GENE E-GENE
. O O
The O O
cyanobacterial B-GENE O
phycobilisome E-GENE O
is O O
a O O
large O O
protein O O
complex O O
located O O
on O O
the O O
photosynthetic O O
membrane O O
. O O
One O O
day O O
after O O
injection O O
48 O O
% O O
of O O
the O O
injected O O
activity O O
was O O
in O O
the O O
skeleton O O
, O O
9 O O
. O O
3 O O
% O O
in O O
the O O
liver O O
, O O
3 O O
% O O
in O O
the O O
kidneys O O
and O O
4 O O
. O O
4 O O
% O O
in O O
the O O
rest O O
of O O
the O O
organs O O
. O O
OBJECTIVE O O
: O O
To O O
assess O O
laboratory O O
practice O O
in O O
the O O
examination O O
of O O
blood O O
films O O
for O O
malarial O O
parasites O O
. O O
BACKGROUND O O
: O O
A O O
thorough O O
understanding O O
of O O
malignant O O
fibrous O O
histiocytoma O O
( O O
MFH O O
) O O
, O O
the O O
most O O
common O O
subtype O O
of O O
soft O O
tissue O O
sarcoma O O
, O O
will O O
lead O O
to O O
improved O O
histologic O O
- O O
specific O O
protocols O O
. O O
Sequence O O
analyses O O
revealed O O
a O O
partial O O
941 O O
bp O O
cDNA O O
that O O
encoded O O
a O O
313 O O
- O O
amino O O
- O O
acid O O
polypeptide O O
. O O
Furthermore O O
, O O
CBP S-GENE S-GENE
/ O O
p300 S-GENE S-GENE
stimulated O O
both O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
- O O
and O O
Smad S-GENE O
- O O
induced O O
transcription O O
in O O
a O O
Smad4 S-GENE S-GENE
/ O O
DPC4 S-GENE O
- O O
dependent O O
fashion O O
. O O
Sequences O O
within O O
and O O
flanking O O
hypersensitive O O
sites O O
3 O O
and O O
2 O O
of O O
the O O
beta B-GENE O
- I-GENE O
globin E-GENE O
locus O O
control O O
region O O
required O O
for O O
synergistic O O
versus O O
additive O O
interaction O O
with O O
the O O
epsilon B-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
. O O
Sequence O O
analysis O O
revealed O O
100 O O
% O O
homology O O
of O O
all O O
RA O O
- O O
derived O O
PTEN B-GENE O
fragments E-GENE O
to O O
those O O
from O O
normal O O
SF O O
as O O
well O O
as O O
to O O
the O O
published O O
GenBank O O
sequence O O
( O O
accession O O
number O O
U93051 S-GENE O
) O O
. O O
174 O O
, O O
233 O O
- O O
247 O O
) O O
and O O
Serrate O O
( O O
Serrate1 O O
and O O
2 O O
; O O
Myat O O
, O O
A O O
. O O
, O O
Henrique O O
, O O
D O O
. O O
, O O
Ish O O
- O O
Horowicz O O
, O O
D O O
. O O
and O O
Lewis O O
, O O
J O O
. O O
, O O
1996 O O
. O O
Many O O
retroviruses O O
, O O
including O O
the O O
human O O
and O O
simian O O
immunodeficiency O O
viruses O O
, O O
contain O O
a O O
leucine O O
zipper O O
- O O
like O O
repeat O O
in O O
a O O
highly O O
conserved O O
region O O
of O O
the O O
external O O
domain O O
of O O
the O O
transmembrane O O
( O O
TM O S-GENE
) O O
glycoprotein O O
. O O
Functional O O
importance O O
of O O
a O O
properly O O
folded O O
surface O O
loop O O
covering O O
the O O
catalytic O O
center O O
. O O
The O O
most O O
frequent O O
abnormality O O
was O O
GH S-GENE O
deficiency O O
( O O
six O O
cases O O
) O O
, O O
followed O O
by O O
gonadotropin S-GENE O
( O O
four O O
cases O O
) O O
, O O
cortisol O O
( O O
four O O
cases O O
) O O
, O O
and O O
TSH S-GENE O
( O O
one O O
case O O
) O O
, O O
whereas O O
four O O
patients O O
showed O O
high O O
serum B-GENE O
PRL E-GENE O
values O O
. O O
Recombinant O O
vaccinia O O
viruses O O
that O O
express O O
the O O
bacteriophage B-GENE B-GENE
T3 I-GENE I-GENE
RNA I-GENE I-GENE
polymerase E-GENE E-GENE
( O O
VV B-GENE B-GENE
- I-GENE I-GENE
T3pol E-GENE E-GENE
) O O
or O O
the O O
Escherichia B-GENE O
coli I-GENE O
lac I-GENE O
repressor E-GENE O
( O O
VV B-GENE O
- I-GENE O
lacI E-GENE O
) O O
under O O
control O O
of O O
the O O
early B-GENE O
- I-GENE O
late I-GENE O
vaccinia I-GENE O
promoter I-GENE O
P7 I-GENE O
. I-GENE O
5 E-GENE O
were O O
constructed O O
. O O
Internal O O
controls O O
over O O
the O O
volume O O
of O O
milk O O
suckled O O
do O O
not O O
appear O O
until O O
infant O O
rats O O
are O O
about O O
2 O O
weeks O O
of O O
age O O
at O O
which O O
time O O
gastric O O
distension O O
, O O
milk O O
, O O
systemic O O
dehydration O O
, O O
and O O
intestinal B-GENE O
hormone I-GENE O
cholecystokinin E-GENE O
suppress O O
milk O O
intake O O
derived O O
through O O
suckling O O
. O O
Shields O O
needed O O
for O O
pacemakers O O
. O O
Concerning O O
the O O
practical O O
approach O O
in O O
a O O
clinical O O
setting O O
, O O
it O O
has O O
to O O
be O O
pointed O O
out O O
that O O
with O O
these O O
diseases O O
a O O
hepatitis O O
C O O
infection O O
has O O
to O O
be O O
considered O O
and O O
testing O O
for O O
hepatitis B-GENE O
C I-GENE O
antibodies E-GENE O
and O O
, O O
if O O
positive O O
, O O
hepatitis B-GENE O
C I-GENE O
- I-GENE O
RNA E-GENE O
is O O
indicated O O
. O O
Confocal O O
fluorescent O O
microscopy O O
analysis O O
demonstrated O O
that O O
WT O O
, O O
VaI O O
, O O
and O O
VaII O O
all O O
distribute O O
equally O O
to O O
the O O
cell O O
surface O O
while O O
, O O
as O O
expected O O
, O O
a O O
WT O O
mutant O O
lacking O O
the O O
two O O
C O O
- O O
terminal O O
valine O O
residues O O
does O O
not O O
. O O
However O O
, O O
it O O
is O O
not O O
easy O O
to O O
establish O O
the O O
diagnosis O O
of O O
thoracic O O
MFH O O
. O O
In O O
both O O
cell O O
types O O
, O O
insulin S-GENE O
led O O
to O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
association O O
of O O
tyrosine B-GENE O
phosphorylated I-GENE O
IRS I-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
with O O
the O O
SH2 B-GENE S-GENE
domain E-GENE O
of O O
the O O
p85 B-GENE S-GENE
regulatory I-GENE O
subunit E-GENE O
of O O
PI B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
kinase E-GENE E-GENE
, O O
and O O
also O O
increased O O
the O O
amount O O
of O O
PI B-GENE B-GENE
kinase E-GENE E-GENE
activity O O
detected O O
in O O
anti B-GENE O
- I-GENE O
IRS I-GENE O
- I-GENE O
1 E-GENE O
immunoprecipitates O O
. O O
The O O
" O O
Ulm O O
Zucker O O
Uhr O O
System O O
" O O
comprises O O
a O O
microdialysis O O
probe O O
, O O
a O O
biosensor O O
( O O
Glucosensor O O
Unitec O O
Ulm O O
s O O
. O O
c O O
. O O
) O O
, O O
a O O
sender O O
transferring O O
telemetrically O O
the O O
glucose O O
concentrations O O
, O O
and O O
a O O
receiving O O
indicator O O
. O O
The O O
Xenopus B-GENE B-GENE
annexin I-GENE I-GENE
II I-GENE E-GENE
heavy I-GENE O
chain E-GENE O
lacks O O
the O O
highly O O
conserved O O
tyrosine O O
at O O
position O O
23 O O
which O O
is O O
the O O
site O O
of O O
src B-GENE B-GENE
oncogene E-GENE I-GENE
tyrosine B-GENE I-GENE
kinase E-GENE E-GENE
phosphorylation O O
in O O
the O O
murine O O
protein O O
. O O
No O O
bafilomycin O O
- O O
sensitive O O
ATPase S-GENE O
is O O
detected O O
in O O
a O O
vacuolar O O
fraction O O
. O O
Plasmids O O
bearing O O
the O O
P B-GENE O
. I-GENE O
stipitis I-GENE O
URA3 I-GENE B-GENE
gene E-GENE E-GENE
and O O
ARS2 O S-GENE
element O O
produced O O
more O O
than O O
30 O O
, O O
000 O O
transformants O O
per O O
micrograms O O
of O O
plasmid O O
DNA O O
. O O
Unfractionated O O
heparin O O
( O O
UFH O O
) O O
given O O
at O O
a O O
dose O O
of O O
0 O O
. O O
3 O O
mg O O
x O O
kg O O
- O O
1 O O
bolus O O
+ O O
0 O O
. O O
3 O O
mg O O
x O O
kg O O
- O O
1 O O
x O O
h O O
- O O
1 O O
infusion O O
did O O
not O O
improve O O
the O O
incidence O O
of O O
reperfusion O O
or O O
lower O O
the O O
incidence O O
of O O
reocclusion O O
. O O
The O O
scores O O
for O O
these O O
three O O
factors O O
, O O
which O O
corresponded O O
to O O
recognizable O O
dimensions O O
of O O
depressive O O
illness O O
, O O
were O O
then O O
correlated O O
with O O
rCBF O O
. O O
Cloning O O
, O O
sequence O O
analysis O O
, O O
and O O
expression O O
of O O
the O O
gene B-GENE O
encoding I-GENE O
formaldehyde I-GENE O
dismutase I-GENE O
from I-GENE O
Pseudomonas I-GENE O
putida I-GENE O
F61 E-GENE S-GENE
. O O
However O O
, O O
at O O
the O O
time O O
of O O
salvage O O
treatment O O
, O O
the O O
mean O O
serum B-GENE O
PSA E-GENE O
levels O O
were O O
9 O O
. O O
1 O O
and O O
1 O O
. O O
1 O O
ng O O
/ O O
mL O O
for O O
the O O
salvage O O
RP O O
and O O
salvage O O
RT O O
groups O O
, O O
respectively O O
( O O
P O O
= O O
0 O O
. O O
0001 O O
) O O
. O O
Protease O O
digestion O O
and O O
alkaline O O
extraction O O
of O O
microsomes O O
containing O O
labeled O O
mutant O O
proteins O O
further O O
showed O O
that O O
segment O O
3 O O
was O O
sufficient O O
for O O
stable O O
membrane O O
anchoring O O
of O O
the O O
glycoproteins O O
, O O
indicating O O
that O O
this O O
segment O O
may O O
specify O O
the O O
transmembrane O O
domain O O
of O O
the O O
gB B-GENE B-GENE
glycoprotein E-GENE E-GENE
. O O
The O O
mean O O
times O O
to O O
LNR O O
in O O
these O O
groups O O
were O O
42 O O
. O O
0 O O
months O O
( O O
range O O
, O O
3 O O
. O O
0 O O
- O O
194 O O
. O O
5 O O
months O O
) O O
and O O
49 O O
. O O
0 O O
months O O
( O O
range O O
, O O
3 O O
. O O
6 O O
- O O
209 O O
. O O
0 O O
months O O
) O O
respectively O O
. O O
A O O
gene O O
( O O
FMR B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
was O O
identified O O
within O O
a O O
four O O
cosmid O O
contig O O
of O O
YAC O O
DNA O O
that O O
expresses O O
a O O
4 O O
. O O
8 O O
kb O O
message O O
in O O
human O O
brain O O
. O O
Detailed O O
comparison O O
of O O
the O O
sequences O O
of O O
cp35 S-GENE S-GENE
and O O
human B-GENE B-GENE
calpactin I-GENE I-GENE
II E-GENE E-GENE
shows O O
that O O
the O O
only O O
substantial O O
sequence O O
dissimilarity O O
is O O
a O O
domain O O
encoding O O
amino O O
acids O O
between O O
residues O O
20 O O
and O O
40 O O
which O O
includes O O
a O O
tyrosine O O
phosphorylation O O
site O O
in O O
the O O
human O O
molecule O O
, O O
along O O
with O O
other O O
residues O O
of O O
possible O O
physiological O O
significance O O
. O O
Exogenous O O
heart O O
stress O O
raised O O
log O O
circulating O O
NE O O
concentration O O
in O O
proportion O O
to O O
the O O
rise O O
in O O
heart O O
rate O O
at O O
a O O
given O O
work O O
load O O
so O O
that O O
the O O
usual O O
relationship O O
between O O
these O O
variables O O
, O O
previously O O
observed O O
during O O
other O O
stresses O O
, O O
was O O
preserved O O
. O O
The O O
implication O O
of O O
Rac S-GENE S-GENE
and O O
Cdc42 S-GENE S-GENE
was O O
analyzed O O
in O O
transient O O
transfection O O
experiments O O
using O O
either O O
constitutively O O
active O O
( O O
V12 O O
) O O
or O O
dominant O O
- O O
interfering O O
( O O
N17 O S-GENE
) O O
mutants O O
. O O
Alternative O O
immune B-GENE O
globulin E-GENE O
preparation O O
when O O
standard O O
immune B-GENE O
serum I-GENE O
globulin E-GENE O
is O O
not O O
available O O
. O O
Plasma B-GENE O
insulin E-GENE O
responses O O
to O O
glucose O O
in O O
femoral O O
, O O
hepatic O O
, O O
and O O
pancreatic O O
veins O O
in O O
dogs O O
. O O
The O O
bioconversion O O
of O O
penicillin O O
G O O
, O O
an O O
inexpensive O O
substrate O O
, O O
to O O
the O O
valuable O O
intermediate O O
for O O
semisynthetic O O
cephalosporin O O
production O O
, O O
deacetoxycephalosporin O O
G O O
( O O
DAOG O O
) O O
, O O
had O O
been O O
recently O O
shown O O
to O O
be O O
increased O O
by O O
eliminating O O
agitation O O
and O O
adding O O
decane O O
. O O
Elevated O O
potassium O O
stimulation O O
of O O
GAL B-GENE B-GENE
mRNA E-GENE E-GENE
was O O
completely O O
blocked O O
, O O
but O O
pituitary O O
adenylyl B-GENE O
cyclase I-GENE O
- I-GENE O
activating I-GENE O
polypeptide E-GENE O
and O O
histamine O O
stimulations O O
were O O
only O O
partially O O
blocked O O
, O O
by O O
cycloheximide O O
. O O
In O O
lyzozyme S-GENE O
activity O O
there O O
was O O
periodicity O O
in O O
three O O
groups O O
but O O
not O O
in O O
the O O
youngest O O
foals O O
. O O
GBF1 S-GENE S-GENE
and O O
GBF2 B-GENE B-GENE
mRNA E-GENE E-GENE
is O O
present O O
in O O
light O O
and O O
dark O O
grown O O
leaves O O
as O O
well O O
as O O
in O O
roots O O
. O O
We O O
now O O
report O O
identification O O
and O O
analysis O O
of O O
transcriptional O O
activities O O
mediated O O
by O O
three O O
cis O O
- O O
acting O O
sites O O
within O O
a O O
90 O O
- O O
bp O O
portion O O
of O O
the O O
rDNA O O
enhancer O O
designated O O
the O O
modulator O O
region O O
. O O
A O O
porcine O O
model O O
of O O
diffuse O O
axonal O O
injury O O
, O O
developed O O
with O O
information O O
from O O
these O O
physical O O
models O O
and O O
earlier O O
in O O
vitro O O
tissue O O
modeling O O
studies O O
, O O
is O O
used O O
to O O
correlate O O
histologic O O
and O O
radiologic O O
evidence O O
of O O
axonal O O
injury O O
to O O
predicted O O
regions O O
of O O
injury O O
from O O
the O O
experimental O O
and O O
theoretical O O
analysis O O
. O O
Sample O O
size O O
requirement O O
for O O
repeated O O
measurements O O
in O O
continuous O O
data O O
. O O
A O O
transient O O
induction O O
of O O
both O O
c B-GENE O
- I-GENE O
fos E-GENE O
and O O
c B-GENE B-GENE
- I-GENE I-GENE
jun I-GENE I-GENE
mRNAs E-GENE E-GENE
by O O
TPA O S-GENE
was O O
observed O O
in O O
both O O
cell O O
populations O O
, O O
together O O
with O O
an O O
associated O O
suppression O O
of O O
BSP B-GENE B-GENE
mRNA E-GENE E-GENE
in O O
the O O
fetal O O
rat O O
calvarial O O
cells O O
. O O
Videoanalysis O O
confirms O O
the O O
ballistic O O
character O O
of O O
the O O
initial O O
phase O O
of O O
the O O
reaching O O
movement O O
. O O
The O O
isomerization O O
of O O
the O O
pre O O
- O O
existing O O
closed O O
complex O O
to O O
an O O
open O O
promoter O O
form O O
, O O
as O O
judged O O
by O O
the O O
local O O
denaturation O O
of O O
promoter O O
DNA O O
which O O
rendered O O
sequences O O
from O O
+ O O
5 O O
to O O
- O O
10 O O
reactive O O
towards O O
KMnO4 O O
, O O
was O O
shown O O
to O O
be O O
fully O O
dependent O O
on O O
NifA S-GENE O
. O O
HPV O O
- O O
16 O O
MARs O O
are O O
context O O
dependent O O
transcriptional O O
enhancers O O
, O O
and O O
activated O O
expression O O
of O O
HPV O O
- O O
16 O O
oncogenes O O
dependent O O
on O O
chromosomal O O
integration O O
may O O
positively O O
select O O
tumorigenic O O
cells O O
during O O
the O O
multistep O O
etiology O O
of O O
cervical O O
cancer O O
. O O
Sociological O O
analysis O O
of O O
the O O
family O O
. O O
This O O
enhancer O O
element O O
functioned O O
in O O
a O O
position O O
- O O
and O O
orientation O O
- O O
independent O O
manner O O
both O O
on O O
the O O
Pax B-GENE B-GENE
- I-GENE I-GENE
QNR I-GENE I-GENE
P0 I-GENE I-GENE
promoter E-GENE E-GENE
and O O
the O O
heterologous B-GENE B-GENE
thymidine I-GENE I-GENE
kinase I-GENE I-GENE
promoter E-GENE E-GENE
. O O
These O O
data O O
suggest O O
that O O
overexpression O O
of O O
MT S-GENE O
potentiates O O
the O O
growth O O
of O O
MCF7 O O
cells O O
, O O
whereas O O
downregulation O O
of O O
MT S-GENE O
elicits O O
antiproliferative O O
effects O O
. O O
A O O
multivariant O O
study O O
of O O
pituitary O O
adenoma O O
, O O
obtainment O O
of O O
two O O
logistic O O
regression O O
equations O O
as O O
an O O
auxiliary O O
support O O
in O O
the O O
diagnosis O O
of O O
these O O
tumors O O
. O O
Bile O O
salts O O
, O O
hormonal O O
control O O
, O O
and O O
the O O
male O O
disadvantage O O
. O O
Number O O
of O O
warm O O
- O O
units O O
with O O
higher O O
rates O O
of O O
firing O O
and O O
greater O O
thermal O O
coefficients O O
, O O
comparable O O
to O O
those O O
of O O
warm O O
- O O
units O O
in O O
the O O
adult O O
, O O
gradually O O
increased O O
with O O
growth O O
. O O
Such O O
unique O O
recognition O O
capabilities O O
are O O
generated O O
with O O
minimal O O
alterations O O
in O O
the O O
CDR3 S-GENE O
loops O O
of O O
the O O
TCR S-GENE S-GENE
. O O
To O O
this O O
effect O O
, O O
the O O
present O O
survey O O
puts O O
in O O
evidence O O
that O O
the O O
maximum O O
delay O O
of O O
stream O O
that O O
guarantees O O
the O O
good O O
dimensional O O
stability O O
of O O
these O O
class O O
A O O
alginates O O
is O O
of O O
45 O O
minutes O O
in O O
the O O
hot O O
and O O
humid O O
climatic O O
tropical O O
country O O
conditions O O
. O O
Gene B-GENE O
1 I-GENE O
of I-GENE O
the I-GENE O
murine I-GENE O
coronavirus I-GENE O
, I-GENE O
MHV I-GENE B-GENE
- I-GENE I-GENE
A59 E-GENE E-GENE
, O O
encodes O O
approximately O O
800 O O
kDa O O
of O O
protein O O
products O O
within O O
two O O
overlapping O O
open O O
reading O O
frames O O
( O O
ORFs O O
1a O O
and O O
1b O O
) O O
. O O
For O O
this O O
interaction O O
, O O
the O O
C O O
- O O
terminal O O
part O O
of O O
Sp1 S-GENE S-GENE
and O O
the O O
N O O
terminus O O
of O O
E2F1 S-GENE S-GENE
, O O
a O O
domain O O
also O O
present O O
in O O
E2F2 S-GENE S-GENE
and O O
E2F3 S-GENE S-GENE
but O O
absent O O
in O O
E2F4 S-GENE S-GENE
and O O
E2F5 S-GENE S-GENE
, O O
were O O
essential O O
. O O
Our O O
results O O
suggest O O
a O O
biological O O
role O O
for O O
Elf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
the O O
regulation O O
of O O
IgH B-GENE B-GENE
gene E-GENE E-GENE
expression O O
, O O
attribute O O
a O O
functional O O
role O O
for O O
receptor O O
- O O
induced O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
proteins E-GENE E-GENE
in O O
B O O
lymphocytes O O
and O O
provide O O
evidence O O
for O O
a O O
direct O O
link O O
between O O
IgM B-GENE B-GENE
receptor E-GENE E-GENE
- O O
mediated O O
signalling O O
and O O
3 O O
' O O
enhancer O O
activation O O
. O O
Oncogenic O O
activation O O
of O O
RET S-GENE S-GENE
is O O
detected O O
in O O
human O O
papillary O O
thyroid O O
tumours O O
and O O
in O O
multiple O O
endocrine O O
neoplasia O O
type O O
2 O O
syndromes O O
. O O
CD4 S-GENE S-GENE
degradation O O
mediated O O
by O O
Vpu S-GENE S-GENE
does O O
not O O
require O O
the O O
ER O B-GENE
chaperone O I-GENE
calnexin S-GENE E-GENE
and O O
is O O
dependent O O
on O O
an O O
intact O O
ubiquitin S-GENE O
- O O
conjugating O O
system O O
. O O
The O O
maternal B-GENE O
par I-GENE O
genes E-GENE O
and O O
the O O
segregation O O
of O O
cell O O
fate O O
specification O O
activities O O
in O O
early O O
Caenorhabditis O O
elegans O O
embryos O O
. O O
These O O
effects O O
were O O
antagonized O O
by O O
prior O O
administration O O
of O O
1 O O
- O O
( O O
2 O O
- O O
methoxyphenyl O O
) O O
- O O
4 O O
- O O
[ O O
- O O
( O O
2 O O
- O O
phthalimido O O
) O O
butyl O O
] O O
piperazine O O
) O O
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O
PURPOSE O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
adding O O
a O O
pulsating O O
bristle O O
action O O
to O O
the O O
established O O
oscillating O O
/ O O
rotating O O
action O O
of O O
the O O
Braun O O
Oral O O
- O O
B O O
Ultra O O
Plaque O O
Remover O O
( O O
D9 O O
) O O
on O O
plaque O O
removal O O
. O O
Detailed O O
analysis O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
revealed O O
sequence O O
elements O O
which O O
are O O
conserved O O
in O O
many O O
DNA B-GENE O
and I-GENE O
RNA I-GENE O
polymerases E-GENE O
. O O
Sub O O
- O O
inhibitory O O
and O O
post O O
- O O
antibiotic O O
effects O O
of O O
spiramycin O O
and O O
erythromycin O O
on O O
Staphylococcus O O
aureus O O
. O O
The O O
CydDC B-GENE O
system E-GENE O
appears O O
to O O
be O O
the O O
first O O
prokaryotic O O
example O O
of O O
a O O
heterodimeric B-GENE O
ABC I-GENE O
transport I-GENE O
system E-GENE O
in O O
which O O
each O O
polypeptide O O
contains O O
both O O
hydrophobic O O
and O O
ATP O O
- O O
binding O O
domains O O
. O O
The O O
single O O
- O O
copy O O
U20 B-GENE O
sequence E-GENE O
is O O
located O O
on O O
the O O
same O O
DNA O O
strand O O
as O O
the O O
nucleolin B-GENE B-GENE
mRNA E-GENE E-GENE
. O O
Gel O O
shift O O
and O O
southwestern O O
experiments O O
revealed O O
nuclear O O
proteins O O
of O O
43 O O
kDa O O
and O O
30 O O
kDa O O
in O O
GC O O
and O O
fish O O
cells O O
, O O
respectively O O
, O O
that O O
bind O O
specifically O O
to O O
the O O
tGH S-GENE B-GENE
CRE O E-GENE
, O O
suggesting O O
the O O
involvement O O
of O O
CRE B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
- I-GENE I-GENE
protein E-GENE E-GENE
/ O O
activating B-GENE O
- I-GENE O
transcription I-GENE O
- I-GENE O
factor I-GENE O
- I-GENE O
l E-GENE O
- O O
related O O
peptides O O
in O O
cAMP O O
response O O
. O O
The O O
coding O O
sequence O O
of O O
rat B-GENE B-GENE
MEK I-GENE I-GENE
kinase I-GENE I-GENE
1 E-GENE E-GENE
( O O
MEKK1 S-GENE S-GENE
) O O
has O O
been O O
determined O O
from O O
multiple O O
, O O
independent O O
cDNA O O
clones O O
. O O
In O O
response O O
to O O
the O O
need O O
for O O
better O O
quantitative O O
estimates O O
of O O
the O O
regional O O
distribution O O
of O O
the O O
active O O
bone O O
marrow O O
organ O O
in O O
infants O O
and O O
children O O
, O O
a O O
method O O
using O O
various O O
anatomical O O
data O O
has O O
been O O
developed O O
. O O
We O O
compared O O
these O O
responses O O
for O O
six O O
hatchling O O
and O O
eight O O
adult O O
Chrysemys O O
picta O O
from O O
an O O
Ohio O O
population O O
. O O
On O O
the O O
basis O O
of O O
experiments O O
with O O
mutant O O
virus O O
and O O
transfection O O
with O O
isolated O O
genes O O
, O O
the O O
herpes B-GENE O
simplex I-GENE O
virus I-GENE O
immediate I-GENE O
- I-GENE O
early I-GENE O
gene E-GENE O
product O O
ICP4 S-GENE S-GENE
is O O
known O O
to O O
positively O O
regulate O O
the O O
transcription O O
of O O
viral B-GENE O
early I-GENE O
and I-GENE O
late I-GENE O
genes E-GENE O
and O O
negatively O O
regulate O O
expression O O
from O O
its O O
own O O
promoter O O
. O O
A O O
female O O
infant O O
with O O
isolated O O
noncompaction O O
of O O
ventricular O O
myocardium O O
who O O
developed O O
ventricular O O
tachyarrhythmia O O
is O O
described O O
. O O
Recent O O
, O O
highly O O
visible O O
reviews O O
on O O
the O O
subject O O
have O O
clearly O O
pointed O O
out O O
that O O
little O O
is O O
known O O
about O O
the O O
cellular O O
mechanisms O O
through O O
which O O
inhaled O O
asbestos O O
fibers O O
cause O O
the O O
well O O
known O O
, O O
debilitating O O
lung O O
disease O O
- O O
asbestosis O O
( O O
i O O
. O O
e O O
. O O
interstitial O O
pulmonary O O
fibrosis O O
) O O
. O O
The O O
POU S-GENE O
- O O
specific O O
domain O O
of O O
Pit B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
essential O O
for O O
sequence O O
- O O
specific O O
, O O
high O O
affinity O O
DNA O O
binding O O
and O O
DNA O O
- O O
dependent O O
Pit B-GENE O
- I-GENE O
1 E-GENE O
- O O
Pit B-GENE O
- I-GENE O
1 E-GENE O
interactions O O
. O O
Also O O
, O O
the O O
placebo O O
nondepressed O O
patients O O
had O O
significantly O O
better O O
treatment O O
outcome O O
compared O O
with O O
the O O
placebo O O
depressed O O
patients O O
. O O
Obtaining O O
kidney O O
cells O O
from O O
a O O
beagle O O
puppy O O
( O O
RPB O O
- O O
1 O O
) O O
and O O
the O O
establishment O O
of O O
a O O
cryopreservation O O
bank O O
These O O
results O O
suggest O O
an O O
essential O O
role O O
of O O
the O O
binding O O
of O O
HNF B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
and O O
/ O O
or O O
HNF B-GENE O
- I-GENE O
4 I-GENE O
- I-GENE O
related I-GENE O
nuclear I-GENE O
factors E-GENE O
to O O
the O O
6 O O
beta O O
A O O
- O O
A O O
site O O
on O O
the O O
basal O O
transcriptional O O
activation O O
of O O
the O O
CYP3A2 B-GENE B-GENE
gene E-GENE E-GENE
in O O
liver O O
cells O O
. O O
It O O
is O O
envisaged O O
that O O
the O O
WHOQOL O O
- O O
BREF O O
will O O
be O O
most O O
useful O O
in O O
studies O O
that O O
require O O
a O O
brief O O
assessment O O
of O O
quality O O
of O O
life O O
, O O
for O O
example O O
, O O
in O O
large O O
epidemiological O O
studies O O
and O O
clinical O O
trials O O
where O O
quality O O
of O O
life O O
is O O
of O O
interest O O
. O O
Restriction O O
mapping O O
showed O O
that O O
the O O
two O O
recombinant O O
plasmids O O
shared O O
an O O
EcoRI B-GENE O
fragment E-GENE O
of O O
8 O O
. O O
9 O O
kb O O
. O O
Usefulness O O
of O O
glucocorticoids O O
in O O
the O O
treatment O O
of O O
congestive O O
heart O O
failure O O
The O O
chromosomal O O
location O O
of O O
these O O
YACs O S-GENE
was O O
verified O O
using O O
FISH O O
, O O
which O O
also O O
demonstrated O O
their O O
nonchimeric O O
nature O O
. O O
After O O
first O O
strand O O
cDNA O O
synthesis O O
from O O
fetal O O
brain O O
mRNAs O O
, O O
short O O
fragment O O
cDNAs O O
( O O
sf O O
- O O
cDNAs O O
) O O
were O O
synthesized O O
with O O
a O O
two O O
- O O
step O O
amplification O O
system O O
by O O
use O O
of O O
our O O
modified O O
Degenerate O O
Oligonucleotide O O
Primed O O
Shuttle O O
Polymerase O O
Chain O O
Reaction O O
( O O
DOP O O
- O O
Shuttle O O
- O O
PCR O O
) O O
method O O
. O O
For O O
evaluation O O
of O O
the O O
model O O
, O O
simulations O O
of O O
physiological O O
excitation O O
and O O
of O O
pathologies O O
( O O
Wolff O O
- O O
Parkinson O O
- O O
White O O
syndrome O O
, O O
complete O O
AV O O
- O O
block O O
, O O
inferior O O
wall O O
ischaemia O O
) O O
were O O
examined O O
. O O
Profilins B-GENE O
IIa I-GENE O
and I-GENE O
IIb E-GENE O
are O O
also O O
present O O
in O O
humans O O
, O O
suggesting O O
that O O
all O O
mammals O O
have O O
three O O
profilin B-GENE O
isoforms E-GENE O
. O O
Using O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
, O O
we O O
have O O
isolated O O
an O O
835 O O
amino O O
acid O O
RING O O
finger O O
( O O
C3HC4 O O
zinc O O
finger O O
) O O
protein O O
, O O
TIF1 B-GENE B-GENE
beta E-GENE E-GENE
( O O
also O O
named O O
KAP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
KRAB B-GENE S-GENE
domain E-GENE O
of O O
the O O
human O O
zinc O O
finger O O
factor O O
KOX1 S-GENE S-GENE
/ O O
ZNF10 S-GENE S-GENE
. O O
The O O
authors O O
report O O
about O O
the O O
exeresis O O
of O O
a O O
pyelonephrictic O O
left O O
small O O
kidney O O
with O O
laparoscopic O O
surgery O O
. O O
New O O
protein O O
- O O
free O O
products O O
for O O
diet O O
therapy O O
in O O
chronic O O
renal O O
insufficiency O O
Unestablished O O
quail O O
myoblasts O O
were O O
infected O O
with O O
a O O
retroviral O O
vector O O
encoding O O
the O O
oncogenic O O
form O O
of O O
H B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
in O O
order O O
to O O
investigate O O
the O O
mechanism O O
by O O
which O O
this O O
oncoprotein O O
interferes O O
with O O
terminal O O
differentiation O O
. O O
Early O O
detection O O
and O O
signs O O
of O O
hepatoangiosarcoma O O
among O O
vinyl O O
chloride O O
workers O O
. O O
The O O
reduced O O
expression O O
caused O O
by O O
multimerization O O
of O O
UAS2 O S-GENE
in O O
the O O
native O O
promoter O O
was O O
observed O O
only O O
in O O
the O O
presence O O
of O O
ADR1 S-GENE S-GENE
. O O
VP4 S-GENE S-GENE
differentially O O
regulates O O
TRAF2 S-GENE S-GENE
signaling O O
, O O
disengaging O O
JNK S-GENE S-GENE
activation O O
while O O
directing O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
to O O
effect O O
rotavirus O O
- O O
specific O O
cellular O O
responses O O
. O O
On O O
the O O
3rd O O
day O O
after O O
ischemia O O
of O O
the O O
remained O O
kidney O O
for O O
30 O O
min O O
, O O
structural O O
components O O
of O O
the O O
walls O O
of O O
the O O
glomerular O O
arterioles O O
and O O
those O O
of O O
the O O
filtration O O
- O O
reabsorption O O
barrier O O
undergo O O
certain O O
ultrastructural O O
changes O O
, O O
that O O
with O O
time O O
elapsed O O
( O O
7 O O
, O O
14 O O
days O O
) O O
gradually O O
pass O O
away O O
, O O
and O O
amount O O
of O O
cells O O
with O O
hypertrophic O O
processes O O
increases O O
. O O
The O O
purified O O
RAG1 B-GENE B-GENE
protein E-GENE E-GENE
overexpressed O O
in O O
E O O
. O O
coli O O
exhibited O O
the O O
expected O O
cleavage O O
activity O O
when O O
combined O O
with O O
RAG2 S-GENE O
purified O O
from O O
transfected O O
293T O O
cells O O
. O O
19 O O
, O O
4967 O O
- O O
4973 O O
) O O
. O O
Preventing O O
the O O
heterosexual O O
spread O O
of O O
HIV O O
into O O
this O O
vulnerable O O
population O O
is O O
a O O
formidable O O
public O O
health O O
challenge O O
. O O
Moreover O O
, O O
we O O
show O O
that O O
GATA B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
Sp1 S-GENE S-GENE
synergize O O
from O O
a O O
distance O O
in O O
constructs O O
designed O O
to O O
mimic O O
the O O
architecture O O
of O O
globin B-GENE O
locus I-GENE O
control I-GENE O
regions E-GENE O
and O O
downstream O O
globin B-GENE O
promoters E-GENE O
. O O
Superovulation O O
with O O
intrauterine O O
insemination O O
( O O
SO O O
- O O
IUI O O
) O O
has O O
been O O
suggested O O
as O O
an O O
alternative O O
to O O
gamete O O
intrafallopian O O
transfer O O
( O O
GIFT O O
) O O
, O O
despite O O
the O O
absence O O
of O O
controlled O O
or O O
comparative O O
trials O O
. O O
Mammalian O O
chromosome O O
ends O O
contain O O
long O O
arrays O O
of O O
TTAGGG O S-GENE
repeats O O
that O O
are O O
complexed O O
to O O
a O O
telomere O O
specific O O
protein O O
, O O
the O O
TTAGGG B-GENE B-GENE
repeat I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
, O O
TRF1 S-GENE S-GENE
. O O
Genotype O O
- O O
phenotype O O
correlations O O
in O O
male O O
patients O O
with O O
a O O
partial O O
nullisomy O O
of O O
the O O
X O O
chromosome O O
have O O
suggested O O
that O O
at O O
least O O
one O O
locus O O
involved O O
in O O
MRX O O
is O O
on O O
Xp22 O O
. O O
3 O O
. O O
Mean O O
disposition O O
constants O O
( O O
+ O O
/ O O
- O O
SD O O
) O O
were O O
obtained O O
from O O
individualized O O
fits O O
( O O
V1 O O
: O O
0 O O
. O O
398 O O
+ O O
/ O O
- O O
0 O O
. O O
336 O O
LITER O O
/ O O
KG O O
, O O
Vdarea O O
: O O
2 O O
. O O
53 O O
+ O O
/ O O
- O O
0 O O
. O O
72 O O
liter O O
/ O O
kg O O
, O O
alpha O O
: O O
0 O O
. O O
316 O O
+ O O
/ O O
- O O
0 O O
. O O
294 O O
min O O
- O O
1 O O
, O O
beta O O
: O O
0 O O
. O O
00204 O O
+ O O
/ O O
- O O
0 O O
. O O
00262 O O
min O O
- O O
1 O O
, O O
k2 O O
: O O
0 O O
. O O
0305 O O
+ O O
/ O O
- O O
0 O O
. O O
0101 O O
min O O
- O O
1 O O
) O O
. O O
The O O
gene O O
, O O
from O O
the O O
initiator O O
methionine O O
to O O
the O O
polyadenylation O O
site O O
, O O
is O O
contained O O
within O O
13 O O
244 O O
basepairs O O
and O O
contains O O
19 O O
exons O O
. O O
In O O
the O O
unit O O
housing O O
of O O
a O O
compact O O
cyclotron O O
and O O
positron O O
emission O O
CT O O
( O O
PET O O
) O O
, O O
positron O O
emitting O O
gas O O
such O O
as O O
15O O O
, O O
11C O O
, O O
C15O2 O O
, O O
C15O O O
etc O O
. O O
is O O
supplied O O
from O O
a O O
cyclotron O O
to O O
a O O
PET O O
room O O
through O O
a O O
transportation O O
pipe O O
with O O
an O O
appropriate O O
shield O O
to O O
reduce O O
positron O O
annihilation O O
radiation O O
. O O
Adhesion O O
was O O
inhibited O O
by O O
mAbs O S-GENE
against O O
the O O
COOH O O
- O O
terminus O O
and O O
central O O
cell O O
binding O O
domains O O
of O O
fibronectin S-GENE O
, O O
as O O
well O O
as O O
by O O
the O O
corresponding O O
CS1 S-GENE S-GENE
and O O
RGD B-GENE B-GENE
peptides E-GENE E-GENE
. O O
These O O
results O O
were O O
not O O
obtained O O
using O O
either O O
preimmune O O
sera O O
or O O
antiserum O O
specific O O
for O O
the O O
luminal O O
portion O O
of O O
the O O
glycoprotein O O
precursor O O
. O O
Cerebral O O
blood O O
flow O O
was O O
measured O O
using O O
the O O
iv O O
method O O
of O O
133 O O
- O O
Xe O O
CBF O O
determination O O
and O O
AVDO2 O O
was O O
measured O O
using O O
systemic O O
arterial O O
- O O
jugular O O
venous O O
oxygen O O
content O O
differences O O
. O O
Activation O O
of O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MAPK S-GENE S-GENE
) O O
pathway O O
enhances O O
long O O
- O O
range O O
transactivation O O
by O O
the O O
beta B-GENE O
- I-GENE O
globin I-GENE O
locus I-GENE O
control I-GENE O
region E-GENE O
( O O
LCR O O
) O O
( O O
W O O
. O O
In O O
situ O O
hybridization O O
of O O
whole O O
- O O
mount O O
mouse O O
embryos O O
with O O
Mex5 B-GENE O
antisense I-GENE O
RNA E-GENE O
provide O O
no O O
evidence O O
for O O
the O O
exclusion O O
of O O
Mex5 S-GENE O
during O O
embryonic O O
development O O
. O O
In O O
three O O
other O O
patients O O
the O O
electrophysiologic O O
characteristics O O
of O O
atrioventricular O O
conduction O O
prevented O O
a O O
demonstration O O
of O O
these O O
differences O O
. O O
Human O O
psychophysical O O
analysis O O
of O O
receptive O O
field O O
- O O
like O O
properties O O
- O O
- O O
II O O
. O O
3 O O
. O O
New O O
strategies O O
are O O
needed O O
to O O
prevent O O
coronary O O
rethrombosis O O
in O O
patients O O
with O O
minimal O O
atherosclerosis O O
after O O
thrombolytic O O
therapy O O
for O O
acute O O
myocardial O O
infarction O O
. O O
The O O
Ick S-GENE B-GENE
protein B-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
is O O
not O O
involved O O
in O O
antibody O O
- O O
mediated O O
CD4 S-GENE S-GENE
( O O
CDR3 B-GENE S-GENE
- I-GENE O
loop E-GENE O
) O O
signal O O
transduction O O
that O O
inhibits O O
HIV O O
- O O
1 O O
transcription O O
. O O
Programmed O O
peritoneal O O
lavage O O
in O O
suppurative O O
complications O O
of O O
perforated O O
ulcer O O
of O O
the O O
stomach O O
Deletion O O
analysis O O
of O O
the O O
7 B-GENE O
. I-GENE O
3 I-GENE O
- I-GENE O
kb I-GENE O
GATA I-GENE O
- I-GENE O
2 I-GENE O
promoter I-GENE O
region E-GENE O
revealed O O
that O O
a O O
1 O O
. O O
1 O O
- O O
kb O O
DNA O O
sequence O O
is O O
critical O O
for O O
expression O O
of O O
GATA B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
in O O
neurons O O
. O O
The O O
model O O
therefore O O
predicts O O
that O O
1 O O
) O O
on O O
- O O
line O O
calculation O O
of O O
airway O O
dead O O
space O O
and O O
end O O
- O O
expired O O
lung O O
volume O O
can O O
be O O
made O O
by O O
the O O
addition O O
of O O
an O O
oxygen O O
sine O O
- O O
wave O O
perturbation O O
component O O
to O O
the O O
mean O O
FIO2 O O
; O O
and O O
( O O
2 O O
) O O
QS O O
/ O O
QT O O
can O O
be O O
measured O O
from O O
the O O
resultant O O
oxygen O O
perturbation O O
sine O O
- O O
wave O O
amplitudes O O
in O O
the O O
expired O O
gas O O
and O O
in O O
arterial O O
and O O
mixed O O
- O O
venous O O
blood O O
and O O
is O O
independent O O
of O O
the O O
mean O O
blood O O
oxygen O O
partial O O
pressure O O
and O O
oxyhemoglobin S-GENE O
saturation O O
values O O
. O O
Consistent O O
with O O
this O O
, O O
rh5 S-GENE S-GENE
expression O O
in O O
R8 S-GENE O
disappears O O
when O O
R7 O O
cells O O
are O O
absent O O
( O O
in O O
sevenless B-GENE O
mutant E-GENE O
) O O
. O O
The O O
fusion O O
gene O O
cassette O O
was O O
placed O O
under O O
the O O
control O O
of O O
a O O
vaccinia B-GENE O
virus I-GENE O
early I-GENE O
promoter E-GENE O
and O O
cloned O O
in O O
a O O
host O O
- O O
restricted O O
fowlpox O O
viral O O
vector O O
. O O
Psoriasis O O
on O O
tumor O O
. O O
Fulminant O O
hepatic O O
failure O O
in O O
these O O
cases O O
could O O
be O O
characterized O O
by O O
: O O
( O O
1 O O
) O O
rapid O O
decrease O O
in O O
serum B-GENE O
alanine I-GENE O
transaminase E-GENE O
( O O
ALT S-GENE O
) O O
level O O
after O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
2 O O
) O O
prolonged O O
jaundice O O
despite O O
discontinuation O O
of O O
ecarazine O O
, O O
( O O
3 O O
) O O
high O O
incidence O O
of O O
anti B-GENE O
- I-GENE O
nuclear I-GENE O
antibody E-GENE O
( O O
ANA S-GENE O
) O O
( O O
57 O O
% O O
) O O
, O O
and O O
( O O
4 O O
) O O
histological O O
findings O O
of O O
extensive O O
hepatocellular O O
necrosis O O
ranging O O
from O O
bridging O O
necrosis O O
to O O
massive O O
necrosis O O
. O O
These O O
data O O
suggest O O
that O O
the O O
secreted O O
, O O
truncated O O
receptor O O
encoded O O
by O O
the O O
2 B-GENE O
. I-GENE O
6 I-GENE O
- I-GENE O
kb I-GENE O
c I-GENE O
- I-GENE O
erbB I-GENE O
transcript E-GENE O
can O O
bind O O
to O O
TGF B-GENE B-GENE
alpha E-GENE E-GENE
and O O
may O O
play O O
an O O
important O O
growth O O
- O O
regulatory O O
function O O
in O O
vitro O O
. O O
Localization O O
of O O
the O O
porcine O O
enzyme O O
in O O
the O O
endoplasmic O O
reticulum O O
is O O
consistent O O
with O O
immuno O O
- O O
electron O O
- O O
microscopic O O
studies O O
using O O
pig O O
hepatocytes O O
. O O
A O O
close O O
homologue O O
of O O
the O O
APK2a B-GENE B-GENE
gene E-GENE E-GENE
, O O
named O O
APK2b S-GENE S-GENE
, O O
was O O
also O O
isolated O O
from O O
the O O
Arabidopsis O O
cDNA O O
library O O
. O O
Thus O O
, O O
the O O
rates O O
of O O
a B-GENE O
- I-GENE O
factor I-GENE O
receptor E-GENE O
endocytosis O O
and O O
consequent O O
vacuolar O O
turnover O O
depend O O
on O O
the O O
available O O
level O O
of O O
ubiquitin S-GENE O
in O O
the O O
cell O O
. O O
Using O O
the O O
same O O
approach O O
we O O
have O O
shown O O
that O O
hFIRE S-GENE S-GENE
binds O O
the O O
stimulatory O O
proteins O O
Sp1 S-GENE S-GENE
and O O
Sp3 S-GENE S-GENE
in O O
addition O O
to O O
CBF S-GENE S-GENE
. O O
Non O O
- O O
specific O O
immunological O O
abnormalities O O
were O O
detected O O
in O O
8 O O
of O O
the O O
13 O O
patients O O
in O O
whom O O
they O O
were O O
looked O O
for O O
. O O
Using O O
a O O
combined O O
pharmacokinetic O O
- O O
pharmacodynamic O O
model O O
, O O
the O O
impact O O
of O O
various O O
factors O O
on O O
the O O
effective O O
bioavailability O O
and O O
on O O
its O O
estimation O O
, O O
using O O
the O O
intravenous O O
- O O
to O O
- O O
oral O O
dose O O
ratio O O
required O O
to O O
produce O O
the O O
same O O
area O O
under O O
the O O
response O O
time O O
curve O O
after O O
acute O O
administration O O
, O O
are O O
explored O O
. O O
CONCLUSIONS O O
: O O
The O O
RRM O O
is O O
one O O
of O O
the O O
most O O
common O O
and O O
best O O
characterized O O
RNA O O
- O O
binding O O
motifs O O
. O O
The O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase E-GENE I-GENE
Cdk2 S-GENE E-GENE
associates O O
with O O
cyclins B-GENE O
A I-GENE O
, I-GENE O
D I-GENE O
, I-GENE O
and I-GENE O
E E-GENE O
and O O
has O O
been O O
implicated O O
in O O
the O O
control O O
of O O
the O O
G1 O O
to O O
S O O
phase O O
transition O O
in O O
mammals O O
. O O
Mol O O
. O O
The O O
amino B-GENE O
- I-GENE O
terminal I-GENE O
gag I-GENE O
- I-GENE O
encoded I-GENE O
region E-GENE O
of O O
P140gag S-GENE B-GENE
- O I-GENE
fps S-GENE E-GENE
contains O O
a O O
phosphotyrosine O O
residue O O
in O O
addition O O
to O O
normal O O
gag S-GENE O
phosphorylation O O
sites O O
. O O
Rad18 S-GENE S-GENE
is O O
required O O
for O O
DNA O O
repair O O
and O O
checkpoint O O
responses O O
in O O
fission O O
yeast O O
. O O
A O O
less O O
common O O
and O O
much O O
more O O
perplexing O O
circumstance O O
occurs O O
when O O
evaluating O O
patients O O
with O O
sarcoidosis O O
established O O
for O O
several O O
years O O
present O O
with O O
evidence O O
of O O
progressive O O
or O O
chronic O O
pulmonary O O
involvement O O
and O O
dyspnea O O
. O O
2 O O
, O O
4 O O
- O O
and O O
2 O O
, O O
6 O O
- O O
toluenediamine O O
in O O
hydrolysed O O
plasma O O
and O O
urine O O
after O O
test O O
- O O
chamber O O
exposure O O
of O O
humans O O
to O O
2 O O
, O O
4 O O
- O O
and O O
2 O O
, O O
6 O O
- O O
toluene O O
diisocyanate O O
. O O
Further O O
studies O O
are O O
warranted O O
to O O
determine O O
whether O O
these O O
findings O O
are O O
idiosyncratic O O
, O O
coincidental O O
, O O
or O O
a O O
more O O
general O O
phenomenon O O
. O O
After O O
1 O O
day O O
, O O
none O O
of O O
the O O
labeled O O
erythrocytes O O
were O O
detected O O
. O O
This O O
substrate O O
was O O
cleaved O O
efficiently O O
in O O
trans O O
by O O
protease B-GENE O
3C E-GENE O
derived O O
from O O
another O O
recombinant O O
vaccinia O O
virus O O
expressing O O
a O O
3C B-GENE O
precursor I-GENE O
protein E-GENE O
. O O
The O O
activity O O
of O O
gamma B-GENE O
- I-GENE O
glutamyl I-GENE O
transpeptidase E-GENE O
in O O
the O O
serum O O
of O O
problem O O
drinkers O O
. O O
Patients O O
with O O
endocarditis O O
or O O
vascular O O
infection O O
were O O
more O O
frequently O O
immunocompromised O O
and O O
older O O
than O O
those O O
with O O
acute O O
Q O O
fever O O
. O O
The O O
effects O O
of O O
oxalate O O
- O O
containing O O
products O O
on O O
the O O
exposed O O
dentine O O
surface O O
: O O
an O O
SEM O O
investigation O O
. O O
The O O
technique O O
used O O
by O O
this O O
system O O
involves O O
a O O
transient O O
, O O
externally O O
applied O O
increase O O
in O O
resistance O O
to O O
breathing O O
. O O
We O O
evaluated O O
99mTc O O
- O O
ECD O O
SPECT O O
comparing O O
with O O
rCBF O O
images O O
obtained O O
by O O
PET O O
in O O
12 O O
patients O O
with O O
spinocerebellar O O
degeneration O O
( O O
SCD O O
) O O
. O O
Monoclonal O O
antibodies O O
to O O
the O O
hapten O O
phenyloxazolone O O
were O O
raised O O
7 O O
days O O
after O O
immunization O O
in O O
mice O O
of O O
six O O
strains O O
( O O
BALB O O
/ O O
c O O
, O O
C57BL O O
- O O
Igha O O
, O O
DBA2 O O
, O O
RF O O
, O O
A O O
/ O O
J O O
, O O
and O O
CE O O
) O O
. O O
In O O
particular O O
, O O
lacZ B-GENE O
transcripts E-GENE O
synthesised O O
this O O
way O O
are O O
highly O O
unstable O O
and O O
yield O O
little O O
beta B-GENE O
- I-GENE O
galactosidase E-GENE O
. O O
Six O O
cDNAs O S-GENE
represent O O
human O O
homologs O O
of O O
genes O O
known O O
in O O
other O O
species O O
, O O
namely O O
, O O
mouse B-GENE O
HSPE71 E-GENE S-GENE
, O O
Rat B-GENE B-GENE
RhoGAP I-GENE I-GENE
protein E-GENE E-GENE
, O O
S B-GENE B-GENE
cerevisiae I-GENE I-GENE
leucyl I-GENE I-GENE
tRNA I-GENE I-GENE
synthetase E-GENE E-GENE
and O O
S B-GENE B-GENE
cerevisiae I-GENE I-GENE
chromosome I-GENE I-GENE
II I-GENE I-GENE
ORF I-GENE I-GENE
YBLO44W E-GENE E-GENE
. O O
The O O
thalamic O O
SD O O
was O O
regularly O O
triggered O O
by O O
short O O
( O O
0 O O
. O O
02 O O
- O O
0 O O
. O O
05 O O
s O O
) O O
high O O
- O O
frequency O O
( O O
200 O O
- O O
500 O O
Hz O O
) O O
ES O O
of O O
the O O
parietal O O
cortical O O
surface O O
. O O
All O O
three O O
SSV O O
- O O
transformed O O
cells O O
secreted O O
v B-GENE B-GENE
- I-GENE I-GENE
sis I-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
( O O
p44 S-GENE S-GENE
) O O
. O O
p44 S-GENE S-GENE
was O O
secreted O O
but O O
remained O O
tightly O O
associated O O
with O O
the O O
cell O O
surface O O
. O O
It O O
is O O
suggested O O
that O O
the O O
mechanism O O
of O O
intestinal O O
absorption O O
of O O
vitamin O O
D O O
and O O
25 O O
- O O
hydroxy O O
- O O
vitamin O O
D O O
may O O
differ O O
in O O
man O O
, O O
the O O
absorption O O
of O O
25 O O
- O O
hydroxy O O
- O O
vitamin O O
D O O
possibly O O
being O O
less O O
dependent O O
on O O
bile O O
acids O O
. O O
To O O
determine O O
the O O
role O O
of O O
elevated O O
FAK S-GENE S-GENE
expression O O
in O O
facilitating O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
EGF S-GENE S-GENE
) O O
- O O
stimulated O O
human O O
adenocarcinoma O O
( O O
A549 O S-GENE
) O O
cell O O
motility O O
, O O
antisense O O
oligonucleotides O O
were O O
used O O
to O O
reduce O O
FAK B-GENE B-GENE
protein E-GENE E-GENE
expression O O
> O O
75 O O
% O O
. O O
It O O
tends O O
to O O
be O O
higher O O
between O O
frazioni O O
of O O
the O O
same O O
community O O
than O O
between O O
communities O O
. O O
The O O
BRSV B-GENE B-GENE
L I-GENE I-GENE
gene E-GENE E-GENE
is O O
6573 O O
nt O O
in O O
length O O
and O O
the O O
derived O O
polypeptide O O
has O O
2162 O O
aa O O
. O O
To O O
further O O
study O O
the O O
role O O
of O O
tTG S-GENE O
in O O
liver O O
disease O O
, O O
we O O
initiated O O
investigations O O
into O O
the O O
effect O O
of O O
a O O
proinflammatory O O
mediator O O
, O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
TNF I-GENE S-GENE
) I-GENE O
- I-GENE O
alpha E-GENE O
, O O
on O O
tTG S-GENE S-GENE
activity O O
in O O
cultured O O
liver O O
cells O O
. O O
Availability O O
of O O
a O O
less O O
palatable O O
diet O O
( O O
chow O O
) O O
following O O
presentation O O
of O O
palatable O O
diets O O
will O O
not O O
result O O
in O O
diminished O O
caloric O O
intake O O
, O O
body O O
weight O O
, O O
obesity O O
and O O
hyperinsulinemia O O
. O O
By O O
contrast O O
, O O
CIS S-GENE O
failed O O
to O O
affect O O
the O O
IL B-GENE B-GENE
- I-GENE I-GENE
9 E-GENE E-GENE
response O O
. O O
METHODS O O
AND O O
RESULTS O O
: O O
With O O
an O O
array O O
of O O
112 O O
unipole O O
, O O
epicardial O O
maps O O
of O O
electrically O O
induced O O
AF O O
in O O
6 O O
dogs O O
( O O
acute O O
group O O
) O O
, O O
self O O
- O O
sustained O O
AF O O
in O O
6 O O
dogs O O
( O O
chronic O O
group O O
) O O
, O O
and O O
sinus O O
rhythm O O
and O O
atrial O O
pacing O O
in O O
3 O O
dogs O O
( O O
control O O
group O O
) O O
were O O
analyzed O O
before O O
and O O
after O O
creating O O
linear O O
radiofrequency O O
ablation O O
lesions O O
in O O
both O O
atria O O
that O O
eliminated O O
the O O
AF O O
. O O
In O O
response O O
to O O
phosphorus O O
limitation O O
, O O
the O O
fungus O O
Neurospora O O
crassa O O
synthesizes O O
a O O
number O O
of O O
enzymes O O
that O O
function O O
to O O
bring O O
more O O
phosphate O O
into O O
the O O
cell O O
. O O
The O O
effects O O
of O O
inoculum O O
size O O
, O O
medium O O
, O O
temperature O O
, O O
and O O
duration O O
of O O
growth O O
on O O
the O O
in O O
vitro O O
susceptibility O O
testing O O
of O O
Aspergillus O O
fumigatus O O
were O O
investigated O O
using O O
broth O O
micro O O
- O O
and O O
macro O O
- O O
dilution O O
techniques O O
. O O
We O O
have O O
analyzed O O
the O O
function O O
of O O
these O O
putative O O
SL O O
structures O O
in O O
RNA O O
translation O O
by O O
constructing O O
chimeric B-GENE O
chloramphenicol I-GENE B-GENE
acetyltransferase E-GENE E-GENE
( B-GENE O
CAT I-GENE O
) I-GENE O
RNAs E-GENE O
, O O
flanked O O
either O O
by O O
both O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
terminal O O
sequence O O
domains O O
from O O
the O O
RV O O
genome O O
or O O
several O O
deletion O O
derivatives O O
of O O
the O O
same O O
sequences O O
. O O
Periarteritis O O
nodosa O O
with O O
ruptures O O
of O O
the O O
renal O O
vessels O O
and O O
the O O
persistence O O
of O O
the O O
hepatitis O O
B O O
and O O
C O O
viruses O O
in O O
the O O
blood O O
Despite O O
the O O
fact O O
that O O
biochemical O O
estimates O O
of O O
bone O O
turnover O O
indicate O O
that O O
( O O
short O O
- O O
term O O
) O O
administration O O
of O O
rhGH S-GENE S-GENE
and O O
IGF B-GENE B-GENE
- I-GENE I-GENE
I E-GENE E-GENE
stimulates O O
bone O O
metabolism O O
in O O
non O O
- O O
osteoporotic O O
older O O
people O O
, O O
no O O
significant O O
changes O O
have O O
been O O
observed O O
in O O
bone O O
mineral O O
density O O
at O O
the O O
proximal O O
femur O O
. O O
Compression O O
of O O
pulmonary O O
artery O O
and O O
right O O
ventricular O O
outflow O O
tract O O
by O O
aneurysm O O
of O O
ascending O O
aorta O O
. O O
However O O
, O O
patients O O
with O O
DPX O O
should O O
be O O
observed O O
for O O
the O O
potential O O
occurrence O O
of O O
an O O
associated O O
condition O O
. O O
Blood O O
pressure O O
was O O
controlled O O
long O O
term O O
( O O
with O O
/ O O
without O O
diuretics O O
/ O O
beta B-GENE O
- I-GENE O
adrenoreceptor E-GENE O
blocking O O
drugs O O
) O O
in O O
sixteen O O
out O O
of O O
nineteen O O
patients O O
with O O
mild O O
- O O
moderate O O
hypertension O O
. O O
However O O
, O O
FosB B-GENE B-GENE
- I-GENE I-GENE
L E-GENE E-GENE
and O O
FosB B-GENE O
- I-GENE O
S E-GENE O
do O O
not O O
differ O O
in O O
all O O
trans O O
- O O
regulatory O O
properties O O
: O O
Trans O O
- O O
activation O O
of O O
a O O
5x O O
TRE B-GENE O
- I-GENE O
CAT E-GENE O
reporter O O
construct O O
in O O
HeLa O O
and O O
NIH O O
- O O
3T3 O O
cells O O
was O O
found O O
with O O
both O O
FosB S-GENE O
forms O O
. O O
Mutations O O
in O O
glnB S-GENE S-GENE
, O O
nifR1 S-GENE S-GENE
( O O
ntrC S-GENE S-GENE
) O O
, O O
and O O
NifR4 S-GENE S-GENE
( O O
ntrA S-GENE O
encoding O O
sigma B-GENE O
54 E-GENE O
) O O
had O O
no O O
influence O O
on O O
put B-GENE O
gene E-GENE O
expression O O
. O O
Disruption O O
of O O
INP53 S-GENE S-GENE
, O O
but O O
not O O
the O O
related O O
INP51 S-GENE S-GENE
and O O
INP52 B-GENE B-GENE
genes E-GENE E-GENE
, O O
resulted O O
in O O
alpha B-GENE B-GENE
- I-GENE I-GENE
factor E-GENE E-GENE
maturation O O
defects O O
and O O
exacerbated O O
alpha B-GENE B-GENE
- I-GENE I-GENE
factor E-GENE E-GENE
maturation O O
defects O O
when O O
combined O O
with O O
chc1 B-GENE O
- I-GENE O
521 E-GENE O
. O O
Impact O O
of O O
cytokine O O
gene O O
polymorphisms O O
on O O
outcomes O O
of O O
coronary O O
artery O O
bypass O O
graft O O
surgery O O
. O O
Regardless O O
of O O
muscle O O
tensioning O O
or O O
marination O O
treatments O O
, O O
aging O O
of O O
the O O
carcass O O
for O O
24 O O
h O O
( O O
T1 O O
, O O
T2 O O
, O O
and O O
T3 O O
) O O
produced O O
meats O O
with O O
lower O O
shear O O
values O O
than O O
those O O
from O O
hot O O
- O O
boned O O
carcasses O O
( O O
T4 O O
and O O
T5 O O
) O O
. O O
Blood O O
and O O
whole O O
- O O
brain O O
mercury O O
concentrations O O
were O O
determined O O
in O O
pups O O
on O O
PN O O
0 O O
( O O
birth O O
) O O
and O O
PN O O
21 O O
( O O
weaning O O
) O O
. O O
By O O
subtractive O O
and O O
differential O O
screening O O
, O O
we O O
have O O
cloned O O
12 O O
of O O
these O O
sequences O O
, O O
2 O O
of O O
which O O
were O O
c B-GENE O
- I-GENE O
fos E-GENE O
and O O
krox B-GENE O
- I-GENE O
24 E-GENE O
. O O
When O O
stratifying O O
FLM O O
values O O
< O O
34 O O
and O O
> O O
34 O O
wks O O
' O O
gestation O O
, O O
again O O
no O O
difference O O
was O O
found O O
in O O
mean O O
difference O O
of O O
L O O
/ O O
S O O
and O O
LB O O
before O O
and O O
after O O
34 O O
wks O O
. O O
Cotransfection O O
of O O
a O O
junB S-GENE O
stimulated O O
the O O
basal O O
activity O O
of O O
the O O
alpha B-GENE B-GENE
2 I-GENE E-GENE
( I-GENE O
I I-GENE O
) I-GENE O
collagen I-GENE O
promoter E-GENE O
93 O O
- O O
fold O O
, O O
respectively O O
. O O
Glutathione B-GENE B-GENE
reductase E-GENE E-GENE
( O O
GR S-GENE S-GENE
) O O
was O O
purified O O
from O O
the O O
cyanobacterium O O
Anabaena O O
PCC O O
7120 O S-GENE
. O O
Additional O O
simulations O O
account O O
for O O
interactions O O
of O O
spatial O O
frequency O O
with O O
stimulus O O
duration O O
, O O
effects O O
of O O
adaptation O O
, O O
and O O
properties O O
of O O
residual O O
traces O O
, O O
as O O
opposed O O
to O O
visual O O
persistence O O
. O O
Fractional O O
Ca O O
retention O O
was O O
measured O O
from O O
the O O
72 O O
- O O
h O O
postdose O O
WBR O O
divided O O
by O O
WBR O O
at O O
time O O
0 O O
. O O
METHODS O O
: O O
The O O
study O O
population O O
included O O
70 O O
patients O O
with O O
acute O O
coronary O O
syndromes O O
( O O
14 O O
with O O
recent O O
acute O O
myocardial O O
infarction O O
and O O
56 O O
with O O
unstable O O
angina O O
pectoris O O
) O O
, O O
105 O O
patients O O
with O O
stable O O
angina O O
pectoris O O
, O O
and O O
75 O O
control O O
subjects O O
. O O
Furthermore O O
, O O
rubella B-GENE O
IgM I-GENE O
antibody E-GENE O
was O O
never O O
detected O O
after O O
immunization O O
in O O
women O O
who O O
were O O
HAI O O
- O O
negative O O
and O O
LA O O
- O O
positive O O
during O O
pregnancy O O
. O O
Disease O O
- O O
free O O
interval O O
was O O
greater O O
in O O
node O O
- O O
negative O O
Lx O O
patients O O
for O O
both O O
T1 O O
( O O
P O O
less O O
than O O
0 O O
. O O
007 O O
) O O
and O O
T2 O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
presentations O O
. O O
5 O O
' O O
- O O
Deletion O O
of O O
the O O
Stat B-GENE O
- I-GENE O
binding I-GENE O
sites E-GENE O
abolished O O
all O O
promoter O O
- O O
reporter O O
activity O O
in O O
response O O
to O O
PRL S-GENE O
. O O
A O O
review O O
of O O
156 O O
patients O O
younger O O
than O O
40 O O
treated O O
at O O
our O O
Department O O
between O O
1960 O O
and O O
1991 O O
with O O
transitional O O
cell O O
carcinoma O O
of O O
the O O
bladder O O
revealed O O
that O O
89 O O
. O O
1 O O
% O O
had O O
superficial O O
( O O
Ta O O
/ O O
T1 O O
) O O
disease O O
and O O
the O O
remaining O O
10 O O
. O O
9 O O
% O O
presented O O
with O O
invasive O O
disease O O
. O O
Plasma B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
thromboglobulin E-GENE E-GENE
( O O
beta B-GENE B-GENE
- I-GENE I-GENE
TG E-GENE E-GENE
) O O
, O O
a O O
platelet O O
- O O
specific O O
protein O O
, O O
is O O
a O O
marker O O
of O O
intravascular O O
platelet O O
degranulation O O
. O O
John O O
' O O
s O O
wort O O
DESIGN O O
, O O
SETTING O O
AND O O
SUBJECTS O O
: O O
The O O
analysis O O
is O O
based O O
on O O
data O O
collected O O
in O O
the O O
first O O
two O O
rounds O O
of O O
the O O
nationally O O
representative O O
Ghana O O
Living O O
Standards O O
Survey O O
, O O
held O O
in O O
1987 O O
/ O O
88 O O
( O O
GLSS O O
- O O
I O O
) O O
and O O
1988 O O
/ O O
89 O O
( O O
GLSS O O
- O O
II O O
) O O
, O O
with O O
both O O
surveys O O
covering O O
approximately O O
3000 O O
households O O
. O O
The O O
DNA O O
- O O
binding O O
proteins O O
are O O
without O O
effect O O
on O O
the O O
transcription O O
of O O
plasmids O O
lacking O O
binding O O
sites O O
or O O
when O O
the O O
binding O O
sites O O
are O O
located O O
further O O
upstream O O
. O O
The O O
Gastrointestinal O O
Tumor O O
Study O O
Group O O
( O O
GITSG O O
) O O
protocol O O
GI O O
- O O
7175 O O
randomized O O
227 O O
patients O O
between O O
1975 O O
and O O
1980 O O
following O O
complete O O
surgical O O
resection O O
of O O
stages O O
B2 O O
and O O
C O O
rectal O O
adenocarcinoma O O
to O O
four O O
treatment O O
arms O O
: O O
( O O
1 O O
) O O
no O O
adjuvant O O
therapy O O
, O O
( O O
2 O O
) O O
chemotherapy O O
only O O
, O O
( O O
3 O O
) O O
radiotherapy O O
only O O
, O O
and O O
( O O
4 O O
) O O
radiotherapy O O
and O O
chemotherapy O O
( O O
combined O O
modality O O
) O O
. O O
The O O
RTI40 B-GENE B-GENE
gene E-GENE E-GENE
spans O O
35 O O
kilobase O O
pairs O O
; O O
it O O
contains O O
6 O O
exons O O
and O O
at O O
least O O
6 O O
rat O O
Identifier O O
repetitive O O
elements O O
. O O
The O O
DNA O O
element O O
through O O
which O O
EBNA B-GENE O
- I-GENE O
3C E-GENE O
activates O O
the O O
LMP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
promoter E-GENE E-GENE
includes O O
a O O
Spi B-GENE O
- I-GENE O
1 E-GENE O
/ O O
Spi B-GENE O
- I-GENE O
B E-GENE O
binding O O
site O O
, O O
previously O O
characterized O O
as O O
an O O
important O O
EBNA B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
response I-GENE O
element E-GENE O
. O O
DP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
DP B-GENE O
- I-GENE O
2 E-GENE O
encode O O
maternally O O
stored O O
transcripts O O
that O O
are O O
expressed O O
during O O
early O O
development O O
. O O
Furthermore O O
, O O
deletion O O
of O O
two O O
potential O O
Ste11 B-GENE S-GENE
recognition I-GENE O
sites E-GENE O
in O O
the O O
fus1 B-GENE B-GENE
promoter E-GENE E-GENE
region O O
abolished O O
transcription O O
, O O
and O O
expression O O
could O O
be O O
restored O O
when O O
we O O
inserted O O
a O O
different O O
Ste11 B-GENE O
site E-GENE O
from O O
the O O
mat1 B-GENE B-GENE
- I-GENE I-GENE
P I-GENE I-GENE
promoter E-GENE E-GENE
. O O
However O O
, O O
an O O
analogous O O
myristoylated O O
peptide O O
derived O O
from O O
c B-GENE O
- I-GENE O
Yes E-GENE O
also O O
has O O
no O O
inhibitory O O
activity O O
. O O
The O O
oral O O
movements O O
which O O
did O O
occur O O
in O O
the O O
HAL O O
- O O
treated O O
rats O O
were O O
slower O O
than O O
normal O O
. O O
Finally O O
, O O
we O O
demonstrate O O
that O O
animals O O
carrying O O
a O O
snf S-GENE O
mutation O O
that O O
converts O O
SNF S-GENE S-GENE
from O O
a O O
bifunctional O O
protein O O
to O O
a O O
U1 B-GENE B-GENE
snRNP I-GENE I-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
protein E-GENE E-GENE
are O O
viable O O
. O O
These O O
sequence O O
differences O O
are O O
reflected O O
in O O
differences O O
in O O
gene O O
expression O O
in O O
three O O
cell O O
lines O O
. O O
This O O
pathway O O
has O O
been O O
reported O O
to O O
mediate O O
heterodimer O O
interactions O O
with O O
the O O
proapoptotic O O
regulator O O
, O O
Bad S-GENE O
. O O
Mutating O O
bases O O
- O O
142 O O
to O O
- O O
151 O O
abolishes O O
formation O O
of O O
complex O O
VII O O
and O O
partially O O
inhibits O O
complex O O
IV O O
, O O
suggesting O O
that O O
the O O
proteins O O
forming O O
these O O
complexes O O
bind O O
neighboring O O
segments O O
of O O
DNA O O
. O O
The O O
DFA O O
slide O O
prepared O O
from O O
the O O
ThinPrep O O
Test O O
and O O
the O O
conventional O O
DFA O O
sample O O
prepared O O
from O O
the O O
endocervical O O
swab O O
were O O
evaluated O O
independently O O
. O O
Moclobemide O O
is O O
a O O
well O O
- O O
tolerated O O
alternative O O
antidepressant O O
, O O
but O O
there O O
is O O
a O O
need O O
for O O
prospective O O
controlled O O
trials O O
to O O
evaluate O O
its O O
long O O
- O O
term O O
efficacy O O
. O O
METHODS O O
: O O
Autocapture O O
devices O O
( O O
Pacesetter O O
Microny O O
SR O O
+ O O
/ O O
- O O
and O O
Regency O O
SR O O
+ O O
/ O O
- O O
; O O
Pacesetter O O
, O O
Solna O O
, O O
Sweden O O
) O O
and O O
steroid O O
- O O
eluting O O
epicardial O O
pacing O O
leads O O
( O O
Medtronic O O
CapSure O O
Epi O O
10366 O O
; O O
Medtronic O O
, O O
Inc O O
, O O
Minneapolis O O
, O O
MN O O
) O O
were O O
implanted O O
in O O
14 O O
children O O
. O O
Hormonal O O
replacement O O
therapy O O
for O O
women O O
with O O
a O O
personal O O
history O O
of O O
breast O O
cancer O O
? O O
Recently O O
, O O
we O O
reported O O
that O O
SMRT S-GENE S-GENE
also O O
directly O O
associates O O
with O O
LAZ3 S-GENE S-GENE
( O O
BCL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
) O O
, O O
a O O
POZ O S-GENE
/ O O
Zn O O
finger O O
transcriptional O O
repressor O O
involvedin O O
the O O
pathogenesis O O
of O O
non O O
- O O
Hodgkin O O
lymphomas O O
. O O
Using O O
reporter O O
gene O O
constructs O O
driven O O
by O O
the O O
CD4 B-GENE B-GENE
promoter E-GENE E-GENE
, O O
we O O
report O O
that O O
HHV O B-GENE
- O I-GENE
6 O E-GENE
can O O
efficiently O O
transactivate O O
such O O
genetic O O
elements O O
. O O
Characterization O O
of O O
a O O
cDNA B-GENE O
encoding I-GENE O
CNN E-GENE O
predicts O O
a O O
novel O O
structural O O
protein O O
with O O
three O O
leucine O O
zipper O O
motifs O O
and O O
several O O
coiled O O
- O O
coil O O
domains O O
exhibiting O O
limited O O
homology O O
to O O
the O O
rod O O
portion O O
of O O
myosin S-GENE O
. O O
A O O
preformed O O
SREBP B-GENE O
- I-GENE O
1a I-GENE O
: I-GENE O
[ I-GENE O
32P I-GENE O
] I-GENE O
DNA I-GENE O
complex E-GENE O
bound O O
specifically O O
to O O
membrane O O
- O O
immobilized O O
GST S-GENE B-GENE
- O I-GENE
CBP S-GENE I-GENE
fusion O I-GENE
proteins O E-GENE
that O O
contained O O
amino O O
- O O
terminal O O
portions O O
of O O
CBP S-GENE S-GENE
. O O
Pyridostigmine O O
pretreatment O O
was O O
supplemented O O
by O O
therapy O O
with O O
two O O
doses O O
of O O
an O O
antidotal O O
combination O O
( O O
A O O
, O O
TM O O
, O O
B O O
) O O
consisting O O
of O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
atropine O O
, O O
2 O O
. O O
24 O O
mg O O
/ O O
kg O O
TMB O O
- O O
4 O O
, O O
and O O
0 O O
. O O
4 O O
mg O O
/ O O
kg O O
benactyzine O O
which O O
assured O O
survival O O
in O O
five O O
of O O
six O O
animals O O
following O O
three O O
separate O O
exposures O O
to O O
10 O O
LD50 O O
soman O O
. O O
Previous O O
work O O
established O O
that O O
the O O
TAL1 B-GENE B-GENE
proteins E-GENE E-GENE
are O O
phosphorylated O O
exclusively O O
on O O
serine O O
and O O
identified O O
Ser122 O S-GENE
as O O
a O O
substrate O O
for O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
ERK B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
Rapid O O
, O O
sensitive O O
gas O O
chromatographic O O
analysis O O
of O O
8 O O
- O O
methoxypsoralen O O
in O O
human O O
plasma O O
. O O
If O O
the O O
size O O
of O O
the O O
cystic O O
liver O O
- O O
lesions O O
excludes O O
a O O
curative O O
operative O O
treatment O O
or O O
if O O
the O O
patient O O
refuses O O
surgery O O
, O O
the O O
indication O O
for O O
chemotherapy O O
with O O
mebendazole O O
is O O
given O O
. O O
When O O
cotransfected O O
with O O
the O O
HIV B-GENE O
LTR E-GENE O
CAT S-GENE O
into O O
CV O O
- O O
1 O O
cells O O
, O O
both O O
the O O
pCD41 S-GENE S-GENE
and O O
pGD41 S-GENE O
clones O O
trans O O
- O O
activated O O
the O O
HIV B-GENE O
LTR E-GENE O
. O O
The O O
induction O O
of O O
the O O
composite O O
H B-GENE O
- I-GENE O
PK E-GENE O
/ O O
Tag S-GENE O
and O O
SV B-GENE O
- I-GENE O
PK E-GENE O
/ O O
Tag S-GENE O
transgenes O O
by O O
a O O
carbohydrate O O
- O O
rich O O
diet O O
in O O
the O O
liver O O
was O O
similar O O
to O O
that O O
of O O
the O O
endogenous B-GENE B-GENE
L I-GENE I-GENE
- I-GENE I-GENE
PK I-GENE I-GENE
gene E-GENE E-GENE
. O O
Patients O O
with O O
advanced O O
ovarian O O
carcinoma O O
, O O
Stage O O
III O O
or O O
IV O O
( O O
International O O
Federation O O
of O O
Gynaecology O O
and O O
Obstetrics O O
) O O
, O O
were O O
randomized O O
to O O
primary O O
chemotherapy O O
with O O
doxorubicin O O
( O O
Adriamycin O O
) O O
and O O
cisplatin O O
plus O O
or O O
minus O O
hexamethylmelamine O O
, O O
and O O
cyclophosphamide O O
( O O
CHAP O O
) O O
. O O
Exit O O
from O O
mitosis O O
in O O
Drosophila O O
syncytial O O
embryos O O
requires O O
proteolysis O O
and O O
cyclin S-GENE O
degradation O O
, O O
and O O
is O O
associated O O
with O O
localized O O
dephosphorylation O O
. O O
Cough O O
- O O
CPR O O
, O O
a O O
deep O O
rhythmic O O
forceful O O
cough O O
repeated O O
30 O O
- O O
60 O O
times O O
per O O
minute O O
, O O
can O O
be O O
an O O
effective O O
resuscitative O O
technique O O
during O O
emergencies O O
occurring O O
in O O
the O O
cardiac O O
catheterization O O
laboratory O O
. O O
To O O
understand O O
this O O
dramatic O O
effect O O
, O O
we O O
examined O O
the O O
localization O O
of O O
SR B-GENE B-GENE
proteins E-GENE E-GENE
and O O
found O O
that O O
SC35 S-GENE S-GENE
was O O
shifted O O
to O O
the O O
cytoplasm O O
in O O
sky1Delta S-GENE O
yeast O O
, O O
although O O
this O O
phenomenon O O
was O O
not O O
obvious O O
with O O
ASF S-GENE S-GENE
/ O O
SF2 S-GENE S-GENE
, O O
indicating O O
that O O
nuclear O O
import O O
of O O
SR B-GENE B-GENE
proteins E-GENE E-GENE
may O O
be O O
differentially O O
regulated O O
by O O
phosphorylation O O
. O O
Probiotics O O
, O O
prebiotics O O
, O O
vaccination O O
, O O
and O O
acidification O O
of O O
drinking O O
water O O
were O O
assessed O O
as O O
means O O
of O O
reducing O O
Salmonella O O
. O O
On O O
the O O
contrary O O
i O O
. O O
v O O
. O O
administration O O
of O O
calcitonin S-GENE O
increased O O
intrapyloric O O
pressure O O
via O O
vagal O O
nerves O O
in O O
atropinized O O
or O O
gallaminized O O
animals O O
. O O
We O O
conclude O O
that O O
in O O
the O O
presence O O
of O O
fatty O O
acids O O
in O O
the O O
medium O O
transcription O O
of O O
SPS19 S-GENE S-GENE
is O O
directly O O
regulated O O
by O O
both O O
Pip2p S-GENE B-GENE
- O I-GENE
Oaf1p S-GENE E-GENE
and O O
Adr1p S-GENE S-GENE
. O O
Gas O O
exchange O O
was O O
measured O O
breath O O
by O O
breath O O
. O O
We O O
found O O
that O O
in O O
premature O O
infants O O
plasminogen S-GENE O
levels O O
are O O
low O O
; O O
thus O O
, O O
defense O O
against O O
intra O O
- O O
alveolar O O
fibrin S-GENE O
deposition O O
during O O
birth O O
trauma O O
is O O
reduced O O
. O O
Analysis O O
of O O
nt O O
sequence O O
was O O
carried O O
out O O
on O O
three O O
out O O
of O O
the O O
more O O
than O O
15 O O
of O O
these O O
regions O O
present O O
in O O
the O O
mouse O O
genome O O
. O O
Studies O O
on O O
the O O
reaction O O
of O O
cytochrome B-GENE O
c E-GENE O
with O O
corticosteroids O O
. O O
However O O
, O O
both O O
RAR S-GENE O
- O O
and O O
RXR S-GENE O
- O O
specific O O
ligands O O
increase O O
CaSki O O
number O O
by O O
> O O
or O O
= O O
20 O O
% O O
. O O
Also O O
, O O
in O O
patients O O
with O O
MYD O O
, O O
there O O
was O O
a O O
significant O O
decrease O O
in O O
arterial O O
PO2 O O
from O O
the O O
seated O O
posture O O
to O O
the O O
supine O O
posture O O
, O O
without O O
a O O
significant O O
change O O
in O O
the O O
arterial O O
PCO2 O O
. O O
The O O
primary O O
structures O O
of O O
the O O
human B-GENE O
KB I-GENE O
cell I-GENE O
( I-GENE O
FR I-GENE B-GENE
- I-GENE I-GENE
KB1 I-GENE I-GENE
) I-GENE I-GENE
folate I-GENE I-GENE
receptor E-GENE E-GENE
( O O
FR S-GENE S-GENE
) O O
and O O
of O O
a O O
human B-GENE O
placental I-GENE O
( I-GENE O
FR I-GENE B-GENE
- I-GENE I-GENE
P2 I-GENE E-GENE
) I-GENE O
FR E-GENE S-GENE
, O O
proteins O O
important O O
in O O
cellular O O
accumulation O O
of O O
folates O O
, O O
have O O
been O O
deduced O O
from O O
cDNA O O
sequences O O
. O O
The O O
general O O
concept O O
of O O
RARE S-GENE O
- O O
cleavage O O
mapping O O
as O O
well O O
as O O
its O O
applications O O
and O O
limitations O O
are O O
discussed O O
. O O
To O O
further O O
investigate O O
the O O
role O O
of O O
PKR S-GENE S-GENE
in O O
transcriptional O O
signaling O O
, O O
we O O
expressed O O
the O O
wild B-GENE O
type I-GENE O
human I-GENE O
PKR E-GENE S-GENE
and O O
a O O
catalytically O O
inactive O O
dominant O O
negative O O
PKR B-GENE B-GENE
mutant E-GENE E-GENE
in O O
the O O
murine O O
pre O O
- O O
B O O
lymphoma O O
70Z O O
/ O O
3 O O
cells O O
. O O
Selective O O
upper O O
abdominal O O
sympathectomy O O
increased O O
basal O O
acid O O
output O O
in O O
rats O O
but O O
was O O
without O O
effect O O
on O O
stimulated O O
acid O O
output O O
, O O
serum B-GENE O
gastrin E-GENE O
concentration O O
, O O
and O O
gastric B-GENE O
mucosal I-GENE O
histidine I-GENE O
decarboxylase E-GENE O
activity O O
. O O
Reasons O O
are O O
presented O O
to O O
support O O
the O O
contention O O
that O O
this O O
increase O O
is O O
in O O
part O O
real O O
. O O
Patients O O
received O O
either O O
sodium O O
cephalothin O O
or O O
placebo O O
intravenously O O
before O O
the O O
procedure O O
and O O
for O O
up O O
to O O
8 O O
additional O O
doses O O
. O O
In O O
- O O
111 O O
- O O
BLMC O O
uptake O O
was O O
directly O O
proportional O O
to O O
Ki B-GENE O
- I-GENE O
67 E-GENE O
/ O O
MIB B-GENE O
- I-GENE O
1 E-GENE O
activity O O
and O O
number O O
of O O
mitoses O O
in O O
tumor O O
tissue O O
. O O
Heating O O
had O O
no O O
effect O O
upon O O
either O O
force O O
decline O O
or O O
slowing O O
of O O
relaxation O O
during O O
fatiguing O O
contractions O O
. O O
Binding O O
of O O
transformed O O
Ah B-GENE O
receptor I-GENE O
complex E-GENE O
to O O
a O O
dioxin O O
responsive O O
transcriptional O O
enhancer O O
: O O
evidence O O
for O O
two O O
distinct O O
heteromeric O O
DNA O O
- O O
binding O O
forms O O
. O O
Interestingly O O
, O O
VDR S-GENE S-GENE
was O O
able O O
to O O
bind O O
to O O
VDREs O S-GENE
with O O
high O O
affinity O O
and O O
to O O
fully O O
activate O O
transcription O O
in O O
intact O O
yeast O O
cells O O
in O O
the O O
presence O O
of O O
the O O
retinoid B-GENE B-GENE
X I-GENE I-GENE
receptor E-GENE E-GENE
( O O
RXR S-GENE S-GENE
) O O
. O O
Thus O O
, O O
it O O
appears O O
that O O
moxalactam O O
is O O
a O O
reliable O O
and O O
useful O O
antibiotic O O
for O O
the O O
treatment O O
of O O
complicated O O
urinary O O
tract O O
infections O O
. O O
A O O
fine O O
- O O
structure O O
radiation O O
hybrid O O
map O O
for O O
the O O
region O O
that O O
extends O O
from O O
D8S520 S-GENE O
( O O
distal O O
) O O
to O O
D8S1759 S-GENE O
( O O
proximal O O
) O O
was O O
prepared O O
, O O
followed O O
by O O
construction O O
of O O
a O O
single O O
, O O
integrated O O
YAC O O
/ O O
BAC O O
contig O O
for O O
the O O
interval O O
. O O
The O O
protein O O
contains O O
a O O
SHAQKYF O S-GENE
amino O O
acid O O
signature O O
motif O O
in O O
the O O
second O O
myb B-GENE O
- I-GENE O
like I-GENE O
repeat E-GENE O
, O O
which O O
is O O
highly O O
conserved O O
in O O
a O O
number O O
of O O
recently O O
identified O O
plant B-GENE O
myb I-GENE O
- I-GENE O
related I-GENE O
genes E-GENE O
, O O
thus O O
defining O O
a O O
new O O
class O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
. O O
IV O O
. O O
It O O
has O O
been O O
shown O O
that O O
renin S-GENE O
secretion O O
is O O
stimulated O O
by O O
endothelin S-GENE O
, O O
a O O
recently O O
discovered O O
peptide O O
with O O
strong O O
vasoconstrictive O O
properties O O
and O O
stimulating O O
effects O O
on O O
renin S-GENE O
secretion O O
. O O
Here O O
we O O
describe O O
the O O
cloning O O
and O O
initial O O
characterization O O
of O O
IPP S-GENE S-GENE
, O O
a O O
novel O O
human O O
gene O O
that O O
predicts O O
a O O
kelch B-GENE O
family I-GENE O
protein E-GENE O
homologous O O
to O O
the O O
mouse B-GENE B-GENE
Ipp I-GENE I-GENE
gene E-GENE E-GENE
, O O
a O O
previously O O
described O O
kelch B-GENE O
family I-GENE O
member E-GENE O
. O O
The O O
encoded O O
260 B-GENE O
- I-GENE O
amino I-GENE O
- I-GENE O
acid I-GENE O
( I-GENE O
aa I-GENE O
) I-GENE O
( I-GENE O
H1 I-GENE O
- I-GENE O
I I-GENE O
) E-GENE O
and O O
240 B-GENE O
- I-GENE O
aa I-GENE O
( I-GENE O
H1 I-GENE B-GENE
- I-GENE I-GENE
II I-GENE E-GENE
) I-GENE O
polypeptides E-GENE O
possess O O
the O O
typical O O
tripartite O O
organization O O
of O O
animal B-GENE O
H1 I-GENE S-GENE
histones E-GENE O
, O O
with O O
variable O O
N O O
- O O
and O O
C O O
- O O
terminal O O
domains O O
flanking O O
a O O
conserved O O
' O O
globular O O
' O O
DNA O O
- O O
binding O O
domain O O
. O O
Instead O O
, O O
the O O
large O O
difference O O
in O O
ssDNA O O
- O O
binding O O
affinities O O
reflects O O
the O O
loss O O
of O O
hexamerization O O
ability O O
by O O
uvsY S-GENE O
, O O
suggesting O O
that O O
a O O
form O O
of O O
intrahexamer O O
synergism O O
or O O
cooperativity O O
between O O
binding O O
sites O O
within O O
the O O
uvsY B-GENE O
hexamer E-GENE O
leads O O
to O O
its O O
high O O
observed O O
affinity O O
for O O
ssDNA O O
. O O
No O O
significant O O
difference O O
was O O
seen O O
found O O
between O O
the O O
two O O
groups O O
in O O
the O O
degree O O
of O O
postoperative O O
deterioration O O
in O O
cardiopulmonary O O
function O O
or O O
in O O
interleukin B-GENE O
- I-GENE O
6 E-GENE O
levels O O
. O O
The O O
PK O B-GENE
domain O E-GENE
showed O O
pairwise O O
in O O
vitro O O
binding O O
interactions O O
with O O
the O O
pseudokinase O O
, O O
HisRS S-GENE S-GENE
, O O
and O O
C O O
- O O
term O O
domains O O
; O O
additionally O O
, O O
the O O
HisRS B-GENE B-GENE
domain E-GENE E-GENE
interacted O O
with O O
the O O
C O O
- O O
term O O
region O O
. O O
The O O
effects O O
of O O
erythrosine O O
( O O
Red O O
3 O O
) O O
, O O
rose O O
bengal O O
B O O
( O O
Red O O
105 O O
) O O
and O O
thyroidectomy O O
on O O
the O O
development O O
of O O
thyroid O O
tumor O O
were O O
examined O O
in O O
male O O
Wistar O O
rats O O
treated O O
with O O
N O O
- O O
bis O O
( O O
2 O O
- O O
hydroxypropyl O O
) O O
nitrosamine O O
( O O
DHPN O O
) O O
. O O
The O O
AmyI S-GENE O
specific O O
3 O O
' O O
- O O
UTR O O
is O O
characterized O O
by O O
the O O
absence O O
of O O
IR O O
sequences O O
and O O
the O O
presence O O
of O O
a O O
putative O O
' O O
AATAAA O O
' O O
polyadenylation O O
signal O O
. O O
To O O
initiate O O
our O O
analysis O O
of O O
factors O O
required O O
for O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
alpha E-GENE E-GENE
expression O O
, O O
selected O O
a O O
CAP O O
- O O
proximal O O
element O O
shown O O
by O O
in O O
vivo O O
methylation O O
protection O O
analysis O O
to O O
bind O O
a O O
potential O O
regulatory O O
factor O O
. O O
Furthermore O O
, O O
addition O O
of O O
the O O
recombinant B-GENE B-GENE
NF I-GENE I-GENE
- I-GENE I-GENE
YA I-GENE I-GENE
subunit E-GENE E-GENE
restores O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
binding O O
. O O
Reversible O O
pressure O O
- O O
induced O O
amorphization O O
in O O
solid O O
C70 O O
: O O
Raman O O
and O O
photoluminescence O O
study O O
. O O
Alternative O O
roles O O
of O O
these O O
DNA O O
motifs O O
as O O
activators O O
of O O
early O O
mRNA O O
transcription O O
and O O
as O O
an O O
initiator O O
element O O
for O O
late O O
mRNA O O
transcription O O
help O O
explain O O
how O O
polyomavirus O B-GENE
gene O E-GENE
expression O O
is O O
regulated O O
during O O
lytic O O
growth O O
and O O
provides O O
a O O
model O O
for O O
cellular O O
transcription O O
during O O
development O O
. O O
Our O O
results O O
suggest O O
that O O
Sp1 B-GENE S-GENE
binding I-GENE O
site E-GENE O
can O O
function O O
as O O
a O O
distinct O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE E-GENE
responsive I-GENE O
element E-GENE O
for O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
mediated O O
promoter O O
expression O O
and O O
Sp1 S-GENE S-GENE
per O O
se O O
can O O
mediate O O
this O O
response O O
. O O
Effect O O
of O O
bromocriptine O O
and O O
metoclopramide O O
on O O
serum B-GENE O
prolactin E-GENE O
levels O O
in O O
patients O O
with O O
amyotrophic O O
lateral O O
sclerosis O O
. O O
Phase O O
I O O
study O O
of O O
5 O O
- O O
fluorouracil O O
and O O
leucovorin O O
by O O
a O O
14 O O
- O O
day O O
circadian O O
infusion O O
in O O
metastatic O O
adenocarcinoma O O
patients O O
. O O
The O O
results O O
of O O
this O O
study O O
demonstrate O O
that O O
release O O
of O O
a O O
single O O
pulley O O
after O O
repair O O
of O O
the O O
tendons O O
in O O
this O O
area O O
improved O O
gliding O O
excursions O O
of O O
the O O
tendons O O
and O O
reduced O O
resistance O O
to O O
motion O O
of O O
the O O
repaired O O
tendons O O
, O O
and O O
provide O O
support O O
for O O
partial O O
A2 O O
pulley O O
incision O O
after O O
repair O O
of O O
the O O
tendons O O
in O O
the O O
area O O
of O O
the O O
pulley O O
. O O
Heart O O
rate O O
and O O
oxygen O O
consumption O O
increased O O
75 O O
+ O O
/ O O
- O O
4 O O
bpm O O
and O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
ml O O
O2 O O
/ O O
kg O O
x O O
min O O
( O O
- O O
1 O O
) O O
from O O
supine O O
resting O O
values O O
, O O
respectively O O
. O O
To O O
evaluate O O
the O O
effect O O
of O O
selective O O
thromboxane O O
A2 O O
blockade O O
on O O
clinical O O
findings O O
and O O
platelet O O
reactivity O O
in O O
refractory O O
unstable O O
angina O O
, O O
OKY O O
- O O
046 O O
( O O
600 O O
mg O O
/ O O
day O O
, O O
p O O
. O O
o O O
. O O
) O O
was O O
administered O O
to O O
another O O
14 O O
patients O O
with O O
refractory O O
unstable O O
angina O O
in O O
addition O O
to O O
the O O
conventional O O
therapy O O
. O O
Prolongation O O
of O O
prothrombin S-GENE O
time O O
was O O
not O O
due O O
to O O
depletion O O
of O O
vitamin O O
K O O
- O O
dependent O O
coagulation O O
factors O O
or O O
manifest O O
fibrinolysis O O
, O O
but O O
due O O
to O O
the O O
presence O O
of O O
circulating O O
fibrinogen B-GENE O
fibrinmonomer E-GENE O
- O O
FDP O O
complexes O O
. O O
Effect O O
of O O
tetracycline O O
on O O
the O O
glycogen O O
- O O
producing O O
function O O
of O O
the O O
liver O O
and O O
intestinal O O
microflora O O
in O O
white O O
mice O O
A O O
case O O
report O O
. O O
Mutation O O
of O O
K14 O S-GENE
in O O
H3 S-GENE O
, O O
which O O
serves O O
as O O
the O O
major O O
target O O
of O O
recombinant B-GENE O
Gcn5p E-GENE S-GENE
acetylation O O
in O O
vitro O O
, O O
confers O O
a O O
strong O O
, O O
synthetic O O
growth O O
defect O O
in O O
gcn5 S-GENE O
cells O O
. O O
On O O
the O O
other O O
hand O O
, O O
V3 O O
" O O
values O O
were O O
not O O
significantly O O
correlated O O
with O O
the O O
degree O O
of O O
tremor O O
, O O
seborrhea O O
, O O
and O O
duration O O
of O O
the O O
illness O O
. O O
All O O
patients O O
whose O O
PSA S-GENE O
levels O O
reached O O
0 O O
. O O
1 O O
ng O O
. O O
/ O O
ml O O
. O O
In O O
addition O O
, O O
we O O
found O O
that O O
the O O
transactivation O O
mediated O O
by O O
the O O
p68c B-GENE B-GENE
- I-GENE I-GENE
ets I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
pr E-GENE O
p55erg S-GENE O
through O O
the O O
Polyomavirus B-GENE B-GENE
enhancer I-GENE I-GENE
sequence E-GENE E-GENE
is O O
specifically O O
inhibited O O
by O O
the O O
p46kDaPax B-GENE B-GENE
- I-GENE I-GENE
QNR E-GENE E-GENE
in O O
transient O O
transfection O O
assay O O
. O O
Treatment O O
with O O
ACE S-GENE O
inhibitors O O
after O O
acute O O
myocardial O O
infarction O O
Conversely O O
, O O
as O O
a O O
GAL B-GENE O
- I-GENE O
4 I-GENE O
chimera E-GENE O
, O O
the O O
isolated O O
LAZ3 S-GENE S-GENE
/ O O
BCL6 S-GENE O
BTB S-GENE S-GENE
/ O O
POZ O S-GENE
domain O O
appears O O
nearly O O
as O O
efficient O O
as O O
the O O
entire O O
protein O O
at O O
inducing O O
transcriptional O O
repression O O
. O O
A O O
new O O
myocyte B-GENE O
- I-GENE O
specific I-GENE O
enhancer I-GENE O
- I-GENE O
binding I-GENE O
factor E-GENE O
that O O
recognizes O O
a O O
conserved O O
element O O
associated O O
with O O
multiple O O
muscle O O
- O O
specific O O
genes O O
. O O
Diclofenac O O
sodium O O
: O O
blood O O
concentration O O
of O O
the O O
slow O O
- O O
release O O
form O O
and O O
influence O O
on O O
the O O
metabolism O O
of O O
kallikrein S-GENE O
. O O
The O O
LS B-GENE B-GENE
gene I-GENE E-GENE
promoter I-GENE O
sequence E-GENE O
has O O
homology O O
with O O
Escherichia O O
coli O O
promoter O O
sequences O O
; O O
its O O
terminator O O
sequence O O
is O O
capable O O
of O O
forming O O
a O O
stem O O
- O O
and O O
- O O
loop O O
structure O O
. O O
We O O
demonstrate O O
that O O
the O O
recently O O
proposed O O
synthetic O O
imaging O O
technique O O
[ O O
J O O
. O O
Overexpression O O
of O O
either O O
Sp1 S-GENE S-GENE
or O O
phosphorylated B-GENE O
CREB E-GENE S-GENE
transactivated O O
the O O
mCgA B-GENE B-GENE
promoter E-GENE E-GENE
dose O O
dependently O O
, O O
while O O
coexpression O O
of O O
both O O
transcription O O
factors O O
resulted O O
in O O
an O O
additive O O
mCgA B-GENE B-GENE
promoter E-GENE E-GENE
response O O
. O O
mCgA S-GENE O
- O O
92 O O
to O O
- O O
64 O O
bp O O
, O O
comprising O O
the O O
Sp1 S-GENE S-GENE
/ O O
Egr B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE I-GENE
site O E-GENE
and O O
the O O
CRE O B-GENE
motif O E-GENE
, O O
conferred O O
gastrin S-GENE O
responsiveness O O
to O O
a O O
heterologous B-GENE O
thymidine I-GENE B-GENE
kinase I-GENE I-GENE
promoter E-GENE E-GENE
system O O
, O O
and O O
therefore O O
functions O O
as O O
a O O
" O O
true O O
" O O
enhancer O O
element O O
. O O
Together O O
with O O
the O O
up O O
- O O
regulation O O
of O O
the O O
cAMP B-GENE B-GENE
response I-GENE I-GENE
element I-GENE I-GENE
modulator I-GENE I-GENE
protein E-GENE E-GENE
( O O
CREM S-GENE S-GENE
) O O
mRNA O O
and O O
protein O O
levels O O
demonstrated O O
previously O O
in O O
CREB B-GENE B-GENE
mutant E-GENE E-GENE
mice O O
, O O
we O O
suggest O O
that O O
the O O
up O O
- O O
regulation O O
of O O
CREB B-GENE B-GENE
beta E-GENE E-GENE
may O O
also O O
contribute O O
to O O
compensation O O
within O O
the O O
CREB S-GENE S-GENE
/ O O
ATF S-GENE S-GENE
family O O
of O O
transcription O O
factors O O
, O O
when O O
CREB B-GENE B-GENE
delta E-GENE E-GENE
and O O
CREB B-GENE B-GENE
alpha E-GENE E-GENE
are O O
absent O O
. O O
The O O
data O O
obtained O O
with O O
cellular O O
RNA O O
from O O
HepG2 O O
cells O O
demonstrated O O
that O O
transcription O O
is O O
initiated O O
891 O O
bases O O
upstream O O
of O O
the O O
translation O O
- O O
start O O
site O O
and O O
that O O
the O O
polyadenylation O O
site O O
is O O
located O O
550 O O
bases O O
downstream O O
of O O
the O O
stop O O
codon O O
. O O
Finally O O
, O O
there O O
is O O
now O O
appropriate O O
recognition O O
of O O
the O O
pivotal O O
role O O
of O O
BP O O
reduction O O
in O O
forestalling O O
pressure O O
- O O
related O O
cardiovascular O O
complications O O
, O O
even O O
among O O
high O O
- O O
risk O O
persons O O
with O O
diabetes O O
mellitus O O
and O O
renal O O
insufficiency O O
. O O
Individual O O
and O O
combined O O
effects O O
of O O
fumonisin B-GENE O
B1 E-GENE O
present O O
in O O
Fusarium O O
moniliforme O O
culture O O
material O O
and O O
diacetoxyscirpenol O O
or O O
ochratoxin O O
A O O
in O O
turkey O O
poults O O
. O O
It O O
is O O
hypothesized O O
this O O
occurs O O
through O O
antagonism O O
of O O
PML S-GENE S-GENE
/ O O
RAR B-GENE B-GENE
alpha E-GENE E-GENE
actions O O
in O O
these O O
leukemic O O
cells O O
. O O
13 O O
: O O
961 O O
- O O
969 O O
, O O
1993 O O
) O O
suggested O O
that O O
T B-GENE O
antigen E-GENE O
could O O
mediate O O
transcriptional O O
activation O O
through O O
interaction O O
with O O
the O O
TATA B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
, O O
as O O
well O O
as O O
upstream O O
bound O O
transcription O O
factors O O
. O O
The O O
Grb2 S-GENE B-GENE
SH3 B-GENE E-GENE
( I-GENE O
C I-GENE O
) I-GENE O
binding I-GENE O
region E-GENE O
of O O
Gab1 S-GENE S-GENE
has O O
significant O O
homology O O
to O O
a O O
region O O
of O O
the O O
adapter B-GENE B-GENE
protein I-GENE I-GENE
SLP I-GENE I-GENE
- I-GENE I-GENE
76 E-GENE E-GENE
. O O
A O O
phase O O
II O O
study O O
of O O
interferon B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
, O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
5 O O
- O O
fluorouracil O O
in O O
advanced O O
renal O O
carcinoma O O
: O O
clinical O O
data O O
and O O
laboratory O O
evidence O O
of O O
protease O O
activation O O
. O O
Activation O O
of O O
the O O
cytotactin B-GENE B-GENE
promoter E-GENE E-GENE
by O O
the O O
homeobox B-GENE O
- I-GENE O
containing I-GENE O
gene I-GENE O
Evx I-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
CONCLUSION O O
/ O O
INTERPRETATION O O
: O O
We O O
found O O
an O O
increased O O
risk O O
of O O
hip O O
fracture O O
in O O
women O O
younger O O
than O O
75 O O
years O O
with O O
Type O O
I O O
diabetes O O
or O O
with O O
Type O O
II O O
diabetes O O
of O O
long O O
duration O O
. O O
Maternal O O
behavior O O
was O O
assessed O O
using O O
observational O O
techniques O O
. O O
Rat B-GENE B-GENE
p8 I-GENE I-GENE
mRNA E-GENE E-GENE
was O O
discovered O O
because O O
of O O
its O O
strong O O
activation O O
in O O
pancreas O O
during O O
the O O
acute O O
phase O O
of O O
pancreatitis O O
. O O
LV O O
compliance O O
was O O
determined O O
from O O
the O O
slope O O
of O O
the O O
LV O O
end O O
- O O
diastolic O O
pressure O O
( O O
LVEDP O O
) O O
vs O O
. O O
The O O
practice O O
of O O
measuring O O
of O O
AChE S-GENE O
levels O O
in O O
acute O O
poisoning O O
is O O
limited O O
. O O
Vasodilation O O
in O O
congestive O O
heart O O
failure O O
is O O
an O O
established O O
therapeutic O O
principal O O
. O O
The O O
collicular O O
labels O O
found O O
after O O
injections O O
within O O
the O O
MST O O
area O O
exhibited O O
their O O
distribution O O
over O O
the O O
deep O O
SC O O
subdivision O O
, O O
whereas O O
they O O
spared O O
all O O
the O O
superficial O O
layers O O
but O O
the O O
deep O O
part O O
of O O
the O O
SO O O
. O O
When O O
furA S-GENE O
alone O O
was O O
introduced O O
into O O
the O O
Delta O O
( O O
furA S-GENE O
- O O
katG S-GENE O
) O O
mutant O O
, O O
survival O O
in O O
mouse O O
lungs O O
was O O
moderately O O
increased O O
, O O
suggesting O O
that O O
FurA S-GENE O
could O O
regulate O O
genes O O
, O O
other O O
than O O
katG S-GENE O
, O O
that O O
are O O
involved O O
in O O
pathogenesis O O
. O O
The O O
effects O O
of O O
cefazolin O O
, O O
given O O
into O O
the O O
III O O
cerebral O O
ventricle O O
at O O
different O O
doses O O
were O O
studied O O
on O O
GABA O S-GENE
content O O
, O O
GAD O S-GENE
and O O
GABA O O
- O O
T O O
in O O
the O O
brain O O
- O O
stem O O
of O O
young O O
chickens O O
( O O
Gallus O O
domesticus O O
) O O
. O O
Subclones O O
of O O
R15 O O
which O O
reverted O O
to O O
kappa B-GENE O
light I-GENE O
chain E-GENE O
production O O
contained O O
genomic O O
deletions O O
of O O
R15ns O S-GENE
and O O
/ O O
or O O
the O O
surrounding O O
intron O O
. O O
The O O
disorders O O
are O O
accompanied O O
by O O
consistent O O
, O O
but O O
similarly O O
reversible O O
, O O
electroencephalographic O O
changes O O
. O O
The O O
delayed O O
activation O O
of O O
the O O
prostaglandin B-GENE B-GENE
G I-GENE I-GENE
/ I-GENE I-GENE
H I-GENE I-GENE
synthase I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE I-GENE
promoter O E-GENE
in O O
bovine O O
granulosa O O
cells O O
is O O
associated O O
with O O
down O O
- O O
regulation O O
of O O
truncated O O
upstream B-GENE O
stimulatory I-GENE O
factor I-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
. O O
The O O
authors O O
recommend O O
in O O
cases O O
with O O
an O O
elevated O O
transaminase O O
serum O O
activity O O
more O O
frequent O O
check O O
- O O
up O O
examinations O O
to O O
avoid O O
missing O O
of O O
a O O
relapse O O
, O O
and O O
to O O
examine O O
repeatedly O O
IgM S-GENE O
anti B-GENE O
- I-GENE O
HAV E-GENE O
as O O
in O O
protracted O O
forms O O
of O O
hepatitis O O
IgM S-GENE O
anti B-GENE O
- I-GENE O
HAV E-GENE O
may O O
persist O O
even O O
when O O
the O O
transaminase O O
activity O O
is O O
normal O O
. O O
Mean O O
latency O O
periods O O
were O O
29 O O
. O O
6 O O
among O O
insulators O O
, O O
35 O O
. O O
4 O O
among O O
dock O O
workers O O
, O O
43 O O
. O O
7 O O
in O O
a O O
heterogeneous O O
group O O
defined O O
as O O
various O O
, O O
46 O O
. O O
4 O O
in O O
non O O
- O O
shipbuilding O O
industry O O
workers O O
, O O
49 O O
. O O
4 O O
in O O
shipyard O O
workers O O
, O O
51 O O
. O O
7 O O
among O O
women O O
with O O
a O O
history O O
of O O
domestic O O
exposure O O
to O O
asbestos O O
, O O
and O O
56 O O
. O O
2 O O
in O O
people O O
employed O O
in O O
maritime O O
trades O O
. O O
The O O
strategy O O
uses O O
RNA B-GENE O
ligase E-GENE O
to O O
add O O
DNA O O
oligonucleotide O O
priming O O
sites O O
to O O
the O O
RNA O O
for O O
subsequent O O
reverse O O
transcription O O
and O O
PCR O S-GENE
( O O
RNA B-GENE B-GENE
ligase E-GENE E-GENE
, O O
reverse O O
transcription O O
- O O
PCR O O
, O O
or O O
RL O O
/ O O
RT O O
/ O O
PCR O O
) O O
. O O
We O O
analyzed O O
the O O
effects O O
of O O
light O O
on O O
tubulin B-GENE O
mRNA E-GENE O
abundance O O
in O O
Arabidopsis O O
seedlings O O
using O O
RNA O O
gel O O
blot O O
hybridizations O O
and O O
gene O O
- O O
specific O O
probes O O
. O O
More O O
important O O
, O O
ligand O O
- O O
activated O O
insulin S-GENE S-GENE
and O O
IGF B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
receptors E-GENE E-GENE
phosphorylate O O
SHC B-GENE B-GENE
proteins E-GENE E-GENE
in O O
vitro O O
, O O
indicating O O
that O O
SHC B-GENE B-GENE
proteins E-GENE E-GENE
could O O
be O O
direct O O
substrates O O
for O O
insulin S-GENE S-GENE
and O O
IGF B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
receptors E-GENE E-GENE
. O O
This O O
chimera O O
transduced O O
IL B-GENE O
- I-GENE O
4 E-GENE O
- O O
specific O O
signals O O
in O O
response O O
to O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
binding O O
and O O
dramatically O O
enhanced O O
type O O
2 O O
responses O O
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
, O O
IL B-GENE B-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
, O O
and O O
immunoglobulin B-GENE O
E E-GENE O
production O O
) O O
upon O O
in O O
vitro O O
TCR S-GENE O
stimulation O O
or O O
in O O
vivo O O
antigen O O
challenge O O
. O O
A O O
distinct O O
5 O O
' O O
- O O
sequence O O
in O O
clone O O
hMIWC2 O S-GENE
suggested O O
an O O
alternative O O
upstream O O
transcription O O
initiation O O
site O O
. O O
Two O O
human B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
, I-GENE O
6 I-GENE O
- I-GENE O
N I-GENE O
- I-GENE O
acetylglucosaminyltransferases E-GENE O
forming O O
the O O
core O O
2 O O
O O O
- O O
glycan O O
branch O O
, O O
C2GnT O S-GENE
and O O
the O O
I B-GENE B-GENE
antigen E-GENE E-GENE
, O O
IGnT S-GENE S-GENE
, O O
are O O
homologous O O
to O O
each O O
other O O
in O O
three O O
regions O O
of O O
the O O
catalytic O O
domain O O
( O O
A O O
, O O
B O O
, O O
C O O
) O O
and O O
their O O
genes O O
reside O O
at O O
the O O
same O O
locus O O
, O O
chromosome O O
9 O O
, O O
band O O
q21 O O
( O O
Bierhuizen O O
, O O
M O O
. O O
F O O
. O O
A O O
. O O
, O O
Mattei O O
, O O
M O O
. O O
- O O
G O O
. O O
and O O
Fukuda O O
, O O
M O O
. O O
, O O
Genes O O
Dev O O
. O O
, O O
7 O O
, O O
468 O O
- O O
478 O O
, O O
1993 O O
) O O
. O O
Significantly O O
higher O O
levels O O
of O O
vitamin O O
C O O
and O O
catalase S-GENE O
activity O O
were O O
found O O
in O O
vegetarians O O
( O O
C O O
- O O
63 O O
. O O
6 O O
and O O
86 O O
. O O
5 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1497 O O
and O O
1313 O O
U O O
/ O O
ml O O
for O O
males O O
and O O
females O O
, O O
respectively O O
) O O
when O O
compared O O
to O O
nonvegetarians O O
( O O
C O O
- O O
41 O O
. O O
3 O O
and O O
54 O O
. O O
4 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1192 O O
and O O
1086 O O
U O O
/ O O
ml O O
) O O
. O O
Cutting O O
the O O
intraorbital O O
nerves O O
produced O O
a O O
temporary O O
retrieval O O
impairment O O
that O O
was O O
indistinguishable O O
from O O
that O O
produced O O
by O O
intramystacial O O
lidocaine O O
injection O O
. O O
Developmental O O
regulation O O
of O O
expression O O
of O O
the O O
malate B-GENE B-GENE
synthase I-GENE I-GENE
gene E-GENE E-GENE
in O O
transgenic O O
plants O O
. O O
In O O
contrast O O
, O O
no O O
change O O
in O O
the O O
level O O
of O O
either O O
p53 S-GENE S-GENE
or O O
activation O O
of O O
mdm2 B-GENE B-GENE
protein E-GENE E-GENE
by O O
p53 S-GENE S-GENE
was O O
observed O O
in O O
hamster O O
UV61 O O
cells O O
after O O
UV O O
exposure O O
. O O
On O O
day O O
1 O O
at O O
3500 O O
m O O
, O O
RI O O
showed O O
a O O
significant O O
fall O O
in O O
body O O
weight O O
( O O
BW O O
) O O
with O O
respect O O
to O O
SL O O
but O O
AI O O
maintained O O
it O O
. O O
Transcriptional O O
activation O O
of O O
the O O
proopiomelanocortin B-GENE B-GENE
gene E-GENE E-GENE
by O O
cyclic B-GENE O
AMP I-GENE O
- I-GENE O
responsive I-GENE O
element I-GENE O
binding I-GENE O
protein E-GENE O
. O O
The O O
NF1 B-GENE B-GENE
family E-GENE E-GENE
members O O
and O O
HNF4 S-GENE S-GENE
interacted O O
with O O
overlapping O O
sequences O O
of O O
the O O
L O O
- O O
II O O
element O O
, O O
wherein O O
the O O
5 O O
' O O
half O O
- O O
site O O
was O O
more O O
critical O O
for O O
NF1 S-GENE O
binding O O
, O O
and O O
the O O
3 O O
' O O
site O O
was O O
more O O
important O O
for O O
HNF4 S-GENE S-GENE
binding O O
. O O
RAP S-GENE O
has O O
been O O
shown O O
to O O
be O O
a O O
useful O O
vaccine O O
target O O
site O O
, O O
and O O
RIP S-GENE O
and O O
inhibitory O O
AIPs S-GENE S-GENE
as O O
therapeutic O O
molecules O O
to O O
prevent O O
and O O
suppress O O
S O O
. O O
aureus O O
infections O O
. O O
After O O
institution O O
of O O
insulin S-GENE O
treatment O O
, O O
diabetic O O
control O O
was O O
improved O O
as O O
demonstrated O O
by O O
decreasing O O
levels O O
of O O
HbA1 S-GENE O
. O O
The O O
mouse O B-GENE
lactoferrin S-GENE I-GENE
gene O I-GENE
promoter O E-GENE
was O O
active O O
in O O
human O O
endometrium O O
carcinoma O O
RL O O
95 O O
- O O
2 O O
cells O O
and O O
in O O
rat O O
glioma O O
C6 O O
cells O O
. O O
The O O
1 O O
- O O
year O O
and O O
2 O O
- O O
year O O
survival O O
rates O O
for O O
the O O
patients O O
with O O
N0 O O
- O O
3 O O
significantly O O
exceeded O O
those O O
of O O
N4 O O
patients O O
. O O
Measurement O O
of O O
the O O
spectral O O
sensitivity O O
and O O
the O O
ERG O O
can O O
thus O O
help O O
in O O
the O O
diagnosis O O
of O O
these O O
three O O
hereditary O O
diseases O O
. O O
As O O
a O O
quantitative O O
index O O
of O O
cochlear O O
function O O
, O O
2f1 O O
- O O
f2 O O
distortion O O
- O O
product O O
otoacoustic O O
emissions O O
( O O
DPOAEs O O
) O O
were O O
monitored O O
systematically O O
over O O
time O O
in O O
three O O
groups O O
of O O
rabbits O O
, O O
with O O
each O O
group O O
experiencing O O
a O O
unique O O
paradigm O O
that O O
incorporated O O
repeated O O
exposure O O
to O O
the O O
low O O
- O O
frequency O O
tone O O
. O O
The O O
subjects O O
' O O
lungs O O
were O O
ventilated O O
with O O
N2O O O
in O O
O2 O O
( O O
FIO2 O O
0 O O
. O O
3 O O
) O O
to O O
the O O
end O O
- O O
tidal O O
CO2 O O
present O O
before O O
anesthesia O O
, O O
and O O
then O O
CBF O O
was O O
measured O O
using O O
intravenous O O
133Xe O O
and O O
ten O O
scintillation O O
counters O O
, O O
five O O
over O O
each O O
cerebral O O
hemisphere O O
. O O
This O O
indicates O O
changes O O
in O O
postvaccination O O
allergy O O
to O O
BCG O O
. O O
Analysis O O
of O O
1 O O
Mb O O
of O O
published O O
sequence O O
from O O
the O O
region O O
of O O
conserved O O
synteny O O
on O O
human O O
chromosome O O
5q31 O B-GENE
- O I-GENE
q33 O E-GENE
identified O O
45 O O
gene O O
candidates O O
, O O
including O O
35 O O
expressed O O
genes O O
in O O
the O O
human B-GENE B-GENE
IL I-GENE I-GENE
- I-GENE I-GENE
4 I-GENE I-GENE
cytokine I-GENE I-GENE
gene E-GENE E-GENE
cluster O O
. O O
There O O
is O O
no O O
indication O O
from O O
these O O
experiments O O
that O O
linker B-GENE O
histones E-GENE O
bind O O
fundamentally O O
differently O O
to O O
5 B-GENE O
S E-GENE O
and O O
bulk O O
nucleosomes O O
. O O
Km O O
values O O
of O O
the O O
uncoupled O O
enzymes O O
IIGlc S-GENE O
for O O
glucose O O
ranged O O
from O O
0 O O
. O O
5 O O
to O O
2 O O
. O O
5 O O
mM O O
, O O
2 O O
orders O O
of O O
magnitude O O
higher O O
than O O
the O O
value O O
of O O
normal O O
IIGlc S-GENE O
. O O
Cytochrome B-GENE O
bd E-GENE O
biosynthesis O O
in O O
Escherichia O O
coli O O
: O O
the O O
sequences O O
of O O
the O O
cydC S-GENE S-GENE
and O O
cydD B-GENE B-GENE
genes E-GENE E-GENE
suggest O O
that O O
they O O
encode O O
the O O
components O O
of O O
an O O
ABC B-GENE O
membrane I-GENE O
transporter E-GENE O
. O O
In O O
contrast O O
, O O
inhibition O O
of O O
MAPK S-GENE S-GENE
activity O O
by O O
MAPK B-GENE B-GENE
kinase E-GENE I-GENE
inhibitor O E-GENE
( O O
PD O B-GENE
98059 O E-GENE
) O O
or O O
by O O
overexpression O O
of O O
kinase O O
- O O
deficient O O
MAPKs S-GENE S-GENE
activated O O
basal O O
and O O
GnRH B-GENE O
- I-GENE O
A E-GENE O
- O O
stimulated O O
GnRHR S-GENE O
- O O
Luc S-GENE O
activity O O
. O O
The O O
influence O O
of O O
gas O O
composition O O
in O O
the O O
air O O
cell O O
on O O
pipping O O
and O O
liver O O
metabolism O O
in O O
embryonic O O
chicks O O
. O O
Historically O O
, O O
Cyps S-GENE O
were O O
first O O
identified O O
by O O
their O O
ability O O
to O O
bind O O
the O O
immunosuppressive O O
agent O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
with O O
high O O
affinity O O
; O O
they O O
later O O
were O O
found O O
to O O
have O O
peptidyl B-GENE B-GENE
- I-GENE I-GENE
prolyl I-GENE I-GENE
cis I-GENE I-GENE
- I-GENE I-GENE
trans I-GENE I-GENE
isomerase E-GENE E-GENE
( O O
PPIase S-GENE S-GENE
) O O
activity O O
, O O
which O O
catalyzes O O
the O O
folding O O
of O O
oligopeptides O O
at O O
proline O O
- O O
peptide O O
bonds O O
in O O
vitro O O
and O O
may O O
be O O
important O O
for O O
protein O O
folding O O
in O O
vivo O O
. O O
Thus O O
, O O
oxyR B-GENE B-GENE
mutants E-GENE E-GENE
are O O
locked O O
on O O
for O O
Ag43 S-GENE S-GENE
expression O O
, O O
whereas O O
dam B-GENE O
mutants E-GENE O
are O O
locked O O
off O O
for O O
Ag43 S-GENE S-GENE
expression O O
. O O
A O O
rare O O
tRNA B-GENE B-GENE
- I-GENE I-GENE
Arg I-GENE E-GENE
( I-GENE O
CCU I-GENE S-GENE
) E-GENE O
that O O
regulates O O
Ty1 B-GENE B-GENE
element E-GENE I-GENE
ribosomal O I-GENE
frameshifting O E-GENE
is O O
essential O O
for O O
Ty1 S-GENE S-GENE
retrotransposition O O
in O O
Saccharomyces O O
cerevisiae O O
. O O
Several O O
35 O O
- O O
mm O O
slides O O
of O O
dystrophin S-GENE O
- O O
, O O
laminin S-GENE O
- O O
, O O
and O O
concanavalin B-GENE O
A E-GENE O
( O O
ConA S-GENE O
) O O
- O O
stained O O
muscle O O
sections O O
were O O
used O O
to O O
calculate O O
myofiber O O
cross O O
- O O
sectional O O
areas O O
and O O
to O O
compare O O
different O O
techniques O O
and O O
settings O O
of O O
an O O
image O O
capture O O
system O O
. O O
In O O
addition O O
, O O
both O O
inhibitors O O
blocked O O
phosphatidylcholine O O
hydrolysis O O
and O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
translocation O O
. O O
New O O
, O O
selective O O
catechol B-GENE O
- I-GENE O
O I-GENE O
- I-GENE O
methyltransferase E-GENE O
inhibitors O O
as O O
therapeutic O O
agents O O
in O O
Parkinson O O
' O O
s O O
disease O O
. O O
Furthermore O O
, O O
the O O
social O O
learning O O
theory O O
of O O
depression O O
, O O
developed O O
by O O
Lewinsohn O O
, O O
is O O
described O O
. O O
Laser O O
soldering O O
with O O
exogenous O O
fibrinogen S-GENE O
is O O
feasible O O
without O O
topical O O
administration O O
of O O
additional O O
clotting O O
agents O O
, O O
significantly O O
improves O O
the O O
bursting O O
strength O O
of O O
primary O O
laser O O
welded O O
anastomoses O O
, O O
and O O
appears O O
to O O
result O O
from O O
urokinase S-GENE O
- O O
resistant O O
fibrinogen S-GENE O
cross O O
- O O
linking O O
. O O
Intensity O O
variations O O
from O O
the O O
variable O O
TR O O
were O O
removed O O
, O O
and O O
the O O
data O O
were O O
evaluated O O
for O O
correlation O O
with O O
the O O
lateralized O O
stimulus O O
. O O
Routine O O
imaging O O
modalities O O
revealed O O
a O O
total O O
of O O
79 O O
metastases O O
. O O
We O O
have O O
previously O O
reported O O
that O O
analgesic O O
doses O O
of O O
morphine O O
accelerate O O
mortality O O
of O O
rats O O
exposed O O
to O O
hemorrhage O O
( O O
Feuerstein O O
and O O
Siren O O
: O O
Circ O O
Shock O O
19 O O
: O O
293 O O
- O O
300 O O
, O O
1986 O O
) O O
. O O
We O O
describe O O
a O O
novel O O
stat B-GENE O
- I-GENE O
related I-GENE O
factor E-GENE O
, O O
p93 S-GENE S-GENE
, O O
that O O
is O O
found O O
in O O
EGF S-GENE S-GENE
- O O
treated O O
A431 O O
cell O O
extracts O O
but O O
appears O O
to O O
be O O
absent O O
in O O
bovine B-GENE B-GENE
fibroblast I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
bFGF S-GENE S-GENE
) O O
, O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
, O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
( O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
) O O
, O O
and O O
untreated O O
cells O O
. O O
p93 S-GENE S-GENE
appears O O
to O O
be O O
antigenically O O
related O O
to O O
stat91 S-GENE O
. O O
p185c S-GENE B-GENE
- O I-GENE
neu S-GENE I-GENE
+ O E-GENE
, O O
EGFr B-GENE B-GENE
+ E-GENE E-GENE
( O O
M1 S-GENE O
) O O
, O O
and O O
p185c S-GENE B-GENE
- O I-GENE
neu S-GENE I-GENE
- O I-GENE
kinase O E-GENE
inactive O O
, O O
EGFr B-GENE B-GENE
+ E-GENE E-GENE
( O O
NEN757 S-GENE S-GENE
) O O
expressing O O
cells O O
undergo O O
different O O
mitotic O O
responses O O
to O O
EGF S-GENE S-GENE
. O O
In O O
addition O O
, O O
Fc B-GENE B-GENE
epsilon I-GENE I-GENE
R1 E-GENE E-GENE
cross O O
- O O
linking O O
activates O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
. O O
When O O
single O O
- O O
point O O
mutation O O
was O O
introduced O O
to O O
each O O
GC O O
box O O
, O O
EBS S-GENE O
, O O
and O O
GT O O
box O O
in O O
PFP9a20 S-GENE O
, O O
at O O
least O O
3 O O
- O O
fold O O
less O O
CAT S-GENE O
activity O O
was O O
observed O O
in O O
CTLL O O
- O O
R8 O O
cells O O
. O O
Ribosome O O
association O O
of O O
GCN2 B-GENE B-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
, O O
a O O
translational O O
activator O O
of O O
the O O
GCN4 B-GENE B-GENE
gene E-GENE E-GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O
Treatment O O
with O O
H7 O O
did O O
not O O
affect O O
IL B-GENE O
- I-GENE O
4R E-GENE O
- O O
mediated O O
immediate O O
signaling O O
events O O
such O O
as O O
tyrosine O O
phosphorylation O O
of O O
Jak1 S-GENE S-GENE
, O O
Jak3 S-GENE S-GENE
, O O
insulin B-GENE B-GENE
receptor I-GENE E-GENE
substrate I-GENE O
( I-GENE O
IRS I-GENE B-GENE
) I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
IRS B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
or O O
tyrosine O O
phosphorylation O O
and O O
DNA O O
binding O O
of O O
Stat6 S-GENE S-GENE
. O O
Thus O O
, O O
STK1 S-GENE S-GENE
is O O
most O O
likely O O
the O O
human B-GENE O
homologue I-GENE O
of I-GENE O
MO15 E-GENE S-GENE
. O O
BACKGROUND O O
: O O
Recent O O
iterative O O
methods O O
for O O
sequence O O
alignment O O
have O O
indicated O O
that O O
the O O
380 O O
kDa O O
motor O O
unit O O
of O O
dynein S-GENE O
belongs O O
to O O
the O O
AAA B-GENE O
class E-GENE O
of O O
chaperone B-GENE O
- I-GENE O
like I-GENE O
ATPases E-GENE O
. O O
When O O
the O O
VBP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
protein E-GENE E-GENE
was O O
solely O O
expressed O O
, O O
it O O
located O O
to O O
the O O
cytoplasm O O
and O O
did O O
not O O
localize O O
to O O
the O O
nucleus O O
. O O
Consistent O O
with O O
other O O
experiments O O
with O O
these O O
compounds O O
, O O
cocaine O O
was O O
the O O
most O O
potent O O
of O O
the O O
group O O
. O O
The O O
significance O O
of O O
these O O
changes O O
in O O
relation O O
to O O
the O O
control O O
of O O
phosphorus O O
balance O O
in O O
ruminants O O
is O O
discussed O O
. O O
Transfection O O
assays O O
using O O
the O O
first O O
600 O O
bp O O
of O O
the O O
upstream O O
nucleotide O O
sequences O O
indicated O O
that O O
a O O
region O O
from O O
- O O
75 O O
to O O
- O O
120 O O
was O O
necessary O O
for O O
the O O
ALDH2 B-GENE B-GENE
gene E-GENE E-GENE
expression O O
, O O
and O O
especially O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
/ O O
CP1 S-GENE S-GENE
binding O O
site O O
from O O
- O O
92 O O
to O O
- O O
96 O O
( O O
CCAAT O O
box O O
) O O
is O O
important O O
in O O
the O O
expression O O
of O O
the O O
gene O O
. O O
This O O
distinct O O
biochemical O O
difference O O
between O O
STAT5A S-GENE S-GENE
and O O
STAT5B S-GENE S-GENE
was O O
confirmed O O
with O O
purified O O
activated O O
STAT5 B-GENE B-GENE
recombinant I-GENE I-GENE
proteins E-GENE E-GENE
. O O
The O O
results O O
show O O
that O O
in O O
uninfected O O
NIH O O
- O O
3T3 O O
cells O O
Avarol O O
( O O
i O O
) O O
causes O O
a O O
50 O O
% O O
reduction O O
of O O
the O O
growth O O
rate O O
only O O
at O O
the O O
high O O
concentration O O
of O O
29 O O
. O O
6 O O
microM O O
and O O
( O O
ii O O
) O O
is O O
accumulated O O
in O O
the O O
cytoplasm O O
close O O
to O O
the O O
nucleus O O
. O O
Blood B-GENE O
coagulation I-GENE B-GENE
Factor I-GENE I-GENE
X E-GENE E-GENE
and O O
its O O
activated O O
form O O
Factor B-GENE B-GENE
Xa E-GENE E-GENE
play O O
an O O
essential O O
role O O
in O O
the O O
midphase O O
of O O
the O O
clotting O O
cascade O O
. O O
The O O
exon O O
sequences O O
determined O O
from O O
genomic O O
DNA O O
sequencing O O
showed O O
some O O
differences O O
when O O
compared O O
to O O
the O O
published O O
rat B-GENE O
GLUT2 I-GENE O
cDNA E-GENE O
. O O
Intramolecular O O
interaction O O
is O O
believed O O
to O O
result O O
in O O
the O O
formation O O
of O O
MxA B-GENE S-GENE
monomers E-GENE O
, O O
whereas O O
intermolecular O O
interaction O O
may O O
induce O O
the O O
formation O O
of O O
large B-GENE O
MxA I-GENE O
oligomers E-GENE O
. O O
The O O
psbA B-GENE B-GENE
gene E-GENE E-GENE
encodes O O
the O O
D1 B-GENE B-GENE
protein E-GENE E-GENE
of O O
photosystem B-GENE B-GENE
II E-GENE E-GENE
, O O
which O O
is O O
synthesized O O
at O O
very O O
high O O
rates O O
in O O
the O O
light O O
in O O
order O O
to O O
replace O O
photodamaged O O
protein O O
. O O
The O O
three O O
more O O
slower O O
migrating O O
Stat5B S-GENE O
bands O O
observed O O
in O O
response O O
to O O
GH S-GENE O
contain O O
phosphorylated O O
tyrosyl O O
residues O O
. O O
The O O
maximum O O
levels O O
of O O
reporter O O
proteins O O
attained O O
in O O
transformed O O
cells O O
after O O
prolonged O O
induction O O
represented O O
from O O
1 O O
% O O
to O O
7 O O
% O O
of O O
total O O
cellular O O
protein O O
. O O
Specifically O O
, O O
we O O
demonstrate O O
that O O
this O O
25 O O
- O O
base O O
pair O O
region O O
mediates O O
the O O
up O O
- O O
regulatory O O
effect O O
of O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
on O O
COL1A2 B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
and O O
allows O O
antagonistic O O
activity O O
of O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
on O O
the O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
effect O O
. O O
Sin4 S-GENE S-GENE
and O O
Srb10 S-GENE S-GENE
, O O
components O O
of O O
specific O O
RNA B-GENE O
polymerase I-GENE O
II I-GENE O
sub I-GENE O
- I-GENE O
complexes E-GENE O
that O O
are O O
required O O
for O O
Ssn6 S-GENE B-GENE
- O I-GENE
Tup1 S-GENE E-GENE
repression O O
activity O O
, O O
are O O
found O O
to O O
be O O
required O O
for O O
Sfl1 S-GENE O
repression O O
function O O
. O O
Translation O O
of O O
mok S-GENE S-GENE
is O O
tightly O O
regulated O O
by O O
Sok B-GENE B-GENE
RNA E-GENE E-GENE
, O O
and O O
Sok B-GENE B-GENE
RNA E-GENE E-GENE
thus O O
regulates O O
hok S-GENE O
translation O O
indirectly O O
through O O
mok S-GENE O
. O O
Depending O O
on O O
the O O
patient O O
' O O
s O O
body O O
position O O
telemetrically O O
measured O O
CSF O O
- O O
pressures O O
varied O O
between O O
- O O
20 O O
cmH2O O O
in O O
erect O O
and O O
15 O O
cmH2O O O
in O O
supine O O
position O O
. O O
One O O
- O O
hour O O
O3 O O
, O O
NO2 O O
, O O
and O O
SO2 O O
personal O O
exposures O O
were O O
measured O O
using O O
samplers O O
developed O O
in O O
our O O
laboratory O O
, O O
while O O
short O O
- O O
term O O
PM2 O O
. O O
5 O O
, O O
CO O O
, O O
and O O
VOCs O O
exposures O O
were O O
measured O O
using O O
currently O O
available O O
monitors O O
. O O
These O O
Tlr B-GENE B-GENE
family I-GENE E-GENE
members E-GENE O
, O O
unlike O O
others O O
reported O O
to O O
date O O
, O O
were O O
identified O O
within O O
a O O
genomic O O
database O O
. O O
We O O
hypothesized O O
that O O
subjects O O
would O O
demonstrate O O
PKAR O S-GENE
during O O
both O O
hopping O O
and O O
stepping O O
, O O
adding O O
support O O
to O O
the O O
hypothesis O O
that O O
PKAR O S-GENE
is O O
a O O
centrally O O
mediated O O
adaptation O O
of O O
general O O
locomotor O O
trajectory O O
that O O
is O O
not O O
specific O O
to O O
the O O
form O O
of O O
locomotion O O
used O O
while O O
on O O
the O O
rotating O O
disk O O
. O O
In O O
this O O
study O O
, O O
transcriptional O O
fusions O O
were O O
constructed O O
between O O
the O O
xcpP S-GENE S-GENE
and O O
xcpR B-GENE B-GENE
genes E-GENE E-GENE
and O O
the O O
lacZ B-GENE O
reporter E-GENE O
. O O
To O O
explore O O
the O O
mechanism O O
of O O
insulin B-GENE B-GENE
receptor E-GENE E-GENE
phosphorylation O O
we O O
have O O
used O O
NIH3T3 O O
cells O O
transfected O O
with O O
two O O
receptor O O
constructs O O
: O O
one O O
encoding O O
a O O
chimeric O O
receptor O O
composed O O
of O O
the O O
extracellular O O
domain O O
of O O
the O O
human B-GENE B-GENE
EGF I-GENE I-GENE
receptor E-GENE E-GENE
and O O
the O O
cytosolic O O
domain O O
of O O
the O O
human B-GENE B-GENE
insulin I-GENE I-GENE
receptor I-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
subunit E-GENE E-GENE
, O O
and O O
a O O
second O O
construct O O
encoding O O
a O O
kinase O B-GENE
- O I-GENE
defiecient O I-GENE
human B-GENE I-GENE
insulin I-GENE I-GENE
receptor E-GENE E-GENE
. O O
It O O
is O O
pathogenetically O O
proved O O
to O O
use O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
concentrate O O
preparations O O
with O O
anti O O
- O O
and O O
dysaggregatory O O
properties O O
, O O
fibronectin S-GENE O
preparations O O
, O O
trasylol O O
or O O
its O O
analogs O O
during O O
complex O O
preoperative O O
preparation O O
of O O
patients O O
. O O
Stimulation O O
of O O
the O O
endosteal O O
bone O O
formation O O
rate O O
was O O
mainly O O
impaired O O
in O O
D O O
- O O
depleted O O
rats O O
, O O
resulting O O
in O O
trabecular O O
bone O O
loss O O
, O O
which O O
, O O
in O O
- O O
D O O
mother O O
rats O O
, O O
was O O
associated O O
with O O
decreased O O
bone O O
ash O O
and O O
total O O
bone O O
calcium O O
. O O
Hematopoietic B-GENE B-GENE
progenitor I-GENE I-GENE
kinase I-GENE I-GENE
1 E-GENE E-GENE
( O O
HPK1 S-GENE S-GENE
) O O
is O O
a O O
member O O
of O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
kinase I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MAP4K S-GENE S-GENE
) O O
family O O
and O O
an O O
upstream O O
activator O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
( O O
JNK S-GENE S-GENE
) O O
signaling O O
cascade O O
. O O
We O O
have O O
used O O
the O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
reporter O O
gene O O
system O O
to O O
study O O
the O O
effect O O
of O O
T S-GENE O
on O O
the O O
long O O
terminal O O
repeats O O
( O O
LTRs O S-GENE
) O O
of O O
a O O
large O O
family O O
of O O
human O O
endogenous O O
retrovirus O O
- O O
like O O
sequences O O
, O O
RTVL O B-GENE
- O I-GENE
H O E-GENE
. O O
To O O
investigate O O
this O O
possibility O O
, O O
we O O
conducted O O
split O O
- O O
visual O O
- O O
field O O
studies O O
in O O
which O O
we O O
manipulated O O
stimulus O O
sets O O
, O O
recognition O O
task O O
, O O
and O O
exposure O O
duration O O
. O O
In O O
conclusion O O
, O O
ANH O S-GENE
had O O
no O O
negative O O
effects O O
on O O
the O O
endocrine O O
stress O O
response O O
during O O
orthopedic O O
surgery O O
under O O
epidural O O
anesthesia O O
. O O
Finally O O
, O O
the O O
conservation O O
of O O
the O O
two O O
residues O O
most O O
sensitive O O
to O O
mutations O O
( O O
Y949 O S-GENE
and O O
Y953 O S-GENE
) O O
in O O
TM11 O S-GENE
, O O
and O O
in O O
the O O
homologous O O
TM5 O S-GENE
, O O
of O O
all O O
mammalian B-GENE O
P I-GENE O
- I-GENE O
gps E-GENE O
and O O
also O O
in O O
other O O
ABC B-GENE O
transporters E-GENE O
, O O
suggests O O
that O O
these O O
residues O O
and O O
domains O O
may O O
play O O
an O O
important O O
role O O
in O O
structural O O
as O O
well O O
as O O
mechanistic O O
aspects O O
common O O
to O O
this O O
family O O
of O O
proteins O O
. O O
Based O O
on O O
the O O
requirement O O
for O O
CREM S-GENE S-GENE
/ O O
ICER S-GENE S-GENE
and O O
Rad6B B-GENE B-GENE
proteins E-GENE E-GENE
in O O
spermatogenesis O O
, O O
we O O
determined O O
expression O O
of O O
Cdc34 S-GENE S-GENE
, O O
Rad6B S-GENE S-GENE
, O O
CREM S-GENE S-GENE
/ O O
ICER S-GENE B-GENE
isoforms O E-GENE
, O O
and O O
the O O
Skp1 S-GENE B-GENE
- O I-GENE
Cullin S-GENE I-GENE
- O I-GENE
F O I-GENE
- O I-GENE
box O I-GENE
ubiquitin S-GENE I-GENE
protein O I-GENE
ligase O I-GENE
subunits O I-GENE
Cul B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
Cul B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
, O O
which O O
are O O
associated O O
with O O
Cdc34 S-GENE S-GENE
activity O O
during O O
murine O O
testicular O O
development O O
. O O
The O O
enigma O O
of O O
aging O O
bone O O
loss O O
. O O
Transcription B-GENE O
factor I-GENE O
IIIC E-GENE S-GENE
( O O
TFIIIC S-GENE S-GENE
) O O
is O O
required O O
for O O
the O O
assembly O O
of O O
a O O
preinitiation O O
complex O O
on O O
5S B-GENE B-GENE
RNA E-GENE E-GENE
, O O
tRNA O S-GENE
, O O
and O O
adenovirus B-GENE B-GENE
VA E-GENE I-GENE
RNA O I-GENE
genes O E-GENE
and O O
contains O O
two O O
separable O O
components O O
, O O
TFIIIC1 S-GENE S-GENE
and O O
TFIIIC2 S-GENE S-GENE
. O O
Furthermore O O
, O O
we O O
show O O
that O O
Nck B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
is O O
capable O O
of O O
recognizing O O
several O O
key O O
components O O
of O O
growth B-GENE B-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
kinase E-GENE E-GENE
- O O
signaling O O
pathways O O
including O O
EGF B-GENE B-GENE
receptors E-GENE E-GENE
, O O
PDGF B-GENE B-GENE
receptor I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
, O O
and O O
IRS B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
These O O
two O O
enhancer O O
elements O O
also O O
enhanced O O
transcription O O
when O O
fused O O
separately O O
to O O
the O O
basal O O
promoter O O
region O O
of O O
the O O
chicken B-GENE B-GENE
vimentin I-GENE I-GENE
gene E-GENE E-GENE
. O O
When O O
they O O
were O O
exposed O O
to O O
intermittent O O
schedules O O
of O O
punishment O O
( O O
fixed O O
- O O
interval O O
[ O O
FI O O
] O O
120 O O
s O O
or O O
FI O O
300 O O
s O O
) O O
, O O
SIB O O
for O O
all O O
but O O
1 O O
of O O
the O O
participants O O
increased O O
to O O
levels O O
similar O O
to O O
those O O
observed O O
during O O
baseline O O
. O O
Deep O O
bite O O
CL O O
II O O
Div O O
. O O
Patients O O
with O O
binocular O O
pregeniculate O O
visual O O
loss O O
, O O
patients O O
with O O
balanced O O
binocular O O
pregeniculate O O
loss O O
without O O
RAPD O O
, O O
and O O
patients O O
with O O
monocular O O
pregeniculate O O
visual O O
loss O O
had O O
significantly O O
larger O O
pupils O O
than O O
age O O
- O O
matched O O
controls O O
. O O
Protein O O
sequencing O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
and O O
immunoblot O O
analyses O O
identify O O
p54 S-GENE S-GENE
and O O
p47 B-GENE S-GENE
/ I-GENE O
48 E-GENE O
as O O
members O O
of O O
the O O
hepatocyte B-GENE B-GENE
nuclear I-GENE I-GENE
factor I-GENE I-GENE
3 E-GENE E-GENE
( O O
HNF3 S-GENE S-GENE
[ O O
forkhead S-GENE O
] O O
) O O
family O O
of O O
transcription O O
factors O O
. O O
p54 S-GENE S-GENE
belongs O O
to O O
the O O
subfamily O O
of O O
HNF3 B-GENE B-GENE
beta I-GENE I-GENE
proteins E-GENE E-GENE
, O O
while O O
p47 B-GENE S-GENE
/ I-GENE O
48 E-GENE O
binding O O
activity O O
includes O O
HNF3 B-GENE B-GENE
gamma E-GENE E-GENE
. O O
In O O
this O O
cross O O
- O O
over O O
controlled O O
study O O
, O O
five O O
male O O
volunteers O O
donated O O
one O O
unit O O
of O O
red O O
cells O O
by O O
MCS O O
and O O
one O O
unit O O
of O O
whole O O
blood O O
by O O
the O O
conventional O O
manual O O
method O O
, O O
3 O O
months O O
apart O O
. O O
Promoter O O
activity O O
was O O
assayed O O
by O O
transient O O
transfection O O
of O O
luciferase B-GENE O
reporter I-GENE O
constructs E-GENE O
containing O O
nested O O
deletions O O
of O O
the O O
upstream O O
sequence O O
in O O
the O O
human O O
RPE O O
cell O O
lines O O
ARPE19 O S-GENE
and O O
D407 O O
, O O
as O O
well O O
as O O
in O O
the O O
SK O O
- O O
Mel O O
- O O
28 O O
and O O
HeLa O O
cell O O
lines O O
. O O
This O O
model O O
system O O
exploits O O
the O O
polyomavirus O O
late O O
transcription O O
termination O O
and O O
polyadenylation O O
signals O O
, O O
which O O
are O O
sufficiently O O
weak O O
to O O
allow O O
the O O
production O O
of O O
many O O
multigenome O O
- O O
length O O
primary O O
transcripts O O
with O O
repeating O O
introns O O
, O O
exons O O
, O O
and O O
poly O O
( O O
A O O
) O O
sites O O
. O O
Magnification O O
- O O
corrected O O
planimetry O O
of O O
the O O
parapapillary O O
region O O
was O O
performed O O
according O O
to O O
Littmann O O
' O O
s O O
method O O
in O O
312 O O
unselected O O
eyes O O
with O O
chronic O O
primary O O
open O O
- O O
angle O O
glaucoma O O
and O O
in O O
125 O O
normal O O
eyes O O
of O O
an O O
age O O
- O O
and O O
refraction O O
- O O
matched O O
control O O
group O O
using O O
optic O O
disk O O
photographs O O
. O O
Although O O
the O O
elevated O O
signalling O O
is O O
eliminated O O
by O O
deletion O O
of O O
Ste20p S-GENE O
( O O
or O O
components O O
downstream O O
of O O
Ste20p S-GENE O
) O O
, O O
the O O
growth O O
and O O
morphological O O
abnormalities O O
of O O
cells O O
lacking O O
Akr1p S-GENE O
are O O
not O O
rescued O O
by O O
deletion O O
of O O
any O O
of O O
the O O
known O O
pheromone O O
response O O
pathway O O
components O O
. O O
Southern O O
hybridization O O
of O O
genomic O O
DNA O O
from O O
WT O O
and O O
Lp S-GENE O
/ O O
Lp S-GENE O
embryos O O
failed O O
to O O
identify O O
specific O O
rearrangements O O
at O O
or O O
near O O
the O O
Nhlh1 B-GENE B-GENE
locus E-GENE E-GENE
, O O
and O O
Northern O O
RNA O O
blotting O O
and O O
RT O O
- O O
PCR O O
evaluation O O
of O O
Nhlh1 B-GENE B-GENE
mRNA E-GENE E-GENE
expression O O
indicated O O
that O O
both O O
the O O
levels O O
and O O
types O O
of O O
Nhlh1 B-GENE B-GENE
mRNAs E-GENE E-GENE
produced O O
in O O
WT O O
and O O
Lp S-GENE O
/ O O
Lp S-GENE O
embryos O O
were O O
indistinguishable O O
. O O
In O O
addition O O
, O O
mrp17 B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
in O O
combination O O
with O O
some O O
mutations O O
affecting O O
another O O
mitochondrial O O
ribosomal O O
protein O O
, O O
caused O O
a O O
synthetic O O
defective O O
phenotype O O
. O O
Expression O O
, O O
characterization O O
, O O
and O O
genomic O O
structure O O
of O O
carp B-GENE B-GENE
JAK1 I-GENE I-GENE
kinase I-GENE I-GENE
gene E-GENE E-GENE
. O O
Significantly O O
, O O
the O O
murine B-GENE B-GENE
P I-GENE I-GENE
- I-GENE I-GENE
selectin I-GENE I-GENE
gene E-GENE E-GENE
had O O
several O O
features O O
not O O
found O O
in O O
the O O
human O O
gene O O
. O O
Fluorescent O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
analysis O O
showed O O
that O O
the O O
novel O O
regions O O
involved O O
in O O
the O O
NFKB2 S-GENE S-GENE
rearrangement O O
originated O O
from O O
chromosome O O
7q34 O O
, O O
thus O O
implying O O
the O O
occurrence O O
of O O
a O O
t O O
( O O
7 O O
; O O
10 O O
) O O
( O O
q34 O O
; O O
q24 O O
) O O
reciprocal O O
chromosomal O O
translocation O O
. O O
Transient O O
- O O
expression O O
assay O O
analysis O O
of O O
subclones O O
of O O
pPstI O O
- O O
G O O
localized O O
the O O
trans O O
- O O
active O O
factor O O
to O O
a O O
3 B-GENE O
. I-GENE O
0 I-GENE O
- I-GENE O
kilobase I-GENE O
XbaI I-GENE O
fragment E-GENE O
. O O
MGF S-GENE S-GENE
is O O
a O O
novel O O
member O O
of O O
the O O
cytokine B-GENE B-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
. O O
This O O
is O O
the O O
first O O
report O O
that O O
the O O
PH B-GENE O
domain E-GENE O
of O O
an O O
IRS B-GENE O
protein E-GENE O
can O O
function O O
in O O
a O O
dominant O O
negative O O
manner O O
to O O
inhibit O O
insulin S-GENE O
signaling O O
. O O
A O O
29 O O
. O O
425 O O
kb O O
segment O O
on O O
the O O
left O O
arm O O
of O O
yeast O O
chromosome O O
XV O O
contains O O
more O O
than O O
twice O O
as O O
many O O
unknown O O
as O O
known O O
open O O
reading O O
frames O O
. O O
This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B-GENE B-GENE
V I-GENE I-GENE
kappa I-GENE I-GENE
genes E-GENE E-GENE
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B-GENE B-GENE
kappa E-GENE E-GENE
and O O
C B-GENE B-GENE
kappa I-GENE I-GENE
loci E-GENE E-GENE
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged O O
V B-GENE B-GENE
kappa E-GENE I-GENE
- O I-GENE
C B-GENE I-GENE
kappa E-GENE I-GENE
gene O E-GENE
. O O
The O O
first O O
270 O O
bp O O
of O O
the O O
promoter O O
region O O
were O O
sequenced O O
and O O
found O O
to O O
contain O O
a O O
CATAA O O
box O O
rather O O
than O O
a O O
TATAA O O
box O O
and O O
several O O
DNA O O
motifs O O
found O O
in O O
activation O O
genes O O
. O O
C O O
. O O
glabrata O O
cells O O
containing O O
the O O
CBF1 B-GENE B-GENE
gene E-GENE E-GENE
under O O
the O O
influence O O
of O O
a O O
shutdown O O
promoter O O
( O O
tetO O O
- O O
ScHOP O O
) O O
arrested O O
their O O
growth O O
after O O
5 O O
h O O
of O O
cultivation O O
in O O
the O O
presence O O
of O O
the O O
reactive O O
drug O O
doxycycline O O
. O O
SF1 S-GENE S-GENE
/ O O
mBBP S-GENE O
utilizes O O
a O O
" B-GENE O
maxi I-GENE O
- I-GENE O
K I-GENE O
homology I-GENE O
" E-GENE O
( O O
maxi B-GENE O
- I-GENE O
KH E-GENE O
) O O
domain O O
for O O
recognition O O
of O O
the O O
single O O
- O O
stranded O O
BPS O O
and O O
requires O O
a O O
cooperative O O
interaction O O
with O O
splicing O O
factor O O
U2AF65 S-GENE S-GENE
bound O O
to O O
an O O
adjacent O O
polypyrimidine O O
tract O O
( O O
PPT O O
) O O
for O O
high O O
- O O
affinity O O
binding O O
. O O
An O O
X O O
- O O
linked O O
zinc B-GENE O
finger I-GENE O
gene E-GENE O
mapping O O
to O O
Xq21 O O
. O O
1 O O
- O O
q21 O O
. O O
3 O O
closely O O
related O O
to O O
ZFX S-GENE S-GENE
and O O
ZFY S-GENE S-GENE
: O O
possible O O
origins O O
from O O
a O O
common O O
ancestral O O
gene O O
. O O
Validity O O
of O O
the O O
short O O
- O O
form O O
QIF O O
was O O
assessed O O
by O O
correlation O O
with O O
motor O O
scores O O
and O O
using O O
analysis O O
of O O
variance O O
by O O
motor O O
levels O O
and O O
motor O O
score O O
groupings O O
. O O
Juvenile O O
angiofibromas O O
. O O
Comment O O
on O O
" O O
Critical O O
behavior O O
of O O
a O O
binary O O
mixture O O
of O O
protein O O
and O O
salt O O
water O O
" O O
The O O
pineal O O
hormone O O
melatonin O O
( O O
MLT O O
) O O
is O O
able O O
to O O
exert O O
an O O
oncostatic O O
action O O
. O O
In O O
addition O O
, O O
there O O
was O O
an O O
increase O O
in O O
the O O
amount O O
of O O
p120 B-GENE B-GENE
Ras E-GENE I-GENE
- O I-GENE
specific O I-GENE
GTPase B-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
( O O
GAP S-GENE O
) O O
and O O
GAP S-GENE O
- O O
associated O O
p190 O S-GENE
. O O
Additional O O
transection O O
of O O
both O O
ADN O O
eliminated O O
the O O
remaining O O
sigmoidal O O
correlation O O
between O O
MAP O O
and O O
RSNA O O
with O O
further O O
increases O O
in O O
resting O O
MAP O O
and O O
RSNA O O
. O O
Pregnancy O O
was O O
ensued O O
in O O
4 O O
cases O O
in O O
group O O
I O O
. O O
The O O
1 O O
. O O
3 O O
- O O
kb O O
DNA O O
, O O
when O O
placed O O
upstream O O
of O O
the O O
chloramphenicol B-GENE B-GENE
acetyltransferase I-GENE I-GENE
gene E-GENE E-GENE
, O O
was O O
shown O O
to O O
be O O
functionally O O
active O O
. O O
Controversy O O
exists O O
regarding O O
both O O
the O O
natural O O
life O O
cycle O O
for O O
this O O
parasite O O
as O O
well O O
as O O
the O O
species O O
identity O O
of O O
opossum O O
Sarcocystis O O
. O O
The O O
mean O O
was O O
66 O O
cells O O
/ O O
mm2 O O
in O O
the O O
laser O O
group O O
and O O
63 O O
. O O
7 O O
cells O O
/ O O
mm2 O O
in O O
the O O
control O O
group O O
. O O
Prazosin O O
in O O
the O O
treatment O O
of O O
high O O
blood O O
pressure O O
The O O
5 B-GENE O
- I-GENE O
HT3 E-GENE O
antagonist O O
ondansetron O O
reduced O O
alcohol O O
intake O O
in O O
both O O
the O O
medium O O
and O O
high O O
alcohol O O
preferring O O
rats O O
at O O
doses O O
between O O
0 O O
. O O
01 O O
and O O
0 O O
. O O
16 O O
mg O O
/ O O
kg O O
. O O
Oral O O
hypoglycemic O O
agents O O
1 O O
. O O
In O O
this O O
system O O
, O O
enhancers O O
act O O
primarily O O
to O O
increase O O
the O O
probability O O
of O O
rapid O O
and O O
efficient O O
transcription O O
complex O O
formation O O
and O O
initiation O O
. O O
The O O
relationship O O
between O O
donor O O
status O O
for O O
antibody O O
to O O
hepatitis B-GENE O
B I-GENE O
core I-GENE O
antigen E-GENE O
and O O
the O O
occurrence O O
of O O
non O O
- O O
A O O
, O O
non O O
- O O
B O O
posttransfusion O O
hepatitis O O
in O O
the O O
recipient O O
was O O
prospectively O O
studied O O
in O O
112 O O
patients O O
undergoing O O
open O O
- O O
heart O O
surgery O O
who O O
were O O
followed O O
for O O
6 O O
. O O
5 O O
months O O
after O O
surgery O O
. O O
By O O
sequencing O O
of O O
exonuclease B-GENE O
III E-GENE O
deletion O O
clones O O
an O O
open O O
reading O O
frame O O
of O O
405 O O
nucleotides O O
was O O
found O O
coding O O
for O O
a O O
protein O O
of O O
135 O O
amino O O
acids O O
with O O
a O O
molecular O O
mass O O
of O O
15 O O
kDa O O
. O O
The O O
pepI B-GENE B-GENE
gene E-GENE E-GENE
was O O
overexpressed O O
in O O
Escherichia O O
coli O O
. O O
Treatment O O
of O O
steroid O O
resistant O O
rejection O O
following O O
renal O O
transplantation O O
: O O
benefits O O
and O O
risks O O
of O O
OKT3 S-GENE O
therapy O O
. O O
The O O
level O O
of O O
transcription O O
generated O O
by O O
all O O
of O O
these O O
activators O O
is O O
greater O O
than O O
the O O
sum O O
of O O
the O O
levels O O
generated O O
by O O
individual O O
factors O O
, O O
a O O
phenomenon O O
designated O O
transcriptional O O
synergy O O
. O O
Conservation O O
of O O
this O O
zinc O O
finger O O
motif O O
from O O
yeast O O
to O O
mouse O O
and O O
human O O
implies O O
functional O O
importance O O
. O O
This O O
nuclear O O
/ O O
organellar O O
gene O O
transfer O O
event O O
is O O
strikingly O O
similar O O
to O O
the O O
experimentally O O
accessible O O
process O O
of O O
nuclear O O
integration O O
of O O
introduced O O
heterologous O O
DNA O O
. O O
RESULTS O O
: O O
In O O
the O O
test O O
data O O
set O O
, O O
the O O
single O O
- O O
sample O O
model O O
was O O
confirmed O O
to O O
give O O
excellent O O
estimation O O
of O O
the O O
AUC O O
: O O
AUC O O
( O O
mg O O
/ O O
ml O O
x O O
min O O
) O O
= O O
0 O O
. O O
93 O O
x O O
C3h O O
+ O O
0 O O
. O O
47 O O
( O O
MPE O O
% O O
= O O
4 O O
. O O
4 O O
% O O
, O O
RMSE O O
% O O
= O O
8 O O
. O O
9 O O
% O O
) O O
. O O
SH3A S-GENE S-GENE
competes O O
with O O
the O O
SH3 B-GENE B-GENE
domains E-GENE E-GENE
of O O
Grb2 S-GENE S-GENE
in O O
binding O O
to O O
mSos1 S-GENE S-GENE
, O O
and O O
the O O
intersectin S-GENE O
- O O
mSos1 S-GENE O
complex O O
can O O
be O O
separated O O
from O O
Grb2 S-GENE S-GENE
by O O
sucrose O O
gradient O O
centrifugation O O
. O O
Comparison O O
between O O
the O O
Ricketts O O
and O O
Bimler O O
therapeutic O O
technics O O
in O O
the O O
treatment O O
of O O
cases O O
of O O
class O O
II O O
, O O
division O O
I O O
mmalocclusion O O
This O O
resulted O O
in O O
a O O
shift O O
of O O
C1 O O
/ O O
C2 O O
, O O
so O O
that O O
the O O
effect O O
of O O
collagen S-GENE O
was O O
more O O
pronounced O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
134 O O
% O O
) O O
than O O
ADP O O
( O O
maximal O O
increase O O
of O O
C1 O O
/ O O
C2 O O
= O O
79 O O
% O O
) O O
. O O
We O O
conclude O O
that O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
elevation O O
in O O
patients O O
without O O
a O O
history O O
of O O
myocardial O O
infarction O O
or O O
left O O
ventricular O O
aneurysm O O
is O O
caused O O
by O O
coronary O O
spasm O O
of O O
a O O
major O O
coronary O O
vessel O O
. O O
Xnr3 S-GENE S-GENE
is O O
transcriptionally O O
activated O O
by O O
wnt S-GENE S-GENE
signaling O O
during O O
gastrulation O O
in O O
the O O
Xenopus O O
embryo O O
. O O
For O O
economical O O
reasons O O
, O O
we O O
could O O
not O O
send O O
a O O
questionnaire O O
to O O
all O O
the O O
35 O O
, O O
779 O O
individuals O O
, O O
but O O
based O O
the O O
investigation O O
on O O
a O O
SRS O O
of O O
4 O O
, O O
000 O O
men O O
, O O
post O O
- O O
stratified O O
in O O
a O O
high O O
- O O
risk O O
and O O
a O O
low O O
- O O
risk O O
group O O
. O O
Several O O
waveforms O O
of O O
both O O
the O O
somatosensory O O
( O O
N20 O O
, O O
P O O
/ O O
N O O
30 O O
, O O
and O O
P200 O O
) O O
and O O
the O O
brainstem O O
auditory O O
- O O
evoked O O
response O O
( O O
I O O
, O O
III O O
, O O
IV O O
, O O
and O O
V O O
) O O
demonstrated O O
shorter O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
latencies O O
in O O
growth O O
- O O
retarded O O
fetuses O O
relative O O
to O O
normal O O
- O O
sized O O
fetuses O O
. O O
Effect O O
of O O
choline O O
magnesium O O
trisalicylate O O
on O O
prostacyclin O O
production O O
by O O
isolated O O
vascular O O
tissue O O
of O O
the O O
rat O O
. O O
The O O
sequences O O
of O O
two O O
previously O O
known O O
tail B-GENE O
genes E-GENE O
, O O
R S-GENE O
and O O
S S-GENE O
, O O
of O O
the O O
temperate O O
bacteriophage O O
P2 O O
and O O
the O O
sequence O O
of O O
an O O
additional O O
open O O
reading O O
frame O O
( O O
orf O O
- O O
30 O O
) O O
located O O
between O O
S S-GENE O
and O O
V S-GENE O
, O O
were O O
determined O O
. O O
The O O
high O O
prevalence O O
of O O
atrial O O
septal O O
defect O O
in O O
tetralogy O O
of O O
Fallot O O
is O O
cited O O
as O O
a O O
possible O O
analogy O O
because O O
right O O
ventricular O O
pressure O O
is O O
high O O
and O O
right O O
ventricular O O
compliance O O
is O O
low O O
from O O
birth O O
. O O
The O O
stress O O
/ O O
BHV O O
- O O
1 O O
model O O
resulted O O
in O O
a O O
mild O O
respiratory O O
infection O O
in O O
all O O
calves O O
with O O
no O O
difference O O
observed O O
between O O
treatment O O
groups O O
. O O
Solution O O
of O O
the O O
Boltzmann O O
equation O O
in O O
a O O
random O O
magnetic O O
field O O
. O O
GH S-GENE S-GENE
signals O O
by O O
interacting O O
with O O
GH B-GENE B-GENE
receptor E-GENE E-GENE
( O O
GHR S-GENE S-GENE
) O O
. O O
Ultraviolet O O
crosslinking O O
experiments O O
using O O
element O O
B O O
revealed O O
the O O
specific O O
binding O O
of O O
two O O
proteins O O
of O O
approximately O O
43 O O
and O O
80 O O
kDa O O
. O O
RESULTS O O
: O O
At O O
short O O
dwell O O
times O O
, O O
uncorrected O O
( O O
whole O O
plasma O O
) O O
D O O
/ O O
P O O
and O O
Cp O O
of O O
urea O O
values O O
were O O
higher O O
than O O
the O O
corrected O O
( O O
plasma O O
water O O
) O O
values O O
by O O
5 O O
. O O
7 O O
% O O
- O O
5 O O
. O O
9 O O
% O O
. O O
The O O
recovery O O
of O O
xanthomegnin O O
added O O
to O O
corn O O
samples O O
at O O
levels O O
of O O
0 O O
. O O
75 O O
- O O
- O O
9 O O
. O O
6 O O
mg O O
/ O O
kg O O
averaged O O
41 O O
% O O
with O O
a O O
coefficient O O
of O O
variation O O
of O O
25 O O
% O O
. O O
The O O
extraordinary O O
high O O
substrate O O
specificity O O
of O O
rPulA S-GENE S-GENE
together O O
with O O
its O O
thermal O O
stability O O
makes O O
this O O
enzyme O O
a O O
good O O
candidate O O
for O O
biotechnological O O
applications O O
in O O
the O O
starch O O
- O O
processing O O
industry O O
. O O
A O O
relationship O O
between O O
the O O
immunological O O
changes O O
and O O
the O O
disease O O
stage O O
was O O
discovered O O
: O O
the O O
index O O
of O O
the O O
3H O O
- O O
thymidine O O
incorporation O O
was O O
found O O
to O O
be O O
67 O O
. O O
9 O O
at O O
the O O
stage O O
of O O
disease O O
exacerbation O O
, O O
and O O
208 O O
. O O
8 O O
at O O
the O O
stage O O
of O O
remission O O
; O O
the O O
complement O O
titre O O
reached O O
, O O
respectively O O
, O O
46 O O
. O O
64 O O
+ O O
/ O O
- O O
5 O O
. O O
28 O O
and O O
112 O O
. O O
0 O O
+ O O
/ O O
- O O
6 O O
. O O
0 O O
units O O
per O O
ml O O
. O O
Sodium O O
dodecylsulfate O O
polyacrylamide O O
gel O O
electrophoresis O O
( O O
SDS O O
- O O
PAGE O O
) O O
showed O O
two O O
bands O O
of O O
about O O
the O O
same O O
intensity O O
with O O
apparent O O
molecular O O
masses O O
of O O
24 O O
. O O
5 O O
and O O
22 O O
. O O
5 O O
kDa O O
. O O
Consistent O O
with O O
an O O
effect O O
on O O
transcription O O
, O O
p21 S-GENE S-GENE
was O O
localized O O
in O O
nuclei O O
of O O
transfected O O
cells O O
. O O
Analysis O O
of O O
pseudo B-GENE O
VH I-GENE B-GENE
gene I-GENE E-GENE
segment I-GENE O
recombination I-GENE O
products E-GENE O
reveals O O
no O O
bias O O
in O O
D B-GENE O
gene I-GENE O
segment E-GENE O
reading O O
frame O O
utilization O O
. O O
Plasma B-GENE O
prolactin E-GENE O
concentrations O O
during O O
incubation O O
, O O
25 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
3 O O
ng O O
/ O O
ml O O
, O O
decreased O O
to O O
baseline O O
levels O O
, O O
10 O O
. O O
8 O O
+ O O
/ O O
- O O
1 O O
. O O
9 O O
ng O O
/ O O
ml O O
, O O
within O O
24 O O
hr O O
after O O
nestbox O O
removal O O
. O O
After O O
30 O O
weeks O O
of O O
amifostine O O
therapy O O
, O O
the O O
morphology O O
of O O
the O O
MDS O O
switched O O
to O O
a O O
chronic O O
myelomonocytic O O
leukemia O O
( O O
CMML O O
) O O
- O O
like O O
appearance O O
, O O
with O O
continuously O O
increasing O O
leukocytes O O
, O O
so O O
that O O
we O O
discontinued O O
amifostine O O
therapy O O
for O O
1 O O
month O O
to O O
exclude O O
a O O
possible O O
side O O
effect O O
of O O
amifostine O O
. O O
Heart O O
disease O O
. O O
A O O
new O O
B O O
- O O
cell O O
- O O
specific O O
enhancer O O
element O O
has O O
been O O
identified O O
3 O O
' O O
of O O
E4 S-GENE O
and O O
the O O
octamerlike O O
motifs O O
in O O
the O O
human B-GENE B-GENE
immunoglobulin I-GENE I-GENE
heavy I-GENE I-GENE
- I-GENE I-GENE
chain I-GENE I-GENE
gene I-GENE I-GENE
enhancer E-GENE E-GENE
. O O
CONCLUSIONS O O
: O O
This O O
initial O O
experience O O
indicates O O
that O O
there O O
is O O
short O O
- O O
to O O
middle O O
- O O
term O O
efficiency O O
and O O
safety O O
when O O
using O O
GKS O O
to O O
treat O O
MTLE O O
. O O
Two O O
cases O O
of O O
Paraquat O O
poisoning O O
of O O
anticonservative O O
origin O O
are O O
described O O
. O O
Genetic O O
mutation O O
or O O
loss O O
of O O
activin S-GENE B-GENE
/ O I-GENE
transforming B-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
beta I-GENE E-GENE
( I-GENE O
TGFbeta I-GENE S-GENE
) I-GENE O
receptor E-GENE O
function O O
has O O
been O O
shown O O
in O O
human O O
lymphoid O O
, O O
breast O O
, O O
and O O
colorectal O O
tumors O O
as O O
well O O
as O O
Hep2B O O
and O O
Mv1Lu O O
cell O O
lines O O
. O O
A O O
poly O O
( O O
ortho O O
ester O O
) O O
designed O O
for O O
combined O O
ocular O O
delivery O O
of O O
dexamethasone O O
sodium O O
phosphate O O
and O O
5 O O
- O O
fluorouracil O O
: O O
subconjunctival O O
tolerance O O
and O O
in O O
vitro O O
release O O
. O O
We O O
now O O
describe O O
a O O
HepG2 B-GENE B-GENE
cell I-GENE I-GENE
casein I-GENE I-GENE
kinase I-GENE I-GENE
II I-GENE I-GENE
beta I-GENE I-GENE
subunit I-GENE E-GENE
cDNA E-GENE O
of O O
2 O O
. O O
57 O O
kb O O
containing O O
96 O O
bases O O
of O O
5 O O
' O O
untranslated O O
sequence O O
, O O
645 O O
bases O O
of O O
open O O
reading O O
frame O O
, O O
and O O
1832 O O
bases O O
of O O
3 O O
' O O
untranslated O O
sequence O O
with O O
two O O
polyadenylation O O
consensus O O
signal O O
sequences O O
and O O
two O O
poly O O
( O O
A O O
) O O
stretches O O
. O O
Brome B-GENE O
mosaic I-GENE O
virus I-GENE O
polymerase E-GENE O
- O O
like O O
protein B-GENE O
2a E-GENE O
is O O
directed O O
to O O
the O O
endoplasmic O O
reticulum O O
by O O
helicase S-GENE O
- O O
like O O
viral B-GENE O
protein I-GENE O
1a E-GENE O
. O O
Diagnostic O O
importance O O
of O O
determining O O
leucine B-GENE O
aminotransferase E-GENE O
activity O O
in O O
acute O O
pancreatitis O O
Therapeutic O O
iodine O O
125 O O
for O O
hyperthyroidism O O
: O O
evidence O O
for O O
a O O
special O O
radiobiological O O
effect O O
on O O
the O O
follicular O O
cell O O
. O O
Maintenance O O
metabolizable O O
- O O
energy O O
( O O
ME O O
) O O
requirement O O
averaged O O
31 O O
. O O
0 O O
kcal O O
/ O O
kg O O
body O O
wt O O
. O O
This O O
finding O O
is O O
of O O
importance O O
because O O
it O O
completes O O
an O O
explanation O O
for O O
central O O
near O O
- O O
location O O
errors O O
in O O
the O O
partial O O
- O O
report O O
bar O O
- O O
probe O O
task O O
. O O
A O O
DNA O O
binding O O
protein O O
was O O
identified O O
which O O
binds O O
to O O
two O O
novel O O
target O O
- O O
like O O
sequences O O
: O O
( O O
i O O
) O O
at O O
the O O
5 O O
' O O
flanking O O
site O O
of O O
the O O
breakpoint O O
junction O O
of O O
chromosome O O
8 O O
in O O
a O O
patient O O
with O O
T O O
- O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
carrying O O
the O O
t O O
( O O
8 O O
; O O
14 O O
) O O
( O O
q24 O O
; O O
q11 O O
) O O
rearrangement O O
and O O
( O O
ii O O
) O O
on O O
chromosome O O
1 O O
in O O
three O O
of O O
five O O
T O O
- O O
ALL O O
patients O O
with O O
the O O
t O O
( O O
1 O O
; O O
14 O O
) O O
( O O
p32 O O
; O O
q11 O O
) O O
rearrangement O O
. O O
Nedocromil O O
sodium O O
shifted O O
the O O
severity O O
of O O
the O O
early O O
allergic O O
reaction O O
( O O
EAR O O
) O O
from O O
mean O O
- O O
34 O O
. O O
8 O O
% O O
to O O
- O O
6 O O
. O O
9 O O
% O O
and O O
inhibited O O
the O O
later O O
allergic O O
reaction O O
( O O
LAR O O
) O O
from O O
- O O
30 O O
. O O
5 O O
% O O
to O O
+ O O
0 O O
. O O
4 O O
% O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
. O O
The O O
Mer1 B-GENE B-GENE
protein E-GENE E-GENE
contains O O
the O O
KH O B-GENE
motif O E-GENE
found O O
in O O
some O O
RNA O O
- O O
binding O O
proteins O O
, O O
and O O
RNA O O
gel O O
mobility O O
shift O O
assays O O
demonstrate O O
that O O
Mer1 S-GENE S-GENE
binds O O
specifically O O
to O O
MER2 B-GENE B-GENE
RNA E-GENE E-GENE
. O O
Results O O
obtained O O
from O O
the O O
tritium O O
test O O
and O O
direct O O
chemical O O
analysis O O
were O O
compared O O
. O O
We O O
found O O
that O O
in O O
anesthetized O O
, O O
paralyzed O O
cats O O
, O O
the O O
visual O O
evoked O O
potential O O
( O O
VEP O O
) O O
was O O
dependent O O
only O O
on O O
magnitude O O
of O O
delta O O
C O O
at O O
each O O
pattern O O
transition O O
, O O
and O O
was O O
independent O O
of O O
the O O
starting O O
or O O
ending O O
contrast O O
level O O
. O O
Experiment O O
B O O
: O O
Clinical O O
, O O
biochemical O O
, O O
and O O
histological O O
variables O O
were O O
measured O O
over O O
a O O
12 O O
- O O
day O O
period O O
after O O
the O O
zymosan O O
had O O
been O O
given O O
. O O
Direct O O
saturation O O
analysis O O
From O O
this O O
asymmetry O O
, O O
we O O
suggested O O
previously O O
that O O
GCN4 S-GENE S-GENE
interacts O O
with O O
nonequivalent O O
and O O
possibly O O
overlapping O O
half O O
- O O
sites O O
( O O
ATGAC O S-GENE
and O O
ATGAG O S-GENE
) O O
that O O
have O O
different O O
affinities O O
. O O
Furthermore O O
the O O
aldosterone O O
stimulating O O
effect O O
of O O
low O O
sodium O O
diet O O
( O O
17 O O
children O O
) O O
, O O
severe O O
and O O
prolonged O O
vomiting O O
( O O
19 O O
children O O
) O O
and O O
synthetic O O
ACTH S-GENE O
( O O
10 O O
children O O
) O O
has O O
been O O
studied O O
by O O
our O O
modified O O
method O O
. O O
A O O
case O O
control O O
study O O
( O O
1 O O
: O O
2 O O
) O O
of O O
182 O O
pairs O O
of O O
Hepatitis O O
A O O
was O O
carried O O
out O O
in O O
Weng O O
- O O
ling O O
Zhe O O
- O O
jiang O O
during O O
April O O
1988 O O
. O O
The O O
mutant O O
strain O O
carries O O
three O O
tandem O O
copies O O
of O O
the O O
18 O O
bp O O
sequence O O
that O O
is O O
duplicated O O
in O O
the O O
amdI66 S-GENE O
mutation O O
. O O
Although O O
cDNA O O
encoding O O
a O O
human B-GENE O
phagocyte I-GENE O
formyl I-GENE O
peptide I-GENE O
- I-GENE O
binding I-GENE O
protein E-GENE O
has O O
been O O
reported O O
recently O O
( O O
Boulay O O
, O O
F O O
. O O
, O O
Tardif O O
, O O
M O O
. O O
, O O
Brouchon O O
, O O
L O O
. O O
, O O
and O O
Vignais O O
, O O
P O O
. O O
In O O
NIH O O
3T3 O O
fibroblasts O O
the O O
high O O
affinity O O
IL B-GENE O
- I-GENE O
2R E-GENE O
bearing O O
a O O
deletion O O
of O O
a O O
region O O
rich O O
in O O
acidic O O
amino O O
acids O O
( O O
the O O
" O O
acidic O O
" O O
region O O
) O O
in O O
the O O
IL B-GENE B-GENE
- I-GENE I-GENE
2R I-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
chain E-GENE E-GENE
failed O O
to O O
induce O O
the O O
tyrosine O O
phosphorylation O O
of O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
as O O
well O O
as O O
the O O
expression O O
of O O
the O O
all O O
three O O
nuclear O O
proto O O
- O O
oncogenes O O
. O O
A O O
small O O
molecule O O
ILK S-GENE S-GENE
inhibitor O O
suppresses O O
the O O
phosphorylation O O
of O O
PKB S-GENE S-GENE
at O O
the O O
Ser O O
- O O
473 O O
but O O
not O O
the O O
Thr O O
- O O
308 O O
site O O
in O O
the O O
PTEN S-GENE B-GENE
mutant O E-GENE
cells O O
. O O
The O O
avian O O
carcinoma O O
virus O O
MH2 O O
contains O O
a O O
hybrid O O
gene O O
delta B-GENE O
gag E-GENE O
- O O
mht S-GENE O
with O O
a O O
contiguous O O
open O O
reading O O
frame O O
of O O
2682 O O
base O O
pairs O O
as O O
well O O
as O O
v B-GENE B-GENE
- I-GENE I-GENE
myc E-GENE E-GENE
and O O
avian O O
helper O O
virus O O
- O O
related O O
sequences O O
. O O
delta B-GENE O
gag E-GENE O
is O O
a O O
partial O O
retroviral B-GENE O
core I-GENE O
protein I-GENE O
gene E-GENE O
while O O
v B-GENE B-GENE
- I-GENE I-GENE
mht E-GENE E-GENE
and O O
v B-GENE B-GENE
- I-GENE I-GENE
myc E-GENE E-GENE
are O O
cell O O
- O O
drived O O
sequences O O
. O O
The O O
results O O
in O O
the O O
untreated O O
patients O O
demonstrate O O
the O O
primary O O
importance O O
of O O
bulk O O
reduction O O
at O O
initial O O
laparotomy O O
. O O
Of O O
3841 O O
serum O O
samples O O
from O O
sows O O
received O O
from O O
the O O
Tennessee O O
State O O
Diagnostic O O
Laboratory O O
in O O
1991 O O
- O O
1992 O O
, O O
1130 O O
were O O
positive O O
for O O
Toxoplasma B-GENE O
gondii I-GENE O
antibody E-GENE O
. O O
These O O
findings O O
also O O
demonstrate O O
that O O
unless O O
excluded O O
by O O
other O O
factors O O
, O O
the O O
C B-GENE B-GENE
proteins E-GENE E-GENE
are O O
likely O O
to O O
be O O
located O O
along O O
the O O
length O O
of O O
nascent O O
transcripts O O
. O O
In O O
this O O
group O O
of O O
patients O O
, O O
the O O
mean O O
LH S-GENE O
( O O
9 O O
. O O
3 O O
+ O O
/ O O
- O O
5 O O
. O O
9 O O
IU O O
/ O O
l O O
) O O
and O O
sex B-GENE O
- I-GENE O
hormone I-GENE O
binding I-GENE O
globulin E-GENE O
( O O
SHBG S-GENE O
) O O
( O O
54 O O
. O O
5 O O
+ O O
/ O O
- O O
22 O O
. O O
9 O O
nmol O O
/ O O
l O O
) O O
concentrations O O
were O O
significantly O O
greater O O
than O O
those O O
of O O
five O O
normal O O
control O O
subjects O O
( O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
11 O O
IU O O
/ O O
l O O
and O O
26 O O
. O O
0 O O
+ O O
/ O O
- O O
7 O O
. O O
0 O O
nmol O O
/ O O
l O O
respectively O O
) O O
. O O
We O O
have O O
now O O
completed O O
the O O
primary O O
structure O O
of O O
fibrillin S-GENE O
, O O
elucidated O O
the O O
exon O O
/ O O
intron O O
organization O O
of O O
the O O
gene O O
and O O
derived O O
a O O
physical O O
map O O
of O O
the O O
genetic O O
locus O O
. O O
The O O
BCL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE I-GENE
POZ O I-GENE
domain O E-GENE
and O O
other O O
POZ O B-GENE
domains O E-GENE
interact O O
with O O
the O O
co O O
- O O
repressors O O
N B-GENE O
- I-GENE O
CoR E-GENE S-GENE
and O O
SMRT S-GENE S-GENE
. O O
Cytokine O O
inducibility O O
of O O
VCAM1 S-GENE S-GENE
in O O
endothelial O O
cells O O
utilizes O O
the O O
interaction O O
of O O
heterodimeric O O
p50 S-GENE S-GENE
/ O O
p65 S-GENE B-GENE
proteins O E-GENE
with O O
IRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
In O O
particular O O
, O O
MF O O
males O O
receiving O O
either O O
a O O
5 O O
. O O
0 O O
- O O
mg O O
/ O O
kg O O
CDP O O
dose O O
or O O
a O O
3 O O
. O O
0 O O
- O O
mg O O
/ O O
kg O O
RO O O
dose O O
explored O O
the O O
object O O
more O O
often O O
than O O
MM O O
males O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
To O O
gain O O
additional O O
insights O O
into O O
this O O
novel O O
apoptotic O O
checkpoint O O
, O O
we O O
have O O
now O O
characterized O O
the O O
mouse B-GENE O
survivin I-GENE O
locus E-GENE O
. O O
Both O O
proteins O O
share O O
sequence O O
similarity O O
with O O
the O O
myelin B-GENE O
- I-GENE O
associated I-GENE O
glycoprotein E-GENE O
, O O
an O O
adhesion O O
molecule O O
of O O
oligodendrocytes O O
and O O
Schwann O O
cells O O
that O O
has O O
been O O
implicated O O
in O O
the O O
process O O
of O O
myelination O O
, O O
raising O O
the O O
important O O
question O O
of O O
whether O O
myelin B-GENE O
- I-GENE O
associated I-GENE O
glycoprotein E-GENE O
is O O
also O O
a O O
sialic B-GENE O
acid I-GENE O
- I-GENE O
binding I-GENE O
protein E-GENE O
. O O
Localized O O
Bicaudal B-GENE O
- I-GENE O
C I-GENE O
RNA E-GENE O
encodes O O
a O O
protein O O
containing O O
a O O
KH O B-GENE
domain O E-GENE
, O O
the O O
RNA O O
binding O O
motif O O
of O O
FMR1 S-GENE S-GENE
. O O
To O O
facilitate O O
the O O
characterization O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
E2 E-GENE E-GENE
functions O O
in O O
human O O
cells O O
, O O
we O O
isolated O O
cDNAs O O
encoding O O
two O O
members O O
of O O
the O O
small B-GENE O
Maf I-GENE B-GENE
family E-GENE E-GENE
, O O
MafK S-GENE S-GENE
and O O
MafG S-GENE S-GENE
. O O
Indigenous O O
microbial O O
flora O O
and O O
the O O
large O O
intestine O O
in O O
tadpoles O O
. O O
Copyright O O
1998 O O
The O O
Association O O
for O O
the O O
Study O O
of O O
Animal O O
Behaviour O O
. O O
In O O
contrast O O
to O O
the O O
restricted O O
tissue O O
expression O O
of O O
gonadotropin S-GENE O
and O O
TSH B-GENE B-GENE
receptors E-GENE E-GENE
in O O
gonads O O
and O O
thyroid O O
, O O
respectively O O
, O O
LGR4 S-GENE S-GENE
is O O
expressed O O
in O O
diverse O O
tissues O O
including O O
ovary O O
, O O
testis O O
, O O
adrenal O O
, O O
placenta O O
, O O
thymus O O
, O O
spinal O O
cord O O
, O O
and O O
thyroid O O
, O O
whereas O O
LGR5 S-GENE O
is O O
found O O
in O O
muscle O O
, O O
placenta O O
, O O
spinal O O
cord O O
, O O
and O O
brain O O
. O O
Not O O
only O O
will O O
it O O
substantially O O
reduce O O
incident O O
cases O O
of O O
hepatitis O O
B O O
for O O
the O O
next O O
decade O O
, O O
it O O
will O O
also O O
provide O O
a O O
framework O O
for O O
the O O
successful O O
introduction O O
of O O
future O O
adolescent O O
vaccine O O
initiatives O O
in O O
Australia O O
. O O
A O O
new O O
technique O O
for O O
the O O
identification O O
of O O
phases O O
contained O O
within O O
a O O
polymer O O
blend O O
is O O
described O O
in O O
this O O
paper O O
. O O
Radioactively O O
labeled O O
microspheres O O
were O O
used O O
to O O
determine O O
and O O
compare O O
the O O
hemodynamic O O
effects O O
of O O
sodium O O
nitroprusside O O
( O O
SNP O O
) O O
, O O
nitroglycerin O O
( O O
NTG O O
) O O
, O O
and O O
deep O O
enflurane O O
anesthesia O O
on O O
oral O O
tissues O O
during O O
controlled O O
hypotension O O
when O O
compared O O
with O O
controls O O
. O O
Their O O
central O O
projections O O
were O O
indistinguishable O O
from O O
those O O
of O O
control O O
axons O O
in O O
all O O
four O O
trigeminal O O
subnuclei O O
. O O
The O O
JNK S-GENE S-GENE
/ O O
SAPK S-GENE S-GENE
activator O O
mixed B-GENE O
lineage I-GENE B-GENE
kinase I-GENE I-GENE
3 E-GENE E-GENE
( O O
MLK3 S-GENE S-GENE
) O O
transforms O O
NIH O O
3T3 O O
cells O O
in O O
a O O
MEK S-GENE O
- O O
dependent O O
fashion O O
. O O
The O O
decision O O
support O O
system O O
uses O O
the O O
network O O
at O O
its O O
core O O
and O O
helps O O
not O O
only O O
in O O
reaching O O
a O O
diagnosis O O
but O O
also O O
in O O
finding O O
the O O
optimal O O
way O O
to O O
reach O O
that O O
diagnosis O O
. O O
In O O
contrast O O
to O O
the O O
effect O O
on O O
DNA O O
replication O O
, O O
the O O
L13V O S-GENE
substitution O O
in O O
large B-GENE O
T I-GENE O
antigen E-GENE O
did O O
not O O
prevent O O
complex O O
formation O O
with O O
Hsc70 S-GENE S-GENE
and O O
the O O
Rb B-GENE B-GENE
protein E-GENE E-GENE
. O O
To O O
explore O O
the O O
effect O O
of O O
persistent O O
cardiomegaly O O
on O O
cardiovascular O O
function O O
, O O
groups O O
of O O
newborn O O
rats O O
inhaled O O
up O O
to O O
500 O O
ppm O O
CO O O
for O O
33 O O
days O O
, O O
after O O
which O O
development O O
continued O O
in O O
ambient O O
air O O
. O O
Bandwidth O O
of O O
auditory O O
units O O
in O O
the O O
chick O O
forebrain O O
( O O
field O O
L O O
/ O O
Hv O O
complex O O
) O O
was O O
measured O O
with O O
isointensity O O
tone O O
stimuli O O
. O O
Members O O
of O O
the O O
steroid B-GENE O
/ I-GENE O
hormone I-GENE B-GENE
nuclear I-GENE I-GENE
receptor I-GENE I-GENE
superfamily E-GENE E-GENE
regulate O O
target O O
gene O O
transcription O O
via O O
recognition O O
and O O
association O O
with O O
specific O O
cis O O
- O O
acting O O
sequences O O
of O O
DNA O O
, O O
called O O
hormone O O
response O O
elements O O
( O O
HREs O S-GENE
) O O
. O O
Indeed O O
, O O
DEX O S-GENE
also O O
enhanced O O
the O O
RA O O
- O O
dependent O O
increase O O
in O O
RARbeta B-GENE B-GENE
mRNA E-GENE E-GENE
in O O
a O O
cycloheximide O O
- O O
sensitive O O
manner O O
. O O
The O O
highest O O
concentration O O
of O O
respirable O O
mineral O O
fibres O O
was O O
found O O
during O O
the O O
overhaul O O
of O O
a O O
truck O O
with O O
asbestos O O
insulation O O
; O O
respirable O O
fibre O O
concentration O O
reached O O
the O O
value O O
of O O
5 O O
f O O
/ O O
cm3 O O
, O O
and O O
total O O
dust O O
concentration O O
- O O
the O O
value O O
of O O
about O O
80 O O
mg O O
/ O O
m3 O O
. O O
Avian B-GENE O
EMILIN E-GENE O
was O O
extracted O O
from O O
19 O O
- O O
day O O
- O O
old O O
embryonic O O
chick O O
aortas O O
and O O
associated O O
blood O O
vessels O O
and O O
purified O O
by O O
ion O O
- O O
exchange O O
chromatography O O
and O O
gel O O
filtration O O
. O O
CYP51P1 S-GENE S-GENE
is O O
96 O O
. O O
5 O O
% O O
identical O O
to O O
the O O
human B-GENE B-GENE
CYP51 E-GENE I-GENE
coding O I-GENE
sequence O E-GENE
and O O
is O O
not O O
interrupted O O
with O O
introns O O
but O O
has O O
six O O
in O O
- O O
frame O O
stop O O
codons O O
resulting O O
from O O
point O O
mutations O O
. O O
We O O
report O O
here O O
that O O
AChE S-GENE S-GENE
activity O O
tends O O
to O O
decrease O O
in O O
individuals O O
sampled O O
in O O
tanks O O
at O O
a O O
salinity O O
of O O
30 O O
per O O
thousand O O
as O O
temperature O O
increases O O
. O O
Three O O
RasV12 B-GENE B-GENE
mutants E-GENE E-GENE
( O O
S35 S-GENE O
, O O
G37 S-GENE O
, O O
and O O
C40 S-GENE O
) O O
which O O
differ O O
by O O
their O O
ability O O
to O O
bind O O
to O O
Ras B-GENE B-GENE
effectors E-GENE E-GENE
( O O
Raf S-GENE S-GENE
, O O
Ral B-GENE B-GENE
- I-GENE I-GENE
GEFs E-GENE E-GENE
, O O
and O O
the O O
p110 B-GENE B-GENE
subunit I-GENE E-GENE
of I-GENE O
PI I-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
, O O
respectively O O
) O O
were O O
able O O
to O O
induce O O
sustained O O
NR O O
cell O O
proliferation O O
, O O
although O O
none O O
of O O
these O O
mutants O O
was O O
reported O O
to O O
transform O O
NIH O O
3T3 O O
cells O O
. O O
Mating O O
response O O
, O O
ovulation O O
rate O O
, O O
follicle O O
and O O
corpus O O
luteum O O
size O O
, O O
gestation O O
length O O
, O O
pregnancy O O
rate O O
, O O
lambing O O
rate O O
, O O
and O O
lamb O O
birth O O
weight O O
were O O
recorded O O
. O O
Membrane O O
extraction O O
has O O
been O O
interfaced O O
with O O
gas O O
chromatography O O
and O O
mass O O
spectroscopy O O
for O O
the O O
analysis O O
of O O
volatile O O
organics O O
in O O
water O O
. O O
A O O
significant O O
difference O O
in O O
the O O
distribution O O
of O O
antibodies O O
to O O
thyroglobulin S-GENE O
and O O
thyroid B-GENE O
peroxidase E-GENE O
was O O
found O O
in O O
subgroup O O
2 O O
. O O
Here O O
, O O
we O O
characterize O O
TCR S-GENE S-GENE
/ O O
CD48 S-GENE S-GENE
and O O
TCR S-GENE S-GENE
/ O O
CD28 S-GENE S-GENE
costimulation O O
in O O
T O O
cells O O
expressing O O
Lck S-GENE B-GENE
Src B-GENE I-GENE
homology I-GENE I-GENE
3 E-GENE E-GENE
( O O
SH3 S-GENE S-GENE
) O O
mutants O O
. O O
High O O
expression O O
of O O
p51A S-GENE S-GENE
( O O
TAp63gamma S-GENE O
) O O
in O O
the O O
skeletal O O
muscle O O
tissue O O
drove O O
us O O
to O O
investigate O O
a O O
differentiation O O
- O O
inducible O O
myoblastic O O
cell O O
line O O
which O O
showed O O
increased O O
p51A S-GENE S-GENE
expression O O
after O O
differentiation O O
induction O O
. O O
The O O
rate O O
for O O
Arm O O
III O O
( O O
CAF O O
therapy O O
) O O
was O O
61 O O
. O O
5 O O
% O O
( O O
32 O O
/ O O
52 O O
) O O
, O O
a O O
little O O
higher O O
than O O
that O O
for O O
the O O
other O O
two O O
. O O
These O O
results O O
induce O O
that O O
the O O
putative O O
TATA O O
box O O
and O O
initiator O O
are O O
not O O
involved O O
in O O
the O O
promoter O O
activity O O
, O O
and O O
that O O
the O O
vitronectin B-GENE B-GENE
promoter E-GENE E-GENE
lacks O O
the O O
TATA O O
box O O
, O O
initiator O O
and O O
GC O O
box O O
. O O
Using O O
the O O
interaction O O
- O O
trap O O
assay O O
to O O
identify O O
candidate O O
proteins O O
that O O
bind O O
the O O
cytoplasmic O O
region O O
of O O
the O O
LAR B-GENE B-GENE
transmembrane I-GENE I-GENE
protein I-GENE I-GENE
tyrosine I-GENE I-GENE
phosphatase E-GENE E-GENE
( O O
PT B-GENE B-GENE
- I-GENE I-GENE
Pase E-GENE E-GENE
) O O
, O O
we O O
isolated O O
a O O
cDNA O O
encoding O O
a O O
2861 O S-GENE
- O O
amino O O
acid O O
protein O O
termed O O
Trio S-GENE O
that O O
contains O O
three O O
enzyme O O
domains O O
: O O
two O O
functional O O
GEF B-GENE B-GENE
domains E-GENE E-GENE
and O O
a O O
protein B-GENE B-GENE
serine I-GENE I-GENE
/ I-GENE I-GENE
threonine I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PSK S-GENE S-GENE
) O O
domain O O
. O O
We O O
have O O
isolated O O
two O O
H19 B-GENE B-GENE
cDNAs E-GENE E-GENE
( O O
AP S-GENE O
and O O
ES S-GENE O
) O O
that O O
contain O O
this O O
ORF4 O S-GENE
and O O
correspond O O
to O O
incomplete O O
copies O O
of O O
the O O
unique O O
2 B-GENE O
. I-GENE O
3 I-GENE O
kb I-GENE O
H19 I-GENE O
RNA E-GENE O
. O O
The O O
combined O O
in O O
vitro O O
effects O O
of O O
ethanol O O
wih O O
methaqualone O O
, O O
phenobarbital O O
, O O
pyrazole O O
or O O
disulfiram O O
were O O
studied O O
using O O
rat B-GENE O
brain I-GENE O
microsomal I-GENE O
NA I-GENE B-GENE
- I-GENE I-GENE
K I-GENE I-GENE
- I-GENE I-GENE
ATPase E-GENE E-GENE
. O O
The O O
related O O
adhesion B-GENE O
focal I-GENE O
tyrosine I-GENE B-GENE
kinase E-GENE E-GENE
is O O
tyrosine O O
- O O
phosphorylated O O
after O O
beta1 B-GENE O
- I-GENE O
integrin E-GENE O
stimulation O O
in O O
B O O
cells O O
and O O
binds O O
to O O
p130cas S-GENE S-GENE
. O O
Earlier O O
reports O O
have O O
localized O O
mutations O O
which O O
affect O O
the O O
processing O O
and O O
transport O O
of O O
herpes O O
simplex O O
virus O O
1 O O
glycoproteins O O
to O O
a O O
region O O
located O O
between O O
the O O
genes O O
specifying O O
glycoprotein B-GENE O
B E-GENE O
and O O
the O O
major O O
viral O O
DNA O O
- O O
binding O O
protein O O
( O O
beta B-GENE O
8 E-GENE O
) O O
. O O
These O O
results O O
indicate O O
that O O
the O O
2127 O O
- O O
bp O O
cDNA O O
encodes O O
a O O
functional O O
feline O O
L B-GENE O
/ I-GENE O
B I-GENE O
/ I-GENE O
K I-GENE O
- I-GENE O
type I-GENE O
ALP E-GENE O
expressed O O
on O O
cell O O
surfaces O O
via O O
phosphatidylinositol O O
- O O
glycan O O
linkage O O
. O O
Our O O
experience O O
suggests O O
that O O
T2 O O
weighting O O
is O O
adequate O O
and O O
is O O
the O O
method O O
of O O
choice O O
for O O
the O O
early O O
recognition O O
of O O
necrosis O O
of O O
the O O
lunate O O
. O O
Analysis O O
of O O
a O O
Het S-GENE O
- O O
mutation O O
in O O
Anabaena O O
sp O O
. O O
strain O O
PCC O O
7120 O O
implicates O O
a O O
secondary O O
metabolite O O
in O O
the O O
regulation O O
of O O
heterocyst O O
spacing O O
. O O
Here O O
we O O
report O O
that O O
components O O
of O O
the O O
Ras S-GENE S-GENE
/ O O
Raf S-GENE S-GENE
/ O O
MAPK S-GENE S-GENE
pathway O O
are O O
constitutively O O
activated O O
in O O
these O O
lck S-GENE S-GENE
- O O
transformed O O
immature O O
thymoblasts O O
. O O
p56 S-GENE S-GENE
( O O
lck S-GENE S-GENE
) O O
utilizes O O
Shc S-GENE S-GENE
and O O
Grb2 B-GENE S-GENE
adaptors E-GENE O
to O O
mediate O O
activation O O
of O O
p21 S-GENE S-GENE
( O O
ras S-GENE S-GENE
) O O
in O O
the O O
thymoblast O O
lines O O
by O O
promoting O O
tyrosine O O
phosphorylation O O
of O O
the O O
Shc B-GENE B-GENE
protein E-GENE E-GENE
and O O
constitutive O O
interaction O O
between O O
Shc S-GENE S-GENE
and O O
Grb2 S-GENE S-GENE
. O O
The O O
rec8 B-GENE O
( I-GENE O
+ I-GENE O
) E-GENE O
, O O
rec10 B-GENE O
( I-GENE O
+ I-GENE O
) E-GENE O
, O O
and O O
rec11 B-GENE O
( I-GENE O
+ I-GENE O
) I-GENE O
genes I-GENE O
of I-GENE O
the I-GENE O
fission I-GENE O
yeast I-GENE O
Schizosaccharomyces I-GENE O
pombe E-GENE O
exhibit O O
similar O O
specificities O O
for O O
meiotic O O
recombination O O
and O O
rec8 B-GENE S-GENE
( I-GENE O
+ I-GENE O
) E-GENE O
is O O
required O O
for O O
sister O O
chromatid O O
cohesion O O
and O O
homolog O O
pairing O O
. O O
Based O O
on O O
the O O
results O O
of O O
this O O
analysis O O
, O O
we O O
also O O
predict O O
that O O
the O O
budding B-GENE O
yeast I-GENE O
arsenate I-GENE O
resistance I-GENE O
protein E-GENE O
Acr2 S-GENE S-GENE
and O O
the O O
ORF B-GENE B-GENE
Ygr203w E-GENE I-GENE
encode O I-GENE
protein O I-GENE
phosphatases O E-GENE
with O O
catalytic O O
properties O O
similar O O
to O O
that O O
of O O
the O O
Cdc25 B-GENE B-GENE
family E-GENE E-GENE
. O O
At O O
onset O O
of O O
first O O
post O O
- O O
weaning O O
estrus O O
, O O
sows O O
received O O
either O O
an O O
intravulval O O
injection O O
of O O
3 O O
. O O
75 O O
mg O O
of O O
prostaglandin O O
analogue O O
( O O
PGF O O
) O O
or O O
, O O
served O O
as O O
a O O
non O O
- O O
injected O O
control O O
( O O
CON O O
) O O
. O O
We O O
concluded O O
that O O
HFV O O
can O O
achieve O O
values O O
of O O
CO2 O O
elimination O O
close O O
to O O
the O O
estimated O O
metabolic O O
CO2 O O
production O O
in O O
normal O O
unintubated O O
subjects O O
over O O
short O O
periods O O
of O O
time O O
. O O
The O O
PHO5 B-GENE B-GENE
gene E-GENE E-GENE
is O O
activated O O
by O O
the O O
Pho4p B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
, O O
which O O
itself O O
is O O
negatively O O
regulated O O
through O O
phosphorylation O O
by O O
the O O
products O O
of O O
PHO80 S-GENE S-GENE
and O O
PHO85 S-GENE S-GENE
. O O
Although O O
the O O
only O O
authoritative O O
way O O
to O O
determine O O
the O O
effect O O
of O O
diet O O
on O O
urinary O O
pH O O
is O O
a O O
feeding O O
trial O O
, O O
there O O
is O O
no O O
universally O O
accepted O O
protocol O O
for O O
measuring O O
urinary O O
pH O O
. O O
Analysis O O
of O O
the O O
DNA O O
sequence O O
upstream O O
of O O
the O O
narQ B-GENE B-GENE
gene E-GENE E-GENE
, O O
which O O
encodes O O
the O O
second O O
nitrate O O
- O O
responsive O O
sensor O O
- O O
transmitter O O
protein O O
in O O
Escherichia O O
coli O O
, O O
revealed O O
an O O
open O O
reading O O
frame O O
( O O
ORF O O
) O O
whose O O
product O O
shows O O
a O O
high O O
degree O O
of O O
similarity O O
to O O
a O O
number O O
of O O
iron B-GENE O
- I-GENE O
sulfur I-GENE O
proteins E-GENE O
as O O
well O O
as O O
to O O
the O O
beta O O
subunit O O
of O O
glutamate B-GENE B-GENE
synthase E-GENE E-GENE
( O O
gltD S-GENE O
) O O
of O O
E O O
. O O
coli O O
. O O
Endothelial O O
purine O O
content O O
. O O
We O O
suggest O O
that O O
the O O
responses O O
to O O
types B-GENE O
I I-GENE O
and I-GENE O
II I-GENE O
collagen E-GENE O
were O O
caused O O
by O O
a O O
cross O O
- O O
reaction O O
with O O
type B-GENE O
III I-GENE O
collagen E-GENE O
peptides O O
. O O
Possibilities O O
and O O
limints O O
of O O
immunofluorescence O O
in O O
the O O
laboratory O O
diagnosis O O
of O O
rabies O O
The O O
5 O O
' O O
half O O
of O O
the O O
EWS B-GENE B-GENE
gene E-GENE E-GENE
has O O
recently O O
been O O
described O O
to O O
be O O
fused O O
to O O
the O O
3 O O
' O O
regions O O
of O O
genes O O
encoding O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
several O O
transcriptional O O
regulators O O
, O O
including O O
ATF1 S-GENE S-GENE
, O O
FLI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
ERG S-GENE O
, O O
in O O
several O O
human O O
tumors O O
. O O
PDGF S-GENE S-GENE
stimulated O O
CDK2 S-GENE S-GENE
activity O O
in O O
mesangial O O
cells O O
and O O
decreased O O
the O O
level O O
of O O
p27 S-GENE S-GENE
( O O
kip1 S-GENE S-GENE
) O O
cyclin O B-GENE
kinase O I-GENE
inhibitor O I-GENE
protein O E-GENE
. O O
Recombinant B-GENE B-GENE
apoA I-GENE I-GENE
- I-GENE I-GENE
I I-GENE I-GENE
protein E-GENE E-GENE
recovered O O
from O O
the O O
soluble O O
fraction O O
of O O
the O O
bacterial O O
cell O O
pellet O O
was O O
purified O O
to O O
greater O O
than O O
95 O O
% O O
homogeneity O O
by O O
reversed O O
- O O
phase O O
high O O
- O O
performance O O
liquid O O
chromatography O O
. O O
The O O
influence O O
of O O
different O O
temperatures O O
between O O
13 O O
degrees O O
C O O
and O O
45 O O
degrees O O
C O O
on O O
coagulation O O
factors O O
in O O
vitro O O
was O O
studied O O
by O O
measuring O O
clotting O O
time O O
with O O
the O O
recalcification O O
time O O
, O O
partial O O
thromboplastin S-GENE O
time O O
( O O
PTT O O
) O O
, O O
and O O
thromboplastin S-GENE O
time O O
test O O
. O O
On O O
average O O
, O O
rCMRglc O O
values O O
were O O
23 O O
% O O
below O O
control O O
values O O
for O O
all O O
regions O O
studied O O
, O O
with O O
the O O
greatest O O
differences O O
in O O
posterior O O
brain O O
regions O O
( O O
visual O O
association O O
cortex O O
, O O
primary O O
visual O O
cortex O O
, O O
and O O
parietal O O
cortex O O
) O O
and O O
thalamus O O
. O O
Thus O O
, O O
transgene O O
expression O O
directed O O
by O O
both O O
the O O
human O O
and O O
mouse B-GENE O
Rb I-GENE O
promoters E-GENE O
is O O
restricted O O
to O O
a O O
subset O O
of O O
tissues O O
in O O
which O O
Rb S-GENE O
is O O
normally O O
expressed O O
during O O
embryogenesis O O
. O O
Thus O O
, O O
Tax1 S-GENE S-GENE
activates O O
CArG O S-GENE
- O O
mediated O O
transcription O O
without O O
mitogenic O O
signals O O
through O O
interaction O O
with O O
a O O
CArG B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
, O O
p67SRF S-GENE S-GENE
. O O
In O O
experiment O O
1 O O
, O O
subjects O O
were O O
required O O
to O O
discriminate O O
male O O
from O O
female O O
faces O O
and O O
no O O
hemispheric O O
asymmetries O O
were O O
found O O
. O O
Membrane O O
depolarization O O
is O O
a O O
critical O O
element O O
of O O
neuronal O O
signaling O O
. O O
The O O
transcription O O
start O O
site O O
was O O
localized O O
224 O O
bp O O
upstream O O
the O O
ATG O S-GENE
codon O O
by O O
RNase S-GENE O
protection O O
and O O
primer O O
extension O O
mapping O O
. O O
All O O
the O O
cognate O O
gene O O
clones O O
were O O
constructed O O
, O O
using O O
either O O
PCR O O
products O O
amplified O O
from O O
genomic O O
DNA O O
, O O
or O O
gap O O
- O O
repair O O
. O O
Rising O O
antibody O O
titres O O
to O O
the O O
astrovirus O O
particles O O
were O O
demonstrated O O
in O O
one O O
child O O
, O O
and O O
IgM S-GENE O
was O O
also O O
demonstrated O O
in O O
this O O
patient O O
' O O
s O O
serum O O
. O O
Effect O O
of O O
isobarin O O
on O O
electrocardiographic O O
indices O O
in O O
hypertensive O O
disease O O
Although O O
RAD17 S-GENE O
, O O
RAD24 S-GENE S-GENE
and O O
MEC3 S-GENE S-GENE
are O O
not O O
required O O
for O O
cell O O
cycle O O
arrest O O
when O O
S O O
phase O O
is O O
inhibited O O
by O O
hydroxyurea O O
( O O
HU O O
) O O
, O O
they O O
do O O
contribute O O
to O O
the O O
viability O O
of O O
yeast O O
cells O O
grown O O
in O O
the O O
presence O O
of O O
HU O O
, O O
possibly O O
because O O
they O O
are O O
required O O
for O O
the O O
repair O O
of O O
HU O O
- O O
induced O O
DNA O O
damage O O
. O O
Long O O
chain O O
acyl O O
- O O
CoA O O
esters O O
are O O
important O O
intermediates O O
in O O
degradation O O
and O O
synthesis O O
of O O
fatty O O
acids O O
, O O
as O O
well O O
as O O
having O O
important O O
functions O O
in O O
regulation O O
of O O
intermediary O O
metabolism O O
and O O
gene O O
expression O O
. O O
PTP1 S-GENE B-GENE
- O I-GENE
lacZ S-GENE E-GENE
studies O O
indicate O O
that O O
PTP1 S-GENE S-GENE
is O O
spatially O O
localized O O
to O O
prestalk O O
and O O
anterior O O
- O O
like O O
cell O O
types O O
. O O
When O O
translated O O
in O O
- O O
frame O O
with O O
PKC B-GENE B-GENE
zeta E-GENE E-GENE
, O O
a O O
stop O O
codon O O
is O O
located O O
28 O O
amino O O
acids O O
towards O O
the O O
N O O
- O O
terminus O O
of O O
the O O
divergence O O
point O O
and O O
the O O
intervening O O
sequence O O
lacks O O
an O O
expected O O
initiating O O
methionine O O
. O O
psi B-GENE B-GENE
PKC I-GENE I-GENE
zeta E-GENE E-GENE
is O O
non O O
- O O
functional O O
in O O
terms O O
of O O
protein O O
synthesis O O
since O O
Western O O
blotting O O
with O O
an O O
antibody O O
directed O O
against O O
the O O
C O O
- O O
terminus O O
of O O
PKC B-GENE B-GENE
zeta E-GENE E-GENE
failed O O
to O O
reveal O O
a O O
protein O O
smaller O O
than O O
PKC B-GENE B-GENE
zeta E-GENE E-GENE
, O O
and O O
synthetic O O
psi B-GENE B-GENE
PKC I-GENE I-GENE
zeta I-GENE I-GENE
RNA E-GENE E-GENE
failed O O
to O O
support O O
protein O O
synthesis O O
in O O
a O O
translation O O
system O O
in O O
vitro O O
. O O
W O O
. O O
, O O
and O O
Touster O O
, O O
O O O
. O O
Electrically O O
induced O O
undulations O O
and O O
their O O
competition O O
with O O
electrically O O
induced O O
convection O O
in O O
cholesteric O O
liquid O O
crystals O O
. O O
The O O
sequence O O
immediately O O
upstream O O
of O O
the O O
translation O O
start O O
site O O
was O O
G O O
+ O O
C O O
rich O O
( O O
greater O O
than O O
75 O O
% O O
) O O
and O O
contained O O
a O O
consensus O O
CCAAT O O
sequence O O
despite O O
the O O
absence O O
of O O
a O O
TATA O O
box O O
. O O
These O O
conditions O O
may O O
determine O O
an O O
increase O O
in O O
the O O
level O O
of O O
indoor O O
pollutants O O
( O O
tobacco O O
smoke O O
, O O
gases O O
produced O O
by O O
cooling O O
processes O O
etc O O
. O O
) O O
and O O
of O O
allergens O O
derived O O
from O O
mites O O
, O O
domestic O O
animals O O
and O O
cockroaches O O
. O O
Nevertheless O O
, O O
lower O O
doses O O
which O O
alone O O
were O O
lacking O O
in O O
activity O O
( O O
100 O O
- O O
250 O O
mg O O
/ O O
kg O O
B1 O O
and O O
B6 O O
, O O
1 O O
- O O
2 O O
. O O
5 O O
mg O O
/ O O
kg O O
B12 O O
p O O
. O O
o O O
. O O
) O O
dose O O
- O O
dependently O O
potentiated O O
the O O
antinociceptive O O
of O O
diclofenac O O
. O O
For O O
O3 O O
, O O
the O O
correlation O O
between O O
personal O O
exposures O O
and O O
ambient O O
levels O O
was O O
weakest O O
in O O
the O O
winter O O
for O O
residential O O
microenvironments O O
( O O
rs O O
= O O
0 O O
. O O
05 O O
, O O
p O O
> O O
0 O O
. O O
05 O O
) O O
, O O
and O O
was O O
strongest O O
in O O
the O O
summer O O
for O O
outdoor O O
near O O
- O O
roadway O O
microenvironments O O
( O O
rs O O
= O O
0 O O
. O O
91 O O
, O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O
Changes O O
in O O
water O O
and O O
electrolyte O O
content O O
of O O
the O O
brain O O
and O O
edema O O
formation O O
after O O
acute O O
, O O
drug O O
- O O
induced O O
hypertension O O
were O O
studied O O
in O O
albino O O
rabbits O O
. O O
Like O O
Rev S-GENE B-GENE
- O I-GENE
Erb S-GENE E-GENE
, O O
BD73 S-GENE S-GENE
binds O O
as O O
a O O
monomer O O
to O O
a O O
DNA O O
sequence O O
which O O
consists O O
of O O
a O O
specific O O
A O O
/ O O
T O O
- O O
rich O O
sequence O O
upstream O O
of O O
the O O
consensus O O
hexameric O O
half O O
- O O
site O O
specified O O
by O O
the O O
P O O
box O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
. O O
In O O
contrast O O
, O O
the O O
holo B-GENE O
- I-GENE O
dTFIIA E-GENE O
( O O
L O O
/ O O
S O O
) O O
binds O O
TBP S-GENE S-GENE
with O O
high O O
affinity O O
. O O
Overexpression O O
of O O
wild O O
type O O
and O O
SeCys O S-GENE
/ O O
Cys O O
mutant O O
of O O
human B-GENE B-GENE
thioredoxin I-GENE I-GENE
reductase E-GENE E-GENE
in O O
E O O
. O O
coli O O
: O O
the O O
role O O
of O O
selenocysteine O O
in O O
the O O
catalytic O O
activity O O
. O O
Biopsy O O
of O O
the O O
lesion O O
revealed O O
granulomatous O O
inflammation O O
and O O
numerous O O
septate O O
hyphae O O
. O O
Western O O
and O O
immunocytochemical O O
analysis O O
implied O O
that O O
PREB S-GENE S-GENE
accumulates O O
specifically O O
in O O
GH3 O O
cell O O
nuclei O O
. O O
Two O O
genes O O
from O O
the O O
family O O
encoding O O
mouse B-GENE O
ribosomal I-GENE O
protein I-GENE O
S16 E-GENE S-GENE
were O O
cloned O O
, O O
sequenced O O
, O O
and O O
analyzed O O
. O O
A O O
novel O O
serine B-GENE B-GENE
kinase E-GENE E-GENE
activated O O
by O O
rac1 S-GENE S-GENE
/ O O
CDC42Hs S-GENE S-GENE
- O O
dependent O O
autophosphorylation O O
is O O
related O O
to O O
PAK65 S-GENE S-GENE
and O O
STE20 S-GENE S-GENE
. O O
The O O
deduced O O
gene O O
product O O
was O O
found O O
to O O
have O O
significant O O
sequence O O
similarity O O
to O O
the O O
yeast B-GENE O
and I-GENE O
prokaryotic I-GENE O
RNA I-GENE O
polymerase I-GENE O
subunits E-GENE O
involved O O
with O O
subunit O O
assembly O O
. O O
Maximum O O
overexpression O O
of O O
holoenzyme O O
activity O O
was O O
achieved O O
by O O
the O O
inclusion O O
in O O
such O O
plasmids O O
of O O
Salmonella O O
typhimurium O O
cysG O O
, O O
which O O
encodes O O
a O O
uroporphyrinogen B-GENE O
III I-GENE O
methyltransferase E-GENE O
required O O
for O O
the O O
synthesis O O
of O O
siroheme O O
, O O
a O O
cofactor O O
for O O
the O O
hemoprotein O O
. O O
Overexpression O O
of O O
SNURF S-GENE S-GENE
in O O
cultured O O
mammalian O O
cells O O
enhanced O O
not O O
only O O
androgen O O
, O O
glucocorticoid O O
, O O
and O O
progesterone B-GENE O
receptor E-GENE O
- O O
dependent O O
transactivation O O
but O O
also O O
basal O O
transcription O O
from O O
steroid O O
- O O
regulated O O
promoters O O
. O O
The O O
human O O
protein O O
binds O O
most O O
strongly O O
to O O
the O O
SH3 B-GENE B-GENE
domain E-GENE E-GENE
from O O
the O O
abl B-GENE B-GENE
proto I-GENE I-GENE
- I-GENE I-GENE
oncogene E-GENE E-GENE
. O O
Suprapubic O O
and O O
intravesical O O
methods O O
These O O
data O O
show O O
that O O
tyrosine O O
phosphorylation O O
by O O
FES S-GENE S-GENE
affects O O
the O O
interaction O O
of O O
BCR S-GENE S-GENE
with O O
multiple O O
signaling O O
partners O O
and O O
suggest O O
a O O
general O O
role O O
for O O
BCR S-GENE S-GENE
in O O
non O B-GENE
- O I-GENE
receptor O I-GENE
protein B-GENE I-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
regulation O O
and O O
signal O O
transduction O O
. O O
We O O
have O O
shown O O
that O O
the O O
human O O
cell O O
MRC O O
closely O O
resembles O O
the O O
murine O O
cell O O
MRC O O
, O O
in O O
both O O
its O O
protein O O
composition O O
and O O
its O O
fractionation O O
and O O
chromatographic O O
profile O O
. O O
From O O
1977 O O
to O O
1985 O O
, O O
42 O O
patients O O
with O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
anal O O
canal O O
were O O
treated O O
with O O
mitomycin O O
C O O
( O O
15 O O
mg O O
/ O O
m2 O O
) O O
and O O
5 O O
- O O
fluorouracil O O
( O O
750 O O
mg O O
/ O O
m2 O O
) O O
on O O
day O O
1 O O
, O O
5 O O
- O O
FU O O
( O O
750 O O
mg O O
/ O O
m2 O O
/ O O
d O O
) O O
alone O O
on O O
days O O
2 O O
to O O
5 O O
, O O
and O O
radiation O O
therapy O O
( O O
3000 O O
cGy O O
) O O
on O O
days O O
7 O O
to O O
28 O O
. O O
For O O
any O O
given O O
age O O
, O O
high O O
- O O
stressed O O
plantaris O O
tendons O O
were O O
of O O
a O O
higher O O
fatigue O O
quality O O
than O O
low O O
- O O
stressed O O
extensor O O
tendons O O
. O O
In O O
addition O O
to O O
TAK1 S-GENE S-GENE
, O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
also O O
stimulated O O
JNK S-GENE S-GENE
activity O O
. O O
Foamy O O
viruses O O
( O O
FVs O O
) O O
express O O
the O O
Gag B-GENE O
protein E-GENE O
as O O
a O O
precursor O O
with O O
a O O
molecular O O
mass O O
of O O
74 O O
kDa O O
( O O
pr74 S-GENE O
) O O
from O O
which O O
a O O
70 O O
- O O
kDa O O
protein O O
( O O
p70 S-GENE S-GENE
) O O
is O O
cleaved O O
by O O
the O O
viral O O
protease O O
. O O
Our O O
results O O
suggest O O
that O O
at O O
least O O
some O O
chloroplast B-GENE O
- I-GENE O
like I-GENE O
tRNA I-GENE O
genes E-GENE O
in O O
wheat O O
mtDNA O O
are O O
transcribed O O
, O O
with O O
transcripts O O
undergoing O O
processing O O
, O O
post O O
- O O
transcriptional O O
modification O O
and O O
3 O O
' O O
- O O
CCA O O
addition O O
, O O
to O O
produce O O
mature O O
tRNAs O O
that O O
may O O
participate O O
in O O
mitochondrial O O
protein O O
synthesis O O
. O O
If O O
, O O
however O O
, O O
myocardial O O
stunning O O
is O O
severe O O
, O O
and O O
it O O
involves O O
large O O
parts O O
of O O
the O O
LV O O
and O O
thus O O
impairs O O
global O O
LV O O
function O O
, O O
it O O
can O O
be O O
reversed O O
with O O
inotropic O O
agents O O
and O O
procedures O O
. O O
268 O O
, O O
6858 O O
- O O
6861 O O
) O O
. O O
The O O
occurrence O O
of O O
the O O
different O O
types O O
of O O
TCRB S-GENE S-GENE
rearrangement O O
patterns O O
has O O
implications O O
for O O
PCR O O
- O O
based O O
clonality O O
assessment O O
and O O
for O O
PCR O O
- O O
based O O
detection O O
of O O
minimal O O
residual O O
disease O O
via O O
TCRB B-GENE B-GENE
gene E-GENE E-GENE
analysis O O
. O O
Under O O
control O O
conditions O O
, O O
pretreatment O O
with O O
lithium O O
during O O
7 O O
days O O
did O O
not O O
modify O O
the O O
hyperlocomotion O O
produced O O
by O O
d O O
- O O
amphetamine O O
. O O
Six O O
patients O O
underwent O O
an O O
electrophysiologic O O
study O O
. O O
Rats O O
on O O
the O O
multiple O O
oral O O
dosage O O
regimen O O
were O O
given O O
unlabelled O O
HMCF O O
in O O
their O O
drinking O O
water O O
for O O
13 O O
days O O
before O O
the O O
administration O O
of O O
a O O
bolus O O
dose O O
of O O
[ O O
14C O O
] O O
HMCF O O
on O O
day O O
14 O O
. O O
After O O
multivariate O O
analysis O O
, O O
TWA O O
correlated O O
with O O
age O O
( O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
LV O O
function O O
( O O
P O O
= O O
0 O O
. O O
002 O O
) O O
and O O
occurred O O
more O O
often O O
in O O
patients O O
after O O
nonanterior O O
MI O O
( O O
P O O
= O O
0 O O
. O O
03 O O
) O O
. O O
No O O
patient O O
demonstrated O O
a O O
decrease O O
in O O
bone O O
marrow O O
fibrosis O O
as O O
determined O O
by O O
serial O O
procollagen S-GENE O
( O O
PC B-GENE O
III E-GENE O
) O O
serum O O
level O O
analysis O O
. O O
Asthma O O
diagnoses O O
were O O
made O O
according O O
to O O
recommended O O
National O O
Asthma O O
Expert O O
Panel O O
Guidelines O O
. O O
Charcot O O
joints O O
. O O
Idealized O O
versus O O
realized O O
overall O O
treatment O O
times O O
. O O
Non O O
- O O
suppressed O O
thyroidal O O
radioactive O O
iodine O O
uptake O O
( O O
RAIU O O
) O O
in O O
thyrotoxic O O
phase O O
in O O
a O O
case O O
of O O
subacute O O
thyroiditis O O
with O O
thyroid O O
- O O
stimulating O O
antibodies O O
( O O
TSAb O O
) O O
. O O
Ultra O O
- O O
energy O O
( O O
UHE O O
) O O
imaging O O
is O O
usually O O
performed O O
in O O
simultaneous O O
F O O
- O O
18 O O
FDG O O
/ O O
Tc O O
- O O
99m O O
MIBI O O
studies O O
. O O
Bilateral O O
renal O O
oncocytoma O O
in O O
a O O
Greyhound O O
dog O O
. O O
Uncoupling O O
gene O O
activity O O
from O O
chromatin O O
structure O O
: O O
promoter O O
mutations O O
can O O
inactivate O O
transcription O O
of O O
the O O
yeast B-GENE B-GENE
HSP82 I-GENE I-GENE
gene E-GENE E-GENE
without O O
eliminating O O
nucleosome O O
- O O
free O O
regions O O
. O O
Ectopic O O
expression O O
of O O
cyclin B-GENE B-GENE
D1 E-GENE E-GENE
in O O
progestin O O
- O O
inhibited O O
cells O O
led O O
to O O
the O O
reappearance O O
of O O
the O O
120 O O
- O O
kDa O O
active O O
form O O
of O O
cyclin B-GENE B-GENE
E E-GENE I-GENE
- O I-GENE
Cdk2 S-GENE E-GENE
preceding O O
the O O
resumption O O
of O O
cell O O
cycle O O
progression O O
. O O
Unlike O O
these O O
contaminant O O
- O O
responsive O O
T O O
cells O O
, O O
those O O
that O O
are O O
truly O O
specific O O
for O O
natural O O
AChR B-GENE O
epitopes E-GENE O
appear O O
less O O
heterogeneous O O
and O O
therefore O O
more O O
suitable O O
targets O O
for O O
selective O O
immunotherapy O O
. O O
Because O O
the O O
wa B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
mutation E-GENE O
was O O
mapped O O
previously O O
to O O
the O O
vicinity O O
of O O
the O O
EGF B-GENE S-GENE
/ I-GENE O
TGF I-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
receptor E-GENE E-GENE
( O O
EGFR S-GENE S-GENE
) O O
gene O O
on O O
mouse O O
chromosome O O
11 O O
, O O
we O O
hypothesized O O
that O O
the O O
wa B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
phenotype E-GENE O
might O O
result O O
from O O
a O O
defect O O
in O O
either O O
the O O
expression O O
or O O
activity O O
of O O
EGFR S-GENE S-GENE
, O O
or O O
both O O
. O O
Region O O
I O O
includes O O
the O O
two O O
cysteine O O
- O O
cysteine O O
zinc O O
fingers O O
that O O
comprise O O
a O O
DNA O O
- O O
binding O O
domain O O
which O O
typifies O O
all O O
members O O
of O O
the O O
superfamily O O
. O O
Southern O O
zoo O O
blot O O
analysis O O
indicated O O
that O O
ZNF236 S-GENE S-GENE
is O O
conserved O O
in O O
the O O
genomes O O
of O O
all O O
mammalian O O
species O O
tested O O
, O O
but O O
not O O
in O O
yeast O O
. O O
RNA O O
determinants O O
required O O
for O O
L4 S-GENE O
- O O
mediated O O
attenuation O O
control O O
of O O
the O O
S10 B-GENE B-GENE
r I-GENE I-GENE
- I-GENE I-GENE
protein I-GENE E-GENE
operon I-GENE O
of I-GENE O
Escherichia I-GENE O
coli E-GENE O
. O O
Spodoptera O O
frugiperda O O
( O O
Sf9 O O
) O O
cells O O
have O O
proved O O
a O O
suitable O O
cell O O
system O O
in O O
which O O
to O O
study O O
this O O
association O O
and O O
to O O
produce O O
recombinant B-GENE O
CR3 E-GENE O
, O O
and O O
we O O
show O O
here O O
that O O
another O O
lepidopteran O O
cell O O
line O O
, O O
Trichoplusia O O
niTN O O
- O O
5B1 O O
- O O
4 O O
( O O
High O O
- O O
Five O O
) O O
cells O O
, O O
allows O O
the O O
recovery O O
of O O
large O O
amounts O O
of O O
functional B-GENE O
recombinant I-GENE O
CR3 E-GENE S-GENE
. O O
INTERVENTIONS O O
: O O
Postoperative O O
follow O O
- O O
up O O
consisted O O
of O O
serial O O
determination O O
of O O
different O O
biochemical O O
markers O O
( O O
CK S-GENE O
, O O
CK B-GENE O
- I-GENE O
MB E-GENE O
, O O
cTnI S-GENE O
) O O
, O O
ECGs O O
, O O
and O O
echocardiography O O
. O O
At O O
the O O
first O O
phase O O
( O O
1 O O
- O O
43 O O
ms O O
for O O
the O O
VMN O O
and O O
1 O O
- O O
10 O O
ms O O
for O O
the O O
LN O O
) O O
the O O
hypothalamic O O
- O O
cortical O O
responses O O
completely O O
inhibited O O
the O O
formation O O
of O O
the O O
VC O O
response O O
to O O
the O O
light O O
stimulus O O
. O O
6 O O
, O O
320 O O
cells O O
/ O O
mm3 O O
, O O
respectively O O
; O O
P O O
less O O
than O O
. O O
005 O O
) O O
; O O
twelve O O
( O O
86 O O
% O O
) O O
of O O
the O O
14 O O
inmates O O
who O O
developed O O
AIDS O O
had O O
counts O O
of O O
less O O
than O O
5 O O
, O O
000 O O
cells O O
/ O O
mm3 O O
, O O
compared O O
with O O
only O O
six O O
( O O
14 O O
% O O
) O O
of O O
the O O
42 O O
controls O O
( O O
P O O
less O O
than O O
. O O
00001 O O
) O O
. O O
There O O
is O O
, O O
however O O
, O O
uncertainty O O
as O O
to O O
how O O
results O O
obtained O O
in O O
recent O O
experiments O O
scale O O
up O O
to O O
landscape O O
and O O
regional O O
levels O O
and O O
generalize O O
across O O
ecosystem O O
types O O
and O O
processes O O
. O O
The O O
facilitation O O
started O O
preceding O O
the O O
onset O O
of O O
electromyographic O O
activity O O
of O O
the O O
masseter O O
muscle O O
. O O
The O O
recruitment O O
of O O
constitutively O O
phosphorylated O O
p185 S-GENE S-GENE
( O O
neu S-GENE S-GENE
) O O
and O O
the O O
activated O O
mitogenic O O
pathway O O
proteins O O
to O O
this O O
membrane O O
- O O
microfilament O O
interaction O O
site O O
provides O O
a O O
physical O O
model O O
for O O
integrating O O
the O O
assembly O O
of O O
the O O
mitogenic O O
pathway O O
with O O
the O O
transmission O O
of O O
growth O O
factor O O
signal O O
to O O
the O O
cytoskeleton O O
. O O
Deletion O O
of O O
the O O
region O O
from O O
amino O O
acid O O
residues O O
2 O O
- O O
67 O O
in O O
E1A S-GENE O
, O O
which O O
has O O
been O O
postulated O O
to O O
interact O O
with O O
p300 S-GENE S-GENE
/ O O
CBP S-GENE S-GENE
, O O
also O O
abolished O O
the O O
inhibitory O O
effect O O
of O O
E1A S-GENE S-GENE
, O O
whereas O O
deletion O O
of O O
the O O
region O O
from O O
residues O O
120 O O
to O O
140 O O
had O O
no O O
effect O O
. O O
Quantitative O O
Tl O O
- O O
201 O O
analysis O O
after O O
stress O O
has O O
also O O
shown O O
viable O O
myocardium O O
in O O
most O O
mild O O
to O O
moderate O O
( O O
51 O O
% O O
to O O
85 O O
% O O
of O O
normal O O
uptake O O
) O O
irreversible O O
Tl O O
- O O
201 O O
defects O O
. O O
The O O
point O O
mutation O O
Asp O O
- O O
316 O O
- O O
- O O
> O O
Asn O O
in O O
the O O
C O O
- O O
terminus O O
of O O
p38 S-GENE S-GENE
, O O
analogous O O
to O O
the O O
ERK2 S-GENE S-GENE
( O O
extracellular B-GENE O
- I-GENE O
signal I-GENE O
- I-GENE O
regulated I-GENE O
kinase I-GENE B-GENE
2 E-GENE E-GENE
) O O
sevenmaker S-GENE O
mutation O O
, O O
dramatically O O
decreases O O
its O O
binding O O
to O O
MKP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
substantially O O
compromises O O
its O O
stimulatory O O
effect O O
on O O
the O O
catalytic O O
activity O O
of O O
this O O
phosphatase O O
. O O
J O O
. O O
Causal O O
modeling O O
combines O O
theory O O
and O O
research O O
, O O
and O O
because O O
the O O
interpretation O O
of O O
data O O
is O O
possible O O
only O O
within O O
the O O
context O O
of O O
the O O
proposed O O
theory O O
, O O
it O O
offers O O
an O O
important O O
method O O
for O O
advancing O O
the O O
science O O
while O O
maintaining O O
the O O
specificity O O
of O O
the O O
practice O O
. O O
In O O
one O O
trial O O
, O O
116 O O
subjects O O
with O O
transfusion O O
- O O
related O O
chronic O O
hepatitis O O
C O O
were O O
treated O O
with O O
lymphoblastoid B-GENE O
interferon E-GENE O
( O O
5 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
2 O O
mo O O
, O O
then O O
3 O O
MU O O
/ O O
m2 O O
three O O
times O O
a O O
week O O
for O O
4 O O
or O O
10 O O
mo O O
) O O
. O O
A O O
derived O O
RA O O
- O O
resistant O O
line O O
, O O
NT2 O O
/ O O
D1 O O
- O O
R1 O O
, O O
is O O
deficient O O
in O O
this O O
activity O O
and O O
is O O
co O O
- O O
resistant O O
to O O
cisplatin O O
. O O
BCR S-GENE B-GENE
- O I-GENE
ABL S-GENE E-GENE
elicits O O
transformation O O
of O O
both O O
fibroblast O O
and O O
hematopoietic O O
cells O O
and O O
blocks O O
apoptosis O O
following O O
cytokine O O
deprivation O O
in O O
various O O
factor O O
- O O
dependent O O
cells O O
. O O
Aggregation O O
in O O
washed O O
platelets O O
from O O
rats O O
with O O
diabetes O O
was O O
enhanced O O
. O O
Sequence O O
analysis O O
of O O
this O O
region O O
showed O O
it O O
contained O O
five O O
potential O O
copies O O
of O O
the O O
sterol O O
regulatory O O
element O O
( O O
SRE O O
- O O
1 O O
) O O
( O O
Smith O O
, O O
J O O
. O O
R O O
. O O
, O O
Osborne O O
, O O
T O O
. O O
F O O
. O O
, O O
Brown O O
, O O
M O O
. O O
S O O
. O O
, O O
Goldstein O O
, O O
J O O
. O O
L O O
. O O
, O O
and O O
Gil O O
, O O
G O O
. O O
Mutations O O
in O O
Saccharomyces O O
cerevisiae O O
that O O
block O O
meiotic O O
prophase O O
chromosome O O
metabolism O O
and O O
confer O O
cell O O
cycle O O
arrest O O
at O O
pachytene O O
identify O O
two O O
new O O
meiosis B-GENE O
- I-GENE O
specific I-GENE O
genes I-GENE O
SAE1 E-GENE S-GENE
and O O
SAE3 S-GENE S-GENE
. O O
Isolation O O
and O O
characterization O O
of O O
human O O
orthologs O O
of O O
yeast O O
CCR4 S-GENE O
- O O
NOT S-GENE O
complex O O
subunits O O
. O O
Thus O O
, O O
the O O
i B-GENE O
- I-GENE O
leader I-GENE O
protein E-GENE O
is O O
a O O
viral O O
gene O O
product O O
of O O
unknown O O
function O O
and O O
high O O
stability O O
that O O
is O O
made O O
in O O
large O O
quantities O O
at O O
intermediate O O
times O O
of O O
productive O O
infection O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O
CONCLUSIONS O O
: O O
Latanoprost O O
administered O O
once O O
daily O O
was O O
significantly O O
more O O
effective O O
in O O
reducing O O
IOP O O
compared O O
with O O
unoprostone O O
administered O O
twice O O
daily O O
in O O
patients O O
with O O
POAG O O
and O O
OH O O
. O O
The O O
molecular O O
dynamics O O
simulations O O
provide O O
insight O O
into O O
the O O
conformational O O
flexibility O O
of O O
these O O
analogs O O
. O O
In O O
alfalfa O O
, O O
the O O
insecticides O O
caused O O
significant O O
mortality O O
to O O
most O O
of O O
the O O
insects O O
evaluated O O
. O O
Therefore O O
, O O
we O O
have O O
reevaluated O O
the O O
age O O
- O O
related O O
changes O O
in O O
serum B-GENE O
leptin E-GENE O
levels O O
and O O
their O O
relationship O O
with O O
adiposity O O
and O O
androgen O O
levels O O
in O O
a O O
large O O
group O O
of O O
community O O
dwelling O O
men O O
. O O
Injections O O
of O O
PD O O
solutions O O
with O O
13 O O
. O O
6 O O
, O O
22 O O
. O O
7 O O
, O O
and O O
38 O O
. O O
6 O O
g O O
/ O O
liter O O
of O O
glucose O O
reduced O O
the O O
ingestion O O
of O O
sucrose O O
by O O
12 O O
. O O
4 O O
% O O
, O O
23 O O
. O O
6 O O
% O O
and O O
36 O O
. O O
1 O O
% O O
, O O
respectively O O
, O O
but O O
did O O
not O O
affect O O
the O O
ingestion O O
of O O
protein O O
. O O
It O O
is O O
recommended O O
that O O
area O O
correction O O
be O O
attempted O O
in O O
bioequivalence O O
studies O O
of O O
drugs O O
where O O
high O O
intrasubject O O
variability O O
in O O
clearance O O
is O O
known O O
or O O
suspected O O
. O O
Expression O O
of O O
the O O
E2 B-GENE B-GENE
protein E-GENE E-GENE
resulted O O
in O O
rapid O O
repression O O
of O O
HPV B-GENE O
E6 E-GENE O
and O O
E7 S-GENE S-GENE
expression O O
, O O
followed O O
approximately O O
12 O O
h O O
later O O
by O O
profound O O
inhibition O O
of O O
cellular O O
DNA O O
synthesis O O
. O O
Plasma B-GENE O
renin E-GENE O
activity O O
in O O
end O O
- O O
stage O O
kidney O O
disease O O
. O O
Immunoblotting O O
with O O
antiphosphotyrosine O O
antibody O O
showed O O
that O O
many O O
yeast O O
proteins O O
, O O
including O O
the O O
p34CDC28 B-GENE B-GENE
kinase E-GENE E-GENE
, O O
became O O
phosphorylated O O
at O O
tyrosine O O
in O O
cells O O
expressing O O
v B-GENE B-GENE
- I-GENE I-GENE
src E-GENE E-GENE
. O O
Renal O O
cell O O
carcinoma O O
induced O O
Coombs O O
negative O O
autoimmune O O
hemolytic O O
anemia O O
and O O
severe O O
thrombocytopenia O O
responsive O O
to O O
nephrectomy O O
. O O
Pretreatment O O
of O O
rats O O
with O O
different O O
dose O O
levels O O
of O O
CCl4 O O
resulted O O
in O O
a O O
prolongation O O
of O O
TMO O O
half O O
- O O
life O O
, O O
and O O
increase O O
of O O
the O O
area O O
under O O
the O O
curve O O
( O O
AUC O O
) O O
, O O
and O O
a O O
decrease O O
of O O
clearance O O
, O O
but O O
the O O
apparent O O
volume O O
of O O
distribution O O
( O O
Vd O O
) O O
was O O
not O O
significantly O O
decreased O O
. O O
In O O
cells O O
co O O
- O O
expressing O O
high O O
levels O O
of O O
the O O
p38 S-GENE S-GENE
( O O
MAPK S-GENE B-GENE
) O I-GENE
kinase O E-GENE
( O O
MKK3 S-GENE S-GENE
) O O
together O O
with O O
the O O
p38 S-GENE S-GENE
( O O
MAPK S-GENE S-GENE
) O O
, O O
a O O
significant O O
inhibition O O
of O O
mitogen O O
- O O
induced O O
cyclin B-GENE B-GENE
D1 E-GENE E-GENE
expression O O
was O O
observed O O
. O O
In O O
patients O O
autografted O O
in O O
CR1 O O
, O O
the O O
transplant O O
- O O
related O O
mortality O O
( O O
TRM O O
) O O
was O O
15 O O
+ O O
/ O O
- O O
4 O O
% O O
, O O
the O O
relapse O O
incidence O O
( O O
RI O O
) O O
was O O
58 O O
+ O O
/ O O
- O O
5 O O
% O O
, O O
the O O
leukaemia O O
- O O
free O O
survival O O
( O O
LFS O O
) O O
was O O
36 O O
+ O O
/ O O
- O O
5 O O
% O O
and O O
the O O
overall O O
survival O O
was O O
47 O O
+ O O
/ O O
- O O
5 O O
% O O
at O O
3 O O
years O O
. O O
Administration O O
of O O
FR O O
34235 O O
reduced O O
aortic O O
blood O O
pressure O O
and O O
increased O O
cardiac O O
output O O
in O O
anesthetized O O
dogs O O
with O O
an O O
ameroid O O
- O O
induced O O
coronary O O
artery O O
occlusion O O
. O O
The O O
primary O O
conditions O O
for O O
acceptable O O
hospital O O
use O O
were O O
that O O
exhaled O O
- O O
volume O O
monitoring O O
be O O
performed O O
for O O
all O O
patients O O
and O O
that O O
O2 O O
monitoring O O
be O O
performed O O
both O O
when O O
setting O O
FIO2 O O
and O O
continuously O O
when O O
FIO2 O O
levels O O
are O O
critical O O
. O O
The O O
RHO1 B-GENE B-GENE
gene E-GENE E-GENE
encodes O O
a O O
homolog O O
of O O
the O O
mammalian O O
RhoA B-GENE S-GENE
small I-GENE O
GTP I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
in O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
. O O
As O O
regards O O
the O O
short O O
stature O O
, O O
they O O
have O O
proved O O
that O O
the O O
syndrome O O
is O O
related O O
to O O
low O O
levels O O
of O O
somatomedin B-GENE O
C E-GENE O
( O O
SmC S-GENE O
) O O
. O O
2 O O
. O O
Menstrual O O
and O O
lunar O O
cycles O O
. O O
HBO O O
had O O
marked O O
effects O O
on O O
these O O
enzymes O O
: O O
lung B-GENE O
SOD E-GENE O
increased O O
( O O
guinea O O
pigs O O
47 O O
% O O
, O O
rats O O
88 O O
% O O
) O O
and O O
CAT S-GENE O
and O O
GSHPx S-GENE O
activities O O
decreased O O
( O O
33 O O
% O O
) O O
in O O
brain O O
and O O
lung O O
. O O
Smectic O O
- O O
A O O
ordering O O
at O O
a O O
liquid O O
- O O
vapor O O
interface O O
. O O
Phylogenetic O O
analysis O O
of O O
yeast O O
, O O
invertebrate O O
, O O
and O O
multiple O O
mammalian O O
isoforms O O
of O O
SNF4 S-GENE S-GENE
shows O O
that O O
the O O
gene O O
duplication O O
likely O O
occurred O O
early O O
in O O
the O O
metazoan O O
lineage O O
, O O
as O O
the O O
protein O O
products O O
of O O
the O O
different O O
loci O O
are O O
relatively O O
divergent O O
. O O
Hard O O
methacrylic O O
polymers O O
. O O
Thus O O
the O O
Hi O O
- O O
RARE O O
represents O O
a O O
new O O
type O O
of O O
RA O O
response O O
element O O
with O O
a O O
role O O
in O O
the O O
modulation O O
of O O
the O O
expression O O
of O O
MHC B-GENE B-GENE
class I-GENE I-GENE
1 E-GENE I-GENE
family O I-GENE
genes O E-GENE
. O O
We O O
found O O
multiple O O
transcription O O
start O O
sites O O
located O O
within O O
a O O
15 O O
- O O
base O O
pair O O
region O O
, O O
205 O O
base O O
pairs O O
upstream O O
of O O
the O O
translation O O
start O O
codon O O
. O O
During O O
the O O
last O O
three O O
days O O
of O O
the O O
study O O
, O O
mean O O
urine O O
osmolality O O
( O O
Uosm O O
) O O
and O O
free O O
water O O
reabsorption O O
( O O
TCH2O O O
) O O
increased O O
significantly O O
: O O
[ O O
formula O O
: O O
see O O
text O O
] O O
. O O
The O O
structural O O
intestinal O O
defects O O
are O O
presumed O O
to O O
be O O
the O O
result O O
of O O
defective O O
collagen S-GENE O
synthesis O O
in O O
these O O
hereditary O O
connective O O
tissue O O
disorders O O
. O O
Rev O O
. O O
Although O O
indomethacin O O
is O O
useful O O
for O O
examining O O
the O O
role O O
of O O
cyclooxygenase B-GENE O
products E-GENE O
in O O
asthmatic O O
responses O O
, O O
it O O
should O O
not O O
be O O
considered O O
in O O
the O O
treatment O O
of O O
asthma O O
. O O
Incidence O O
of O O
beta O O
- O O
thalassemia O O
carriers O O
and O O
those O O
deficient O O
in O O
erythrocyte B-GENE B-GENE
glucose I-GENE I-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
dehydrogenase E-GENE E-GENE
in O O
the O O
greater O O
Buenos O O
Aires O O
area O O
Both O O
v B-GENE B-GENE
- I-GENE I-GENE
Myb E-GENE E-GENE
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb E-GENE E-GENE
bind O O
specifically O O
to O O
delta B-GENE O
E3 E-GENE O
. O O
Anatomical O O
considerations O O
in O O
transsphenoidal O O
hypophysectomy O O
. O O
The O O
salt O O
sensitivity O O
of O O
the O O
interaction O O
indicated O O
that O O
two O O
ion O O
pairs O O
are O O
involved O O
in O O
the O O
association O O
of O O
Zn2 O O
+ O O
( O O
NC O O
- O O
F1 O O
) O O
with O O
polynucleotide O O
, O O
whereas O O
one O O
ion O O
pair O O
is O O
found O O
in O O
the O O
metal O O
- O O
free O O
peptide O O
- O O
nucleic O O
acid O O
complex O O
. O O
Investigation O O
on O O
the O O
asymmetrical O O
induced O O
yields O O
in O O
90Sr O O
- O O
90Y O O
- O O
beta O O
- O O
irradiated O O
D O O
- O O
and O O
L O O
- O O
alanines O O
. O O
An O O
hcr1 S-GENE O
null O O
mutant O O
was O O
viable O O
, O O
but O O
showed O O
slight O O
reduction O O
of O O
growth O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
strain O O
. O O
Serum O O
levels O O
of O O
total O O
and O O
specific B-GENE O
immunoglobulin I-GENE B-GENE
E E-GENE E-GENE
( O O
IgE S-GENE S-GENE
) O O
have O O
been O O
determined O O
by O O
radioimmunoassays O O
in O O
sixty O O
- O O
nine O O
allergic O O
subjects O O
. O O
IgE B-GENE S-GENE
- I-GENE O
binding I-GENE O
proteins E-GENE O
of O O
Psocoptera O O
were O O
determined O O
by O O
immunoblotting O O
experiments O O
. O O
We O O
also O O
show O O
that O O
the O O
products O O
of O O
both O O
the O O
GIY B-GENE B-GENE
- I-GENE I-GENE
YIG E-GENE I-GENE
ORF O E-GENE
and O O
the O O
non O O
- O O
canonical O O
LAGLI B-GENE O
- I-GENE O
DADG I-GENE O
- I-GENE O
GIY I-GENE O
- I-GENE O
YIG E-GENE O
ORF O O
, O O
which O O
is O O
generated O O
by O O
its O O
integration O O
, O O
have O O
endonuclease O O
activities O O
which O O
recognize O O
and O O
cut O O
the O O
insertion O O
site O O
of O O
the O O
optional O O
sequence O O
. O O
Further O O
, O O
we O O
find O O
that O O
the O O
BMI1 B-GENE B-GENE
protein E-GENE E-GENE
can O O
also O O
interact O O
with O O
itself O O
. O O
Indeed O O
, O O
ectopic O O
expression O O
of O O
MOX4 S-GENE S-GENE
in O O
aerobic O O
cells O O
resulted O O
in O O
partially O O
constitutive O O
expression O O
of O O
DAN1 S-GENE S-GENE
. O O
We O O
measured O O
electromyograms O O
( O O
EMG O O
) O O
of O O
the O O
alae O O
nasi O O
to O O
determine O O
the O O
relationship O O
between O O
their O O
activity O O
and O O
timing O O
to O O
contraction O O
of O O
the O O
rib O O
cage O O
muscles O O
and O O
diaphragm O O
during O O
obstructive O O
apnea O O
in O O
nine O O
patients O O
. O O
Hybridization O O
was O O
detected O O
between O O
polyadenylated B-GENE O
H I-GENE O
chain I-GENE O
mRNA E-GENE O
, O O
isolated O O
from O O
the O O
majority O O
of O O
the O O
hybridomas O O
, O O
and O O
the O O
VH S-GENE O
probe O O
. O O
Identification O O
of O O
a O O
putative O O
infC S-GENE O
- O O
rpmI S-GENE S-GENE
- O O
rplT S-GENE O
operon O O
flanked O O
by O O
long O O
inverted O O
repeats O O
in O O
Mycoplasma O O
fermentans O O
( O O
incognitus O O
strain O O
) O O
. O O
The O O
standardized O O
incidence O O
in O O
Europeans O O
has O O
risen O O
significantly O O
to O O
4 O O
. O O
7 O O
/ O O
10 O O
( O O
5 O O
) O O
/ O O
year O O
from O O
3 O O
. O O
4 O O
/ O O
10 O O
( O O
5 O O
) O O
/ O O
year O O
in O O
the O O
1970s O O
( O O
chi O O
2 O O
= O O
8 O O
. O O
1 O O
, O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
. O O
Neurological O O
toxicity O O
occurred O O
in O O
8 O O
/ O O
219 O O
patients O O
treated O O
with O O
fludarabine O O
( O O
FAMP O O
) O O
, O O
30 O O
mg O O
/ O O
m2 O O
per O O
day O O
and O O
cytosine O O
arabinoside O O
( O O
Ara O O
- O O
C O O
) O O
, O O
0 O O
. O O
5 O O
g O O
/ O O
m2 O O
per O O
hour O O
for O O
2 O O
- O O
6 O O
hours O O
for O O
5 O O
days O O
, O O
for O O
new O O
or O O
relapsed O O
acute O O
leukemia O O
or O O
myelodysplasia O O
. O O
Evaluation O O
of O O
gamma B-GENE O
- I-GENE O
glutamyl I-GENE O
transpeptidase E-GENE O
in O O
myocardial O O
infarction O O
. O O
Loss O O
of O O
pRb S-GENE O
or O O
p107 S-GENE O
binding O O
results O O
in O O
the O O
loss O O
of O O
transforming O O
activity O O
. O O
The O O
analysis O O
of O O
results O O
suggests O O
that O O
seroprevalence O O
of O O
Lyme O O
borreliosis O O
in O O
dogs O O
of O O
the O O
Kosice O O
region O O
is O O
not O O
negligible O O
. O O
Peak O O
insulin S-GENE O
response O O
to O O
glucose O O
infusion O O
declined O O
from O O
Groups O O
1 O O
to O O
3 O O
( O O
51 O O
+ O O
/ O O
- O O
14 O O
, O O
42 O O
. O O
4 O O
+ O O
/ O O
- O O
31 O O
, O O
20 O O
. O O
4 O O
+ O O
/ O O
- O O
6 O O
. O O
8 O O
microU O O
/ O O
ml O O
, O O
respectively O O
) O O
with O O
Group O O
3 O O
exhibiting O O
a O O
significantly O O
decreased O O
mean O O
peak O O
level O O
compared O O
to O O
the O O
other O O
groups O O
. O O
Iris O O
binding O O
and O O
bioavailability O O
. O O
The O O
influence O O
of O O
a O O
high O O
n O O
- O O
3 O O
PUFA O O
intake O O
on O O
measures O O
of O O
lipid O O
peroxidation O O
has O O
been O O
equivocal O O
. O O
The O O
proliferative O O
potential O O
of O O
the O O
pilocytic O O
astrocytoma O O
: O O
the O O
relation O O
between O O
MIB B-GENE O
- I-GENE O
1 E-GENE O
labeling O O
and O O
clinical O O
and O O
neuro O O
- O O
radiological O O
follow O O
- O O
up O O
. O O
RESULTS O O
: O O
Here O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
major O O
and O O
novel O O
Shc S-GENE B-GENE
tyrosine O E-GENE
phosphorylation O O
sites O O
, O O
Y239 O S-GENE
and O O
Y240 O S-GENE
. O O
Dominant O O
- O O
negative O O
upf1 S-GENE S-GENE
mutations O O
were O O
isolated O O
following O O
in O O
vitro O O
mutagenesis O O
of O O
a O O
plasmid O O
containing O O
the O O
UPF1 B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
tensile O O
strengths O O
of O O
an O O
adhesive O O
luting O O
resin O O
' O O
Panavia O O
EX O O
' O O
to O O
the O O
bovine O O
dentin O O
decreased O O
significantly O O
by O O
the O O
zinc O O
iontophoresis O O
. O O
We O O
previously O O
identified O O
a O O
highly O O
conserved O O
L O O
- O O
X O O
- O O
X O O
- O O
L O O
- O O
F O O
sequence O O
near O O
the O O
C O O
terminus O O
of O O
the O O
p6 B-GENE O
domain E-GENE O
of O O
the O O
Gag B-GENE O
precursor E-GENE O
as O O
the O O
major O O
virion O O
association O O
motif O O
for O O
HIV B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
Vpr E-GENE E-GENE
. O O
Papillomavirus O O
type O O
16 O O
oncogenes O O
downregulate O O
expression O O
of O O
interferon S-GENE O
- O O
responsive O O
genes O O
and O O
upregulate O O
proliferation O O
- O O
associated O O
and O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
- O O
responsive O O
genes O O
in O O
cervical O O
keratinocytes O O
. O O
The O O
A3B3 O O
domain O O
had O O
a O O
mass O O
of O O
34 O O
, O O
462 O O
, O O
with O O
a O O
glycosylation O O
mass O O
of O O
14 O O
, O O
900 O O
, O O
in O O
good O O
agreement O O
with O O
seven O O
N O O
- O O
linked O O
glycosylation O O
sites O O
of O O
average O O
mass O O
2100 O O
. O O
We O O
found O O
that O O
the O O
frequency O O
spectrum O O
of O O
physiologic O O
chest O O
sounds O O
is O O
contained O O
entirely O O
within O O
that O O
of O O
jet O O
rotocraft O O
noise O O
. O O
The O O
human B-GENE B-GENE
CA11 I-GENE I-GENE
gene E-GENE E-GENE
appears O O
to O O
be O O
located O O
between O O
the O O
secretor B-GENE B-GENE
type I-GENE I-GENE
alpha I-GENE E-GENE
( I-GENE O
1 I-GENE O
, I-GENE O
2 I-GENE O
) I-GENE O
- I-GENE O
fucosyltransferase I-GENE O
gene I-GENE O
cluster E-GENE O
( O O
FUT1 S-GENE B-GENE
- O I-GENE
FUT2 S-GENE I-GENE
- O I-GENE
FUT2P S-GENE E-GENE
) O O
and O O
the O O
D B-GENE B-GENE
- I-GENE I-GENE
site I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
gene E-GENE E-GENE
( O O
DBP S-GENE S-GENE
) O O
on O O
chromosome O O
19q13 O O
. O O
3 O O
. O O
An O O
anoerxiant O O
, O O
mazindol O O
suppresses O O
food O O
intake O O
by O O
1 O O
) O O
stimulating O O
beta B-GENE O
- I-GENE O
adrenergic I-GENE O
receptors E-GENE O
, O O
2 O O
) O O
inhibiting O O
the O O
feeding O O
center O O
and O O
, O O
3 O O
) O O
stimulating O O
the O O
satiety O O
center O O
in O O
the O O
hypothalamus O O
. O O
These O O
segments O O
may O O
represent O O
pseudogenes O O
. O O
The O O
fusion O O
of O O
AML1 S-GENE O
to O O
MDS1 S-GENE S-GENE
is O O
in O O
frame O O
, O O
and O O
adds O O
127 O O
codons O O
to O O
the O O
interrupted O O
AML1 S-GENE O
. O O
In O O
this O O
study O O
, O O
the O O
effect O O
of O O
the O O
antibiotic O O
lasalocid O O
on O O
the O O
rumen O O
anaerobic O O
fungus O O
Neocallimastix O O
frontalis O O
RK O O
21 O O
was O O
examined O O
. O O
WBC O O
differential O O
( O O
SEG O O
, O O
BAND O O
, O O
LYMPH O O
, O O
MONO O O
, O O
EOSINO O O
, O O
BASO O O
) O O
usually O O
showed O O
log O O
- O O
normal O O
distribution O O
. O O
A O O
model O O
for O O
oligomerization O O
- O O
dependent O O
subunit O O
folding O O
. O O
Chromosome O O
- O O
specific O O
STSs O O
for O O
27 O O
telomeres O O
were O O
identified O O
from O O
the O O
196 O O
TYACs O O
. O O
Second O O
, O O
overexpression O O
of O O
RIM11 S-GENE S-GENE
can O O
suppress O O
an O O
ime1 S-GENE O
missense O O
mutation O O
( O O
ime1 B-GENE O
- I-GENE O
L321F E-GENE O
) O O
but O O
not O O
an O O
ime1 S-GENE O
deletion O O
. O O
Calculation O O
of O O
energy O O
levels O O
, O O
E1 O O
transition O O
amplitudes O O
, O O
and O O
parity O O
violation O O
in O O
francium O O
. O O
All O O
except O O
the O O
last O O
two O O
interventions O O
are O O
physical O O
treatments O O
that O O
create O O
a O O
wound O O
- O O
tissue O O
environment O O
conducive O O
to O O
healing O O
. O O
This O O
50 O O
- O O
kDa O O
protein O O
contains O O
two O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
and O O
an O O
inter B-GENE O
- I-GENE O
SH2 I-GENE S-GENE
domain E-GENE O
of O O
p85alpha S-GENE S-GENE
, O O
but O O
the O O
SH3 S-GENE S-GENE
and O O
bcr B-GENE S-GENE
homology I-GENE O
domains E-GENE O
of O O
p85alpha S-GENE S-GENE
were O O
replaced O O
by O O
a O O
unique O O
6 O O
- O O
amino O O
acid O O
sequence O O
. O O
Hydropathy O O
analysis O O
of O O
deduced O O
A4 O O
amino O O
acid O O
sequence O O
revealed O O
four O O
putative O O
membrane O O
- O O
spanning O O
alpha O O
- O O
helices O O
. O O
A O O
clinical O O
double O O
- O O
blind O O
trial O O
of O O
topical O O
miconazole O O
and O O
clotrimazole O O
against O O
superficial O O
fungal O O
infections O O
and O O
erythrasma O O
. O O
Studies O O
on O O
low O O
- O O
dose O O
oral O O
contraceptives O O
: O O
cervical O O
mucus O O
and O O
plasma O O
hormone O O
changes O O
in O O
relation O O
to O O
circulating O O
D O O
- O O
norgestrel O O
and O O
17alpha O O
ethynyl O O
- O O
estradiol O O
concentrations O O
. O O
Herewith O O
C O O
. O O
psittaci O O
could O O
be O O
diagnosed O O
in O O
all O O
positive O O
samples O O
. O O
The O O
more O O
sustained O O
effect O O
of O O
cyclofenil O O
on O O
prolactin S-GENE O
secretion O O
with O O
a O O
reduced O O
frequency O O
of O O
relapse O O
, O O
and O O
the O O
lower O O
oestradiol O O
level O O
, O O
which O O
might O O
indicate O O
a O O
reduced O O
risk O O
of O O
thromboembolism O O
, O O
suggest O O
that O O
this O O
drug O O
has O O
some O O
advantage O O
over O O
bromocriptine O O
in O O
the O O
inhibition O O
of O O
postpartum O O
lactation O O
. O O
Response O O
surface O O
methodology O O
was O O
employed O O
to O O
describe O O
the O O
relationship O O
between O O
soman O O
- O O
induced O O
incapacitation O O
and O O
the O O
ATR O O
/ O O
DZ O O
or O O
ATR O O
/ O O
SCP O O
dosages O O
. O O
The O O
brains O O
were O O
bisected O O
and O O
T1 O O
and O O
T2 O O
relaxation O O
times O O
were O O
determined O O
for O O
the O O
right O O
and O O
left O O
hemispheres O O
by O O
MR O O
spectroscopy O O
immediately O O
after O O
dissection O O
. O O
Simulations O O
of O O
velocities O O
, O O
vorticity O O
, O O
pressure O O
and O O
certain O O
stress O O
values O O
were O O
developed O O
by O O
a O O
computer O O
and O O
displayed O O
for O O
man O O
- O O
machine O O
interaction O O
. O O
In O O
the O O
present O O
study O O
, O O
we O O
report O O
the O O
entire O O
genomic O O
structure O O
of O O
KCNQ1 S-GENE O
, O O
which O O
consists O O
of O O
19 O O
exons O O
spanning O O
400 O O
kb O O
on O O
chromosome O O
11p15 O O
. O O
5 O O
. O O
Northern O O
( O O
RNA O O
) O O
blot O O
hybridization O O
analysis O O
with O O
the O O
p68c B-GENE O
- I-GENE O
ets I-GENE O
- I-GENE O
1 E-GENE O
- O O
specific O O
sequence O O
and O O
RNase S-GENE O
protection O O
experiments O O
showed O O
that O O
the O O
corresponding O O
mRNA O O
was O O
expressed O O
in O O
normal O O
chicken O O
spleen O O
and O O
not O O
in O O
normal O O
chicken O O
thymus O O
or O O
in O O
various O O
T O O
lymphoid O O
cell O O
lines O O
. O O
To O O
investigate O O
this O O
issue O O
, O O
we O O
used O O
a O O
recognition O O
task O O
in O O
which O O
two O O
strings O O
of O O
letters O O
are O O
presented O O
sequentially O O
. O O
Kettin S-GENE O
is O O
a O O
large O O
modular O O
protein O O
associated O O
with O O
thin O O
filaments O O
in O O
the O O
Z O O
- O O
disc O O
region O O
of O O
insect O O
muscles O O
. O O
Enzymatic O O
and O O
chemical O O
structure O O
probing O O
revealed O O
mainly O O
the O O
conserved O O
terminal O O
part O O
( O O
termed O O
3 O O
' O O
C O O
) O O
of O O
the O O
DI9c O O
3 O O
' O O
UTR O O
containing O O
distinctive O O
RNA O O
motifs O O
, O O
i O O
. O O
e O O
. O O
, O O
a O O
stable O O
stem O O
- O O
loop O O
, O O
SL O O
I O O
, O O
near O O
the O O
RNA O O
3 O O
' O O
terminus O O
and O O
a O O
considerably O O
less O O
stable O O
stem O O
- O O
loop O O
, O O
SL O O
II O O
, O O
that O O
forms O O
the O O
5 O O
' O O
portion O O
of O O
3 O O
' O O
C O O
. O O
This O O
review O O
chronicles O O
the O O
characteristics O O
of O O
deliberate O O
and O O
accidental O O
mass O O
poisonings O O
that O O
occurred O O
in O O
World O O
Wars O O
I O O
and O O
II O O
, O O
in O O
Bhopal O O
, O O
and O O
in O O
other O O
historical O O
cases O O
up O O
to O O
and O O
including O O
modern O O
wars O O
. O O
The O O
effects O O
of O O
4 O O
weeks O O
of O O
cyclosporin O O
A O O
( O O
7 O O
mg O O
/ O O
kg O O
per O O
day O O
) O O
( O O
CyA O O
) O O
on O O
the O O
survival O O
of O O
vascularized O O
osteochondral O O
grafts O O
between O O
rat O O
strains O O
[ O O
DA O O
( O O
donor O O
) O O
and O O
Lewis O O
( O O
recipient O O
) O O
] O O
and O O
the O O
presence O O
and O O
significance O O
of O O
host O O
immune O O
tolerance O O
and O O
graft O O
antigen O O
modulation O O
after O O
cessation O O
of O O
immunosuppression O O
have O O
been O O
examined O O
. O O
By O O
incorporating O O
a O O
stent O O
with O O
posts O O
that O O
pivot O O
about O O
their O O
base O O
, O O
such O O
that O O
a O O
10 O O
% O O
expansion O O
at O O
the O O
commissures O O
is O O
realized O O
, O O
we O O
were O O
able O O
to O O
reduce O O
the O O
compressive O O
commissural O O
stressing O O
from O O
250 O O
to O O
150 O O
kPa O O
. O O
In O O
group O O
1 O O
, O O
mean O O
z O O
- O O
score O O
for O O
GFR O O
was O O
- O O
0 O O
. O O
27 O O
( O O
94 O O
. O O
6 O O
% O O
of O O
normal O O
) O O
and O O
in O O
group O O
2 O O
mean O O
z O O
- O O
score O O
was O O
- O O
1 O O
. O O
51 O O
( O O
72 O O
. O O
7 O O
% O O
of O O
normal O O
for O O
two O O
kidneys O O
) O O
( O O
P O O
= O O
0 O O
. O O
022 O O
, O O
Mann O O
- O O
Whitney O O
U O O
- O O
test O O
) O O
. O O
The O O
cooperation O O
between O O
health O O
and O O
hospital O O
services O O
The O O
free O O
fraction O O
of O O
amitriptyline O O
( O O
AT O O
) O O
, O O
measured O O
by O O
equilibrium O O
dialysis O O
in O O
plasma O O
from O O
29 O O
AT O O
- O O
treated O O
depressed O O
patients O O
, O O
was O O
5 O O
. O O
4 O O
- O O
9 O O
. O O
8 O O
% O O
( O O
mean O O
7 O O
. O O
7 O O
% O O
) O O
, O O
which O O
was O O
the O O
same O O
as O O
the O O
values O O
in O O
26 O O
healthy O O
controls O O
( O O
4 O O
. O O
9 O O
- O O
9 O O
. O O
6 O O
% O O
, O O
mean O O
7 O O
. O O
6 O O
% O O
) O O
. O O
Different O O
effects O O
of O O
reoxygenation O O
on O O
the O O
electrical O O
activity O O
of O O
ventricular O O
muscle O O
. O O
Metastatic O O
tumours O O
of O O
bone O O
in O O
Nigerians O O
. O O
However O O
, O O
microinjection O O
of O O
reconstituted O O
mRNPs O O
into O O
Xenopus O O
oocytes O O
demonstrates O O
that O O
although O O
translational O O
repression O O
occurs O O
in O O
the O O
absence O O
of O O
consensus O O
RNA O O
binding O O
sequences O O
for O O
FRGY2 S-GENE S-GENE
, O O
the O O
presence O O
of O O
FRGY2 B-GENE S-GENE
recognition I-GENE O
elements E-GENE O
within O O
mRNA O O
potentiates O O
translational O O
repression O O
. O O
Any O O
respectative O O
material O O
( O O
class O O
0 O O
) O O
was O O
not O O
obtained O O
from O O
334 O O
patients O O
( O O
4 O O
. O O
2 O O
% O O
) O O
, O O
class O O
I O O
- O O
II O O
findings O O
belonged O O
to O O
6m141 O O
patients O O
( O O
76 O O
. O O
7 O O
% O O
) O O
, O O
950 O O
patients O O
( O O
11 O O
. O O
9 O O
% O O
) O O
were O O
classified O O
as O O
class O O
HII O O
and O O
IV O O
, O O
578 O O
patients O O
( O O
7 O O
. O O
2 O O
% O O
) O O
as O O
class O O
V O O
. O O
However O O
, O O
whether O O
this O O
was O O
associated O O
with O O
spleen O O
removal O O
after O O
adjustment O O
for O O
risk O O
factors O O
was O O
not O O
determined O O
. O O
Virgin O O
, O O
P O O
. O O
IL B-GENE O
- I-GENE O
6 E-GENE O
was O O
detected O O
in O O
the O O
urine O O
of O O
52 O O
% O O
of O O
children O O
with O O
pyelonephritis O O
compared O O
with O O
15 O O
% O O
of O O
other O O
children O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O
We O O
have O O
determined O O
the O O
complete O O
cDNA O O
sequence O O
of O O
rat B-GENE O
plectin E-GENE O
from O O
a O O
number O O
of O O
well O O
- O O
characterized O O
overlapping O O
lambda O O
gt11 O O
clones O O
. O O
SETTING O O
- O O
- O O
Hospital O O
laboratories O O
in O O
the O O
United O O
States O O
submitting O O
pneumococcal O O
isolates O O
to O O
the O O
CDC O O
between O O
October O O
1 O O
, O O
1991 O O
, O O
and O O
September O O
30 O O
, O O
1992 O O
. O O
The O O
terminal O O
a O O
sequence O O
of O O
the O O
herpes O O
simplex O O
virus O O
genome O O
contains O O
the O O
promoter O O
of O O
a O O
gene O O
located O O
in O O
the O O
repeat O O
sequences O O
of O O
the O O
L O O
component O O
. O O
In O O
contrast O O
to O O
p62 S-GENE S-GENE
( O O
dok S-GENE S-GENE
) O O
, O O
DOKL S-GENE S-GENE
lacks O O
YxxP O S-GENE
motifs O O
in O O
the O O
C O O
terminus O O
and O O
does O O
not O O
bind O O
to O O
Ras B-GENE B-GENE
GTPase I-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
protein E-GENE E-GENE
( O O
RasGAP S-GENE S-GENE
) O O
upon O O
phosphorylation O O
. O O
These O O
observations O O
demonstrate O O
that O O
KSR S-GENE S-GENE
is O O
capable O O
of O O
uncoupling O O
the O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
activation O O
from O O
its O O
target O O
phosphorylation O O
, O O
and O O
thus O O
provide O O
a O O
novel O O
mechanism O O
for O O
modulating O O
the O O
Ras S-GENE B-GENE
- O I-GENE
MAP B-GENE I-GENE
kinase E-GENE E-GENE
signaling O O
pathway O O
. O O
G B-GENE O
- I-GENE O
CSF E-GENE O
( O O
10 O O
microg O O
/ O O
kg O O
) O O
was O O
started O O
on O O
day O O
+ O O
1 O O
and O O
all O O
patients O O
engrafted O O
within O O
a O O
median O O
day O O
number O O
of O O
12 O O
( O O
range O O
, O O
10 O O
- O O
22 O O
) O O
until O O
leukocytes O O
> O O
1 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
and O O
a O O
median O O
day O O
number O O
of O O
56 O O
( O O
range O O
, O O
10 O O
- O O
180 O O
) O O
until O O
platelets O O
> O O
20 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
( O O
ie O O
platelet O O
transfusion O O
independence O O
) O O
. O O
A O O
higher O O
percentage O O
of O O
children O O
with O O
cerebral O O
malaria O O
( O O
40 O O
per O O
cent O O
) O O
than O O
with O O
non O O
- O O
cerebral O O
malaria O O
( O O
29 O O
per O O
cent O O
) O O
or O O
controls O O
( O O
20 O O
per O O
cent O O
) O O
also O O
had O O
either O O
serum B-GENE O
ferritin E-GENE O
< O O
100 O O
micrograms O O
/ O O
l O O
and O O
inflammation O O
or O O
sTfR S-GENE O
> O O
7 O O
. O O
3 O O
mg O O
/ O O
l O O
or O O
both O O
. O O
During O O
the O O
burst O O
period O O
( O O
approximately O O
5 O O
- O O
10 O O
min O O
) O O
, O O
local O O
blood O O
H2O2 O O
concentrations O O
and O O
xanthine B-GENE O
oxidase E-GENE O
activities O O
were O O
highly O O
correlated O O
( O O
r O O
= O O
0 O O
. O O
999 O O
) O O
. O O
Previous O O
studies O O
have O O
demonstrated O O
that O O
the O O
21 O O
- O O
or O O
the O O
72 O O
- O O
bp O O
repeat O O
transcriptional O O
control O O
elements O O
enhance O O
the O O
efficiency O O
of O O
SV40 O O
DNA O O
replication O O
in O O
vivo O O
, O O
provided O O
either O O
of O O
these O O
repeats O O
is O O
located O O
near O O
the O O
end O O
of O O
the O O
core O O
replication O O
origin O O
containing O O
the O O
17 O O
- O O
bp O O
A O O
+ O O
T O O
- O O
containing O O
sequence O O
. O O
UV O O
cross O O
- O O
linking O O
and O O
Southwestern O O
analysis O O
suggested O O
that O O
KTP1 S-GENE S-GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
clearly O O
distinct O O
from O O
AP2 S-GENE S-GENE
, O O
and O O
this O O
protein O O
may O O
be O O
responsible O O
for O O
the O O
basal O O
keratinocyte O O
- O O
specific O O
expression O O
of O O
the O O
BPAG1 B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
model O O
of O O
the O O
complex O O
provides O O
a O O
rationale O O
for O O
conserved O O
ITAM S-GENE O
residues O O
, O O
substrate O O
specificity O O
, O O
and O O
suggests O O
that O O
substrate O O
binds O O
only O O
the O O
active O O
conformation O O
of O O
the O O
Src B-GENE B-GENE
family I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
, O O
unlike O O
the O O
ATP O B-GENE
cofactor O E-GENE
, O O
which O O
can O O
bind O O
the O O
inactive O O
form O O
. O O
Here O O
we O O
demonstrate O O
that O O
a O O
region O O
of O O
high O O
homology O O
between O O
the O O
members O O
of O O
this O O
class O O
of O O
proteins O O
contains O O
a O O
type O O
A O O
nucleotide O O
binding O O
site O O
consensus O O
sequence O O
which O O
has O O
ATPase S-GENE S-GENE
activity O O
and O O
is O O
sufficient O O
to O O
bind O O
DNA O O
containing O O
specific O O
mismatched O O
residues O O
. O O
Copyright O O
1999 O O
Academic O O
Press O O
. O O
Nickel O O
release O O
from O O
tools O O
on O O
the O O
Swedish O O
market O O
. O O
S O O
- O O
phase O O
- O O
promoting O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinases E-GENE E-GENE
( O O
Cdks S-GENE S-GENE
) O O
and O O
the O O
kinase O B-GENE
Dbf4 S-GENE I-GENE
- O I-GENE
Cdc7 S-GENE E-GENE
then O O
act O O
to O O
initiate O O
replication O O
. O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
only O O
partially O O
mediates O O
Epstein B-GENE O
- I-GENE O
Barr I-GENE O
virus I-GENE O
latent I-GENE O
membrane I-GENE O
protein I-GENE O
1 E-GENE O
activation O O
of O O
B O O
cells O O
. O O
Purified O O
fER S-GENE O
exhibited O O
a O O
distribution O O
constant O O
( O O
KD O O
) O O
for O O
17 O O
beta O O
- O O
estradiol O O
of O O
0 O O
. O O
45 O O
nM O O
. O O
The O O
long O O
terminal O O
repeat O O
is O O
590 O O
bp O O
in O O
length O O
, O O
with O O
the O O
U3 O O
region O O
containing O O
consensus O O
sequences O O
likely O O
to O O
be O O
involved O O
in O O
viral O O
gene O O
expression O O
. O O
An O O
incorrect O O
response O O
on O O
the O O
previous O O
trial O O
enhanced O O
the O O
accuracy O O
in O O
the O O
current O O
trial O O
only O O
in O O
the O O
left O O
visual O O
field O O
( O O
LVF O O
) O O
. O O
The O O
peptides O O
are O O
generated O O
in O O
the O O
cytosol O O
, O O
then O O
translocated O O
across O O
the O O
membrane O O
of O O
the O O
endoplasmic O O
reticulum O O
by O O
the O O
transporter B-GENE O
associated I-GENE O
with I-GENE O
antigen I-GENE O
processing E-GENE O
( O O
TAP S-GENE O
) O O
. O O
It O O
competes O O
with O O
the O O
calcium O O
ion O O
which O O
brings O O
about O O
inhibition O O
of O O
myosine B-GENE B-GENE
kinase E-GENE E-GENE
, O O
and O O
therefore O O
a O O
drop O O
in O O
phosphorylated O O
myosine O O
. O O
Comparison O O
with O O
the O O
data O O
of O O
clinical O O
development O O
and O O
hemodynamic O O
results O O
Sera O O
collected O O
in O O
1973 O O
- O O
1975 O O
from O O
3053 O O
residents O O
of O O
12 O O
selected O O
Alaskan O O
Eskimo O O
villages O O
were O O
tested O O
for O O
evidence O O
of O O
hepatitis O O
B O O
virus O O
infection O O
. O O
Injection O O
of O O
horseradish B-GENE O
peroxidase E-GENE O
( O O
HRP S-GENE O
) O O
into O O
the O O
cerebellar O O
flocculus O O
of O O
the O O
rat O O
was O O
employed O O
to O O
identify O O
neurons O O
in O O
the O O
abducens O O
nucleus O O
that O O
project O O
to O O
the O O
flocculus O O
. O O
To O O
assay O O
for O O
sequences O O
that O O
could O O
potentially O O
regulate O O
Xenopus B-GENE O
proenkephalin E-GENE O
expression O O
, O O
we O O
transfected O O
constructs O O
that O O
contained O O
upstream O O
genomic O O
sequences O O
linked O O
to O O
the O O
CAT B-GENE B-GENE
reporter I-GENE I-GENE
gene E-GENE E-GENE
into O O
various O O
eukaryotic O O
cell O O
lines O O
. O O
This O O
suggests O O
that O O
the O O
ratio O O
of O O
IL B-GENE O
- I-GENE O
6 E-GENE O
to O O
IL B-GENE O
- I-GENE O
10 E-GENE O
may O O
be O O
used O O
to O O
predict O O
the O O
injury O O
severity O O
after O O
trauma O O
. O O
UVB O O
- O O
induced O O
association O O
of O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
TNF I-GENE S-GENE
) I-GENE O
receptor I-GENE B-GENE
1 E-GENE E-GENE
/ O O
TNF B-GENE B-GENE
receptor I-GENE I-GENE
- I-GENE I-GENE
associated I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
mediates O O
activation O O
of O O
Rel B-GENE B-GENE
proteins E-GENE E-GENE
. O O
A O O
major O O
feature O O
of O O
this O O
genomic O O
sequence O O
is O O
the O O
presence O O
of O O
a O O
first O O
intron O O
( O O
Il O O
) O O
, O O
215 O O
bp O O
long O O
, O O
located O O
48 O O
bp O O
downstream O O
of O O
the O O
translation O O
start O O
ATG O O
codon O O
. O O
Experimental O O
studies O O
and O O
clinical O O
application O O
of O O
plasma B-GENE O
ACTH E-GENE O
radioimmunoassay O O
kit O O
without O O
extraction O O
process O O
In O O
the O O
cervical O O
enlargement O O
they O O
were O O
located O O
in O O
the O O
middle O O
part O O
of O O
lamina O O
VII O O
and O O
in O O
lamina O O
VIII O O
, O O
accounting O O
for O O
about O O
25 O O
% O O
of O O
the O O
total O O
labeled O O
neurons O O
. O O
Nature O O
and O O
incidence O O
of O O
conditioned O O
responses O O
in O O
a O O
methadone O O
population O O
: O O
a O O
comparison O O
of O O
laboratory O O
, O O
clinic O O
, O O
and O O
naturalistic O O
settings O O
. O O
While O O
some O O
still O O
automatically O O
refuse O O
all O O
patients O O
with O O
positive O O
mediastinoscopy O O
, O O
most O O
authors O O
still O O
remain O O
very O O
interventionistic O O
for O O
N2 O O
patients O O
selected O O
on O O
very O O
accurate O O
criteria O O
that O O
are O O
analyzed O O
above O O
. O O
Our O O
previous O O
studies O O
demonstrated O O
that O O
the O O
promyelocytic O B-GENE
leukemia O I-GENE
gene O E-GENE
, O O
PML S-GENE O
which O O
involved O O
in O O
the O O
15 O O
; O O
17 O O
translocation O O
in O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
a O O
growth O O
and O O
transformation O O
suppressor O O
. O O
A O O
sharp O O
transition O O
from O O
a O O
random O O
chaotic O O
state O O
to O O
a O O
correlated O O
turbulent O O
state O O
of O O
finite O O
coherence O O
time O O
is O O
found O O
when O O
the O O
Rayleigh O O
number O O
becomes O O
larger O O
than O O
a O O
critical O O
value O O
Ra O O
( O O
c O O
) O O
approximately O O
equal O O
to O O
5 O O
x O O
10 O O
( O O
7 O O
) O O
. O O
Our O O
data O O
define O O
Ile O O
( O O
16 O O
) O O
, O O
Val O O
( O O
18 O O
) O O
, O O
Val O O
( O O
31 O O
) O O
, O O
and O O
Ile O O
( O O
33 O O
) O O
as O O
crucial O O
for O O
protein B-GENE O
S E-GENE O
binding O O
, O O
with O O
secondary O O
effects O O
from O O
Leu O O
( O O
38 O O
) O O
and O O
Val O O
( O O
39 O O
) O O
. O O
In O O
the O O
yeast O O
two O O
- O O
hybrid O O
assays O O
, O O
PNRC S-GENE S-GENE
interacted O O
with O O
the O O
orphan O O
receptors O O
SF1 S-GENE S-GENE
and O O
ERRalpha1 S-GENE S-GENE
in O O
a O O
ligand O O
- O O
independent O O
manner O O
. O O
Nuclear O O
export O O
of O O
proteins O O
in O O
plants O O
: O O
AtXPO1 S-GENE S-GENE
is O O
the O O
export O O
receptor O O
for O O
leucine O O
- O O
rich O O
nuclear O O
export O O
signals O O
in O O
Arabidopsis O O
thaliana O O
. O O
Thus O O
, O O
CR2 S-GENE S-GENE
possesses O O
an O O
essential O O
function O O
besides O O
pRb S-GENE O
- O O
binding O O
. O O
From O O
the O O
autopsy O O
findings O O
, O O
in O O
5 O O
out O O
of O O
the O O
remaining O O
23 O O
expired O O
patients O O
, O O
Legionella O O
pneumonia O O
seemed O O
to O O
be O O
successfully O O
treated O O
, O O
but O O
other O O
disease O O
or O O
other O O
bacterial O O
pneumonia O O
put O O
an O O
end O O
to O O
the O O
patients O O
. O O
Nitroglycerin O O
( O O
glyceryl O O
trinitrate O O
) O O
as O O
a O O
monoamine B-GENE O
oxidase E-GENE O
inhibitor O O
. O O
This O O
high O O
dose O O
5 O O
- O O
FU O O
+ O O
Act O O
- O O
D O O
protocol O O
was O O
effective O O
for O O
drug O O
resistant O O
cases O O
with O O
MEA O O
protocol O O
. O O
With O O
stimulation O O
beyond O O
the O O
theta O O
- O O
range O O
three O O
phenomena O O
occurred O O
: O O
shift O O
of O O
the O O
burst O O
frequencies O O
to O O
higher O O
or O O
lower O O
harmonics O O
of O O
stimulation O O
frequencies O O
; O O
complex O O
interactions O O
of O O
basic O O
background O O
frequency O O
with O O
rhythm O O
of O O
stimulation O O
( O O
" O O
beating O O
" O O
) O O
; O O
return O O
to O O
background O O
theta O O
- O O
burst O O
frequency O O
in O O
spite O O
of O O
continuing O O
stimulation O O
( O O
" O O
escape O O
" O O
) O O
. O O
CONCLUSIONS O O
: O O
Transpulmonary O O
stable O O
air O O
microbubbles O O
bound O O
to O O
a O O
galactose O O
carrier O O
represent O O
a O O
useful O O
and O O
safe O O
contrast O O
agent O O
in O O
case O O
of O O
an O O
insufficient O O
native O O
signal O O
in O O
transcranial O O
Doppler O O
investigation O O
. O O
K562 O S-GENE
erythroleukemia O O
cells O O
stably O O
transfected O O
with O O
constructs O O
containing O O
the O O
human B-GENE B-GENE
Agamma I-GENE I-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
promoter E-GENE E-GENE
linked O O
to O O
an O O
enhanced B-GENE O
green I-GENE O
fluorescent I-GENE O
protein E-GENE O
( O O
EGFP S-GENE S-GENE
) O O
reporter O O
, O O
with O O
or O O
without O O
HS2 O O
, O O
were O O
analyzed O O
for O O
EGFP S-GENE S-GENE
expression O O
by O O
flow O O
cytometry O O
. O O
Gastrin S-GENE O
stimulates O O
transcription O O
of O O
the O O
human B-GENE B-GENE
histidine I-GENE I-GENE
decarboxylase E-GENE E-GENE
( O O
HDC S-GENE S-GENE
) O O
gene O O
through O O
binding O O
to O O
the O O
G B-GENE O
- I-GENE O
protein E-GENE O
- O O
coupled O O
cholecystokinin B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
/ O O
gastrin B-GENE B-GENE
receptor E-GENE E-GENE
. O O
Here O O
, O O
we O O
report O O
the O O
isolation O O
of O O
a O O
new O O
spindle O O
checkpoint O O
gene O O
, O O
mph1 S-GENE S-GENE
( O O
Mps1p B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
pombe I-GENE I-GENE
homolog E-GENE E-GENE
) O O
, O O
in O O
the O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
, O O
that O O
is O O
required O O
for O O
checkpoint O O
activation O O
in O O
response O O
to O O
spindle O O
defects O O
. O O
mph1 S-GENE S-GENE
functions O O
upstream O O
of O O
mad2 S-GENE O
, O O
a O O
previously O O
characterized O O
component O O
of O O
the O O
spindle O O
checkpoint O O
. O O
Hepatocyte B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
HGF S-GENE S-GENE
) O O
is O O
an O O
inducible O O
cytokine O O
that O O
is O O
essential O O
for O O
the O O
normal O O
growth O O
and O O
development O O
of O O
various O O
tissues O O
, O O
such O O
as O O
the O O
liver O O
. O O
However O O
, O O
all O O
pathophysiologic O O
assessments O O
reported O O
to O O
date O O
have O O
been O O
carried O O
out O O
during O O
or O O
immediately O O
after O O
IVOX O O
utilization O O
. O O
Reduced O O
concentrations O O
of O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
, O O
plasminogen S-GENE O
, O O
( O O
free O O
) O O
protein B-GENE O
S E-GENE O
, O O
and O O
protein B-GENE O
C E-GENE O
were O O
found O O
in O O
some O O
patients O O
but O O
were O O
not O O
associated O O
with O O
either O O
thrombosis O O
or O O
lupus O O
anticoagulant O O
. O O
The O O
first O O
decision O O
in O O
management O O
is O O
to O O
consider O O
cardioversion O O
which O O
can O O
be O O
achieved O O
in O O
suitable O O
cases O O
electrically O O
, O O
or O O
pharmacologically O O
with O O
a O O
class O O
Ic O O
antiarrhythmic O O
drug O O
like O O
flecainide O O
or O O
propafenone O O
. O O
Structure O O
and O O
chromosomal O O
localization O O
of O O
the O O
human O O
gene O O
of O O
the O O
phosphotyrosyl B-GENE B-GENE
phosphatase I-GENE I-GENE
activator E-GENE E-GENE
( O O
PTPA S-GENE S-GENE
) O O
of O O
protein B-GENE B-GENE
phosphatase I-GENE I-GENE
2A E-GENE E-GENE
. O O
R O O
of O O
the O O
chest O O
wall O O
was O O
maximum O O
( O O
35 O O
. O O
6 O O
cmH2O O O
. O O
L O O
- O O
1 O O
. O O
sec O O
- O O
1 O O
+ O O
/ O O
- O O
2 O O
. O O
2 O O
SE O O
) O O
at O O
0 O O
. O O
2 O O
Hz O O
- O O
10 O O
ml O O
and O O
decreased O O
with O O
increasing O O
f O O
and O O
VT O O
, O O
although O O
the O O
VT O O
effect O O
diminished O O
at O O
the O O
higher O O
f O O
. O O
Since O O
1988 O O
Modulit O O
- O O
SZ O O
- O O
20 O O
has O O
been O O
tested O O
for O O
localization O O
of O O
nephroliths O O
and O O
ureteroliths O O
. O O
JCAHO O O
moves O O
to O O
rewrite O O
many O O
rules O O
to O O
lessen O O
hospitals O O
' O O
regulatory O O
burden O O
. O O
These O O
transcripts O O
directed O O
the O O
synthesis O O
of O O
three O O
proteins O O
: O O
the O O
virus B-GENE B-GENE
trans I-GENE I-GENE
- I-GENE I-GENE
activator I-GENE I-GENE
protein E-GENE E-GENE
( O O
EIAV B-GENE B-GENE
Tat E-GENE E-GENE
) O O
encoded O O
by O O
ORF O B-GENE
S1 O E-GENE
, O O
a O O
protein O O
of O O
unknown O O
function O O
encoded O O
by O O
ORF O B-GENE
S2 O E-GENE
, O O
and O O
the O O
virus O O
envelope B-GENE O
glycoprotein E-GENE O
. O O
However O O
, O O
no O O
significant O O
difference O O
in O O
either O O
the O O
Valsalva O O
ratio O O
or O O
delta O O
SBP O O
was O O
found O O
between O O
diabetic O O
patients O O
and O O
controls O O
. O O
Transmural O O
metabolic O O
heterogeneity O O
at O O
high O O
cardiac O O
work O O
states O O
. O O
We O O
therefore O O
investigated O O
whether O O
the O O
promoter O O
activity O O
of O O
the O O
mouse B-GENE B-GENE
TRH I-GENE I-GENE
gene E-GENE E-GENE
is O O
directly O O
regulated O O
by O O
RA O O
using O O
a O O
transient O O
transfection O O
assay O O
into O O
CV O O
- O O
1 O O
cells O O
. O O
Spinal O O
injuries O O
in O O
a O O
multiple O O
trauma O O
patient O O
. O O
The O O
unusual O O
properties O O
of O O
TRAC S-GENE S-GENE
activity O O
and O O
its O O
relationship O O
, O O
if O O
any O O
, O O
with O O
the O O
enigmatic O O
Ku B-GENE B-GENE
protein E-GENE E-GENE
, O O
are O O
discussed O O
. O O
Statistical O O
aspects O O
of O O
the O O
relation O O
of O O
the O O
radioprotective O O
action O O
of O O
mercaptoethylamine O O
derivatives O O
and O O
analogs O O
to O O
their O O
electron O O
parameters O O
Cerebellar O O
functional O O
compensation O O
after O O
its O O
complete O O
destruction O O
by O O
a O O
neoplasm O O
The O O
RNA O O
, O O
whether O O
antisense O O
, O O
ribozyme O O
, O O
or O O
RNA O O
aptamer O O
, O O
must O O
be O O
efficiently O O
transcribed O O
, O O
stabilized O O
against O O
rapid O O
degradation O O
, O O
folded O O
correctly O O
, O O
and O O
directed O O
to O O
the O O
part O O
of O O
the O O
cell O O
where O O
it O O
can O O
be O O
most O O
effective O O
. O O
We O O
have O O
isolated O O
and O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
another O O
operon O O
, O O
cpeCD S-GENE S-GENE
, O O
that O O
encodes O O
the O O
linker O O
proteins O O
associated O O
with O O
phycoerythrin B-GENE O
hexamers E-GENE O
in O O
the O O
phycobilisome S-GENE O
. O O
A B-GENE O
. I-GENE O
thaliana I-GENE O
cystathionine I-GENE O
beta I-GENE O
- I-GENE O
lyase E-GENE O
exhibits O O
22 O O
% O O
sequence O O
identity O O
with O O
the O O
E O O
. O O
coli O O
corresponding O O
enzyme O O
and O O
contains O O
a O O
70 O O
amino O O
acid O O
N O O
- O O
terminal O O
additional O O
sequence O O
compared O O
with O O
the O O
bacterial O O
protein O O
. O O
The O O
enzyme B-GENE B-GENE
ACC I-GENE I-GENE
oxidase E-GENE E-GENE
catalyses O O
the O O
last O O
step O O
of O O
ethylene O O
biosynthesis O O
in O O
plants O O
, O O
converting O O
1 O O
- O O
aminocyclopropane O O
- O O
1 O O
- O O
carboxylic O O
acid O O
( O O
ACC O O
) O O
to O O
ethylene O O
. O O
A O O
99m O O
Tc O O
bone O O
scan O O
showed O O
a O O
focal O O
area O O
of O O
an O O
increased O O
uptake O O
at O O
the O O
site O O
of O O
the O O
mass O O
below O O
the O O
calcaneus O O
. O O
Renal O O
function O O
was O O
evaluated O O
in O O
a O O
group O O
of O O
24 O O
patients O O
( O O
21 O O
men O O
and O O
3 O O
women O O
, O O
mean O O
age O O
47 O O
years O O
) O O
who O O
had O O
survived O O
the O O
malignant O O
phase O O
of O O
hypertension O O
during O O
the O O
period O O
of O O
1969 O O
- O O
1979 O O
. O O
The O O
need O O
for O O
such O O
guidelines O O
is O O
clear O O
on O O
both O O
clinical O O
and O O
scientific O O
grounds O O
. O O
When O O
expressed O O
in O O
thymidine B-GENE O
kinase E-GENE O
- O O
deficient O O
L O O
cells O O
or O O
3T3 O O
cells O O
, O O
C B-GENE O
/ I-GENE O
EBPalpha E-GENE S-GENE
is O O
detected O O
in O O
a O O
protein O O
complex O O
which O O
binds O O
to O O
the O O
E2F B-GENE S-GENE
binding I-GENE O
sites E-GENE O
found O O
in O O
the O O
promoters O O
of O O
the O O
genes O O
for O O
E2F B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
dihydrofolate B-GENE B-GENE
reductase E-GENE E-GENE
( O O
DHFR S-GENE S-GENE
) O O
. O O
Members O O
of O O
the O O
CRE B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
CREB S-GENE S-GENE
) O O
/ O O
activating B-GENE O
transcription I-GENE O
factor E-GENE O
transcription O O
family O O
as O O
well O O
as O O
members O O
of O O
the O O
Jun S-GENE S-GENE
/ O O
Fos S-GENE B-GENE
family O E-GENE
have O O
been O O
shown O O
to O O
bind O O
to O O
this O O
sequence O O
. O O
Csk S-GENE S-GENE
( O O
C B-GENE O
- I-GENE O
terminal I-GENE O
Src I-GENE B-GENE
kinase E-GENE E-GENE
) O O
is O O
a O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
that O O
phosphorylates O B-GENE
Src B-GENE I-GENE
family I-GENE E-GENE
member I-GENE O
C I-GENE O
- I-GENE O
terminal I-GENE O
tails E-GENE O
, O O
resulting O O
in O O
downregulation O O
of O O
Src S-GENE B-GENE
family O E-GENE
members O O
. O O
Role O O
of O O
double B-GENE O
- I-GENE O
stranded I-GENE O
RNA I-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
in O O
mediating O O
hypersensitivity O O
of O O
Fanconi O O
anemia O O
complementation O O
group O O
C O O
cells O O
to O O
interferon B-GENE B-GENE
gamma E-GENE E-GENE
, O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
, O O
and O O
double O O
- O O
stranded O O
RNA O O
. O O
In O O
clinical O O
stroke O O
cardiovascular O O
abnormalities O O
are O O
frequently O O
neglected O O
although O O
they O O
occur O O
more O O
often O O
than O O
it O O
is O O
generally O O
assumed O O
. O O
In O O
the O O
presence O O
of O O
high O O
concentrations O O
( O O
propofol O O
100 O O
microg O O
mL O O
- O O
1 O O
, O O
thiopental O O
50 O O
microg O O
mL O O
- O O
1 O O
) O O
marked O O
relaxation O O
was O O
observed O O
( O O
propofol O O
- O O
32 O O
% O O
up O O
to O O
- O O
49 O O
% O O
, O O
P O O
< O O
0 O O
, O O
05 O O
; O O
thiopental O O
- O O
23 O O
% O O
up O O
to O O
- O O
67 O O
% O O
, O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O
Our O O
results O O
suggest O O
a O O
dose O O
- O O
dependent O O
activity O O
of O O
lysine B-GENE O
vasopressin E-GENE O
on O O
the O O
EEG O O
, O O
which O O
might O O
be O O
similar O O
to O O
that O O
observed O O
in O O
animal O O
and O O
man O O
after O O
administration O O
of O O
nicotine O O
. O O
Mutations O O
of O O
the O O
human B-GENE B-GENE
PTEN I-GENE I-GENE
gene E-GENE E-GENE
. O O
Guanylyl B-GENE B-GENE
cyclase I-GENE I-GENE
C E-GENE E-GENE
, O O
the O O
apparent O O
guanylin B-GENE B-GENE
receptor E-GENE E-GENE
, O O
was O O
found O O
in O O
abundant O O
amounts O O
in O O
the O O
intestine O O
by O O
Northern O O
analysis O O
, O O
and O O
by O O
the O O
polymerase O O
chain O O
reaction O O
or O O
cDNA O O
cloning O O
it O O
was O O
also O O
found O O
in O O
adrenal O O
gland O O
, O O
airway O O
epithelial O O
cells O O
, O O
brain O O
, O O
and O O
olfactory O O
and O O
tracheal O O
mucosa O O
. O O
In O O
the O O
present O O
study O O
we O O
have O O
used O O
Southern O O
blot O O
analysis O O
to O O
demonstrate O O
that O O
TSG6 S-GENE S-GENE
is O O
a O O
single O O
- O O
copy O O
gene O O
in O O
the O O
human O O
and O O
murine O O
species O O
. O O
Reaction O O
of O O
aromatic O O
/ O O
heterocyclic O O
sulfonamides O O
possessing O O
free O O
amino O O
, O O
imino O O
or O O
hydrazino O O
moieties O O
with O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
chloromethylcoumarin O O
afforded O O
a O O
series O O
of O O
N O O
- O O
[ O O
( O O
7 O O
- O O
chloro O O
- O O
4 O O
- O O
coumarinyl O O
) O O
- O O
methyl O O
] O O
- O O
derivatives O O
which O O
showed O O
effective O O
inhibition O O
of O O
three O O
carbonic B-GENE O
anhydrase E-GENE O
( O O
CA S-GENE O
) O O
isozymes O O
. O O
As O O
well O O
, O O
variation O O
in O O
capillary O O
size O O
and O O
density O O
was O O
apparent O O
between O O
ventricles O O
in O O
the O O
fetal O O
and O O
neonatal O O
periods O O
. O O
The O O
Polycomb B-GENE O
group I-GENE O
proteins E-GENE O
are O O
involved O O
in O O
maintenance O O
of O O
the O O
silenced O O
state O O
of O O
several O O
developmentally O O
regulated O O
genes O O
. O O
Uncertainty O O
exists O O
about O O
the O O
function O O
of O O
these O O
potential O O
isoforms O O
of O O
the O O
Cbfa1 B-GENE B-GENE
gene E-GENE E-GENE
. O O
When O O
using O O
the O O
high O O
- O O
impedance O O
testing O O
device O O
, O O
the O O
post O O
shock O O
rhythm O O
was O O
initially O O
displayed O O
as O O
' O O
no O O
signal O O
' O O
( O O
Hewlett O O
Packard O O
XL O O
) O O
or O O
' O O
asystole O O
' O O
( O O
Physio O O
- O O
Control O O
LIFEPAK O O
9 O O
) O O
. O O
Human B-GENE B-GENE
CD38 E-GENE E-GENE
, O O
a O O
leukocyte O B-GENE
receptor O E-GENE
and O O
ectoenzyme O O
, O O
is O O
a O O
member O O
of O O
a O O
novel O O
eukaryotic O O
gene O O
family O O
of O O
nicotinamide B-GENE O
adenine I-GENE O
dinucleotide I-GENE O
+ I-GENE O
- I-GENE O
converting I-GENE O
enzymes E-GENE O
: O O
extensive O O
structural O O
homology O O
with O O
the O O
genes O O
for O O
murine B-GENE O
bone I-GENE O
marrow I-GENE O
stromal I-GENE B-GENE
cell I-GENE I-GENE
antigen I-GENE I-GENE
1 E-GENE E-GENE
and O O
aplysian B-GENE B-GENE
ADP I-GENE I-GENE
- I-GENE I-GENE
ribosyl I-GENE I-GENE
cyclase E-GENE E-GENE
. O O
It O O
is O O
noteworthy O O
that O O
under O O
more O O
physiological O O
conditions O O
mimicking O O
the O O
cellular O O
GDP O O
/ O O
GTP O O
ratio O O
, O O
Raf S-GENE O
enhances O O
the O O
GEF S-GENE O
- O O
stimulated O O
GDP O O
/ O O
GTP O S-GENE
exchange O O
on O O
Ha B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
, O O
in O O
agreement O O
with O O
the O O
sequestration O O
of O O
Ras B-GENE S-GENE
. I-GENE O
GTP E-GENE S-GENE
by O O
Raf S-GENE O
. O O
When O O
O O O
- O O
2A O O
/ O O
c B-GENE O
- I-GENE O
myc E-GENE O
cells O O
underwent O O
terminal O O
differentiation O O
APprog B-GENE O
complexes E-GENE O
were O O
lost O O
and O O
conventional O O
AP B-GENE O
- I-GENE O
1 E-GENE O
DNA O O
- O O
binding O O
activity O O
became O O
evident O O
, O O
particularly O O
in O O
astrocytes O O
. O O
From O O
the O O
deduced O O
amino O O
acid O O
sequence O O
, O O
a O O
molecular O O
weight O O
of O O
38 O O
, O O
549 O O
was O O
calculated O O
for O O
the O O
ADH B-GENE B-GENE
subunit E-GENE E-GENE
. O O
The O O
higher O O
level O O
of O O
calories O O
was O O
attained O O
by O O
an O O
increased O O
intake O O
of O O
carbohydrates O O
. O O
A O O
simple O O
algorithm O O
fitting O O
the O O
data O O
for O O
the O O
moving O O
192Ir O O
source O O
is O O
proposed O O
. O O
TAF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
activates O O
transcription O O
constitutively O O
and O O
was O O
mapped O O
to O O
the O O
first O O
32 O O
amino O O
acids O O
of O O
the O O
A O O
- O O
region O O
. O O
For O O
the O O
first O O
, O O
short O O
- O O
term O O
( O O
concurrent O O
) O O
TAL O O
, O O
two O O
different O O
- O O
flavored O O
stimuli O O
were O O
presented O O
at O O
the O O
same O O
time O O
, O O
one O O
associated O O
with O O
simultaneous O O
intragastric O O
administration O O
of O O
an O O
aversive O O
product O O
, O O
hypertonic O O
NaCl O O
, O O
and O O
the O O
other O O
with O O
saline O O
. O O
The O O
great O O
cardiac O O
vein O O
flow O O
became O O
zero O O
due O O
to O O
the O O
cardiac O O
arrest O O
and O O
remained O O
at O O
zero O O
for O O
a O O
moment O O
( O O
dead O O
time O O
) O O
after O O
the O O
initiation O O
of O O
reperfusion O O
. O O
INTERNET O O
is O O
literally O O
a O O
world O O
of O O
data O O
, O O
dialogue O O
, O O
and O O
discourse O O
on O O
any O O
topic O O
imaginable O O
, O O
right O O
at O O
your O O
fingertips O O
. O O
Attention O O
is O O
devoted O O
in O O
particular O O
to O O
the O O
action O O
of O O
thermoregulating O O
nervous O O
and O O
hormonal O O
mechanisms O O
. O O
The O O
mammalian O O
UPR O S-GENE
is O O
mediated O O
by O O
the O O
cis O O
- O O
acting O O
ER O O
stress O O
response O O
element O O
consisting O O
of O O
19 O O
nt O O
( O O
CCAATN O O
( O O
9 O O
) O O
CCACG O O
) O O
, O O
the O O
CCACG O O
part O O
of O O
which O O
is O O
considered O O
to O O
provide O O
specificity O O
. O O
The O O
formation O O
of O O
a O O
D O O
- O O
loop O O
is O O
an O O
essential O O
step O O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
through O O
recombination O O
. O O
The O O
cDNA O O
is O O
predicted O O
to O O
encode O O
a O O
polypeptide O O
of O O
298 O O
amino O O
acids O O
that O O
is O O
homologous O O
to O O
the O O
Y B-GENE B-GENE
- I-GENE I-GENE
box I-GENE E-GENE
( I-GENE O
inverted I-GENE O
CCAAT I-GENE S-GENE
) I-GENE O
family I-GENE O
of I-GENE O
DNA I-GENE O
- I-GENE O
binding I-GENE O
transcription I-GENE O
factors E-GENE O
. O O
Toward O O
this O O
end O O
, O O
we O O
used O O
two O O
cultured O O
colon O O
cancer O O
cell O O
lines O O
; O O
one O O
( O O
RKO O O
) O O
has O O
a O O
transcriptionally O O
activated O O
u B-GENE B-GENE
- I-GENE I-GENE
PAR I-GENE I-GENE
gene E-GENE E-GENE
, O O
and O O
the O O
other O O
( O O
GEO O O
) O O
overexpresses O O
the O O
receptor O O
only O O
after O O
phorbol O O
ester O O
treatment O O
. O O
Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
conserved O O
cysteine O O
residue O O
( O O
tom1C3235A S-GENE S-GENE
) O O
in O O
the O O
hect B-GENE O
- I-GENE O
domain E-GENE O
, O O
supposed O O
to O O
be O O
necessary O O
for O O
thioester O O
- O O
bond O O
formation O O
with O O
ubiquitin S-GENE O
, O O
abolished O O
the O O
gene O O
function O O
. O O
The O O
two O O
yeast B-GENE O
pheromone I-GENE O
receptors E-GENE O
, O O
the O O
a B-GENE O
and I-GENE O
alpha I-GENE B-GENE
- I-GENE I-GENE
factor I-GENE I-GENE
receptors E-GENE E-GENE
, O O
share O O
many O O
functional O O
similarities O O
: O O
both O O
G B-GENE O
protein I-GENE O
- I-GENE O
coupled I-GENE O
receptors E-GENE O
couple O O
to O O
the O O
same O O
downstream O O
signal O O
transduction O O
pathway O O
, O O
and O O
both O O
receptors O O
undergo O O
feedback O O
regulation O O
involving O O
increased O O
phosphorylation O O
on O O
their O O
C O O
- O O
terminal O O
domains O O
in O O
response O O
to O O
ligand O O
challenge O O
. O O
Moreover O O
, O O
the O O
formation O O
of O O
the O O
complex O O
between O O
IclR S-GENE S-GENE
and O O
the O O
operator O O
/ O O
promoter O O
region O O
has O O
been O O
found O O
to O O
be O O
impaired O O
by O O
phosphoenol O O
pyruvate O O
but O O
insensitive O O
to O O
acetate O O
, O O
acetyl O B-GENE
- O I-GENE
CoA O E-GENE
, O O
pyruvate O O
, O O
and O O
oxaloacetate O O
. O O
After O O
enzymatic O O
hydrolysis O O
of O O
the O O
water O O
soluble O O
fraction O O
, O O
it O O
is O O
shown O O
that O O
28 O O
% O O
is O O
again O O
extractable O O
by O O
DCM O O
of O O
which O O
57 O O
% O O
consists O O
of O O
unchanged O O
SC4453 O O
which O O
is O O
therefore O O
the O O
main O O
partner O O
of O O
conjugated O O
products O O
. O O
The O O
expression O O
pattern O O
of O O
the O O
reporter O O
gene O O
was O O
compared O O
to O O
that O O
of O O
the O O
endogenous B-GENE B-GENE
PDGFbeta I-GENE I-GENE
r I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
two O O
SH3 B-GENE B-GENE
domains E-GENE E-GENE
are O O
separated O O
by O O
a O O
54 O O
amino O O
acid O O
linker O O
region O O
, O O
whose O O
length O O
is O O
highly O O
conserved O O
in O O
xenopus O O
, O O
chicken O O
, O O
and O O
mamalian B-GENE B-GENE
Crk I-GENE I-GENE
II I-GENE I-GENE
proteins E-GENE E-GENE
. O O
This O O
complex O O
was O O
eliminated O O
by O O
mutation O O
of O O
either O O
half O O
- O O
site O O
, O O
and O O
it O O
was O O
supershifted O O
by O O
antibodies O O
against O O
chicken B-GENE B-GENE
ovalbumin I-GENE I-GENE
upstream I-GENE I-GENE
promoter I-GENE I-GENE
- I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
( O O
COUP B-GENE B-GENE
- I-GENE I-GENE
TF E-GENE E-GENE
) O O
. O O
The O O
fz B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
fz B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
genes E-GENE E-GENE
are O O
widely O O
expressed O O
in O O
rat O O
tissues O O
with O O
the O O
highest O O
steady O O
- O O
state O O
levels O O
of O O
mRNA O O
in O O
kidney O O
, O O
liver O O
, O O
heart O O
, O O
uterus O O
, O O
and O O
ovary O O
. O O
fz B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
and I-GENE O
- I-GENE O
2 I-GENE O
mRNA E-GENE O
levels O O
were O O
greater O O
in O O
neonatal O O
than O O
in O O
corresponding O O
adult O O
tissues O O
. O O
These O O
results O O
indicate O O
that O O
the O O
changes O O
in O O
the O O
patient O O
' O O
s O O
thyroid O O
scan O O
and O O
RAIU O O
were O O
attributable O O
to O O
the O O
presence O O
of O O
TSAb O O
. O O
The O O
methods O O
used O O
were O O
the O O
AOAC O O
method O O
of O O
dilution O O
and O O
heating O O
; O O
the O O
addition O O
of O O
mercuric O O
chloride O O
, O O
charcoal O O
, O O
and O O
Carrez O O
reagents O O
at O O
2 O O
different O O
pH O O
values O O
; O O
and O O
direct O O
analysis O O
of O O
sample O O
supernatants O O
with O O
no O O
treatment O O
( O O
control O O
) O O
. O O
Cytochemical O O
and O O
ultrastructural O O
observations O O
on O O
the O O
tegument O O
of O O
the O O
trematode O O
Megalodiscus O O
temperatus O O
. O O
In O O
this O O
report O O
, O O
we O O
establish O O
that O O
the O O
heteromeric O B-GENE
CCAAT B-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE I-GENE
CBF S-GENE E-GENE
is O O
the O O
major O O
component O O
of O O
the O O
C1 B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
( O O
C1F S-GENE S-GENE
) O O
in O O
human O O
cells O O
. O O
A O O
40 O O
- O O
fold O O
stimulation O O
of O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
activity O O
mediated O O
by O O
four O O
tandem O O
repeats O O
of O O
the O O
SNE S-GENE O
could O O
be O O
induced O O
within O O
2 O O
h O O
( O O
and O O
up O O
to O O
250 O O
- O O
fold O O
within O O
6 O O
h O O
) O O
after O O
addition O O
of O O
TPA O O
in O O
DNA O O
- O O
transfected O O
U O O
- O O
937 O O
cells O O
, O O
indicating O O
that O O
the O O
stimulation O O
appeared O O
likely O O
to O O
be O O
a O O
true O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
- O O
mediated O O
signal O O
transduction O O
event O O
rather O O
than O O
a O O
differentiation O O
response O O
. O O
This O O
increased O O
frequency O O
of O O
infection O O
has O O
been O O
accompanied O O
by O O
significant O O
excess O O
mortality O O
. O O
Deletion O O
mutants O O
of O O
the O O
human B-GENE B-GENE
CHOP I-GENE I-GENE
promoter E-GENE E-GENE
identify O O
a O O
region O O
comprising O O
nucleotides O O
- O O
75 O O
to O O
- O O
104 O O
required O O
for O O
both O O
constitutive O O
and O O
ER O O
- O O
stress O O
- O O
inducible O O
expression O O
. O O
The O O
duration O O
of O O
PGE2 O S-GENE
and O O
PGF2 O B-GENE
alpha O E-GENE
elevations O O
as O O
well O O
as O O
the O O
peak O O
values O O
were O O
influenced O O
by O O
day O O
of O O
the O O
cycle O O
. O O
We O O
propose O O
that O O
the O O
cDNA O O
encodes O O
an O O
apical O O
plasma O O
membrane O O
protein O O
that O O
plays O O
a O O
role O O
in O O
the O O
functional O O
expression O O
of O O
the O O
amiloride O O
- O O
sensitive O O
epithelial O O
sodium O O
channel O O
. O O
Electrophysiology O O
and O O
pharmacology O O
of O O
epicardial O O
, O O
endocardial O O
, O O
and O O
M O O
cells O O
. O O
In O O
contrast O O
, O O
an O O
N B-GENE O
- I-GENE O
terminal I-GENE O
RNAP I-GENE B-GENE
mutant E-GENE E-GENE
that O O
has O O
a O O
decreased O O
capacity O O
to O O
bind O O
single O O
- O O
stranded O O
RNA O O
forms O O
halted O O
complexes O O
with O O
much O O
lower O O
levels O O
of O O
stability O O
than O O
the O O
WT O B-GENE
enzyme O E-GENE
, O O
and O O
these O O
complexes O O
are O O
not O O
stabilized O O
by O O
the O O
presence O O
of O O
the O O
NT O O
strand O O
. O O
A O O
cephalothoracophagus O O
disymmetros O O
buffalo O O
calf O O
. O O
A O O
mouse O O
brain O O
cDNA O O
library O O
in O O
lambdagt11 O O
was O O
screened O O
for O O
this O O
association O O
, O O
and O O
two O O
positive O O
clones O O
encoding O O
tyrosine B-GENE O
phosphatase E-GENE O
SH B-GENE O
- I-GENE O
PTP2 E-GENE S-GENE
were O O
isolated O O
. O O
Disorganization O O
scores O O
of O O
the O O
hypertrophy O O
zone O O
and O O
trabecular O O
bone O O
were O O
low O O
, O O
approaching O O
normal O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
, O O
for O O
turkey O O
poults O O
fed O O
on O O
diets O O
with O O
phytase S-GENE O
supplementation O O
, O O
and O O
tibial O O
abnormality O O
scores O O
were O O
linearly O O
decreased O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
as O O
nP O O
levels O O
increased O O
( O O
zero O O
score O O
is O O
considered O O
normal O O
) O O
. O O
Repression O O
was O O
strictly O O
dependent O O
on O O
the O O
presence O O
of O O
upstream O O
Oshox1 S-GENE O
binding O O
sites O O
in O O
the O O
reporter O O
gene O O
constructs O O
and O O
a O O
function O O
of O O
the O O
N O O
- O O
terminal O O
region O O
of O O
Oshox1 S-GENE S-GENE
, O O
preceding O O
the O O
homeodomain S-GENE O
. O O
Ondansetron O O
is O O
thus O O
an O O
effective O O
first O O
- O O
line O O
antiemetic O O
in O O
children O O
undergoing O O
chemotherapy O O
, O O
radiotherapy O O
and O O
surgery O O
. O O
To O O
elucidate O O
the O O
molecular O O
mechanism O O
by O O
which O O
the O O
Ras S-GENE S-GENE
signaling O O
pathway O O
activates O O
a O O
cell O O
- O O
type O O
- O O
specific O O
gene O O
, O O
we O O
have O O
used O O
the O O
pituitary B-GENE O
- I-GENE O
specific I-GENE O
rat I-GENE O
prolactin E-GENE O
( O O
rPRL S-GENE S-GENE
) O O
promoter O O
as O O
a O O
target O O
of O O
oncogenic B-GENE B-GENE
Ras E-GENE E-GENE
and O O
Raf S-GENE S-GENE
in O O
GH4 O S-GENE
rat O O
pituitary O O
cells O O
. O O
The O O
human O B-GENE
RFC B-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
differs O O
from O O
the O O
mouse O O
and O O
hamster O O
genes O O
both O O
in O O
terms O O
of O O
the O O
total O O
number O O
of O O
exons O O
and O O
in O O
regard O O
to O O
alternatives O O
of O O
exon O O
1 O O
which O O
encode O O
5 O O
' O O
end O O
heterogeneity O O
. O O
Type O O
C O O
units O O
summate O O
the O O
responses O O
to O O
the O O
two O O
- O O
tone O O
stimulus O O
, O O
and O O
show O O
little O O
or O O
no O O
inhibitory O O
influences O O
. O O
HGF S-GENE S-GENE
treatment O O
increased O O
cyclin B-GENE O
A E-GENE O
, O O
cyclin B-GENE B-GENE
G1 E-GENE E-GENE
and O O
nuclear O B-GENE
transcriptional O I-GENE
factor O E-GENE
( O O
NFkappaB S-GENE S-GENE
) O O
protein O O
expression O O
. O O
Since O O
blood O O
serotonin O O
is O O
primarily O O
produced O O
peripherally O O
, O O
these O O
results O O
suggest O O
that O O
some O O
aspect O O
of O O
peripheral O O
serotonin O O
metabolism O O
is O O
abnormal O O
in O O
major O O
depression O O
. O O
Although O O
several O O
large O O
waterborne O O
outbreaks O O
occurred O O
during O O
the O O
past O O
decade O O
, O O
most O O
were O O
in O O
small O O
communities O O
. O O
Cytogenetic O O
structures O O
showed O O
a O O
mixte O O
karyotype O O
: O O
mosaicim O O
46 O O
XX O O
/ O O
46 O O
XY O O
with O O
a O O
ratio O O
of O O
a O O
80 O O
/ O O
20 O O
. O O
The O O
1 O O
. O O
6 O O
- O O
kb O O
cDNA O O
( O O
CBF B-GENE O
- I-GENE O
A E-GENE O
) O O
encoding O O
285 O O
amino O O
acids O O
( O O
aa O O
) O O
was O O
obtained O O
, O O
and O O
a O O
beta B-GENE O
- I-GENE O
galactosidase I-GENE O
fusion I-GENE O
protein E-GENE O
, O O
bacterially O O
produced O O
from O O
the O O
cDNA O O
, O O
bound O O
to O O
DNA O O
fragments O O
containing O O
several O O
CArG O O
boxes O O
. O O
Mutant B-GENE O
M I-GENE O
proteins E-GENE O
were O O
tested O O
for O O
their O O
ability O O
to O O
complement O O
growth O O
of O O
the O O
temperature O O
- O O
sensitive O O
M B-GENE O
protein I-GENE O
mutant E-GENE O
virus O O
tsO23 O O
at O O
the O O
nonpermissive O O
temperature O O
. O O
In O O
this O O
paper O O
we O O
review O O
evidence O O
on O O
smoking O O
and O O
lung O O
cancer O O
among O O
Latinos O O
, O O
including O O
findings O O
from O O
several O O
unpublished O O
studies O O
and O O
technical O O
reports O O
. O O
The O O
yjr041c B-GENE O
delta E-GENE O
haploid O O
cells O O
gave O O
rise O O
to O O
microcolonies O O
comprising O O
about O O
20 O O
to O O
50 O O
cells O O
. O O
Despite O O
these O O
high O O
initial O O
rates O O
of O O
transcription O O
, O O
of O O
all O O
the O O
promoter O O
constructs O O
only O O
LAT S-GENE B-GENE
- O I-GENE
LTR O E-GENE
was O O
able O O
to O O
remain O O
transcriptionally O O
active O O
after O O
the O O
establishment O O
of O O
a O O
latent O O
state O O
. O O
Two O O
mutants O O
, O O
mapping O O
at O O
the O O
HindIII B-GENE B-GENE
site E-GENE E-GENE
( O O
between O O
the O O
consensus O O
sequences O O
) O O
of O O
the O O
pSC101 B-GENE B-GENE
tetA I-GENE I-GENE
promoter E-GENE E-GENE
, O O
were O O
studied O O
: O O
MA2 O O
corresponds O O
to O O
a O O
4 O O
bp O O
deletion O O
between O O
positions O O
- O O
12 O O
and O O
- O O
15 O O
; O O
B30 O O
bears O O
a O O
44 O O
bp O O
insertion O O
C O O
( O O
TA O O
) O O
21 O O
G O O
at O O
the O O
HindIII B-GENE O
site E-GENE O
. O O
We O O
concluded O O
that O O
these O O
results O O
support O O
the O O
feasibility O O
and O O
usefulness O O
of O O
N O O
- O O
of O O
- O O
1 O O
RCT O O
in O O
rheumatology O O
practice O O
. O O
Sci O O
. O O
Effects O O
of O O
timepidium O O
bromide O O
( O O
TB O O
; O O
anticholinergic O O
agent O O
) O O
, O O
acetylcholine O O
( O O
ACh O O
) O O
and O O
neostigmine O O
( O O
Neost O O
) O O
on O O
gastric O O
and O O
duodenal O O
blood O O
flow O O
distribution O O
were O O
studied O O
by O O
the O O
use O O
of O O
131I O B-GENE
- O I-GENE
labeled O I-GENE
macroaggregated O I-GENE
human O I-GENE
serum O I-GENE
albumin O E-GENE
( O O
MAA S-GENE O
) O O
in O O
rabbits O O
. O O
These O O
extrachromosomal O O
copies O O
can O O
be O O
isolated O O
as O O
covalently O O
closed O O
molecules O O
with O O
lengths O O
around O O
3mu O O
. O O
Comparison O O
of O O
the O O
footprint O O
patterns O O
of O O
the O O
mouse B-GENE O
and I-GENE O
human I-GENE B-GENE
HPRT I-GENE I-GENE
genes E-GENE E-GENE
demonstrated O O
that O O
the O O
in O O
vivo O O
binding O O
of O O
regulatory O O
proteins O O
between O O
these O O
species O O
is O O
generally O O
conserved O O
but O O
not O O
identical O O
. O O
Here O O
, O O
we O O
describe O O
the O O
three O O
- O O
dimensional O O
structure O O
of O O
the O O
enzyme O O
from O O
Escherichia O O
colidetermined O O
and O O
refined O O
to O O
2 O O
. O O
0 O O
A O O
resolution O O
. O O
Our O O
Northern O O
and O O
Southern O O
blot O O
analyses O O
of O O
meningiomas O O
clearly O O
suggest O O
the O O
CLH B-GENE B-GENE
- I-GENE I-GENE
22 I-GENE I-GENE
gene E-GENE E-GENE
may O O
be O O
involved O O
in O O
the O O
tumor O O
development O O
and O O
can O O
be O O
considered O O
as O O
a O O
candidate O O
for O O
a O O
tumor O O
suppressor O O
. O O
Plasmodium O O
vivax O O
malaria O O
. O O
This O O
set O O
of O O
genetic O O
and O O
physical O O
interactions O O
suggests O O
a O O
role O O
for O O
yeast O O
RNA O O
- O O
binding O O
proteins O O
in O O
transcriptional O O
regulation O O
. O O
POPULATION O O
AND O O
METHODS O O
: O O
105 O O
patients O O
were O O
followed O O
prospectively O O
( O O
male O O
: O O
87 O O
% O O
; O O
age O O
: O O
56 O O
+ O O
/ O O
- O O
10 O O
) O O
; O O
clinical O O
evaluation O O
was O O
performed O O
in O O
the O O
1st O O
, O O
3rd O O
and O O
6th O O
month O O
, O O
SEKG O O
in O O
the O O
4th O O
month O O
and O O
recatheterization O O
for O O
angiographic O O
control O O
in O O
the O O
6th O O
month O O
. O O
All O O
other O O
cysts O O
showed O O
a O O
unilocular O O
, O O
purely O O
cystic O O
pattern O O
, O O
with O O
homogeneous O O
fluids O O
, O O
although O O
the O O
T2 O O
relaxation O O
times O O
of O O
four O O
lesions O O
overlapped O O
those O O
of O O
odontogenic O O
keratocysts O O
. O O
Genetic O O
diagnosis O O
of O O
respiratory O O
diseases O O
The O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE E-GENE
delta I-GENE O
- I-GENE O
domain E-GENE O
inhibits O O
neuroendocrine O O
promoter O O
activity O O
in O O
a O O
DNA O O
sequence O O
- O O
and O O
pituitary O O
- O O
specific O O
manner O O
. O O
Cross O O
- O O
sectional O O
studies O O
continue O O
to O O
dominate O O
. O O
The O O
role O O
of O O
the O O
medical O O
facilities O O
in O O
the O O
prognosis O O
of O O
the O O
patient O O
with O O
tetanus O O
specially O O
the O O
importance O O
of O O
considering O O
at O O
the O O
same O O
time O O
the O O
severity O O
of O O
the O O
disease O O
and O O
the O O
characteristics O O
of O O
the O O
therapy O O
deserve O O
further O O
study O O
in O O
order O O
to O O
contribute O O
to O O
the O O
development O O
of O O
the O O
medical O O
assistance O O
to O O
the O O
patients O O
with O O
tetanus O O
. O O
Differences O O
were O O
not O O
found O O
in O O
colons O O
by O O
SEM O O
. O O
Increasing O O
the O O
height O O
of O O
the O O
agar O O
column O O
overlying O O
the O O
SN O O
fabric O O
diminished O O
the O O
inhibitory O O
effect O O
of O O
SN O O
on O O
microbial O O
growth O O
. O O
Neither O O
raw O O
nor O O
retrograded O O
resistant O O
starch O O
lowers O O
fasting O O
serum O O
cholesterol O O
concentrations O O
in O O
healthy O O
normolipidemic O O
subjects O O
. O O
( O O
5 O O
) O O
. O O
Hepatitis O O
B O O
markers O O
in O O
Lancashire O O
police O O
officers O O
. O O
In O O
the O O
other O O
two O O
groups O O
( O O
NAAR O O
and O O
PLA O O
) O O
, O O
no O O
variation O O
in O O
this O O
serum O O
protease O O
was O O
observed O O
. O O
Maximum O O
likelihood O O
estimation O O
in O O
covariance O O
structure O O
analysis O O
with O O
truncated O O
data O O
. O O
A O O
single O O
dose O O
of O O
Cef O O
was O O
administered O O
intravenously O O
to O O
11 O O
patients O O
with O O
autoimmune O O
diseases O O
and O O
varying O O
degrees O O
of O O
renal O O
impairment O O
( O O
Group O O
I O O
CLCR O O
less O O
than O O
50 O O
ml O O
/ O O
min O O
, O O
Group O O
II O O
CLCR O O
greater O O
than O O
50 O O
ml O O
/ O O
min O O
) O O
. O O
The O O
liver O O
- O O
specific O O
sequence O O
contains O O
unique O O
consensus O O
sites O O
for O O
phosphorylation O O
by O O
cyclic B-GENE B-GENE
AMP I-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
and O O
by O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
. O O
Effect O O
of O O
gentamycin O O
on O O
the O O
kidney O O
functional O O
state O O
in O O
experimental O O
pyelonephritis O O
They O O
represent O O
a O O
physiologically O O
more O O
meaningful O O
pattern O O
than O O
the O O
arithmetic O O
mean O O
with O O
standard O O
deviation O O
. O O
The O O
Valpha S-GENE O
and O O
Vbeta B-GENE O
domains E-GENE O
have O O
the O O
canonical O O
features O O
of O O
known O O
teleost B-GENE O
and I-GENE O
mammalian I-GENE B-GENE
TCR I-GENE I-GENE
V I-GENE I-GENE
domains E-GENE E-GENE
, O O
including O O
conserved O O
residues O O
in O O
the O O
beginning O O
of O O
FR2 S-GENE S-GENE
and O O
at O O
the O O
end O O
of O O
FR3 S-GENE O
. O O
Whether O O
this O O
lack O O
of O O
preferential O O
repair O O
has O O
to O O
be O O
explained O O
by O O
a O O
defect O O
in O O
repair O O
or O O
in O O
general O O
transcription O O
is O O
unclear O O
at O O
present O O
. O O
This O O
study O O
examines O O
LEIBNIZ O O
' O O
idea O O
of O O
Veterinary O O
medicine O O
in O O
a O O
biographical O O
context O O
. O O
Dipetalonema O O
( O O
Acanthocheilonema O O
) O O
didelphis O O
sp O O
. O O
n O O
. O O
However O O
, O O
the O O
MCMI O O
- O O
III O O
group O O
profile O O
was O O
significantly O O
lower O O
in O O
magnitude O O
compared O O
with O O
the O O
MCMI O O
- O O
II O O
. O O
While O O
there O O
is O O
growing O O
evidence O O
that O O
perception O O
and O O
imagery O O
share O O
common O O
neural O O
substrates O O
, O O
the O O
fact O O
that O O
D O O
. O O
F O O
. O O
shows O O
intact O O
visual O O
imagery O O
in O O
the O O
face O O
of O O
a O O
massive O O
perceptual O O
deficit O O
in O O
form O O
vision O O
challenges O O
recent O O
suggestions O O
that O O
these O O
two O O
psychological O O
processes O O
share O O
common O O
input O O
pathways O O
in O O
early O O
vision O O
. O O
An O O
ethnic O O
analysis O O
was O O
made O O
of O O
8947 O O
cases O O
of O O
primary O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
tumors O O
seen O O
at O O
the O O
Armed O O
Forces O O
Institute O O
of O O
Pathology O O
( O O
AFIP O O
) O O
, O O
Washington O O
, O O
DC O O
, O O
from O O
1971 O O
to O O
1985 O O
. O O
The O O
exact O O
function O O
of O O
IP B-GENE B-GENE
- I-GENE I-GENE
30 E-GENE E-GENE
is O O
not O O
yet O O
known O O
, O O
but O O
it O O
may O O
play O O
a O O
role O O
in O O
gamma B-GENE O
- I-GENE O
interferon E-GENE O
mediated O O
immune O O
reactions O O
. O O
The O O
levels O O
of O O
products O O
expressed O O
from O O
these O O
chimeric O O
cDNAs O O
in O O
COS O O
cells O O
were O O
assessed O O
by O O
activity O O
assay O O
and O O
by O O
metabolic O O
labeling O O
of O O
the O O
proteins O O
followed O O
by O O
immunoprecipitation O O
and O O
SDS O B-GENE
- O I-GENE
PAGE O E-GENE
. O O
In O O
this O O
report O O
, O O
we O O
demonstrate O O
that O O
FRS2 S-GENE S-GENE
forms O O
a O O
complex O O
with O O
the O O
N B-GENE O
- I-GENE O
terminal I-GENE O
SH2 I-GENE S-GENE
domain E-GENE O
of O O
the O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
phosphatase I-GENE I-GENE
Shp2 E-GENE E-GENE
in O O
response O O
to O O
FGF S-GENE S-GENE
stimulation O O
. O O
It O O
is O O
concluded O O
that O O
the O O
drinking O O
ampules O O
of O O
VP O O
- O O
16 O O
- O O
213 O O
can O O
be O O
replaced O O
with O O
the O O
new O O
oral O O
capsules O O
with O O
a O O
recommended O O
initial O O
dose O O
of O O
100 O O
- O O
130 O O
mg O O
/ O O
m2 O O
given O O
in O O
5 O O
- O O
day O O
courses O O
every O O
21 O O
- O O
28 O O
days O O
. O O
The O O
H5 B-GENE O
mutants E-GENE O
were O O
: O O
DH5 S-GENE O
( O O
all O O
amino O O
acids O O
in O O
D O O
configuration O O
) O O
and O O
H5F S-GENE O
( O O
where O O
all O O
His O O
are O O
replaced O O
by O O
Phe O O
at O O
positions O O
3 O O
, O O
7 O O
, O O
8 O O
, O O
15 O O
, O O
18 O O
, O O
19 O O
, O O
21 O O
) O O
. O O
Although O O
the O O
number O O
of O O
kits O O
has O O
increased O O
, O O
the O O
precision O O
has O O
improved O O
, O O
showing O O
that O O
more O O
robust O O
methods O O
are O O
now O O
employed O O
. O O
These O O
results O O
establish O O
that O O
the O O
DNA O O
fragment O O
we O O
have O O
isolated O O
contains O O
the O O
human B-GENE B-GENE
gp130 I-GENE I-GENE
promoter E-GENE E-GENE
and O O
that O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE E-GENE
type I-GENE O
cytokines E-GENE O
may O O
influence O O
the O O
activity O O
of O O
this O O
promoter O O
via O O
activated O O
STATs S-GENE O
. O O
When O O
targeted O O
to O O
the O O
GAL1 B-GENE B-GENE
promoter E-GENE E-GENE
by O O
fusing O O
with O O
the O O
Gal4p B-GENE O
DNA I-GENE O
- I-GENE O
binding I-GENE O
domain E-GENE O
, O O
Sko1p S-GENE S-GENE
acts O O
as O O
an O O
Ssn6 S-GENE S-GENE
/ O O
Tup1p S-GENE S-GENE
- O O
dependent O O
repressor O O
regulated O O
by O O
osmotic O O
stress O O
. O O
The O O
unexpected O O
prevalence O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
myc E-GENE E-GENE
and O O
alpha B-GENE O
- I-GENE O
tubulin E-GENE O
in O O
the O O
S O O
- O O
phase O O
library O O
is O O
supported O O
by O O
Northern O O
analysis O O
of O O
RNA O O
from O O
phase O O
- O O
synchronous O O
cells O O
. O O
Growth O O
factors O O
promote O O
cell O O
survival O O
through O O
phosphorylation O O
of O O
Bad S-GENE O
, O O
resulting O O
in O O
its O O
dissociation O O
from O O
Bcl B-GENE O
- I-GENE O
2 E-GENE O
and O O
Bcl B-GENE O
- I-GENE O
x I-GENE O
( I-GENE O
L I-GENE O
) E-GENE O
and O O
its O O
association O O
with O O
14 B-GENE O
- I-GENE O
3 I-GENE O
- I-GENE O
3tau E-GENE O
. O O
A O O
representative O O
group O O
of O O
patients O O
undergoing O O
open O O
radical O O
nephrectomy O O
for O O
clinical O O
T1 O O
, O O
T2 O O
lesions O O
was O O
also O O
identified O O
. O O
By O O
applying O O
a O O
sufficiently O O
strong O O
crusher O O
gradient O O
in O O
the O O
EPI O O
pulse O O
sequence O O
, O O
the O O
temporal O O
variation O O
induced O O
by O O
SSFP O O
disturbance O O
can O O
be O O
suppressed O O
due O O
to O O
diffusion O O
. O O
However O O
, O O
in O O
each O O
case O O
in O O
which O O
either O O
the O O
DQ B-GENE O
alpha I-GENE O
- I-GENE O
or I-GENE O
DQ I-GENE O
beta I-GENE O
- I-GENE O
chain E-GENE O
was O O
exchanged O O
, O O
major O O
alterations O O
or O O
reversals O O
of O O
this O O
pattern O O
of O O
interaction O O
were O O
observed O O
. O O
Only O O
the O O
native O O
structure O O
of O O
phosphorylated O O
ERK S-GENE S-GENE
was O O
recognized O O
by O O
VHR S-GENE S-GENE
and O O
was O O
inactivated O O
with O O
a O O
second O O
- O O
order O O
rate O O
constant O O
of O O
40 O O
, O O
000 O O
M O O
- O O
1 O O
s O O
- O O
1 O O
. O O
From O O
1998 O O
to O O
1999 O O
, O O
a O O
large O O
number O O
of O O
community O O
- O O
acquired O O
respiratory O O
tract O O
isolates O O
of O O
Streptococcus O O
pneumoniae O O
( O O
n O O
= O O
566 O O
) O O
, O O
Haemophilus O O
influenzae O O
( O O
n O O
= O O
513 O O
) O O
and O O
Moraxella O O
catarrhalis O O
( O O
n O O
= O O
228 O O
) O O
were O O
collected O O
from O O
15 O O
centres O O
in O O
Australia O O
, O O
Hong O O
Kong O O
, O O
Japan O O
, O O
China O O
, O O
the O O
Philippines O O
, O O
Singapore O O
, O O
South O O
Africa O O
and O O
Taiwan O O
through O O
the O O
SENTRY O O
Antimicrobial O O
Surveillance O O
Program O O
. O O
Diethyldithiocarbamate O O
and O O
amphetamine O O
stereotype O O
behavior O O
. O O
We O O
used O O
an O O
immobilized O O
template O O
- O O
based O O
assay O O
to O O
examine O O
transcription O O
termination O O
by O O
VA1 S-GENE S-GENE
, O O
7SL S-GENE S-GENE
, O O
and O O
Alu B-GENE O
class I-GENE O
III E-GENE O
templates O O
and O O
the O O
role O O
of O O
transcript O O
release O O
in O O
the O O
pol B-GENE B-GENE
III E-GENE E-GENE
terminator O O
- O O
dependent O O
inhibition O O
of O O
processing O O
of O O
B1 S-GENE B-GENE
- O I-GENE
Alu S-GENE I-GENE
transcripts O E-GENE
. O O
A O O
novel O O
zinc O O
finger O O
- O O
containing O O
RNA O O
- O O
binding O O
protein O O
conserved O O
from O O
fruitflies O O
to O O
humans O O
. O O
Although O O
IL B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
can O O
activate O O
ERK B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
HepG2 O O
cells O O
, O O
STAT3 S-GENE S-GENE
transactivation O O
and O O
Ser O S-GENE
( O O
727 O O
) O O
phosphorylation O O
were O O
not O O
reduced O O
by O O
using O O
the O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
/ O O
ERK B-GENE B-GENE
kinase E-GENE E-GENE
( O O
MEK S-GENE S-GENE
) O O
inhibitor O O
PD98059 O S-GENE
or O O
by O O
overexpression O O
of O O
dominant O O
- O O
negative O O
Raf S-GENE O
. O O
6 O O
h O O
after O O
ingestion O O
of O O
aspirin O O
on O O
day O O
1 O O
to O O
day O O
14 O O
, O O
both O O
TX O O
and O O
PGI2 O O
levels O O
also O O
significantly O O
decreased O O
( O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
. O O
Tritiated O O
1 O O
, O O
24 O O
, O O
25 O O
- O O
trihydroxyvitamin O O
D3 O O
was O O
synthesized O O
biologically O O
and O O
used O O
as O O
tracer O O
to O O
monitor O O
the O O
recovery O O
of O O
endogenous O O
metabolite O O
during O O
isolation O O
from O O
serum O O
. O O
Joint O O
ultrasonography O O
demonstrating O O
thickening O O
of O O
synoviae O O
and O O
tendons O O
has O O
become O O
a O O
useful O O
non O O
- O O
invasive O O
diagnostic O O
tool O O
, O O
although O O
it O O
is O O
not O O
specific O O
for O O
beta B-GENE O
2 I-GENE O
- I-GENE O
M E-GENE O
amyloidosis O O
, O O
and O O
results O O
depend O O
on O O
observer O O
experience O O
. O O
Immunofluorescence O O
tests O O
for O O
Borrelia B-GENE O
burgdorferi I-GENE O
serum I-GENE O
antibodies E-GENE O
had O O
positive O O
results O O
, O O
but O O
G O O
- O O
penicillin O O
treatment O O
was O O
ineffective O O
. O O
The O O
size O O
and O O
the O O
predicted O O
N O O
- O O
terminal O O
sequence O O
of O O
the O O
mouse O O
protein O O
were O O
confirmed O O
experimentally O O
. O O
Nuclear O O
runoff O O
assays O O
show O O
that O O
complementation O O
by O O
HPV16 B-GENE B-GENE
E7 E-GENE E-GENE
restores O O
the O O
ability O O
of O O
the O O
E1A B-GENE B-GENE
mutants E-GENE E-GENE
to O O
stimulate O O
early B-GENE O
gene E-GENE O
expression O O
at O O
the O O
level O O
of O O
transcription O O
. O O
Yet O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
production O O
are O O
independently O O
regulated O O
, O O
as O O
demonstrated O O
by O O
their O O
differential O O
expression O O
in O O
certain O O
T O O
cell O O
subsets O O
, O O
suggesting O O
that O O
the O O
regulatory O O
elements O O
in O O
these O O
two O O
genes O O
must O O
differ O O
. O O
We O O
conclude O O
that O O
a O O
0 O O
. O O
25 O O
mg O O
dose O O
of O O
triazolam O O
does O O
not O O
effectively O O
counteract O O
a O O
posture O O
- O O
induced O O
sleep O O
disturbance O O
, O O
but O O
induces O O
changes O O
in O O
the O O
EEG O O
spectra O O
which O O
are O O
typical O O
for O O
benzodiazepine B-GENE O
receptor E-GENE O
agonists O O
. O O
Anisotropy O O
of O O
Hc2 O S-GENE
and O O
the O O
breadth O O
of O O
the O O
resistive O O
transition O O
of O O
polycrystalline O O
YBa2Cu O O
Microscopic O O
examination O O
of O O
these O O
colonies O O
showed O O
a O O
high O O
percentage O O
of O O
histiocytes O O
identical O O
to O O
those O O
seen O O
in O O
the O O
patient O O
' O O
s O O
bone O O
marrow O O
. O O
Functional O O
uncoupling O O
of O O
the O O
Janus B-GENE B-GENE
kinase I-GENE E-GENE
3 E-GENE O
- O O
Stat5 S-GENE O
pathway O O
in O O
malignant O O
growth O O
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
- O O
transformed O O
human O O
T O O
cells O O
. O O
The O O
herpesvirus B-GENE O
entry I-GENE O
mediator I-GENE O
C E-GENE O
( O O
HveC S-GENE S-GENE
) O O
, O O
previously O O
known O O
as O O
poliovirus B-GENE B-GENE
receptor I-GENE I-GENE
- I-GENE I-GENE
related I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
( O O
PRR1 S-GENE S-GENE
) O O
, O O
and O O
the O O
herpesvirus B-GENE B-GENE
Ig I-GENE I-GENE
- I-GENE I-GENE
like I-GENE I-GENE
receptor E-GENE E-GENE
( O O
HIgR S-GENE S-GENE
) O O
are O O
the O O
bona O O
fide O O
receptors O O
employed O O
by O O
herpes O O
simplex O O
virus O O
- O O
1 O O
and O O
- O O
2 O O
( O O
HSV O O
- O O
1 O O
and O O
- O O
2 O O
) O O
for O O
entry O O
into O O
the O O
human O O
cell O O
lines O O
most O O
frequently O O
used O O
in O O
HSV O O
studies O O
. O O
4 O O
- O O
Hydroxyproline O O
assays O O
were O O
performed O O
to O O
determine O O
collagen S-GENE O
content O O
. O O
The O O
combination O O
of O O
ICP47 S-GENE S-GENE
and O O
US11 S-GENE S-GENE
rendered O O
fibroblasts O O
negative O O
for O O
surface B-GENE O
class I-GENE O
I I-GENE O
MHC E-GENE O
and O O
allowed O O
a O O
class B-GENE O
I I-GENE O
MHC E-GENE O
- O O
low O O
population O O
of O O
T O O
cells O O
to O O
be O O
sorted O O
by O O
flow O O
cytometry O O
. O O
Although O O
IRS B-GENE O
- I-GENE O
1 I-GENE O
, I-GENE O
- I-GENE O
2 I-GENE O
, I-GENE O
and I-GENE O
- I-GENE O
4 E-GENE O
are O O
similar O O
in O O
overall O O
structure O O
, O O
IRS B-GENE O
- I-GENE O
3 E-GENE O
is O O
approximately O O
50 O O
% O O
shorter O O
and O O
differs O O
with O O
respect O O
to O O
sites O O
of O O
tyrosine O O
phosphorylation O O
. O O
The O O
interaction O O
of O O
different O O
protein O O
systems O O
with O O
microtubules O O
is O O
a O O
critical O O
step O O
in O O
the O O
cellular O O
function O O
of O O
these O O
organelles O O
. O O
In O O
addition O O
, O O
we O O
mapped O O
a O O
putative O O
hnRNP B-GENE B-GENE
A1 I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
in O O
U5 B-GENE B-GENE
RNA E-GENE E-GENE
and O O
demonstrated O O
that O O
p40CRS S-GENE S-GENE
( O O
hnRNP B-GENE B-GENE
A1 E-GENE E-GENE
) O O
binding O O
to O O
that O O
site O O
correlates O O
with O O
CRS S-GENE S-GENE
function O O
. O O
Sailer O O
, O O
K O O
. O O
Copyright O O
2000 O O
Academic O O
Press O O
. O O
This O O
element O O
was O O
required O O
for O O
both O O
basal O O
and O O
activated O O
expression O O
and O O
almost O O
certainly O O
functions O O
as O O
a O O
TATA B-GENE O
- I-GENE O
binding I-GENE O
protein E-GENE O
interaction O O
site O O
. O O
In O O
HepG2 O O
cells O O
, O O
SREBP B-GENE B-GENE
- I-GENE I-GENE
1c I-GENE I-GENE
mRNA E-GENE E-GENE
and O O
precursor O O
protein O O
levels O O
were O O
induced O O
by O O
treatment O O
with O O
22 O O
( O O
R O O
) O O
- O O
hydroxycholesterol O O
and O O
9 O O
- O O
cis O O
- O O
retinoic O O
acid O O
, O O
confirming O O
that O O
endogenous O O
LXR S-GENE S-GENE
- O O
RXR S-GENE S-GENE
activation O O
can O O
induce O O
endogenous B-GENE O
SREBP I-GENE B-GENE
- I-GENE I-GENE
1c E-GENE E-GENE
expression O O
. O O
Univariate O O
and O O
multivariate O O
analysis O O
was O O
used O O
to O O
calculate O O
the O O
5 O O
- O O
year O O
survival O O
probabilities O O
with O O
respect O O
to O O
the O O
following O O
variables O O
: O O
age O O
( O O
< O O
or O O
= O O
65 O O
, O O
> O O
65 O O
) O O
, O O
sex O O
, O O
depth O O
of O O
invasion O O
( O O
mucosal O O
, O O
submucosal O O
) O O
tumor O O
location O O
( O O
upper O O
, O O
middle O O
and O O
lower O O
third O O
) O O
, O O
gross O O
appearance O O
( O O
type O O
I O O
, O O
type O O
II O O
and O O
type O O
III O O
) O O
, O O
size O O
( O O
< O O
or O O
= O O
1 O O
. O O
5 O O
cm O O
, O O
> O O
1 O O
. O O
5 O O
cm O O
) O O
, O O
presence O O
or O O
absence O O
of O O
lymph O O
node O O
metastasis O O
, O O
histological O O
type O O
( O O
intestinal O O
, O O
diffuse O O
) O O
, O O
extent O O
of O O
lymphadenectomy O O
( O O
limited O O
or O O
extended O O
) O O
, O O
and O O
type O O
of O O
gastrectomy O O
( O O
total O O
or O O
distal O O
subtotal O O
) O O
. O O
This O O
integration O O
results O O
in O O
the O O
production O O
of O O
MMTV B-GENE S-GENE
/ I-GENE O
mdr3 I-GENE O
fusion I-GENE O
transcripts E-GENE O
that O O
originate O O
from O O
the O O
antisense O O
5 B-GENE O
' I-GENE O
LTR E-GENE O
of O O
the O O
provirus O O
. O O
In O O
32 O O
of O O
them O O
the O O
results O O
of O O
an O O
exercise O O
performance O O
test O O
based O O
on O O
heart O O
rate O O
response O O
to O O
submaximal O O
exercise O O
( O O
VO2 O O
, O O
170 O O
[ O O
bpm O O
] O O
) O O
was O O
compared O O
with O O
another O O
index O O
of O O
physical O O
performance O O
capacity O O
, O O
which O O
is O O
independent O O
from O O
heart O O
rate O O
: O O
the O O
ventilatory O O
threshold O O
. O O
Sequence O O
comparisons O O
reveal O O
that O O
the O O
P B-GENE O
. I-GENE O
woesei I-GENE O
GTP I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
is O O
strikingly O O
related O O
in O O
sequence O O
to O O
eubacterial B-GENE O
FtsZ E-GENE S-GENE
and O O
is O O
marginally O O
more O O
similar O O
to O O
eukaryotic B-GENE O
tubulins E-GENE O
than O O
are O O
bacterial B-GENE B-GENE
FtsZ I-GENE I-GENE
proteins E-GENE E-GENE
. O O
Four O O
of O O
15 O O
patients O O
with O O
R2 S-GENE O
had O O
rheumatoid O O
arthritis O O
and O O
in O O
two O O
of O O
these O O
four O O
cases O O
the O O
antibody O O
was O O
of O O
the O O
IgA S-GENE O
class O O
. O O
Phosphate O O
compounds O O
in O O
isolated O O
, O O
perfused O O
hearts O O
during O O
pH O O
variation O O
due O O
to O O
changes O O
in O O
extracellular O O
PCO2 O O
and O O
bicarbonate O O
Vav S-GENE S-GENE
and O O
Dbl S-GENE O
are O O
members O O
of O O
a O O
novel O O
class O O
of O O
oncogene O O
proteins O O
that O O
share O O
significant O O
sequence O O
identity O O
in O O
a O O
approximately O O
250 O O
- O O
amino O O
- O O
acid O O
domain O O
, O O
designated O O
the O O
Dbl B-GENE B-GENE
homology I-GENE I-GENE
domain E-GENE E-GENE
. O O
Serum O O
AFP S-GENE O
is O O
a O O
useful O O
tumor O O
marker O O
for O O
monitoring O O
the O O
results O O
of O O
therapy O O
. O O
The O O
possible O O
equivalency O O
of O O
a O O
short O O
form O O
and O O
the O O
long O O
form O O
of O O
the O O
Multiple O O
Affect O O
Adjective O O
Check O O
List O O
- O O
Revised O O
( O O
MAACL O O
- O O
R O O
; O O
Zuckerman O O
& O O
Lubin O O
, O O
1985 O O
) O O
was O O
studied O O
by O O
correlating O O
both O O
forms O O
of O O
the O O
MAACL O O
- O O
R O O
with O O
the O O
State O O
Trait O O
Personality O O
Inventory O O
( O O
Spielberger O O
, O O
1995 O O
) O O
; O O
the O O
Affect O O
Balance O O
Scale O O
( O O
Bradburn O O
, O O
1969 O O
) O O
; O O
and O O
the O O
Sensation O O
Seeking O O
Scale O O
( O O
Zuckerman O O
, O O
1978 O O
) O O
. O O
The O O
data O O
show O O
that O O
processing O O
time O O
as O O
a O O
function O O
of O O
intensity O O
is O O
modified O O
not O O
only O O
at O O
the O O
retina O O
but O O
also O O
at O O
later O O
processing O O
sites O O
. O O
Identification O O
of O O
masked O O
toxins O O
in O O
the O O
exotoxin O O
complex O O
of O O
Staphylococcus O O
pyogenes O O
und O O
Cl O O
. O O
perfringens O O
; O O
significance O O
of O O
their O O
existence O O
for O O
clarifying O O
of O O
the O O
masking O O
mechanism O O
Unlike O O
LANA1 S-GENE O
, O O
LANA2 S-GENE S-GENE
does O O
not O O
elicit O O
a O O
serologic O O
response O O
from O O
patients O O
with O O
KS O O
, O O
PEL O O
, O O
or O O
CD O O
as O O
measured O O
by O O
Western O O
blot O O
hybridization O O
. O O
However O O
, O O
this O O
posttranslational O O
modification O O
of O O
the O O
gar2 B-GENE B-GENE
protein E-GENE E-GENE
does O O
not O O
appear O O
to O O
be O O
essential O O
for O O
normal O O
production O O
of O O
18S B-GENE B-GENE
rRNA E-GENE E-GENE
. O O
Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
CYT B-GENE B-GENE
- I-GENE I-GENE
18 E-GENE E-GENE
with O O
a O O
small O O
RNA O O
( O O
P4 B-GENE B-GENE
- I-GENE I-GENE
P6 I-GENE I-GENE
RNA E-GENE E-GENE
) O O
corresponding O O
to O O
the O O
isolated O O
P4 B-GENE O
- I-GENE O
P6 I-GENE O
domain E-GENE O
of O O
the O O
N B-GENE O
. I-GENE O
crassa I-GENE O
mitochondrial I-GENE O
large I-GENE O
subunit I-GENE O
ribosomal I-GENE O
RNA I-GENE O
intron E-GENE O
. O O
The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
PutR S-GENE S-GENE
( O O
154 O O
amino O O
acid O O
residues O O
) O O
showed O O
homology O O
to O O
the O O
small O O
regulatory O O
proteins O O
Lrp S-GENE O
, O O
BkdR S-GENE S-GENE
, O O
and O O
AsnC S-GENE S-GENE
. O O
When O O
yeast O O
cells O O
reach O O
a O O
critical O O
size O O
in O O
late O O
G1 O O
they O O
simultaneously O O
start O O
budding O O
, O O
initiate O O
DNA O O
synthesis O O
, O O
and O O
activate O O
transcription O O
of O O
a O O
set O O
of O O
genes O O
that O O
includes O O
G1 B-GENE O
cyclins E-GENE O
CLN1 S-GENE S-GENE
, O O
CLN2 S-GENE S-GENE
, O O
and O O
many O O
DNA O O
synthesis O O
genes O O
. O O
Functional O O
PET O O
scanning O O
in O O
the O O
preoperative O O
assessment O O
of O O
cerebral O O
arteriovenous O O
malformations O O
. O O
In O O
addition O O
, O O
269 O O
mice O O
from O O
a O O
( O O
Mus O O
spretus O O
x O O
C57BL O O
/ O O
6J O O
) O O
F1 O O
x O O
C57BL O O
/ O O
6J O O
interspecific O O
backcross O O
were O O
also O O
used O O
to O O
order O O
marker O O
loci O O
and O O
calculate O O
intergene O O
distances O O
for O O
this O O
region O O
. O O
Accordingly O O
, O O
superpeptide O O
antigenic O O
material O O
was O O
readily O O
detected O O
by O O
immunoblotting O O
cell O O
extracts O O
and O O
enriched O O
in O O
vacuolar O O
preparations O O
of O O
PrA S-GENE O
deficient O O
mutant O O
cells O O
. O O
Blockade O O
of O O
T O O
cell O O
activation O O
using O O
a O O
surface O O
- O O
linked O O
single O O
- O O
chain O O
antibody O O
to O O
CTLA B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
( O O
CD152 S-GENE S-GENE
) O O
. O O
Water O O
pair O O
and O O
three O O
- O O
body O O
potential O O
of O O
spectroscopic O O
quality O O
from O O
Ab O O
initio O O
calculations O O
4 O O
) O O
Mutation O O
of O O
the O O
three O O
extracellular O O
cysteine O O
residues O O
of O O
GFKAR B-GENE B-GENE
beta E-GENE E-GENE
indicated O O
that O O
the O O
two O O
conserved O O
cysteine O O
residues O O
( O O
C305 O S-GENE
and O O
C385 O S-GENE
) O O
, O O
located O O
between O O
two O O
transmembrane O O
segments O O
, O O
form O O
a O O
solvent O O
- O O
accessible O O
disulfide O O
bond O O
. O O
In O O
this O O
work O O
, O O
we O O
have O O
used O O
Xenopus O O
oocyte O O
maturation O O
as O O
a O O
read O O
- O O
out O O
for O O
examining O O
the O O
ability O O
of O O
the O O
neu S-GENE B-GENE
tyrosine B-GENE I-GENE
kinase E-GENE E-GENE
( O O
p185neu S-GENE S-GENE
) O O
to O O
participate O O
with O O
the O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
EGF I-GENE S-GENE
) I-GENE O
receptor E-GENE O
in O O
a O O
common O O
signal O O
transduction O O
pathway O O
. O O
The O O
best O O
- O O
studied O O
neurotrophin O O
, O O
nerve B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
NGF S-GENE S-GENE
) O O
, O O
is O O
a O O
major O O
survival O O
factor O O
in O O
sympathetic O O
and O O
sensory O O
neurons O O
and O O
promotes O O
differentiation O O
in O O
a O O
well O O
- O O
studied O O
model O O
system O O
, O O
PC12 O O
cells O O
. O O
In O O
contrast O O
, O O
MAPK S-GENE S-GENE
activation O O
stimulated O O
by O O
the O O
Gq S-GENE B-GENE
- O I-GENE
coupled O I-GENE
alpha O I-GENE
1B O I-GENE
AR O E-GENE
or O O
M1 S-GENE B-GENE
muscarinic B-GENE I-GENE
cholinergic I-GENE I-GENE
receptor E-GENE E-GENE
is O O
unaffected O O
by O O
expression O O
of O O
beta B-GENE B-GENE
ARKct E-GENE E-GENE
or O O
RasN17 S-GENE S-GENE
expression O O
or O O
by O O
PTK S-GENE S-GENE
inhibitors O O
, O O
but O O
is O O
blocked O O
by O O
expression O O
of O O
N B-GENE O
delta I-GENE O
Raf E-GENE O
or O O
by O O
PKC S-GENE S-GENE
depletion O O
. O O
Transcriptional O O
analysis O O
indicates O O
that O O
human B-GENE B-GENE
TBP E-GENE E-GENE
functions O O
poorly O O
at O O
promoters O O
recognized O O
by O O
RNA B-GENE O
polymerases I-GENE O
I I-GENE O
and I-GENE O
III E-GENE O
and O O
at O O
RNA B-GENE O
Pol I-GENE O
II I-GENE O
promoters E-GENE O
lacking O O
a O O
conventional O O
TATA O O
element O O
. O O
The O O
steady O O
- O O
state O O
levels O O
of O O
Cdk2 S-GENE S-GENE
, O O
Cdk4 S-GENE S-GENE
and O O
Cyclin B-GENE B-GENE
A I-GENE I-GENE
proteins E-GENE E-GENE
were O O
unaffected O O
by O O
HPR O S-GENE
, O O
while O O
those O O
of O O
Cyclin B-GENE B-GENE
D1 E-GENE E-GENE
were O O
significantly O O
reduced O O
in O O
all O O
three O O
cell O O
lines O O
. O O
Mapping O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
TED B-GENE O
RNAs E-GENE O
indicated O O
that O O
the O O
LTRs O S-GENE
have O O
a O O
retroviral O O
U3 O O
- O O
R O O
- O O
U5 O O
structural O O
organization O O
that O O
is O O
capable O O
of O O
directing O O
the O O
synthesis O O
of O O
transcripts O O
that O O
represent O O
potential O O
substrates O O
for O O
reverse O O
transcription O O
and O O
intermediates O O
in O O
transposition O O
. O O
Human O O
forearm O O
was O O
used O O
as O O
a O O
dummy O O
ear O O
and O O
the O O
electrode O O
HN O O
- O O
5 O O
was O O
fixed O O
thereon O O
, O O
and O O
a O O
sound O O
stimulus O O
of O O
90dBnHL O O
was O O
delivered O O
by O O
the O O
earphone O O
( O O
NC O O
- O O
3 O O
) O O
. O O
These O O
proteins O O
were O O
detected O O
by O O
an O O
antibody O O
which O O
recognizes O O
the O O
N O O
- O O
terminus O O
of O O
SRK3 S-GENE S-GENE
and O O
, O O
in O O
an O O
F2 O O
progeny O O
segregating O O
for O O
the O O
S3 B-GENE O
haplotype E-GENE O
, O O
were O O
only O O
expressed O O
in O O
plants O O
possessing O O
the O O
S3 B-GENE B-GENE
haplotype E-GENE E-GENE
. O O
The O O
blood O O
pressures O O
in O O
43 O O
subjects O O
were O O
compared O O
during O O
rapid O O
weight O O
loss O O
and O O
at O O
identical O O
weights O O
during O O
post O O
- O O
fast O O
weight O O
gain O O
( O O
Study O O
A O O
) O O
. O O
The O O
animals O O
were O O
followed O O
over O O
a O O
1 O O
- O O
to O O
6 O O
- O O
h O O
posttraumatic O O
course O O
, O O
and O O
processed O O
for O O
the O O
LM O O
and O O
TEM O O
visualization O O
of O O
HRP S-GENE O
. O O
Total O O
body O O
water O O
and O O
distribution O O
space O O
of O O
Na24 O O
in O O
women O O
with O O
various O O
body O O
weight O O
Three O O
experiments O O
using O O
20 O O
microM O O
2 O O
- O O
( O O
hydroxyamino O O
) O O
- O O
1 O O
- O O
methyl O O
- O O
6 O O
- O O
phenylimidazo O O
[ O O
4 O O
, O O
5 O O
- O O
b O O
] O O
pyridine O O
( O O
N O O
- O O
OH O O
- O O
PhIP O O
) O O
were O O
performed O O
to O O
induce O O
mutations O O
in O O
the O O
dihydrofolate B-GENE B-GENE
reductase E-GENE E-GENE
( O O
DHFR S-GENE S-GENE
) O O
gene O O
of O O
a O O
hemizygous O O
Chinese O O
hamster O O
ovary O O
( O O
CHO O O
) O O
cell O O
line O O
( O O
UA21 O O
) O O
. O O
This O O
is O O
mediated O O
by O O
vascular O O
remodeling O O
, O O
an O O
active O O
process O O
that O O
results O O
in O O
a O O
change O O
in O O
the O O
geometry O O
of O O
the O O
blood O O
vessel O O
. O O
Our O O
results O O
separate O O
these O O
factors O O
into O O
four O O
regulatory O O
classes O O
: O O
( O O
i O O
) O O
constitutive O O
factors O O
, O O
such O O
as O O
Oct B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
probably O O
Sp1 S-GENE S-GENE
, O O
that O O
are O O
expressed O O
in O O
thymocytes O O
at O O
all O O
stages O O
; O O
( O O
ii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
and O O
complexes O O
binding O O
to O O
the O O
region O O
of O O
a O O
CD28 B-GENE O
response I-GENE O
element E-GENE O
, O O
that O O
can O O
be O O
activated O O
in O O
all O O
thymocytes O O
, O O
including O O
those O O
cells O O
( O O
CD4 B-GENE O
+ E-GENE O
CD8 B-GENE O
+ E-GENE O
TcRlow S-GENE O
) O O
that O O
can O O
undergo O O
selection O O
; O O
( O O
iii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B-GENE O
- I-GENE O
AT E-GENE O
and O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
that O O
can O O
be O O
activated O O
in O O
mature O O
( O O
CD4 B-GENE O
+ E-GENE O
CD8 B-GENE O
- E-GENE O
TcRhigh S-GENE O
) O O
and O O
immature O O
( O O
CD4 B-GENE S-GENE
- E-GENE O
CD8 B-GENE O
- E-GENE O
TcR B-GENE O
- E-GENE O
) O O
thymocytes O O
alike O O
but O O
not O O
in O O
the O O
transitional O O
stages O O
when O O
the O O
cells O O
( O O
CD4 B-GENE B-GENE
+ E-GENE I-GENE
CD8 B-GENE I-GENE
+ E-GENE I-GENE
TcRlow S-GENE E-GENE
) O O
are O O
subject O O
to O O
selection O O
; O O
and O O
( O O
iv O O
) O O
a O O
factor O O
containing O O
CREB S-GENE S-GENE
, O O
which O O
can O O
be O O
activated O O
in O O
thymocytes O O
of O O
all O O
developmental O O
stages O O
by O O
culture O O
but O O
does O O
not O O
require O O
specific O O
induction O O
. O O
Thus O O
, O O
22 O O
% O O
of O O
MDS O O
responded O O
to O O
oral O O
PLAC O O
. O O
Posterior O O
osteophytes O O
around O O
the O O
posterior O O
edges O O
of O O
vertebral O O
body O O
resulted O O
in O O
intervertebral O O
insufficiency O O
, O O
and O O
corresponded O O
to O O
hypertrophic O O
spur O O
in O O
osteochondrosis O O
. O O
They O O
showed O O
moderate O O
in O O
vitro O O
antifungal O O
activity O O
against O O
a O O
wide O O
variety O O
of O O
fungi O O
and O O
yeasts O O
including O O
clinically O O
important O O
pathogens O O
, O O
and O O
were O O
highly O O
effective O O
in O O
systemic O O
infection O O
with O O
Candida O O
albicans O O
in O O
mice O O
after O O
iv O O
and O O
im O O
administrations O O
. O O
Of O O
these O O
four O O
PP2C B-GENE B-GENE
genes E-GENE E-GENE
, O O
the O O
expression O O
of O O
the O O
PP2Cbeta B-GENE B-GENE
gene E-GENE E-GENE
has O O
been O O
reported O O
to O O
be O O
tissue O O
- O O
specific O O
and O O
development O O
- O O
dependent O O
. O O
We O O
also O O
show O O
that O O
in O O
fusions O O
with O O
the O O
DNA O O
binding O O
domain O O
of O O
GAL4 S-GENE S-GENE
, O O
full O O
activity O O
requires O O
the O O
entire O O
BHV B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
TIF E-GENE E-GENE
, O O
although O O
both O O
amino O O
and O O
carboxyl O O
termini O O
display O O
some O O
activity O O
on O O
their O O
own O O
. O O
The O O
induction O O
by O O
dexamethasone O O
of O O
rat B-GENE O
liver I-GENE O
CYP3A1 E-GENE O
differs O O
from O O
classical O O
glucocorticoid O O
gene O O
regulation O O
in O O
part O O
because O O
both O O
glucocorticoids O O
and O O
antiglucocorticoids O O
such O O
as O O
pregnenolone O O
16 O O
alpha O O
- O O
carbonitrile O O
( O O
PCN O O
) O O
induce O O
CYP3A1 S-GENE S-GENE
through O O
transcriptional O O
gene O O
activation O O
. O O
Moreover O O
, O O
antibody O O
binding O O
to O O
the O O
same O O
two O O
determinants O O
was O O
also O O
inhibited O O
when O O
ZAP B-GENE O
- I-GENE O
70 E-GENE O
or O O
the O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
bound O O
to O O
the O O
zeta O O
chain O O
or O O
to O O
a O O
2pY B-GENE B-GENE
- I-GENE I-GENE
ITAM E-GENE E-GENE
. O O
This O O
surface O O
in O O
specimens O O
from O O
unfertilized O O
eggs O O
is O O
almost O O
flat O O
. O O
Fetal O O
transplants O O
rescue O O
axial O O
muscle O O
representations O O
in O O
M1 O O
cortex O O
of O O
neonatally O O
transected O O
rats O O
that O O
develop O O
weight O O
support O O
. O O
We O O
examined O O
the O O
contribution O O
of O O
the O O
M B-GENE O
- I-GENE O
MuLV I-GENE O
enhancers E-GENE O
to O O
the O O
transcriptional O O
activity O O
and O O
pathogenesis O O
of O O
M O B-GENE
- O I-GENE
MuLV O E-GENE
by O O
constructing O O
LTRs O S-GENE
containing O O
heterologous O O
enhancer O O
elements O O
. O O
There O O
were O O
no O O
major O O
postoperative O O
complications O O
and O O
at O O
follow O O
- O O
up O O
of O O
the O O
13 O O
patients O O
at O O
10 O O
to O O
26 O O
months O O
after O O
operation O O
the O O
results O O
were O O
satisfactory O O
. O O
The O O
immunoreactive O B-GENE
antithrombin B-GENE I-GENE
III E-GENE E-GENE
increased O O
significantly O O
while O O
the O O
increase O O
in O O
antithrombin B-GENE B-GENE
III E-GENE E-GENE
activity O O
was O O
insignificant O O
in O O
20 O O
male O O
Caucasian O O
Danes O O
upon O O
3 O O
weeks O O
supplementation O O
of O O
the O O
diet O O
with O O
10 O O
ml O O
daily O O
of O O
a O O
cod O O
liver O O
oil O O
concentrate O O
. O O
Northern O O
blot O O
analysis O O
confirmed O O
that O O
ADAMTS B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
was O O
up O O
- O O
regulated O O
in O O
both O O
metaphyseal O O
( O O
14 O O
- O O
to O O
35 O O
- O O
fold O O
) O O
and O O
diaphyseal O O
( O O
4 O O
. O O
2 O O
- O O
fold O O
) O O
bone O O
1 O O
h O O
after O O
PTH B-GENE O
- I-GENE O
( I-GENE O
1 I-GENE O
- I-GENE O
38 I-GENE O
) E-GENE O
injection O O
and O O
returned O O
to O O
control O O
levels O O
by O O
24 O O
h O O
. O O
The O O
transcriptional B-GENE O
transactivator E-GENE O
( O O
Tas S-GENE O
) O O
of O O
simian O O
foamy O O
virus O O
type O O
1 O O
strongly O O
augments O O
gene O O
expression O O
directed O O
by O O
both O O
the O O
promoter O O
in O O
the O O
viral O O
long O O
terminal O O
repeat O O
and O O
the O O
newly O O
discovered O O
internal O O
promoter O O
located O O
within O O
the O O
env B-GENE B-GENE
gene E-GENE E-GENE
. O O
In O O
the O O
other O O
two O O
cases O O
, O O
fluoxetine O O
adjunct O O
produced O O
benefits O O
with O O
no O O
additional O O
side O O
effects O O
. O O
Deletion O O
of O O
this O O
consensus O O
element O O
from O O
the O O
spo6 B-GENE B-GENE
promoter E-GENE E-GENE
abolished O O
the O O
transcription O O
of O O
spo6 B-GENE O
+ E-GENE O
and O O
resulted O O
in O O
a O O
sporulation O O
deficiency O O
. O O
Chem O O
. O O
Mutations O O
in O O
the O O
beta B-GENE B-GENE
- I-GENE I-GENE
galactosidase I-GENE I-GENE
gene E-GENE E-GENE
result O O
in O O
the O O
lysosomal O O
storage O O
disorders O O
GM1 O O
- O O
gangliosidosis O O
and O O
Morquio O O
B O O
syndrome O O
. O O
Results O O
indicated O O
that O O
hobbies O O
/ O O
leisure O O
activities O O
, O O
mobility O O
, O O
transport O O
, O O
social O O
relationships O O
, O O
working O O
capacity O O
, O O
energy O O
and O O
doing O O
things O O
slower O O
were O O
aspects O O
relevant O O
to O O
IPF O O
patients O O
' O O
QOL O O
. O O
We O O
have O O
generated O O
transgenic O O
fly O O
strains O O
with O O
mutations O O
affecting O O
specific O O
TRA B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
isoforms E-GENE E-GENE
to O O
investigate O O
their O O
individual O O
roles O O
in O O
regulating O O
the O O
alternative O O
processing O O
of O O
doublesex S-GENE O
, O O
exuperantia S-GENE O
and O O
tra B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
pre I-GENE I-GENE
- I-GENE I-GENE
mRNA E-GENE E-GENE
. O O
The O O
IR4 O B-GENE
ORF O E-GENE
exhibits O O
significant O O
homology O O
to O O
the O O
immediate B-GENE O
- I-GENE O
early I-GENE O
gene E-GENE O
US1 S-GENE O
( O O
ICP22 S-GENE O
) O O
of O O
herpes O O
simplex O O
virus O O
type O O
1 O O
and O O
to O O
the O O
ICP22 S-GENE O
homologs O O
of O O
varicella O O
- O O
zoster O O
virus O O
( O O
ORF63 S-GENE O
) O O
, O O
pseudorabies O O
virus O O
( O O
RSp40 S-GENE O
) O O
, O O
and O O
equine O O
herpesvirus O O
4 O O
( O O
ORF4 O O
) O O
. O O
These O O
studies O O
define O O
a O O
class O O
of O O
DNA O O
elements O O
with O O
a O O
mode O O
of O O
action O O
that O O
has O O
not O O
been O O
heretofore O O
described O O
. O O
We O O
were O O
able O O
to O O
demonstrate O O
a O O
significant O O
statistical O O
interaction O O
effect O O
between O O
gender O O
and O O
globulin B-GENE O
protein E-GENE O
concentration O O
on O O
Vu O O
( O O
p O O
= O O
0 O O
. O O
022 O O
) O O
. O O
Chest O O
X O O
- O O
P O O
revealed O O
an O O
abnormal O O
shadow O O
in O O
the O O
left O O
upper O O
lobe O O
. O O
From O O
the O O
frozen O O
specimen O O
, O O
a O O
large O O
number O O
of O O
sections O O
with O O
good O O
morphologic O O
characteristics O O
may O O
be O O
produced O O
. O O
These O O
include O O
not O O
only O O
antioxidants O O
, O O
N B-GENE O
- I-GENE O
methyl I-GENE O
- I-GENE O
D I-GENE O
- I-GENE O
aspartate I-GENE O
receptor E-GENE O
antagonists O O
, O O
inhibitors O O
of O O
glutamate O O
release O O
, O O
calcium O O
channel O O
blockers O O
, O O
polyamine O O
antagonists O O
, O O
and O O
nitric B-GENE O
oxide I-GENE O
synthase E-GENE O
inhibitors O O
, O O
but O O
cannabinoids O O
, O O
aspirin O O
, O O
melatonin O O
, O O
and O O
vitamin O O
B O O
- O O
12 O O
. O O
A O O
series O O
of O O
mutations O O
were O O
constructed O O
within O O
the O O
E2 S-GENE O
open O O
reading O O
frame O O
which O O
delete O O
various O O
regions O O
of O O
the O O
conserved O O
DNA O O
binding O O
and O O
transactivation O O
domains O O
as O O
well O O
as O O
the O O
internal O O
hinge O O
region O O
. O O
CrkII S-GENE S-GENE
and O O
CrkL S-GENE S-GENE
constitutively O O
formed O O
complex O O
with O O
the O O
guanine B-GENE O
nucleotide I-GENE O
exchange I-GENE O
factor E-GENE O
C3G S-GENE S-GENE
, O O
in O O
unstimulated O O
as O O
well O O
as O O
PDGF S-GENE S-GENE
- O O
stimulated O O
cells O O
. O O
In O O
further O O
support O O
of O O
the O O
biological O O
significance O O
of O O
these O O
DNA O O
- O O
protein O O
interactions O O
, O O
the O O
IL2RA S-GENE S-GENE
oligonucleotide O O
from O O
- O O
291 O O
to O O
- O O
245 O O
proved O O
to O O
be O O
sufficient O O
in O O
either O O
orientation O O
to O O
confer O O
PMA O O
inducibility O O
to O O
the O O
mitogen O O
- O O
insensitive O O
thymidine B-GENE B-GENE
kinase I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
in O O
Jurkat O O
cells O O
. O O
The O O
plasma O O
steroid O O
levels O O
in O O
the O O
CAPD O O
patients O O
after O O
each O O
infusion O O
rate O O
were O O
equal O O
to O O
or O O
greater O O
than O O
the O O
levels O O
in O O
normal O O
subjects O O
. O O
With O O
BCPP O O
protocol O O
, O O
12 O O
achieved O O
a O O
complete O O
response O O
, O O
11 O O
evidenced O O
a O O
75 O O
% O O
response O O
, O O
and O O
7 O O
displayed O O
a O O
50 O O
% O O
response O O
. O O
The O O
RPC31 B-GENE B-GENE
gene E-GENE E-GENE
encoding O O
the O O
C31 B-GENE B-GENE
subunit I-GENE E-GENE
of I-GENE O
Saccharomyces I-GENE B-GENE
cerevisiae I-GENE I-GENE
RNA I-GENE I-GENE
polymerase I-GENE I-GENE
C I-GENE E-GENE
( I-GENE O
III I-GENE O
) E-GENE O
has O O
been O O
isolated O O
, O O
starting O O
from O O
a O O
C O O
- O O
terminal O O
fragment O O
cloned O O
on O O
a O O
lambda O O
gt11 O O
library O O
. O O
Electrophoretic O O
mobility O O
shift O O
assays O O
demonstrated O O
that O O
sequences O O
within O O
this O O
region O O
bind O O
members O O
of O O
the O O
Sp1 B-GENE B-GENE
family I-GENE E-GENE
of I-GENE O
transcription I-GENE O
factors E-GENE O
. O O
The O O
phosphatase O O
active O O
site O O
is O O
located O O
within O O
residues O O
367 O O
- O O
374 O O
. O O
After O O
at O O
least O O
one O O
year O O
follow O O
- O O
up O O
, O O
argon O O
laser O O
showed O O
a O O
statistically O O
significant O O
effect O O
( O O
p O O
less O O
of O O
0 O O
, O O
01 O O
; O O
Kolmogorow O O
- O O
Smirnov O O
test O O
) O O
on O O
the O O
stabilization O O
or O O
the O O
amelioration O O
of O O
visual O O
acuity O O
compared O O
with O O
the O O
non O O
treated O O
group O O
. O O
Further O O
studies O O
aim O O
at O O
characterizing O O
the O O
trans O O
- O O
acting O O
factors O O
that O O
mediate O O
the O O
spatial O O
and O O
temporal O O
expression O O
of O O
Hox B-GENE B-GENE
genes E-GENE E-GENE
in O O
the O O
developing O O
embryo O O
. O O
Contraindications O O
to O O
adenosine O O
and O O
drug O O
interactions O O
are O O
noted O O
in O O
this O O
article O O
. O O
As O O
to O O
the O O
side O O
effects O O
of O O
SISO O O
, O O
cylindruria O O
with O O
aggravation O O
of O O
microscopic O O
hematuria O O
and O O
elevations O O
of O O
GOT S-GENE O
, O O
GPT S-GENE O
and O O
A1 B-GENE O
- I-GENE O
P E-GENE O
were O O
observed O O
each O O
one O O
of O O
them O O
, O O
respectively O O
. O O
Serum B-GENE O
C3 E-GENE O
was O O
measured O O
in O O
1 O O
, O O
282 O O
school O O
children O O
with O O
abnormal O O
urinary O O
findings O O
between O O
1980 O O
and O O
1997 O O
. O O
Two O O
measures O O
of O O
sensory O O
inhibition O O
were O O
employed O O
, O O
S2 O O
/ O O
S1 O O
x O O
100 O O
amplitude O O
ratio O O
and O O
S1 O O
- O O
S2 O O
amplitude O O
difference O O
. O O
Computer O O
analysis O O
revealed O O
that O O
the O O
human B-GENE B-GENE
protein I-GENE I-GENE
P1 I-GENE I-GENE
sequence E-GENE E-GENE
corresponding O O
to O O
amino O O
acid O O
residues O O
within O O
the O O
N O O
- O O
terminal O O
RNA O O
binding O O
domain O O
displays O O
high O O
homology O O
( O O
greater O O
than O O
54 O O
% O O
identity O O
; O O
61 O O
to O O
94 O O
% O O
similarity O O
) O O
with O O
two O O
animal O O
virus O O
proteins O O
which O O
possess O O
RNA O O
binding O O
activity O O
( O O
vaccinia B-GENE O
virus I-GENE O
E3L E-GENE S-GENE
; O O
rotavirus B-GENE O
VP2 E-GENE S-GENE
) O O
and O O
two O O
proteins O O
of O O
unknown O O
function O O
( O O
murine B-GENE O
TIK E-GENE S-GENE
; O O
rotavirus B-GENE O
NS34 E-GENE O
) O O
, O O
but O O
which O O
are O O
likely O O
RNA O O
binding O O
proteins O O
. O O
Determinants O O
of O O
recurrent O O
ischaemia O O
and O O
revascularisation O O
procedures O O
after O O
thrombolysis O O
with O O
recombinant O O
tissue B-GENE O
plasminogen I-GENE O
activator E-GENE O
in O O
primary O O
coronary O O
occlusion O O
. O O
For O O
large O O
breasts O O
( O O
> O O
70 O O
mm O O
) O O
the O O
use O O
of O O
X O O
- O O
ray O O
sets O O
such O O
as O O
the O O
IGE O B-GENE
DMR O E-GENE
, O O
which O O
automatically O O
select O O
the O O
beam O O
quality O O
for O O
each O O
breast O O
, O O
resulted O O
in O O
lower O O
doses O O
compared O O
with O O
sets O O
using O O
manual O O
tube O O
potential O O
selection O O
. O O
Experimental O O
exposure O O
of O O
poults O O
with O O
each O O
of O O
two O O
strains O O
representing O O
the O O
rarely O O
reported O O
capsular O O
group O O
B O O
indicated O O
that O O
both O O
were O O
virulent O O
. O O
Computer O O
system O O
trains O O
employees O O
to O O
meet O O
JCAHO O O
safety O O
ED O O
requirements O O
. O O
Finally O O
, O O
transfection O O
of O O
Grb10 B-GENE B-GENE
genes E-GENE E-GENE
with O O
specific O O
mutations O O
in O O
their O O
SH2 B-GENE S-GENE
domains E-GENE O
induces O O
apoptosis O O
in O O
HTC O B-GENE
- O I-GENE
IR O E-GENE
and O O
COS O O
- O O
7 O O
cells O O
. O O
Comparison O O
of O O
dose O O
volume O O
histograms O O
revealed O O
that O O
the O O
6 O O
- O O
field O O
plan O O
spared O O
relatively O O
more O O
heart O O
whereas O O
the O O
8 O O
- O O
field O O
plan O O
spared O O
relatively O O
more O O
lung O O
. O O
We O O
have O O
demonstrated O O
that O O
a O O
putative O O
HOX B-GENE O
cofactor E-GENE O
, O O
PBX1A S-GENE S-GENE
, O O
participates O O
in O O
cooperative O O
DNA O O
binding O O
with O O
HOXA B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
the O O
Deformed S-GENE O
group O O
protein O O
HOXD B-GENE B-GENE
- I-GENE I-GENE
4 E-GENE E-GENE
. O O
The O O
CHL B-GENE B-GENE
1 E-GENE I-GENE
( O I-GENE
CTF B-GENE I-GENE
1 E-GENE E-GENE
) O O
gene O O
product O O
of O O
Saccharomyces O O
cerevisiae O O
is O O
important O O
for O O
chromosome O O
transmission O O
and O O
normal O O
cell O O
cycle O O
progression O O
in O O
G2 O O
/ O O
M O O
. O O
Heterotrimeric O B-GENE
guanine B-GENE I-GENE
nucleotide I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
( O O
G B-GENE B-GENE
- I-GENE I-GENE
proteins E-GENE E-GENE
) O O
function O O
as O O
signal O O
transducers O O
for O O
a O O
variety O O
of O O
hormone O O
- O O
coupled O O
enzyme O O
and O O
ion O O
transport O O
systems O O
in O O
eukaryotic O O
cells O O
. O O
In O O
contrast O O
, O O
polypropylene O O
glycol O O
, O O
PG O O
- O O
C O O
, O O
and O O
corn O O
oil O O
all O O
removed O O
68 O O
- O O
86 O O
% O O
of O O
the O O
MDI O O
in O O
the O O
first O O
h O O
, O O
74 O O
- O O
79 O O
% O O
at O O
4 O O
h O O
, O O
and O O
72 O O
- O O
86 O O
% O O
at O O
8 O O
h O O
. O O
DDD O O
( O O
R O O
) O O
pacing O O
with O O
automatic O O
mode O O
switch O O
in O O
patients O O
with O O
paroxysmal O O
atrial O O
fibrillation O O
following O O
AV O O
nodal O O
ablation O O
. O O
There O O
was O O
a O O
highly O O
significant O O
decrease O O
in O O
serum B-GENE B-GENE
eosinophil I-GENE I-GENE
cationic I-GENE I-GENE
protein E-GENE E-GENE
in O O
patients O O
with O O
elevated O O
AGA S-GENE O
. O O
Sequence O O
analysis O O
revealed O O
that O O
Hv B-GENE O
- I-GENE O
p68 E-GENE O
belongs O O
to O O
the O O
large O O
family O O
of O O
FAD B-GENE O
- I-GENE O
dependent I-GENE O
glucose I-GENE O
methanol I-GENE O
choline I-GENE O
oxidoreductases E-GENE O
and O O
that O O
it O O
shares O O
significant O O
sequence O O
identity O O
( O O
> O O
67 O O
% O O
) O O
with O O
the O O
alcohol B-GENE O
oxidases E-GENE O
of O O
the O O
methylotrophic O O
yeasts O O
. O O
It O O
is O O
required O O
for O O
correct O O
expression O O
of O O
both O O
genes O O
. O O
In O O
the O O
HIV B-GENE O
LTR E-GENE O
, O O
this O O
region O O
has O O
been O O
demonstrated O O
to O O
have O O
both O O
positive O O
and O O
negative O O
regulatory O O
effects O O
on O O
HIV O O
gene O O
expression O O
. O O
A O O
comparison O O
between O O
attenuation O O
- O O
corrected O O
and O O
- O O
uncorrected O O
transmission O O
- O O
emission O O
SPECT O O
images O O
obtained O O
with O O
Tl O O
- O O
201 O O
in O O
CAD O O
patients O O
Accumulation O O
of O O
amines O O
in O O
the O O
isolated O O
perfused O O
rabbit O O
lung O O
. O O
Since O O
it O O
is O O
often O O
necessary O O
to O O
resort O O
to O O
thoracotomy O O
as O O
a O O
final O O
step O O
in O O
making O O
such O O
a O O
diagnosis O O
, O O
we O O
have O O
sought O O
a O O
procedure O O
that O O
is O O
simpler O O
while O O
capable O O
of O O
providing O O
the O O
same O O
information O O
. O O
Both O O
control O O
and O O
Mn O O
- O O
exposed O O
quail O O
accumulated O O
5 O O
to O O
10 O O
times O O
more O O
Mn O O
in O O
their O O
livers O O
than O O
similarly O O
treated O O
rodents O O
. O O
Small B-GENE O
t E-GENE O
also O O
inhibited O O
the O O
dephosphorylation O O
of O O
cAMP B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PKA S-GENE S-GENE
) O O
- O O
phosphorylated O O
CREB S-GENE S-GENE
in O O
rat O O
liver O O
nuclear O O
extracts O O
. O O
A O O
retrospective O O
analysis O O
of O O
data O O
accumulated O O
over O O
a O O
21 O O
- O O
month O O
period O O
, O O
from O O
December O O
1989 O O
to O O
September O O
1991 O O
, O O
regarding O O
investigational O O
use O O
of O O
a O O
308 O O
nanometer O O
Xenon O O
Chloride O O
Excimer O O
Laser O O
Coronary O O
Angioplasty O O
( O O
ELCA O O
) O O
system O O
( O O
Advanced O O
Interventional O O
Systems O O
, O O
Inc O O
. O O
, O O
Irvine O O
, O O
CA O O
) O O
was O O
performed O O
. O O
Presently O O
, O O
we O O
made O O
chain O O
pair O O
switch O O
, O O
chimeric O O
, O O
and O O
site O O
mutant B-GENE O
gamma I-GENE O
delta I-GENE O
TCRs E-GENE S-GENE
and O O
transfected O O
them O O
into O O
TCR O S-GENE
- O O
mutant O O
Jurkat O O
T O O
cells O O
to O O
examine O O
the O O
effects O O
of O O
changing O O
the O O
TCR B-GENE B-GENE
gamma I-GENE E-GENE
junctional I-GENE O
region I-GENE O
sequences E-GENE O
on O O
reactivity O O
to O O
prenyl B-GENE O
pyrophosphate I-GENE O
Ags E-GENE O
. O O
Fos S-GENE O
/ O O
Jun S-GENE O
bound O O
to O O
an O O
unacetylated O O
nucleosome O O
with O O
only O O
a O O
4 O O
- O O
to O O
5 O O
- O O
fold O O
reduction O O
in O O
DNA O O
binding O O
affinity O O
compared O O
with O O
naked O O
DNA O O
. O O
Activated B-GENE O
Ki I-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
suppresses O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
activation O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
NH2 I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase I-GENE E-GENE
pathway E-GENE O
in O O
human O O
colon O O
cancer O O
cells O O
. O O
Electromobility O O
shift O O
analysis O O
using O O
oligonucleotides O O
encompassing O O
the O O
proximal O O
, O O
distal O O
, O O
and O O
BED O O
/ O O
AP B-GENE O
- I-GENE O
1 E-GENE O
- O O
binding O O
regions O O
failed O O
to O O
demonstrate O O
selective O O
transactivation O O
after O O
CD2 S-GENE O
signaling O O
of O O
LPMC O S-GENE
. O O
The O O
present O O
report O O
shows O O
that O O
a O O
cis O O
- O O
acting O O
element O O
between O O
- O O
189 O O
and O O
- O O
175 O O
bp O O
, O O
which O O
binds O O
thyroid B-GENE O
transcription I-GENE O
factor I-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
( O O
TTF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
, O O
is O O
involved O O
in O O
both O O
activities O O
. O O
Increased O O
platelet B-GENE O
- I-GENE O
derived I-GENE O
growth I-GENE O
factor E-GENE O
production O O
and O O
intimal O O
thickening O O
during O O
healing O O
of O O
Dacron O O
grafts O O
in O O
a O O
canine O O
model O O
. O O
Despite O O
their O O
high O O
degree O O
of O O
sequence O O
similarity O O
, O O
all O O
five O O
RFC B-GENE B-GENE
genes E-GENE E-GENE
are O O
essential O O
for O O
cell O O
proliferation O O
in O O
S O O
. O O
cerevisiae O O
. O O
Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B-GENE B-GENE
protein E-GENE I-GENE
E12 S-GENE E-GENE
in O O
this O O
macrophage O O
line O O
results O O
in O O
the O O
induction O O
of O O
many O O
B O O
lineage O O
genes O O
, O O
including O O
EBF S-GENE S-GENE
, O O
IL7Ralpha S-GENE S-GENE
, O O
lambda5 S-GENE O
, O O
and O O
Rag B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B-GENE O
light I-GENE O
chain E-GENE O
in O O
response O O
to O O
mitogen O O
. O O
Also O O
, O O
anti B-GENE O
- I-GENE O
HIV I-GENE O
gp120 E-GENE O
and O O
anti B-GENE O
- I-GENE O
CD4 E-GENE O
crosslinking O O
induced O O
a O O
10 O O
- O O
15 O O
- O O
fold O O
increase O O
in O O
levels O O
of O O
both O O
PI B-GENE O
3 I-GENE O
- I-GENE O
and I-GENE O
PI I-GENE B-GENE
4 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
in O O
anti B-GENE O
- I-GENE O
CD4 E-GENE O
precipitates O O
. O O
The O O
differences O O
of O O
percentages O O
for O O
HIV O O
- O O
1 O O
infection O O
in O O
intravenous O O
drug O O
users O O
( O O
IVDU O O
) O O
were O O
67 O O
. O O
7 O O
% O O
and O O
in O O
non O O
IVDU O O
were O O
3 O O
. O O
8 O O
% O O
with O O
a O O
significant O O
statistical O O
difference O O
( O O
chi O O
2 O O
= O O
557 O O
. O O
5 O O
; O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
. O O
One O O
of O O
the O O
ORFs O O
in O O
the O O
Methanococcus O O
jannaschii O O
genome O O
possesses O O
high O O
similarity O O
to O O
the O O
M B-GENE O
. I-GENE O
aeolicus I-GENE O
ilvB E-GENE O
, O O
indicating O O
that O O
it O O
is O O
an O O
authentic O O
AHAS S-GENE O
. O O
More O O
than O O
80 O O
% O O
appropriate O O
lever O O
responding O O
was O O
established O O
after O O
27 O O
, O O
38 O O
and O O
44 O O
daily O O
training O O
sessions O O
with O O
DN O O
- O O
2327 O O
, O O
diazepam O O
and O O
PTZ O O
, O O
respectively O O
, O O
as O O
the O O
training O O
drug O O
. O O
We O O
have O O
used O O
nuclear O O
magnetic O O
resonance O O
( O O
NMR O O
) O O
to O O
obtain O O
the O O
structure O O
of O O
an O O
RNA O O
" O O
kissing O O
" O O
hairpin O O
complex O O
formed O O
between O O
the O O
HIV O O
- O O
2 O O
TAR O O
hairpin O O
loop O O
and O O
a O O
hairpin O O
with O O
a O O
complementary O O
loop O O
sequence O O
. O O
RESULTS O O
: O O
In O O
men O O
, O O
weight O O
/ O O
height2 O O
met O O
the O O
criteria O O
for O O
a O O
satisfactory O O
index O O
in O O
that O O
there O O
was O O
a O O
very O O
strong O O
correlation O O
with O O
triceps O O
skinfold O O
, O O
and O O
a O O
negligible O O
correlation O O
with O O
height O O
. O O
PRP20 S-GENE S-GENE
is O O
related O O
, O O
both O O
in O O
structure O O
and O O
function O O
, O O
to O O
the O O
RCC1 B-GENE B-GENE
gene E-GENE E-GENE
of O O
mammals O O
and O O
the O O
PIM1 B-GENE B-GENE
gene E-GENE E-GENE
of O O
Schizosaccharomyces O O
pombe O O
, O O
both O O
of O O
which O O
appear O O
to O O
regulate O O
entry O O
into O O
mitosis O O
and O O
chromosome O O
condensation O O
. O O
No O O
consensus O O
binding O O
sequence O O
could O O
be O O
discerned O O
in O O
these O O
fragments O O
and O O
bound O O
factor O O
is O O
in O O
rapid O O
equilibrium O O
with O O
unbound O O
. O O
A O O
selective O O
transcriptional O O
induction O O
system O O
for O O
mammalian O O
cells O O
based O O
on O O
Gal4 S-GENE B-GENE
- O I-GENE
estrogen B-GENE I-GENE
receptor E-GENE I-GENE
fusion O I-GENE
proteins O E-GENE
. O O
Kinase O O
renaturation O O
tests O O
designed O O
to O O
detect O O
reactivated O O
protein O O
kinases O O
after O O
electrophoresis O O
in O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gels O O
revealed O O
the O O
presence O O
of O O
a O O
60 O O
- O O
kDa O O
kinase O O
in O O
the O O
washed O O
immunoprecipitate O O
obtained O O
from O O
liver O O
cytosol O O
using O O
anti B-GENE B-GENE
- I-GENE I-GENE
AHR I-GENE I-GENE
antibody E-GENE E-GENE
( O O
IgG S-GENE S-GENE
) O O
and O O
protein O O
A O O
/ O O
G O O
/ O O
agarose O O
beads O O
but O O
not O O
when O O
a O O
nonspecific O O
IgG S-GENE S-GENE
was O O
used O O
instead O O
of O O
anti B-GENE B-GENE
- I-GENE I-GENE
AHR I-GENE I-GENE
antibody E-GENE E-GENE
. O O
Immunoblotting O O
using O O
a O O
phosphospecific B-GENE O
anti I-GENE O
- I-GENE O
Src I-GENE S-GENE
( I-GENE O
416Y I-GENE S-GENE
) I-GENE O
antibody E-GENE O
showed O O
a O O
ceramide O O
- O O
induced O O
increase O O
in O O
pp60 S-GENE S-GENE
( O O
src S-GENE S-GENE
) O O
tyrosine O O
phosphorylation O O
. O O
In O O
contrast O O
, O O
dominant B-GENE O
negative I-GENE O
Rac E-GENE O
( O O
N17Rac1 S-GENE S-GENE
) O O
inhibited O O
JNK S-GENE S-GENE
activation O O
by O O
Galpha12 S-GENE S-GENE
in O O
HEK293 O O
cells O O
as O O
well O O
as O O
three O O
other O O
cell O O
lines O O
. O O
Metabolic O O
studies O O
of O O
tetrabenazine O O
, O O
a O O
psychotropic O O
drug O O
in O O
animals O O
and O O
man O O
. O O
Reading O O
disability O O
in O O
twins O O
. O O
These O O
results O O
suggest O O
that O O
1a S-GENE O
, O O
which O O
also O O
interacts O O
independently O O
with O O
the O O
ER O S-GENE
and O O
viral O O
RNA O O
, O O
is O O
a O O
key O O
organizer O O
of O O
RNA O O
replication O O
complex O O
assembly O O
. O O
HrpE S-GENE S-GENE
is O O
similar O O
to O O
YscL S-GENE O
of O O
Yersinia O O
spp O O
. O O
Effect O O
of O O
a O O
high O O
sugar O O
intake O O
on O O
some O O
metabolic O O
and O O
regulatory O O
indicators O O
in O O
young O O
men O O
. O O
Production O O
of O O
a O O
chicken O O
meat O O
infusion O O
broth O O
suitable O O
for O O
the O O
mass O O
production O O
of O O
a O O
Haemophilus O O
gallinarum O O
bacterin O O
. O O
The O O
results O O
indicate O O
that O O
expression O O
of O O
proU S-GENE O
in O O
E O O
. O O
coli O O
is O O
directed O O
from O O
two O O
promoters O O
, O O
one O O
( O O
P2 O O
) O O
characterized O O
earlier O O
by O O
other O O
workers O O
with O O
the O O
start O O
site O O
of O O
transcription O O
60 O O
nucleotides O O
upstream O O
of O O
the O O
initiation O O
codon O O
of O O
the O O
first O O
structural O O
gene O O
( O O
proV S-GENE O
) O O
, O O
and O O
the O O
other O O
( O O
P1 O O
) O O
situated O O
250 O O
nucleotides O O
upstream O O
of O O
proV S-GENE O
. O O
The O O
maximal O O
rise O O
in O O
plasma O O
adrenaline O O
was O O
of O O
similar O O
magnitude O O
in O O
all O O
three O O
groups O O
but O O
a O O
lower O O
plasma O O
glucose O O
was O O
required O O
to O O
stimulate O O
this O O
hormonal O O
response O O
in O O
the O O
' O O
unaware O O
' O O
patients O O
, O O
in O O
whom O O
the O O
plasma O O
adrenaline O O
concentration O O
was O O
lower O O
at O O
the O O
time O O
of O O
the O O
reaction O O
. O O
Through O O
interactions O O
with O O
the O O
pre O O
- O O
mRNA O O
and O O
the O O
CTD O B-GENE
domain O E-GENE
of O O
the O O
Polymerase B-GENE B-GENE
II E-GENE E-GENE
, O O
SR B-GENE B-GENE
proteins E-GENE E-GENE
have O O
been O O
shown O O
to O O
regulate O O
alternative O O
splicing O O
. O O
One O O
child O O
, O O
recently O O
fed O O
, O O
vomited O O
a O O
small O O
amount O O
of O O
breast O O
milk O O
after O O
a O O
short O O
period O O
of O O
crying O O
and O O
apparently O O
had O O
a O O
laryngospasm O O
, O O
shown O O
by O O
a O O
sudden O O
drop O O
in O O
the O O
PtcO2 O O
level O O
without O O
any O O
other O O
signs O O
of O O
discomfort O O
. O O
Changes O O
in O O
the O O
size O O
and O O
organisation O O
of O O
the O O
brain O O
in O O
man O O
and O O
his O O
ancestors O O
. O O
Only O O
Staphylococcus O O
xylosus O O
SX63 O O
was O O
detected O O
as O O
a O O
strain O O
with O O
high O O
adherence O O
activity O O
. O O
It O O
also O O
produces O O
an O O
NH2 O O
terminus O O
that O O
corresponds O O
to O O
an O O
equivalent O O
NH2 O O
terminus O O
on O O
the O O
processed O O
matrix O O
form O O
of O O
the O O
similar O O
alpha1 B-GENE O
( I-GENE O
XI I-GENE O
) I-GENE O
chain E-GENE O
, O O
thus O O
suggesting O O
physiological O O
significance O O
. O O
Transmission O O
of O O
mutans O O
streptococci O O
to O O
infants O O
following O O
short O O
term O O
application O O
of O O
an O O
iodine O O
- O O
NaF O O
solution O O
to O O
mothers O O
' O O
dentition O O
. O O
Expression O O
of O O
Msx B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
Msx B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
has O O
been O O
studied O O
during O O
development O O
of O O
the O O
osteoblast O O
phenotype O O
, O O
but O O
the O O
role O O
of O O
Dlx S-GENE S-GENE
in O O
this O O
context O O
and O O
in O O
the O O
regulation O O
of O O
bone O O
- O O
expressed O O
genes O O
is O O
unknown O O
. O O
Scalp O O
blood O O
flow O O
was O O
recorded O O
by O O
a O O
laser O O
Doppler O O
flow O O
sensor O O
that O O
was O O
incorporated O O
in O O
the O O
transcutaneous O O
PO2 O O
electrode O O
. O O
DESIGN O O
: O O
Activating B-GENE O
protein I-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
( O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
and O O
Tat S-GENE O
- O O
induced O O
transcription O O
were O O
assessed O O
using O O
Jun S-GENE S-GENE
and O O
hybrid O O
Tat S-GENE S-GENE
/ O O
Jun S-GENE S-GENE
- O O
expression O O
plasmids O O
and O O
reporter O O
gene O O
constructs O O
which O O
contained O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
binding I-GENE O
sites E-GENE O
upstream O O
of O O
the O O
rat B-GENE B-GENE
prolactin I-GENE I-GENE
TATAA I-GENE I-GENE
element E-GENE E-GENE
or O O
an O O
HIV B-GENE O
- I-GENE O
1 I-GENE O
LTR I-GENE O
construct E-GENE O
in O O
which O O
AP B-GENE O
- I-GENE O
1 I-GENE O
binding I-GENE O
sites E-GENE O
replaced O O
the O O
TAR O O
element O O
. O O
Mycobacterium O O
tuberculosis O O
inhibits O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
transcriptional O O
responses O O
without O O
inhibiting O O
activation O O
of O O
STAT1 S-GENE S-GENE
. O O
Rabbit B-GENE O
KCC1 E-GENE O
( O O
rbKCC1 S-GENE O
) O O
and O O
rat B-GENE O
KCC1 E-GENE O
( O O
rtKCC1 S-GENE O
) O O
were O O
cloned O O
by O O
screening O O
rabbit O O
kidney O O
and O O
rat O O
brain O O
cDNA O O
libraries O O
using O O
homologous O O
cDNA O O
probes O O
. O O
However O O
, O O
using O O
wet O O
weight O O
/ O O
dry O O
weight O O
methodology O O
, O O
we O O
found O O
that O O
administration O O
of O O
U74006F O O
significantly O O
reduced O O
water O O
content O O
in O O
the O O
right O O
hippocampus O O
( O O
contralateral O O
to O O
the O O
site O O
of O O
injury O O
) O O
compared O O
to O O
saline O O
- O O
treated O O
animals O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O
GH S-GENE S-GENE
stimulated O O
the O O
activity O O
of O O
promoter O O
fragments O O
with O O
5 O O
' O O
- O O
ends O O
between O O
nucleotide O O
( O O
nt O O
) O O
- O O
2001 O O
and O O
nt O O
- O O
653 O O
by O O
1 O O
. O O
9 O O
- O O
to O O
2 O O
. O O
7 O O
- O O
fold O O
. O O
We O O
have O O
recently O O
shown O O
that O O
induced O O
expression O O
of O O
a O O
CDK S-GENE S-GENE
target O O
site O O
- O O
deficient O O
mutant O O
, O O
Op18 S-GENE B-GENE
- O I-GENE
S25A O E-GENE
, O O
S38A O S-GENE
, O O
blocks O O
human O O
cell O O
lines O O
during O O
G2 O O
/ O O
M O O
transition O O
. O O
A O O
protein O O
which O O
promotes O O
DNA O O
strand O O
transfer O O
between O O
linear O O
double O O
- O O
stranded O O
M13mp19 O O
DNA O O
and O O
single O O
- O O
stranded O O
viral O O
M13mp19 O O
DNA O O
has O O
been O O
isolated O O
from O O
recA B-GENE O
- E-GENE O
E O O
. O O
coli O O
. O O
The O O
brains O O
were O O
processed O O
according O O
to O O
the O O
tetramethylbenzidine O O
( O O
TMB O O
) O O
protocol O O
of O O
Mesulam O O
( O O
' O O
78 O O
) O O
and O O
studied O O
with O O
darkfield O O
microscopy O O
. O O
Seizure O O
recurrence O O
( O O
HR O O
1 O O
. O O
30 O O
; O O
95 O O
% O O
CI O O
= O O
0 O O
. O O
84 O O
, O O
2 O O
. O O
01 O O
) O O
and O O
antiepileptic O O
drug O O
treatment O O
( O O
HR O O
0 O O
. O O
97 O O
; O O
95 O O
% O O
CI O O
= O O
0 O O
. O O
67 O O
, O O
1 O O
. O O
38 O O
) O O
did O O
not O O
influence O O
mortality O O
rate O O
. O O
One O O
day O O
postoperatively O O
, O O
the O O
mononuclear O B-GENE
leukocyte O I-GENE
beta B-GENE I-GENE
2 I-GENE I-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
density O O
decreased O O
maximally O O
by O O
45 O O
+ O O
/ O O
- O O
11 O O
% O O
in O O
the O O
enflurane O O
patients O O
, O O
and O O
by O O
53 O O
+ O O
/ O O
- O O
6 O O
% O O
in O O
the O O
neurolept O O
patients O O
. O O
The O O
serum O O
levels O O
of O O
cortisol O O
and O O
prolactin S-GENE O
after O O
nasal O O
instillation O O
of O O
a O O
suspension O O
of O O
vaginal O O
exudate O O
showed O O
lower O O
values O O
than O O
in O O
control O O
conditions O O
( O O
nasal O O
instillation O O
of O O
saline O O
) O O
. O O
IgE B-GENE S-GENE
antibody E-GENE O
to O O
twelve O O
common O O
food O O
and O O
inhalant O O
allergens O O
was O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
in O O
the O O
sera O O
of O O
thirteen O O
atopic O O
patients O O
with O O
one O O
or O O
more O O
allergic O O
disorders O O
( O O
asthma O O
occurring O O
in O O
eleven O O
; O O
rhinitis O O
in O O
ten O O
; O O
eczema O O
in O O
six O O
; O O
urticaria O O
in O O
four O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
six O O
) O O
, O O
of O O
twelve O O
non O O
- O O
atopic O O
patients O O
with O O
various O O
clinical O O
symptoms O O
( O O
asthma O O
in O O
four O O
; O O
rhinitis O O
in O O
four O O
; O O
eczema O O
in O O
one O O
; O O
urticaria O O
in O O
two O O
; O O
mouth O O
and O O
gastro O O
- O O
intestinal O O
symptoms O O
in O O
four O O
) O O
and O O
sixteen O O
cord O O
blood O O
sera O O
. O O
Innervation O O
of O O
reticular O O
papillae O O
in O O
sheep O O
and O O
goats O O
. O O
Biochemical O O
status O O
was O O
examined O O
using O O
erythrocyte O O
enzyme O O
function O O
and O O
blood O O
vitamin O O
levels O O
. O O
Sexual O O
adventurism O O
, O O
high O O
- O O
risk O O
behavior O O
, O O
and O O
human O O
immunodeficiency O O
virus O O
- O O
1 O O
seroconversion O O
among O O
the O O
Chicago O O
MACS O O
- O O
CCS O O
cohort O O
, O O
1984 O O
to O O
1992 O O
. O O
Pendulin S-GENE O
, O O
a O O
Drosophila O O
protein O O
with O O
cell O O
cycle O O
- O O
dependent O O
nuclear O O
localization O O
, O O
is O O
required O O
for O O
normal O O
cell O O
proliferation O O
. O O
Paradoxically O O
there O O
is O O
a O O
decrease O O
in O O
the O O
level O O
of O O
soluble B-GENE O
A I-GENE O
beta E-GENE O
secreted O O
from O O
the O O
cells O O
. O O
Signaling O O
through O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
and O O
Rac S-GENE S-GENE
/ O O
Rho S-GENE S-GENE
does O O
not O O
duplicate O O
the O O
effects O O
of O O
activated O O
Ras S-GENE O
on O O
skeletal O O
myogenesis O O
. O O
Internalization O O
of O O
prolactin B-GENE B-GENE
receptor E-GENE E-GENE
and O O
prolactin S-GENE O
in O O
transfected O O
cells O O
does O O
not O O
involve O O
nuclear O O
translocation O O
. O O
Using O O
mammalian O O
expression O O
vectors O O
( O O
pRSV O S-GENE
- O O
neo O O
and O O
pSV2 O B-GENE
- O I-GENE
neo O E-GENE
) O O
, O O
antisense O O
constructs O O
for O O
perforin S-GENE O
and O O
granzyme B-GENE O
B E-GENE O
were O O
independently O O
electroporated O O
into O O
YT O O
- O O
INDY O O
, O O
a O O
human O O
non O O
- O O
MHC S-GENE O
- O O
restricted O O
, O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
- O O
independent O O
, O O
cytotoxic O O
lymphocyte O O
. O O
When O O
expressed O O
in O O
Escherichia O O
coli O O
, O O
SH B-GENE O
- I-GENE O
PTP2 E-GENE O
displays O O
tyrosine B-GENE O
- I-GENE O
specific I-GENE O
phosphatase E-GENE O
activity O O
. O O
The O O
structure O O
elucidation O O
of O O
the O O
iridoid O O
compounds O O
2 O O
and O O
3 O O
are O O
discussed O O
in O O
detail O O
. O O
The O O
results O O
of O O
a O O
study O O
to O O
investigate O O
the O O
effectiveness O O
of O O
a O O
propolis O O
- O O
containing O O
mouthrinse O O
in O O
the O O
inhibition O O
of O O
de O O
novo O O
plaque O O
formation O O
are O O
presented O O
. O O
Effects O O
of O O
shosaikoto O O
, O O
an O O
oriental O O
herbal O O
medicinal O O
mixture O O
, O O
on O O
restraint O O
- O O
stressed O O
mice O O
. O O
The O O
region O O
surrounding O O
the O O
ZNF35 B-GENE B-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
protein I-GENE I-GENE
gene E-GENE E-GENE
on O O
3p21 O S-GENE
is O O
of O O
particular O O
interest O O
, O O
as O O
this O O
region O O
of O O
chromosome O O
3 O O
is O O
frequently O O
involved O O
in O O
rearrangements O O
and O O
/ O O
or O O
deletions O O
associated O O
with O O
various O O
human O O
tumors O O
including O O
lung O O
and O O
renal O O
carcinoma O O
. O O
In O O
the O O
promoters O O
of O O
many O O
immediate B-GENE O
early I-GENE O
genes E-GENE O
, O O
including O O
c B-GENE B-GENE
- I-GENE I-GENE
fos E-GENE E-GENE
, O O
CArG O O
DNA O O
regulatory O O
elements O O
mediate O O
basal O O
constituitive O O
expression O O
and O O
rapid O O
and O O
transient O O
serum O O
induction O O
. O O
The O O
biological O O
activity O O
of O O
these O O
mutants O O
was O O
tested O O
by O O
determining O O
their O O
capacity O O
to O O
( O O
i O O
) O O
reconstitute O O
RNA B-GENE O
polymerase E-GENE O
activity O O
in O O
vivo O O
by O O
cotransfection O O
with O O
proteins O O
NP S-GENE S-GENE
, O O
PB1 S-GENE S-GENE
, O O
and O O
PA S-GENE S-GENE
and O O
a O O
virion O O
- O O
like O O
RNA O O
encoding O O
the O O
cat S-GENE O
gene O O
into O O
vaccinia O O
virus O O
T7 O O
- O O
infected O O
COS O O
- O O
1 O O
cells O O
and O O
( O O
ii O O
) O O
complete O O
with O O
the O O
wild B-GENE O
- I-GENE O
type I-GENE O
PB2 E-GENE O
activity O O
. O O
Transient O O
thyrotoxicosis O O
in O O
primary O O
anti O O
- O O
phospholipid O O
syndrome O O
. O O
We O O
were O O
unable O O
to O O
construct O O
chvI S-GENE O
or O O
chvG B-GENE O
insertion I-GENE O
mutants E-GENE O
of O O
R O O
. O O
meliloti O O
, O O
whereas O O
mutants O O
carrying O O
insertions O O
outside O O
of O O
these O O
genes O O
were O O
readily O O
obtained O O
. O O
Western O O
blot O O
analyses O O
reveals O O
that O O
cJun S-GENE S-GENE
and O O
the O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
family I-GENE E-GENE
member E-GENE O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
are O O
physiologically O O
relevant O O
transcription O O
factors O O
whose O O
expression O O
corresponds O O
with O O
mda B-GENE B-GENE
- I-GENE I-GENE
7 I-GENE I-GENE
mRNA E-GENE E-GENE
expression O O
. O O
In O O
isolated O O
olfactory O O
cilia O O
certain O O
odorants O O
elicit O O
a O O
rapid O O
and O O
transient O O
cAMP O O
response O O
, O O
terminated O O
by O O
a O O
concerted O O
process O O
which O O
requires O O
the O O
action O O
of O O
two O O
protein O O
kinases O O
, O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
A E-GENE E-GENE
( O O
PKA S-GENE S-GENE
) O O
and O O
a O O
receptor B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
kinase E-GENE E-GENE
( O O
GRK3 S-GENE S-GENE
) O O
( O O
Schleicher O O
, O O
S O O
. O O
, O O
Boekhoff O O
, O O
I O O
. O O
Acetyl B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
carboxylase E-GENE E-GENE
from O O
yeast O O
is O O
an O O
essential O O
enzyme O O
and O O
is O O
regulated O O
by O O
factors O O
that O O
control O O
phospholipid O O
metabolism O O
. O O
To O O
investigate O O
the O O
role O O
of O O
this O O
domain O O
in O O
the O O
incorporation O O
of O O
the O O
SIV B-GENE B-GENE
Env E-GENE E-GENE
into O O
virions O O
, O O
we O O
generated O O
a O O
series O O
of O O
SIV B-GENE B-GENE
Env I-GENE I-GENE
mutants E-GENE E-GENE
carrying O O
small O O
in O O
- O O
frame O O
deletions O O
within O O
the O O
cytoplasmic O O
domain O O
. O O
Computer O O
analysis O O
, O O
simple O O
correlation O O
hypothesis O O
, O O
and O O
distribution O O
method O O
with O O
1 O O
degree O O
of O O
freedom O O
revealed O O
significant O O
correlation O O
between O O
vertical O O
root O O
fracture O O
and O O
the O O
technique O O
of O O
instrumentation O O
and O O
obturation O O
of O O
the O O
canal O O
( O O
p O O
= O O
0 O O
. O O
025 O O
) O O
, O O
the O O
length O O
of O O
the O O
post O O
( O O
p O O
= O O
0 O O
. O O
05 O O
) O O
, O O
and O O
the O O
existence O O
of O O
the O O
post O O
( O O
p O O
= O O
0 O O
. O O
05 O O
) O O
. O O
Minute B-GENE O
virus I-GENE O
of I-GENE O
mice I-GENE O
NS1 E-GENE O
, O O
an O O
83 O O
- O O
kDa O O
mainly O O
nuclear O O
phosphoprotein O O
, O O
is O O
the O O
only O O
viral O O
nonstructural O O
protein O O
required O O
in O O
all O O
cell O O
types O O
and O O
it O O
is O O
involved O O
in O O
multiple O O
processes O O
necessary O O
for O O
virus O O
propagation O O
. O O
The O O
TDx O O
assay O O
for O O
cyclosporine O O
and O O
its O O
metabolites O O
in O O
blood O O
samples O O
compared O O
with O O
HPLC O O
and O O
RIA O O
methods O O
. O O
However O O
, O O
the O O
sequence O O
of O O
mRAR B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
3 I-GENE E-GENE
region I-GENE O
A E-GENE O
differs O O
from O O
that O O
of O O
mRAR B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
1 E-GENE E-GENE
by O O
an O O
additional O O
27 O O
C O O
- O O
terminal O O
amino O O
acids O O
encoded O O
in O O
an O O
81 O O
nucleotide O O
- O O
long O O
putative O O
exon O O
which O O
is O O
spliced O O
in O O
between O O
the O O
exons O O
encoding O O
the O O
A B-GENE O
and I-GENE O
B I-GENE O
regions I-GENE O
of I-GENE O
mRAR I-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
1 E-GENE E-GENE
. O O
We O O
propose O O
that O O
GCD7 S-GENE S-GENE
and O O
GCD2 S-GENE S-GENE
play O O
important O O
roles O O
in O O
the O O
regulatory O O
interaction O O
between O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2B E-GENE E-GENE
and O O
that O O
the O O
suppressor O O
mutations O O
we O O
isolated O O
in O O
these O O
genes O O
decrease O O
the O O
susceptibility O O
of O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2B E-GENE E-GENE
to O O
the O O
inhibitory O O
effects O O
of O O
phosphorylated O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
without O O
impairing O O
the O O
essential O O
catalytic O O
function O O
of O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2B E-GENE E-GENE
in O O
translation O O
initiation O O
. O O
The O O
3 O O
' O O
region O O
of O O
the O O
transcript O O
contained O O
a O O
fully O O
conserved O O
, O O
correctly O O
spliced O O
TCR B-GENE B-GENE
alpha I-GENE I-GENE
C I-GENE E-GENE
region E-GENE O
which O O
was O O
polyadenylated O O
at O O
the O O
3 O O
' O O
end O O
. O O
These O O
data O O
demonstrate O O
that O O
CCTalpha S-GENE S-GENE
can O O
be O O
regulated O O
by O O
lipids O O
by O O
two O O
independent O O
domains O O
: O O
( O O
i O O
) O O
the O O
three O O
amphipathic O O
alpha O O
- O O
helical O O
repeats O O
that O O
interact O O
with O O
both O O
neutral O O
and O O
anionic O O
lipid O O
mixtures O O
and O O
( O O
ii O O
) O O
the O O
last O O
57 O O
residues O O
that O O
interact O O
with O O
anionic O O
lipids O O
. O O
Sorting O O
information O O
to O O
the O O
chloroplastic O O
inner O O
envelope O O
is O O
contained O O
in O O
an O O
NH2 O O
- O O
proximal O O
part O O
of O O
mature B-GENE O
IEP110 E-GENE O
( O O
110N S-GENE O
) O O
. O O
Most O O
of O O
these O O
elements O O
are O O
adjacent O O
to O O
type O O
X O O
telomeric O O
repeats O O
, O O
and O O
regions O O
flanking O O
four O O
of O O
five O O
characterized O O
S O O
. O O
paradoxus O O
insertions O O
carry O O
autonomously O O
replicating O O
sequences O O
. O O
From O O
1981 O O
to O O
1989 O O
, O O
a O O
total O O
of O O
26 O O
women O O
with O O
locally O O
or O O
regionally O O
advanced O O
carcinoma O O
of O O
the O O
uterine O O
cervix O O
were O O
treated O O
with O O
radiotherapy O O
( O O
RT O O
) O O
and O O
pelvic O O
regional O O
hyperthermia O O
( O O
HT O O
) O O
, O O
in O O
the O O
Divisions O O
of O O
Radiation O O
Oncology O O
at O O
the O O
University O O
of O O
Utah O O
Medical O O
Center O O
( O O
UU O O
) O O
and O O
the O O
Kenneth O O
Norris O O
Jr O O
Cancer O O
Hospital O O
of O O
the O O
University O O
of O O
Southern O O
California O O
( O O
USC O O
) O O
. O O
The O O
ARE O O
is O O
loosely O O
defined O O
as O O
the O O
five O O
- O O
nucleotide O O
sequence O O
AUUUA O O
embedded O O
in O O
a O O
uracil O O
- O O
rich O O
region O O
. O O
Lack O O
of O O
changes O O
in O O
milk O O
production O O
and O O
milk O O
composition O O
suggest O O
that O O
acute O O
increases O O
in O O
somatotropin S-GENE O
with O O
concomitant O O
increases O O
in O O
insulin S-GENE O
are O O
not O O
sufficient O O
to O O
stimulate O O
synthesis O O
of O O
milk O O
and O O
milk O O
components O O
by O O
cows O O
during O O
established O O
lactation O O
. O O
The O O
material O O
then O O
was O O
cut O O
with O O
a O O
diamond O O
saw O O
into O O
sheets O O
of O O
8 O O
x O O
10 O O
x O O
3 O O
mm O O
, O O
and O O
the O O
upper O O
surface O O
was O O
polished O O
by O O
colloidal O O
SiO2 O O
and O O
/ O O
or O O
covered O O
with O O
a O O
carbon O O
- O O
titanium O O
( O O
C O O
: O O
Ti O O
) O O
layer O O
( O O
3 O O
. O O
3 O O
microm O O
) O O
using O O
the O O
plasma O O
- O O
enhanced O O
physical O O
vapor O O
deposition O O
method O O
. O O
Iomazenil O O
- O O
SPECT O O
revealed O O
a O O
highly O O
significant O O
increase O O
in O O
the O O
benzodiazepine B-GENE O
receptor E-GENE O
uptake O O
in O O
all O O
studied O O
cortical O O
regions O O
except O O
temporal O O
cortices O O
. O O
Both O O
in O O
the O O
Federal O O
Republic O O
of O O
Germany O O
and O O
in O O
some O O
neighbouring O O
countries O O
the O O
epizootic O O
situation O O
of O O
Aujeszky O O
' O O
s O O
disease O O
has O O
been O O
unsatisfactory O O
for O O
a O O
long O O
time O O
, O O
especially O O
in O O
areas O O
with O O
a O O
high O O
pig O O
density O O
. O O
Since O O
RIP140 S-GENE S-GENE
generally O O
down O O
- O O
regulates O O
receptor O O
activity O O
in O O
mammalian O O
cells O O
and O O
specifically O O
down O O
- O O
regulates O O
coactivation O O
mediated O O
by O O
SRC B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
we O O
propose O O
a O O
model O O
in O O
which O O
RIP140 S-GENE S-GENE
indirectly O O
regulates O O
nuclear B-GENE O
receptor I-GENE O
AF I-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
activity O O
by O O
competition O O
for O O
coactivators O O
such O O
as O O
SRC B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
DIC O O
and O O
low O O
grade O O
fibrinolysis O O
may O O
account O O
for O O
the O O
coagulation O O
abnormalities O O
of O O
the O O
syndrome O O
. O O
As O O
in O O
the O O
case O O
of O O
the O O
chicken O O
homologue O O
, O O
there O O
are O O
two O O
hPR S-GENE O
forms O O
, O O
A O O
and O O
B O O
, O O
which O O
originate O O
from O O
translational O O
initiation O O
at O O
AUG2 O O
( O O
codon O O
165 O O
) O O
and O O
AUG1 O O
, O O
respectively O O
. O O
Fluctuations O O
of O O
the O O
measured O O
ECF O O
energy O O
- O O
related O O
substances O O
corresponded O O
to O O
various O O
clinical O O
events O O
presumably O O
involving O O
hypoxia O O
/ O O
ischemia O O
. O O
Using O O
lasers O O
in O O
diabetic O O
wound O O
healing O O
. O O
Furthermore O O
, O O
the O O
zincon O O
- O O
loaded O O
resin O O
was O O
applied O O
to O O
the O O
selective O O
concentration O O
of O O
trace O O
amounts O O
of O O
chalcophile O O
elements O O
in O O
natural O O
water O O
samples O O
prior O O
to O O
neutron O O
activation O O
analysis O O
. O O
In O O
cells O O
stably O O
transfected O O
with O O
G B-GENE B-GENE
alpha I-GENE I-GENE
i I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE I-GENE
or O I-GENE
G B-GENE I-GENE
alpha I-GENE I-GENE
i I-GENE I-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
gene E-GENE E-GENE
5 O O
' O O
- O O
flanking O O
sequences O O
fused O O
to O O
firefly O O
luciferase S-GENE O
cDNA O O
reporter O O
, O O
temporal O O
10 O O
- O O
15 O O
- O O
fold O O
transcriptional O O
activation O O
of O O
both O O
genes O O
occurred O O
before O O
cellular O O
polarization O O
. O O
CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
histamine B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
receptor E-GENE E-GENE
activation O O
mechanisms O O
may O O
not O O
be O O
involved O O
in O O
postoperative O O
IL B-GENE O
- I-GENE O
6 E-GENE O
synthesis O O
. O O
In O O
resume O O
response O O
to O O
treatment O O
with O O
usual O O
regimens O O
, O O
doxycycline O O
plus O O
streptomycin O O
of O O
doxycycline O O
rifampicin O O
is O O
good O O
, O O
being O O
however O O
time O O
elapsed O O
until O O
pain O O
ceases O O
of O O
mean O O
length O O
in O O
hospital O O
stay O O
shorter O O
in O O
the O O
group O O
receiving O O
doxycycline O O
plus O O
streptomycin O O
. O O
Fibrosis O O
of O O
the O O
adjacent O O
myocardium O O
was O O
seen O O
in O O
five O O
cases O O
. O O
Purified O O
preparations O O
of O O
all O O
four O O
AGT O O
mutants O O
showed O O
an O O
approximately O O
similar O O
degree O O
( O O
74 O O
- O O
120 O O
- O O
fold O O
) O O
of O O
reduction O O
in O O
the O O
rate O O
of O O
reaction O O
with O O
O6 O O
- O O
benzylguanine O O
. O O
Significant O O
reductions O O
were O O
noted O O
in O O
vertical O O
GRFs O O
per O O
newton O O
of O O
body O O
weight O O
exerted O O
at O O
10 O O
% O O
( O O
P O O
= O O
0 O O
. O O
0009 O O
) O O
and O O
20 O O
% O O
( O O
P O O
= O O
0 O O
. O O
0383 O O
) O O
of O O
stance O O
phase O O
and O O
in O O
anteroposterior O O
GRFs O O
exerted O O
at O O
10 O O
% O O
( O O
P O O
= O O
0 O O
. O O
0009 O O
) O O
and O O
50 O O
% O O
( O O
P O O
= O O
0 O O
. O O
0033 O O
) O O
of O O
stance O O
phase O O
when O O
ambulation O O
was O O
compared O O
with O O
and O O
without O O
the O O
orthotic O O
device O O
. O O
Identification O O
of O O
a O O
68 B-GENE O
- I-GENE O
kilodalton I-GENE O
nuclear I-GENE O
ATP I-GENE O
- I-GENE O
binding I-GENE O
phosphoprotein E-GENE O
encoded O O
by O O
bovine O O
papillomavirus O O
type O O
1 O O
. O O
It O O
is O O
suggested O O
that O O
biliary O O
secretion O O
of O O
both O O
TBZ O S-GENE
and O O
FBZ O S-GENE
and O O
their O O
metabolites O O
may O O
contribute O O
to O O
this O O
recycling O O
. O O
During O O
chordotonal O O
organ O O
development O O
, O O
the O O
3 O O
' O O
enhancer O O
directs O O
expression O O
in O O
proneural O O
clusters O O
; O O
whereas O O
successive O O
modular O O
enhancers O O
located O O
in O O
the O O
5 O O
' O O
region O O
drive O O
tissue O O
- O O
specific O O
expression O O
in O O
chordotonal O O
organ O O
precursors O O
in O O
the O O
embryo O O
and O O
larval O O
leg O O
, O O
wing O O
and O O
antennal O O
imaginal O O
discs O O
. O O
The O O
use O O
of O O
self O O
- O O
measured O O
blood O O
pressure O O
determinations O O
in O O
assessing O O
dynamics O O
of O O
drug O O
compliance O O
in O O
a O O
study O O
with O O
amlodipine O O
once O O
a O O
day O O
, O O
morning O O
versus O O
evening O O
. O O
Nucleocapsid O O
structure O O
and O O
thermostability O O
of O O
the O O
virion O O
, O O
nucleocapsid O O
and O O
polymerase O O
complex O O
. O O
A O O
vascular O O
component O O
to O O
impotence O O
was O O
shown O O
to O O
be O O
common O O
in O O
those O O
with O O
neurological O O
impairment O O
, O O
and O O
may O O
alter O O
management O O
. O O
RESULTS O O
- O O
- O O
The O O
maximal O O
early O O
asthmatic O O
response O O
after O O
allergen O O
with O O
placebo O O
treatment O O
was O O
18 O O
. O O
4 O O
% O O
( O O
SE O O
4 O O
. O O
4 O O
% O O
) O O
and O O
with O O
WEB O O
2086 O O
18 O O
. O O
9 O O
% O O
( O O
4 O O
. O O
4 O O
% O O
) O O
. O O
Column O O
chromatographic O O
determination O O
of O O
polymyxin O O
B O O
sulfate O O
. O O
Usefulness O O
of O O
computerized O O
tomography O O
in O O
hemodialysis O O
patients O O
. O O
The O O
aim O O
of O O
our O O
study O O
was O O
to O O
determine O O
whether O O
exercise O O
training O O
can O O
augment O O
left O O
ventricular O O
diastolic O O
filling O O
at O O
rest O O
and O O
during O O
exercise O O
in O O
patients O O
with O O
ischemic O O
cardiomyopathy O O
and O O
whether O O
any O O
correlation O O
exists O O
between O O
changes O O
in O O
diastolic O O
filling O O
and O O
changes O O
in O O
exercise O O
tolerance O O
. O O
On O O
the O O
pharmacology O O
of O O
9 O O
, O O
10 O O
- O O
dihydro O O
- O O
10 O O
- O O
( O O
1 O O
- O O
methyl O O
- O O
4 O O
- O O
piperidylidene O O
) O O
- O O
9 O O
- O O
anthrol O O
( O O
WA O O
335 O O
) O O
, O O
a O O
histamine O O
and O O
serotonin O O
antagonist O O
METHODOLOGY O O
: O O
A O O
case O O
control O O
study O O
of O O
survivors O O
with O O
gestational O O
age O O
( O O
GA O O
) O O
< O O
28 O O
weeks O O
or O O
birthweight O O
( O O
BW O O
) O O
< O O
1000 O O
g O O
using O O
data O O
collected O O
prospectively O O
in O O
our O O
Neonatal O O
Intensive O O
Care O O
Unit O O
database O O
. O O
There O O
are O O
two O O
regulatory O O
regions O O
between O O
the O O
US3 S-GENE O
and O O
the O O
US6 B-GENE O
transcription I-GENE O
units E-GENE O
. O O
Database O O
searches O O
revealed O O
a O O
50 O O
- O O
63 O O
% O O
similarity O O
and O O
34 O O
- O O
42 O O
% O O
identity O O
with O O
several O O
families O O
of O O
serine B-GENE O
proteases E-GENE O
, O O
in O O
particular O O
the O O
trypsin B-GENE O
- I-GENE O
like I-GENE O
proteases E-GENE O
, O O
members O O
of O O
the O O
glandular B-GENE B-GENE
kallikrein I-GENE I-GENE
family E-GENE E-GENE
( O O
including O O
prostate B-GENE O
- I-GENE O
specific I-GENE O
antigen E-GENE O
, O O
nerve B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
gamma E-GENE E-GENE
, O O
and O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
) O O
and O O
the O O
activators O O
for O O
the O O
kringle B-GENE B-GENE
family I-GENE I-GENE
proteins E-GENE E-GENE
( O O
including O O
the O O
human B-GENE O
tissue I-GENE O
plasminogen I-GENE O
activator E-GENE O
and O O
human B-GENE B-GENE
hepatocyte I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
activator E-GENE E-GENE
) O O
. O O
Manifestation O O
of O O
superfluidity O O
in O O
an O O
evolving O O
bose O O
- O O
einstein O O
condensed O O
Gas O O
We O O
study O O
the O O
generation O O
of O O
excitations O O
due O O
to O O
an O O
" O O
impurity O O
" O O
( O O
static O O
perturbation O O
) O O
placed O O
into O O
an O O
oscillating O O
Bose O O
- O O
Einstein O O
condensed O O
gas O O
in O O
the O O
time O O
- O O
dependent O O
trapping O O
field O O
. O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
micromol O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
) O O
but O O
was O O
not O O
changed O O
by O O
training O O
. O O
We O O
established O O
that O O
, O O
in O O
unstimulated O O
lymphocytes O O
, O O
the O O
Src B-GENE B-GENE
homology I-GENE I-GENE
2 E-GENE E-GENE
( O O
SH2 S-GENE S-GENE
) O O
and O O
SH3 B-GENE S-GENE
domain I-GENE O
- I-GENE O
containing I-GENE O
protein E-GENE O
Grb2 S-GENE S-GENE
and O O
the O O
p85 S-GENE B-GENE
subunit O E-GENE
of O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
, O O
associate O O
constitutively O O
with O O
Cbl S-GENE S-GENE
via O O
their O O
SH3 B-GENE B-GENE
domains E-GENE E-GENE
. O O
Zta S-GENE S-GENE
stimulated O O
the O O
HAT S-GENE O
activity O O
of O O
CBP S-GENE S-GENE
that O O
had O O
been O O
partially O O
purified O O
or O O
immunoprecipitated O O
from O O
mammalian O O
cells O O
as O O
well O O
as O O
from O O
affinity O O
- O O
purified O O
, O O
baculovirus O O
expressed O O
CBP S-GENE S-GENE
. O O
Increased O O
gliadin B-GENE O
antibody E-GENE O
levels O O
were O O
found O O
more O O
frequently O O
in O O
patients O O
with O O
subtotal O O
villous O O
atrophy O O
( O O
9 O O
out O O
of O O
17 O O
patients O O
, O O
or O O
53 O O
% O O
; O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
than O O
in O O
patients O O
with O O
partial O O
villous O O
atrophy O O
( O O
2 O O
out O O
of O O
13 O O
patients O O
, O O
or O O
15 O O
% O O
) O O
or O O
normal O O
villous O O
appearance O O
( O O
2 O O
out O O
of O O
10 O O
patients O O
, O O
or O O
20 O O
% O O
) O O
. O O
However O O
, O O
the O O
optimum O O
compressive O O
strength O O
reached O O
values O O
up O O
to O O
40 O O
% O O
higher O O
than O O
CC O O
- O O
free O O
samples O O
. O O
Expression O O
of O O
the O O
Hox B-GENE B-GENE
genes E-GENE I-GENE
egl B-GENE I-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
and O O
mab B-GENE B-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
is O O
reduced O O
in O O
lin B-GENE O
- I-GENE O
49 E-GENE O
and O O
lin B-GENE O
- I-GENE O
59 I-GENE O
mutants E-GENE O
, O O
suggesting O O
lin B-GENE O
- I-GENE O
49 E-GENE O
and O O
lin B-GENE O
- I-GENE O
59 E-GENE O
regulate O O
HOM B-GENE B-GENE
- I-GENE I-GENE
C I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
C O O
. O O
elegans O O
as O O
the O O
trx B-GENE B-GENE
- I-GENE I-GENE
G I-GENE I-GENE
genes E-GENE E-GENE
do O O
in O O
Drosophila O O
. O O
lin B-GENE O
- I-GENE O
49 E-GENE O
and O O
lin B-GENE O
- I-GENE O
59 I-GENE O
transgenes E-GENE O
are O O
expressed O O
widely O O
throughout O O
C O O
. O O
elegans O O
animals O O
. O O
Interleukin B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
increased O O
the O O
noradrenaline O O
release O O
. O O
Magnetic O O
field O O
influence O O
on O O
central O O
nervous O O
system O O
function O O
. O O
3 O O
patients O O
with O O
acute O O
leukaemia O O
, O O
HLA S-GENE O
antibodies O O
and O O
thrombocytopenia O O
refractory O O
to O O
random O O
donor O O
platelet O O
transfusions O O
were O O
treated O O
with O O
high O O
- O O
dose O O
i O O
. O O
v O O
. O O
immunoglobulin S-GENE O
. O O
Two O O
genes O O
( O O
ptsI S-GENE S-GENE
and O O
ptsA S-GENE S-GENE
) O O
that O O
encode O O
homologues O O
of O O
the O O
energy O O
coupling O O
Enzyme B-GENE O
I E-GENE O
of O O
the O O
phosphoenolpyruvate B-GENE O
- I-GENE O
dependent I-GENE O
sugar I-GENE O
- I-GENE O
transporting I-GENE O
phosphotransferase E-GENE O
system O O
( O O
PTS O O
) O O
have O O
previously O O
been O O
identified O O
on O O
the O O
Escherichia O O
coli O O
chromosome O O
. O O
Eight O O
of O O
these O O
suppressors O O
for O O
into O O
two O O
complementation O O
groups O O
, O O
designated O O
KCS1 S-GENE S-GENE
and O O
KCS2 S-GENE S-GENE
. O O
These O O
results O O
point O O
towards O O
post O O
- O O
translational O O
steric O O
and O O
/ O O
or O O
allosteric O O
control O O
of O O
EKLF S-GENE S-GENE
function O O
that O O
may O O
be O O
important O O
not O O
just O O
for O O
its O O
DNA O O
binding O O
ability O O
, O O
but O O
also O O
for O O
its O O
potential O O
to O O
interact O O
with O O
other O O
proteins O O
that O O
fully O O
establish O O
the O O
correct O O
stereospecific O O
array O O
leading O O
to O O
efficient O O
switching O O
of O O
beta B-GENE O
- I-GENE O
globin E-GENE O
transcription O O
during O O
development O O
. O O
Oxalates O O
and O O
the O O
digestive O O
tract O O
However O O
, O O
the O O
addition O O
of O O
intravenous O O
injection O O
of O O
FPFD O O
101 O O
resulted O O
in O O
a O O
marked O O
improvement O O
in O O
their O O
symptoms O O
. O O
Western O O
blot O O
experiments O O
detected O O
SMBP S-GENE O
as O O
a O O
70 O O
kDa O O
protein O O
that O O
may O O
be O O
further O O
cleaved O O
into O O
an O O
active O O
34 O O
kDa O O
N O O
- O O
terminal O O
polypeptide O O
. O O
The O O
aetiology O O
and O O
management O O
of O O
diabetic O O
impotence O O
is O O
well O O
- O O
documented O O
; O O
the O O
effects O O
of O O
diabetes O O
on O O
female O O
sexuality O O
are O O
not O O
so O O
clear O O
. O O
Treatment O O
of O O
diabetes O O
and O O
retinal O O
complications O O
The O O
activated O O
glucocorticoid B-GENE O
receptor E-GENE O
forms O O
a O O
complex O O
with O O
Stat5 S-GENE S-GENE
and O O
enhances O O
Stat5 S-GENE S-GENE
- O O
mediated O O
transcriptional O O
induction O O
. O O
Taken O O
together O O
, O O
these O O
findings O O
demonstrate O O
that O O
ZNF76 S-GENE S-GENE
and O O
ZNF143 S-GENE S-GENE
are O O
two O O
members O O
of O O
a O O
same O O
family O O
of O O
transactivator O B-GENE
proteins O E-GENE
. O O
For O O
example O O
, O O
the O O
presence O O
of O O
two O O
related O O
genes O O
, O O
b S-GENE O
and O O
b B-GENE O
' E-GENE O
, O O
in O O
the O O
cyanobacterium O O
suggests O O
that O O
its O O
ATP B-GENE B-GENE
synthase E-GENE E-GENE
is O O
a O O
complex O O
of O O
nine O O
polypeptides O O
, O O
and O O
that O O
it O O
may O O
have O O
single O O
copies O O
of O O
related O O
b S-GENE O
and O O
b B-GENE O
' I-GENE O
proteins E-GENE O
rather O O
than O O
two O O
copies O O
of O O
identical O O
b B-GENE O
subunits E-GENE O
as O O
found O O
in O O
the O O
E O O
. O O
coli O O
enzyme O O
. O O
4 O O
+ O O
off O O
Antiserum O O
raised O O
against O O
rat B-GENE B-GENE
liver I-GENE I-GENE
S6 I-GENE I-GENE
kinase E-GENE E-GENE
specifically O O
immunoprecipitates O O
the O O
purified O O
32P O O
- O O
labeled O O
H4 O O
hepatoma O O
insulin O O
- O O
stimulated O O
S6 B-GENE B-GENE
kinase E-GENE E-GENE
. O O
CRKL S-GENE S-GENE
, O O
an O O
SH2 S-GENE S-GENE
- O O
SH3 S-GENE S-GENE
- O O
SH3 S-GENE B-GENE
adapter O I-GENE
protein O E-GENE
, O O
is O O
one O O
of O O
the O O
major O O
tyrosine B-GENE O
phosphoproteins E-GENE O
detected O O
in O O
primary O O
leukemic O O
neutrophils O O
from O O
patients O O
with O O
CML O O
. O O
KU O O
- O O
1257 O O
also O O
significantly O O
accelerated O O
the O O
healing O O
of O O
acetic O O
acid O O
- O O
induced O O
duodenal O O
ulcers O O
as O O
well O O
as O O
famotidine O O
and O O
roxatidine O O
acetate O O
. O O
To O O
further O O
identify O O
the O O
residues O O
responsible O O
for O O
the O O
activity O O
, O O
we O O
isolated O O
the O O
mutant O O
viruses O O
that O O
were O O
not O O
neutralized O O
with O O
the O O
soluble O O
form O O
of O O
MHV B-GENE B-GENE
receptor I-GENE I-GENE
proteins E-GENE E-GENE
, O O
since O O
such O O
mutants O O
were O O
expected O O
to O O
have O O
mutations O O
in O O
amino O O
acids O O
responsible O O
for O O
receptor O O
- O O
binding O O
activity O O
. O O
It O O
is O O
suggested O O
that O O
death O O
of O O
S O O
. O O
mansoni O O
cercariae O O
during O O
penetration O O
of O O
mammalian O O
host O O
skin O O
is O O
probably O O
due O O
to O O
exhaustion O O
of O O
their O O
energy O O
reserves O O
. O O
Especially O O
if O O
the O O
number O O
of O O
dimensions O O
of O O
the O O
samples O O
is O O
large O O
, O O
it O O
can O O
be O O
said O O
that O O
BPN O O
is O O
better O O
than O O
k O O
- O O
NN O O
in O O
classification O O
ability O O
. O O
In O O
contrast O O
, O O
inactivation O O
of O O
the O O
Sir4p B-GENE S-GENE
- I-GENE O
interacting I-GENE O
protein I-GENE O
Rap1p E-GENE S-GENE
reduces O O
partitioning O O
by O O
a O O
LexA S-GENE S-GENE
- O O
Sir4p S-GENE O
fusion O O
. O O
Nine O O
individuals O O
who O O
were O O
stable O O
after O O
1 O O
month O O
of O O
therapy O O
at O O
low O O
dosage O O
were O O
randomized O O
to O O
a O O
further O O
month O O
of O O
therapy O O
at O O
low O O
or O O
high O O
dosage O O
, O O
during O O
which O O
one O O
of O O
four O O
at O O
high O O
dosage O O
had O O
a O O
partial O O
response O O
, O O
and O O
none O O
of O O
five O O
at O O
low O O
dosage O O
manifested O O
response O O
. O O
BACKGROUND O O
: O O
Murine B-GENE O
Nramp E-GENE O
is O O
a O O
candidate O O
for O O
the O O
macrophage O B-GENE
resistance O I-GENE
gene O I-GENE
Ity S-GENE E-GENE
/ O O
Lsh S-GENE S-GENE
/ O O
Bcg S-GENE S-GENE
. O O
In O O
cases O O
in O O
which O O
it O O
was O O
identified O O
, O O
insulitis O O
affected O O
23 O O
% O O
of O O
islets O O
containing O O
insulin S-GENE O
, O O
but O O
affected O O
only O O
1 O O
% O O
of O O
islets O O
which O O
were O O
insulin S-GENE O
deficient O O
, O O
thus O O
supporting O O
the O O
concept O O
that O O
insulitis O O
represents O O
an O O
immunologically O O
mediated O O
destruction O O
of O O
insulin S-GENE O
secreting O O
B O O
cells O O
. O O
( O O
4 O O
) O O
Expression O O
in O O
different O O
sites O O
in O O
the O O
central O O
nervous O O
system O O
is O O
driven O O
by O O
separable O O
elements O O
widely O O
dispersed O O
throughout O O
8 O O
kb O O
3 O O
' O O
of O O
the O O
gene O O
. O O
To O O
investigate O O
possible O O
roles O O
for O O
HCP S-GENE O
during O O
late O O
erythroid O O
differentiation O O
, O O
effects O O
of O O
manipulating O O
HCP S-GENE S-GENE
expression O O
or O O
recruitment O O
on O O
EPO S-GENE O
- O O
induced O O
hemoglobinization O O
in O O
erythroleukemic O O
SKT6 O O
cells O O
have O O
been O O
investigated O O
. O O
The O O
other O O
end O O
of O O
this O O
cluster O O
contained O O
the O O
human B-GENE O
type I-GENE O
I I-GENE O
cytokeratin E-GENE O
K20 S-GENE S-GENE
and O O
K12 B-GENE B-GENE
gene E-GENE E-GENE
loci O O
. O O
An O O
11 O O
. O O
5 O O
- O O
kb O O
intron O O
is O O
found O O
at O O
the O O
end O O
of O O
transmembrane O O
6 O O
, O O
and O O
the O O
rest O O
of O O
the O O
ORF O O
is O O
in O O
exon O O
3 O O
. O O
Are O O
there O O
any O O
lessons O O
to O O
be O O
learnt O O
? O O
Eighteen O O
patients O O
with O O
advanced O O
epidermoid O O
carcinoma O O
of O O
the O O
head O O
and O O
neck O O
were O O
entered O O
into O O
a O O
phase O O
II O O
trial O O
of O O
N O O
- O O
Methylformamide O O
( O O
NMF O O
) O O
, O O
800 O O
mg O O
/ O O
M2 O O
IV O O
daily O O
for O O
5 O O
days O O
every O O
4 O O
weeks O O
. O O
We O O
provided O O
evidence O O
that O O
CaM B-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
played O O
a O O
role O O
in O O
regulating O O
neurite O O
outgrowth O O
and O O
growth O O
cone O O
motility O O
in O O
these O O
cells O O
, O O
and O O
that O O
the O O
autophosphorylation O O
is O O
essential O O
for O O
the O O
kinase O O
to O O
sufficiently O O
exert O O
its O O
cellular O O
function O O
in O O
vivo O O
[ O O
Y O O
. O O
However O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
a O O
truncation O O
of O O
as O O
little O O
as O O
15 O O
Nurr1 S-GENE O
COOH O O
- O O
terminal O O
amino O O
acids O O
diminished O O
transcriptional O O
activation O O
of O O
B1A S-GENE B-GENE
- O I-GENE
thymidine B-GENE I-GENE
kinase E-GENE E-GENE
- O O
chloramphenicol B-GENE O
acetyltransferase E-GENE O
reporter O O
. O O
All O O
sows O O
nursed O O
nine O O
pigs O O
. O O
In O O
the O O
second O O
group O O
the O O
untreated O O
fellow O O
eye O O
was O O
microscopically O O
intact O O
, O O
but O O
was O O
shown O O
( O O
as O O
the O O
treated O O
eye O O
) O O
to O O
alter O O
the O O
concentration O O
of O O
uronic O O
acid O O
in O O
different O O
parts O O
of O O
the O O
sclera O O
. O O
Effects O O
were O O
studied O O
of O O
extremely O O
high O O
- O O
frequency O O
electromagnetic O O
radiation O O
( O O
EHF O O
EMR O O
) O O
on O O
indices O O
for O O
the O O
immune O O
and O O
endocrine O O
systems O O
in O O
a O O
series O O
of O O
48 O O
patients O O
presenting O O
with O O
hyperplastic O O
processes O O
in O O
endometrium O O
. O O
Characterization O O
of O O
human B-GENE B-GENE
activating I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
4 E-GENE E-GENE
, O O
a O O
transcriptional O O
activator O O
that O O
interacts O O
with O O
multiple O O
domains O O
of O O
cAMP B-GENE B-GENE
- I-GENE I-GENE
responsive I-GENE I-GENE
element I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
CREB S-GENE S-GENE
) O O
- O O
binding O O
protein O O
. O O
Effect O O
of O O
a O O
constant O O
magnetic O O
field O O
on O O
different O O
models O O
of O O
carcinogenesis O O
In O O
contrast O O
to O O
the O O
reciprocal O O
effects O O
of O O
Gab1 S-GENE S-GENE
and O O
Gab2 S-GENE S-GENE
in O O
mediating O O
Elk B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
induction O O
, O O
these O O
two O O
molecules O O
have O O
a O O
similar O O
function O O
in O O
extracellular B-GENE O
signal I-GENE O
- I-GENE O
regulated I-GENE O
kinase E-GENE O
activation O O
induced O O
by O O
either O O
oncogenic O O
Ras S-GENE S-GENE
or O O
growth O O
factor O O
stimulation O O
. O O
This O O
result O O
is O O
consistent O O
with O O
the O O
previous O O
observation O O
that O O
expression O O
of O O
the O O
hsp70 B-GENE B-GENE
genes I-GENE E-GENE
in I-GENE O
T I-GENE O
. I-GENE O
brucei E-GENE O
is O O
mainly O O
controlled O O
at O O
the O O
posttranscriptional O O
level O O
. O O
A O O
definition O O
of O O
bias O O
founded O O
on O O
the O O
concept O O
of O O
the O O
study O O
base O O
. O O
Chromaffin O O
cells O O
transfected O O
with O O
a O O
plasmid O O
with O O
the O O
entire O O
coding O O
sequence O O
of O O
c B-GENE O
- I-GENE O
Rabphilin3a E-GENE O
inserted O O
in O O
the O O
antisense O O
orientation O O
inhibited O O
secretion O O
of O O
co O O
- O O
expressed O O
GH S-GENE O
by O O
approximately O O
30 O O
% O O
. O O
Using O O
a O O
set O O
of O O
sera O O
for O O
which O O
full O O
chlamydial O O
micro O O
- O O
immunofluorescence O O
results O O
suggested O O
a O O
clear O O
diagnosis O O
, O O
we O O
have O O
evaluated O O
the O O
Chlamydia O O
Spot O O
- O O
IF O O
test O O
( O O
bioMerieux O O
) O O
, O O
which O O
allows O O
a O O
comparison O O
of O O
titres O O
to O O
Chlamydia B-GENE O
trachomatis I-GENE O
and I-GENE O
C I-GENE O
. I-GENE O
psittaci I-GENE O
antigens E-GENE O
. O O
An O O
environmental O O
investigation O O
found O O
evidence O O
of O O
suboptimal O O
food O O
storage O O
and O O
cooking O O
temperatures O O
at O O
Restaurant O O
A O O
; O O
cross O O
contamination O O
of O O
foods O O
may O O
have O O
contributed O O
to O O
the O O
low O O
attributable O O
risk O O
identified O O
for O O
chile O O
rellenos O O
. O O
Evidence O O
from O O
four O O
areas O O
- O O
- O O
sensory O O
deprivation O O
, O O
enriched O O
environments O O
, O O
nervous O O
system O O
plasticity O O
, O O
and O O
sensitive O O
periods O O
of O O
neurodevelopment O O
- O O
- O O
suggests O O
that O O
sensory O O
stimulation O O
programs O O
are O O
potentially O O
beneficial O O
for O O
STR O O
patients O O
. O O
In O O
each O O
study O O
group O O
, O O
elevated O O
levels O O
of O O
serum O O
I O O
were O O
observed O O
. O O
With O O
repetitive O O
intermittent O O
exercise O O
, O O
gradual O O
increases O O
in O O
blood O O
lactate O O
concentration O O
[ O O
( O O
LA O O
] O O
b O O
) O O
occurred O O
, O O
whereas O O
its O O
rate O O
of O O
accumulation O O
( O O
delta O O
[ O O
LA O O
] O O
b O O
) O O
decreased O O
. O O
A O O
physical O O
and O O
genetic O O
map O O
covering O O
the O O
entire O O
RP12 B-GENE S-GENE
candidate I-GENE O
gene I-GENE O
region E-GENE O
was O O
constructed O O
. O O
The O O
single O O
copy O O
flotillin B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
is O O
located O O
at O O
6p21 O O
. O O
3 O O
in O O
the O O
MHC B-GENE O
class I-GENE O
I I-GENE O
region E-GENE O
and O O
consists O O
of O O
13 O O
exons O O
over O O
15 O O
kb O O
. O O
An O O
atypical O O
form O O
of O O
juvenile O O
myasthenia O O
gravis O O
associated O O
with O O
severe O O
emaciation O O
, O O
muscle O O
atrophy O O
, O O
ophthalmoplegia O O
, O O
bulbar O O
signs O O
and O O
joint O O
contracture O O
The O O
in O O
vivo O O
response O O
of O O
the O O
PacC B-GENE O
- I-GENE O
like I-GENE O
decamers E-GENE O
to O O
external O O
pH O O
was O O
dependent O O
on O O
the O O
status O O
of O O
the O O
pH O O
- O O
regulated O O
activator O O
YlRim101p S-GENE S-GENE
, O O
which O O
is O O
homologous O O
to O O
the O O
A O O
. O O
nidulans O O
PacC S-GENE O
regulator O O
. O O
Electron O O
microscopic O O
visualization O O
of O O
the O O
general O O
population O O
of O O
active O O
genes O O
in O O
flies O O
overexpressing O O
hnRNP B-GENE B-GENE
proteins E-GENE E-GENE
also O O
indicated O O
that O O
the O O
great O O
majority O O
of O O
genes O O
seemed O O
normal O O
in O O
terms O O
of O O
cotranscriptional O O
RNA O O
processing O O
events O O
, O O
although O O
there O O
were O O
a O O
few O O
abnormalities O O
consistent O O
with O O
rare O O
exon O O
- O O
skipping O O
events O O
. O O
Having O O
demonstrated O O
proper O O
localization O O
of O O
GFP S-GENE B-GENE
- O I-GENE
calmodulin S-GENE E-GENE
in O O
budding O O
yeast O O
, O O
we O O
examined O O
the O O
localization O O
of O O
a O O
fusion O O
between O O
GFP S-GENE S-GENE
and O O
calmodulin S-GENE S-GENE
( O O
GFP B-GENE B-GENE
- I-GENE I-GENE
Camlp E-GENE E-GENE
) O O
in O O
fission O O
yeast O O
, O O
where O O
calmodulin S-GENE O
had O O
not O O
been O O
localized O O
by O O
any O O
method O O
. O O
Sera O O
from O O
33 O O
newborn O O
infants O O
with O O
gestational O O
ages O O
ranging O O
from O O
27 O O
to O O
41 O O
weeks O O
were O O
tested O O
by O O
radioimmunoassay O O
for O O
IgG S-GENE S-GENE
antibodies O O
to O O
surface O O
antigens O O
of O O
group O O
B O O
streptococci O O
( O O
GBS O O
) O O
types O O
Ia O O
, O O
Ib O O
, O O
II O O
and O O
III O O
. O O
In O O
frozen O O
sections O O
the O O
spots O O
appear O O
as O O
blue O O
labelled O O
neurones O O
with O O
a O O
light O O
microscope O O
, O O
or O O
as O O
a O O
brilliant O O
red O O
neurones O O
surrounded O O
by O O
reddish O O
tissue O O
with O O
a O O
fluorescence O O
microscope O O
. O O
The O O
percentage O O
distribution O O
of O O
types O O
of O O
fixation O O
disparity O O
curves O O
was O O
found O O
to O O
be O O
similar O O
to O O
some O O
previous O O
studies O O
, O O
with O O
a O O
higher O O
prevalence O O
of O O
Type O O
I O O
curve O O
( O O
64 O O
. O O
3 O O
% O O
) O O
, O O
followed O O
by O O
Type O O
II O O
( O O
28 O O
. O O
6 O O
% O O
) O O
and O O
Type O O
III O O
( O O
7 O O
. O O
1 O O
% O O
) O O
curves O O
. O O
The O O
BUR O O
was O O
set O O
at O O
20 O O
/ O O
min O O
and O O
the O O
IT O O
at O O
. O O
5 O O
seconds O O
. O O
These O O
data O O
are O O
discussed O O
in O O
the O O
context O O
of O O
the O O
pathogenesis O O
and O O
differential O O
diagnosis O O
of O O
EEC O O
. O O
Seminal O O
prolactin S-GENE O
levels O O
were O O
significantly O O
elevated O O
in O O
all O O
infertile O O
males O O
. O O
Northern O O
blot O O
analysis O O
identified O O
retina O O
- O O
specific O O
transcripts O O
of O O
3 O O
. O O
0 O O
kb O O
for O O
rod B-GENE O
G I-GENE O
alpha I-GENE O
t E-GENE O
and O O
2 O O
. O O
6 O O
kb O O
for O O
cone B-GENE O
G I-GENE O
alpha I-GENE O
t E-GENE O
. O O
In O O
the O O
univariate O O
models O O
of O O
either O O
fixed O O
or O O
time O O
dependent O O
covariates O O
, O O
many O O
variables O O
were O O
significantly O O
associated O O
with O O
risk O O
of O O
progression O O
to O O
AIDS O O
( O O
T4 O O
cell O O
count O O
, O O
T4 O O
/ O O
T8 O O
ratio O O
, O O
blastogenic O O
responses O O
to O O
phytohemagglutinin S-GENE O
, O O
concanavalin B-GENE O
A E-GENE O
, O O
and O O
pokeweed B-GENE O
mitogen E-GENE O
, O O
serum B-GENE B-GENE
IgA E-GENE E-GENE
, O O
appearance O O
of O O
p24 B-GENE B-GENE
antigen E-GENE E-GENE
, O O
and O O
the O O
development O O
of O O
oral O O
hairy O O
leukoplakia O O
, O O
thrush O O
, O O
or O O
herpes O O
zoster O O
) O O
. O O
Adenovirus O O
- O O
mediated O O
gene O O
transfer O O
of O O
MMAC1 S-GENE S-GENE
/ O O
PTEN S-GENE S-GENE
to O O
glioblastoma O O
cells O O
inhibits O O
S O O
phase O O
entry O O
by O O
the O O
recruitment O O
of O O
p27Kip1 S-GENE S-GENE
into O O
cyclin B-GENE B-GENE
E E-GENE E-GENE
/ O O
CDK2 S-GENE S-GENE
complexes O O
. O O
Cost O O
analysis O O
and O O
the O O
HSA O O
: O O
a O O
framework O O
. O O
These O O
cells O O
also O O
showed O O
an O O
increase O O
in O O
cyclin B-GENE O
A E-GENE O
and O O
cyclin B-GENE O
A I-GENE O
- I-GENE O
and I-GENE O
E I-GENE B-GENE
- I-GENE I-GENE
associated I-GENE I-GENE
kinase E-GENE E-GENE
activities O O
characteristic O O
of O O
S O O
phase O O
induction O O
. O O
Characterization O O
of O O
a O O
tonB S-GENE B-GENE
- O I-GENE
phoA S-GENE I-GENE
gene O E-GENE
fusion O O
suggests O O
that O O
the O O
amino O O
- O O
terminal O O
41 O O
amino O O
acids O O
of O O
TonB S-GENE S-GENE
are O O
sufficient O O
to O O
promote O O
export O O
of O O
the O O
fusion O O
protein O O
and O O
presumably O O
TonB S-GENE S-GENE
as O O
well O O
. O O
Calcium O O
bilirubinate O O
crystals O O
were O O
seen O O
in O O
gallbladder O O
bile O O
or O O
wall O O
scrapings O O
of O O
7 O O
of O O
8 O O
TPN O O
animals O O
but O O
in O O
none O O
of O O
the O O
controls O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O
This O O
domain O O
encompasses O O
the O O
region O O
of O O
ARP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
/ O O
COUP B-GENE O
- I-GENE O
TFII E-GENE O
corresponding O O
to O O
helices O O
3 O O
to O O
12 O O
in O O
the O O
recently O O
published O O
crystal O O
structure O O
of O O
other O O
members O O
of O O
the O O
nuclear B-GENE O
receptor I-GENE O
superfamily E-GENE O
. O O
Different O O
clinical O O
variants O O
of O O
the O O
empty O O
sella O O
turcica O O
syndrome O O
are O O
demonstrated O O
, O O
including O O
variants O O
resultant O O
from O O
substitution O O
therapy O O
of O O
thyroid O O
hypofunction O O
, O O
from O O
dopamine O O
agonist O O
therapy O O
for O O
hyperprolactinemic O O
hypogonadism O O
, O O
from O O
radiotherapy O O
of O O
hypophyseal O O
adenoma O O
. O O
Both O O
genes B-GENE O
ARO3 E-GENE S-GENE
and O O
ARO4 S-GENE S-GENE
are O O
strongly O O
regulated O O
under O O
the O O
general O O
control O O
regulatory O O
system O O
. O O
Polar O O
effects O O
of O O
transposon O O
insertions O O
demonstrated O O
that O O
all O O
of O O
these O O
mRNAs O O
arose O O
from O O
a O O
single O O
promoter O O
region O O
, O O
where O O
transcription O O
initiated O O
80 O O
bp O O
5 O O
' O O
to O O
nifH S-GENE O
. O O
J O O
. O O
, O O
& O O
Olefsky O O
, O O
J O O
. O O
Importantly O O
, O O
a O O
single O O
base O O
change O O
in O O
the O O
fifth O O
position O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
sequence E-GENE E-GENE
( O O
GGTCTnnnAGACC O S-GENE
to O O
GGTCA O S-GENE
/ O O
GnnnAGACC O S-GENE
) O O
produced O O
an O O
element O O
that O O
bound O O
the O O
estrogen B-GENE B-GENE
receptor E-GENE E-GENE
and O O
conferred O O
estrogen O O
- O O
dependent O O
transcriptional O O
activation O O
of O O
a O O
reporter O O
gene O O
. O O
Measuring O O
the O O
dim O O
light O O
melatonin O O
onset O O
( O O
DLMO O O
) O O
is O O
a O O
useful O O
and O O
practical O O
way O O
to O O
assess O O
circadian O O
phase O O
position O O
in O O
humans O O
. O O
Co O O
- O O
expression O O
of O O
a O O
gag S-GENE B-GENE
- O I-GENE
TRalpha S-GENE I-GENE
fusion O I-GENE
protein O E-GENE
in O O
AEV O S-GENE
- O O
transformed O O
cells O O
and O O
addition O O
of O O
ligand O O
derepresses O O
CAII S-GENE S-GENE
transcription O O
. O O
The O O
IB2 B-GENE B-GENE
gene E-GENE E-GENE
( O O
HGMW O O
- O O
approved O O
symbol O O
MAPK8IP2 S-GENE S-GENE
) O O
maps O O
to O O
human O O
chromosome O O
22q13 O S-GENE
and O O
contains O O
10 O O
coding O O
exons O O
. O O
Transcription O O
start O O
sites O O
of O O
sal S-GENE S-GENE
and O O
salR B-GENE B-GENE
genes E-GENE E-GENE
were O O
determined O O
to O O
lie O O
30 O O
- O O
and O O
24 O O
- O O
bp O O
upstream O O
of O O
the O O
respective O O
initiation O O
codons O O
and O O
separated O O
from O O
each O O
other O O
by O O
78 O O
nucleotides O O
. O O
1 O O
. O O
23 O O
) O O
as O O
a O O
PPARalpha B-GENE O
- I-GENE O
interacting I-GENE O
protein E-GENE O
. O O
Here O O
we O O
demonstrate O O
that O O
the O O
T B-GENE B-GENE
cell I-GENE I-GENE
antigen I-GENE I-GENE
receptor I-GENE E-GENE
zeta I-GENE O
- I-GENE O
chain I-GENE O
- I-GENE O
associated I-GENE O
ZAP I-GENE B-GENE
- I-GENE I-GENE
70 I-GENE I-GENE
kinase E-GENE E-GENE
and O O
T B-GENE B-GENE
cell I-GENE I-GENE
antigen I-GENE I-GENE
receptor I-GENE E-GENE
zeta I-GENE O
- I-GENE O
chain I-GENE O
immunoreceptor I-GENE O
tyrosine I-GENE O
- I-GENE O
based I-GENE O
activation I-GENE O
motifs E-GENE O
are O O
essential O O
for O O
the O O
membrane O O
recruitment O O
of O O
SOS S-GENE S-GENE
and O O
Vav S-GENE S-GENE
. O O
We O O
carried O O
out O O
two O O
experiments O O
to O O
investigate O O
this O O
problem O O
. O O
When O O
linked O O
to O O
the O O
herpes O B-GENE
simplex O I-GENE
thymidine B-GENE I-GENE
kinase E-GENE E-GENE
minimal O O
promoter O O
, O O
this O O
fragment O O
acts O O
as O O
an O O
enhancing O O
element O O
in O O
Rcho O O
but O O
not O O
GC O O
cells O O
. O O
A O O
mammalian O O
protein O O
called O O
RFX S-GENE S-GENE
or O O
NF B-GENE B-GENE
- I-GENE I-GENE
X E-GENE E-GENE
binds O O
to O O
the O O
X O O
box O O
( O O
or O O
X1 O O
box O O
) O O
in O O
the O O
promoters O O
of O O
a O O
number O O
of O O
major B-GENE O
histocompatibility I-GENE O
( I-GENE O
MHC I-GENE B-GENE
) I-GENE I-GENE
class I-GENE I-GENE
II I-GENE I-GENE
genes E-GENE E-GENE
. O O
Site O O
- O O
directed O O
mutagenesis O O
was O O
conducted O O
to O O
investigate O O
the O O
functional O O
significance O O
of O O
this O O
element O O
and O O
the O O
3 O O
' O O
minus O O
- O O
strand O O
terminal O O
sequence O O
" O O
3 O O
' O O
- O O
OH O O
- O O
CCCUAU O O
, O O
" O O
which O O
contains O O
the O O
minus O O
- O O
strand O O
3 O O
' O O
- O O
end O O
sequence O O
" O O
3 O O
' O O
- O O
OH O O
- O O
CC O O
( O O
1 O O
- O O
2 O O
) O O
( O O
A O O
/ O O
U O O
) O O
( O O
A O O
/ O O
U O O
) O O
( O O
A O O
/ O O
U O O
) O O
" O O
found O O
in O O
all O O
carmovirus O O
RNAs O O
. O O
The O O
incidence O O
of O O
the O O
variability O O
of O O
the O O
free O O
PSA S-GENE O
/ O O
total O O
PSA S-GENE O
ratio O O
on O O
the O O
early O O
diagnosis O O
of O O
prostate O O
cancer O O
VBP S-GENE S-GENE
and O O
a1 B-GENE O
/ I-GENE O
EBP E-GENE O
could O O
mediate O O
the O O
high O O
rates O O
of O O
ALV O O
and O O
RSV B-GENE O
LTR E-GENE O
- O O
enhanced O O
transcription O O
in O O
bursal O O
lymphoma O O
cells O O
and O O
many O O
other O O
cell O O
types O O
. O O
In O O
the O O
second O O
, O O
37 O O
students O O
were O O
given O O
trimethoprim O O
/ O O
sulphamethoxazole O O
( O O
160 O O
mg O O
TMP O O
- O O
SMX O O
800 O O
mg O O
) O O
, O O
38 O O
TMP O O
( O O
200 O O
mg O O
) O O
, O O
and O O
in O O
35 O O
a O O
placebo O O
was O O
given O O
b O O
. O O
i O O
. O O
d O O
. O O
for O O
five O O
days O O
. O O
Developmental O O
slot O O
blots O O
demonstrate O O
that O O
mRNAs O O
corresponding O O
to O O
the O O
three O O
LHM B-GENE B-GENE
cDNAs E-GENE E-GENE
are O O
transcribed O O
from O O
prophase O O
of O O
meiosis O O
I O O
to O O
the O O
uninucleate O O
microspore O O
stage O O
, O O
while O O
Northern O O
analysis O O
reveals O O
these O O
tapetally O O
expressed O O
cDNAs O S-GENE
to O O
correspond O O
with O O
transcripts O O
of O O
some O O
500 O O
bp O O
. O O
One O O
hundred O O
men O O
who O O
received O O
alpha O O
- O O
tocopherol O O
were O O
matched O O
on O O
age O O
, O O
study O O
center O O
, O O
and O O
length O O
of O O
time O O
between O O
blood O O
draws O O
to O O
100 O O
men O O
who O O
received O O
a O O
placebo O O
. O O
The O O
contribution O O
of O O
residues O O
outside O O
the O O
Ras B-GENE S-GENE
binding I-GENE O
domain E-GENE O
of O O
Raf S-GENE S-GENE
( O O
RafRBD S-GENE S-GENE
) O O
to O O
Ras S-GENE B-GENE
- O I-GENE
Raf S-GENE E-GENE
interaction O O
and O O
Ras S-GENE S-GENE
- O O
dependent O O
Raf S-GENE O
activation O O
has O O
remained O O
unresolved O O
. O O
Other O O
recommendations O O
for O O
enhancing O O
the O O
safety O O
of O O
potent O O
antiplatelet O O
agents O O
in O O
a O O
variety O O
of O O
clinical O O
situations O O
are O O
provided O O
. O O
RESULTS O O
- O O
- O O
261 O O
patients O O
were O O
enrolled O O
into O O
this O O
study O O
; O O
of O O
these O O
, O O
138 O O
( O O
53 O O
% O O
) O O
patients O O
attended O O
for O O
repeat O O
colposcopy O O
and O O
cytology O O
at O O
one O O
year O O
. O O
Changes O O
in O O
the O O
greater O O
omentum O O
of O O
mice O O
of O O
different O O
strains O O
after O O
intraperitoneal O O
immunization O O
with O O
sheep O O
erythrocytes O O
. O O
In O O
this O O
study O O
, O O
we O O
sought O O
to O O
determine O O
the O O
specific O O
effect O O
of O O
HIV B-GENE O
protease E-GENE O
inhibitors O O
on O O
patient O O
weight O O
. O O
However O O
massive O O
necrosis O O
of O O
the O O
renal O O
tubules O O
had O O
been O O
found O O
with O O
more O O
than O O
15mg O O
of O O
DSM O O
administration O O
. O O
The O O
characteristics O O
of O O
a O O
simple O O
apparatus O O
for O O
clinical O O
use O O
to O O
measure O O
DEOAEs O O
are O O
described O O
together O O
with O O
typical O O
examples O O
of O O
emissions O O
. O O
To O O
obtain O O
information O O
on O O
the O O
functional O O
role O O
of O O
the O O
Rac1 S-GENE S-GENE
/ O O
p38 S-GENE S-GENE
/ O O
MAPKAPK B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
pathway O O
in O O
RA O S-GENE
signaling O O
, O O
the O O
effects O O
of O O
pharmacological O O
inhibition O O
of O O
p38 S-GENE S-GENE
on O O
RA O S-GENE
- O O
induced O O
gene O O
transcription O O
and O O
cell O O
differentiation O O
were O O
determined O O
. O O
The O O
cost O O
and O O
effectiveness O O
of O O
nurse O O
education O O
- O O
- O O
1 O O
. O O
The O O
ATF S-GENE B-GENE
/ O I-GENE
CRE O I-GENE
site O E-GENE
is O O
also O O
essential O O
for O O
CD4 B-GENE B-GENE
promoter E-GENE E-GENE
activation O O
by O O
forskolin O O
, O O
an O O
activator O O
of O O
adenylate B-GENE B-GENE
cyclase E-GENE E-GENE
. O O
YLL031c S-GENE S-GENE
is O O
an O O
essential O O
gene O O
. O O
Restricted O O
expression O O
of O O
a O O
novel O O
murine B-GENE O
atonal I-GENE O
- I-GENE O
related I-GENE O
bHLH I-GENE B-GENE
protein E-GENE E-GENE
in O O
undifferentiated O O
neural O O
precursors O O
. O O
Since O O
the O O
early O O
1900s O O
, O O
a O O
genetic O O
hypothesis O O
has O O
been O O
suggested O O
. O O
We O O
report O O
the O O
genomic O O
organization O O
of O O
the O O
mouse O B-GENE
orphan B-GENE I-GENE
receptor I-GENE E-GENE
related I-GENE O
to I-GENE O
tyrosine I-GENE B-GENE
kinases E-GENE E-GENE
( O O
Ryk S-GENE S-GENE
) O O
, O O
a O O
structurally O O
unclassified O O
member O O
of O O
the O O
growth B-GENE B-GENE
factor I-GENE I-GENE
receptor E-GENE I-GENE
family O E-GENE
. O O
In O O
contrast O O
, O O
T229E B-GENE O
- I-GENE O
p70s6k E-GENE O
migrated O O
more O O
slowly O O
in O O
SDS O O
- O O
polyacrylamide O O
gels O O
, O O
but O O
demonstrated O O
partial O O
kinase O O
activity O O
( O O
approximately O O
20 O O
% O O
compared O O
with O O
the O O
wild O O
type O O
) O O
. O O
The O O
structure O O
and O O
expression O O
of O O
the O O
murine B-GENE O
gene I-GENE O
encoding I-GENE O
granulocyte I-GENE O
- I-GENE O
macrophage I-GENE O
colony I-GENE O
stimulating I-GENE O
factor E-GENE O
: O O
evidence O O
for O O
utilisation O O
of O O
alternative O O
promoters O O
. O O
Thus O O
, O O
the O O
search O O
for O O
genetic O O
and O O
acquired O O
susceptibility O O
to O O
nontuberculous O O
mycobacteria O O
is O O
also O O
a O O
search O O
for O O
susceptibility O O
factors O O
for O O
MTB O O
as O O
well O O
as O O
an O O
opportunity O O
to O O
recognize O O
endogenous O O
pathways O O
that O O
can O O
be O O
exploited O O
therapeutically O O
. O O
Liver O O
disease O O
and O O
HCV O O
infection O O
after O O
transplantation O O
of O O
organs O O
from O O
hepatitis B-GENE O
C I-GENE O
antibody E-GENE O
positive O O
donors O O
. O O
After O O
dialysis O O
online O O
, O O
lactate O O
was O O
converted O O
by O O
means O O
of O O
lactate B-GENE O
oxidase E-GENE O
immobilized O O
to O O
porous O O
glass O O
, O O
and O O
the O O
depletion O O
of O O
oxygen O O
was O O
registered O O
by O O
means O O
of O O
a O O
Clark O O
electrode O O
. O O
The O O
deduced O O
amino O O
- O O
acid O O
sequence O O
of O O
the O O
mature O O
enzyme O O
showed O O
very O O
low O O
homology O O
( O O
< O O
20 O O
. O O
4 O O
% O O
identity O O
) O O
to O O
those O O
of O O
known O O
pectinolytic O O
enzymes O O
in O O
the O O
large O O
pectate B-GENE B-GENE
lyase I-GENE I-GENE
superfamily E-GENE E-GENE
( O O
the O O
polysaccharide B-GENE B-GENE
lyase I-GENE I-GENE
family I-GENE I-GENE
1 E-GENE E-GENE
) O O
. O O
Incubation O O
of O O
HeLa O O
cell O O
cytoplasmic O O
extracts O O
with O O
a O O
purified O O
recombinant O B-GENE
glutathione B-GENE I-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE I-GENE
- O I-GENE
raf S-GENE I-GENE
fusion O I-GENE
protein O E-GENE
in O O
the O O
presence O O
of O O
ATP O O
released O O
active O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
that O O
could O O
be O O
detected O O
by O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
. O O
Despite O O
this O O
loss O O
, O O
YEpFAS1 S-GENE S-GENE
is O O
still O O
able O O
to O O
complement O O
a O O
fas1 S-GENE S-GENE
mutation O O
at O O
the O O
enoyl B-GENE B-GENE
reductase E-GENE I-GENE
domain O E-GENE
. O O
Cross O O
- O O
species O O
characterization O O
of O O
the O O
promoter B-GENE O
region I-GENE O
of I-GENE O
the I-GENE O
cystic I-GENE O
fibrosis I-GENE O
transmembrane I-GENE O
conductance I-GENE O
regulator I-GENE O
gene E-GENE O
reveals O O
multiple O O
levels O O
of O O
regulation O O
. O O
Pretreatment O O
with O O
lipid O O
X O O
was O O
not O O
necessary O O
to O O
improve O O
survival O O
: O O
16 O O
of O O
17 O O
( O O
94 O O
% O O
) O O
infected O O
and O O
visibly O O
ill O O
animals O O
that O O
received O O
lipid O O
X O O
and O O
ticarcillin O O
6 O O
h O O
after O O
thigh O O
inoculation O O
survived O O
versus O O
30 O O
of O O
44 O O
( O O
68 O O
% O O
) O O
control O O
animals O O
treated O O
with O O
ticarcillin O O
alone O O
( O O
P O O
less O O
than O O
0 O O
. O O
0001 O O
) O O
. O O
The O O
predicted O O
vav B-GENE O
oncogene I-GENE O
protein I-GENE O
sequence E-GENE O
exhibits O O
several O O
motifs O O
reminiscent O O
of O O
transcriptional O O
factors O O
. O O
The O O
pharmacokinetics O O
were O O
best O O
described O O
by O O
a O O
two O O
- O O
compartment O O
open O O
model O O
giving O O
distribution O O
half O O
- O O
lives O O
of O O
0 O O
. O O
31 O O
h O O
and O O
1 O O
. O O
53 O O
h O O
, O O
and O O
elimination O O
half O O
- O O
lives O O
of O O
69 O O
. O O
7 O O
h O O
and O O
60 O O
. O O
3 O O
h O O
for O O
oxolinic O O
acid O O
and O O
oxytetracycline O O
, O O
respectively O O
. O O
The O O
predictive O O
value O O
of O O
the O O
remotely O O
sensed O O
map O O
based O O
on O O
NDVI O O
data O O
appears O O
to O O
be O O
better O O
than O O
that O O
from O O
forecast O O
indices O O
based O O
only O O
on O O
climatic O O
data O O
. O O
It O O
has O O
been O O
confirmed O O
in O O
animal O O
experiments O O
that O O
the O O
number O O
of O O
microspheres O O
in O O
a O O
myocardial O O
sample O O
approximately O O
follows O O
a O O
Poisson O O
distribution O O
, O O
under O O
adequate O O
experimental O O
conditions O O
. O O
Hepatitis B-GENE O
B I-GENE O
immune I-GENE O
globulins E-GENE O
and O O
HIV B-GENE O
antibodies E-GENE O
. O O
This O O
gene O O
is O O
divided O O
into O O
six O O
exons O O
spanning O O
about O O
3kb O S-GENE
, O O
and O O
encodes O O
a O O
175 O O
amino O O
acid O O
protein O O
with O O
40 O O
- O O
52 O O
% O O
identity O O
with O O
the O O
other O O
five O O
mouse B-GENE O
Reg E-GENE O
( O O
regenerating B-GENE O
gene I-GENE O
product E-GENE O
) O O
proteins O O
. O O
The O O
p63 B-GENE B-GENE
sequence E-GENE E-GENE
also O O
features O O
an O O
acidic O O
domain O O
characteristic O O
of O O
transcriptional O O
activation O O
factors O O
, O O
as O O
well O O
as O O
sequence O O
blocks O O
displaying O O
limited O O
similarity O O
to O O
positionally O O
equivalent O O
regions O O
in O O
sigma B-GENE O
factors E-GENE O
from O O
eubacteria O O
related O O
to O O
mitochondria O O
. O O
In O O
contrast O O
, O O
a O O
similar O O
fusion O O
protein O O
( O O
hGH S-GENE B-GENE
- O I-GENE
LDLR S-GENE I-GENE
- O I-GENE
DAF17 S-GENE E-GENE
, O O
abbreviated O O
HLD S-GENE O
) O O
containing O O
a O O
fragment O O
of O O
the O O
serine O O
/ O O
threonine O O
- O O
rich O O
domain O O
of O O
the O O
LDL B-GENE B-GENE
receptor E-GENE E-GENE
( O O
LDLR S-GENE S-GENE
) O O
in O O
place O O
of O O
the O O
DAF B-GENE B-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
serine I-GENE E-GENE
/ I-GENE O
threonine I-GENE O
- I-GENE O
rich I-GENE O
sequences E-GENE O
, O O
does O O
not O O
become O O
GPI O O
anchored O O
. O O
Thus O O
, O O
the O O
pathway O O
to O O
Fc B-GENE O
epsilonRI E-GENE O
- O O
mediated O O
MEK S-GENE S-GENE
/ O O
ERK S-GENE S-GENE
and O O
ERK S-GENE S-GENE
activation O O
can O O
apparently O O
bypass O O
Ras S-GENE O
and O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
To O O
assess O O
whether O O
thallium O O
- O O
201 O O
thallous O O
chloride O O
( O O
Tl O O
) O O
can O O
detect O O
childhood O O
tumors O O
and O O
whether O O
diagnostic O O
effectiveness O O
improves O O
with O O
combined O O
blood O O
flow O O
imaging O O
, O O
28 O O
children O O
( O O
1 O O
. O O
0 O O
- O O
18 O O
. O O
6 O O
years O O
) O O
were O O
studied O O
using O O
single O O
photon O O
emission O O
computed O O
tomography O O
( O O
SPECT O O
) O O
: O O
Tl O O
( O O
1 O O
. O O
3 O O
- O O
1 O O
. O O
8 O O
mCi O O
intravenously O O
) O O
, O O
followed O O
in O O
13 O O
of O O
the O O
patients O O
by O O
technetium O O
- O O
99m O O
- O O
hexamethylpropyleneamine O O
oxime O O
( O O
99mTc O O
- O O
HMPAO O O
; O O
8 O O
- O O
18 O O
mCi O O
intravenously O O
) O O
. O O
Ftz S-GENE S-GENE
, O O
on O O
the O O
other O O
hand O O
, O O
influences O O
Ftz S-GENE B-GENE
- O I-GENE
F1 S-GENE E-GENE
activity O O
by O O
interacting O O
with O O
its O O
AF O B-GENE
- O I-GENE
2 O I-GENE
domain O E-GENE
in O O
a O O
manner O O
that O O
mimics O O
a O O
nuclear O O
receptor O O
coactivator O O
. O O
Successive O O
5 O O
' O O
deletions O O
of O O
the O O
[ O O
- O O
326 O O
; O O
+ O O
20 O O
] O O
type B-GENE O
II I-GENE B-GENE
sPLA2 I-GENE I-GENE
promoter E-GENE E-GENE
indicated O O
that O O
the O O
region O O
upstream O O
of O O
position O O
- O O
195 O O
inhibits O O
the O O
transcription O O
activity O O
sixfold O O
in O O
HepG2 O O
cells O O
but O O
not O O
in O O
HeLa O O
cells O O
. O O
Forty O O
- O O
five O O
patients O O
with O O
recent O O
- O O
onset O O
hyperthyroidism O O
( O O
< O O
12 O O
weeks O O
) O O
were O O
sex O O
and O O
menopause O O
stratified O O
and O O
randomly O O
allocated O O
to O O
treatment O O
with O O
carbimazole O O
( O O
Neotomizol O O
) O O
, O O
carbimazole O O
plus O O
low O O
dose O O
CT O O
( O O
Calsynar O O
; O O
100 O O
IU O O
/ O O
day O O
, O O
2 O O
days O O
/ O O
week O O
) O O
, O O
or O O
carbimazole O O
plus O O
high O O
dose O O
CT O O
( O O
Calsynar O O
; O O
100 O O
IU O O
/ O O
day O O
, O O
14 O O
days O O
/ O O
month O O
) O O
. O O
The O O
cloning O O
of O O
CWH43 S-GENE S-GENE
showed O O
that O O
it O O
corresponds O O
to O O
YCR017c S-GENE S-GENE
and O O
encodes O O
a O O
protein O O
with O O
14 O O
- O O
16 O O
transmembrane O O
segments O O
containing O O
several O O
putative O O
phosphorylation O O
and O O
glycosylation O O
sites O O
. O O
However O O
, O O
strains O O
in O O
which O O
both O O
of O O
the O O
two O O
most O O
highly O O
related O O
genes O O
, O O
DdPIK1 S-GENE S-GENE
and O O
DdPIK2 S-GENE S-GENE
, O O
were O O
disrupted O O
showed O O
both O O
growth O O
and O O
developmental O O
defects O O
, O O
while O O
double O O
knockouts O O
of O O
DdPIK1 S-GENE O
and O O
DdPIK3 S-GENE O
and O O
DdPIK2 S-GENE O
and O O
DdPIK3 S-GENE O
appear O O
to O O
be O O
lethal O O
. O O
This O O
mechanism O O
seems O O
to O O
be O O
involved O O
in O O
VIP S-GENE O
- O O
induced O O
PRL B-GENE B-GENE
gene E-GENE E-GENE
regulation O O
. O O
Competition O O
and O O
methylation O O
interference O O
assays O O
showed O O
that O O
the O O
binding O O
site O O
for O O
the O O
novel O O
factor O O
was O O
limited O O
to O O
nucleotides O O
in O O
the O O
3 O O
' O O
half O O
of O O
the O O
kappa B-GENE B-GENE
B I-GENE I-GENE
site E-GENE E-GENE
. O O
These O O
properties O O
prompted O O
us O O
to O O
investigate O O
Ets B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
expression O O
in O O
32 O O
human O O
astroglial O O
tumors O O
of O O
WHO O O
grades O O
I O O
- O O
IV O O
and O O
to O O
correlate O O
the O O
data O O
with O O
the O O
expression O O
pattern O O
of O O
VEGF S-GENE S-GENE
, O O
Flt B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
and O O
KDR S-GENE S-GENE
. O O
Mean O O
concentration O O
of O O
insulin S-GENE O
in O O
maternal O O
plasma O O
across O O
all O O
sampling O O
times O O
was O O
higher O O
in O O
ethanol O O
treated O O
animals O O
. O O
The O O
strongly O O
DNA O O
binding O O
p50 B-GENE B-GENE
subunit E-GENE E-GENE
showed O O
only O O
very O O
weak O O
, O O
if O O
any O O
, O O
induction O O
of O O
gene O O
expression O O
. O O
The O O
results O O
obtained O O
demonstrate O O
the O O
applicability O O
of O O
countercurrent O O
chromatography O O
to O O
the O O
determination O O
of O O
ultratrace O O
elements O O
. O O
E1A S-GENE B-GENE
+ O I-GENE
cHa B-GENE I-GENE
- I-GENE I-GENE
ras E-GENE E-GENE
transformed O O
rat O O
embryo O O
fibroblast O O
cells O O
are O O
characterized O O
by O O
high O O
and O O
constitutive O O
DNA O O
binding O O
activities O O
of O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
dimers E-GENE O
with O O
significantly O O
altered O O
composition O O
. O O
Minor O O
changes O O
within O O
the O O
transmembrane O O
domains O O
( O O
TMs O O
) O O
sometimes O O
produced O O
major O O
effects O O
and O O
more O O
drastic O O
changes O O
in O O
the O O
TMs O O
ablated O O
surface O O
expression O O
entirely O O
. O O
Nuclear O O
localization O O
of O O
this O O
SNF2 B-GENE S-GENE
- I-GENE O
like E-GENE O
putative O O
helicase S-GENE O
is O O
dependent O O
on O O
a O O
nuclear O O
localization O O
sequence O O
located O O
in O O
the O O
NH2 O O
- O O
terminal O O
region O O
. O O
The O O
feasibility O O
of O O
creating O O
CR1 S-GENE S-GENE
/ O O
Ig S-GENE O
chimeras O O
makes O O
possible O O
a O O
new O O
strategy O O
of O O
targeting O O
complement O O
inhibition O O
by O O
the O O
use O O
of O O
Ig B-GENE O
fusion I-GENE O
partners E-GENE O
having O O
particular O O
antigenic O O
specificities O O
. O O
Morphological O O
- O O
functional O O
status O O
of O O
the O O
edentulous O O
mandible O O
and O O
selection O O
of O O
the O O
most O O
effective O O
method O O
for O O
functional O O
impression O O
- O O
taking O O
They O O
are O O
both O O
insensitive O O
to O O
inhibitors O O
of O O
serine B-GENE O
and I-GENE O
aspartyl I-GENE O
proteinases E-GENE O
but O O
are O O
sensitive O O
to O O
sulfhydryl O O
reagents O O
and O O
0 O O
. O O
5 O O
mM O O
ZnCl2 O O
. O O
The O O
tau O O
v O O
at O O
rest O O
was O O
4 O O
. O O
06 O O
+ O O
/ O O
- O O
2 O O
. O O
16 O O
s O O
and O O
decreased O O
to O O
2 O O
. O O
44 O O
+ O O
/ O O
- O O
1 O O
. O O
07 O O
s O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
at O O
1 O O
Hz O O
and O O
to O O
1 O O
. O O
81 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
s O O
at O O
5 O O
Hz O O
. O O
The O O
authors O O
investigate O O
in O O
a O O
group O O
of O O
211 O O
children O O
aged O O
2 O O
- O O
6 O O
years O O
, O O
incl O O
. O O
in O O
particular O O
a O O
group O O
of O O
33 O O
2 O O
- O O
year O O
- O O
old O O
ones O O
, O O
in O O
1990 O O
and O O
checked O O
in O O
1991 O O
at O O
two O O
sites O O
in O O
Bratislava O O
- O O
- O O
a O O
town O O
with O O
a O O
varying O O
concentration O O
of O O
NOX O O
, O O
SO2 O O
, O O
dustiness O O
and O O
dust O O
fallout O O
- O O
- O O
their O O
influence O O
on O O
the O O
incidence O O
, O O
type O O
and O O
course O O
of O O
relapsing O O
respiratory O O
disease O O
. O O
However O O
, O O
no O O
statistical O O
difference O O
in O O
the O O
Ca O O
/ O O
P O O
ratio O O
, O O
carbon O O
concentration O O
and O O
surface O O
energy O O
were O O
observed O O
with O O
different O O
heat O O
treatments O O
. O O
Using O O
in O O
vivo O O
genomic O O
dimethyl O O
sulfate O O
and O O
KMnO4 O O
footprinting O O
, O O
we O O
showed O O
that O O
the O O
promoter O O
region O O
is O O
differentially O O
protected O O
, O O
depending O O
upon O O
which O O
holoenzyme O O
is O O
bound O O
. O O
Here O O
we O O
show O O
that O O
inhibition O O
occurs O O
with O O
a O O
NS1 S-GENE B-GENE
- O I-GENE
Rev S-GENE I-GENE
chimera O E-GENE
in O O
which O O
the O O
78 O O
amino O O
- O O
terminal O O
amino O O
acids O O
of O O
the O O
NS1A B-GENE B-GENE
protein E-GENE E-GENE
comprising O O
its O O
entire O O
RNA O O
- O O
binding O O
domain O O
is O O
deleted O O
, O O
thereby O O
establishing O O
that O O
this O O
carboxyl O O
portion O O
of O O
the O O
NS1A B-GENE B-GENE
protein E-GENE E-GENE
can O O
function O O
as O O
an O O
independent O O
effector O O
domain O O
. O O
Overall O O
, O O
it O O
appears O O
that O O
prenatal O O
exposure O O
to O O
androgen O O
- O O
based O O
synthetic O O
progestin O O
exerted O O
a O O
masculinizing O O
and O O
/ O O
or O O
defeminizing O O
influence O O
on O O
human O O
behavioral O O
development O O
, O O
whereas O O
prenatal O O
exposure O O
to O O
natural O O
progesterone O O
and O O
progesterone O O
- O O
based O O
synthetic O O
progestin O O
had O O
a O O
feminizing O O
and O O
/ O O
or O O
demasculinizing O O
influence O O
, O O
particularly O O
among O O
female O O
subjects O O
. O O
The O O
testes O O
of O O
8 O O
specimens O O
of O O
Triturus O O
marmoratus O O
were O O
collected O O
during O O
each O O
month O O
of O O
1987 O O
and O O
processed O O
for O O
electron O O
microscopy O O
and O O
light O O
microscopy O O
demonstration O O
of O O
testosterone O O
( O O
T O O
) O O
following O O
the O O
ABC S-GENE O
( O O
avidin B-GENE O
- I-GENE O
biotin I-GENE O
peroxidase I-GENE O
complex E-GENE O
) O O
method O O
. O O
MTX O O
therapy O O
decreased O O
Ga O O
- O O
67 O O
uptake O O
in O O
liver O O
, O O
tumor O O
, O O
and O O
muscle O O
. O O
In O O
stage O O
I O O
, O O
histochemistry O O
for O O
copper O O
was O O
positive O O
in O O
11 O O
out O O
of O O
21 O O
cases O O
: O O
6 O O
cases O O
were O O
T O O
+ O O
; O O
1 O O
case O O
R O O
+ O O
and O O
2 O O
cases O O
O O O
+ O O
; O O
2 O O
cases O O
were O O
T O O
+ O O
, O O
R O O
+ O O
, O O
O O O
+ O O
. O O
Encapsulation O O
of O O
sodium O O
fluorescein O O
for O O
dye O O
release O O
studies O O
. O O
Primer O O
extension O O
analysis O O
and O O
subcloning O O
of O O
the O O
virJ S-GENE O
- O O
phoA S-GENE O
fusion O O
indicate O O
that O O
the O O
acetosyringone O O
- O O
inducible O O
promoter O O
lies O O
directly O O
upstream O O
of O O
the O O
virJ B-GENE B-GENE
structural I-GENE I-GENE
gene E-GENE E-GENE
. O O
To O O
isolate O O
genes O O
that O O
contain O O
zinc O O
finger O O
motifs O O
, O O
a O O
human O O
brain O O
cDNA O O
library O O
was O O
screened O O
with O O
an O O
oligonucleotide O O
complementary O O
to O O
the O O
conserved O O
" O O
linker O O
" O O
sequence O O
between O O
adjacent O O
zinc O O
fingers O O
. O O
Percentage O O
incremental O O
18 O O
- O O
OHB O O
responses O O
to O O
metoclopramide O O
were O O
greater O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
in O O
the O O
subjects O O
after O O
5 O O
days O O
on O O
a O O
200 O O
- O O
meq O O
sodium O O
intake O O
than O O
after O O
5 O O
days O O
on O O
a O O
10 O O
- O O
meq O O
sodium O O
intake O O
. O O
Using O O
in O O
vivo O O
screening O O
, O O
we O O
first O O
identified O O
a O O
gene O O
that O O
appeared O O
to O O
interfere O O
with O O
the O O
His O O
- O O
Asp O O
phosphorelay O O
between O O
the O O
HPt O B-GENE
domain O E-GENE
and O O
the O O
receiver O O
domain O O
of O O
OmpR S-GENE S-GENE
, O O
provided O O
that O O
the O O
gene O O
product O O
was O O
expressed O O
through O O
a O O
multicopy O O
plasmid O O
. O O
The O O
non B-GENE O
- I-GENE O
major I-GENE O
histocompatibility I-GENE O
complex E-GENE O
( O O
MHC S-GENE S-GENE
) O O
- O O
encoded O O
CD1 B-GENE B-GENE
family E-GENE E-GENE
has O O
recently O O
emerged O O
as O O
a O O
new O O
antigen O O
- O O
presenting O O
system O O
that O O
is O O
distinct O O
from O O
either O O
MHC B-GENE B-GENE
class I-GENE I-GENE
I I-GENE E-GENE
or I-GENE O
class I-GENE O
II I-GENE O
molecules E-GENE O
. O O
The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
Pst1p S-GENE S-GENE
possessed O O
high O O
sequence O O
homology O O
with O O
the O O
Sin3 B-GENE B-GENE
family E-GENE E-GENE
of O O
proteins O O
, O O
known O O
for O O
their O O
interaction O O
with O O
histone B-GENE O
deacetylases E-GENE O
. O O
Quinethazone O O
Studies O O
on O O
nitrogen O O
- O O
containing O O
heterocyclic O O
compounds O O
. O O
Removal O O
of O O
ink4a S-GENE O
dramatically O O
reduces O O
the O O
lymphoid O O
and O O
neurological O O
defects O O
seen O O
in O O
bmi B-GENE O
- I-GENE O
1 E-GENE O
- O O
deficient O O
mice O O
, O O
indicating O O
that O O
ink4a S-GENE O
is O O
a O O
critical O O
in O O
vivo O O
target O O
for O O
Bmi B-GENE O
- I-GENE O
1 E-GENE O
. O O
We O O
found O O
that O O
RXR S-GENE S-GENE
and O O
VDR S-GENE O
transactivated O O
selectively O O
from O O
VDRE O O
- O O
linked O O
templates O O
exclusively O O
as O O
a O O
heterodimeric O O
complex O O
, O O
since O O
neither O O
receptor O O
alone O O
enhanced O O
transcription O O
in O O
vitro O O
. O O
METHODS O O
: O O
We O O
performed O O
nasal O O
mupirocin O O
treatment O O
on O O
10 O O
infants O O
who O O
were O O
MRSA O O
- O O
positive O O
either O O
in O O
the O O
nose O O
or O O
the O O
pharynx O O
and O O
evaluated O O
the O O
effect O O
of O O
mupirocin O O
on O O
the O O
eradication O O
of O O
MRSA O O
. O O
RESULTS O O
: O O
Of O O
10 O O
, O O
709 O O
, O O
701 O O
chemistry O O
specimens O O
submitted O O
to O O
the O O
participating O O
laboratories O O
during O O
the O O
data O O
collection O O
period O O
, O O
37 O O
, O O
208 O O
( O O
0 O O
. O O
35 O O
% O O
) O O
were O O
rejected O O
prior O O
to O O
testing O O
. O O
Early O O
complement O O
components O O
, O O
C1q S-GENE S-GENE
and O O
C4 S-GENE O
, O O
and O O
IgA S-GENE S-GENE
secretory O O
piece O O
were O O
absent O O
. O O
Administration O O
of O O
SnCl2 O O
and O O
ZnSO4 O O
( O O
group O O
V O O
) O O
resulted O O
in O O
a O O
decrease O O
of O O
ALA B-GENE O
- I-GENE O
D E-GENE O
activity O O
and O O
in O O
an O O
increase O O
in O O
CP O O
- O O
U O O
. O O
Using O O
a O O
dominant O O
negative O O
form O O
of O O
Sp3 S-GENE S-GENE
and O O
transcriptional O O
activation O O
assays O O
in O O
Schneider O O
SL O O
- O O
2 O O
insect O O
cells O O
, O O
it O O
was O O
confirmed O O
that O O
ERalpha S-GENE B-GENE
- O I-GENE
Sp3 S-GENE E-GENE
interactions O O
define O O
a O O
pathway O O
for O O
E2 S-GENE S-GENE
- O O
mediated O O
inhibition O O
of O O
gene O O
expression O O
, O O
and O O
this O O
represents O O
a O O
new O O
mechanism O O
for O O
decreased O O
gene O O
expression O O
by O O
E2 S-GENE S-GENE
. O O
From O O
the O O
supposition O O
that O O
there O O
exists O O
a O O
possible O O
connection O O
between O O
certain O O
psychopathological O O
symptoms O O
, O O
and O O
/ O O
or O O
syndromes O O
( O O
e O O
. O O
g O O
. O O
, O O
hallucinations O O
) O O
and O O
regional O O
cerebral O O
dysfunction O O
, O O
patients O O
suffering O O
from O O
auditory O O
and O O
tactile O O
hallucinations O O
were O O
investigated O O
, O O
in O O
a O O
symptom O O
- O O
oriented O O
study O O
, O O
using O O
the O O
method O O
of O O
technetium O O
- O O
99m O O
- O O
Hexamethyl O O
- O O
propylenamine O O
Oxime O O
( O O
99m O O
- O O
Tc O O
- O O
HMPAO O O
) O O
- O O
Single O O
Photon O O
Emission O O
Computed O O
Tomography O O
( O O
SPECT O O
) O O
and O O
compared O O
with O O
normal O O
controls O O
. O O
The O O
lack O O
of O O
chronically O O
depressed O O
LCBF O O
( O O
after O O
1 O O
day O O
) O O
may O O
be O O
related O O
to O O
the O O
quick O O
structural O O
repair O O
of O O
endothelium O O
. O O
In O O
this O O
study O O
, O O
to O O
elucidate O O
the O O
possible O O
mechanism O O
of O O
action O O
of O O
EM O O
, O O
we O O
examined O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
expression O O
of O O
neutrophil O O
adhesion O O
molecules O O
such O O
as O O
L B-GENE O
- I-GENE O
selectin E-GENE O
and O O
Mac B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
. O O
Tissue O O
expansion O O
was O O
used O O
successfully O O
to O O
prepare O O
adequate O O
soft O O
tissue O O
for O O
closure O O
following O O
a O O
difficult O O
clubfoot O O
correction O O
. O O
The O O
transcription O O
start O O
site O O
was O O
identified O O
by O O
primer O O
extension O O
analysis O O
and O O
over O O
800 O O
bp O O
of O O
5 O O
' O O
flanking O O
DNA O O
was O O
sequenced O O
. O O
The O O
reporter O O
gene O O
with O O
two O O
copies O O
of O O
the O O
wild O O
- O O
type O O
Repeat O O
2 O O
+ O O
3 O O
sequence O O
was O O
transcribed O O
actively O O
in O O
sterol O O
- O O
deprived O O
cells O O
and O O
was O O
repressed O O
by O O
more O O
than O O
80 O O
% O O
when O O
sterols O O
were O O
present O O
. O O
Changes O O
in O O
tension O O
were O O
monitored O O
isometrically O O
on O O
spiral O O
strips O O
of O O
freshly O O
obtained O O
bovine O O
basilar O O
arteries O O
. O O
A O O
1 O O
. O O
5 O O
- O O
month O O
- O O
old O O
boy O O
with O O
Sandifer O O
' O O
s O O
syndrome O O
is O O
described O O
. O O
However O O
, O O
PC12 O O
cell O O
clones O O
which O O
expressed O O
p33rsu B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
at O O
an O O
increased O O
level O O
in O O
a O O
regulatable O O
fashion O O
in O O
response O O
to O O
dexamethasone O O
were O O
isolated O O
. O O
In O O
this O O
study O O
, O O
we O O
verified O O
that O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
associates O O
with O O
the O O
CD4 S-GENE S-GENE
: O O
p56lck B-GENE S-GENE
complex E-GENE O
as O O
judged O O
by O O
the O O
presence O O
of O O
PI O O
3 O O
- O O
phosphate O O
generated O O
from O O
anti B-GENE O
- I-GENE O
CD4 E-GENE O
immunoprecipitates O O
and O O
detected O O
by O O
high O O
- O O
pressure O O
liquid O O
chromatographic O O
analysis O O
. O O
The O O
clinical O O
picture O O
, O O
the O O
light O O
and O O
electron O O
microscopic O O
appearance O O
, O O
and O O
the O O
histochemical O O
findings O O
are O O
described O O
in O O
six O O
cases O O
of O O
fibroma O O
of O O
tendon O O
sheath O O
. O O
However O O
, O O
their O O
stability O O
was O O
low O O
as O O
already O O
reported O O
for O O
the O O
ARS O O
in O O
S O O
. O O
occidentalis O O
. O O
In O O
this O O
study O O
, O O
a O O
site O O
of O O
PDGF S-GENE S-GENE
- O O
induced O O
tyrosine O O
phosphorylation O O
was O O
mapped O O
to O O
Tyr O O
138 O O
in O O
the O O
SH3 B-GENE B-GENE
domain E-GENE E-GENE
; O O
Tyr O O
138 O O
is O O
exposed O O
on O O
the O O
SH3 B-GENE B-GENE
peptide I-GENE E-GENE
binding I-GENE O
surface E-GENE O
. O O
The O O
results O O
of O O
this O O
study O O
suggest O O
that O O
in O O
patients O O
with O O
syndrome O O
X O O
, O O
myocardial O O
ischemia O O
frequently O O
develops O O
during O O
daily O O
life O O
; O O
silent O O
ischemia O O
is O O
an O O
important O O
component O O
of O O
this O O
syndrome O O
; O O
and O O
increased O O
oxygen O O
demand O O
in O O
the O O
presence O O
of O O
impaired O O
coronary O O
vasodilatory O O
capacity O O
is O O
not O O
the O O
only O O
cause O O
of O O
myocardial O O
ischemia O O
. O O
We O O
also O O
identified O O
a O O
DNA O O
fragment O O
, O O
10 O O
. O O
7 O O
kbp O O
upstream O O
from O O
the O O
first O O
coding O O
exon O O
of O O
human B-GENE B-GENE
aFGF E-GENE E-GENE
, O O
whose O O
sequence O O
is O O
conserved O O
in O O
both O O
the O O
primate O O
and O O
rodent O O
genomes O O
. O O
The O O
false O O
positive O O
fraction O O
( O O
FPF O O
) O O
decreased O O
significantly O O
if O O
the O O
count O O
density O O
increased O O
; O O
no O O
difference O O
in O O
FPF O O
was O O
found O O
for O O
a O O
change O O
in O O
lesion O O
tracer O O
concentration O O
. O O
These O O
events O O
were O O
only O O
weakly O O
stimulated O O
by O O
the O O
activated B-GENE O
PDGF I-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
. O O
Human B-GENE B-GENE
plastin I-GENE I-GENE
genes E-GENE E-GENE
. O O
Buserelin O O
offers O O
an O O
effective O O
alternative O O
medical O O
treatment O O
of O O
carcinoma O O
of O O
the O O
prostate O O
and O O
, O O
apart O O
from O O
impotence O O
, O O
does O O
not O O
have O O
the O O
side O O
effects O O
of O O
oestrogens O O
. O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
delta E-GENE E-GENE
( O O
NFIL B-GENE O
- I-GENE O
6 I-GENE O
beta E-GENE O
) O O
was O O
not O O
detected O O
in O O
complexes O O
utilizing O O
extracts O O
from O O
the O O
IL B-GENE O
- I-GENE O
1 E-GENE O
nonproducing O O
T O O
cell O O
line O O
. O O
Reduced O O
risk O O
of O O
upper O O
gastrointestinal O O
ulcer O O
complications O O
with O O
celecoxib O O
, O O
a O O
novel O O
COX B-GENE O
- I-GENE O
2 E-GENE O
inhibitor O O
. O O
Moreover O O
, O O
our O O
recent O O
findings O O
on O O
the O O
Tc52 B-GENE B-GENE
encoding I-GENE I-GENE
gene E-GENE E-GENE
underline O O
the O O
interest O O
of O O
genetic O O
manipulation O O
of O O
T O O
. O O
cruzi O O
, O O
not O O
only O O
making O O
it O O
possible O O
to O O
use O O
more O O
closely O O
an O O
in O O
vitro O O
approach O O
to O O
find O O
out O O
how O O
genes O O
function O O
, O O
but O O
also O O
to O O
obtain O O
' O O
attenuated O O
' O O
strains O O
that O O
could O O
be O O
used O O
in O O
the O O
development O O
of O O
vaccinal O O
strategies O O
. O O
Infra O O
- O O
red O O
spectroscopy O O
of O O
tissues O O
in O O
the O O
700 O O
- O O
400 O O
cm O O
- O O
1 O O
region O O
. O O
YDL003w S-GENE S-GENE
( O O
also O O
termed O O
MCD1 S-GENE S-GENE
) O O
is O O
a O O
homologue O O
of O O
Schizosaccharomyces B-GENE O
pombe I-GENE O
rad21 E-GENE O
, O O
an O O
essential O O
gene O O
implicated O O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
and O O
nuclear O O
organization O O
in O O
fission O O
yeast O O
. O O
The O O
recent O O
concept O O
of O O
a O O
bioartificial O O
organ O O
is O O
an O O
attempt O O
to O O
avoid O O
such O O
disadvantages O O
. O O
The O O
objectives O O
of O O
this O O
study O O
were O O
1 O O
) O O
to O O
quantify O O
the O O
comparative O O
structural O O
static O O
and O O
fatigue O O
properties O O
of O O
the O O
pointe O O
shoe O O
toe O O
box O O
, O O
and O O
2 O O
) O O
to O O
evaluate O O
the O O
preferred O O
shoe O O
characteristics O O
as O O
determined O O
by O O
a O O
survey O O
of O O
local O O
dancers O O
. O O
In O O
the O O
postoperative O O
patient O O
with O O
tetralogy O O
of O O
Fallot O O
with O O
symptomatic O O
ventricular O O
arrhythmias O O
, O O
it O O
is O O
concluded O O
that O O
electrophysiologic O O
study O O
is O O
useful O O
in O O
reproducing O O
clinical O O
episodes O O
of O O
VT O O
and O O
in O O
selecting O O
effective O O
antiarrhythmic O O
medication O O
; O O
a O O
small O O
number O O
of O O
patients O O
with O O
ventricular O O
premature O O
complexes O O
alone O O
will O O
have O O
inducible O O
sustained O O
VT O O
during O O
electrophysiologic O O
study O O
; O O
prognosis O O
of O O
these O O
patients O O
may O O
be O O
improved O O
by O O
treatment O O
that O O
results O O
in O O
prevention O O
of O O
VT O O
induction O O
; O O
and O O
in O O
patients O O
with O O
right O O
ventricular O O
hypertension O O
, O O
VT O O
is O O
likely O O
to O O
be O O
refractory O O
to O O
drug O O
treatment O O
. O O
Indications O O
for O O
therapy O O
using O O
MAO S-GENE O
inhibitors O O
The O O
absorbance O O
of O O
the O O
eluent O O
was O O
monitored O O
at O O
254 O O
nm O O
. O O
Here O O
, O O
we O O
describe O O
the O O
results O O
of O O
a O O
detailed O O
study O O
aimed O O
at O O
identifying O O
the O O
gene O O
or O O
genes O O
responsible O O
for O O
the O O
rapid O O
growth O O
- O O
arrest O O
response O O
obtained O O
with O O
human O O
chromosome O O
- O O
9 O O
. O O
Footprints O O
on O O
the O O
HPV B-GENE O
18 I-GENE O
enhancer E-GENE O
show O O
five O O
protected O O
regions O O
with O O
homologies O O
to O O
NF1 S-GENE S-GENE
, O O
AP1 S-GENE S-GENE
and O O
EFII B-GENE S-GENE
transcription I-GENE O
factor I-GENE O
binding I-GENE O
motifs E-GENE O
. O O
Insulin S-GENE O
binding O O
to O O
the O O
alpha O B-GENE
- O I-GENE
subunit O E-GENE
of O O
its O O
receptor O O
stimulates O O
the O O
receptor B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
to O O
phosphorylate O O
the O O
beta O B-GENE
- O I-GENE
subunit O E-GENE
and O O
several O O
endogenous O O
protein O O
substrates O O
, O O
including O O
pp120 S-GENE S-GENE
/ O O
HA4 S-GENE S-GENE
, O O
a O O
liver O O
- O O
specific O O
plasma O O
membrane O O
glycoprotein O O
of O O
M O O
( O O
r O O
) O O
20 O O
, O O
000 O O
. O O
Motilin S-GENE O
serum O O
levels O O
were O O
measured O O
for O O
one O O
hour O O
. O O
The O O
role O O
of O O
phosphorylation O O
on O O
receptor O O
desensitization O O
was O O
assessed O O
using O O
receptor O O
mutants O O
expressed O O
in O O
COS O O
cells O O
or O O
Chinese O O
hamster O O
lung O O
fibroblasts O O
. O O
First O O
aid O O
. O O
Improvement O O
of O O
some O O
pharmaceutical O O
properties O O
of O O
clofibrate O O
by O O
cyclodextrin O O
complexation O O
. O O
The O O
detection O O
limits O O
obtained O O
by O O
using O O
the O O
mixed O O
eluent O O
were O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
13 O O
mg O O
/ O O
L O O
, O O
several O O
times O O
lower O O
than O O
those O O
obtained O O
by O O
using O O
single O O
KHPh O O
eluent O O
. O O
Early O O
diagnosis O O
and O O
early O O
surgical O O
division O O
of O O
the O O
biliary O O
tract O O
and O O
pancreatic O O
duct O O
is O O
recommended O O
for O O
children O O
with O O
AAPBD O O
. O O
We O O
have O O
analyzed O O
herein O O
the O O
roles O O
that O O
four O O
different O O
PIAS B-GENE B-GENE
proteins E-GENE E-GENE
( O O
ARIP3 S-GENE S-GENE
/ O O
PIASx B-GENE B-GENE
alpha E-GENE E-GENE
, O O
Miz1 S-GENE S-GENE
/ O O
PIASx B-GENE B-GENE
beta E-GENE E-GENE
, O O
GBP S-GENE S-GENE
/ O O
PIAS1 S-GENE S-GENE
, O O
and O O
PIAS3 S-GENE S-GENE
) O O
play O O
in O O
the O O
regulation O O
of O O
steroid B-GENE O
receptor E-GENE O
- O O
or O O
STAT S-GENE O
- O O
mediated O O
transcriptional O O
activation O O
. O O
Comparison O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
Drosophila B-GENE B-GENE
virilis I-GENE I-GENE
gene E-GENE E-GENE
shows O O
that O O
several O O
blocks O O
of O O
amino O O
acid O O
sequence O O
have O O
been O O
very O O
highly O O
conserved O O
. O O
Analyses O O
focused O O
on O O
two O O
platyrrhine O O
( O O
New O O
World O O
monkey O O
) O O
species O O
: O O
the O O
common O O
marmoset O O
( O O
Callithrix O O
jacchus O O
) O O
and O O
the O O
brown O O
capuchin O O
monkey O O
( O O
Cebus O O
apella O O
) O O
, O O
each O O
of O O
which O O
has O O
paired O O
, O O
non O O
- O O
allelic O O
gamma O O
loci O O
( O O
5 O O
' O O
- O O
gamma O O
1 O O
- O O
gamma O O
2 O O
- O O
3 O O
' O O
) O O
. O O
A O O
phase O O
II O O
clinical O O
trial O O
on O O
MDS O O
was O O
conducted O O
in O O
a O O
cooperative O O
study O O
with O O
orally O O
administrable O O
ara O O
- O O
C O O
analogue O O
, O O
PLAC O O
, O O
which O O
is O O
resistant O O
to O O
cytidine B-GENE O
deaminase E-GENE O
and O O
had O O
shown O O
an O O
anti O O
- O O
tumor O O
activity O O
on O O
various O O
experimental O O
tumors O O
by O O
oral O O
route O O
. O O
A O O
decrease O O
was O O
also O O
found O O
of O O
the O O
levels O O
of O O
total O O
cholesterol O O
and O O
LDL B-GENE O
- I-GENE O
cholesterol E-GENE O
. O O
Previously O O
, O O
we O O
had O O
shown O O
that O O
interleukin B-GENE O
8 E-GENE O
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
8 E-GENE E-GENE
) O O
is O O
constitutively O O
expressed O O
in O O
HTLV O O
- O O
I O O
- O O
infected O O
cells O O
and O O
in O O
cells O O
transiently O O
expressing O O
Tax S-GENE O
. O O
Unlike O O
JNK S-GENE S-GENE
activation O O
, O O
ERK S-GENE S-GENE
activation O O
could O O
not O O
be O O
mapped O O
to O O
specific O O
reovirus O O
gene O O
segments O O
, O O
suggesting O O
that O O
ERK S-GENE S-GENE
activation O O
and O O
JNK S-GENE S-GENE
activation O O
are O O
triggered O O
by O O
different O O
events O O
during O O
virus O O
- O O
host O O
cell O O
interaction O O
. O O
Despite O O
the O O
same O O
decreases O O
or O O
increases O O
in O O
MAP O O
, O O
RSNA O O
was O O
attenuated O O
after O O
15 O O
and O O
30 O O
min O O
of O O
propofol O O
infusion O O
in O O
both O O
groups O O
compared O O
with O O
control O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O
To O O
address O O
this O O
question O O
with O O
respect O O
to O O
skeletal O O
muscle O O
, O O
we O O
have O O
examined O O
the O O
effects O O
of O O
the O O
Providence O O
mutation O O
in O O
cultured O O
muscle O O
cells O O
, O O
after O O
adoptive O O
gene O O
transfer O O
to O O
adult O O
mice O O
, O O
and O O
in O O
two O O
infants O O
homozygous O O
for O O
spectrin B-GENE O
Providence E-GENE O
. O O
It O O
appears O O
to O O
be O O
useful O O
in O O
untreated O O
patients O O
with O O
stage O O
I O O
or O O
II O O
NHL O O
but O O
no O O
definite O O
radiographic O O
abnormalities O O
, O O
or O O
with O O
abnormal O O
radiographs O O
but O O
no O O
extrathoracic O O
spread O O
, O O
and O O
in O O
treated O O
patients O O
with O O
questionable O O
radiographs O O
. O O
B S-GENE O
and O O
C1 B-GENE O
fusions E-GENE O
with O O
yeast B-GENE O
GAL4 I-GENE O
DNA I-GENE O
- I-GENE O
binding I-GENE O
and I-GENE O
transcriptional I-GENE O
activation I-GENE O
domains E-GENE O
were O O
also O O
found O O
to O O
interact O O
when O O
synthesized O O
and O O
assayed O O
in O O
yeast O O
. O O
Because O O
of O O
the O O
data O O
, O O
we O O
suggest O O
that O O
LAC9 S-GENE O
contacts O O
positions O O
6 O O
, O O
7 O O
, O O
and O O
8 O O
, O O
both O O
plus O O
and O O
minus O O
, O O
of O O
the O O
UAS O O
, O O
which O O
are O O
separated O O
by O O
more O O
than O O
one O O
turn O O
of O O
the O O
DNA O O
helix O O
, O O
and O O
twists O O
part O O
way O O
around O O
the O O
DNA O O
, O O
thus O O
protecting O O
the O O
broad O O
region O O
of O O
the O O
minor O O
groove O O
between O O
the O O
major O O
- O O
groove O O
contacts O O
. O O
On O O
the O O
optic O O
tentacle O O
- O O
gonadal O O
axis O O
in O O
the O O
control O O
of O O
the O O
male O O
- O O
phase O O
ovotestis O O
in O O
the O O
slug O O
( O O
Ariolimax O O
californicus O O
) O O
. O O
Substitution O O
of O O
cholinergic O O
drugs O O
in O O
the O O
treatment O O
of O O
Alzheimer O O
type O O
dementia O O
( O O
AD O O
/ O O
SDAT O O
) O O
has O O
hitherto O O
not O O
been O O
very O O
successful O O
. O O
Here O O
we O O
show O O
that O O
the O O
nucleotide O O
in O O
the O O
middle O O
of O O
the O O
anticodon O O
( O O
i O O
. O O
e O O
. O O
, O O
psi O O
35 O O
) O O
also O O
contributes O O
to O O
the O O
suppressor O O
efficiency O O
displayed O O
by O O
cytoplasmic B-GENE B-GENE
tRNA I-GENE E-GENE
( I-GENE O
Tyr I-GENE S-GENE
) E-GENE O
. O O
The O O
root O O
- O O
mean O O
- O O
square O O
deviation O O
of O O
bond O O
lengths O O
from O O
the O O
ideal O O
values O O
is O O
0 O O
. O O
02 O O
A O O
. O O
Jet O O
lag O O
and O O
melatonin O O
. O O
In O O
addition O O
, O O
these O O
results O O
suggest O O
that O O
the O O
interactions O O
, O O
and O O
consequently O O
the O O
mechanisms O O
, O O
governing O O
transcriptional O O
activation O O
by O O
CTF S-GENE S-GENE
are O O
distinct O O
from O O
those O O
mediating O O
DNA O O
replication O O
. O O
A O O
TAAATA O O
sequence O O
is O O
present O O
26 O O
nt O O
upstream O O
from O O
the O O
major O O
CAP O O
site O O
, O O
and O O
within O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
there O O
are O O
several O O
putative O O
transcription O O
factor O O
binding O O
sites O O
. O O
It O O
was O O
found O O
that O O
both O O
versions O O
of O O
the O O
brief O O
SL O O
& O O
amp O O
; O O
shy O O
; O O
ASIA O O
had O O
similar O O
correlations O O
to O O
the O O
target O O
variables O O
as O O
the O O
full O O
scale O O
SL O O
& O O
amp O O
; O O
shy O O
; O O
ASIA O O
. O O
The O O
reconstituted O O
enzyme O O
binds O O
DNA O O
with O O
an O O
affinity O O
that O O
is O O
approximately O O
20 O O
- O O
fold O O
lower O O
than O O
that O O
of O O
the O O
intact O O
topo70 S-GENE O
. O O
Treatment O O
with O O
KP O O
- O O
45 O O
preparation O O
usually O O
resulted O O
in O O
partial O O
regression O O
of O O
tumor O O
growth O O
, O O
accompanied O O
by O O
improvement O O
of O O
the O O
clinical O O
state O O
of O O
these O O
patients O O
, O O
as O O
well O O
as O O
reappearance O O
of O O
normal O O
values O O
of O O
blood O O
picture O O
and O O
biochemical O O
parameters O O
. O O
Istanbul O O
, O O
Turkey O O
. O O
We O O
propose O O
that O O
optimal O O
transcription O O
of O O
the O O
gD B-GENE B-GENE
gene E-GENE E-GENE
depends O O
on O O
the O O
interaction O O
of O O
ICP4 S-GENE S-GENE
with O O
multiple O O
binding O O
sites O O
across O O
the O O
gene O O
and O O
cellular O O
factors O O
that O O
recognize O O
specific O O
sequence O O
elements O O
in O O
the O O
promoter O O
. O O
Recently O O
, O O
we O O
and O O
other O O
laboratories O O
have O O
identified O O
a O O
family O O
of O O
caveolin B-GENE O
- I-GENE O
related I-GENE O
proteins E-GENE O
; O O
caveolin S-GENE O
has O O
been O O
re O O
- O O
termed O O
caveolin B-GENE O
- I-GENE O
1 E-GENE O
. O O
Role O O
of O O
zinc B-GENE O
- I-GENE O
finger I-GENE O
proteins I-GENE O
Sp1 E-GENE S-GENE
and O O
zif268 S-GENE S-GENE
/ O O
egr B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
in O O
transcriptional O O
regulation O O
of O O
the O O
human B-GENE B-GENE
synaptobrevin I-GENE I-GENE
II I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
human B-GENE B-GENE
Fc I-GENE I-GENE
gamma I-GENE I-GENE
receptor I-GENE I-GENE
gene E-GENE E-GENE
Fc B-GENE O
gamma I-GENE O
RIIA E-GENE S-GENE
is O O
expressed O O
in O O
platelets O O
, O O
neutrophils O O
, O O
monocytes O O
and O O
macrophages O O
. O O
This O O
dip O O
also O O
occurred O O
during O O
prednisone O O
and O O
vitamin O O
D O O
treatment O O
, O O
but O O
did O O
not O O
occur O O
when O O
calcium O O
was O O
added O O
to O O
prednisone O O
, O O
although O O
the O O
baseline O O
value O O
was O O
lower O O
at O O
the O O
start O O
of O O
combined O O
treatment O O
with O O
prednisone O O
and O O
calcium O O
. O O
E O O
. O O
granulosus O O
infection O O
has O O
been O O
confirmed O O
in O O
25 O O
patients O O
( O O
20 O O
. O O
6 O O
% O O
) O O
, O O
in O O
16 O O
cases O O
by O O
finding O O
parasite O O
protoscoleces O O
or O O
hooks O O
and O O
in O O
nine O O
cases O O
by O O
detection O O
of O O
an O O
antigen O O
specific O O
for O O
E B-GENE O
. I-GENE O
granulosus I-GENE O
, I-GENE O
antigen I-GENE O
5 E-GENE O
( O O
Ag5 S-GENE O
) O O
. O O
The O O
effect O O
of O O
stimulation O O
of O O
the O O
entopeduncular O O
nucleus O O
( O O
EP O O
) O O
on O O
the O O
jaw O O
- O O
opening O O
reflex O O
( O O
JOR O O
) O O
was O O
studied O O
in O O
the O O
cat O O
anesthetized O O
with O O
sodium O O
pentobarbital O O
. O O
A O O
Premenstrual O O
Syndrome O O
, O O
the O O
late O O
luteal O O
phase O O
disorder O O
of O O
DSM O O
- O O
IIIR O O
criteria O O
, O O
was O O
identified O O
in O O
6 O O
% O O
of O O
the O O
women O O
. O O
First O O
, O O
mutations O O
in O O
the O O
IFNgamma B-GENE O
- I-GENE O
activated I-GENE O
sequence E-GENE O
( O O
GAS S-GENE O
) O O
, O O
either O O
multimerized O O
or O O
in O O
the O O
context O O
of O O
the O O
1 B-GENE O
. I-GENE O
7 I-GENE O
- I-GENE O
kb I-GENE O
IRF I-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
promoter E-GENE E-GENE
, O O
failed O O
to O O
mediate O O
a O O
PRL S-GENE O
response O O
, O O
showing O O
that O O
the O O
IRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
GAS S-GENE O
is O O
a O O
target O O
of O O
PRL S-GENE S-GENE
signaling O O
. O O
025 O O
) O O
. O O
RESULTS O O
: O O
PET O O
revealed O O
wide O O
variations O O
in O O
CBF O O
between O O
regions O O
during O O
isoflurane O O
anaesthesia O O
, O O
particularly O O
in O O
comparison O O
with O O
propofol O O
anaesthesia O O
, O O
while O O
rCMRO2 O O
decreased O O
globally O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
during O O
both O O
isoflurane O O
and O O
propofol O O
anaesthesia O O
. O O
This O O
selective O O
squelching O O
activity O O
suggests O O
that O O
GRIM S-GENE O
can O O
interact O O
with O O
an O O
essential O O
component O O
of O O
the O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II E-GENE E-GENE
transcription O O
machinery O O
. O O
This O O
is O O
the O O
first O O
description O O
of O O
an O O
integron O O
located O O
on O O
a O O
composite O O
transposon O O
. O O
The O O
nine O O
subjects O O
were O O
treated O O
in O O
random O O
sequence O O
with O O
cimetidine O O
0 O O
- O O
8 O O
- O O
1 O O
- O O
0 O O
g O O
on O O
one O O
day O O
and O O
placebo O O
capsules O O
on O O
the O O
other O O
. O O
The O O
protein O O
was O O
overexpressed O O
in O O
Escherichia O O
coli O O
and O O
purified O O
to O O
homogeneity O O
. O O
Identification O O
and O O
characterization O O
of O O
a O O
yeast O O
gene O O
encoding O O
the O O
U2 B-GENE B-GENE
small I-GENE I-GENE
nuclear I-GENE I-GENE
ribonucleoprotein I-GENE I-GENE
particle I-GENE I-GENE
B I-GENE I-GENE
" I-GENE I-GENE
protein E-GENE E-GENE
. O O
A O O
360 O O
- O O
bp O O
DNA O O
fragment O O
located O O
over O O
500 O O
bp O O
upstream O O
from O O
the O O
cfl S-GENE O
transcriptional O O
start O O
site O O
was O O
used O O
in O O
DNase B-GENE O
I E-GENE O
protection O O
assays O O
to O O
define O O
the O O
specific O O
bases O O
bound O O
by O O
CorR S-GENE O
. O O
Taking O O
into O O
account O O
certain O O
well O O
defined O O
conditions O O
( O O
frequent O O
feedings O O
, O O
no O O
supplementary O O
feeding O O
before O O
4 O O
- O O
6 O O
months O O
, O O
method O O
only O O
to O O
be O O
used O O
in O O
the O O
absence O O
of O O
menstruation O O
) O O
, O O
LAM O O
can O O
be O O
relied O O
on O O
for O O
contraceptive O O
protection O O
for O O
up O O
to O O
1 O O
year O O
post O O
partum O O
. O O
Nramp2 S-GENE O
contains O O
a O O
classical O O
iron O O
responsive O O
element O O
in O O
the O O
3 O O
' O O
untranslated O O
region O O
that O O
confers O O
iron O O
dependent O O
mRNA O O
stabilization O O
. O O
Likewise O O
, O O
epidural O O
morphine O O
does O O
not O O
modify O O
the O O
intraoperative O O
metabolic O O
and O O
hormonal O O
responses O O
. O O
CONCLUSIONS O O
- O O
- O O
Postlumbar O O
puncture O O
headache O O
may O O
be O O
mediated O O
by O O
the O O
release O O
of O O
substance B-GENE O
P E-GENE O
triggered O O
by O O
lumbar O O
puncture O O
, O O
in O O
patients O O
predisposed O O
to O O
headache O O
by O O
a O O
hypersensitivity O O
to O O
substance B-GENE O
P E-GENE O
. O O
Continuous O O
arterial O O
blood O O
sampling O O
method O O
based O O
on O O
the O O
microsphere O O
model O O
was O O
used O O
as O O
a O O
quantitative O O
rCBF O O
measurement O O
. O O
A O O
mutated B-GENE O
ABF1 I-GENE O
site E-GENE O
that O O
displays O O
a O O
very O O
low O O
affinity O O
for O O
ABF1 S-GENE S-GENE
does O O
not O O
functionally O O
replace O O
the O O
ILV1 S-GENE B-GENE
REB1 B-GENE I-GENE
site E-GENE E-GENE
. O O
Given O O
a O O
rapid O O
induction O O
of O O
Egr B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
on O O
stimulation O O
with O O
growth O O
factors O O
or O O
injury O O
, O O
these O O
findings O O
may O O
represent O O
at O O
least O O
one O O
of O O
the O O
molecular O O
mechanisms O O
underlying O O
phenotypic O O
modulation O O
of O O
smooth O O
muscles O O
after O O
vascular O O
injury O O
. O O
A O O
nationwide O O
survey O O
uncovered O O
a O O
tenfold O O
variation O O
between O O
counties O O
in O O
the O O
prescribing O O
of O O
IFNB S-GENE O
. O O
In O O
this O O
first O O
- O O
person O O
account O O
, O O
the O O
author O O
chronicles O O
her O O
experience O O
of O O
being O O
mentally O O
ill O O
and O O
homeless O O
in O O
New O O
York O O
and O O
New O O
Jersey O O
in O O
the O O
early O O
1980s O O
. O O
Rectal O O
temperatures O O
after O O
the O O
walk O O
were O O
greater O O
( O O
P O O
< O O
. O O
001 O O
) O O
in O O
native O O
Simmental O O
( O O
39 O O
. O O
87 O O
+ O O
/ O O
- O O
. O O
05 O O
degrees O O
C O O
) O O
than O O
in O O
Bos O O
indicus O O
( O O
39 O O
. O O
46 O O
+ O O
/ O O
- O O
. O O
05 O O
degrees O O
C O O
) O O
. O O
Dominant O O
- O O
negative O O
mutations O O
in O O
the O O
G B-GENE B-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
coupled I-GENE I-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
factor I-GENE I-GENE
receptor E-GENE E-GENE
map O O
to O O
the O O
extracellular O O
ends O O
of O O
the O O
transmembrane O O
segments O O
. O O
Such O O
simple O O
injuries O O
may O O
however O O
be O O
accompanied O O
by O O
far O O
reaching O O
consequences O O
. O O
This O O
is O O
the O O
first O O
report O O
which O O
clearly O O
proved O O
CEA S-GENE O
synthesis O O
in O O
the O O
cells O O
of O O
HCC O O
. O O
By O O
screening O O
a O O
human O O
testis O O
cDNA O O
library O O
with O O
a O O
probe O O
containing O O
the O O
mouse B-GENE B-GENE
PEA3 E-GENE I-GENE
ETS S-GENE I-GENE
domain O E-GENE
, O O
we O O
isolated O O
a O O
2 O O
. O O
2 O O
kb O O
clone O O
containing O O
a O O
510 O O
AA O O
open O O
reading O O
frame O O
. O O
AU O O
- O O
rich O O
elements O O
in O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
a O O
new O O
mucin B-GENE O
- I-GENE O
type I-GENE O
gene E-GENE O
family O O
of O O
Trypanosoma O O
cruzi O O
confers O O
mRNA O O
instability O O
and O O
modulates O O
translation O O
efficiency O O
. O O
These O O
findings O O
suggest O O
that O O
IL B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
- O O
stimulated O O
, O O
Rho S-GENE S-GENE
- O O
dependent O O
cytoskeletal O O
reorganization O O
may O O
cluster O O
signaling O O
molecules O O
in O O
specific O O
architectures O O
that O O
are O O
necessary O O
for O O
persistent O O
cell O O
activation O O
in O O
chronic O O
inflammatory O O
disease O O
. O O
Changes O O
in O O
testicular O O
testosterone O O
and O O
acid O O
and O O
alkaline B-GENE O
phosphatase E-GENE O
activity O O
in O O
testis O O
and O O
accessory O O
sex O O
organs O O
after O O
induction O O
of O O
varicocele O O
in O O
Noble O O
rats O O
. O O
M O O
. O O
, O O
Apps O O
, O O
D O O
. O O
These O O
data O O
suggest O O
that O O
weight O O
gain O O
or O O
increased O O
caloric O O
intake O O
, O O
in O O
contrast O O
to O O
its O O
large O O
effect O O
on O O
peripheral O O
thyroid O O
function O O
, O O
has O O
relatively O O
little O O
effect O O
on O O
CNS B-GENE B-GENE
TRH E-GENE E-GENE
activity O O
. O O
Alfalfa O O
phosphorus O O
release O O
kinetics O O
showed O O
high O O
bacterial O O
phosphorus O O
contamination O O
. O O
The O O
quantitative O O
analysis O O
of O O
1 O O
- O O
alpha O O
- O O
acetylmethadol O O
and O O
its O O
principal O O
metabolites O O
in O O
biological O O
specimens O O
by O O
gas O O
chromatography O O
- O O
chemical O O
ionization O O
- O O
multiple O O
ion O O
monitoring O O
mass O O
spectrometry O O
. O O
Clinical O O
evidence O O
provides O O
tentative O O
suggestions O O
on O O
( O O
a O O
) O O
possible O O
additional O O
risk O O
of O O
cigarette O O
smoking O O
( O O
b O O
) O O
avoidance O O
of O O
venography O O
( O O
c O O
) O O
avoidance O O
of O O
varicose O O
vein O O
surgery O O
. O O
Effects O O
of O O
prolonged O O
inhibition O O
of O O
labour O O
pains O O
with O O
Th O O
1165a O O
and O O
Isoptin O O
on O O
the O O
heart O O
, O O
circulation O O
, O O
organ O O
- O O
and O O
metabolic O O
parameters O O
of O O
the O O
mother O O
Skytthe O O
, O O
and O O
K O O
. O O
In O O
the O O
Saccharomyces B-GENE O
cerevisiae I-GENE O
actin I-GENE O
intron E-GENE O
a O O
silent O O
branch O O
point O O
- O O
like O O
sequence O O
( O O
UACUAAG O O
) O O
is O O
located O O
7 O O
nt O O
upstream O O
of O O
the O O
canonical O O
sequence O O
. O O
The O O
requirement O O
for O O
an O O
essential O O
interaction O O
between O O
NPH B-GENE B-GENE
I E-GENE E-GENE
and O O
H4L S-GENE S-GENE
provides O O
an O O
explanation O O
for O O
the O O
observed O O
restriction O O
of O O
transcription O O
termination O O
to O O
early O O
viral O O
genes O O
. O O
After O O
birth O O
, O O
there O O
was O O
a O O
significantly O O
higher O O
increase O O
of O O
IgA S-GENE O
and O O
IgM B-GENE O
anti I-GENE O
- I-GENE O
M I-GENE O
. I-GENE O
leprae I-GENE O
antibody E-GENE O
activity O O
in O O
sera O O
taken O O
3 O O
- O O
6 O O
months O O
after O O
birth O O
from O O
babies O O
of O O
Group O O
1 O O
compared O O
to O O
Group O O
2 O O
, O O
but O O
the O O
IgA S-GENE O
and O O
IgM S-GENE S-GENE
activity O O
in O O
sera O O
taken O O
after O O
6 O O
months O O
of O O
age O O
showed O O
the O O
same O O
increase O O
in O O
the O O
two O O
groups O O
. O O
The O O
relation O O
between O O
the O O
changes O O
of O O
bone O O
density O O
and O O
the O O
level O O
of O O
blood O O
calcium O O
, O O
blood O O
phosphorus O O
and O O
alkaline B-GENE O
phosphatase E-GENE O
( O O
AKP S-GENE O
) O O
as O O
well O O
as O O
the O O
metabolism O O
of O O
vitamin O O
D O O
was O O
studied O O
. O O
These O O
results O O
demonstrate O O
the O O
extensive O O
homology O O
in O O
sequence O O
among O O
light O O
chains O O
of O O
IgM B-GENE B-GENE
kappa I-GENE E-GENE
autoantibodies E-GENE O
and O O
indicate O O
that O O
a O O
particular O O
V B-GENE B-GENE
kappa I-GENE I-GENE
germ I-GENE I-GENE
line I-GENE I-GENE
gene E-GENE E-GENE
, O O
kappa B-GENE B-GENE
IIIb E-GENE E-GENE
, O O
is O O
expressed O O
as O O
a O O
phylogenetic O O
response O O
to O O
certain O O
self O O
antigens O O
or O O
as O O
part O O
of O O
a O O
selection O O
process O O
by O O
which O O
these O O
autoimmune O O
responses O O
are O O
regulated O O
. O O
In O O
addition O O
, O O
the O O
findings O O
confirmed O O
previous O O
studies O O
which O O
showed O O
that O O
monkeys O O
with O O
total O O
bilateral O O
striatectomies O O
could O O
require O O
the O O
ability O O
to O O
execute O O
accurate O O
visually O O
guided O O
reaches O O
. O O
Comparison O O
of O O
the O O
sequences O O
of O O
the O O
alpha B-GENE O
- I-GENE O
like I-GENE O
DNA I-GENE O
polymerases E-GENE O
including O O
E B-GENE O
. I-GENE O
coli I-GENE O
DNA I-GENE O
polymerase I-GENE O
II E-GENE O
showed O O
that O O
there O O
were O O
nine O O
highly O O
conserved O O
regions O O
, O O
and O O
we O O
constructed O O
an O O
unrooted O O
phylogenetic O O
tree O O
of O O
the O O
DNA B-GENE O
polymerases E-GENE O
based O O
on O O
the O O
differences O O
in O O
these O O
conserved O O
regions O O
. O O
Before O O
and O O
6 O O
and O O
12 O O
months O O
after O O
H O O
. O O
pylori O O
eradication O O
the O O
patients O O
were O O
evaluated O O
for O O
fasting O O
gastrinemia O O
and O O
pepsinogen B-GENE O
I E-GENE O
, O O
basal O O
and O O
peak O O
acid O O
output O O
, O O
and O O
detailed O O
histological O O
assessment O O
including O O
the O O
ECL O O
cell O O
proliferative O O
patterns O O
. O O
Four O O
experiments O O
examined O O
the O O
role O O
of O O
the O O
cholinergic O O
projections O O
from O O
the O O
septum O O
and O O
vertical O O
limb O O
nucleus O O
of O O
the O O
diagonal O O
band O O
of O O
Broca O O
( O O
VDB O O
) O O
in O O
acquisition O O
and O O
performance O O
of O O
a O O
conditional O O
visual O O
discrimination O O
. O O
trans O O
- O O
activation O O
of O O
the O O
HIV B-GENE O
- I-GENE O
1 I-GENE O
LTR E-GENE O
by O O
the O O
HIV B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
Tat E-GENE E-GENE
and O O
HTLV B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
Tax I-GENE I-GENE
proteins E-GENE E-GENE
is O O
mediated O O
by O O
different O O
cis O O
- O O
acting O O
sequences O O
. O O
Defective O O
concanavalin B-GENE O
A E-GENE O
- O O
induced O O
suppression O O
in O O
bancroftian O O
filariasis O O
. O O
For O O
more O O
detailed O O
mapping O O
, O O
we O O
constructed O O
mouse O O
A9 O O
cells O O
containing O O
STFs O O
derived O O
from O O
human O O
chromosome O O
2 O O
tagged O O
with O O
pSTneo O O
at O O
different O O
regions O O
in O O
2q31 O O
- O O
qter O O
. O O
Left O O
ventricular O O
insufficiency O O
requires O O
two O O
SP O O
/ O O
patient O O
, O O
with O O
good O O
results O O
in O O
approximately O O
81 O O
p O O
. O O
cent O O
. O O
However O O
, O O
there O O
are O O
some O O
cows O O
that O O
fail O O
to O O
produce O O
adequate O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D O O
at O O
the O O
onset O O
of O O
lactation O O
. O O
Acidic O O
carboxyl O O
- O O
terminal O O
domain O O
of O O
gene B-GENE B-GENE
2 I-GENE I-GENE
. I-GENE I-GENE
5 I-GENE I-GENE
protein I-GENE E-GENE
of I-GENE O
bacteriophage I-GENE O
T7 E-GENE O
is O O
essential O O
for O O
protein O O
- O O
protein O O
interactions O O
. O O
This O O
result O O
, O O
together O O
with O O
the O O
fact O O
that O O
unrearranged B-GENE B-GENE
V I-GENE I-GENE
kappa I-GENE I-GENE
genes E-GENE E-GENE
are O O
transcriptionally O O
silent O O
, O O
suggests O O
that O O
structural O O
features O O
of O O
both O O
the O O
V B-GENE B-GENE
kappa E-GENE E-GENE
and O O
C B-GENE B-GENE
kappa I-GENE I-GENE
loci E-GENE E-GENE
contribute O O
to O O
the O O
overall O O
transcriptional O O
efficiency O O
of O O
a O O
rearranged B-GENE O
V I-GENE B-GENE
kappa I-GENE I-GENE
- I-GENE I-GENE
C I-GENE I-GENE
kappa I-GENE I-GENE
gene E-GENE E-GENE
. O O
A O O
total O O
of O O
10 O O
, O O
763 O O
men O O
and O O
3 O O
, O O
118 O O
women O O
has O O
been O O
studied O O
, O O
of O O
whom O O
97 O O
% O O
and O O
89 O O
% O O
, O O
respectively O O
, O O
have O O
been O O
traced O O
and O O
36 O O
% O O
and O O
16 O O
% O O
have O O
died O O
. O O
NSD1 S-GENE S-GENE
contains O O
a O O
SET B-GENE O
domain E-GENE O
and O O
multiple O O
PHD O O
fingers O O
. O O
EMG O O
- O O
based O O
measures O O
of O O
fatigue O O
during O O
a O O
repetitive O O
squat O O
exercise O O
. O O
We O O
have O O
introduced O O
the O O
same O O
change O O
in O O
a O O
yeast B-GENE B-GENE
tRNA I-GENE E-GENE
( I-GENE O
Trp I-GENE S-GENE
) I-GENE O
gene E-GENE O
and O O
demonstrated O O
that O O
the O O
tRNA O O
acts O O
as O O
an O O
efficient O O
amber O O
suppressor O O
in O O
vivo O O
. O O
This O O
evaluation O O
examines O O
several O O
analytical O O
and O O
cost O O
parameters O O
for O O
five O O
representative O O
assays O O
: O O
IgG S-GENE S-GENE
, O O
IgA S-GENE S-GENE
, O O
IgM S-GENE S-GENE
, O O
phenytoin O O
, O O
and O O
phenobarbital O O
. O O
These O O
results O O
suggest O O
that O O
UvrA S-GENE S-GENE
is O O
involved O O
in O O
triplet O O
repeat O O
instability O O
in O O
cells O O
. O O
Among O O
women O O
, O O
plasma B-GENE B-GENE
factor I-GENE I-GENE
VII E-GENE I-GENE
: O I-GENE
Ag O E-GENE
was O O
inversely O O
associated O O
with O O
income O O
. O O
A O O
novel O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
( O O
PKC S-GENE S-GENE
) O O
- O O
interacting O O
protein O O
was O O
identified O O
by O O
the O O
yeast O O
two O O
- O O
hybrid O O
screening O O
using O O
the O O
regulatory O O
domain O O
of O O
PKC B-GENE B-GENE
beta I-GENE I-GENE
I E-GENE E-GENE
as O O
a O O
bait O O
. O O
CONCLUSIONS O O
: O O
The O O
number O O
of O O
Spanish O O
articles O O
published O O
in O O
Anesthesiology O O
, O O
BJA O O
, O O
and O O
Anesth O O
Analg O O
is O O
low O O
, O O
although O O
the O O
comparison O O
of O O
our O O
productivity O O
with O O
that O O
of O O
other O O
EU O O
countries O O
in O O
function O O
of O O
GNPpc O O
places O O
us O O
in O O
an O O
intermediate O O
position O O
. O O
One O O
of O O
the O O
repeating O O
domains O O
( O O
Yheb1 S-GENE O
) O O
, O O
consisting O O
of O O
67 O O
amino O O
acids O O
, O O
was O O
cloned O O
from O O
the O O
E O O
. O O
coli O O
chromosome O O
and O O
purified O O
by O O
metal O O
chelating O O
chromatography O O
. O O
Phosphorylation O O
at O O
Ser O O
( O O
670 O O
) O O
impairs O O
the O O
ability O O
of O O
GRK2 S-GENE S-GENE
to O O
phosphorylate O O
both O O
soluble O O
and O O
membrane O O
- O O
incorporated O O
receptor O O
substrates O O
and O O
dramatically O O
attenuates O O
Gbetagamma S-GENE O
- O O
mediated O O
activation O O
of O O
this O O
enzyme O O
. O O
METHODS O O
: O O
CD4 S-GENE O
cell O O
counts O O
and O O
interview O O
data O O
were O O
recorded O O
in O O
a O O
survey O O
of O O
136 O O
adult O O
patients O O
attending O O
a O O
community O O
hospital O O
- O O
based O O
HIV O O
outpatient O O
clinic O O
. O O
Biol O O
. O O
Inhibition O O
of O O
endogenous B-GENE O
Cdk2 E-GENE S-GENE
by O O
dominant B-GENE O
negative I-GENE O
Cdk2 E-GENE O
attenuated O O
phosphorylation O O
of O O
Thr447 O S-GENE
, O O
Thr490 O S-GENE
and O O
Thr497 O S-GENE
, O O
but O O
had O O
no O O
effect O O
upon O O
Ser581 O O
modification O O
. O O
A O O
rabbit O O
antiserum O O
raised O O
against O O
a O O
unique O O
( O O
V3 O B-GENE
domain O E-GENE
) O O
bacterially O O
expressed O O
PKC B-GENE B-GENE
theta I-GENE E-GENE
fragment E-GENE O
immunoprecipitated O O
specifically O O
an O O
82 O O
- O O
kDa O O
protein O O
from O O
Jurkat O O
cell O O
lysates O O
. O O
Histological O O
examination O O
revealed O O
variable O O
loss O O
of O O
motor O O
neurons O O
limited O O
to O O
the O O
injection O O
site O O
. O O
This O O
is O O
the O O
most O O
northern O O
and O O
, O O
at O O
the O O
same O O
time O O
largest O O
, O O
Q O O
fever O O
epidemic O O
recorded O O
in O O
Germany O O
over O O
the O O
last O O
28 O O
years O O
. O O
Symptoms O O
, O O
skin O O
- O O
prick O O
tests O O
( O O
SPT O O
) O O
with O O
environmental O O
allergens O O
and O O
Pt O O
salt O O
, O O
total O O
serum B-GENE O
IgE E-GENE S-GENE
, O O
lung O O
function O O
, O O
and O O
bronchial O O
hyperresponsiveness O O
were O O
assessed O O
by O O
standard O O
procedures O O
. O O
Binding O O
sites O O
were O O
mapped O O
for O O
each O O
factor O O
. O O
Complementary O O
DNA O O
libraries O O
from O O
liver O O
and O O
ovary O O
of O O
an O O
immature O O
female O O
channel O O
catfish O O
were O O
screened O O
with O O
a O O
homologous B-GENE O
ERalpha I-GENE O
cDNA E-GENE O
probe O O
. O O
The O O
binding O O
of O O
PTB S-GENE S-GENE
was O O
antagonistic O O
to O O
the O O
binding O O
of O O
U2AF S-GENE S-GENE
to O O
the O O
enhancer O O
- O O
located O O
pyrimidine O O
tract O O
. O O
VLA B-GENE B-GENE
- I-GENE I-GENE
4 I-GENE I-GENE
integrin E-GENE E-GENE
cross O O
- O O
linking O O
on O O
human O O
monocytic O O
THP O O
- O O
1 O O
cells O O
induces O O
tissue O O
factor O O
expression O O
by O O
a O O
mechanism O O
involving O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
. O O
However O O
, O O
studies O O
using O O
the O O
A20 B-GENE B-GENE
promoter E-GENE E-GENE
demonstrated O O
that O O
LMP1 S-GENE S-GENE
transcriptionally O O
activates O O
the O O
A20 B-GENE B-GENE
gene E-GENE E-GENE
through O O
cis O O
- O O
acting O O
kappa B-GENE B-GENE
B I-GENE I-GENE
sites E-GENE E-GENE
. O O
Southern O O
blot O O
analysis O O
revealed O O
that O O
CCaMK S-GENE S-GENE
is O O
encoded O O
by O O
a O O
single O O
gene O O
. O O
Surgical O O
methods O O
in O O
the O O
treatment O O
of O O
rhinophyma O O
. O O
Phenazopyridine O O
- O O
induced O O
hemolytic O O
anemia O O
in O O
a O O
patient O O
with O O
G6PD S-GENE O
deficiency O O
. O O
Finally O O
, O O
we O O
demonstrated O O
that O O
although O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE E-GENE
is O O
required O O
for O O
both O O
the O O
differentiation O O
block O O
and O O
the O O
shift O O
in O O
cell O O
cycle O O
after O O
PMA O O
treatment O O
, O O
phosphorylation O O
by O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
and O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
at O O
positions O O
11 O O
and O O
12 O O
or O O
532 O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE E-GENE
, O O
respectively O O
, O O
are O O
not O O
. O O
The O O
activation O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
- O O
dependent O O
reporter O O
gene O O
transcription O O
by O O
E1A S-GENE S-GENE
was O O
potently O O
suppressed O O
upon O O
coexpression O O
of O O
the O O
E1B B-GENE B-GENE
19 I-GENE I-GENE
- I-GENE I-GENE
kDa I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
19K I-GENE S-GENE
) E-GENE O
. O O
Our O O
results O O
showed O O
that O O
direct O O
enantiomeric O O
separation O O
of O O
mephenytoin O O
was O O
obtained O O
by O O
using O O
a O O
chiral O O
capillary O O
column O O
, O O
the O O
retention O O
times O O
for O O
S O O
- O O
and O O
R O O
- O O
mephenytoin O O
were O O
25 O O
. O O
5 O O
and O O
26 O O
. O O
2 O O
min O O
respectively O O
, O O
with O O
a O O
detection O O
limit O O
less O O
than O O
50 O O
ng O O
/ O O
ml O O
of O O
mephenytoin O O
. O O
The O O
myeloid B-GENE B-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
gene I-GENE I-GENE
1 E-GENE E-GENE
( O O
MZF1 S-GENE S-GENE
) O O
encodes O O
a O O
C B-GENE B-GENE
( I-GENE I-GENE
2 I-GENE I-GENE
) I-GENE I-GENE
H I-GENE I-GENE
( I-GENE I-GENE
2 I-GENE E-GENE
) I-GENE O
zinc I-GENE O
finger I-GENE O
transcription I-GENE O
factor E-GENE O
that O O
regulates O O
granulopoiesis O O
and O O
may O O
have O O
a O O
regulatory O O
role O O
in O O
cellular O O
proliferation O O
and O O
oncogenesis O O
. O O
Snails O O
infected O O
with O O
three O O
or O O
five O O
miracidia O O
produced O O
more O O
metacercariae O O
than O O
those O O
infected O O
with O O
a O O
single O O
miracidium O O
. O O
We O O
conclude O O
that O O
GRF1 S-GENE S-GENE
and O O
GRF2 S-GENE S-GENE
can O O
form O O
homo O O
- O O
and O O
hetero O O
- O O
oligomers O O
via O O
their O O
DH B-GENE O
domains E-GENE O
, O O
that O O
mutational O O
inactivation O O
of O O
oligomer O O
formation O O
by O O
GRF1 S-GENE S-GENE
is O O
associated O O
with O O
impaired O O
biological O O
and O O
signaling O O
activities O O
, O O
and O O
that O O
in O O
293T O O
cells O O
GRF1 S-GENE S-GENE
mediates O O
at O O
least O O
two O O
pathways O O
for O O
Raf S-GENE O
activation O O
: O O
one O O
a O O
constitutive O O
signal O O
that O O
is O O
mainly O O
Ras S-GENE O
- O O
dependent O O
, O O
and O O
one O O
an O O
ionomycin O O
- O O
induced O O
signal O O
that O O
cooperates O O
with O O
the O O
constitutive O O
signal O O
without O O
further O O
augmenting O O
the O O
level O O
of O O
GTP B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
. O O
For O O
the O O
target O O
stimuli O O
, O O
P3 O O
amplitude O O
and O O
latency O O
were O O
negatively O O
correlated O O
and O O
most O O
tightly O O
coupled O O
over O O
the O O
frontal O O
- O O
central O O
and O O
right O O
medial O O
/ O O
lateral O O
recording O O
sites O O
. O O
Mitoxantrone O O
plus O O
ara O O
- O O
C O O
is O O
an O O
active O O
combination O O
with O O
great O O
promise O O
for O O
the O O
therapy O O
of O O
previously O O
untreated O O
patients O O
with O O
AML O O
. O O
In O O
the O O
renal O O
cortex O O
, O O
spleen O O
, O O
distal O O
colon O O
, O O
ileum O O
, O O
gallbladder O O
, O O
and O O
stomach O O
body O O
, O O
regional O O
O2 O O
delivery O O
was O O
significantly O O
decreased O O
with O O
hemodilution O O
to O O
20 O O
% O O
in O O
both O O
groups O O
. O O
( O O
A O O
short O O
account O O
of O O
Karl O O
Touton O O
' O O
s O O
life O O
is O O
also O O
included O O
. O O
) O O
After O O
reviewing O O
the O O
historical O O
development O O
of O O
the O O
concept O O
of O O
giant O O
cells O O
and O O
current O O
interpretations O O
of O O
their O O
nature O O
, O O
the O O
unitarian O O
view O O
of O O
polykaryons O O
now O O
favored O O
by O O
workers O O
in O O
the O O
field O O
is O O
extended O O
to O O
include O O
also O O
the O O
" O O
xanthelasmatic O O
giant O O
cell O O
" O O
of O O
Touton O O
, O O
whose O O
characteristic O O
appearance O O
is O O
determined O O
merely O O
by O O
the O O
presence O O
of O O
demonstrable O O
lipid O O
in O O
the O O
cytoplasm O O
. O O
Chronic O O
active O O
hepatitis O O
and O O
pregnancy O O
. O O
Influenza O O
virus O O
- O O
induced O O
NF B-GENE O
- I-GENE O
kappaB I-GENE O
- I-GENE O
dependent I-GENE O
gene E-GENE O
expression O O
is O O
mediated O O
by O O
overexpression O O
of O O
viral O O
proteins O O
and O O
involves O O
oxidative O O
radicals O O
and O O
activation O O
of O O
IkappaB B-GENE B-GENE
kinase E-GENE E-GENE
. O O
These O O
observed O O
changes O O
were O O
not O O
found O O
when O O
assessing O O
NPY S-GENE O
level O O
in O O
plasma O O
fluid O O
. O O
Reversible O O
topology O O
of O O
a O O
bifunctional O O
transmembrane O O
protein O O
depends O O
upon O O
the O O
charge O O
balance O O
around O O
its O O
transmembrane O O
domain O O
. O O
Protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
( O O
PKC S-GENE S-GENE
) O O
activation O O
after O O
treatment O O
of O O
human O O
neuroblastoma O O
SK O O
- O O
N O O
- O O
BE O O
( O O
2 O O
) O O
C O O
cells O O
with O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
( O O
PMA O O
) O O
was O O
found O O
to O O
enhance O O
transcription O O
of O O
the O O
human O B-GENE
dopamine B-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
hydroxylase E-GENE E-GENE
( O O
DBH S-GENE O
) O O
in O O
those O O
cells O O
. O O
The O O
second O O
( O O
control O O
) O O
group O O
was O O
represented O O
by O O
cases O O
diagnosed O O
as O O
HSIL O O
by O O
cytology O O
. O O
The O O
illuminator O O
uses O O
a O O
grain O O
- O O
of O O
- O O
wheat O O
light O O
bulb O O
and O O
an O O
adjustable O O
bulb O O
holder O O
fashioned O O
from O O
bent O O
paper O O
clips O O
. O O
Bedbug O O
( O O
Cimex O O
lectularius O O
) O O
samples O O
adult O O
and O O
nymphs O O
either O O
engorged O O
or O O
starved O O
from O O
Central O O
Security O O
Forces O O
sleeping O O
wards O O
, O O
laboratory O O
animal O O
house O O
and O O
control O O
samples O O
from O O
laboratory O O
reared O O
colonies O O
were O O
ground O O
and O O
subjected O O
to O O
ELISA O O
test O O
of O O
hepatitis B-GENE O
B I-GENE O
surface I-GENE O
antigen E-GENE O
together O O
with O O
276 O O
serum O O
samples O O
from O O
the O O
recruits O O
slept O O
in O O
those O O
wards O O
. O O
The O O
genomic O O
organization O O
in O O
this O O
region O O
is O O
similar O O
to O O
the O O
neural O O
- O O
restricted O O
family O O
members O O
, O O
Hel B-GENE B-GENE
- I-GENE I-GENE
N1 E-GENE E-GENE
( O O
ELAVL2 S-GENE S-GENE
) O O
and O O
mHuD S-GENE S-GENE
( O O
Elavl4 S-GENE O
) O O
. O O
Synergistic O O
induction O O
of O O
apoptosis O O
in O O
human O O
leukemia O O
cells O O
( O O
U937 O O
) O O
exposed O O
to O O
bryostatin O O
1 O O
and O O
the O O
proteasome O O
inhibitor O O
lactacystin O O
involves O O
dysregulation O O
of O O
the O O
PKC S-GENE S-GENE
/ O O
MAPK S-GENE S-GENE
cascade O O
. O O
With O O
the O O
help O O
of O O
partially O O
overlapping O O
parenchymatous O O
sutures O O
, O O
different O O
renal O O
segments O O
were O O
devitalized O O
. O O
Promoter O O
elements O O
and O O
transcriptional O O
control O O
of O O
the O O
mouse B-GENE B-GENE
acetylcholinesterase I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
average O O
cumulative O O
UVA O O
dose O O
was O O
65 O O
J O O
/ O O
cm2 O O
; O O
40 O O
patients O O
had O O
received O O
more O O
than O O
200 O O
J O O
/ O O
cm2 O O
. O O
Malformations O O
of O O
the O O
regenerating O O
optic O O
tectum O O
of O O
larvae O O
of O O
the O O
Egyptian O O
toad O O
, O O
Bufo O O
regularis O O
Reuss O O
. O O
These O O
morphological O O
changes O O
are O O
associated O O
with O O
a O O
marked O O
induction O O
of O O
P450arom B-GENE B-GENE
gene E-GENE E-GENE
expression O O
. O O
The O O
immunoprofile O O
of O O
60 O O
adult O O
patients O O
of O O
pulmonary O O
tuberculosis O O
was O O
studied O O
and O O
compared O O
with O O
22 O O
normal O O
controls O O
. O O
Central O O
- O O
venous O O
- O O
catheter O O
- O O
related O O
infection O O
is O O
readily O O
diagnosed O O
by O O
comparing O O
simultaneous O O
quantitative O O
cultures O O
of O O
blood O O
samples O O
obtained O O
via O O
the O O
catheter O O
and O O
a O O
peripheral O O
vein O O
. O O
The O O
role O O
of O O
haptoglobin S-GENE O
in O O
asphyxia O O
mechanism O O
( O O
II O O
) O O
- O O
- O O
Acute O O
drowning O O
and O O
hanging O O
Processing O O
MES O O
data O O
requires O O
large O O
bit O O
manipulations O O
and O O
heavy O O
memory O O
storage O O
requirements O O
. O O
Thus O O
, O O
BCR S-GENE S-GENE
ligation O O
initiates O O
a O O
PI B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
/ O O
Akt S-GENE S-GENE
/ O O
GSK B-GENE B-GENE
- I-GENE I-GENE
3 E-GENE E-GENE
signaling O O
pathway O O
. O O
cDNA O O
cloning O O
and O O
transcriptional O O
properties O O
of O O
a O O
novel O O
GC B-GENE B-GENE
box I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
, O O
BTEB2 S-GENE S-GENE
. O O
This O O
activity O O
creates O O
a O O
4 O O
- O O
bp O O
staggered O O
cut O O
with O O
3 O O
' O O
OH O O
overhangs O O
within O O
a O O
specific O O
sequence O O
of O O
the O O
21S B-GENE B-GENE
rRNA I-GENE I-GENE
gene E-GENE E-GENE
of O O
omega O O
- O O
strains O O
. O O
The O O
two O O
ORFs O O
had O O
significant O O
similarity O O
with O O
the O O
putative O O
replication O O
protein O O
from O O
plasmid O O
pTiK12 O S-GENE
of O O
Thiobacillus O O
intermedius O O
and O O
other O O
CoIE2 O O
- O O
related O O
plasmids O O
. O O
In O O
contrast O O
SF S-GENE O
, O O
but O O
not O O
GM B-GENE O
- I-GENE O
CSF E-GENE O
or O O
IL B-GENE B-GENE
- I-GENE I-GENE
3 E-GENE E-GENE
, O O
induced O O
tyrosine O O
phosphorylation O O
of O O
phospholipase B-GENE B-GENE
C I-GENE I-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
( O O
PLC B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
) O O
. O O
Phase O O
I O O
clinical O O
trial O O
with O O
a O O
combination O O
of O O
methotrexate O O
and O O
mitomycin O O
C O O
. O O
Replacement O O
of O O
Val20 O B-GENE
- O I-GENE
Leu21 O E-GENE
with O O
Ala O B-GENE
- O I-GENE
Ala O E-GENE
produced O O
a O O
dimeric B-GENE O
RII I-GENE B-GENE
beta I-GENE I-GENE
protein E-GENE E-GENE
that O O
binds O O
AKAP75 S-GENE S-GENE
approximately O O
4 O O
% O O
as O O
avidly O O
as O O
wild B-GENE O
- I-GENE O
type I-GENE O
RII I-GENE B-GENE
beta E-GENE E-GENE
. O O
The O O
temporal O O
expression O O
of O O
CRAlBP S-GENE S-GENE
is O O
similar O O
to O O
IRBP S-GENE S-GENE
while O O
bFGF S-GENE S-GENE
is O O
not O O
expressed O O
until O O
after O O
photoreceptor O O
differentiation O O
is O O
complete O O
. O O
I O O
. O O
In O O
T O O
cells O O
these O O
two O O
signal O O
pathways O O
are O O
critical O O
for O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
production O O
. O O
Replacement O O
of O O
a O O
valine O O
( O O
V68 O O
) O O
in O O
the O O
ETS S-GENE O
domain O O
of O O
SAP1a S-GENE S-GENE
by O O
aspartic O O
acid O O
( O O
as O O
found O O
in O O
c B-GENE O
- I-GENE O
Ets I-GENE O
- I-GENE O
1 E-GENE O
, O O
Elk B-GENE O
- I-GENE O
1 E-GENE O
, O O
and O O
Net S-GENE O
) O O
enhanced O O
ternary O O
complex O O
formation O O
by O O
more O O
than O O
60 O O
- O O
fold O O
. O O
In O O
order O O
to O O
investigate O O
the O O
effect O O
of O O
the O O
local O O
direct O O
action O O
of O O
danazol O O
upon O O
endometriosis O O
, O O
intravaginal O O
and O O
intrauterine O O
application O O
were O O
tried O O
. O O
The O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
/ O O
Rel S-GENE S-GENE
transcription O O
factors O O
participate O O
in O O
the O O
activation O O
of O O
immune O O
system O O
regulatory O O
genes O O
and O O
viral B-GENE O
early I-GENE O
genes E-GENE O
including O O
the O O
human B-GENE O
immunodeficiency I-GENE O
virus I-GENE O
type I-GENE O
1 I-GENE O
long I-GENE O
terminal I-GENE O
repeat E-GENE O
. O O
A O O
total O O
of O O
4 O O
, O O
916 O O
children O O
were O O
examined O O
and O O
the O O
questionnaire O O
satisfactorily O O
completed O O
by O O
a O O
relative O O
or O O
guardian O O
( O O
usually O O
the O O
mother O O
) O O
of O O
4 O O
, O O
651 O O
. O O
cDNA O O
cloning O O
reveals O O
two O O
mouse B-GENE O
beta5 I-GENE O
integrin I-GENE O
transcripts E-GENE O
distinct O O
in O O
cytoplasmic O O
domains O O
as O O
a O O
result O O
of O O
alternative O O
splicing O O
. O O
Earlier O O
nonoptical O O
methods O O
probably O O
did O O
not O O
include O O
the O O
portion O O
of O O
the O O
film O O
that O O
contained O O
mucus O O
. O O
OBJECTIVE O O
: O O
To O O
summarise O O
quantitatively O O
the O O
association O O
between O O
moderate O O
alcohol O O
intake O O
and O O
biological O O
markers O O
of O O
risk O O
of O O
coronary O O
heart O O
disease O O
and O O
to O O
predict O O
how O O
these O O
changes O O
would O O
lower O O
the O O
risk O O
. O O
Like O O
other O O
known O O
GCD B-GENE B-GENE
genes E-GENE E-GENE
, O O
GCD14 S-GENE S-GENE
and O O
GCD15 S-GENE S-GENE
are O O
therefore O O
probably O O
required O O
for O O
general O O
translation O O
initiation O O
in O O
addition O O
to O O
their O O
roles O O
in O O
GCN4 S-GENE O
- O O
specific O O
translational O O
control O O
. O O
The O O
presence O O
of O O
highly O O
correlated O O
frequencies O O
provided O O
strong O O
evidence O O
of O O
a O O
medium O O
- O O
frequency O O
pattern O O
generator O O
which O O
may O O
remain O O
operative O O
beyond O O
the O O
neonatal O O
period O O
. O O
This O O
gene O O
is O O
named O O
PKNOX1 S-GENE S-GENE
by O O
the O O
Human O O
Nomenclature O O
Committee O O
. O O
Differentiation O O
of O O
porcine O O
mycoplasma O O
strains O O
by O O
means O O
of O O
a O O
simple O O
paper O O
chromatography O O
test O O
. O O
HIV O O
- O O
2 O O
in O O
Spain O O
. O O
No O O
effect O O
of O O
4 O O
beta O O
- O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
was O O
observed O O
on O O
the O O
expression O O
of O O
hnRNP B-GENE B-GENE
H E-GENE E-GENE
. O O
Patients O O
commonly O O
considered O O
the O O
external O O
frame O O
cumbersome O O
. O O
D O O
. O O
The O O
atf1 B-GENE B-GENE
+ I-GENE I-GENE
gene I-GENE E-GENE
of I-GENE O
Schizosaccharomyces I-GENE O
pombe E-GENE O
encodes O O
a O O
bZIP B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
with O O
strong O O
homology O O
to O O
the O O
mammalian B-GENE B-GENE
factor I-GENE I-GENE
ATF I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
. O O
The O O
effects O O
of O O
different O O
sources O O
of O O
commercial O O
rations O O
on O O
the O O
humoral O O
immune O O
response O O
of O O
broilers O O
to O O
Newcastle O O
disease O O
vaccination O O
. O O
Multiple O O
attempts O O
aimed O O
at O O
disruption O O
of O O
the O O
chromosomal B-GENE O
fabG I-GENE B-GENE
gene E-GENE E-GENE
were O O
unsuccessful O O
. O O
Primary O O
TJRs O O
were O O
clinically O O
evaluated O O
for O O
degree O O
of O O
osteoarthrosis O O
. O O
Radiation O O
sensitivity O O
of O O
rats O O
irradiated O O
in O O
a O O
condition O O
of O O
hypoxia O O
The O O
activity O O
of O O
plasminogen B-GENE O
activator E-GENE O
has O O
been O O
measured O O
in O O
tissue O O
sections O O
with O O
the O O
aid O O
of O O
a O O
modified O O
Todd O O
technique O O
. O O
The O O
complexity O O
of O O
some O O
of O O
the O O
reports O O
of O O
VACURG O O
studies O O
has O O
led O O
some O O
to O O
believe O O
that O O
this O O
group O O
was O O
opposed O O
to O O
estrogens O O
, O O
but O O
that O O
is O O
not O O
true O O
. O O
Thus O O
, O O
the O O
mutants O O
are O O
deficient O O
in O O
production O O
of O O
the O O
O B-GENE B-GENE
- I-GENE I-GENE
antigen I-GENE I-GENE
polymerase E-GENE E-GENE
and O O
were O O
termed O O
rfc B-GENE O
mutants E-GENE O
. O O
Up O O
to O O
1988 O O
, O O
145 O O
cases O O
had O O
been O O
reported O O
in O O
literature O O
and O O
32 O O
cases O O
in O O
our O O
country O O
. O O
Focal O O
glomerulosclerosis O O
- O O
like O O
disease O O
with O O
nephrotic O O
syndrome O O
in O O
a O O
horse O O
. O O
The O O
antihypertensive O O
action O O
corresponds O O
to O O
those O O
of O O
established O O
diuretics O O
. O O
Interconversions O O
between O O
haloperidol O O
and O O
reduced O O
haloperidol O O
in O O
schizophrenic O O
patients O O
and O O
guinea O O
pigs O O
: O O
a O O
steady O O
- O O
state O O
study O O
. O O
The O O
frequency O O
of O O
eating O O
dark O O
- O O
meat O O
fish O O
was O O
positively O O
associated O O
with O O
serum O O
eicosapentaenoic O O
acid O O
and O O
docosahexaenoic O O
acid O O
, O O
omega3 O O
fatty O O
acids O O
, O O
and O O
inversely O O
associated O O
with O O
serum O O
stearic O O
acid O O
and O O
linoleic O O
acid O O
. O O
Effect O O
of O O
food O O
on O O
hemodynamics O O
. O O
The O O
D443N B-GENE S-GENE
substitution E-GENE O
is O O
an O O
activating O O
mutation O O
that O O
increases O O
the O O
activity O O
of O O
SCAP S-GENE S-GENE
and O O
renders O O
it O O
resistant O O
to O O
inhibition O O
by O O
25 O O
- O O
hydroxycholesterol O O
. O O
Central O O
( O O
heart O O
rate O O
, O O
VE O O
, O O
VO2 O O
) O O
or O O
local O O
( O O
muscle O O
and O O
blood O O
lactate O O
, O O
adenosine O O
triphosphate O O
, O O
creatine B-GENE O
phosphokinase E-GENE O
, O O
glycogen O O
) O O
cues O O
highlighted O O
in O O
these O O
studies O O
demonstrate O O
both O O
the O O
complexity O O
of O O
effort O O
perception O O
, O O
and O O
the O O
need O O
for O O
better O O
understanding O O
of O O
the O O
physiological O O
components O O
upon O O
which O O
it O O
is O O
based O O
. O O
The O O
gene O O
is O O
predicted O O
to O O
encode O O
an O O
880 O O
- O O
amino O O
- O O
acid O O
protein O O
which O O
contains O O
two O O
C2H2 O S-GENE
zinc O O
fingers O O
, O O
a O O
nuclear O O
localization O O
sequence O O
and O O
two O O
transcriptional O O
activation O O
domains O O
. O O
This O O
approach O O
allowed O O
examination O O
of O O
baseline O O
factors O O
as O O
well O O
as O O
the O O
effect O O
of O O
change O O
in O O
mileage O O
, O O
the O O
occurrence O O
of O O
a O O
musculoskeletal O O
problem O O
, O O
or O O
the O O
occurrence O O
of O O
another O O
health O O
problem O O
on O O
the O O
rate O O
of O O
dropout O O
. O O
Microalbuminuria O O
: O O
a O O
marker O O
of O O
systemic O O
disease O O
. O O
Regulation O O
of O O
activating B-GENE B-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
the O O
cAMP B-GENE O
response I-GENE O
element I-GENE O
- I-GENE O
binding I-GENE O
protein E-GENE O
by O O
Ca2 B-GENE B-GENE
+ I-GENE E-GENE
/ I-GENE O
calmodulin I-GENE O
- I-GENE O
dependent I-GENE O
protein I-GENE O
kinases I-GENE O
type I-GENE O
I I-GENE O
, I-GENE O
II I-GENE O
, I-GENE O
and I-GENE O
IV E-GENE O
. O O
Coronary O O
arteries O O
were O O
found O O
in O O
the O O
biopsy O O
tissue O O
of O O
30 O O
( O O
76 O O
% O O
) O O
of O O
the O O
39 O O
patients O O
who O O
formed O O
the O O
study O O
group O O
. O O
Serum B-GENE O
amyloid I-GENE O
A E-GENE O
( O O
SAA S-GENE S-GENE
) O O
is O O
a O O
plasma O O
protein O O
which O O
has O O
been O O
associated O O
with O O
several O O
diseases O O
, O O
including O O
amyloidosis O O
, O O
arthritis O O
, O O
and O O
atherosclerosis O O
, O O
and O O
its O O
abnormal O O
expression O O
, O O
particularly O O
in O O
nonhepatic O O
cells O O
, O O
is O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
these O O
diseases O O
. O O
Phenacetin O O
nephritis O O
We O O
have O O
been O O
developing O O
a O O
digital O O
fluoroscopic O O
imaging O O
system O O
to O O
replace O O
the O O
portal O O
films O O
that O O
are O O
currently O O
used O O
to O O
verify O O
patient O O
positioning O O
during O O
radiotherapy O O
treatments O O
. O O
The O O
human B-GENE B-GENE
p18 I-GENE I-GENE
gene E-GENE E-GENE
spans O O
at O O
least O O
7 O O
. O O
5 O O
kb O O
and O O
is O O
composed O O
of O O
three O O
exons O O
, O O
two O O
of O O
which O O
encode O O
the O O
p18 B-GENE B-GENE
protein E-GENE E-GENE
. O O
Serum O B-GENE
creatinine B-GENE I-GENE
kinase E-GENE E-GENE
activity O O
was O O
7 O O
, O O
800 O O
- O O
17 O O
, O O
500 O O
U O O
/ O O
l O O
, O O
making O O
acute O O
muscle O O
damage O O
likely O O
, O O
probably O O
rhabdomyolysis O O
. O O
These O O
results O O
suggest O O
that O O
termination O O
is O O
a O O
highly O O
specific O O
event O O
, O O
and O O
not O O
merely O O
a O O
consequence O O
of O O
decreased O O
stability O O
of O O
the O O
EC O O
. O O
Like O O
Mdm2 S-GENE S-GENE
, O O
MdmX S-GENE S-GENE
is O O
able O O
to O O
bind O O
p53 S-GENE S-GENE
and O O
inhibit O O
p53 S-GENE S-GENE
transactivation O O
; O O
however O O
, O O
the O O
ability O O
of O O
MdmX S-GENE S-GENE
to O O
degrade O O
p53 S-GENE S-GENE
has O O
yet O O
to O O
be O O
examined O O
. O O
PURPOSE O O
: O O
Second O O
malignant O O
neoplasms O O
( O O
SMNs O O
) O O
are O O
a O O
rare O O
occurrence O O
after O O
the O O
successful O O
treatment O O
of O O
childhood O O
cancer O O
. O O
Recent O O
geological O O
studies O O
focusing O O
on O O
the O O
Davie O O
Fracture O O
Zone O O
of O O
the O O
Mozambique O O
Channel O O
offer O O
a O O
resolution O O
to O O
this O O
situation O O
, O O
by O O
suggesting O O
the O O
presence O O
of O O
a O O
land O O
- O O
bridge O O
from O O
the O O
mid O O
- O O
Eocene O O
to O O
the O O
early O O
Miocene O O
, O O
an O O
interval O O
that O O
matches O O
the O O
ages O O
of O O
Madagascar O O
' O O
s O O
mammalian O O
groups O O
. O O
The O O
nucleotide O O
sequence O O
of O O
a O O
PCR O O
- O O
amplified O O
SMT3A S-GENE O
genomic O O
DNA O O
fragment O O
was O O
found O O
to O O
be O O
identical O O
to O O
that O O
of O O
SMT3A B-GENE B-GENE
cDNA E-GENE E-GENE
, O O
indicating O O
the O O
absence O O
of O O
intron O O
( O O
s O O
) O O
in O O
its O O
protein O O
coding O O
region O O
. O O
Mutant O B-GENE
p53 B-GENE E-GENE
DNA E-GENE O
clones O O
from O O
human O O
colon O O
carcinomas O O
cooperate O O
with O O
ras S-GENE S-GENE
in O O
transforming O O
primary O O
rat O O
cells O O
: O O
a O O
comparison O O
of O O
the O O
" O O
hot O O
spot O O
" O O
mutant O O
phenotypes O O
. O O
Gas O O
chromatographic O O
analysis O O
of O O
headspace O O
samples O O
of O O
alkalinized O O
vaginal O O
discharges O O
indicated O O
the O O
presence O O
of O O
trimethylamine O O
in O O
all O O
11 O O
samples O O
with O O
the O O
fishy O O
odor O O
but O O
not O O
in O O
the O O
other O O
samples O O
. O O
Standing O O
values O O
: O O
placebo O O
114 O O
/ O O
79 O O
; O O
BHT O O
- O O
933 O O
92 O O
/ O O
67 O O
. O O
The O O
Ixodes O O
fauna O O
in O O
the O O
Michourin O O
region O O
, O O
where O O
the O O
pastures O O
in O O
1971 O O
were O O
grazed O O
only O O
by O O
sheep O O
, O O
shows O O
the O O
following O O
trends O O
: O O
H O O
. O O
punctata O O
and O O
R O O
. O O
turanicus O O
ticks O O
, O O
which O O
are O O
preferably O O
parasitising O O
in O O
sheep O O
, O O
increase O O
their O O
relative O O
share O O
. O O
The O O
SEC27 B-GENE B-GENE
gene E-GENE E-GENE
was O O
cloned O O
, O O
and O O
the O O
sequence O O
predicts O O
a O O
99 O O
. O O
4 O O
- O O
kDa O O
protein O O
with O O
45 O O
% O O
sequence O O
identity O O
to O O
mammalian O B-GENE
beta B-GENE I-GENE
' I-GENE I-GENE
- I-GENE I-GENE
COP E-GENE E-GENE
. O O
Studies O O
of O O
fetal O O
maturity O O
Fetal O O
arterial O O
and O O
sagittal O O
sinus O O
pH O O
, O O
base O O
excess O O
, O O
po2 O O
, O O
and O O
oxygen O O
saturation O O
decreased O O
, O O
and O O
hydrogen O O
ion O O
concentrations O O
and O O
pco2 O O
increased O O
during O O
asphyxia O O
alone O O
and O O
asphyxia O O
plus O O
isoflurane O O
- O O
oxygen O O
. O O
Therefore O O
, O O
it O O
appears O O
that O O
GCN2 B-GENE B-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
function O O
is O O
stimulated O O
posttranslationally O O
in O O
amino O O
acid O O
- O O
starved O O
cells O O
. O O
Although O O
paclitaxel O O
alone O O
failed O O
to O O
induce O O
p38 S-GENE B-GENE
MAPK O E-GENE
activation O O
, O O
subsequent O O
( O O
but O O
not O O
prior O O
) O O
exposure O O
to O O
PD98059 O O
induced O O
a O O
dramatic O O
increase O O
in O O
p38 S-GENE B-GENE
MAPK O E-GENE
phosphorylation O O
. O O
In O O
3 O O
of O O
the O O
5 O O
patients O O
with O O
AVNRT O O
and O O
AJR O O
, O O
junctional O O
beats O O
served O O
as O O
a O O
trigger O O
for O O
reentry O O
. O O
The O O
three O O
respective O O
time O O
control O O
groups O O
( O O
C5 O O
, O O
C10 O O
, O O
and O O
C15 O O
) O O
were O O
injected O O
with O O
saline O O
solution O O
. O O
Sequence O O
analysis O O
of O O
cDNA O O
clones O O
encoding O O
human O O
gamma O O
revealed O O
an O O
open O O
reading O O
frame O O
predicting O O
a O O
protein O O
of O O
299 O O
amino O O
acids O O
( O O
approximately O O
32 O O
kDa O O
) O O
, O O
half O O
the O O
size O O
of O O
the O O
bovine O B-GENE
gamma O I-GENE
subunit O E-GENE
. O O
A O O
positive O O
FTA B-GENE O
- I-GENE O
ABS I-GENE O
- I-GENE O
19S I-GENE O
- I-GENE O
IgM E-GENE O
test O O
indicates O O
the O O
necessity O O
of O O
treatment O O
. O O
Our O O
data O O
suggest O O
that O O
some O O
defects O O
observed O O
in O O
BS O O
, O O
WS O O
or O O
RTS O O
are O O
the O O
consequence O O
of O O
unrestrained O O
recombination O O
. O O
The O O
promoter O O
for O O
HMG B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
synthase E-GENE E-GENE
contains O O
two O O
binding O O
sites O O
for O O
the O O
sterol B-GENE O
regulatory I-GENE O
element I-GENE O
- I-GENE O
binding I-GENE O
proteins E-GENE O
( O O
SREBPs S-GENE S-GENE
) O O
. O O
These O O
data O O
indicate O O
that O O
chromatic O O
processing O O
in O O
areas O O
V1 O O
and O O
V2 O O
is O O
normal O O
after O O
V4 O O
lesions O O
and O O
, O O
together O O
with O O
the O O
behavioural O O
evidence O O
, O O
that O O
these O O
areas O O
are O O
sufficient O O
for O O
some O O
basic O O
aspects O O
of O O
colour O O
perception O O
. O O
The O O
curse O O
of O O
the O O
Pharaohs O O
. O O
Covariates O O
were O O
lower O O
extremity O O
range O O
of O O
motion O O
and O O
sensory O O
status O O
. O O
Characterization O O
and O O
targeted O O
disruption O O
of O O
murine B-GENE O
Nup50 E-GENE O
, O O
a O O
p27 S-GENE S-GENE
( O O
Kip1 S-GENE O
) O O
- O O
interacting O O
component O O
of O O
the O O
nuclear O O
pore O O
complex O O
. O O
p27 S-GENE S-GENE
( O O
Kip1 S-GENE S-GENE
) O O
is O O
a O O
member O O
of O O
the O O
Cip S-GENE B-GENE
- O I-GENE
Kip S-GENE I-GENE
family O E-GENE
of O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase E-GENE E-GENE
( O O
Cdk S-GENE S-GENE
) O O
inhibitors O O
that O O
binds O O
to O O
cyclin S-GENE B-GENE
- O I-GENE
Cdk S-GENE E-GENE
complexes O O
and O O
inhibits O O
their O O
catalytic O O
activity O O
in O O
response O O
to O O
antiproliferative O O
stimuli O O
. O O
p27 S-GENE S-GENE
( O O
Kip1 S-GENE S-GENE
) O O
is O O
regulated O O
by O O
several O O
posttranscriptional O O
mechanisms O O
, O O
including O O
subcellular O O
localization O O
. O O
Therefore O O
, O O
the O O
Ogg1 B-GENE B-GENE
protein E-GENE E-GENE
is O O
a O O
eukaryotic O O
DNA B-GENE O
glycosylase E-GENE O
/ O O
AP B-GENE B-GENE
lyase E-GENE E-GENE
. O O
One O O
patient O O
had O O
chronic O O
dysphoria O O
and O O
one O O
encephalopatia O O
toxica O O
. O O
Alveoli O O
- O O
capillary O O
diffusion O O
. O O
Mutations O O
of O O
SIN4 S-GENE S-GENE
, O O
ROX3 S-GENE S-GENE
, O O
SRB8 S-GENE S-GENE
, O O
SRB9 S-GENE S-GENE
, O O
SRB10 S-GENE S-GENE
, O O
SRB11 S-GENE S-GENE
, O O
and O O
two O O
novel O O
genes O O
, O O
NUT1 S-GENE S-GENE
and O O
NUT2 S-GENE S-GENE
, O O
relieve O O
the O O
requirement O O
of O O
Swi4p S-GENE S-GENE
for O O
expression O O
of O O
this O O
reporter O O
. O O
The O O
software O O
is O O
in O O
BASIC O O
adapted O O
for O O
the O O
Hewlett O O
- O O
Packard O O
calculators O O
HP O O
- O O
9845B O O
and O O
HP O O
- O O
85A O O
. O O
For O O
Thermus O O
strain O O
ZO5 B-GENE O
dihydroorotase E-GENE O
( O O
DHOase S-GENE O
; O O
encoded O O
by O O
pyrC S-GENE O
) O O
, O O
the O O
highest O O
similarity O O
scores O O
( O O
about O O
40 O O
% O O
identity O O
) O O
were O O
obtained O O
with O O
DHOases S-GENE O
from O O
B O O
. O O
caldolyticus O O
and O O
Bacillus O O
subtilis O O
. O O
Precision O O
of O O
data O O
from O O
models O O
of O O
sodium O O
kinetics O O
in O O
hemodialysis O O
These O O
data O O
suggest O O
that O O
the O O
fibrinogen B-GENE B-GENE
gamma I-GENE I-GENE
chain I-GENE I-GENE
region I-GENE I-GENE
Gly190 I-GENE I-GENE
- I-GENE I-GENE
Val202 E-GENE E-GENE
functions O O
as O O
a O O
minimal O O
recognition O O
sequence O O
for O O
the O O
leukocyte O O
integrin O O
CD11b S-GENE S-GENE
/ O O
CD18 S-GENE S-GENE
. O O
Attenuated O O
serum O O
cortisol O O
responses O O
were O O
found O O
in O O
six O O
of O O
the O O
patients O O
despite O O
a O O
normal O O
ACTH S-GENE O
test O O
. O O
We O O
recently O O
described O O
the O O
isolation O O
and O O
characterization O O
of O O
nontoxic O O
PAP B-GENE O
mutants E-GENE O
, O O
NT123 O B-GENE
- O I-GENE
2 O E-GENE
, O O
which O O
has O O
a O O
point O O
mutation O O
( O O
E176V O O
) O O
in O O
the O O
active O O
site O O
that O O
abolishes O O
enzymatic O O
activity O O
, O O
and O O
NT124 O B-GENE
- O I-GENE
3 O E-GENE
, O O
which O O
has O O
a O O
nonsense O O
mutation O O
that O O
results O O
in O O
deletion O O
of O O
the O O
C O O
- O O
terminal O O
25 O O
aa O O
( O O
W237Stop O O
) O O
. O O
Toxicity O O
of O O
benzoyl O O
chloride O O
( O O
2 O O
, O O
4 O O
, O O
6 O O
- O O
trichlorophenyl O O
) O O
hydrazone O O
( O O
Banamite O O
) O O
and O O
potential O O
metabolites O O
to O O
twospotted O O
spider O O
mites O O
and O O
potency O O
as O O
inhibitors O O
of O O
rat B-GENE B-GENE
liver I-GENE I-GENE
monoamine I-GENE I-GENE
oxidase E-GENE E-GENE
. O O
The O O
screen O O
identifies O O
mutants O O
whose O O
growth O O
depends O O
on O O
high O O
levels O O
of O O
expression O O
of O O
that O O
gene O O
. O O
The O O
genes O O
expressed O O
during O O
the O O
embryonic O O
( O O
zeta S-GENE O
) O O
or O O
fetal O O
and O O
adult O O
stage O O
( O O
alpha B-GENE O
2 E-GENE O
and O O
alpha B-GENE B-GENE
1 E-GENE E-GENE
) O O
can O O
be O O
modified O O
by O O
point O O
mutations O O
which O O
affect O O
either O O
the O O
processing O O
- O O
translation O O
of O O
mRNA O O
or O O
make O O
the O O
polypeptide O O
chains O O
extremely O O
unstable O O
. O O
In O O
a O O
study O O
in O O
Singapore O O
, O O
Chinese O O
, O O
Malay O O
and O O
Indian O O
patients O O
with O O
pulmonary O O
tuberculosis O O
received O O
2 O O
months O O
of O O
daily O O
treatment O O
with O O
streptomycin O O
, O O
isoniazid O O
, O O
rifampicin O O
, O O
and O O
pyrazinamide O O
followed O O
by O O
daily O O
isoniazid O O
, O O
and O O
rifampicin O O
either O O
with O O
pyrazinamide O O
( O O
SHRZ O O
/ O O
HRZ O O
) O O
or O O
without O O
it O O
( O O
SHRZ O O
/ O O
HR O O
) O O
, O O
allocated O O
at O O
random O O
. O O
Kaposi O O
' O O
s O O
sarcoma O O
- O O
associated O O
herpesvirus O O
/ O O
human O B-GENE
herpesvirus O I-GENE
- O I-GENE
8 O I-GENE
ORF50 S-GENE I-GENE
gene O E-GENE
product O O
contains O O
a O O
potent O O
C O O
- O O
terminal O O
activation O O
domain O O
which O O
activates O O
gene O O
expression O O
via O O
a O O
specific O O
target O O
sequence O O
. O O
NSAIDS O O
and O O
the O O
microcirculation O O
of O O
the O O
stomach O O
. O O
The O O
efficiency O O
of O O
transfections O O
was O O
normalized O O
relative O O
to O O
the O O
net O O
amount O O
of O O
CAT S-GENE O
plasmid O O
actually O O
transfected O O
into O O
recipient O O
cells O O
, O O
determined O O
by O O
a O O
modified O O
Southern O O
hybridization O O
procedure O O
. O O
Genomic O O
Southern O O
blot O O
analysis O O
suggests O O
that O O
the O O
human O O
haploid O O
genome O O
contains O O
a O O
single O O
Gs B-GENE B-GENE
alpha I-GENE I-GENE
gene E-GENE E-GENE
. O O
Evaluation O O
of O O
the O O
effects O O
of O O
chelation O O
therapy O O
with O O
time O O
following O O
strontium O O
exposure O O
to O O
mice O O
. O O
In O O
the O O
present O O
study O O
we O O
found O O
that O O
CD34 S-GENE S-GENE
downregulation O O
during O O
hematopoiesis O O
occured O O
at O O
the O O
level O O
of O O
transcriptional O O
initiation O O
. O O
Allergen O O
- O O
stimulated O O
levels O O
of O O
PGD2 O O
were O O
1274 O O
+ O O
/ O O
- O O
565 O O
versus O O
1468 O O
+ O O
/ O O
- O O
679 O O
after O O
prednisone O O
; O O
likewise O O
, O O
allergen O O
- O O
stimulated O O
5 O O
- O O
HETE O O
levels O O
were O O
95 O O
+ O O
/ O O
- O O
21 O O
versus O O
82 O O
+ O O
/ O O
- O O
21 O O
; O O
those O O
of O O
LTE4 O O
were O O
54 O O
+ O O
/ O O
- O O
20 O O
versus O O
91 O O
+ O O
/ O O
- O O
51 O O
; O O
and O O
those O O
of O O
15 O O
- O O
HETE O O
were O O
63 O O
+ O O
/ O O
- O O
19 O O
versus O O
60 O O
+ O O
/ O O
- O O
25 O O
. O O
Foreign O O
DNA O O
inserts O O
contained O O
within O O
the O O
fowlpox O O
virus O O
sequence O O
were O O
transferred O O
to O O
the O O
viral O O
genome O O
by O O
homologous O O
recombination O O
occurring O O
in O O
cells O O
infected O O
with O O
a O O
fowlpox O O
virus O O
temperature O O
- O O
sensitive O O
mutant O O
and O O
transfected O O
with O O
both O O
wild O O
- O O
type O O
viral O O
DNA O O
and O O
plasmid O O
DNA O O
. O O
Although O O
there O O
is O O
evidence O O
that O O
cone O O
ratios O O
do O O
determine O O
colour O O
appearance O O
under O O
many O O
conditions O O
, O O
the O O
site O O
or O O
sites O O
of O O
their O O
computation O O
is O O
unknown O O
. O O
Furthermore O O
, O O
we O O
demonstrate O O
that O O
in O O
myeloid O O
and O O
B O O
cell O O
extracts O O
, O O
PU B-GENE O
. I-GENE O
1 E-GENE O
forms O O
a O O
novel O O
, O O
specific O O
, O O
more O O
slowly O O
migrating O O
complex O O
( O O
PU B-GENE B-GENE
- I-GENE I-GENE
SF E-GENE E-GENE
) O O
when O O
binding O O
the O O
GM B-GENE B-GENE
- I-GENE I-GENE
CSF I-GENE I-GENE
receptor I-GENE I-GENE
alpha E-GENE I-GENE
promoter O I-GENE
PU B-GENE I-GENE
. I-GENE I-GENE
1 E-GENE I-GENE
site O E-GENE
. O O
Several O O
components O O
in O O
cytokine O O
signaling O O
remain O O
unidentified O O
. O O
This O O
is O O
the O O
first O O
report O O
demonstrating O O
specificity O O
at O O
the O O
level O O
of O O
the O O
energy O O
coupling O O
proteins O O
of O O
the O O
PTS O O
. O O
In O O
contrast O O
, O O
stem O O
- O O
loop O O
structures O O
2 O O
, O O
3 O O
, O O
and O O
4 O O
of O O
the O O
3 O O
' O O
domain O O
showed O O
great O O
variations O O
in O O
size O O
, O O
sequence O O
, O O
and O O
structure O O
. O O
A O O
spectrophotometric O O
method O O
for O O
the O O
microdetermination O O
of O O
periodate O O
. O O
Result O O
were O O
as O O
followed O O
: O O
1 O O
) O O
Early O O
cancer O O
- O O
like O O
advanced O O
cancers O O
were O O
consisted O O
of O O
133 O O
lesions O O
, O O
of O O
which O O
128 O O
lesions O O
( O O
96 O O
. O O
2 O O
% O O
) O O
had O O
peptic O O
ulcer O O
in O O
cancerous O O
lesion O O
( O O
73 O O
lesions O O
were O O
active O O
stage O O
and O O
55 O O
lesions O O
were O O
scarring O O
stage O O
) O O
. O O
Effect O O
of O O
hyperaemia O O
on O O
thallium O O
- O O
201 O O
redistribution O O
in O O
normal O O
canine O O
myocardium O O
. O O
Immunoblotting O O
showed O O
that O O
both O O
the O O
( O O
1 O O
- O O
404 O O
) O O
- O O
peptide O O
and O O
( O O
1 O O
- O O
506 O O
) O O
- O O
peptide O O
are O O
recognized O O
by O O
95J10 S-GENE S-GENE
, O O
a O O
monoclonal O O
antibody O O
that O O
was O O
previously O O
raised O O
against O O
perlecan B-GENE O
- I-GENE O
( I-GENE O
24 I-GENE O
- I-GENE O
404 I-GENE O
) I-GENE O
- I-GENE O
peptide E-GENE O
expressed O O
in O O
Escherichia O O
coli O O
. O O
The O O
anesthesiologist O O
and O O
the O O
cardiac O O
surgeon O O
. O O
To O O
gain O O
further O O
insights O O
into O O
these O O
events O O
, O O
the O O
porcine B-GENE B-GENE
G I-GENE I-GENE
alpha I-GENE I-GENE
i I-GENE I-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
gene I-GENE E-GENE
minimal I-GENE O
promoter E-GENE O
was O O
characterized O O
and O O
found O O
67 O O
base O O
pairs O O
upstream O O
from O O
the O O
major O O
transcription O O
start O O
site O O
. O O
FDP O O
- O O
1 O O
( O O
200 O O
micrograms O O
. O O
kg O O
- O O
1 O O
) O O
of O O
intracoronary O O
injection O O
increased O O
collateral O O
flow O O
, O O
reduced O O
systemic O O
artery O O
resistance O O
, O O
and O O
coronary O O
systolic O O
pressure O O
in O O
infarcted O O
region O O
and O O
the O O
area O O
of O O
infarction O O
decreased O O
from O O
28 O O
. O O
9 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
% O O
to O O
15 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
% O O
( O O
P O O
< O O
0 O O
. O O
01 O O
, O O
n O O
= O O
6 O O
) O O
. O O
Pathophysiologic O O
mechanisms O O
underlying O O
spatial O O
disorientation O O
in O O
patients O O
with O O
Alzheimer O O
' O O
s O O
disease O O
. O O
Many O O
human O O
malignant O O
cells O O
lack O O
methylthioadenosine B-GENE O
phosphorylase E-GENE O
( O O
MTAP S-GENE S-GENE
) O O
enzyme O O
activity O O
. O O
Following O O
40 O O
min O O
" O O
ischemia O O
" O O
, O O
preparations O O
treated O O
with O O
PC O O
recovered O O
from O O
transmural O O
conduction O O
block O O
more O O
rapidly O O
( O O
PC1 O O
group O O
, O O
4 O O
min O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
; O O
PC2 O O
group O O
, O O
23 O O
min O O
, O O
ns O O
) O O
, O O
compared O O
to O O
control O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
The O O
novel O O
gene O O
spans O O
16 O O
. O O
7 O O
kb O O
of O O
genomic O O
sequence O O
and O O
it O O
is O O
formed O O
of O O
11 O O
exons O O
and O O
10 O O
intervening O O
introns O O
. O O
G B-GENE O
- I-GENE O
box I-GENE O
binding I-GENE O
factors E-GENE O
( O O
GBFs S-GENE S-GENE
) O O
constitute O O
a O O
family O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
that O O
bind O O
to O O
the O O
G O O
- O O
box O O
motif O O
, O O
a O O
regulatory O O
cis O O
element O O
present O O
in O O
many O O
plant O O
genes O O
with O O
a O O
palindromic O O
DNA O O
motif O O
of O O
CACGTG O S-GENE
. O O
CONCLUSION O O
: O O
In O O
an O O
acute O O
canine O O
model O O
of O O
progressive O O
LCX O O
coronary O O
stenosis O O
, O O
CFR O O
was O O
impaired O O
in O O
both O O
ischemic O O
and O O
remote O O
nonischemic O O
regions O O
in O O
association O O
with O O
mild O O
to O O
moderate O O
ischemic O O
- O O
induced O O
regional O O
myocardial O O
dysfunction O O
. O O
A O O
third O O
- O O
order O O
polynominal O O
fit O O
showed O O
a O O
good O O
correlation O O
for O O
the O O
parameter O O
Q O O
* O O
and O O
MTT O O
, O O
whereas O O
T O O
and O O
SImax O O
were O O
found O O
to O O
have O O
a O O
poor O O
correlation O O
. O O
Late O O
results O O
in O O
the O O
treatment O O
of O O
urotuberculosis O O
Changes O O
in O O
the O O
frequency O O
of O O
X O O
- O O
chromatin O O
in O O
women O O
under O O
Prednisone O O
therapy O O
Other O O
toxicities O O
attributed O O
to O O
CPT O O
- O O
11 O O
included O O
dehydration O O
, O O
nausea O O
, O O
vomiting O O
, O O
and O O
asthenia O O
. O O
Proceedings O O
: O O
Influence O O
of O O
halothane O O
on O O
mortality O O
from O O
murine O O
hepatitis O O
virus O O
( O O
MHV3 O O
) O O
. O O
These O O
results O O
extend O O
our O O
knowledge O O
of O O
this O O
SNF2 B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
family I-GENE E-GENE
member E-GENE O
and O O
suggest O O
a O O
role O O
for O O
PASG S-GENE S-GENE
in O O
leukemogenesis O O
. O O
The O O
difference O O
between O O
the O O
results O O
in O O
the O O
high O O
dose O O
AHLG S-GENE O
and O O
in O O
the O O
control O O
group O O
was O O
significant O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O
Results O O
of O O
this O O
study O O
indicate O O
that O O
when O O
amniotic O O
fluid O O
samples O O
are O O
stored O O
frozen O O
and O O
strict O O
quality O O
control O O
is O O
maintained O O
in O O
analytic O O
procedures O O
, O O
only O O
minimal O O
changes O O
occur O O
in O O
phospholipid O O
concentrations O O
over O O
12 O O
months O O
. O O
Retinoic O O
acid O O
, O O
which O O
inhibits O O
the O O
progression O O
of O O
certain O O
cancers O O
, O O
repressed O O
v B-GENE O
- I-GENE O
src E-GENE O
- O O
induced O O
MMP B-GENE O
- I-GENE O
1 E-GENE O
transcription O O
. O O
The O O
pattern O O
of O O
net B-GENE O
RNA E-GENE O
expression O O
in O O
adult O O
mouse O O
tissues O O
is O O
different O O
. O O
Immunoprecipitation O O
of O O
spinophilin S-GENE O
or O O
neurabin S-GENE O
from O O
crude O O
brain O O
extracts O O
selectively O O
coprecipitated O O
PP1gamma B-GENE O
( I-GENE O
1 I-GENE O
) E-GENE O
over O O
PP1beta S-GENE O
. O O
The O O
authors O O
discussed O O
their O O
experience O O
in O O
investigating O O
20 O O
patients O O
with O O
maxillary O O
malignant O O
tumors O O
using O O
routine O O
x O O
- O O
ray O O
studies O O
and O O
MR O O
- O O
tomography O O
, O O
and O O
13 O O
patients O O
, O O
investigated O O
in O O
the O O
same O O
way O O
plus O O
CT O O
. O O
Reduction O O
of O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
was O O
detected O O
after O O
1 O O
day O O
of O O
OM S-GENE O
treatment O O
and O O
reached O O
maximal O O
suppression O O
of O O
10 O O
- O O
20 O O
% O O
of O O
control O O
after O O
3 O O
days O O
in O O
H3922 O O
and O O
40 O O
% O O
of O O
control O O
after O O
4 O O
days O O
in O O
MCF O O
- O O
7 O O
cells O O
. O O
Association O O
of O O
Syk S-GENE B-GENE
protein B-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PTK S-GENE S-GENE
) O O
with O O
LMP2A S-GENE S-GENE
occurs O O
at O O
the O O
two O O
tyrosines O O
of O O
the O O
LMP2A B-GENE B-GENE
immunoreceptor E-GENE I-GENE
tyrosine O E-GENE
- O O
based O O
activation O O
motif O O
, O O
and O O
it O O
is O O
hypothesized O O
that O O
Lyn S-GENE B-GENE
PTK S-GENE E-GENE
associates O O
with O O
the O O
YEEA O S-GENE
amino O O
acid O O
motif O O
at O O
LMP2A S-GENE B-GENE
tyrosine O I-GENE
112 O E-GENE
( O O
Y112 O S-GENE
) O O
. O O
The O O
treatment O O
with O O
glucocorticoids O O
and O O
immunosuppressants O O
resulted O O
in O O
a O O
more O O
noticeable O O
decrease O O
in O O
the O O
levels O O
of O O
T3 O O
and O O
E B-GENE O
- I-GENE O
RCF E-GENE O
. O O
Four O O
of O O
these O O
fibroblast O O
clones O O
were O O
infected O O
with O O
a O O
retrovirus O O
containing O O
the O O
cDNA B-GENE O
encoding I-GENE O
myoD E-GENE O
and O O
a O O
puromycin O O
selection O O
marker O O
. O O
Serum O B-GENE
estriol O E-GENE
levels O O
during O O
beta B-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
agonist O O
infusion O O
in O O
the O O
third O O
trimester O O
of O O
pregnancy O O
. O O
In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
by O O
which O O
Tax S-GENE O
activates O O
gene O O
expression O O
in O O
conjunction O O
with O O
members O O
of O O
the O O
ATF S-GENE S-GENE
/ O O
CREB S-GENE B-GENE
family O E-GENE
. O O
Four O O
of O O
12 O O
patients O O
( O O
33 O O
% O O
) O O
were O O
initially O O
diagnosed O O
as O O
having O O
a O O
benign O O
disease O O
( O O
false O O
- O O
negatives O O
) O O
. O O
However O O
, O O
it O O
was O O
observed O O
that O O
storage O O
time O O
affected O O
significantly O O
the O O
biochemical O O
changes O O
occurring O O
in O O
the O O
constituents O O
of O O
carrots O O
exposed O O
to O O
gamma O O
- O O
irradiation O O
. O O
Suppression O O
of O O
the O O
cka1 B-GENE B-GENE
delta I-GENE I-GENE
cka2 I-GENE I-GENE
- I-GENE I-GENE
8 I-GENE I-GENE
mutant E-GENE E-GENE
phenotype O O
occurs O O
by O O
interaction O O
of O O
CKB1 S-GENE S-GENE
with O O
the O O
defective O O
, O O
cka2 B-GENE B-GENE
- I-GENE I-GENE
8 E-GENE I-GENE
- O I-GENE
encoded O E-GENE
, O O
catalytic O O
subunit O O
. O O
The O O
median O O
cumulative O O
incidence O O
rates O O
were O O
found O O
to O O
be O O
341 O O
per O O
million O O
for O O
males O O
and O O
296 O O
per O O
million O O
for O O
females O O
. O O
Thomas O O
, O O
S O O
. O O
S O O
. O O
Similarly O O
, O O
antisense B-GENE O
TGF I-GENE B-GENE
- I-GENE I-GENE
beta I-GENE I-GENE
type I-GENE I-GENE
II I-GENE I-GENE
receptor I-GENE I-GENE
oligodeoxynucleotides I-GENE E-GENE
( I-GENE O
40 I-GENE O
microM I-GENE O
) E-GENE O
resulted O O
in O O
a O O
58 O O
% O O
increase O O
in O O
branching O O
, O O
compared O O
to O O
scrambled O O
and O O
mismatched O O
sequence O O
controls O O
, O O
while O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta I-GENE E-GENE
, I-GENE O
type I-GENE B-GENE
II I-GENE I-GENE
receptor I-GENE I-GENE
mRNA E-GENE E-GENE
and O O
its O O
protein O O
expression O O
levels O O
were O O
suppressed O O
by O O
95 O O
and O O
84 O O
% O O
, O O
respectively O O
. O O
Secretion O O
of O O
cuticle O O
over O O
and O O
between O O
the O O
domed O O
apical O O
surfaces O O
of O O
these O O
cells O O
leads O O
to O O
a O O
honeycomb O O
- O O
like O O
structure O O
and O O
gives O O
the O O
superficial O O
wart O O
- O O
like O O
phenotype O O
of O O
mitotic O O
clones O O
on O O
the O O
adult O O
. O O
Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
ICSBP S-GENE S-GENE
and O O
PU B-GENE B-GENE
. I-GENE I-GENE
1 E-GENE E-GENE
are O O
critical O O
elements O O
for O O
IL B-GENE B-GENE
- I-GENE I-GENE
18 I-GENE I-GENE
gene E-GENE E-GENE
expression O O
. O O
Based O O
on O O
these O O
results O O
, O O
it O O
has O O
been O O
concluded O O
that O O
an O O
IPFSA O O
can O O
promote O O
the O O
healing O O
process O O
in O O
the O O
avascular O O
zone O O
of O O
a O O
torn O O
meniscus O O
in O O
rabbits O O
and O O
that O O
systemic O O
vascularity O O
to O O
the O O
synovium O O
or O O
the O O
meniscus O O
is O O
not O O
essential O O
for O O
healing O O
to O O
occur O O
. O O
NASA O O
CR O O
- O O
1223 O O
. O O
The O O
magnitude O O
of O O
all O O
four O O
parameters O O
increased O O
in O O
an O O
exponential O O
fashion O O
with O O
increasing O O
sperm O O
number O O
up O O
to O O
400 O O
x O O
10 O O
( O O
6 O O
) O O
per O O
ejaculate O O
. O O
We O O
studied O O
about O O
the O O
histological O O
findings O O
of O O
the O O
kidneys O O
including O O
of O O
the O O
infiltrated O O
macrophages O O
in O O
one O O
hour O O
post O O
- O O
transplantation O O
kidney O O
biopsies O O
( O O
one O O
hour O O
biopsies O O
) O O
and O O
re O O
- O O
biopsies O O
on O O
11 O O
patients O O
. O O
An O O
additional O O
stimulation O O
of O O
D1 B-GENE B-GENE
receptors E-GENE E-GENE
by O O
giving O O
SKF38393 O O
30 O O
min O O
later O O
produced O O
an O O
almost O O
continuous O O
pattern O O
of O O
jaw O O
openings O O
but O O
less O O
closure O O
movements O O
from O O
the O O
rest O O
position O O
, O O
and O O
the O O
openings O O
were O O
accompanied O O
by O O
frequent O O
tongue O O
protrusions O O
. O O
( O O
control O O
hearts O O
) O O
. O O
The O O
( O O
0 O O
0 O O
2 O O
) O O
diffraction O O
of O O
the O O
synthesized O O
HAp O O
crystals O O
on O O
a O O
Col O O
fiber O O
showed O O
an O O
around O O
60 O O
arching O O
angle O O
, O O
while O O
that O O
on O O
a O O
ChS O O
fiber O O
showed O O
just O O
around O O
10 O O
degrees O O
. O O
During O O
4 O O
% O O
O2 O O
ventilation O O
, O O
baseline O O
pulmonary O O
vascular O O
resistance O O
( O O
PVR O O
) O O
and O O
the O O
dilator O O
response O O
to O O
both O O
ACh O O
and O O
SNP O O
were O O
greater O O
in O O
2D O O
lungs O O
. O O
To O O
determine O O
the O O
role O O
of O O
the O O
transmembrane O O
region O O
of O O
HN S-GENE S-GENE
on O O
fusion O O
- O O
promoting O O
activity O O
, O O
mutant B-GENE B-GENE
HN I-GENE I-GENE
proteins E-GENE E-GENE
were O O
expressed O O
and O O
their O O
biological O O
activities O O
examined O O
. O O
To O O
be O O
a O O
nurse O O
. O O
Transient O O
transfection O O
assays O O
indicated O O
that O O
the O O
( O O
- O O
4551 O O
) O O
UCP1 S-GENE O
- O O
CAT S-GENE O
construct O O
, O O
containing O O
the O O
5 O O
' O O
- O O
regulatory O O
region O O
of O O
the O O
rat B-GENE B-GENE
ucp I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
, O O
was O O
activated O O
by O O
PPARalpha S-GENE S-GENE
co O O
- O O
transfection O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
and O O
this O O
activation O O
was O O
potentiated O O
by O O
Wy O O
14 O O
, O O
643 O O
and O O
retinoid B-GENE B-GENE
X I-GENE I-GENE
receptor I-GENE I-GENE
alpha E-GENE E-GENE
. O O
Synthesis O O
of O O
2 O O
- O O
( O O
2 O O
' O O
- O O
thiazolyl O O
) O O
alkanebenzimidazoles O O
- O O
- O O
potential O O
anthelmintics O O
Human B-GENE B-GENE
CR2 E-GENE E-GENE
has O O
a O O
restricted O O
cellular O O
distribution O O
, O O
being O O
expressed O O
on O O
B O O
lymphocytes O O
, O O
dendritic O O
cells O O
of O O
the O O
spleen O O
, O O
pharyngeal O O
epithelial O O
cells O O
, O O
and O O
at O O
low O O
levels O O
on O O
some O O
T O O
lymphocytes O O
. O O
ADR1 S-GENE S-GENE
in O O
extracts O O
made O O
from O O
glucose O O
- O O
repressed O O
and O O
- O O
derepressed O O
cells O O
bound O O
UAS1 O O
DNA O O
with O O
similar O O
affinities O O
despite O O
having O O
greatly O O
different O O
abilities O O
to O O
activate O O
ADH2 B-GENE B-GENE
gene E-GENE E-GENE
expression O O
in O O
vivo O O
. O O
Furthermore O O
, O O
agonist O O
action O O
at O O
a O O
5 B-GENE B-GENE
- I-GENE I-GENE
HT1 I-GENE I-GENE
receptor E-GENE E-GENE
and O O
antagonist O O
action O O
at O O
5 B-GENE B-GENE
- I-GENE I-GENE
HT2 I-GENE I-GENE
receptors E-GENE E-GENE
both O O
appear O O
to O O
contribute O O
to O O
antidepressant O O
- O O
like O O
activity O O
on O O
the O O
DRL O O
72 O O
- O O
s O O
schedule O O
. O O
MsEPV O B-GENE
genes O E-GENE
with O O
putative O O
functions O O
in O O
prevention O O
and O O
repair O O
of O O
DNA O O
damage O O
include O O
a O O
complete O O
base O O
excision O O
repair O O
pathway O O
( O O
uracil B-GENE O
DNA I-GENE O
glycosylase E-GENE O
, O O
AP B-GENE B-GENE
endonuclease E-GENE E-GENE
, O O
DNA B-GENE O
polymerase I-GENE O
beta E-GENE O
, O O
and O O
an O O
NAD B-GENE B-GENE
+ I-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
DNA I-GENE I-GENE
ligase E-GENE E-GENE
) O O
, O O
a O O
photoreactivation O O
repair O O
pathway O O
( O O
cyclobutane B-GENE O
pyrimidine I-GENE O
dimer I-GENE O
photolyase E-GENE O
) O O
, O O
a O O
LINE B-GENE O
- I-GENE O
type I-GENE O
reverse I-GENE O
transcriptase E-GENE O
, O O
and O O
a O O
mutT B-GENE O
homologue E-GENE O
. O O
These O O
three O O
groups O O
were O O
further O O
examined O O
with O O
regard O O
to O O
the O O
modulation O O
of O O
discharge O O
rate O O
i O O
) O O
during O O
motor O O
activity O O
in O O
W O O
, O O
ii O O
) O O
at O O
the O O
transitional O O
phase O O
from O O
SS O O
to O O
paradoxical O O
sleep O O
( O O
PS O O
) O O
, O O
iii O O
) O O
during O O
rapid O O
eye O O
movements O O
( O O
REMs O O
) O O
in O O
PS O O
, O O
and O O
iv O O
) O O
following O O
electrical O O
stimulation O O
of O O
the O O
midbrain O O
reticular O O
formation O O
( O O
MRF O O
) O O
. O O
Likewise O O
, O O
the O O
consensus O O
signal O O
believed O O
to O O
be O O
involved O O
in O O
terminating O O
VV B-GENE O
early I-GENE O
gene E-GENE O
transcription O O
, O O
TTTTTNT O S-GENE
, O O
was O O
evident O O
at O O
the O O
3 O O
' O O
- O O
boundary O O
of O O
both O O
the O O
N2 O O
and O O
M1 O O
ORFs O O
suggesting O O
that O O
these O O
genes O O
may O O
be O O
VV B-GENE O
early I-GENE O
genes E-GENE O
. O O
This O O
radiolabeled O O
, O O
900 O O
- O O
bp O O
amplicon O O
was O O
used O O
as O O
a O O
hybridization O O
probe O O
to O O
screen O O
a O O
cDNA O O
library O O
constructed O O
from O O
poly O O
( O O
A O O
) O O
( O O
+ O O
) O O
RNA O O
isolated O O
from O O
induced O O
Taxus O O
cells O O
, O O
from O O
which O O
a O O
full O O
- O O
length O O
transacetylase O O
sequence O O
was O O
obtained O O
. O O
Low O O
temperature O O
( O O
8 O O
degrees O O
C O O
) O O
impairs O O
secretory O O
activity O O
, O O
again O O
independently O O
of O O
the O O
photoperiod O O
selected O O
. O O
Left O O
ventricle O O
to O O
coronary O O
sinus O O
fistula O O
. O O
In O O
this O O
report O O
we O O
describe O O
the O O
structure O O
and O O
DNA O O
sequence O O
of O O
transcriptional O O
control O O
regions O O
from O O
both O O
human B-GENE O
and I-GENE O
Wistar I-GENE O
- I-GENE O
rat I-GENE O
single I-GENE O
copy I-GENE O
EGF I-GENE B-GENE
genes E-GENE E-GENE
and O O
their O O
functional O O
analysis O O
in O O
epithelial O O
cell O O
cultures O O
. O O
The O O
magnesium O O
content O O
in O O
leukocytes O O
could O O
not O O
be O O
estimated O O
because O O
of O O
interaction O O
between O O
the O O
ion O O
and O O
the O O
Percoll O O
( O O
R O O
) O O
media O O
. O O
The O O
sequence O O
of O O
three O O
of O O
them O O
revealed O O
pure O O
CAG O O
stretches O O
. O O
Furthermore O O
, O O
mutations O O
in O O
element O O
II O O
result O O
in O O
changes O O
in O O
the O O
RNA O O
structure O O
near O O
element O O
III O O
, O O
consistent O O
with O O
a O O
long O O
- O O
range O O
interaction O O
that O O
may O O
promote O O
translation O O
. O O
Although O O
the O O
QT O O
duration O O
was O O
higher O O
( O O
p O O
= O O
0 O O
. O O
0001 O O
) O O
at O O
night O O
, O O
the O O
beat O O
- O O
to O O
- O O
beat O O
variability O O
of O O
this O O
interval O O
was O O
lower O O
: O O
in O O
the O O
time O O
domain O O
( O O
decreased O O
standard O O
deviation O O
, O O
p O O
= O O
0 O O
. O O
0005 O O
) O O
, O O
in O O
the O O
frequency O O
domain O O
( O O
decreased O O
low O O
- O O
frequency O O
power O O
of O O
the O O
spectra O O
, O O
p O O
= O O
0 O O
. O O
004 O O
) O O
, O O
and O O
the O O
chaotic O O
domain O O
( O O
tighter O O
clustering O O
of O O
the O O
points O O
in O O
the O O
Poincare O O
plots O O
) O O
. O O
The O O
biological O O
functions O O
of O O
rat O B-GENE
surfactant B-GENE I-GENE
protein I-GENE E-GENE
A E-GENE O
( O O
SP B-GENE O
- I-GENE O
A E-GENE O
) O O
, O O
an O O
oligomer O O
composed O O
of O O
18 O O
polypeptide O O
subunits O O
derived O O
from O O
a O O
single O O
gene O O
, O O
are O O
dependent O O
on O O
intact O O
disulfide O O
bonds O O
. O O
A O O
V1 B-GENE O
mutant E-GENE O
generated O O
in O O
vivo O O
with O O
11 O O
of O O
the O O
14 O O
N O O
- O O
terminal O O
amino O O
acids O O
altered O O
, O O
was O O
viable O O
and O O
produced O O
symptoms O O
typical O O
of O O
a O O
wild O O
- O O
type O O
infection O O
. O O
This O O
seems O O
to O O
take O O
place O O
in O O
the O O
same O O
nuclear O O
compartment O O
as O O
normal O O
cis O O
splicing O O
and O O
proceeds O O
through O O
Y O O
- O O
branched O O
intermediates O O
analogous O O
to O O
the O O
lariats O O
formed O O
in O O
cis O O
splicing O O
. O O
We O O
have O O
demonstrated O O
that O O
the O O
specific O O
determination O O
and O O
identification O O
of O O
plasma O O
FbDP S-GENE O
alone O O
is O O
not O O
sufficient O O
to O O
follow O O
the O O
effectiveness O O
of O O
thrombolytic O O
therapy O O
. O O
Chronic O O
, O O
recurrent O O
multifocal O O
osteomyelitis O O
. O O
Maximum O O
baroreceptor O O
activity O O
measured O O
at O O
140 O O
mm O O
Hg O O
and O O
the O O
slope O O
of O O
the O O
pressure O O
- O O
activity O O
curve O O
were O O
reduced O O
in O O
atherosclerotic O O
( O O
n O O
= O O
15 O O
) O O
compared O O
with O O
normal O O
( O O
n O O
= O O
13 O O
) O O
rabbits O O
( O O
425 O O
+ O O
/ O O
- O O
34 O O
versus O O
721 O O
+ O O
/ O O
- O O
30 O O
spikes O O
per O O
second O O
and O O
6 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
versus O O
10 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
spikes O O
per O O
second O O
per O O
mm O O
Hg O O
, O O
respectively O O
, O O
P O O
< O O
. O O
05 O O
) O O
. O O
A O O
pathogenetic O O
relation O O
with O O
the O O
Eisenmenger O O
' O O
s O O
syndrome O O
is O O
discussed O O
. O O
Coronary O O
vasoconstriction O O
caused O O
by O O
endothelin B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
is O O
enhanced O O
by O O
ischemia O O
- O O
reperfusion O O
and O O
by O O
norepinephrine O O
present O O
in O O
concentrations O O
typically O O
observed O O
after O O
neonatal O O
cardiopulmonary O O
bypass O O
. O O
Located O O
between O O
the O O
3 O O
' O O
trans O O
- O O
spliced O O
leader O O
acceptor O O
site O O
and O O
the O O
translational O O
initiation O O
codon O O
of O O
the O O
GP63 B-GENE B-GENE
gene E-GENE E-GENE
is O O
an O O
area O O
of O O
conserved O O
hexanucleotide O O
direct O O
repeats O O
( O O
CTCGCC O S-GENE
) O O
which O O
vary O O
in O O
number O O
according O O
to O O
species O O
. O O
An O O
association O O
was O O
found O O
between O O
zafirlukast O O
plasma O O
concentrations O O
and O O
increases O O
in O O
PC8SRaw O O
10 O O
h O O
after O O
treatment O O
( O O
p O O
= O O
0 O O
. O O
001 O O
) O O
. O O
Insulin S-GENE O
- O O
secreting O O
islet O O
- O O
cell O O
tumours O O
of O O
the O O
pancreas O O
. O O
Disruption O O
and O O
reconstruction O O
: O O
narrative O O
insights O O
into O O
the O O
experience O O
of O O
family O O
members O O
caring O O
for O O
a O O
relative O O
diagnosed O O
with O O
serious O O
mental O O
illness O O
. O O
The O O
results O O
suggest O O
that O O
the O O
posterior O O
wall O O
is O O
more O O
compliant O O
than O O
the O O
anterior O O
wall O O
( O O
that O O
is O O
, O O
for O O
a O O
given O O
difference O O
in O O
transmural O O
pressure O O
, O O
the O O
local O O
segment O O
length O O
change O O
of O O
the O O
posterior O O
wall O O
was O O
greater O O
) O O
. O O
We O O
have O O
previously O O
demonstrated O O
that O O
pyrene O O
in O O
diesel O O
- O O
exhaust O O
particles O O
( O O
DEP O O
) O O
has O O
an O O
adjuvant O O
activity O O
on O O
immunoglobulin B-GENE B-GENE
E E-GENE E-GENE
( O O
IgE S-GENE S-GENE
) O O
antibody O O
production O O
in O O
mice O O
immunized O O
with O O
Japanese O O
cedar O O
pollen O O
allergen O O
( O O
JCPA O O
) O O
or O O
ovalbumin S-GENE O
( O O
OA S-GENE O
) O O
intraperitoneally O O
. O O
Partial O O
characterization O O
of O O
the O O
CCAAT O O
box O O
in O O
the O O
promoter O O
of O O
the O O
hLGFBP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
: O O
interaction O O
with O O
negatively O O
acting O O
transcription O O
factors O O
in O O
decidualized O O
human O O
endometrial O O
stromal O O
cells O O
. O O
We O O
conclude O O
that O O
transcription O O
of O O
both O O
SCD1 S-GENE S-GENE
and O O
SCD2 B-GENE B-GENE
genes E-GENE E-GENE
is O O
responsive O O
to O O
cellular O O
sterol O O
levels O O
and O O
to O O
the O O
levels O O
of O O
nuclear O O
SREBP S-GENE S-GENE
/ O O
ADD1 S-GENE S-GENE
and O O
that O O
transcriptional O O
induction O O
requires O O
three O O
spatially O O
conserved O O
cis O O
elements O O
, O O
that O O
bind O O
SREBP S-GENE S-GENE
and O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
. O O
Three O O
transcriptional O O
control O O
elements O O
within O O
300 O O
base O O
pairs O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
rat B-GENE B-GENE
glucagon I-GENE I-GENE
gene E-GENE E-GENE
interact O O
with O O
regulatory O O
cellular O O
proteins O O
and O O
direct O O
transcription O O
only O O
in O O
glucagon S-GENE O
- O O
producing O O
islet O O
cells O O
. O O
A O O
role O O
for O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
in O O
the O O
regulation O O
of O O
beta B-GENE B-GENE
1 I-GENE I-GENE
integrin E-GENE E-GENE
activity O O
by O O
the O O
CD2 S-GENE B-GENE
antigen O E-GENE
. O O
Relationship O O
between O O
age O O
- O O
associated O O
endocrine O O
deficiencies O O
and O O
muscle O O
function O O
in O O
elderly O O
women O O
: O O
a O O
cross O O
- O O
sectional O O
study O O
. O O
In O O
contrast O O
, O O
the O O
sequences O O
essential O O
for O O
the O O
transcription O O
of O O
EFT1 S-GENE S-GENE
were O O
localized O O
to O O
the O O
region O O
between O O
the O O
start O O
ATG O O
and O O
the O O
stop O O
codon O O
of O O
the O O
VPS17 B-GENE B-GENE
gene E-GENE E-GENE
that O O
terminates O O
267 O O
nt O O
upstream O O
on O O
the O O
same O O
strand O O
. O O
Exposure O O
of O O
raft O O
cultures O O
to O O
activators O O
of O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
, O O
such O O
as O O
phorbol O O
esters O O
, O O
results O O
in O O
the O O
further O O
induction O O
of O O
late B-GENE O
gene E-GENE O
expression O O
as O O
well O O
as O O
virion O O
assembly O O
. O O
A O O
case O O
of O O
2 O O
cancers O O
of O O
the O O
colon O O
The O O
" O O
Gregg O O
phenomenon O O
" O O
implies O O
that O O
myocardial O O
function O O
and O O
oxygen O O
consumption O O
( O O
MVO2 O O
) O O
increase O O
when O O
coronary O O
perfusion O O
is O O
enhanced O O
within O O
or O O
above O O
the O O
autoregulatory O O
range O O
. O O
We O O
have O O
mapped O O
the O O
specific O O
domains O O
within O O
each O O
of O O
the O O
proteins O O
responsible O O
for O O
this O O
interaction O O
. O O
In O O
each O O
of O O
the O O
studied O O
HPV O O
types O O
, O O
the O O
two O O
CDP S-GENE O
/ O O
Cut S-GENE O
binding O O
sites O O
of O O
PSM S-GENE S-GENE
overlap O O
with O O
the O O
known O O
or O O
presumed O O
binding O O
sites O O
of O O
the O O
replication B-GENE B-GENE
initiator I-GENE I-GENE
protein I-GENE I-GENE
E1 E-GENE E-GENE
. O O
Reduced O O
cell O O
numbers O O
72 O O
h O O
after O O
insonation O O
were O O
recorded O O
when O O
the O O
cells O O
were O O
insonated O O
at O O
an O O
antinode O O
but O O
not O O
when O O
they O O
were O O
at O O
a O O
node O O
. O O
Hydroxyl O O
radical O O
footprinting O O
of O O
DNA O O
complexes O O
of O O
the O O
ets B-GENE O
domain E-GENE O
of O O
PU B-GENE B-GENE
. I-GENE I-GENE
1 E-GENE E-GENE
and O O
its O O
comparison O O
to O O
the O O
crystal O O
structure O O
. O O
ATF O S-GENE
is O O
formulated O O
from O O
the O O
prothrombin S-GENE O
time O O
( O O
PT O O
) O O
, O O
fibrinogen S-GENE O
transformation O O
rate O O
( O O
FTR O O
) O O
( O O
a O O
representation O O
of O O
thrombin S-GENE O
activity O O
) O O
, O O
and O O
a O O
consideration O O
of O O
the O O
fibrinogen S-GENE O
( O O
FBG S-GENE O
) O O
content O O
of O O
blood O O
plasma O O
. O O
( O O
LH S-GENE O
P O O
< O O
0 O O
. O O
05 O O
, O O
LH S-GENE O
/ O O
FSH S-GENE O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O
Inhibition O O
of O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
signaling O O
by O O
a O O
monoclonal O O
antibody O O
, O O
which O O
interferes O O
with O O
Raf B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
activation O O
and O O
with O O
Mek S-GENE O
substrate O O
binding O O
. O O
Phenotypic O O
and O O
molecular O O
analyses O O
of O O
patients O O
with O O
partial O O
chromosome O O
21 O O
monosomy O O
enabled O O
us O O
to O O
define O O
a O O
region O O
, O O
spanning O O
2 O O
. O O
4 O O
Mb O O
between O O
D21S190 S-GENE O
and O O
D21S226 S-GENE O
, O O
associated O O
with O O
arthrogryposis O O
, O O
mental O O
retardation O O
, O O
hypertonia O O
, O O
and O O
several O O
facial O O
anomalies O O
. O O
The O O
classic O O
sterol O O
regulatory O O
cis O O
element O O
( O O
sre O B-GENE
- O I-GENE
1 O E-GENE
) O O
in O O
the O O
LDL B-GENE B-GENE
receptor E-GENE I-GENE
promoter O I-GENE
mediates O I-GENE
sterol B-GENE I-GENE
regulatory I-GENE I-GENE
element I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
SREBP S-GENE S-GENE
) O O
- O O
binding O O
and O O
the O O
effects O O
of O O
insulin S-GENE S-GENE
and O O
platelet B-GENE B-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
PDGF S-GENE S-GENE
) O O
. O O
The O O
Ca2 O O
+ O O
concentration O O
in O O
rats O O
serum O O
after O O
intragastrically O O
fenarimol O O
administration O O
( O O
doses O O
1 O O
/ O O
40 O O
, O O
1 O O
/ O O
20 O O
and O O
1 O O
/ O O
10 O O
LD50 O O
) O O
during O O
5 O O
days O O
was O O
investigated O O
. O O
In O O
Cos O O
7 O O
cells O O
transfected O O
with O O
oCRF1var S-GENE O
, O O
cAMP O O
accumulation O O
was O O
only O O
observed O O
at O O
the O O
highest O O
concentration O O
of O O
oCRF S-GENE O
utilized O O
( O O
100 O O
nM O O
) O O
. O O
Pyknotic O O
osteocytes O O
increased O O
at O O
12 O O
h O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
and O O
2 O O
days O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
of O O
ischemia O O
. O O
The O O
right O O
cornea O O
of O O
rats O O
was O O
cauterized O O
by O O
drops O O
of O O
1 O O
. O O
5 O O
N O O
HC1 O O
over O O
30 O O
s O O
; O O
the O O
left O O
one O O
served O O
as O O
a O O
control O O
. O O
The O O
isoproterenol O O
infusion O O
was O O
adjusted O O
so O O
that O O
heart O O
rate O O
( O O
HR O O
) O O
was O O
at O O
least O O
30 O O
beats O O
/ O O
min O O
greater O O
than O O
baseline O O
. O O
This O O
is O O
probably O O
because O O
, O O
in O O
vivo O O
, O O
some O O
bacteria O O
( O O
perhaps O O
dormant O O
forms O O
) O O
are O O
not O O
entirely O O
dependent O O
upon O O
urease S-GENE O
for O O
survival O O
. O O
The O O
system O O
consists O O
of O O
a O O
microcomputer O O
and O O
six O O
laboratory O O
analyzers O O
: O O
a O O
blood O O
gas O O
analyzer O O
, O O
a O O
flame O O
photometer O O
, O O
a O O
plasma O O
osmotic O O
pressure O O
meter O O
, O O
a O O
chloride O O
ion O O
titrator O O
, O O
a O O
blood O O
sugar O O
analyzer O O
, O O
and O O
a O O
hemoglobin S-GENE O
concentration O O
and O O
saturation O O
meter O O
. O O
Comparing O O
the O O
outcome O O
of O O
the O O
group O O
having O O
histologically O O
normal O O
biopsies O O
with O O
the O O
group O O
having O O
nonspecifically O O
abnormal O O
ones O O
it O O
is O O
concluded O O
that O O
frontal O O
biopsy O O
is O O
not O O
of O O
such O O
high O O
prognostic O O
value O O
as O O
has O O
been O O
claimed O O
in O O
previous O O
reports O O
. O O
He O O
presented O O
with O O
left O O
lower O O
abdominal O O
pain O O
and O O
hematoma O O
after O O
a O O
fall O O
. O O
Fusion O O
of O O
mouse B-GENE B-GENE
CD8 I-GENE I-GENE
+ E-GENE I-GENE
class B-GENE I-GENE
I I-GENE I-GENE
MHC E-GENE E-GENE
- O O
restricted O O
T O O
cells O O
with O O
the O O
BW5147 O O
thymoma O O
invariably O O
yields O O
CD8 B-GENE O
- E-GENE O
hybridomas O O
in O O
which O O
RNA O O
transcribed O O
from O O
the O O
CD8 B-GENE B-GENE
alpha E-GENE E-GENE
( O O
Lyt B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE I-GENE
) O I-GENE
gene O E-GENE
is O O
undetectable O O
. O O
Peak O O
plasma O O
ACTH S-GENE O
responses O O
were O O
not O O
significantly O O
different O O
between O O
control O O
and O O
patient O O
groups O O
. O O
For O O
the O O
P B-GENE O
transcript E-GENE O
from O O
phage O O
with O O
the O O
G O O
( O O
- O O
) O O
orientation O O
, O O
full O O
termination O O
activity O O
required O O
both O O
the O O
region O O
containing O O
the O O
stem O O
- O O
loop O O
structure O O
and O O
upstream O O
sequences O O
. O O
Development O O
of O O
neural O O
control O O
of O O
alimentary O O
motor O O
function O O
in O O
the O O
vertebrates O O
. O O
Nb2 O O
- O O
11C O O
cells O O
expressed O O
three O O
PNR B-GENE O
- I-GENE O
related I-GENE O
mRNA I-GENE O
transcripts E-GENE O
of O O
2 O O
. O O
5 O O
, O O
3 O O
. O O
0 O O
and O O
> O O
10 O O
kb O O
. O O
These O O
results O O
suggest O O
that O O
the O O
Reg1 S-GENE B-GENE
- O I-GENE
Glc7 S-GENE I-GENE
phosphatase O E-GENE
is O O
a O O
cytoplasmic O O
component O O
of O O
the O O
machinery O O
responsible O O
for O O
returning O O
Snf1 B-GENE B-GENE
kinase E-GENE E-GENE
activity O O
to O O
its O O
basal O O
level O O
and O O
reestablishing O O
glucose O O
repression O O
. O O
However O O
, O O
the O O
blend O O
of O O
Metanil O O
yellow O O
and O O
Orange O O
II O O
( O O
1 O O
: O O
1 O O
) O O
resulted O O
in O O
the O O
D1 O O
50 O O
. O O
value O O
of O O
288 O O
min O O
. O O
The O O
majority O O
of O O
these O O
cells O O
were O O
also O O
OKT4 S-GENE S-GENE
positive O O
( O O
helper O O
/ O O
inducer O O
T O O
lymphocytes O O
) O O
, O O
while O O
the O O
minority O O
were O O
OKT8 S-GENE S-GENE
positive O O
( O O
suppressor O O
/ O O
cytotoxic O O
T O O
lymphocytes O O
) O O
. O O
AIMS O O
: O O
We O O
postulated O O
that O O
perhexiline O O
, O O
a O O
novel O O
anti O O
- O O
ischaemic O O
agent O O
with O O
an O O
oxygen O O
- O O
sparing O O
metabolic O O
effect O O
in O O
the O O
myocardium O O
( O O
via O O
inhibition O O
of O O
carnitine B-GENE O
palmitoyltransferase I-GENE O
- I-GENE O
1 E-GENE O
) O O
and O O
no O O
adverse O O
haemodynamic O O
effects O O
, O O
may O O
improve O O
symptomatic O O
status O O
in O O
elderly O O
patients O O
with O O
severe O O
aortic O O
stenosis O O
. O O
The O O
IFNAR B-GENE S-GENE
chain E-GENE O
interacts O O
with O O
both O O
IFN B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
2 E-GENE E-GENE
and O O
IFN B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
, O O
as O O
demonstrated O O
by O O
cross O O
- O O
linking O O
. O O
To O O
clone O O
cDNAs O O
for O O
the O O
beta O O
subunit O O
of O O
rabbit B-GENE O
eIF I-GENE B-GENE
- I-GENE I-GENE
2B E-GENE E-GENE
, O O
amino O O
acid O O
sequence O O
data O O
was O O
first O O
obtained O O
and O O
used O O
to O O
design O O
redundant O O
oligonucleotide O O
primers O O
for O O
use O O
in O O
PCR O O
. O O
We O O
report O O
the O O
cloning O O
of O O
the O O
ade1 B-GENE B-GENE
gene E-GENE E-GENE
on O O
a O O
4 B-GENE O
. I-GENE O
4 I-GENE O
kb I-GENE O
Sau3A I-GENE O
insert E-GENE O
in O O
the O O
yeast O O
shuttle O O
vector O O
pWH5 O S-GENE
. O O
Nimodipine O O
( O O
5 O O
micrograms O O
/ O O
kg O O
) O O
followed O O
by O O
infusion O O
of O O
0 O O
. O O
75 O O
microgram O O
/ O O
kg O O
/ O O
min O O
lowered O O
the O O
blood O O
pressure O O
by O O
10 O O
% O O
in O O
both O O
normotensive O O
and O O
hypertensive O O
rats O O
; O O
the O O
same O O
dose O O
schedule O O
of O O
nifedipine O O
did O O
not O O
lower O O
MAP O O
. O O
Results O O
of O O
these O O
in O O
vitro O O
studies O O
may O O
be O O
relevant O O
to O O
the O O
pathogenesis O O
of O O
alveolitis O O
in O O
organic O O
dust O O
- O O
induced O O
lung O O
diseases O O
. O O
The O O
odds O O
of O O
atopy O O
( O O
defined O O
as O O
a O O
positive O O
test O O
for O O
at O O
least O O
one O O
of O O
the O O
antigens O O
) O O
were O O
5 O O
times O O
higher O O
( O O
odds O O
ratio O O
= O O
7 O O
. O O
0 O O
; O O
95 O O
% O O
confidence O O
interval O O
= O O
1 O O
. O O
6 O O
- O O
31 O O
. O O
1 O O
% O O
; O O
p O O
= O O
0 O O
. O O
01 O O
) O O
in O O
the O O
uninfected O O
group O O
, O O
after O O
taking O O
into O O
account O O
the O O
potential O O
influence O O
of O O
gender O O
and O O
age O O
. O O
A O O
selectable O O
marker O O
for O O
transformation O O
was O O
constructed O O
by O O
transcriptional O O
fusion O O
of O O
a O O
Ustilago B-GENE O
maydis I-GENE O
heat I-GENE O
shock I-GENE O
gene I-GENE O
promoter E-GENE O
with O O
the O O
hygromycin B-GENE B-GENE
B I-GENE I-GENE
phosphotransferase I-GENE I-GENE
gene I-GENE E-GENE
of I-GENE O
Escherichia I-GENE O
coli E-GENE O
. O O
The O O
structure O O
of O O
the O O
mAR S-GENE B-GENE
ORF O E-GENE
was O O
confirmed O O
by O O
sequence O O
analysis O O
of O O
mAR S-GENE O
cDNA O O
fragments O O
, O O
which O O
were O O
obtained O O
by O O
PCR O O
amplification O O
of O O
mouse O O
testis O O
cDNA O O
, O O
using O O
mAR S-GENE O
specific O O
primers O O
. O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
response O O
properties O O
of O O
the O O
human O O
visual O O
cortex O O
to O O
chromatic O O
stimuli O O
using O O
magnetoencephalography O O
( O O
MEG O O
) O O
. O O
The O O
role O O
of O O
NUT1 S-GENE S-GENE
and O O
regulation O O
of O O
nitrogen O O
metabolism O O
in O O
the O O
disease O O
process O O
was O O
evaluated O O
by O O
pathogenicity O O
assays O O
. O O
These O O
three O O
phases O O
of O O
cyclin B-GENE B-GENE
E E-GENE E-GENE
association O O
with O O
chromatin O O
may O O
facilitate O O
the O O
diverse O O
activities O O
of O O
cyclin B-GENE B-GENE
E E-GENE I-GENE
- O I-GENE
- O I-GENE
Cdk2 S-GENE E-GENE
in O O
initiating O O
replication O O
, O O
blocking O O
rereplication O O
, O O
and O O
allowing O O
resetting O O
of O O
origins O O
after O O
mitosis O O
. O O
No O O
IORT O O
related O O
mortality O O
has O O
been O O
observed O O
. O O
Dermatophagoides O O
farinae O O
- O O
sensitized O O
lymphocytes O O
in O O
asthmatic O O
children O O
as O O
evaluated O O
by O O
interleukin B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
( O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
) O O
production O O
and O O
acquisition O O
of O O
IL B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
responsiveness O O
Enterotoxin O O
production O O
by O O
staphylococci O O
isolated O O
from O O
foods O O
in O O
France O O
. O O
Measurements O O
in O O
rats O O
given O O
a O O
dose O O
of O O
propranolol O O
that O O
partially O O
inhibited O O
the O O
NA O O
- O O
induced O O
increase O O
in O O
Q O O
to O O
IBAT O O
indicated O O
that O O
the O O
decline O O
in O O
ENAIBAT O O
was O O
attributable O O
primarily O O
to O O
the O O
increase O O
in O O
Q O O
rather O O
than O O
to O O
increasing O O
saturation O O
of O O
uptake O O
mechanisms O O
. O O
Plasma B-GENE O
LH E-GENE S-GENE
and O O
progesterone O O
levels O O
after O O
single O O
or O O
multiple O O
injections O O
of O O
synthetic O O
LH S-GENE O
- O O
RH S-GENE O
in O O
anoestrous O O
ewes O O
and O O
comparison O O
with O O
levels O O
during O O
the O O
oestrous O O
cycle O O
. O O
MATERIAL O O
AND O O
METHODS O O
: O O
But O O
, O O
when O O
mated O O
males O O
built O O
nests O O
in O O
the O O
absence O O
of O O
young O O
, O O
T O O
levels O O
were O O
higher O O
than O O
in O O
all O O
other O O
conditions O O
, O O
though O O
only O O
for O O
early O O
broods O O
. O O
Primers O O
were O O
developed O O
for O O
specific O O
amplification O O
of O O
9804 B-GENE B-GENE
gene I-GENE E-GENE
fragments E-GENE O
. O O
The O O
promyelocytic B-GENE O
leukemia I-GENE O
protein E-GENE O
interacts O O
with O O
Sp1 S-GENE S-GENE
and O O
inhibits O O
its O O
transactivation O O
of O O
the O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor E-GENE I-GENE
promoter O E-GENE
. O O
The O O
mutants O O
retained O O
the O O
parental O O
ability O O
to O O
participate O O
in O O
intergeneric O O
coaggregation O O
with O O
human O O
oral O O
actinomyces O O
, O O
indicating O O
the O O
specificity O O
of O O
the O O
mutation O O
in O O
altering O O
intrageneric O O
coaggregations O O
. O O
The O O
Saccharomyces O O
cerevisiae O O
targets O O
of O O
rapamycin O O
, O O
TOR1 S-GENE S-GENE
and O O
TOR2 S-GENE S-GENE
, O O
signal O O
activation O O
of O O
cell O O
growth O O
in O O
response O O
to O O
nutrient O O
availability O O
. O O
Biology O O
of O O
Anopheles O O
quadrimaculatus O O
under O O
field O O
conditions O O
in O O
central O O
Florida O O
. O O
Immunogenicity O O
tested O O
in O O
experiments O O
on O O
guinea O O
pigs O O
and O O
rabbits O O
was O O
not O O
reduced O O
and O O
corresponded O O
to O O
that O O
of O O
the O O
reference O O
STI O O
- O O
1 O O
vaccine O O
. O O
The O O
Thrombolysis O O
in O O
Myocardial O O
Infarction O O
( O O
TIMI O O
) O O
Phase O O
II O O
Trial O O
randomized O O
3 O O
, O O
339 O O
patients O O
to O O
either O O
an O O
invasive O O
( O O
INV O O
, O O
n O O
= O O
1 O O
, O O
681 O O
) O O
or O O
a O O
conservative O O
( O O
CON O O
, O O
n O O
= O O
1 O O
, O O
658 O O
) O O
strategy O O
after O O
intravenous O O
recombinant B-GENE O
tissue I-GENE O
- I-GENE O
type I-GENE O
plasminogen I-GENE O
activator E-GENE O
( O O
rt B-GENE O
- I-GENE O
PA E-GENE O
) O O
for O O
acute O O
myocardial O O
infarction O O
. O O
In O O
addition O O
, O O
mutations O O
within O O
the O O
Ubx B-GENE B-GENE
unit I-GENE I-GENE
exons E-GENE E-GENE
are O O
known O O
and O O
most O O
of O O
these O O
behave O O
as O O
null O O
alleles O O
. O O
Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
the O O
Smad3 S-GENE S-GENE
/ O O
Smad4 S-GENE O
complex O O
has O O
at O O
least O O
two O O
separable O O
nuclear O O
functions O O
: O O
it O O
forms O O
a O O
rapid O O
, O O
yet O O
transient O O
sequence O O
- O O
specific O O
DNA O O
binding O O
complex O O
, O O
and O O
it O O
potentiates O O
AP1 S-GENE S-GENE
- O O
dependent O O
transcriptional O O
activation O O
. O O
When O O
phentermine O O
was O O
mixed O O
with O O
other O O
unlabeled O O
reversible O O
MAO S-GENE O
inhibitors O O
( O O
e O O
. O O
g O O
. O O
pseudoephedrine O O
, O O
ephedrine O O
, O O
norephedrine O O
; O O
estradiol O O
benzoate O O
) O O
, O O
the O O
degree O O
of O O
MAO S-GENE O
inhibition O O
was O O
additive O O
. O O
Here O O
we O O
report O O
that O O
point O O
mutations O O
of O O
the O O
Abd B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
gene E-GENE E-GENE
in O O
trans O O
suppress O O
the O O
Fab B-GENE O
- I-GENE O
7 I-GENE O
phenotype E-GENE O
in O O
a O O
pairing O O
- O O
dependent O O
manner O O
and O O
thus O O
represent O O
a O O
type O O
of O O
transvection O O
. O O
4 O O
382 O O
new O O
mothers O O
were O O
examined O O
retrospectively O O
with O O
the O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
for O O
IgG S-GENE S-GENE
activity O O
to O O
cytomegalovirus O O
( O O
CMV O O
) O O
during O O
pregnancy O O
. O O
Also O O
, O O
residues O O
273 O O
to O O
287 O O
, O O
which O O
are O O
identical O O
in O O
sequence O O
to O O
a O O
15 O O
- O O
amino O O
- O O
acid O O
segment O O
near O O
the O O
carboxy O O
terminus O O
of O O
the O O
simian B-GENE O
foamy I-GENE O
virus I-GENE O
transcriptional I-GENE O
activator I-GENE O
Taf E-GENE S-GENE
, O O
can O O
independently O O
enhance O O
the O O
activity O O
of O O
the O O
minimal O O
activator O O
region O O
. O O
An O O
analogue O O
of O O
calcium O O
, O O
strontium O O
chloride O O
Sr O O
89 O O
is O O
rapidly O O
cleared O O
from O O
the O O
blood O O
after O O
i O O
. O O
v O O
. O O
injection O O
. O O
The O O
effect O O
of O O
pneumoperitoneum O O
on O O
dissemination O O
and O O
scar O O
implantation O O
of O O
intra O O
- O O
abdominal O O
tumor O O
cells O O
. O O
In O O
two O O
of O O
these O O
nine O O
patients O O
, O O
a O O
decrease O O
in O O
dyskinesia O O
score O O
was O O
observed O O
without O O
a O O
concomitant O O
worsening O O
of O O
parkinsonian O O
symptoms O O
, O O
whereas O O
in O O
the O O
remaining O O
seven O O
, O O
full O O
parkinsonian O O
akinesia O O
followed O O
THDL O O
administration O O
. O O
Alterations O O
in O O
TCR S-GENE B-GENE
- O I-GENE
MHC S-GENE E-GENE
contacts O O
subsequent O O
to O O
cross O O
- O O
recognition O O
of O O
class B-GENE O
I I-GENE B-GENE
MHC E-GENE E-GENE
and O O
singly O O
substituted O O
peptide O O
variants O O
. O O
Two O O
patients O O
with O O
Ewing O O
' O O
s O O
sarcoma O O
relapsed O O
( O O
1 O O
patient O O
with O O
both O O
local O O
and O O
distant O O
failure O O
) O O
at O O
26 O O
and O O
58 O O
months O O
and O O
were O O
again O O
rendered O O
disease O O
- O O
free O O
with O O
surgery O O
, O O
total O O
body O O
irradiation O O
and O O
further O O
chemotherapy O O
. O O
The O O
cloning O O
of O O
human B-GENE O
apo I-GENE O
B I-GENE O
- I-GENE O
100 E-GENE O
has O O
provided O O
new O O
insights O O
into O O
the O O
structure O O
and O O
physicochemical O O
properties O O
of O O
apo B-GENE B-GENE
B I-GENE I-GENE
- I-GENE I-GENE
100 E-GENE E-GENE
and O O
will O O
facilitate O O
studies O O
on O O
the O O
factors O O
modulating O O
apo B-GENE O
B I-GENE O
- I-GENE O
100 E-GENE O
biosynthesis O O
and O O
the O O
expression O O
of O O
the O O
apo B-GENE B-GENE
B I-GENE I-GENE
- I-GENE I-GENE
100 I-GENE I-GENE
gene E-GENE E-GENE
in O O
patients O O
with O O
dyslipoproteinemias O O
. O O
Angiographic O O
follow O O
- O O
up O O
was O O
obtained O O
in O O
92 O O
% O O
of O O
patients O O
with O O
a O O
primary O O
success O O
of O O
angioplasty O O
. O O
Acceptability O O
of O O
home O O
monitoring O O
as O O
an O O
aid O O
to O O
conception O O
. O O
Repeated O O
interferon B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
( O O
IFN B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
) O O
silencer O O
B O O
motifs O O
and O O
a O O
lysozyme B-GENE O
silencer I-GENE O
1 I-GENE O
motif E-GENE O
have O O
been O O
found O O
in O O
the O O
CD95 B-GENE B-GENE
gene E-GENE E-GENE
at O O
approximately O O
- O O
1 O O
, O O
600 O O
and O O
- O O
1 O O
, O O
100 O O
, O O
respectively O O
. O O
Action O O
against O O
Vibrio O O
cholerae O O
O1 O O
Tox B-GENE O
+ E-GENE O
of O O
chemical O O
products O O
used O O
in O O
the O O
lemon O O
production O O
. O O
Patients O O
with O O
the O O
chronic O O
photosensitivity O O
dermatitis O O
with O O
actinic O O
reticuloid O O
syndrome O O
have O O
high O O
total O O
serum O B-GENE
IgE S-GENE E-GENE
concentrations O O
. O O
The O O
sequence O O
of O O
the O O
25 O O
- O O
kDa O O
chain O O
of O O
the O O
alpha O B-GENE
subunit O E-GENE
was O O
found O O
in O O
a O O
cDNA O O
clone O O
, O O
and O O
the O O
amino O O
acid O O
sequence O O
deduced O O
from O O
the O O
cDNA O O
establishes O O
the O O
complete O O
amino O O
acid O O
sequence O O
of O O
the O O
25 O O
- O O
kDa O O
chain O O
. O O
Characterization O O
of O O
the O O
chromosome O O
19 O O
breakpoint O O
region O O
revealed O O
that O O
the O O
transcription B-GENE O
factor I-GENE O
- I-GENE O
encoding I-GENE O
USF2 I-GENE B-GENE
gene E-GENE E-GENE
is O O
affected O O
. O O
Tax S-GENE O
and O O
the O O
active O O
Tax B-GENE O
mutants E-GENE O
were O O
able O O
to O O
abrogate O O
the O O
G1 O O
arrest O O
and O O
apoptosis O O
induced O O
by O O
p53 S-GENE S-GENE
, O O
and O O
this O O
effect O O
does O O
not O O
correlate O O
with O O
an O O
altered O O
localization O O
of O O
nuclear B-GENE O
p53 E-GENE S-GENE
or O O
with O O
the O O
disruption O O
of O O
p53 B-GENE S-GENE
- I-GENE O
DNA I-GENE O
complexes E-GENE O
. O O
When O O
patients O O
were O O
admitted O O
within O O
one O O
week O O
of O O
the O O
onset O O
of O O
dark O O
urine O O
, O O
45 O O
% O O
were O O
found O O
to O O
be O O
shedding O O
HAV O O
, O O
whereas O O
only O O
11 O O
% O O
of O O
specimens O O
obtained O O
from O O
patients O O
admitted O O
during O O
the O O
second O O
week O O
contained O O
virus O O
. O O
Biochemical O O
studies O O
have O O
identified O O
a O O
cellular O O
non B-GENE O
- I-GENE O
P I-GENE O
element I-GENE O
- I-GENE O
encoded I-GENE O
DNA I-GENE O
binding I-GENE O
protein E-GENE O
, O O
termed O O
the O O
inverted B-GENE O
repeat I-GENE O
binding I-GENE O
protein E-GENE O
( O O
IRBP S-GENE S-GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
outer O O
half O O
of O O
the O O
31 O O
- O O
bp O O
terminal O O
inverted O O
repeats O O
. O O
Threefold O O
risks O O
were O O
observed O O
for O O
men O O
with O O
the O O
highest O O
level O O
of O O
intensity O O
and O O
for O O
those O O
with O O
the O O
highest O O
probability O O
of O O
EMF O O
exposure O O
, O O
although O O
women O O
with O O
heavy O O
EMF O O
exposure O O
did O O
not O O
experience O O
increased O O
risk O O
. O O
In O O
the O O
spontaneous O O
abortion O O
group O O
, O O
the O O
levels O O
of O O
PAPP B-GENE O
- I-GENE O
A E-GENE O
were O O
significantly O O
lower O O
than O O
in O O
normal O O
pregnancy O O
but O O
higher O O
than O O
in O O
non O O
- O O
pregnant O O
controls O O
. O O
We O O
report O O
the O O
sequence O O
of O O
a O O
7941 O O
bp O O
DNA O O
fragment O O
from O O
the O O
left O O
arm O O
of O O
chromosome O O
VII O O
of O O
Saccharomyces O O
cerevisiae O O
which O O
contains O O
four O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
of O O
greater O O
than O O
100 O O
amino O O
acid O O
residues O O
. O O
A O O
4 O O
. O O
0 O O
- O O
kb O O
Nlk B-GENE O
message E-GENE O
is O O
also O O
present O O
during O O
embryogenesis O O
, O O
detectable O O
at O O
day O O
E10 O O
. O O
Promoting O O
fat O O
utilisation O O
by O O
reducing O O
the O O
carbohydrate O O
- O O
fat O O
ratio O O
of O O
the O O
TPN O O
reduces O O
free O O
radical O O
activity O O
to O O
a O O
similar O O
extent O O
as O O
fat O O
exclusion O O
. O O
In O O
cells O O
infected O O
with O O
a O O
recombinant O O
vaccinia O O
virus O O
expressing O O
HCV O B-GENE
structural O I-GENE
proteins O E-GENE
( O O
core S-GENE O
, O O
E1 S-GENE S-GENE
, O O
and O O
E2 S-GENE S-GENE
) O O
, O O
DDX3 S-GENE S-GENE
and O O
core S-GENE O
colocalized O O
in O O
distinct O O
spots O O
in O O
the O O
perinuclear O O
region O O
of O O
the O O
cytoplasm O O
. O O
Mutating O O
this O O
sequence O O
eliminated O O
complex O O
formation O O
and O O
markedly O O
reduced O O
basal O O
and O O
cAMP O O
- O O
dependent O O
promoter O O
activity O O
of O O
transfected O O
reporter O O
genes O O
. O O
The O O
lowest O O
PaCO2 O O
values O O
were O O
significantly O O
lower O O
in O O
MCE O O
than O O
in O O
the O O
F O O
, O O
W O O
, O O
and O O
D O O
( O O
F O O
+ O O
W O O
+ O O
D O O
) O O
group O O
or O O
controls O O
. O O
The O O
translational O O
product O O
of O O
UL26 B-GENE O
. I-GENE O
5 E-GENE O
is O O
infected B-GENE O
- I-GENE O
cell I-GENE O
protein I-GENE O
35c I-GENE O
, I-GENE O
d E-GENE O
( O O
ICP35c B-GENE O
, I-GENE O
d E-GENE O
) O O
( O O
F O O
. O O
The O O
mouse B-GENE B-GENE
tapasin I-GENE I-GENE
gene E-GENE E-GENE
was O O
mapped O O
about O O
70 O O
kilobases O O
from O O
H2 B-GENE O
- I-GENE O
K E-GENE O
at O O
the O O
centromeric O O
end O O
of O O
the O O
mouse B-GENE B-GENE
MHC E-GENE E-GENE
. O O
Due O O
to O O
significant O O
homology O O
to O O
the O O
C O O
- O O
terminus O O
of O O
the O O
Mutator B-GENE O
transposase E-GENE O
this O O
alternative O O
gene O O
product O O
was O O
named O O
Trap S-GENE O
( O O
transposon B-GENE O
- I-GENE O
associated I-GENE O
protein E-GENE O
) O O
. O O
Nonetheless O O
, O O
the O O
majority O O
were O O
located O O
within O O
three O O
short O O
sequences O O
at O O
the O O
N O O
terminus O O
, O O
middle O O
, O O
and O O
C O O
terminus O O
that O O
are O O
phylogenetically O O
conserved O O
among O O
all O O
known O O
eubacterial O O
and O O
chloroplast O O
versions O O
of O O
this O O
protein O O
. O O
The O O
c B-GENE B-GENE
- I-GENE I-GENE
raf I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
proto I-GENE I-GENE
- I-GENE I-GENE
oncogene E-GENE E-GENE
is O O
the O O
cellular B-GENE O
homologue I-GENE O
of I-GENE O
v I-GENE B-GENE
- I-GENE I-GENE
raf E-GENE E-GENE
, O O
the O O
oncogene O O
of O O
the O O
acutely O O
transforming O O
retrovirus O O
3611 O B-GENE
- O I-GENE
MSV O E-GENE
. O O
Using O O
gel O O
retardation O O
analysis O O
, O O
four O O
binding O O
sites O O
for O O
Rap1p S-GENE S-GENE
have O O
been O O
identified O O
within O O
the O O
promoter O O
of O O
the O O
RAP1 B-GENE B-GENE
gene E-GENE E-GENE
. O O
In O O
general O O
, O O
the O O
scallop O O
extract O O
potentiated O O
phototactic O O
suppression O O
. O O
Alcohol O O
abuse O O
and O O
treatment O O
resistance O O
in O O
skin O O
disease O O
. O O
The O O
mean O O
serum O O
CDT O O
increased O O
from O O
8 O O
. O O
5 O O
( O O
SD O O
2 O O
. O O
2 O O
) O O
U O O
/ O O
l O O
to O O
16 O O
. O O
6 O O
( O O
SD O O
7 O O
. O O
2 O O
) O O
U O O
/ O O
l O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O
Subsequent O O
analysis O O
revealed O O
that O O
MyD88 S-GENE S-GENE
possesses O O
a O O
unique O O
modular O O
structure O O
, O O
which O O
consists O O
of O O
an O O
N O O
- O O
terminal O O
" O O
death O O
domain O O
, O O
" O O
similar O O
to O O
the O O
intracellular O O
segments O O
of O O
TNF B-GENE B-GENE
receptor I-GENE I-GENE
1 E-GENE E-GENE
and O O
Fas S-GENE S-GENE
, O O
and O O
a O O
C O O
- O O
terminal O O
region O O
related O O
to O O
the O O
cytoplasmic O O
domains O O
of O O
the O O
Drosophila B-GENE O
morphogen I-GENE O
Toll E-GENE O
and O O
vertebrate O B-GENE
interleukin B-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
receptors E-GENE E-GENE
. O O
RT O O
- O O
PCR O O
analysis O O
of O O
FGFR B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
mRNA E-GENE E-GENE
showed O O
the O O
presence O O
of O O
a O O
splice O O
variant O O
in O O
which O O
exons O O
7 O O
and O O
8 O O
are O O
deleted O O
. O O
In O O
human O O
myxoid O O
liposarcoma O O
, O O
a O O
chromosomal O O
rearrangement O O
leads O O
to O O
fusion O O
of O O
the O O
growth O O
- O O
arresting O O
and O O
DNA O O
- O O
damage O O
- O O
inducible O O
transcription O O
factor O O
CHOP S-GENE S-GENE
( O O
GADD153 S-GENE S-GENE
) O O
to O O
a O O
peptide O O
fragment O O
encoded O O
by O O
the O O
TLS B-GENE B-GENE
gene E-GENE E-GENE
. O O
They O O
also O O
show O O
that O O
M O O
. O O
malmoense O O
can O O
be O O
isolated O O
from O O
the O O
environment O O
which O O
may O O
be O O
the O O
source O O
of O O
the O O
infection O O
. O O
The O O
monkeys O O
had O O
been O O
administered O O
a O O
common O O
lead O O
isotope O O
" O O
mix O O
" O O
at O O
the O O
rate O O
of O O
about O O
1300 O O
micrograms O O
Pb O O
/ O O
kg O O
body O O
wt O O
/ O O
day O O
from O O
age O O
10 O O
months O O
until O O
the O O
start O O
of O O
the O O
study O O
. O O
We O O
previously O O
described O O
the O O
upregulation O O
of O O
the O O
MT2 B-GENE B-GENE
antigen E-GENE E-GENE
during O O
urodele O O
limb O O
regeneration O O
and O O
characterized O O
the O O
MT2 B-GENE B-GENE
antigen E-GENE E-GENE
as O O
a O O
310 O O
- O O
to O O
325 O O
- O O
kDa O O
chondroitin O O
- O O
sulfated O O
glycoprotein O O
with O O
a O O
core O O
protein O O
of O O
285 O O
- O O
300 O O
kDa O O
. O O
Analysis O O
of O O
the O O
MCV B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
RPO1 E-GENE E-GENE
revealed O O
high O O
amino O O
acid O O
homologies O O
to O O
the O O
corresponding O O
polypeptides O O
of O O
vaccinia O O
and O O
variola O O
virus O O
. O O
The O O
effects O O
of O O
dopamine O O
and O O
of O O
dopamine B-GENE B-GENE
D2 I-GENE I-GENE
receptor E-GENE E-GENE
blocker O O
haloperidol O O
on O O
the O O
activity O O
of O O
carotid O O
chemoreceptors O O
were O O
studied O O
in O O
24 O O
anesthetized O O
, O O
paralyzed O O
and O O
artificially O O
ventilated O O
newborn O O
kittens O O
aged O O
0 O O
- O O
17 O O
days O O
. O O
Fifty O O
- O O
seven O O
per O O
cent O O
of O O
the O O
primary O O
patients O O
reporting O O
mild O O
symptoms O O
had O O
abnormal O O
levels O O
of O O
leucocytes O O
in O O
their O O
CSF O O
. O O
When O O
proper O O
controls O O
were O O
used O O
, O O
the O O
psychophysical O O
data O O
and O O
computer O O
simulation O O
gave O O
remarkably O O
comparable O O
results O O
. O O
Patients O O
were O O
treated O O
with O O
either O O
4 O O
. O O
8 O O
million O O
units O O
of O O
procaine O O
penicillin O O
with O O
1 O O
g O O
probenecid O O
, O O
3 O O
. O O
5 O O
or O O
4 O O
. O O
5 O O
g O O
of O O
ampicillin O O
with O O
1 O O
g O O
probenecid O O
, O O
or O O
9 O O
. O O
5 O O
g O O
of O O
tetracycline O O
given O O
over O O
4 O O
days O O
. O O
The O O
results O O
of O O
this O O
study O O
indicate O O
that O O
the O O
Improved O O
Crest O O
Complete O O
with O O
longer O O
rippled O O
outer O O
bristles O O
provided O O
significantly O O
superior O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
interproximal O O
penetration O O
overall O O
and O O
at O O
the O O
gumline O O
than O O
the O O
Colgate O O
Total O O
and O O
Oral O O
- O O
B O O
Advantage O O
brushes O O
. O O
Cardiac O O
NE O O
spillover O O
was O O
higher O O
( O O
P O O
< O O
. O O
05 O O
) O O
at O O
baseline O O
in O O
the O O
patient O O
group O O
than O O
in O O
healthy O O
subjects O O
, O O
whereas O O
renal O O
and O O
whole O O
- O O
body O O
NE O O
spillovers O O
were O O
similar O O
between O O
the O O
study O O
groups O O
. O O
The O O
activity O O
of O O
platelet B-GENE B-GENE
factor I-GENE I-GENE
4 E-GENE E-GENE
in O O
plasma O O
of O O
healthy O O
and O O
high O O
risk O O
newborns O O
. O O
Plasma B-GENE O
renin E-GENE O
activity O O
in O O
essential O O
arterial O O
hypertension O O
. O O
A O O
trend O O
was O O
observed O O
toward O O
increased O O
graft O O
half O O
- O O
life O O
in O O
era O O
2 O O
( O O
p O O
= O O
NS O O
) O O
. O O
The O O
proteins O O
encoded O O
by O O
these O O
genes O O
, O O
called O O
GF14 B-GENE B-GENE
proteins E-GENE E-GENE
, O O
participate O O
in O O
protein O O
/ O O
DNA O O
complexes O O
and O O
show O O
more O O
than O O
60 O O
% O O
identity O O
with O O
a O O
highly O O
conserved O O
, O O
widely O O
distributed O O
protein O O
family O O
, O O
collectively O O
referred O O
to O O
as O O
14 B-GENE B-GENE
- I-GENE I-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
3 E-GENE I-GENE
proteins O E-GENE
. O O
The O O
p58 S-GENE S-GENE
( O O
PITSLRE B-GENE B-GENE
beta I-GENE I-GENE
1 E-GENE I-GENE
) O I-GENE
protein O I-GENE
kinase O E-GENE
( O O
PK O S-GENE
) O O
is O O
a O O
member O O
of O O
a O O
large O O
supergene O O
family O O
related O O
to O O
the O O
master B-GENE O
mitotic I-GENE B-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
, O O
p34cdc2 S-GENE S-GENE
. O O
Maximal O O
exercise O O
duration O O
and O O
peak O O
oxygen O O
consumption O O
were O O
not O O
changed O O
. O O
In O O
contrast O O
, O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
activation O O
was O O
observed O O
in O O
these O O
cells O O
after O O
PMA O O
stimulation O O
. O O
PtdIns B-GENE O
( I-GENE O
4 I-GENE O
, I-GENE O
5 I-GENE O
) I-GENE O
P2 E-GENE O
synthesis O O
, O O
on O O
the O O
other O O
hand O O
, O O
is O O
only O O
moderately O O
affected O O
even O O
in O O
fab1Delta B-GENE O
mutants E-GENE O
. O O
A O O
simple O O
procedure O O
for O O
accurate O O
quantitation O O
of O O
factor B-GENE B-GENE
VIII E-GENE E-GENE
inhibitors O O
. O O
We O O
found O O
that O O
48 O O
% O O
of O O
the O O
patients O O
had O O
their O O
thoracolumbar O O
blood O O
supply O O
based O O
on O O
two O O
anterior O O
radiculospinal O O
arteries O O
the O O
lowest O O
of O O
which O O
was O O
located O O
at O O
, O O
or O O
lower O O
than O O
, O O
T12 O O
, O O
and O O
the O O
second O O
and O O
higher O O
one O O
between O O
T6 O O
and O O
T10 O O
. O O
Low O O
serum B-GENE O
C3 E-GENE O
values O O
were O O
observed O O
in O O
all O O
11 O O
children O O
at O O
some O O
stage O O
of O O
their O O
illness O O
. O O
The O O
plants O O
were O O
then O O
brought O O
to O O
our O O
Houston O O
laboratory O O
where O O
they O O
were O O
measured O O
and O O
analyzed O O
for O O
lignin O O
and O O
protein O O
content O O
and O O
for O O
phenylalanine B-GENE O
ammonia I-GENE O
- I-GENE O
lyase E-GENE O
( O O
PAL S-GENE O
) O O
and O O
peroxidase S-GENE O
activities O O
. O O
Pax B-GENE B-GENE
- I-GENE I-GENE
6 E-GENE E-GENE
constructs O O
lacking O O
the O O
C O O
- O O
terminal O O
activation O O
domain O O
repressed O O
betaB1 B-GENE B-GENE
- I-GENE I-GENE
crystallin I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
as O O
effectively O O
as O O
the O O
full O O
- O O
length O O
protein O O
, O O
but O O
the O O
PD S-GENE O
alone O O
or O O
Pax B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE E-GENE
( I-GENE O
5a I-GENE O
) E-GENE O
, O O
a O O
splice O O
variant O O
with O O
an O O
altered O O
PD S-GENE O
affecting O O
its O O
DNA O O
binding O O
specificity O O
, O O
did O O
not O O
. O O
A O O
regression O O
analysis O O
showed O O
that O O
86 O O
% O O
of O O
the O O
variance O O
in O O
weight O O
gain O O
was O O
predicted O O
by O O
two O O
leading O O
indicators O O
in O O
the O O
middle O O
phase O O
of O O
treatment O O
. O O
OBJECTIVE O O
: O O
Respiratory O O
- O O
related O O
electromyographic O O
( O O
EMG O O
) O O
activity O O
of O O
the O O
superior O O
pharyngeal O O
constrictor O O
( O O
SPC O O
) O O
muscle O O
was O O
analyzed O O
during O O
the O O
early O O
stage O O
of O O
forced O O
breathing O O
. O O
The O O
predicted O O
amino O O
acid O O
sequence O O
contained O O
all O O
consensus O O
regions O O
for O O
S B-GENE O
- I-GENE O
adenosyl I-GENE O
methionine I-GENE O
methyltransferases E-GENE O
and O O
presented O O
26 O O
% O O
identity O O
with O O
Saccharomyces B-GENE B-GENE
cerevisiae I-GENE I-GENE
DHHB I-GENE I-GENE
- I-GENE I-GENE
methyltransferase E-GENE E-GENE
and O O
38 O O
% O O
identity O O
with O O
the O O
rat O O
protein O O
, O O
as O O
well O O
as O O
with O O
a O O
bacterial O O
( O O
Escherichia O O
coli O O
and O O
Salmonella O O
typhimurium O O
) O O
methyltransferase S-GENE O
encoded O O
by O O
the O O
UBIG B-GENE B-GENE
gene E-GENE E-GENE
. O O
Letter O O
: O O
Ballistocardiography O O
. O O
The O O
introduction O O
of O O
FWD1 S-GENE O
into O O
cells O O
significantly O O
promotes O O
ubiquitination O O
and O O
degradation O O
of O O
IkappaBalpha S-GENE S-GENE
in O O
concert O O
with O O
IkappaB B-GENE B-GENE
kinases E-GENE E-GENE
, O O
resulting O O
in O O
nuclear O O
translocation O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
. O O
Fosinopril O O
decreased O O
blood O O
pressure O O
from O O
174 O O
/ O O
101 O O
mm O O
Hg O O
to O O
149 O O
/ O O
88 O O
mm O O
Hg O O
in O O
patients O O
with O O
diastolic O O
hypertension O O
and O O
from O O
182 O O
/ O O
86 O O
mm O O
Hg O O
to O O
151 O O
/ O O
80 O O
mm O O
Hg O O
in O O
patients O O
with O O
ISH O O
. O O
Although O O
CB O O
- O O
4 O O
isolates O O
were O O
less O O
resistant O O
to O O
chlorine O O
than O O
CB O O
- O O
5 O O
isolates O O
, O O
after O O
1 O O
, O O
000 O O
min O O
of O O
contact O O
0 O O
. O O
01 O O
% O O
of O O
the O O
input O O
virus O O
was O O
still O O
infectious O O
. O O
The O O
treatment O O
of O O
Sudeck O O
' O O
s O O
atrophy O O
in O O
the O O
upper O O
limb O O
by O O
sympathetic O O
blockade O O
. O O
To O O
assess O O
the O O
effect O O
on O O
thrombus O O
growth O O
, O O
we O O
determined O O
the O O
accretion O O
of O O
125I O O
- O O
labeled O O
fibrinogen S-GENE O
onto O O
autologous O O
non O O
- O O
radioactive O O
thrombi O O
preformed O O
in O O
the O O
jugular O O
veins O O
of O O
rabbits O O
. O O
Thallium O O
- O O
201 O O
scintigraphy O O
after O O
dipyridamole O O
infusion O O
with O O
low O O
level O O
exercise O O
. O O
A O O
kinetic O O
model O O
for O O
99mTc O O
- O O
DMSA O O
in O O
the O O
rat O O
. O O
Crude O O
drugs O O
from O O
aquatic O O
plants O O
. O O
Yet O O
testosterone O O
was O O
predominant O O
in O O
the O O
plasma O O
of O O
the O O
Type O O
II O O
male O O
morph O O
which O O
neither O O
courts O O
females O O
nor O O
nests O O
, O O
but O O
instead O O
parasitizes O O
Type O O
I O O
males O O
with O O
sneak O O
or O O
satellite O O
spawning O O
tactics O O
. O O
Comparison O O
of O O
the O O
therapeutic O O
effectiveness O O
of O O
membrane O O
and O O
centrifugation O O
plasmapheresis O O
Amino O O
- O O
terminal O O
polymorphisms O O
of O O
the O O
human B-GENE B-GENE
beta I-GENE I-GENE
2 I-GENE I-GENE
- I-GENE I-GENE
adrenergic I-GENE I-GENE
receptor E-GENE E-GENE
impart O O
distinct O O
agonist O O
- O O
promoted O O
regulatory O O
properties O O
. O O
Hence O O
, O O
it O O
is O O
perhaps O O
not O O
necessary O O
to O O
perform O O
spinal O O
puncture O O
if O O
the O O
only O O
purpose O O
is O O
to O O
determine O O
the O O
CSF O O
/ O O
serum O O
ratio O O
. O O
Two O O
plasmids O O
, O O
one O O
containing O O
the O O
amino O O
terminus O O
of O O
P O O
fused O O
to O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
the O O
yeast O O
transactivator O O
, O O
GAL4 S-GENE S-GENE
, O O
and O O
the O O
other O O
containing O O
the O O
amino O O
terminus O O
of O O
NP S-GENE O
fused O O
to O O
the O O
herpesvirus O O
transactivator O O
, O O
VP16 S-GENE S-GENE
, O O
were O O
transfected O O
in O O
COS O O
- O O
1 O O
cells O O
along O O
with O O
a O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
reporter O O
plasmid O O
containing O O
GAL4 S-GENE O
DNA O O
- O O
binding O O
sites O O
. O O
Biochemical O O
experiments O O
and O O
genome O O
sequencing O O
have O O
shown O O
that O O
, O O
despite O O
the O O
prokaryotic O O
cell O O
and O O
genome O O
organization O O
, O O
basal O O
transcriptional O O
elements O O
of O O
members O O
of O O
the O O
domain O O
Archaea O O
( O O
i O O
. O O
e O O
. O O
, O O
TATA O O
box O O
- O O
like O O
sequences O O
, O O
RNA B-GENE O
polymerase E-GENE O
, O O
and O O
transcription O O
factors O O
TBP S-GENE S-GENE
, O O
TFIIB S-GENE S-GENE
, O O
and O O
TFIIS S-GENE S-GENE
) O O
are O O
of O O
the O O
eukaryotic O O
type O O
. O O
Humoral O O
immunity O O
is O O
altered O O
with O O
the O O
drop O O
in O O
IgG S-GENE S-GENE
levels O O
. O O
For O O
the O O
second O O
phase O O
, O O
it O O
was O O
12 O O
. O O
5 O O
wk O O
for O O
RIR O O
and O O
10 O O
for O O
WL O O
males O O
, O O
whereas O O
it O O
was O O
5 O O
wk O O
for O O
RIR O O
and O O
6 O O
for O O
WL O O
females O O
. O O
Modified O O
Grocott O O
' O O
s O O
methenamine O O
silver O O
nitrate O O
method O O
for O O
quick O O
staining O O
of O O
Pneumocystis O O
carinii O O
. O O
Additionally O O
, O O
VAHS O S-GENE
is O O
often O O
associated O O
with O O
fatal O O
infectious O O
mononucleosis O O
( O O
IM O O
) O O
. O O
RESULTS O O
: O O
In O O
patients O O
with O O
necrotising O O
fasciitis O O
the O O
arterial O O
PO2 O O
rose O O
about O O
7 O O
- O O
fold O O
whereas O O
the O O
arterial O O
PCO2 O O
increased O O
only O O
slightly O O
during O O
exposure O O
to O O
2 O O
. O O
5 O O
absolute O O
atmospheres O O
( O O
ATA O O
) O O
of O O
oxygen O O
. O O
We O O
report O O
on O O
a O O
case O O
of O O
a O O
43 O O
- O O
old O O
- O O
male O O
with O O
a O O
bronchogenic O O
cyst O O
in O O
the O O
distal O O
esophagus O O
, O O
which O O
was O O
misdiagnosed O O
as O O
a O O
malignant O O
esophageal O O
tumor O O
based O O
on O O
preoperative O O
imaging O O
and O O
high O O
levels O O
of O O
the O O
tumor O O
markers O O
CA B-GENE O
19 I-GENE O
- I-GENE O
9 E-GENE O
and O O
CA B-GENE O
125 E-GENE O
. O O
100 O O
and O O
51 O O
p O O
. O O
A O O
plasma O O
cell O O
- O O
rich O O
infiltrate O O
was O O
present O O
in O O
the O O
connective O O
tissue O O
cores O O
of O O
the O O
papillae O O
. O O
During O O
normoxic O O
exercise O O
, O O
at O O
a O O
mean O O
O2 O O
uptake O O
( O O
VO2 O O
) O O
of O O
4 O O
. O O
0 O O
l O O
/ O O
min O O
, O O
almitrine O O
increased O O
arterial O O
PO2 O O
( O O
PaO2 O O
) O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
, O O
SaO2 O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
VE O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
and O O
decreased O O
arterial O O
PCO2 O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
, O O
without O O
affecting O O
pulmonary O O
hemodynamics O O
or O O
ventilation O O
- O O
perfusion O O
distributions O O
. O O
Gene B-GENE O
GPR I-GENE O
51 E-GENE O
was O O
localized O O
by O O
radiation O O
hybrid O O
mapping O O
to O O
chromosome O O
9 O O
, O O
4 O O
. O O
81 O O
cR O O
from O O
the O O
WI O O
- O O
8684 O O
marker O O
, O O
and O O
proximal O O
to O O
the O O
hereditary B-GENE O
sensory I-GENE O
neuropathy I-GENE O
type I-GENE O
1 I-GENE O
locus E-GENE O
. O O
We O O
conclude O O
that O O
the O O
outcome O O
of O O
patients O O
with O O
uterine O O
MMMT O O
is O O
mainly O O
influenced O O
by O O
the O O
initial O O
stage O O
and O O
the O O
type O O
of O O
epithelial O O
component O O
. O O
The O O
expression O O
of O O
the O O
leukocyte B-GENE B-GENE
EL I-GENE I-GENE
- I-GENE I-GENE
246 I-GENE I-GENE
antigen E-GENE E-GENE
was O O
regulated O O
in O O
the O O
same O O
manner O O
as O O
L B-GENE O
- I-GENE O
selectin E-GENE O
and O O
EL B-GENE O
- I-GENE O
246 E-GENE O
recognized O O
anti B-GENE O
- I-GENE O
L I-GENE O
- I-GENE O
selectin I-GENE O
mAb E-GENE O
affinity O O
- O O
purified O O
antigen O O
in O O
SDS O S-GENE
/ O O
PAGE O O
Western O O
blot O O
analysis O O
. O O
Other O O
Fischer O O
- O O
344 O O
rats O O
were O O
also O O
exposed O O
for O O
1 O O
hr O O
to O O
0 O O
. O O
0 O O
or O O
to O O
0 O O
. O O
6 O O
ppm O O
O3 O O
. O O
A O O
computerized O O
database O O
of O O
veterans O O
discharged O O
from O O
the O O
military O O
after O O
1967 O O
was O O
selected O O
as O O
the O O
source O O
because O O
it O O
contains O O
about O O
50 O O
% O O
of O O
the O O
total O O
Vietnam O O
era O O
veteran O O
population O O
, O O
is O O
reasonably O O
unbiased O O
, O O
and O O
provides O O
a O O
feasible O O
method O O
for O O
identifying O O
twins O O
. O O
To O O
examine O O
the O O
functional O O
relationship O O
between O O
distinct O O
cis O O
- O O
active O O
elements O O
within O O
the O O
distal O O
enhancer O O
region O O
of O O
the O O
rat B-GENE B-GENE
PRL I-GENE I-GENE
gene E-GENE E-GENE
, O O
we O O
have O O
used O O
deletional O O
and O O
mutational O O
analysis O O
of O O
that O O
region O O
in O O
transient O O
transfection O O
studies O O
in O O
GH3 O O
pituitary O O
tumor O O
cells O O
. O O
The O O
entire O O
coding O O
region O O
of O O
an O O
ovine B-GENE B-GENE
endometrial I-GENE I-GENE
oxytocin I-GENE I-GENE
receptor E-GENE E-GENE
( O O
OTR S-GENE S-GENE
) O O
cDNA O O
was O O
generated O O
by O O
PCR O O
, O O
subcloned O O
into O O
the O O
SV40 B-GENE O
major I-GENE O
late I-GENE O
promoter E-GENE O
expression O O
vector O O
pSVLJ O S-GENE
and O O
transiently O O
expressed O O
in O O
Cos O O
- O O
7 O O
cells O O
. O O
Alcohol O O
and O O
stomach O O
diseases O O
These O O
operons O O
encode O O
subunits O O
of O O
photosystems B-GENE B-GENE
I E-GENE E-GENE
( O O
psa S-GENE O
) O O
and O O
II O O
( O O
psb S-GENE S-GENE
) O O
, O O
the O O
cytochrome B-GENE B-GENE
bGf I-GENE I-GENE
complex E-GENE E-GENE
( O O
pet S-GENE O
) O O
, O O
the O O
plastid O B-GENE
NAD B-GENE I-GENE
( I-GENE I-GENE
P I-GENE I-GENE
) I-GENE I-GENE
H I-GENE I-GENE
dehydrogenase E-GENE E-GENE
( O O
ndh S-GENE O
) O O
, O O
and O O
the O O
unidentified O O
open O O
reading O O
frame O O
ycf9 S-GENE O
. O O
The O O
phosphatidylglycerol B-GENE O
/ I-GENE O
phosphatidylinositol I-GENE B-GENE
transfer I-GENE I-GENE
protein E-GENE E-GENE
( O O
PG B-GENE S-GENE
/ I-GENE O
PI I-GENE B-GENE
- I-GENE I-GENE
TP E-GENE E-GENE
) O O
is O O
a O O
new O O
and O O
original O O
phospholipid B-GENE O
transfer I-GENE O
protein E-GENE O
( O O
PLTP S-GENE S-GENE
) O O
isolated O O
from O O
the O O
Deuteromycete O O
, O O
Aspergillus O O
oryzae O O
. O O
Transcriptional O O
modulation O O
of O O
the O O
anti B-GENE O
- I-GENE O
apoptotic I-GENE O
protein I-GENE O
BCL I-GENE B-GENE
- I-GENE I-GENE
XL E-GENE E-GENE
by O O
the O O
paired B-GENE O
box I-GENE O
transcription I-GENE O
factors E-GENE O
PAX3 S-GENE S-GENE
and O O
PAX3 S-GENE S-GENE
/ O O
FKHR S-GENE S-GENE
. O O
The O O
level O O
of O O
expression O O
of O O
the O O
PDE B-GENE B-GENE
protein E-GENE E-GENE
was O O
monitored O O
by O O
immunoblot O O
analysis O O
using O O
two O O
specific O O
cAMP B-GENE O
- I-GENE O
PDE I-GENE O
polyclonal I-GENE O
antibodies E-GENE O
and O O
by O O
measuring O O
the O O
PDE S-GENE S-GENE
activity O O
. O O
Blotting O O
analysis O O
of O O
intestinal O O
RNA O O
and O O
hybridization O O
of O O
the O O
blots O O
with O O
carboxy O O
apoB S-GENE O
cDNA O O
probes O O
produced O O
a O O
single O O
15 O O
- O O
kb O O
hybridization O O
band O O
whereas O O
hybridization O O
with O O
amino O O
terminal O O
probes O O
produced O O
two O O
hybridization O O
bands O O
of O O
15 O O
and O O
8 O O
kb O O
. O O
Since O O
UmuD B-GENE B-GENE
protein E-GENE E-GENE
is O O
proteolytically O O
processed O O
to O O
an O O
active O O
form O O
( O O
UmuD B-GENE O
* E-GENE O
) O O
in O O
a O O
RecA S-GENE O
* O O
- O O
dependent O O
fashion O O
, O O
and O O
MucA S-GENE O
shares O O
extensive O O
amino O O
acid O O
homology O O
with O O
UmuD S-GENE S-GENE
, O O
we O O
examined O O
whether O O
MucA S-GENE S-GENE
is O O
similarly O O
processed O O
in O O
the O O
cell O O
, O O
using O O
antiserum O O
against O O
a O O
LacZ B-GENE B-GENE
' E-GENE I-GENE
- O I-GENE
' B-GENE I-GENE
MucA E-GENE I-GENE
fusion O I-GENE
protein O E-GENE
. O O
Influence O O
of O O
long O O
- O O
term O O
zimelidine O O
treatment O O
on O O
LSD O O
- O O
induced O O
behavioural O O
effects O O
. O O
We O O
have O O
determined O O
the O O
molecular O O
organization O O
and O O
transcription O O
start O O
points O O
( O O
tsp O O
) O O
for O O
the O O
murine O B-GENE
gene O E-GENE
( O O
TK S-GENE S-GENE
) O O
encoding O O
thymidine B-GENE B-GENE
kinase E-GENE E-GENE
. O O
Together O O
with O O
a O O
number O O
of O O
phase O O
II O O
trials O O
, O O
phase O O
I O O
trials O O
utilizing O O
escalating O O
doses O O
of O O
carboplatin O O
and O O
paclitaxel O O
with O O
growth O O
factor O O
or O O
growth O O
factor O O
and O O
blood O O
stem O O
- O O
cell O O
support O O
have O O
shown O O
that O O
substantial O O
increases O O
in O O
dose O O
intensity O O
can O O
be O O
achieved O O
. O O
It O O
is O O
an O O
untested O O
argument O O
that O O
conventional O O
beta B-GENE O
- I-GENE O
adrenoceptor E-GENE O
antagonists O O
possess O O
unwanted O O
metabolic O O
effects O O
that O O
may O O
counter O O
some O O
of O O
their O O
potential O O
cardiac O O
benefits O O
. O O
Genetic O O
polymorphisms O O
in O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
change O O
transcriptional O O
regulation O O
of O O
the O O
human B-GENE B-GENE
cytochrome I-GENE I-GENE
P450IIE1 I-GENE I-GENE
gene E-GENE E-GENE
. O O
Although O O
the O O
occurrence O O
of O O
any O O
ventricular O O
ectopic O O
activity O O
, O O
as O O
detected O O
by O O
either O O
or O O
both O O
methods O O
, O O
was O O
common O O
, O O
the O O
incidence O O
was O O
significantly O O
higher O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
in O O
patients O O
with O O
coronary O O
heart O O
disease O O
( O O
86 O O
percent O O
; O O
77 O O
/ O O
90 O O
) O O
, O O
as O O
compared O O
to O O
that O O
in O O
normal O O
subjects O O
( O O
40 O O
percent O O
; O O
12 O O
/ O O
30 O O
) O O
. O O
Increased O O
trabecular O O
spacing O O
, O O
such O O
as O O
it O O
occurs O O
in O O
osteoporosis O O
, O O
reduces O O
the O O
spatial O O
field O O
inhomogeneity O O
and O O
thus O O
prolongs O O
T2 O O
* O O
, O O
which O O
has O O
been O O
shown O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O
Healthy O O
preterm O O
infants O O
of O O
gestational O O
age O O
26 O O
- O O
29 O O
weeks O O
showed O O
a O O
' O O
mature O O
' O O
pattern O O
of O O
permeability O O
at O O
birth O O
, O O
followed O O
by O O
a O O
temporary O O
period O O
of O O
enhanced O O
permeability O O
after O O
3 O O
- O O
4 O O
weeks O O
of O O
life O O
. O O
These O O
studies O O
reveal O O
that O O
CREM S-GENE O
, O O
a O O
tissue O O
- O O
specific O O
factor O O
, O O
is O O
expressed O O
and O O
regulated O O
by O O
gonadotropins S-GENE O
in O O
the O O
ovary O O
, O O
that O O
the O O
predominant O O
CREM S-GENE O
transcripts O O
encode O O
the O O
repressor B-GENE O
protein I-GENE O
ICER E-GENE S-GENE
, O O
and O O
that O O
ICER S-GENE S-GENE
is O O
capable O O
of O O
inhibiting O O
cAMP O O
- O O
induced O O
expression O O
of O O
the O O
inhibin B-GENE B-GENE
alpha I-GENE I-GENE
- I-GENE I-GENE
subunit I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
Brassica B-GENE B-GENE
BTH1 I-GENE I-GENE
gene E-GENE E-GENE
may O O
correspond O O
to O O
the O O
Arabidopsis B-GENE B-GENE
TH I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
same O O
pattern O O
of O O
firing O O
was O O
seen O O
with O O
saccades O O
in O O
light O O
and O O
in O O
complete O O
darkness O O
. O O
While O O
these O O
could O O
be O O
unusual O O
cases O O
of O O
chronic O O
non O O
- O O
A O O
, O O
non O O
- O O
B O O
hepatitis O O
, O O
this O O
can O O
be O O
only O O
speculation O O
until O O
a O O
serologic O O
test O O
for O O
non O O
- O O
A O O
, O O
non O O
- O O
B O O
hepatitis O O
becomes O O
available O O
. O O
Acanthamoeba B-GENE B-GENE
myosin I-GENE I-GENE
I I-GENE I-GENE
heavy I-GENE I-GENE
chain I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MIHCK S-GENE S-GENE
) O O
phosphorylates O O
the O O
heavy O O
chains O O
of O O
amoeba B-GENE B-GENE
myosins I-GENE I-GENE
I E-GENE E-GENE
, O O
increasing O O
their O O
actin S-GENE O
- O O
activated O O
ATPase S-GENE O
activities O O
. O O
Mutation O O
of O O
the O O
HNF3 B-GENE S-GENE
element E-GENE O
significantly O O
reduced O O
promoter O O
activity O O
in O O
HepG2 O O
cells O O
, O O
whereas O O
this O O
element O O
in O O
isolation O O
conferred O O
HNF3beta S-GENE O
responsiveness O O
to O O
a O O
heterologous O O
promoter O O
. O O
The O O
mitochondrial B-GENE B-GENE
tyrosyl I-GENE I-GENE
- I-GENE I-GENE
tRNA I-GENE I-GENE
synthetase E-GENE E-GENE
of O O
Podospora O O
anserina O O
is O O
a O O
bifunctional O O
enzyme O O
active O O
in O O
protein O O
synthesis O O
and O O
RNA O O
splicing O O
. O O
The O O
findings O O
in O O
the O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
represent O O
the O O
first O O
examples O O
of O O
B O O
cells O O
with O O
downregulated O O
PU B-GENE O
. I-GENE O
1 E-GENE O
expression O O
and O O
apparently O O
contradict O O
observations O O
in O O
the O O
murine O O
system O O
in O O
which O O
PU B-GENE O
. I-GENE O
1 E-GENE O
is O O
expressed O O
and O O
active O O
in O O
plasmacytoma O O
cell O O
lines O O
. O O
The O O
traW B-GENE B-GENE
gene I-GENE E-GENE
of I-GENE O
the I-GENE O
Escherichia I-GENE B-GENE
coli I-GENE I-GENE
K I-GENE I-GENE
- I-GENE I-GENE
12 I-GENE I-GENE
sex I-GENE I-GENE
factor E-GENE E-GENE
, O O
F O O
, O O
encodes O O
one O O
of O O
the O O
numerous O O
proteins O O
required O O
for O O
conjugative O O
transfer O O
of O O
this O O
plasmid O O
. O O
Mibefradil O O
( O O
Ro O O
40 O O
- O O
5967 O O
) O O
is O O
a O O
novel O O
nondihydropyridine O O
calcium O O
antagonist O O
. O O
However O O
, O O
technical O O
advances O O
have O O
shown O O
the O O
limitations O O
of O O
these O O
tests O O
as O O
tests O O
for O O
IgM S-GENE O
can O O
be O O
positive O O
because O O
of O O
residual O O
specific O O
IgM S-GENE O
or O O
even O O
in O O
subjects O O
free O O
of O O
acute O O
infection O O
due O O
to O O
the O O
existence O O
of O O
natural O O
interfering O O
IgM S-GENE O
. O O
Carcinogenic O O
action O O
of O O
groundnut O O
meal O O
containing O O
aflatoxin O O
in O O
rats O O
. O O
( O O
1991 O O
) O O
EMBO O O
J O O
. O O
We O O
have O O
utilized O O
transient O O
transfections O O
, O O
mutation O O
analysis O O
, O O
electromobility O O
gel O O
- O O
shifts O O
, O O
and O O
immunoblot O O
analysis O O
to O O
test O O
the O O
hypothesis O O
that O O
expression O O
of O O
the O O
CTalpha B-GENE B-GENE
gene E-GENE E-GENE
is O O
controlled O O
in O O
part O O
by O O
the O O
binding O O
of O O
three O O
trans O O
- O O
acting O O
nuclear O O
factors O O
, O O
Sp1 S-GENE S-GENE
, O O
Sp2 S-GENE S-GENE
, O O
and O O
Sp3 S-GENE S-GENE
. O O
AMPK S-GENE S-GENE
is O O
a O O
heterotrimer O O
composed O O
of O O
a O O
catalytic O O
subunit O O
( O O
alpha O O
) O O
and O O
two O O
regulatory O O
subunits O O
( O O
beta O O
and O O
gamma O O
) O O
. O O
The O O
evolutionary O O
significance O O
of O O
the O O
similarities O O
of O O
intron O O
secondary O O
structures O O
and O O
open O O
reading O O
frames O O
of O O
the O O
ND3 B-GENE O
, I-GENE O
4 I-GENE O
and I-GENE O
ATPase I-GENE B-GENE
6 I-GENE I-GENE
genes E-GENE E-GENE
is O O
discussed O O
, O O
including O O
the O O
possible O O
separate O O
evolution O O
of O O
structural O O
and O O
coding O O
sequences O O
. O O
Antinuclear O O
antibodies O O
, O O
rheumatoid B-GENE O
factor E-GENE O
and O O
C B-GENE O
- I-GENE O
reactive I-GENE O
protein E-GENE O
in O O
serum O O
of O O
normal O O
women O O
using O O
oral O O
contraceptives O O
. O O
The O O
destruction O O
of O O
the O O
mesometrium O O
did O O
not O O
lengthen O O
the O O
oestrous O O
cycle O O
. O O
Concentrations O O
of O O
platelet O O
nitrite O O
and O O
total O O
nitrate O O
/ O O
nitrite O O
were O O
determined O O
using O O
simple O O
and O O
sensitive O O
nitrate O O
/ O O
nitrite O O
fluorometric O O
assay O O
techniques O O
. O O
Power O O
deposition O O
by O O
inverse O O
- O O
bremsstrahlung O O
is O O
modeled O O
with O O
a O O
scheme O O
based O O
on O O
Gaussian O O
quadrature O O
to O O
accommodate O O
a O O
deposition O O
rate O O
whose O O
spatial O O
variation O O
is O O
highly O O
nonuniform O O
. O O
The O O
sulfur O O
species O O
could O O
be O O
separated O O
within O O
less O O
than O O
4 O O
min O O
by O O
CZE O O
with O O
a O O
pyromellitic O O
acid O O
electrolyte O O
at O O
pH O O
3 O O
. O O
5 O O
to O O
5 O O
. O O
0 O O
. O O
We O O
propose O O
that O O
unc B-GENE O
- I-GENE O
37 E-GENE O
may O O
be O O
regulated O O
by O O
unc B-GENE O
- I-GENE O
4 E-GENE O
. O O
Adenovirus O O
infection O O
of O O
hepatoma O O
cells O O
inhibited O O
transcription O O
of O O
the O O
phosphoenolpyruvate B-GENE O
carboxykinase E-GENE O
( O O
GTP O O
) O O
( O O
EC B-GENE O
4 I-GENE O
. I-GENE O
1 I-GENE O
. I-GENE O
1 I-GENE O
. I-GENE O
32 E-GENE O
) O O
( O O
PEPCK S-GENE O
) O O
gene O O
and O O
virtually O O
eliminated O O
transcription O O
of O O
a O O
chimeric O O
gene O O
which O O
contained O O
the O O
PEPCK B-GENE B-GENE
promoter E-GENE E-GENE
linked O O
to O O
the O O
structural O O
gene O O
for O O
chloramphenicol B-GENE B-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE O
) O O
. O O
After O O
discharge O O
, O O
he O O
was O O
finally O O
given O O
a O O
diagnosis O O
of O O
PCH O O
because O O
a O O
Donath O O
- O O
Landsteiner O O
test O O
was O O
positive O O
. O O
The O O
second O O
intron O O
is O O
the O O
smallest O O
of O O
all O O
the O O
introns O O
( O O
116 O O
bp O O
) O O
. O O
Expression O O
of O O
the O O
gene O O
encoding O O
transcription B-GENE O
factor I-GENE O
cyclic I-GENE O
adenosine I-GENE O
3 I-GENE O
' I-GENE O
, I-GENE O
5 I-GENE O
' I-GENE O
- I-GENE O
monophosphate I-GENE O
( I-GENE O
cAMP I-GENE O
) I-GENE O
response I-GENE O
element I-GENE O
- I-GENE O
binding I-GENE O
protein E-GENE O
( O O
CREB S-GENE S-GENE
) O O
: O O
regulation O O
by O O
follicle B-GENE O
- I-GENE O
stimulating I-GENE O
hormone E-GENE O
- O O
induced O O
cAMP O O
signaling O O
in O O
primary O O
rat O O
Sertoli O O
cells O O
. O O
Efficacy O O
was O O
evaluated O O
in O O
24 O O
patients O O
, O O
of O O
whom O O
eight O O
received O O
RD O O
and O O
16 O O
SD O O
. O O
A O O
silica O O
- O O
based O O
, O O
fluoride O O
- O O
free O O
placebo O O
containing O O
NaTPP O O
, O O
and O O
a O O
NaF O O
- O O
containing O O
silica O O
- O O
based O O
USP O O
reference O O
standard O O
toothpaste O O
were O O
used O O
as O O
negative O O
and O O
positive O O
control O O
toothpastes O O
, O O
respectively O O
. O O
The O O
overall O O
response O O
rate O O
including O O
CR O O
and O O
PR O O
was O O
23 O O
. O O
5 O O
% O O
( O O
4 O O
/ O O
17 O O
) O O
. O O
High O O
and O O
pathological O O
PAI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
levels O O
before O O
and O O
after O O
the O O
VO O O
test O O
were O O
consistent O O
with O O
a O O
defective O O
fibrinolytic O O
potential O O
due O O
to O O
the O O
inhibitory O O
effect O O
of O O
PAI B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
on O O
plasminogen S-GENE O
activation O O
. O O
During O O
hexamethylene O O
bisactamide O O
( O O
HMBA O O
) O O
- O O
induced O O
differentiation O O
of O O
murine O O
erythroleukemia O O
( O O
MEL O O
) O O
cells O O
erythroid O O
genes O O
are O O
transcriptionally O O
activated O O
while O O
c B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE E-GENE
and O O
several O O
other O O
nuclear O O
proto O O
- O O
oncogenes O O
are O O
down O O
- O O
regulated O O
. O O
The O O
recovery O O
of O O
adults O O
schistosomes O O
by O O
extracorporeal O O
filtration O O
. O O
Torsion O O
of O O
the O O
contralateral O O
testis O O
5 O O
years O O
after O O
orchiopexy O O
. O O
Frequency O O
of O O
recurrence O O
of O O
fibroids O O
after O O
myomectomy O O
has O O
been O O
evaluated O O
in O O
145 O O
women O O
( O O
median O O
age O O
38 O O
years O O
, O O
range O O
21 O O
- O O
52 O O
) O O
who O O
underwent O O
myomectomy O O
. O O
Choline B-GENE O
acetyltransferase E-GENE O
immunohistochemistry O O
combined O O
with O O
the O O
retrograde O O
transport O O
of O O
horseradish B-GENE O
peroxidase E-GENE O
showed O O
that O O
the O O
reticular O O
and O O
mediodorsal O O
thalamic O O
nuclei O O
of O O
the O O
cat O O
receive O O
an O O
important O O
input O O
from O O
cholinergic O O
and O O
non O O
- O O
cholinergic O O
neurons O O
of O O
substantia O O
innominata O O
and O O
adjacent O O
structures O O
in O O
the O O
basal O O
forebrain O O
. O O
( O O
i O O
) O O
The O O
chimeric O O
gene O O
consisting O O
of O O
the O O
coding O O
and O O
5 O O
' O O
nontranslated O O
leader O O
regions O O
of O O
the O O
TK B-GENE B-GENE
gene E-GENE E-GENE
fused O O
to O O
portions O O
of O O
the O O
domain O O
of O O
alpha B-GENE B-GENE
gene I-GENE I-GENE
0 E-GENE E-GENE
extending O O
largely O O
upstream O O
from O O
the O O
site O O
of O O
initiation O O
of O O
transcription O O
of O O
alpha B-GENE B-GENE
gene I-GENE I-GENE
0 E-GENE E-GENE
was O O
regulated O O
in O O
the O O
same O O
fashion O O
as O O
the O O
alpha B-GENE O
4 I-GENE O
- I-GENE O
and I-GENE O
alpha I-GENE O
27 I-GENE O
- I-GENE O
TK E-GENE O
chimeras O O
. O O
Ethanol O O
preference O O
in O O
strains O O
of O O
rats O O
selectively O O
bred O O
for O O
behavioral O O
characteristics O O
. O O
For O O
the O O
albino O O
, O O
both O O
the O O
ST1 O O
and O O
ST2 O O
spatial O O
responses O O
peak O O
at O O
around O O
0 O O
. O O
3 O O
cycles O O
deg O O
- O O
1 O O
, O O
and O O
both O O
curves O O
are O O
displaced O O
considerably O O
to O O
the O O
low O O
spatial O O
frequency O O
side O O
of O O
the O O
normal O O
ST2 O O
spatial O O
response O O
. O O
Nuclear O O
proteins O O
bound O O
the O O
cad B-GENE O
+ I-GENE O
55 I-GENE O
/ I-GENE O
+ I-GENE O
75 I-GENE O
element E-GENE O
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
in O O
electromobility O O
shift O O
assays O O
; O O
antibodies O O
specific O O
to O O
USF S-GENE S-GENE
and O O
Max S-GENE O
blocked O O
the O O
DNA O O
- O O
binding O O
activity O O
of O O
different O O
growth O O
- O O
regulated O O
protein O O
- O O
DNA O O
complexes O O
. O O
Thus O O
, O O
an O O
unmodified O O
threonine O O
at O O
position O O
169 O O
in O O
Cdc28 S-GENE O
is O O
important O O
for O O
interaction O O
with O O
G1 B-GENE B-GENE
cyclins E-GENE E-GENE
. O O
Additional O O
genetic O O
analyses O O
described O O
herein O O
suggest O O
that O O
Skb1 S-GENE S-GENE
is O O
a O O
component O O
of O O
the O O
morphology O O
control O O
branch O O
of O O
the O O
Ras S-GENE S-GENE
signaling O O
cascade O O
in O O
S O O
. O O
pombe O O
and O O
that O O
it O O
positively O O
modulates O O
Shk1 S-GENE S-GENE
function O O
. O O
Recent O O
studies O O
have O O
concentrated O O
on O O
the O O
methods O O
of O O
preparation O O
of O O
coffee O O
, O O
which O O
vary O O
from O O
country O O
to O O
country O O
. O O
From O O
a O O
chromosomal O O
cosmid O O
library O O
of O O
Streptomyces O O
argillaceus O O
, O O
a O O
Mtm S-GENE O
producer O O
, O O
a O O
clone O O
( O O
cosAR7 O O
) O O
was O O
isolated O O
by O O
homology O O
to O O
the O O
actI B-GENE O
/ I-GENE O
III I-GENE O
region E-GENE O
of O O
S O O
. O O
coelicolor O O
and O O
the O O
strDEM B-GENE B-GENE
genes E-GENE E-GENE
of O O
S O O
. O O
griseus O O
. O O
In O O
this O O
report O O
, O O
we O O
investigated O O
whether O O
the O O
cleavage O O
of O O
the O O
RRKR O S-GENE
motif O O
of O O
MT B-GENE B-GENE
- I-GENE I-GENE
MMP1 E-GENE E-GENE
by O O
Golgi B-GENE O
- I-GENE O
associated I-GENE O
furin E-GENE O
is O O
analogous O O
to O O
a O O
similar O O
enzyme O O
activation O O
mechanism O O
observed O O
with O O
stromelysin B-GENE O
- I-GENE O
3 E-GENE O
. O O
Coexpression O O
of O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
alpha E-GENE E-GENE
altered O O
the O O
cell O O
specificity O O
. O O
A O O
preterm O O
formula O O
with O O
a O O
traditional O O
corn O O
oil O O
/ O O
MCT O O
blend O O
containing O O
38 O O
% O O
MCTs O O
( O O
MCT O O
group O O
) O O
was O O
compared O O
to O O
a O O
new O O
fat O O
blend O O
, O O
designed O O
to O O
resemble O O
human O O
milk O O
more O O
, O O
containing O O
6 O O
% O O
MCTs O O
( O O
LCT O O
group O O
) O O
. O O
Thirty O O
- O O
three O O
small O O
glottic O O
carcinomas O O
( O O
T1 O O
and O O
small O O
T2 O O
; O O
UICC O O
, O O
1978 O O
) O O
were O O
examined O O
by O O
malignancy O O
grading O O
using O O
the O O
8 O O
- O O
factor O O
system O O
proposed O O
by O O
Jakobsson O O
et O O
al O O
. O O
Phenylalanine O O
and O O
tyrosine O O
levels O O
were O O
higher O O
in O O
those O O
who O O
received O O
Vamin O O
9 O O
glucose O O
but O O
55 O O
% O O
of O O
infants O O
given O O
Vamin O O
Infant O O
had O O
tyrosine O O
levels O O
below O O
the O O
lower O O
limit O O
of O O
the O O
target O O
range O O
. O O
We O O
sought O O
to O O
test O O
whether O O
a O O
prolonged O O
infusion O O
of O O
magnesium O O
sulfate O O
( O O
MgSO O O
( O O
4 O O
) O O
; O O
40 O O
mmol O O
/ O O
24 O O
hours O O
) O O
would O O
normalize O O
QT O O
interval O O
variability O O
in O O
patients O O
with O O
compensated O O
heart O O
failure O O
. O O
Escherichia O O
coli O O
strains O O
carrying O O
recA730 S-GENE O
( O O
or O O
other O O
recA B-GENE B-GENE
* I-GENE I-GENE
alleles E-GENE E-GENE
) O O
exhibit O O
dramatic O O
increases O O
in O O
SOS O O
- O O
dependent O O
spontaneous O O
mutator O O
activity O O
. O O
Outlook O O
in O O
oral O O
and O O
cutaneous O O
Kaposi O O
' O O
s O O
sarcoma O O
. O O
We O O
report O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
camC B-GENE B-GENE
gene E-GENE E-GENE
along O O
with O O
155 O O
base O O
pairs O O
of O O
5 O O
' O O
and O O
175 O O
base O O
pairs O O
of O O
3 O O
' O O
flanking O O
sequence O O
. O O
However O O
, O O
it O O
is O O
only O O
loosely O O
associated O O
, O O
or O O
not O O
associated O O
, O O
with O O
viral O O
particles O O
. O O
gp170 S-GENE S-GENE
is O O
generated O O
by O O
an O O
alternatively O O
spliced O O
Env B-GENE B-GENE
mRNA E-GENE E-GENE
using O O
a O O
splice O O
donor O O
and O O
splice O O
acceptor O O
pair O O
localized O O
within O O
the O O
env B-GENE O
open I-GENE O
reading I-GENE O
frame I-GENE O
( I-GENE O
ORF I-GENE O
) E-GENE O
, O O
which O O
is O O
normally O O
used O O
to O O
generate O O
Bell S-GENE O
and O O
Bet B-GENE O
transcripts E-GENE O
derived O O
from O O
the O O
internal O O
promoter O O
within O O
the O O
env B-GENE B-GENE
ORF E-GENE E-GENE
. O O
gp170 S-GENE S-GENE
is O O
expressed O O
at O O
a O O
level O O
30 O O
to O O
50 O O
% O O
of O O
the O O
Env B-GENE B-GENE
precursor E-GENE I-GENE
gp130 S-GENE E-GENE
. O O
In O O
marked O O
contrast O O
to O O
the O O
previously O O
published O O
human B-GENE B-GENE
CD6 I-GENE I-GENE
sequence E-GENE E-GENE
, O O
the O O
mouse O O
sequence O O
predicts O O
a O O
long O O
cytoplasmic O O
tail O O
that O O
is O O
not O O
closely O O
related O O
to O O
other O O
proteins O O
and O O
possesses O O
two O O
proline O O
- O O
rich O O
motifs O O
containing O O
the O O
SH3 B-GENE S-GENE
- I-GENE O
domain I-GENE O
binding I-GENE O
consensus I-GENE O
sequence E-GENE O
, O O
three O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C I-GENE E-GENE
phosphorylation I-GENE O
site I-GENE O
motifs E-GENE O
, O O
nine O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
phosphorylation I-GENE O
site I-GENE O
motifs E-GENE O
, O O
and O O
a O O
serine O O
- O O
threonine O O
- O O
rich O O
motif O O
repeated O O
three O O
times O O
. O O
ET B-GENE O
- I-GENE O
1 E-GENE O
limited O O
the O O
electrocardiographic O O
evidence O O
of O O
subendocardial O O
ischemia O O
and O O
attenuated O O
contractile O O
dysfunction O O
compared O O
with O O
mechanical O O
stenosis O O
at O O
the O O
same O O
coronary O O
flows O O
, O O
even O O
though O O
lactate O O
flux O O
was O O
similar O O
. O O
Our O O
results O O
are O O
consistent O O
with O O
TCOF1 B-GENE S-GENE
mutations E-GENE O
leading O O
to O O
the O O
Treacher O O
Collins O O
syndrome O O
phenotype O O
. O O
Experimental O O
production O O
of O O
a O O
syndrome O O
analogous O O
to O O
hydramnios O O
in O O
the O O
rat O O
fetus O O
Total O O
cross O O
sections O O
for O O
electron O O
scattering O O
by O O
CO2 O O
molecules O O
in O O
the O O
energy O O
range O O
400 O O
- O O
5000 O O
eV O O
. O O
Thus O O
, O O
the O O
cognitive O O
performance O O
of O O
elderly O O
subjects O O
could O O
be O O
trained O O
to O O
a O O
large O O
extent O O
. O O
Partial O O
albinism O O
and O O
immunodeficiency O O
: O O
ultrastructural O O
study O O
of O O
haemophagocytosis O O
and O O
bone O O
marrow O O
erythroblasts O O
in O O
one O O
case O O
. O O
Residues O O
that O O
affect O O
PLCbeta S-GENE S-GENE
and O O
adenylyl B-GENE B-GENE
cyclase I-GENE I-GENE
II E-GENE E-GENE
activity O O
are O O
found O O
on O O
opposite O O
sides O O
of O O
the O O
central O O
tunnel O O
, O O
suggesting O O
that O O
PLC S-GENE O
and O O
adenylyl B-GENE O
cyclase E-GENE O
, O O
like O O
the O O
alpha O B-GENE
subunit O E-GENE
, O O
make O O
many O O
contacts O O
on O O
the O O
top O O
surface O O
. O O
The O O
dynamics O O
of O O
protozoa O O
were O O
studied O O
in O O
two O O
groups O O
of O O
rumen O O
- O O
fistulated O O
cattle O O
fed O O
on O O
a O O
basal O O
diet O O
of O O
molasses O O
ad O O
lib O O
. O O
, O O
with O O
oaten O O
chaff O O
given O O
at O O
6 O O
or O O
18 O O
g O O
/ O O
kg O O
live O O
weight O O
. O O
The O O
CBS B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
was O O
mapped O O
to O O
human O O
chromosome O O
10p12 O O
between O O
markers O O
WI B-GENE O
- I-GENE O
8535 E-GENE O
and O O
WI B-GENE B-GENE
- I-GENE I-GENE
4724 E-GENE E-GENE
, O O
and O O
is O O
tightly O O
linked O O
to O O
the O O
two O O
STRP O O
markers O O
of O O
D10S1789 S-GENE S-GENE
and O O
D10S550 S-GENE S-GENE
. O O
Blood O O
ammonia O O
concentration O O
was O O
significantly O O
higher O O
in O O
males O O
at O O
70 O O
, O O
80 O O
and O O
90 O O
% O O
of O O
VO2 O O
peak O O
. O O
Value O O
of O O
bone O O
scintigraphy O O
with O O
Tc99MDP O O
in O O
the O O
early O O
diagnosis O O
of O O
mobilization O O
of O O
the O O
total O O
hip O O
prosthesis O O
Youssoufian O O
, O O
A O O
. O O
The O O
dipper O O
( O O
RONF O O
of O O
BP O O
( O O
or O O
HR O O
) O O
> O O
or O O
= O O
10 O O
% O O
2 O O
. O O
In O O
the O O
present O O
study O O
, O O
we O O
have O O
investigated O O
the O O
effects O O
of O O
SDZ O O
ENA O O
713 O O
on O O
spatial O O
learning O O
deficits O O
in O O
aged O O
rats O O
. O O
MATERIALS O O
AND O O
METHODS O O
: O O
A O O
seven O O
- O O
wavelength O O
frequency O O
- O O
domain O O
photon O O
migration O O
probe O O
was O O
used O O
to O O
perform O O
noninvasive O O
NIR O O
measurements O O
in O O
the O O
breasts O O
of O O
28 O O
healthy O O
women O O
, O O
both O O
pre O O
- O O
and O O
postmenopausal O O
, O O
aged O O
18 O O
- O O
64 O O
years O O
. O O
YACs O S-GENE
, O O
BACs O O
, O O
cosmids O O
, O O
and O O
STSs O S-GENE
are O O
defined O O
to O O
aid O O
in O O
further O O
study O O
of O O
this O O
gene O O
. O O
HCVR O O
- O O
L O O
significantly O O
increased O O
dVAS O O
/ O O
dPCO2 O O
to O O
4 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mm O O
/ O O
Torr O O
compared O O
to O O
HCVR O O
- O O
S O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O
The O O
MEF B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
proteins E-GENE E-GENE
are O O
a O O
family O O
of O O
transcriptional O O
activators O O
that O O
have O O
been O O
detected O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
. O O
The O O
ferric B-GENE O
uptake I-GENE O
regulation E-GENE O
( O O
fur S-GENE O
) O O
gene O O
product O O
participates O O
in O O
regulating O O
expression O O
of O O
the O O
manganese O O
- O O
and O O
iron O O
- O O
containing O O
superoxide B-GENE O
dismutase I-GENE O
genes I-GENE O
of I-GENE O
Escherichia I-GENE O
coli E-GENE O
. O O
To O O
date O O
, O O
6 O O
mammalian O O
GRKs S-GENE O
have O O
been O O
identified O O
by O O
molecular O O
cloning O O
. O O
[ O O
( O O
OP O O
) O O
2Cu O O
] O O
+ O O
also O O
detected O O
protections O O
in O O
the O O
C O B-GENE
alpha O I-GENE
- O I-GENE
helix O E-GENE
, O O
the O O
interdomain O O
hinge O O
, O O
and O O
beta O O
- O O
strands O O
2 O O
- O O
7 O O
. O O
The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
influence O O
of O O
long O O
term O O
intravenous O O
administration O O
of O O
naftidrofuryl O O
( O O
Dusodril O O
- O O
Lipha O O
Arzn O O
) O O
twice O O
daily O O
in O O
a O O
dose O O
of O O
200 O O
mg O O
in O O
continuous O O
, O O
4 O O
- O O
hour O O
infusion O O
in O O
500 O O
ml O O
0 O O
. O O
9 O O
% O O
NaCl O O
to O O
the O O
patients O O
suffering O O
from O O
a O O
peripheral O O
arterial O O
occlusive O O
disease O O
( O O
PAOD O O
) O O
in O O
a O O
clinical O O
condition O O
with O O
special O O
attention O O
paid O O
to O O
transcutaneous O O
partial O O
oxygen O O
pressure O O
measurements O O
( O O
tcPO2 O O
) O O
and O O
rheographic O O
parameters O O
. O O
Vertebrate O O
U6 B-GENE O
small I-GENE O
nuclear I-GENE O
RNA E-GENE O
( O O
snRNA O S-GENE
) O O
loci O O
exemplify O O
a O O
novel O O
class O O
of O O
polymerase B-GENE O
III E-GENE O
- O O
transcribed O O
genes O O
that O O
lack O O
an O O
intragenic O O
control O O
region O O
( O O
ICR O O
) O O
. O O
Elements O O
of O O
the O O
hAT B-GENE O
transposon I-GENE O
family E-GENE O
, O O
such O O
as O O
the O O
maize B-GENE O
activator E-GENE O
( O O
Ac S-GENE O
) O O
, O O
have O O
been O O
discovered O O
in O O
a O O
large O O
number O O
of O O
eukaryotic O O
species O O
. O O
Judge O O
Christian O O
Byk O O
renders O O
service O O
to O O
the O O
Steering O O
Committee O O
on O O
Bioethics O O
of O O
the O O
Council O O
of O O
Europe O O
( O O
CDBI O O
) O O
by O O
proposing O O
a O O
draft O O
of O O
the O O
protocol O O
destined O O
to O O
fill O O
in O O
a O O
gap O O
in O O
international O O
law O O
on O O
the O O
status O O
of O O
the O O
human O O
embryo O O
. O O
Correlation O O
coefficients O O
between O O
SF O O
thickness O O
and O O
NIR O O
optical O O
density O O
readings O O
at O O
940 O O
nm O O
( O O
OD1 O O
) O O
and O O
950 O O
nm O O
( O O
OD2 O O
) O O
wavelengths O O
ranged O O
from O O
r O O
= O O
- O O
0 O O
. O O
30 O O
( O O
subscapula O O
) O O
to O O
r O O
= O O
- O O
0 O O
. O O
67 O O
( O O
biceps O O
) O O
for O O
OD1 O O
and O O
r O O
= O O
- O O
0 O O
. O O
39 O O
( O O
axilla O O
) O O
to O O
r O O
= O O
- O O
0 O O
. O O
68 O O
( O O
biceps O O
) O O
for O O
OD2 O O
. O O
We O O
found O O
both O O
the O O
v B-GENE O
- I-GENE O
Ras E-GENE O
- O O
and O O
PC B-GENE O
- I-GENE O
PLC E-GENE O
- O O
transformed O O
cells O O
to O O
be O O
insensitive O O
to O O
stimulation O O
with O O
platelet B-GENE B-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
PDGF S-GENE S-GENE
) O O
. O O
Analysis O O
of O O
domain O O
deletion O O
mutants O O
demonstrated O O
strong O O
synergy O O
between O O
the O O
RRM O S-GENE
and O O
a O O
central O O
degenerate O O
RRM O O
repeat O O
in O O
binding O O
to O O
RNA O O
. O O
Sequence O O
analysis O O
of O O
the O O
catfish O O
JH S-GENE B-GENE
- O I-GENE
CH S-GENE I-GENE
intron O E-GENE
suggests O O
that O O
several O O
sequences O O
are O O
present O O
which O O
appear O O
similar O O
to O O
important O O
transcriptional O O
regulatory O O
elements O O
found O O
within O O
JH S-GENE B-GENE
- O I-GENE
CH S-GENE I-GENE
introns O E-GENE
of O O
higher O O
vertebrates O O
. O O
The O O
patient O O
groups O O
consisted O O
of O O
31 O O
with O O
dilated O O
cardiomyopathy O O
, O O
22 O O
with O O
hypertrophic O O
cardiomyopathy O O
, O O
38 O O
with O O
myocardial O O
infarction O O
, O O
15 O O
with O O
angina O O
pectoris O O
and O O
26 O O
with O O
rheumatic O O
valvular O O
disease O O
. O O
100 O O
. O O
However O O
, O O
the O O
pre3 B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE E-GENE
mutation E-GENE O
strengthened O O
phenotypes O O
induced O O
by O O
other O O
20 B-GENE O
S I-GENE O
proteasomal I-GENE O
mutations E-GENE O
, O O
indicating O O
that O O
the O O
peptidylglutamyl O O
peptide O O
- O O
hydrolyzing O O
activity O O
has O O
to O O
fulfill O O
some O O
rescue O O
functions O O
. O O
Whereas O O
Sprague O O
- O O
Dawleys O O
displayed O O
lights O O
- O O
off O O
and O O
lights O O
- O O
on O O
peaks O O
of O O
ingestive O O
activity O O
, O O
only O O
a O O
minority O O
of O O
Fisher O O
- O O
344s O O
displayed O O
a O O
consistent O O
lights O O
- O O
on O O
peak O O
of O O
ingestive O O
activity O O
. O O
RESULTS O O
: O O
In O O
76 O O
trials O O
, O O
5 O O
, O O
351 O O
patients O O
received O O
24 O O
different O O
regimens O O
of O O
droperidol O O
. O O
The O O
tro B-GENE B-GENE
operon E-GENE E-GENE
is O O
flanked O O
by O O
a O O
Holliday B-GENE O
structure I-GENE O
DNA I-GENE B-GENE
helicase E-GENE I-GENE
homolog O E-GENE
( O O
upstream O O
) O O
and O O
two O O
ORFs O O
representing O O
a O O
purine B-GENE B-GENE
nucleoside I-GENE I-GENE
phosphorylase E-GENE I-GENE
homolog O E-GENE
and O O
tpp15 S-GENE S-GENE
, O O
a O O
previously O O
characterized O O
gene O O
encoding O O
a O O
membrane O O
lipoprotein O O
( O O
downstream O O
) O O
. O O
We O O
report O O
nine O O
consecutive O O
cases O O
of O O
ACB O O
, O O
which O O
occurred O O
in O O
five O O
males O O
and O O
four O O
females O O
and O O
were O O
detected O O
in O O
11 O O
, O O
159 O O
routine O O
spiral O O
CT O O
examinations O O
of O O
the O O
chest O O
, O O
performed O O
between O O
1994 O O
and O O
1998 O O
. O O
In O O
order O O
to O O
search O O
for O O
mutations O O
in O O
the O O
multicopy B-GENE B-GENE
RBM I-GENE I-GENE
genes E-GENE E-GENE
that O O
might O O
be O O
associated O O
with O O
male O O
infertility O O
, O O
we O O
have O O
used O O
sequence O O
data O O
from O O
the O O
reported O O
cDNA O O
clone O O
to O O
determine O O
the O O
intron O O
exon O O
boundaries O O
of O O
the O O
YRRM B-GENE B-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
. O O
98 O O
, O O
93 O O
- O O
98 O O
) O O
. O O
Studies O O
on O O
the O O
excretion O O
of O O
selenium O O
in O O
urine O O
and O O
feces O O
and O O
distribution O O
in O O
the O O
organs O O
of O O
rats O O
by O O
a O O
method O O
of O O
radioactivity O O
measurement O O
The O O
use O O
of O O
the O O
two O O
pharmacokinetic O O
parameters O O
, O O
t1 O O
/ O O
2 O O
and O O
Cltp O O
, O O
as O O
indices O O
of O O
drug O O
elimination O O
ability O O
are O O
discussed O O
. O O
Gastric O O
secretory O O
inhibition O O
induced O O
by O O
three O O
methyl O O
analogs O O
of O O
prostaglandin O O
E2 O O
administered O O
intragastrically O O
to O O
man O O
. O O
By O O
RT O O
- O O
PCR O O
, O O
different O O
levels O O
of O O
E75 S-GENE O
expression O O
can O O
be O O
detected O O
in O O
the O O
epidermis O O
, O O
nerve O O
cord O O
and O O
the O O
eyestalk O O
of O O
early O O
pre O O
- O O
molt O O
shrimp O O
. O O
The O O
vicinity O O
of O O
large O O
industrial O O
emissions O O
of O O
lead O O
, O O
where O O
mean O O
Pb O O
- O O
B O O
concentrations O O
were O O
usually O O
twice O O
as O O
high O O
as O O
in O O
rural O O
areas O O
of O O
the O O
Katowice O O
voivodship O O
. O O
Forty O O
- O O
five O O
per O O
cent O O
of O O
the O O
dose O O
was O O
excreted O O
as O O
methyldopa O O
as O O
opposed O O
to O O
18 O O
% O O
normally O O
seen O O
after O O
oral O O
methyldopa O O
dosages O O
. O O
No O O
cleavage O O
of O O
gp B-GENE O
130 E-GENE O
was O O
observed O O
in O O
analogous O O
pulse O O
- O O
chase O O
radiolabelling O O
of O O
Ad O O
- O O
gB S-GENE O
- O O
infected O O
human O O
fibroblasts O O
, O O
even O O
though O O
these O O
cells O O
are O O
permissive O O
for O O
HCMV O O
replication O O
and O O
can O O
process O O
the O O
native B-GENE O
gB I-GENE O
molecule E-GENE O
. O O
A O O
phylogenetic O O
comparison O O
of O O
32 O O
species O O
showed O O
minor O O
differences O O
in O O
the O O
apoB B-GENE B-GENE
mRNA I-GENE I-GENE
sequence E-GENE E-GENE
, O O
and O O
the O O
apoB B-GENE B-GENE
mRNA E-GENE E-GENE
from O O
31 O O
species O O
was O O
robustly O O
edited O O
in O O
vitro O O
. O O
The O O
other O O
five O O
from O O
within O O
the O O
SRO O O
may O O
provide O O
an O O
entrance O O
point O O
for O O
the O O
cloning O O
of O O
candidate O O
genes O O
for O O
neuroblastoma O O
. O O
Sugar O O
analysis O O
was O O
performed O O
on O O
alpha B-GENE B-GENE
- I-GENE I-GENE
TM E-GENE E-GENE
to O O
investigate O O
a O O
possible O O
biosynthetic O O
mechanism O O
for O O
part O O
- O O
time O O
PGs O O
. O O
Pediatric O O
patients O O
- O O
- O O
handle O O
with O O
care O O
. O O
These O O
include O O
the O O
genes O O
, O O
undefined B-GENE O
1 E-GENE O
( O O
UD1 S-GENE S-GENE
) O O
, O O
UD2 S-GENE S-GENE
, O O
and O O
UD3 S-GENE S-GENE
, O O
each O O
coding O O
for O O
proteins O O
of O O
unknown O O
function O O
, O O
the O O
ken B-GENE O
gene E-GENE O
encoding O O
a O O
new O O
Kruppel B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
putative I-GENE I-GENE
transcription I-GENE I-GENE
factor E-GENE E-GENE
, O O
the O O
fly O O
homologues O O
of O O
the O O
mammalian B-GENE B-GENE
mitochondrial I-GENE I-GENE
trifunctional I-GENE I-GENE
enzyme E-GENE E-GENE
( O O
thiolase S-GENE O
) O O
, O O
and O O
the O O
TAR B-GENE B-GENE
DNA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
43 E-GENE E-GENE
( O O
TBPH S-GENE S-GENE
) O O
, O O
the O O
first O O
nonvertebrate O O
member O O
of O O
the O O
transmembrane B-GENE B-GENE
4 I-GENE I-GENE
superfamily E-GENE E-GENE
( O O
TM4SF S-GENE S-GENE
) O O
gene O O
, O O
a O O
new O O
homeodomain B-GENE B-GENE
gene E-GENE E-GENE
, O O
and O O
a O O
gene O O
coding O O
for O O
a O O
putative O O
nuclear O O
binding O O
protein O O
( O O
PNBP O S-GENE
) O O
that O O
is O O
homologous O O
to O O
maleless S-GENE O
, O O
and O O
a O O
Copia B-GENE O
- I-GENE O
like I-GENE O
element E-GENE O
. O O
TRAF2 S-GENE S-GENE
has O O
previously O O
been O O
demonstrated O O
to O O
activate O O
both O O
transcription O O
factor O O
nuclear B-GENE O
factor I-GENE O
kappaB E-GENE S-GENE
( O O
NFkappaB S-GENE S-GENE
) O O
and O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
/ O O
stress B-GENE O
- I-GENE O
activated I-GENE B-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
JNK S-GENE S-GENE
/ O O
SAPK S-GENE S-GENE
) O O
pathway O O
, O O
which O O
in O O
turn O O
stimulates O B-GENE
transcription B-GENE I-GENE
factor I-GENE I-GENE
activating I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
( O O
AP1 S-GENE S-GENE
) O O
mainly O O
via O O
phosphorylation O O
of O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
component O O
. O O
A O O
procaryotic O O
regulatory O O
factor O O
with O O
a O O
histone B-GENE O
H1 I-GENE S-GENE
- I-GENE O
like I-GENE O
carboxy I-GENE O
- I-GENE O
terminal I-GENE O
domain E-GENE O
: O O
clonal O O
variation O O
of O O
repeats O O
within O O
algP S-GENE S-GENE
, O O
a O O
gene O O
involved O O
in O O
regulation O O
of O O
mucoidy O O
in O O
Pseudomonas O O
aeruginosa O O
. O O
The O O
host O O
range O O
( O O
HR O O
) O O
of O O
poliovirus O O
is O O
thought O O
to O O
be O O
primarily O O
determined O O
by O O
a O O
cell O O
surface O O
molecule O O
that O O
functions O O
as O O
poliovirus B-GENE B-GENE
receptor E-GENE E-GENE
( O O
PVR S-GENE S-GENE
) O O
, O O
since O O
it O O
has O O
been O O
shown O O
that O O
transgenic O O
mice O O
are O O
made O O
poliovirus O O
sensitive O O
by O O
introducing O O
the O O
human B-GENE B-GENE
PVR I-GENE I-GENE
gene E-GENE E-GENE
into O O
the O O
genome O O
. O O
Human B-GENE B-GENE
alcohol I-GENE I-GENE
dehydrogenase E-GENE E-GENE
( O O
ADH S-GENE S-GENE
) O O
exists O O
as O O
a O O
heterogeneous O O
group O O
of O O
isozymes O O
capable O O
of O O
oxidizing O O
a O O
wide O O
variety O O
of O O
aliphatic O O
and O O
aromatic O O
alcohols O O
. O O
The O O
control O O
of O O
human B-GENE O
aromatase E-GENE O
expression O O
is O O
complex O O
in O O
that O O
several O O
promoters O O
drive O O
aromatase S-GENE O
expression O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
. O O
In O O
addition O O
, O O
renal O O
sympathetic O O
activity O O
was O O
measured O O
in O O
a O O
separate O O
group O O
of O O
rats O O
. O O
This O O
incompatibility O O
phenotype O O
requires O O
the O O
global O O
transcriptional O O
repressor O O
, O O
KorB S-GENE S-GENE
, O O
and O O
the O O
target O O
for O O
incC S-GENE O
- O O
mediated O O
incompatibility O O
is O O
a O O
KorB B-GENE O
- I-GENE O
binding I-GENE O
site I-GENE O
( I-GENE O
O I-GENE O
( I-GENE O
B I-GENE O
) I-GENE O
) E-GENE O
. O O
Bodily O O
referents O O
and O O
the O O
experience O O
of O O
affect O O
. O O
The O O
effect O O
of O O
the O O
negative O O
regulatory O O
element O O
is O O
negated O O
by O O
the O O
viral B-GENE B-GENE
IE2 I-GENE I-GENE
protein E-GENE E-GENE
( O O
L O O
. O O
RXRalpha S-GENE S-GENE
/ O O
RARalpha S-GENE O
heterodimers O O
and O O
HNF B-GENE O
- I-GENE O
4 I-GENE O
homodimers E-GENE O
bind O O
to O O
DR O O
- O O
1 O O
motifs O O
on O O
elements O O
B O O
and O O
I4 O O
, O O
respectively O O
. O O
Evidence O O
for O O
involvement O O
of O O
proteins O O
HU S-GENE O
and O O
RpoS S-GENE S-GENE
in O O
transcription O O
of O O
the O O
osmoresponsive O O
proU B-GENE O
operon E-GENE O
in O O
Escherichia O O
coli O O
. O O
However O O
, O O
a O O
lesser O O
extent O O
effect O O
was O O
noticed O O
in O O
nonpregnant O O
than O O
seen O O
in O O
pregnant O O
rats O O
. O O
Morphine O O
administration O O
acutely O O
reduced O O
plasma O O
clearance O O
of O O
sulfobromophthalein O O
( O O
BSP O O
) O O
in O O
mice O O
and O O
increased O O
hepatic O O
retention O O
of O O
this O O
dye O O
. O O
Buchstein O O
, O O
L O O
. O O
- O O
L O O
. O O
Intraspinal O O
and O O
mediastinal O O
foregut O O
cyst O O
compressing O O
the O O
spinal O O
cord O O
. O O
The O O
nutraceuticals O O
of O O
specific O O
vitamins O O
, O O
minerals O O
, O O
phytoestrogens O O
, O O
and O O
essential O O
fatty O O
acid O O
supplementations O O
are O O
a O O
vital O O
component O O
of O O
the O O
risk O O
reduction O O
health O O
program O O
. O O
Characterization O O
of O O
a O O
unique O O
protein O O
component O O
of O O
yeast B-GENE B-GENE
RNase I-GENE I-GENE
MRP E-GENE E-GENE
: O O
an O O
RNA O O
- O O
binding O O
protein O O
with O O
a O O
zinc O O
- O O
cluster O O
domain O O
. O O
The O O
present O O
study O O
indicates O O
that O O
the O O
high O O
- O O
dose O O
5 O O
- O O
fluorouracil O O
regimen O O
shows O O
weak O O
activity O O
in O O
advanced O O
pancreatic O O
cancer O O
which O O
seems O O
comparable O O
to O O
gemcitabine O O
. O O
Like O O
the O O
nuclear O O
envelope O O
, O O
the O O
intranuclear O O
double O O
membrane O O
lamellae O O
enclosed O O
a O O
defined O O
cisterna O O
that O O
was O O
interrupted O O
by O O
pores O O
but O O
, O O
unlike O O
the O O
nuclear O O
envelope O O
pores O O
, O O
they O O
lacked O O
NPCs O O
. O O
The O O
22 O O
- O O
d O O
orbital O O
flight O O
of O O
rats O O
onboard O O
the O O
Cosmos O O
- O O
605 O O
biosatellite O O
was O O
followed O O
by O O
inhibition O O
of O O
erythroblastosis O O
, O O
alteration O O
in O O
the O O
morphology O O
of O O
megakaryocytes O O
, O O
and O O
stimulation O O
of O O
myelopoiesis O O
. O O
An O O
OD O O
650 O O
greater O O
than O O
0 O O
. O O
15 O O
appears O O
to O O
be O O
a O O
rapid O O
, O O
reliable O O
indicator O O
of O O
fetal O O
lung O O
maturity O O
. O O
The O O
role O O
of O O
PORT O O
in O O
the O O
treatment O O
of O O
N2 O O
tumours O O
is O O
not O O
clear O O
and O O
may O O
justify O O
further O O
research O O
. O O
We O O
concluded O O
that O O
RXR B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
induced O O
terminal O O
differentiation O O
in O O
SCC O O
lines O O
, O O
suggesting O O
a O O
potential O O
tumor O O
suppressor O O
function O O
for O O
this O O
transcription O O
factor O O
. O O
Phosphorylated O O
tyrosine O O
residues O O
were O O
subsequently O O
identified O O
by O O
sequencing O O
the O O
separated O O
phosphopeptides O O
by O O
matrix O O
assisted O O
laser O O
desorption O O
ionization O O
mass O O
spectrometry O O
( O O
MALDI O O
- O O
MS O O
) O O
and O O
Edman O O
degradation O O
. O O
The O O
infection O O
of O O
cells O O
with O O
Moloney O O
murine O O
leukemia O O
virus O O
( O O
M O O
- O O
MuLV O O
) O O
causes O O
an O O
increase O O
in O O
specific O O
cellular O O
gene O O
products O O
, O O
including O O
the O O
major B-GENE O
histocompatibility I-GENE O
complex I-GENE O
( I-GENE O
MHC I-GENE S-GENE
) I-GENE O
class I-GENE O
I I-GENE O
antigens E-GENE O
. O O
These O O
data O O
demonstrate O O
that O O
oleosin B-GENE B-GENE
gene E-GENE E-GENE
transcription O O
is O O
regulated O O
in O O
a O O
tissue O O
- O O
specific O O
and O O
temporally O O
regulated O O
manner O O
and O O
clearly O O
indicate O O
that O O
oleosin B-GENE B-GENE
protein E-GENE E-GENE
expression O O
is O O
co O O
- O O
ordinated O O
primarily O O
at O O
the O O
transcriptional O O
level O O
. O O
Myocardial O O
technetium O O
- O O
99m O O
- O O
teboroxime O O
uptake O O
during O O
adenosine O O
- O O
induced O O
hyperemia O O
in O O
dogs O O
with O O
either O O
a O O
critical O O
or O O
mild O O
coronary O O
stenosis O O
: O O
comparison O O
to O O
thallium O O
- O O
201 O O
and O O
regional O O
blood O O
flow O O
. O O
UICC O S-GENE
criteria O O
) O O
for O O
VM O O
and O O
35 O O
% O O
for O O
VE O O
( O O
not O O
significant O O
) O O
. O O
Although O O
immunoglobulin S-GENE O
and O O
CRP S-GENE S-GENE
concentration O O
increased O O
, O O
anemia O O
obviously O O
improved O O
with O O
hemoglobin S-GENE O
levels O O
increasing O O
from O O
4 O O
. O O
8 O O
g O O
/ O O
dl O O
to O O
8 O O
. O O
5 O O
g O O
/ O O
dl O O
without O O
any O O
side O O
effects O O
. O O
Diff O O
- O O
Quik O O
stain O O
for O O
Tzanck O O
smears O O
. O O
Experience O O
in O O
using O O
the O O
Romashka O O
- O O
1 O O
laser O O
surgical O O
unit O O
in O O
treating O O
suppurative O O
wounds O O
At O O
D28 O O
, O O
149 O O
of O O
386 O O
patients O O
( O O
49 O O
% O O
) O O
had O O
had O O
episodes O O
of O O
automatic O O
mode O O
switch O O
prompted O O
by O O
atrial O O
arrhythmias O O
. O O
Together O O
, O O
these O O
results O O
implicate O O
Fal1p S-GENE S-GENE
in O O
the O O
18S B-GENE B-GENE
rRNA E-GENE E-GENE
maturation O O
pathway O O
rather O O
than O O
in O O
translation O O
initiation O O
. O O
Most O O
other O O
differences O O
between O O
these O O
two O O
Leporipoxviruses O O
are O O
located O O
in O O
the O O
telomeres O O
. O O
We O O
challenge O O
each O O
of O O
55 O O
consecutive O O
ragweed O O
( O O
RW O O
) O O
- O O
allergic O O
patients O O
with O O
hay O O
fever O O
and O O
with O O
graded O O
increasing O O
doses O O
of O O
ragweed O O
extract O O
to O O
investigate O O
the O O
frequency O O
and O O
relationship O O
between O O
the O O
early O O
( O O
ER O O
) O O
, O O
late O O
( O O
LPR O O
) O O
, O O
and O O
rechallenge O O
reactions O O
( O O
RCRs O O
) O O
to O O
nasal O O
challenge O O
. O O
The O O
expression O O
of O O
CAPL S-GENE S-GENE
, O O
a O O
second O O
protein O O
involved O O
in O O
calcium O O
metabolism O O
, O O
was O O
only O O
moderately O O
elevated O O
in O O
the O O
doxorubicin O O
- O O
resistant O O
cells O O
. O O
The O O
central O O
region O O
of O O
the O O
sarcomere O O
, O O
coincident O O
with O O
the O O
M O O
line O O
, O O
was O O
selectively O O
labeled O O
with O O
antibodies O O
to O O
the O O
short O O
C O O
- O O
terminal O O
form O O
. O O
Despite O O
this O O
dependency O O
, O O
however O O
, O O
a O O
B B-GENE O
. I-GENE O
japonicum I-GENE B-GENE
fixK I-GENE I-GENE
mutant E-GENE E-GENE
did O O
not O O
have O O
the O O
phenotypic O O
characteristics O O
of O O
B B-GENE O
. I-GENE O
japonicum I-GENE O
fixL E-GENE S-GENE
and O O
fixJ B-GENE B-GENE
mutants E-GENE E-GENE
: O O
the O O
fixK B-GENE B-GENE
mutant E-GENE E-GENE
was O O
neither O O
Fix O O
- O O
in O O
symbiosis O O
with O O
soybean O O
plants O O
nor O O
defective O O
in O O
anaerobic O O
respiration O O
with O O
nitrate O O
as O O
the O O
terminal O O
electron O O
acceptor O O
. O O
ANL O B-GENE
- O I-GENE
7535 O E-GENE
. O O
The O O
QCS O O
appears O O
comparable O O
with O O
the O O
MMSE O O
and O O
is O O
quicker O O
to O O
administer O O
. O O
We O O
used O O
high O O
- O O
resolution O O
ultrasound O O
to O O
characterize O O
postprandial O O
antral O O
excursion O O
characteristics O O
in O O
15 O O
healthy O O
volunteers O O
. O O
Copyright O O
1998 O O
Academic O O
Press O O
. O O
Human B-GENE B-GENE
PDNP3 E-GENE E-GENE
is O O
expressed O O
in O O
glioma O O
cells O O
, O O
prostate O O
, O O
and O O
uterus O O
, O O
but O O
not O O
in O O
the O O
alimentary O O
tract O O
. O O
Epithelial O O
cells O O
had O O
abnormal O O
and O O
accelerated O O
exfoliation O O
which O O
resulted O O
in O O
multifocal O O
epithelial O O
defects O O
. O O
Tight O O
- O O
binding O O
band O O
structure O O
calculations O O
for O O
beta O O
- O O
MNX O O
( O O
M O O
= O O
Zr O O
, O O
X O O
= O O
Cl O O
, O O
Br O O
; O O
M O O
= O O
Hf O O
, O O
X O O
= O O
Cl O O
) O O
, O O
ZrCl O O
, O O
and O O
Y O O
( O O
2 O O
) O O
C O O
( O O
2 O O
) O O
Br O O
( O O
2 O O
) O O
are O O
reported O O
. O O
Screening O O
of O O
a O O
human O O
foetal O O
brain O O
genomic O O
DNA O O
library O O
allowed O O
us O O
to O O
isolate O O
an O O
EcoRI S-GENE O
- O O
EcoRI S-GENE O
fragment O O
containing O O
6 O O
kb O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
, O O
the O O
open O O
reading O O
frame O O
and O O
4 O O
kb O O
of O O
the O O
3 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
alpha2C4 B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
psychosomatic O O
approach O O
to O O
temporomandibular O O
arthrosis O O
The O O
rate O O
of O O
decrease O O
of O O
PRA O O
after O O
REM O O
onset O O
closely O O
approximates O O
the O O
most O O
recent O O
estimations O O
of O O
PRA O O
half O O
- O O
life O O
, O O
which O O
suggests O O
that O O
REM O O
onset O O
is O O
associated O O
with O O
a O O
virtual O O
cessation O O
in O O
renin S-GENE O
production O O
. O O
Similarly O O
, O O
interfering O O
with O O
MEKK S-GENE S-GENE
, O O
which O O
lies O O
upstream O O
of O O
JNK1 S-GENE S-GENE
, O O
using O O
a O O
dominant O O
negative O O
expression O O
vector O O
reduced O O
MMP B-GENE B-GENE
- I-GENE I-GENE
9 I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
over O O
the O O
same O O
concentration O O
range O O
which O O
repressed O O
the O O
AP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE I-GENE
- O I-GENE
thymidine B-GENE I-GENE
kinase E-GENE E-GENE
CAT S-GENE O
reporter O O
construct O O
. O O
There O O
was O O
no O O
difference O O
in O O
serum B-GENE O
albumin E-GENE O
and O O
transferrin S-GENE O
levels O O
, O O
but O O
serum B-GENE O
prealbumin E-GENE O
levels O O
in O O
the O O
group O O
fed O O
early O O
were O O
more O O
desirable O O
than O O
those O O
of O O
the O O
control O O
group O O
( O O
from O O
15 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
mg O O
/ O O
dl O O
to O O
28 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
8 O O
mg O O
/ O O
dl O O
vs O O
from O O
18 O O
. O O
0 O O
+ O O
/ O O
- O O
2 O O
. O O
0 O O
mg O O
/ O O
dl O O
to O O
25 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
9 O O
mg O O
/ O O
dl O O
) O O
. O O
The O O
repeats O O
are O O
highly O O
conserved O O
both O O
within O O
a O O
given O O
element O O
as O O
well O O
as O O
between O O
different O O
members O O
of O O
the O O
family O O
( O O
less O O
than O O
10 O O
% O O
divergence O O
) O O
. O O
Utility O O
of O O
thallium O O
- O O
201 O O
scintigraphy O O
in O O
detecting O O
right O O
ventricular O O
dysfunction O O
in O O
pulmonary O O
embolism O O
. O O
CONCLUSIONS O O
: O O
The O O
system O O
developed O O
in O O
this O O
study O O
can O O
be O O
used O O
as O O
a O O
method O O
to O O
detect O O
air O O
- O O
trapping O O
during O O
TGI O O
. O O
The O O
carboxyl O O
- O O
terminal O O
75 O O
amino O O
acids O O
of O O
the O O
two O O
proteins O O
contain O O
the O O
bHLH O B-GENE
motif O E-GENE
and O O
differ O O
from O O
each O O
other O O
by O O
only O O
three O O
conservative O O
amino O O
acid O O
changes O O
, O O
while O O
the O O
amino O O
- O O
terminal O O
portions O O
are O O
markedly O O
divergent O O
from O O
each O O
other O O
. O O
In O O
a O O
rat O O
model O O
of O O
SAH O O
, O O
we O O
assessed O O
BBB O O
changes O O
by O O
means O O
of O O
the O O
quantitative O O
[ O O
14C O O
] O O
- O O
alpha O O
- O O
aminoisobutyric O O
acid O O
technique O O
. O O
Pollinosis O O
in O O
the O O
U O O
. O O
A O O
. O O
R O O
. O O
Northern O O
blot O O
analysis O O
of O O
enoyl B-GENE B-GENE
- I-GENE I-GENE
ACP I-GENE I-GENE
reductase I-GENE I-GENE
mRNA E-GENE E-GENE
steady O O
- O O
state O O
levels O O
during O O
seed O O
development O O
suggests O O
that O O
the O O
increase O O
in O O
enzyme O O
activity O O
during O O
the O O
phase O O
of O O
storage O O
lipid O O
accumulation O O
is O O
regulated O O
at O O
the O O
level O O
of O O
gene O O
expression O O
. O O
Time O O
between O O
tests O O
( O O
usually O O
less O O
than O O
one O O
year O O
) O O
did O O
not O O
affect O O
the O O
correlations O O
, O O
but O O
MMPI O O
response O O
- O O
set O O
variables O O
( O O
L O O
, O O
F O O
, O O
K O O
, O O
F O O
- O O
K O O
) O O
did O O
. O O
The O O
differences O O
in O O
binding O O
( O O
Kdapp O O
) O O
, O O
incorporation O O
, O O
and O O
extension O O
kinetics O O
of O O
8 O O
- O O
oxo O O
- O O
dGTP O O
compared O O
to O O
normal O O
dNTP O O
incorporation O O
at O O
template O O
8 O O
- O O
oxo O O
- O O
G O O
adducts O O
indicate O O
that O O
polymerase O O
fidelity O O
does O O
not O O
depend O O
solely O O
upon O O
the O O
overall O O
geometry O O
of O O
Watson O O
- O O
Crick O O
base O O
pairs O O
and O O
reflects O O
the O O
asymmetry O O
of O O
the O O
enzyme O O
active O O
site O O
. O O
This O O
constant O O
expression O O
profile O O
, O O
coupled O O
with O O
the O O
observation O O
that O O
over O O
- O O
expression O O
of O O
mSin3A S-GENE S-GENE
does O O
not O O
augment O O
the O O
anti B-GENE B-GENE
- I-GENE I-GENE
Myc E-GENE E-GENE
activity O O
of O O
Mxi1 S-GENE B-GENE
- O I-GENE
SR O E-GENE
in O O
the O O
rat O B-GENE
embryo O I-GENE
fibroblast O E-GENE
( O O
REF O S-GENE
) O O
transformation O O
assay O O
, O O
suggests O O
that O O
mSin3A S-GENE S-GENE
is O O
not O O
a O O
limiting O O
factor O O
in O O
the O O
regulation O O
of O O
Myc B-GENE B-GENE
superfamily E-GENE E-GENE
function O O
. O O
The O O
sequences O O
at O O
- O O
10 O O
and O O
- O O
35 O O
relative O O
to O O
the O O
transcriptional O O
starting O O
site O O
showed O O
55 O O
% O O
homology O O
with O O
the O O
consensus O O
sequences O O
of O O
the O O
Escherichia B-GENE O
coli I-GENE O
sigma I-GENE O
70 I-GENE O
- I-GENE O
type I-GENE O
promoter E-GENE O
. O O
The O O
results O O
were O O
subjected O O
to O O
analysis O O
of O O
23 O O
autopsies O O
carried O O
out O O
in O O
children O O
dying O O
of O O
intoxication O O
with O O
Amanita O O
phalloides O O
. O O
METHODS O O
: O O
The O O
Die O O
Deutsche O O
Diabetes O O
Dialyse O O
Studie O O
is O O
a O O
prospective O O
randomized O O
placebo O O
- O O
controlled O O
trial O O
that O O
tests O O
the O O
hypothesis O O
that O O
atorvastatin O O
, O O
a O O
hydroxymethyl B-GENE O
- I-GENE O
glutaryl I-GENE O
coenzyme I-GENE O
A I-GENE O
reductase E-GENE O
inhibitor O O
, O O
decreases O O
the O O
rate O O
of O O
cardiovascular O O
mortality O O
and O O
of O O
nonfatal O O
myocardial O O
infarction O O
in O O
patients O O
with O O
type O O
2 O O
diabetes O O
who O O
have O O
been O O
on O O
hemodialysis O O
treatment O O
for O O
no O O
more O O
than O O
two O O
years O O
. O O
There O O
was O O
no O O
significant O O
correlation O O
between O O
serum O O
amiodarone O O
or O O
desethylamiodarone O O
levels O O
and O O
dosage O O
of O O
amiodarone O O
. O O
The O O
effect O O
of O O
monaural O O
middle O O
ear O O
destruction O O
on O O
postnatal O O
development O O
of O O
mouse O O
inferior O O
colliculus O O
. O O
This O O
unusual O O
behaviour O O
may O O
be O O
explained O O
by O O
the O O
18 B-GENE O
amino I-GENE O
acid I-GENE O
- I-GENE O
long I-GENE O
CDR I-GENE O
- I-GENE O
H3 E-GENE O
and O O
could O O
be O O
of O O
value O O
in O O
the O O
design O O
of O O
' O O
single O O
domain O O
' O O
antibodies O O
. O O
A O O
definitive O O
answer O O
to O O
the O O
question O O
must O O
come O O
from O O
large O O
scale O O
mortality O O
studies O O
of O O
patients O O
in O O
whom O O
the O O
risk O O
/ O O
benefit O O
ratio O O
of O O
thrombolysis O O
is O O
not O O
unacceptably O O
high O O
, O O
in O O
whom O O
electrocardiographic O O
criteria O O
of O O
infarction O O
are O O
unequivocal O O
, O O
and O O
in O O
whom O O
treatment O O
can O O
be O O
initiated O O
early O O
after O O
the O O
onset O O
of O O
symptoms O O
with O O
regimens O O
that O O
will O O
induce O O
not O O
only O O
early O O
recanalization O O
, O O
but O O
also O O
sustained O O
patency O O
in O O
infarct O O
- O O
related O O
arteries O O
. O O
Parameters O O
of O O
sperm O O
quality O O
were O O
evaluated O O
before O O
and O O
after O O
freezing O O
/ O O
thawing O O
. O O
It O O
has O O
also O O
been O O
previously O O
demonstrated O O
that O O
LPS O O
treatment O O
of O O
splenic O O
B O O
cells O O
from O O
athymic O O
mice O O
results O O
in O O
a O O
decrease O O
in O O
steady O O
state O O
mRNA O O
encoding O O
the O O
A B-GENE O
alpha I-GENE B-GENE
class I-GENE I-GENE
II I-GENE I-GENE
protein E-GENE E-GENE
. O O
Amongst O O
53 O O
" O O
inoperable O O
" O O
( O O
T4 O O
, O O
N0 O O
, O O
N1 O O
, O O
T O O
. O O
, O O
N2 O O
, O O
N3 O O
) O O
cases O O
, O O
5 O O
( O O
10 O O
% O O
) O O
had O O
a O O
positive O O
scan O O
and O O
5 O O
a O O
doubtful O O
scan O O
. O O
Chemical O O
structure O O
of O O
antibiotic O O
SF O O
- O O
837 O O
. O O
Aspirin O O
therapy O O
in O O
the O O
rheumatic O O
diseases O O
. O O
Is O O
conventional O O
sperm O O
analysis O O
of O O
any O O
use O O
? O O
The O O
computerised O O
records O O
of O O
867 O O
couples O O
were O O
used O O
to O O
investigate O O
the O O
prognostic O O
significance O O
of O O
semen O O
volume O O
, O O
motility O O
, O O
density O O
and O O
morphology O O
. O O
It O O
was O O
observed O O
that O O
muscle O O
infarction O O
in O O
the O O
IPC O O
( O O
24 O O
+ O O
/ O O
- O O
2 O O
% O O
) O O
and O O
preischemic O O
LMK O O
( O O
21 O O
+ O O
/ O O
- O O
2 O O
% O O
) O O
groups O O
were O O
smaller O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
than O O
that O O
in O O
the O O
control O O
( O O
42 O O
+ O O
/ O O
- O O
2 O O
% O O
) O O
. O O
High O O
- O O
affinity O O
binding O O
was O O
also O O
observed O O
with O O
recombinant B-GENE B-GENE
SH2 I-GENE I-GENE
domains E-GENE E-GENE
from O O
v B-GENE B-GENE
- I-GENE I-GENE
src E-GENE E-GENE
and O O
v B-GENE B-GENE
- I-GENE I-GENE
fps E-GENE E-GENE
, O O
raising O O
the O O
possibility O O
of O O
protein O O
- O O
protein O O
interactions O O
between O O
various O O
members O O
of O O
the O O
cytoplasmic B-GENE B-GENE
PTK I-GENE I-GENE
family E-GENE E-GENE
. O O
Mutational O O
analysis O O
of O O
the O O
putative O O
effector O O
domain O O
of O O
the O O
GTP B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
Ypt1 I-GENE I-GENE
protein E-GENE E-GENE
in O O
yeast O O
suggests O O
specific O O
regulation O O
by O O
a O O
novel O O
GAP S-GENE O
activity O O
. O O
The O O
interaction O O
obtained O O
with O O
DBM O O
scores O O
was O O
further O O
qualified O O
by O O
a O O
three O O
- O O
way O O
interaction O O
that O O
limited O O
this O O
pattern O O
to O O
participants O O
scoring O O
higher O O
on O O
self O O
- O O
deception O O
. O O
The O O
broad O O
range O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
inhibitor O O
genistein O O
and O O
the O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
inhibitors O O
wortmannin O O
and O O
LY O B-GENE
294002 O E-GENE
( O O
2 O O
- O O
( O O
4 O O
- O O
morpholinyl O O
) O O
- O O
8 O O
- O O
phenyl O O
- O O
4H O O
- O O
1 O O
- O O
benzopyran O O
- O O
4 O O
- O O
one O O
) O O
also O O
blocked O O
adenosine B-GENE B-GENE
A3 I-GENE I-GENE
receptor E-GENE E-GENE
stimulation O O
of O O
p42 S-GENE S-GENE
/ O O
p44 S-GENE O
MAPK O S-GENE
. O O
Surprisingly O O
, O O
although O O
Mist1 S-GENE O
binds O O
to O O
E O O
- O O
boxes O O
in O O
vivo O O
, O O
the O O
Mist1 B-GENE B-GENE
protein E-GENE E-GENE
lacks O O
a O O
functional O O
transcription O O
activation O O
domain O O
. O O
As O O
exogenously O O
expressed O O
PKR S-GENE S-GENE
can O O
form O O
heterodimers O O
with O O
endogenous B-GENE O
PKR E-GENE S-GENE
, O O
the O O
results O O
obtained O O
on O O
the O O
functional O O
characterization O O
of O O
mutant O O
forms O O
of O O
PKR S-GENE S-GENE
have O O
been O O
taken O O
with O O
caution O O
. O O
Orlistat O O
is O O
a O O
specific O O
lipase S-GENE O
inhibitor O O
that O O
impairs O O
fat O O
absorption O O
, O O
thereby O O
reducing O O
fat O O
uptake O O
. O O
The O O
metalloproteinase S-GENE O
mediating O O
Met S-GENE O
cleavage O O
was O O
specifically O O
inhibited O O
by O O
the O O
tissue B-GENE O
inhibitor I-GENE O
of I-GENE O
metalloproteinases I-GENE O
( I-GENE O
TIMP I-GENE O
) I-GENE O
- I-GENE O
3 E-GENE O
, O O
but O O
not O O
by O O
TIMP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
or O O
TIMP B-GENE O
- I-GENE O
2 E-GENE O
. O O
This O O
demonstrates O O
a O O
relative O O
independence O O
of O O
the O O
given O O
synchronizer O O
of O O
rhythmicity O O
at O O
a O O
tissue O O
level O O
from O O
any O O
influence O O
of O O
the O O
higher O O
regulatory O O
center O O
. O O
It O O
is O O
also O O
conceivable O O
that O O
elevated O O
insulin S-GENE O
levels O O
may O O
cause O O
hypertriglyceridaemia O O
and O O
possibly O O
other O O
abnormalities O O
of O O
lipid O O
metabolism O O
. O O
Flicker O O
thresholds O O
were O O
measured O O
from O O
1 O O
to O O
40 O O
Hz O O
with O O
a O O
vertical O O
- O O
line O O
target O O
used O O
for O O
the O O
asynchrony O O
thresholds O O
. O O
The O O
clr1 B-GENE B-GENE
locus E-GENE E-GENE
regulates O O
the O O
expression O O
of O O
the O O
cryptic B-GENE O
mating I-GENE O
- I-GENE O
type I-GENE O
loci I-GENE O
of I-GENE O
fission I-GENE O
yeast E-GENE O
. O O
Use O O
of O O
ELISAs O O
for O O
the O O
diagnosis O O
of O O
canine O O
atopy O O
. O O
A O O
clinical O O
study O O
. O O
METHODS O O
. O O
Instead O O
, O O
HBx S-GENE S-GENE
is O O
shown O O
to O O
activate O O
the O O
cyclin B-GENE B-GENE
A I-GENE I-GENE
promoter E-GENE E-GENE
, O O
induce O O
cyclin B-GENE B-GENE
A E-GENE I-GENE
- O I-GENE
cyclin B-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase I-GENE E-GENE
2 E-GENE O
complexes O O
, O O
and O O
promote O O
cycling O O
of O O
growth O O
- O O
arrested O O
cells O O
into O O
G1 O O
through O O
a O O
pathway O O
involving O O
activation O O
of O O
Src B-GENE B-GENE
tyrosine I-GENE I-GENE
kinases E-GENE E-GENE
. O O
Growth B-GENE O
hormone E-GENE O
exerts O O
its O O
effects O O
on O O
the O O
ovarian O O
follicular O O
cycle O O
directly O O
or O O
by O O
local O O
production O O
of O O
insulin B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
( O O
IGF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
. O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
impact O O
of O O
the O O
ESRD O O
treatment O O
modality O O
on O O
the O O
quality O O
of O O
life O O
in O O
patients O O
with O O
Type O O
I O O
( O O
insulin S-GENE O
- O O
dependent O O
) O O
diabetes O O
mellitus O O
. O O
The O O
subjects O O
were O O
started O O
on O O
indomethacin O O
25 O O
mg O O
thrice O O
daily O O
. O O
A O O
Buddhist O O
view O O
of O O
abortion O O
. O O
The O O
arterial O O
blood O O
pressure O O
was O O
measured O O
by O O
using O O
bloody O O
method O O
in O O
anesthizied O O
animals O O
. O O
After O O
15 O O
min O O
of O O
hemorrhage O O
the O O
cardiovascular O O
parameters O O
were O O
the O O
same O O
in O O
fed O O
and O O
starved O O
animals O O
, O O
but O O
at O O
45 O O
min O O
striking O O
differences O O
were O O
observed O O
. O O
Decidual B-GENE O
/ I-GENE O
trophoblast I-GENE O
prolactin I-GENE O
- I-GENE O
related I-GENE O
protein E-GENE O
: O O
characterization O O
of O O
gene O O
structure O O
and O O
cell O O
- O O
specific O O
expression O O
. O O
Fluorescence O O
in O O
situ O O
hybridization O O
was O O
used O O
to O O
investigate O O
the O O
physical O O
distribution O O
and O O
revealed O O
that O O
both O O
retrotransposon O O
families O O
are O O
present O O
on O O
all O O
sugar O O
beet O O
chromosomes O O
and O O
largely O O
excluded O O
from O O
chromosomal O O
regions O O
harbouring O O
the O O
18S S-GENE B-GENE
- O I-GENE
5 B-GENE I-GENE
. I-GENE I-GENE
8S E-GENE I-GENE
- O I-GENE
25S S-GENE I-GENE
rRNA O I-GENE
genes O E-GENE
. O O
Plasma O O
NE O O
and O O
E O O
increased O O
to O O
significantly O O
higher O O
values O O
after O O
15 O O
min O O
in O O
the O O
young O O
subjects O O
: O O
1 O O
. O O
68 O O
+ O O
/ O O
- O O
0 O O
. O O
18 O O
vs O O
. O O
An O O
insertion O O
sequence O O
element O O
( O O
IS1170 O S-GENE
) O O
was O O
identified O O
upstream O O
of O O
the O O
nimC B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
organelles O O
synthesize O O
their O O
own O O
set O O
of O O
Fe B-GENE B-GENE
/ I-GENE I-GENE
S I-GENE I-GENE
proteins E-GENE E-GENE
, O O
and O O
they O O
initiate O O
the O O
generation O O
of O O
extramitochondrial B-GENE B-GENE
Fe I-GENE I-GENE
/ I-GENE I-GENE
S I-GENE I-GENE
proteins E-GENE E-GENE
. O O
Most O O
significantly O O
, O O
the O O
cyclin B-GENE B-GENE
E E-GENE I-GENE
- O I-GENE
Cdk2 S-GENE I-GENE
complex O E-GENE
is O O
maximally O O
active O O
at O O
the O O
G1 O O
/ O O
S O O
transition O O
, O O
and O O
overexpression O O
of O O
cyclin B-GENE B-GENE
E E-GENE E-GENE
decreases O O
the O O
time O O
it O O
takes O O
the O O
cell O O
to O O
complete O O
G1 O O
and O O
enter O O
S O O
phase O O
. O O
A O O
genomic O O
clone O O
of O O
the O O
chicken B-GENE B-GENE
osteopontin I-GENE I-GENE
- I-GENE I-GENE
encoding I-GENE I-GENE
gene E-GENE E-GENE
( O O
opn S-GENE S-GENE
) O O
was O O
isolated O O
and O O
found O O
to O O
be O O
organized O O
as O O
follows O O
: O O
an O O
untranslated O O
5 O O
' O O
exon O O
; O O
a O O
signal O O
peptide O O
; O O
a O O
recognition O O
sequence O O
for O O
phosphorylation O O
by O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
; O O
a O O
domain O O
containing O O
a O O
possible O O
O O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
a O O
second O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
II I-GENE E-GENE
phosphorylation I-GENE O
site E-GENE O
; O O
an O O
exon O O
containing O O
three O O
functional O O
regions O O
, O O
the O O
poly O O
- O O
Asp O O
sequence O O
of O O
seven O O
consecutive O O
Asp O O
residues O O
, O O
the O O
RGD B-GENE B-GENE
integrin I-GENE E-GENE
recognition I-GENE O
site E-GENE O
and O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
; O O
and O O
a O O
large O O
C O O
- O O
terminal O O
exon O O
which O O
also O O
contains O O
a O O
potential O O
N O O
- O O
linkage O O
site O O
for O O
glycosylation O O
. O O
However O O
, O O
neither O O
SF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
nor O O
NGF B-GENE B-GENE
- I-GENE I-GENE
IB E-GENE E-GENE
alone O O
, O O
binding O O
as O O
monomers O O
, O O
increases O O
transcription O O
. O O
Satisfactory O O
correlation O O
was O O
also O O
obtained O O
between O O
the O O
in O O
vivo O O
and O O
the O O
in O O
vitro O O
results O O
. O O
Structural O O
organization O O
of O O
the O O
human B-GENE B-GENE
Elk1 I-GENE I-GENE
gene E-GENE E-GENE
and O O
its O O
processed O O
pseudogene B-GENE O
Elk2 E-GENE S-GENE
. O O
After O O
cumulative O O
occlusions O O
of O O
15 O O
, O O
30 O O
, O O
45 O O
, O O
and O O
90 O O
min O O
, O O
transmural O O
needle O O
biopsies O O
were O O
taken O O
from O O
the O O
ischemic O O
area O O
to O O
be O O
analyzed O O
for O O
adenine O O
nucleotides O O
, O O
nucleosides O O
, O O
creatine O O
phosphate O O
, O O
and O O
ultrastructural O O
changes O O
. O O
The O O
prevalence O O
of O O
ocular O O
/ O O
adnexal O O
SCC O O
was O O
significantly O O
greater O O
for O O
all O O
hair O O
colors O O
when O O
compared O O
with O O
bay O O
, O O
brown O O
, O O
or O O
black O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O
Seven O O
patients O O
were O O
without O O
a O O
syndromic O O
diagnosis O O
. O O
In O O
treatments O O
R1 O O
and O O
R2 O O
, O O
feed O O
quality O O
was O O
restricted O O
by O O
withholding O O
concentrates O O
for O O
3 O O
and O O
4 O O
. O O
5 O O
mo O O
, O O
respectively O O
. O O
In O O
addition O O
, O O
while O O
GCN1 S-GENE S-GENE
is O O
required O O
in O O
vivo O O
for O O
phosphorylation O O
of O O
eIF B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
alpha E-GENE E-GENE
by O O
GCN2 S-GENE S-GENE
, O O
cell O O
extracts O O
from O O
gcn1 B-GENE O
delta E-GENE O
strains O O
contained O O
wild O O
- O O
type O O
levels O O
of O O
GCN2 S-GENE B-GENE
eIF B-GENE I-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
alpha E-GENE I-GENE
- O I-GENE
kinase O E-GENE
activity O O
. O O
SCOF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
localized O O
to O O
the O O
nucleus O O
but O O
did O O
not O O
bind O O
directly O O
to O O
either O O
C O O
- O O
repeat O O
/ O O
dehydration O O
( O O
CRT O O
/ O O
DRE O O
) O O
or O O
ABA O O
responsive O O
element O O
( O O
ABRE O O
) O O
, O O
cis O O
- O O
acting O O
DNA O O
regulatory O O
elements O O
present O O
in O O
COR B-GENE B-GENE
gene I-GENE E-GENE
promoters E-GENE O
. O O
On O O
the O O
basis O O
of O O
these O O
findings O O
we O O
suggest O O
that O O
the O O
acceptor O O
peptide O O
binds O O
the O O
transferase O O
in O O
a O O
beta O O
- O O
like O O
conformation O O
and O O
that O O
penultimate O O
residue O O
side O O
chain O O
steric O O
interactions O O
may O O
play O O
a O O
role O O
in O O
determining O O
extent O O
that O O
a O O
given O O
Ser O O
or O O
Thr O O
is O O
glycosylated O O
. O O
The O O
concentration O O
of O O
vitamin O O
B1 O O
, O O
B2 O O
and O O
B6 O O
are O O
found O O
to O O
be O O
9 O O
. O O
96 O O
, O O
9 O O
. O O
92 O O
and O O
3 O O
. O O
01 O O
mg O O
, O O
respectively O O
in O O
240 O O
mg O O
of O O
capsule O O
powder O O
of O O
a O O
standard O O
company O O
( O O
name O O
has O O
not O O
been O O
disclosed O O
due O O
to O O
secrecy O O
purpose O O
) O O
. O O
Polymorphisms O O
in O O
the O O
CCR5 B-GENE B-GENE
genes E-GENE E-GENE
of O O
African O O
green O O
monkeys O O
and O O
mice O O
implicate O O
specific O O
amino O O
acids O O
in O O
infections O O
by O O
simian O O
and O O
human O O
immunodeficiency O O
viruses O O
. O O
Furthermore O O
, O O
we O O
detect O O
hCoch B-GENE O
- I-GENE O
5B2 E-GENE O
on O O
three O O
overlapping O O
YACs O O
, O O
two O O
of O O
which O O
also O O
contain O O
one O O
of O O
the O O
markers O O
linked O O
to O O
DFNA9 S-GENE O
. O O
mCoch B-GENE B-GENE
- I-GENE I-GENE
5B2 E-GENE E-GENE
was O O
genetically O O
mapped O O
in O O
the O O
mouse O O
to O O
chromosome O O
12 O O
, O O
in O O
a O O
region O O
of O O
homologous O O
synteny O O
with O O
human O B-GENE
14q11 O I-GENE
. O I-GENE
2 O I-GENE
- O I-GENE
q13 O E-GENE
, O O
which O O
contains O O
the O O
asp1 S-GENE S-GENE
( O O
audiogenic B-GENE O
seizure I-GENE O
prone E-GENE O
) O O
locus O O
in O O
the O O
mouse O O
. O O
Absence O O
of O O
nitroso O O
formation O O
from O O
( O O
14C O O
) O O
methomyl O O
and O O
sodium O O
nitrite O O
under O O
simulated O O
stomach O O
conditions O O
. O O
Although O O
no O O
detectable O O
phenotypes O O
are O O
associated O O
with O O
a O O
disruption O O
allele O O
of O O
ABP1 S-GENE S-GENE
, O O
mutations O O
that O O
create O O
a O O
requirement O O
for O O
this O O
protein O O
have O O
now O O
been O O
isolated O O
in O O
the O O
previously O O
identified O O
gene B-GENE O
SAC6 E-GENE S-GENE
and O O
in O O
two O O
new O O
genes O O
, O O
SLA1 S-GENE S-GENE
and O O
SLA2 S-GENE S-GENE
. O O
The O O
local O O
median O O
scores O O
( O O
ranges O O
) O O
of O O
the O O
above O O
tests O O
were O O
as O O
follows O O
- O O
AMT O O
: O O
9 O O
( O O
6 O O
- O O
10 O O
) O O
; O O
CMMS O O
: O O
25 O O
( O O
16 O O
- O O
28 O O
) O O
; O O
SBT O O
: O O
2 O O
( O O
0 O O
- O O
10 O O
) O O
; O O
WL O O
- O O
i O O
: O O
17 O O
( O O
8 O O
- O O
27 O O
) O O
; O O
WL O O
- O O
d O O
: O O
5 O O
( O O
0 O O
- O O
10 O O
) O O
; O O
WL O O
- O O
r O O
: O O
9 O O
( O O
1 O O
- O O
10 O O
) O O
; O O
ST O O
: O O
13 O O
( O O
6 O O
- O O
25 O O
) O O
; O O
BNT O O
: O O
14 O O
( O O
10 O O
- O O
15 O O
) O O
; O O
CPT O O
: O O
1 O O
( O O
0 O O
- O O
3 O O
) O O
; O O
BDT O O
: O O
19 O O
( O O
0 O O
- O O
42 O O
) O O
; O O
OAT O O
: O O
20 O O
( O O
3 O O
- O O
33 O O
) O O
. O O
Antigen O O
dose O O
- O O
response O O
curves O O
were O O
drawn O O
, O O
and O O
the O O
cumulative O O
dose O O
required O O
for O O
a O O
35 O O
% O O
reduction O O
in O O
specific O O
airway O O
conductance O O
was O O
calculated O O
and O O
designated O O
Provocation O O
Dose O O
( O O
PD35 O O
) O O
. O O
Cross O O
- O O
talk O O
between O O
transcription O O
factors O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
and O O
C B-GENE S-GENE
/ I-GENE O
EBP E-GENE S-GENE
in O O
the O O
transcriptional O O
regulation O O
of O O
genes O O
. O O
Elective O O
replacement O O
of O O
the O O
aortic O O
root O O
in O O
Marfan O O
' O O
s O O
syndrome O O
. O O
The O O
detergent O O
- O O
solubilized O O
complex O O
oxidizes O O
caldariella O O
quinol O O
at O O
high O O
rates O O
and O O
is O O
completely O O
inhibited O O
by O O
cyanide O O
and O O
by O O
quinolone O O
analogs O O
, O O
potent O O
inhibitors O O
of O O
quinol B-GENE O
oxidases E-GENE O
. O O
We O O
have O O
characterized O O
a O O
new O O
cDNA O O
, O O
33k O B-GENE
- O I-GENE
6 O E-GENE
, O O
potentially O O
encoding O O
a O O
tobacco B-GENE O
33 I-GENE O
kDa I-GENE O
chloroplast I-GENE O
RNP I-GENE O
( I-GENE O
cp33 I-GENE O
) I-GENE O
homologue E-GENE O
. O O
The O O
regions O O
encoding O O
the O O
mature O O
proteinases O O
were O O
cloned O O
into O O
an O O
expression O O
vector O O
and O O
recombinant O O
protein O O
produced O O
in O O
Escherichia O O
coli O O
. O O
Furthermore O O
, O O
CL100 S-GENE S-GENE
suppresses O O
the O O
[ O O
val12 O S-GENE
] O O
ras S-GENE O
- O O
induced O O
activation O O
of O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
in O O
a O O
cell O O
- O O
free O O
system O O
from O O
Xenopus O O
oocytes O O
. O O
The O O
Xenopus B-GENE B-GENE
homeobox I-GENE I-GENE
gene I-GENE E-GENE
twin E-GENE O
mediates O O
Wnt S-GENE O
induction O O
of O O
goosecoid S-GENE O
in O O
establishment O O
of O O
Spemann O O
' O O
s O O
organizer O O
. O O
Between O O
1988 O O
and O O
1994 O O
, O O
data O O
from O O
3 O O
large O O
sites O O
revealed O O
a O O
3 O O
- O O
5 O O
fold O O
increase O O
in O O
the O O
prevalence O O
of O O
antidepressant O O
( O O
ATD O O
) O O
treatment O O
for O O
U O O
. O O
S O O
. O O
youths O O
aged O O
2 O O
- O O
19 O O
years O O
. O O
The O O
vaccinia O O
virus O O
D6R S-GENE O
open O O
reading O O
frame O O
encodes O O
the O O
small O O
subunit O O
of O O
the O O
heterodimeric O O
vaccinia B-GENE O
virus I-GENE O
early I-GENE O
transcription I-GENE O
factor E-GENE O
( O O
VETF S-GENE S-GENE
) O O
that O O
activates O O
transcription O O
of O O
early B-GENE O
genes E-GENE O
in O O
vitro O O
. O O
The O O
Sensititre O O
MIC O O
panels O O
containing O O
meropenem O O
offer O O
a O O
convenient O O
and O O
valid O O
alternative O O
to O O
the O O
NCCLS O O
reference O O
method O O
for O O
the O O
susceptibility O O
testing O O
of O O
potential O O
pathogens O O
likely O O
to O O
be O O
recovered O O
from O O
mixed O O
infections O O
. O O
Recognition O O
of O O
DNA O O
by O O
single O O
- O O
chain O O
derivatives O O
of O O
the O O
phage O O
434 O O
repressor O O
: O O
high O O
affinity O O
binding O O
depends O O
on O O
both O O
the O O
contacted O O
and O O
non O O
- O O
contacted O O
base O O
pairs O O
. O O
The O O
paper O O
calls O O
for O O
standardized O O
question O O
formats O O
and O O
a O O
centralized O O
body O O
to O O
monitor O O
changes O O
in O O
these O O
parameters O O
of O O
sexual O O
behaviour O O
. O O
We O O
show O O
that O O
GCNF S-GENE S-GENE
binds O O
to O O
one O O
of O O
the O O
two O O
DRO O B-GENE
sequences O E-GENE
in O O
the O O
Prm1 B-GENE B-GENE
promoter E-GENE E-GENE
, O O
and O O
to O O
the O O
DRO O B-GENE
sequence O E-GENE
in O O
the O O
Prm2 B-GENE B-GENE
promoter E-GENE E-GENE
in O O
a O O
specific O O
manner O O
. O O
139La O O
NQR O O
relaxation O O
and O O
microSR O O
study O O
of O O
Zn O O
- O O
doping O O
effects O O
in O O
La2CuO4 O O
. O O
The O O
data O O
also O O
suggest O O
that O O
gamma B-GENE O
CACCC I-GENE S-GENE
box I-GENE O
binding I-GENE O
factors E-GENE O
mediate O O
LCR B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
interactions O O
which O O
normally O O
enhance O O
gamma B-GENE B-GENE
- I-GENE I-GENE
globin E-GENE E-GENE
and O O
suppress O O
beta B-GENE B-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
fetal O O
erythroid O O
cells O O
. O O
However O O
, O O
the O O
in O O
vivo O O
attachment O O
strength O O
of O O
the O O
CSTi O O
- O O
2 O O
coating O O
was O O
comparable O O
both O O
to O O
CSTi O O
- O O
1 O O
and O O
to O O
an O O
HA O O
- O O
coated O O
control O O
after O O
8 O O
weeks O O
. O O
Octamer O O
recognition O O
is O O
mediated O O
by O O
the O O
POU S-GENE B-GENE
domain O E-GENE
, O O
a O O
conserved O O
structural O O
motif O O
which O O
- O O
- O O
like O O
the O O
zinc O O
finger O O
and O O
leucine O O
zipper O O
- O O
- O O
defines O O
a O O
family O O
of O O
related O O
transcription O O
factors O O
. O O
All O O
testosterone O O
treatments O O
raised O O
plasma O O
testosterone O O
concentrations O O
above O O
control O O
and O O
pretreatment O O
levels O O
( O O
testosterone O O
and O O
synovex O O
+ O O
testosterone O O
> O O
synovex O O
> O O
control O O
; O O
all O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O
Lifestyle O O
characteristics O O
were O O
ascertained O O
by O O
a O O
self O O
- O O
administered O O
questionnaire O O
. O O
The O O
major O O
promoter O O
element O O
of O O
the O O
Xenopus B-GENE B-GENE
laevis I-GENE I-GENE
5S I-GENE I-GENE
RNA I-GENE I-GENE
gene E-GENE E-GENE
is O O
located O O
within O O
the O O
transcribed O O
region O O
of O O
the O O
gene O O
and O O
forms O O
the O O
binding O O
site O O
for O O
the O O
transcription O O
initiation O O
factor O O
TFIIIA S-GENE S-GENE
. O O
During O O
each O O
step O O
of O O
the O O
pulse O O
infusion O O
the O O
osteocalcin S-GENE O
responses O O
to O O
changes O O
in O O
CaI O O
in O O
general O O
were O O
parallel O O
to O O
the O O
changes O O
in O O
PTH S-GENE O
( O O
r O O
= O O
0 O O
. O O
462 O O
; O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
were O O
inversely O O
correlated O O
to O O
CaI O O
( O O
r O O
= O O
- O O
0 O O
. O O
562 O O
; O O
P O O
= O O
0 O O
. O O
003 O O
) O O
. O O
The O O
gamma B-GENE B-GENE
- I-GENE I-GENE
GCS I-GENE I-GENE
gene E-GENE E-GENE
is O O
expressed O O
ubiquitously O O
and O O
induced O O
coordinately O O
with O O
NAD B-GENE O
( I-GENE O
P I-GENE O
) I-GENE O
H I-GENE O
: I-GENE O
quinone I-GENE O
oxidoreductase I-GENE O
( I-GENE O
1 I-GENE O
) E-GENE O
( O O
NQO1 S-GENE O
) O O
and O O
glutathione B-GENE O
S I-GENE O
- I-GENE O
transferase I-GENE O
Ya E-GENE O
( O O
GST B-GENE O
Ya E-GENE O
) O O
in O O
response O O
to O O
xenobiotics O O
and O O
antioxidants O O
. O O
Interestingly O O
, O O
the O O
expression O O
of O O
Id4 S-GENE O
in O O
Sertoli O O
cells O O
is O O
only O O
detectable O O
after O O
stimulation O O
with O O
FSH S-GENE S-GENE
or O O
cAMP O O
. O O
We O O
determined O O
their O O
N O O
- O O
terminal O O
amino O O
acid O O
sequence O O
and O O
found O O
that O O
these O O
polypeptides O O
were O O
CotT S-GENE O
, O O
YeeK S-GENE O
, O O
YxeE S-GENE O
, O O
CotF S-GENE O
, O O
YrbA S-GENE O
( O O
31 O O
and O O
45 O O
kDa O O
) O O
, O O
and O O
SpoIVA S-GENE O
, O O
respectively O O
. O O
The O O
effect O O
of O O
betamethasone O O
on O O
duodenal O O
calcium O O
absorption O O
and O O
1 O O
, O O
25 O O
- O O
dihydroxy O O
vitamin O O
D3 O O
production O O
in O O
the O O
chick O O
. O O
Furthermore O O
, O O
it O O
is O O
also O O
established O O
that O O
serine O O
phosphorylation O O
of O O
STAT5a S-GENE S-GENE
transactivation O O
domain O O
, O O
via O O
the O O
MAPK S-GENE S-GENE
pathway O O
, O O
is O O
a O O
means O O
of O O
modifying O O
GH S-GENE S-GENE
- O O
induced O O
transcriptional O O
activation O O
. O O
ES O O
cells O O
in O O
which O O
the O O
gene O O
for O O
the O O
erythroid O B-GENE
transcription O I-GENE
factor O I-GENE
GATA B-GENE I-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
has O O
been O O
disrupted O O
fail O O
to O O
produce O O
mature O O
erythroid O O
cells O O
either O O
in O O
vivo O O
or O O
in O O
vitro O O
. O O
Two O O
conserved O O
motifs O O
, O O
W89RKRRY94 O S-GENE
and O O
P156KKIKP161 O S-GENE
, O O
seemed O O
to O O
act O O
as O O
nuclear O O
addressing O O
signals O O
. O O
It O O
is O O
concluded O O
that O O
the O O
predominant O O
action O O
of O O
LSD O O
on O O
the O O
female O O
copulatory O O
response O O
is O O
not O O
mediated O O
by O O
increased O O
dopamine B-GENE B-GENE
receptor E-GENE E-GENE
activity O O
but O O
that O O
the O O
LSD O O
effect O O
might O O
be O O
modulated O O
by O O
decreased O O
dopaminergic O O
activity O O
. O O
Therefore O O
, O O
in O O
VDR S-GENE S-GENE
- O O
mediated O O
transcriptional O O
activation O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O S-GENE
binding O O
to O O
VDR S-GENE S-GENE
alters O O
the O O
conformation O O
of O O
the O O
ligand O O
binding O O
domain O O
such O O
that O O
it O O
: O O
( O O
i O O
) O O
engages O O
in O O
strong O O
heterodimerization O O
with O O
RXR S-GENE S-GENE
to O O
facilitate O O
VDRE O S-GENE
binding O O
, O O
( O O
ii O O
) O O
influences O O
the O O
RXR B-GENE B-GENE
ligand I-GENE E-GENE
binding I-GENE O
domain E-GENE O
such O O
that O O
it O O
is O O
resistant O O
to O O
the O O
binding O O
of O O
9 O O
- O O
cis O O
RA O O
but O O
active O O
in O O
recruiting O O
coactivator O O
to O O
its O O
AF O B-GENE
- O I-GENE
2 O E-GENE
and O O
( O O
iii O O
) O O
presents O O
the O O
AF O B-GENE
- O I-GENE
2 O E-GENE
region O O
in O O
VDR S-GENE O
for O O
coactivator O O
association O O
. O O
In O O
patients O O
, O O
750 O O
mL O O
of O O
saline O O
lowered O O
DL O O
( O O
CO O O
) O O
( O O
- O O
8 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
D O O
( O O
M O O
) O O
( O O
- O O
10 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
aldosterone O O
( O O
- O O
29 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
renin S-GENE O
( O O
- O O
52 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
and O O
hematocrit O O
( O O
- O O
6 O O
% O O
, O O
P O O
< O O
0 O O
. O O
05 O O
versus O O
baseline O O
) O O
and O O
increased O O
V O O
( O O
C O O
) O O
( O O
20 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
without O O
changing O O
rap O O
and O O
wpp O O
. O O
We O O
have O O
previously O O
identified O O
LIT1 S-GENE S-GENE
, O O
a O O
paternally O O
expressed O O
antisense O O
RNA O O
within O O
the O O
KvLQT1 B-GENE B-GENE
locus E-GENE E-GENE
through O O
a O O
positional O O
screening O O
approach O O
using O O
human O O
monochromosomal O O
hybrids O O
. O O
A O O
series O O
of O O
deletion O O
mutants O O
was O O
expressed O O
transiently O O
in O O
two O O
human O O
hepatocytes O O
, O O
HepG2 O S-GENE
and O O
PLC O O
. O O
The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
the O O
FlaB2 B-GENE B-GENE
polypeptide E-GENE E-GENE
was O O
92 O O
% O O
identical O O
to O O
that O O
of O O
T B-GENE O
. I-GENE O
pallidum I-GENE O
FlaB2 E-GENE O
, O O
with O O
a O O
76 O O
% O O
identity O O
at O O
the O O
nucleotide O O
level O O
. O O
Comparative O O
analyses O O
indicate O O
that O O
the O O
5 O O
' O O
- O O
peripheral O O
domain O O
exhibits O O
a O O
75 O O
- O O
bp O O
length O O
polymorphism O O
near O O
sequences O O
associated O O
with O O
the O O
termination O O
of O O
the O O
H O O
- O O
strand O O
replication O O
. O O
The O O
survival O O
of O O
patients O O
with O O
a O O
short O O
bowel O O
, O O
even O O
if O O
they O O
need O O
long O O
- O O
term O O
parenteral O O
nutrition O O
, O O
is O O
good O O
. O O
Thus O O
, O O
cross O O
- O O
resistance O O
between O O
fluoroquinolones O O
was O O
shown O O
for O O
both O O
enterococci O O
and O O
MRSA O O
. O O
The O O
5 O O
' O O
ends O O
of O O
the O O
P S-GENE O
and O O
O B-GENE B-GENE
gene I-GENE I-GENE
mRNAs E-GENE E-GENE
are O O
separated O O
by O O
109 O O
nucleotide O O
pairs O O
in O O
the O O
DNA O O
template O O
. O O
Using O O
community O O
development O O
approaches O O
. O O
Biol O O
. O O
We O O
have O O
cloned O O
the O O
cDNA O O
for O O
the O O
SLBP S-GENE O
from O O
humans O O
, O O
mice O O
, O O
and O O
frogs O O
, O O
using O O
the O O
recently O O
developed O O
yeast O O
three O O
- O O
hybrid O O
system O O
. O O
Along O O
with O O
these O O
species O O
, O O
F O O
. O O
graminearum O O
group O O
2 O O
( O O
ZON O O
, O O
DON O O
and O O
/ O O
or O O
3AcDON O O
or O O
15AcDON O O
) O O
; O O
F O O
. O O
chlamydosporum O O
; O O
F O O
. O O
acuminatum O O
( O O
type O O
- O O
A O O
trichothecene O O
derivatives O O
) O O
; O O
and O O
F O O
. O O
semitectum O O
were O O
often O O
found O O
to O O
be O O
associated O O
. O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
induced O O
phosphorylation O O
of O O
Smad2 S-GENE S-GENE
and O O
Smad3 S-GENE S-GENE
in O O
Mv1Lu O O
mink O O
lung O O
epithelial O O
cells O O
. O O
There O O
is O O
little O O
supportive O O
evidence O O
that O O
ACE S-GENE B-GENE
inhibitors O E-GENE
( O O
captopril O O
or O O
enalapril O O
) O O
are O O
teratogenic O O
. O O
Thus O O
, O O
the O O
potential O O
induction O O
of O O
this O O
gene O O
rearrangement O O
by O O
E1A B-GENE B-GENE
gene E-GENE E-GENE
therapy O O
is O O
unlikely O O
to O O
be O O
clinically O O
significant O O
in O O
the O O
treatment O O
of O O
advanced O O
malignant O O
disease O O
. O O
Although O O
the O O
cDNAs O O
of O O
HMG B-GENE O
- I-GENE O
14 E-GENE O
and O O
HMG B-GENE O
- I-GENE O
17 E-GENE O
do O O
not O O
cross O O
- O O
hybridize O O
, O O
they O O
have O O
several O O
similar O O
structural O O
features O O
: O O
the O O
open O O
reading O O
frame O O
comprises O O
only O O
23 O O
% O O
of O O
the O O
transcripts O O
, O O
the O O
5 O O
' O O
- O O
untranslated O O
region O O
is O O
extremely O O
GC O O
rich O O
whereas O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
is O O
unusually O O
long O O
and O O
AT O O
rich O O
. O O
Previously O O
, O O
we O O
reported O O
the O O
identification O O
of O O
a O O
23 O O
- O O
kD O O
protein O O
that O O
interacts O O
with O O
zyxin S-GENE O
in O O
vitro O O
( O O
Sadler O O
et O O
al O O
. O O
, O O
1992 O O
) O O
. O O
If O O
vascular O O
induction O O
between O O
a O O
vascular O O
carrier O O
and O O
the O O
selected O O
jejunal O O
segment O O
is O O
done O O
as O O
a O O
kind O O
of O O
flap O O
prefabrication O O
, O O
the O O
jejunal O O
interposition O O
flap O O
can O O
be O O
used O O
without O O
the O O
need O O
for O O
complex O O
microsurgery O O
. O O
In O O
gel O O
mobility O O
shift O O
assays O O
, O O
high O O
binding O O
activities O O
of O O
ATPC B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
low O O
binding O O
activities O O
of O O
CBF S-GENE S-GENE
were O O
observed O O
with O O
nuclear O O
extracts O O
from O O
tissue O O
with O O
low O O
AtpC S-GENE O
expression O O
levels O O
, O O
and O O
the O O
opposite O O
was O O
observed O O
with O O
extracts O O
from O O
tissues O O
with O O
high O O
AtpC S-GENE O
expression O O
levels O O
. O O
Activation O O
of O O
tyrosine B-GENE B-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
receptors E-GENE E-GENE
, O O
heterotrimeric B-GENE B-GENE
G I-GENE I-GENE
proteins E-GENE E-GENE
, O O
and O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
enhanced O O
the O O
activities O O
of O O
both O O
MEK B-GENE B-GENE
isoforms E-GENE E-GENE
in O O
293 O O
and O O
PC12 O O
cells O O
. O O
The O O
Fugu O B-GENE
rubripes O E-GENE
( O O
Fugu O S-GENE
) O O
gene O O
fragment O O
was O O
used O O
to O O
isolate O O
the O O
GH B-GENE B-GENE
gene E-GENE E-GENE
from O O
a O O
Fugu O O
genomic O O
library O O
. O O
An O O
in O O
vitro O O
' O O
glass O O
stomach O O
' O O
( O O
containing O O
various O O
volumes O O
of O O
hydrochloric O O
acid O O
[ O O
HCl O O
] O O
and O O
ammonium O O
chloride O O
[ O O
NH4Cl O O
] O O
) O O
was O O
used O O
to O O
evaluate O O
the O O
means O O
of O O
increasing O O
' O O
gastric O O
' O O
pH O O
to O O
that O O
of O O
the O O
NH4 O O
+ O O
- O O
- O O
> O O
NH3 O O
transition O O
that O O
occurs O O
significantly O O
at O O
pH O O
9 O O
. O O
24 O O
. O O
Acyclovir O O
( O O
3 O O
% O O
ointment O O
) O O
used O O
topically O O
one O O
to O O
five O O
times O O
a O O
day O O
on O O
acute O O
ocular O O
HSV O O
infection O O
gave O O
beneficial O O
results O O
as O O
measured O O
by O O
a O O
reduction O O
in O O
corneal O O
involvement O O
, O O
conjunctivitis O O
, O O
iritis O O
, O O
and O O
corneal O O
clouding O O
. O O
We O O
have O O
documented O O
previously O O
that O O
glucocorticoid O O
hormones O O
modulate O O
the O O
posttranslational O O
localization O O
of O O
cell O O
surface O O
mouse O O
mammary O O
tumor O O
virus O O
( O O
MMTV O O
) O O
glycoproteins O O
in O O
the O O
viral O O
- O O
infected O O
M1 O O
. O O
54 O O
rat O O
HTC O O
hepatoma O O
cell O O
line O O
. O O
Partial O O
proteolysis O O
of O O
cell O O
surface O O
- O O
iodinated O O
B B-GENE O
- I-GENE O
G I-GENE O
molecules E-GENE O
generates O O
extremely O O
similar O O
patterns O O
of O O
spots O O
, O O
both O O
within O O
and O O
between O O
haplotypes O O
. O O
SETTING O O
: O O
University O O
research O O
laboratory O O
. O O
There O O
was O O
a O O
57 O O
% O O
reduction O O
in O O
IGF B-GENE B-GENE
IR I-GENE I-GENE
mRNA E-GENE E-GENE
levels O O
in O O
clone O O
CA9 O O
after O O
confluence O O
compared O O
with O O
clone O O
ME10 O O
. O O
Oligomers O O
corresponding O O
to O O
the O O
region O O
of O O
the O O
mlc B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
/ I-GENE I-GENE
3 I-GENE I-GENE
enhancer E-GENE E-GENE
, O O
which O O
encompasses O O
this O O
conserved O O
sequence O O
, O O
bound O O
MEF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
and O O
competed O O
for O O
its O O
binding O O
to O O
the O O
mck S-GENE B-GENE
enhancer O E-GENE
. O O
Similar O O
tissue O O
- O O
specific O O
patterns O O
are O O
observed O O
with O O
a O O
fusion O O
between O O
the O O
caufliflower B-GENE O
mosaic I-GENE O
virus I-GENE O
35S I-GENE O
RNA I-GENE O
promotor E-GENE O
and O O
the O O
GUS B-GENE B-GENE
gene E-GENE E-GENE
. O O
This O O
difference O O
between O O
SP B-GENE O
- I-GENE O
1 E-GENE O
and O O
SP B-GENE O
- I-GENE O
2 I-GENE O
peptides E-GENE O
was O O
not O O
due O O
to O O
their O O
differential O O
uptake O O
by O O
cell O O
, O O
since O O
approximately O O
100 O O
times O O
more O O
SP B-GENE O
- I-GENE O
2 I-GENE O
peptide E-GENE O
could O O
be O O
found O O
in O O
cytoplasmic O O
extracts O O
than O O
SP B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
peptide E-GENE E-GENE
in O O
experiments O O
using O O
radiolabeled O O
peptides O O
. O O
One O O
function O O
of O O
p53 S-GENE S-GENE
is O O
in O O
regulating O O
cell O O
cycle O O
check O O
- O O
point O O
control O O
after O O
DNA O O
damage O O
. O O
We O O
used O O
event O O
- O O
related O O
functional O O
magnetic O O
resonance O O
imaging O O
( O O
fMRI O O
) O O
during O O
a O O
cued O O
spatial O O
- O O
attention O O
task O O
to O O
dissociate O O
brain O O
activity O O
related O O
to O O
attentional O O
control O O
from O O
that O O
related O O
to O O
selective O O
processing O O
of O O
target O O
stimuli O O
. O O
BACKGROUND O O
: O O
The O O
extract O O
of O O
medicinal O O
plants O O
containing O O
curcumin O O
is O O
traditionally O O
believed O O
to O O
have O O
a O O
positive O O
contraction O O
effect O O
on O O
the O O
human O O
gall O O
- O O
bladder O O
. O O
Apoptosis O O
triggered O O
through O O
Fas S-GENE O
and O O
F B-GENE O
/ I-GENE O
F E-GENE O
was O O
inhibited O O
by O O
coexpression O O
of O O
CrmA S-GENE S-GENE
and O O
p35 S-GENE S-GENE
, O O
but O O
not O O
Bcl B-GENE B-GENE
- I-GENE I-GENE
xL E-GENE E-GENE
. O O
The O O
product O O
of O O
one O O
gene O O
, O O
Bv80 S-GENE S-GENE
, O O
has O O
a O O
single O O
divergent O O
copy O O
of O O
a O O
sequence O O
of O O
149 O O
amino O O
acids O O
( O O
approx O O
. O O
The O O
1031 B-GENE O
- I-GENE O
bp I-GENE O
wild I-GENE O
- I-GENE O
type I-GENE O
HIT1 I-GENE O
DNA E-GENE O
which O O
contained O O
an O O
open O O
reading O O
frame O O
encoding O O
a O O
protein O O
of O O
164 O O
amino O O
acids O O
and O O
the O O
AGG B-GENE B-GENE
arginine I-GENE I-GENE
tRNA I-GENE I-GENE
gene E-GENE E-GENE
complemented O O
all O O
hit1 B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
mutant I-GENE E-GENE
phenotypes E-GENE O
, O O
indicating O O
that O O
the O O
mutant O O
phenotypes O O
were O O
caused O O
by O O
the O O
deletion O O
of O O
these O O
genes O O
. O O
We O O
found O O
a O O
prevalence O O
of O O
eating O O
disorders O O
of O O
5 O O
. O O
9 O O
% O O
( O O
lifetime O O
prevalence O O
of O O
10 O O
% O O
) O O
, O O
irrespective O O
of O O
gender O O
and O O
type O O
of O O
diabetes O O
; O O
4 O O
. O O
1 O O
% O O
of O O
the O O
whole O O
sample O O
reported O O
intentional O O
insulin S-GENE O
undertreatment O O
or O O
omission O O
. O O
Tilisolol O O
and O O
carboxymethylcellulose O O
sodium O O
salt O O
( O O
CMC O O
) O O
were O O
used O O
as O O
the O O
model O O
ophthalmic O O
drug O O
and O O
viscous O O
polymer O O
, O O
respectively O O
. O O
These O O
results O O
are O O
discussed O O
in O O
the O O
context O O
of O O
a O O
model O O
of O O
the O O
myogenic O O
lineage O O
that O O
is O O
based O O
on O O
the O O
expression O O
of O O
desmin S-GENE O
. O O
We O O
identified O O
two O O
potential O O
phosphorylation O O
sites O O
at O O
serine49 O O
and O O
serine133 O O
, O O
both O O
of O O
which O O
seem O O
to O O
be O O
necessary O O
for O O
Myf B-GENE B-GENE
- I-GENE I-GENE
5 E-GENE E-GENE
activity O O
. O O
We O O
constructed O O
a O O
series O O
of O O
chimeric O O
genes O O
containing O O
part O O
of O O
the O O
first O O
exon O O
and O O
increasingly O O
longer O O
5 O O
' O O
flanking O O
sequences O O
of O O
the O O
ODC B-GENE B-GENE
gene E-GENE E-GENE
fused O O
to O O
either O O
bacterial B-GENE B-GENE
chloramphenicol I-GENE I-GENE
acetyltransferase E-GENE E-GENE
( O O
CAT S-GENE S-GENE
) O O
or O O
luciferase B-GENE O
reporter I-GENE O
genes E-GENE O
. O O
CVO2 O S-GENE
saturation O O
is O O
a O O
reliable O O
and O O
sensitive O O
method O O
for O O
detecting O O
blood O O
loss O O
. O O
The O O
gene O O
encoding O O
the O O
Neisseria B-GENE B-GENE
lactamica I-GENE I-GENE
III I-GENE I-GENE
DNA I-GENE I-GENE
methyltransferase E-GENE E-GENE
( O O
M B-GENE O
. I-GENE O
NlaIII E-GENE O
) O O
which O O
recognizes O O
the O O
sequence O O
CATG O S-GENE
has O O
been O O
cloned O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
. O O
This O O
latter O O
complex O O
reacts O O
with O O
an O O
antibody O O
to O O
serum B-GENE B-GENE
response I-GENE I-GENE
factor E-GENE E-GENE
( O O
SRF S-GENE S-GENE
) O O
and O O
exhibits O O
the O O
same O O
binding O O
characteristics O O
as O O
purified O O
SRF S-GENE O
. O O
The O O
second O O
patient O O
was O O
successfully O O
treated O O
with O O
intravenous O O
prostaglandin O B-GENE
F2 O I-GENE
alpha O E-GENE
( O O
PGF2 O B-GENE
alpha O E-GENE
) O O
. O O
Alignment O O
of O O
the O O
rat B-GENE O
and I-GENE O
human I-GENE O
WIN I-GENE O
cDNAs E-GENE S-GENE
and O O
their O O
comparison O O
with O O
mouse O O
genomic O O
sequence O O
revealed O O
that O O
the O O
WIN B-GENE O
DNA I-GENE O
binding I-GENE O
domain E-GENE O
is O O
encoded O O
by O O
four O O
exons O O
, O O
two O O
of O O
which O O
( O O
exons O O
4 O O
and O O
6 O O
) O O
are O O
alternatively O O
spliced O O
to O O
generate O O
at O O
least O O
three O O
classes O O
of O O
mRNA O O
transcripts O O
. O O
In O O
a O O
pilot O O
study O O
in O O
which O O
two O O
dogs O O
were O O
given O O
parenteral O O
rifampin O O
before O O
and O O
after O O
operation O O
and O O
grafts O O
were O O
preclotted O O
with O O
blood O O
that O O
contained O O
rifampin O O
, O O
it O O
was O O
suggested O O
that O O
there O O
was O O
a O O
slight O O
increase O O
in O O
inhibition O O
at O O
24 O O
hours O O
( O O
93 O O
% O O
) O O
. O O
A O O
flow O O
probe O O
for O O
direct O O
measurement O O
of O O
blood O O
flow O O
of O O
the O O
mitral O O
valve O O
was O O
devised O O
. O O
Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
the O O
Lactococcus B-GENE O
lactis I-GENE O
Ll I-GENE O
. I-GENE O
LtrB I-GENE O
group I-GENE O
II I-GENE O
intron I-GENE O
endonuclease E-GENE O
with O O
its O O
DNA O O
target O O
site O O
by O O
DNA O O
footprinting O O
and O O
modification O O
- O O
interference O O
approaches O O
. O O
Clinical O O
trials O O
bring O O
informations O O
for O O
pharmacology O O
and O O
epidemiology O O
. O O
In O O
several O O
steps O O
we O O
converted O O
the O O
retinoid O O
specific O O
response O O
element O O
of O O
the O O
human B-GENE B-GENE
retinoic I-GENE I-GENE
acid I-GENE I-GENE
receptor I-GENE I-GENE
beta I-GENE I-GENE
promoter E-GENE E-GENE
into O O
the O O
vitamin O O
D O O
/ O O
retinoic O O
acid O O
response O O
element O O
of O O
the O O
human B-GENE B-GENE
osteocalcin I-GENE I-GENE
promoter E-GENE E-GENE
. O O
The O O
immediate O O
5 O O
' O O
- O O
flanking O O
region O O
was O O
GC O O
- O O
rich O O
with O O
3 O O
SP B-GENE O
- I-GENE O
1 I-GENE O
- I-GENE O
like E-GENE O
and O O
2 O O
AP B-GENE O
- I-GENE O
2 I-GENE O
sites E-GENE O
identified O O
in O O
close O O
proximity O O
to O O
the O O
transcription O O
start O O
site O O
. O O
Akt S-GENE S-GENE
- O O
dependent O O
antiapoptotic O O
action O O
of O O
insulin S-GENE S-GENE
is O O
sensitive O O
to O O
farnesyltransferase O O
inhibitor O O
. O O
For O O
all O O
samples O O
, O O
the O O
sensitivity O O
of O O
the O O
blast O O
flag O O
on O O
the O O
CD3500 O O
was O O
85 O O
% O O
with O O
a O O
specificity O O
of O O
91 O O
% O O
( O O
STKS O O
: O O
sensitivity O O
, O O
75 O O
% O O
; O O
specificity O O
, O O
85 O O
% O O
) O O
; O O
the O O
sensitivity O O
of O O
the O O
CD3500 O O
IG O O
flag O O
was O O
72 O O
% O O
with O O
a O O
specificity O O
of O O
76 O O
% O O
( O O
STKS O O
: O O
sensitivity O O
, O O
75 O O
% O O
: O O
specificity O O
, O O
73 O O
% O O
) O O
; O O
and O O
the O O
sensitivity O O
of O O
the O O
NRBC O O
flag O O
was O O
43 O O
% O O
with O O
a O O
specificity O O
of O O
94 O O
% O O
( O O
STKS O O
sensitivity O O
, O O
37 O O
% O O
; O O
specificity O O
, O O
88 O O
% O O
) O O
. O O
Control O O
of O O
ovulation O O
in O O
mares O O
in O O
the O O
early O O
breeding O O
season O O
with O O
ovarian O O
steroids O O
and O O
prostaglandin O O
. O O
Reasons O O
are O O
given O O
for O O
suggesting O O
that O O
tiapamil O O
warrants O O
further O O
clinical O O
evaluation O O
, O O
after O O
which O O
it O O
may O O
join O O
the O O
more O O
established O O
calcium O O
antagonists O O
as O O
a O O
valuable O O
therapeutic O O
agent O O
. O O
The O O
central O O
venous O O
O2 O O
saturation O O
test O O
in O O
acute O O
pulmonary O O
fat O O
embolism O O
. O O
Two O O
of O O
the O O
proteins O O
UPRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
and O O
UPRF B-GENE B-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
( O O
which O O
is O O
apparently O O
a O O
proteolytic O O
degradation O O
product O O
of O O
UPRF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
) O O
bind O O
inefficiently O O
to O O
mutant O O
versions O O
of O O
the O O
UPR O S-GENE
that O O
are O O
unable O O
to O O
confer O O
responsiveness O O
to O O
unfolded O O
proteins O O
to O O
the O O
( O O
CYC1 S-GENE S-GENE
) O O
promoter O O
. O O
Identification O O
of O O
domains O O
mediating O O
transcription O O
activation O O
, O O
repression O O
, O O
and O O
inhibition O O
in O O
the O O
paired B-GENE O
- I-GENE O
related I-GENE O
homeobox I-GENE O
protein E-GENE O
, O O
Prx2 S-GENE S-GENE
( O O
S8 S-GENE S-GENE
) O O
. O O
METHODS O O
: O O
A O O
spatial O O
counting O O
approach O O
in O O
which O O
the O O
location O O
of O O
each O O
and O O
every O O
PN O O
and O O
NP O O
in O O
the O O
stratum O O
pyramidale O O
of O O
sectors O O
CA1 O O
- O O
4 O O
was O O
applied O O
to O O
11 O O
normal O O
control O O
( O O
CONs O O
) O O
and O O
10 O O
SZs O O
matched O O
for O O
age O O
and O O
postmortem O O
interval O O
, O O
as O O
well O O
as O O
4 O O
manic O O
depressive O O
( O O
MD O O
) O O
subjects O O
matched O O
for O O
age O O
. O O
Analytical O O
scanning O O
isoelectrofocusing O O
. O O
Upstream B-GENE O
stimulatory I-GENE O
factor E-GENE O
USF S-GENE S-GENE
is O O
a O O
human O O
transcriptional O O
activation O O
factor O O
, O O
which O O
uses O O
a O O
basic O O
/ O O
helix O O
- O O
loop O O
- O O
helix O O
/ O O
leucin O O
zipper O O
( O O
b O O
/ O O
HLH O S-GENE
/ O O
Z O O
) O O
motif O O
to O O
homodimerize O O
and O O
recognize O O
specific O O
sequences O O
in O O
the O O
promoter O O
region O O
of O O
both O O
nuclear O O
and O O
viral O O
genes O O
transcribed O O
by O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II E-GENE E-GENE
. O O
43 O O
% O O
, O O
6 O O
/ O O
14 O O
; O O
P O O
= O O
0 O O
. O O
013 O O
) O O
, O O
whereas O O
, O O
in O O
RCC O O
samples O O
with O O
VHL S-GENE O
methylation O O
or O O
mutation O O
, O O
the O O
frequency O O
of O O
3p14 O B-GENE
- O I-GENE
p21 O E-GENE
LOH O O
did O O
not O O
differ O O
from O O
that O O
of O O
sp25 O O
- O O
p26 O O
( O O
72 O O
% O O
, O O
18 O O
/ O O
25 O O
vs O O
. O O
Sequences O O
homologous O O
to O O
the O O
consensus O O
TUF B-GENE O
- I-GENE O
binding I-GENE O
UAS I-GENE O
boxes E-GENE O
are O O
present O O
in O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
both O O
genes O O
. O O
The O O
analysis O O
predicted O O
that O O
progressive O O
increases O O
in O O
serum O O
creatinine O O
or O O
aspartate B-GENE O
transaminase E-GENE O
activity O O
will O O
result O O
in O O
only O O
a O O
50 O O
% O O
reduction O O
of O O
clearance O O
. O O
RESULTS O O
: O O
Although O O
low O O
levels O O
of O O
vIRF B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
mRNAs E-GENE E-GENE
can O O
be O O
detected O O
in O O
the O O
HHV O O
- O O
8 O O
- O O
positive O O
BCBL O O
- O O
1 O O
tumor O O
cell O O
line O O
, O O
12 O O
- O O
0 O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
( O O
TPA O O
) O O
treatment O O
does O O
not O O
stimulate O O
expression O O
of O O
vIRF B-GENE B-GENE
- I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
together O O
with O O
primary O O
lytic O O
cycle O O
genes O O
. O O
Central O O
projections O O
of O O
gastric O O
afferent O O
vagal O O
inputs O O
. O O
DNA O O
sequence O O
of O O
the O O
UL6 S-GENE S-GENE
to O O
UL20 B-GENE B-GENE
genes E-GENE E-GENE
of O O
infectious O O
laryngotracheitis O O
virus O O
and O O
characterization O O
of O O
the O O
UL10 B-GENE B-GENE
gene I-GENE E-GENE
product E-GENE O
as O O
a O O
nonglycosylated O O
and O O
nonessential O O
virion O O
protein O O
. O O
Coimmunoprecipitation O O
analysis O O
suggests O O
that O O
these O O
residues O O
likely O O
contribute O O
to O O
the O O
multimerization O O
function O O
required O O
for O O
homomeric O O
complex O O
formation O O
or O O
heteromeric O O
complex O O
formation O O
with O O
p50 S-GENE O
in O O
that O O
no O O
association O O
of O O
p65 B-GENE O
delta E-GENE O
with O O
itself O O
or O O
with O O
p50 S-GENE O
was O O
evident O O
. O O
Cytostatic O O
activity O O
of O O
some O O
essential O O
oils O O
against O O
HEp O O
- O O
2 O O
cells O O
. O O
A O O
yeast O O
mitochondrial O O
translation O O
initiation O O
codon O O
mutation O O
affecting O O
the O O
gene O O
for O O
cytochrome B-GENE B-GENE
oxidase I-GENE I-GENE
subunit I-GENE I-GENE
III E-GENE E-GENE
( O O
COX3 S-GENE S-GENE
) O O
was O O
partially O O
suppressed O O
by O O
a O O
spontaneous O O
nuclear O O
mutation O O
. O O
Only O O
the O O
27 O O
- O O
kDa O O
protein O O
was O O
detected O O
after O O
N B-GENE O
- I-GENE O
glycosidase E-GENE O
treatment O O
, O O
indicating O O
that O O
PLP B-GENE B-GENE
- I-GENE I-GENE
H E-GENE E-GENE
is O O
a O O
glycoprotein O O
. O O
Moreover O O
, O O
we O O
studied O O
the O O
relationship O O
between O O
initial O O
percentage O O
of O O
bone O O
marrow O O
plasma O O
cells O O
and O O
prognosis O O
. O O
These O O
results O O
demonstrate O O
that O O
GGTase B-GENE B-GENE
- I-GENE I-GENE
I E-GENE E-GENE
inhibitors O O
arrest O O
cells O O
in O O
G0 O S-GENE
/ O O
G1 O O
and O O
induce O O
accumulation O O
of O O
p21WAF S-GENE S-GENE
in O O
a O O
p53 S-GENE S-GENE
- O O
independent O O
manner O O
and O O
that O O
FTase S-GENE S-GENE
inhibitors O O
can O O
interfere O O
with O O
cell O O
cycle O O
events O O
by O O
a O O
mechanism O O
that O O
involves O O
neither O O
p21WAF S-GENE S-GENE
nor O O
p27KIP S-GENE S-GENE
. O O
We O O
report O O
here O O
on O O
an O O
eight O O
- O O
year O O
- O O
old O O
boy O O
who O O
first O O
developed O O
acute O O
intravascular O O
hemolysis O O
following O O
therapy O O
with O O
amphotericin O O
B O O
( O O
AmB O O
) O O
and O O
subsequently O O
a O O
delayed O O
hemolytic O O
transfusion O O
reaction O O
due O O
to O O
alloantibodies O O
. O O
The O O
temporal O O
sequence O O
of O O
organ O O
failure O O
was O O
lung O O
, O O
clotting O O
system O O
, O O
kidney O O
, O O
and O O
liver O O
. O O
The O O
potential O O
biological O O
significance O O
of O O
the O O
identified O O
structural O O
motif O O
shared O O
by O O
the O O
human B-GENE B-GENE
CCR5 E-GENE E-GENE
, O O
CCR3 S-GENE S-GENE
, O O
CCR2B S-GENE S-GENE
and O O
other O O
GPCRs S-GENE S-GENE
is O O
discussed O O
. O O
Analysis O O
of O O
rat O O
brain O O
, O O
heart O O
, O O
lung O O
, O O
liver O O
, O O
kidney O O
and O O
skeletal O O
muscle O O
revealed O O
psi B-GENE B-GENE
PKC I-GENE I-GENE
zeta I-GENE I-GENE
mRNA E-GENE E-GENE
only O O
in O O
brain O O
. O O
The O O
papers O O
provide O O
a O O
broad O O
perspective O O
of O O
MPAs O O
and O O
include O O
social O O
, O O
economic O O
, O O
cultural O O
, O O
biological O O
and O O
statistical O O
components O O
. O O
Management O O
of O O
patients O O
with O O
Ewing O O
' O O
s O O
sarcoma O O
has O O
been O O
discussed O O
with O O
reference O O
to O O
the O O
need O O
to O O
achieve O O
an O O
excellent O O
local O O
result O O
from O O
radiation O O
therapy O O
now O O
that O O
patients O O
are O O
experiencing O O
long O O
- O O
term O O
survival O O
. O O
Furthermore O O
, O O
the O O
rapid O O
light O O
- O O
mediated O O
increase O O
of O O
CPRF B-GENE B-GENE
proteins E-GENE E-GENE
was O O
insensitive O O
to O O
transcriptional O O
inhibitors O O
, O O
suggesting O O
that O O
a O O
post O O
- O O
transcriptional O O
mechanism O O
controls O O
CPRF S-GENE O
accumulation O O
. O O
In O O
those O O
patients O O
who O O
before O O
transplantation O O
were O O
serological O O
negative O O
for O O
CMV O O
but O O
had O O
received O O
organs O O
from O O
CMV B-GENE O
- I-GENE O
IgG E-GENE S-GENE
positive O O
donors O O
, O O
the O O
incidence O O
of O O
the O O
disease O O
was O O
highest O O
. O O
Since O O
1985 O O
the O O
combination O O
of O O
chlorambucil O O
( O O
10 O O
mg O O
daily O O
, O O
initially O O
for O O
six O O
weeks O O
, O O
then O O
alternating O O
fortnights O O
for O O
12 O O
weeks O O
) O O
and O O
interferon B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
2b E-GENE E-GENE
( O O
Schering O O
- O O
Plough O O
; O O
2 O O
x O O
10 O O
( O O
6 O O
) O O
U O O
/ O O
m2 O O
three O O
times O O
weekly O O
by O O
subcutaneous O O
injection O O
for O O
18 O O
weeks O O
) O O
has O O
been O O
compared O O
in O O
a O O
randomised O O
trial O O
with O O
chlorambucil O O
alone O O
in O O
previously O O
untreated O O
patients O O
with O O
stage O O
III O O
or O O
IV O O
follicular O O
lymphoma O O
. O O
The O O
BDU O O
neurons O O
and O O
the O O
ALM O O
touch O O
neurons O O
are O O
lineal O O
sister O O
cells O O
in O O
the O O
AB O O
. O O
a O O
lineage O O
and O O
the O O
VA O O
and O O
VB O O
motor O O
neurons O O
are O O
lineal O O
sister O O
cells O O
in O O
the O O
AB O O
. O O
p O O
lineage O O
. O O
We O O
compared O O
retrospectively O O
the O O
efficacy O O
of O O
granulocyte B-GENE O
colony I-GENE O
stimulating I-GENE O
factor E-GENE O
( O O
G B-GENE O
- I-GENE O
CSF E-GENE O
) O O
alone O O
with O O
chemotherapy O O
plus O O
G B-GENE O
- I-GENE O
CSF E-GENE O
in O O
mobilizing O O
CD34 S-GENE O
- O O
positive O O
cells O O
in O O
patients O O
with O O
malignant O O
lymphoma O O
. O O
Serum O O
concentrations O O
of O O
hormones O O
in O O
patients O O
classified O O
as O O
C O O
were O O
characteristically O O
and O O
inclined O O
to O O
be O O
hypergonadotropic O O
and O O
hypoestrogenic O O
. O O
Cervical O O
CT O O
revealed O O
an O O
irregular O O
low O O
density O O
at O O
the O O
periphery O O
of O O
the O O
cervical O O
vertebra O O
from O O
the O O
C2 O O
to O O
C4 O O
level O O
. O O
Incorporation O O
of O O
this O O
information O O
in O O
the O O
data O O
brought O O
about O O
a O O
revised O O
five O O
- O O
year O O
survival O O
estimate O O
of O O
55 O O
percent O O
. O O
These O O
motifs O O
, O O
and O O
their O O
cognate O O
transcription O O
factors O O
, O O
appear O O
to O O
act O O
in O O
concert O O
, O O
with O O
partial O O
redundancy O O
, O O
so O O
that O O
discrete O O
mutations O O
were O O
only O O
partially O O
effective O O
in O O
reducing O O
transcriptional O O
activity O O
. O O
We O O
now O O
show O O
that O O
purified O O
recombinant O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
sis E-GENE E-GENE
/ O O
PDGF S-GENE S-GENE
can O O
induce O O
this O O
binding O O
activity O O
which O O
we O O
have O O
termed O O
SIF S-GENE S-GENE
, O O
for O O
sis B-GENE B-GENE
- I-GENE I-GENE
inducible I-GENE I-GENE
factor E-GENE E-GENE
. O O
Statistical O O
conservation O O
laws O O
in O O
turbulent O O
transport O O
. O O
Expression O O
of O O
the O O
bacteriophage B-GENE B-GENE
T4 I-GENE I-GENE
DNA I-GENE I-GENE
terminase I-GENE I-GENE
genes I-GENE E-GENE
16 I-GENE O
and I-GENE O
17 E-GENE O
yields O O
multiple O O
proteins O O
. O O
Erdheim O O
- O O
Chester O O
disease O O
: O O
a O O
distinct O O
lipoidosis O O
or O O
part O O
of O O
the O O
spectrum O O
of O O
histiocytosis O O
? O O
Erdheim O O
- O O
Chester O O
disease O O
has O O
always O O
been O O
considered O O
a O O
distinct O O
lipoidosis O O
based O O
on O O
clinical O O
and O O
radiographic O O
criteria O O
. O O
Self O O
- O O
consistent O O
calculation O O
of O O
the O O
surface O O
electronic O O
structure O O
of O O
the O O
( O O
1 O O
x O O
2 O O
) O O
reconstructed O O
Au O O
( O O
110 O O
) O O
surface O O
. O O
The O O
plasmid O O
was O O
found O O
to O O
confer O O
drug O O
resistance O O
specifically O O
to O O
LMB O O
. O O
Two O O
pharmacokinetic O O
models O O
were O O
compared O O
. O O
A O O
higher O O
median O O
proportion O O
of O O
spirochaetes O O
was O O
observed O O
in O O
sites O O
after O O
diagnosis O O
of O O
loss O O
of O O
attachment O O
. O O
Ocular O O
injuries O O
during O O
general O O
anesthesia O O
. O O
Of O O
81 O O
girls O O
cured O O
from O O
the O O
bacteriuria O O
24 O O
recurred O O
, O O
5 O O
with O O
a O O
symptomatic O O
pyelonephritis O O
and O O
3 O O
with O O
cystitis O O
. O O
The O O
performances O O
of O O
two O O
tests O O
, O O
the O O
ProstAsure O O
index O O
and O O
the O O
percent O O
free O O
PSA S-GENE O
test O O
, O O
were O O
evaluated O O
in O O
detecting O O
cancer O O
. O O
The O O
protein O O
encoded O O
by O O
the O O
NF2 B-GENE B-GENE
gene E-GENE E-GENE
has O O
a O O
similarity O O
to O O
ezrin S-GENE O
, O O
radixin S-GENE O
and O O
moesin S-GENE S-GENE
( O O
ERM S-GENE S-GENE
) O O
proteins O O
that O O
link O O
membrane O O
proteins O O
to O O
the O O
cytoskeleton O O
. O O
PATIENTS O O
- O O
- O O
125 O O
women O O
consulting O O
the O O
general O O
practitioner O O
for O O
symptomatic O O
bacterial O O
vaginosis O O
. O O
In O O
the O O
healing O O
tendons O O
, O O
the O O
rate O O
of O O
collagen S-GENE O
synthesis O O
decreased O O
and O O
the O O
rate O O
of O O
noncollagen O O
protein O O
synthesis O O
remained O O
unchanged O O
. O O
From O O
our O O
own O O
investigations O O
on O O
phantoms O O
, O O
the O O
smallest O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
( O O
delta O O
S O O
min O O
/ O O
delta O O
R O O
) O O
was O O
obtained O O
which O O
determines O O
the O O
minimal O O
contrast O O
, O O
given O O
the O O
film O O
properties O O
( O O
film O O
response O O
S O O
, O O
film O O
gradient O O
gamma O O
) O O
and O O
the O O
amount O O
of O O
scatter O O
. O O
However O O
, O O
one O O
activity O O
binds O O
preferentially O O
to O O
G O O
+ O O
C O O
- O O
rich O O
promoters O O
, O O
and O O
another O O
activity O O
appears O O
to O O
bind O O
preferentially O O
to O O
only O O
two O O
of O O
the O O
promoters O O
tested O O
. O O
Cardiovascular O O
effects O O
in O O
man O O
of O O
intravenous O O
prizidilol O O
hydrochloride O O
( O O
SK O O
& O O
F O O
92657 O O
) O O
; O O
a O O
new O O
antihypertensive O O
agent O O
. O O
From O O
the O O
Centers O O
for O O
Disease O O
Control O O
and O O
Prevention O O
. O O
Expression O O
of O O
a O O
cDNA O O
clone O O
in O O
yeast O O
containing O O
a O O
large O O
portion O O
of O O
the O O
open O O
reading O O
frame O O
produced O O
cAMP B-GENE O
PDEase E-GENE O
activity O O
identical O O
in O O
properties O O
to O O
the O O
Drosophila O O
enzyme O O
affected O O
by O O
the O O
dnc B-GENE O
mutation E-GENE O
. O O
FdsR S-GENE S-GENE
purified O O
to O O
homogeneity O O
after O O
overexpression O O
of O O
fdsR S-GENE S-GENE
in O O
E O O
. O O
coli O O
is O O
a O O
130 O O
kDa O O
homotetramer O O
binding O O
to O O
the O O
fds S-GENE O
control O O
region O O
located O O
between O O
the O O
fdsR S-GENE S-GENE
and O O
fdsG B-GENE B-GENE
genes E-GENE E-GENE
. O O
ZNS O O
, O O
in O O
the O O
mmolar O O
range O O
, O O
scavenged O O
hydroxyl O O
and O O
nitric O O
oxide O O
radicals O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O
The O O
orthologs O O
of O O
the O O
Y B-GENE O
( I-GENE O
1 I-GENE O
) E-GENE O
and O O
Y B-GENE O
( I-GENE O
2 I-GENE O
) I-GENE O
subtypes E-GENE O
display O O
high O O
amino O O
acid O O
sequence O O
identities O O
between O O
pig O O
, O O
human O O
, O O
and O O
mouse O O
( O O
92 O O
% O O
- O O
94 O O
% O O
) O O
, O O
whereas O O
the O O
Y B-GENE O
( I-GENE O
4 I-GENE O
) E-GENE O
, O O
Y B-GENE O
( I-GENE O
5 I-GENE O
) E-GENE O
, O O
and O O
y B-GENE O
( I-GENE O
6 I-GENE O
) I-GENE O
subtypes E-GENE O
display O O
lower O O
identities O O
( O O
76 O O
% O O
- O O
87 O O
% O O
) O O
. O O
Binding O O
of O O
ZAP B-GENE O
- I-GENE O
70 E-GENE O
to O O
phospho O O
- O O
TAMs O O
is O O
notable O O
for O O
the O O
high O O
level O O
of O O
cooperativity O O
between O O
the O O
two O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
, O O
which O O
individually O O
demonstrate O O
low O O
affinity O O
interaction O O
with O O
the O O
ligand O O
. O O
The O O
benzo O O
- O O
pyrone O O
drug O O
Venalot O O
had O O
a O O
considerable O O
effect O O
in O O
reducing O O
the O O
protein O O
concentration O O
in O O
the O O
air O O
spaces O O
and O O
the O O
interstitial O O
tissue O O
, O O
and O O
of O O
the O O
oedema O O
in O O
the O O
latter O O
. O O
Radiation O O
was O O
delivered O O
in O O
a O O
single O O
4 O O
- O O
mJ O O
pulse O O
of O O
200 O O
microseconds O O
duration O O
by O O
means O O
of O O
an O O
articulated O O
zirconium O O
fluoride O O
optical O O
fibre O O
and O O
a O O
320 O O
- O O
microns O O
quartz O O
- O O
fibre O O
tip O O
. O O
Perception O O
of O O
sweetness O O
cannot O O
be O O
used O O
to O O
accurately O O
meter O O
the O O
metabolizable O O
energy O O
or O O
nutritive O O
value O O
of O O
a O O
food O O
. O O
The O O
leader O O
peptide O O
was O O
hypothesized O O
to O O
inhibit O O
ribosome O O
release O O
at O O
the O O
tnaC B-GENE S-GENE
stop I-GENE O
codon E-GENE O
, O O
thereby O O
blocking O O
Rho S-GENE O
' O O
s O O
access O O
to O O
the O O
transcript O O
. O O
Response O O
properties O O
of O O
single O O
units O O
in O O
the O O
accessory O O
optic O O
system O O
of O O
the O O
dark O O
- O O
reared O O
cat O O
. O O
Excretion O O
of O O
radiopharmaceuticals O O
into O O
breast O O
milk O O
. O O
Influence O O
of O O
huanglian O O
used O O
in O O
combination O O
with O O
huangqin O O
and O O
gancao O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
experimental O O
glucose B-GENE O
- I-GENE O
6 I-GENE O
- I-GENE O
phosphate I-GENE O
dehydrogenase E-GENE O
deficiency O O
in O O
rats O O
] O O
OBJECTIVE O O
: O O
To O O
study O O
the O O
influence O O
of O O
common O O
combination O O
of O O
Huanglian O O
( O O
Coptis O O
chinensis O O
) O O
on O O
the O O
erythrocytic O O
osmotic O O
fragilitas O O
of O O
glucose B-GENE B-GENE
- I-GENE I-GENE
6 I-GENE I-GENE
- I-GENE I-GENE
phosphate I-GENE I-GENE
dehydrogenase E-GENE E-GENE
( O O
G6PD S-GENE S-GENE
) O O
deficiency O O
in O O
rats O O
. O O
The O O
leukotriene B-GENE B-GENE
receptor E-GENE E-GENE
antagonist O O
zafirlukast O O
inhibits O O
sulfur O O
dioxide O O
- O O
induced O O
bronchoconstriction O O
in O O
patients O O
with O O
asthma O O
. O O
This O O
sequence O O
was O O
sufficient O O
to O O
confer O O
p53 S-GENE S-GENE
- O O
dependent O O
activation O O
to O O
a O O
heterologous O O
promoter O O
and O O
p53 S-GENE S-GENE
was O O
capable O O
of O O
binding O O
to O O
this O O
sequence O O
as O O
assessed O O
by O O
gel O O
shift O O
analysis O O
. O O
The O O
embryology O O
of O O
the O O
vertebral O O
column O O
is O O
reviewed O O
briefly O O
, O O
and O O
the O O
origin O O
of O O
each O O
anomaly O O
of O O
the O O
C2 O O
vertebra O O
is O O
traced O O
to O O
one O O
of O O
the O O
two O O
early O O
stages O O
in O O
development O O
as O O
follows O O
: O O
1 O O
) O O
the O O
formation O O
of O O
the O O
mesenchymal O O
vertebra O O
or O O
2 O O
) O O
its O O
induction O O
to O O
cartilage O O
. O O
Two O O
of O O
the O O
three O O
groups O O
were O O
submitted O O
to O O
two O O
different O O
levels O O
of O O
hypoxia O O
( O O
FiO2 O O
= O O
0 O O
. O O
05 O O
, O O
group O O
F5 O O
and O O
FiO2 O O
= O O
0 O O
. O O
1 O O
, O O
group O O
F10 O O
) O O
and O O
the O O
third O O
to O O
normoxia O O
( O O
FiO2 O O
= O O
0 O O
. O O
21 O O
, O O
group O O
F21 O O
) O O
in O O
a O O
thermoneutral O O
and O O
controlled O O
environment O O
. O O
Parathyroid B-GENE O
hormone E-GENE O
responses O O
of O O
cyclic O O
AMP O O
- O O
, O O
serum O O
- O O
and O O
phorbol O O
ester O O
- O O
responsive O O
reporter O O
genes O O
in O O
osteoblast O O
- O O
like O O
UMR O O
- O O
106 O O
cells O O
. O O
Our O O
results O O
strongly O O
suggest O O
that O O
activation O O
of O O
the O O
beta O O
origin O O
by O O
a O O
distant O O
replication O O
enhancer O O
element O O
requires O O
a O O
small O O
target O O
sequence O O
essential O O
for O O
initiator O O
protein O O
- O O
mediated O O
DNA O O
looping O O
. O O
HNF4alpha7 B-GENE B-GENE
mRNA E-GENE E-GENE
is O O
also O O
found O O
in O O
totipotent O O
embryonic O O
stem O O
cells O O
. O O
Penicillamine O O
- O O
induced O O
myasthenia O O
gravis O O
associated O O
with O O
antibodies O O
to O O
acetylcholine B-GENE B-GENE
receptor E-GENE E-GENE
. O O
Magnetic O O
force O O
and O O
torque O O
at O O
1 O O
. O O
5 O O
T O O
did O O
not O O
dislodge O O
the O O
GF O O
or O O
result O O
in O O
perforation O O
of O O
canine O O
IVC O O
by O O
the O O
GF O O
. O O
A O O
. O O
LCCH1 S-GENE S-GENE
was O O
identical O O
to O O
the O O
Rdl B-GENE B-GENE
gene E-GENE E-GENE
, O O
a O O
known O O
GABA B-GENE B-GENE
receptor I-GENE I-GENE
subunit I-GENE I-GENE
gene E-GENE E-GENE
from O O
D O O
. O O
melanogaster O O
, O O
whereas O O
LCCH2 S-GENE S-GENE
and O O
LCCH3 S-GENE S-GENE
were O O
novel O O
D O O
. O O
melanogaster O O
sequences O O
that O O
exhibited O O
structural O O
similarity O O
to O O
other O O
members O O
of O O
the O O
ligand B-GENE O
- I-GENE O
gated I-GENE O
chloride I-GENE O
channel I-GENE O
gene I-GENE O
family E-GENE O
. O O
A O O
significant O O
increase O O
of O O
gastric O O
mucosal O O
permeability O O
was O O
observed O O
in O O
six O O
normal O O
human O O
subjects O O
after O O
instillation O O
of O O
ethanol O O
( O O
20 O O
percent O O
v O O
/ O O
v O O
) O O
. O O
Using O O
a O O
simulated O O
cough O O
machine O O
, O O
we O O
analyzed O O
the O O
effect O O
of O O
adding O O
tensio O O
- O O
active O O
liquids O O
as O O
sol O O
phase O O
simulant O O
on O O
the O O
clearance O O
of O O
gel O O
mucus O O
simulant O O
by O O
cough O O
. O O
First O O
, O O
the O O
amino O O
- O O
terminal O O
regulatory O O
arm O O
of O O
the O O
GDI S-GENE S-GENE
binds O O
to O O
the O O
switch O O
I O O
and O O
II O O
domains O O
of O O
Cdc42 S-GENE S-GENE
leading O O
to O O
the O O
inhibition O O
of O O
both O O
GDP O O
dissociation O O
and O O
GTP O S-GENE
hydrolysis O O
. O O
By O O
a O O
combination O O
of O O
alternative O O
promoter O O
usage O O
and O O
exon O O
splicing O O
, O O
each O O
ROR B-GENE B-GENE
gene E-GENE E-GENE
generates O O
several O O
isoforms O O
that O O
differ O O
only O O
in O O
their O O
amino O O
terminus O O
. O O
Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
showed O O
a O O
rapid O O
induction O O
of O O
nuclear O O
proteins O O
that O O
bound O O
to O O
the O O
consensus B-GENE O
kappa I-GENE B-GENE
B I-GENE I-GENE
motif E-GENE E-GENE
. O O
Analysis O O
of O O
larger O O
cDNA O O
clones O O
demonstrates O O
that O O
there O O
are O O
at O O
least O O
two O O
isoforms O O
of O O
RIP14 S-GENE S-GENE
that O O
differ O O
in O O
the O O
N O O
- O O
terminal O O
( O O
A O O
and O O
B O O
) O O
and O O
hinge O O
( O O
D O O
) O O
domains O O
. O O
Multiple O O
copies O O
of O O
this O O
binding O O
site O O
are O O
found O O
in O O
the O O
viral O O
genomes O O
. O O
During O O
subsequent O O
CS O O
- O O
alone O O
trials O O
, O O
the O O
responses O O
of O O
( O O
+ O O
) O O
MK O O
- O O
801 O O
- O O
injected O O
mice O O
were O O
extinguished O O
as O O
easily O O
as O O
those O O
of O O
saline O O
- O O
injected O O
mice O O
. O O
In O O
contrast O O
, O O
the O O
tail O O
deviated O O
ipsilaterally O O
in O O
cats O O
with O O
a O O
hemisection O O
, O O
and O O
the O O
tail O O
was O O
ventroflexed O O
in O O
cats O O
with O O
a O O
transection O O
. O O
The O O
major O O
open O O
reading O O
frame O O
of O O
the O O
cDNA O O
predicts O O
a O O
protein O O
of O O
59 O O
kD O O
, O O
with O O
a O O
leucine O O
zipper O O
situated O O
adjacent O O
to O O
an O O
myc B-GENE O
- I-GENE O
related I-GENE O
motif E-GENE O
that O O
has O O
been O O
proposed O O
to O O
assume O O
a O O
helix O O
- O O
loop O O
- O O
helix O O
structure O O
. O O
This O O
residue O O
, O O
although O O
located O O
55 O O
rather O O
than O O
35 O O
residues O O
NH2 O O
- O O
terminal O O
of O O
the O O
essential O O
glutamate O O
, O O
is O O
undoubtedly O O
the O O
analog O O
of O O
the O O
second O O
aspartate O O
of O O
the O O
Asp O O
- O O
Asp O O
- O O
35 O O
- O O
Glu O O
motif O O
found O O
in O O
other O O
family O O
members O O
. O O
In O O
addition O O
to O O
loss O O
of O O
digit O O
identity O O
and O O
varying O O
degrees O O
of O O
polydactyly O O
, O O
proximal O O
skeletal O O
elements O O
are O O
severely O O
shortened O O
in O O
Xt S-GENE O
; O O
ld S-GENE O
double O O
homozygous O O
limbs O O
. O O
The O O
PEP4 B-GENE B-GENE
gene E-GENE E-GENE
was O O
isolated O O
from O O
a O O
genomic O O
DNA O O
library O O
by O O
complementation O O
of O O
the O O
pep4 B-GENE B-GENE
- I-GENE I-GENE
3 E-GENE I-GENE
mutation O E-GENE
. O O
A O O
gene O O
with O O
a O O
high O O
degree O O
of O O
sequence O O
identity O O
with O O
mammalian B-GENE B-GENE
ADP I-GENE I-GENE
- I-GENE I-GENE
ribosylation I-GENE I-GENE
factors E-GENE E-GENE
( O O
ARFs S-GENE S-GENE
) O O
, O O
believed O O
to O O
be O O
important O O
in O O
vesicular O O
transport O O
, O O
was O O
identified O O
. O O
Off O O
- O O
shell O O
effect O O
in O O
Rydberg O O
- O O
atom O O
- O O
alkali O O
- O O
metal O O
- O O
atom O O
scattering O O
. O O
Short O O
- O O
term O O
growth O O
: O O
rhythms O O
, O O
chaos O O
, O O
or O O
noise O O
? O O
Association O O
between O O
diaphragm O O
use O O
and O O
asymptomatic O O
bacteriuria O O
. O O
The O O
effect O O
of O O
iron O O
on O O
the O O
toxigenicity O O
of O O
Vibrio O O
cholerae O O
. O O
The O O
Tat B-GENE B-GENE
protein E-GENE E-GENE
coded O O
by O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
is O O
a O O
strong O O
activator O O
of O O
viral O O
gene O O
expression O O
from O O
the O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O
Is O O
it O O
time O O
for O O
a O O
wine O O
trial O O
? O O
The O O
average O O
coefficient O O
of O O
variation O O
between O O
assays O O
for O O
gas O O
chromatography O O
mass O O
spectrometry O O
was O O
5 O O
. O O
8 O O
% O O
and O O
for O O
radioimmunoassay O O
was O O
12 O O
. O O
3 O O
% O O
, O O
while O O
the O O
average O O
coefficient O O
of O O
variation O O
within O O
assays O O
for O O
gas O O
chromatography O O
mass O O
spectrometry O O
was O O
4 O O
. O O
9 O O
% O O
and O O
for O O
radioimmunoassay O O
6 O O
. O O
9 O O
% O O
. O O
Macrophages O O
: O O
modulators O O
of O O
immunity O O
. O O
The O O
NH2 O O
- O O
terminal O O
fragments O O
were O O
tested O O
for O O
susceptibility O O
to O O
modification O O
with O O
Nalpha O O
- O O
( O O
3 O O
- O O
maleimidylpropionyl O O
) O O
biocytin O O
, O O
which O O
attaches O O
a O O
biotin O O
group O O
to O O
cysteine O O
sulfhydryls O O
. O O
Production O O
of O O
VT O O
was O O
also O O
examined O O
retrospectively O O
in O O
32 O O
E O O
. O O
coli O O
strains O O
of O O
serotype O O
O26 O O
: O O
H11 O O
isolated O O
from O O
children O O
with O O
diarrhoea O O
; O O
eight O O
( O O
25 O O
% O O
) O O
of O O
them O O
produced O O
moderate O O
to O O
high O O
levels O O
of O O
verotoxin B-GENE O
1 E-GENE O
despite O O
several O O
years O O
storage O O
in O O
vitro O O
. O O
Serum O O
pituitary O O
and O O
steroid O O
hormone O O
levels O O
in O O
the O O
adult O O
male O O
: O O
one O O
value O O
is O O
as O O
good O O
as O O
the O O
mean O O
of O O
three O O
. O O
The O O
sections O O
were O O
stained O O
with O O
anti O O
- O O
polymorphonuclear O O
leukocyte O O
antibody O O
, O O
the O O
endothelial O B-GENE
marker O I-GENE
factor B-GENE I-GENE
VIII I-GENE I-GENE
- I-GENE I-GENE
related I-GENE I-GENE
antigen E-GENE E-GENE
, O O
and O O
with O O
hematoxylin O O
and O O
eosin O O
. O O
Mapping O O
of O O
the O O
region O O
in O O
KAP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
required O O
for O O
HP1 S-GENE S-GENE
interaction O O
showed O O
that O O
amino O O
acid O O
substitutions O O
which O O
abolish O O
HP1 S-GENE S-GENE
binding O O
in O O
vitro O O
reduce O O
KAP B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
mediated O O
repression O O
in O O
vivo O O
. O O
The O O
flanking O O
open O O
reading O O
frames O O
in O O
pARGC2 O S-GENE
showed O O
no O O
homologies O O
to O O
arginine O O
biosynthetic O O
genes O O
. O O
Promoter O O
activity O O
of O O
the O O
proliferating B-GENE B-GENE
- I-GENE I-GENE
cell I-GENE I-GENE
nuclear I-GENE I-GENE
antigen I-GENE I-GENE
gene E-GENE E-GENE
is O O
associated O O
with O O
inducible O O
CRE B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
in O O
interleukin B-GENE O
2 E-GENE O
- O O
stimulated O O
T O O
lymphocytes O O
. O O
METHODS O O
: O O
Levels O O
of O O
sIL B-GENE O
- I-GENE O
2R E-GENE O
were O O
measured O O
simultaneously O O
in O O
plasma O O
and O O
pleural O O
fluid O O
in O O
111 O O
patients O O
with O O
pleural O O
effusions O O
of O O
unknown O O
causes O O
. O O
The O O
GIS O O
software O O
program O O
, O O
ArcView O O
, O O
was O O
used O O
for O O
spatial O O
analysis O O
and O O
distance O O
calculations O O
. O O
chi2 O O
Tests O O
were O O
used O O
to O O
compare O O
the O O
distribution O O
of O O
the O O
characteristics O O
between O O
intersection O O
and O O
midblock O O
collisions O O
. O O
A O O
phase O O
II O O
study O O
was O O
initiated O O
to O O
evaluate O O
the O O
effect O O
of O O
a O O
combination O O
of O O
the O O
pure O O
L O O
- O O
isomer O O
of O O
LV O O
and O O
5 O O
- O O
FU O O
along O O
with O O
epirubicin O O
in O O
patients O O
with O O
advanced O O
pancreatic O O
cancer O O
. O O
RESULTS O O
: O O
After O O
3 O O
weeks O O
of O O
therapy O O
, O O
the O O
patient O O
had O O
an O O
increase O O
in O O
platelet O O
count O O
from O O
a O O
baseline O O
of O O
5 O O
, O O
000 O O
to O O
8 O O
, O O
000 O O
/ O O
microliter O O
to O O
a O O
maximal O O
level O O
of O O
33 O O
, O O
000 O O
/ O O
microliter O O
. O O
The O O
specificity O O
of O O
the O O
transcriptional O O
activation O O
by O O
ISGF3 S-GENE S-GENE
is O O
mediated O O
by O O
specific O O
elements O O
termed O O
IFN B-GENE S-GENE
- I-GENE O
stimulatory I-GENE O
response I-GENE O
element E-GENE O
( O O
ISRE S-GENE S-GENE
) O O
located O O
in O O
the O O
promoter O O
region O O
of O O
IFN S-GENE B-GENE
- O I-GENE
inducible O I-GENE
genes O E-GENE
. O O
It O O
appears O O
that O O
the O O
K O O
- O O
ABC O O
is O O
a O O
relatively O O
nonbiased O O
test O O
suitable O O
for O O
the O O
evaluation O O
of O O
both O O
gifted O O
and O O
nongifted O O
children O O
regardless O O
of O O
race O O
or O O
gender O O
. O O
In O O
another O O
patient O O
, O O
IRPF O O
recurred O O
in O O
the O O
ureter O O
of O O
a O O
living O O
related O O
renal O O
graft O O
6 O O
months O O
after O O
transplantation O O
. O O
These O O
mutants O O
, O O
assayed O O
by O O
injection O O
into O O
Xenopus O O
oocyte O O
nuclei O O
, O O
delimit O O
the O O
promoter O O
to O O
36 O O
bp O O
of O O
DNA O O
upstream O O
of O O
the O O
cap O O
site O O
and O O
73 O O
bp O O
of O O
the O O
untranslated O O
mRNA O O
leader O O
. O O
Upstream O O
tissue B-GENE O
inhibitor I-GENE O
of I-GENE O
metalloproteinases I-GENE B-GENE
- I-GENE I-GENE
1 I-GENE E-GENE
( I-GENE O
TIMP I-GENE O
- I-GENE O
1 I-GENE O
) I-GENE O
element I-GENE O
- I-GENE O
1 E-GENE O
, O O
a O O
novel O O
and O O
essential O O
regulatory O O
DNA O O
motif O O
in O O
the O O
human B-GENE B-GENE
TIMP I-GENE I-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
, O O
directly O O
interacts O O
with O O
a O O
30 O O
- O O
kDa O O
nuclear O O
protein O O
. O O
The O O
results O O
of O O
these O O
experiments O O
indicated O O
that O O
charcoal O O
, O O
imbiber O O
beads O O
, O O
and O O
the O O
anion O O
exchanges O O
resins O O
, O O
Dowex O O
XFS O O
- O O
4022 O O
and O O
Dowex O O
SBR O O
- O O
C1 O O
, O O
would O O
not O O
be O O
useful O O
agents O O
for O O
increasing O O
the O O
amount O O
of O O
dieldrin O O
eliminated O O
via O O
feces O O
( O O
droppings O O
) O O
of O O
chickens O O
. O O
The O O
receptor O O
for O O
CSF B-GENE B-GENE
- I-GENE I-GENE
1 E-GENE E-GENE
, O O
c B-GENE B-GENE
- I-GENE I-GENE
Fms E-GENE E-GENE
, O O
is O O
expressed O O
in O O
osteoclasts O O
, O O
possesses O O
intrinsic O O
tyrosine B-GENE B-GENE
- I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
, O O
and O O
signals O O
via O O
rapid O O
phosphorylation O O
of O O
selected O O
proteins O O
. O O
Adaptive O O
effects O O
of O O
repeated O O
immersion O O
exposure O O
on O O
the O O
human O O
body O O
To O O
this O O
end O O
we O O
generated O O
a O O
detailed O O
physical O O
map O O
of O O
the O O
genomic O O
region O O
spanning O O
between O O
sequence O O
- O O
tagged O O
site O O
markers O O
D16S518 S-GENE S-GENE
and O O
D16S516 S-GENE S-GENE
. O O
Spinophilin S-GENE O
, O O
a O O
novel O O
protein B-GENE B-GENE
phosphatase I-GENE I-GENE
1 I-GENE E-GENE
binding I-GENE O
protein E-GENE O
localized O O
to O O
dendritic O O
spines O O
. O O
We O O
have O O
found O O
that O O
pro B-GENE B-GENE
- I-GENE I-GENE
IGF I-GENE I-GENE
- I-GENE I-GENE
2 E-GENE E-GENE
can O O
initially O O
form O O
two O O
disulfide O O
isomers O O
that O O
undergo O O
rearrangement O O
to O O
a O O
single O O
conformation O O
in O O
vivo O O
. O O
While O O
working O O
on O O
the O O
toxicity O O
of O O
war O O
gases O O
. O O
he O O
formulated O O
' O O
Haber O O
' O O
s O O
rule O O
' O O
, O O
also O O
known O O
as O O
C O O
x O O
T O O
= O O
constant O O
in O O
order O O
to O O
characterize O O
the O O
toxicity O O
of O O
an O O
inhalant O O
. O O
The O O
existence O O
of O O
a O O
TFIIIB S-GENE S-GENE
assembly O O
pathway O O
leading O O
to O O
the O O
faithful O O
transcription O O
of O O
natural O O
eukaryotic O O
tRNA O B-GENE
genes O E-GENE
in O O
the O O
absence O O
of O O
TFIIIC S-GENE S-GENE
provides O O
novel O O
insights O O
into O O
the O O
functional O O
flexibility O O
of O O
the O O
eukaryotic O B-GENE
tRNA O I-GENE
gene O E-GENE
transcription O O
machinery O O
and O O
on O O
its O O
evolution O O
from O O
an O O
ancestral O O
RNA B-GENE O
polymerase I-GENE O
III E-GENE O
system O O
relying O O
on O O
upstream O O
, O O
TATA O O
- O O
centered O O
control O O
elements O O
. O O
Ectopic O O
Xbra S-GENE O
can O O
induce O O
Xegr B-GENE O
- I-GENE O
1 E-GENE O
transcription O O
by O O
an O O
indirect O O
mechanism O O
that O O
appears O O
to O O
operate O O
via O O
primary O O
activation O O
of O O
fibroblast B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
secretion O O
. O O
A O O
rapid O O
mixing O O
device O O
for O O
quasielastic O O
light O O
scattering O O
studies O O
of O O
reacting O O
systems O O
. O O
The O O
major O O
transcription O O
start O O
site O O
, O O
designated O O
as O O
+ O O
1 O O
, O O
was O O
determined O O
by O O
RACE O O
( O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
) O O
analysis O O
of O O
human O O
liver O O
cDNA O O
and O O
was O O
found O O
to O O
be O O
located O O
50 O O
bp O O
upstream O O
from O O
the O O
translation O O
start O O
site O O
. O O
These O O
aa O O
residues O O
correspond O O
to O O
codons O O
59 O O
and O O
108 O O
in O O
the O O
P B-GENE O
. I-GENE O
falciparum I-GENE O
DHFR I-GENE O
active I-GENE O
site E-GENE O
in O O
which O O
similar O O
aa O O
substitutions O O
( O O
Cys O O
Arg O O
- O O
59 O O
and O O
Ser O O
Asn O O
- O O
108 O O
) O O
are O O
associated O O
with O O
pyrimethamine O O
resistance O O
. O O
Of O O
all O O
YASR O O
syndromes O O
, O O
the O O
highest O O
stability O O
was O O
for O O
the O O
Anxious O O
/ O O
Depressed O O
scale O O
. O O
Here O O
we O O
investigate O O
the O O
mechanism O O
of O O
TPA O S-GENE
induction O O
of O O
FGF B-GENE B-GENE
- I-GENE I-GENE
BP E-GENE I-GENE
gene O E-GENE
expression O O
in O O
the O O
human O O
ME O O
- O O
180 O O
SCC O O
cell O O
line O O
. O O
Between O O
the O O
RNA O O
initiation O O
site O O
and O O
the O O
coding O O
region O O
is O O
a O O
GC O O
- O O
rich O O
hairpin O O
structure O O
followed O O
by O O
8 O O
T O O
residues O O
that O O
looks O O
like O O
a O O
rho B-GENE O
- I-GENE O
independent I-GENE O
transcription I-GENE O
terminator E-GENE O
. O O
Conversely O O
the O O
rate O O
of O O
bioavailability O O
was O O
significantly O O
different O O
, O O
because O O
from O O
the O O
Reference O O
patch O O
the O O
release O O
rate O O
is O O
fast O O
in O O
the O O
first O O
24 O O
h O O
, O O
leading O O
to O O
an O O
E2 O O
peak O O
at O O
8 O O
h O O
and O O
to O O
a O O
Cmax O O
in O O
average O O
at O O
23 O O
h O O
. O O
3 O O
) O O
The O O
progress O O
of O O
fibrinolysis O O
was O O
observed O O
by O O
serial O O
collection O O
of O O
middle O O
ear O O
fluid O O
in O O
the O O
same O O
side O O
ear O O
of O O
5 O O
cases O O
out O O
of O O
17 O O
cases O O
having O O
much O O
activity O O
for O O
fibrin S-GENE O
degradation O O
, O O
and O O
lowering O O
of O O
fibrinolytic O O
activity O O
was O O
revealed O O
in O O
4 O O
out O O
of O O
these O O
5 O O
cases O O
as O O
the O O
result O O
. O O
Thus O O
G17 S-GENE O
targets O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
fos I-GENE I-GENE
promoter I-GENE I-GENE
CArG I-GENE I-GENE
sequence E-GENE E-GENE
via O O
Rho B-GENE O
A E-GENE O
- O O
dependent O O
pathways O O
, O O
and O O
Rho B-GENE O
A E-GENE O
appears O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
the O O
trophic O O
action O O
of O O
G17 S-GENE S-GENE
. O O
The O O
MIC90 O O
of O O
ABK O O
against O O
coagulase B-GENE O
type I-GENE O
IV E-GENE O
strains O O
was O O
rather O O
high O O
, O O
12 O O
. O O
5 O O
micrograms O O
/ O O
ml O O
. O O
In O O
each O O
patient O O
, O O
MBF O O
was O O
quantified O O
in O O
the O O
three O O
major O O
vascular O O
territories O O
: O O
the O O
left O O
anterior O O
descending O O
and O O
left O O
circumflex O O
coronary O O
artery O O
territories O O
and O O
the O O
right O O
coronary O O
artery O O
( O O
control O O
region O O
) O O
territory O O
. O O
These O O
results O O
demonstrate O O
that O O
m2 B-GENE B-GENE
receptors E-GENE E-GENE
couple O O
to O O
both O O
G B-GENE B-GENE
alpha I-GENE I-GENE
i2 E-GENE E-GENE
and O O
G B-GENE B-GENE
alpha I-GENE I-GENE
i3 E-GENE E-GENE
in O O
vivo O O
and O O
that O O
this O O
interaction O O
is O O
integral O O
to O O
both O O
positive O O
and O O
negative O O
regulatory O O
pathways O O
leading O O
to O O
activation O O
of O O
PLC S-GENE O
and O O
desensitization O O
of O O
receptor O O
signaling O O
. O O
Platelet O O
count O O
and O O
plasma O O
volume O O
were O O
significantly O O
higher O O
in O O
group O O
A O O
than O O
in O O
group O O
B O O
throughout O O
pregnancy O O
. O O
The O O
fru B-GENE B-GENE
gene E-GENE E-GENE
has O O
seven O O
exons O O
spanning O O
15 O O
- O O
kb O O
encoding O O
two O O
transcripts O O
with O O
ORFs O O
of O O
841 O O
and O O
695 O O
amino O O
acids O O
. O O
HC B-GENE B-GENE
- I-GENE I-GENE
toxin E-GENE E-GENE
exerts O O
a O O
potent O O
cytostatic O O
effect O O
on O O
plant O O
and O O
animal O O
cells O O
by O O
inhibiting O O
histone B-GENE O
deacetylase E-GENE O
. O O
The O O
human O B-GENE
RIL B-GENE I-GENE
gene E-GENE E-GENE
: O O
mapping O O
to O O
human O B-GENE
chromosome O I-GENE
5q31 O I-GENE
. O I-GENE
1 O E-GENE
, O O
genomic O O
organization O O
and O O
alternative O O
transcripts O O
. O O
The O O
delta O O
mean O O
VAF O S-GENE
and O O
delta O O
mean O O
SABP O S-GENE
indicated O O
varied O O
mean O O
values O O
of O O
VAF O S-GENE
and O O
SABP O S-GENE
, O O
respectively O O
. O O
Azoospermia O O
was O O
graded O O
in O O
the O O
following O O
way O O
: O O
adequate O O
spermatozoa O O
( O O
A1 O O
) O O
, O O
low O O
, O O
scanty O O
or O O
rare O O
spermatozoa O O
( O O
A2 O O
) O O
, O O
spermatid O O
arrest O O
( O O
B1 O O
) O O
, O O
spermatocyte O O
arrest O O
( O O
B2 O O
) O O
, O O
Sertoli O O
cell O O
- O O
only O O
pattern O O
( O O
C O O
) O O
and O O
sclerosis O O
( O O
D O O
) O O
. O O
